PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Akey, D; Martins, A; Aniukwu, J; Glickman, MS; Shuman, S; Berger, JM				Akey, D; Martins, A; Aniukwu, J; Glickman, MS; Shuman, S; Berger, JM			Crystal structure and nonhomologous end-joining function of the ligase component of Mycobacterium DNA ligase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; PHOSPHODIESTER BOND FORMATION; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; NUCLEOTIDYL TRANSFER; ATOMIC-STRUCTURE; IN-VITRO; DOMAIN; PROTEIN; REPAIR	DNA ligase D ( LigD) is a large polyfunctional enzyme involved in nonhomologous end- joining ( NHEJ) in mycobacteria. LigD consists of a C- terminal ATP- dependent ligase domain fused to upstream polymerase and phosphoesterase modules. Here we report the 2.4 angstrom crystal structure of the ligase domain of Mycobacterium LigD, captured as the covalent ligase- AMP intermediate with a divalent metal in the active site. A chloride anion on the protein surface coordinated by the ribose 3 '- OH and caged by arginine and lysine side chains is a putative mimetic of the 5 '- phosphate at a DNA nick. Structure- guided mutational analysis revealed distinct requirements for the adenylylation and end- sealing reactions catalyzed by LigD. We found that amutation of Mycobacterium LigD that ablates only ligase activity results in decreased fidelity of NHEJ in vivo and a strong bias of mutagenic events toward deletions instead of insertions at the sealed DNA ends. This phenotype contrasts with the increased fidelity of double- strand break repair in Delta ligD cells or in a strain in which only the polymerase function of LigD is defective. We surmise that the signature error- prone quality of bacterial NHEJ in vivo arises from a dynamic balance between the end- remodeling and end- sealing steps.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Div Infect Dis, New York, NY 10021 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California Berkeley	Berger, JM (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	jmberger@berkeley.edu	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497; Glickman, Michael S/0000-0001-7918-5164	NIAID NIH HHS [AI064693, R01 AI064693-03, R01 AI064693] Funding Source: Medline; NIGMS NIH HHS [T32 GM007739, GM62410, GM07739, GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410, T32GM007739, R01GM063611] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; CONG PJ, 1993, J BIOL CHEM, V268, P7256; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Deng JP, 2004, J MOL BIOL, V343, P601, DOI 10.1016/j.jmb.2004.08.041; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; El Omari K, 2006, J BIOL CHEM, V281, P1573, DOI 10.1074/jbc.M509658200; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Gajiwala KS, 2004, STRUCTURE, V12, P1449, DOI 10.1016/j.str.2004.05.017; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; MacDowell AA, 2004, J SYNCHROTRON RADIAT, V11, P447, DOI 10.1107/S0909049504024835; Magnet S, 2004, BIOCHEMISTRY-US, V43, P710, DOI 10.1021/bi0355387; Martin IV, 2002, GENOME BIOL, V3; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Odell M, 2003, NUCLEIC ACIDS RES, V31, P5090, DOI 10.1093/nar/gkg665; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Pitcher RS, 2005, J MOL BIOL, V351, P531, DOI 10.1016/j.jmb.2005.06.038; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Shuman S, 2004, CURR OPIN STRUC BIOL, V14, P757, DOI 10.1016/j.sbi.2004.10.006; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; Srivastava SK, 2005, J BIOL CHEM, V280, P30273, DOI 10.1074/jbc.M503780200; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P33707, DOI 10.1074/jbc.M506838200; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P12137, DOI 10.1074/jbc.M413685200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200	63	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13412	13423		10.1074/jbc.M513550200	http://dx.doi.org/10.1074/jbc.M513550200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16476729	hybrid			2022-12-27	WOS:000237336600048
J	Yeung, BHY; Huang, DC; Sinicrope, FA				Yeung, BHY; Huang, DC; Sinicrope, FA			PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED HEPATOCYTE APOPTOSIS; CYTOCHROME-C RELEASE; PROTEASOME INHIBITOR; CASPASE-2; ACTIVATION; BAX; DYSFUNCTION; CLEAVAGE; RESISTANCE; EXPRESSION	PS-341 (bortezomib) is a potent and reversible proteosome inhibitor that functions to degrade intracellular polyubiquitinated proteins. PS-341 induces apoptosis and has shown broad antitumor activity with selectivity for transformed cells. We studied the effect of PS-341 on lysosomal and mitochondrial permeabilization, including the role of caspase-2 activation in apoptosis induction in the BxPC-3 human pancreatic carcinoma cell line. PS-341 induced a dose-dependent apoptosis in association with reactive oxygen species generation and cleavage of caspase-2 to its 33- and 14-kDa fragments. PS-341 disrupted lysosomes with redistribution of cathepsin B to the cytosol, as shown using fluorescence confocal microscopy, that was blocked by the free radical scavenger tiron but not by a caspase-2 inhibitor ( benzyloxycarbonyl (Z)-VDVAD-fluoromethyl ketone (FMK)). PS-341-induced caspase-2 activation was attenuated by a selective pharmacological inhibitor of cathepsin B (R-3032), suggesting that cathepsin B release occurs upstream of caspase-2. PS-341-induced mitochondrial depolarization was attenuated by Z-VDVAD-FMK, tiron, and an inhibitor of the mitochondrial permeability transition pore (bongkrekic acid). Regulation of mitochondrial permeability by caspase-2 was confirmed using caspase-2 small interfering RNA. PS-341-induced cytochrome c release and phosphatidylserine externalization were attenuated by Z-VDVAD-FMK and partially by R-3032. PS-341 activated the BH3-only proteins Bik and Bim and down-regulated Bcl-2 and Bcl-x(L) mRNA and protein expression. Taken together, PS-341 induces lysosomal cathepsin B redistribution upstream of caspase-2. Caspase-2 activation regulates PS-341-induced mitochondrial depolarization and apoptosis, suggesting that caspase-2 can serve as a link between lysosomal and mitochondrial permeabilization.	Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin, Div Oncol, Rochester, MN 55905 USA; Mayo Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Sinicrope, FA (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	sinicrope.frank@mayo.edu						Adams J, 1999, CANCER RES, V59, P2615; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Canbay A, 2003, J CLIN INVEST, V112, P152, DOI 10.1172/JCI200317740; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Dirsch VM, 2004, ONCOGENE, V23, P1586, DOI 10.1038/sj.onc.1207281; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Hideshima T, 2001, CANCER RES, V61, P3071; Hishita T, 2001, CANCER RES, V61, P2878; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Lassus P, 2004, SCIENCE, V306, P1683; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lebedeva IV, 2003, CANCER RES, V63, P8138; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Ling YH, 2002, MOL CANCER THER, V1, P841; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Nikrad M, 2005, MOL CANCER THER, V4, P443; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paquet C, 2005, LEUKEMIA, V19, P784, DOI 10.1038/sj.leu.2403717; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tatebe S, 2002, INT J CANCER, V97, P21, DOI 10.1002/ijc.1574; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225	52	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11923	11932		10.1074/jbc.M508533200	http://dx.doi.org/10.1074/jbc.M508533200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16446371	hybrid			2022-12-27	WOS:000236988100061
J	Cauvi, DM; Tian, XF; von Loehneysen, K; Robertson, MW				Cauvi, DM; Tian, XF; von Loehneysen, K; Robertson, MW			Transport of the IgE receptor alpha-chain is controlled by a multicomponent intracellular retention signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; CELL ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; MAST-CELL; TRANSMEMBRANE DOMAINS; AMINOGLYCOSIDE ANTIBIOTICS; MEMBRANE-PROTEINS; CYTOPLASMIC TAIL	The human high affinity IgE receptor(Fc epsilon RI) is a central component of the allergic response and is expressed as either a trimeric alpha gamma 2 or tetrameric alpha beta gamma 2 complex. It has been previously described that the cytoplasmic domain (CD) of the alpha-chain carries a dilysine motif at positions -3/-7 from the C terminus that functions in intracellular retention prior to assembly with other Fc epsilon RI subunits. In this report we have further explored the role of the -3/-7 dilysine signal in controlling steady-state alpha-chain transport by mutational analysis and found little surface expression of a -3/-7 dialanine alpha-chain mutant but significant Golgi localization. We compared the transport properties of a series of alpha-chain cytoplasmic domain truncation mutants and observed that truncation mutants lacking 23 or more C-terminal residues showed a dramatic increase in steady-state transport suggesting a role for the membrane-proximal CD sequence in alpha-chain retention. By performing alanine-scanning mutagenesis we identified a dilysine sequence (Lys(212)-Lys(216)) proximal to the transmembrane domain (TMD) that is important for both alpha-chain cell-surface expression and intracellular stability. Furthermore, co-mutation of the Lys(212)-Lys(216) residues with the -3/-7 dilysine signal produced a dramatic increase in alpha-chain surface expression that was further increased by co-mutation of the lone charged residue (Asp(192)) in the TMD thereby defining three regions that function to regulate alpha-chain transport and in a highly synergistic manner.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Robertson, MW (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-131,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mwr@scripps.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047238] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 47238] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe M, 2004, J CELL SCI, V117, P5687, DOI 10.1242/jcs.01491; Albrecht B, 2000, J IMMUNOL, V165, P5686, DOI 10.4049/jimmunol.165.10.5686; Allam JP, 2004, J INVEST DERMATOL, V123, P676, DOI 10.1111/j.0022-202X.2004.23428.x; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Baldwin TA, 2002, J BIOL CHEM, V277, P50333, DOI 10.1074/jbc.M209075200; Belden WJ, 2001, J BIOL CHEM, V276, P43040, DOI 10.1074/jbc.M108113200; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Delgado P, 2005, J EXP MED, V201, P555, DOI 10.1084/jem.20041133; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; Donnadieu E, 2003, IMMUNITY, V18, P665, DOI 10.1016/S1074-7613(03)00115-8; Draper RK, 2001, METHOD ENZYMOL, V329, P372; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fiebiger E, 2005, J EXP MED, V201, P267, DOI 10.1084/jem.20041384; Fiedler K, 1997, J BIOL CHEM, V272, P24739, DOI 10.1074/jbc.272.40.24739; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Geiger E, 2000, J ALLERGY CLIN IMMUN, V105, P150, DOI 10.1016/S0091-6749(00)90190-8; Gomez G, 2005, J IMMUNOL, V174, P5987, DOI 10.4049/jimmunol.174.10.5987; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; GREENE WC, 1985, J CELL SCI, P97; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Hasegawa S, 1999, BLOOD, V93, P2543, DOI 10.1182/blood.V93.8.2543.408k14_2543_2551; HENNECKE S, 1993, J BIOL CHEM, V268, P26607; Hudson RT, 1997, MOL BIOL CELL, V8, P1901, DOI 10.1091/mbc.8.10.1901; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kraft S, 2004, INT ARCH ALLERGY IMM, V135, P62, DOI 10.1159/000080231; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Nylander S, 1999, J IMMUNOL METHODS, V224, P69, DOI 10.1016/S0022-1759(99)00010-1; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; Saini SS, 2002, CURR OPIN IMMUNOL, V14, P694, DOI 10.1016/S0952-7915(02)00404-1; Saini SS, 2001, J ALLERGY CLIN IMMUN, V107, P832, DOI 10.1067/mai.2001.114653; Sato K, 2001, J CELL BIOL, V152, P935, DOI 10.1083/jcb.152.5.935; Schroder-Kohne S, 1998, J CELL SCI, V111, P3459; Scott M, 2004, BIOINFORMATICS, V20, P937, DOI 10.1093/bioinformatics/bth010; Seminario MC, 1999, J IMMUNOL, V162, P6893; Smith SJ, 2000, J ALLERGY CLIN IMMUN, V105, P309, DOI 10.1016/S0091-6749(00)90081-2; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Toru H, 1996, INT IMMUNOL, V8, P1367; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	66	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10448	10460		10.1074/jbc.M510751200	http://dx.doi.org/10.1074/jbc.M510751200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459334	hybrid			2022-12-27	WOS:000236594300074
J	Long, XH; Nephew, KP				Long, XH; Nephew, KP			Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; INTERMEDIATE FILAMENT; PURE-ANTIESTROGEN; ER-ALPHA; DEPENDENT DEGRADATION; NUCLEAR RECEPTORS; PROTEASOME; LIGAND; TURNOVER; STABILITY	The antiestrogen fulvestrant (ICI 182,780) causes immobilization of estrogen receptor-alpha(ER alpha) in the nuclear matrix accompanied by rapid degradation by the ubiquitin-proteasome pathway. In this study we tested the hypothesis that fulvestrant induces specific nuclear matrix protein-ER alpha interactions that mediate receptor immobilization and turnover. A glutathione S-transferase (GST)ER alpha-activating function-2 (AF2) fusion protein was used to isolate and purify receptor-interacting proteins in cell lysates prepared from human MCF-7 breast cancer cells. After SDS-PAGE and gel excision, mass spectrometry was used to identify two major ER alpha-interacting proteins, cytokeratins 8 and 18 (CK8 . CK18). We determined, using ER alpha-activating function-2 mutants, that helix 12 (H12) of ER alpha, but not its F domain, is essential for fulvestrant-induced ER alpha-CK8 and CK18 interactions. To investigate the in vivo role of H12 in fulvestrant-induced ER alpha immobilization/degradation, transient transfection assays were performed using wild type ER alpha, ER alpha with amutated H12, and ER alpha with a deleted F domain. Of those, only the ER alpha H12 mutant was resistant to fulvestrant-induced immobilization to the nuclear matrix and protein degradation. Fulvestrant treatment caused ER alpha degradation in CK8 . CK18-positive human breast cancer cells, and CK8 and CK18 depletion by small interference RNAs partially blocked fulvestrant-induced receptor degradation. Furthermore, fulvestrant-induced ER alpha degradation was not observed in CK8 or CK18-negative cancer cells, suggesting that these two intermediate filament proteins are necessary for fulvestrant-induced receptor turnover. Using an ER alpha-green fluorescent protein construct in fluorescence microscopy revealed that fulvestrant-induced cytoplasmic localization of newly synthesized receptor is mediated by its interaction with CK8 and CK18. In summary, this study provides the first direct evidence linking ER alpha immobilization and degradation to the nuclear matrix. We suggest that fulvestrant induces ER alpha to interact with CK8 and CK18, drawing the receptor into close proximity to nuclear matrix-associated proteasomes that facilitate ER alpha turnover.	Indiana Univ, Sch Med, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Nephew, KP (corresponding author), Indiana Univ, Sch Med, 302 Jordan Hall,1001 E 3rd St, Bloomington, IN 47405 USA.	knephew@indiana.edu						Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Arcangeletti C, 2000, EUR J CELL BIOL, V79, P423, DOI 10.1078/0171-9335-00059; Arcangeletti C, 1997, J STRUCT BIOL, V119, P35, DOI 10.1006/jsbi.1997.3871; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; BARRACK ER, 1987, J STEROID BIOCHEM, V27, P115, DOI 10.1016/0022-4731(87)90302-5; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Coutts AS, 1996, J CELL BIOCHEM, V63, P174, DOI 10.1002/(SICI)1097-4644(19961101)63:2<174::AID-JCB5>3.0.CO;2-V; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Fan MY, 2002, MOL ENDOCRINOL, V16, P315, DOI 10.1210/me.16.2.315; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; Fuqua SAW, 2000, CANCER RES, V60, P4026; Giamarchi C, 2002, BBA-GENE STRUCT EXPR, V1578, P12, DOI 10.1016/S0167-4781(02)00480-3; GRAHAM ML, 1990, CANCER RES, V50, P6208; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Howell A, 2000, EUR J CANCER, V36, pS87; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Iwaya K, 2003, CANCER SCI, V94, P864, DOI 10.1111/j.1349-7006.2003.tb01368.x; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; McDonnell DP, 2005, CLIN CANCER RES, V11, p871S; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; NARDULLI AM, 1986, ENDOCRINOLOGY, V119, P2038, DOI 10.1210/endo-119-5-2038; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Oesterreich S, 2001, CANCER RES, V61, P5771; OLINKCOUX M, 1994, J CELL SCI, V107, P353; Oliveira Cleida A, 2003, Reprod Biol Endocrinol, V1, P75, DOI 10.1186/1477-7827-1-75; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Peekhaus NT, 2004, J MOL ENDOCRINOL, V32, P987, DOI 10.1677/jme.0.0320987; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schaller G, 1996, CLIN CANCER RES, V2, P1879; Seo HS, 1998, INT J CANCER, V78, P760, DOI 10.1002/(SICI)1097-0215(19981209)78:6<760::AID-IJC14>3.0.CO;2-U; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu YL, 2005, MOL CELL, V18, P413, DOI 10.1016/j.molcel.2005.04.014	56	110	114	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9607	9615		10.1074/jbc.M510809200	http://dx.doi.org/10.1074/jbc.M510809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16459337	hybrid			2022-12-27	WOS:000236404700072
J	Reyes, F; Marchant, L; Norambuena, L; Nilo, R; Silva, H; Orellana, A				Reyes, F; Marchant, L; Norambuena, L; Nilo, R; Silva, H; Orellana, A			AtUTr1, a UDP-glucose/UDP-galactose transporter from Arabidopsis thaliana, is located in the endoplasmic reticulum and up-regulated by the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; GLYCOPROTEIN GLUCOSYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; IDENTIFICATION; CALNEXIN; OLIGOSACCHARIDE; PURIFICATION; RECOGNITION; EXPRESSION	The folding of glycoproteins in the endoplasmic reticulum (ER) depends on a quality control mechanism mediated by the calnexin/calreticulin cycle. During this process, continuous glucose trimming and UDP-glucose-dependent re-glucosylation of unfolded glycoproteins takes place. To ensure proper folding, increases in misfolded proteins lead to up-regulation of the components involved in quality control through a process known as the unfolded protein response (UPR). Reglucosylation is catalyzed by the ER lumenal located enzyme UDP-glucose glycoprotein glucosyltransferase, but as UDP-glucose is synthesized in the cytosol, a UDPglucose transporter is required in the calnexin/calreticulin cycle. Even though such a transporter has been hypothesized, no protein playing this role in the ER yet has been identified. Here we provide evidence that AtUTr1, a UDP-galactose/glucose transporter from Arabidopsis thaliana, responds to stimuli that trigger the UPR increasing its expression around 9-fold. The accumulation of AtUTr1 transcript is accompanied by an increase in the level of the AtUTr1 protein. Moreover, subcellular localization studies indicate that AtUTr1 is localized in the ER of plant cells. We reasoned that an impairment in AtUTr1 expression should perturb the calnexin/calreticulin cycle leading to an increase in misfolded protein and triggering the UPR. Toward that end, we analyzed an AtUTr1 insertional mutant and found an up-regulation of the ER chaperones BiP and calnexin, suggesting that these plants may be constitutively activating the UPR. Thus, we propose that in A. thaliana, AtUTr1 is the UDP-glucose transporter involved in quality control in the ER.	Univ Chile, Fac Sci, Plant Cell Biol Millennium Nucleus, Santiago, Chile; Univ Chile, Fac Sci, Grad Sch, Santiago, Chile; Univ Andres Bello, Ctr Plant Biotechnol, Santiago, Chile	Universidad de Chile; Universidad de Chile; Universidad Andres Bello	Orellana, A (corresponding author), Univ Chile, Fac Sci, Plant Cell Biol Millennium Nucleus, Casilla 653, Santiago, Chile.	aorellana@unab.cl	Orellana, Ariel/E-2166-2014; Norambuena, Lorena/I-1248-2013; Poyanco, Ricardo Nilo/AAJ-8006-2021; Silva, Herman P/C-7252-2012; Orellana, Ariel/AAE-4866-2021	Orellana, Ariel/0000-0002-9243-808X; Norambuena, Lorena/0000-0002-6031-2394; Poyanco, Ricardo Nilo/0000-0003-3041-7539; Silva, Herman P/0000-0003-1007-7442; Orellana, Ariel/0000-0002-9243-808X				Baldwin TC, 2001, PLANT CELL, V13, P2283, DOI 10.1105/tpc.13.10.2283; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Boisson M, 2001, EMBO J, V20, P1010, DOI 10.1093/emboj/20.5.1010; BOLLAG DM, 1993, PROTEIN METHODS, P184; BOYCE JM, 1994, PLANT PHYSIOL, V106, P1691, DOI 10.1104/pp.106.4.1691; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRISKIN DP, 1987, METHOD ENZYMOL, V148, P542; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; DENECKE J, 1991, PLANT CELL, V3, P1025, DOI 10.1105/tpc.3.9.1025; Dhugga KS, 1997, P NATL ACAD SCI USA, V94, P7679, DOI 10.1073/pnas.94.14.7679; Fanchiotti S, 1998, J CELL BIOL, V143, P625, DOI 10.1083/jcb.143.3.625; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; FONTES EBP, 1991, PLANT CELL, V3, P483, DOI 10.1105/tpc.3.5.483; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hodges T K, 1974, Methods Enzymol, V32, P392; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; Iwata Y, 2005, P NATL ACAD SCI USA, V102, P5280, DOI 10.1073/pnas.0408941102; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kamauchi S, 2005, FEBS J, V272, P3461, DOI 10.1111/j.1742-4658.2005.04770.x; Kato N, 2002, PLANT PHYSIOL, V129, P931, DOI 10.1104/pp.005496; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Martinez IM, 2003, PLANT CELL, V15, P561, DOI 10.1105/tpc.007609; Munoz P, 1996, PLANT PHYSIOL, V112, P1585, DOI 10.1104/pp.112.4.1585; Nakanishi H, 2001, YEAST, V18, P543, DOI 10.1002/yea.707; Nelson DE, 1997, PLANT PHYSIOL, V114, P29, DOI 10.1104/pp.114.1.29; Norambuena L, 2005, PLANTA, V222, P521, DOI 10.1007/s00425-005-1557-x; Norambuena L, 2002, J BIOL CHEM, V277, P32923, DOI 10.1074/jbc.M204081200; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Parinov S, 1999, PLANT CELL, V11, P2263, DOI 10.1105/tpc.11.12.2263; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Silva H, 1999, MOL PLANT MICROBE IN, V12, P1053, DOI 10.1094/MPMI.1999.12.12.1053; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; Steinhauser D, 2004, BIOINFORMATICS, V20, P3647, DOI 10.1093/bioinformatics/bth398; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Vanzin GF, 2002, P NATL ACAD SCI USA, V99, P3340, DOI 10.1073/pnas.052450699	46	39	41	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9145	9151		10.1074/jbc.M512210200	http://dx.doi.org/10.1074/jbc.M512210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467298	hybrid			2022-12-27	WOS:000236404700020
J	Asante-Appiah, E; Patel, S; Desponts, C; Taylor, JM; Lau, C; Dufresne, C; Therien, M; Friesen, R; Becker, JW; Leblanc, Y; Kennedy, BP; Scapin, G				Asante-Appiah, E; Patel, S; Desponts, C; Taylor, JM; Lau, C; Dufresne, C; Therien, M; Friesen, R; Becker, JW; Leblanc, Y; Kennedy, BP; Scapin, G			Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURES; INSULIN SENSITIVITY; 1B; REFINEMENT; POTENT; DEPHOSPHORYLATION; DISCOVERY; SUBSTRATE; RECEPTOR; REVEALS	PTP-1B represents an attractive target for the treatment of type 2 diabetes and obesity. Given the role that protein phosphatases play in the regulation of many biologically relevant processes, inhibitors against PTP-1B must be not only potent, but also selective. It has been extremely difficult to synthesize inhibitors that are selective over the highly homologous TCPTP. We have successfully exploited the conservative Leu(119) to Val substitution between the two enzymes to synthesize a PTP-1B inhibitor that is an order of magnitude more selective over TCPTP. Structural analyses of PTP1B/inhibitor complexes show a conformation-assisted inhibition mechanism as the basis for selectivity. Such an inhibitory mechanism may be applicable to other homologous enzymes.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ H9R 4P8, Canada; Merck & Co Inc, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Asante-Appiah, E (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	ernest_asanteappiah@merck.com						AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Asante-Appiah E, 2002, BIOCHEMISTRY-US, V41, P9043, DOI 10.1021/bi0259554; Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Erlanson DA, 2003, J AM CHEM SOC, V125, P5602, DOI 10.1021/ja034440c; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HOWARD AJ, 2001, CRYSTALLOGRAPHIC COM, V7, P150; Huang Z, 1999, J BIOMOL SCREEN, V4, P327, DOI 10.1177/108705719900400608; Iversen LF, 2002, J BIOL CHEM, V277, P19982, DOI 10.1074/jbc.M200567200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lau CK, 2004, BIOORG MED CHEM LETT, V14, P1043, DOI 10.1016/j.bmcl.2003.11.076; Liu G, 2003, J MED CHEM, V46, P2093, DOI 10.1021/jm0205696; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Romsicki Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P40, DOI 10.1016/S0003-9861(03)00178-4; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Scapin G, 2003, BIOCHEMISTRY-US, V42, P11451, DOI 10.1021/bi035098j; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; Xin ZL, 2003, BIOORG MED CHEM LETT, V13, P1887, DOI 10.1016/S0960-894X(03)00302-0; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	39	38	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8010	8015		10.1074/jbc.M511827200	http://dx.doi.org/10.1074/jbc.M511827200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407290	hybrid			2022-12-27	WOS:000236031000037
J	Surjit, M; Oberoi, R; Kumar, R; Lal, SK				Surjit, M; Oberoi, R; Kumar, R; Lal, SK			Enhanced alpha(1) microglobulin secretion from hepatitis E virus ORF3-expressing human hepatoma cells is mediated by the tumor susceptibility gene 101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORF3 PROTEIN; UBIQUITIN LIGASE; VP40 PROTEIN; ESCRT-I; TSG101; ALPHA(1)-MICROGLOBULIN; INTERACTS; COMPLEX; DOMAIN; INTERNALIZATION	Viruses are known to exploit the host cell machinery for their benefit during different stages of their life cycle within the infected host. One of the major challenges for a virus during the early stages of infection is to escape recognition by the host immune system. Viruses have adopted many novel strategies to evade the host immune response or to create an immune suppressed environment. An earlier study in our laboratory has demonstrated that the ORF3 protein of the hepatitis E virus expedites the secretion of alpha(1) microglobulin, an immunosuppressant molecule. Based on this observation, we proposed that enhanced secretion of alpha(1) microglobulin may help maintain an immunosuppressed milieu around the infected hepatocyte (Tyagi, S., Surjit, M., Roy, A. K., Jameel, S., and Lal, S. K. ( 2004) J. Biol. Chem. 279, 29308 - 29319). In the present study, we discovered that the ability of the ORF3 protein to expedite alpha(1) microglobulin secretion is attributed to the PSAP motif present at the C terminus of the former. The ORF3 protein was able to associate with the tumor susceptibility gene 101 (TSG101) through the PSAP motif. Further, a PSAP motif-mutated ORF3 protein was unable to associate with TSG101 and also lost its ability to enhance the secretion of alpha(1) microglobulin. In addition, the ORF3 protein was found to associate simultaneously with TSG101 and alpha(1) microglobulin because all three of them were co-precipitated as a ternary complex. Finally, a dominant negative mutant of the VPS4 protein was shown to block the enhanced alpha(1) microglobulin secretion in ORF3-expressing hepatocytes. These results suggest a mechanism by which the ORF3 protein exploits the endosomal sorting machinery to enhance the secretion of an immunosuppressant molecule (alpha(1) microglobulin) from the cultured hepatocytes.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Lal, SK (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, Aruna Asaf Ali Rd, New Delhi 110067, India.	sunillal@icgeb.res.in						Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P172, DOI 10.1016/S0167-4838(00)00157-6; Amara A, 2003, J CELL BIOL, V162, P371, DOI 10.1083/jcb.200307062; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BEGGARD T, 1998, J HISTOCHEM CYTOCHEM, V46, P887; Beyer A, 2003, GENE, V305, P47, DOI 10.1016/S0378-1119(02)01205-2; Goff A, 2003, J VIROL, V77, P9173, DOI 10.1128/JVI.77.17.9173-9182.2003; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; James P, 1996, GENETICS, V144, P1425; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; LOGDBERG L, 1981, SCAND J IMMUNOL, V13, P383, DOI 10.1111/j.1365-3083.1981.tb00148.x; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; MENDEZ E, 1986, P NATL ACAD SCI USA, V83, P1472, DOI 10.1073/pnas.83.5.1472; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stuchell MD, 2004, J BIOL CHEM, V279, P36059, DOI 10.1074/jbc.M405226200; Timmins J, 2003, J MOL BIOL, V326, P493, DOI 10.1016/S0022-2836(02)01406-7; Tyagi S, 2004, J BIOL CHEM, V279, P29308, DOI 10.1074/jbc.M402017200; Tyagi S, 2002, J BIOL CHEM, V277, P22759, DOI 10.1074/jbc.M200185200; Tyagi S, 2001, J VIROL, V75, P2493, DOI 10.1128/JVI.75.5.2493-2498.2001; Wester L, 1997, PROTEIN EXPRES PURIF, V11, P95, DOI 10.1006/prep.1997.0760; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997	29	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8135	8142		10.1074/jbc.M509568200	http://dx.doi.org/10.1074/jbc.M509568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407257	hybrid			2022-12-27	WOS:000236031000051
J	Allen, JM; Bateman, JF; Hansen, U; Wilson, R; Bruckner, P; Owens, RT; Sasaki, T; Timpl, R; Fitzgerald, J				Allen, JM; Bateman, JF; Hansen, U; Wilson, R; Bruckner, P; Owens, RT; Sasaki, T; Timpl, R; Fitzgerald, J			WARP is a novel multimeric component of the chondrocyte pericellular matrix that interacts with perlecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; SITE-DIRECTED MUTAGENESIS; FIBROBLAST-GROWTH-FACTOR; BASEMENT-MEMBRANE; PROTEIN CORE; CARTILAGE MATRIX; DOMAIN I; CELL-ADHESION; COLLAGEN; BINDS	WARP is a novel member of the von Willebrand factor A domain superfamily of extracellular matrix proteins that is expressed by chondrocytes. WARP is restricted to the presumptive articular cartilage zone prior to joint cavitation and to the articular cartilage and fibrocartilaginous elements in the joint, spine, and sternum during mouse embryonic development. In mature articular cartilage, WARP is highly specific for the chondrocyte pericellular microenvironment and co-localizes with perlecan, a prominent component of the chondrocyte pericellular region. WARP is present in the guanidine-soluble fraction of cartilage matrix extracts as a disulfide-bonded multimer, indicating that WARP is a strongly interacting component of the cartilage matrix. To investigate how WARP is integrated with the pericellular environment, we studied WARP binding to mouse perlecan using solid phase and surface plasmon resonance analysis. WARP interacts with domain III-2 of the perlecan core protein and the heparan sulfate chains of the perlecan domain I with K-D values in the low nanomolar range. We conclude that WARP forms macromolecular structures that interact with perlecan to contribute to the assembly and/or maintenance of "permanent" cartilage structures during development and in mature cartilages.	Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia; Univ Hosp Muenster, Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany; LifeCell Corp, Branchburg, NJ 08876 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; University of Munster; Max Planck Society	Fitzgerald, J (corresponding author), Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Matrix Biol Res Unit, Flemington Rd, Parkville, Vic 3052, Australia.	j.fitzgerald@mcri.edu.au	Wilson, Richard/H-8429-2012; Bruckner, Peter/F-4817-2019	Wilson, Richard/0000-0003-0152-4394; Bruckner, Peter/0000-0002-5566-5611; Bateman, John/0000-0001-8542-0730				BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Braissant O, 1998, BIOCHEMICA, V1, P10; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Costell M, 1996, FEBS LETT, V396, P127, DOI 10.1016/0014-5793(96)01082-4; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Fitzgerald J, 2003, FEBS LETT, V552, P91, DOI 10.1016/S0014-5793(03)00968-2; Fitzgerald J, 2002, FEBS LETT, V517, P61, DOI 10.1016/S0014-5793(02)02579-6; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; French MM, 2002, J BONE MINER RES, V17, P48, DOI 10.1359/jbmr.2002.17.1.48; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Govindraj P, 2002, J BIOL CHEM, V277, P19461, DOI 10.1074/jbc.M200786200; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; Hohenester E, 2002, MATRIX BIOL, V21, P115, DOI 10.1016/S0945-053X(01)00191-3; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Melrose J, 2003, J HISTOCHEM CYTOCHEM, V51, P1331, DOI 10.1177/002215540305101010; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; Poole CA, 1997, J ANAT, V191, P1, DOI 10.1046/j.1469-7580.1997.19110001.x; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Tiedemann K, 2005, J BIOL CHEM, V280, P11404, DOI 10.1074/jbc.M409882200; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433	44	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7341	7349		10.1074/jbc.M513746200	http://dx.doi.org/10.1074/jbc.M513746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407285	hybrid			2022-12-27	WOS:000236030900053
J	Hansch, R; Lang, C; Riebeseel, E; Lindigkeit, R; Gessler, A; Rennenberg, H; Mendel, RR				Hansch, R; Lang, C; Riebeseel, E; Lindigkeit, R; Gessler, A; Rennenberg, H; Mendel, RR			Plant sulfite oxidase as novel producer of H2O2 - Combination of enzyme catalysis with a subsequent non-enzymatic reaction step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; SULFUR-DIOXIDE; ARABIDOPSIS-THALIANA; PROSTHETIC GROUPS; OXYGEN-EXCHANGE; PURIFICATION; METABOLISM; OXIDATION; IDENTIFICATION; LOCALIZATION	Sulfite oxidase (EC 1.8.3.1) from the plant Arabidopsis thaliana is the smallest eukaryotic molybdenum enzyme consisting of a molybdenum cofactor-binding domain but lacking the heme domain that is known from vertebrate sulfite oxidase. While vertebrate sulfite oxidase is a mitochondrial enzyme with cytochrome c as the physiological electron acceptor, plant sulfite oxidase is localized in peroxisomes and does not react with cytochrome c. Here we describe results that identified oxygen as the terminal electron acceptor for plant sulfite oxidase and hydrogen peroxide as the product of this reaction in addition to sulfate. The latter finding might explain the peroxisomal localization of plant sulfite oxidase. O-18 labeling experiments and the use of catalase provided evidence that plant sulfite oxidase combines its catalytic reaction with a subsequent non-enzymatic step where its reaction product hydrogen peroxide oxidizes another molecule of sulfite. In vitro, for each catalytic cycle plant SO will bring about the oxidation of two molecules of sulfite by one molecule of oxygen. In the plant, sulfite oxidase could be responsible for removing sulfite as a toxic metabolite, which might represent a means to protect the cell against excess of sulfite derived from SO2 gas in the atmosphere ( acid rain) or during the decomposition of sulfur-containing amino acids. Finally we present a model for the metabolic interaction between sulfite and catalase in the peroxisome.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Dept Pharmaceut Biol, D-38023 Braunschweig, Germany; Univ Freiburg, Dept Tree Physiol, D-79085 Freiburg, Germany	Braunschweig University of Technology; Braunschweig University of Technology; University of Freiburg	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	r.mendel@tu-bs.de	Rennenberg, Heinz/A-2083-2013; Gessler, Arthur/C-7121-2008	Gessler, Arthur/0000-0002-1910-9589; Hansch, Robert/0000-0003-1310-8419; Rennenberg, Heinz/0000-0001-6224-2927				Clegg SM, 2001, ATMOS CHEM PHYS, V1, P73, DOI 10.5194/acp-1-73-2001; COHEN HJ, 1971, J BIOL CHEM, V246, P367; COHEN HJ, 1972, J BIOL CHEM, V247, P7759; COHEN HJ, 1971, J BIOL CHEM, V246, P359; Eilers T, 2001, J BIOL CHEM, V276, P46989, DOI 10.1074/jbc.M108078200; FREDERICK SE, 1969, J CELL BIOL, V43, P343, DOI 10.1083/jcb.43.2.343; Garrett RM, 1998, P NATL ACAD SCI USA, V95, P6394, DOI 10.1073/pnas.95.11.6394; GARSED SG, 1977, NEW PHYTOL, V78, P111, DOI 10.1111/j.1469-8137.1977.tb01549.x; Heber U, 1998, INT REV CYTOL, V177, P255; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Horner DA, 2003, INORG CHEM, V42, P1884, DOI 10.1021/ic020692n; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; Karpinski S, 1999, SCIENCE, V284, P654, DOI 10.1126/science.284.5414.654; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Laloi C, 2004, CURR OPIN PLANT BIOL, V7, P323, DOI 10.1016/j.pbi.2004.03.005; Leustek Thomas, 2002, Arabidopsis Book, V1, pe0017, DOI 10.1199/tab.0017; Lindigkeit R, 1997, EUR J BIOCHEM, V245, P626, DOI 10.1111/j.1432-1033.1997.00626.x; MACLEOD RM, 1961, J BIOL CHEM, V236, P1841; MCARDLE JV, 1983, J PHYS CHEM-US, V87, P5425, DOI 10.1021/j150644a024; Mills GA, 1940, J AM CHEM SOC, V62, P2833, DOI 10.1021/ja01867a058; MISZALSKI Z, 1992, Z NATURFORSCH C, V47, P360; Nag S, 2000, PLANT SCI, V157, P157, DOI 10.1016/S0168-9452(00)00281-8; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; Neill S, 2002, CURR OPIN PLANT BIOL, V5, P388, DOI 10.1016/S1369-5266(02)00282-0; Nowak K, 2004, PLANT CELL PHYSIOL, V45, P1889, DOI 10.1093/pcp/pch212; Rost M, 1998, J BIOLUM CHEMILUM, V13, P355, DOI 10.1002/(SICI)1099-1271(199811/12)13:6<355::AID-BIO502>3.0.CO;2-L; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.104.046755; Schrader N, 2003, STRUCTURE, V11, P1251, DOI 10.1016/j.str.2003.09.001; Seinfeld J.H, 1998, WILEY INT, V40, P1326, DOI [10.1080/00139157.1999.10544295, DOI 10.1080/00139157.1999.10544295]; vanderKooij TAW, 1997, NEW PHYTOL, V135, P101, DOI 10.1046/j.1469-8137.1997.00619.x; Veljovic-Jovanovic S, 1998, PLANT CELL PHYSIOL, V39, P1203, DOI 10.1093/oxfordjournals.pcp.a029321; Veljovic-Jovanovic SD, 2001, PLANT PHYSIOL, V127, P426, DOI 10.1104/pp.010141; Wilson HL, 2004, J BIOL CHEM, V279, P15105, DOI 10.1074/jbc.M314288200; Winner W. E., 1985, Sulfur dioxide and vegetation. Physiology, ecology, and policy issues.	34	99	109	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6884	6888		10.1074/jbc.M513054200	http://dx.doi.org/10.1074/jbc.M513054200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407262	hybrid			2022-12-27	WOS:000236030800086
J	Arima, J; Uesugi, Y; Uraji, M; Yatsuhiro, S; Tsuboi, S; Iwabuchi, M; Hatanaka, T				Arima, J; Uesugi, Y; Uraji, M; Yatsuhiro, S; Tsuboi, S; Iwabuchi, M; Hatanaka, T			Modulation of Streptomyces leucine aminopeptidase by calcium - Identification and functional analysis of key residues in activation and stabilization by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMERCIAL PREPARATION PRONASE; AEROMONAS-PROTEOLYTICA AMINOPEPTIDASE; GRISEUS AMINOPEPTIDASE; K-1 STRAIN; CRYSTALLOGRAPHIC CHARACTERIZATION; SEPTATUS TH-2; BINDING; ENZYMES; ACID; PURIFICATION	Streptomyces griseus leucine aminopeptidase (SGAP), which has two zinc atoms in its active site, is clinically important as a model for understanding the structure and mechanism of action of other metallopeptidases. SGAP is a calcium-activated and calcium-stabilized enzyme, and its activation by calcium correlates with substrate specificity. In our previous study, we found a non-calcium-modulated leucine aminopeptidase secreted by Streptomyces septatus, the primary structure of which showed 71% identity with SGAP. In this study, we constructed chimeras of SGAP and S. septatus aminopeptidase by using an in vivo DNA shuffling system and several mutant enzymes by site-directed mutagenesis to identify the key residues in this modulation by calcium. We identified the key residues Asp-173 and Asp-174 of SGAP associated with both SGAP activation and stabilization by calcium. We also showed that the known calcium-binding site, which is composed of Asp-3, Ile-4, Asp-262, and Asp-266 of SGAP, only contributes to SGAP stabilization by calcium. Furthermore, we identified an important residue, Glu-196, that functions in cooperation with Asp-173, Asp-174, and calcium to increase the catalytic activity of SGAP.	Res Inst Biol Sci, Okayama 7161241, Japan; Shujitsu Univ, Sch Pharm, Dept Biol Pharm, Okayama 7038516, Japan		Hatanaka, T (corresponding author), Res Inst Biol Sci, 7549-1 Kibichuo Cho, Okayama 7161241, Japan.	hatanaka@bio-ribs.com						ALLAIN CC, 1974, CLIN CHEM, V20, P470; Arima J, 2005, APPL ENVIRON MICROB, V71, P7229, DOI 10.1128/AEM.71.11.7229-7235.2005; Arima J, 2004, BIOCHEM BIOPH RES CO, V317, P531, DOI 10.1016/j.bbrc.2004.03.082; ARIMA J, 2006, IN PRESS APPL MICROB; BENMEIR D, 1993, EUR J BIOCHEM, V212, P107, DOI 10.1111/j.1432-1033.1993.tb17639.x; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; BURLEY SK, 1992, J MOL BIOL, V224, P113, DOI 10.1016/0022-2836(92)90580-D; Bzymek KP, 2004, J BIOL CHEM, V279, P31018, DOI 10.1074/jbc.M404035200; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; De Paola CC, 1999, BIOCHEMISTRY-US, V38, P9048, DOI 10.1021/bi9900572; Desmarais WT, 2002, STRUCTURE, V10, P1063, DOI 10.1016/S0969-2126(02)00810-9; Fundoiano-Hershcovitz Y, 2004, FEBS LETT, V571, P192, DOI 10.1016/j.febslet.2004.07.001; Gilboa R, 2001, PROTEINS, V44, P490, DOI 10.1002/prot.1115; Gilboa R, 2000, ACTA CRYSTALLOGR D, V56, P551, DOI 10.1107/S0907444900002420; Greenblatt HM, 1997, J MOL BIOL, V265, P620, DOI 10.1006/jmbi.1996.0729; Kato J, 2002, J BACTERIOL, V184, P6016, DOI 10.1128/JB.184.21.6016-6025.2002; KLOTZ IM, 1981, BIOCHEMISTRY-US, V10, P3065; Lee BI, 2003, J BIOL INORG CHEM, V8, P341, DOI 10.1007/s00775-002-0421-8; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; Maras B, 1996, EUR J BIOCHEM, V236, P843, DOI 10.1111/j.1432-1033.1996.00843.x; MASSEY V, 1967, J BIOL CHEM, V242, P1259; Mishima N, 1997, BIOTECHNOL PROGR, V13, P864, DOI 10.1021/bp970084o; Mori K, 2005, APPL ENVIRON MICROB, V71, P754, DOI 10.1128/AEM.71.2.754-760.2005; Mukaihara T, 1997, GENETICS, V145, P563; Papir G, 1998, EUR J BIOCHEM, V258, P313, DOI 10.1046/j.1432-1327.1998.2580313.x; Park TJ, 2002, BBA-PROTEINS PROTEOM, V1599, P36, DOI 10.1016/S1570-9639(02)00379-5; POST LE, 1980, J BIOL CHEM, V255, P4660; Prescott J M, 1976, Methods Enzymol, V45, P530; SANDERINK GJ, 1988, J CLIN CHEM CLIN BIO, V26, P795; SPUNGIN A, 1989, EUR J BIOCHEM, V183, P471, DOI 10.1111/j.1432-1033.1989.tb14952.x; Stamper C, 2001, BIOCHEMISTRY-US, V40, P7035, DOI 10.1021/bi0100891; Stamper CC, 2004, BIOCHEMISTRY-US, V43, P9620, DOI 10.1021/bi049126p; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Taylor A, 1996, AMINOPEPTIDASES, P1; VOSBECK KD, 1973, J BIOL CHEM, V248, P6029; VOSBECK KD, 1975, J BIOL CHEM, V250, P3981; VOSBECK KD, 1978, J BIOL CHEM, V253, P257; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5885	5894		10.1074/jbc.M509025200	http://dx.doi.org/10.1074/jbc.M509025200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407307	hybrid			2022-12-27	WOS:000235568900069
J	Mitaksov, V; Fremont, DH				Mitaksov, V; Fremont, DH			Structural definition of the H-2K(d) peptide-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELLS RECOGNIZE; 3-DIMENSIONAL STRUCTURE; CIRCUMSPOROZOITE PROTEIN; ANTIGENIC PEPTIDES; CRYSTAL-STRUCTURES; VIRAL PEPTIDES; COMPLEX; EPITOPE; IDENTIFICATION	Classic major histocompatibility complex (MHC) proteins associate with antigen- and self-derived peptides in an allele-specific manner. Herein we present the crystal structure of the MHC class I protein H-2K(d) (K-d) expressed by BALB/c mice in complex with an antigenic peptide derived from influenza A/PR/8/34 nucleoprotein ( Flu, residues 147-155, TYQRTRALV). Analysis of our structure in conjunction with the sequences of naturally processed epitopes provides a comprehensive understanding of the dominant K-d peptide-binding motif. We find that Flu residues Tyr(P2), Thr(P5), and Val(P9) are sequestered into the B, C, and F pockets of the K-d groove, respectively. The shape and chemistry of the polymorphic B pocket make it an optimal binding site for the side chain of Tyr(P2) as the dominant anchoring residue of nonameric peptides. The non-polar F pocket limits the amino acid repertoire at P9 to hydrophobic residues such as Ile, Leu, or Val, whereas the C pocket restricts the size of the P5-anchoring side chain. We also show that Flu is accommodated in the complex through an unfavorable kink in the otherwise extended peptide backbone due to the presence of a prominent ridge in the K-d groove. Surprisingly, this backbone conformation is strikingly similar to D-b-presented peptides despite the fact that these proteins employ distinct motif-anchoring strategies. The results presented in this study provide a solid foundation for the understanding of K-d-restricted antigen presentation and recognition events.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Fremont, DH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	fremont@immunology.wustl.edu		Fremont, Daved/0000-0002-8544-2689	NIGMS NIH HHS [GM 62414-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1993, J IMMUNOL, V151, P3569; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balendiran GK, 1997, P NATL ACAD SCI USA, V94, P6880, DOI 10.1073/pnas.94.13.6880; Bhasin M, 2003, BIOINFORMATICS, V19, P665, DOI 10.1093/bioinformatics/btg055; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brusic V, 1998, NUCLEIC ACIDS RES, V26, P368, DOI 10.1093/nar/26.1.368; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Ciatto C, 2001, J MOL BIOL, V312, P1059, DOI 10.1006/jmbi.2001.5016; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; EBERL G, 1993, INT IMMUNOL, V5, P1489, DOI 10.1093/intimm/5.11.1489; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; HARDING CV, 1995, J IMMUNOL, V155, P1767; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; Ikeda H, 1997, P NATL ACAD SCI USA, V94, P6375, DOI 10.1073/pnas.94.12.6375; Jones EY, 1997, CURR OPIN IMMUNOL, V9, P75, DOI 10.1016/S0952-7915(97)80162-8; Kersh GJ, 2001, J IMMUNOL, V166, P3345, DOI 10.4049/jimmunol.166.5.3345; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MARYANSKI JL, 1991, INT IMMUNOL, V3, P1035, DOI 10.1093/intimm/3.10.1035; Matsui K, 2003, INT IMMUNOL, V15, P797, DOI 10.1093/intimm/dxg078; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Miley MJ, 2004, J EXP MED, V200, P1445, DOI 10.1084/jem.20040217; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Nagata Y, 1997, J IMMUNOL, V159, P1336; Natarajan K, 1999, Rev Immunogenet, V1, P32; Ostrov DA, 2002, J IMMUNOL, V168, P283, DOI 10.4049/jimmunol.168.1.283; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; QUESNEL A, 1995, PEPTIDE RES, V8, P44; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; Spaulding AC, 1999, J VIROL, V73, P398, DOI 10.1128/JVI.73.1.398-403.1999; Suri A, 2006, EUR J IMMUNOL, V36, P544, DOI 10.1002/eji.200526235; Tamura M, 1998, J VIROL, V72, P9404, DOI 10.1128/JVI.72.11.9404-9406.1998; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; Tissot AC, 2000, J MOL BIOL, V302, P873, DOI 10.1006/jmbi.2000.4501; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; WALLNY HJ, 1992, INT IMMUNOL, V4, P1085, DOI 10.1093/intimm/4.10.1085; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; Wilson I A, 1993, Semin Immunol, V5, P75, DOI 10.1006/smim.1993.1011; Wong FS, 2002, P NATL ACAD SCI USA, V99, P5551, DOI 10.1073/pnas.072037299; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; YOUNG ACM, 1995, FASEB J, V9, P26, DOI 10.1096/fasebj.9.1.7821756	60	26	28	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10618	10625		10.1074/jbc.M510511200	http://dx.doi.org/10.1074/jbc.M510511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16473882	hybrid			2022-12-27	WOS:000236594300094
J	Hanson, SM; Francis, DJ; Vishnivetskiy, SA; Klug, CS; Gurevich, VV				Hanson, SM; Francis, DJ; Vishnivetskiy, SA; Klug, CS; Gurevich, VV			Visual arrestin binding to microtubules involves a distinct conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; RHODOPSIN; EXPRESSION; MECHANISM; TAU; LOCALIZATION; SELECTIVITY; MUTAGENESIS; ACTIVATION	Recently we found that visual arrestin binds microtubules and that this interaction plays an important role in arrestin localization in photoreceptor cells. Here we use site-directed mutagenesis and spin labeling to explore the molecular mechanism of this novel regulatory interaction. The microtubule binding site maps to the concave sides of the two arrestin domains, overlapping with the rhodopsin binding site, which makes arrestin interactions with rhodopsin and microtubules mutually exclusive. Arrestin interaction with microtubules is enhanced by several "activating mutations" and involves multiple positive charges and hydrophobic elements. The comparable affinity of visual arrestin for microtubules and unpolymerized tubulin (K-D > 40 mu M and > 65 mu M, respectively) suggests that the arrestin binding site is largely localized on the individual alpha beta-dimer. The changes in the spin-spin interaction of a double-labeled arrestin indicate that the conformation of microtubule-bound arrestin differs from that of free arrestin in solution. In sharp contrast to rhodopsin, where tight binding requires an extended interdomain hinge, arrestin binding to microtubules is enhanced by deletions in this region, suggesting that in the process of microtubule binding the domains may move in the opposite direction. Thus, microtubule and rhodopsin binding induce different conformational changes in arrestin, suggesting that arrestin assumes three distinct conformations in the cell, likely with different functional properties.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Medical College of Wisconsin; Vanderbilt University	Gurevich, VV (corresponding author), Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.	vsevolod.gurevich@vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008; Vishnivetskiy, Sergey/AAJ-8661-2020	Gurevich, Vsevolod/0000-0002-3950-5351; 	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097, T32GM007628, R56GM070642, R01GM070642] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011500, R01 EY011500-10, EY11500] Funding Source: Medline; NIAID NIH HHS [R01 AI058024-02, AI58024, R01 AI058024] Funding Source: Medline; NIGMS NIH HHS [GM63097, R56 GM070642, R01 GM063097, R01 GM070642, GM07628, GM70642, R01 GM070642-03, R01 GM063097-05] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Amos LA, 2000, CURR OPIN STRUC BIOL, V10, P236, DOI 10.1016/S0959-440X(00)00070-1; ARSHAVSKY VY, 2003, SCI STKE, pPE43; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Eckmiller MS, 2000, VISUAL NEUROSCI, V17, P711, DOI 10.1017/S0952523800175054; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 2006, IN PRESS PHARM THER; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hanson SM, 2006, J BIOL CHEM, V281, P3458, DOI 10.1074/jbc.M512148200; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Imamoto Y, 2003, BIOPHYS J, V85, P1186, DOI 10.1016/S0006-3495(03)74554-8; Klug Candice S., 2004, V24, P269; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; Nair KS, 2004, J BIOL CHEM, V279, P41240, DOI 10.1074/jbc.M406768200; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Osawa S, 2000, METHOD ENZYMOL, V315, P411; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Seitz A, 2002, EMBO J, V21, P4896, DOI 10.1093/emboj/cdf503; Shilton BH, 2002, EUR J BIOCHEM, V269, P3801, DOI 10.1046/j.1432-1033.2002.03071.x; SMITH WC, 1994, J BIOL CHEM, V269, P15407; Strissel KJ, 2006, J NEUROSCI, V26, P1146, DOI 10.1523/JNEUROSCI.4289-05.2006; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WALLIS KT, 1993, J BIOL CHEM, V268, P15158	47	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9765	9772		10.1074/jbc.M510738200	http://dx.doi.org/10.1074/jbc.M510738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461350	Green Accepted, hybrid			2022-12-27	WOS:000236404700089
J	Jiang, Y; Yan, YB; Zhou, HM				Jiang, Y; Yan, YB; Zhou, HM			Polyvinylpyrrolidone 40 assists the refolding of bovine carbonic anhydrase B by accelerating the refolding of the first molten globule intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE; PROTEIN AGGREGATION; THERMAL-STABILITY; MOLECULAR-WEIGHT; GROWTH-HORMONE; FOLDING AIDS; MECHANISM; DETERGENT; STABILIZATION; DENATURATION	Protecting proteins from aggregation is one of the most important issues in both protein science and protein engineering. In this research, the mechanism of enhancing the refolding of guanidine hydrochloride-denatured carbonic anhydrase B by polyvinylpyrrolidone 40 (PVP40) was studied by both kinetic and equilibrium refolding experiments. The reactivation and refolding kinetics indicated that the rate constant of refolding the first refolding intermediate (I-1) to the second one (I-2) is promoted by the addition of PVP. Fluorescence quenching studies further indicated that PVP could bind to the aggregation-prone species I-1, resulting in the protection of the exposed hydrophobic surface, a minimization of the protein surface, and more importantly, an increase of the refolding rate of I-1. These properties were quite different from those of poly(ethylene glycol) (PEG), which has been shown to have a strong and stoichiometric binding to I-1 and does not interfere with the refolding pathway. Unlike PEG, the binding of PVP to I-1 does not block the aggregation pathway directly but decreases the energy barrier for I-1 to refold to I-2 and thus reduces the accumulation of I-1. These results suggested that PVP works by a quite different mechanism from those well established ones in chaperones and chemical promoters. PVP is more like a folding catalyst rather than a chemical chaperone. The distinct mechanism of enhancing protein aggregation by PVP is expected to facilitate the attempt to develop new chemical compounds as well as new strategies to protect proteins from aggregation.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Minist Educ, Prot Sci Lab, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University	Yan, YB (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	ybyan@tsinghua.edu.cn; zhm-dbs@tsinghua.edu.cn	Yan, Yong-Bin/A-4282-2008	Yan, Yong-Bin/0000-0002-8565-3558				Bolen D W, 2001, Methods Mol Biol, V168, P17; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHARMAN SA, 1993, PHARM RES-DORDR, V10, P954, DOI 10.1023/A:1018994102218; Chi EY, 2003, PHARM RES-DORDR, V20, P1325, DOI 10.1023/A:1025771421906; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; CLELAND JL, 1992, J BIOL CHEM, V267, P3147; CLELAND JL, 1992, BIOTECHNOL PROGR, V8, P97, DOI 10.1021/bp00014a002; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; CLELAND JL, 1991, ACS SYM SER, V470, P169; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; FIELDS GB, 1992, J PHYS CHEM-US, V96, P3974, DOI 10.1021/j100189a013; Finke JM, 2000, BIOCHEMISTRY-US, V39, P575, DOI 10.1021/bi991518m; GOMBOTZ WR, 1994, PHARMACEUT RES, V11, P624, DOI 10.1023/A:1018903624373; HARRISON RAP, 1988, BIOCHEM J, V252, P875, DOI 10.1042/bj2520875; Jackson C., 1989, J APPL POLYM SCI APP, V43, P99; Jonasson P, 1997, BIOCHEMISTRY-US, V36, P5142, DOI 10.1021/bi961882a; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kurganov BI, 2002, BIOCHEMISTRY-MOSCOW+, V67, P409, DOI 10.1023/A:1015277805345; LEE LLY, 1987, BIOCHEMISTRY-US, V26, P7813, DOI 10.1021/bi00398a042; Li S, 2001, INT J BIOCHEM CELL B, V33, P279, DOI 10.1016/S1357-2725(01)00003-6; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; Maa YF, 1998, J PHARM SCI, V87, P152, DOI 10.1021/js970308x; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Meng FG, 2004, BIOPHYS J, V87, P2247, DOI 10.1529/biophysj.104.044784; Meng FG, 2001, INT J BIOCHEM CELL B, V33, P701, DOI 10.1016/S1357-2725(01)00048-6; Ou WB, 2002, INT J BIOCHEM CELL B, V34, P136, DOI 10.1016/S1357-2725(01)00113-3; Ou WB, 2001, EUR J BIOCHEM, V268, P5901, DOI 10.1046/j.0014-2956.2001.02539.x; Pan JC, 2004, PROTEIN SCI, V13, P1892, DOI 10.1110/ps.03464804; PESCE AJ, 1971, FLUORESCENCE SPECTRO, P20; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; POLSON A, 1964, BIOCHIM BIOPHYS ACTA, V82, P463, DOI 10.1016/0304-4165(64)90438-6; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ptitsyn Oleg B., 1992, P243; Randolph Theodore W, 2002, Pharm Biotechnol, V13, P159; RAVIN HA, 1952, NEW ENGL J MED, V247, P921, DOI 10.1056/NEJM195212112472403; Remmele RL, 1998, PHARMACEUT RES, V15, P200; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; Rozema D, 1996, BIOCHEMISTRY-US, V35, P15760, DOI 10.1021/bi961638j; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SEMISOTNOV GV, 1990, J MOL BIOL, V213, P561, DOI 10.1016/S0022-2836(05)80215-3; Singh R, 2005, J BIOL CHEM, V280, P11035, DOI 10.1074/jbc.M410716200; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; STEIN PJ, 1978, J BIOL CHEM, V253, P8016; TANDON S, 1986, J BIOL CHEM, V261, P5615; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; TOWNSEND M W, 1988, Journal of Parenteral Science and Technology, V42, P190; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; Uversky VN, 1996, J MOL BIOL, V255, P215, DOI 10.1006/jmbi.1996.0018; VANGELDER P, 1994, EUR J BIOCHEM, V226, P783; VRKLJAN M, 1994, PHARMACEUT RES, V11, P1004, DOI 10.1023/A:1018935420680; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	55	77	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9058	9065		10.1074/jbc.M507874200	http://dx.doi.org/10.1074/jbc.M507874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16459336	hybrid			2022-12-27	WOS:000236404700010
J	Ma, XH; Hu, SJ; Ni, H; Zhao, YC; Tian, Z; Liu, JL; Ren, G; Liang, XH; Yu, H; Wan, P; Yang, ZM				Ma, XH; Hu, SJ; Ni, H; Zhao, YC; Tian, Z; Liu, JL; Ren, G; Liang, XH; Yu, H; Wan, P; Yang, ZM			Serial analysis of gene expression in mouse uterus at the implantation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; LEUKEMIA INHIBITORY FACTOR; FACTOR BINDING PROTEIN-4; EMBRYO IMPLANTATION; DELAYED IMPLANTATION; PLATELET ACTIVATION; LUMINAL EPITHELIUM; RNA HELICASE; SAGE; TRANSCRIPTOME	Although oligonucleotide chips, cDNA microarrays, differential display reverse transcription-PCR, and other approaches have been used to screen implantation-related molecules, the mechanism by which embryo implantation occurs is still unknown. The aim of this study was to profile the differential gene expression between interimplantation site and implantation site in mouse uterus on day 5 of pregnancy by serial analysis of gene expression (SAGE). In our two SAGE libraries of 11-bp tags, the total numbers of tags sequenced were 48,121 for the interimplantation site and 50,227 for the implantation site. There were 1,039 tags specifically expressed at interimplantation site, and 1,252 tags specifically expressed at the implantation site. Based on the p value, there were 195 tags significantly up-regulated at the interimplantation site and 261 tags significantly up-regulated at the implantation site, of which 100 genes were single matched at the interimplantation site and 127 genes were single matched at the implantation site, respectively. By reverse transcription-PCR, the tag ratio between the implantation site and interimplantation site was verified on 14 significantly changed genes. Using in situ hybridization, 1810014L12Rik, Psmb5, Cd63, Npm1, Fads3, and Tagln2 were shown to be highly expressed at the implantation site compared with the interimplantation site. Compared with the interimplantation site, Ddx39 was strongly expressed in the subluminal stromal cells at the implantation site on day 5 of pregnancy. Ddx39 expression at the implantation site was specifically induced by active blastocysts. Additionally, Ddx39 expression was significantly up-regulated by estrogen in the ovariectomized mice. In our SAGE data, many implantation-related genes were identified in mouse uterus. Our data could be a valuable source for future study on embryo implantation.	NE Agr Univ, Coll Life Sci, Harbin 150030, Peoples R China; Shanghai Huaguan Biochip Co, Shanghai 201203, Peoples R China	Northeast Agricultural University - China	Yang, ZM (corresponding author), NE Agr Univ, Coll Life Sci, Harbin 150030, Peoples R China.	zmyang@neau.edu.cn	Hu, Shijun/I-5818-2012; Yang, ZM/G-4627-2010	Tian, Zhen/0000-0001-9044-637X; Hu, Shijun/0000-0002-0068-8429; Liu, Ji-Long/0000-0002-6948-2576; Ma, Xing-Hong/0000-0001-7905-8050; Ren, Gang/0000-0002-2555-7804				Blomberg LA, 2004, REPROD FERT DEVELOP, V16, P87, DOI 10.1071/RD03081; Bolduc C, 2004, OBES RES, V12, P750, DOI 10.1038/oby.2004.90; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chen Jian-Jun, 2003, Methods Mol Biol, V221, P207; Chen JJ, 2002, GENE CHROMOSOME CANC, V33, P252, DOI 10.1002/gcc.10017; Chen SH, 2005, PHYSIOL GENOMICS, V22, P257, DOI 10.1152/physiolgenomics.00063.2005; Cho-Vega JH, 2005, MODERN PATHOL, V18, P577, DOI 10.1038/modpathol.3800327; Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020; Ding CM, 2004, J BIOCHEM MOL BIOL, V37, P1; Divina P, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-29; Divina P, 2004, NUCLEIC ACIDS RES, V32, pD482, DOI 10.1093/nar/gkh058; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FINN CA, 1975, UTERUS CELLS TISSUES; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Henemyre C, 1998, BIOL REPROD, V58, P801, DOI 10.1095/biolreprod58.3.801; Hewitt SC, 2002, BIOL REPROD, V67, P1268, DOI [10.1095/biolreprod67.4.1268, 10.1095/biolreprod.102.002436]; HOLMAN RT, 1983, P NATL ACAD SCI-BIOL, V80, P2375, DOI 10.1073/pnas.80.8.2375; Holthe MR, 2004, AM J OBSTET GYNECOL, V190, P1128, DOI 10.1016/j.ajog.2003.10.699; Jones RL, 2005, HUM REPROD, V20, P2724, DOI 10.1093/humrep/dei140; Jones RL, 2004, J CLIN ENDOCR METAB, V89, P6155, DOI 10.1210/jc.2004-0507; Joswig Anike, 2003, Reprod Biol Endocrinol, V1, P44; KAISER M, 1990, ENDOCRINOLOGY, V126, P2768, DOI 10.1210/endo-126-5-2768; Konijnenberg A, 1997, AM J OBSTET GYNECOL, V177, P434, DOI 10.1016/S0002-9378(97)70212-6; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lal A, 1999, CANCER RES, V59, P5403; Larose M, 2004, MOL REPROD DEV, V68, P142, DOI 10.1002/mrd.20065; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Leaw CL, 2004, CELL MOL LIFE SCI, V61, P2264, DOI 10.1007/s00018-004-4205-x; Lepourcelet M, 2005, DEVELOPMENT, V132, P415, DOI 10.1242/dev.01579; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Linder P, 2000, NAT STRUCT BIOL, V7, P97, DOI 10.1038/72464; LOBB L, 1998, NAT MED, V4, P303; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lu J, 2004, GENOMICS, V84, P631, DOI 10.1016/j.ygeno.2004.06.014; Luu KC, 2004, P NATL ACAD SCI USA, V101, P8028, DOI 10.1073/pnas.0401069101; Margulies EH, 2000, BIOINFORMATICS, V16, P650, DOI 10.1093/bioinformatics/16.7.650; MARKOFF E, 1995, BIOL REPROD, V53, P1103, DOI 10.1095/biolreprod53.5.1103; McRae RS, 2005, ENDOCRINOLOGY, V146, P309, DOI 10.1210/en.2004-0999; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211; Ni H, 2002, BIOL REPROD, V67, P351, DOI 10.1095/biolreprod67.1.351; Ni H, 2002, MOL REPROD DEV, V63, P143, DOI 10.1002/mrd.10168; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Okada H, 1999, MOL HUM REPROD, V5, P554, DOI 10.1093/molehr/5.6.554; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; PARR EL, 1987, BIOL REPROD, V36, P211, DOI 10.1095/biolreprod36.1.211; POISSON JPG, 1991, J NUTR BIOCHEM, V2, P60, DOI 10.1016/0955-2863(91)90030-9; Reese J, 2001, J BIOL CHEM, V276, P44137, DOI 10.1074/jbc.M107563200; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sidhu SS, 1999, BIOL REPROD, V60, P147, DOI 10.1095/biolreprod60.1.147; Song HS, 2000, MOL ENDOCRINOL, V14, P1147, DOI 10.1210/me.14.8.1147; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Tatsumi K, 2001, MOL REPROD DEV, V58, P159, DOI 10.1002/1098-2795(200102)58:2&lt;159::AID-MRD4&gt;3.0.CO;2-T; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wang Y, 1998, RNA, V4, P1216, DOI 10.1017/S1355838298980992; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Yoon SJ, 2004, MOL CELL ENDOCRINOL, V219, P95, DOI 10.1016/j.mce.2004.01.007; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593; Yoshioka K, 2000, BIOCHEM BIOPH RES CO, V272, P531, DOI 10.1006/bbrc.2000.2818; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zolfaghari R, 2003, PROSTAG LEUKOTR ESS, V68, P171, DOI 10.1016/S0952-3278(02)00267-3	66	55	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9351	9360		10.1074/jbc.M511512200	http://dx.doi.org/10.1074/jbc.M511512200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16434403	hybrid			2022-12-27	WOS:000236404700044
J	Peterson, JH; Szabady, RL; Bernstein, HD				Peterson, JH; Szabady, RL; Bernstein, HD			An unusual signal peptide extension inhibits the binding of bacterial presecretory proteins to the signal recognition particle, trigger factor, and the SecYEG complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEINS; ESCHERICHIA-COLI; DEPENDENT TRANSLOCATION; TARGETING PATHWAY; 2-PARTNER SECRETION; CRYSTAL-STRUCTURE; NASCENT CHAINS; RIBOSOME; EXPORT; AUTOTRANSPORTER	Considerable evidence indicates that the Escherichia coli signal recognition particle (SRP) selectively targets proteins that contain highly hydrophobic signal peptides to the SecYEG complex cotranslationally. Presecretory proteins that contain only moderately hydrophobic signal peptides typically interact with trigger factor (TF) and are targeted post-translationally. Here we describe a striking exception to this rule that has emerged from the analysis of an unusual 55-amino acid signal peptide associated with the E. coli autotransporter EspP. The EspP signal peptide consists of a C-terminal domain that resembles a classical signal peptide plus an N-terminal extension that is conserved in other autotransporter signal peptides. Although a previous study showed that proteins containing the C-terminal domain of the EspP signal peptide are targeted cotranslationally by SRP, we found that proteins containing the full-length signal peptide were targeted post-translationally via a novel TF-independent mechanism. Mutation of an invariant asparagine residue in the N-terminal extension, however, restored cotranslational targeting. Remarkably, proteins containing extremely hydrophobic derivatives of the EspP signal peptide were also targeted post-translationally. These and other results suggest that the N-terminal extension alters the accessibility of the signal peptide to SRP and TF and promotes post-translational export by reducing the efficiency of the interaction between the signal peptide and the SecYEG complex. Based on data, we propose that the N-terminal extension mediates an interaction with an unidentified cytoplasmic factor or induces the formation of an unusual signal peptide conformation prior to the onset of protein translocation.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 5,Rm 201, Bethesda, MD 20892 USA.	harris_bernstein@nih.gov		Szabady, Rose/0000-0002-1281-7064	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052022, ZIADK052022] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKITA M, 1990, J BIOL CHEM, V265, P8164; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beha D, 2003, J BIOL CHEM, V278, P22161, DOI 10.1074/jbc.M300929200; Brandon LD, 2003, MOL MICROBIOL, V50, P45, DOI 10.1046/j.1365-2958.2003.03674.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chevalier N, 2004, J MOL MICROB BIOTECH, V8, P7, DOI 10.1159/000082076; Clantin B, 2004, P NATL ACAD SCI USA, V101, P6194, DOI 10.1073/pnas.0400291101; Cristobal S, 1999, J BIOL CHEM, V274, P20068, DOI 10.1074/jbc.274.29.20068; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Henderson IR, 2004, MICROBIOL MOL BIOL R, V68, P692, DOI 10.1128/MMBR.68.4.692-744.2004; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Huber D, 2005, J BACTERIOL, V187, P2983, DOI 10.1128/JB.187.9.2983-2991.2005; Jacob-Dubuisson F, 2001, MOL MICROBIOL, V40, P306, DOI 10.1046/j.1365-2958.2001.02278.x; Karamyshev AL, 2005, J BIOL CHEM, V280, P37930, DOI 10.1074/jbc.M509100200; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; Lee HC, 2002, J BIOL CHEM, V277, P43527, DOI 10.1074/jbc.M205950200; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Oomen CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/sj.emboj.7600148; Otto BR, 2005, J BIOL CHEM, V280, P17339, DOI 10.1074/jbc.M412885200; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; Peterson JH, 2003, J BIOL CHEM, V278, P46155, DOI 10.1074/jbc.M309082200; POGLIANO KJ, 1993, GENETICS, V133, P763; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Qi HY, 2002, J BIOL CHEM, V277, P51077, DOI 10.1074/jbc.M209238200; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; Szabady RL, 2005, P NATL ACAD SCI USA, V102, P221, DOI 10.1073/pnas.0406055102; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2	45	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9038	9048		10.1074/jbc.M508681200	http://dx.doi.org/10.1074/jbc.M508681200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455668	hybrid			2022-12-27	WOS:000236404700008
J	Yu, ZY; Kuncewicz, T; Dubinsky, WP; Kone, BC				Yu, ZY; Kuncewicz, T; Dubinsky, WP; Kone, BC			Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitric-oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN S-NITROSYLATION; DNA-BINDING-ACTIVITY; POLY(ADP-RIBOSE) POLYMERASE-1; TRANSCRIPTIONAL ACTIVATION; MESANGIAL CELLS; INHIBITION; INFLAMMATION; INDUCTION; ACETYLATION	Nitric oxide (NO) participates in a variety of physiologic and pathophysiologic processes in diverse tissues, including the kidney. Although mechanisms for cytokine induction of inducible nitric-oxide synthase (iNOS) have been increasingly clarified, the controls for termination of NO production remain unclear. Because excessive NO production can be cytotoxic to host cells, feedback inhibition of iNOS transcription would represent a means of cytoprotection. Many of the cGMP-independent functions of NO are mediated by S-nitrosylation of cysteine thiols of target proteins. We hypothesized that NO-mediated S-nitrosylation of transcription factors might serve to feedback inhibit their trans-activation potential and deactivate iNOS gene transcription. Transient transfection of murine mesangial cells with iNOS promoter deletion-luciferase constructs revealed the region -915 to -849 to be NO sensitive with respect to IL-1 beta-induced promoter activity. In vitro DNase I footprinting identified a footprint at -865/-842 in the absence of NO, but not in the presence of endogenous or exogenously delivered NO. Southwestern blotting using this probe coupled with partial peptide sequencing of the protein bands revealed that poly(ADPribose) polymerase isoform 1 (PARP-1) bound the probe in a sequence-specific manner. Gel shift/supershift experiments and chromatin immunoprecipitation assay analysis confirmed this binding in vitro and in vivo. Functionally, mutation of the -859/-850 site to prevent PARP-1 binding or PARP-1 knockdown by RNA interference relieved the inhibitory effects of NO on iNOS promoter activity. Biotin-switch assays and co-immunoprecipitation with an anti-nitrocysteine antibody indicated that PARP-1 was S-nitrosylated. We conclude that NO feedback inhibits iNOS gene transcription by S-nitrosylating the trans-activator PARP-1 and decreasing its binding and/or action at the iNOS promoter.	Univ Texas, Sch Med, Dept Internal Med, Hlth Sci Ctr, Houston, TX 77030 USA; Univ Texas, Dept Integrat Biol & Pharmacol, Hlth Sci Ctr, Houston, TX 77030 USA; Univ Texas, Brown Fdn Inst Mol Med Prevent Human Dis, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Kone, BC (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Hlth Sci Ctr, 6431 Fannin,MSB 1-150, Houston, TX 77030 USA.	Bruce.C.Kone@uth.tmc.edu			NIDDK NIH HHS [R01 DK50745] Funding Source: Medline; NIGMS NIH HHS [P50 GM38529] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM038529] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Andreone TL, 2003, J IMMUNOL, V170, P2113, DOI 10.4049/jimmunol.170.4.2113; Boulares AH, 2003, AM J RESP CELL MOL, V28, P322, DOI 10.1165/rcmb.2001-0015OC; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Evgenov Oleg V., 2005, Current Vascular Pharmacology, V3, P293, DOI 10.2174/1570161054368580; Gao CJ, 2004, J BIOL CHEM, V279, P11236, DOI 10.1074/jbc.M313385200; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Gupta AK, 2000, KIDNEY INT, V57, P2239, DOI 10.1046/j.1523-1755.2000.00084.x; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kone BC, 1997, AM J KIDNEY DIS, V30, P311, DOI 10.1016/S0272-6386(97)90275-4; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Li M, 2004, BIOCHEM J, V382, P323, DOI 10.1042/BJ20040593; Mabley Jon G., 2005, Current Vascular Pharmacology, V3, P247, DOI 10.2174/1570161054368571; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; Mohr S, 1996, J BIOL CHEM, V271, P4209; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; NAGELE A, 1995, RADIAT ENVIRON BIOPH, V34, P251, DOI 10.1007/BF01209751; Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Szabo C, 2006, NITRIC OXIDE-BIOL CH, V14, P169, DOI 10.1016/j.niox.2005.06.008; van Wijk SJL, 2005, FREE RADICAL BIO MED, V39, P81, DOI 10.1016/j.freeadbiomed.2005.03.021; Veres B, 2004, J PHARMACOL EXP THER, V310, P247, DOI 10.1124/jpet.104.065151; Vossen Christine, 2002, Med Sci Monit, V8, pRA217; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yu ZT, 2002, J AM SOC NEPHROL, V13, P2009, DOI 10.1097/01.ASN.0000024253.59665.F1; Yu ZY, 2006, AM J PHYSIOL-RENAL, V290, pF496, DOI 10.1152/ajprenal.00316.2005; Zhang WZ, 2001, J AM SOC NEPHROL, V12, P2554, DOI 10.1681/ASN.V12122554; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	45	58	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9101	9109		10.1074/jbc.M511049200	http://dx.doi.org/10.1074/jbc.M511049200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464859	hybrid			2022-12-27	WOS:000236404700015
J	Fritz, TA; Raman, J; Tabak, LA				Fritz, TA; Raman, J; Tabak, LA			Dynamic association between the catalytic and lectin domains of human UDP-GalNAc : polypeptide alpha-N-acetylgalactosaminyltransferase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; N-ACETYLGALACTOSAMINYLTRANSFERASE FAMILY; O-LINKED GLYCOSYLATION; MUCIN TANDEM REPEAT; CRYSTAL-STRUCTURE; SEQUENCE ALIGNMENT; CDNA CLONING; GLYCOPEPTIDE; SPECIFICITY; GALACTOSYLTRANSFERASE	The family of UDP-GalNAc: polypeptide alpha-N-acetylgalactosaminyltransferases (ppGalNAcTs) is unique among glycosyltransferases, containing both catalytic and lectin domains that we have previously shown to be closely associated. Here we describe the x-ray crystal structures of human ppGalNAcT-2 (hT2) bound to the product UDP at 2.75 angstrom resolution and to UDP and an acceptor peptide substrate EA2 (PTTDSTTPAPTTK) at 1.64 angstrom resolution. The conformations of both UDP and residues Arg(362) - Ser(372) vary greatly between the two structures. In the hT2-UDP-EA2 complex, residues Arg(362) - Ser(373) comprise a loop that forms a lid over UDP, sealing it in the active site, whereas in the hT2-UDP complex this loop is folded back, exposing UDP to bulk solvent. EA2 binds in a shallow groove with threonine 7 positioned consistent with in vitro data showing it to be the preferred site of glycosylation. The relative orientations of the hT2 catalytic and lectin domains differ dramatically from that of murine ppGalNAcT-1 and also vary considerably between the two hT2 complexes. Indeed, in the hT2-UDP-EA2 complex essentially no contact is made between the catalytic and lectin domains except for the peptide bridge between them. Thus, the hT2 structures reveal an unexpected flexibility between the catalytic and lectin domains and suggest a new mechanism used by hT2 to capture glycosylated substrates. Kinetic analysis of hT2 lacking the lectin domain confirmed the importance of this domain in acting on glycopeptide but not peptide substrates. The structure of the hT2-UDP-EA2 complex also resolves long standing questions regarding ppGalNAcT acceptor substrate specificity.	NIDDK, Sect Biol Chem, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Tabak, LA (corresponding author), NIDCR, NIH, Bldg 31,Room 2C39,31 Ctr Dr,MSC 2290, Bethesda, MD 20892 USA.	tabakl@mail.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK070012, Z01DK070012] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; Fritz TA, 2004, P NATL ACAD SCI USA, V101, P15307, DOI 10.1073/pnas.0405657101; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Gerken TA, 2004, GLYCOBIOLOGY, V14, P1190; Gerken TA, 2004, BIOCHEMISTRY-US, V43, P9888, DOI 10.1021/bi049178e; Gerken TA, 2002, J BIOL CHEM, V277, P7736, DOI 10.1074/jbc.M111690200; Gerken TA, 1997, J BIOL CHEM, V272, P9709; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kawakubo M, 2004, SCIENCE, V305, P1003, DOI 10.1126/science.1099250; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MORRISON JF, 1971, J BIOL CHEM, V246, P3977; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Pratt MR, 2004, CHEM BIOL, V11, P1009, DOI 10.1016/j.chembiol.2004.05.009; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Rosen SD, 1997, BIOCHEM SOC T, V25, P428, DOI 10.1042/bst0250428; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Ten Hagen KG, 2003, J BIOL CHEM, V278, P35039, DOI 10.1074/jbc.M303836200; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; TENHAGEN KG, 2003, GLYCOBIOLOGY, V13, P1; Tenno M, 2005, GLYCOBIOLOGY, V15, P1238; Tenno M, 2002, J BIOL CHEM, V277, P47088, DOI 10.1074/jbc.M207369200; Tetaert D, 2001, BIOCHEM J, V357, P313, DOI 10.1042/0264-6021:3570313; Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358; Ulrich SM, 2003, BIOCHEMISTRY-US, V42, P7915, DOI 10.1021/bi030042a; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; Zhang Y, 2003, J BIOL CHEM, V278, P573, DOI 10.1074/jbc.M203094200	49	121	130	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8613	8619		10.1074/jbc.M513590200	http://dx.doi.org/10.1074/jbc.M513590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16434399	hybrid			2022-12-27	WOS:000236247100038
J	Reissner, KJ; Paranandi, MV; Luc, TM; Doyle, HA; Mamula, MJ; Lowenson, JD; Aswad, DW				Reissner, KJ; Paranandi, MV; Luc, TM; Doyle, HA; Mamula, MJ; Lowenson, JD; Aswad, DW			Synapsin I is a major endogenous substrate for protein L-isoaspartyl methyltransferase in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL O-METHYLTRANSFERASE; DEFICIENT MICE; SYNAPTIC-TRANSMISSION; DAMAGED PROTEINS; REPAIR ENZYME; AFFINITY-CHROMATOGRAPHY; PRESYNAPTIC TERMINALS; METHYLATION; CALMODULIN; PEPTIDES	The accumulation of potentially deleterious L- isoaspartyl linkages in proteins is prevented by the action of protein L- isoaspartyl O- methyltransferase, a widely distributed enzyme that is particularly active in mammalian brain. Methyltransferase- deficient ( knock- out) mice exhibit greatly increased levels of isoaspartate and typically succumb to fatal epileptic seizures at 4 - 10 weeks of age. The link between isoaspartate accumulation and the neurological abnormalities of these mice is poorly understood. Here, we demonstrate that synapsin I from knock- out mice contains 0.9 +/- 0.3 mol of isoaspartate/ mol of synapsin, whereas the levels in wild- type and heterozygous mice are undetectable. Transgenic mice that selectively express methyltransferase only in neurons show reduced levels of synapsin damage, and the degree of reduction correlates with the phenotype of these mice. Isoaspartate levels in synapsin from the knock- out mice are five to seven times greater than those in the average protein from brain cytosol or from a synaptic vesicle- enriched fraction. The isoaspartyl sites in synapsin from knock- out mice are efficiently repaired in vitro by incubation with purified methyltransferase and S- adenosyl- L- methionine. These findings demonstrate that synapsin I is a major substrate for the isoaspartyl methyltransferase in neurons and suggest that isoaspartate- related alterations in the function of presynaptic proteins may contribute to the neurological abnormalities of mice deficient in this enzyme.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06510 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Irvine; Yale University; University of California System; University of California Los Angeles	Aswad, DW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 McGaugh Hall, Irvine, CA 92697 USA.	dwaswad@uci.edu	Lowenson, Jonathan/AAN-6768-2020; Reissner, Kathryn J/K-7187-2015		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR047759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36529] Funding Source: Medline; NIAMS NIH HHS [F32-AR47759] Funding Source: Medline; NIGMS NIH HHS [GM026020] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aswad D W, 1988, Adv Exp Med Biol, V231, P247; Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; CHIRPICH T, 1968, THESIS U CALIFORNIA; Clarke S, 2003, AGEING RES REV, V2, P263, DOI 10.1016/S1568-1637(03)00011-4; DAVID CL, 1995, PROTEIN EXPRES PURIF, V6, P312, DOI 10.1006/prep.1995.1041; David CL, 1998, J BIOL CHEM, V273, P32063, DOI 10.1074/jbc.273.48.32063; Farrar C, 2005, AGING CELL, V4, P1, DOI 10.1111/j.1474-9728.2004.00136.x; GALLETTI P, 1988, EUR J BIOCHEM, V177, P233, DOI 10.1111/j.1432-1033.1988.tb14367.x; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; Gitler D, 2004, J NEUROSCI, V24, P3711, DOI 10.1523/JNEUROSCI.5225-03.2004; Gitlits VM, 2001, J INVEST MED, V49, P276, DOI 10.2310/6650.2001.33973; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Ikegaya Y, 2001, HIPPOCAMPUS, V11, P287, DOI 10.1002/hipo.1043; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1985, BIOCHEMISTRY-US, V24, P2581, DOI 10.1021/bi00331a028; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; KIM S, 1978, ANAL BIOCHEM, V84, P415, DOI 10.1016/0003-2697(78)90059-3; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; Lowenson JD, 2001, J BIOL CHEM, V276, P20695, DOI 10.1074/jbc.M100987200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MURRAY ED, 1984, J BIOL CHEM, V259, P722; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; OHTA K, 1987, BIOCHIMIE, V69, P1227, DOI 10.1016/0300-9084(87)90150-7; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; PARANANDI MV, 1995, BIOCHEM BIOPH RES CO, V212, P442, DOI 10.1006/bbrc.1995.1989; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; Reissner KJ, 2001, FASEB J, V15, pA888; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Schurter BT, 2000, ANAL BIOCHEM, V282, P227, DOI 10.1006/abio.2000.4601; Shimizu T, 2002, J NEUROSCI RES, V69, P341, DOI 10.1002/jnr.10301; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; Terada S, 1999, J CELL BIOL, V145, P1039, DOI 10.1083/jcb.145.5.1039; TERWILLIGER TC, 1981, J BIOL CHEM, V256, P3067; TESHIMA G, 1995, DEAMIDATION ISOASPAR, P167; Volkin DB, 1997, MOL BIOTECHNOL, V8, P105, DOI 10.1007/BF02752255; Yamamoto A, 1998, J NEUROSCI, V18, P2063; Young AL, 2001, J BIOL CHEM, V276, P37161, DOI 10.1074/jbc.M106682200	58	31	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8389	8398		10.1074/jbc.M510716200	http://dx.doi.org/10.1074/jbc.M510716200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16443604	hybrid			2022-12-27	WOS:000236247100013
J	Tisdale, EJ; Artalejo, CR				Tisdale, EJ; Artalejo, CR			Src-dependent aprotein kinase C iota/lambda (aPKC iota/lambda) tyrosine phosphorylation is required for aPKC iota/lambda association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; VESICLE FORMATION; IN-VITRO; PROTEIN; INTERACTS; LOCALIZATION; COMPARTMENTS; ACTIVATION	The small GTPase Rab2 is required for membrane transport between the endoplasmic reticulum ( ER) and the Golgi complex. Rab2 associates with pre- Golgi intermediates ( also termed vesicular tubular clusters; VTCs) that sort cargo to the anterograde pathway from recycling proteins retrieved to the ER. Our previous studies have shown that Rab2 stimulates atypical protein kinase C iota/lambda ( aPKC iota/lambda) and glyceraldehyde- 3- phosphate dehydrogenase (GAPDH) recruitment to VTCs. Both aPKC iota/lambda and GAPDH bind directly to Rab2 and aPKC iota/lambda and GAPDH interact. Based on the reports demonstrating aPKC iota- Src interaction and Src activity in the retrograde pathway ( Golgi- ER), studies were initiated to learn whether Rab2 also promoted Src recruitment to VTCs. Using a quantitative membrane binding assay, we found that Rab2- stimulated Src membrane association in a dose- dependent manner. The recruited Src binds to aPKC iota/lambda and GAPDH on the membrane; however, Src does not interact with Rab2. The membrane- associated Src tyrosine phosphorylates aPKC iota/lambda on the VTC. To determine the consequence of aPKC iota/lambda tyrosine phosphorylation, the membrane binding assay was supplemented with the Src- specific tyrosine kinase inhibitor 4- amino- 5-( 4- chlorophenyl)- 7-( t- butyl) pyrazolo( 3,4- d) pyrimidine ( PP2). Although Rab2, Src, and GAPDH recruitment was not affected, the Rab2- PP2- treated membranes contained a negligible amount of aPKC iota/lambda. Since Rab2 requires aPKC iota/lambda for the downstream recruitment of beta- coat protein (beta-COP) to VTCs, the Rab2- PP2- treated membranes were evaluated for the presence of beta-COP. Like aPKC iota/lambda, the membranes contained a negligible amount of beta- COP that was reflected by the drastic reduction in Rab2- dependent vesicle formation. These data suggest that Src- mediated tyrosine phosphorylation of aPKC iota/lambda facilitates aPKC iota/lambda association with Rab2- Src- GAPDH on VTCs, which is ultimately necessary for the downstream recruitment of beta-COP and release of Rab2- mediated retrograde- directed vesicles.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave,6374 Scott Hall, Detroit, MI 48201 USA.	etisdale@med.wayne.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068813] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK576637, DK58921, R01 DK058921] Funding Source: Medline; NIGMS NIH HHS [GM068813, R01 GM068813, R01 GM068813-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan-Bonnet N, 2004, CURR OPIN CELL BIOL, V16, P364, DOI 10.1016/j.ceb.2004.06.011; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bard F, 2003, J BIOL CHEM, V278, P46601, DOI 10.1074/jbc.M302221200; Bard F, 2002, EUR J CELL BIOL, V81, P26, DOI 10.1078/0171-9335-00217; BECKERS CJ, 1989, CELL, V50, P523; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Ding J, 2003, BIOCHEM BIOPH RES CO, V312, P670, DOI 10.1016/j.bbrc.2003.10.171; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; Poole AAW, 2004, TRENDS PHARMACOL SCI, V25, P528, DOI 10.1016/j.tips.2004.08.006; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Seibenhener M L, 1999, Mol Cell Biol Res Commun, V2, P28, DOI 10.1006/mcbr.1999.0140; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Tisdale EJ, 2004, J BIOL CHEM, V279, P54046, DOI 10.1074/jbc.M409472200; Tisdale EJ, 2003, J BIOL CHEM, V278, P52524, DOI 10.1074/jbc.M309343200; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	32	32	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8436	8442		10.1074/jbc.M513031200	http://dx.doi.org/10.1074/jbc.M513031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452474	hybrid, Green Accepted			2022-12-27	WOS:000236247100018
J	Carissimi, C; Saieva, L; Baccon, J; Chiarella, P; Maiolica, A; Sawyer, A; Rappsilber, J; Pellizzoni, L				Carissimi, C; Saieva, L; Baccon, J; Chiarella, P; Maiolica, A; Sawyer, A; Rappsilber, J; Pellizzoni, L			Gemin8 is a novel component of the survival motor neuron complex and functions in small nuclear ribonucleoprotein assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; REPEAT PROTEIN-COMPONENT; BINDS SM PROTEINS; SNRNP PROTEINS; COILED BODIES; GENE-PRODUCT; IDENTIFICATION; SIP1; GEMS; LOCALIZATION	The survival motor neuron (SMN) protein is the product of the spinal muscular atrophy disease gene. SMN and Gemin2 - 7 proteins form a large macromolecular complex that localizes in the cytoplasm as well as in the nucleoplasm and in nuclear Gems. The SMN complex interacts with several additional proteins and likely functions in multiple cellular pathways. In the cytoplasm, a subset of SMN complexes containing unrip and Sm proteins mediates the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs). Here, by mass spectrometry analysis of SMN complexes purified from HeLa cells, we identified a novel protein that is evolutionarily conserved in metazoans, and we named it Gemin8. Co-immunoprecipitation and immunolocalization experiments demonstrated that Gemin8 is associated with the SMN complex and is localized in the cytoplasm and in the nucleus, where it is highly concentrated in Gems. Gemin8 interacts directly with the Gemin6-Gemin7 heterodimer and, together with unrip, these proteins form a heteromeric subunit of the SMN complex. Gemin8 is also associated with Sm proteins, and Gemin8-containing SMN complexes are competent to carry out snRNP assembly. Importantly, RNA interference experiments indicate that Gemin8 knock-down impairs snRNP assembly, and Gemin8 expression is down-regulated in cells with low levels of SMN. These results demonstrate that Gemin8 is a novel integral component of the SMN complex and extend the repertoire of cellular proteins involved in the pathway of snRNP biogenesis.	CNR, Inst Cell Biol, Dulbecco Telethon Inst, I-00016 Monterotondo, Rome, Italy; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; EMBL Monoclonal Antibody Core Facil, I-00016 Monterotondo, Rome, Italy; FIRC Inst Mol Oncol Fdn, I-20139 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Pennsylvania; European Molecular Biology Laboratory (EMBL); IFOM - FIRC Institute of Molecular Oncology	Pellizzoni, L (corresponding author), CNR, Inst Cell Biol, Dulbecco Telethon Inst, Via E Ramarini 32, I-00016 Monterotondo, Rome, Italy.	livio.pellizzoni@ibc.cnr.it	carissimi, claudia/AAU-7414-2021; Rappsilber, Juri/ABF-3328-2020; Rappsilber, Juri/B-7265-2015	carissimi, claudia/0000-0002-9885-2855; Rappsilber, Juri/0000-0001-5999-1310; Pellizzoni, Livio/0000-0002-9168-5628; Sawyer, Alan/0000-0001-5942-4498	Telethon [TCP02011] Funding Source: Medline	Telethon(Fondazione Telethon)		Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Carissimi C, 2005, FEBS LETT, V579, P2348, DOI 10.1016/j.febslet.2005.03.034; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; De Masi F, 2005, PROTEOMICS, V5, P4070, DOI 10.1002/pmic.200401279; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Gall JG, 2003, NAT REV MOL CELL BIO, V4, P975, DOI 10.1038/nrm1262; Golembe TJ, 2005, MOL CELL BIOL, V25, P602, DOI 10.1128/MCB.25.2.602-611.2005; Grimmler M, 2005, HUM MOL GENET, V14, P3099, DOI 10.1093/hmg/ddi343; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Hane B, 1999, AM J MED GENET, V85, P271; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Hebert MD, 2002, DEV CELL, V3, P329, DOI 10.1016/S1534-5807(02)00222-8; Helmken C, 2003, HUM GENET, V114, P11, DOI 10.1007/s00439-003-1025-2; IONASESCU VV, 1995, MUSCLE NERVE, V18, P267, DOI 10.1002/mus.880180302; Jablonka S, 2001, HUM MOL GENET, V10, P497, DOI 10.1093/hmg/10.5.497; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kiss T, 2004, J CELL SCI, V117, P5949, DOI 10.1242/jcs.01487; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Ma YL, 2005, STRUCTURE, V13, P883, DOI 10.1016/j.str.2005.03.014; Martinez F, 2001, AM J MED GENET, V102, P200, DOI 10.1002/ajmg.1416; Massenet S, 2002, MOL CELL BIOL, V22, P6533, DOI 10.1128/MCB.22.18.6533-6541.2002; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Narayanan U, 2002, HUM MOL GENET, V11, P1785, DOI 10.1093/hmg/11.15.1785; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Pillai RS, 2003, GENE DEV, V17, P2321, DOI 10.1101/gad.274403; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Wang J, 2001, J BIOL CHEM, V276, P9599, DOI 10.1074/jbc.M009162200; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yong J, 2004, MOL CELL BIOL, V24, P2747, DOI 10.1128/MCB.24.7.2747-2756.2004; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858	48	84	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8126	8134		10.1074/jbc.M512243200	http://dx.doi.org/10.1074/jbc.M512243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434402	hybrid			2022-12-27	WOS:000236031000050
J	Dai, EB; Viswanathan, K; Sun, YM; Li, X; Liu, LY; Togonu-Bickersteth, B; Richardson, J; Macaulay, C; Nash, P; Turner, P; Nazarian, SH; Moyer, R; McFadden, G; Lucas, AR				Dai, EB; Viswanathan, K; Sun, YM; Li, X; Liu, LY; Togonu-Bickersteth, B; Richardson, J; Macaulay, C; Nash, P; Turner, P; Nazarian, SH; Moyer, R; McFadden, G; Lucas, AR			Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; NEOINTIMA FORMATION; SERINE PROTEINASE; GLYCOSAMINOGLYCAN BINDING; INHIBITORY SPECIFICITY; FIBRINOLYTIC SYSTEM; DIFFERENT ROLES; GENE-TRANSFER; VIRUS SERP2; UROKINASE	The thrombolytic serine protease cascade is intricately involved in activation of innate immune responses. The urokinase-type plasminogen activator and receptor form complexes that aid inflammatory cell invasion at sites of arterial injury. Plasminogen activator inhibitor-1 is a mammalian serpin that binds and regulates the urokinase receptor complex. Serp-1, a myxomaviral serpin, also targets the urokinase receptor, displaying profound anti-inflammatory and anti-atherogenic activity in a wide range of animal models. Serp-1 reactive center site mutations, mimicking known mammalian and viral serpins, were constructed in order to define sequences responsible for regulation of inflammation. Thrombosis, inflammation, and plaque growth were assessed after treatment with Serp-1, Serp-1 chimeras, plasminogen activator inhibitor-1, or unrelated viral serpins in plasminogen activator inhibitor or urokinase receptor-deficient mouse aortic transplants. Altering the P1-P1' Arg-Asn sequence compromised Serp-1 protease-inhibitory activity and anti-inflammatory activity in animal models; P1-P1' Ala-Ala mutants were inactive, P1 Met increased remodeling, and P1' Thr increased thrombosis. Substitution of Serp-1 P2-P7 with Ala(6) allowed for inhibition of urokinase but lost plasmin inhibition, unexpectedly inducing a diametrically opposed, proinflammatory response with mononuclear cell activation, thrombosis, and aneurysm formation (p<0.03). Other serpins did not reproduce Serp-1 activity; plasminogen activator inhibitor-1 increased thrombosis (p<0.0001), and unrelated viral serpin, CrmA, increased inflammation. Deficiency of urokinase receptor in mouse transplants blocked Serp-1 and chimera activity, in some cases increasing inflammation. In summary, 1) Serp-1 anti-inflammatory activity is highly dependent upon the reactive center loop sequence, and 2) plasmin inhibition is central to anti-inflammatory activity.	Univ Western Ontario, Robarts Res Inst, Vasc Biol Res Grp, London, ON N6A 2K8, Canada; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Viron Therapeut Inc, Res & Dev, London, ON N6G 4X8, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 2K8, Canada	Western University (University of Western Ontario); State University System of Florida; University of Florida; Western University (University of Western Ontario)	Lucas, AR (corresponding author), Univ Western Ontario, Robarts Res Inst, Vasc Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 2K8, Canada.	arl@robarts.ca		Macaulay, Colin/0000-0003-0118-7674; Turner, Peter/0000-0002-7706-4593; McFadden, Grant/0000-0002-2556-3526				AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; Alessi MC, 2004, ARCH MAL COEUR VAISS, V97, P673; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Barbour KW, 2002, MOL BIOL EVOL, V19, P718, DOI 10.1093/oxfordjournals.molbev.a004130; Bot I, 2003, CIRC RES, V93, P464, DOI 10.1161/01.RES.0000090993.01633.D4; BRAUTBOUCHER F, 1995, J IMMUNOL METHODS, V178, P41, DOI 10.1016/0022-1759(94)00239-S; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; CARMELIET P, 1995, FASEB J, V9, P934, DOI 10.1096/fasebj.9.10.7615162; Chavakis T, 2002, BIOCHEM SOC T, V30, P168, DOI 10.1042/BST0300168; Chen VC, 2000, J BIOL CHEM, V275, P38457, DOI 10.1074/jbc.M005605200; Christov A, 2000, PHOTOCHEM PHOTOBIOL, V72, P242, DOI 10.1562/0031-8655(2000)072<0242:ODOTAP>2.0.CO;2; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Dai E, 2003, J BIOL CHEM, V278, P18563, DOI 10.1074/jbc.M209683200; DALY LE, 1991, INTERPRETATION USES, P139; FALKENBERG M, 1990, THROMB HAEMOSTASIS, V72, P933; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gu JM, 2005, J CELL PHYSIOL, V204, P73, DOI 10.1002/jcp.20262; Krettek A, 2003, ARTERIOSCL THROM VAS, V23, P582, DOI 10.1161/01.ATV.0000064372.78561.A5; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; LOMAS DA, 1993, J BIOL CHEM, V268, P516; Lucas A, 2004, J IMMUNOL, V173, P4765, DOI 10.4049/jimmunol.173.8.4765; Lucas A, 1996, CIRCULATION, V94, P2890, DOI 10.1161/01.CIR.94.11.2890; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Matsuno H, 2002, THROMB HAEMOSTASIS, V87, P98; Matsuno H, 2002, J CARDIOVASC PHARM, V39, P278, DOI 10.1097/00005344-200202000-00015; Matsuno H, 1999, THROMB HAEMOSTASIS, V81, P601; Miller LW, 2000, CIRCULATION, V101, P1598, DOI 10.1161/01.CIR.101.13.1598; Mitchell JW, 2002, J BIOL CHEM, V277, P19823, DOI 10.1074/jbc.M200630200; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; Nash P, 2000, FEBS LETT, V475, P1, DOI 10.1016/S0014-5793(00)01620-3; Nash P, 1998, J BIOL CHEM, V273, P20982, DOI 10.1074/jbc.273.33.20982; Nathaniel R, 2004, J GEN VIROL, V85, P1267, DOI 10.1099/vir.0.79905-0; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Patston PA, 2004, METHODS, V32, P93, DOI 10.1016/S1046-2023(03)00201-9; Ploplis VA, 2001, ANN NY ACAD SCI, V936, P466; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Schechter NM, 2004, METHODS, V32, P159, DOI 10.1016/S1046-2023(03)00207-X; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stein CM, 1998, J AM COLL CARDIOL, V32, P117, DOI 10.1016/S0735-1097(98)00210-1; Turner PC, 1999, J VIROL, V73, P6394, DOI 10.1128/JVI.73.8.6394-6404.1999; Wiman J, 2000, HEMATOL ONCOL CLIN N, V14, P325, DOI 10.1016/S0889-8588(05)70136-2; Zalai CV, 2002, FUND CL CAR, V45, P447; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	50	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8041	8050		10.1074/jbc.M509454200	http://dx.doi.org/10.1074/jbc.M509454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407226	hybrid			2022-12-27	WOS:000236031000041
J	Montana, ES; Littleton, JT				Montana, ES; Littleton, JT			Expression profiling of a hypercontraction-induced myopathy in Drosophila suggests a compensatory cytoskeletal remodeling response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LONG-TERM POTENTIATION; IMMEDIATE-EARLY GENE; CARDIAC-HYPERTROPHY; MESSENGER-RNA; MEMORY CONSOLIDATION; SYNAPTIC PLASTICITY; MUSCLE ATTACHMENTS; SKELETAL-MUSCLE; CDNA MICROARRAY	Mutations that alter muscle contraction lead to a large array of diseases, including muscular dystrophies and cardiomyopathies. Although the molecular lesions underlying many hereditary muscle diseases are known, the downstream pathways that contribute to disease pathogenesis and compensatory muscle remodeling are poorly defined. We have recently identified and characterized mutations in Myosin Heavy Chain (Mhc) that lead to hypercontraction and subsequent degeneration of flight muscles in Drosophila. To characterize the genomic response to hypercontraction-induced myopathy, we performed expression analysis using Affymetrix high density oligonucleotide microarrays in Drosophila Mhc hypercontraction alleles. The altered transcriptional profile of dystrophic Mhc muscles suggests an actin-dependent remodeling of the muscle cytoskeleton. Specifically, a subset of the highly up-regulated transcripts is involved in actin regulation and structural support for the contractile machinery. In addition, we identified previously uncharacterized proteins with putative actin-interaction domains that are up-regulated in Mhc mutants and differentially expressed in muscles. Several of the up-regulated proteins, including the dystrophin-related protein, MSP-300, and the homolog of the neuronal activity-regulated protein, ARC, localize to specific subcellular muscle structures that may provide key structural sites for cytoskeletal remodeling in dystrophic muscles. Defining the genome-wide transcriptional response to muscle hypercontraction in Drosophila has revealed candidate loci that may participate in the pathogenesis of muscular dystrophy and in compensatory muscle repair pathways through modulation of the actin cytoskeleton.	MIT, Picower Inst Learning & Memory, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Northwell Health; Massachusetts Institute of Technology (MIT)	Littleton, JT (corresponding author), MIT, Picower Inst Learning & Memory, Dept Biol, 46-3243, Cambridge, MA 02139 USA.	troy@mit.edu		Littleton, J. Troy/0000-0001-5576-2887	NINDS NIH HHS [R01 NS043244, R01 NS043244-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043244] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aronow BJ, 2001, PHYSIOL GENOMICS, V6, P19, DOI 10.1152/physiolgenomics.2001.6.1.19; Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4; Baum B, 2000, CURR BIOL, V10, P964, DOI 10.1016/S0960-9822(00)00640-0; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Campanaro S, 2002, HUM MOL GENET, V11, P3283, DOI 10.1093/hmg/11.26.3283; Chamberlain JS, 2000, J CELL BIOL, V151, pF43, DOI 10.1083/jcb.151.6.F43; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHOH RD, 2000, MUSCLE NERVE, V10, P1456; Ferrus A, 2000, TRENDS CARDIOVAS MED, V10, P293, DOI 10.1016/S1050-1738(01)00063-9; FOSNAUGH JS, 1995, J NEUROCHEM, V64, P2377; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; Guan Z, 2005, NEURON, V48, P91, DOI 10.1016/j.neuron.2005.08.036; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Hakeda S, 2000, J CELL BIOL, V148, P101, DOI 10.1083/jcb.148.1.101; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Kronert WA, 1999, J CELL BIOL, V144, P989, DOI 10.1083/jcb.144.5.989; Kuelzer F, 1999, J NEUROBIOL, V41, P482, DOI 10.1002/(SICI)1097-4695(199912)41:4<482::AID-NEU4>3.0.CO;2-X; Labuhn M, 1997, GERONTOLOGY, V43, P261; LAKEY A, 1993, EMBO J, V12, P2863, DOI 10.1002/j.1460-2075.1993.tb05948.x; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Lim DS, 2001, J AM COLL CARDIOL, V38, P1175, DOI 10.1016/S0735-1097(01)01509-1; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MALENKA RC, 1991, MOL NEUROBIOL, V5, P289, DOI 10.1007/BF02935552; Martonosi AN, 2003, ACTA BIOCHIM POL, V50, P1; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montana ES, 2004, J CELL BIOL, V164, P1045, DOI 10.1083/jcb.200308158; Nedivi E, 1996, P NATL ACAD SCI USA, V93, P2048, DOI 10.1073/pnas.93.5.2048; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; Piper HM, 2004, CARDIOVASC RES, V61, P365, DOI 10.1016/j.cardiores.2003.12.012; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Raghavan S, 2000, CURR BIOL, V10, P269, DOI 10.1016/S0960-9822(00)00364-X; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; RosenbergHasson Y, 1996, MECH DEVELOP, V60, P83, DOI 10.1016/S0925-4773(96)00602-8; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Semsarian C, 2002, J CLIN INVEST, V109, P1013, DOI 10.1172/JCI200214677; Shinozaki K, 1997, BIOCHEM BIOPH RES CO, V240, P766, DOI 10.1006/bbrc.1997.7660; Steward O, 2002, NEURON, V36, P338, DOI 10.1016/S0896-6273(02)01006-1; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; Steward O, 2002, NEUROBIOL LEARN MEM, V78, P508, DOI 10.1006/nlme.2002.4102; Stronach BE, 1996, J CELL BIOL, V134, P1179, DOI 10.1083/jcb.134.5.1179; Stronach BE, 1999, MOL BIOL CELL, V10, P2329, DOI 10.1091/mbc.10.7.2329; TOBIN SL, 1990, DEV GENET, V11, P15, DOI 10.1002/dvg.1020110104; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Straaten M, 1999, J MOL BIOL, V285, P1549, DOI 10.1006/jmbi.1998.2386; Vigoreaux JO, 2001, BIOESSAYS, V23, P1047, DOI 10.1002/bies.1150; VOLK T, 1992, DEVELOPMENT, V116, P721; Wallace CS, 1998, J NEUROSCI, V18, P26; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang QP, 2002, GENOMICS, V80, P473, DOI 10.1006/geno.2002.6859	59	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8100	8109		10.1074/jbc.M512468200	http://dx.doi.org/10.1074/jbc.M512468200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415344	hybrid			2022-12-27	WOS:000236031000047
J	Eisner, G; Moser, M; Schafer, U; Beck, K; Muller, M				Eisner, G; Moser, M; Schafer, U; Beck, K; Muller, M			Alternate recruitment of signal recognition particle and trigger factor to the signal sequence of a growing nascent polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; MANNITOL PERMEASE; MEMBRANE-PROTEINS; DEPENDENT TRANSLOCATION; TARGETING PATHWAY; IN-VITRO; SRP; BINDING; SECA; COMPLEX	Different from cytoplasmic membrane proteins, presecretory proteins of bacteria usually do not require the signal recognition particle for targeting to the Sec translocon. Nevertheless signal sequences of presecretory proteins have been found in close proximity to signal recognition particle immediately after they have emerged from the ribosome. We show here that at the ribosome, the molecular environment of a signal sequence depends on the nature of downstream sequence elements that can cause an alternate recruitment of signal recognition particle and the ribosome-associated chaperone Trigger factor to a growing nascent chain. While signal recognition particle and Trigger factor might remain bound to the same ribosome, both ligands are clearly able to displace each other from a nascent chain. The data also imply that a signal sequence owes its molecular environment to the fact that it remains closely apposed to the ribosomal exit site during growth of a nascent secretory protein.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Muller, M (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	matthias.mueller@biochemie.uni-freiburg.de						Aboulwafa M, 2003, MOL MICROBIOL, V48, P131, DOI 10.1046/j.1365-2958.2003.03394.x; Agashe VR, 2004, CELL, V117, P199, DOI 10.1016/S0092-8674(04)00299-5; Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Beha D, 2003, J BIOL CHEM, V278, P22161, DOI 10.1074/jbc.M300929200; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; Chevalier N, 2004, J MOL MICROB BIOTECH, V8, P7, DOI 10.1159/000082076; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Ezraty B, 2004, EMBO J, V23, P1868, DOI 10.1038/sj.emboj.7600172; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Karamyshev AL, 2005, J BIOL CHEM, V280, P37930, DOI 10.1074/jbc.M509100200; Kim J, 2001, FEBS LETT, V505, P245, DOI 10.1016/S0014-5793(01)02784-3; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; MANEEWANNAKUL S, 1994, PLASMID, V31, P300, DOI 10.1006/plas.1994.1032; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Patzelt H, 2002, BIOL CHEM, V383, P1611, DOI 10.1515/BC.2002.182; Peterson JH, 2003, J BIOL CHEM, V278, P46155, DOI 10.1074/jbc.M309082200; Pool MR, 2005, MOL MEMBR BIOL, V22, P3, DOI 10.1080/09687860400026348; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Vervoort EB, 2005, J MOL BIOL, V346, P733, DOI 10.1016/j.jmb.2004.12.011; WERNER PK, 1992, J BIOL CHEM, V267, P24523	49	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7172	7179		10.1074/jbc.M511388200	http://dx.doi.org/10.1074/jbc.M511388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421097	hybrid			2022-12-27	WOS:000236030900032
J	Richie-Jannetta, R; Busch, JL; Higgins, KA; Corbin, JD; Francis, SH				Richie-Jannetta, R; Busch, JL; Higgins, KA; Corbin, JD; Francis, SH			Isolated regulatory domains of cGMP-dependent protein kinase I alpha and I beta retain dimerization and native cGMP-binding properties and undergo isoform-specific conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; SITES; ISOZYME; AUTOINHIBITION; SEQUENCE; CLONING; CAMP	Molecular mechanisms that provide for cGMP activation of cGMP-dependent protein kinase (PKG) are unknown. PKGs are dimeric; each monomer contains a regulatory ( R) and catalytic ( C) domain. In this study, isolated recombinant R domains of PKGI alpha(Delta 349-670) and PKGI beta- (Delta 364-685) containing the dimerization and autoinhibitory subdomains and two allosteric cGMP-binding sites were expressed in Sf9 cells. Both R domains were dimers with elongated conformations ( Stokes radii of 44 and 51 A, respectively, and frictional coefficients of 1.6 and 1.8, respectively). Exchange dissociation kinetics and K-D values for cGMP were similar for each holoenzyme and its isolated R domain, indicating that under these conditions the C domain does not appreciably alter cGMP-binding functions of the R domain. As determined by gel filtration chromatography, cGMP binding caused elongation of the PKGI alpha-isolated R domain and contraction of the PKGI alpha-isolated R domain. Cyclic GMP-bound forms of the isoforms have similar physical dimensions that may reflect a common conformation of active isoforms. Elongation of the PKGI beta holoenzyme associated with cGMP binding and PKG activation cannot be explained solely by conformational change in its R domain, but elongation of the PKGI alpha R domain may partially account for the elongation of wild type PKGI alpha associated with cGMP binding. The cGMP-induced conformational changes in the respective R domains are likely to be critical for kinase activation.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Francis, SH (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Light Hall Rm 702, Nashville, TN 37232 USA.	Sharron.francis@vanderbilt.edu			NIDDK NIH HHS [DK 40029, DK 58277] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029, R01DK058277] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; Busch JL, 2002, J BIOL CHEM, V277, P34048, DOI 10.1074/jbc.M202761200; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; Dostmann WRG, 1996, FEBS LETT, V398, P206, DOI 10.1016/S0014-5793(96)01242-2; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 2002, FRONT BIOSCI-LANDMRK, V7, pD580, DOI 10.2741/francis; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; FRANCIS SH, 1993, CYCLIC GMP SYNTHESIS, P115; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kotera J, 2003, BIOCHEM J, V372, P419, DOI 10.1042/BJ20030107; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; Richie-Jannetta R, 2003, J BIOL CHEM, V278, P50070, DOI 10.1074/jbc.M306796200; Ruth P, 1997, J BIOL CHEM, V272, P10522; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Wall ME, 2003, P NATL ACAD SCI USA, V100, P2380, DOI 10.1073/pnas.0534892100; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	30	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6977	6984		10.1074/jbc.M510886200	http://dx.doi.org/10.1074/jbc.M510886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407222	hybrid			2022-12-27	WOS:000236030900010
J	Grant, JE; Guo, LW; Vestling, MM; Martemyanov, KA; Arshavsky, VY; Ruoho, AE				Grant, JE; Guo, LW; Vestling, MM; Martemyanov, KA; Arshavsky, VY; Ruoho, AE			The N terminus of GTP gamma S-activated transducin alpha-subunit interacts with the C terminus of the cGMP phosphodiesterase gamma-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; LIPID MODIFICATIONS; INHIBITORY SUBUNIT; AMINO-TERMINUS; BINDING-SITES; 2.0 ANGSTROM; BETA-GAMMA; PHOTORECEPTORS	Dynamic regulation of G-protein signaling in the phototransduction cascade ensures the high temporal resolution of vision. In a key step, the activated alpha-subunit of transducin (G alpha(t)-GTP) activates the cGMP phosphodiesterase (PDE) by binding the inhibitory gamma-subunit (PDE gamma). Significant progress in understanding the interaction between G alpha(t) and PDE gamma was achieved by solving the crystal structure of the PDE gamma C-terminal peptide bound to G alpha(t) in the transition state for GTP hydrolysis (Slep, K. C., Kercher, M. A., He, W., Cowan, C. W., Wensel, T. G., and Sigler, P. B. ( 2001) Nature 409, 1071 1077). However, some of the structural elements of each molecule were absent in the crystal structure. We have probed the binding surface between the PDE gamma C terminus and activated G alpha(t) bound to guanosine 5'-O-(3-thio)-triphosphate (GTP gamma S) using a series of full-length PDE gamma photoprobes generated by intein-mediated expressed protein ligation. For each of seven PDE gamma photoprobe species, expressed protein ligation allowed one benzoyl-L-phenylalaine substitution at selected hydrophobic C-terminal positions, and the addition of a biotin affinity tag at the extreme C terminus. We have detected photocross-linking from several PDE gamma C-terminal positions to the G alpha(t)-GTP gamma S N terminus, particularly from PDE gamma residue 73. The overall percentage of cross-linking to the G alpha(t)-GTP gamma S N terminus was analyzed using a far Western method for examining G alpha(t)-GTP gamma S proteolytic digestion patterns. Furthermore, mass spectrometric analysis of cross-links to G alpha(t) from a benzoyl-phenylalanine replacement at PDE gamma position 86 localized the region of photoinsertion to G alpha(t) N-terminal residues G alpha(t)-(22 - 26). This novel G alpha(t)/PDE gamma interaction suggests that the transducin N terminus plays an active role in signal transduction.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School	Ruoho, AE (corresponding author), 1300 Univ Ave, Madison, WI 53706 USA.	aeruoho@facstaff.wisc.edu			NEI NIH HHS [EY12859] Funding Source: Medline; NIGMS NIH HHS [GM33138] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033138] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Granovsky AE, 2001, BIOCHEMISTRY-US, V40, P13209, DOI 10.1021/bi011127j; Guo LW, 2005, J BIOL CHEM, V280, P12585, DOI 10.1074/jbc.M410380200; Hashimoto Y, 2004, J BIOCHEM, V135, P319, DOI 10.1093/jb/mvh039; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; KUHN H, 1980, NATURE, V283, P749; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Martemyanov KA, 2004, METHOD ENZYMOL, V390, P196; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Medkova M, 2002, BIOCHEMISTRY-US, V41, P9962, DOI 10.1021/bi0255726; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NEUBERT TA, 1995, METHOD ENZYMOL, V250, P487; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Preininger AM, 2003, BIOCHEMISTRY-US, V42, P7931, DOI 10.1021/bi0345438; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; TING TD, 1993, METH NEUROSCI, V15, P180	40	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6194	6202		10.1074/jbc.M509511200	http://dx.doi.org/10.1074/jbc.M509511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407279	hybrid			2022-12-27	WOS:000236030800011
J	Schrodt, S; Koch, J; Tampe, R				Schrodt, S; Koch, J; Tampe, R			Membrane topology of the transporter associated with antigen processing (TAP1) within an assembled functional peptide-loading complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ABC TRANSPORTERS; STRUCTURE PREDICTION; RAT-BRAIN; BINDING; PROTEIN; MECHANISM; SUBUNITS; MSBA; HOMOLOG	The transporter associated with antigen processing (TAP) translocates antigenic peptides from the cytosol into the endoplasmic reticular lumen for subsequent loading onto major histocompatibility complex (MHC) class I molecules. These peptide-MHC complexes are inspected at the cell surface by cytotoxic T-lymphocytes. Assembly of the functional peptide transport and loading complex depends on intra- and intermolecular packing of transmembrane helices (TMs). Here, we have examined the membrane topology of human TAP1 within an assembled and functional transport complex by cysteine-scanning mutagenesis. The accessibility of single cysteine residues facing the cytosol or endoplasmic reticular lumen was probed by aminimally invasive approach using membrane-impermeable, thiol-specific fluorophores in semipermeabilized "living" cells. TAP1 contains ten transmembrane segments, which place the N and C termini in the cytosol. The transmembrane domain consists of a translocation core of six TMs, a building block conserved among most ATP-binding cassette transporters, and a unique additional N-terminal domain of four TMs, essential for tapasin binding and assembly of the peptide-loading complex. This study provides a first map of the structural organization of the TAP machinery within the macromolecular MHCI peptide-loading complex.	Univ Frankfurt, Bioctr, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Univ Frankfurt, Bioctr, Inst Biochem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Beismann-Driemeyer S, 2004, ANGEW CHEM INT EDIT, V43, P4014, DOI 10.1002/anie.200300642; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen M, 2004, J BIOL CHEM, V279, P46073, DOI 10.1074/jbc.M404042200; Gileadi U, 1997, J BIOL CHEM, V272, P11103; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Heintke S, 2003, FEBS LETT, V533, P42, DOI 10.1016/S0014-5793(02)03746-8; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Koch J, 2005, FEBS LETT, V579, P4413, DOI 10.1016/j.febslet.2005.07.006; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lankat-Buttgereit B, 1999, FEBS LETT, V464, P108, DOI 10.1016/S0014-5793(99)01676-2; Lehner PJ, 2004, CURR OPIN IMMUNOL, V16, P82, DOI 10.1016/j.coi.2003.11.012; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; STOFFEL W, 1993, FEBS LETT, V333, P119, DOI 10.1016/0014-5793(93)80387-A; TAMPE R, 1997, UNUSUAL SECRETORY PA, P115; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	33	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6455	6462		10.1074/jbc.M509784200	http://dx.doi.org/10.1074/jbc.M509784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407277	hybrid			2022-12-27	WOS:000236030800040
J	Chang, YF; Carman, GM				Chang, YF; Carman, GM			Casein kinase II phosphorylation of the yeast phospholipid synthesis transcription factor Opi1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN OPI1P; SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; COORDINATE REGULATION; FUNCTIONAL-ANALYSIS; NEGATIVE REGULATOR; GENETIC-REGULATION; STRUCTURAL GENE; SHUTTLE VECTORS	The transcription factor Opi1p regulates phospholipid synthesis in the yeast Saccharomyces cerevisiae by repressing the expression of several UAS(INO)-containing genes (e.g. INO1). Opi1p repressor activity is most active in inositol-supplemented cells. Regulation of Opi1p repressor activity is mediated by multiple phosphorylations catalyzed by protein kinases A and C. In this work, we showed that Opi1p was also phosphorylated by casein kinase II. Using purified maltose-binding protein-Opi1p as a substrate, casein kinase II activity was dose-and time-dependent and dependent on the concentrations of maltose-binding protein-Opi1p (K-m = 25 mu g/ml) and ATP (K-m = 7 mu M). Of three mutations (S10A, S38A, and S239A) in putative phosphorylation sites, only the S10A mutation affected Opi1p phosphorylation. That Ser(10) was a specific target of casein kinase II was confirmed by the loss of a phosphopeptide in the S10A mutant protein. The S10A mutation did not affect phosphorylation of Opi1p by either protein kinase A or protein kinase C. Likewise, phosphorylation of Opi1p by casein kinase II was not affected by mutations in protein kinase A (S31A and S251A) and protein kinase C (S26A) phosphorylation sites. Expression of the OPI1(S10A) allele in an opi1 Delta mutant attenuated (2-fold) the repressive effect of Opi1p on INO1 expression, and this effect was only observed when cells were grown in the absence of inositol. These data supported the conclusion that casein kinase II phosphorylation at Ser10 played a role in stimulating the repression of INO1 when Opi1p was not in its most active state (i.e. in inositol-dprived cells).	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [R01 GM050679, GM50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 2005, BIOCHEM SOC T, V33, P1150, DOI 10.1042/BST0331150; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CHESTER N, 1995, J BIOL CHEM, V270, P7501, DOI 10.1074/jbc.270.13.7501; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARLOW F, 1988, ANTIBODIES LAB MANUA; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER RL, 1993, ADV LIPID RES, V26, P253; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MORASH SC, 1994, J BIOL CHEM, V269, P28769; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; REED JC, 1994, J BIOL CHEM, V269, P18192; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SIKORSKI RS, 1989, GENETICS, V122, P19; Sreenivas A, 2003, J BIOL CHEM, V278, P20673, DOI 10.1074/jbc.M300132200; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WHITE MJ, 1991, J BIOL CHEM, V266, P863; WU WI, 1993, J BIOL CHEM, V268, P13830; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777	74	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4754	4761		10.1074/jbc.M513064200	http://dx.doi.org/10.1074/jbc.M513064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16407309	Green Accepted, hybrid			2022-12-27	WOS:000235426200025
J	Surjit, M; Liu, BP; Chow, VTK; Lal, SK				Surjit, M; Liu, BP; Chow, VTK; Lal, SK			The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS K-BZIP; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; LYTIC REPLICATION; SARS CORONAVIRUS; G(1); P53; ARREST; GROWTH; INDUCTION	Deregulation of the cell cycle is a common strategy employed by many DNA and RNA viruses to trap and exploit the host cell machinery toward their own benefit. In many coronaviruses, the nucleocapsid protein (N protein) has been shown to inhibit cell cycle progression although the mechanism behind this is poorly understood. The N protein of severe acute respiratory syndrome-coronavirus (SARS-CoV) bears signature motifs for binding to cyclin and phosphorylation by cyclin-dependent kinase (CDK) and has recently been reported by us to get phosphorylated by the cyclin-CDK complex (Surjit, M., Kumar, R., Mishra, R. N., Reddy, M. K., Chow, V. T., and Lal, S. K. (2005) J. Virol. 79, 11476-11486). In the present study, we prove that the N protein of SARS-CoV can inhibit S phase progression in mammalian cell lines. N protein expression was found to directly inhibit the activity of the cyclin-CDK complex, resulting in hypophosphorylation of retinoblastoma protein with a concomitant down-regulation in E2F1-mediated transactivation. Coexpression of E2F1 under such conditions could restore the expression of S phase genes. Analysis of RXL and CDK phosphorylation mutant N protein identified the mechanism of inhibition of CDK4 and CDK2 activity to be different. Whereas N protein could directly bind to cyclin D and inhibit the activity of CDK4-cyclin D complex; inhibition of CDK2 activity appeared to be achieved in two different ways: indirectly by down-regulation of protein levels of CDK2, cyclin E, and cyclin A and by direct binding of N protein to CDK2-cyclin complex. Down-regulation of E2F1 targets was also observed in SARS-CoV-infected VeroE6 cells. These data suggest that the S phase inhibitory activity of the N protein may have major significance during viral pathogenesis.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India; Natl Univ Singapore, Fac Med, Dept Microbiol, Human Genome Lab, Singapore 117597, Singapore	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; National University of Singapore	Lal, SK (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, Aruna Asaf Ali Rd, New Delhi 110067, India.	sunillal@icgeb.res.in		Chow, Vincent/0000-0003-2634-6213				Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; Chen CJ, 2004, J VIROL, V78, P10410, DOI 10.1128/JVI.78.19.10410-10419.2004; Flemington EK, 2001, J VIROL, V75, P4475, DOI 10.1128/JVI.75.10.4475-4481.2001; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hobbs WE, 1999, J VIROL, V73, P8245, DOI 10.1128/JVI.73.10.8245-8255.1999; Ikeda K, 1998, J HISTOCHEM CYTOCHEM, V46, P397, DOI 10.1177/002215549804600314; Izumiya Y, 2003, J VIROL, V77, P9652, DOI 10.1128/JVI.77.17.9652-9661.2003; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kramer MF, 2003, J VIROL, V77, P9533, DOI 10.1128/JVI.77.17.9533-9541.2003; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Lu MS, 1999, J VIROL, V73, P676, DOI 10.1128/JVI.73.1.676-683.1999; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Munir S, 2003, J VIROL, V77, P4899, DOI 10.1128/JVI.77.8.4899-4910.2003; Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Polson AG, 2001, J VIROL, V75, P3175, DOI 10.1128/JVI.75.7.3175-3184.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 2000, CANCER RES, V60, P3489; Song BW, 2001, VIROLOGY, V290, P320, DOI 10.1006/viro.2001.1175; Surjit M, 2005, J VIROL, V79, P11476, DOI 10.1128/JVI.79.17.11476-11486.2005; Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wiebusch L, 1999, J VIROL, V73, P9274, DOI 10.1128/JVI.73.11.9274-9283.1999; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	35	140	146	6	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10669	10681		10.1074/jbc.M509233200	http://dx.doi.org/10.1074/jbc.M509233200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16431923	Green Published, hybrid			2022-12-27	WOS:000236822200005
J	Zhang, H; Schmidt, BZ; Sun, F; Condliffe, SB; Butterworth, MB; Youker, RT; Brodsky, JL; Aridor, M; Frizzell, RA				Zhang, H; Schmidt, BZ; Sun, F; Condliffe, SB; Butterworth, MB; Youker, RT; Brodsky, JL; Aridor, M; Frizzell, RA			Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN-VIRUS-40 LARGE T; DELTA F508 MUTATION; HEAT-SHOCK-PROTEIN; QUALITY-CONTROL; KINASE-A; CHAPERONE; CFTR; EXOCYTOSIS; COPII; HSP70	We examined the role of the cysteine string protein (Csp) in cystic fibrosis transmembrane conductance regulator ( CFTR) biogenesis in relation to another J-domain protein, Hdj-2, a recognized CFTR cochaperone. Increased expression of Csp produced a dose-dependent reduction in mature(band C) CFTR and an increase in immature( band B) CFTR. Exogenous expression of Hdj-2 also increased CFTR band B, but unlike Csp, Hdj-2 increased band C as well. The Csp-induced block of CFTR maturation required Hsp70, because a J-domain mutant (H43Q) that interferes with the ability of Csp to stimulate Hsp70 ATPase activity relieved the Csp-induced block of CFTR maturation. Nevertheless, Csp H43Q still increased immature CFTR. Csp-induced band B CFTR was found adjacent to the nucleus, co-localizing with calnexin, and it remained detergent-soluble. These data indicate that Csp did not block CFTR maturation by promoting the aggregation or degradation of immature CFTR. Csp knockdown by RNA interference produced a 5-fold increase in mature CFTR and augmented cAMP-stimulated CFTR currents. Thus, the production of mature CFTR is inversely related to the expression level of Csp. Both Csp and Hdj-2 associated with the CFTR R-domain in vitro, and Hdj-2 binding was displaced by Csp, suggesting common interaction sites. Combined expression of Csp and Hdj-2 mimicked the effect of Csp alone, a block of CFTR maturation. But together, Csp and Hdj-2 produced additive increases in CFTR band B, and this did not depend on their interactions with Hsp70, consistent with direct chaperone actions of these proteins. Like Hdj-2, Csp reduced the aggregation of NBD1 in vitro in the absence of Hsp70. Our data suggest that both Csp and Hdj-2 facilitate the biosynthesis of immature CFTR, acting as direct CFTR chaperones, but in addition, Csp is positioned later in the CFTR biogenesis cascade where it regulates the production of mature CFTR by limiting its exit from the endoplasmic reticulum.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu	Youker, Robert/AAP-8725-2021	Schmidt, Bela Z/0000-0003-1085-9372; Youker, Robert/0000-0002-3986-1655; Butterworth, Michael/0000-0002-2173-8333	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062318, R21DK060835, P30DK072506, R56DK062318, R01DK068196] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62318, DK68196, DK60835, R01 DK062318, DK72506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Aridor M, 1996, NATURE, V383, P220, DOI 10.1038/383220a0; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; Barlowe C, 2003, CELL, V114, P395, DOI 10.1016/S0092-8674(03)00650-0; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Boal F, 2004, BIOCHEMISTRY-US, V43, P16212, DOI 10.1021/bi048612+; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6; Butterworth MB, 2005, AM J PHYSIOL-RENAL, V289, pF969, DOI 10.1152/ajprenal.00390.2003; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Coppola T, 1996, FEBS LETT, V391, P269, DOI 10.1016/0014-5793(96)00750-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Eberle KK, 1998, CELL TISSUE RES, V294, P203, DOI 10.1007/s004410051170; Evans GJO, 2003, BIOCHEM SOC T, V31, P824, DOI 10.1042/bst0310824; Evans GJO, 2003, TRAFFIC, V4, P653, DOI 10.1034/j.1600-0854.2003.00127.x; Fewell SW, 2004, J BIOL CHEM, V279, P51131, DOI 10.1074/jbc.M404857200; Fewell SW, 2002, P NATL ACAD SCI USA, V99, P2002, DOI 10.1073/pnas.042670999; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Mancias JD, 2005, TRAFFIC, V6, P278, DOI 10.1111/j.1600-0854.2005.00279.x; MASTROGIACOMO A, 1994, J NEUROCHEM, V62, P873; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; PIND S, 1994, J BIOL CHEM, V269, P12784; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Sakisaka T, 2002, EMBO J, V21, P6125, DOI 10.1093/emboj/cdf603; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Smith GB, 2005, J BIOL CHEM, V280, P32669, DOI 10.1074/jbc.M501806200; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; STRONG TV, 1993, HUM MOL GENET, V2, P225, DOI 10.1093/hmg/2.3.225; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welch WJ, 2004, SEMIN CELL DEV BIOL, V15, P31, DOI 10.1016/j.semcdb.2003.12.011; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200; Zhu KM, 1998, CANCER CAUSE CONTROL, V9, P77, DOI 10.1023/A:1008853421083; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	61	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11312	11321		10.1074/jbc.M512013200	http://dx.doi.org/10.1074/jbc.M512013200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16469739	Green Published, hybrid			2022-12-27	WOS:000236822200074
J	Kovacevic, S; Anderson, D; Morita, YS; Patterson, J; Haites, R; McMillan, BNI; Coppel, R; McConville, MJ; Billman-Jacobe, H				Kovacevic, S; Anderson, D; Morita, YS; Patterson, J; Haites, R; McMillan, BNI; Coppel, R; McConville, MJ; Billman-Jacobe, H			Identification of a novel protein with a role in lipoarabinomannan biosynthesis in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMEGMATIS; PHOSPHATIDYLINOSITOL; TUBERCULOSIS; BIOGENESIS; GENE	All species of Mycobacteria synthesize distinctive cell walls that are rich in phosphatidylinositol mannosides (PIMs), lipomannan (LM), and lipoarabinomannan (LAM). PIM glycolipids, having 2-4 mannose residues, can either be channeled into polar PIM species (with 6 Man residues) or hypermannosylated to form LM and LAM. In this study, we have identified a Mycobacterium smegmatis gene, termed lpqW, that is required for the conversion of PIMs to LAM and is highly conserved in all mycobacteria. A transposon mutant, Myco481, containing an insertion near the 3' end of lpqW exhibited altered colony morphology on complex agar medium. This mutant was unstable and was consistently overgrown by a second mutant, represented by Myco481.1, that had normal growth and colony characteristics. Biochemical analysis and metabolic labeling studies showed that Myco481 synthesized the complete spectrum of apolar and polar PIMs but was unable to make LAM. LAM biosynthesis was restored to near wild type levels in Myco481.1. However, this mutant was unable to synthesize the major polar PIM (AcPIM6) and accumulated a smaller intermediate, AcPIM4. Targeted disruption of the lpqW gene and complementation of the initial Myco481 mutant with the wild type gene confirmed that the phenotype of this mutant was due to loss of LpqW. These studies suggest that LpqW has a role in regulating the flux of early PIM intermediates into polar PIM or LAM biosynthesis. They also suggest that AcPIM4 is the likely branch point intermediate in polar PIM and LAM biosynthesis.	Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Inst Mol Sci & Biotechnol, Parkville, Vic 3010, Australia; Monash Univ, Dept Microbiol, ARC Ctr Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia	University of Melbourne; University of Melbourne; Monash University	Billman-Jacobe, H (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.	hbj@unimelb.edu.au	Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124; Billman-Jacobe, Helen/0000-0001-5713-4657; Morita, Yasu/0000-0002-4514-9242				Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; Brennan PJ, 1997, BIOCHEM SOC T, V25, P188, DOI 10.1042/bst0250188; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Gibson KJC, 2003, BIOCHEM J, V372, P821, DOI 10.1042/BJ20030197; GUILHOT C, 1994, J BACTERIOL, V176, P535, DOI 10.1128/JB.176.2.535-539.1994; Haites RE, 2005, J BIOL CHEM, V280, P10981, DOI 10.1074/jbc.M413443200; HENRY RJ, 1983, J CHROMATOGR, V256, P419, DOI 10.1016/S0021-9673(01)88259-5; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; Jeevarajah D, 2004, J BACTERIOL, V186, P6792, DOI 10.1128/JB.186.20.6792-6799.2004; KORDULAKOVA J, 2002, J BIOL CHEM, V14, P14; Morita YS, 2005, J BIOL CHEM, V280, P21645, DOI 10.1074/jbc.m414181200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Prod'hom G, 1998, FEMS MICROBIOL LETT, V158, P75, DOI 10.1111/j.1574-6968.1998.tb12803.x; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; Rawat M, 2003, MICROBIOL-SGM, V149, P1341, DOI 10.1099/mic.0.26084-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Sauton B., 1912, CR HEBD ACAD SCI, V92, P85; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	31	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9011	9017		10.1074/jbc.M511709200	http://dx.doi.org/10.1074/jbc.M511709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455649	hybrid			2022-12-27	WOS:000236404700005
J	Wang, S; Raven, JF; Baltzis, D; Kazemi, S; Brunet, DV; Hatzoglou, M; Tremblay, ML; Koromilas, AE				Wang, S; Raven, JF; Baltzis, D; Kazemi, S; Brunet, DV; Hatzoglou, M; Tremblay, ML; Koromilas, AE			The catalytic activity of the eukaryotic initiation factor-2 alpha kinase PKR is required to negatively regulate Stat1 and Stat3 via activation of the T-cell protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOMATITIS-VIRUS INFECTION; TARGETED DISRUPTION; GENE-EXPRESSION; INNATE IMMUNITY; MICE; PHOSPHORYLATION; SPECIFICITY; RESISTANCE; APOPTOSIS; PATHWAY	Tyrosine phosphorylation of the transcription factors Stat1 and Stat3 is required for them to dimerize, translocate to the nucleus, and induce gene transcription. Nuclear Stat1 and Stat3 are dephosphorylated and deactivated by the T-cell protein-tyrosine phosphatase (TC-PTP), which facilitates the return of both proteins to the cytoplasm. The protein kinase PKR plays an important role in translational control through the modulation of eukaryotic initiation factor-2 alpha phosphorylation. Previous data have implicated PKR in cell signaling via regulation of Stat1 and Stat3, but the molecular mechanisms underlying these events have remained elusive. Using PKR-/- mouse embryonic fibroblasts and a conditionally active form of human PKR, we demonstrate herein that tyrosine ( but not serine) phosphorylation of either Stat1 or Stat3 is impaired in cells with activated kinase. This reduction in Stat1 and Stat3 tyrosine phosphorylation by active PKR proceeds through TC-PTP, which is a substrate of the eukaryotic initiation factor-2 alpha kinase both in vitro and in vivo. TC-PTP phosphorylation alone is insufficient to increase its in vivo phosphatase activity unless accompanied by the inhibition of protein synthesis as a result of PKR activation. These data reveal a novel function of PKR as a negative regulator of Stat1 and Stat3 with important implications in cell signaling.	McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; Case Western Reserve University	Koromilas, AE (corresponding author), McGill Univ, Lady Davis Inst Med Res, Rm 508,3755 Cote St Catherine St, Montreal, PQ H3T 1E2, Canada.	antonis.koromilas@mcgill.ca						Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baltzis D, 2004, J VIROL, V78, P12747, DOI 10.1128/JVI.78.23.12747-12761.2004; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bukczynska P, 2004, BIOCHEM J, V380, P939, DOI 10.1042/BJ20031780; Deb A, 2001, EMBO J, V20, P2487, DOI 10.1093/emboj/20.10.2487; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Kazemi S, 2004, MOL CELL BIOL, V24, P3415, DOI 10.1128/MCB.24.8.3415-3429.2004; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lam MHC, 2001, J BIOL CHEM, V276, P37700, DOI 10.1074/jbc.M105128200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; McBride Kevin M, 2003, Sci STKE, V2003, pRE13; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer T, 2004, EUR J BIOCHEM, V271, P4606, DOI 10.1111/j.1432-1033.2004.04423.x; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wong AHT, 2001, J BIOL CHEM, V276, P13727, DOI 10.1074/jbc.M011240200; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	44	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9439	9449		10.1074/jbc.M504977200	http://dx.doi.org/10.1074/jbc.M504977200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431927	hybrid			2022-12-27	WOS:000236404700054
J	Augustus, AS; Buchanan, J; Park, TS; Hirata, K; Noh, HL; Sun, J; Homma, S; D'armiento, J; Abel, ED; Goldberg, IJ				Augustus, AS; Buchanan, J; Park, TS; Hirata, K; Noh, HL; Sun, J; Homma, S; D'armiento, J; Abel, ED; Goldberg, IJ			Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTROPHIED RAT HEARTS; TISSUE GROWTH-FACTOR; PRESSURE-OVERLOAD; TRANSGENIC MICE; ISCHEMIC-HEART; MOUSE HEARTS; TGF-BETA; OXIDATION; EXPRESSION; INHIBITION	Long-chain fatty acids (FAs) are the predominant energy substrate utilized by the adult heart. The heart can utilize unesterified FA bound to albumin or FA obtained from lipolysis of lipoprotein-bound triglyceride (TG). We used heart-specific lipoprotein lipase knock-out mice (hLpL0) to test whether these two sources of FA are interchangeable and necessary for optimal heart function. Hearts unable to obtain FA from lipoprotein TG were able to compensate by increasing glucose uptake, glycolysis, and glucose oxidation. HLpL0 hearts had decreased expression of pyruvate dehydrogenase kinase 4 and increased cardiomyocyte expression of glucose transporter 4. Conversely, FA oxidation rates were reduced in isolated perfused hLpL0 hearts. Following abdominal aortic constriction expression levels of genes regulating FA and glucose metabolism were acutely up-regulated in control and hLpL0 mice, yet all hLpL0 mice died within 48 h of abdominal aortic constriction. Older hLpL0 mice developed cardiac dysfunction characterized by decreased fractional shortening and interstitial and perivascular fibrosis. HLpL0 hearts had increased expression of several genes associated with transforming growth factor-beta signaling. Thus, long term reduction of lipoprotein FA uptake is associated with impaired cardiac function despite a compensatory increase in glucose utilization.	Columbia Univ, Dept Med, Div Prevent Med & Nutr, New York, NY 10032 USA; Columbia Univ, Dept Med, Div Cardiol, New York, NY 10032 USA; Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Univ Utah, Sch Med, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84112 USA	Columbia University; Columbia University; Columbia University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Goldberg, IJ (corresponding author), Columbia Univ, Dept Med, Div Prevent Med & Nutr, 630 W 168th St, New York, NY 10032 USA.	ijg3@columbia.edu		Abel, E. Dale/0000-0001-5290-0738	NHLBI NIH HHS [R01 HL045095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; ALLARD MF, 1994, AM J PHYSIOL, V267, pH66, DOI 10.1152/ajpheart.1994.267.1.H66; Augustus A, 2004, J BIOL CHEM, V279, P25050, DOI 10.1074/jbc.M401028200; Augustus AS, 2003, AM J PHYSIOL-ENDOC M, V284, pE331, DOI 10.1152/ajpendo.00298.2002; BALLARD FB, 1960, J CLIN INVEST, V39, P717, DOI 10.1172/JCI104088; Belke DD, 2000, AM J PHYSIOL-ENDOC M, V279, pE1104, DOI 10.1152/ajpendo.2000.279.5.E1104; Belke DD, 2001, AM J PHYSIOL-ENDOC M, V280, pE420, DOI 10.1152/ajpendo.2001.280.3.E420; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Belke DD, 1999, AM J PHYSIOL-REG I, V277, pR1210, DOI 10.1152/ajpregu.1999.277.4.R1210; Chandler MP, 2003, CARDIOVASC RES, V59, P143, DOI 10.1016/S0008-6363(03)00327-4; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; Clements ML, 1997, HYPERTENSION, V29, P1156, DOI 10.1161/01.HYP.29.5.1156; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Djouadi F, 1999, PROSTAG LEUKOTR ESS, V60, P339, DOI 10.1016/S0952-3278(99)80009-X; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; FOLCH J, 1957, J BIOL CHEM, V226, P497; Folmes Clifford D L, 2005, Curr Atheroscler Rep, V7, P63, DOI 10.1007/s11883-005-0077-2; Grynberg A, 1996, J CARDIOVASC PHARM, V28, pS11; Hocquette JF, 1998, COMP BIOCHEM PHYS B, V121, P201, DOI 10.1016/S0305-0491(98)10090-1; Hu P, 2003, AM J PHYSIOL-HEART C, V285, pH1261, DOI 10.1152/ajpheart.00108.2003; Irie H, 2003, P NATL ACAD SCI USA, V100, P6819, DOI 10.1073/pnas.1132094100; Kelly MM, 2005, AM J RESP CELL MOL, V32, P99, DOI 10.1165/rcmb.2004-0190OC; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kuang M, 2004, CIRCULATION, V109, P1550, DOI 10.1161/01.CIR.0000121730.41801.12; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Liao RL, 2002, CIRCULATION, V106, P2125, DOI 10.1161/01.CIR.0000034049.61181.F3; LITWIN SE, 1990, AM J PHYSIOL, V258, pH51, DOI 10.1152/ajpheart.1990.258.1.H51; Liu Q, 2002, J AM COLL CARDIOL, V39, P718, DOI 10.1016/S0735-1097(01)01803-4; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; Mazumder PK, 2004, DIABETES, V53, P2366, DOI 10.2337/diabetes.53.9.2366; Moncrieff J, 2004, CURR OPIN CARDIOL, V19, P326, DOI 10.1097/01.hco.0000127134.66225.97; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Ohnishi H, 1998, J MOL CELL CARDIOL, V30, P2411, DOI 10.1006/jmcc.1998.0799; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; Pillutla P, 2005, AM J PHYSIOL-ENDOC M, V288, pE1229, DOI 10.1152/ajpendo.00273.2004; Sambandam Nandakumar, 2002, Heart Fail Rev, V7, P161; Siri PW, 2003, METABOLISM, V52, P659, DOI 10.1016/S0026-0495(03)00061-1; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Stanley William C, 2002, Heart Fail Rev, V7, P115, DOI 10.1023/A:1015320423577; Syed F, 2004, CIRC RES, V95, P1200, DOI 10.1161/01.RES.0000150366.08972.7f; Takuma S, 2001, AM J PHYSIOL-HEART C, V280, pH2364, DOI 10.1152/ajpheart.2001.280.5.H2364; Tian R, 2001, CIRCULATION, V103, P2961, DOI 10.1161/01.CIR.103.24.2961; van der Vusse GJ, 2000, CARDIOVASC RES, V45, P279, DOI 10.1016/S0008-6363(99)00263-1; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; Wambolt RB, 2000, J AM COLL CARDIOL, V36, P1378, DOI 10.1016/S0735-1097(00)00856-1; Wang CY, 2002, CIRCULATION, V105, P1609, DOI 10.1161/01.CIR.0000013022.11250.30; Yagyu H, 2003, J CLIN INVEST, V111, P419, DOI [10.1172/JCI200316751, 10.1172/JCI16751]	48	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8716	8723		10.1074/jbc.M509890200	http://dx.doi.org/10.1074/jbc.M509890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16410253	hybrid			2022-12-27	WOS:000236247100049
J	Peloponese, JM; Jeang, KT				Peloponese, JM; Jeang, KT			Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 tax oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR AP-1; I TAX; SIGNALING PATHWAY; GROWTH-FACTOR; HUMAN CANCER; C-FOS; PHOSPHATIDYLINOSITOL 3'-KINASE; TRANSGENIC MICE; TRANSFORMATION	Human T-cell leukemia virus type 1 is an oncogenic retrovirus etiologically causal of adult T-cell leukemia. The virus encodes a Tax oncoprotein, which functions in transcriptional regulation, cell cycle control, and transformation. Because adult T-cell leukemia is a highly virulent cancer that is resistant to numerous chemotherapeutic treatments, to understand better this disease it is important to comprehend how human T-cell leukemia virus type 1 promotes cellular growth and survival. Most of the existing data point to Tax activation of NF-kappa B as important for cellular proliferation and transformation. We show here that Tax, in the absence of NF-kappa B signaling, can activate activator protein-1 to promote cellular proliferation and survival. Tax is shown to activate activator protein-1 through the phosphatidylinositol 3-kinase/Akt pathway.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kjeang@niaid.nih.gov	Jeang, Kuan-Teh/A-2424-2008	Peloponese, Jean-Marie/0000-0002-9677-9703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Asquith B, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-75; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Breslin EM, 2005, BRIT J PHARMACOL, V144, P791, DOI 10.1038/sj.bjp.0706061; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dong ZG, 1999, ANTICANCER RES, V19, P3743; Fraedrich K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-54; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Fujii MI, 2000, AIDS RES HUM RETROV, V16, P1603, DOI 10.1089/08892220050193029; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 2003, IMMUNOL REV, V192, P7, DOI 10.1034/j.1600-065X.2003.00008.x; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kannagi Mari, 2004, Expert Rev Anticancer Ther, V4, P369, DOI 10.1586/14737140.4.3.369; Katabami M, 2005, J BIOL CHEM, V280, P16728, DOI 10.1074/jbc.M413892200; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kim R, 2003, ANTI-CANCER DRUG, V14, P3, DOI 10.1097/00001813-200301000-00002; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Lazo A, 1996, J MED PRIMATOL, V25, P257, DOI 10.1111/j.1600-0684.1996.tb00208.x; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Martelli AM, 2005, HISTOL HISTOPATHOL, V20, P239, DOI 10.14670/HH-20.239; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Mori N, 2000, BLOOD, V95, P3915; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ozes ON, 1999, NATURE, V401, P82; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Pim D, 2005, ONCOGENE, V24, P7830, DOI 10.1038/sj.onc.1208935; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Xu X, 1996, J INVEST MED, V44, P113; Xu X, 1996, ONCOGENE, V13, P135; Yakova Maria, 2005, Retrovirology, V2, P4, DOI 10.1186/1742-4690-2-4; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	80	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8927	8938		10.1074/jbc.M510598200	http://dx.doi.org/10.1074/jbc.M510598200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16436385	Green Published, hybrid			2022-12-27	WOS:000236247100073
J	Xu, Y; Huang, S; Liu, ZG; Han, JH				Xu, Y; Huang, S; Liu, ZG; Han, JH			Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; APOPTOSIS-INDUCING FACTOR; RECEPTOR-INTERACTING PROTEIN; PERMEABILITY TRANSITION; CEREBRAL-ISCHEMIA; DNA-DAMAGE; PATHWAY; BCL-2; RIP	Poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation-induced necrosis has been implicated in several pathophysiological conditions. Although mitochondrial dysfunction and apoptosis-inducing factor translocation from the mitochondria to the nucleus have been suggested to play very important roles in PARP-1-mediated cell death, the signaling events downstream of PARP-1 activation in initiating mitochondria dysfunction are not clear. Here we used the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine, a potent PARP-1 activator, to study PARP-1 activation-mediated cell death. We found, based on genetic knockouts and pharmacological inhibition, that c-Jun N-terminal kinase (JNK), especially JNK1, but not the other groups of mitogen-activated protein kinase, is required for PARP-1-induced mitochondrial dysfunction, apoptosis-inducing factor translocation, and subsequent cell death. We reveal that receptor-interacting protein 1 (RIP1) and tumor necrosis factor receptor-associated factor 2 (TRAF2), are upstream of JNK in PARP-1 hyperactivated cells, because PARP-1-induced JNK activation was attenuated in RIP1-/- and TRAF2-/- mouse embryonic fibroblast cells. Consistently, knockouts of RIP1 and TRAF2 caused a resistance to PARP-1-induced cell death. Therefore, our study uncovers that RIP1, TRAF2, and JNK comprise a pathway to mediate the signaling from PARP-1 overactivation to mitochondrial dysfunction.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xu, Y (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mcbxuyue@scripps.edu	Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637, R01AI054796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067101, P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI054796, AI41637] Funding Source: Medline; NIGMS NIH HHS [GM67101, GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Bajenova O, 2004, APOPTOSIS, V9, P561, DOI 10.1023/B:APPT.0000038030.47068.49; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kanduc D, 2002, INT J ONCOL, V21, P165; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Shrivastava P, 2004, MOL CELL BIOL, V24, P6763, DOI 10.1128/MCB.24.15.6763-6772.2004; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	50	89	93	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8788	8795		10.1074/jbc.M508135200	http://dx.doi.org/10.1074/jbc.M508135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446354	hybrid			2022-12-27	WOS:000236247100058
J	Chen, HY; Challa, AK; Varki, A				Chen, HY; Challa, AK; Varki, A			9-O-acetylation of exogenously added ganglioside GD3 - The GD3 molecule induces its own O-acetylation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; DE-ORTHO-ACETYLATION; HAMSTER OVARY CELLS; PLASMA-MEMBRANE; RAT-LIVER; MONOCLONAL-ANTIBODY; SKIN FIBROBLASTS; GOLGI-APPARATUS; CULTURED-CELLS; SIALIC ACIDS	Sialic acids are sometimes 9-O-acetylated in a developmentally regulated and cell-type-specific manner. Cells naturally expressing the disialoganglioside GD3 often O-acetylate the terminal sialic acid residue, giving 9-O-acetyl-GD3 (9AcGD3), a marker of neural differentiation and malignant transformation. We also reported that Chinese hamster ovary cells transfected with GD3 synthase can spontaneously O-acetylate some of the newly synthesized GD3. It is unclear whether such phenomena result from induction of the 9-O-acetylation machinery and whether induction is caused by the GD3 synthase protein or by the GD3 molecule itself. We now show that exogenously added GD3 rapidly incorporates into the plasma membrane of Chinese hamster ovary cells, and 9AcGD3 is detected after similar to 6 h. The incorporated GD3 and newly synthesized 9AcGD3 have a half-life of similar to 24 h. This phenomenon is also seen in other cell types, such as human diploid fibroblasts. Inhibitors of gene transcription, protein translation, or endoplasmic reticulum-to-Golgi transport each prevent induction of 9-O-acetylation, without affecting GD3 incorporation. Inhibition of the initial clathrin-independent internalization of incorporated GD3 also blocks induction of 9-O-acetylation. Thus, new synthesis of one or more components of the 9-O-acetylation machinery is induced by incorporation and internalization of GD3. Prepriming with structurally related gangliosides fails to accelerate the onset of 9-O-acetylation of subsequently added GD3, indicating a requirement for specific recognition of GD3. To our knowledge, this is the first example wherein a newly expressed or exogenously introduced ganglioside induces de novo synthesis of an enzymatic machinery to modify itself, and the first evidence for a mechanism of induction of sialic acid O-acetylation.	Univ Calif San Diego, CMM E, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, CMM E, Glycobiol Res & Training Ctr, Dept Med, Rm 1065,Mail Code 0687, La Jolla, CA 92093 USA.	a1varki@ucsd.edu	Challa, Anil Kumar/AAQ-3306-2021; Challa, Anil Kumar/A-5819-2009	Challa, Anil Kumar/0000-0002-3633-3304	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; BERNHARD H, 1989, INT J CANCER, V44, P155, DOI 10.1002/ijc.2910440127; CALLIES R, 1977, EUR J BIOCHEM, V80, P425, DOI 10.1111/j.1432-1033.1977.tb11897.x; Chen HY, 2002, J EXP MED, V196, P1529, DOI 10.1084/jem.20021915; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DIAZ S, 1989, J BIOL CHEM, V264, P19416; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; Fox DA, 2001, IMMUNOL INVEST, V30, P67, DOI 10.1081/IMM-100104017; GU XB, 1995, J NEUROCHEM, V64, P2295; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; HEIDENHEIM M, 1995, BRIT J DERMATOL, V133, P392, DOI 10.1111/j.1365-2133.1995.tb02666.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; Iwersen M, 1998, GLYCOCONJUGATE J, V15, P895, DOI 10.1023/A:1006911100081; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Kanamori A, 1997, P NATL ACAD SCI USA, V94, P2897, DOI 10.1073/pnas.94.7.2897; Kolter T, 2002, J BIOL CHEM, V277, P25859, DOI 10.1074/jbc.R200001200; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; LEVINE JM, 1984, J NEUROSCI, V4, P820; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Mobius W, 1999, J HISTOCHEM CYTOCHEM, V47, P1005; Negreiros EMA, 2003, J NEUROBIOL, V57, P31, DOI 10.1002/neu.10248; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; PRETI A, 1980, J NEUROCHEM, V35, P281, DOI 10.1111/j.1471-4159.1980.tb06263.x; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; REIVINEN J, 1992, KIDNEY INT, V42, P624, DOI 10.1038/ki.1992.327; REIVINEN J, 1994, INT IMMUNOL, V6, P1409, DOI 10.1093/intimm/6.9.1409; Riboni L, 2000, METHOD ENZYMOL, V311, P656; SAITO M, 1992, J NEUROCHEM, V58, P83, DOI 10.1111/j.1471-4159.1992.tb09280.x; Satake H, 2003, J BIOL CHEM, V278, P7942, DOI 10.1074/jbc.M210565200; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; Schwarzmann G, 2001, SEMIN CELL DEV BIOL, V12, P163, DOI 10.1006/scdb.2000.0233; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P3041; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Shi WX, 1996, J BIOL CHEM, V271, P15130, DOI 10.1074/jbc.271.25.15130; Simon BM, 2002, CELL DEATH DIFFER, V9, P758, DOI 10.1038/sj.cdd.4401027; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SONDERFELD S, 1985, EUR J BIOCHEM, V149, P247, DOI 10.1111/j.1432-1033.1985.tb08919.x; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TETTAMANTI G, 1972, BRAIN RES, V47, P515, DOI 10.1016/0006-8993(72)90661-0; TRINCHERA M, 1990, J BIOCHEM-TOKYO, V107, P619, DOI 10.1093/oxfordjournals.jbchem.a123096; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; Vyas AA, 2001, BIOCHIMIE, V83, P677, DOI 10.1016/S0300-9084(01)01308-6; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	59	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7825	7833		10.1074/jbc.M512379200	http://dx.doi.org/10.1074/jbc.M512379200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434401	hybrid			2022-12-27	WOS:000236031000016
J	Dutkiewicz, R; Marszalek, J; Schillke, B; Craig, EA; Lill, R; Muhlenhoff, U				Dutkiewicz, R; Marszalek, J; Schillke, B; Craig, EA; Lill, R; Muhlenhoff, U			The Hsp70 chaperone Ssq1p is dispensable for iron-sulfur cluster formation on the scaffold protein Isu1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL HSP70; 4FE-4S CLUSTERS; 2FE-2S CLUSTER; ISCU; YEAST; BIOSYNTHESIS; BIOGENESIS; MATURATION; SYSTEM; NIFU	The specialized yeast mitochondrial chaperone system, composed of the Hsp70 Ssq1p, its co-chaperone J-protein Jac1p, and the nucleotide release factor Mge1p, perform a critical function in the biogenesis of iron-sulfur (Fe/S) proteins. Using a spectroscopic assay, we have analyzed the potential role of the chaperones in Fe/S cluster assembly on the scaffold protein Isu1p in vitro in the presence of the cysteine desulfurase Nfs1p. In the absence of chaperones, the kinetics of Fe/S cluster formation on Isu1p were compatible with a chemical reconstitution pathway with Nfs1p functioning as a sulfide donor. Addition of Ssq1p improved the rates of Fe/S cluster assembly 3-fold. However, this stimulatory effect of Ssq1p required neither ATP nor Jac1p and could be fully attributed to the activation of the Nfs1p desulfurase activity by Ssq1p. Furthermore, chaperone-stimulated Fe/S cluster assembly did not involve the specific interaction between Isu1p and Ssq1p, since the effect was observed with Isu1p mutant proteins defective in this interaction, suggesting that nonspecific binding of Ssq1p to Nfs1p helped to prevent its unfolding. Consistent with this idea, these Isu1p mutants were capable of binding an Fe/S cluster in vivo but failed to restore the growth and Fe/S cluster assembly defects of a Isu1p/ Isu2p-deficient yeast strain. Taken together, these data suggest that Ssq1p/Jac1p/Mge1p are not important for Fe/S cluster synthesis on Isu1p. Hence, consistent with previous in vivo data, these chaperones likely function in steps subsequent to the de novo synthesis of the Fe/S cluster on Isu1p.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Philipps University Marburg; Fahrenheit Universities; University of Gdansk; University of Wisconsin System; University of Wisconsin Madison	Muhlenhoff, U (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 6, D-35033 Marburg, Germany.	muehlenh@mailer.uni-marburg.de	Dutkiewicz, Rafal/F-5956-2011; Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/ABE-6979-2020	Dutkiewicz, Rafal/0000-0003-4150-0450; Lill, Roland/0000-0002-8345-6518; Marszalek, Jaroslaw/0000-0002-6978-1189	NIGMS NIH HHS [R01GM27870] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Bonomi F, 2005, J BIOL CHEM, V280, P29513, DOI 10.1074/jbc.M504344200; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Cupp-Vickery JR, 2004, J MOL BIOL, V342, P1265, DOI 10.1016/j.jmb.2004.07.025; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Dos Santos PC, 2004, J BIOL CHEM, V279, P19705, DOI 10.1074/jbc.M400278200; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Frazzon J, 2002, BIOCHEM SOC T, V30, P680, DOI 10.1042/BST0300680; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gerber J, 2004, MOL CELL BIOL, V24, P4848, DOI 10.1128/MCB.24.11.4848-4857.2004; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; Johnson DC, 2005, BIOCHEM SOC T, V33, P90, DOI 10.1042/BST0330090; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knieszner H, 2005, J BIOL CHEM, V280, P28966, DOI 10.1074/jbc.M503031200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Papenbrock J, 2000, EUR J BIOCHEM, V267, P145, DOI 10.1046/j.1432-1327.2000.00980.x; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Sambrook J., 2001, MOL CLONING LAB MANU; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Schmidt S, 2001, J MOL BIOL, V313, P13, DOI 10.1006/jmbi.2001.5013; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2004, J BIOL CHEM, V279, P53924, DOI 10.1074/jbc.M410117200; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Smith AD, 2005, BIOCHEMISTRY-US, V44, P12955, DOI 10.1021/bi051257i; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Sutton VR, 2004, J BACTERIOL, V186, P8018, DOI 10.1128/JB.186.23.8018-8025.2004; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu SP, 2005, BIOCHEMISTRY-US, V44, P4284, DOI 10.1021/bi0483007; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	56	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7801	7808		10.1074/jbc.M513301200	http://dx.doi.org/10.1074/jbc.M513301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431909	hybrid			2022-12-27	WOS:000236031000013
J	Ma, B; Audette, GF; Lin, SJ; Palcic, MM; Hazes, B; Taylor, DE				Ma, B; Audette, GF; Lin, SJ; Palcic, MM; Hazes, B; Taylor, DE			Purification, kinetic characterization, and mapping of the minimal catalytic domain and the key polar groups of Helicobacter pylori alpha-(1,3/1,4)-fucosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1,3-FUCOSYL-TRANSFERASE V; ALPHA-1,3/4 FUCOSYL-TRANSFERASES; SITE-DIRECTED MUTAGENESIS; SINGLE AMINO-ACID; SIALYL-LEWIS-X; PHASE VARIATION; HUMAN ALPHA-1,3/4-FUCOSYL-TRANSFERASES; SUBSTRATE-SPECIFICITY; ACCEPTOR SPECIFICITY; MOLECULAR-CLONING	The minimal catalytic domain of alpha-(1,3/1,4)-fucosyltransferases (FucTs) from Helicobacter pylori strains NCTC11639 and UA948 was mapped by N- and C-terminal truncations. Only the C terminus could be truncated without significant loss of activity. 11639FucT and UA948FucT contain 10 and 8 heptad repeats, respectively, which connect the catalytic domain with the C-terminal putative amphipathic alpha-helices. Deletion of all heptad repeats almost completely abolished enzyme activity. Nevertheless, with only one heptad repeat 11639FucT is fully active, whereas UA948FucT is partially active. Removal of the two putative amphipathic alpha-helices dramatically increased protein expression and solubility, enabling purification with yields of milligrams/liter. Steady-state kinetic analysis of the purified FucTs showed that 11639FucTs possessed slightly tighter binding affinity for both Type II acceptor and GDPfucose donor than UA948FucT, and its k(cat) of 2.3 s(-1) was double that of UA948FucT, which had a k(cat) value of 1.1 s(-1) for both Type II and Type I acceptors. UA948FucT strongly favors Type II over the Type I acceptor with a 20-fold difference in acceptor K-m. Sixteen modified Type I and Type II series acceptors were employed to map the molecular determinants of acceptors required for recognition by H. pylori alpha- (1,3/1,4)-FucTs. Deoxygenation at 6-C of the galactose in Type II acceptor caused a 5000-fold decrease in alpha 1,3 activity, whereas in Type I acceptor this completely abolished alpha 1,4 activity, indicating that this hydroxyl group is a key polar group.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Alberta; University of Alberta	Taylor, DE (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 1-63 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	diane.taylor@ualberta.ca	Audette, Gerald F./E-2609-2012	Audette, Gerald F./0000-0002-5695-9830				Altman E, 2003, GLYCOBIOLOGY, V13, P777, DOI 10.1093/glycob/cwg106; Appelmelk BJ, 2000, INFECT IMMUN, V68, P5928, DOI 10.1128/IAI.68.10.5928-5932.2000; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Appelmelk BJ, 1999, INFECT IMMUN, V67, P5361, DOI 10.1128/IAI.67.10.5361-5366.1999; Appelmelk BJ, 1998, INFECT IMMUN, V66, P70, DOI 10.1128/IAI.66.1.70-76.1998; Azurmendi HF, 2002, BIOPOLYMERS, V63, P89, DOI 10.1002/bip.10015; Bergman MP, 2004, J EXP MED, V200, P979, DOI 10.1084/jem.20041061; Chiu CPC, 2004, NAT STRUCT MOL BIOL, V11, P163, DOI 10.1038/nsmb720; de Vries T, 2001, GLYCOBIOLOGY, V11, P711, DOI 10.1093/glycob/11.9.711; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; Du M, 1996, CARBOHYD RES, V286, P87, DOI 10.1016/0008-6215(96)00047-X; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Dupuy F, 2004, GLYCOBIOLOGY, V14, P347, DOI 10.1093/glycob/cwh053; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Eaton KA, 2004, INFECT IMMUN, V72, P3925, DOI 10.1128/IAI.72.7.3925-3931.2004; El-Battari A, 2003, GLYCOBIOLOGY, V13, P941, DOI 10.1093/glycob/cwg117; Endo T, 2000, CURR OPIN STRUC BIOL, V10, P536, DOI 10.1016/S0959-440X(00)00127-5; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gosselin S, 1996, BIOORGAN MED CHEM, V4, P2023, DOI 10.1016/S0968-0896(97)81455-1; Guo ZM, 1997, APPL BIOCHEM BIOTECH, V68, P1, DOI 10.1007/BF02785977; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Holmes EH, 2000, J BIOL CHEM, V275, P24237, DOI 10.1074/jbc.M000888200; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOUNSELL EF, 1988, CARBOHYD RES, V178, P67, DOI 10.1016/0008-6215(88)80102-2; Jost F, 2005, GLYCOBIOLOGY, V15, P165, DOI 10.1093/glycob/cwh157; Kimura H, 1997, BIOCHEM BIOPH RES CO, V237, P131, DOI 10.1006/bbrc.1997.7100; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Ma B, 2005, J BIOL CHEM, V280, P36848, DOI 10.1074/jbc.M504415200; Ma B, 2003, J BIOL CHEM, V278, P21893, DOI 10.1074/jbc.M301704200; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Monteiro MA, 2001, BIOCHEM CELL BIOL, V79, P449, DOI 10.1139/bcb-79-4-449; Murray BW, 1997, BIOCHEMISTRY-US, V36, P823, DOI 10.1021/bi962284z; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Qiao L, 1996, J AM CHEM SOC, V118, P7653, DOI 10.1021/ja960274f; Rabbani S, 2005, GLYCOBIOLOGY, V15, P1076, DOI 10.1093/glycob/cwj004; Rasko DA, 2000, EUR J BIOCHEM, V267, P6059, DOI 10.1046/j.1432-1327.2000.01683.x; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; Rasko DA, 2001, J INFECT DIS, V184, P315, DOI 10.1086/322025; RASKO DA, 2000, THESIS U ALBERTA EDM; Sambrook J., 2001, MOL CLONING LAB MANU; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Sherwood AL, 2002, GLYCOBIOLOGY, V12, P599, DOI 10.1093/glycob/cwf075; Shinoda K, 1998, GLYCOCONJUGATE J, V15, P969, DOI 10.1023/A:1006933808303; Suresh MR, 2000, J PHARM PHARM SCI, V3, P259; Takata T, 2002, INFECT IMMUN, V70, P3073, DOI 10.1128/IAI.70.6.3073-3079.2002; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; Wang G, 1999, MICROBIOL-SGM, V145, P3245, DOI 10.1099/00221287-145-11-3245; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wang G, 2000, MOL MICROBIOL, V36, P1187, DOI 10.1046/j.1365-2958.2000.01934.x; Watt GM, 1997, CURR OPIN STRUC BIOL, V7, P652, DOI 10.1016/S0959-440X(97)80074-7; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	62	25	28	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6385	6394		10.1074/jbc.M511320200	http://dx.doi.org/10.1074/jbc.M511320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407247	hybrid			2022-12-27	WOS:000236030800032
J	Pentia, DC; Hosier, S; Cote, RH				Pentia, DC; Hosier, S; Cote, RH			The glutamic acid-rich protein-2 (GARP2) is a high affinity rod photoreceptor phosphodiesterase (PDE6)-binding protein that modulates its catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CGMP-GATED CHANNEL; OUTER SEGMENTS; BINDING-SITES; DARK NOISE; VISUAL TRANSDUCTION; RETINAL CONES; BETA-SUBUNIT; ADAPTATION; PHOTOTRANSDUCTION	The glutamic acid-rich protein-2 (GARP2) is a splice variant of the beta-subunit of the cGMP-gated ion channel of rod photoreceptors. GARP2 is believed to interact with several membrane-associated phototransduction proteins in rod photoreceptors. In this study, we demonstrated that GARP2 is a high affinity PDE6-binding protein and that PDE6 co-purifies with GARP2 during several stages of chromatographic purification. We found that hydrophobic interaction chromatography succeeds in quantitatively separating GARP2 from the PDE6 holoenzyme. Furthermore, the 17-kDa prenyl-binding protein, abundant in retinal cells, selectively released PDE6 ( but not GARP2) from rod outer segment membranes, demonstrating the specificity of the interaction between GARP2 and PDE6. Purified GARP2 was able to suppress 80% of the basal activity of the nonactivated, membrane-bound PDE6 holoenzyme at concentrations equivalent to its endogenous concentration in rod outer segment membranes. However, GARP2 was unable to reverse the transducin activation of PDE6 ( in contrast to a previous study) nor did it significantly alter catalysis of the fully activated PDE6 catalytic dimer. The high binding affinity of GARP2 for PDE6 and its ability to regulate PDE6 activity in its dark-adapted state suggest a novel role for GARP2 as a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor "dark noise" and allowing these sensory cells to operate at the single photon detection limit.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.	rick.cote@unh.edu	Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	NEI NIH HHS [R01 EY005798, R01 EY005798-18A1, EY 05798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BAEHR W, 1979, J BIOL CHEM, V254, P1669; Batra-Safferling R, 2006, J BIOL CHEM, V281, P1449, DOI 10.1074/jbc.M505012200; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Calvert PD, 2002, J GEN PHYSIOL, V119, P129, DOI 10.1085/jgp.119.2.129; Colville CA, 1996, J BIOL CHEM, V271, P32968, DOI 10.1074/jbc.271.51.32968; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; COTE RH, 1993, J BIOL CHEM, V268, P17190; Cote RH, 2000, METHOD ENZYMOL, V315, P646; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FLORIO SK, 1996, J BIOL CHEM, V271, P1; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Gallagher S., 1998, CURRENT PROTOCOLS PR; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; Holcman D, 2005, J GEN PHYSIOL, V125, P641, DOI 10.1085/jgp.200509277; Huang DM, 2004, J BIOL CHEM, V279, P48143, DOI 10.1074/jbc.M404338200; HURWITZ RL, 1984, J BIOL CHEM, V259, P8612; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Norton AW, 2005, J BIOL CHEM, V280, P1248, DOI 10.1074/jbc.M410475200; Pentia Dana C., 2005, V307, P125; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; Rieke F, 1996, BIOPHYS J, V71, P2553, DOI 10.1016/S0006-3495(96)79448-1; Rieke F, 2000, NEURON, V26, P181, DOI 10.1016/S0896-6273(00)81148-4; Rodieck R.W., 1998, 1 STEPS SEEING; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; Zhang XJ, 2005, FRONT BIOSCI-LANDMRK, V10, P1191, DOI 10.2741/1612	40	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5500	5505		10.1074/jbc.M507488200	http://dx.doi.org/10.1074/jbc.M507488200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407240	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000235568900023
J	Duggin, IG; Bell, SD				Duggin, Iain G.; Bell, Stephen D.			The chromosome replication machinery of the archaeon Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CLAMP-LOADING COMPLEX; B DNA-POLYMERASES; LARGE T-ANTIGEN; METHANOBACTERIUM-THERMOAUTOTROPHICUM; BIOCHEMICAL-CHARACTERIZATION; SIMIAN-VIRUS-40 ORIGIN; HEXAMERIC HELICASE; MCM PROTEINS; BINDING; PRIMASE	In the three domains of life, the archaea, bacteria, and eukarya, there are two general lineages of DNA replication proteins: the bacterial and the eukaryal/archaeal lineages. The hyperthermophilic archaeon Sulfolobus solfataricus provides an attractive model for biochemical study of DNA replication. Its relative simplicity in both genomic and biochemical contexts, together with high protein thermostability, has already provided insight into the function of the more complex yet homologous molecules of the eukaryotic domain. Here, we provide an overview of recent insights into the functioning of the chromosome replication machinery of S. solfataricus, focusing on some of the relatively well characterized core components that act at the DNA replication fork.	MRC, Hutchinson Res Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England		Bell, SD (corresponding author), MRC, Hutchinson Res Ctr, Canc Cell Unit, Hills Rd, Cambridge CB2 2XZ, England.	sdb@mole.bio.cam.ac.uk	Duggin, Iain/B-3904-2011	Duggin, Iain/0000-0003-4868-7350; Bell, Stephen/0000-0002-8474-6592				Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Capaldi SA, 2004, NUCLEIC ACIDS RES, V32, P4821, DOI 10.1093/nar/gkh819; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; De Falco M, 2004, NUCLEIC ACIDS RES, V32, P5223, DOI 10.1093/nar/gkh865; De Felice M, 2003, J BIOL CHEM, V278, P46424, DOI 10.1074/jbc.M306075200; Dionne I, 2005, BIOCHEM J, V387, P859, DOI 10.1042/BJ20041661; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Doolittle RF, 2005, CURR OPIN STRUC BIOL, V15, P248, DOI 10.1016/j.sbi.2005.04.001; Evguenieva-Hackenberg E, 2003, EMBO REP, V4, P889, DOI 10.1038/sj.embor.embor929; Fletcher RJ, 2005, J BIOL CHEM, V280, P42405, DOI 10.1074/jbc.M509773200; Fogg MJ, 2002, NAT STRUCT BIOL, V9, P922, DOI 10.1038/nsb867; Forterre P, 2002, THEOR POPUL BIOL, V61, P409, DOI 10.1006/tpbi.2002.1592; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Giraldo R, 2003, FEMS MICROBIOL REV, V26, P533, DOI 10.1111/j.1574-6976.2003.tb00629.x; Gomez-Llorente Y, 2005, J BIOL CHEM, V280, P40909, DOI 10.1074/jbc.M509760200; Gomez-Lorenzo MG, 2003, EMBO J, V22, P6205, DOI 10.1093/emboj/cdg612; Gruz P, 2003, NUCLEIC ACIDS RES, V31, P4024, DOI 10.1093/nar/gkg447; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Kasiviswanathan R, 2005, NUCLEIC ACIDS RES, V33, P4940, DOI 10.1093/nar/gki807; Kelman Z, 2005, CURR OPIN MICROBIOL, V8, P669, DOI 10.1016/j.mib.2005.10.001; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lao-Sirieix SH, 2005, NAT STRUCT MOL BIOL, V12, P1137, DOI 10.1038/nsmb1013; Lao-Sirieix SH, 2005, TRENDS GENET, V21, P568, DOI 10.1016/j.tig.2005.07.010; Lao-Sirieix SH, 2004, J MOL BIOL, V344, P1251, DOI 10.1016/j.jmb.2004.10.018; Lundgren M, 2004, P NATL ACAD SCI USA, V101, P7046, DOI 10.1073/pnas.0400656101; McGeoch AT, 2005, NAT STRUCT MOL BIOL, V12, P756, DOI 10.1038/nsmb974; Miyata T, 2005, P NATL ACAD SCI USA, V102, P13795, DOI 10.1073/pnas.0506447102; Miyata T, 2004, NAT STRUCT MOL BIOL, V11, P632, DOI 10.1038/nsmb788; Prangishvili D, 2005, TRENDS MICROBIOL, V13, P535, DOI 10.1016/j.tim.2005.08.013; Robinson NP, 2004, CELL, V116, P25, DOI 10.1016/S0092-8674(03)01034-1; Savino C, 2004, STRUCTURE, V12, P2001, DOI 10.1016/j.str.2004.09.007; Schaeffer PM, 2005, IUBMB LIFE, V57, P5, DOI 10.1080/15216540500058956; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shen JP, 2005, P NATL ACAD SCI USA, V102, P11248, DOI 10.1073/pnas.0409646102; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Shuttleworth G, 2004, J MOL BIOL, V337, P621, DOI 10.1016/j.jmb.2004.01.021; Singleton MR, 2004, J MOL BIOL, V343, P547, DOI 10.1016/j.jmb.2004.08.044; Speck C, 2005, NAT STRUCT MOL BIOL, V12, P965, DOI 10.1038/nsmb1002; Takahashi TS, 2005, TRENDS BIOCHEM SCI, V30, P437, DOI 10.1016/j.tibs.2005.06.007; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Vaisman A, 2005, EMBO J, V24, P2957, DOI 10.1038/sj.emboj.7600786; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; Wang YL, 2006, PROTEIN SCI, V15, P135, DOI 10.1110/ps.051726906; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zang H, 2006, J BIOL CHEM, V281, P2358, DOI 10.1074/jbc.M510889200	50	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15029	15032		10.1074/jbc.R500029200	http://dx.doi.org/10.1074/jbc.R500029200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16467299	hybrid			2022-12-27	WOS:000237922200002
J	Yanyan, JY; Peter, O; Davies, KE; Platt, N				Yanyan, JY; Peter, O; Davies, KE; Platt, N			Identification and characterization of murine SCARA5, a novel class A scavenger receptor that is expressed by populations of epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONONUCLEAR PHAGOCYTE SYSTEM; SURFACE EXPRESSION; ESCHERICHIA-COLI; IMMUNE-SYSTEM; IMMUNOHISTOCHEMICAL LOCALIZATION; PATTERN-RECOGNITION; POLYANIONIC LIGANDS; CYTOKINE RESPONSES; MOLECULAR-CLONING; APOPTOTIC CELLS	Epithelia are positioned at a critical interface to prevent invasion by microorganisms from the environment. Pattern recognition receptors are important components of innate immunity because of their ability to interact with specific microbe-associated structures and initiate immune responses. Several distinct groups of receptors have been recognized. One of these, the scavenger receptors, has been classified into at least eight separate classes. The class A scavenger receptors are characterized by the presence of a collagen-like domain and include macrophage scavenger receptor type A (SR-A1 I/II, SCARA1) and MARCO (SCARA2). These receptors are known to make important contributions to host defense. Here, we identify a novel murine scavenger receptor, SCARA5, which has a structure typical of this class. The cDNA encodes 491 amino acids, which predict a type II protein that contains C-terminal intracellular, transmembrane, extracellular spacer, collagenous, and N-terminal scavenger receptor cysteine rich domains. Expression in Chinese hamster ovary cells confirmed that the receptor assembles as a homotrimer and is expressed at the plasma membrane. SCARA5-transfected cells bound Escherichia coli and Staphylococcus aureus, but not zymosan, in a polyanionic-inhibitable manner. Unlike other class A scavenger receptors, the receptor was unable to endocytose acetylated or oxidized low density lipoprotein. Quantitative RTPCR and in situ hybridization demonstrate SCARA5 has a tissue and cellular distribution unique among class A scavenger receptors. Because of the restriction of SCARA5 transcripts to populations of epithelial cells, we propose that this receptor may play important roles in the innate immune activities of these cells.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England	University of Oxford; University of Southampton	Platt, N (corresponding author), Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England.	N.Platt@soton.ac.uk	Oliver, Peter/F-1453-2010; Jiang, Yanyan/AAE-2495-2020; Eckhardt, Erik/G-1567-2010; Yan, Yong-Bin/A-4282-2008	Jiang, Yanyan/0000-0001-6014-811X; Yan, Yong-Bin/0000-0002-8565-3558	MRC [MC_U137761449] Funding Source: UKRI; Medical Research Council [MC_U137761449, G0800158] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ACTON S, 1993, J BIOL CHEM, V268, P3530; Akira S, 2004, SEMIN IMMUNOL, V16, P1, DOI 10.1016/j.smim.2003.10.001; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; ASHKENAS J, 1993, J LIPID RES, V34, P983; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DOI T, 1993, J BIOL CHEM, V268, P2126; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; Eckmann Lars, 1995, Trends in Microbiology, V3, P118, DOI 10.1016/S0966-842X(00)88894-0; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Elshourbagy MA, 2000, EUR J BIOCHEM, V267, P919, DOI 10.1046/j.1432-1327.2000.01077.x; Eskola V, 1998, MOL CELL ENDOCRINOL, V139, P143, DOI 10.1016/S0303-7207(98)00063-X; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Godaly G, 2001, J LEUKOCYTE BIOL, V69, P899; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hoshino K, 1999, J IMMUNOL, V162, P3749; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; HUME DA, 1984, ANAT REC, V210, P503, DOI 10.1002/ar.1092100311; HUME DA, 1984, P NATL ACAD SCI-BIOL, V81, P4174, DOI 10.1073/pnas.81.13.4174; Isaacs AM, 2003, J NEUROSCI, V23, P1631; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kodama T, 1996, CURR OPIN LIPIDOL, V7, P287, DOI 10.1097/00041433-199610000-00005; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Levy E, 2004, J CELL SCI, V117, P327, DOI 10.1242/jcs.00856; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Morimoto K, 1999, BIOL PHARM BULL, V22, P1022; Nakagawa A, 2005, MOL REPROD DEV, V71, P166, DOI 10.1002/mrd.20278; Nakamura K, 2001, BBA-GENE STRUCT EXPR, V1522, P53, DOI 10.1016/S0167-4781(01)00284-6; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Peiser L, 2000, INFECT IMMUN, V68, P1953, DOI 10.1128/IAI.68.4.1953-1963.2000; Platt N, 1998, CHEM BIOL, V5, pR193, DOI 10.1016/S1074-5521(98)90156-9; Platt N, 2002, INT REV CYTOL, V212, P1; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schilling JD, 2003, P NATL ACAD SCI USA, V100, P4203, DOI 10.1073/pnas.0736473100; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Svanborg C, 1996, ANN NY ACAD SCI, V797, P177, DOI 10.1111/j.1749-6632.1996.tb52959.x; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Tian G, 2004, J BIOL CHEM, V279, P39303, DOI 10.1074/jbc.M405219200; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	58	57	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11834	11845		10.1074/jbc.M507599200	http://dx.doi.org/10.1074/jbc.M507599200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16407294	hybrid			2022-12-27	WOS:000236988100050
J	Krejci, E; Valenzuela, IMPY; Ameziane, R; Akaaboune, M				Krejci, E; Valenzuela, IMPY; Ameziane, R; Akaaboune, M			Acetylcholinesterase dynamics at the neuromuscular junction of live animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAINS; IN-VIVO; RECEPTOR DENSITY; ANCHORING ACETYLCHOLINESTERASE; ANTICHOLINESTERASE TOXINS; TAIL SUBUNIT; MUSCLE; MICE; BUTYRYLCHOLINESTERASE; NEUROTRANSMITTER	At cholinergic synapses, acetylcholinesterase (AChE) is critical for ensuring normal synaptic transmission. However, little is known about how this enzyme is maintained and regulated in vivo. In this work, we demonstrate that the dissociation of fluorescently-tagged fasciculin 2 ( a specific and selective peptide inhibitor of AChE) from AChE is extremely slow. This fluorescent probe was used to study the removal and insertion of AChE at individual synapses of living adult mice. After a one-time blockade of AChEs with fluorescent fasciculin 2, AChEs are removed from synapses initially at a faster rate (t(1/2) of similar to 3 days) and later at a slower rate (t(1/2) of similar to 12 days). Most of the removed AChEs are replaced by newly inserted AChEs over time. However, when AChEs are continuously blocked with fasciculin 2, the removal rate increases substantially (t(1/2) of similar to 12 h), and most of the lost AChEs are not replaced by newly inserted AChE. Furthermore, complete one-time inactivation of AChE activity significantly increases the removal of postsynaptic nicotinic acetylcholine receptors (AChRs). Finally, time lapse imaging reveals that synaptic AChEs and AChRs that are removed from synapses are co-localized in the same pool after being internalized. These results demonstrate a remarkable AChE dynamism and argue for a potential link between AChE function and postsynaptic receptor lifetime.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Neurosci Program, Ann Arbor, MI 48109 USA; INSERM, U686, F-75006 Paris, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Institut National de la Sante et de la Recherche Medicale (Inserm)	Akaaboune, M (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	makaabou@umich.edu	Martinez-Pena y Valenzuela, Isabel/AAI-9845-2020	, Isabel/0000-0002-2196-9297	NINDS NIH HHS [NS 047332] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047332] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler M, 2004, MUSCLE NERVE, V30, P317, DOI 10.1002/mus.20099; Akaaboune M, 2002, NEURON, V34, P865, DOI 10.1016/S0896-6273(02)00739-0; Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; ANDREOSE JS, 1993, J NEUROSCI, V13, P3433; Anglister L, 1998, J NEUROSCI METH, V81, P63, DOI 10.1016/S0165-0270(98)00015-6; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BERMAN HA, 1987, DEV BIOL, V120, P154, DOI 10.1016/0012-1606(87)90113-8; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bruneau E, 2005, J NEUROSCI, V25, P9949, DOI 10.1523/JNEUROSCI.3169-05.2005; Cartaud A, 2004, J CELL BIOL, V165, P505, DOI 10.1083/jcb.200307164; Casanueva OI, 1998, J BIOL CHEM, V273, P4258, DOI 10.1074/jbc.273.7.4258; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200; DUXSON MJ, 1982, J NEUROCYTOL, V11, P395, DOI 10.1007/BF01257985; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KARLSSON E, 1985, PHARMACOL THERAPEUT, V30, P259, DOI 10.1016/0163-7258(85)90051-8; KASPRZAK H, 1985, J NEUROSCI, V5, P951; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Katz EJ, 1997, TOXICOL APPL PHARM, V146, P227, DOI 10.1006/taap.1997.8201; Kimbell LM, 2004, J BIOL CHEM, V279, P10997, DOI 10.1074/jbc.M305462200; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; LEONARD JP, 1979, J CELL BIOL, V82, P811, DOI 10.1083/jcb.82.3.811; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; Lin WC, 2005, NEURON, V46, P569, DOI 10.1016/j.neuron.2005.04.002; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Misgeld T, 2005, P NATL ACAD SCI USA, V102, P11088, DOI 10.1073/pnas.0504806102; Moreno RD, 1998, INT J DEV NEUROSCI, V16, P123, DOI 10.1016/S0736-5748(98)00008-2; Nguyen-Huu T, 2005, ANESTHESIOLOGY, V103, P788, DOI 10.1097/00000542-200510000-00017; Panchuk-Voloshina N, 1999, J HISTOCHEM CYTOCHEM, V47, P1179, DOI 10.1177/002215549904700910; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; Rotundo RL, 2003, J NEUROCYTOL, V32, P743, DOI 10.1023/B:NEUR.0000020621.58197.d4; SALPETER MM, 1978, J CELL BIOL, V78, P274, DOI 10.1083/jcb.78.1.274; SALPETER MM, 1979, J NEUROCYTOL, V8, P95, DOI 10.1007/BF01206461; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; THESLEFF S, 1955, NATURE, V175, P594, DOI 10.1038/175594b0; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2; VALENZUELA IMP, 2005, J BIOL CHEM, V280, P31801; ZISKINDCONHAIM L, 1984, DEV BIOL, V103, P369, DOI 10.1016/0012-1606(84)90325-7	46	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10347	10354		10.1074/jbc.M507502200	http://dx.doi.org/10.1074/jbc.M507502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455662	hybrid			2022-12-27	WOS:000236594300063
J	Lu, D; Wolfgang, CD; Hai, T				Lu, D; Wolfgang, CD; Hai, T			Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC FUNCTION; FACTOR ATF3; EMBRYO FIBROBLASTS; LIVER DYSFUNCTION; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; OVER-EXPRESSION; BETA; P53; GROWTH	ATF3 is a stress-inducible gene that encodes a member of the ATF/CREB family of transcription factors. Current literature indicates that ATF3 affects cell death and cell cycle progression. However, controversies exist, because it has been demonstrated to be a negative or positive regulator of these processes. We sought to study the roles of ATF3 in both cell death and cell cycle regulation in the same cell type using mouse fibroblasts. We show that ATF3 promotes apoptosis and cell cycle arrest. Fibroblasts deficient in ATF3 (ATF3(-/-)) were partially protected from UV-induced apoptosis, and fibroblasts ectopically expressing ATF3 under the tet-off system exhibited features characteristic of apoptosis upon ATF3 induction. Furthermore, ATF3(-/-) fibroblasts transitioned from G(1) to S phase more efficiently than the ATF3(+/+) fibroblasts, suggesting a growth arrest role of ATF3. Consistent with the growth arrest and pro-apoptotic roles of ATF3, ATF3(-/-) fibroblasts upon Ras transformation exhibited higher growth rate, produced more colonies in soft agar, and formed larger tumor upon xenograft injection than the ATF3(+/+) counterparts. ATF3(-/-) cells, either with or without Ras transformation, had increased Rb phosphorylation and higher levels of various cyclins. Significantly, ATF3 bound to the cyclin D1 promoter as shown by chromatin immunoprecipitation (ChIP) assay and repressed its transcription by a transcription assay. Taken together, our results indicate that ATF3 promotes cell death and cell arrest, and suppresses Ras-mediated tumorigenesis. Potential explanations for the controversy about the roles of ATF3 in cell cycle and cell death are discussed.	Ohio State Univ, Ohio State Biochem Program, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, T (corresponding author), Ohio State Univ, Ohio State Biochem Program, Dept Mol & Cellular Biochem, Rm 174 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	hai.2@osu.edu	Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL CANCER INSTITUTE [R01CA118306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059605] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA118306] Funding Source: Medline; NIDDK NIH HHS [DK 59605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Allen-Jennings AE, 2002, J BIOL CHEM, V277, P20020, DOI 10.1074/jbc.M200727200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Francis JS, 2004, MOL BRAIN RES, V124, P199, DOI 10.1016/j.molbrainres.2003.10.027; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Inoue K, 2004, GENES CELLS, V9, P59, DOI 10.1111/j.1356-9597.2004.00707.x; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 2000, JPN J CANCER RES, V91, P833, DOI 10.1111/j.1349-7006.2000.tb01021.x; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Nawa T, 2002, ATHEROSCLEROSIS, V161, P281, DOI 10.1016/S0021-9150(01)00639-6; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; Pearson AG, 2003, MOL BRAIN RES, V120, P38, DOI 10.1016/j.molbrainres.2003.09.014; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2005, MOL CANCER THER, V4, P233; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200	66	163	170	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10473	10481		10.1074/jbc.M509278200	http://dx.doi.org/10.1074/jbc.M509278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469745	hybrid			2022-12-27	WOS:000236594300076
J	Montagnoli, A; Valsasina, B; Brotherton, D; Troiani, S; Rainoldi, S; Tenca, P; Molinari, A; Santocanale, C				Montagnoli, A; Valsasina, B; Brotherton, D; Troiani, S; Rainoldi, S; Tenca, P; Molinari, A; Santocanale, C			Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC7-RELATED KINASE; DNA-REPLICATION; PROTEINS; COMPLEX; CHECKPOINT; INITIATION; CDC7; CELLS; CYCLE; INHIBITION	Minichromosome maintenance 2 - 7 proteins play a pivotal role in replication of the genome in eukaryotic organisms. Upon entry into S-phase several subunits of the MCM hexameric complex are phosphorylated. It is thought that phosphorylation activates the intrinsic MCM DNA helicase activity, thus allowing formation of active replication forks. Cdc7, Cdk2, and ataxia telangiectasia and Rad3-related kinases regulate S-phase entry and S-phase progression and are known to phosphorylate the Mcm2 subunit. In this work, by in vitro kinase reactions and mass spectrometry analysis of the products, we have mapped phosphorylation sites in the N terminus of Mcm2 by Cdc7, Cdk2, Cdk1, and CK2. We found that Cdc7 phosphorylates Mcm2 in at least three different sites, one of which corresponds to a site also reported to be phosphorylated by ataxia telangiectasia and Rad3-related. Three serine/proline sites were identified for Cdk2 and Cdk1, and a unique site was phosphorylated by CK2. We raised specific anti-phosphopeptide antibodies and found that all the sites identified in vitro are also phosphorylated in cells. Importantly, although all the Cdc7-dependent Mcm2 phosphosites fluctuate during the cell cycle with kinetics similar to Cdc7 kinase activity and Cdc7 protein levels, phosphorylation of Mcm2 in the putative cyclin-dependent kinase (Cdk) consensus sites is constant during the cell cycle. Furthermore, our analysis indicates that the majority of the Mcm2 isoforms phosphorylated by Cdc7 are not stably associated with chromatin. This study forms the basis for understanding how MCM functions are regulated by multiple kinases within the cell cycle and in response to external perturbations.	Nerviano Med Sci Oncol, Dept Biol, I-20014 Nerviano, Italy	Nerviano Medical Sciences S.r.l	Santocanale, C (corresponding author), Nerviano Med Sci Oncol, Dept Biol, Via Pasteur 10, I-20014 Nerviano, Italy.	Corrado.Santocanale@nervianoms.com		Santocanale, Corrado/0000-0003-1337-5656				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Diffley JFX, 2002, J CELL SCI, V115, P869; Dimitrova DS, 2002, J CELL SCI, V115, P51; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Ishimi Y, 2001, J BIOL CHEM, V276, P42744, DOI 10.1074/jbc.M106861200; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Krude T, 1996, J CELL SCI, V109, P309; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Kulartz M, 2004, BIOCHEM BIOPH RES CO, V315, P1011, DOI 10.1016/j.bbrc.2004.01.164; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lolli G, 2003, PROTEOMICS, V3, P1287, DOI 10.1002/pmic.200300431; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Rialland M, 2002, J CELL SCI, V115, P1435; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200	29	169	179	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10281	10290		10.1074/jbc.M512921200	http://dx.doi.org/10.1074/jbc.M512921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16446360	hybrid			2022-12-27	WOS:000236594300056
J	Raichaudhuri, A; Bhattacharyya, R; Chaudhuri, S; Chakrabarti, P; DasGupta, M				Raichaudhuri, A; Bhattacharyya, R; Chaudhuri, S; Chakrabarti, P; DasGupta, M			Domain analysis of a groundnut calcium-dependent protein kinase - Nuclear localization sequence in the junction domain is coupled with nonconsensus calcium binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-LIKE DOMAIN; IMPORTIN-ALPHA HOMOLOG; INTRAMOLECULAR BINDING; TARGET RECOGNITION; MODULATED PROTEINS; STRUCTURAL BASIS; ACTIVATION; CDPK; EVOLUTION; COMPLEX	The signature of calcium-dependent protein kinases (CDPKs) is a C-terminal calmodulin-like domain (CaMLD) with four consensus calcium-binding sites. A junction domain (JD) joins the kinase with CaMLD and interacts with them through its autoinhibitory and CaMLD binding subdomains, respectively. We noted several CDPKs additionally have a bipartite nuclear localization signal (NLS) sequence as a subdomain in their JD, and this feature is obligatorily coupled with the absence of consensus calcium-binding sites in their respective CaMLDs. These predicted features are substantiated by undertaking investigations on a CDPK (gi: 67479988) isolated from cultured groundnut ( Arachis hypogea) cells. This kinase can bind 3.1 mol of Ca2+ under saturating conditions with a considerably high K-d of 392 mu M as compared with its canonical counterparts. CD spectroscopic analysis, however, indicates the intramolecular structural changes accompanied with calcium binding to be similar to canonical CDPKs. Attesting to the presence of NLS in the JD, the endogenous kinase is localized in the nucleus of osmotically stressed Arachis cells, and in vitro binding assays indicate the NLS in the JD to interact with nuclear transport factors of the importin family. Homology modeling also indicates the feasibility of interaction of importins with the NLS present in the JD of such CDPKs in their activated form. The possible significance of obligatory coupling between the presence of NLS in the junction domain and atypical calcium binding properties of these CDPKs is discussed in the light of the known mechanisms of activation of these kinases.	Univ Calcutta, Dept Biochem, Kolkata 700019, W Bengal, India; Bose Inst, Dept Biochem, Kolkata 700054, W Bengal, India; Bose Inst, Bioinformat Ctr, Kolkata 700054, W Bengal, India	University of Calcutta; Department of Science & Technology (India); Bose Institute; Department of Science & Technology (India); Bose Institute	DasGupta, M (corresponding author), Univ Calcutta, Dept Biochem, 35 Ballygunge Circular Rd, Kolkata 700019, W Bengal, India.	maitrayee_d@hotmail.com		/0000-0002-7260-3746				Anil VS, 2000, PLANT PHYSIOL, V122, P1035, DOI 10.1104/pp.122.4.1035; Asano T, 2005, PLANT CELL PHYSIOL, V46, P356, DOI 10.1093/pcp/pci035; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; Chaudhuri S, 1999, PLANT PHYSIOL, V120, P859, DOI 10.1104/pp.120.3.859; CHEHAB EW, 2004, PLANT PHYSIOL, V135, P1; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Chico JM, 2002, PLANT PHYSIOL, V128, P256, DOI 10.1104/pp.010649; Christodoulou J, 2004, J BIOL CHEM, V279, P29092, DOI 10.1074/jbc.M401297200; CORNISHBOWDEN A, 1975, J MOL BIOL, V95, P201, DOI 10.1016/0022-2836(75)90390-3; Dahlquist F W, 1978, Methods Enzymol, V48, P270; Dammann C, 2003, PLANT PHYSIOL, V132, P1840, DOI 10.1104/pp.103.020008; DASGUPTA M, 1994, PLANT PHYSIOL, V104, P961, DOI 10.1104/pp.104.3.961; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Drykova D, 2003, PLANT CELL, V15, P465, DOI 10.1105/tpc.007005; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Jiang CJ, 2001, J BIOL CHEM, V276, P9322, DOI 10.1074/jbc.M006430200; Jiang CJ, 1998, J BIOL CHEM, V273, P24083, DOI 10.1074/jbc.273.37.24083; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu SX, 2002, PLANT PHYSIOL, V128, P1008, DOI 10.1104/pp.010770; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Nag R, 2006, PLANT CELL TISS ORG, V84, P17, DOI 10.1007/s11240-005-6902-z; Nag R, 2005, PLANT MOL BIOL, V59, P821, DOI 10.1007/s11103-005-1387-z; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Patharkar OR, 2000, PLANT J, V24, P679, DOI 10.1046/j.1365-313x.2000.00912.x; Pazos F, 2002, PROTEINS, V47, P219, DOI 10.1002/prot.10074; PICAL C, 1993, FEBS LETT, V336, P347, DOI 10.1016/0014-5793(93)80835-I; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; Seal A, 2001, PLANT CELL REP, V20, P567, DOI 10.1007/s002990100359; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; URAO T, 1994, MOL GEN GENET, V244, P331, DOI 10.1007/BF00286684; VAKSER IA, 1995, PROTEIN ENG, V8, P371, DOI 10.1093/protein/8.4.371; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; Velentza AV, 2001, J BIOL CHEM, V276, P38956, DOI 10.1074/jbc.M104273200; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Vitart V, 2000, BIOCHEMISTRY-US, V39, P4004, DOI 10.1021/bi992373m; Weljie AM, 2004, J BIOL CHEM, V279, P35494, DOI 10.1074/jbc.M311520200; Weljie AM, 2000, PROTEINS, V39, P343, DOI 10.1002/(SICI)1097-0134(20000601)39:4<343::AID-PROT70>3.0.CO;2-2; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612; Zhang XRS, 2001, J MOL EVOL, V53, P214, DOI 10.1007/s002390010211; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031	70	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10399	10409		10.1074/jbc.M511001200	http://dx.doi.org/10.1074/jbc.M511001200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16464867	hybrid			2022-12-27	WOS:000236594300069
J	Liang, MD; Zhang, Y; McDevit, D; Marecki, S; Nikolajczyk, BS				Liang, MD; Zhang, Y; McDevit, D; Marecki, S; Nikolajczyk, BS			The interleukin-1 beta gene is transcribed from a poised promoter architecture in monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; HEMATOPOIETIC STEM-CELLS; NECROSIS-FACTOR-ALPHA; HISTONE ACETYLATION; CHROMATIN ACCESSIBILITY; TRANSCRIPTIONAL REGULATION; IL-1-BETA GENE; PROXIMAL PROMOTER; CUTTING EDGE	Cytokine transcription is usually regulated by transcription factor binding and chromatin remodeling following an inducing signal. By contrast, these data showed the interleukin (IL)-1 beta promoter assembles into a "poised" structure, as evidenced by nuclease accessibility and loss of core histones immediately surrounding the transcription start site. Strikingly, these properties do not change upon transcriptional activation by lipopolysaccharide. Furthermore, association of two key transcriptional activators, PU.1 and C/EBP beta, is robust pre- and post-stimulation indicating the IL-1 beta promoter is packaged into a nontranscribed but poised promoter architecture in cells capable of rapidly inducing IL-1 beta. Monocyte stimulation causes recruitment of a third factor, IRF-4, to the IL-1 beta enhancer. PU.1 phosphorylation at a CK2 kinase consensus element is required for this recruitment. We showed that CK2 phosphorylates PU.1, CK2 inhibitors abrogate IL-1 beta induction, and CK2 inducibly associates with the IL-1 beta enhancer. Taken together, these data indicate a novel two-step mechanism for IL-1 beta transcription: 1) formation of a poised chromatin architecture, and 2) phosphorylation of an enhancer-bound factor that recruits other activators. We propose that this poised structure may generally characterize rapidly activated genes.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Med Ctr, Evans Mem Dept Clin Res, Dept Med, Immunobiol Unit, Boston, MA USA	Boston University; Boston University; Boston Medical Center	Nikolajczyk, BS (corresponding author), Boston Univ, Sch Med, Dept Microbiol, 715 Albany St L516, Boston, MA 02118 USA.	bnikol@bumc.bu.edu			NHLBI NIH HHS [T32 HL07501] Funding Source: Medline; NIAID NIH HHS [R01 AI54611] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054611] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Barthel R, 2003, J IMMUNOL, V171, P3612, DOI 10.4049/jimmunol.171.7.3612; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; Bream JH, 2004, J BIOL CHEM, V279, P41249, DOI 10.1074/jbc.M401168200; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; BURAS JA, 1994, J IMMUNOL, V152, P4444; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; Chan C, 2005, J IMMUNOL, V175, P461, DOI 10.4049/jimmunol.175.1.461; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; GODAMBE SA, 1995, MOL CELL BIOL, V15, P112, DOI 10.1128/MCB.15.1.112; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Holloway AF, 2003, J EXP MED, V197, P413, DOI 10.1084/jem.20021039; Im SH, 2004, J BIOL CHEM, V279, P46818, DOI 10.1074/jbc.M401722200; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Kim HG, 2004, BLOOD, V104, P3894, DOI 10.1182/blood-2002-08-2425; Kim HY, 2000, INFECT IMMUN, V68, P3394, DOI 10.1128/IAI.68.6.3394-3402.2000; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Kwan M, 2005, EUR J IMMUNOL, V35, P1267, DOI 10.1002/eji.200425619; Lee JY, 2003, J LEUKOCYTE BIOL, V73, P862, DOI 10.1189/jlb.1202618; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lodie TA, 1997, J IMMUNOL, V158, P1848; Lodie TA, 1998, J IMMUNOL, V161, P268; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Lucas M, 2005, J IMMUNOL, V175, P469, DOI 10.4049/jimmunol.175.1.469; Marecki S, 2004, MOL IMMUNOL, V40, P723, DOI 10.1016/j.molimm.2003.08.007; Marecki S, 1999, J IMMUNOL, V163, P2713; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McCarthy KM, 2003, J BIOL CHEM, V278, P42106, DOI 10.1074/jbc.M308586200; McDevit DC, 2005, J IMMUNOL, V174, P2834, DOI 10.4049/jimmunol.174.5.2834; MONKS BG, 1994, MOL IMMUNOL, V31, P139, DOI 10.1016/0161-5890(94)90086-8; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Vicente R, 2005, J IMMUNOL, V174, P4736, DOI 10.4049/jimmunol.174.8.4736; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Watari K, 1996, J CLIN INVEST, V97, P1666, DOI 10.1172/JCI118593; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	63	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9227	9237		10.1074/jbc.M510700200	http://dx.doi.org/10.1074/jbc.M510700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16439360	hybrid			2022-12-27	WOS:000236404700030
J	Wang, Y; Jiang, HB				Wang, Y; Jiang, HB			Interaction of beta-1,3-glucan with its recognition protein activates hemolymph proteinase 14, an initiation enzyme of the prophenoloxidase activation system in Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC REACTIONS; SERINE PROTEINASES; TOBACCO HORNWORM; DROSOPHILA TOLL; INSECT; LECTIN; BACTERIA; DEFENSE; IDENTIFICATION; MELANIZATION	A serine proteinase pathway in insect hemolymph leads to prophenoloxidase activation, an innate immune response against pathogen infection. In the tobacco hornworm Manduca sexta, recombinant hemolymph proteinase 14 precursor (pro-HP14) interacts with peptidoglycan, autoactivates, and initiates the proteinase cascade (Ji, C., Wang, Y., Guo, X., Hartson, S., and Jiang, H. (2004) J. Biol. Chem. 279, 34101-34106). Here, we report the purification and characterization of pro-HP14 from the hemolymph of bacteria-injected M. sexta larvae. The zymogen, consisting of a single polypeptide with a molecular mass of 68.5 kDa, is truncated at the amino terminus. It is converted to a two-chain active form in the presence of beta-1,3-glucan (a fungal cell wall component) and beta-1,3-glucan recognition protein-2. The 45-kDa heavy chain contains four low-density lipoprotein receptor A repeats, one Sushi domain, and one unique cysteine-rich region, whereas the 30-kDa light chain contains a serine proteinase domain, which was labeled by [H-3]diisopropyl fluorophosphate. Pro-HP14 in the plasma strongly binds curdlan, zymosan, and yeast and interacts with peptidoglycan and Micrococcus luteus. Addition of autoactivated HP14 elevated phenoloxidase activity level in the larval plasma. Recombinant M. sexta serpin-1I reduced prophenoloxidase activation by inhibiting HP14. These data are consistent with the current model on initiation and regulation of the prophenoloxidase activation cascade upon recognition of pathogen-associated molecular patterns by specific pattern recognition proteins.	Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Jiang, HB (corresponding author), Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA.	haobo.jiang@okstate.edu	Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058634] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashida Masaaki, 1998, P135; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Finehout EJ, 2003, ELECTROPHORESIS, V24, P3508, DOI 10.1002/elps.200305615; Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Iwanaga S, 1998, J BIOCHEM, V123, P1; JI C, 2003, PROTEIN EXPRES PURIF, V23, P328; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; Jiang HB, 2005, INSECT BIOCHEM MOLEC, V35, P931, DOI 10.1016/j.ibmb.2005.03.009; Jiang HB, 2004, INSECT BIOCHEM MOLEC, V34, P89, DOI 10.1016/j.ibmb.2003.09.006; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; JUNGREIS AM, 1973, J INSECT PHYSIOL, V19, P225, DOI 10.1016/0022-1910(73)90235-7; Kanost MR, 2004, IMMUNOL REV, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P731, DOI 10.1016/j.ibmb.2004.03.008; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200; Zou Z, 2005, J BIOL CHEM, V280, P14341, DOI 10.1074/jbc.M500570200	35	76	83	0	24	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9271	9278		10.1074/jbc.M513797200	http://dx.doi.org/10.1074/jbc.M513797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461344	Green Accepted, hybrid			2022-12-27	WOS:000236404700034
J	Janovick, JA; Knollman, PE; Brothers, SP; Ayala-Yanez, R; Aziz, AS; Conn, PM				Janovick, JA; Knollman, PE; Brothers, SP; Ayala-Yanez, R; Aziz, AS; Conn, PM			Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression - Molecular basis of an evolved strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR; HYPOGONADOTROPIC HYPOGONADISM; PHARMACOLOGICAL CHAPERONES; DISEASE ETIOLOGY; MUTANTS; BINDING; RESCUE; MUTATIONS; SEQUENCE; NUMBERS	Despite the prevalence of G protein- coupled receptors as transducers of signals from hormones, neurotransmitters, odorants, and light, little is known about mechanisms that regulate their plasma membrane expression ( PME), although misfolded receptors are recognized and retained by a cellular quality control system ( QCS). Convergent evolution of the gonadotropin- releasing hormone ( GnRH) receptor ( GnRHR) progressively decreases inositol phosphate production in response to agonist, validated as a measure of PME of receptor. A pharmacological chaperone that optimizes folding also increases PME of human, but not of rat or mouse, GnRHR because a higher percentage of human GnRHRs are misfolded structures due to their failure to form an apparent sulfhydryl bridge, and they are retained by the QCS. Bridge formation is increased by deleting ( primate-specific) Lys(191). In rat or mouse GnRHR that lacks Lys(191), the bridge is non- essential and receptor is efficiently routed to the plasma membrane. Addition of Lys(191) alone to the rat sequence did not diminish PME, indicating that other changes are required for its effects. A strategy, based on identification of amino acids that both 1) co-evolved with the Lys(191) and 2) were thermodynamically unfavorable substitutions, identified motifs in multiple domains of the human receptor that control the destabilizing influence of Lys(191) on a particular Cys bridge, resulting in diminished PME. The data show a novel and underappreciated means of posttranslational control of a G protein- coupled receptor by altering its interaction with the QCS and provide a biochemical explanation of the basis of disease- causing mutations of this receptor.	Oregon Hlth & Sci Univ, ONPRC, Div Neurosci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, ONPRC, Div Reprod Biol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University	Conn, PM (corresponding author), Oregon Hlth & Sci Univ, ONPRC, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	connm@ohsu.edu	Brothers, Shaun/G-8690-2012	Brothers, Shaun/0000-0003-2184-4037	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019899, R37HD019899] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00163] Funding Source: Medline; NICHD NIH HHS [HD-19899, TW/HD-00668, HD-18185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arora KK, 1999, MOL ENDOCRINOL, V13, P890, DOI 10.1210/me.13.6.890; Ashton WT, 2001, BIOORG MED CHEM LETT, V11, P1727, DOI 10.1016/S0960-894X(01)00275-X; Beranova M, 2001, J CLIN ENDOCR METAB, V86, P1580, DOI 10.1210/jc.86.4.1580; Brothers SP, 2003, J CLIN ENDOCR METAB, V88, P6107, DOI 10.1210/jc.2003-031047; Brothers SP, 2002, MOL CELL ENDOCRINOL, V190, P19, DOI 10.1016/S0303-7207(02)00040-0; Castro-Fernandez C, 2005, ENDOCR REV, V26, P479, DOI 10.1210/er.2004-0010; Conn P Michael, 2002, Mol Interv, V2, P308, DOI 10.1124/mi.2.5.308; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; Costa EMF, 2001, J CLIN ENDOCR METAB, V86, P2680, DOI 10.1210/jc.86.6.2680; HUCKLE WR, 1987, METHOD ENZYMOL, V141, P149; Janovick JA, 2003, ENDOCRINE, V22, P317, DOI 10.1385/ENDO:22:3:317; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; Karges B, 2003, HUM REPROD UPDATE, V9, P523, DOI 10.1093/humupd/dmg040; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; Knollman PE, 2005, J BIOL CHEM, V280, P24506, DOI 10.1074/jbc.M501978200; Leanos-Miranda A, 2003, J CLIN ENDOCR METAB, V88, P3360, DOI 10.1210/jc.2003-030084; Leanos-Miranda A, 2002, J CLIN ENDOCR METAB, V87, P4825, DOI 10.1210/jc.2002-020961; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; MARIAN J, 1981, MOL PHARMACOL, V19, P399; Millar RP, 2004, ENDOCR REV, V25, P235, DOI 10.1210/er.2003-0002; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petrovska R, 2005, BRIT J PHARMACOL, V144, P651, DOI 10.1038/sj.bjp.0706087; Pietila EM, 2005, J BIOL CHEM, V280, P26622, DOI 10.1074/jbc.M413815200; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; SAVOYMOORE RT, 1980, SCIENCE, V209, P942, DOI 10.1126/science.6250218; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Ulloa-Aguirre A, 2003, EXPERT OPIN THER TAR, V7, P175, DOI 10.1517/eott.7.2.175.23780; Vandenberghe W, 2005, J NEUROSCI, V25, P1095, DOI 10.1523/JNEUROSCI.3568-04.2005	30	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8417	8425		10.1074/jbc.M510601200	http://dx.doi.org/10.1074/jbc.M510601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446355	hybrid			2022-12-27	WOS:000236247100016
J	Jiang, HB; Jiang, Q; Liu, WH; Feng, J				Jiang, HB; Jiang, Q; Liu, WH; Feng, J			Parkin suppresses the expression of monoamine oxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DAMAGE; HUMAN-BRAIN; PROTEIN; DOPAMINE; DISEASE; UBIQUITIN; MUTATIONS; MICROTUBULES; MITOCHONDRIA; SOLUBILITY	Mutations of parkin are linked to early onset Parkinson disease. Here we show that stable transfection of parkin in the human dopaminergic neuroblastoma cell line SH-SY5Y markedly reduced the activities of both monoamine oxidase (MAO) A and B. The amount of 3,4-dihydroxyphenylacetic acid, which is produced during dopamine oxidation by MAO, was greatly reduced by parkin overexpression. Radioligand binding assays showed that MAO binding sites were decreased accordingly. Consistent with these, MAO-B protein level was much lower, whereas the amount of MAO-A protein was not determined due to the lack of a suitable antibody. Co-transfection of either MAO with parkin in HEK293 cells did not significantly alter ubiquitination and degradation of each MAO. When we measured MAO expression by real-time quantitative reverse transcription-PCR, marked reductions were seen in SH-SY5Y cells stably expressing parkin compared with the parental cells or a control line stably transfected with luciferase. In addition, parkin mutants defective in E3 ligase activity exhibited different effects on MAO expression. We found that parkin also significantly decreased mRNA levels of both MAOs in the mouse fibroblast cell line NIH3T3. Furthermore, MAO expression was significantly increased in human B lymphocyte cell lines derived from Parkinson disease patients with homozygous but not heterozygous deletion of exon 4 of parkin. Together these results suggest that parkin suppresses MAO expression. This function may limit the production of reactive oxygen species generated by MAO in dopamine oxidation and would, thus, be beneficial to the survival of dopaminergic neurons.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu	Resource Center, NINDS Human Genetics/AGF-2474-2022; Sander-Effron, Samuel/AAX-2231-2020	Liu, Wenhua/0000-0003-0903-8497	NINDS NIH HHS [NS41722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alam ZI, 1997, J NEUROCHEM, V69, P1326; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; BERGQUIST J, 1994, P NATL ACAD SCI USA, V91, P12912, DOI 10.1073/pnas.91.26.12912; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; Burke WJ, 2003, CNS NEUROL DISORD-DR, V2, P143, DOI 10.2174/1568007033482913; Casarejos MJ, 2005, J NEUROCHEM, V94, P1005, DOI 10.1111/j.1471-4159.2005.03249.x; CHEN S, 1984, J NEUROCHEM, V43, P1680, DOI 10.1111/j.1471-4159.1984.tb06095.x; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172; Dogu O, 2004, MOVEMENT DISORD, V19, P812, DOI 10.1002/mds.20028; Feng Jian, 2003, Current Neuropharmacology, V1, P301, DOI 10.2174/1570159033477053; Finney N, 2003, J BIOL CHEM, V278, P16054, DOI 10.1074/jbc.C300051200; Floor E, 1998, J NEUROCHEM, V70, P268; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Greene JC, 2005, HUM MOL GENET, V14, P799, DOI 10.1093/hmg/ddi074; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Grimsby J, 1997, NAT GENET, V17, P206, DOI 10.1038/ng1097-206; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Kahle PJ, 2004, EMBO REP, V5, P681, DOI 10.1038/sj.embor.7400188; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; KRUEGER MJ, 1993, ANAL BIOCHEM, V214, P116, DOI 10.1006/abio.1993.1464; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; OCARROLL AM, 1983, N-S ARCH PHARMACOL, V322, P198, DOI 10.1007/BF00500765; OCARROLL AM, 1989, BIOCHEM PHARMACOL, V38, P901, DOI 10.1016/0006-2952(89)90278-5; Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Periquet M, 2003, BRAIN, V126, P1271, DOI 10.1093/brain/awg136; Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095; Rebrin I, 2001, J BIOL CHEM, V276, P29499, DOI 10.1074/jbc.M100431200; Ren Y, 2003, J NEUROSCI, V23, P3316; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Scott WK, 2001, JAMA-J AM MED ASSOC, V286, P2239, DOI 10.1001/jama.286.18.2239; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Tatematsu K, 1998, BIOCHEM BIOPH RES CO, V247, P392, DOI 10.1006/bbrc.1998.8795; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Wang C, 2005, J NEUROCHEM, V93, P422, DOI 10.1111/j.1471-4159.2005.03023.x; Yang F, 2005, J BIOL CHEM, V280, P17154, DOI 10.1074/jbc.M500843200; Youdim MBH, 2004, NEUROLOGY, V63, pS32, DOI 10.1212/WNL.63.7_suppl_2.S32; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	52	61	64	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8591	8599		10.1074/jbc.M510926200	http://dx.doi.org/10.1074/jbc.M510926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455660	hybrid			2022-12-27	WOS:000236247100035
J	Martin, C; Cao, R; Zhang, Y				Martin, C; Cao, R; Zhang, Y			Substrate preferences of the EZH2 histone methyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H3 LYSINE-27 METHYLATION; POLYCOMB; MECHANISMS; CHROMATIN; ENHANCER; MEMORY; SUZ12; H1	Histone methylation plays an important role in chromatin dynamics and gene expression. Methylation of histone H3- lysine 27 by the EZH2 complex has been linked to the silencing of homeotic genes and the inactivation of the X chromosome. Here we report a characterization of the substrate preferences of the enzyme complex using a reconstituted chromatin and enzyme system. We found that the linker histone H1, when incorporated into nucleosomes, stimulates the enzymatic activity toward histone H3. This stimulatory activity may be explained by protein- protein interactions between H1 and components of the EZH2 complex. In addition, we found that the EZH2 complex exhibits a dramatic preference for dinucleosomes when compared with mononucleosomes and that the stimulation of H3 methylation by H1 requires dinucleosomes or oligonucleosome substrates. Furthermore, in contrast with a recent study suggesting that Embryonic Ectoderm Development EED isoforms may affect substrate specificity, we found that EZH2 complexes reconstituted with different EED isoforms exhibit similar substrate preference and specificity. Our work supports the hypothesis that linker histone H1 and chromatin structure are important factors in determining the substrate preference of the EZH2 histone methyltransferase complex.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA	Howard Hughes Medical Institute; University of North Carolina; University of North Carolina Chapel Hill	Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA.	yi_zhang@med.unc.edu		Zhang, Yi/0000-0002-2789-0811	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068804] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM68804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bender LB, 2004, CURR BIOL, V14, P1639, DOI 10.1016/j.cub.2004.08.062; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Fang J, 2004, METHOD ENZYMOL, V377, P213; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781	23	71	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8365	8370		10.1074/jbc.M513425200	http://dx.doi.org/10.1074/jbc.M513425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431907	Green Published, hybrid			2022-12-27	WOS:000236247100010
J	Zheng, PS; Reis, M; Sparling, C; Lee, DY; La Pierre, DP; Wong, CKA; Deng, ZQ; Kahai, S; Wen, JP; Yang, BB				Zheng, PS; Reis, M; Sparling, C; Lee, DY; La Pierre, DP; Wong, CKA; Deng, ZQ; Kahai, S; Wen, JP; Yang, BB			Versican G3 domain promotes blood coagulation through suppressing the activity of tissue factor pathway inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; PG-M/VERSICAN; PROTEOGLYCAN; BINDING; ATHEROSCLEROSIS; PROLIFERATION; EXPRESSION; ADHESION; MATRIX	We have detected versican, a member of the large chondroitin sulfate proteoglycans, and its degraded C-terminal G3 fragments in human plasma and observed that the versican G3 domain promoted blood coagulation. Silencing G3 expression with small interfering RNA reduced the effect of G3 on coagulation. Plasma coagulation assays suggest that G3 enhances coagulation irrespective of its actions on platelets and white blood cells. To examine how versican affected blood coagulation, we used normal human plasma and different types of coagulation factor-deficient plasmas. The experiments indicated that versican enhanced coagulation through the extrinsic pathway, and that Factor VII was the target molecule. FVII activity assays showed that G3 activated FVII in the presence of plasma but not with purified FVII directly. Yeast two-hybrid, immunoprecipitation, and gel co-migration assays showed that G3 interacted with the tissue factor pathway inhibitor-1 (TFPI-1). TFPI-1 activity assays suggested that G3 inhibited TFPI-1 activity, allowing FVIIa and FXa to facilitate the coagulation process. G3-induced blood coagulation was further confirmed with a mouse model in a real-time manner. Taken together, these results indicate that versican may represent a new target for the development of therapies against atherosclerosis.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	burton.yang@sw.ca						Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen LW, 2003, BIOCHEMISTRY-US, V42, P8332, DOI 10.1021/bi034335f; FAIR DS, 1987, J BIOL CHEM, V262, P11692; Kenagy RD, 2002, ARTERIOSCL THROM VAS, V22, P400, DOI 10.1161/hq0302.105376; KOCH AE, 1990, AM J PATHOL, V137, P1199; Kolodgie FD, 2002, ARTERIOSCL THROM VAS, V22, P1642, DOI 10.1161/01.ATV.0000034021.92658.4C; Lee V, 2002, J BIOL CHEM, V277, P22279, DOI 10.1074/jbc.M110227200; Lemire JM, 2002, J CELL PHYSIOL, V190, P38, DOI 10.1002/jcp.10043; Lijnen HR, 2001, THROMB HAEMOSTASIS, V86, P324; Lin H, 1996, J HEART LUNG TRANSPL, V15, P1233; Little PJ, 2002, ARTERIOSCL THROM VAS, V22, P55, DOI 10.1161/hq0102.101100; Matsuura R, 1996, J PATHOL, V180, P311, DOI 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B; McGee M, 2003, ARTERIOSCL THROM VAS, V23, P1921, DOI 10.1161/01.ATV.0000090673.96120.67; Merrilees MJ, 2001, CORONARY ARTERY DIS, V12, P7, DOI 10.1097/00019501-200102000-00002; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Sheng W, 2005, MOL BIOL CELL, V16, P1330, DOI 10.1091/mbc.e04-04-0295; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; SRINIVASAN SR, 1995, BBA-MOL BASIS DIS, V1272, P61, DOI 10.1016/0925-4439(95)00068-F; Strassel C, 2003, BIOCHEMISTRY-US, V42, P4452, DOI 10.1021/bi026213d; Vandendries ER, 2004, THROMB HAEMOSTASIS, V92, P459, DOI 10.1160/TH04-05-0306; Vijayagopal P, 1996, ATHEROSCLEROSIS, V127, P195, DOI 10.1016/S0021-9150(96)05954-0; Wight TN, 1997, AM J PATHOL, V151, P963; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zheng PS, 2004, J CELL SCI, V117, P5887, DOI 10.1242/jcs.01516; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje	33	17	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8175	8182		10.1074/jbc.M509182200	http://dx.doi.org/10.1074/jbc.M509182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431924	hybrid			2022-12-27	WOS:000236031000056
J	Li, JZ; Lee, B; Lee, AS				Li, JZ; Lee, B; Lee, AS			Endoplasmic reticulum stress-induced apoptosis - Multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH PROGRAM; BH3-ONLY PROTEINS; GENE; BAX; CASPASE-12; INDUCTION; EXPRESSION; CHOP; ER; TRANSLOCATION	Endoplasmic reticulum ( ER) stress-induced apoptosis has been implicated in the development of multiple diseases. However, the in vivo signaling pathways are still not fully understood. In this report, through the use of genetically deficient mouse embryo fibroblasts (MEFs) and their matched wild-type controls, we have demonstrated that the mitochondrial apoptotic pathway mediated by Apaf-1 is an integral part of ER stress-induced apoptosis and that ER stress activates different caspases through Apaf-1-dependent and - independent mechanisms. In search of the molecular link between ER stress and the mitochondrial apoptotic pathway, we have discovered that in MEFs, ER stress selectively activates BH3-only proteins PUMA and NOXA at the transcript level through the tumor suppressor gene p53. In p53(-/-) MEFs, ER stress-induced apoptosis is partially suppressed. The p53-independent apoptotic pathway may be mediated by C/EBP homologous protein ( CHOP) and caspase-12, as their activation is intact in p53(-/-) MEFs. In multiple MEF lines, p53 is primarily nuclear and its level is elevated upon ER stress. To establish the role of NOXA and PUMA in ER stress-induced apoptosis, we have shown that, in MEFs deficient in NOXA or PUMA, ER stress-induced apoptosis is reduced. Reversibly, overexpression of NOXA or PUMA induces apoptosis as evidenced by the activation of BAK and caspase-7. Our results provide new evidence that, in MEFs, in addition to PUMA, p53 and NOXA are novel components of the ER stress-induced apoptotic pathway, and both contribute to ER stress-induced apoptosis.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA 027607, CA 111700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607, R01CA111700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Ho AT, 2004, EMBO J, V23, P460, DOI 10.1038/sj.emboj.7600039; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Hong M, 2004, J BIOL CHEM, V279, P11354, DOI 10.1074/jbc.M309804200; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Lamkanfi M, 2004, CELL DEATH DIFFER, V11, P365, DOI 10.1038/sj.cdd.4401364; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Perkins CL, 2000, CANCER RES, V60, P1645; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rao RV, 2004, J BIOL CHEM, V279, P177, DOI 10.1074/jbc.M304490200; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RAO RV, 2005, IN PRESS CELL DEATH; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	51	402	419	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7260	7270		10.1074/jbc.M509868200	http://dx.doi.org/10.1074/jbc.M509868200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407291	hybrid			2022-12-27	WOS:000236030900044
J	Yoon, SO; Lee, TS; Kim, SJ; Jang, MH; Kang, YJ; Park, JH; Kim, KS; Lee, HS; Ryu, CJ; Gonzales, NR; Kashmiri, SVS; Lim, SM; Choi, CW; Hong, HJ				Yoon, SO; Lee, TS; Kim, SJ; Jang, MH; Kang, YJ; Park, JH; Kim, KS; Lee, HS; Ryu, CJ; Gonzales, NR; Kashmiri, SVS; Lim, SM; Choi, CW; Hong, HJ			Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND-GENERATION MONOCLONAL-ANTIBODIES; METASTATIC COLON-CARCINOMA; HEPATITIS-B-VIRUS; RADIOIMMUNOTHERAPY TRIAL; ANTICARCINOMA ANTIBODY; PHASE-I; IMMUNOGENICITY; CC49; BINDING; B72.3	The tumor-associated glycoprotein (TAG)-72 is expressed in the majority of human adenocarcinomas but is rarely expressed in most normal tissues, which makes it a potential target for the diagnosis and therapy of a variety of human cancers. Here we describe the construction, affinity maturation, and biological characterization of an anti-TAG-72 humanized antibody with minimum potential immunogenicity. The humanized antibody was constructed by grafting only the specificity-determining residues (SDRs) within the complementarity-determining regions (CDRs) onto homologous human immunoglobulin germ line segments while retaining two mouse heavy chain framework residues that support the conformation of the CDRs. The resulting humanized antibody ( AKA) showed only about 2-fold lower affinity compared with the original murine monoclonal antibody CC49 and 27-fold lower reactivity to patient serum compared with the humanized antibody HuCC49 that was constructed by CDR grafting. The affinity of AKA was improved by random mutagenesis of the heavy chain CDR3 (HCDR3). The highest affinity variant (3E8) showed 22-fold higher affinity compared with AKA and retained the original epitope specificity. Mutational analysis of the HCDR3 residues revealed that the replacement of Asn(97) by isoleucine or valine was critical for the affinity maturation. The 3E8 labeled with I-125 or I-131 showed efficient tumor targeting or therapeutic effects, respectively, in athymic mice with human colon carcinoma xenografts, suggesting that 3E8 may be beneficial for the diagnosis and therapy of tumors expressing TAG-72.	Korea Inst Radiol & Med Sci, Dept Nucl Med, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Cyclotron Applicat, Seoul 139706, South Korea; Aprogen Inc, Korea Res Inst Biosci & Biotechnol, Lab Antibody Engn, Taejon 305333, South Korea; NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Choi, CW (corresponding author), Korea Inst Radiol & Med Sci, Dept Nucl Med, 215-4 Gongneung, Seoul 139706, South Korea.	cwchoi@kcch.re.kr; hjhong@kribb.re.kr	LEE, TAE SUP/K-9638-2019; Cheon, Gi Jeong/G-6064-2018	Cheon, Gi Jeong/0000-0002-1360-5186; Kang, Young Jun/0000-0001-9778-1963				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; Bell SJ, 2000, ALIMENT PHARM THER, V14, P501; BUCHSBAUM D, 1995, CANCER RES, V55, pS5881; COLCHER D, 1990, J NUCL MED, V31, P1133; COLCHER D, 1988, CANCER RES, V48, P4597; Coligan JKA, 1991, CURRENT PROTOCOLS IM; De Pascalis R, 2003, CLIN CANCER RES, V9, P5521; DIVGI CR, 1994, NUCL MED BIOL, V21, P9, DOI 10.1016/0969-8051(94)90124-4; Divgi CR, 1995, CLIN CANCER RES, V1, P1503; DIVGI CR, 1995, J NUCL MED, V36, P586; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GLASER SM, 1992, J IMMUNOL, V149, P2607; Gonzales NR, 2003, MOL IMMUNOL, V40, P337, DOI 10.1016/S0161-5890(03)00166-4; Gonzales NR, 2002, J IMMUNOL METHODS, V268, P197, DOI 10.1016/S0022-1759(02)00205-3; Hong HJ, 2004, VIROLOGY, V318, P134, DOI 10.1016/j.virol.2003.09.014; Hwang WYK, 2005, METHODS, V36, P3, DOI 10.1016/j.ymeth.2005.01.001; Iwahashi M, 1999, MOL IMMUNOL, V36, P1079, DOI 10.1016/S0161-5890(99)00094-2; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kabat E.A., 1991, NIH PUBLICATION, V91-3242, P103; KASHMIRI SVS, 1995, HYBRIDOMA, V14, P461, DOI 10.1089/hyb.1995.14.461; Kim SJ, 2004, VIROLOGY, V318, P598, DOI 10.1016/j.virol.2003.10.014; KJELDSEN T, 1988, CANCER RES, V48, P2214; KUROKI M, 1990, CANCER RES, V50, P4872; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; Mulligan T, 1995, CLIN CANCER RES, V1, P1447; MURARO R, 1988, CANCER RES, V48, P4588; O'Donoghue JA, 2002, CANCER BIOTHER RADIO, V17, P435, DOI 10.1089/108497802760363222; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; PADLAN EA, 1995, FASEB J, V9, P133, DOI 10.1096/fasebj.9.1.7821752; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Park SS, 1996, HYBRIDOMA, V15, P435, DOI 10.1089/hyb.1996.15.435; Peterson JA, 1997, CANCER RES, V57, P1103; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; Radosevic K, 2003, J IMMUNOL METHODS, V272, P219, DOI 10.1016/S0022-1759(02)00208-9; Reichert JM, 2001, NAT BIOTECHNOL, V19, P819, DOI 10.1038/nbt0901-819; Ryu Chun Jeih, 1996, Human Antibodies and Hybridomas, V7, P113; SECCAMANI E, 1989, NUCL MED BIOL, V16, P167, DOI 10.1016/0883-2897(89)90191-8; STEPHENS S, 1995, IMMUNOLOGY, V85, P668; Tamura M, 2000, J IMMUNOL, V164, P1432, DOI 10.4049/jimmunol.164.3.1432; Tangri S, 2002, CURR MED CHEM, V9, P2191, DOI 10.2174/0929867023368647; THOR A, 1986, CANCER RES, V46, P3118; THOR A, 1987, INT J GYNECOL PATHOL, V6, P235, DOI 10.1097/00004347-198709000-00005; WINTER G, 1993, IMMUNOL TODAY, V14, P243, DOI 10.1016/0167-5699(93)90039-N	45	40	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6985	6992		10.1074/jbc.M511165200	http://dx.doi.org/10.1074/jbc.M511165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407221	hybrid			2022-12-27	WOS:000236030900011
J	Zachariae, U; Kluhspies, T; De, S; Engelhardt, H; Zeth, K				Zachariae, U; Kluhspies, T; De, S; Engelhardt, H; Zeth, K			High resolution crystal structures and molecular dynamics studies reveal substrate binding in the porin Omp32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE PORIN; OUTER-MEMBRANE PROTEINS; COMAMONAS-ACIDOVORANS; ESCHERICHIA-COLI; ELECTROSTATIC PROPERTIES; SALMONELLA-TYPHIMURIUM; SUGAR-TRANSPORT; ION PERMEATION; CHANNEL; TRANSLOCATION	The porin Omp32 is the major outer membrane protein of the bacterium Delftia acidovorans. The crystal structures of the strongly anion-selective porin alone and in complex with the substrate malate were solved at 1.5 and 1.45 angstrom resolution, respectively, and revealed a malate-binding motif adjacent to the channel constriction zone. Binding is mediated by interaction with a cluster of two arginine residues and two threonines. This binding site is specific for Omp32 and reflects the physiological adaptation of the organism to organic acids. Structural studies are combined with a 7-ns unbiased molecular dynamics simulation of the trimeric channel in a model membrane. Molecular dynamics trajectories show how malate ions are efficiently captured from the surrounding bulk solution by the electrostatic potential of the channel, translocated to the binding site region, and immobilized in the constriction zone. In accordance with these results, conductance measurements with Omp32 inserted in planar lipid membranes revealed binding of malate. The anion-selective channel Omp32 is the first reported example of a porin with a 16-stranded beta-barrel and proven substrate specificity. This finding suggests a new view on the correlation of porin structure with substrate binding in specific channels.	Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Membrane Biochem, D-82152 Martinsried, Germany; Dinabandhu Mahavidyalaya, Dept Phys, Bongaon 743235, W Bengal, India	Max Planck Society; Max Planck Society	Engelhardt, H (corresponding author), Max Planck Inst Biochem, Dept Mol Struct Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	engelhar@biochem.mpg.de		Zachariae, Ulrich/0000-0003-3287-8494				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldermann C, 1998, J BACTERIOL, V180, P3741, DOI 10.1128/JB.180.15.3741-3749.1998; BEREZKHOVSKII AM, 2005, BIOPHYS J, V88, P17; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Ceccarelli M, 2004, BIOPHYS J, V87, P58, DOI 10.1529/biophysj.103.037283; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Danelon C, 2003, BIOPHYS CHEM, V104, P591, DOI 10.1016/S0301-4622(03)00062-0; Domene C, 2003, ADV PROTEIN CHEM, V66, P159; Dutzler R, 2002, STRUCTURE, V10, P1273, DOI 10.1016/S0969-2126(02)00811-0; Dutzler R, 1999, STRUCT FOLD DES, V7, P425, DOI 10.1016/S0969-2126(99)80055-0; ENGELHARDT H, 1990, J STRUCT BIOL, V105, P92, DOI 10.1016/1047-8477(90)90103-J; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; Godde C, 1999, FEMS MICROBIOL LETT, V173, P365; Grizot S, 2004, MOL MICROBIOL, V51, P1027, DOI 10.1111/j.1365-2958.2003.03903.x; Hirsch A, 1997, FEBS LETT, V404, P208, DOI 10.1016/S0014-5793(97)00131-2; HOROWITZ H, 1990, J CLIN MICROBIOL, V28, P143, DOI 10.1128/JCM.28.1.143-145.1990; Im W, 2002, J MOL BIOL, V322, P851, DOI 10.1016/S0022-2836(02)00778-7; Im W, 2002, J MOL BIOL, V319, P1177, DOI 10.1016/S0022-2836(02)00380-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordy M, 1996, J MOL BIOL, V259, P666, DOI 10.1006/jmbi.1996.0348; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Kosztin I, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.238102; KREUSCH A, 1994, J MOL BIOL, V243, P891, DOI 10.1006/jmbi.1994.1690; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mathes A, 1998, BIOPHYS J, V75, P1255, DOI 10.1016/S0006-3495(98)74045-7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meyer JEW, 1997, J MOL BIOL, V266, P761, DOI 10.1006/jmbi.1996.0823; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Nestorovich EM, 2002, P NATL ACAD SCI USA, V99, P9789, DOI 10.1073/pnas.152206799; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Prinz T, 2000, FEMS MICROBIOL LETT, V183, P49, DOI 10.1111/j.1574-6968.2000.tb08932.x; Robertson KM, 2002, FEBS LETT, V528, P53, DOI 10.1016/S0014-5793(02)03173-3; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schirmer T, 1998, J STRUCT BIOL, V121, P101, DOI 10.1006/jsbi.1997.3946; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schulz GE, 2003, ADV PROTEIN CHEM, V63, P47; Suenaga A, 1998, BIOSCIENCE REP, V18, P39, DOI 10.1023/A:1022292801256; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; van den Berg B, 2004, SCIENCE, V304, P1506, DOI 10.1126/science.1097524; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; Willems A., 1992, PROKARYOTES HDB BIOL, P2583; Winterhalter M, 1999, COLLOID SURFACE A, V149, P547, DOI 10.1016/S0927-7757(98)00290-8; WOOLF TB, 1994, P NATL ACAD SCI USA, V91, P11631, DOI 10.1073/pnas.91.24.11631; Woolf TB, 1996, PROTEINS, V24, P92; Ye JQ, 2004, EMBO J, V23, P3187, DOI 10.1038/sj.emboj.7600330; Zachariae U, 2003, BIOPHYS J, V85, P954, DOI 10.1016/S0006-3495(03)74534-2; Zachariae U, 2002, PROTEIN SCI, V11, P1309, DOI 10.1110/ps.4910102; Zeth K, 2000, STRUCTURE, V8, P981, DOI 10.1016/S0969-2126(00)00189-1	53	25	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7413	7420		10.1074/jbc.M510939200	http://dx.doi.org/10.1074/jbc.M510939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16434398	hybrid, Green Submitted			2022-12-27	WOS:000236030900062
J	Xu, Y; Liu, C; Clark, JC; Whitsett, JA				Xu, Y; Liu, C; Clark, JC; Whitsett, JA			Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR Delta 508 in the lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FACTOR-BINDING PROTEIN-3; GROWTH-FACTOR-I; NONSELECTIVE CATION CHANNEL; INDUCIBLE EARLY GENE-1; CHLORIDE CHANNELS; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; MEDIATES APOPTOSIS; ARACHIDONIC-ACID; DELTA-F508 CFTR	Cystic fibrosis (CF), a common lethal pulmonary disorder in Caucasians, is caused by mutations in the cystic fibrosis transmembrane conductance regulator gene ( CFTR) that disturbs fluid homeostasis and host defense in target organs. The effects of CFTR and Delta 508-CFTR were assessed in transgenic mice that 1) lack CFTR expression (Cftr(-/-)); 2) express the human Delta 508 CFTR (CFTR Delta 508); 3) overexpress the normal human CFTR (CFTRtg) in respiratory epithelial cells. Genes were selected from Affymetrix Murine GeneChips analysis and subjected to functional classification, k-means clustering, promoter cis-elements/modules searching, literature mining, and pathway exploring. Genomic responses to Cftr(-/-) were not corrected by expression of CFTR Delta 508. Genes regulating host defense, inflammation, fluid and electrolyte transport were similarly altered in Cftr(-/-) and CFTR Delta 508 mice. CFTR Delta 508 induced a primary disturbance in expression of genes regulating redox and antioxidant systems. Genomic responses to CFTRtg were modest and were not associated with lung pathology. CFTRtg and CFTR Delta 508 induced genes encoding heat shock proteins and other chaperones but did not activate the endoplasmic reticulum-associated degradation pathway. RNAs encoding proteins that directly interact with CFTR were identified in each of the CFTR mouse models, supporting the hypothesis that CFTR functions within amultiprotein complex whose members interact at the level of protein-protein interactions and gene expression. Promoters of genes influenced by CFTR shared common regulatory elements, suggesting that their co-expression may be mediated by shared regulatory mechanisms. Genes and pathways involved in the response to CFTR may be of interest as modifiers of CF.	Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Dept Pediat, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Dept Pediat, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Xu, Y (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yan.xu@cchmc.org		, Yan/0000-0003-2025-027X				Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; Antonello D, 2002, CANCER LETT, V183, P179, DOI 10.1016/S0304-3835(01)00802-3; Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8; BAKER RT, 1992, GENOMICS, V14, P520, DOI 10.1016/S0888-7543(05)80258-7; Barski OA, 2004, GENOMICS, V83, P119, DOI 10.1016/S0888-7543(03)00213-1; Berruyer C, 2004, MOL CELL BIOL, V24, P7214, DOI 10.1128/MCB.24.16.7214-7224.2004; Cai Zhiwei, 2004, J Cyst Fibros, V3 Suppl 2, P141, DOI 10.1016/j.jcf.2004.05.030; Cantin AM, 2004, CURR OPIN PULM MED, V10, P531, DOI 10.1097/01.mcp.0000138997.29276.a1; Cayrol C, 1996, J BIOL CHEM, V271, P31799, DOI 10.1074/jbc.271.50.31799; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clain J, 2005, HUM GENET, V116, P454, DOI 10.1007/s00439-004-1246-z; Clain J, 2005, HUM MUTAT, V25, P360, DOI 10.1002/humu.20156; Corazzari M, 2003, MOL PHARMACOL, V64, P1370, DOI 10.1124/mol.64.6.1370; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; Fuller W, 2000, J BIOL CHEM, V275, P37462, DOI 10.1074/jbc.M006278200; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; Genter MB, 2003, PHYSIOL GENOMICS, V16, P67, DOI 10.1152/physiolgenomics.00117.2003; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Gotoh T, 2001, CELL DEATH DIFFER, V8, P357, DOI 10.1038/sj.cdd.4400829; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; HARRIS A, 1991, DEVELOPMENT, V113, P305; Hatayama T, 1998, BIOCHEM BIOPH RES CO, V248, P395, DOI 10.1006/bbrc.1998.8979; Hiyama TY, 2004, J NEUROSCI, V24, P9276, DOI 10.1523/JNEUROSCI.2795-04.2004; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; Hudson Valerie M, 2004, Treat Respir Med, V3, P353, DOI 10.2165/00151829-200403060-00003; Hudson VM, 2001, FREE RADICAL BIO MED, V30, P1440, DOI 10.1016/S0891-5849(01)00530-5; Hutton JJ, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-82; Igase M, 2001, CLIN SCI, V100, P275, DOI 10.1042/CS20000220; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Jegga AG, 2005, NUCLEIC ACIDS RES, V33, pW408, DOI 10.1093/nar/gki486; Jiang QS, 1998, EUR J HUM GENET, V6, P12, DOI 10.1038/sj.ejhg.5200158; Johannessen M, 2003, BIOCHEM PHARMACOL, V65, P1317, DOI 10.1016/S0006-2952(03)00071-6; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; KERSTING U, 1993, P NATL ACAD SCI USA, V90, P4047, DOI 10.1073/pnas.90.9.4047; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Kida Y, 2004, NEW ENGL J MED, V350, P2000; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Kutsuwada K, 1999, BBA-GENE STRUCT EXPR, V1444, P92, DOI 10.1016/S0167-4781(98)00269-3; Lebeau C, 2002, PFLUG ARCH EUR J PHY, V444, P722, DOI 10.1007/s00424-002-0880-3; Lebl J, 2001, ACTA PAEDIATR, V90, P868, DOI 10.1080/08035250152509564; LevinsonDushnik M, 1997, MOL CELL BIOL, V17, P3817, DOI 10.1128/MCB.17.7.3817; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Mastruzzo C, 2002, Monaldi Arch Chest Dis, V57, P173; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Matthews RP, 1996, J BIOL CHEM, V271, P31869, DOI 10.1074/jbc.271.50.31869; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Miyoshi T, 1999, BIOCHEM BIOPH RES CO, V265, P13, DOI 10.1006/bbrc.1999.1622; Moriscot AS, 1997, ENDOCRINOLOGY, V138, P26, DOI 10.1210/en.138.1.26; Mouchel N, 2004, BIOCHEM J, V378, P909, DOI 10.1042/BJ20031157; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Nikitin A, 2003, BIOINFORMATICS, V19, P2155, DOI 10.1093/bioinformatics/btg290; Norkina O, 2004, AM J PHYSIOL-GASTR L, V286, pG1032, DOI 10.1152/ajpgi.00473.2003; Novichkova S, 2003, BIOINFORMATICS, V19, P1699, DOI 10.1093/bioinformatics/btg207; Nuthall HN, 1999, BIOCHEM J, V341, P601, DOI 10.1042/0264-6021:3410601; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Ozen M, 2004, PEDIATR INT, V46, P429, DOI 10.1111/j.1442-200x.2004.01925.x; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1999, ANTIOXID REDOX SIGN, V1, P425, DOI 10.1089/ars.1999.1.4-425; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; RIORDAN JR, 1989, SCIENCE, V245, P1066; Ropeleski MJ, 2005, GASTROENTEROLOGY, V129, P170, DOI 10.1053/j.gastro.2005.05.017; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; Sashchenko LP, 2004, J BIOL CHEM, V279, P2117, DOI 10.1074/jbc.M307513200; Satoh J, 2000, MOL CELL ENDOCRINOL, V160, P165, DOI 10.1016/S0303-7207(99)00214-2; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schraw TD, 2003, BIOCHEM J, V374, P207, DOI 10.1042/BJ20030610; Smith AN, 1996, J BIOL CHEM, V271, P9947, DOI 10.1074/jbc.271.17.9947; SNOUWAERT JN, 1995, AM J RESP CRIT CARE, V151, pS59, DOI 10.1164/ajrccm/151.3_Pt_2.S59; Steger B, 2004, NEW ENGL J MED, V350, P2000; Strandvik B, 2004, NEW ENGL J MED, V350, P605, DOI 10.1056/NEJMe038217; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tojo M, 2002, J BIOL CHEM, V277, P46576, DOI 10.1074/jbc.M205987200; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Tseng YH, 2002, J BIOL CHEM, V277, P31601, DOI 10.1074/jbc.M202932200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang H, 2004, EUR J NEUROSCI, V20, P2049, DOI 10.1111/j.1460-9568.2004.03650.x; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; Watanabe E, 2002, NEUROSCI LETT, V330, P109, DOI 10.1016/S0304-3940(02)00708-5; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13; Xu Y, 2003, J BIOL CHEM, V278, P7674, DOI 10.1074/jbc.M210277200; Yamagishi N, 2004, J BIOL CHEM, V279, P41727, DOI 10.1074/jbc.M407947200; Yoneda-Kato N, 1999, ONCOGENE, V18, P3716, DOI 10.1038/sj.onc.1202711; ZHOU L, 1994, SCIENCE, V266, P1705, DOI 10.1126/science.7527588	107	26	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11279	11291		10.1074/jbc.M512072200	http://dx.doi.org/10.1074/jbc.M512072200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16455659	hybrid			2022-12-27	WOS:000236822200071
J	Liu, YX; Cheng, K; Gong, K; Fu, AKY; Ip, NY				Liu, YX; Cheng, K; Gong, K; Fu, AKY; Ip, NY			Pctaire1 phosphorylates N-ethylmaleimide-sensitive fusion protein - Implications in the regulation of its hexamerization and exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; NEUROTRANSMITTER RELEASE; SYNAPSIN-I; BINDING; CDK5; ATP; FAMILY; DOMAIN; NSF; IDENTIFICATION	Pctaire1, a member of the cyclin-dependent kinase (Cdk)-related family, has recently been shown to be phosphorylated and regulated by Cdk5/p35. Although Pctaire1 is expressed in both neuronal and non-neuronal cells, its precise functions remain elusive. We performed a yeast two-hybrid screen to identify proteins that interact with Pctaire1. N-Ethylmaleimide- sensitive fusion protein (NSF), a crucial factor in vesicular transport and membrane fusion, was identified as one of the Pctaire1 interacting proteins. We demonstrate that the D2 domain of NSF, which is required for the oligomerization of NSF subunits, binds directly to and is phosphorylated by Pctaire1 on serine 569. Mutation of this phosphorylation site on NSF (S569A) augments its ability to oligomerize. Moreover, inhibition of Pctaire1 activity by transfecting its kinase-dead (KD) mutant into COS-7 cells enhances the self-association of NSF. Interestingly, Pctaire1 associates with NSF and synaptic vesicle-associated proteins in adult rat brain. To investigate whether Pctaire1 phosphorylation of NSF is involved in regulation of Ca2+-dependent exocytosis, we examined the effect of expressing Pctaire1 or NSF phosphorylation mutants on the regulated secretion of growth hormone from PC12 cells. Interestingly, expression of either Pctaire1-KD or NSF-S569A in PC12 cells significantly increases high K+-stimulated growth hormone release. Taken together, our findings provide the first demonstration that Pctaire1 phosphorylation of NSF regulates the ability of NSF to oligomerize, implicating an unexpected role of this kinase in modulating exocytosis. These findings open a new avenue of research in studying the functional roles of Pctaire1 in the nervous system.	Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.	BOIP@UST.HK		Fu, Kit Yu/0000-0003-4085-6201; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Charrasse S, 1999, CELL GROWTH DIFFER, V10, P611; Cheng K, 2002, J BIOL CHEM, V277, P31988, DOI 10.1074/jbc.M201161200; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Graeser R, 2002, J CELL SCI, V115, P3479; Han SY, 2000, BIOCHEM J, V352, P165, DOI 10.1042/0264-6021:3520165; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Khvotchev MV, 2003, J NEUROSCI, V23, P10531; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; Matveeva EA, 2001, J BIOL CHEM, V276, P12174, DOI 10.1074/jbc.M007394200; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Morgan A, 2004, CURR BIOL, V14, pR968, DOI 10.1016/j.cub.2004.10.045; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; OKUDA T, 1992, ONCOGENE, V7, P2249; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; RHEE K, 1995, DEV DYNAM, V204, P406, DOI 10.1002/aja.1002040407; Schweizer FE, 1998, SCIENCE, V279, P1203, DOI 10.1126/science.279.5354.1203; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Tolar LA, 1998, J NEUROSCI, V18, P10250; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Whiteheart SW, 2004, J STRUCT BIOL, V146, P32, DOI 10.1016/j.jsb.2003.09.015; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	39	49	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9852	9858		10.1074/jbc.M513496200	http://dx.doi.org/10.1074/jbc.M513496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16461345	hybrid			2022-12-27	WOS:000236594300006
J	Ding, J; Li, JX; Chen, JY; Chen, HB; Ouyang, WM; Zhang, RH; Xue, CF; Zhang, DY; Amin, S; Desai, D; Huang, CS				Ding, J; Li, JX; Chen, JY; Chen, HB; Ouyang, WM; Zhang, RH; Xue, CF; Zhang, DY; Amin, S; Desai, D; Huang, CS			Effects of polycyclic aromatic hydrocarbons (PAHs) on vascular endothelial growth factor induction through phosphatidylinositol 3-kinase/AP-1-dependent, HIF-1 alpha-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATOR PROTEIN-1 ACTIVATION; CANCER MUTATIONAL HOTSPOTS; PHOSPHOINOSITIDE 3-KINASE; AP-1 TRANSACTIVATION; CELL-TRANSFORMATION; CATALYTIC SUBUNIT; DIOL-EPOXIDE; FACTOR VEGF; EXPRESSION	Previous studies have demonstrated that exposure to polycyclic aromatic hydrocarbons (PAHs) and its derivatives is associated with an increased risk of skin cancers, and the carcinogenic effect of PAHs is thought to involve both tumor initiation and promotion. Whereas PAH tumor initiation is well characterized, the mechanisms involved in the tumor promotion of PAHs remain elusive. In the present study, we investigated the effects of PAHs on vascular endothelial growth factor (VEGF) expression by comparison of its induction between the active metabolite and its parent compound (B[a]PDE versus B[a]P) or between active compound and its relatively inactive analog (5-MCDE versus CDE). We found that exposure of cells to (+/-)-anti-benzo[a]pyrene-7,8-diol-9,10-epoxide (B[a]PDE) or (+/-)-anti-5-methylchrysene-1,2-diol-3,4-epoxide (5-MCDE) led to marked induction of VEGF in Cl41 cells, whereas benzo[a]pyrene (B[a]P) or chrysene-1,2-diol-3,4-epoxide (CDE) did not exhibit significant inductive effects. Exposure of cells to B[a]PDE and 5-MCDE did not induce HIF-1 alpha activation, whereas AP-1 was significantly activated. Moreover, overexpression of TAM67 (a dominant-negative mutant c-Jun) dramatically blocked that VEGF induction. Electrophoretic mobility shift assay showed that AP-1 was only able to specifically recognize and bind to its AP-1 potential binding site within -1136 and -1115 of the VEGF promoter region. Site-directed mutation of this AP-1 binding site eliminated the VEGF transcriptional activity induced by B[a]PDE, suggesting that the AP-1 binding site between -1136 and -1115 in the VEGF promoter region is critical for VEGF induction by B[a]PDE. In addition, overexpression of Delta p85 (a dominant-negative mutant PI-3K) impaired B[a]PDE- and 5-MCDE-induced VEGF induction. Considering our previous findings that PI3K is an upstream mediator for c-Jun/AP-1 activation, we conclude that the VEGF induction by B[a]PDE and 5-MCDE is through PI-3K/AP-1-dependent and HIF-1 alpha-independent pathways. These findings may help us to understand the mechanisms involved in PAH carcinogenic effects.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Fourth Mil Med Univ, Dept Etiol, Xian 710032, Shaanxi, Peoples R China; Fourth Mil Med Univ, Dept Occupat & Environm Hlth Sci, Xian 710032, Shaanxi, Peoples R China; Penn State Univ, Sch Med, Dept Pharmacol, Hershey, PA 17033 USA	New York University; Air Force Military Medical University; Air Force Military Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R01CA103180, R01CA112557, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260, R01ES012451, P42ES010344] Funding Source: NIH RePORTER; NCI NIH HHS [CA094964, CA103180, CA112557] Funding Source: Medline; NIEHS NIH HHS [ES000260, ES012451, ES010344] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMIN S, 1985, CANCER RES, V45, P6406; [Anonymous], 1983, IARC Monogr Eval Carcinog Risk Chem Hum, V32, P1; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Brandt HCA, 2003, ANN OCCUP HYG, V47, P349, DOI 10.1093/annhyg/meg052; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; CONTI CJ, 2000, CANC THERAPY S3, V7, P4; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Fuh G, 2000, J BIOL CHEM, V275, P26690; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Hecht SS, 2002, CARCINOGENESIS, V23, P907, DOI 10.1093/carcin/23.6.907; HECHT SS, 1998, NAT REV CANCER, V3, P733; Hoffmann D, 1997, PREV MED, V26, P427, DOI 10.1006/pmed.1997.0183; Huang CS, 1998, INT J ONCOL, V13, P711; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1984, IARC MON EV CARC RIS, V34, P37; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JAMES EK, 2004, ANN REV PHARM TOXICO, V44, P239; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; JULIANE H, 2000, J CHROMATOGR B, V739, P225; JURGEN G, 2000, J CHROMATOGR B, V738, P47; Jyonouchi H, 1999, CARCINOGENESIS, V20, P139, DOI 10.1093/carcin/20.1.139; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LEVIN W, 1977, CANCER RES, V37, P3356; Li JX, 2004, MOL CARCINOGEN, V40, P104, DOI 10.1002/mc.20020; Li JX, 2004, ONCOGENE, V23, P3932, DOI 10.1038/sj.onc.1207501; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Li JX, 2004, CANCER RES, V64, P94, DOI 10.1158/0008-5472.CAN-03-0737; MATTHIAS S, 2001, ANAL CHEM, V73, P5669; Merimsky O, 1998, CLIN DERMATOL, V16, P585, DOI 10.1016/S0738-081X(98)00043-1; Nesnow S, 1998, ENVIRON HEALTH PERSP, V106, P1337, DOI 10.1289/ehp.98106s61337; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Robinson CJ, 2001, J CELL SCI, V114, P853; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sinha R, 2005, CANCER RES, V65, P8034, DOI 10.1158/0008-5472.CAN-04-3429; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Szeliga J, 2000, CHEM-BIOL INTERACT, V128, P159, DOI 10.1016/S0009-2797(00)00184-8; Tannheimer SL, 1998, CARCINOGENESIS, V19, P1291, DOI 10.1093/carcin/19.7.1291; TISCHER E, 1991, J BIOL CHEM, V266, P11947; YOU L, 1994, CARCINOGENESIS, V15, P2613, DOI 10.1093/carcin/15.11.2613	55	24	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9093	9100		10.1074/jbc.M510537200	http://dx.doi.org/10.1074/jbc.M510537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461351	hybrid			2022-12-27	WOS:000236404700014
J	Lau, KHW; Kapur, S; Kesavan, C; Baylink, DJ				Lau, KHW; Kapur, S; Kesavan, C; Baylink, DJ			Up-regulation of the Wnt, estrogen receptor, insulin-like growth factor-I, and bone morphogenetic protein pathways in C57BL/6J osteoblasts as opposed to C3H/HeJ osteoblasts in part contributes to the differential anabolic response to fluid shear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNLOADING INDUCES RESISTANCE; MECHANICAL STRAIN; GENE-EXPRESSION; SIGNALING PATHWAYS; IGF-I; MC3T3-E1 OSTEOBLASTS; CELLS; MICE; ALPHA; PROLIFERATION	C57BL/6J (B6), but not C3H/HeJ (C3H), mice responded to mechanical loading with an increase in bone formation. A 30-min steady fluid shear of 20 dynes/cm(2) increased [H-3] thymidine incorporation and alkaline phosphatase activity and up-regulated the expression of early mechanoresponsive genes ( integrin beta 1 (Igtb1) and cyclooxygenase-2 (Cox-2)) in B6 but not C3H osteoblasts, indicating that the differential mechanosensitivity was intrinsic to osteoblasts. In-house microarray analysis with 5,500 gene fragments revealed that the expression of 669 genes in B6 osteoblasts and 474 genes in C3H osteoblasts was altered 4 h after the fluid shear. Several genes associated with the insulin-like growth factor (IGF)-I, the estrogen receptor ( ER), the bone morphogenetic protein (BMP)/transforming growth factor-beta, and Wnt pathways were differentially up-regulated in B6 osteoblasts. In vitro mechanical loading also led to up-regulation of these genes in the bones of B6 but not C3H mice. Pretreatment of B6 osteoblasts with inhibitors of the Wnt pathway ( endostatin), the BMP pathway ( Noggin), or the ER pathway (ICI182780) blocked the fluid shear-induced proliferation. Inhibition of integrin and Cox-2 activation by echistatin and indomethacin, respectively, each blocked the fluid shear-induced up-regulation of genes associated with these four pathways. In summary, up-regulation of the IGF-I, ER, BMP, and Wnt pathways is involved in mechanotransduction. These four pathways are downstream to the early mechanoresponsive genes, i.e. Igtb1 and Cox-2. In conclusion, differential up-regulation of these anabolic pathways may in part contribute to the good and poor response, respectively, in the B6 and C3H mice to mechanical loading.	Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA	Loma Linda University	Lau, KHW (corresponding author), Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, 151,11201 Benton St, Loma Linda, CA 92357 USA.	William.Lau@med.va.gov		Lau, Kin-Hing/0000-0003-1109-5052				AKHTER MP, 1992, J BIOMECH, V25, P1241, DOI 10.1016/0021-9290(92)90082-C; Akhter MP, 1998, CALCIFIED TISSUE INT, V63, P442, DOI 10.1007/s002239900554; Bikle DD, 1999, J BONE MINER METAB, V17, P233, DOI 10.1007/s007740050090; Bonewald L. F., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P239; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Cheng MZ, 1999, J BONE MINER RES, V14, P1742, DOI 10.1359/jbmr.1999.14.10.1742; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; Damien E, 2000, J BONE MINER RES, V15, P2169, DOI 10.1359/jbmr.2000.15.11.2169; DEFRIEND DJ, 1994, BRIT J CANCER, V70, P204, DOI 10.1038/bjc.1994.281; FARLEY JR, 1983, ARCH BIOCHEM BIOPHYS, V221, P477, DOI 10.1016/0003-9861(83)90166-2; FROST HM, 1982, METAB BONE DIS RELAT, V4, P217, DOI 10.1016/0221-8747(82)90031-5; Gu W.-K., 2003, Current Genomics, V4, P75, DOI 10.2174/1389202033350146; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; HE XY, 1993, ANN BIOMED ENG, V21, P45, DOI 10.1007/BF02368163; Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210; HILLAM RA, 1995, J BONE MINER RES, V10, P683; HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706; Hughes-Fulford Millie, 2004, Sci STKE, V2004, pRE12; Jessop HL, 2004, J BONE MINER RES, V19, P938, DOI 10.1359/jbmr.2004.19.6.938; Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045; Johnson M. L., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P135; Kapur S, 2005, J BONE MINER RES, V20, pS240; Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200; Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1; KAPUR S, 2004, BONE NY, V35, P534; Karjalainen HM, 2003, BIORHEOLOGY, V40, P93; Kesavan C, 2005, J APPL PHYSIOL, V99, P1951, DOI 10.1152/japplphysiol.00401.2005; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; KLEINNULEND J, 1995, J CELL PHYSIOL, V163, P115, DOI 10.1002/jcp.1041630113; Kodama Y, 2000, CALCIFIED TISSUE INT, V66, P298, DOI 10.1007/s002230010060; Kodama Y, 1999, BONE, V25, P183, DOI 10.1016/S8756-3282(99)00155-6; Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; LAU KHW, 1985, BIOCHIM BIOPHYS ACTA, V840, P56, DOI 10.1016/0304-4165(85)90162-X; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a; Lee KCL, 2004, J ENDOCRINOL, V182, P193, DOI 10.1677/joe.0.1820193; Li XM, 2001, MAMM GENOME, V12, P52, DOI 10.1007/s003350010230; Liegibel UM, 2004, EXP CLIN ENDOCR DIAB, V112, P356, DOI 10.1055/s-2004-821014; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003; RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562; RAWLINSON SCF, 1993, CALCIFIED TISSUE INT, V53, P324, DOI 10.1007/BF01351837; Rhee ST, 2005, ANN PLAS SURG, V55, P207, DOI 10.1097/01.sap.0000164576.10754.aa; Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756-3282(02)00871-2; Robling AG, 2002, FASEB J, V16, P324, DOI 10.1096/fj.02-0393fje; Sakai K, 1998, CALCIFIED TISSUE INT, V63, P515, DOI 10.1007/s002239900567; Sakata T, 2004, J BONE MINER RES, V19, P436, DOI 10.1359/JBMR.0301241; Sakata T, 2003, BONE, V32, P669, DOI 10.1016/S8756-3282(03)00088-7; Segev O, 2004, BONE, V34, P246, DOI 10.1016/j.bone.2003.10.003; Sheng MHC, 2004, BONE, V35, P711, DOI 10.1016/j.bone.2004.05.013; Sheng MHC, 2002, BONE, V30, P486, DOI 10.1016/S8756-3282(01)00693-7; Srivastava AK, 2005, J BONE MINER RES, V20, P1041, DOI 10.1359/JBMR.041239; Tanaka SM, 2005, CALCIFIED TISSUE INT, V76, P261, DOI 10.1007/s00223-004-0238-2; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044	60	128	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9576	9588		10.1074/jbc.M509205200	http://dx.doi.org/10.1074/jbc.M509205200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461770	hybrid			2022-12-27	WOS:000236404700069
J	Xu, DS; Brumm, K; Zhang, LW				Xu, DS; Brumm, K; Zhang, LW			The latent membrane protein 1 of Epstein-Barr virus (EBV) primes EBV latency cells for type I interferon production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN 1; TREATED HUMAN-CELLS; REGULATORY FACTOR-7; HUMAN CYTOMEGALOVIRUS; ALPHA-INTERFERON; LYMPHOMA-CELLS; SIGNAL TRANSDUCERS; POSITIVE FEEDBACK; ANTIVIRAL STATE; GENE-EXPRESSION	Epstein-Barr virus (EBV) latency has been associated with a variety of human cancers. Latent membrane protein 1 (LMP-1) is one of the key viral proteins required for transformation of primary B cells in vitro and establishment of EBV latency. We have previously shown that LMP-1 induces the expression of several interferon (IFN)-stimulated genes and has antiviral effect (Zhang, J., Das, S. C., Kotalik, C., Pattnaik, A. K., and Zhang, L. (2004) J. Biol. Chem. 279, 46335-46342). In this report, a novel mechanism related to the antiviral effect of LMP-1 is identified. We show that EBV type III latency cells, in which LMP-1 is expressed, are primed to produce robust levels of endogenous IFNs upon infection of Sendai virus. The priming action is due to the expression of LMP-1 but not EBV nuclear antigen 2 (EBNA-2). The signaling events from the C-terminal activator regions of LMP-1 are essential to prime cells for high IFN production. LMP-1-mediated activation of NF-kappa B is apparently necessary and sufficient for LMP-1-mediated priming effect in DG75 cells, a human B cell line. IFN regulatory factor 7 (IRF-7) that can be activated by LMP-1 is also implicated in the priming action. Taken together, these data strongly suggest that LMP-1 may prime EBV latency cells for IFN production and that the antiviral property of LMP-1 may be an intrinsic part of EBV latency program, which may assist the establishment and/or maintenance of viral latency.	Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Zhang, LW (corresponding author), Univ Nebraska, Nebraska Ctr Virol, E141 Beadle Ctr,1901 Vine St, Lincoln, NE 68588 USA.	lzhang2@unlnotes.unl.edu			NATIONAL CANCER INSTITUTE [R01CA108951] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059132] Funding Source: NIH RePORTER; NCI NIH HHS [CA108951] Funding Source: Medline; NCRR NIH HHS [P20RR15635] Funding Source: Medline; NIAID NIH HHS [U54 AI057160, AI59132] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; AMAN P, 1990, EMBO J, V9, P147, DOI 10.1002/j.1460-2075.1990.tb08090.x; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; Carter KL, 2002, J VIROL, V76, P10427, DOI 10.1128/JVI.76.20.10427-10436.2002; Cassady KA, 2005, J VIROL, V79, P8707, DOI 10.1128/JVI.79.14.8707-8715.2005; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLARKE PA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P167, DOI 10.1016/0167-4781(90)90161-T; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; FUJITA T, 1979, J GEN VIROL, V45, P301, DOI 10.1099/0022-1317-45-2-301; GHOSH D, 1990, J VIROL, V64, P1855, DOI 10.1128/JVI.64.4.1855-1858.1990; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Gotoh B, 2003, J VIROL, V77, P3360, DOI 10.1128/JVI.77.6.3360-3370.2003; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Hahn AM, 2005, J VIROL, V79, P10040, DOI 10.1128/JVI.79.15.10040-10052.2005; HAVELL EA, 1972, ANTIMICROB AGENTS CH, V2, P476, DOI 10.1128/AAC.2.6.476; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Higuchi M, 2002, J VIROL, V76, P455, DOI 10.1128/JVI.76.1.455-459.2002; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; KIEFF E, 1996, FIELDS VIROLOGY, V3, P2343; Komatsu T, 2000, J VIROL, V74, P2477, DOI 10.1128/JVI.74.5.2477-2480.2000; Komatsu T, 2002, FEBS LETT, V511, P139, DOI 10.1016/S0014-5793(01)03301-4; Krug LT, 2004, J VIROL, V78, P8359, DOI 10.1128/jvi.78.15.8359-8371.2004; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; MITTNACHT S, 1988, VIROLOGY, V164, P201, DOI 10.1016/0042-6822(88)90637-X; Monini P, 1999, J VIROL, V73, P4029, DOI 10.1128/JVI.73.5.4029-4041.1999; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Mossman KL, 2002, J VIROL, V76, P1995, DOI 10.1128/JVI.76.4.1995-1998.2002; NIR U, 1984, NUCLEIC ACIDS RES, V12, P6979, DOI 10.1093/nar/12.18.6979; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; OBERMAN F, 1989, J INTERFERON RES, V9, P563, DOI 10.1089/jir.1989.9.563; OBERMAN F, 1988, J GEN VIROL, V69, P1167, DOI 10.1099/0022-1317-69-6-1167; Pozharskaya VP, 2004, J GEN VIROL, V85, P2779, DOI 10.1099/vir.0.80214-0; Richardson C, 2003, J VIROL, V77, P4439, DOI 10.1128/JVI.77.7.4439-4443.2003; RICKINSON AB, 1996, FIELDS VIROLOGY, V3, P2397; Roberts RM, 1998, J INTERF CYTOK RES, V18, P805, DOI 10.1089/jir.1998.18.805; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SHARP NA, 1989, J GEN VIROL, V70, P2521, DOI 10.1099/0022-1317-70-9-2521; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Simmen KA, 2001, P NATL ACAD SCI USA, V98, P7140, DOI 10.1073/pnas.121177598; STEWART WE, 1971, J VIROL, V7, P792, DOI 10.1128/JVI.7.6.792-801.1971; Tolo H, 2001, J INTERF CYTOK RES, V21, P913, DOI 10.1089/107999001753289523; TSANG SF, 1991, J VIROL, V65, P6765, DOI 10.1128/JVI.65.12.6765-6771.1991; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zhang J, 2005, J VIROL, V79, P5640, DOI 10.1128/JVI.79.9.5640-5652.2005; Zhang J, 2004, J BIOL CHEM, V279, P46335, DOI 10.1074/jbc.M403966200; ZHANG L, 2000, J VIROL, V74, P5748; Zhang LW, 2004, J VIROL, V78, P12987, DOI 10.1128/JVI.78.23.12987-12995.2004; Zhang LW, 2004, VIROLOGY, V323, P141, DOI 10.1016/j.virol.2004.03.007; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2000, MOL BIOTECHNOL, V14, P73, DOI 10.1385/MB:14:1:73; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700; Zhang LW, 2001, SEMIN CANCER BIOL, V11, P445, DOI 10.1006/scbi.2001.0411; Zhang LW, 2001, J VIROL, V75, P12393, DOI 10.1128/JVI.75.24.12393-12401.2001; Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	71	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9163	9169		10.1074/jbc.M511884200	http://dx.doi.org/10.1074/jbc.M511884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469740	hybrid, Green Published			2022-12-27	WOS:000236404700022
J	Zhang, YM; Wang, H; Li, JR; Dong, L; Xu, P; Chen, WZ; Neve, RL; Volpe, JJ; Rosenberg, PA				Zhang, YM; Wang, H; Li, JR; Dong, L; Xu, P; Chen, WZ; Neve, RL; Volpe, JJ; Rosenberg, PA			Intracellular zinc release and ERK phosphorylation are required upstream of 12-lipoxygenase activation in peroxynitrite toxicity to mature rat oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ACTIVE MULTIPLE-SCLEROSIS; INDUCED CELL-DEATH; INDUCED NEURONAL APOPTOSIS; SIGNAL-REGULATED KINASE; GLUTATHIONE DEPLETION; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID	Peroxynitrite toxicity has been implicated in the pathogenesis of white matter injury. The mechanisms of peroxynitrite toxicity to oligodendrocytes (OLs), the major cell type of the white matter, are unknown. Using primary cultures of mature OLs that express myelin basic protein, we found that 3-morpholinosydnonimine, a peroxynitrite generator, caused toxicity to OLs. N, N, N', N'-tetrakis (2-pyridylmethyl) ethylenediamine, a zinc chelator, completely blocked peroxynitrite-induced toxicity. Use of FluoZin-3, a specific fluorescence zinc indicator, demonstrated the liberation of zinc from intracellular stores by peroxynitrite. Peroxynitrite caused the sequential activation of extracellular signal-regulated kinase 42/44 (ERK42/44), 12-lipoxygenase, and generation of reactive oxygen species, which were all dependent upon the intracellular release of zinc. The same cell death pathway was also activated when exogenous zinc was used. These results suggest that in addition to preventing the formation of peroxynitrite, useful strategies in preventing disease progression in pathologies in which peroxynitrite toxicity plays a critical role might include maintaining intracellular zinc homeostasis, blocking phosphorylation of ERK42/44, inhibiting activation of 12-lipoxygenase, and eliminating the accumulation of reactive oxygen species.	Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Program Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; McLean Hosp, Belmont, MA 02478 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; McLean Hospital	Rosenberg, PA (corresponding author), 300 Longwood Ave, Boston, MA 02115 USA.	paul.rosenberg@childrens.harvard.edu	Li, Jianrong/C-4126-2011	Li, Jianrong/0000-0002-8232-9322; Rosenberg, Paul/0000-0002-5185-1118	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038475] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18655] Funding Source: Medline; NINDS NIH HHS [NS 38475] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Armstrong C, 2001, BRAIN RES, V892, P51, DOI 10.1016/S0006-8993(00)03195-4; Arnett HA, 2002, J IMMUNOL, V168, P427, DOI 10.4049/jimmunol.168.1.427; Back SA, 1999, J NEUROSCI METH, V91, P47, DOI 10.1016/S0165-0270(99)00062-X; Back SA, 1998, J NEUROSCI, V18, P6241; Baud O, 2004, EUR J NEUROSCI, V20, P1713, DOI 10.1111/j.1460-9568.2004.03616.x; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bhat NR, 1996, J NEUROCHEM, V66, P1986; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brenner T, 1997, J IMMUNOL, V158, P2940; Calabrese V, 2003, NEUROCHEM RES, V28, P1321, DOI 10.1023/A:1024984013069; Calabrese V, 2002, J NEUROSCI RES, V70, P580, DOI 10.1002/jnr.10408; Canals S, 2003, J BIOL CHEM, V278, P21542, DOI 10.1074/jbc.M213174200; Cross AH, 2000, J NEUROIMMUNOL, V107, P21, DOI 10.1016/S0165-5728(00)00242-3; Crow JP, 1997, J NEUROCHEM, V69, P1945; Cuzzocrea S, 1998, BRIT J PHARMACOL, V123, P525, DOI 10.1038/sj.bjp.0701612; Dikalov SI, 2001, FREE RADICAL BIO MED, V30, P187, DOI 10.1016/S0891-5849(00)00456-1; Ding XZ, 2001, INT J CANCER, V94, P630, DOI 10.1002/ijc.1527.abs; Du S, 2002, J NEUROSCI, V22, P7408; Fragoso G, 2004, J NEUROCHEM, V90, P392, DOI 10.1111/j.1471-4159.2004.02488.x; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Gee KR, 2002, J AM CHEM SOC, V124, P776, DOI 10.1021/ja011774y; Guidarelli A, 2000, BRIT J PHARMACOL, V129, P1539, DOI 10.1038/sj.bjp.0703275; Guidarelli A, 2002, BIOCHEM J, V366, P307, DOI 10.1042/BJ20020284; Hill KE, 2004, J NEUROIMMUNOL, V151, P171, DOI 10.1016/j.jneuroim.2004.02.005; HONN KV, 1994, EXP CELL RES, V210, P1, DOI 10.1006/excr.1994.1001; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Khanna S, 2003, J BIOL CHEM, V278, P43508, DOI 10.1074/jbc.M307075200; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Lebeau A, 2004, CELL DEATH DIFFER, V11, P875, DOI 10.1038/sj.cdd.4401395; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li JR, 2003, J NEUROSCI, V23, P5816; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lindahl M, 1996, INFLAMMATION, V20, P599, DOI 10.1007/BF01488798; Liu JSH, 2001, AM J PATHOL, V158, P2057, DOI 10.1016/S0002-9440(10)64677-9; MANCINI JA, 1992, MOL PHARMACOL, V41, P267; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; MITROVIC B, 1995, NEUROSCIENCE, V65, P531, DOI 10.1016/0306-4522(94)00491-M; Moskowitz SI, 2001, BRAIN RES, V913, P207, DOI 10.1016/S0006-8993(01)02756-1; Nabeyrat E, 2003, AM J PHYSIOL-LUNG C, V284, pL1112, DOI 10.1152/ajplung.00178.2002; NAKADATE T, 1985, J PHARM PHARMACOL, V37, P71, DOI 10.1111/j.2042-7158.1985.tb04938.x; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Pal S, 2004, PFLUG ARCH EUR J PHY, V448, P296, DOI 10.1007/s00424-004-1256-7; Palomba L, 2000, FREE RADICAL BIO MED, V29, P783, DOI 10.1016/S0891-5849(00)00381-6; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Sahrbacher UC, 1998, EUR J IMMUNOL, V28, P1332, DOI 10.1002/(SICI)1521-4141(199804)28:04<1332::AID-IMMU1332>3.0.CO;2-G; Scott GS, 2002, P NATL ACAD SCI USA, V99, P16303, DOI 10.1073/pnas.212645999; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; SEGER R, 1994, J BIOL CHEM, V269, P25699; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sharpe MA, 2002, BIOCHEM J, V366, P97, DOI 10.1042/bj20020154; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Sloane JA, 1999, NEUROBIOL AGING, V20, P395, DOI 10.1016/S0197-4580(99)00066-4; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Szekeres CK, 2000, J BIOL CHEM, V275, P38831, DOI 10.1074/jbc.M002673200; Thome U, 2003, FREE RADICAL BIO MED, V35, P662, DOI 10.1016/S0891-5849(03)00392-7; Tommasini I, 2002, MOL PHARMACOL, V61, P870, DOI 10.1124/mol.61.4.870; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Upmacis RK, 2004, AM J PHYSIOL-CELL PH, V286, pC1271, DOI 10.1152/ajpcell.00143.2003; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang H, 2004, EUR J NEUROSCI, V20, P2049, DOI 10.1111/j.1460-9568.2004.03650.x; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004; Zhang YM, 2002, EUR J NEUROSCI, V16, P1015, DOI 10.1046/j.1460-9568.2002.02169.x	78	54	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9460	9470		10.1074/jbc.M510650200	http://dx.doi.org/10.1074/jbc.M510650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431921	hybrid			2022-12-27	WOS:000236404700056
J	Meyer, RD; Qian, XF; Guo, HC; Rahimi, N				Meyer, RD; Qian, XF; Guo, HC; Rahimi, N			Leucine motif-dependent tyrosine autophosphorylation of type III receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CARBOXYL-TERMINUS; ENDOTHELIAL-CELLS; INSULIN-RECEPTOR; VEGF RECEPTOR-2; SRC KINASE; C-SRC; GROWTH; ACTIVATION; DOMAIN	Activation loop tyrosine autophosphorylation is an essential requirement for full kinase activation of receptor tyrosine kinases (RTKs). However, mechanisms involved are not fully understood. In general, kinase domains of RTKs are folded into two main lobes, NH2- and COOH-terminal lobes. The COOH-terminal lobe of vascular endothelial growth factor receptor-2 (VEGFR-2) is folded into seven alpha-helices (alpha D-alpha I). In the studies presented here we demonstrate that leucine residues of helix I (alpha I) regulate tyrosine autophosphorylation and phosphotransferase activity of VEGFR-2. The presence of leucines 1158, 1161, and 1162 are essential for tyrosine autophosphorylation and kinase activation of VEGFR-2 and are involved in helix-helix packing via hydrophobic interactions. The presence of leucine 1158 is critical for kinase activation of VEGFR-2 and appears to interact with alpha E, alpha F, alpha H, and beta 7. The analogous residue, leucine 957 on platelet-derived growth factor receptor-beta and leucine 910 on colony stimulating factor-1R are also found to be critical for tyrosine autophosphorylation of these receptors. Leucines 1161 and 1162 are also involved in helix-helix packing but they play a less critical role in VEGFR-2 activation. Thus, we conclude that leucine motif-mediated helix-helix interactions are critical for kinase regulation of type III RTKs. This mechanism is likely to be shared with other kinases and might provide a basis for the design of a novel class of tyrosine kinase inhibitors.	Boston Univ, Sch Med, Dept Ophthalmol & Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Boston University; Boston University	Rahimi, N (corresponding author), 715 Albany St,Rm L921, Boston, MA 02118 USA.	nrahimi@bu.edu		Rahimi, Nader/0000-0002-6745-1725	NATIONAL EYE INSTITUTE [R01EY012997, R03EY013706] Funding Source: NIH RePORTER; NEI NIH HHS [R03 EY013706, R01 EY012997, EY0137061, EY012997] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Meyer RD, 2004, J BIOL CHEM, V279, P735, DOI 10.1074/jbc.M305575200; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Singh AJ, 2005, MOL BIOL CELL, V16, P2106, DOI 10.1091/mbc.E04-08-0749; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	37	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8620	8627		10.1074/jbc.M512309200	http://dx.doi.org/10.1074/jbc.M512309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431914	Green Accepted, hybrid			2022-12-27	WOS:000236247100039
J	Toruner, M; Fernandez-Zapico, M; Sha, JJ; Pham, L; Urrutia, R; Egan, LJ				Toruner, M; Fernandez-Zapico, M; Sha, JJ; Pham, L; Urrutia, R; Egan, LJ			Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; APOPTOSIS-INDUCING LIGAND; IKK-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CANCER-CELLS; TNF-ALPHA; ACTIVATION; SURVIVAL	Epithelial cells undergo a form of apoptosis termed anoikis when they lose extracellular attachments. We evaluated the role of transcription factor NF-kappa B in the regulation of anoikis susceptibility of intestinal epithelial cells. Culture of rat intestinal epithelial cells in suspension induced NF-kappa B activation, which blocked the anoikis of those cells, as assessed by internucleosomal DNA fragmentation and caspase-3 cleavage. Activation of NF-kappa B after the loss of extracellular attachments required focal adhesion kinase tyrosine 397 phosphorylation. This triggered a signaling cascade through phosphatidylinositol 3-kinase and AKT, to induce DNA binding of the RelA/p65 NF-kappa B polypeptide. NF-kappa B activated in this manner induced the up-regulated expression of a distinct program of genes that included osteoprotegerin, BCL-2, and IAP-1 ( inhibitor of apoptosis protein-1). Chromatin immunoprecipitation experiments revealed that NF-kappa B directly regulated the promoters of these 3 genes. Knock-down of the expression of osteoprotegerin, BCL-2, or inhibitor of apoptosis protein-1 by RNA interference showed that these factors inhibit anoikis, and genetic reconstitution of their expression alone or in combination restored normal levels of anoikis to NF-kappa B-inactive intestinal epithelial cells. Together, these findings have identified the molecular components of a previously unrecognized antianoikis pathway in intestinal epithelial cells.	Mayo Clin & Mayo Fdn, Gastroenterol Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Natl Univ Ireland, Dept Pharmacol & Therapeut, Galway, Ireland	Mayo Clinic; Mayo Clinic; Ollscoil na Gaillimhe-University of Galway	Egan, LJ (corresponding author), Univ Coll Hosp, Inst Clin Sci, Dept Pharmacol & Therapeut, Galway, Ireland.		Törüner, Murat/AAQ-1826-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060792] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60792] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLACOSA A, 1993, ONCOGENE, V8, P745; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; DEL PL, 1997, SCIENCE, V278, P687; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Dufour G, 2004, J BIOL CHEM, V279, P44113, DOI 10.1074/jbc.M405323200; Egan LJ, 2004, P NATL ACAD SCI USA, V101, P2452, DOI 10.1073/pnas.0306734101; Egan LJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1028, DOI 10.1152/ajpcell.00167.2003; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; EGAN LJ, 2003, AM J PHYSIOL, V25, pC25; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; HALL PA, 1994, J CELL SCI, V107, P3569; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jobin C, 1997, J IMMUNOL, V158, P226; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LEIST M, 1994, J IMMUNOL, V153, P1778; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pritzker LB, 2004, MOL BIOL CELL, V15, P2834, DOI 10.1091/mbc.E04-01-0059; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Scaife CL, 2002, CANCER RES, V62, P6870; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Vidal K, 2004, AM J PHYSIOL-GASTR L, V287, pG836, DOI 10.1152/ajpgi.00428.2003; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	58	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8686	8696		10.1074/jbc.M512178200	http://dx.doi.org/10.1074/jbc.M512178200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407217	hybrid			2022-12-27	WOS:000236247100046
J	Wang, MH; Yao, Y; Kuang, DH; Hampson, DR				Wang, MH; Yao, Y; Kuang, DH; Hampson, DR			Activation of family C G-protein-coupled receptors by the tripeptide glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; BINDING POCKET; CA2+; POTENTIATION; CLONING; DOMAIN; HYDRA	The Family C G-protein-coupled receptors include the metabotropic glutamate receptors, the gamma-aminobutyric acid, type B (GABA(B)) receptor, the calcium-sensing receptor (CaSR), which participates in the regulation of calcium homeostasis in the body, and a diverse group of sensory receptors that encompass the amino acid-activated fish 5.24 chemosensory receptor, the mammalian T1R taste receptors, and the V2R pheromone receptors. A common feature of Family C receptors is the presence of an amino acid binding site. In this study, a preliminary in silico analysis of the size and shape of the amino acid binding pocket in selected Family C receptors suggested that some members of this family could accommodate larger ligands such as peptides. Subsequent screening and docking experiments identified GSH as a potential ligand or co-ligand at the fish 5.24 receptor and the rat CaSR. These in silico predictions were confirmed using an [H-3] GSH radioligand binding assay and a fluorescence-based functional assay performed on wildtype and chimeric receptors. Glutathione was shown to act as an orthosteric agonist at the 5.24 receptor and as a potent enhancer of calcium-induced activation of the CaSR. Within the mammalian receptors, this effect was specific to the CaSR because GSH neither directly activated nor potentiated other Family C receptors including GPRC6A (the putative mammalian homolog of the fish 5.24 receptor), the metabotropic glutamate receptors, or the GABA(B) receptor. Our findings reveal a potential new role for GSH and suggest that this peptide may act as an endogenous modulator of the CaSR in the parathyroid gland where this receptor is known to control the release of parathyroid hormone, and in other tissues such as the brain and gastrointestinal tract where the role of the calcium receptor appears to subserve other, as yet unknown, physiological functions.	Univ Toronto, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada	University of Toronto; University of Toronto	Hampson, DR (corresponding author), Univ Toronto, Dept Pharmaceut Sci, 19 Russell St, Toronto, ON M5S 2S2, Canada.	d.hampson@utoronto.ca	Kuang, Donghui/H-3518-2013; Centeno, Patricia Pacios/O-8368-2016					Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Conigrave AD, 2004, J BIOL CHEM, V279, P38151, DOI 10.1074/jbc.M406373200; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Hanai K, 1998, COMP BIOCHEM PHYS A, V119, P333, DOI 10.1016/S1095-6433(97)00432-7; HERBERT SC, 2004, CELL CALCIUM, V35, P239; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Janaky R, 1999, J NEUROCHEM, V73, P889, DOI 10.1046/j.1471-4159.1999.0730889.x; Janaky R, 2000, NEUROSCIENCE, V95, P617; Kimoto H, 2005, NATURE, V437, P898, DOI 10.1038/nature04033; Kuang DH, 2003, J BIOL CHEM, V278, P42551, DOI 10.1074/jbc.M307120200; Kuang DH, 2005, J NEUROCHEM, V93, P383, DOI 10.1111/j.1471-4159.2005.03025.x; LENHOFF HM, 1961, J GEN PHYSIOL, V45, P331, DOI 10.1085/jgp.45.2.331; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Luu P, 2004, J NEUROSCI, V24, P10128, DOI 10.1523/JNEUROSCI.3117-04.2004; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Mun HC, 2005, J BIOL CHEM, V280, P29067, DOI 10.1074/jbc.M500002200; Nagano N, 2005, J PHARMACOL SCI, V97, P355, DOI 10.1254/jphs.FMJ04007X6; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Nearing J, 2002, P NATL ACAD SCI USA, V99, P9231, DOI 10.1073/pnas.152294399; OGITA K, 1988, BRAIN RES, V463, P37, DOI 10.1016/0006-8993(88)90524-0; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pierobon P, 2004, EUR J NEUROSCI, V20, P2598, DOI 10.1111/j.1460-9568.2004.03759.x; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Riccardi D, 2005, BIOCHEM SOC T, V33, P316, DOI 10.1042/BST0330316; Rosemond E, 2004, MOL PHARMACOL, V66, P834, DOI 10.1124/mol.104.002956; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Silve C, 2005, J BIOL CHEM, V280, P37917, DOI 10.1074/jbc.M506263200; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Wang MH, 2006, BIOORGAN MED CHEM, V14, P2032, DOI 10.1016/j.bmc.2005.10.052; Wellendorph P, 2005, MOL PHARMACOL, V67, P589, DOI 10.1124/mol.104.007559; Yano S, 2004, CELL CALCIUM, V35, P257, DOI 10.1016/j.ceca.2003.10.008; Yao Y, 2003, J NEUROCHEM, V86, P947, DOI 10.1046/j.1471-4159.2003.01906.x; Ye CP, 1997, J NEUROSCI RES, V47, P547, DOI 10.1002/(SICI)1097-4547(19970301)47:5<547::AID-JNR10>3.0.CO;2-V; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200	39	100	113	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8864	8870		10.1074/jbc.M512865200	http://dx.doi.org/10.1074/jbc.M512865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455645	hybrid			2022-12-27	WOS:000236247100066
J	Zhang, L; Gao, X; Wen, J; Ning, YH; Chen, YG				Zhang, L; Gao, X; Wen, J; Ning, YH; Chen, YG			Dapper 1 antagonizes Wnt signaling by promoting dishevelled degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; IDENTIFICATION; INVOLVEMENT; ACTIVATION; MESODERM; FRODO	Wnt signaling plays pivotal roles in the regulation of embryogenesis and cancer development. Xenopus Dapper (Dpr) was identified as an interacting protein for Dishevelled (Dvl), a Wnt signaling mediator, and modulates Wnt signaling. However, it is largely unclear how Dpr regulates Wnt signaling. Here, we present evidence that human Dpr1, the ortholog of Xenopus Dpr, inhibits Wnt signaling. We have identified the regions responsible for the Dpr-Dvl interaction in both proteins and found that the interaction interface is formed between the DEP ( Dishevelled, Egl-10, and pleckstrin) domain of Dvl and the central and the C-terminal regions of Dpr1. The inhibitory function of human Dpr1 requires both its N and C terminus. Overexpression of the C-terminal region corresponding to the last 225 amino acids of Dpr1, in contrast to wild-type Dpr1, enhances Wnt signaling, suggesting a dominant negative function of this region. Furthermore, we have shown that Dpr1 induces Dvl degradation via a lysosome inhibitor-sensitive and proteasome inhibitor-insensitive mechanism. Knockdown of Dpr1 by RNA interference up-regulates endogenous Dvl2 protein. Taken together, our data indicate that the inhibitory activity of Dpr on Wnt signaling is conserved from Xenopus to human and that Dpr1 antagonizes Wnt signaling by inducing Dvl degradation.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Chen, YG (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	ygchen@tsinghua.edu.cn	Zhang, Long/AAT-6571-2021; Chen, Ye-Guang/L-6998-2019	Zhang, Long/0000-0001-8139-0474; 				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; Gillhouse M, 2004, DEV DYNAM, V230, P403, DOI 10.1002/dvdy.20060; Gloy J, 2002, NAT CELL BIOL, V4, P351, DOI 10.1038/ncb784; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hikasa H, 2004, DEVELOPMENT, V131, P4725, DOI 10.1242/dev.01369; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Katoh M, 2005, INT J MOL MED, V15, P1045; Katoh M, 2003, INT J ONCOL, V22, P907; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Medina A, 2000, DEV DYNAM, V218, P671, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1017>3.0.CO;2-9; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Yau TO, 2005, ONCOGENE, V24, P1607, DOI 10.1038/sj.onc.1208340; Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200	25	123	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8607	8612		10.1074/jbc.M600274200	http://dx.doi.org/10.1074/jbc.M600274200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446366	hybrid			2022-12-27	WOS:000236247100037
J	Cho, SJ; Kang, MJ; Homer, RJ; Kang, HR; Zhang, XC; Lee, PJ; Elias, JA; Lee, CG				Cho, SJ; Kang, MJ; Homer, RJ; Kang, HR; Zhang, XC; Lee, PJ; Elias, JA; Lee, CG			Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-13-INDUCED INFLAMMATION; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-TRANSCRIPTION; PULMONARY-FIBROSIS; PATHOGENESIS; IL-13; LUNG; INDUCTION; RECEPTOR; CELLS	IL-13 is an important stimulator of inflammation and tissue remodeling at sites of Th2 inflammation, which plays a key role in the pathogenesis of a variety of human disorders. We hypothesized that the ubiquitous transcription factor, early growth response-1 (Egr-1), plays a key role in IL-13-induced tissue responses. To test this hypothesis we compared the expression of Egr-1 and related moieties in lungs from wild type mice and transgenic mice in which IL-13 was overexpressed in a lung-specific fashion. We simultaneously characterized the effects of a null mutation of Egr-1 on the tissue effects of transgenic IL-13. These studies demonstrate that IL-13 stimulates Egr-1 via an Erk1/2-independent Stat6-dependent pathway(s). They also demonstrate that IL-13 is a potent stimulator of eosinophil- and mononuclear cell-rich inflammation, alveolar remodeling, and tissue fibrosis in mice with wild type Egr-1 loci and that these alterations are ameliorated in the absence of Egr-1. Lastly, they provide insights into the mechanisms of these processes by demonstrating that IL-13 stimulates select CC and CXC chemokines (MIP-1 alpha/CCL-3, MIP-1 beta/CCL-4, MIP-2/CXCL2/3, MCP-1/ CCL-2, MCP-2/CCL-8, MCP-3/CCL-7, MCP-5/CCL-12, KC/CXCL-1, and Lix/CXCL-5), matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and apoptosis regulators(caspase-3,- 6,- 8, and- 9 and Bax) and activates transforming growth factor-beta(1) and pulmonary caspases via Egr-1-dependent pathways. These studies demonstrate that Egr-1 plays a key role in the pathogenesis of IL-13-induced inflammatory and remodeling responses.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Lee, CG (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 300 Cedar St,S425A, New Haven, CT 06520 USA.	chungeun.lee@yale.edu	homer, robert/P-3884-2019; Lee, Chun Geun/AAC-2838-2021; zhang, xu/GYE-3558-2022	homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658; Zhang, Xuchen/0000-0002-1484-4672	NHLBI NIH HHS [HL-64242, HL-56389, HL-78744, HL-66571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056389, R01HL066571, R01HL064242, R01HL078744, P01HL056389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bahouth SW, 2002, MOL PHARMACOL, V61, P379, DOI 10.1124/mol.61.2.379; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Corry David B, 2002, Am J Respir Med, V1, P185; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; De Sousa LP, 2005, BIOCHEM BIOPH RES CO, V329, P237, DOI 10.1016/j.bbrc.2005.01.123; Du BH, 2000, J BIOL CHEM, V275, P39039, DOI 10.1074/jbc.M005159200; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hancock A, 1998, AM J RESP CELL MOL, V18, P60, DOI 10.1165/ajrcmb.18.1.2627; Hasegawa M, 1997, J RHEUMATOL, V24, P328; He CH, 2005, J CLIN INVEST, V115, P1039, DOI 10.1172/JCI200523004; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Kane S, 2002, ANTICANCER RES, V22, P1433; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kojima S, 2000, BLOOD, V95, P1309; Kraan TCTMV, 2002, GENES IMMUN, V3, P436, DOI 10.1038/sj.gene.6363896; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lee Y, 2005, MANUSCRIPTA MATH, V116, P173, DOI 10.1007/s00229-004-0530-5; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Lukacs NW, 2001, J IMMUNOL, V167, P1060, DOI 10.4049/jimmunol.167.2.1060; Ma B, 2004, J IMMUNOL, V172, P1872, DOI 10.4049/jimmunol.172.3.1872; Nandurkar HH, 1997, BLOOD, V90, P2148; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ohshima K, 2001, HISTOPATHOLOGY, V38, P368, DOI 10.1046/j.1365-2559.2001.01083.x; Okada M, 2002, CIRC RES, V91, P135, DOI 10.1161/01.RES.0000027815.75000.33; Revest JM, 2005, NAT NEUROSCI, V8, P664, DOI 10.1038/nn1441; SHINGU T, 1994, J BIOL CHEM, V269, P32551; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Sime PJ, 2001, CLIN IMMUNOL, V99, P308, DOI 10.1006/clim.2001.5008; Takahra T, 2004, INT J BIOCHEM CELL B, V36, P353, DOI 10.1016/S1357-2725(03)00260-7; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang JM, 2000, J IMMUNOL, V165, P2222, DOI 10.4049/jimmunol.165.4.2222; Wills-Karp M, 2004, CURR ALLERGY ASTHM R, V4, P123; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Yu Q, 2000, GENE DEV, V14, P163; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953	47	83	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8161	8168		10.1074/jbc.M506770200	http://dx.doi.org/10.1074/jbc.M506770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439363	hybrid			2022-12-27	WOS:000236031000054
J	Goumon, Y; Muller, A; Glattard, E; Marban, C; Gasnier, C; Strub, JM; Chasserot-Golaz, S; Rohr, O; Stefano, GB; Welters, ID; Van Dorsselaer, A; Schoentgen, F; Aunis, D; Metz-Boutigue, MH				Goumon, Y; Muller, A; Glattard, E; Marban, C; Gasnier, C; Strub, JM; Chasserot-Golaz, S; Rohr, O; Stefano, GB; Welters, ID; Van Dorsselaer, A; Schoentgen, F; Aunis, D; Metz-Boutigue, MH			Identification of morphine-6-glucuronide in chromaffin cell secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; BOVINE BRAIN CYTOSOL; ENDOGENOUS MORPHINE; MORPHINE-6-BETA-GLUCURONIDE ANALGESIA; UDP-GLUCURONOSYLTRANSFERASE; NOMENCLATURE UPDATE; TISSUE DISTRIBUTION; HEALTHY-VOLUNTEERS; GENE SUPERFAMILY; LIGAND-BINDING	We report for the first time that morphine-6-glucuronide, a highly analgesic morphine-derived molecule, is present in adrenal chromaffin granules and secreted from chromaffin cells upon stimulation. We also demonstrate that phosphatidylethanolamine-binding protein (alternatively named Raf-1 kinase inhibitor protein or RKIP) acts as an endogenous morphine-6-glucuronide-binding protein. An UDP-glucuronosyltransferase 2B-like enzyme, described to transform morphine into morphine-6-glucuronide, has been immunodetected in the chromaffin granule matrix, and morphine-6-glucuronide de novo synthesis has been characterized, demonstrating the possible involvement of intragranular UDP-glucuronosyltransferase 2B-like enzyme in morphine-6-glucuronide metabolism. Once secreted into the circulation, morphine-6-glucuronide may mediate several systemic actions (e.g. on immune cells) based on its affinity for mu-opioid receptors. These activities could be facilitated by phosphatidylethanolamine-binding protein (PEBP), acting as a molecular shield and preventing morphine-6-glucuronide from rapid clearance. Taken together, our data represent an important observation on the role of morphine-6-glucuronide as a new endocrine factor.	INSERM, U Physiopathol Syst Nerveux 575, F-67084 Strasbourg, France; CNRS, Ctr Biophys Mol, UPR 4301, F-45071 Orleans, France; Univ Giessen, Dept Anesthesiol Intens Care & Pain Med, D-35385 Giessen, Germany; SUNY Coll Old Westbury, Neurosci Res Inst, New York, NY 11568 USA; CNRS, UPR 2356, Lab Neurotransmiss & Secret Neuroendocrine, F-67084 Strasbourg, France; CNRS, UMR 7168 LC2, Lab Spectrometrie Mass Bioorgan, F-67087 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Justus Liebig University Giessen; State University of New York (SUNY) System; SUNY Old Westbury; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Goumon, Y (corresponding author), INSERM, U Physiopathol Syst Nerveux 575, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	goumon@neurochem.u-strasbg.fr	Stefano, George Bogdan/ABD-9152-2021; Dominique, Aunis/W-1419-2019; Chasserot-Golaz, Sylvette/K-7625-2017	Stefano, George Bogdan/0000-0002-8146-0740; Welters, Ingeborg/0000-0002-3408-8798; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; ROHR, Olivier/0000-0001-8992-2025; , Elise/0000-0002-4501-9675; Strub, Jean-Marc/0000-0001-6224-3428; Goumon, Yannick/0000-0003-4336-3437				AMANN T, 1995, HETEROCYCLES, V40, P425; Armstrong SC, 2003, PSYCHOSOMATICS, V44, P515, DOI 10.1176/appi.psy.44.6.515; Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2; Barbier O, 2000, BIOCHEMISTRY-US, V39, P11540, DOI 10.1021/bi000779p; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; Boettcher C, 2005, P NATL ACAD SCI USA, V102, P8495, DOI 10.1073/pnas.0503244102; Cadet P, 2004, FRONT BIOSCI-LANDMRK, V9, P3176, DOI 10.2741/1471; Duplan H, 2000, EXP NEUROL, V163, P331, DOI 10.1006/exnr.1999.7352; EPPLE A, 1994, LIFE SCI, V54, P695, DOI 10.1016/0024-3205(94)90157-0; Fimiani C, 1999, CANCER LETT, V146, P45, DOI 10.1016/S0304-3835(99)00227-X; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; FRANCES B, 1990, PROG CLIN BIOL RES, V328, P477; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; Gasnier C, 2004, PROTEOMICS, V4, P1789, DOI 10.1002/pmic.200300693; GOLDSTEIN A, 1985, P NATL ACAD SCI USA, V82, P5203, DOI 10.1073/pnas.82.15.5203; Goumon Y, 2000, J BIOL CHEM, V275, P38355, DOI 10.1074/jbc.M007557200; Goumon Y, 2000, MOL BRAIN RES, V77, P267, DOI 10.1016/S0169-328X(00)00056-5; Goumon Y, 2000, J IMMUNOL, V165, P339, DOI 10.4049/jimmunol.165.1.339; Goumon Y, 2004, J BIOL CHEM, V279, P13054, DOI 10.1074/jbc.M308533200; Goumon Y, 2000, MOL BRAIN RES, V81, P177, DOI 10.1016/S0169-328X(00)00141-8; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; Herbert RB, 2000, NAT PROD REP, V17, P317, DOI 10.1039/a809409h; LEOW KP, 1993, THER DRUG MONIT, V15, P440, DOI 10.1097/00007691-199310000-00014; LEUNG MK, 1995, EXP PARASITOL, V81, P208, DOI 10.1006/expr.1995.1110; Levesque E, 2001, BIOCHEMISTRY-US, V40, P3869, DOI 10.1021/bi002607y; Lotsch J, 2001, CLIN PHARMACOKINET, V40, P485; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; Mackenzie PI, 2005, PHARMACOGENET GENOM, V15, P677, DOI 10.1097/01.fpc.0000173483.13689.56; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MAKMAN MH, 1995, EUR J PHARMACOL, V273, pR5, DOI 10.1016/0014-2999(95)00002-3; Marban C, 2005, NUCLEIC ACIDS RES, V33, P2318, DOI 10.1093/nar/gki529; Massotte D, 1998, ESSAYS BIOCHEM, V33, P65, DOI 10.1042/bse0330065; Meijerink WJHJ, 1999, SHOCK, V12, P165, DOI 10.1097/00024382-199909000-00001; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; OLSEN GD, 1975, CLIN PHARMACOL THER, V17, P31; Poeaknapo C, 2004, P NATL ACAD SCI USA, V101, P14091, DOI 10.1073/pnas.0405430101; Romberg R, 2004, ANESTHESIOLOGY, V100, P120, DOI 10.1097/00000542-200401000-00021; Romberg R, 2003, ANESTHESIOLOGY, V99, P788, DOI 10.1097/00000542-200310000-00008; ROSSI GC, 1995, FEBS LETT, V369, P192, DOI 10.1016/0014-5793(95)00757-Z; Rossi GC, 1996, NEUROSCI LETT, V216, P1; Rossi GC, 1997, J PHARMACOL EXP THER, V281, P109; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706; Seematter G, 2004, CURR OPIN CLIN NUTR, V7, P169, DOI 10.1097/00075197-200403000-00011; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; Sol JC, 2004, EXP NEUROL, V186, P198, DOI 10.1016/j.expneurol.2003.10.018; Sonetti D, 1999, BRAIN RES, V835, P137, DOI 10.1016/S0006-8993(99)01534-6; Stefano GB, 2000, TRENDS NEUROSCI, V23, P436, DOI 10.1016/S0166-2236(00)01611-8; STEFANO GB, 1994, ADV NEUROIMMUNOL, V4, P57, DOI 10.1016/S0960-5428(05)80001-4; Stone AN, 2003, DRUG METAB DISPOS, V31, P1086, DOI 10.1124/dmd.31.9.1086; Turgeon D, 2001, ENDOCRINOLOGY, V142, P778, DOI 10.1210/en.142.2.778; Yamada Hideyuki, 2003, J Toxicol Sci, V28, P395, DOI 10.2131/jts.28.395; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhu W, 2005, MED SCI MONITOR, V11, pBR397; Zhu W, 2005, J IMMUNOL, V175, P7357, DOI 10.4049/jimmunol.175.11.7357; Zhu W, 2001, MOL BRAIN RES, V88, P155, DOI 10.1016/S0169-328X(01)00048-1	56	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8082	8089		10.1074/jbc.M502298200	http://dx.doi.org/10.1074/jbc.M502298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434406	Green Published, hybrid			2022-12-27	WOS:000236031000045
J	Bush, LA; Nelson, RW; Di Cera, E				Bush, LA; Nelson, RW; Di Cera, E			Murine thrombin lacks Na+ activation but retains high catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT CATION SPECIFICITY; HEPARIN-COFACTOR-II; SERINE PROTEASES; BINDING-SITE; CRYSTAL-STRUCTURE; FACTOR XA; ANTICOAGULANT THROMBIN; PROTHROMBINASE COMPLEX; SUBSTRATE-SPECIFICITY; ALLOSTERIC REGULATION	Human thrombin utilizes Na+ as a driving force for the cleavage of substrates mediating its procoagulant, prothrombotic, and signaling functions. Murine thrombin has Asp-222 in the Na+ binding site of the human enzyme replaced by Lys. The charge reversal substitution abrogates Na+ activation, which is partially restored with the K222D mutation, and ensures high activity even in the absence of Na+. This property makes the murine enzyme more resistant to the effect of mutations that destabilize Na+ binding and shift thrombin to its anticoagulant slow form. Compared with the human enzyme, murine thrombin cleaves fibrinogen and protein C with similar k(cat)/K-m values but activates PAR1 and PAR4 with k(cat)/K-m values 4- and 26-fold higher, respectively. The significantly higher specificity constant toward PAR4 accounts for the dominant role of this receptor in platelet activation in the mouse. Murine thrombin can also cleave substrates carrying Phe at P1, which potentially broadens the repertoire of molecular targets available to the enzyme in vivo.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@wustl.edu		Nelson, Ryan/0000-0003-2327-9481	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073813, R01HL049413, R29HL049413, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49413, HL 58141, HL 73813] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARNES WM, 2003, PCR PRIMER LAB MANUA, P441; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Butenas S, 1997, THROMB HAEMOSTASIS, V78, P1193; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; De Simone G, 2003, BIOCHEMISTRY-US, V42, P9013, DOI 10.1021/bi020512l; DEGEN SJF, 1995, THROMB HAEMOSTASIS, V73, P203; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gosalia DN, 2005, PROTEOMICS, V5, P1292, DOI 10.1002/pmic.200401011; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Henriksen RA, 1998, BLOOD, V91, P2026, DOI 10.1182/blood.V91.6.2026.2026_2026_2031; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KEZDY FJ, 1965, BIOCHEMISTRY-US, V4, P2302, DOI 10.1021/bi00887a007; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; Laughlin LT, 1997, ARCH BIOCHEM BIOPHYS, V348, P262, DOI 10.1006/abbi.1997.0448; Lee SL, 1997, BIOCHEMISTRY-US, V36, P13180, DOI 10.1021/bi970912m; LORAND L, 1962, ARCH BIOCHEM BIOPHYS, V96, P147, DOI 10.1016/0003-9861(62)90463-0; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; Malikayil JA, 1997, BIOCHEMISTRY-US, V36, P1034, DOI 10.1021/bi9622231; Mann KG, 2003, CHEST, V124, p4S, DOI 10.1378/chest.124.3_suppl.4S; MARTIN CJ, 1959, J BIOL CHEM, V234, P1718; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; Monnaie D, 2000, BIOCHEMISTRY-US, V39, P5349, DOI 10.1021/bi9926781; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; Pineda AO, 2004, BIOPHYS CHEM, V112, P253, DOI 10.1016/j.bpc.2004.07.027; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rezaie AR, 2004, J BIOL CHEM, V279, P48262, DOI 10.1074/jbc.M409964200; Riester D, 2005, P NATL ACAD SCI USA, V102, P8597, DOI 10.1073/pnas.0501983102; Roy DB, 2001, PROTEINS, V43, P315, DOI 10.1002/prot.1042; Schmidt AE, 2005, J MOL BIOL, V350, P78, DOI 10.1016/j.jmb.2005.04.052; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; Vindigni A, 2000, PROTEIN SCI, V9, P619; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Wilbanks SM, 1998, BIOCHEMISTRY-US, V37, P7456, DOI 10.1021/bi973046m; Zhang B, 2004, J THROMB HAEMOST, V2, P1564, DOI 10.1111/j.1538-7836.2004.00857.x	62	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7183	7188		10.1074/jbc.M512082200	http://dx.doi.org/10.1074/jbc.M512082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16428384	hybrid			2022-12-27	WOS:000236030900034
J	Meyer, A; Eskandari, S; Grallath, S; Rentsch, D				Meyer, A; Eskandari, S; Grallath, S; Rentsch, D			AtGAT1, a high affinity transporter for gamma-aminobutyric acid in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; SUBSTRATE-SPECIFICITY; DIFFERENTIAL EXPRESSION; 4-AMINOBUTYRATE GABA; PROLINE TRANSPORTER; GENE-EXPRESSION; PERMEASE; METABOLISM; IDENTIFICATION; SENESCENCE	Functional characterization of Arabidopsis thaliana GAT1 in heterologous expression systems, i.e. Saccharomyces cerevisiae and Xenopus laevis oocytes, revealed that AtGAT1 (At1g08230) codes for an H+-driven, high affinity gamma-aminobutyric acid ( GABA) transporter. In addition to GABA, other omega-aminofatty acids and butylamine are recognized. In contrast to the most closely related proteins of the proline transporter family, proline and glycine betaine are not transported by AtGAT1. AtGAT1 does not share sequence similarity with any of the non-plant GABA transporters described so far, and analyses of substrate selectivity and kinetic properties showed that AtGAT1-mediated transport is similar but distinct from that of mammalian, bacterial, and S. cerevisiae GABA transporters. Consistent with a role in GABA uptake into cells, transient expression of AtGAT1/green fluorescent protein fusion proteins in tobacco protoplasts revealed localization at the plasma membrane. In planta, AtGAT1 expression was highest in flowers and under conditions of elevated GABA concentrations such as wounding or senescence.	Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA	University of Bern; California State University System; California State Polytechnic University Pomona	Rentsch, D (corresponding author), Univ Bern, Inst Plant Sci, Altenbergrain 21, CH-3013 Bern, Switzerland.	doris.rentsch@ips.unibe.ch		Rentsch, Doris/0000-0003-4313-7683	NIGMS NIH HHS [S06 GM053933, S06 GM 53933, S06 GM053933-090006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM053933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Bouche N, 2004, TRENDS PLANT SCI, V9, P110, DOI 10.1016/j.tplants.2004.01.006; Bouche N, 2003, TRENDS CELL BIOL, V13, P607, DOI 10.1016/j.tcb.2003.10.001; Bouche N, 2003, P NATL ACAD SCI USA, V100, P6843, DOI 10.1073/pnas.1037532100; Brechtel CE, 1998, BIOCHEM J, V333, P565, DOI 10.1042/bj3330565; Breitkreuz KE, 1999, FEBS LETT, V450, P280, DOI 10.1016/S0014-5793(99)00516-5; Breitkreuz KE, 2003, J BIOL CHEM, V278, P41552, DOI 10.1074/jbc.M305717200; Buchanan-Wollaston V, 2005, PLANT J, V42, P567, DOI 10.1111/j.1365-313X.2005.02399.x; BURKE D, 2000, METHODS YEAST GENETI, P172; Chen LS, 2001, PLANT PHYSIOL, V125, P1813, DOI 10.1104/pp.125.4.1813; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; CHUNG ID, 1992, PLANT PHYSIOL, V99, P659, DOI 10.1104/pp.99.2.659; Coleman ST, 2001, J BIOL CHEM, V276, P244, DOI 10.1074/jbc.M007103200; Diaz C, 2005, PLANT PHYSIOL, V138, P898, DOI 10.1104/pp.105.060764; Dietrich D, 2004, PLANT J, V40, P488, DOI 10.1111/j.1365-313X.2004.02224.x; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; Doring F, 1998, J CLIN INVEST, V101, P2761, DOI 10.1172/JCI1909; Doring F, 1998, J BIOL CHEM, V273, P23211, DOI 10.1074/jbc.273.36.23211; Fang G, 2000, J BACTERIOL, V182, P2530, DOI 10.1128/JB.182.9.2530-2535.2000; Fischer WN, 1998, TRENDS PLANT SCI, V3, P188, DOI 10.1016/S1360-1385(98)01231-X; Fischer WN, 2002, PLANT J, V29, P717, DOI 10.1046/j.1365-313X.2002.01248.x; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Grallath S, 2005, PLANT PHYSIOL, V137, P117, DOI 10.1104/pp.104.055079; Hosie AHF, 2002, J BACTERIOL, V184, P4071, DOI 10.1128/JB.184.15.4071-4080.2002; Igarashi Y, 2000, PLANT CELL PHYSIOL, V41, P750, DOI 10.1093/pcp/41.6.750; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; Kragler A, 2005, EUR J PHARMACOL, V519, P43, DOI 10.1016/j.ejphar.2005.06.053; Kumar S, 1997, MYCOL RES, V101, P403, DOI 10.1017/S0953756296002742; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LIU QR, 1993, J BIOL CHEM, V268, P2106; Moretti MB, 2002, BRIT J CANCER, V87, P471, DOI 10.1038/sj.bjc.6600481; Moretti MB, 1996, CELL MOL BIOL, V42, P519; Noh YS, 1999, PLANT MOL BIOL, V41, P181, DOI 10.1023/A:1006342412688; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Palanivelu R, 2003, CELL, V114, P47, DOI 10.1016/S0092-8674(03)00479-3; Pruzinska A, 2005, PLANT PHYSIOL, V139, P52, DOI 10.1104/pp.105.065870; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; Rubinstein B, 2000, PLANT MOL BIOL, V44, P303, DOI 10.1023/A:1026540524990; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Schwacke R, 1999, PLANT CELL, V11, P377, DOI 10.1105/tpc.11.3.377; Schwacke R, 2003, PLANT PHYSIOL, V131, P16, DOI 10.1104/pp.011577; Serraj R, 1998, PHYSIOL PLANTARUM, V102, P79, DOI 10.1034/j.1399-3054.1998.1020111.x; SERVAITES JC, 1979, PLANT PHYSIOL, V64, P546, DOI 10.1104/pp.64.4.546; SHAIBE E, 1985, J BACTERIOL, V163, P933, DOI 10.1128/JB.163.3.933-937.1985; Shelp BJ, 1999, TRENDS PLANT SCI, V4, P446, DOI 10.1016/S1360-1385(99)01486-7; Solomon PS, 2002, PLANTA, V214, P414, DOI 10.1007/s004250100632; STEWARD FC, 1949, SCIENCE, V110, P439; Strain HH, 1971, METHOD ENZYMOL, V23, P452, DOI DOI 10.1016/S0076-6879(71)23118-9; Swofford D.L., 2003, PAUP VERSION 40 B10; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; Temple CS, 1998, J BIOL CHEM, V273, P20, DOI 10.1074/jbc.273.1.20; Theis S, 2002, MOL PHARMACOL, V61, P214, DOI 10.1124/mol.61.1.214; Tilsner J, 2005, PLANTA, V221, P328, DOI 10.1007/s00425-004-1446-8; Ueda A, 2001, PLANT CELL PHYSIOL, V42, P1282, DOI 10.1093/pcp/pce166; van Dongen JT, 2003, PLANT PHYSIOL, V131, P1529, DOI 10.1104/pp.102.017202; Waditee R, 2002, J BIOL CHEM, V277, P18373, DOI 10.1074/jbc.M112012200; WALLACE W, 1984, PLANT PHYSIOL, V75, P170, DOI 10.1104/pp.75.1.170; Whitlow RD, 2003, J BIOL CHEM, V278, P17716, DOI 10.1074/jbc.M207582200; Wipf D, 2002, TRENDS BIOCHEM SCI, V27, P139, DOI 10.1016/S0968-0004(01)02054-0; Yohannes E, 2004, J BACTERIOL, V186, P192, DOI 10.1128/JB.186.1.192-199.2004; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; Zheng XQ, 2005, J EXP BOT, V56, P1615, DOI 10.1093/jxb/eri156	68	94	98	5	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7197	7204		10.1074/jbc.M510766200	http://dx.doi.org/10.1074/jbc.M510766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407306	Green Accepted, hybrid			2022-12-27	WOS:000236030900036
J	Teran, W; Krell, T; Ramos, JL; Gallegos, MT				Teran, W; Krell, T; Ramos, JL; Gallegos, MT			Effector-repressor interactions, binding of a single effector molecule to the operator-bound TtgR homodimer mediates derepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMPS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURES; RESISTANCE; INHIBITORS; REGULATOR; RECOGNITION; TOLERANCE; MECHANISM; DRUGS	The RND family transporter TtgABC and its cognate repressor TtgR from Pseudomonas putida DOT-T1E were both shown to possess multidrug recognition properties. Structurally unrelated molecules such as chloramphenicol, butyl paraben, 1,3-dihydroxynaphthalene, and several flavonoids are substrates of TtgABC and activate pump expression by binding to the TtgR-operator complex. Isothermal titration calorimetry was employed to determine the thermodynamic parameters for the binding of these molecules to TtgR. Dissociation constants were in the range from 1 to 150 mu M, the binding stoichiometry was one effector molecule per dimer of TtgR, and the process was driven by favorable enthalpy changes. Although TtgR exhibits a large multidrug binding profile, the plant-derived compounds phloretin and quercetin were shown to bind with the highest affinity (K-D of around 1 mu M), in contrast to other effectors ( chloramphenicol and aromatic solvents) for which exhibited a more reduced affinity. Structure-function studies of effectors indicate that the presence of aromatic rings as well as hydroxyl groups are determinants for TtgR binding. The binding of TtgR to its operator DNA does not alter the protein effector profile nor the effector binding stoichiometry. Moreover, we demonstrate here for the first time that the binding of a single effector molecule to the DNA-bound TtgR homodimer induces the dissociation of the repressor-operator complex. This provides important insight into the molecular mechanism of effector-mediated derepression.	CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, E-18008 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Gallegos, MT (corresponding author), CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, Apartado de Correos 419, E-18008 Granada, Spain.	maritrini.gallegos@eez.csic.es	Krell, Tino/G-7296-2015; Teran, Wilson/AAG-3072-2019; Gallegos, María-Trinidad M.T./K-6501-2014	Krell, Tino/0000-0002-9040-3166; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Teran, Wilson/0000-0002-7597-5190; Ramos, Juan L./0000-0002-8731-7435				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMSTERDAM D, 1991, ANTIBIOTICS LAB MED, P53; Borges-Waimsley MI, 2005, J MOL BIOL, V349, P387, DOI 10.1016/j.jmb.2005.03.045; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Burse A, 2004, MOL PLANT MICROBE IN, V17, P43, DOI 10.1094/MPMI.2004.17.1.43; Dastidar SG, 2001, IN VIVO, V15, P519; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Duque E, 2001, MOL MICROBIOL, V39, P1100, DOI 10.1046/j.1365-2958.2001.02310.x; Espinosa-Urgel Manuel, 2002, Microbiology (Reading), V148, P341, DOI 10.1099/00221287-148-2-341; Gonzalez-Pasayo R, 2000, MOL PLANT MICROBE IN, V13, P572, DOI 10.1094/MPMI.2000.13.5.572; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Guazzaroni MAE, 2005, J BIOL CHEM, V280, P20887, DOI 10.1074/jbc.M500783200; HAGMAN KE, 1995, MICROBIOL-SGM, V141, P611, DOI 10.1099/13500872-141-3-611; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Kuiper I, 2001, MOL PLANT MICROBE IN, V14, P1197, DOI 10.1094/MPMI.2001.14.10.1197; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee EH, 1999, MOL MICROBIOL, V33, P839, DOI 10.1046/j.1365-2958.1999.01530.x; Levy SB, 2002, J APPL MICROBIOL, V92, p65S, DOI 10.1046/j.1365-2672.92.5s1.4.x; Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247; Lomovskaya O, 2001, ANTIMICROB AGENTS CH, V45, P105, DOI 10.1128/AAC.45.1.105-116.2001; Markham PN, 1996, J BACTERIOL, V178, P1473, DOI 10.1128/jb.178.5.1473-1475.1996; Molina L, 2000, SOIL BIOL BIOCHEM, V32, P315, DOI 10.1016/S0038-0717(99)00156-X; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Neyfakh AA, 2001, J MOL MICROB BIOTECH, V3, P151; Neyfakh AA, 1997, TRENDS MICROBIOL, V5, P309, DOI 10.1016/S0966-842X(97)01064-0; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Palumbo JD, 1998, J BACTERIOL, V180, P3107, DOI 10.1128/JB.180.12.3107-3113.1998; Peng WT, 2001, GENE, V270, P245, DOI 10.1016/S0378-1119(01)00468-1; Plaper A, 2003, BIOCHEM BIOPH RES CO, V306, P530, DOI 10.1016/S0006-291X(03)01006-4; Poole K, 2004, CLIN MICROBIOL INFEC, V10, P12, DOI 10.1111/j.1469-0691.2004.00763.x; Poole K, 2002, J APPL MICROBIOL, V92, p55S, DOI 10.1046/j.1365-2672.92.5s1.8.x; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Ramos JL, 2005, MICROBIOL MOL BIOL R, V69, P326, DOI 10.1128/MMBR.69.2.326-356.2005; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; Rauha JP, 2000, INT J FOOD MICROBIOL, V56, P3, DOI 10.1016/S0168-1605(00)00218-X; Renau TE, 1999, J MED CHEM, V42, P4928, DOI 10.1021/jm9904598; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; Schumacher MA, 2003, RES MICROBIOL, V154, P69, DOI 10.1016/S0923-2508(02)00013-X; Schweizer Herbert P, 2003, Genet Mol Res, V2, P48; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; Tegos G, 2002, ANTIMICROB AGENTS CH, V46, P3133, DOI 10.1128/AAC.46.10.3133-3141.2002; Teran W, 2003, ANTIMICROB AGENTS CH, V47, P3067, DOI 10.1128/AAC.47.10.3067-3072.2003; TERAN W, 2005, THESIS U GRANADA GRA; vanVeen HW, 1997, BIOL CHEM, V378, P769; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhang L, 2000, ANTIMICROB AGENTS CH, V44, P287, DOI 10.1128/AAC.44.2.287-293.2000; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	58	60	62	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7102	7109		10.1074/jbc.M511095200	http://dx.doi.org/10.1074/jbc.M511095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407274	hybrid			2022-12-27	WOS:000236030900024
J	Islam, A; Adamik, B; Hawari, FI; Ma, G; Rouhani, FN; Zhang, J; Levine, SJ				Islam, A; Adamik, B; Hawari, FI; Ma, G; Rouhani, FN; Zhang, J; Levine, SJ			Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCYL-SPECIFIC AMINOPEPTIDASE; NECROSIS-FACTOR-ALPHA; FACTOR-BINDING-PROTEIN; CELL-DERIVED EXOSOMES; MOLECULAR-CLONING; MULTIVESICULAR BODY; RECEPTOR; ACTIVATION; DISTINCT; NEFA	Extracellular tumor necrosis factor (TNF) receptors function as TNF-binding proteins that modulate TNF activity. In human vascular endothelial cells ( HUVEC), extracellular TNFR1 ( type I TNF receptor, TNFRSF1A) is generated by two mechanisms, proteolytic cleavage of soluble TNFR1 ectodomains and the release of full-length 55-kDa TNFR1 in the membranes of exosome-like vesicles. TNFR1 release from HUVEC is known to involve the association between ARTS-1 ( aminopeptidase regulator of TNFR1 shedding), an integral membrane aminopeptidase, and TNFR1. The goal of this study was to identify ARTS-1 binding partners that modulate TNFR1 release to the extracellular space. A yeast two-hybrid screen of a human placenta cDNA library showed that NUCB2( nucleobindin 2), via its helix-loop-helix domains, binds the ARTS-1 extracellular domain. The association between endogenous ARTS-1 and NUCB2 in HUVEC was demonstrated by co-immunoprecipitation experiments, which showed the formation of a calcium-dependent NUCB2 . ARTS-1 complex that associated with a subset of total cellular TNFR1. Confocal microscopy experiments demonstrated that this association involved a distinct population of NUCB2-containing intracytoplasmic vesicles. RNA interference was utilized to specifically knock down NUCB2 and ARTS-1 expression, which demonstrated that both are required for the constitutive release of a full-length 55-kDa TNFR1 within exosome-like vesicles as well as the inducible proteolytic cleavage of soluble TNFR1 ectodomains. We propose that calcium-dependent NUCB2 . ARTS-1 complexes, which associate with TNFR1 prior to its commitment to pathways that result in either the constitutive release of TNFR1 exosome-like vesicles or the inducible proteolytic cleavage of TNFR1 ectodomains, play an important role in mediating TNFR1 release to the extracellular compartment.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, SJ (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 6D03,MSC 1590, Bethesda, MD 20892 USA.	levines@nhlbi.nih.gov	Adamik, Barbara/H-8696-2016	Adamik, Barbara/0000-0002-0541-841X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002544, ZIAHL002544] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BARNIKOLWATANABE S, 1994, BIOL CHEM H-S, V375, P497, DOI 10.1515/bchm3.1994.375.8.497; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; Denzer K, 2000, J CELL SCI, V113, P3365; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; Hattori A, 2001, J BIOCHEM-TOKYO, V130, P235, DOI 10.1093/oxfordjournals.jbchem.a002977; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; HOE MH, 1992, J BIOL CHEM, V267, P4916; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kroll KA, 1999, BIOCHEM BIOPH RES CO, V260, P1, DOI 10.1006/bbrc.1999.0867; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Miyashita H, 2002, BLOOD, V99, P3241, DOI 10.1182/blood.V99.9.3241; Morel-Huaux VM, 2002, EUR J CELL BIOL, V81, P87, DOI 10.1078/0171-9335-00224; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Moss ML, 2004, BIOCHEMISTRY-US, V43, P7227, DOI 10.1021/bi049677f; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schomburg L, 2000, EUR J BIOCHEM, V267, P3198, DOI 10.1046/j.1432-1327.2000.01348.x; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Taniguchi N, 2000, J BIOL CHEM, V275, P31674, DOI 10.1074/jbc.M005103200; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; WALLACH D, TUMOR NECROSIS FACTO; Wang J, 2003, J BIOL CHEM, V278, P21751, DOI 10.1074/jbc.M212662200; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Yamamoto N, 2002, HUM MUTAT, V19, P251, DOI 10.1002/humu.10047; Yamazaki T, 2004, BLOOD, V104, P2345, DOI 10.1182/blood-2003-12-4260; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860	52	69	70	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6860	6873		10.1074/jbc.M509397200	http://dx.doi.org/10.1074/jbc.M509397200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407280	hybrid			2022-12-27	WOS:000236030800084
J	Munteanu, A; Taddei, M; Tamburini, I; Bergamini, E; Azzi, A; Zingg, JM				Munteanu, A; Taddei, M; Tamburini, I; Bergamini, E; Azzi, A; Zingg, JM			Antagonistic effects of oxidized low density lipoprotein and alpha-tocopherol on CD36 scavenger receptor expression in monocytes - Involvement of protein kinase B and peroxisome proliferator-activated receptor-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; INHIBITS MACROPHAGE APOPTOSIS; ELEMENT-BINDING PROTEIN-1; CHAIN FATTY-ACIDS; NF-KAPPA-B; VITAMIN-E; PPAR-GAMMA; GENE-EXPRESSION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY	Vitamin E deficiency increases expression of the CD36 scavenger receptor, suggesting specific molecular mechanisms and signaling pathways modulated by alpha-tocopherol. We show here that alpha-tocopherol down-regulated CD36 expression ( mRNA and protein) in oxidized low density lipoprotein (oxLDL)-stimulated THP-1 monocytes, but not in unstimulated cells. Furthermore, alpha-tocopherol treatment of monocytes led to reduction of fluorescent oxLDL-3,3'-dioctadecyloxacarbocyanine perchlorate binding and uptake. Protein kinase C (PKC) appears not to be involved because neither activation of PKC by phorbol 12-myristate 13-acetate nor inhibition by PKC412 was affected by alpha-tocopherol. However, alpha-tocopherol could partially prevent CD36 induction after stimulation with a specific agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma; troglitazone), indicating that this pathway is susceptible to alpha-tocopherol action. Phosphorylation of protein kinase B (PKB) at Ser(473) was increased by oxLDL, and alpha-tocopherol could prevent this event. Expression of PKB stimulated the CD36 promoter as well as a PPAR gamma element-driven reporter gene, whereas an inactive PKB mutant had no effect. Moreover, coexpression of PPAR gamma and PKB led to additive induction of CD36 expression. Altogether, our results support the existence of PKB/PPAR gamma signaling pathways that mediate CD36 expression in response to oxLDL. The activation of CD36 expression by PKB suggests that both lipid biosynthesis and fatty acid uptake are stimulated by PKB.	Univ Bern, Inst Biochem & Mol Med, CH-3012 Bern, Switzerland; Univ Pisa, Ctr Ric Biol & Patol Invecchiamento, I-56126 Pisa, Italy	University of Bern; University of Pisa	Zingg, JM (corresponding author), Univ Bern, Inst Biochem & Mol Med, Buhlstr 28, CH-3012 Bern, Switzerland.	zin34@swissonline.ch	Zingg, Jean-Marc/H-6960-2019; Vlad, Adelina/C-6288-2012	Vlad, Adelina/0000-0002-2282-6802				Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Akazawa A, 2002, JPN J PHARMACOL, V89, P417, DOI 10.1254/jjp.89.417; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Antoniades C, 2003, HERZ, V28, P628, DOI 10.1007/s00059-003-2417-8; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Brigelius-Flohe R, 2002, AM J CLIN NUTR, V76, P703, DOI 10.1093/ajcn/76.4.703; Campbell SE, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-25; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Chabowski A, 2004, AM J PHYSIOL-ENDOC M, V287, pE781, DOI 10.1152/ajpendo.00573.2003; Chan SS, 2001, FREE RADICAL RES, V35, P843, DOI 10.1080/10715760100301341; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Chien MW, 2003, J LIPID RES, V44, P1667, DOI 10.1194/jlr.M300006-JLR200; d'Abramo C, 2005, BIOCHEM J, V391, P693, DOI 10.1042/BJ20050560; Devaraj S, 2001, J LIPID RES, V42, P521; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Feng JW, 2000, J LIPID RES, V41, P688; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Frank GD, 2000, ENDOCRINOLOGY, V141, P3120, DOI 10.1210/en.141.9.3120; Fu MG, 2001, CIRC RES, V89, P1058, DOI 10.1161/hh2301.099642; Fu YC, 2000, J LIPID RES, V41, P2017; Ghanim H, 2001, J CLIN ENDOCR METAB, V86, P1306, DOI 10.1210/jc.86.3.1306; Goti D, 2000, J NEUROCHEM, V74, P1374, DOI 10.1046/j.1471-4159.2000.0741374.x; Guthmann F, 1999, AM J PHYSIOL-LUNG C, V277, pL191, DOI 10.1152/ajplung.1999.277.1.L191; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HAMMER A, 1995, ARTERIOSCL THROM VAS, V15, P704, DOI 10.1161/01.ATV.15.5.704; Han JH, 1999, J LIPID RES, V40, P830; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Han S, 2002, IMMUNOLOGY, V106, P53, DOI 10.1046/j.1365-2567.2002.01404.x; Hathcock JN, 2005, AM J CLIN NUTR, V81, P736, DOI 10.1093/ajcn/81.4.736; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hayden JM, 2002, J LIPID RES, V43, P26; Hodis HN, 2002, CIRCULATION, V106, P1453, DOI 10.1161/01.CIR.0000029092.99946.08; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huh HY, 1996, BLOOD, V87, P2020; Hundal RS, 2003, J BIOL CHEM, V278, P24399, DOI 10.1074/jbc.M209179200; Hundal RS, 2001, J LIPID RES, V42, P1483; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Iynedjian PB, 2000, BIOCHEM J, V351, P621, DOI 10.1042/0264-6021:3510621; Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953; JIALAL I, 1995, ARTERIOSCL THROM VAS, V15, P190, DOI 10.1161/01.ATV.15.2.190; Jostarndt K, 2004, BIOCHEM PHARMACOL, V67, P841, DOI 10.1016/j.bcp.2003.09.041; Kelly DP, 2001, CIRC RES, V89, P935, DOI 10.1161/res.89.11.935; Kempna P, 2004, J BIOL CHEM, V279, P50700, DOI 10.1074/jbc.M410800200; Kempna P, 2003, FREE RADICAL BIO MED, V34, P1458, DOI 10.1016/S0891-5849(03)00173-4; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Lamharzi N, 2004, DIABETES, V53, P3217, DOI 10.2337/diabetes.53.12.3217; Landes N, 2003, BIOCHEM PHARMACOL, V65, P269, DOI 10.1016/S0006-2952(02)01520-4; Maziere C, 2001, FREE RADICAL BIO MED, V31, P1334, DOI 10.1016/S0891-5849(01)00649-9; Mikita T, 2001, J BIOL CHEM, V276, P45729, DOI 10.1074/jbc.M106114200; Morganelli PM, 1997, ARTERIOSCL THROM VAS, V17, P3248, DOI 10.1161/01.ATV.17.11.3248; Munteanu A, 2004, J CELL MOL MED, V8, P59, DOI 10.1111/j.1582-4934.2004.tb00260.x; Munteanu A, 2004, BIOCHEM BIOPH RES CO, V318, P311, DOI 10.1016/j.bbrc.2004.04.028; Munteanu A, 2005, FREE RADICAL BIO MED, V38, P1047, DOI 10.1016/j.freeradbiomed.2004.12.030; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; Ni J, 2005, CANCER RES, V65, P9807, DOI 10.1158/0008-5472.CAN-05-1334; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; Noguchi N, 2003, FREE RADICAL BIO MED, V34, P1614, DOI 10.1016/S0891-5849(03)00216-8; Noushmehr H, 2005, DIABETES, V54, P472, DOI 10.2337/diabetes.54.2.472; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; Ribaux PG, 2003, BIOCHEM J, V376, P697, DOI 10.1042/BJ20031287; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; Ricciarelli R, 2004, FREE RADICAL BIO MED, V36, P1018, DOI 10.1016/j.freeradbiomed.2004.01.007; Ricciarelli R, 2001, FASEB J, V15, P2314, DOI 10.1096/fj.01-0258rev; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Shah S, 2004, EXP BIOL MED, V229, P745, DOI 10.1177/153537020422900806; Sugano R, 2001, ATHEROSCLEROSIS, V158, P351, DOI 10.1016/S0021-9150(01)00456-7; Sylvester PW, 2005, FRONT BIOSCI, V10, P699, DOI 10.2741/1565; Sylvester PW, 2002, ASIA PAC J CLIN NUTR, V11, pS452, DOI 10.1046/j.1440-6047.11.s.7.9.x; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Teupser D, 1999, ATHEROSCLEROSIS, V144, P109, DOI 10.1016/S0021-9150(99)00040-4; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsukamoto Kayo, 2002, J Atheroscler Thromb, V9, P57; Venugopal SK, 2004, ATHEROSCLEROSIS, V175, P213, DOI 10.1016/j.atherosclerosis.2004.03.012; Viana M, 2005, FREE RADICAL RES, V39, P973, DOI 10.1080/10715760500073758; Vicca S, 2000, BIOCHEM BIOPH RES CO, V273, P948, DOI 10.1006/bbrc.2000.3017; Villacorta L, 2003, CIRC RES, V92, P104, DOI 10.1161/01.RES.0000049103.38175.1B; Wang XS, 1999, ANAL BIOCHEM, V267, P271, DOI 10.1006/abio.1998.3023; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Zingg JM, 2000, BIOFACTORS, V11, P189, DOI 10.1002/biof.5520110305; Zingg JM, 2004, CURR MED CHEM, V11, P1113, DOI 10.2174/0929867043365332; Zingg JM, 2002, ARTERIOSCL THROM VAS, V22, P412, DOI 10.1161/hq0302.104517	100	78	80	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6489	6497		10.1074/jbc.M508799200	http://dx.doi.org/10.1074/jbc.M508799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407258	hybrid			2022-12-27	WOS:000236030800044
J	Sunderhaus, S; Dudkina, NV; Jansch, L; Klodmann, J; Heinemeyer, J; Perales, M; Zabaleta, E; Boekema, EJ; Braun, HP				Sunderhaus, S; Dudkina, NV; Jansch, L; Klodmann, J; Heinemeyer, J; Perales, M; Zabaleta, E; Boekema, EJ; Braun, HP			Carbonic anhydrase subunits form a matrix-exposed domain attached to the membrane arm of mitochondrial complex I in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE REDUCTASE; CHLAMYDOMONAS-REINHARDTII; RESPIRATORY-CHAIN; POLYACRYLAMIDE GELS; BLUE DYES; PURIFICATION; ARABIDOPSIS; COMPONENTS; QUANTIFICATION; SUPERCOMPLEXES	Complex I of Arabidopsis includes five structurally related subunits representing gamma-type carbonic anhydrases termed CA1, CA2, CA3, CAL1, and CAL2. The position of these subunits within complex I was investigated. Direct analysis of isolated subcomplexes of complex I by liquid chromatography linked to tandem mass spectrometry allowed the assignment of the CA subunits to the membrane arm of complex I. Carbonate extraction experiments revealed that CA2 is an integral membrane protein that is protected upon protease treatment of isolated mitoplasts, indicating a location on the matrix-exposed side of the complex. A structural characterization by single particle electron microscopy of complex I from the green alga Polytomella and a previous analysis from Arabidopsis indicate a plant-specific spherical extra-domain of about 60 angstrom in diameter, which is attached to the central part of the membrane arm of complex I on its matrix face. This spherical domain is proposed to contain a heterotrimer of three CA subunits, which are anchored with their C termini to the hydrophobic arm of complex I. Functional implications of the complex I-integrated CA subunits are discussed.	Leibniz Univ Hannover, Inst Angew Genet, D-30419 Hannover, Germany; Univ Groningen, Dept Biophys Chem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany; Univ Nacl Mar del Plata, Fac Ciencias Exactas & Nat, Inst Invest Biol, RA-7600 Mar Del Plata, Argentina	Leibniz University Hannover; University of Groningen; Gesellschaft fur Biotechnologische Forschung mbH; National University of Mar del Plata	Braun, HP (corresponding author), Leibniz Univ Hannover, Inst Angew Genet, Herrenhauser Str 2, D-30419 Hannover, Germany.	braun@genetik.uni-hannover.de	Klodmann, Jennifer/B-2131-2013; perales, mariano/L-5412-2014; Braun, Hans-Peter/E-7149-2011	perales, mariano/0000-0002-7351-8439; Braun, Hans-Peter/0000-0002-4459-9727; Senkler, Jennifer/0000-0002-1377-3841; zabaleta, eduardo/0000-0001-5767-141X				Abdrakhmanova A, 2004, BBA-BIOENERGETICS, V1658, P148, DOI 10.1016/j.bbabio.2004.04.019; Atteia A, 2003, PLANT MOL BIOL, V53, P175, DOI 10.1023/B:PLAN.0000009274.19340.36; Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Cardol P, 2004, BBA-BIOENERGETICS, V1658, P212, DOI 10.1016/j.bbabio.2004.06.001; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Dudkina NV, 2005, FEBS LETT, V579, P5769, DOI 10.1016/j.febslet.2005.09.065; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Friedrich T, 2004, BBA-BIOENERGETICS, V1608, P1, DOI 10.1016/j.bbabio.2003.10.002; Heazlewood JL, 2003, BBA-BIOENERGETICS, V1604, P159, DOI 10.1016/S0005-2728(03)00045-8; Heinemeyer J, 2004, PHYTOCHEMISTRY, V65, P1683, DOI 10.1016/j.phytochem.2004.04.022; HEINEMEYER J, 2005, IN PRESS PLANT PROTE; HERZ U, 1994, J BIOL CHEM, V269, P2263; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Iverson TM, 2000, BIOCHEMISTRY-US, V39, P9222, DOI 10.1021/bi000204s; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; LETERME S, 1993, PLANT PHYSIOL, V102, P435, DOI 10.1104/pp.102.2.435; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Moroney JV, 2001, PLANT CELL ENVIRON, V24, P141, DOI 10.1111/j.1365-3040.2001.00669.x; NEUHOFF V, 1985, ELECTROPHORESIS, V6, P427, DOI 10.1002/elps.1150060905; NEUHOFF V, 1990, ELECTROPHORESIS, V11, P101, DOI 10.1002/elps.1150110202; Parisi G, 2004, PLANT MOL BIOL, V55, P193, DOI 10.1007/s11103-004-0149-7; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Perales M, 2005, J MOL BIOL, V350, P263, DOI 10.1016/j.jmb.2005.04.062; Perales M, 2004, PLANT MOL BIOL, V56, P947, DOI 10.1007/s11103-004-6324-z; RASMUSSON AG, 1994, PHYSIOL PLANTARUM, V90, P607, DOI 10.1111/j.1399-3054.1994.tb08821.x; Rasmusson AG, 1998, BBA-BIOENERGETICS, V1364, P101, DOI 10.1016/S0005-2728(98)00021-8; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUNDERHAUS S, 2005, IN PRESS MITOCHONDRI; TROST P, 1995, EUR J BIOCHEM, V234, P452, DOI 10.1111/j.1432-1033.1995.452_b.x; van Lis R, 2003, PLANT PHYSIOL, V132, P318, DOI 10.1104/pp.102.018325; van Lis R, 2005, BBA-BIOENERGETICS, V1708, P23, DOI 10.1016/j.bbabio.2004.12.010; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; Werhahn W, 2001, PLANT PHYSIOL, V125, P943, DOI 10.1104/pp.125.2.943; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131	37	139	151	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6482	6488		10.1074/jbc.M511542200	http://dx.doi.org/10.1074/jbc.M511542200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407270	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000236030800043
J	Duke-Cohan, JS; Kang, H; Liu, H; Rudd, CE				Duke-Cohan, JS; Kang, H; Liu, H; Rudd, CE			Regulation and function of SKAP-55 non-canonical motif binding to the SH3c domain of adhesion and degranulation-promoting adaptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; SIGNAL-TRANSDUCTION; INTEGRIN ADHESION; FYN; SKAP55; ACTIVATION; RECEPTOR; SLP-76; TRANSCRIPTION; RECOGNITION	The immune cell adaptor adhesion and degranulation promoting adaptor protein ( ADAP) and its binding to T- cell adaptor Src kinase-associated protein of 55 kDa ( SKAP- 55) play a key role in the modulation of T- cell adhesion. While primary binding occurs via SKAP- 55 SH3 domain binding to a proline- rich region in ADAP, a second interaction occurs between the ADAP C- terminal SH3 domain ( ADAP-SH3c) and a non- canonical (RKXXYXXY297)-X-294 motif in SKAP- 55. Increasing numbers of non- canonical SH3 domain binding motifs have been identified in a number of biological systems. The presence of tyrosine residues in the SKAP- 55 RKXXY294XXY297 motif suggested that phosphorylation might influence this unusual SH3 domain interaction. Here, we show that the Src kinase p59(fyn) can induce the in vivo phosphorylation of the motif, and this event blocks ADAP- SH3c domain binding to the peptide motif. The importance of tyrosine phosphorylation was confirmed by plasmon resonance interaction analysis showing that phosphorylation of Tyr(294) residue plays a central role in mediating dissociation, whereas phosphorylation of the second Tyr(297) had no effect. Although loss of this secondary interaction did not result in the disruption of the complex, the Y294F mutation blocked T- cell receptor- induced up- regulation of lymphocyte function- associated antigen- 1- mediated adhesion to intercellular adhesion molecule- 1and interleukin- 2 promoter activity. Our findings identify a RKXXY294 motif in SKAP- 55 that mediates unique ADAP SH3c domain binding and is needed for LFA- 1- mediated adhesion and cytokine production.	Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Imperial Coll, Mol Immunol Sect, Dept Immunol, Div Invest Sci,Div Med, London W12 0NN, England	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Imperial College London	Duke-Cohan, JS (corresponding author), Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA.	jonathan_duke-cohan@dfci.harvard.edu; c.rudd@imperial.ac.uk	Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022; Duke-Cohan, Jonathan/A-5812-2010	Rudd, Christopher E/0000-0001-5295-9019; Duke-Cohan, Jonathan/0000-0002-9478-9609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broome MA, 1997, ONCOGENE, V14, P17, DOI 10.1038/sj.onc.1200798; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Geng LP, 1999, J IMMUNOL, V163, P5753; Geng LP, 2001, BIOCHEM BIOPH RES CO, V289, P1135, DOI 10.1006/bbrc.2001.6117; Geng LP, 2001, P NATL ACAD SCI USA, V98, P11527, DOI 10.1073/pnas.191378198; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Griffiths EK, 2001, SCIENCE, V293, P2260, DOI 10.1126/science.1063397; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Heuer K, 2005, J MOL BIOL, V348, P1025, DOI 10.1016/j.jmb.2005.02.069; Heuer K, 2004, STRUCTURE, V12, P603, DOI 10.1016/j.str.2004.02.021; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; Huang YP, 2005, J BIOL CHEM, V280, P23576, DOI 10.1074/jbc.M413201200; Jo EK, 2005, J EXP MED, V201, P1733, DOI 10.1084/jem.20042577; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kelly AE, 2002, J AM CHEM SOC, V124, P12013, DOI 10.1021/ja026121b; Lewitzky M, 2004, J BIOL CHEM, V279, P28724, DOI 10.1074/jbc.M402745200; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Musacchio A, 2003, ADV PROTEIN CHEM, V61, P211; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Veale M, 1999, J BIOL CHEM, V274, P28427, DOI 10.1074/jbc.274.40.28427; Wang HY, 2004, J EXP MED, V200, P1063, DOI 10.1084/jem.20040780; Wang HY, 2003, NAT IMMUNOL, V4, P366, DOI 10.1038/ni913	39	25	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13743	13750		10.1074/jbc.M508774200	http://dx.doi.org/10.1074/jbc.M508774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16461356	hybrid			2022-12-27	WOS:000237336600085
J	Saitoh, T; Ikegami, T; Nakayama, M; Teshima, K; Akutsu, H; Hase, T				Saitoh, T; Ikegami, T; Nakayama, M; Teshima, K; Akutsu, H; Hase, T			NMR study of the electron transfer complex of plant ferredoxin and sulfite reductase - Mapping the interaction sites of ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; BINDING-SITES; CLONING	Plant ferredoxin serves as the physiological electron donor for sulfite reductase, which catalyzes the reduction of sulfite to sulfide. Ferredoxin and sulfite reductase form an electrostatically stabilized 1:1 complex for the intermolecular electron transfer. The protein-protein interaction between these proteins from maize leaves was analyzed by nuclear magnetic resonance spectroscopy. Chemical shift perturbation and cross-saturation experiments successfully mapped the location of two major interaction sites of ferredoxin: region 1 including Glu-29, Glu-30, and Asp-34 and region 2 including Glu-92, Glu-93, and Glu-94. The importance of these two acidic patches for interaction with sulfite reductase was confirmed by site-specific mutation of acidic ferredoxin residues in regions 1 and 2, separately and in combination, by which the ability of mutant ferredoxins to transfer electrons and bind to sulfite reductase was additively lowered. Taken together, this study gives a clear illustration of the molecular interaction between ferredoxin and sulfite reductase. We also present data showing that this interaction surface of ferredoxin significantly differs from that when ferredoxin-NADP(+) reductase is the interaction partner.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan	Osaka University; Hiroshima University	Saitoh, T (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	enzyme@protein.osaka-u.ac.jp	Hase, Toshiharu/H-9271-2013; Ikegami, Takahisa/I-9626-2017	Ikegami, Takahisa/0000-0002-1429-1844; Akutsu, Hideo/0000-0001-7236-5285				Akashi T, 1999, J BIOL CHEM, V274, P29399, DOI 10.1074/jbc.274.41.29399; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Crowley PB, 2002, J BIOL CHEM, V277, P48685, DOI 10.1074/jbc.M203983200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; Garcia-Sanchez MI, 2000, J BIOL INORG CHEM, V5, P713, DOI 10.1007/s007750000160; HASE T, 1991, PLANT PHYSIOL, V96, P77, DOI 10.1104/pp.96.1.77; Hirasawa M, 2005, PHOTOSYNTH RES, V86, P325, DOI 10.1007/s11120-005-6966-y; HIRASAWA M, 1987, FEBS LETT, V221, P343, DOI 10.1016/0014-5793(87)80953-5; Hirasawa M, 2004, BBA-BIOENERGETICS, V1608, P140, DOI 10.1016/j.bbabio.2003.11.004; Jacquot JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; Knaff D.B., 1996, OXYGENIC PHOTOSYNTHE, V4, P333; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Leustek T, 1999, PLANT PHYSIOL, V120, P637, DOI 10.1104/pp.120.3.637; Matsumura T, 1999, PLANT PHYSIOL, V119, P481, DOI 10.1104/pp.119.2.481; Nakanishi T, 2002, J MOL BIOL, V318, P245, DOI 10.1016/S0022-2836(02)00018-9; Nakayama M, 2000, J INORG BIOCHEM, V82, P27, DOI 10.1016/S0162-0134(00)00138-0; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Wienk H, 2003, BIOCHEMISTRY-US, V42, P6005, DOI 10.1021/bi027198f; Yonekura-Sakakibara K, 2000, PLANT PHYSIOL, V122, P887, DOI 10.1104/pp.122.3.887; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	25	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10482	10488		10.1074/jbc.M510530200	http://dx.doi.org/10.1074/jbc.M510530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469743	hybrid			2022-12-27	WOS:000236594300077
J	Majumdar, S; Ramachandran, S; Cerione, RA				Majumdar, S; Ramachandran, S; Cerione, RA			New insights into the role of conserved, essential residues in the GTP binding/GTP hydrolytic cycle of large G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-ALPHA-SUBUNIT; CRYSTAL-STRUCTURE; ADENYLYL CYCLASE; PITUITARY-TUMORS; EFFECTOR-BINDING; RAS MUTANTS; GAMMA-S; ACTIVATION; MECHANISM; MUTATIONS	The GTP hydrolytic (GTPase) reaction terminates signaling by both large (heterotrimeric) and small (Ras-related) GTP-binding proteins (G proteins). Two residues that are necessary for GTPase activity are an arginine (often called the "arginine finger") found either in the Switch I domains of the alpha subunits of large G proteins or contributed by the GTPase-activating proteins of small G proteins, and a glutamine that is highly conserved in the Switch II domains of G alpha subunits and small G proteins. However, questions still exist regarding the mechanism of the GTPase reaction and the exact role played by the Switch II glutamine. Here, we have characterized the GTP binding and GTPase activities of mutants in which the essential arginine or glutamine residue has been changed within the background of a G alpha chimera (designated alpha(T)*), comprised mainly of the alpha subunit of retinal transducin (alpha(T)) and the Switch III region from the alpha subunit of G(i1). As expected, both the alpha(T)*(R174C) and alpha(T)*(Q200L) mutants exhibited severely compromised GTPase activity. Neither mutant was capable of responding to aluminum fluoride when monitoring changes in the fluorescence of Trp-207 in Switch II, although both stimulated effector activity in the absence of rhodopsin and G beta gamma. Surprisingly, each mutant also showed some capability for being activated by rhodopsin and G beta gamma to undergo GDP-[S-35]GTP gamma S exchange. The ability of the mutants to couple to rhodopsin was not consistent with the assumption that they contained only bound GTP, prompting us to examine their nucleotide-bound states following their expression and purification from Escherichia coli. Indeed, both mutants contained bound GDP as well as GTP, with 35-45% of each mutant being isolated as GDP-P-i complexes. Overall, these findings suggest that the R174C and Q200L mutations reveal G alpha subunit states that occur subsequent to GTP hydrolysis but are still capable of fully stimulating effector activity.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu	Ramachandran, Sekar/AAP-2287-2020	Ramachandran, Sekar/0000-0002-2243-1368	NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NEI NIH HHS [EY6429] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Berghuis AM, 1996, STRUCTURE, V4, P1277, DOI 10.1016/S0969-2126(96)00136-0; BOURNE HR, 1987, NATURE, V330, P517, DOI 10.1038/330517a0; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGEN R, 1992, BIOCHEMISTRY-US, V31, P8691, DOI 10.1021/bi00152a002; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Majumdar S, 2004, J BIOL CHEM, V279, P40137, DOI 10.1074/jbc.M405420200; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Pasqualato S, 2005, STRUCTURE, V13, P533, DOI 10.1016/j.str.2005.01.014; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	34	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9219	9226		10.1074/jbc.M513837200	http://dx.doi.org/10.1074/jbc.M513837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469737	hybrid			2022-12-27	WOS:000236404700029
J	Ragona, L; Catalano, M; Luppi, M; Cicero, D; Eliseo, T; Foote, J; Fogolari, F; Zetta, L; Molinari, H				Ragona, L; Catalano, M; Luppi, M; Cicero, D; Eliseo, T; Foote, J; Fogolari, F; Zetta, L; Molinari, H			NMR dynamic studies suggest that allosteric activation regulates ligand binding in chicken liver bile acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT EXPORT PUMP; MOLECULAR-DYNAMICS; CONFORMATIONAL EXCHANGE; BETA-LACTOGLOBULIN; BACKBONE DYNAMICS; ESCHERICHIA-COLI; RELAXATION; N-15; SYSTEM; SPECTROSCOPY	Apo chicken liver bile acid-binding protein has been structurally characterized by NMR. The dynamic behavior of the protein in its apo- and holo-forms, complexed with chenodeoxycholate, has been determined via N-15 relaxation and steady state heteronuclear N-15(H-1) nuclear Overhauser effect measurements. The dynamic parameters were obtained at two pH values (5.6 and 7.0) for the apoprotein and at pH 7.0 for the holoprotein, using the model free approach. Relaxation studies, performed at three different magnetic fields, revealed a substantial conformational flexibility on the microsecond to millisecond time scales, mainly localized in the C-terminal face of the beta-barrel. The observed dynamics are primarily caused by the protonation/deprotonation of a buried histidine residue, His(98), located on this flexible face. A network of polar buried side chains, defining a spine going from the E to J strand, is likely to provide the long range connectivity needed to communicate motion from His(98) to the EF loop region. NMR data are accompanied by molecular dynamics simulations, suggesting that His(98) protonation equilibrium is the triggering event for the modulation of a functionally important motion, i.e. the opening/closing at the protein open end, whereas ligand binding stabilizes one of the preexisting conformations ( the open form). The results presented here, complemented with an analysis of proteins belonging to the intracellular lipid-binding protein family, are consistent with a model of allosteric activation governing the binding mechanism. The functional role of this mechanism is thoroughly discussed within the framework of the mechanism for the enterohepatic circulation of bile acids.	Univ Verona, Dept Sci & Tecnol, I-37134 Verona, Italy; CNR, ISMAC, Lab NMR, I-20133 Milan, Italy; Univ Roma Tor Vergata, Dipartimento Sci & Tecnol Chim, I-00133 Rome, Italy; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-43100 Udine, Italy	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto per lo Studio delle Macromolecole (ISMAC-CNR); University of Rome Tor Vergata; Fred Hutchinson Cancer Center; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Molinari, H (corresponding author), Univ Verona, Dept Sci & Tecnol, Strada Grazie 15, I-37134 Verona, Italy.	molinari@sci.univr.it	molinari, henriette/ABE-9775-2021; Molinari, Henriette/A-1695-2008; Cicero, Daniel/AAV-5203-2021; Ragona, Laura/AAB-9691-2020	Molinari, Henriette/0000-0002-3678-130X; Ragona, Laura/0000-0003-3893-7117; Fogolari, Federico/0000-0001-9862-250X				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M, P315; ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; Bakowies D, 2002, J MOL BIOL, V315, P713, DOI 10.1006/jmbi.2001.5202; Ballatori N, 2000, AM J PHYSIOL-GASTR L, V278, pG57, DOI 10.1152/ajpgi.2000.278.1.G57; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Cicero DO, 2003, INT J BIOL MACROMOL, V33, P193, DOI 10.1016/j.ijbiomac.2003.08.010; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eberini I, 2004, PROTEINS, V54, P744, DOI 10.1002/prot.10643; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fogolari F, 2005, PROTEINS, V59, P91, DOI 10.1002/prot.20384; Fogolari F, 2001, J COMPUT CHEM, V22, P1830, DOI 10.1002/jcc.1134; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hass MAS, 2004, J AM CHEM SOC, V126, P753, DOI 10.1021/ja030366m; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kramer W, 1997, EUR J BIOCHEM, V249, P456, DOI 10.1111/j.1432-1033.1997.00456.x; Kramer W, 1998, BIOCHEM J, V333, P335, DOI 10.1042/bj3330335; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kurz M, 2003, PROTEINS, V50, P312, DOI 10.1002/prot.10289; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LIPARI G, 1981, BIOCHEMISTRY-US, V20, P6250, DOI 10.1021/bi00524a053; Lucke C, 2000, EUR J BIOCHEM, V267, P2929, DOI 10.1046/j.1432-1327.2000.01307.x; Lucke C, 1996, STRUCTURE, V4, P785, DOI 10.1016/S0969-2126(96)00086-X; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Marin JJG, 2003, BBA-BIOMEMBRANES, V1611, P249, DOI 10.1016/S0005-2736(03)00080-4; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; Nichesola D, 2004, BIOCHEMISTRY-US, V43, P14072, DOI 10.1021/bi0489661; Pawley NH, 2001, J BIOMOL NMR, V20, P149, DOI 10.1023/A:1011249816560; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; Phan IQH, 1996, J BIOMOL NMR, V8, P369, DOI 10.1007/BF00228140; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; Prost E, 2002, J MAGN RESON, V159, P76, DOI 10.1016/S1090-7807(02)00003-4; Ragona L, 2003, J BIOL CHEM, V278, P38840, DOI 10.1074/jbc.M306269200; SCHARSCHMIDT BF, 1987, ANNU REV PHYSIOL, V49, P69; Small DM, 1997, J CLIN INVEST, V99, P1807, DOI 10.1172/JCI119345; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Tochtrop GP, 2004, J AM CHEM SOC, V126, P11024, DOI 10.1021/ja047589c; Tochtrop GP, 2003, BIOCHEMISTRY-US, V42, P11561, DOI 10.1021/bi0346502; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; Vasile F, 2003, J BIOMOL NMR, V25, P157, DOI 10.1023/A:1022277727303; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; WADE RC, 1994, NAT STRUCT BIOL, V1, P65, DOI 10.1038/nsb0194-65	55	50	51	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9697	9709		10.1074/jbc.M513003200	http://dx.doi.org/10.1074/jbc.M513003200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16439356	hybrid			2022-12-27	WOS:000236404700082
J	Volovyk, ZM; Wolf, MJ; Prasad, SVN; Rockman, HA				Volovyk, ZM; Wolf, MJ; Prasad, SVN; Rockman, HA			Agonist-stimulated beta-adrenergic receptor internalization requires dynamic cytoskeletal actin turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; MEDIATED ENDOCYTOSIS; MEMBRANE; RECRUITMENT; PHOSPHORYLATION; ORGANIZATION; MODULATION; MECHANISM; BINDING	Stimulation of beta-adrenergic receptors (beta ARs) leads to sequential recruitment of beta-arrestin, AP-2 adaptor protein, clathrin, and dynamin to the receptor complex, resulting in endocytosis. Whether a dynamic actin cytoskeleton is required for beta AR endocytosis is not known. In this study, we have used beta(1)- and beta(2)ARs, two ubiquitously expressed members of the beta AR family, to comprehensively evaluate the requirement of the actin cytoskeleton in receptor internalization. The integrity of the actin cytoskeleton was manipulated with the agent latrunculin B (LB) and mutants of cofilin to depolymerize actin filaments. Treatment of cells with LB resulted in dose-dependent depolymerization of the cortical actin cytoskeleton that was associated with significant attenuation in internalization of beta(2)ARs, beta(1)ARs, and mutants of beta(1)ARs that internalize via either clathrin- or caveolin-dependent pathways. Importantly, LB treatment did not inhibit beta-arrestin translocation or dynamin recruitment to the agonist-stimulated receptor. To unequivocally demonstrate the requirement of the actin cytoskeleton for beta(2)AR endocytosis, we used an actin-binding protein cofilin that biochemically depolymerizes and severs actin filaments. Isoproterenol-mediated internalization of beta(2)AR was completely blocked in the presence of wild type cofilin, which could be rescued by a mutant of cofilin that mimics a constitutive phosphorylated state and leads to normal agonist-stimulated beta(2)AR endocytosis. Finally, treatment with jasplakinolide, an inhibitor of actin turnover, resulted in dose-dependent inhibition of beta(2)AR internalization, suggesting that turnover of actin filaments at the receptor complex is required for endocytosis. Taken together, these data demonstrate that intact and functional dynamic actin cytoskeleton is required for normal beta AR internalization.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Rockman, HA (corresponding author), Duke Univ, Med Ctr, Dept Med, DUMC 3104, Durham, NC 27710 USA.	h.rockman@duke.edu		Wolf, Matthew/0000-0001-8004-4852	NHLBI NIH HHS [HL61558] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061558] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Calaghan SC, 2004, PROG BIOPHYS MOL BIO, V84, P29, DOI 10.1016/S0079-6107(03)00057-9; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hirasawa A, 1998, BRIT J PHARMACOL, V124, P55, DOI 10.1038/sj.bjp.0701795; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lanzetti L, 2001, EXP CELL RES, V271, P45, DOI 10.1006/excr.2001.5369; Lunn JA, 2000, AM J PHYSIOL-CELL PH, V279, pC2019, DOI 10.1152/ajpcell.2000.279.6.C2019; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Paavilainen VO, 2004, TRENDS CELL BIOL, V14, P386, DOI 10.1016/j.tcb.2004.05.002; Pendleton A, 2003, J BIOL CHEM, V278, P14394, DOI 10.1074/jbc.M206393200; Perrino C, 2005, CIRCULATION, V111, P2579, DOI 10.1161/CIRCULATIONAHA.104.508796; Prasad SVN, 2005, NAT CELL BIOL, V7, P785, DOI 10.1038/ncb1278; Prasad SVN, 2002, J CELL BIOL, V158, P563, DOI 10.1083/jcb.200202113; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Toshima J, 2005, NAT CELL BIOL, V7, P246, DOI 10.1038/ncb1229; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617	29	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9773	9780		10.1074/jbc.M511435200	http://dx.doi.org/10.1074/jbc.M511435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461348	hybrid			2022-12-27	WOS:000236404700090
J	Wewer, UM; Morgelin, M; Holck, P; Jacobsen, J; Lydolph, MC; Johnsen, AH; Kveiborg, M; Albrechtsen, R				Wewer, UM; Morgelin, M; Holck, P; Jacobsen, J; Lydolph, MC; Johnsen, AH; Kveiborg, M; Albrechtsen, R			ADAM12 is a four-leafed clover - The excised prodomain remains bound to the mature enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING ENZYME; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; CELL; METALLOPROTEASE; DISINTEGRIN; EXPRESSION; BINDING; LOCALIZATION; PROTEASE	The ADAMs (a disintegrin and metalloprotease) comprise a family of multidomain proteins with metalloprotease, cell adhesion, and signaling activities. Human ADAM12, which is implicated in diseases such as cancer, is expressed in two splice forms, the transmembrane ADAM12-L and the shorter and soluble ADAM12-S. ADAM12 is synthesized as a zymogen with the prodomain keeping the metalloprotease inactive through a cysteine-switch mechanism. Maturation and activation of the protease involves the cleavage of the prodomain in the trans-Golgi or possibly at the cell surface by a furin-peptidase. The aim of the present study was to determine the fate of the prodomain following furin cleavage. Here we demonstrate that, following cleavage of the human ADAM12-S prodomain in the trans-Golgi by a furin-peptidase, the prodomain remains non-covalently associated with the mature molecule. Accordingly, both the 68-kDa mature form of ADAM12-S and the 25-kDa prodomain could be detected using domain-specific antisera in immuno-precipitation and Western blot analyses of human serum ADAM12 and purified recombinant human ADAM12. Using electron microscopy after negative staining we have furthermore obtained the first visualization of a full-length ADAM molecule, human ADAM12-S, and report that it appears to be a compact clover composed of four globular domains, one of which is the prodomain. Finally, our data demonstrate that the presence of the metalloprotease domain appears to be sufficient for the prodomain to remain associated with the mature ADAM12-S. Thus, we conclude that the prodomain of human ADAM12-S is an integral domain of the mature molecule and as such might have specific biological functions in the extracellular space.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Lund Univ, BMC, Dept Clin Sci, SE-22184 Lund, Sweden; Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	University of Copenhagen; Lund University; Rigshospitalet; University of Copenhagen	Wewer, UM (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.	ullaw@pai.ku.dk	Kveiborg, Marie/AAM-3019-2020	Kveiborg, Marie/0000-0002-1293-1019; Albrechtsen, Reidar/0000-0003-4180-1827				Andreini C, 2005, J PROTEOME RES, V4, P881, DOI 10.1021/pr0500096; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kawaguchi N, 2002, AM J PATHOL, V160, P1895, DOI 10.1016/S0002-9440(10)61136-4; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Laigaard J, 2005, OBSTET GYNECOL, V106, P144, DOI 10.1097/01.AOG.0000165829.65319.65; Laigaard J, 2003, PRENATAL DIAG, V23, P1086, DOI 10.1002/pd.762; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Lendeckel U, 2005, J CANCER RES CLIN, V131, P41, DOI 10.1007/s00432-004-0619-y; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Moss ML, 2004, BIOCHEMISTRY-US, V43, P7227, DOI 10.1021/bi049677f; Oh M, 2004, BIOORG MED CHEM LETT, V14, P6071, DOI 10.1016/j.bmcl.2004.09.082; Orth P, 2004, J MOL BIOL, V335, P129, DOI 10.1016/j.jmb.2003.10.037; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Thodeti CK, 2005, EXP CELL RES, V309, P438, DOI 10.1016/j.yexcr.2005.06.020; Wewer UM, 2005, PROTEAS BIOL DIS, V4, P123; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	34	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9418	9422		10.1074/jbc.M513580200	http://dx.doi.org/10.1074/jbc.M513580200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455653	hybrid			2022-12-27	WOS:000236404700051
J	Kisselev, AF; Callard, A; Goldberg, AL				Kisselev, AF; Callard, A; Goldberg, AL			Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERRING PEPTIDASE ACTIVITY; LACTACYSTIN BETA-LACTONE; I ANTIGEN PRESENTATION; 20S PROTEASOME; MULTIPLE-MYELOMA; PRESENTED PEPTIDES; 26S PROTEASOMES; CELL-PROTEINS; S PROTEASOMES; ACTIVE-SITES	The relative importance of the different proteolytic sites in mammalian proteasomes in protein degradation has not been studied systematically. Nevertheless, it is widely assumed that inhibition of the chymotrypsin-like site, the primary target of the proteasome inhibitors used in research and cancer therapy, reflects the degree of inhibition of protein breakdown. Here we demonstrate that selective inactivation of the chymotrypsin-like site reduced degradation of model proteins by pure 26 S proteasomes by only 11 - 50% and decreased only slightly the breakdown of proteins in HeLa cells. Inactivation of the caspase-like site decreased breakdown of model proteins by 12 - 22% and of the trypsin-like site by 3 - 35%. The relative contributions of these different sites depended on the protein substrate, and the importance of the trypsin-like sites depended on the substrate's content of basic residues. Simultaneous inhibition of the chymotrypsin-like and the caspase-or trypsin-like sites was needed to reduce degradation by > 50%. Thus, 1) all three types of active sites contribute significantly to protein breakdown, 2) their relative importance varies widely with the substrate, 3) assaying the chymotrypsin-like activity overestimates the actual reduction in protein degradation, and 4) inhibition of multiple sites is required to markedly decrease proteolysis.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM046147-10, R01 GM046147] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Altun M, 2005, CANCER RES, V65, P7896, DOI 10.1158/0008-5472.CAN-05-0506; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berkers CR, 2005, NAT METHODS, V2, P357, DOI 10.1038/nmeth759; Cardozo C, 2002, ARCH BIOCHEM BIOPHYS, V408, P103, DOI 10.1016/S0003-9861(02)00493-9; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Goldberg AE, 2005, CONSTR APPROACH LANG, V3, P17; Groll M, 2000, J AM CHEM SOC, V122, P1237, DOI 10.1021/ja993588m; Groll M, 2002, CHEM BIOL, V9, P655, DOI 10.1016/S1074-5521(02)00144-8; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; Hamilton AL, 2005, J CLIN ONCOL, V23, P6107, DOI 10.1200/JCO.2005.01.136; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; Kisselev AF, 2003, J BIOL CHEM, V278, P35869, DOI 10.1074/jbc.M303725200; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Landowski TH, 2005, CANCER RES, V65, P3828, DOI 10.1158/0008-5472.CAN-04-3684; McCormack TA, 1998, BIOCHEMISTRY-US, V37, P7792, DOI 10.1021/bi980097q; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; MYKLES DL, 1995, BIOCHEM J, V306, P285, DOI 10.1042/bj3060285; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Nazif T, 2001, P NATL ACAD SCI USA, V98, P2967, DOI 10.1073/pnas.061028898; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; Oberdorf J, 2001, BIOCHEMISTRY-US, V40, P13397, DOI 10.1021/bi011322y; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Reits E, 2004, IMMUNITY, V20, P495, DOI 10.1016/S1074-7613(04)00074-3; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; ZWICKL P, 1999, PROTEASOMES PROKARYO, P8	54	316	336	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8582	8590		10.1074/jbc.M509043200	http://dx.doi.org/10.1074/jbc.M509043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455650	hybrid			2022-12-27	WOS:000236247100034
J	Stross, C; Radtke, S; Clahsen, T; Gerlach, C; Volkmer-Engert, R; Schaper, F; Heinrich, PC; Hermanns, HM				Stross, C; Radtke, S; Clahsen, T; Gerlach, C; Volkmer-Engert, R; Schaper, F; Heinrich, PC; Hermanns, HM			Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; CYTOKINE SIGNALING-3; RECRUITMENT SITES; INTERFERON-GAMMA; GLYCOPROTEIN 130; SH2 DOMAIN; IN-VIVO; SUPPRESSOR; GP130; PROTEIN	Down- regulation of interleukin ( IL)- 6- type cytokine signaling has been shown to occur, among other mechanisms, via induction of the feedback inhibitor SOCS3 ( suppressor of cytokine signaling 3). Binding of SOCS3 to the phosphorylated Tyr(759) in the cytoplasmic region of gp130, the common signal transducing receptor chain of all IL- 6- type cytokines, is necessary for inhibition of Janus kinase-mediated signaling. In the present study, we analyzed the effect of SOCS3 on signal transduction by the proinflammatory cytokine oncostatin M ( OSM), which signals through a receptor complex of gp130 and the OSM receptor ( OSMR). OSM leads to a much stronger and prolonged induction of SOCS3 in HepG2 hepatoma cells and murine embryonal fibroblasts ( MEF) compared with IL- 6. A negative effect of SOCS3 on OSM signaling was confirmed using MEF cells lacking SOCS3. We can show that the OSMR- mediated signaling is inhibited by SOCS3 to a similar extent as previously described for gp130. However, the inhibition occurs independent of tyrosine motifs within the OSMR. Instead, SOCS3 interacts directly with JAK1 in a stimulation- dependent manner, a mechanism so far only known for SOCS1.	Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, D-52074 Aachen, Germany; Charite Univ Med Berlin, Inst Med Immunol, D-10117 Berlin, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hermanns, HM (corresponding author), Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	hermanns@rwth-aachen.de	Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414; Volkmer, Rudolf/0000-0003-4710-1143				Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Bode JG, 2001, BIOL CHEM, V382, P1447, DOI 10.1515/BC.2001.178; Boing I, 2006, CELL SIGNAL, V18, P50, DOI 10.1016/j.cellsig.2005.03.015; Bonifati C, 1998, ARCH DERMATOL RES, V290, P9, DOI 10.1007/s004030050269; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Clahsen T, 2005, CELL SIGNAL, V17, P559, DOI 10.1016/j.cellsig.2004.09.016; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Cross A, 2004, ARTHRITIS RHEUM-US, V50, P1430, DOI 10.1002/art.20166; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; De Souza D, 2002, BIOCHEMISTRY-US, V41, P9229, DOI 10.1021/bi0259507; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Friederichs K, 2001, EUR J BIOCHEM, V268, P6401, DOI 10.1046/j.0014-2956.2001.02586.x; Gatto L, 2004, J BIOL CHEM, V279, P13746, DOI 10.1074/jbc.M308999200; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Grotzinger J, 1997, PROTEINS, V27, P96; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Hortner M, 2002, EUR J BIOCHEM, V269, P2516, DOI 10.1046/j.1432-1033.2002.02916.x; Hui W, 2005, ARTHRITIS RES THER, V7, pR57, DOI 10.1186/ar1460; Ichihara M, 1997, BLOOD, V90, P165; Langdon C, 2000, AM J PATHOL, V157, P1187, DOI 10.1016/S0002-9440(10)64634-2; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Magrangeas F, 2001, EUR CYTOKINE NETW, V12, P309; Mahboubi K, 2003, J BIOL CHEM, V278, P25014, DOI 10.1074/jbc.M211867200; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nishimoto N, 2004, CURR OPIN PHARMACOL, V4, P386, DOI 10.1016/j.coph.2004.03.005; Pai JK, 2004, NEW ENGL J MED, V351, P2599, DOI 10.1056/NEJMoa040967; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	53	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8458	8468		10.1074/jbc.M511212200	http://dx.doi.org/10.1074/jbc.M511212200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16459330	hybrid			2022-12-27	WOS:000236247100021
J	Aisenbrey, C; Kinder, R; Goormaghtigh, E; Ruysschaert, JM; Bechinger, B				Aisenbrey, C; Kinder, R; Goormaghtigh, E; Ruysschaert, JM; Bechinger, B			Interactions involved in the realignment of membrane-associated helices - An investigation using oriented solid-state NMR and attenuated total reflection Fourier transform infrared spectroscopies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC TRANSMEMBRANE SEGMENTS; AMINO-ACID-COMPOSITION; KNOWLEDGE-BASED SCALE; PROTEIN STRUCTURE; PEPTIDE ANTIBIOTICS; LINEAR DICHROISM; ORIENTATION; PREDICTION; ALIGNMENT; TOPOLOGY	A series of histidine-containing peptides (LAH(4)X(6)) was designed to investigate the membrane interactions of selected side chains. To this purpose, their pH-dependent transitions from in-plane to transmembrane orientations were investigated by attenuated total reflection Fourier transform infrared and oriented solid-state NMR spectroscopies. Peptides of the same family have previously been shown to exhibit antibiotic and DNA transfection activities. Solution NMR spectroscopy indicates that these peptides form amphipathic helical structures in membrane environments, and the technique was also used to characterize the pK values of all histidines in the presence of detergent micelles. Whereas one face of the amphipathic helix is clearly hydrophobic, the opposite side is flanked by four histidines surrounding six leucine, alanine, glycine, tryptophan, or tyrosine residues, respectively. This diversity in peptide composition causes pronounced shifts in the midpoint pH of the in-plane to transmembrane helical transition, which is completely abolished for the peptides carrying the most hydrophilic amino acid residues. These properties open up a conceptually new approach to study in a quantitative manner the hydrophobic as well as specific interactions of amino acids in membranes. Notably, the resulting scale for whole residue transitions from the bilayer interface to the hydrophobic membrane interior is obtained from extended helical sequences in lipid bilayers.	Univ Strasbourg, CNRS, Inst Fac Chim, L3 UMR7177, F-67070 Strasbourg, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Libre Bruxelles, Ctr Struct Biol & Bioinformat, Lab Struct & Funct Biol Membranes, B-1050 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society; Universite Libre de Bruxelles	Bechinger, B (corresponding author), Univ Strasbourg, CNRS, Inst Fac Chim, L3 UMR7177, 4 Rue Blaise Pascal, F-67070 Strasbourg, France.	bechinger@chimie.u-strasbg.fr		Goormaghtigh, Erik/0000-0002-2071-2262				AISENBREY C, 2003, THESIS U L PASTEUR S; ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; Bechinger B, 1996, J MOL BIOL, V263, P768, DOI 10.1006/jmbi.1996.0614; Bechinger B, 2004, BBA-BIOMEMBRANES, V1666, P190, DOI 10.1016/j.bbamem.2004.08.008; BECHINGER B, 1991, J MAGN RESON, V95, P585, DOI 10.1016/0022-2364(91)90173-Q; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; Bechinger B, 2001, FEBS LETT, V504, P161, DOI 10.1016/S0014-5793(01)02741-7; Bechinger B, 2001, BIOPHYS J, V81, P2251, DOI 10.1016/S0006-3495(01)75872-9; Bechinger B., 2003, CONCEPT MAGN RESON A, V18A, P130; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Chatelier RC, 1996, BIOPHYS J, V71, P2367, DOI 10.1016/S0006-3495(96)79430-4; Chen CP, 2002, PROTEIN SCI, V11, P2774, DOI 10.1110/ps.0214502; CHEN CP, 2002, APPL BIOINFORM, V1, P1; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; DEGLIESPOSTI M, 1990, EUR J BIOCHEM, V190, P207, DOI 10.1111/j.1432-1033.1990.tb15566.x; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Gardiennet C, 2005, CHEM COMMUN, P180, DOI 10.1039/b413415j; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Gromiha MM, 1996, INT J PEPT PROT RES, V48, P452; Harzer U, 2000, BIOCHEMISTRY-US, V39, P13106, DOI 10.1021/bi000770n; Henry B, 2002, J AM CHEM SOC, V124, P2025, DOI 10.1021/ja011638t; Hessa T, 2005, SCIENCE, V307, P1427, DOI 10.1126/science.1109176; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Ikeda Masami, 2002, In Silico Biology, V2, P19; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; Ivanov D, 2004, BIOPHYS J, V87, P1307, DOI 10.1529/biophysj.104.041863; Jayasinghe S, 2001, J MOL BIOL, V312, P927, DOI 10.1006/jmbi.2001.5008; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kall L, 2002, FEBS LETT, V532, P415, DOI 10.1016/S0014-5793(02)03730-4; Kichler A, 2003, M S-MED SCI, V19, P1046, DOI 10.1051/medsci/200319111046; Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lopes SCDN, 2004, J AM CHEM SOC, V126, P5396, DOI 10.1021/ja031782+; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Moller S, 2000, BIOINFORMATICS, V16, P1159, DOI 10.1093/bioinformatics/16.12.1159; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; Pilpel Y, 1999, J MOL BIOL, V294, P921, DOI 10.1006/jmbi.1999.3257; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PROMPONAS VJ, 1999, IN SILICO BIOL, V1, P159; Punta M, 2003, PROTEINS, V50, P114, DOI 10.1002/prot.10247; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Vogt B, 2000, BIOPHYS J, V79, P2644, DOI 10.1016/S0006-3495(00)76503-9; Vogt TCB, 1999, J BIOL CHEM, V274, P29115, DOI 10.1074/jbc.274.41.29115; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1981, EUR J BIOCHEM, V120, P275; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WHITE SH, 1994, MEMBRANE PROTEIN STR, P3; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2362, DOI 10.1021/bi00007a032; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2348, DOI 10.1021/bi00007a031	62	40	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7708	7716		10.1074/jbc.M513151200	http://dx.doi.org/10.1074/jbc.M513151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407268	hybrid			2022-12-27	WOS:000236031000003
J	Lee, SS; Ayrapetov, MK; Kemble, DJ; Parang, K; Sun, GQ				Lee, SS; Ayrapetov, MK; Kemble, DJ; Parang, K; Sun, GQ			Docking-based substrate recognition by the catalytic domain of a protein tyrosine kinase, C-terminal Src kinase (Csk)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; PEPTIDE; SITE; AUTOPHOSPHORYLATION; DETERMINANTS; SPECIFICITY; EXPRESSION; MOTIF; SH2	Protein tyrosine kinases are key enzymes of mammalian signal transduction. Substrate specificity is a fundamental property that determines the specificity and fidelity of signaling by protein tyrosine kinases. However, how protein tyrosine kinases recognize the protein substrates is not well understood. C-terminal Src kinase (Csk) specifically phosphorylates Src family kinases on a C-terminal Tyr residue, which down-regulates their activities. We have previously determined that Csk recognizes Src using a substrate-docking site away from the active site. In the current study, we identified the docking determinants in Src recognized by the Csk substrate-docking site and demonstrated an interaction between the docking determinants of Src and the Csk substrate-docking site for this recognition. A similar mechanism was confirmed for Csk recognition of another Src family kinase, Yes. Although both Csk and MAP kinases used docking sites for substrate recognition, their docking sites consisted of different substructures in the catalytic domain. These results helped establish a docking-based substrate recognition mechanism for Csk. This model may provide a framework for understanding substrate recognition and specificity of other protein tyrosine kinases.	Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA; Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA	University of Rhode Island; University of Rhode Island	Sun, GQ (corresponding author), Univ Rhode Isl, Dept Cell & Mol Biol, 117 Morrill Sci Bldg,45 Lower Coll Rd, Kingston, RI 02881 USA.	gsun@uri.edu	Parang, Keykavous/ABC-1584-2021; Parang, Keykavous/F-9236-2010	Parang, Keykavous/0000-0001-8600-0893; 	NATIONAL CANCER INSTITUTE [R01CA111687] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA111687] Funding Source: Medline; NCRR NIH HHS [1 P20 RR16457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Feuillet V, 2002, ONCOGENE, V21, P7205, DOI 10.1038/sj.onc.1205929; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hunter T, 2000, HARVEY LECT, V94, P81; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; LAM KS, 1995, INT J PEPT PROT RES, V45, P587; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lee S, 2002, BIOCHEMISTRY-US, V41, P12107, DOI 10.1021/bi026439g; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lieser SA, 2005, J BIOL CHEM, V280, P7769, DOI 10.1074/jbc.M411736200; Lin XF, 2005, BIOCHEMISTRY-US, V44, P1561, DOI 10.1021/bi048142j; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Miller WT, 2003, ACCOUNTS CHEM RES, V36, P393, DOI 10.1021/ar020116v; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V345, P135, DOI 10.1006/abbi.1997.0236; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Wong L, 2005, J MOL BIOL, V351, P131, DOI 10.1016/j.jmb.2005.05.042; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	35	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8183	8189		10.1074/jbc.M508120200	http://dx.doi.org/10.1074/jbc.M508120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439366	hybrid, Green Published			2022-12-27	WOS:000236031000057
J	Uemura, N; Kajino, T; Sanjo, H; Sato, S; Akira, S; Matsumoto, K; Ninomiya-Tsuji, J				Uemura, N; Kajino, T; Sanjo, H; Sato, S; Akira, S; Matsumoto, K; Ninomiya-Tsuji, J			TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT MEMBRANE-PROTEIN; IL-1 SIGNALING PATHWAY; IMMUNE-RESPONSES; KINASE TAK1; MEMBRANE-PROTEIN-1; TAB2; TRANSDUCTION; TRAF2; TRANSFORMATION; BINDING	Epstein-Barr virus latent membrane protein 1 (LMP1) activates NF-kappa B and c-Jun N-terminal kinase (JNK), which is essential for LMP1 oncogenic activity. Genetic analysis has revealed that tumor necrosis factor receptor-associated factor 6 (TRAF6) is an indispensable intermediate of LMP1 signaling leading to activation of both NF-kappa B and JNK. However, the mechanism by which LMP1 engages TRAF6 for activation of NF-kappa B and JNK is not well understood. Here we demonstrate that TAK1 mitogen-activated protein kinase kinase kinase and TAK1-binding protein 2 (TAB2), together with TRAF6, are recruited to LMP1 through its N-terminal transmembrane region. The C-terminalcytoplasmicregionofLMP1facilitatestheassemblyofthiscomplex and enhances activation of JNK. In contrast, I kappa B kinase gamma is recruited through the C-terminal cytoplasmic region and this is essential for activation of NF-kappa B. Furthermore, we found that ablation of TAK1 resulted in the loss of LMP1-induced activation of JNK but not of NF-kappa B. These results suggest that an LMP1-associated complex containing TRAF6, TAB2, and TAK1 plays an essential role in the activation of JNK. However, TAK1 is not an exclusive intermediate for NF-kappa B activation in LMP1 signaling.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; RIKEN, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan; Japan Sci & Technol, Solut Oriented Res Sci & Technol, Tokyo, Japan	University of North Carolina; North Carolina State University; Nagoya University; RIKEN; Osaka University; Japan Science & Technology Agency (JST)	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Akira, Shizuo/C-3134-2009	Ninomiya-Tsuji, Jun/0000-0002-5584-0176; Sato, Shintaro/0000-0001-5156-3354	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050972, R21 AR050972] Funding Source: Medline; NIGMS NIH HHS [R01 GM068812, GM068812] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Coffin WF, 2003, J VIROL, V77, P3749, DOI 10.1128/JVI.77.6.3749-3758.2003; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Farrell Paul J., 1995, Trends in Microbiology, V3, P105, DOI 10.1016/S0966-842X(00)88891-5; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yasui T, 2004, P NATL ACAD SCI USA, V101, P278, DOI 10.1073/pnas.2237224100	29	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7863	7872		10.1074/jbc.M509834200	http://dx.doi.org/10.1074/jbc.M509834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16446357	hybrid, Green Accepted			2022-12-27	WOS:000236031000021
J	Braathen, R; Sandvik, A; Berntzen, G; Hammerschmidt, S; Fleckenstein, B; Sandlie, I; Brandtzaeg, P; Johansen, FE; Lauvrak, V				Braathen, R; Sandvik, A; Berntzen, G; Hammerschmidt, S; Fleckenstein, B; Sandlie, I; Brandtzaeg, P; Johansen, FE; Lauvrak, V			Identification of a polymeric Ig receptor binding phage-displayed peptide that exploits epithelial transcytosis without dimeric IgA competition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; HUMAN SECRETORY COMPONENT; IMMUNOGLOBULIN RECEPTOR; STREPTOCOCCUS-PNEUMONIAE; CYCLIC-PEPTIDES; GENE-TRANSFER; J-CHAIN; TRANSPORT; MUCOSAL; CELLS	The polymeric Ig receptor (pIgR), also called membrane secretory component (SC), mediates epithelial transcytosis of polymeric immunoglobulins (pIgs). J Chain-containing polymeric IgA (pIgA) and pentameric IgM bind pIgR at the basolateral epithelial surface. After transcytosis, the extracellular portion of the pIgR is cleaved at the apical side, either complexed with pIgs as bound SC or unoccupied as free SC. This transport pathway may be exploited to target bioactive molecules to the mucosal surface. To identify small peptide motifs with specific affinity to human pIgR, we used purified free SC and selection from randomized, cysteine-flanked 6- and 9-mer phage-display libraries. One of the selected phages, called C9A, displaying the peptide CVVWMGFQQVC, showed binding both to human free SC and SC complexed with pIgs. However, the pneumococcal surface protein SpsA ( Streptococcus pneumoniae secretory IgA-binding protein), which binds human SC at a site distinct from the pIg binding site, competed with the C9A phage for binding to SC. The C9A phage showed greatly increased transport through polarized Madin-Darby canine kidney cells transfected with human pIgR. This transport was not affected by pIgA nor did it inhibit pIgR-mediated pIgA transcytosis. A free peptide of identical amino acid sequence as that displayed by the C9A phage inhibited phage interaction with SC. This implied that the C9A peptide sequence may be exploited for pIgR-mediated epithelial transport without interfering with secretory immunity.	Univ Oslo, Rikshosp Univ Hosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Univ Oslo, Rikshosp Univ Hosp, Inst Immunol, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; University of Wurzburg; University of Oslo; National Hospital Norway	Braathen, R (corresponding author), Univ Oslo, Rikshosp Univ Hosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway.	ranveig.braathen@medisin.uio.no	Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681				BERNTZEN G, 2006, IN PRESS PROTEIN ENG; Braathen R, 2002, J BIOL CHEM, V277, P42755, DOI 10.1074/jbc.M205502200; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; BRANDTZAEG P, 1974, SCAND J IMMUNOL, V3, P579, DOI 10.1111/j.1365-3083.1974.tb01291.x; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Crottet P, 1998, J IMMUNOL, V161, P5445; Eckman EA, 1999, AM J RESP CELL MOL, V21, P246, DOI 10.1165/ajrcmb.21.2.3687; Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200; Ferkol T, 2003, AM J RESP CRIT CARE, V167, P1374, DOI 10.1164/rccm.200209-1119OC; FERKOL T, 1993, J CLIN INVEST, V92, P2394, DOI 10.1172/JCI116845; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; Ferkol T, 2000, AM J RESP CRIT CARE, V161, P944, DOI 10.1164/ajrccm.161.3.9907018; Gan YJ, 1997, J VIROL, V71, P519, DOI 10.1128/JVI.71.1.519-526.1997; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Johansen FE, 1999, EUR J IMMUNOL, V29, P1701, DOI 10.1002/(SICI)1521-4141(199905)29:05<1701::AID-IMMU1701>3.0.CO;2-Z; Johansen FE, 2004, TRENDS IMMUNOL, V25, P150, DOI 10.1016/j.it.2004.01.001; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Lauvrak V, 2004, SCAND J IMMUNOL, V59, P373, DOI 10.1111/j.1365-3083.2004.01400.x; Lin CT, 1997, AM J PATHOL, V150, P1745; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; LUO R, 2004, EMBO J; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; Mostov K, 1999, MUCOSAL IMMUNOLOGY, P133; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; Natvig IB, 1997, J IMMUNOL, V159, P4330; Norderhaug IN, 1999, CRIT REV IMMUNOL, V19, P481; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; Roe M, 1999, J IMMUNOL, V162, P6046; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; White KD, 2002, J EXP MED, V196, P551, DOI 10.1084/jem.20020581; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	36	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7075	7081		10.1074/jbc.M508509200	http://dx.doi.org/10.1074/jbc.M508509200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423833	hybrid			2022-12-27	WOS:000236030900021
J	Edosada, CY; Quan, C; Wiesmann, C; Tran, T; Sutherlin, D; Reynolds, M; Elliott, JM; Raab, H; Fairbrother, W; Wolf, BB				Edosada, CY; Quan, C; Wiesmann, C; Tran, T; Sutherlin, D; Reynolds, M; Elliott, JM; Raab, H; Fairbrother, W; Wolf, BB			Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD26/DIPEPTIDYL PEPTIDASE-IV; SERINE-PROTEASE; CRYSTAL-STRUCTURE; STROMAL FIBROBLASTS; MOLECULAR-CLONING; TUMOR-GROWTH; DPP-IV; REVEALS; LOCALIZATION; PURIFICATION	Fibroblast activation protein (FAP) is a transmembrane serine peptidase that belongs to the prolyl peptidase family. FAP has been implicated in cancer; however, its specific role remains elusive because inhibitors that distinguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed. To identify peptide motifs for FAP-selective inhibitor design, we used P-2-Pro(1) and acetyl (Ac)-P-2-Pro(1) dipeptide substrate libraries, where P-2 was varied and substrate hydrolysis occurs between Pro(1) and a fluorescent leaving group. With the P-2-Pro(1) library, FAP preferred Ile, Pro, or Arg at the P-2 residue; however, DPP-4 showed broad reactivity against this library, precluding selectivity. By contrast, with the Ac-P-2-Pro(1) library, FAP cleaved only Ac-Gly-Pro, whereas DPP-4 showed little reactivity with all substrates. FAP also cleaved formyl-, benzyloxycarbonyl-, biotinyl-, and peptidyl-Gly-Pro substrates, which DPP-4 cleaved poorly, suggesting an N-acyl-Gly- Pro motif for inhibitor design. Therefore, we synthesized and tested the compound Ac-Gly-prolineboronic acid, which inhibited FAP with a K-i of 23 +/- 3 nM. This was similar to 9- to similar to 5400-fold lower than the Ki values for other prolyl peptidases, including DPP-4, DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, and acylpeptide hydrolase. These results identify Ac-Gly-BoroPro as a FAP-selective inhibitor and suggest that N-acyl-Gly- Pro-based inhibitors will allow testing of FAP as a therapeutic target.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Med Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Wolf, BB (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS42, San Francisco, CA 94080 USA.	bbwolf@gene.com		Wiesmann, Christian/0000-0002-4092-9880				Abbott CA, 2000, EUR J BIOCHEM, V267, P6140, DOI 10.1046/j.1432-1327.2000.01617.x; Adams S, 2004, CANCER RES, V64, P5471, DOI 10.1158/0008-5472.CAN-04-0447; Aertgeerts K, 2005, J BIOL CHEM, V280, P19441, DOI 10.1074/jbc.C500092200; Aertgeerts K, 2004, PROTEIN SCI, V13, P145, DOI 10.1110/ps.03352504; Ajami K, 2004, BBA-GENE STRUCT EXPR, V1679, P18, DOI 10.1016/j.bbaexp.2004.03.010; Augustyns K, 2005, CURR MED CHEM, V12, P971, DOI 10.2174/0929867053507298; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Cheng JD, 2005, MOL CANCER THER, V4, P351; Cheng JD, 2002, CANCER RES, V62, P4767; CHENG JD, 2004, AM ASS CANC RES 95 A; COPELAND RA, 2000, ENZYMES PRACTICAL IN, P136; Coutts SJ, 1996, J MED CHEM, V39, P2087, DOI 10.1021/jm950732f; Dembitsky VM, 2004, MINI-REV MED CHEM, V4, P1001, DOI 10.2174/1389557043403125; Dolznig H., 2005, CANC IMMUN, V5, P1; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; FIELDS GB, 1988, P NATL ACAD SCI USA, V85, P1384, DOI 10.1073/pnas.85.5.1384; FLENTKE GR, 1991, P NATL ACAD SCI USA, V88, P1556, DOI 10.1073/pnas.88.4.1556; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Ghersi G, 2002, J BIOL CHEM, V277, P29231, DOI 10.1074/jbc.M202770200; Gibson FS, 2002, ORG PROCESS RES DEV, V6, P814, DOI 10.1021/op025587b; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Hiramatsu H, 2004, BIOL CHEM, V385, P561, DOI 10.1515/BC.2004.068; Hu Y, 2005, BIOORG MED CHEM LETT, V15, P4239, DOI 10.1016/j.bmcl.2005.06.075; Huang Y, 2004, CANCER RES, V64, P2712, DOI 10.1158/0008-5472.CAN-03-3184; Huber MA, 2004, J INVEST DERMATOL, V123; Jones B, 2003, BLOOD, V102, P1641, DOI 10.1182/blood-2003-01-0208; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lankas GR, 2005, DIABETES, V54, P2988, DOI 10.2337/diabetes.54.10.2988; Lee KN, 2004, BLOOD, V103, P3783, DOI 10.1182/blood-2003-12-4240; Leiting B, 2003, BIOCHEM J, V371, P525, DOI 10.1042/BJ20021643; Levy MT, 1999, HEPATOLOGY, V29, P1768, DOI 10.1002/hep.510290631; MALY D, 1920, J ORG CHEM, V67, P910; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Mogridge Jeremy, 2004, Methods Mol Biol, V261, P113; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; ODYA CE, 1978, J BIOL CHEM, V253, P5927; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; RETTIG WJ, 1993, CANCER RES, V53, P3327; Rosenblum JS, 2003, CURR OPIN CHEM BIOL, V7, P496, DOI 10.1016/S1367-5931(03)00084-X; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Shreder KR, 2005, BIOORG MED CHEM LETT, V15, P4256, DOI 10.1016/j.bmcl.2005.06.076; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; Underwood R, 1999, J BIOL CHEM, V274, P34053, DOI 10.1074/jbc.274.48.34053; Zhu L, 2003, J BIOL CHEM, V278, P22418, DOI 10.1074/jbc.M212355200	51	89	120	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7437	7444		10.1074/jbc.M511112200	http://dx.doi.org/10.1074/jbc.M511112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410248	hybrid			2022-12-27	WOS:000236030900065
J	Senga, T; Sivaprasad, U; Zhu, WG; Park, JH; Arias, EE; Walter, JC; Dutta, A				Senga, T; Sivaprasad, U; Zhu, WG; Park, JH; Arias, EE; Walter, JC; Dutta, A			PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated N-terminal ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; LICENSING FACTOR; GEMININ BINDING; IN-VIVO; S-PHASE; INHIBITION; P21; REREPLICATION	Cdt1, a protein essential in G(1) for licensing of origins for DNA replication, is inhibited in S-phase, both by binding to geminin and degradation by proteasomes. Cdt1 is also degraded after DNA damage to stop licensing of new origins until after DNA repair. Phosphorylation of Cdt1 by cyclin-dependent kinases promotes its binding to SCF-Skp2 E3 ubiquitin ligase, but the Cdk2/Skp2-mediated pathway is not essential for the degradation of Cdt1. Here we show that the N terminus of Cdt1 contains a second degradation signal that is active after DNA damage and in S-phase and is dependent on the interaction of Cdt1 with proliferating cell nuclear antigen ( PCNA) through a PCNA binding motif. The degradation involves N-terminal ubiquitination and requires Cul4 and Ddb1 proteins, components of an E3 ubiquitin ligase implicated in protein degradation after DNA damage. Therefore PCNA, the matchmaker for many proteins involved in DNA and chromatin metabolism, also serves to promote the targeted degradation of associated proteins in S-phase or after DNA damage.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea	University of Virginia; Harvard University; Harvard Medical School; Seoul National University (SNU)	Dutta, A (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733,1300 Jefferson Pk Ave,Jordan 1240, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Walter, Johannes/0000-0002-4186-7570; Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA060499, R01-CA60499, R01 CA060499-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arias EE, 2006, NAT CELL BIOL, V8, P84, DOI 10.1038/ncb1346; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takeda DY, 2005, J BIOL CHEM, V280, P23416, DOI 10.1074/jbc.M501208200; Ukomadu C, 2003, J BIOL CHEM, V278, P43586, DOI 10.1074/jbc.M307194200; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	31	200	207	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6246	6252		10.1074/jbc.M512705200	http://dx.doi.org/10.1074/jbc.M512705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407252	hybrid			2022-12-27	WOS:000236030800017
J	Yano, T; Li, LS; Weinstein, E; Teh, JS; Rubin, H				Yano, T; Li, LS; Weinstein, E; Teh, JS; Rubin, H			Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; SACCHAROMYCES-CEREVISIAE; IN-VITRO; ACIDIANUS-AMBIVALENS; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; ESCHERICHIA-COLI; DEHYDROGENASE; PURIFICATION; TRIFLUOPERAZINE	Type-II NADH-menaquinone oxidoreductase ( NDH-2) is an essential respiratory enzyme of the pathogenic bacterium Mycobacterium tuberculosis ( Mtb) that plays a pivotal role in its growth. In the present study, we expressed and purified highly active Mtb NDH-2 using a Mycobacterium smegmatis expression system, and the steady-state kinetics and inhibitory actions of phenothiazines were characterized. Purified NDH-2 contains a non-covalently bound flavin adenine dinucleotide cofactor and oxidizes NADH with quinones but does not react with either NADPH or oxygen. Ubiquinone-2 ( Q2) and decylubiquinone showed high electron-accepting activity, and the steady-state kinetics and the NADH-Q2 oxidoreductase reaction were found to operate by a ping-pong reaction mechanism. Phenothiazine analogues, trifluoperazine, Compound 1, and Compound 2 inhibit the NADH-Q2 reductase activity with IC50 = 12, 11, and 13 mu M, respectively. Trifluoperazine inhibition is non-competitive for NADH, whereas the inhibition kinetics is found to be uncompetitive in terms of Q2.	Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Rubin, H (corresponding author), Univ Penn, Dept Med, Div Infect Dis, 522 Johnson Pavil,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	rubinh@mail.med.upenn.edu			NIAID NIH HHS [AI43420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amaral L, 1996, J ANTIMICROB CHEMOTH, V38, P1049, DOI 10.1093/jac/38.6.1049; Bandeiras TM, 2003, BBA-BIOENERGETICS, V1557, P13, DOI 10.1016/S0005-2728(02)00374-2; Bandeiras TM, 2002, FEBS LETT, V531, P273, DOI 10.1016/S0014-5793(02)03514-7; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGSMA J, 1982, EUR J BIOCHEM, V128, P151; Bjorklof K, 2000, FEBS LETT, V467, P105, DOI 10.1016/S0014-5793(00)01130-3; Boshoff HIM, 2004, J BIOL CHEM, V279, P40174, DOI 10.1074/jbc.M406796200; COLLINS MD, 1980, J APPL BACTERIOL, V48, P277, DOI 10.1111/j.1365-2672.1980.tb01227.x; Cook SA, 2002, ARCH BIOCHEM BIOPHYS, V398, P32, DOI 10.1006/abbi.2001.2628; CROWLE AJ, 1992, CHEMOTHERAPY, V38, P410, DOI 10.1159/000239036; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; Eschemann A, 2005, J BIOL CHEM, V280, P3138, DOI 10.1074/jbc.M411217200; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Fang J, 2003, FREE RADICAL BIO MED, V34, P478, DOI 10.1016/S0891-5849(02)01328-X; Gadre DV, 1998, INT CLIN PSYCHOPHARM, V13, P129, DOI 10.1097/00004850-199805000-00006; Gomes CM, 1998, BIOCHEM BIOPH RES CO, V243, P412, DOI 10.1006/bbrc.1998.8111; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HELTZEL A, 1994, J BACTERIOL, V176, P4790, DOI 10.1128/JB.176.15.4790-4793.1994; Katoch VM, 1998, FEMS IMMUNOL MED MIC, V20, P99, DOI 10.1111/j.1574-695X.1998.tb01115.x; KRISTIANSEN JE, 1986, ACTA PATH MICRO IM B, V94, P393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee ASG, 2001, ANTIMICROB AGENTS CH, V45, P2157, DOI 10.1128/AAC.45.7.2157-2159.2001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsushita K, 2001, FEMS MICROBIOL LETT, V204, P271, DOI 10.1016/S0378-1097(01)00417-7; McAdam RA, 2002, MICROBIOL-SGM, V148, P2975, DOI 10.1099/00221287-148-10-2975; Melo AMP, 2004, MICROBIOL MOL BIOL R, V68, P603, DOI 10.1128/MMBR.68.4.603-616.2004; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; Miesel L, 1998, J BACTERIOL, V180, P2459, DOI 10.1128/JB.180.9.2459-2467.1998; MOLNAR J, 1977, ZBL BAKT-INT J MED M, V239, P521; Nantapong N, 2005, BIOSCI BIOTECH BIOCH, V69, P149, DOI 10.1271/bbb.69.149; Nantapong N, 2004, APPL MICROBIOL BIOT, V66, P187, DOI 10.1007/s00253-004-1659-6; Ordway D, 2003, ANTIMICROB AGENTS CH, V47, P917, DOI 10.1128/AAC.47.3.917-922.2003; RATNAKAR P, 1992, FEMS MICROBIOL LETT, V97, P73; Reddy MV, 1996, J ANTIMICROB CHEMOTH, V37, P196, DOI 10.1093/jac/37.1.196; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293; Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; Weinstein EA, 2005, P NATL ACAD SCI USA, V102, P4548, DOI 10.1073/pnas.0500469102; YOUNG IG, 1978, GENE, V4, P175, DOI 10.1016/0378-1119(78)90029-X	41	112	121	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11456	11463		10.1074/jbc.M508844200	http://dx.doi.org/10.1074/jbc.M508844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16469750	hybrid			2022-12-27	WOS:000236988100006
J	Chakraborty, G; Rangaswami, H; Jain, S; Kundu, GC				Chakraborty, G; Rangaswami, H; Jain, S; Kundu, GC			Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PROMATRIX METALLOPROTEINASE-9 ACTIVATION; PROTEIN-TYROSINE KINASE; CELL-ADHESION; MELANOMA-CELLS; TUMOR-GROWTH; MATRIX-METALLOPROTEINASE; GENE-EXPRESSION; PHORBOL ESTER; BLOOD-FLOW	Hypoxia is a key parameter that controls tumor angiogenesis and malignant progression by regulating the expression of several oncogenic molecules. The nonreceptor protein-tyrosine kinases Syk and Lck play crucial roles in the signaling mechanism of various cellular processes. The enhanced expression of Syk in normal breast tissue but not in malignant breast carcinoma has prompted us to investigate its potential role in mammary carcinogenesis. Accordingly, we hypothesized that hypoxia/reoxygenation (H/R) may play an important role in regulating Syk activation, and Lck may be involved in this process. In this study, we have demonstrated that H/R differentially regulates Syk phosphorylation and its subsequent interaction and cross-talk with Lck in MCF-7 cells. Moreover, Syk and Lck play differential roles in regulating Sp1 activation and expressions of melanoma cell adhesion molecule (MelCAM), urokinase-type plasminogen activator (uPA), matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor ( VEGF) in response to H/R. Overexpression of wild type Syk inhibited the H/R-induced uPA, MMP-9, and VEGF expression but up-regulated MelCAM expression. Our data also indicated that MelCAM acts as a tumor suppressor by negatively regulating H/R-induced uPA secretion and MMP-9 activation. The mice xenograft study showed the cross-talk between Syk and Lck regulated H/R-induced breast tumor progression and further correlated with the expressions of MelCAM, uPA, MMP-9, and VEGF. Human clinical specimen analysis supported the in vitro and in vivo findings. To our knowledge, this is first report that the cross-talk between Syk and Lck regulates H/R-induced breast cancer progression and further suggests that Syk may act as potential therapeutic target for the treatment of breast cancer.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Chakraborty, Goutam/U-5559-2019; Chakraborty, Goutam/B-5099-2014; Kundu, Gopal C./ABA-9897-2020					Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; Brennan PA, 2005, J ORAL PATHOL MED, V34, P385, DOI 10.1111/j.1600-0714.2005.00335.x; Bussink J, 2003, RADIOTHER ONCOL, V67, P3, DOI 10.1016/S0167-8140(03)00011-2; Chaplin DJ, 1998, SEMIN RADIAT ONCOL, V8, P151, DOI 10.1016/S1053-4296(98)80041-6; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Folkman J, 1999, NAT BIOTECHNOL, V17, P749, DOI 10.1038/11676; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Karlen S, 1999, J INVEST DERMATOL, V113, P711, DOI 10.1046/j.1523-1747.1999.00746.x; Koong AC, 2000, CANCER RES, V60, P883; KOSTER A, 1991, ANTICANCER RES, V11, P193; Kunz M, 2002, BIOCHEM J, V366, P299, DOI 10.1042/BJ20011749; KUNZ M, 2003, MOL CANCER, V2, P1, DOI DOI 10.1186/1476-4598-2-1.PUBMED:12537587; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Liu LP, 2004, CANCER BIOL THER, V3, P492, DOI 10.4161/cbt.3.6.1010; Lutsenko SV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P286, DOI 10.1023/A:1023002216413; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Natarajan R, 2005, BIOCHEM CELL BIOL, V83, P597, DOI 10.1139/o05-047; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Rummel MM, 1996, CANCER RES, V56, P2218; Said HM, 2005, RADIOTHER ONCOL, V76, P200, DOI 10.1016/j.radonc.2005.06.023; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, AM J PATHOL, V151, P745; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Ulanova M, 2005, AM J PHYSIOL-LUNG C, V288, pL497, DOI 10.1152/ajplung.00246.2004; Vaupel P, 1998, ADV EXP MED BIOL, V454, P591; VAUPEL P, 1989, CANCER RES, V49, P6449; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Xie SH, 1997, CANCER RES, V57, P2295; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S	48	52	58	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11322	11331		10.1074/jbc.M512546200	http://dx.doi.org/10.1074/jbc.M512546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16474166	hybrid			2022-12-27	WOS:000236822200075
J	Gueorguiev, VD; Cheng, SY; Sabban, EL				Gueorguiev, VD; Cheng, SY; Sabban, EL			Prolonged activation of cAMP-response element-binding protein and ATF-2 needed for nicotine-triggered elevation of tyrosine hydroxylase gene transcription in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE BIOSYNTHETIC-ENZYMES; CREB PHOSPHORYLATION; EXPRESSION; KINASE; INVOLVEMENT; IDENTIFICATION; RECEPTORS; MULTIPLE; CALCIUM; DEPENDENCE	Phosphorylation (P-) of cAMP-response element-binding protein (CREB) by protein kinase A or mitogen-activated protein kinases was implicated in mediating the increased tyrosine hydroxylase (TH) gene expression after prolonged exposure to nicotine in vivo and in cell culture. We examined the time course and signaling pathways for phosphorylation of CREB and possible involvement of ATF-2. Treatment of PC12 cells with 200 mu M nicotine triggered rapid but transient elevation of P- CREB followed by a second sustained rise after 2-5 h of continuous nicotine. In contrast, ERK1/2 was only phosphorylated with short term nicotine exposure. MEK inhibitor U0126 abolished nicotine-induced rise in P-ERK1/2, but not P- CREB, nor did it inhibit nicotine-evoked elevation in TH promoter activity, indicating that ERK1/2 was not needed for induction of TH gene expression by nicotine. In contrast, protein kinase A inhibitor H-89 or Ca2+/calmodulin-activated protein kinase inhibitor KN-93 reduced the nicotine-triggered rise in P- CREB and TH promoter activity. There was a delayed elevation of P-ATF-2 after 1 h of nicotine treatment, accompanied by increased ATF-2 protein. Upstream kinase JNK, but not p38, was phosphorylated especially after 5 min to 2 h of nicotine exposure. To examine the requirement for CREB and ATF-2, cells were transfected with dominant negative forms of ATF-2 or CREB. Both reduced the basal TH promoter activity and the response to nicotine. Knockdown of ATF-2 or CREB with siRNA did not alter basal TH promoter activity or mRNA but greatly attenuated the response to nicotine. The results suggest that both ATF-2 and CREB mediate activation of TH gene transcription by nicotine.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Sabban, EL (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	sabban@nymc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; Anney RJL, 2004, PHARMACOGENETICS, V14, P73, DOI 10.1097/00008571-200402000-00001; Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blumenthal EM, 1997, J NEUROSCI, V17, P6094; Brunzell DH, 2003, J NEUROCHEM, V84, P1431, DOI 10.1046/j.1471-4159.2003.01640.x; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Chang KT, 2001, NEURON, V32, P855, DOI 10.1016/S0896-6273(01)00516-5; Cheng SY, 2005, PHARMACOL BIOCHEM BE, V82, P559, DOI 10.1016/j.pbb.2005.10.011; CRAVISO GL, 1992, J NEUROCHEM, V59, P2285; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; Greenberg ME, 2001, SYNAPSES, P357; Gueorguiev VD, 1999, AM J PHYSIOL-CELL PH, V276, pC54, DOI 10.1152/ajpcell.1999.276.1.C54; Gueorguiev VD, 2000, J NEUROCHEM, V75, P1997, DOI 10.1046/j.1471-4159.2000.0751997.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Haass M, 1997, CARDIOVASC DRUG THER, V10, P657, DOI 10.1007/BF00053022; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HIREMAGALUR B, 1995, MOL BRAIN RES, V32, P109, DOI 10.1016/0169-328X(95)00068-4; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; Hu M, 2002, MOL CELL NEUROSCI, V21, P616, DOI 10.1006/mcne.2002.1202; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kilaru S, 2001, J AM COLL SURGEONS, V193, P538, DOI 10.1016/S1072-7515(01)01059-6; KIM KS, 1994, J NEUROCHEM, V63, P834; Kim YH, 2002, LIFE SCI, V70, P2915, DOI 10.1016/S0024-3205(02)01539-4; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; Lewis-Tuffin LJ, 2004, MOL CELL NEUROSCI, V25, P536, DOI 10.1016/j.mcn.2003.10.010; Lim J, 2000, MOL CELL BIOCHEM, V212, P51, DOI 10.1023/A:1007148719497; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MADHOK TC, 1995, MOL BRAIN RES, V32, P143, DOI 10.1016/0169-328X(95)00073-2; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Menezes A, 1996, J NEUROCHEM, V67, P2316; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; Nakashima A, 2003, MOL BRAIN RES, V112, P61, DOI 10.1016/S0169-328X(03)00047-0; Nakayama H, 2006, NEUROSCI LETT, V392, P101, DOI 10.1016/j.neulet.2005.09.003; Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x; Pandey SC, 2001, J NEUROCHEM, V77, P943, DOI 10.1046/j.1471-4159.2001.00309.x; Pearson AG, 2005, NEUROSCIENCE, V133, P437, DOI 10.1016/j.neuroscience.2005.02.029; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANDS SB, 1991, BRAIN RES, V560, P38, DOI 10.1016/0006-8993(91)91211-I; Serova LI, 2004, BRAIN RES, V1015, P1, DOI 10.1016/j.brainres.2004.04.002; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Suzuki T, 2002, J BIOL CHEM, V277, P40768, DOI 10.1074/jbc.M206043200; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Thiel G, 2005, J NEUROCHEM, V92, P321, DOI 10.1111/j.1471-4159.2004.02882.x; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Yang CY, 1998, J NEUROCHEM, V71, P1358	53	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10188	10195		10.1074/jbc.M513806200	http://dx.doi.org/10.1074/jbc.M513806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16452470	hybrid			2022-12-27	WOS:000236594300045
J	Negrerie, M; Kruglik, SG; Lambry, JC; Vos, MH; Martin, JL; Franzen, S				Negrerie, M; Kruglik, SG; Lambry, JC; Vos, MH; Martin, JL; Franzen, S			Role of heme iron coordination and protein structure in the dynamics and geminate rebinding of nitric oxide to the H93G myoglobin mutant - Implications for nitric oxide sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; RESONANCE RAMAN-SPECTROSCOPY; PROXIMAL LIGAND; NO RECOMBINATION; ISOTOPE SHIFTS; CAVITY MUTANT; CO BINDING; POCKET; MOLECULES; PHOTODISSOCIATION	The influence of the heme iron coordination on nitric oxide binding dynamics was investigated for the myoglobin mutant H93G (H93G-Mb) by picosecond absorption and resonance Raman time-resolved spectroscopies. In the H93G-Mb, the glycine replacing the proximal histidine does not interact with the heme iron so that exogenous substituents like imidazole may coordinate to the iron at the proximal position. Nitrosylation of H93G-Mb leads to either 6- or 5-coordinate species depending on the imidazole concentration. At high concentrations, ( imidazole)-(NO)-6-coordinate heme is formed, and the photoinduced rebinding kinetics reveal two exponential picosecond phases ( similar to 10 and similar to 100 ps) similar to those of wild type myoglobin. At low concentrations, imidazole is displaced by the trans effect leading to a (NO)-5-coordinate heme, becoming 4-coordinate immediately after photolysis as revealed from the transient Raman spectrum. In this case, NO rebinding kinetics remain bi-exponential with no change in time constant of the fast component whose amplitude increases with respect to the 6- coordinate species. Bi-exponential NO geminate rebinding in 5-coordinate H93G-Mb is in contrast with the single-exponential process reported for nitrosylated soluble guanylate cyclase ( Negrerie, M., Bouzhir, L., Martin, J. L., and Liebl, U. ( 2001) J. Biol. Chem. 276, 46815 - 46821). Thus, our data show that the iron coordination state or the heme iron out-of-plane motion are not at the origin of the bi-exponential kinetics, which depends upon the protein structure, and that the 4-coordinate state favors the fast phase of NO geminate rebinding. Consequently, the heme coordination state together with the energy barriers provided by the protein structure control the dynamics and affinity for NO-binding enzymes.	INSERM, U696, Lab Opt & Biosci, F-91120 Palaiseau, France; CNRS, UMR 7645, F-91120 Palaiseau, France; Ecole Polytech, F-91120 Palaiseau, France; Univ Paris 06, CNRS, UMR 7033, BioMoCeTi, F-91030 Evry, France; N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of North Carolina; North Carolina State University	Negrerie, M (corresponding author), Ecole Polytech, INSERM, U696, Lab Opt & Biosci, F-91128 Palaiseau, France.	michel.negrerie@polytechnique.fr	Negrerie, Michel/L-2283-2018; Kruglik, Sergei/F-7042-2012	Negrerie, Michel/0000-0001-9918-031X; Kruglik, Sergei/0000-0002-2945-3092; Vos, Marten/0000-0003-0493-4831; Franzen, Stefan/0000-0003-2364-2287; Lambry, Jean-Christophe/0000-0001-8264-0391				Andrew CR, 2005, BIOCHEMISTRY-US, V44, P8664, DOI 10.1021/bi050428g; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Becke AD, 1997, J CHEM PHYS, V107, P8554, DOI 10.1063/1.475007; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Cao WX, 2004, BIOCHEMISTRY-US, V43, P11109, DOI 10.1021/bi049077g; Chowdhury PK, 2003, J PHYS CHEM B, V107, P9122, DOI 10.1021/jp030106r; Cianetti S, 2004, J AM CHEM SOC, V126, P13932, DOI 10.1021/ja046442i; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P3925, DOI 10.1021/bi952625t; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P4939, DOI 10.1021/bi951661p; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452; Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DEPILLIS GD, 1994, J AM CHEM SOC, V116, P6981, DOI 10.1021/ja00094a081; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Franzen S, 2000, J PHYS CHEM B, V104, P10359, DOI 10.1021/jp001231v; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; Franzen S, 2002, P NATL ACAD SCI USA, V99, P16754, DOI 10.1073/pnas.252590999; Franzen S, 2002, J PHYS CHEM B, V106, P4533, DOI 10.1021/jp015567w; Franzen S, 2001, BIOPHYS J, V80, P2372, DOI 10.1016/S0006-3495(01)76207-8; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Ionascu D, 2005, J AM CHEM SOC, V127, P16921, DOI 10.1021/ja054249y; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; Kim S, 2004, J PHYS CHEM B, V108, P20366, DOI 10.1021/jp0489020; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; Marti MA, 2005, J AM CHEM SOC, V127, P7721, DOI 10.1021/ja042870c; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MITCHELL ML, 1987, J PHYS CHEM-US, V91, P4690, DOI 10.1021/j100302a013; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; NEGRERIE M, 2006, IN PRESS J PHYS CH B; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PRESS WH, 1988, NUMERICAL RECIPES, P59; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Shreve AP, 1999, J PHYS CHEM B, V103, P7969, DOI 10.1021/jp991163g; STEINBACH PJ, 1992, BIOPHYS J, V61, P235, DOI 10.1016/S0006-3495(92)81830-1; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; Thomas MR, 2001, BIOCHEMISTRY-US, V40, P15047, DOI 10.1021/bi011440l; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1140, DOI 10.1021/bi00535a005; Wyllie GRA, 2003, INORG CHEM, V42, P5722, DOI 10.1021/ic034473t; Ye X, 2002, J AM CHEM SOC, V124, P5914, DOI 10.1021/ja017359n; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	58	24	24	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10389	10398		10.1074/jbc.M513375200	http://dx.doi.org/10.1074/jbc.M513375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476730	hybrid			2022-12-27	WOS:000236594300068
J	Satoh, T; Sato, K; Kanoh, A; Yamashita, K; Yamada, Y; Igarashi, N; Kato, R; Nakano, A; Wakatsuki, S				Satoh, T; Sato, K; Kanoh, A; Yamashita, K; Yamada, Y; Igarashi, N; Kato, R; Nakano, A; Wakatsuki, S			Structures of the carbohydrate recognition domain of Ca2+-independent cargo receptors Emp46p and Emp47p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTORS V; CRYSTAL-STRUCTURE; LECTIN ERGIC-53; PROTEIN; BINDING; MANNOSE; P58/ERGIC-53; GEOMETRY; HOMOLOG; GLYCANS	Emp46p and Emp47p are type I membrane proteins, which cycle between the endoplasmic reticulum ( ER) and the Golgi apparatus by vesicles coated with coat protein complexes I and II ( COPI and COPII). They are considered to function as cargo receptors for exporting N-linked glycoproteins from the ER. We have determined crystal structures of the carbohydrate recognition domains (CRDs) of Emp46p and Emp47p of Saccharomyces cerevisiae, in the absence and presence of metal ions. Both proteins fold as a beta-sandwich, and resemble that of the mammalian ortholog, p58/ERGIC-53. However, the nature of metal binding is distinct from that of Ca2+-dependent p58/ERGIC-53. Interestingly, the CRD of Emp46p does not bind Ca-2+ ion but instead binds K+ ion at the edge of a concave beta-sheet whose position is distinct from the corresponding site of the Ca2+ ion in p58/ERGIC-53. Binding of K+ ion to Emp46p appears essential for transport of a subset of glycoproteins because the Y131F mutant of Emp46p, which cannot bind K+ ion fails to rescue the transport in disruptants of EMP46 and EMP47 genes. In contrast the CRD of Emp47p binds no metal ions at all. Furthermore, the CRD of Emp46p binds to glycoproteins carrying high mannosetype glycans and the binding is not promoted by the addition of Ca2+ or K+ ion in vitro. These results suggest that Emp46p can be regarded as a Ca2+-independent intracellular lectin at the ER exit sites.	High Energy Accelerator Res Org KEK, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan; RIKEN, Discovery Res Inst, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, PRESTO, Wako, Saitama 3510198, Japan; Sasaki Inst, Dept Biochem, Tokyo 1010062, Japan; Japan Sci & Technol Agcy, CREST, Tokyo 1010062, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	High Energy Accelerator Research Organization (KEK); RIKEN; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); University of Tokyo	Wakatsuki, S (corresponding author), High Energy Accelerator Res Org KEK, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan.	soichi.wakatsuki@kek.jp	Nakano, Akihiko/C-6185-2009; Nakano, Akihiko/A-6420-2016; Nakano, Akihiko/G-4942-2014; Satoh, Tadashi/M-5157-2017	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X; Satoh, Tadashi/0000-0002-4493-4978; Yamada, Yusuke/0000-0002-2651-4005; Kato, Ryuichi/0000-0003-2087-2896; Wakatsuki, Soichi/0000-0001-5896-7968; Igarashi, Noriyuki/0000-0003-2617-3690				Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; BAENZIGER JU, 1979, J BIOL CHEM, V254, P789; Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano WL, 2002, PYMOL USERS MANUAL; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamiya Y, 2005, J BIOL CHEM, V280, P37178, DOI 10.1074/jbc.M505757200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RINI JM, 1993, J BIOL CHEM, V268, P10126; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Sato K, 2003, MOL BIOL CELL, V14, P3055, DOI 10.1091/mbc.E03-02-0115; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; TAI T, 1975, J BIOL CHEM, V250, P8569; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	46	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10410	10419		10.1074/jbc.M512258200	http://dx.doi.org/10.1074/jbc.M512258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16439369	hybrid			2022-12-27	WOS:000236594300070
J	Borghei, A; Ouyang, YB; Westmuckett, AD; Marcello, MR; Landel, CP; Evans, JP; Moore, KL				Borghei, A; Ouyang, YB; Westmuckett, AD; Marcello, MR; Landel, CP; Evans, JP; Moore, KL			Targeted disruption of tyrosylprotein sulfotransferase-2, an enzyme that catalyzes post-translational protein tyrosine O-sulfation, causes male infertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GENE-EXPRESSION; SPERM MOTILITY; FERTILIZATION; MICE; TRANSCRIPTOME; CYRITESTIN; INHIBITION; DEFICIENT; HOMOLOG	Tyrosine O-sulfation is a post-translational modification mediated by one of two Golgi tyrosylprotein sulfotransferases (TPST-1 and -2) expressed in all mammalian cells. Tyrosine sulfation plays an important role in the function of some known TPST substrates by enhancing protein-protein interactions. To explore the role of these enzymes in vivo and gain insight into other potential TPST substrates, TPST-2-deficient mice were generated by targeted disruption of the Tpst2 gene. Tpst2(+/-) mice appear normal and, when interbred, yield litters of normal size with a Mendelian distribution of the targeted mutation. Tpst2(-/-) mice have moderately delayed growth but appear healthy and attain normal body weight by 10 weeks of age. In contrast to Tpst1(-/-) males that have normal fertility, Tpst2(-/-) males are infertile. Tpst2(-/-) sperm are normal in number, morphology, and motility in normal media and appear to capacitate and undergo acrosomal exocytosis normally. However, they are severely defective in their motility in viscous media and in their ability to fertilize zona pellucida-intact eggs. Adhesion of Tpst2(-/-) sperm to the egg plasma membrane is reduced compared with wild type sperm, but sperm-egg fusion is similar or even increased. These data strongly suggest that tyrosine sulfation of unidentified substrate(s) play a crucial role in these processes and document for the first time the critical importance of post-translational tyrosine sulfation in male fertility.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jackson Laboratory; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Moore, KL (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	kevin-moore@omrf.ouhsc.edu	Evans, Janice/Q-8483-2019	Marcello, Matthew/0000-0001-7397-3282	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD045671, R29HD037696, R01HD037696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR009781, P40RR001262] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074015] Funding Source: NIH RePORTER; NCRR NIH HHS [P40 RR009781, P40 RR001262, RR01262, RR09781] Funding Source: Medline; NHLBI NIH HHS [R01 HL074015, HL74015] Funding Source: Medline; NICHD NIH HHS [HD045671, HD037696, R01 HD045671, R29 HD037696, R01 HD037696] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BETTELHEIM FR, 1954, J AM CHEM SOC, V76, P2838, DOI 10.1021/ja01639a073; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Choe H, 2005, MOL MICROBIOL, V55, P1413, DOI 10.1111/j.1365-2958.2004.04478.x; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Evans JP, 2002, NAT CELL BIOL, V4, pS57, DOI 10.1038/ncb-nm-fertilityS57; EVANS JP, 1995, J CELL SCI, V108, P3267; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Johnston DS, 2005, BIOL REPROD, V73, P404, DOI 10.1095/biolreprod.105.039719; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KALAB P, 1991, BIOL REPROD, V45, P783, DOI 10.1095/biolreprod45.5.783; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; Lacourse KA, 1999, AM J PHYSIOL-GASTR L, V276, pG1302, DOI 10.1152/ajpgi.1999.276.5.G1302; McAvey BA, 2002, BIOL REPROD, V67, P1342, DOI 10.1095/biolreprod67.4.1342; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Ouyang YB, 2002, J BIOL CHEM, V277, P23781, DOI 10.1074/jbc.M202420200; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; QUINN P, 1985, FERTIL STERIL, V44, P493; Rehfeld JF, 1998, PHYSIOL REV, V78, P1087, DOI 10.1152/physrev.1998.78.4.1087; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Roberts KP, 2003, BIOL REPROD, V69, P572, DOI 10.1095/biolreprod.102.013771; Seibert C, 2002, P NATL ACAD SCI USA, V99, P11031, DOI 10.1073/pnas.172380899; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; Shima JE, 2004, BIOL REPROD, V71, P319, DOI 10.1095/biolreprod.103.026880; Suarez SS, 2006, HUM REPROD UPDATE, V12, P23, DOI 10.1093/humupd/dmi047; Suarez SS, 2003, REPROD DOMEST ANIM, V38, P119, DOI 10.1046/j.1439-0531.2003.00397.x; Suarez SS, 2003, CELL MOL BIOL, V49, P351; Sztein JM, 2000, BIOL REPROD, V63, P1774, DOI 10.1095/biolreprod63.6.1774	38	57	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9423	9431		10.1074/jbc.M513768200	http://dx.doi.org/10.1074/jbc.M513768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469738	Green Accepted, hybrid			2022-12-27	WOS:000236404700052
J	Kaczocha, M; Hermann, A; Glaser, ST; Bojesen, IN; Deutsch, DG				Kaczocha, M; Hermann, A; Glaser, ST; Bojesen, IN; Deutsch, DG			Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID ANANDAMIDE; N-ARACHIDONOYLETHANOLAMINE ANANDAMIDE; BOVINE SERUM-ALBUMIN; PROBLEM DRUG-USE; CELLULAR UPTAKE; PROSTAGLANDIN TRANSPORTER; MEMBRANE-TRANSPORT; ENDOCANNABINOID SYSTEM; SELECTIVE-INHIBITION; VANILLOID RECEPTOR	The uptake of arachidonoyl ethanolamide (anandamide, AEA) in rat basophilic leukemia cells (RBL-2H3) has been proposed to occur via a saturable transporter that is blocked by specific inhibitors. Measuring uptake at 25 s, when fatty acid amide hydrolase (FAAH) does not appreciably affect uptake, AEA accumulated via a nonsaturable mechanism at 37 degrees C. Interestingly, saturation was observed when uptake was plotted using unbound AEA at 37 degrees C. Such apparent saturation can be explained by rate-limited delivery of AEA through an unstirred water layer surrounding the cells (1). In support of this, we observed kinetics consistent with rate-limited diffusion at 0 degrees C. Novel transport inhibitors have been synthesized that are either weak FAAH inhibitors or do not inhibit FAAH in vitro (e.g. UCM707, OMDM2, and AM1172). In the current study, none of these purported AEA transporter inhibitors affected uptake at 25 s. Longer incubation times illuminate downstream events that drive AEA uptake. Unlike the situation at 25 s, the efficacy of these inhibitors was unmasked at 5 min with appreciable inhibition of AEA accumulation correlating with partial inhibition of AEA hydrolysis. The uptake and hydrolysis profiles observed with UCM707, VDM11, OMDM2, and AM1172 mirrored two selective and potent FAAH inhibitors CAY10400 and URB597 (at low concentrations), indicating that weak inhibition of FAAH can have a pronounced effect upon AEA uptake. At 5 min, the putative transport inhibitors did not reduce AEA uptake in FAAH chemical knock-out cells. This strongly suggests that the target of UCM707, VDM11, OMDM2, and AM1172 is not a transporter at the plasma membrane but rather FAAH, or an uncharacterized intracellular component that delivers AEA to FAAH. This system is therefore unique among neuro/immune modulators because AEA, an uncharged hydrophobic molecule, diffuses into cells and partial inhibition of FAAH has a pronounced effect upon its uptake.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Brookhaven Natl Lab, Ctr Translat Neuroimaging, Upton, NY 11973 USA; Univ Copenhagen, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Copenhagen	Deutsch, DG (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	DDeutsch@notes.sunysb.edu		Kaczocha, Martin/0000-0002-2527-1398	NIDA NIH HHS [DA16419, DA9374] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016419, R01DA009374] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bojesen IN, 2005, J LIPID RES, V46, P1652, DOI 10.1194/jlr.M400498-JLR200; Bojesen IN, 2006, J LIPID RES, V47, P561, DOI 10.1194/jlr.M500411-JLR200; Bojesen IN, 2003, J LIPID RES, V44, P1790, DOI 10.1194/jlr.M300170-JLR200; Bojesen Inge N, 2004, Biol Proced Online, V6, P226, DOI 10.1251/bpo93; Chi YL, 2006, J PHARMACOL EXP THER, V316, P1346, DOI 10.1124/jpet.105.091975; Chiang KP, 2004, HUM MOL GENET, V13, P2113, DOI 10.1093/hmg/ddh216; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2004, J NEUROBIOL, V61, P149, DOI 10.1002/neu.20080; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cupp D, 2004, BIOCHEMISTRY-US, V43, P4473, DOI 10.1021/bi036335l; Day TA, 2001, MOL PHARMACOL, V59, P1369, DOI 10.1124/mol.59.6.1369; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Deutsch DG, 2001, J BIOL CHEM, V276, P6967, DOI 10.1074/jbc.M003161200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fasia L, 2003, EUR J BIOCHEM, V270, P3498, DOI 10.1046/j.1432-1033.2003.03724.x; Fegley D, 2004, P NATL ACAD SCI USA, V101, P8756, DOI 10.1073/pnas.0400997101; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; Fowler CJ, 2004, EUR J PHARMACOL, V492, P1, DOI 10.1016/j.ejphar.2004.03.048; Fowler CJ, 2002, PROSTAG LEUKOTR ESS, V66, P193, DOI 10.1054/plef.2001.0357; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; Giuffrida A, 2001, J PHARMACOL EXP THER, V298, P7; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Glaser ST, 2005, LIFE SCI, V77, P1584, DOI 10.1016/j.lfs.2005.05.007; Goutopoulos A, 2002, PHARMACOL THERAPEUT, V95, P103, DOI 10.1016/S0163-7258(02)00250-4; Hamilton JA, 2002, MOL CELL BIOCHEM, V239, P17, DOI 10.1023/A:1020542220599; Hillard CJ, 2003, BRIT J PHARMACOL, V140, P802, DOI 10.1038/sj.bjp.0705468; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Hillard CJ, 2005, NEUROPHARMACOLOGY, V48, P1072, DOI 10.1016/j.neuropharm.2004.12.012; Hillard CJ, 2000, CHEM PHYS LIPIDS, V108, P123, DOI 10.1016/S0009-3084(00)00191-2; Ibrahimi A, 2002, CURR OPIN CLIN NUTR, V5, P139, DOI 10.1097/00075197-200203000-00004; Jacobsson SOP, 2001, BRIT J PHARMACOL, V132, P1743, DOI 10.1038/sj.bjp.0704029; Jarrahian A, 2000, J NEUROCHEM, V74, P2597, DOI 10.1046/j.1471-4159.2000.0742597.x; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Karlsson M, 2004, EUR J PHARM SCI, V22, P181, DOI 10.1016/j.ejps.2004.03.009; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525-1373.2000.22501.x; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Lichtman AH, 2004, J PHARMACOL EXP THER, V311, P441, DOI 10.1124/jpet.104.069401; Ligresti A, 2004, BIOCHEM J, V380, P265, DOI 10.1042/BJ20031812; Lopez-Rodriguez ML, 2003, J MED CHEM, V46, P1512, DOI 10.1021/jm0210818; Lu R, 1996, J CLIN INVEST, V98, P1142, DOI 10.1172/JCI118897; Maccarrone M, 2000, BIOCHEM BIOPH RES CO, V278, P576, DOI 10.1006/bbrc.2000.3869; McFarland MJ, 2004, J BIOL CHEM, V279, P41991, DOI 10.1074/jbc.M407250200; McFarland MJ, 2004, PHARMACOL THERAPEUT, V104, P117, DOI 10.1016/j.pharmthera.2004.07.008; Mechoulam R, 2005, P NATL ACAD SCI USA, V102, P17541, DOI 10.1073/pnas.0508644102; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Moore SA, 2005, P NATL ACAD SCI USA, V102, P17852, DOI 10.1073/pnas.0507470102; Ortar G, 2003, BIOCHEM PHARMACOL, V65, P1473, DOI 10.1016/S0006-2952(03)00109-6; Ortega-Gutierrez S, 2004, BIOCHEMISTRY-US, V43, P8184, DOI 10.1021/bi049395f; Patricelli MP, 2001, VITAM HORM, V62, P95, DOI 10.1016/S0083-6729(01)62002-8; Price TJ, 2005, NEUROPHARMACOLOGY, V49, P25, DOI 10.1016/j.neuropharm.2005.01.031; Rakhshan F, 2000, J PHARMACOL EXP THER, V292, P960; Rodriguez GJ, 2003, J PHARMACOL EXP THER, V306, P338, DOI 10.1124/jpet.103.048751; Sandberg A, 2005, CHEM PHYS LIPIDS, V134, P131, DOI 10.1016/j.chemphyslip.2004.12.010; Schaffer JE, 2002, AM J PHYSIOL-ENDOC M, V282, pE239, DOI 10.1152/ajpendo.00462.2001; Schuster VL, 2002, PROSTAG OTH LIPID M, V68-9, P633, DOI 10.1016/S0090-6980(02)00061-8; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vandevoorde S, 2005, BRIT J PHARMACOL, V145, P885, DOI 10.1038/sj.bjp.0706253; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	71	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9066	9075		10.1074/jbc.M509721200	http://dx.doi.org/10.1074/jbc.M509721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461355	hybrid			2022-12-27	WOS:000236404700011
J	Milano, SK; Kim, YM; Stefano, FP; Benovic, JL; Brenner, C				Milano, SK; Kim, YM; Stefano, FP; Benovic, JL; Brenner, C			Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hexakisphosphate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; CLATHRIN ADAPTER AP-2; BETA-ARRESTIN; VISUAL ARRESTIN; CRYSTAL-STRUCTURE; BETA(2)-ADRENERGIC RECEPTOR; PROTEIN; ENDOCYTOSIS; ACTIVATION; COMPLEX	Interactions between arrestins and phosphoinositides have been reported to regulate multiple membrane-associated signaling and trafficking events including clathrin-mediated endocytosis and light adaptation in Drosophila. Arrestins have been proposed to have nuclear and cytosolic functions as well, although the ligand dependence of these functions has not been investigated. Here we characterize the structural, molecular, and cellular interactions between arrestin-2 and inositol hexakisphosphate ( inositol 1,2,3,4,5,6-hexakisphosphate (IP6)). The crystal structure of the arrestin-2.IP6 complex was solved to 2.9 angstrom with crystal lattice contacts suggesting two sites on a protein monomer mediating IP6 binding. Mutagenesis coupled to isothermal titration calorimetry and tritiated IP6 binding assays confirmed two-site binding with a low affinity IP6-binding site in the N-domain and a high affinity site in the C-domain. Native gel electrophoresis, gel filtration, and analytical ultracentrifugation demonstrated the ability of IP6 to promote arrestin-2 oligomerization via the two crystallographically defined ligand-binding locations. In addition, analysis in mammalian cells revealed that arrestin-2 not only undergoes homo-oligomerization, but it can also hetero-oligomerize with arrestin-3 in a manner that depends on IP6-binding sites. Mutation of either IP6-binding site in arrestin-2 disrupted oligomerization while interactions with known binding partners including clathrin, AP-2, and ERK2 were maintained. Subcellular localization studies showed that arrestin-2 oligomers are primarily cytoplasmic, whereas arrestin-2 monomers displayed increased nuclear localization. Thus, by promoting cytosolic oligomerization, IP6 binding is proposed to be a negative regulator of interactions of arrestin with plasma membrane and nuclear signaling proteins.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Med Sch, Dept Biochem, Lebanon, NH 03756 USA	Jefferson University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Dartmouth College; Dartmouth College	Brenner, C (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.	benovic@mail.jci.tju.edu; charles.brenner@dartmouth.edu	Brenner, Charles/D-6339-2014; Kim, You-Me/I-5553-2013	Brenner, Charles/0000-0002-4955-3226; Kim, You-Me/0000-0001-8780-704X	NCRR NIH HHS [1S10 RR019431] Funding Source: Medline; NIGMS NIH HHS [GM47417, GM068857] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047417, R01GM068857, R37GM047417] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK KA, 1991, J BIOL CHEM, V266, P4442; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DELANO WL, 2002, PYMOL VERSION 0 97; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Frederick JP, 2005, P NATL ACAD SCI USA, V102, P8454, DOI 10.1073/pnas.0503706102; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Imamoto Y, 2003, BIOPHYS J, V85, P1186, DOI 10.1016/S0006-3495(03)74554-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 2004, J BIOL CHEM, V279, P9912, DOI 10.1074/jbc.M310824200; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Storez H, 2005, J BIOL CHEM, V280, P40210, DOI 10.1074/jbc.M508001200; Verbsky J, 2005, P NATL ACAD SCI USA, V102, P8448, DOI 10.1073/pnas.0503656102; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200	43	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9812	9823		10.1074/jbc.M512703200	http://dx.doi.org/10.1074/jbc.M512703200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16439357	hybrid			2022-12-27	WOS:000236404700094
J	Yu, CL; Palumbo, MJ; Lawrence, CE; Morse, RH				Yu, CL; Palumbo, MJ; Lawrence, CE; Morse, RH			Contribution of the histone H3 and H4 amino termini to Gcn4p- and Gcn5p-mediated transcription in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; IN-VIVO; COACTIVATOR COMPLEX; ACTIVATOR PROTEIN; EUKARYOTIC GENOME; ACETYLATION CODE; BUDDING YEAST	Histone amino termini are post-translationally modified by both transcriptional coactivators and corepressors, but the extent to which the relevant histone modifications contribute to gene expression, and the mechanisms by which they do so, are incompletely understood. To address this issue, we have examined the contributions of the histone H3 and H4 amino termini, and of the coactivator and histone acetyltransferase Gcn5p, to activation of a small group of Gcn4p-activated genes. The histone H3 tail exerts a modest ( about 2-fold) but significant effect on activation that correlates with a requirement for Gcn5p and is distributed over multiple lysine residues. The H4 tail also plays a positive role in activation of some of those genes tested, but this does not correlate as closely with Gcn5p coactivation. Microarray experiments did not reveal a close correspondence between those genes activated by Gcn4p and genes requiring the H3 or H4 tail, and analysis of published microarray data indicates that Gcn4p-regulated genes are not in general strongly dependent on Gcn5p. However, a large fraction of genes activated by Gcn4p were found to be repressed by the H3 and H4 amino termini under non-inducing conditions, indicating that one role for Gcn4p is to overcome repression mediated by the histone tails.	New York State Dept Hlth, Wadsworth Ctr, Lab Dev Genet, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA; Brown Univ, Ctr Computat Mol Biol, Providence, RI 02912 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Brown University	Morse, RH (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Lab Dev Genet, Albany, NY 12201 USA.	Randall.Morse@wadsworth.org		Morse, Randall/0000-0003-0000-8718				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boorsma A, 2005, NUCLEIC ACIDS RES, V33, pW592, DOI 10.1093/nar/gki484; Conlon EM, 2003, P NATL ACAD SCI USA, V100, P3339, DOI 10.1073/pnas.0630591100; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Larschan E, 2005, MOL CELL BIOL, V25, P114, DOI 10.1128/MCB.25.1.114-123.2005; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Martin AM, 2004, GENETICS, V167, P1123, DOI 10.1534/genetics.104.026674; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; Perez-Martin J, 1998, MOL CELL BIOL, V18, P1049, DOI 10.1128/MCB.18.2.1049; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Qiu HF, 2004, MOL CELL BIOL, V24, P4104, DOI 10.1128/MCB.24.10.4104-4117.2004; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sabet N, 2004, MOL CELL BIOL, V24, P8823, DOI 10.1128/MCB.24.20.8823-8833.2004; Sabet N, 2003, P NATL ACAD SCI USA, V100, P4084, DOI 10.1073/pnas.0637524100; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; STADEN R, 1989, COMPUT APPL BIOSCI, V5, P89; Stafford GA, 2001, MOL CELL BIOL, V21, P4568, DOI 10.1128/MCB.21.14.4568-4578.2001; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Swanson MJ, 2003, MOL CELL BIOL, V23, P2800, DOI 10.1128/MCB.23.8.2800-2820.2003; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Thompson W, 2003, NUCLEIC ACIDS RES, V31, P3580, DOI 10.1093/nar/gkg608; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Yu LN, 1999, MOL CELL BIOL, V19, P5279; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	76	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9755	9764		10.1074/jbc.M513178200	http://dx.doi.org/10.1074/jbc.M513178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461773	hybrid			2022-12-27	WOS:000236404700088
J	Cheon, HM; Shin, SW; Bian, GW; Park, JH; Raikhel, AS				Cheon, HM; Shin, SW; Bian, GW; Park, JH; Raikhel, AS			Regulation of lipid metabolism genes, lipid carrier protein lipophorin, and its receptor during immune challenge in the mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPHORIN-III; FAT-BODY; DROSOPHILA IMMUNITY; GALLERIA-MELLONELLA; ACTIVATION; HEMOLYMPH; PATHWAY; COMMON; LIPOPOLYSACCHARIDE; EXPRESSION	In the mosquito Aedes aegypti, the expression of two fat body genes involved in lipid metabolism, a lipid carrier protein lipophorin ( Lp) and its lipophorin receptor ( LpRfb), was significantly increased after infections with Gram ( +) bacteria and fungi, but not with Gram ( -) bacteria. The expression of these genes was enhanced after the infection with Plasmodium gallinaceum. RNA interference ( RNAi) knockdown of Lp strongly restricted the development of Plasmodium oocysts, reducing their number by 90%. In Vg-Delta REL1- A transgenic mosquitoes, with gain- of- function phenotype of Toll/ REL1 immune pathway activated after blood feeding, both the Lp and LpRfb genes were overexpressed independently of septic injury. The same phenotype was observed in the mosquitoes with RNAi knockdown of Cactus, an I kappa B inhibitor in the Toll/ REL1 pathway. These results showed that, in the mosquito fat body, both Lp and LpRfb gene expression were regulated by the Toll/ REL1 pathway during immune induction by pathogen and parasite infections. Indeed, the proximal region of the LpRfb promoter contained closely linked binding motifs for GATA and NF-kappa B transcription factors. Transfection and in vivo RNAi knockdown experiments showed that the bindings of both GATA and NF-kappa B transcription factors to the corresponding motif were required for the induction of the LpRfb gene. These findings suggest that lipid metabolism is involved in the mosquito systemic immune responses to pathogens and parasites.	Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Bian, Guowu/B-1572-2010	Shin, Sang Woon/0000-0001-9467-0803	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [R37-AI24716, R01 AI024716, R01-AI052492] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1993, DEVELOPMENT, V119, P623; Ahmed AM, 2001, INSECT MOL BIOL, V10, P347, DOI 10.1046/j.0962-1075.2001.00273.x; Ahmed AM, 1999, INVERTEBR REPROD DEV, V36, P217, DOI 10.1080/07924259.1999.9652703; Arrese EL, 2001, INSECT BIOCHEM MOLEC, V31, P7, DOI 10.1016/S0965-1748(00)00102-8; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Bansal Devendra, 2005, Lipids Health Dis, V4, P10, DOI 10.1186/1476-511X-4-10; Bian G, 2005, P NATL ACAD SCI USA, V102, P13568, DOI 10.1073/pnas.0502815102; Brodu V, 2001, DEVELOPMENT, V128, P2593; CAPURRO MD, 1994, COMP BIOCHEM PHYS B, V108, P35, DOI 10.1016/0305-0491(94)90161-9; Cheon HM, 2001, INSECT BIOCHEM MOLEC, V31, P753, DOI 10.1016/S0965-1748(01)00068-6; COODIN S, 1992, J INSECT PHYSIOL, V38, P853, DOI 10.1016/0022-1910(92)90096-V; Dantuma NP, 1999, J LIPID RES, V40, P973; de Bont N, 1999, J LIPID RES, V40, P680; Dettloff M, 2001, J INSECT PHYSIOL, V47, P789, DOI 10.1016/S0022-1910(01)00069-5; Fallon AM, 2001, INSECT BIOCHEM MOLEC, V31, P263, DOI 10.1016/S0965-1748(00)00146-6; FEINGOLD KR, 1995, INFECT IMMUN, V63, P2041, DOI 10.1128/IAI.63.5.2041-2046.1995; HAGEDORN HH, 1977, J INSECT PHYSIOL, V23, P203, DOI 10.1016/0022-1910(77)90030-0; Halwani AE, 2000, J INVERTEBR PATHOL, V76, P233, DOI 10.1006/jipa.2000.4978; Halwani AE, 1999, DEV COMP IMMUNOL, V23, P563, DOI 10.1016/S0145-305X(99)00037-3; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Hurd H, 2005, CURR TOP MICROBIOL, V289, P185; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P539, DOI 10.1016/0965-1748(94)90089-2; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P547, DOI 10.1016/0965-1748(94)90090-6; Kim HJ, 2004, INSECT BIOCHEM MOLEC, V34, P1011, DOI 10.1016/j.ibmb.2004.05.005; Kitchens RL, 1999, J BIOL CHEM, V274, P34116, DOI 10.1074/jbc.274.48.34116; Kutty RK, 1996, J BIOL CHEM, V271, P20641, DOI 10.1074/jbc.271.34.20641; Laskowitz DT, 2000, J LIPID RES, V41, P613; LAW JH, 1989, J BIOL CHEM, V264, P16335; Lee CS, 2003, INSECT BIOCHEM MOLEC, V33, P761, DOI 10.1016/S0965-1748(03)00066-3; Mandato CA, 1996, J INSECT PHYSIOL, V42, P143, DOI 10.1016/0022-1910(95)00091-7; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Martin D, 2001, MOL CELL BIOL, V21, P164, DOI 10.1128/MCB.21.1.164-174.2001; Mullen L, 2003, INSECT BIOCHEM MOLEC, V33, P661, DOI 10.1016/S0965-1748(03)00045-6; Petersen UM, 1999, EMBO J, V18, P4013, DOI 10.1093/emboj/18.14.4013; Raikhel AS, 2002, INSECT BIOCHEM MOLEC, V32, P1275, DOI 10.1016/S0965-1748(02)00090-5; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Ryan RO, 2000, ANNU REV ENTOMOL, V45, P233, DOI 10.1146/annurev.ento.45.1.233; Senger K, 2004, MOL CELL, V13, P19, DOI 10.1016/S1097-2765(03)00500-8; Seo SJ, 2003, J BIOL CHEM, V278, P41954, DOI 10.1074/jbc.M308200200; Shin SW, 2005, J BIOL CHEM, V280, P16499, DOI 10.1074/jbc.M500711200; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Sun JX, 2000, INSECT BIOCHEM MOLEC, V30, P1161, DOI 10.1016/S0965-1748(00)00093-X; Sundermeyer K, 1996, INSECT BIOCHEM MOLEC, V26, P735, DOI 10.1016/S0965-1748(96)00060-4; van Heusden MC, 1998, INSECT BIOCHEM MOLEC, V28, P733, DOI 10.1016/S0965-1748(98)00068-X; Van Hoof D, 2003, J LIPID RES, V44, P1431, DOI 10.1194/jlr.M300022-JLR200; Van Hoof D, 2002, J CELL SCI, V115, P4001, DOI 10.1242/jcs.00113; VanHeusden MC, 1997, ARCH INSECT BIOCHEM, V34, P301, DOI 10.1002/(SICI)1520-6327(1997)34:3<301::AID-ARCH5>3.0.CO;2-X; Vernick KD, 2005, CURR TOP MICROBIOL, V295, P383; Vlachou D, 2005, CURR BIOL, V15, P1185, DOI 10.1016/j.cub.2005.06.044; Whitten MMA, 2004, J IMMUNOL, V172, P2177, DOI 10.4049/jimmunol.172.4.2177	52	75	76	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8426	8435		10.1074/jbc.M510957200	http://dx.doi.org/10.1074/jbc.M510957200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16449228	hybrid			2022-12-27	WOS:000236247100017
J	Chong-Kopera, H; Inoki, K; Li, Y; Zhu, TQ; Garcia-Gonzalo, FR; Rosa, JL; Guan, KL				Chong-Kopera, H; Inoki, K; Li, Y; Zhu, TQ; Garcia-Gonzalo, FR; Rosa, JL; Guan, KL			TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TUMOR-SUPPRESSOR PROTEINS; TUBEROUS-SCLEROSIS; SIGNALING PATHWAY; CELL-GROWTH; REGULATOR RCC1; GIANT PROTEIN; GENE-PRODUCTS; RAB PROTEINS; HAMARTIN	Tuberous sclerosis complex ( TSC) is an autosomal dominant disease characterized by hamartoma formation in various organs. Two genes responsible for the disease, TSC1 and TSC2, have been identified. The TSC1 and TSC2 proteins, also called hamartin and tuberin, respectively, have been shown to regulate cell growth through inhibition of the mammalian target of rapamycin pathway. TSC1 is known to stabilize TSC2 by forming a complex with TSC2, which is a GTPase- activating protein for the Rheb small GTPase. We have identified HERC1 as a TSC2- interacting protein. HERC1 is a 532- kDa protein with an E3 ubiquitin ligase homology to E6AP carboxyl terminus ( HECT) domain. We observed that the interaction of TSC1 with TSC2 appears to exclude TSC2 from interacting with HERC1. Disease mutations in TSC2, which result in its destabilization, allow binding to HERC1 in the presence of TSC1. Our study reveals a potential molecular mechanism of how TSC1 stabilizes TSC2 by excluding the HERC1 ubiquitin ligase from the TSC2 complex. Furthermore, these data reveal a possible biochemical basis of how certain disease mutations inactivate TSC2.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Barcelona, IDIBELL, Dept Ciencies Fisiol 2, Barcelona 08907, Spain	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Guan, KL (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	INOKI, KEN/A-1202-2007; Garcia-Gonzalo, Francesc/W-2639-2017; Rosa, Jose Luis/K-6685-2014	Garcia-Gonzalo, Francesc/0000-0002-9152-2191; Rosa, Jose Luis/0000-0002-6161-5688; Kopera, Huira/0000-0002-8347-5567	NIA NIH HHS [T32 AG00114-18] Funding Source: Medline; NIDDK NIH HHS [R01 DK124709] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garcia-Gonzalo FR, 2005, CELL MOL LIFE SCI, V62, P1826, DOI 10.1007/s00018-005-5119-y; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Murthy V, 2004, J BIOL CHEM, V279, P1351, DOI 10.1074/jbc.M310208200; Nellist M, 2005, EUR J HUM GENET, V13, P59, DOI 10.1038/sj.ejhg.5201276; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosa JL, 1997, ONCOGENE, V15, P1, DOI 10.1038/sj.onc.1201170; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	30	168	179	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8313	8316		10.1074/jbc.C500451200	http://dx.doi.org/10.1074/jbc.C500451200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16464865	Green Published, hybrid			2022-12-27	WOS:000236247100003
J	Hopfer, U; Hopfer, H; Jablonski, K; Stahl, RAK; Wolf, G				Hopfer, U; Hopfer, H; Jablonski, K; Stahl, RAK; Wolf, G			The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLASES PHD1; DEPENDENT CELL-DEATH; SMOOTH-MUSCLE-CELLS; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; UBIQUITIN LIGASE; ANGIOTENSIN-II; BETA-SUBUNIT; DNA-BINDING	Hypoxia-inducible factor-1 (HIF-1), a transcriptional complex composed of an oxygen-sensitive alpha- and a beta-subunit, plays a pivotal role in cellular adaptation to low oxygen availability. Under normoxia, the alpha-subunit of HIF-1 is hydroxylated by a family of prolyl hydroxylases (PHDs) and consequently targeted for proteasomal degradation. Three different PHDs have been identified, but the difference among their in vivo roles remain unclear. PHD3 is strikingly expressed by hypoxia, displays high substrate specificity, and has been identified in other signaling pathways. PHD3 may therefore hydroxylate divergent substrates and/or connect divergent cellular responses with HIF. We identified a novel WD-repeat protein, recently designated Morg1 ( MAPK organizer 1), by screening a cDNA library with yeast two-hybrid assays. The interaction between PHD3 and Morg1 was confirmed in vitro and in vivo. We found seven WD-repeat domains by cloning the full-length cDNA of Morg1. By confocal microscopy both proteins co-localize within the cytoplasm and the nucleus and display a similar tissue expression pattern in Northern blots. Binding occurs at a conserved region predicted to the top surface of one propeller blade. Finally, HIF-mediated reporter gene activity is decreased by Morg1 and reduced to basal levels when Morg1 is co-expressed with PHD3. Suppression of Morg1 or PHD3 by stealth RNA leads to a marked increase of HIF-1 activity. These results indicate that Morg1 specifically interacts with PHD3 most likely by acting as a molecular scaffold. This interaction may provide a molecular framework between HIF regulation and other signaling pathways.	Univ Hamburg, Dept Med, D-20246 Hamburg, Germany; Univ Hamburg, Dept Pathol, D-20246 Hamburg, Germany; Univ Jena, Dept Med, D-07747 Jena, Germany	University of Hamburg; University of Hamburg; Friedrich Schiller University of Jena	Hopfer, U (corresponding author), Ctr innovat Med, Dept Med, Falkenried 88,5 St, D-20251 Hamburg, Germany.	u.hopfer@uke.uni-hamburg.de	Hopfer, Helmut/T-5954-2019	Hopfer, Helmut/0000-0003-1755-2170				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Butzmann U, 2002, J AM SOC NEPHROL, V13, p495A; Cheng HL, 2004, MOL CELL BIOL, V24, P2932, DOI 10.1128/MCB.24.7.2932-2943.2004; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erez N, 2002, ONCOGENE, V21, P6713, DOI 10.1038/sj.onc.1205867; Freeman RS, 2003, MOL CELLS, V16, P1; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Harendza S, 2000, J BIOL CHEM, V275, P19552, DOI 10.1074/jbc.M001322200; Hewitson KS, 2003, BIOCHEM SOC T, V31, P510, DOI 10.1042/BST0310510; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hopfer H, 2003, FASEB J, V17, P860, DOI 10.1096/fj.02-0746com; Hopfer U, 2005, FASEB J, V19, P1232, DOI 10.1096/fj.04-3019com; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janda L, 1996, J BACTERIOL, V178, P1487, DOI 10.1128/jb.178.5.1487-1489.1996; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Madden SL, 1996, CANCER RES, V56, P5384; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Menzies K, 2004, BIOCHEM BIOPH RES CO, V317, P801, DOI 10.1016/j.bbrc.2004.03.115; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Straub JA, 2003, J NEUROCHEM, V85, P318, DOI 10.1046/j.1471-4159.2003.01688.x; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; Vodermaier HC, 2001, CURR BIOL, V11, pR834, DOI 10.1016/S0960-9822(01)00498-5; Vomastek T, 2004, P NATL ACAD SCI USA, V101, P6981, DOI 10.1073/pnas.0305894101; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Wax SD, 1996, LAB INVEST, V74, P797; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wilson DK, 2005, J BIOL CHEM, V280, P13944, DOI 10.1074/jbc.M412919200; Wolf C, 2001, FEBS LETT, V488, P154, DOI 10.1016/S0014-5793(00)02403-0; Wolf G, 2004, AM J NEPHROL, V24, P415, DOI 10.1159/000080086; Wolf G, 2002, LAB INVEST, V82, P1305, DOI 10.1097/01.LAB.0000029207.92039.2F; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470; Zahner G, 2002, J BIOL CHEM, V277, P9763, DOI 10.1074/jbc.M106307200	76	52	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8645	8655		10.1074/jbc.M513751200	http://dx.doi.org/10.1074/jbc.M513751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407229	hybrid			2022-12-27	WOS:000236247100042
J	Mao, CH; Tai, WC; Bai, Y; Poizat, C; Lee, AS				Mao, CH; Tai, WC; Bai, Y; Poizat, C; Lee, AS			In vivo regulation of Grp78/BiP transcription in the embryonic heart - Role of the endoplasmic reticulum stress response element and GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSGENIC MOUSE MODEL; ER STRESS; VENTRAL MORPHOGENESIS; CARDIAC DEVELOPMENT; GENE-EXPRESSION; TUBE FORMATION; MESSENGER-RNA; FACTOR YY1; TFII-I	The transcriptional activation of GRP78, which controls multiple signaling pathways of the unfolded protein response, has been used extensively as an indicator for the onset of endoplasmic reticulum stress in tissue culture systems. Here we investigate the mechanism of Grp78 induction during mouse embryonic development. Our results reveal that in transgenic mouse models, reporter gene activity driven by the Grp78 promoter is strongly activated during early embryonic heart development but subsides in later stages. This activation is strictly dependent on a 100-base pair region of the Grp78 promoter containing the endoplasmic reticulum stress response elements (ERSEs). Previous studies establish that endoplasmic reticulum stress induces in vivo binding of YY1 and the nuclear form of ATF6 to the ERSE. Since the expression of YY1 as well as ATF6 is ubiquitous in the mouse embryo, activation of the Grp78 promoter in the early embryonic heart may involve a specific mechanism. Here we report that GATA-4, a transcription factor essential for heart development, binds to the Grp78 promoter in vivo and activates the ERSE, which does not contain a consensus GATA binding site. GATA-4 cooperatively activates the Grp78 promoter with YY1, and the DNA binding domain of YY1 is necessary and sufficient for this cooperation. In addition, GATA-4 activation of the Grp78 promoter is enhanced by the nuclear form of ATF6, and this synergy is further potentiated by YY1. These results suggest that during early heart organogenesis, Grp78 can be activated through cooperation between the cell type-specific transcription factors and ERSE-binding factors.	Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Keck Sch Med, Inst Med Genet, Los Angeles, CA 90089 USA	University of Southern California	Lee, AS (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [C06CA062528, R01CA027607] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR014514, C06RR010600] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA27607, C06 CA62528-01] Funding Source: Medline; NCRR NIH HHS [C06 RR10600-01, C06 RR014514-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abdelrahim M, 2005, J BIOL CHEM, V280, P16508, DOI 10.1074/jbc.C500030200; Barnes JA, 1997, ANAT EMBRYOL, V196, P335, DOI 10.1007/s004290050102; Barnes JA, 1999, CELL STRESS CHAPERON, V4, P250, DOI 10.1379/1466-1268(1999)004<0250:EOGRPG>2.3.CO;2; Barnes JA, 2000, ANAT EMBRYOL, V202, P67, DOI 10.1007/s004290000090; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Dong DZ, 2004, HUM GENE THER, V15, P553, DOI 10.1089/104303404323142006; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Fluck CE, 2004, MOL ENDOCRINOL, V18, P1144, DOI 10.1210/me.2003-0342; GAZIT G, 1995, CANCER RES, V55, P1660; Guo L, 2001, J BIOL CHEM, V276, P2797, DOI 10.1074/jbc.C000822200; Hogan B, 1994, MANIPULATING MOUSE E; Hong M, 2005, J BIOL CHEM, V280, P16821, DOI 10.1074/jbc.M413753200; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kerkela R, 2002, J BIOL CHEM, V277, P13752, DOI 10.1074/jbc.M105736200; KIM KS, 1990, DIFFERENTIATION, V42, P153, DOI 10.1111/j.1432-0436.1990.tb00756.x; KITTEN GT, 1987, ANAT REC, V217, P379, DOI 10.1002/ar.1092170409; KOONG AC, 1994, INT J RADIAT ONCOL, V28, P661, DOI 10.1016/0360-3016(94)90191-0; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Mao CH, 2004, NAT MED, V10, P1013, DOI 10.1038/nm1004-1013; MARKWALD RR, 1990, ANN NY ACAD SCI, V588, P13, DOI 10.1111/j.1749-6632.1990.tb13193.x; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Opie L.H., 1991, HEART PHYSL METABOLI; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Poizat C, 2005, MOL CELL BIOL, V25, P2673, DOI 10.1128/MCB.25.7.2673-2687.2005; Reddy RK, 2002, CANCER RES, V62, P7207; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97	53	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8877	8887		10.1074/jbc.M505784200	http://dx.doi.org/10.1074/jbc.M505784200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452489	hybrid			2022-12-27	WOS:000236247100068
J	Suh, JY; Cai, ML; Williams, DC; Clore, GM				Suh, JY; Cai, ML; Williams, DC; Clore, GM			Solution structure of a post-transition state analog of the phosphotransfer reaction between the A and B cytoplasmic domains of the mannitol transporter IIMannitol of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER COMPLEX; POTATO CARBOXYPEPTIDASE INHIBITOR; NMR STRUCTURE; 3-DIMENSIONAL STRUCTURE; PROTEIN COMPLEXES; ENZYME IIB; PERMEASE; REVEALS; COMPLEMENTATION; IIBCELLOBIOSE	The solution structure of the post-transition state complex between the isolated cytoplasmic A (IIA(Mtl)) and phosphorylated B (phospho-IIBMtl) domains of the mannitol transporter of the Escherichia coli phosphotransferase system has been solved by NMR. The active site His-554 of IIA(Mtl) was mutated to glutamine to block phosphoryl transfer activity, and the active site Cys-384 of IIBMtl ( residues of IIBMtl are denoted in italic type) was substituted by serine to permit the formation of a stable phosphorylated form of IIBMtl. The two complementary interaction surfaces are predominantly hydrophobic, and two methionines on IIBMtl, Met-388 and Met-393, serve as anchors by interacting with two deep pockets on the surface of IIA(Mtl). With the exception of a salt bridge between the conserved Arg-538 of IIA(Mtl) and the phosphoryl group of phospho-IIBMtl, electrostatic interactions between the two proteins are limited to the outer edges of the interface, are few in number, and appear to be weak. This accounts for the low affinity of the complex (K-d similar to 3.7 mM), which is optimally tuned to the intact biological system in which the A and B domains are expressed as a single polypeptide connected by a flexible 21-residue linker. The phosphoryl transition state can readily be modeled with no change in protein-protein orientation and minimal perturbations in both the backbone immediately adjacent to His-554 and Cys-384 and the side chains in close proximity to the phosphoryl group. Comparison with the previously solved structure of the IIA(Mtl)-HPr complex reveals how IIA(Mtl) uses the same interaction surface to recognize two structurally unrelated proteins and explains the much higher affinity of IIA(Mtl) for HPr than IIBMtl.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK029023] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AB E, 1997, PROTEIN SCI, V6, P304; AB E, 2001, J MOL BIOL, V308, P993, DOI 10.1006/jmbi.2001.4623; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P979; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jain NU, 2004, J MOL BIOL, V343, P1379, DOI 10.1016/j.jmb.2004.08.103; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Legler PM, 2004, J BIOL CHEM, V279, P39115, DOI 10.1074/jbc.M406764200; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; Otten R, 2004, J BIOMOL NMR, V30, P461, DOI 10.1007/s10858-004-3498-2; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Sass HJ, 2000, J BIOMOL NMR, V18, P303, DOI 10.1023/A:1026703605147; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; Suh JY, 2005, J MOL BIOL, V353, P1129, DOI 10.1016/j.jmb.2005.09.033; Tchieu JH, 2001, J MOL MICROB BIOTECH, V3, P329; van Montfort BA, 2002, J BIOL CHEM, V277, P14717, DOI 10.1074/jbc.M201533200; van Montfort RLM, 1998, STRUCTURE, V6, P377, DOI 10.1016/S0969-2126(98)00039-2; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Williams DC, 2005, J BIOL CHEM, V280, P20775, DOI 10.1074/jbc.M501986200; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	51	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8939	8949		10.1074/jbc.M513466200	http://dx.doi.org/10.1074/jbc.M513466200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16443929	hybrid			2022-12-27	WOS:000236247100074
J	Meyer, MZ; Deliot, N; Chasserot-Golaz, S; Premont, RT; Bader, MF; Vitale, N				Meyer, MZ; Deliot, N; Chasserot-Golaz, S; Premont, RT; Bader, MF; Vitale, N			Regulation of neuroendocrine exocytosis by the ARF6 GTPase-activating protein GIT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CHROMAFFIN CELLS; SECRETORY GRANULES; PHOSPHOLIPASE D1; EXCHANGE FACTOR; FAMILY; COMPLEX; ACTIN; REQUIRES; FUSION	Neuroendocrine cells release hormones and neuropeptides by exocytosis, a highly regulated process in which secretory granules fuse with the plasma membrane to release their contents in response to a calcium trigger. Using chromaffin and PC12 cells, we have recently described that the granule-associated GTPase ARF6 plays a crucial role in exocytosis by activating phospholipase D1 at the plasma membrane and, presumably, promoting the fusion reaction between the two membrane bilayers. ARF6 is activated by the nucleotide exchange factor ARNO following docking of granules to the plasma membrane. We show here that GIT1, a GTPase-activating protein stimulating GTP hydrolysis on ARF6, is the second molecular partner that turns over the GDP/GTP cycle of ARF6 during cell stimulation. Western blot and immunofluorescence experiments indicated that GIT1 is cytosolic in resting cells but is recruited to the plasma membrane in stimulated cells, where it colocalizes with ARF6 at the granule docking sites. Over-expression of wild-type GIT1 inhibits growth hormone secretion from PC12 cells; this inhibitory effect was not observed in cells expressing a GIT1 mutant impaired in its ARF-GTPase-activating protein ( GAP) activity or in cells expressing other ARF6-GAPs. Conversely reduction of GIT1 by RNA interference increased the exocytotic activity. Using a real time assay for individual chromaffin cells, we found that microinjection of GIT1 strongly reduced the number of exocytotic events. These results provide the first evidence that GIT1 plays a function in calcium-regulated exocytosis in neuroendocrine cells. We propose that GIT1 represents part of the pathway that inactivates ARF6-dependent reactions and thereby negatively regulates and/or terminates exocytotic release.	Univ Strasbourg 1, UMR 7168 CNRS, Dept Neurotransmiss & Neuroendocrine Sect, Inst Neurosci Cellulaires & Integrat, F-67084 Strasbourg, France; Duke Univ, Med Ctr, Dept Med Gastroenterol, Durham, NC 27710 USA	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Duke University	Vitale, N (corresponding author), Univ Strasbourg 1, UMR 7168 CNRS, Dept Neurotransmiss & Neuroendocrine Sect, Inst Neurosci Cellulaires & Integrat, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	vitalen@neurochem.u-strasbg.fr	Chasserot-Golaz, Sylvette/K-7625-2017; Vitale, Nicolas/G-5967-2014; Bader, Marie-France/O-2098-2016	Vitale, Nicolas/0000-0002-4752-4907; deliot, nadine/0000-0002-1258-7377; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; Premont, Richard/0000-0002-8053-5026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059989] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Albertinazzi C, 2003, MOL BIOL CELL, V14, P1295, DOI 10.1091/mbc.E02-07-0406; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Elhamdani A, 2001, NEURON, V31, P819, DOI 10.1016/S0896-6273(01)00418-4; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; Gasman S, 1999, J CELL SCI, V112, P4763; Gensse M, 2000, FEBS LETT, V480, P184, DOI 10.1016/S0014-5793(00)01926-8; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Schweitzer JK, 2002, J BIOL CHEM, V277, P27210, DOI 10.1074/jbc.M201569200; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Zhang HY, 2003, J CELL BIOL, V161, P131, DOI 10.1083/jcb.200211002	30	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7919	7926		10.1074/jbc.M600081200	http://dx.doi.org/10.1074/jbc.M600081200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439353	hybrid			2022-12-27	WOS:000236031000027
J	Race, PR; Lakey, JH; Banfield, MJ				Race, PR; Lakey, JH; Banfield, MJ			Insertion of the enteropathogenic Escherichia coli Tir virulence protein into membranes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PORE-FORMING PROTEIN; EQUINATOXIN-II; SEA-ANEMONE; HOST-CELLS; MAMMALIAN-CELLS; ACTINIA-EQUINA; SECRETION; RECEPTOR; INTIMIN	Insertion of the enteropathogenic Escherichia coli Tir protein into the plasma membrane of intestinal epithelial cells is a crucial event in infection because it provides a receptor for intimate bacterial adherence. This interaction with the bacterial outer membrane protein intimin is also essential in generating a number of signaling activities associated with virulence. Tir can be modified at various sites by phosphorylation and functionally interacts with multiple host proteins. To investigate the mechanism of membrane insertion and to establish a model system in which the multiple interactions/ functions of Tir can be uncoupled and independently characterized, we used intrinsic tryptophan fluorescence, surface plasmon resonance, and protease digestion assays to show that Tir can insert directly into phospholipid vesicles in a composition-dependent manner to generate the topology reported in vivo. This is the first time that Tir has been shown to insert into membranes in a simple model system in the absence of chemical modification or other factors. These data are consistent with the protein interacting with lipids through two sites. The major site is localized to the transmembrane/ intimin-binding domain region and includes Trp(235), which is shown to be an effective reporter of interaction. The minor site is located within the C-terminal domain. Together, these data support a model in which Tir is released into the cytoplasm by the type III translocon and then independently inserts into the plasma membrane from a cytoplasmic location. A thorough understanding of this mechanism will be crucial to understand the subtleties of enteropathogenic E. coli pathogenesis.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Banfield, MJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	M.J.Banfield@ncl.ac.uk	Banfield, Mark/C-7453-2013	Banfield, Mark/0000-0001-8921-3835				Abe A, 1999, MOL MICROBIOL, V33, P1162, DOI 10.1046/j.1365-2958.1999.01558.x; Barlic A, 2004, J BIOL CHEM, V279, P34209, DOI 10.1074/jbc.M313817200; Berne S, 2005, BIOCHEMISTRY-US, V44, P11137, DOI 10.1021/bi051013y; Campellone KG, 2004, J CELL BIOL, V164, P407, DOI 10.1083/jcb.200306032; Chen HD, 2005, FEMS MICROBIOL REV, V29, P83, DOI 10.1016/j.femsre.2004.07.002; Colomer-Pallas A, 2004, BBA-BIOMEMBRANES, V1660, P16, DOI 10.1016/j.bbamem.2003.10.006; Cooper MA, 2000, ANAL BIOCHEM, V277, P196, DOI 10.1006/abio.1999.4389; Daghastanli KRP, 2004, COLLOID SURFACE B, V36, P127, DOI 10.1016/j.colsurfb.2004.03.015; de Grado M, 1999, CELL MICROBIOL, V1, P7, DOI 10.1046/j.1462-5822.1999.00001.x; Dean P, 2005, CURR OPIN MICROBIOL, V8, P28, DOI 10.1016/j.mib.2004.12.010; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Hawrani A, 2003, J BIOL CHEM, V278, P25839, DOI 10.1074/jbc.M212409200; Hayward RD, 2005, MOL MICROBIOL, V56, P590, DOI 10.1111/j.1365-2958.2005.04568.x; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Jakes KS, 1998, P NATL ACAD SCI USA, V95, P4321, DOI 10.1073/pnas.95.8.4321; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; McGhie EJ, 2002, MOL MICROBIOL, V44, P1309, DOI 10.1046/j.1365-2958.2002.02958.x; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Nougayrede JP, 2003, CELL MICROBIOL, V5, P359, DOI 10.1046/j.1462-5822.2003.00281.x; Page AL, 2002, MOL MICROBIOL, V46, P1, DOI 10.1046/j.1365-2958.2002.03138.x; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Ray S, 2004, MOL MEMBR BIOL, V21, P93, DOI 10.1080/09687680310001625800; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Slatin SL, 2002, P NATL ACAD SCI USA, V99, P1286, DOI 10.1073/pnas.022480199; Thomas NA, 2005, MOL MICROBIOL, V57, P1762, DOI 10.1111/j.1365-2958.2005.04802.x; Touze T, 2004, MOL MICROBIOL, V51, P73, DOI 10.1046/j.1365-2958.2003.03830.x; Vallance BA, 2000, P NATL ACAD SCI USA, V97, P8799, DOI 10.1073/pnas.97.16.8799; van der Goot FG, 2004, J BIOL CHEM, V279, P47792, DOI 10.1074/jbc.M406824200; Virtanen JA, 1998, P NATL ACAD SCI USA, V95, P4964, DOI 10.1073/pnas.95.9.4964; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618	37	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7842	7849		10.1074/jbc.M513532200	http://dx.doi.org/10.1074/jbc.M513532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436373	hybrid			2022-12-27	WOS:000236031000018
J	Zhang, XX; Hu, YF; Guo, XR; Lescop, E; Li, Y; Xia, B; Jin, CW				Zhang, XX; Hu, YF; Guo, XR; Lescop, E; Li, Y; Xia, B; Jin, CW			The Bacillus subtilis YkuV is a thiol: Disulfide oxidoreductase revealed by its redox structures and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; THIOREDOXIN-LIKE-PROTEIN; COMPLETE GENOME SEQUENCE; NMR SOLUTION STRUCTURE; MODEL-FREE APPROACH; ESCHERICHIA-COLI; ROTATIONAL DIFFUSION; BACKBONE DYNAMICS; RESOLUTION; SUBSTRATE	The Bacillus subtilis YkuV responds to environmental oxidative stress and plays an important role for the bacteria to adapt to the environment. Bioinformatic analysis suggests that YkuV is a homolog of membrane-anchored proteins and belongs to the thioredoxin-like protein superfamily containing the typical Cys-Xaa-Xaa-Cys active motif. However, the biological function of this protein remains unknown thus far. In order to elucidate the biological function, we have determined the solution structures of both the oxidized and reduced forms of B. subtilis YkuV by NMR spectroscopy and performed biochemical studies. Our results demonstrated that the reduced YkuV has a low midpoint redox potential, allowing it to reduce a variety of protein substrates. The overall structures of both oxidized and reduced forms are similar, with a typical thioredoxin-like fold. However, significant conformational changes in the Cys-Xaa- Xaa-Cys active motif of the tertiary structures are observed between the two forms. In addition, the backbone dynamics provide further insights in understanding the strong redox potential of the reduced YkuV. Furthermore, we demonstrated that YkuV is able to reduce different protein substrates in vitro. Together, our results clearly established that YkuV may function as a general thiol: disulfide oxidoreductase, which acts as an alternative for thioredoxin or thioredoxin reductase to maintain the reducing environment in the cell cytoplasm.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	Lescop, Ewen/AAA-8700-2019; zhang, xinxin/E-8629-2012	Lescop, Ewen/0000-0002-2623-9365				BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Bloomfield KL, 2003, GENE, V319, P107, DOI 10.1016/S0378-1119(03)00799-6; Capitani G, 2001, J MOL BIOL, V311, P1037, DOI 10.1006/jmbi.2001.4913; CERVANTES C, 1994, FEMS MICROBIOL REV, V15, P355, DOI 10.1016/0168-6445(94)90069-8; CHAE HZ, 1995, FASEB J, V9, pA1478; Copley SD, 2004, BIOCHEMISTRY-US, V43, P13981, DOI 10.1021/bi048947r; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Crow A, 2004, J BIOL CHEM, V279, P23654, DOI 10.1074/jbc.M402823200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Friemann R, 2003, FEBS LETT, V554, P301, DOI 10.1016/S0014-5793(03)01173-6; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HUTCHISON RS, 1995, METHOD ENZYMOL, V252, P220; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Messens J, 2004, J MOL BIOL, V339, P527, DOI 10.1016/j.jmb.2004.04.016; Mittard V, 1997, EUR J BIOCHEM, V243, P374, DOI 10.1111/j.1432-1033.1997.0374a.x; Moszer I, 1998, FEBS LETT, V430, P28, DOI 10.1016/S0014-5793(98)00620-6; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; Neira JL, 2001, BIOCHEMISTRY-US, V40, P15246, DOI 10.1021/bi011186x; Nicastro G, 2000, EUR J BIOCHEM, V267, P403, DOI 10.1046/j.1432-1327.2000.01015.x; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peng K, 2004, J BIOMOL NMR, V29, P459, DOI 10.1023/B:JNMR.0000032555.97201.bb; Petersohn A, 2001, J BACTERIOL, V183, P5617, DOI 10.1128/JB.183.19.5617-5631.2001; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Qi Y, 2005, PROTEINS, V58, P376, DOI 10.1002/prot.20329; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Rey MW, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r77; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Scharf C, 1998, J BACTERIOL, V180, P1869, DOI 10.1128/JB.180.7.1869-1877.1998; Schirra HJ, 1998, BIOCHEMISTRY-US, V37, P6263, DOI 10.1021/bi980136y; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X; Smits WK, 2005, J BACTERIOL, V187, P3921, DOI 10.1128/JB.187.12.3921-3930.2005; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhang XX, 2005, J BIOMOL NMR, V32, P258, DOI 10.1007/s10858-005-7195-6	71	12	13	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8296	8304		10.1074/jbc.M512015200	http://dx.doi.org/10.1074/jbc.M512015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418167	hybrid			2022-12-27	WOS:000236031000069
J	Serrano-Heras, G; Salas, M; Bravo, A				Serrano-Heras, G; Salas, M; Bravo, A			A uracil-DNA glycosylase inhibitor encoded by a non-uracil containing viral DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE PHI-29 DNA; PYRUVATE-DEHYDROGENASE COMPLEX; COLI EXONUCLEASE-III; DOUBLE-STRANDED DNA; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEIN MIMICRY; N-GLYCOSIDASE; E2 SUBUNIT	Uracil-DNA glycosylase (UDG) is an enzyme involved in the base excision repair pathway. It specifically removes uracil from both single-stranded and double-stranded DNA. The genome of the Bacillus subtilis phage phi 29 is a linear double-stranded DNA with a terminal protein covalently linked at each 5'-end. Replication of phi 29 DNA starts by a protein-priming mechanism and generates intermediates that have long stretches of single-stranded DNA. By using in vivo chemical cross-linking and affinity chromatography techniques, we found that UDG is a cellular target for the early viral protein p56. Addition of purified protein p56 to B. subtilis extracts inhibited the endogenous UDG activity. Moreover, extracts from phi 29-infected cells were deficient in UDG activity. We suggested that inhibition of the cellular UDG is a defense mechanism developed by phi 29 to prevent the action of the base excision repair pathway if uracil residues arise in their replicative intermediates. Protein p56 is the first example of a UDG inhibitor encoded by a non-uracil-containing viral DNA.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Bravo, A (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain.	abravo@cbm.uam.es	Bravo, Alicia/Y-5060-2019; Salas, Margarita/J-9873-2014; Garcia, Pedro/L-2808-2017	Bravo, Alicia/0000-0002-4410-3584; Salas, Margarita/0000-0001-5939-3441; Garcia, Pedro/0000-0001-6717-8717; Serrano-Heras, Gemma/0000-0001-9368-4832				BARTHELEMY I, 1986, J VIROL, V60, P874, DOI 10.1128/JVI.60.3.874-879.1986; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; Bravo A, 1997, J MOL BIOL, V269, P102, DOI 10.1006/jmbi.1997.1032; Bravo A, 2000, EMBO J, V19, P5575, DOI 10.1093/emboj/19.20.5575; Bravo A, 2005, FEMS MICROBIOL REV, V29, P25, DOI 10.1016/j.femsre.2004.06.003; BRAVO A, 1990, NUCLEIC ACIDS RES, V18, P2881, DOI 10.1093/nar/18.10.2881; Chen RX, 2002, J GEN VIROL, V83, P2339, DOI 10.1099/0022-1317-83-10-2339; CONE R, 1980, J BIOL CHEM, V255, P354; Dianov GL, 2003, MUTAT RES-FUND MOL M, V531, P157, DOI 10.1016/j.mrfmmm.2003.09.003; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Gao HC, 2002, J BACTERIOL, V184, P2780, DOI 10.1128/JB.184.10.2780-2788.2002; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; INCIARTE MR, 1980, J VIROL, V34, P187, DOI 10.1128/JVI.34.1.187-199.1980; JIMENEZ F, 1977, EUR J BIOCHEM, V73, P57, DOI 10.1111/j.1432-1033.1977.tb11291.x; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Marenstein DR, 2004, DNA REPAIR, V3, P527, DOI 10.1016/j.dnarep.2004.01.010; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; MELLADO RP, 1976, EUR J BIOCHEM, V65, P213, DOI 10.1111/j.1432-1033.1976.tb10408.x; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MORENO F, 1974, VIROLOGY, V62, P1, DOI 10.1016/0042-6822(74)90298-0; Neveling U, 1998, BBA-PROTEIN STRUCT M, V1385, P367, DOI 10.1016/S0167-4838(98)00080-6; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; Parsons LM, 2005, PROTEIN SCI, V14, P1684, DOI 10.1110/ps.041275705; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Putnam CD, 1999, J MOL BIOL, V287, P331, DOI 10.1006/jmbi.1999.2605; Rojo F, 1998, PROG NUCLEIC ACID RE, V60, P29, DOI 10.1016/S0079-6603(08)60888-0; Salas M, 1999, GENET ENG P, V21, P159; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serrano-Heras G, 2003, J BIOL CHEM, V278, P40771, DOI 10.1074/jbc.M306935200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; Shida T, 1999, BIOSCI BIOTECH BIOCH, V63, P1528, DOI 10.1271/bbb.63.1528; SOGO JM, 1982, VIROLOGY, V116, P1, DOI 10.1016/0042-6822(82)90398-1; SOGO MJ, 1984, NUCLEIC ACIDS RES, V12, P1943, DOI 10.1093/nar/12.4.1943; Stein A, 2000, J BACTERIOL, V182, P2119, DOI 10.1128/JB.182.8.2119-2124.2000; STEINER M, 1993, J BACTERIOL, V175, P1038, DOI 10.1128/JB.175.4.1038-1042.1993; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; Walter T, 1999, J BIOL CHEM, V274, P7901, DOI 10.1074/jbc.274.12.7901; Wang JB, 2005, VIROLOGY, V332, P45, DOI 10.1016/j.virol.2004.10.049; WANG Z, 1989, J BIOL CHEM, V264, P1163; WARNER HR, 1980, J VIROL, V33, P535, DOI 10.1128/JVI.33.1.535-538.1980; YASBIN RE, 1980, GENE, V12, P155, DOI 10.1016/0378-1119(80)90026-8	48	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7068	7074		10.1074/jbc.M511152200	http://dx.doi.org/10.1074/jbc.M511152200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421108	Green Published, hybrid			2022-12-27	WOS:000236030900020
J	Hoffmann, A; Merz, F; Rutkowska, A; Zachmann-Brand, B; Deuerling, E; Bukau, B				Hoffmann, A; Merz, F; Rutkowska, A; Zachmann-Brand, B; Deuerling, E; Bukau, B			Trigger factor forms a protective shield for nascent polypeptides at the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED PROTEINS; ESCHERICHIA-COLI; IN-VIVO; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; DNAK; BINDING; DOMAIN; ISOMERASE; COMPLEX	In prokaryotes, the ribosome-associated Trigger Factor is the first chaperone newly synthesized polypeptides encounter when they emerge from the ribosomal exit tunnel. The effects that Trigger Factor exerts on nascent polypeptides, however, remain unclear. Here we analyzed the potential of the Trigger Factor to shield nascent polypeptides at the ribosome. A set of arrested nascent polypeptides differing in origin, size, and folding status were synthesized in an Escherichia coli-based in vitro transcription/translation system and tested for sensitivity to degradation by the unspecific protease proteinase K. In the absence of Trigger Factor, nascent polypeptides exposed outside the ribosomal exit tunnel were rapidly degraded unless they were folded into a compact domain. The presence of Trigger Factor, as well as a Trigger Factor fragment lacking its peptidyl-prolyl isomerase domain, counteracted degradation of all unfolded nascent polypeptides tested. This protective function was specific for ribosome-tethered Trigger Factor, since neither non-ribosomal Trigger Factor nor the DnaK system, which cooperates with Trigger Factor in the folding process in vivo, revealed a comparable efficiency in protection. Furthermore, shielding by Trigger Factor was not restricted to short stretches of nascent chains but was evident for large, non-native nascent polypeptides exposing up to 41 kDa outside the ribosome. We suggest that Trigger Factor supports productive de novo folding by shielding nascent polypeptides on the ribosome thereby preventing untimely degradation or aggregation processes. This protected environment provided by Trigger Factor might be particularly important for large multidomain proteins to fold productively into their native states.	Univ Heidelberg, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Deuerling, E (corresponding author), Univ Heidelberg, Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	e.deuerling@zmbh.uni-heidelberg.de; bukau@zmbh.uni-heidelberg.de		Bukau, Bernd/0000-0003-0521-7199				Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Baram D, 2005, FEBS LETT, V579, P948, DOI 10.1016/j.febslet.2004.11.063; Blanco FJ, 1999, J MOL BIOL, V285, P741, DOI 10.1006/jmbi.1998.2333; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Evans MS, 2005, NAT METHODS, V2, P757, DOI 10.1038/NMETH790; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; MULLER M, 1986, CURR TOP MICROBIOL, V125, P33; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	31	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6539	6545		10.1074/jbc.M512345200	http://dx.doi.org/10.1074/jbc.M512345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407311	Green Submitted, hybrid			2022-12-27	WOS:000236030800049
J	Zoraghi, R; Corbin, JD; Francis, SH				Zoraghi, R; Corbin, JD; Francis, SH			Phosphodiesterase-5 Gln(817) is critical for cGMP, vardenafil, or sildenafil affinity - Its orientation impacts cGMP but not cAMP affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; INHIBITOR SELECTIVITY; BINDING; SPECIFICITY; MECHANISM; COMPLEX; PDE5; PROTEIN	The side group of an invariant Gln in cGMP- and cAMP-specific phosphodiesterases (PDE) is held in different orientations by bonds with other amino acids and purportedly discriminates between guanine and adenine in cGMP and cAMP. In cGMP- specific PDE5, Gln(775) constrains the orientation of the invariant Gln(817) side chain, which forms bidentate bonds with 5'-GMP, vardenafil, sildenafil, and 3-isobutyl-1-methylxanthine ( IBMX) ( Sung, B. J., Hwang, K. Y., Jeon, Y. H., Lee, J. I., Heo, Y. S., Kim, J. H., Moon, J., Yoon, J. M., Hyun, Y. L., Kim, E., Eum, S. J., Park, S. Y., Lee, J. O., Lee, T. G., Ro, S., and Cho, J. M. ( 2003) Nature 425, 98 - 102; Huai, Q., Liu, Y., Francis, S. H., Corbin, J. D., and Ke, H. ( 2004) J. Biol. Chem. 279, 13095 - 13101; Zhang, K. Y., Card, G. L., Suzuki, Y., Artis, D. R., Fong, D., Gillette, S., Hsieh, D., Neiman, J., West, B. L., Zhang, C., Milburn, M. V., Kim, S. H., Schlessinger, J., and Bollag, G. ( 2004) Mol. Cell 15, 279 - 286). PDE5(Q817A) and PDE5(Q775A) were generated to test the hypotheses that Gln(817) is critical for cyclic nucleotide or inhibitor affinity and that Gln(775) immobilizes the Gln(817) side chain to provide cGMP/cAMP selectivity. Allosteric cGMP binding and the molecular mass of the mutant proteins were unchanged compared with PDE5(WT). For PDE5(Q817A), K-m for cGMP or cAMP was weakened 60- or 2-fold, respectively. For PDE5(Q775A), K-m for cGMP was weakened similar to 20-fold but was unchanged for cAMP. For PDE5Q817A, vardenafil, sildenafil, and IBMX inhibitory potencies were weakened 610-, 48-, and 60- fold, respectively, indicating that Gln817 is a major determinant of potency, especially for vardenafil, and that binding of vardenafil and sildenafil differs substantially. Sildenafil and vardenafil affinity were not significantly affected in PDE5Q775A. It is concluded that Gln(817) is a positive determinant for PDE5 affinity for cGMP and several inhibitors; Gln(775), which perhaps restricts rotation of Gln(817) side chain, is critical for cGMP affinity but has no measurable effect on affinity for cAMP, sildenafil, or vardenafil.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Francis, SH (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Light Hall Rm 702, Nashville, TN 37232 USA.	Sharron.francis@vanderbilt.edu			NIDDK NIH HHS [DK 58277, DK 40299] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058277, R01DK040299] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PR, 1984, J MED CHEM, V27, P1648, DOI 10.1021/jm00378a021; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Blount MA, 2004, MOL PHARMACOL, V66, P144, DOI 10.1124/mol.66.1.144; Conti M, 2004, NAT STRUCT MOL BIOL, V11, P809, DOI 10.1038/nsmb0904-809; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; Francis SH, 2003, INT J IMPOT RES, V15, P369, DOI 10.1038/sj.ijir.3901040; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Huai Q, 2004, P NATL ACAD SCI USA, V101, P9624, DOI 10.1073/pnas.0401120101; Huai Q, 2004, J BIOL CHEM, V279, P13095, DOI 10.1074/jbc.M311556200; Huai Q, 2003, BIOCHEMISTRY-US, V42, P13220, DOI 10.1021/bi034653e; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Scapin G, 2004, BIOCHEMISTRY-US, V43, P6091, DOI 10.1021/bi049868i; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Zhang KYJ, 2004, MOL CELL, V15, P279, DOI 10.1016/j.molcel.2004.07.005; ZORAGHI R, 2005, IN PRESS INT J IMPOT	26	41	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5553	5558		10.1074/jbc.M510372200	http://dx.doi.org/10.1074/jbc.M510372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407275	hybrid			2022-12-27	WOS:000235568900030
J	Clark, GF; Dell, A				Clark, Gary F.; Dell, Anne			Molecular models for murine sperm-egg binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ZONA-PELLUCIDA GLYCOPROTEINS; O-LINKED OLIGOSACCHARIDES; MOUSE SPERM; STRUCTURAL-CHARACTERIZATION; GAMETE RECOGNITION; COMBINING SITE; PROTEIN SP56; FERTILIZATION; RECEPTOR; ZP3	Murine sperm initiate fertilization by binding to the specialized extracellular matrix of mouse eggs, known as the zona pellucida. Over the past decade, powerful genetic, biophysical, and biochemical techniques have been employed to gain new insights into this interaction. Evidence from these studies does not support either of two major models for binding first proposed over two decades ago. Two more recently established models suggest that protein-protein interactions predominate during this initial stage of fertilization. Another model proposes that about 75-80% of the murine sperm bound to zona pellucida under well defined in vitro conditions is carbohydrate dependent, with the remaining sperm bound via protein-protein interactions. Mounting evidence suggests that the carbohydrate sequences coating the murine egg could be employed as specific immune recognition markers. Continued investigation of this system may resolve many of these controversial findings and reveal novel functions for murine zona pellucida glycoproteins.	Univ Missouri, Sch Med, Dept Obstet Gynecol & Womens Hlth, Div Reprod & Perinatal Res, Columbia, MO 65202 USA; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	University of Missouri System; University of Missouri Columbia; Imperial College London	Clark, GF (corresponding author), Univ Missouri, Sch Med, Dept Obstet Gynecol & Womens Hlth, Div Reprod & Perinatal Res, Columbia, MO 65202 USA.	clarkgf@health.missouri.edu; a.dell@imperial.ac.uk			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI060397] Funding Source: NIH RePORTER; NIAID NIH HHS [AI60397] Funding Source: Medline; NICHD NIH HHS [HD35652] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		BEDFORD JM, 1977, ANAT RECORD, V188, P477, DOI 10.1002/ar.1091880407; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; Boja ES, 2003, J BIOL CHEM, V278, P34189, DOI 10.1074/jbc.M304026200; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; Breed WG, 2002, REPRODUCTION, V123, P13, DOI 10.1530/rep.0.1230013; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; Clark GF, 2006, MED INTELL UNIT, P179; Clark GF, 1996, MOL HUM REPROD, V2, P513, DOI 10.1093/molehr/2.7.513; CLARK GF, 2005, SOC STUD REPR 38 ANN, P155; Cohen N, 2001, INT J DEV BIOL, V45, P569; DABROWSKI J, 1988, BIOCHEMISTRY-US, V27, P5149, DOI 10.1021/bi00414a030; Dell A, 1999, BBA-GEN SUBJECTS, V1473, P196, DOI 10.1016/S0304-4165(99)00179-8; Dell A, 2003, P NATL ACAD SCI USA, V100, P15631, DOI 10.1073/pnas.2635507100; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Easton RL, 2000, J BIOL CHEM, V275, P7731, DOI 10.1074/jbc.275.11.7731; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; Foster JA, 1997, J BIOL CHEM, V272, P12714, DOI 10.1074/jbc.272.19.12714; Hoodbhoy T, 2005, J BIOL CHEM, V280, P12721, DOI 10.1074/jbc.M413569200; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; Jungnickel MK, 2003, CELL, V114, P401, DOI 10.1016/S0092-8674(03)00648-2; Karre K, 2002, SCAND J IMMUNOL, V55, P221, DOI 10.1046/j.1365-3083.2002.01053.x; KIM YB, 1964, REV MOD PHYS, V36, P43, DOI 10.1103/RevModPhys.36.43; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; LANZENDORF SE, 1992, MOL REPROD DEV, V31, P264, DOI 10.1002/mrd.1080310407; Lefievre L, 2004, HUM REPROD, V19, P1580, DOI 10.1093/humrep/deh301; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; Liu DY, 1997, MOL HUM REPROD, V3, P1015, DOI 10.1093/molehr/3.11.1015; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; Lu QX, 1997, DEVELOPMENT, V124, P4121; Mengerink KJ, 2001, GLYCOBIOLOGY, V11, p37R, DOI 10.1093/glycob/11.4.37R; MILLER DJ, 1993, J CELL BIOL, V123, P1431, DOI 10.1083/jcb.123.6.1431; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Mori E, 1997, BIOCHEM BIOPH RES CO, V238, P95, DOI 10.1006/bbrc.1997.7249; NOGUCHI S, 1993, BIOCHIM BIOPHYS ACTA, V1158, P217, DOI 10.1016/0304-4165(93)90018-4; Ohlendieck K, 1996, CURR TOP DEV BIOL, V32, P39, DOI 10.1016/S0070-2153(08)60424-X; Ozgur K, 1998, MOL HUM REPROD, V4, P318, DOI 10.1093/molehr/4.4.318; Patankar MS, 1997, MOL HUM REPROD, V3, P501, DOI 10.1093/molehr/3.6.501; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; Rankin TL, 1998, DEVELOPMENT, V125, P2415; Rankin T, 1996, MOL HUM REPROD, V2, P889, DOI 10.1093/molehr/2.11.889; Rodeheffer C, 2004, DEVELOPMENT, V131, P503, DOI 10.1242/dev.00937; Sandow B.A., 1993, BIOL REPROD, V48, pA166; Shi SL, 2004, MOL CELL BIOL, V24, P9920, DOI 10.1128/MCB.24.22.9920-9929.2004; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Tulsiani DRP, 1997, BIOL REPROD, V57, P487, DOI 10.1095/biolreprod57.3.487; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Williams GH, 2005, J PATHOL, V207, P39; YAMAGATA T, 1983, GLYCOCONJUGATES, P623	58	63	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13853	13856		10.1074/jbc.R600001200	http://dx.doi.org/10.1074/jbc.R600001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16455664	hybrid			2022-12-27	WOS:000237512300002
J	Hemmler, R; Becker, T; Schleiff, E; Bolter, B; Stahl, T; Soll, J; Gotze, TA; Braams, S; Wagner, R				Hemmler, R; Becker, T; Schleiff, E; Bolter, B; Stahl, T; Soll, J; Gotze, TA; Braams, S; Wagner, R			Molecular properties of Oep21, an ATP-regulated anion-selective solute channel from the outer chloroplast membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT CHANNEL; ENVELOPE MEMBRANES; PEA-CHLOROPLASTS; ION CHANNELS; OEP16; PORIN; RECONSTITUTION; TRANSLOCON; PREDICTION; KINETICS	The flux of phosphorylated carbohydrates, the major export products of chloroplasts, is regulated at the level of the inner and presumably also at the level of the outer membrane. This is achieved through modulation of the outer membrane Oep21 channel currents and tuning of its ion selectivity. Refined analysis of the Oep21 channel properties by biochemical and electrophysiological methods revealed a channel formed by eight beta-strands with a wider pore vestibule of d(vest) similar to 2.4 nm at the intermembrane site and a narrower filter pore of d(restr) similar to 1 nm. The Oep21 pore contains two high affinity sites for ATP, one located at a relative transmembrane electrical distance delta = 0.56 and the second close to the vestibule at the intermembrane site. The ATP-dependent current block and reduction in anion selectivity of the Oep21 channel is relieved by the competitive binding of phosphorylated metabolic intermediates like 3-phosphoglycerate and glycerinaldehyde 3-phosphate. Deletion of a C-terminal putative FX4K binding motif in Oep21 decreased the capability of the channel to tune its ion selectivity by about 50%, whereas current block remained unchanged.	Univ Osnabruck, FB Biol Chem, D-49034 Osnabruck, Germany; LMU Munchen, Dept Biol 1, D-80638 Munich, Germany	University Osnabruck; University of Munich	Wagner, R (corresponding author), Univ Osnabruck, FB Biol Chem, Barbarastr 11, D-49034 Osnabruck, Germany.	wagner@uos.de	Becker, Thomas/AAS-9404-2020; Schleiff, Enrico/C-5105-2017; Goetze, Tom/I-1891-2013	Schleiff, Enrico/0000-0002-0518-3489; 				Bainbridge G, 1998, FEBS LETT, V431, P305, DOI 10.1016/S0014-5793(98)00761-3; Becker T, 2004, MOL BIOL CELL, V15, P5130, DOI 10.1091/mbc.E04-05-0405; Bolter B, 1999, EMBO J, V18, P5505, DOI 10.1093/emboj/18.20.5505; Bolter B, 2001, EMBO J, V20, P935, DOI 10.1093/emboj/20.5.935; Brandt S., 1999, DATENANALYSE, V4; BRUNEN M, 1993, EUR J BIOCHEM, V212, P129, DOI 10.1111/j.1432-1033.1993.tb17642.x; Chen D, 1997, BIOPHYS J, V72, P97, DOI 10.1016/S0006-3495(97)78650-8; ERTEL F, 2000, J BIOL CHEM, V280, P28258; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; HILLE B, 2001, ION CHANNELS EXCITAB, P347; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Linke D, 2004, BIOPHYS J, V86, P1479, DOI 10.1016/S0006-3495(04)74216-2; Linke D, 2000, BIOCHEMISTRY-US, V39, P11050, DOI 10.1021/bi001034m; Mathes A, 1998, J MEMBRANE BIOL, V165, P11, DOI 10.1007/s002329900416; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; Neuhaus HE, 2000, BBA-BIOMEMBRANES, V1465, P307, DOI 10.1016/S0005-2736(00)00146-2; Pohlmeyer K, 1997, P NATL ACAD SCI USA, V94, P9504, DOI 10.1073/pnas.94.17.9504; Pohlmeyer K, 1998, PLANT CELL, V10, P1207, DOI 10.1105/tpc.10.7.1207; Rohl T, 1999, FEBS LETT, V460, P491, DOI 10.1016/S0014-5793(99)01399-X; Schleiff E, 2003, PROTEIN SCI, V12, P748, DOI 10.1110/ps.0237503; Smart OS, 1997, BIOPHYS J, V72, P1109, DOI 10.1016/S0006-3495(97)78760-5; Steinkamp T, 2000, J BIOL CHEM, V275, P11758, DOI 10.1074/jbc.275.16.11758; Sveshnikova N, 2000, BIOL CHEM, V381, P687, DOI 10.1515/BC.2000.089; Vojta A, 2004, J BIOL CHEM, V279, P21401, DOI 10.1074/jbc.M401968200; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WOODBURY DJ, 1988, BIOPHYS J, V54, P1053, DOI 10.1016/S0006-3495(88)83042-X; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	30	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12020	12029		10.1074/jbc.M513586200	http://dx.doi.org/10.1074/jbc.M513586200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16473880	hybrid			2022-12-27	WOS:000236988100072
J	De Jaco, A; Comoletti, D; Kovarik, Z; Gaietta, G; Radic, Z; Lockridge, O; Ellisman, MH; Taylor, P				De Jaco, A; Comoletti, D; Kovarik, Z; Gaietta, G; Radic, Z; Lockridge, O; Ellisman, MH; Taylor, P			A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; HUMAN BUTYRYLCHOLINESTERASE; MASS-SPECTROMETRY; DISULFIDE BONDS; C-TERMINUS; BCHE GENE; NEUROLIGINS; TORPEDO; CHOLINESTERASE; EXPRESSION	A mutation linked to autistic spectrum disorders encodes an Arg to Cys replacement in the C-terminal portion of the extracellular domain of neuroligin-3. The solvent-exposed Cys causes virtually complete retention of the protein in the endoplasmic reticulum when the protein is expressed in transfected cells. An identical Cys substitution was reported for butyrylcholinesterase through genotyping patients with post-succinylcholine apnea. Neuroligin, butyrylcholinesterase, and acetylcholinesterase are members of the alpha,beta-hydrolase fold family of proteins sharing sequence similarity and common tertiary structures. Although these proteins have distinct oligomeric assemblies and cellular dispositions, homologous Arg residues in neuroligin-3 (Arg-451), in butyrylcholinesterase (Arg-386), and in acetylcholinesterase (Arg-395) are conserved in all studied mammalian species. To examine whether an homologous Arg to Cys mutation affects related proteins similarly despite their differing capacities to oligomerize, we inserted homologous mutations in the acetylcholinesterase and butyrylcholinesterase cDNAs. Using confocal fluorescence microscopy and analysis of oligosaccharide processing, we find that the homologous Arg to Cys mutation also results in endoplasmic reticulum retention of the two cholinesterases. Small quantities of mutated acetylcholinesterase exported from the cell retain activity but show a greater K-m, a much smaller k(cat), and altered substrate inhibition. The nascent proteins associate with chaperones during processing, but the mutation presumably restricts processing through the endoplasmic reticulum and Golgi apparatus, because of local protein misfolding and inability to oligomerize. The mutation may alter the capacity of these proteins to dissociate from their chaperone prior to oligomerization and processing for export.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Nebraska System; University of Nebraska Medical Center	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu		DE JACO, Antonella/0000-0002-9394-0207	NIEHS NIH HHS [P42-ES 10337] Funding Source: Medline; NIGMS NIH HHS [R37-GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blong RM, 1997, BIOCHEM J, V327, P747, DOI 10.1042/bj3270747; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Chan AOK, 2005, CLIN CHIM ACTA, V351, P155, DOI 10.1016/j.cccn.2004.09.004; Chih B, 2004, HUM MOL GENET, V13, P1471, DOI 10.1093/hmg/ddh158; Chubykin AA, 2005, J BIOL CHEM, V280, P22365, DOI 10.1074/jbc.M410723200; Comoletti D, 2003, J BIOL CHEM, V278, P50497, DOI 10.1074/jbc.M306803200; Comoletti D, 2004, J NEUROSCI, V24, P4889, DOI 10.1523/JNEUROSCI.0468-04.2004; CYGLER M, 1993, PROTEIN SCI, V2, P366; Darvesh S, 2003, NAT REV NEUROSCI, V4, P131, DOI 10.1038/nrn1035; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; DOLGINOVA EA, 1992, BIOCHEMISTRY-US, V31, P12248, DOI 10.1021/bi00163a039; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FUTERMAN AH, 1985, BIOCHEM J, V226, P369, DOI 10.1042/bj2260369; Giacobini E., 2003, BUTYRYLCHOLINESTERAS, V1st; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Haas R, 1996, BIOCHEM J, V314, P817, DOI 10.1042/bj3140817; Hoffman RC, 2004, BIOCHEMISTRY-US, V43, P1496, DOI 10.1021/bi035278t; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Jennings LL, 2003, BIOCHEMISTRY-US, V42, P11083, DOI 10.1021/bi034756x; KEREM A, 1993, J BIOL CHEM, V268, P180; LI Y, 1991, J BIOL CHEM, V266, P23083; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; Marchot P, 1996, PROTEIN SCI, V5, P672; Massoulie J, 1998, J PHYSIOLOGY-PARIS, V92, P183, DOI 10.1016/S0928-4257(98)80007-7; MASSOULIE J, 2000, CHOLINESTERASES CHOL, P81; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Nicolet Y, 2003, J BIOL CHEM, V278, P41141, DOI 10.1074/jbc.M210241200; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Scholl FG, 2003, TRENDS NEUROSCI, V26, P618, DOI 10.1016/j.tins.2003.09.004; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Silman I, 2005, CURR OPIN PHARMACOL, V5, P293, DOI 10.1016/j.coph.2005.01.014; SILMAN I, 1987, EUR J BIOCHEM, V170, P11, DOI 10.1111/j.1432-1033.1987.tb13662.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Souza RLR, 2005, MOL GENET METAB, V84, P349, DOI 10.1016/j.ymgme.2004.12.005; TAYLOR P, 2000, CHOLINESTERASES CHOL, P63; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsigelny I, 2000, PROTEIN SCI, V9, P180; Varoqueaux F, 2004, EUR J CELL BIOL, V83, P449, DOI 10.1078/0171-9335-00410; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Yan J, 2005, MOL PSYCHIATR, V10, P329, DOI 10.1038/sj.mp.4001629; Yen T, 2003, CLIN CHEM, V49, P1297, DOI 10.1373/49.8.1297	53	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9667	9676		10.1074/jbc.M510262200	http://dx.doi.org/10.1074/jbc.M510262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16434405	hybrid			2022-12-27	WOS:000236404700079
J	Monaghan-Benson, E; McKeown-Longo, PJ				Monaghan-Benson, E; McKeown-Longo, PJ			Urokinase-type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; FACTOR EGF RECEPTOR; INTEGRIN ACTIVATION; PLASMA FIBRONECTIN; CELL-MIGRATION; ADHESION; KINASE; PROTEIN; SIGNAL; POLYMERIZATION	Previous studies have indicated that the urokinase-type plasminogen activator receptor ( uPAR) can functionally interact with integrins thereby modulating integrin activity. We have previously demonstrated that treatment of fibroblasts with the uPAR ligand, P25, results in an increase in the activation of the beta 1 integrin and a 35-fold increase in fibronectin matrix assembly ( Monaghan, E., Gueorguiev, V., Wilkins-Port, C., and McKeown-Longo, P. J. ( 2004) J. Biol. Chem. 279, 1400 - 1407). Experiments were conducted to address the mechanism of uPAR regulation of matrix assembly. Treatment of fibroblasts with P25 led to an increase in the activation of the epidermal growth factor receptor ( EGFR) and a colocalization of activated EGFR with beta 1 integrins in cell matrix contacts. The effects of P25 on matrix assembly and beta 1 integrin activation were inhibited by pretreatment with EGFR or Src kinase inhibitors, suggesting a role for both Src and EGFR in integrin activation by uPAR. Phosphorylation of EGFR in response to P25 occurred on Tyr-845, an Src-dependent phosphorylation site and was inhibited by PP2, the Src kinase inhibitor, consistent with Src kinase lying upstream of EGFR and integrin activation. Cells null for Src kinases also showed a loss of P25-induced matrix assembly, integrin activation, and EGFR phosphorylation. These P25-induced effects were restored following Src re-expression. The effects of P25 were specific for uPAR as enhanced matrix assembly by P25 was not seen in uPAR -/- cells, but was restored upon uPAR re-expression. These data provide evidence for a novel pathway of fibronectin matrix assembly through the uPAR-dependent sequential activation of Src kinase, EGFR, and beta 1 integrin.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	McKeown-Longo, PJ (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	mckeowp@mail.amc.edu			NCI NIH HHS [CA-58626] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058626, R56CA058626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Bu XY, 2004, LAB INVEST, V84, P667, DOI 10.1038/labinvest.3700089; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940; Christopher RA, 1999, J CELL SCI, V112, P3225; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Darribere T, 2000, BIOL CELL, V92, P5, DOI 10.1016/S0248-4900(00)88760-2; DENO DC, 1983, AM J PHYSIOL, V245, pR564, DOI 10.1152/ajpregu.1983.245.4.R564; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Guerrero J, 2004, EXP CELL RES, V292, P201, DOI 10.1016/j.yexcr.2003.08.011; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; Hocking DC, 2003, AM J PHYSIOL-LUNG C, V285, pL169, DOI 10.1152/ajplung.00371.2002; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Humphries MJ, 2004, BIOCHEM SOC T, V32, P407, DOI 10.1042/BST0320407; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; Monaghan E, 2004, J BIOL CHEM, V279, P1400, DOI 10.1074/jbc.M310374200; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; OWENS MR, 1982, BLOOD, V59, P1305; Peyruchaud O, 2000, CELL MOL LIFE SCI, V57, P1109; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; Rabbani SA, 2002, CANCER RES, V62, P2390; Rebres RA, 1995, AM J PHYSIOL-GASTR L, V269, pG902, DOI 10.1152/ajpgi.1995.269.6.G902; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sottile J, 1998, J CELL SCI, V111, P2933; Sottile J, 2005, MOL BIOL CELL, V16, P757, DOI 10.1091/mbc.e04-08-0672; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Takagi J, 2001, P NATL ACAD SCI USA, V98, P11175, DOI 10.1073/pnas.201420198; THOMPSON C, 1989, J CLIN INVEST, V84, P1226, DOI 10.1172/JCI114289; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Wanaski SP, 2003, BIOCHEMISTRY-US, V42, P42, DOI 10.1021/bi012097n; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wickstrom SA, 2002, CANCER RES, V62, P5580; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; WU C, 1995, J BIOL CHEM, V266, P9697; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065	68	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9450	9459		10.1074/jbc.M501901200	http://dx.doi.org/10.1074/jbc.M501901200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461772	hybrid			2022-12-27	WOS:000236404700055
J	Schonrock, N; Exner, V; Probst, A; Gruissem, W; Hennig, L				Schonrock, N; Exner, V; Probst, A; Gruissem, W; Hennig, L			Functional genomic analysis of CAF-1 mutants in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN ASSEMBLY FACTOR-1; H3 LYSINE-9 METHYLATION; DNA METHYLATION; FACTOR-I; SEED DEVELOPMENT; P150 SUBUNIT; PROTEIN; HETEROCHROMATIN; MAINTENANCE; CELLS	Duplication of chromatin following DNA replication requires spatial reorganization of chromatin domains assisted by chromatin assembly factor CAF-1. Here, we tested the genomic consequences of CAF-1 loss and the function of chromatin assembly factor CAF-1 in heterochromatin formation. Genes located in heterochromatic regions are usually silent, and we found that this transcriptional repression persists in the absence of CAF-1 in Arabidopsis. However, using microarrays we observed that genes that are active during late S-phase, when heterochromatin is duplicated, were up-regulated in CAF-1 mutants. Arabidopsis CAF-1 mutants also have reduced cytological heterochromatin content; however, DNA methylation of pericentromeric repeats was normal, demonstrating that CAF-1 is not required for maintenance of DNA methylation. Instead, hypomethylation of the genome, which has only mild effects on the development of wild-type plants, completely arrested development of CAF-1 mutants. These results suggest that CAF-1 functions in heterochromatin formation. CAF-1 and DNA methylation, which is also needed for heterochromatin formation, have partially redundant functions that are essential for cell proliferation. Interestingly, transcriptional repression and heterochromatin compaction can be genetically separated, and CAF-1 is required only for the complete compaction of heterochromatin but not to maintain transcriptional repression of heterochromatic genes.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Zurich Basel Plant Sci Ctr, CH-8092 Zurich, Switzerland; Univ Geneva, Dept Plant Biol, CH-1211 Geneva 4, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Geneva	Hennig, L (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland.	lhennig@ipw.biol.ethz.ch	Gruissem, Wilhelm/H-1752-2013; , Probst/F-2267-2015; Hennig, Lars/G-2081-2011	, Probst/0000-0001-9534-8058; Hennig, Lars/0000-0002-6645-1862; Gruissem, Wilhelm/0000-0002-1872-2998				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; ALTMANN T, 2004, GENOMXPRESS, V3, P13; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Chang S, 2005, J BIOL CHEM, V280, P796, DOI 10.1074/jbc.M409053200; Colon-Carmona A, 1999, PLANT J, V20, P503, DOI 10.1046/j.1365-313x.1999.00620.x; Donnelly PM, 1999, DEV BIOL, V215, P407, DOI 10.1006/dbio.1999.9443; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Fransz P, 2003, CHROMOSOME RES, V11, P227, DOI 10.1023/A:1022835825899; Game JC, 1999, GENETICS, V151, P485; Grandin N, 2003, MOL CELL BIOL, V23, P9162, DOI 10.1128/MCB.23.24.9162-9177.2003; Hennig L, 2003, DEVELOPMENT, V130, P2555, DOI 10.1242/dev.00470; Hennig L, 2004, PLANT PHYSIOL, V135, P1765, DOI 10.1104/pp.104.043182; Hennig L, 2005, TRENDS CELL BIOL, V15, P295, DOI 10.1016/j.tcb.2005.04.004; Hirochika H, 2000, PLANT CELL, V12, P357, DOI 10.1105/tpc.12.3.357; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jasencakova Z, 2003, PLANT J, V33, P471, DOI 10.1046/j.1365-313X.2003.01638.x; Jiao RJ, 2004, MOL CELL BIOL, V24, P4710, DOI 10.1128/MCB.24.11.4710-4719.2004; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kaya H, 2001, CELL, V104, P131, DOI 10.1016/S0092-8674(01)00197-0; Keller C, 2000, J BIOL CHEM, V275, P35512, DOI 10.1074/jbc.M003073200; Kohler C, 2003, EMBO J, V22, P4804, DOI 10.1093/emboj/cdg444; Kohler C, 2003, GENE DEV, V17, P1540, DOI 10.1101/gad.257403; LEYSER HMO, 1992, DEVELOPMENT, V116, P397; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Menges M, 2003, PLANT MOL BIOL, V53, P423, DOI 10.1023/B:PLAN.0000019059.56489.ca; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Myung K, 2003, P NATL ACAD SCI USA, V100, P6640, DOI 10.1073/pnas.1232239100; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Probst AV, 2003, PLANT J, V33, P743, DOI 10.1046/j.1365-313X.2003.01667.x; Quivy JP, 2004, EMBO J, V23, P3516, DOI 10.1038/sj.emboj.7600362; Rasmussen LJ, 2000, EXP CELL RES, V257, P127, DOI 10.1006/excr.2000.4865; Reese BE, 2003, MOL CELL BIOL, V23, P3226, DOI 10.1128/MCB.23.9.3226-3236.2003; Reinholz E, 1966, ARAB INF SERV, V3, P19; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Takeda S, 2004, GENE DEV, V18, P782, DOI 10.1101/gad.295404; Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100; Tchenio T, 2001, MOL CELL BIOL, V21, P1953, DOI 10.1128/MCB.21.6.1953-1961.2001; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; WU Z, 2003, TECHNICAL REPORT MOD; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	62	101	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9560	9568		10.1074/jbc.M513426200	http://dx.doi.org/10.1074/jbc.M513426200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452472	hybrid			2022-12-27	WOS:000236404700067
J	Sharon, M; Witt, S; Felderer, K; Rockel, B; Baumeister, W; Robinson, CV				Sharon, M; Witt, S; Felderer, K; Rockel, B; Baumeister, W; Robinson, CV			20S proteasomes have the potential to keep substrates in store for continual degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; THERMOPLASMA-ACIDOPHILUM; PROTEIN-DEGRADATION; ATP HYDROLYSIS; S PROTEASOMES; COMPLEX; DISSOCIATION; STOICHIOMETRY; ARRANGEMENT; ASSEMBLIES	The 20S core of the proteasome, which together with the regulatory particle plays a major role in the degradation of proteins in eukaryotic cells, is traversed by an internal system of cavities, namely two antechambers and one central proteolytic chamber. Little is known about the mechanisms underlying substrate binding and translocation of polypeptide chains into the interior of 20S proteasomes. Specifically, the role of the antechambers is not fully understood, and the number of substrate molecules sequestered within the internal cavities at any one time is unknown. Here we have shown that by applying both electron microscopy and tandem mass spectrometry ( MS) approaches to this multisubunit complex we obtain precise information regarding the stoichiometry and location of substrates within the three chambers. The dissociation pattern in tandem MS allows us to conclude that a maximum of three green fluorescent protein and four cytochrome c substrate molecules are bound within the cavities. Our results also show that > 95% of the population of proteasome molecules contain the maximum number of partially folded substrates. Moreover, we deduce that one green fluorescent protein or two cytochrome c molecules must reside within the central proteolytic chamber while the remaining substrate molecules occupy, singly, both antechambers. The results imply therefore an additional role for 20S proteasomes in the storage of substrates prior to their degradation, specifically in cases where translocation rates are slower than proteolysis. More generally, the ability to locate relatively small protein ligands sequestered within the 28-subunit core particle highlights the tremendous potential of tandem MS for deciphering substrate binding within large macromolecular assemblies.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Dept Mol Struct Biol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Cambridge; Max Planck Society	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk		robinson, carol/0000-0001-7829-5505; Sharon, Michal/0000-0003-3933-0595				Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; Chernushevich IV, 2004, ANAL CHEM, V76, P1754, DOI 10.1021/ac035406j; Dolenc I, 1998, FEBS LETT, V434, P357, DOI 10.1016/S0014-5793(98)01010-2; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huffman HA, 2003, BIOCHEMISTRY-US, V42, P8679, DOI 10.1021/bi027310+; Hutschenreiter S, 2004, EMBO J, V23, P2488, DOI 10.1038/sj.emboj.7600262; Jurchen JC, 2003, J AM CHEM SOC, V125, P2817, DOI 10.1021/ja0211508; Kaltashov IA, 2005, ANAL CHEM, V77, P5370, DOI 10.1021/ac050511+; Kisselev AF, 2003, J BIOL CHEM, V278, P35869, DOI 10.1074/jbc.M303725200; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Loo JA, 2005, J AM SOC MASS SPECTR, V16, P998, DOI 10.1016/j.jasms.2005.02.017; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Luciani F, 2005, BIOPHYS J, V88, P2422, DOI 10.1529/biophysj.104.049221; McCammon MG, 2004, J AM CHEM SOC, V126, P5950, DOI 10.1021/ja0317170; Nettleton EJ, 2000, BIOPHYS J, V79, P1053, DOI 10.1016/S0006-3495(00)76359-4; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Osmulski PA, 2002, BIOCHEMISTRY-US, V41, P7047, DOI 10.1021/bi0159130; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; Reuter CJ, 2004, J BACTERIOL, V186, P7763, DOI 10.1128/JB.186.22.7763-7772.2004; Rostom AA, 2000, P NATL ACAD SCI USA, V97, P5185, DOI 10.1073/pnas.97.10.5185; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SMITH RD, 1992, ORG MASS SPECTROM, V27, P811, DOI 10.1002/oms.1210270709; Sobott F, 2003, INT J MASS SPECTROM, V230, P193, DOI 10.1016/j.ijms.2003.09.008; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Versluis C, 2001, J AM SOC MASS SPECTR, V12, P329, DOI 10.1016/S1044-0305(00)00227-0; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Zwickl P, 1999, PHILOS T R SOC B, V354, P1501, DOI 10.1098/rstb.1999.0494; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7	41	57	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9569	9575		10.1074/jbc.M511951200	http://dx.doi.org/10.1074/jbc.M511951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16446364	hybrid			2022-12-27	WOS:000236404700068
J	Horwitz, AA; Sankaran, S; Parvin, JD				Horwitz, AA; Sankaran, S; Parvin, JD			Direct stimulation of transcription initiation by BRCA1 requires both its amino and carboxyl termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; IN-VITRO; SACCHAROMYCES-CEREVISIAE; ACTIVATED TRANSCRIPTION; BASAL FACTORS; TBP BINDING; PROMOTER; MOT1; HOLOENZYME	Published experiments suggest that BRCA1 interaction with RNAPII and regulation of a number of target genes may be central to its role as a tumor suppressor. Previous in vivo and in vitro work has implicated the carboxyl terminus of BRCA1 in transcriptional stimulation, but the mechanism of action remains unknown, and whether the full- length protein stimulates transcription is controversial. BRCA1 interacts with a number of enhancer- binding transcriptional activators, suggesting that these factors recruit BRCA1 to promoters, where it stimulates RNA synthesis. To investigate whether BRCA1 has intrinsic transcriptional activity, we established a fully purified transcription assay. We demonstrate here that BRCA1 stimulates transcription initiation across a range of promoters. Both the amino and carboxyl termini of BRCA1 are required for this activity, but the BRCA1- binding partner, BARD1, is not. Our data support a model whereby BRCA1 stabilizes productive preinitiation complexes and thus stimulates transcription.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER; NCI NIH HHS [CA90281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba N, 2002, CANCER RES, V62, P4222; Collart MA, 1996, MOL CELL BIOL, V16, P6668; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Krum SA, 2003, ONCOGENE, V22, P6032, DOI 10.1038/sj.onc.1206515; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; Mondal N, 2005, CANCER BIOL THER, V4, P414; Mondal N, 2003, NUCLEIC ACIDS RES, V31, P5016, DOI 10.1093/nar/gkg705; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Muldrow TA, 1999, MOL CELL BIOL, V19, P2835; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	31	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8317	8320		10.1074/jbc.C500475200	http://dx.doi.org/10.1074/jbc.C500475200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16473884	hybrid			2022-12-27	WOS:000236247100004
J	Lavieu, G; Scarlatti, F; Sala, G; Carpentier, S; Levade, T; Ghidoni, R; Botti, J; Codogno, P				Lavieu, G; Scarlatti, F; Sala, G; Carpentier, S; Levade, T; Ghidoni, R; Botti, J; Codogno, P			Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATING ENZYME; ISOLATED RAT HEPATOCYTES; TUMOR-SUPPRESSOR; DAP KINASE; SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID METABOLISM; PHOSPHATIDIC-ACID; UP-REGULATION; DEATH; APOPTOSIS	The sphingolipid ceramide induces macroautophagy ( here called autophagy) and cell death with autophagic features in cancer cells. Here we show that overexpression of sphingosine kinase 1 ( SK1), an enzyme responsible for the production of sphingosine 1- phosphate ( S1P), in MCF- 7 cells stimulates autophagy by increasing the formation of LC3- positive autophagosomes and the rate of proteolysis sensitive to the autophagy inhibitor 3- methyladenine. Autophagy was blocked in the presence of dimethylsphingosine, an inhibitor of SK activity, and in cells expressing a catalytically inactive form of SK1. In SK1(wt)- overexpressing cells, however, autophagy was not sensitive to fumonisin B1, an inhibitor of ceramide synthase. In contrast to ceramide- induced autophagy, SK1( S1P)- induced autophagy is characterized by ( i) the inhibition of mammalian target of rapamycin signaling independently of the Akt/ protein kinase B signaling arm and ( ii) the lack of robust accumulation of the autophagy protein Beclin 1. In addition, nutrient starvation induced both the stimulation of autophagy and SK activity. Knocking down the expression of the autophagy protein Atg7 or that of SK1 by siRNA abolished starvation- induced autophagy and increased cell death with apoptotic hallmarks. In conclusion, these results show that SK1( S1P)- induced autophagy protects cells from death with apoptotic features during nutrient starvation.	Inst Andre Lwoff, INSERM, U504, F-94807 Villejuif, France; Univ Paris Sud, Fac Pharm, INSERM, U756, F-92296 Chatenay Malabry, France; San Paolo Med Sch, Biochem & Mol Biol Lab, I-20142 Milan, Italy; CHU Rangueil, Inst Louis Bugnard, INSERM, U466, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Codogno, P (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U756, F-92296 Chatenay Malabry, France.	codogno@vjf.inserm.fr	Codogno, Patrice/G-1384-2013; Levade, Thierry/O-8948-2014	Codogno, Patrice/0000-0002-5492-3180; GHIDONI, RICCARDO/0000-0002-6300-5867; lavieu, gregory/0000-0001-9852-4977				Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445; AMES BN, 1960, J BIOL CHEM, V235, P769; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gijsbers S, 2001, BBA-MOL CELL BIOL L, V1532, P37, DOI 10.1016/S1388-1981(01)00111-1; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Golstein P, 2005, CELL DEATH DIFFER, V12, P1490, DOI 10.1038/sj.cdd.4401607; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lanterman MM, 1998, BIOCHEM J, V332, P525, DOI 10.1042/bj3320525; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Levade T, 2002, NEUROCHEM RES, V27, P601, DOI 10.1023/A:1020215815013; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Martinet W, 2002, ARTERIOSCL THROM VAS, V22, P2023, DOI 10.1161/01.ATV.0000041843.44312.12; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2004, METHOD ENZYMOL, V390, P17; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shohat G, 2002, EUR CYTOKINE NETW, V13, P398; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Tiesong SS, 2005, J BIOL CHEM, V280, P34644, DOI 10.1074/jbc.M506466200; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Vessey DA, 2005, ANAL BIOCHEM, V337, P136, DOI 10.1016/j.ab.2004.10.032; Yamamoto M, 2002, EUR J BIOCHEM, V269, P139, DOI 10.1046/j.0014-2956.2002.00029.x; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	79	211	217	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8518	8527		10.1074/jbc.M506182200	http://dx.doi.org/10.1074/jbc.M506182200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16415355	hybrid			2022-12-27	WOS:000236247100027
J	Yan, N; Huh, JR; Schirf, V; Demeler, B; Hay, BA; Shi, YG				Yan, N; Huh, JR; Schirf, V; Demeler, B; Hay, BA; Shi, YG			Structure and activation mechanism of the Drosophila initiator caspase Dronc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MOLECULAR-MECHANISMS; APAF-1; DIAP1; INHIBITION; HOMOLOG; HID; PATHWAYS; INSIGHTS; MODEL	Activation of an initiator caspase is essential to the execution of apoptosis. The molecular mechanisms by which initiator caspases are activated remain poorly understood. Here we demonstrate that the autocatalytic cleavage of Dronc, an important initiator caspase in Drosophila, results in a drastic enhancement of its catalytic activity in vitro. The autocleaved Dronc forms a homodimer, whereas the uncleaved Dronc zymogen exists exclusively as a monomer. Thus the autocatalytic cleavage in Dronc induces its stable dimerization, which presumably allows the two adjacent monomers to mutually stabilize their active sites, leading to activation. Crystal structure of a prodomain-deleted Dronc zymogen, determined at 2.5 angstrom resolution, reveals an unproductive conformation at the active site, which is consistent with the observation that the zymogen remains catalytically inactive. This study revealed insights into mechanism of Dronc activation, and in conjunction with other observations, suggests diverse mechanisms for the activation of initiator caspases.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Princeton University; California Institute of Technology; University of Texas System; University of Texas Health San Antonio	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Washington Rd, Princeton, NJ 08544 USA.	ygshi@princeton.edu		Demeler, Borries/0000-0002-2414-9518; Shi, Yigong/0000-0003-2030-168X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chao Y, 2005, PLOS BIOL, V3, P1079, DOI 10.1371/journal.pbio.0030183; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Muro I, 2004, J CELL SCI, V117, P5035, DOI 10.1242/jcs.01376; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang XD, 2001, GENE DEV, V15, P2922; Yan N, 2004, NAT STRUCT MOL BIOL, V11, P420, DOI 10.1038/nsmb764; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Yu XC, 2006, J MOL BIOL, V355, P577, DOI 10.1016/j.jmb.2005.10.040; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8	36	41	41	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8667	8674		10.1074/jbc.M513232200	http://dx.doi.org/10.1074/jbc.M513232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446367	hybrid, Green Accepted			2022-12-27	WOS:000236247100044
J	Bisbis, B; Delmas, F; Joubes, J; Sicard, A; Hernould, M; Inze, D; Mouras, A; Chevalier, C				Bisbis, B; Delmas, F; Joubes, J; Sicard, A; Hernould, M; Inze, D; Mouras, A; Chevalier, C			Cyclin-dependent kinase (CDK) inhibitors regulate the CDK-cyclin complex activities in endoreduplicating cells of developing tomato fruit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA-RELATED PROTEIN; MOLECULAR CHARACTERIZATION; REDUCES ENDOREDUPLICATION; IN-VIVO; ARABIDOPSIS; SIZE; MAIZE; ICK1; DIFFERENTIATION; EXPRESSION	The jelly-like locular ( gel) tissue of tomato fruit is made up of large thin-walled and highly vacuolized cells. The development of the gel tissue is characterized by the arrest of mitotic activities, the inhibition of cyclin-dependent kinase A ( CDKA) activity, and numerous rounds of nuclear DNA endoreduplication. To decipher the molecular determinants controlling these developmental events, we investigated the putative involvement of CDK inhibitors (p27(Kip)-related proteins, or KRPs) during the endoreduplication process. Two cDNAs, LeKRP1 and LeKRP2, encoding tomato CDK inhibitors were isolated. The LeKRP1 and LeKRP2 transcript expression was shown to be enhanced in the differentiating cells of the gel undergoing endoreduplication. At the translational level, LeKRP1 was shown to accumulate in the gel tissue and to participate in the inhibition of the CDK-cyclin kinase activities occurring in endoreduplicating cells of the gel tissue. We here propose that LeKRP1 participates in the control of both the cell cycle and the endoreduplication cycle.	Univ Bordeaux 1, Inst Natl Rech Agron, Inst Biol Vegetale Mol, Unite Mixte Rech Physiol & Biotechnol Vegetales 6, F-33883 Villenave Dornon, France; Univ Bordeaux 2, F-33883 Villenave Dornon, France; State Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	INRAE; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Flanders Institute for Biotechnology (VIB); Ghent University	Chevalier, C (corresponding author), Univ Bordeaux 1, Inst Natl Rech Agron, Inst Biol Vegetale Mol, Unite Mixte Rech Physiol & Biotechnol Vegetales 6, F-33883 Villenave Dornon, France.	chevalie@bordeaux.inra.fr	Sicard, Adrien/E-6246-2013; Hernould, Michel/AAD-5355-2019; Inzé, Dirk/AAW-6381-2021; Chevalier, Christian/AAL-4578-2020; Delmas, Frederic/C-3685-2011	Inzé, Dirk/0000-0002-3217-8407; Joubes, Jerome/0000-0001-5385-450X; Delmas, Frederic/0000-0002-2599-6778; Sicard, Adrien/0000-0002-4104-6844; Hernould, Michel/0000-0003-0676-6173				AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; Boniotti MB, 2001, PLANT J, V28, P341, DOI 10.1046/j.1365-313X.2001.01160.x; Boudolf V, 2004, PLANT CELL, V16, P2683, DOI 10.1105/tpc.104.024398; Cebolla A, 1999, EMBO J, V18, P4476, DOI 10.1093/emboj/18.16.4476; De Veylder L, 2002, EMBO J, V21, P1360, DOI 10.1093/emboj/21.6.1360; De Veylder L, 2001, PLANT CELL, V13, P1653, DOI 10.2307/3871392; Dewitte W, 2003, ANNU REV PLANT BIOL, V54, P235, DOI 10.1146/annurev.arplant.54.031902.134836; GILLASPY G, 1993, PLANT CELL, V5, P1439, DOI 10.1105/tpc.5.10.1439; Gonzalez N, 2004, PLANT MOL BIOL, V56, P849, DOI 10.1007/s11103-004-5110-2; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; Grafi G, 1998, EXP CELL RES, V244, P372, DOI 10.1006/excr.1998.4213; Gutierrez C, 2002, CURR OPIN PLANT BIOL, V5, P480, DOI 10.1016/S1369-5266(02)00301-1; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Healy JMS, 2001, J BIOL CHEM, V276, P7041, DOI 10.1074/jbc.M009074200; Himanen K, 2002, PLANT CELL, V14, P2339, DOI 10.1105/tpc.004960; Jasinski S, 2002, PLANT PHYSIOL, V130, P1871, DOI 10.1104/pp.008573; Jasinski S, 2002, J CELL SCI, V115, P973; Joubes J, 2000, PLANT MOL BIOL, V43, P735, DOI 10.1023/A:1006446417196; Joubes J, 2000, PLANTA, V211, P430, DOI 10.1007/s004250000306; Joubes J, 2001, PLANT PHYSIOL, V126, P1403, DOI 10.1104/pp.126.4.1403; Joubes J, 1999, PLANT PHYSIOL, V121, P857, DOI 10.1104/pp.121.3.857; Kondorosi E, 2000, CURR OPIN PLANT BIOL, V3, P488, DOI 10.1016/S1369-5266(00)00118-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leiva-Neto JT, 2004, PLANT CELL, V16, P1854, DOI 10.1105/tpc.022178; Lui H, 2000, PLANT J, V21, P379, DOI 10.1046/j.1365-313x.2000.00688.x; MAGYAR Z, 1993, PLANT J, V4, P151, DOI 10.1046/j.1365-313X.1993.04010151.x; Martin-Castellanos C, 1996, Prog Cell Cycle Res, V2, P29; Meijer M, 2000, PLANT MOL BIOL, V43, P621, DOI 10.1023/A:1006482115915; MELARAGNO JE, 1993, PLANT CELL, V5, P1661, DOI 10.1105/tpc.5.11.1661; Menges M, 2002, PLANT J, V30, P203, DOI 10.1046/j.1365-313X.2002.01274.x; Nakagami H, 1999, PLANT J, V18, P243, DOI 10.1046/j.1365-313X.1999.00449.x; Nakagami H, 2002, PLANT CELL, V14, P1847, DOI 10.1105/tpc.002550; Park JA, 2005, PLANT J, V42, P153, DOI 10.1111/j.1365-313X.2005.02361.x; Schnittger A, 2003, PLANT CELL, V15, P303, DOI 10.1105/tpc.008342; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P4180, DOI 10.1073/pnas.96.7.4180; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; Verkest A, 2005, PLANT CELL, V17, P1723, DOI 10.1105/tpc.105.032383; Vilhar B, 2002, PLANT PHYSIOL, V129, P23, DOI 10.1104/pp.001826; Vinardell JM, 2003, PLANT CELL, V15, P2093, DOI 10.1105/tpc.014373; Wang H, 1998, PLANT J, V15, P501, DOI 10.1046/j.1365-313X.1998.00231.x; Wang H, 1997, NATURE, V386, P451, DOI 10.1038/386451a0; Weinl C, 2005, PLANT CELL, V17, P1704, DOI 10.1105/tpc.104.030486; Zhou YM, 2003, PLANT J, V35, P476, DOI 10.1046/j.1365-313X.2003.01821.x; Zhou YM, 2003, PLANTA, V216, P604, DOI 10.1007/s00425-002-0935-x	45	52	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7374	7383		10.1074/jbc.M506587200	http://dx.doi.org/10.1074/jbc.M506587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407228	hybrid, Green Published			2022-12-27	WOS:000236030900057
J	Khersonsky, O; Tawfik, DS				Khersonsky, O; Tawfik, DS			The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PON1; RESIDUES; MUTAGENESIS; STABILITY; EVOLUTION	Serum paraoxonases (PONs) are calcium-dependent lactonases that catalyze the hydrolysis and formation of a variety of lactones, with a clear preference for lipophilic lactones. However, the lactonase mechanism of mammalian PON1, a high density lipoprotein-associated enzyme that is the most studied family member, remains unclear, and other family members have not been examined at all. We present a kinetic and site-directed mutagenesis study aimed at deciphering the lactonase mechanism of PON1 and PON3. The pH-rate profile determined for the lactonase activity of PON1 indicated an apparent pK(a) of similar to 7.4. We thus explored the role of all amino acids in the PON1 active site that are not directly ligated to the catalytic calcium and that possess an imidazolyl or carboxyl side chain (His(115), His(134), His(184), His(285), Asp(183), and Asp(269)). Extensive site-directed mutagenesis studies in which each amino acid candidate was replaced with all other 19 amino acids were conducted to identify the residue(s) that mediate the lactonase activity of PONs. The results indicate that the lactonase activity of PON1 and PON3 and the esterase activity of PON1 are mediated by the His(115)-His(134) dyad. Notably, the phosphotriesterase activity of PON1, which is a promiscuous activity of this enzyme, is mediated by other residues. To our knowledge, this is one of few examples of a histidine dyad in enzyme active sites and the first example of a hydrolytic enzyme with such a dyad.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tawfik, DS (corresponding author), Weizmann Inst Sci, Dept Biol Chem, Ullman Bldg, IL-76100 Rehovot, Israel.	tawfik@weizmann.ac.il						Adams TB, 1998, FOOD CHEM TOXICOL, V36, P249, DOI 10.1016/S0278-6915(97)00163-4; Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; Copeland R. A., 2004, ENZYMES PRACTICAL IN; Draganov DI, 2005, J LIPID RES, V46, P1239, DOI 10.1194/jlr.M400511-JLR200; Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1; Edwards SH, 2002, BIOCHEMISTRY-US, V41, P15468, DOI 10.1021/bi020485z; FERSHT A, 1999, STRUCTURE MECH PROTE, P423; Gaidukov L, 2005, BIOCHEMISTRY-US, V44, P11843, DOI 10.1021/bi050862i; Gutteridge A, 2005, TRENDS BIOCHEM SCI, V30, P622, DOI 10.1016/j.tibs.2005.09.006; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P1253, DOI 10.1038/nsmb1204-1253a; Hartleib J, 2001, BBA-PROTEIN STRUCT M, V1546, P312, DOI 10.1016/S0167-4838(01)00153-4; Josse D, 1999, BIOCHEMISTRY-US, V38, P2816, DOI 10.1021/bi982281h; JOSSE D, 2001, J APPL TOXICOL S1, V21, P7, DOI DOI 10.1002/JAT.789; Khersonsky O, 2006, CHEMBIOCHEM, V7, P49, DOI 10.1002/cbic.200500334; Khersonsky O, 2005, BIOCHEMISTRY-US, V44, P6371, DOI 10.1021/bi047440d; Kuo CL, 1998, DRUG METAB DISPOS, V26, P653; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P379, DOI 10.1016/S0009-2797(99)00049-6; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Peracchi A, 2001, TRENDS BIOCHEM SCI, V26, P497, DOI 10.1016/S0968-0004(01)01911-9; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; Rosenblat M, 2006, J BIOL CHEM, V281, P7657, DOI 10.1074/jbc.M512595200; Scharff EI, 2001, STRUCTURE, V9, P493, DOI 10.1016/S0969-2126(01)00610-4; Sekar K, 1997, BIOCHEMISTRY-US, V36, P3104, DOI 10.1021/bi961576x; Teiber JF, 2003, BIOCHEM PHARMACOL, V66, P887, DOI 10.1016/S0006-2952(03)00401-5; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Yeung DT, 2005, FEBS J, V272, P2225, DOI 10.1111/j.1742-4658.2005.04646.x; Yeung DT, 2004, BBA-PROTEINS PROTEOM, V1702, P67, DOI 10.1016/j.bbapap.2004.08.002	31	137	141	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7649	7656		10.1074/jbc.M512594200	http://dx.doi.org/10.1074/jbc.M512594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407305	hybrid			2022-12-27	WOS:000236030900086
J	Mendiratta, G; Eriksson, PR; Shen, CH; Clark, DJ				Mendiratta, G; Eriksson, PR; Shen, CH; Clark, DJ			The DNA-binding domain of the yeast Spt10p activator includes a zinc finger that is homologous to foamy virus integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; CHROMATIN-STRUCTURE; SPT21 GENES; PROTEIN; ACETYLATION; MUTATIONS; IDENTIFICATION; RECOGNITION; HISTONE-H3	The yeast SPT10 gene encodes a putative histone acetyltransferase that binds specifically to pairs of upstream activating sequence (UAS) elements found only in the histone gene promoters. Here, we demonstrate that the DNA-binding domain of Spt10p is located between residues 283 and 396 and includes a His(2)-Cys(2) zinc finger. The binding of Spt10p to the histone UAS is zinc-dependent and is disabled by a zinc finger mutation (C388S). The isolated DNA-binding domain binds to single histone UAS elements with high affinity. In contrast, full-length Spt10p binds with high affinity only to pairs of UAS elements with very strong positive cooperativity and is unable to bind to a single UAS element. This implies the presence of a "blocking" domain in full-length Spt10p, which forces it to search for a pair of UAS elements. Chromatin immunoprecipitation experiments indicate that, unlike wild-type Spt10p, the C388S protein does not bind to the promoter of the gene encoding histone H2A (HTA1) in vivo. The C388S mutant has a phenotype similar to that of the spt10 Delta mutant: poor growth and global aberrations in gene expression. Thus, the C388S mutation disables the DNA-binding function of Spt10p in vitro and in vivo. The zinc finger of Spt10p is homologous to that of foamy virus integrase, perhaps suggesting that this integrase is also a sequence-specific DNA-binding protein.	NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; CUNY Coll Staten Isl, Dept Biol, Staten Isl, NY 10314 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); City University of New York (CUNY) System; College of Staten Island (CUNY)	Clark, DJ (corresponding author), NICHD, Lab Mol Growth Regulat, NIH, Bldg 6A,Rm 2A14,6 Ctr Dr, Bethesda, MD 20892 USA.	clarkda@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM067730] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [1R15 GM 67730-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; COOK WJ, 1994, J BIOL CHEM, V269, P9374; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Delelis O, 2004, CURR OPIN MICROBIOL, V7, P400, DOI 10.1016/j.mib.2004.06.009; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; Eriksson PR, 2005, MOL CELL BIOL, V25, P9127, DOI 10.1128/MCB.25.20.9127-9137.2005; FASSLER JS, 1988, GENETICS, V118, P203; FREEMAN KB, 1992, MOL CELL BIOL, V12, P5455, DOI 10.1128/MCB.12.12.5455; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Green A, 1998, BIOCHEM J, V333, P85, DOI 10.1042/bj3330085; HAZUDA DJ, 1994, J BIOL CHEM, V269, P3999; Hess D, 2004, MOL CELL BIOL, V24, P135, DOI 10.1128/MCB.24.1.135-143.2004; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; NATSOULIS G, 1991, NEW BIOL, V3, P1249; NATSOULIS G, 1994, GENETICS, V136, P93; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Shen CH, 2002, MOL CELL BIOL, V22, P6406, DOI 10.1128/MCB.22.18.6406-6416.2002; SHERWOOD PW, 1991, GENETICS, V128, P729; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Trobridge G, 2004, J VIROL, V78, P2327, DOI 10.1128/JVI.78.5.2327-2335.2004; VANHOLDE KF, 1988, SPRINGER SERIES MOL, P118; Winston F, 1998, COLD SPRING HARB SYM, V63, P553, DOI 10.1101/sqb.1998.63.553; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Yamaguchi Y, 2001, J BIOCHEM, V129, P185, DOI 10.1093/oxfordjournals.jbchem.a002842; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	30	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7040	7048		10.1074/jbc.M511416200	http://dx.doi.org/10.1074/jbc.M511416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415340	hybrid			2022-12-27	WOS:000236030900017
J	Nilsson, EC; Long, YC; Martinsson, S; Glund, S; Garcia-Roves, P; Svensson, LT; Andersson, L; Zierath, JR; Mahlapuu, M				Nilsson, EC; Long, YC; Martinsson, S; Glund, S; Garcia-Roves, P; Svensson, LT; Andersson, L; Zierath, JR; Mahlapuu, M			Opposite transcriptional regulation in skeletal muscle of AMP-activated protein kinase gamma 3 R225Q transgenic versus knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; PROTEIN-KINASE; NITRIC-OXIDE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; ENZYME-ACTIVITIES; LIPID-METABOLISM; CARRIER PIGS; BETA; STIMULATION	AMP-activated protein kinase (AMPK) is an evolutionarily conserved heterotrimer important for metabolic sensing in all eukaryotes. The muscle-specific isoform of the regulatory gamma-subunit of the kinase, AMPK gamma 3, has an important role in glucose uptake, glycogen synthesis, and fat oxidation in white skeletal muscle, as previously demonstrated by physiological characterization of AMPK gamma 3 mutant (R225Q) transgenic (TgPrkag3(225Q)) and gamma 3 knock-out (Prkag3(-/-)) mice. We determined AMPK gamma 3-dependent regulation of gene expression by analyzing global transcription profiles in glycolytic skeletal muscle from gamma 3 mutant transgenic and knock-out mice using oligonucleotide microarray technology. Evidence is provided for coordinated and reciprocal regulation of multiple key components in glucose and fat metabolism, as well as skeletal muscle ergogenics in TgPrkag3(225Q) and Prkag3(-/-) mice. The differential gene expression profile was consistent with the physiological differences between the models, providing a molecular mechanism for the observed phenotype. The striking pattern of opposing transcriptional changes between TgPrkag3(225Q) and Prkag3(-/-) mice identifies differentially expressed targets being truly regulated by AMPK and is consistent with the view that R225Q is an activating mutation, in terms of its downstream effects. Additionally, we identified a wide array of novel targets and regulatory pathways for AMPK in skeletal muscle.	Arexis AB, Biotech Ctr, SE-41346 Gothenburg, Sweden; Karolinska Inst, Dept Mol Med & Surg, SE-17177 Stockholm, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, SE-75124 Uppsala, Sweden	Karolinska Institutet; Uppsala University	Mahlapuu, M (corresponding author), Arexis AB, Biotech Ctr, Arvid Wallgrens Backe 20, SE-41346 Gothenburg, Sweden.	margit.mahlapuu@arexis.com	Roves, Pablo Garcia/A-7113-2015; Garcia-Roves, Pablo M./X-4585-2018	Svensson, Thomas/0000-0002-9190-2979; Zierath, Juleen/0000-0001-6891-7497; Mahlapuu, Margit/0000-0001-8740-8874; Garcia-Roves, Pablo M./0000-0002-8371-2067				*APPL BIOS, 1997, US B APPL BIOS; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Barnes BR, 2005, DIABETES, V54, P3484, DOI 10.2337/diabetes.54.12.3484; Barnes BR, 2005, FASEB J, V19, P773, DOI 10.1096/fj.04-3221com; Barnes BR, 2004, J BIOL CHEM, V279, P38441, DOI 10.1074/jbc.M405533200; BENNETT C, 1995, AM J MED GENET, V60, P1, DOI 10.1002/ajmg.1320600102; BLANCO CE, 1988, HISTOCHEM J, V20, P230, DOI 10.1007/BF01747468; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Brutsaert TD, 2003, AM J CLIN NUTR, V77, P441, DOI 10.1093/ajcn/77.2.441; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Ciobanu D, 2001, GENETICS, V159, P1151; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; ESTRADE M, 1994, COMP BIOCHEM PHYS B, V108, P295, DOI 10.1016/0305-0491(94)90080-9; ESTRADE M, 1993, COMP BIOCHEM PHYS B, V104, P321, DOI 10.1016/0305-0491(93)90375-F; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Gollob MH, 2003, BIOCHEM SOC T, V31, P228, DOI 10.1042/bst0310228; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hedegaard J, 2004, PROTEOMICS, V4, P2448, DOI 10.1002/pmic.200300761; Hirschfield W, 2000, AM J PHYSIOL-REG I, V278, pR95, DOI 10.1152/ajpregu.2000.278.1.R95; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lanone S, 2001, CRIT CARE MED, V29, P1720, DOI 10.1097/00003246-200109000-00011; Lebret B, 1999, J ANIM SCI, V77, P1482; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; Long YC, 2005, DIABETOLOGIA, V48, P2354, DOI 10.1007/s00125-005-1962-5; Mahlapuu M, 2004, AM J PHYSIOL-ENDOC M, V286, pE194, DOI 10.1152/ajpendo.00147.2003; Marechal G, 1999, CELL MOL LIFE SCI, V55, P1088, DOI 10.1007/s000180050359; MCLANE JA, 1981, AM J PHYSIOL, V241, pC47, DOI 10.1152/ajpcell.1981.241.1.C47; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Reid MB, 1998, ACTA PHYSIOL SCAND, V162, P401, DOI 10.1046/j.1365-201X.1998.0303f.x; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Skurat AV, 1996, ARCH BIOCHEM BIOPHYS, V328, P283, DOI 10.1006/abbi.1996.0174; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Taha C, 1997, AM J PHYSIOL-ENDOC M, V273, pE68, DOI 10.1152/ajpendo.1997.273.1.E68; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Wojtaszewski JFP, 2002, DIABETES, V51, P284, DOI 10.2337/diabetes.51.2.284; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	57	43	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7244	7252		10.1074/jbc.M510461200	http://dx.doi.org/10.1074/jbc.M510461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410251	hybrid, Green Published			2022-12-27	WOS:000236030900042
J	Sha, Q; Redman, CM; Lee, S				Sha, Q; Redman, CM; Lee, S			Endothelin-3-converting enzyme activity of the KEL1 and KEL6 phenotypes of the Kell blood group system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND METALLOPROTEASE; MOLECULAR-CLONING; PROTEIN; IDENTIFICATION; ANTIGEN	The Kell blood group protein is a metalloendopeptidase that preferentially cleaves a Trp(21)-Ile(22) bond of big endothelin-3 producing bioactive endothelin-3. Kell is a polymorphic protein, and 25 different phenotypes, because of point mutations resulting in single amino acid substitutions, have been described. It was recently reported that a recombinant form of KEL1 ( K, K1) phenotype, expressed in K562 and HEK293 cells, had no endothelin-3-converting activity, in contrast to the common KEL2 (k, K2) phenotype. We demonstrate that KEL1 red blood cells and also a soluble recombinant form of KEL1 protein (s-Kell KEL1) have similar enzymatic activity as the common Kell phenotype. In addition we show that KEL6 red blood cells, which are more prevalent in persons of African heritage than in Caucasians also have endothelin-3-converting enzyme activity and that the recombinant soluble form of KEL6 protein (s-Kell KEL6) has similar Km values as the wild-type.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	New York Blood Center	Lee, S (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.	solee@nybloodcenter.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075716, P50HL054459] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 075716, HL 54459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Carbonnet F, 1997, BRIT J HAEMATOL, V96, P857, DOI 10.1046/j.1365-2141.1997.d01-2110.x; Claperon A, 2005, J BIOL CHEM, V280, P21272, DOI 10.1074/jbc.M500100200; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; Lee S, 1997, VOX SANG, V73, P1, DOI 10.1046/j.1423-0410.1997.7310001.x; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; Lee S, 2003, BLOOD, V102, P3028, DOI 10.1182/blood-2003-05-1564; Lee S, 2001, J BIOL CHEM, V276, P27281, DOI 10.1074/jbc.M103433200; LEE S, 1995, TRANSFUSION, V35, P822, DOI 10.1046/j.1537-2995.1995.351096026362.x; Lee S, 2000, TRANSFUS MED REV, V14, P93, DOI 10.1016/S0887-7963(00)80001-2; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; Russo D, 1998, J BIOL CHEM, V273, P13950, DOI 10.1074/jbc.273.22.13950; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; Turner AJ, 2000, ADV EXP MED BIOL, V477, P229; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	21	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7180	7182		10.1074/jbc.M507776200	http://dx.doi.org/10.1074/jbc.M507776200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423827	hybrid			2022-12-27	WOS:000236030900033
J	Balestrieri, B; Hsu, VW; Gilbert, H; Leslie, CC; Han, WK; Bonventre, JV; Arm, JP				Balestrieri, B; Hsu, VW; Gilbert, H; Leslie, CC; Han, WK; Bonventre, JV; Arm, JP			Group V secretory phospholipase A(2) translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; TARGETED GENE DISRUPTION; LEUKOTRIENE C-4 SYNTHASE; ARACHIDONIC-ACID RELEASE; LOW-MOLECULAR-WEIGHT; VASCULAR-PERMEABILITY; PROSTAGLANDIN PRODUCTION; RECOMBINANT EXPRESSION; KLEBSIELLA-PNEUMONIAE; P388D(1) MACROPHAGES	We have previously reported that group V secretory phospholipase A(2) (sPLA(2)) amplifies the action of cytosolic phospholipase A2 (cPLA(2)) alpha in regulating eicosanoid biosynthesis by mouse peritoneal macrophages stimulated with zymosan (Satake, Y., Diaz, B. L., Balestrieri, B., Lam, B. K., Kanaoka, Y., Grusby, M. J., and Arm, J. P. ( 2004) J. Biol. Chem. 279, 16488 - 16494). To further understand the role of group V sPLA2, we studied its localization in resting mouse peritoneal macrophages before and after stimulation with zymosan and the effect of deletion of the gene encoding group V sPLA2 on phagocytosis of zymosan. We report that group V sPLA2 is present in the Golgi apparatus and recycling endosome in the juxtanuclear region of resting peritoneal macrophages. Upon ingestion of zymosan by mouse peritoneal macrophages, group V sPLA(2) is recruited to the phagosome. There it co-localizes with cPLA(2) alpha, 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C-4 synthase. Using immunostaining for the cysteinyl leukotrienes in carbodiimide-fixed cells, we show, for the first time, that the phagosome is a site of cysteinyl leukotriene formation. Furthermore, peritoneal macrophages from group V sPLA(2)-null mice demonstrated a> 50% attenuation in phagocytosis of zymosan particles, which was restored by adenoviral expression of group V sPLA(2) but not group IIA sPLA(2). These data demonstrate that group V sPLA(2) contributes to the innate immune response both through regulation of eicosanoid generation in response to a phagocytic stimulus and also as a component of the phagocytic machinery.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Partners Asthma Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Jewish Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Arm, JP (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Res Bldg,Rm 638B,1 Jimmy Fund Way, Boston, MA 02115 USA.	jarm@rics.bwh.harvard.edu	Balestrieri, Barbara/Y-2547-2018	Balestrieri, Barbara/0000-0002-0323-3278	NHLBI NIH HHS [R01 HL061378, P01 HL034303, R01 HL068864, HL070946, HL36110, HL34303] Funding Source: Medline; NIAID NIH HHS [AI07306] Funding Source: Medline; NIDDK NIH HHS [R01 DK039773, DK38452, P01 DK038452, DK74099, DK39773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110, R01HL070946, R01HL061378, R01HL068864, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, R37DK039773, R21DK074099, R01DK039773, R33DK074099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aderem A, 2002, CELL, V110, P5, DOI 10.1016/S0092-8674(02)00819-X; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Bailie MB, 1996, J IMMUNOL, V157, P5221; Balboa MA, 2003, J BIOL CHEM, V278, P48059, DOI 10.1074/jbc.M305904200; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lam BK, 1996, EUR J BIOCHEM, V238, P606, DOI 10.1111/j.1432-1033.1996.0606w.x; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Mancuso P, 1998, INFECT IMMUN, V66, P5140, DOI 10.1128/IAI.66.11.5140-5146.1998; Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001; Mancuso P, 2000, AM J RESP CELL MOL, V23, P727, DOI 10.1165/ajrcmb.23.6.4246; Massoumi R, 2002, J CELL SCI, V115, P3509; MOUNIER CM, 2004, J BIOL CHEM, P19200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; OMANN GM, 1995, J IMMUNOL, V155, P5375; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Rubin BB, 2005, J BIOL CHEM, V280, P7519, DOI 10.1074/jbc.M407438200; Saegusa S, 2001, EUR J PHARMACOL, V413, P163, DOI 10.1016/S0014-2999(01)00773-7; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Soberman RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Touret N, 2005, CELL, V123, P157, DOI 10.1016/j.cell.2005.08.018; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	60	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6691	6698		10.1074/jbc.M508314200	http://dx.doi.org/10.1074/jbc.M508314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407308	Green Accepted, hybrid			2022-12-27	WOS:000236030800066
J	Kim, MW; Kim, EJ; Kim, JY; Park, JS; Oh, DB; Shimma, Y; Chiba, Y; Jigami, Y; Rhee, SK; Kang, HA				Kim, MW; Kim, EJ; Kim, JY; Park, JS; Oh, DB; Shimma, Y; Chiba, Y; Jigami, Y; Rhee, SK; Kang, HA			Functional characterization of the Hansenula polymorpha HOC1, OCH1, and OCR1 genes as members of the yeast OCH1 mannosyltransferase family involved in protein glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER CHAIN ELONGATION; N-LINKED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; ALPHA-1,6-MANNOSYLTRANSFERASE; ENCODES; MNN1; SECRETION; MUTANTS; CLONING; MANNAN	The alpha-1,6-mannosyltransferaseencoded by Saccharomyces cerevisiae OCH1 (ScOCH1) is responsible for the outer chain initiation of N-linked oligosaccharides. To identify the genes involved in the first step of outer chain biosynthesis in the methylotrophic yeast Hansenula polymorpha, we undertook the functional analysis of three H. polymorpha genes, HpHOC1, HpOCH1, and HpOCR1, that belong to the OCH1 family containing seven members with significant sequence identities to ScOCH1. The deletions of these H. polymorpha genes individually resulted in several phenotypes suggestive of cell wall defects. Whereas the deletion of HpHOC1 (Hphoc1 Delta) did not generate any detectable changes in N-glycosylation, the null mutant strains of HpOCH1 (Hpoch1 Delta) and HpOCR1 (Hpocr1 Delta) displayed a remarkable reduction in hypermannosylation. Although the apparent phenotypes of Hpocr1 Delta were most similar to those of S. cerevisiae och1 mutants, the detailed structural analysis of N-glycans revealed that the major defect of Hpocr1 Delta is not in the initiation step but rather in the subsequent step of outer chain elongation by alpha-1,2-mannose addition. Most interestingly, Hpocr1 Delta showed a severe defect in the O-linked glycosylation of extracellular chitinase, representing HpOCR1 as a novel member of the OCH1 family implicated in both N- and O-linked glycosylation. In contrast, addition of the first alpha-1,6-mannose residue onto the core oligosaccharide Man(8)GlcNAc(2) was completely blocked in Hpoch1 Delta despite the comparable growth of its wild type under normal growth conditions. The complementation of the S. cerevisiae och1 null mutation by the expression of HpOCH1 and the lack of in vitro alpha-1,6-mannosyltransferase activity in Hpoch1 Delta provided supportive evidence that HpOCH1 is the functional orthologue of ScOCH1. The engineered Hpoch1 Delta strain with the targeted expression of Aspergillus saitoi alpha-1,2-mannosidase in the endoplasmic reticulum was shown to produce human-compatible high mannose-type Man(5)GlcNAc(2) oligosaccharide as a major N-glycan.	Korea Res Inst Biosci & Biotechnol, Metab Engn Lab, Taejon 305600, South Korea; Chungnam Natl Univ, Dept Microbiol, Taejon 305764, South Korea; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; National Institute of Advanced Industrial Science & Technology (AIST)	Kang, HA (corresponding author), Korea Res Inst Biosci & Biotechnol, Metab Engn Lab, Oun Dong 52, Taejon 305600, South Korea.	hyunkang@kribb.re.kr	Chiba, Yasunori/L-7993-2018	Chiba, Yasunori/0000-0002-6401-5071; Kim, Jeong-Yoon/0000-0001-5873-2069; Oh, Doo-Byoung/0000-0002-4432-0941				Agaphonov MO, 2005, YEAST, V22, P1037, DOI 10.1002/yea.1297; Barnay-Verdier S, 2004, MICROBIOL-SGM, V150, P2185, DOI 10.1099/mic.0.26887-0; Blandin G, 2000, FEBS LETT, V487, P76, DOI 10.1016/S0014-5793(00)02284-5; Chiba Y, 1998, J BIOL CHEM, V273, P26298, DOI 10.1074/jbc.273.41.26298; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DEAN N, 1995, P NATL ACAD SCI USA, V15, P3209; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; Gellissen Gerd, 2001, Yeast, V18, pi, DOI 10.1002/1097-0061(200102)18:3<::AID-YEA695>3.0.CO;2-9; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; INOUE T, 1995, BBA-PROTEIN STRUCT M, V1253, P141, DOI 10.1016/0167-4838(95)00195-6; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Kang HA, 1998, YEAST, V14, P371, DOI 10.1002/(SICI)1097-0061(19980315)14:4<371::AID-YEA231>3.3.CO;2-T; Kang HA, 2002, HANSENULA POLYMORPHA: BIOLOGY AND APPLICATIONS, P124; Kang HA, 2005, PRODUCTION RECOMBINA, P111, DOI [10.1002/3527603670.ch6, DOI 10.1002/3527603670.CH6]; Kim MW, 2004, GLYCOBIOLOGY, V14, P243, DOI 10.1093/glycob/cwh030; Kim SY, 2001, YEAST, V18, P455, DOI 10.1002/yea.699; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; MURAKAMI K, 1997, Patent No. 1997000261; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Nakayama K, 1997, FEBS LETT, V412, P547, DOI 10.1016/S0014-5793(97)00634-0; Neiman AM, 1997, GENETICS, V145, P637; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Ramezani-Rad M, 2003, FEMS YEAST RES, V4, P207, DOI 10.1016/S1567-1356(03)00125-9; Rodriguez L, 1996, YEAST, V12, P815, DOI 10.1002/(SICI)1097-0061(199607)12:9<815::AID-YEA916>3.0.CO;2-H; Seok OK, 2004, J MICROBIOL BIOTECHN, V14, P1239; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yoko-o T, 2001, FEBS LETT, V489, P75, DOI 10.1016/S0014-5793(01)02082-8	36	59	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6261	6272		10.1074/jbc.M508507200	http://dx.doi.org/10.1074/jbc.M508507200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407250	hybrid			2022-12-27	WOS:000236030800019
J	Murat, D; Bance, P; Callebaut, I; Dassa, E				Murat, D; Bance, P; Callebaut, I; Dassa, E			ATP hydrolysis is essential for the function of the Uup ATP-binding cassette ATPase in precise excision of transposons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; ESCHERICHIA-COLI; ABC TRANSPORTER; P-GLYCOPROTEIN; ACTIVE-SITE; AGROBACTERIUM-TUMEFACIENS; SALMONELLA-TYPHIMURIUM; HISTIDINE PERMEASE; MALTOSE TRANSPORT; CRYSTAL-STRUCTURE	In Escherichia coli K-12, the RecA- and transposase-independent precise excision of transposons is thought to be mediated by the slippage of the DNA polymerase between the two short direct repeats that flank the transposon. Inactivation of the uup gene, encoding an ATP-binding cassette (ABC) ATPase, led to an important increase in the frequency of precise excision of transposons Tn10 and Tn5 and a defective growth of bacteriophage Mu. To provide insight into the mechanism of Uup in transposon excision, we purified this protein, and we demonstrated that it is a cytosolic ABC protein. Purified recombinant Uup binds and hydrolyzes ATP and undergoes a large conformational change in the presence of this nucleotide. This change affects a carboxyl-terminal domain of the protein that displays predicted structural homology with the so-called little finger domain of Y family DNA polymerases. In these enzymes, this domain is involved in DNA binding and in the processivity of replication. We show that Uup binds to DNA and that this binding is in part dependent on its carboxyl-terminal domain. Analysis of Walker motif B mutants suggests that ATP hydrolysis at the two ABC domains is strictly coordinated and is essential for the function of Uup in vivo.	Inst Pasteur, Dept Microbiol Fondamentale & Med, Unite Membranes Bacteriennes, CNRS,URA2172, F-75724 Paris 15, France; UP6, Inst Mineral & Phys Milieux Condenses, Dept Biol Struct, CNRS,UMR C7590, F-75252 Paris 05, France; UP7, Inst Mineral & Phys Milieux Condenses, Dept Biol Struct, CNRS,UMR C7590, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paris Cite	Dassa, E (corresponding author), Inst Pasteur, Dept Microbiol Fondamentale & Med, Unite Membranes Bacteriennes, CNRS,URA2172, Site Fernbach,25 Rue Docteur Roux, F-75724 Paris 15, France.	elidassa@pasteur.fr		Dorothee, MURAT/0000-0001-5809-9267				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Belin P, 2004, PROTEIN ENG DES SEL, V17, P491, DOI 10.1093/protein/gzh054; Bellier A, 2004, J BACTERIOL, V186, P3238, DOI 10.1128/JB.186.10.3238-3248.2004; Boyd D, 2000, J BACTERIOL, V182, P842, DOI 10.1128/JB.182.3.842-847.2000; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Chaveroche MK, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e97; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; FOSTER TJ, 1981, CELL, V23, P215, DOI 10.1016/0092-8674(81)90286-5; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HOPKINS JD, 1983, J BACTERIOL, V153, P384, DOI 10.1128/JB.153.1.384-389.1983; Jha S, 2003, BIOCHEMISTRY-US, V42, P10822, DOI 10.1021/bi0345900; Karcher A, 2005, STRUCTURE, V13, P649, DOI 10.1016/j.str.2005.02.008; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kerr ID, 2004, BIOCHEM BIOPH RES CO, V315, P166, DOI 10.1016/j.bbrc.2004.01.044; KORONAKIS E, 1995, MOL MICROBIOL, V16, P87, DOI 10.1111/j.1365-2958.1995.tb02394.x; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUHNAU S, 1991, J BACTERIOL, V173, P2180; KURTZ HD, 1994, FEMS MICROBIOL LETT, V116, P175, DOI 10.1111/j.1574-6968.1994.tb06697.x; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Liu ZY, 2001, J BACTERIOL, V183, P3310, DOI 10.1128/JB.183.11.3310-3317.2001; Llama-Palacios A, 2002, APPL ENVIRON MICROB, V68, P1624, DOI 10.1128/AEM.68.4.1624-1630.2002; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lovett ST, 2004, MOL MICROBIOL, V52, P1243, DOI 10.1111/j.1365-2958.2004.04076.x; LUNDBLAD V, 1984, P NATL ACAD SCI-BIOL, V81, P824, DOI 10.1073/pnas.81.3.824; Lundblad V, 1982, Basic Life Sci, V20, P245; LUNDBLAD V, 1985, GENETICS, V109, P3; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; Miller J. H., 1972, EXPT MOL GENETICS, P439; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Mourez M, 1998, MOL MICROBIOL, V30, P353, DOI 10.1046/j.1365-2958.1998.01070.x; Nagel R, 2000, MUTAT RES-DNA REPAIR, V459, P275, DOI 10.1016/S0921-8777(00)00008-2; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Reddy M, 1997, J BACTERIOL, V179, P2892, DOI 10.1128/jb.179.9.2892-2899.1997; Reddy M, 2000, J BACTERIOL, V182, P1978, DOI 10.1128/JB.182.7.1978-1986.2000; Roux A, 2005, J BACTERIOL, V187, P1001, DOI 10.1128/JB.187.3.1001-1013.2005; SCHNEIDER E, 1995, PROTEIN EXPRES PURIF, V6, P10, DOI 10.1006/prep.1995.1002; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Tyzack JK, 2000, J BIOL CHEM, V275, P34131, DOI 10.1074/jbc.M002868200; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; van Belkum A, 1999, CELL MOL LIFE SCI, V56, P729, DOI 10.1007/s000180050019; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Verdon G, 2002, ACTA CRYSTALLOGR D, V58, P362, DOI 10.1107/S0907444901020765; WANG JT, 1994, J BIOL CHEM, V269, P10771; WINANS SC, 1988, J BACTERIOL, V170, P4047, DOI 10.1128/jb.170.9.4047-4054.1988; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	60	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6850	6859		10.1074/jbc.M509926200	http://dx.doi.org/10.1074/jbc.M509926200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407313	hybrid			2022-12-27	WOS:000236030800083
J	Chou, HYE; Chou, HT; Lee, SC				Chou, Han-Yi E.; Chou, Han Ting; Lee, Sheng-Chung			CDK-dependent activation of poly(ADP-ribose) polymerase member 10 (PARP10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; TANKYRASE; PROTEIN; GENE; IDENTIFICATION; LOCALIZATION; ASSOCIATION; EG5	Proteins of the poly(ADP-ribose) polymerase ( PARP) family play a wide array of functions, covering virtually every aspect of DNA metabolism and function, most notably with the response to DNA damage, transcription, and the maintenance of genomic stability. Here we report the identification and characterization of a novel PARP family member, PARP10 (FLJ14464 or hypothetical protein LOC84875). Overexpression of PARP10 results in loss of cell viability, although down-expression by short hairpin RNA leads to delayed G(1) progression and concomitant cell death. PARP10 exists in both cytoplasm and nucleus, but only nucleolar PARP10 acquires CDK-dependent phosphorylation through late-G1 to S phase, and from prometaphase to cytokinesis in the nucleolar organizing regions. The PARP activity of PARP10 depends on phosphorylation by CDK2-cyclin E in vitro. CDK-phosphorylated PARP10 is absent in growth-arrested cells. These results suggest that PARP10 functions in cell proliferation and may serve as a marker for proliferating cells.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 10617, Taiwan	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan.	slee@ntu.edu.tw						Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Katoh M, 2003, INT J ONCOL, V23, P541; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Liu Y, 2004, MOL CELL BIOL, V24, P5314, DOI 10.1128/MCB.24.12.5314-5323.2004; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Ma Q, 2001, BIOCHEM BIOPH RES CO, V289, P499, DOI 10.1006/bbrc.2001.5987; Matsuo R, 2000, J NEUROCHEM, V74, P2239, DOI 10.1046/j.1471-4159.2000.0742239.x; MENISSIERDEMURC.J, 1999, J BIOL CHEM, V274, P17860; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shall Sydney, 2002, Bioessays, V24, P197, DOI 10.1002/bies.10012; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Yu M, 2005, ONCOGENE, V24, P1982, DOI 10.1038/sj.onc.1208410	26	38	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15201	15207		10.1074/jbc.M506745200	http://dx.doi.org/10.1074/jbc.M506745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16455663	hybrid			2022-12-27	WOS:000237922200023
J	Cripps, D; Thomas, SN; Jeng, Y; Yang, F; Davies, P; Yang, AJ				Cripps, D; Thomas, SN; Jeng, Y; Yang, F; Davies, P; Yang, AJ			Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; NEUROFIBRILLARY PATHOLOGY; ABNORMAL PHOSPHORYLATION; STATISTICAL-MODEL; MASS-SPECTROMETRY; BINDING; PROTEASOME; SITES; DOMAINS; TANGLES	One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of paired helical filaments (PHFs) of hyperphosphorylated microtubule-associated protein Tau. Tandem mass spectrometry was employed to examine PHF-Tau post-translational modifications, in particular protein phosphorylation and ubiquitination, to shed light on their role in the early stages of Alzheimer disease. PHF-Tau from Alzheimer disease brain was affinity-purified by MC1 monoclonal antibody to isolate a soluble fraction of PHF-Tau in a conformation unique to human AD brain. A large number of phosphorylation sites were identified by employing a data-dependent neutral loss algorithm to trigger MS3 scans of phosphopeptides. It was found that soluble PHF-Tau is ubiquitinated at its microtubule-binding domain at residues Lys-254, Lys-311, and Lys-353, suggesting that ubiquitination of PHF-Tau may be an earlier pathological event than previously thought and that ubiquitination could play a regulatory role in modulating the integrity of microtubules during the course of AD. Tandem mass spectrometry data for ubiquitin itself indicate that PHF-Tau is modified by three polyubiquitin linkages, at Lys-6, Lys-11, and Lys-48. Relative quantitative analysis indicates that Lys-48-linked polyubiquitination is the primary form of polyubiquitination with a minor portion of ubiquitin linked at Lys-6 and Lys-11. Because modification by Lys-48-linked polyubiquitin chains is known to serve as the essential means of targeting proteins for degradation by the ubiquitin-proteasome system, and it has been reported that modification at Lys-6 inhibits ubiquitin-dependent protein degradation, a failure of the ubiquitin-proteasome system could play a role in initiating the formation of degradation-resistant PHF tangles.	Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Micro Tech Sci Inc, Vista, CA 92081 USA	University of Southern California; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Yang, AJ (corresponding author), Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.	austiny@usc.edu	Thomas, Stefani/AAF-4212-2021	Thomas, Stefani/0000-0003-1679-5453	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020069, R01MH059786, R01MH038623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025323] Funding Source: NIH RePORTER; NIA NIH HHS [AG25323, R01 AG025323] Funding Source: Medline; NIMH NIH HHS [T32 MH020069, MH59786, R01 MH059786, R01 MH038623] Funding Source: Medline; PHS HHS [38623] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Arrasate M, 2000, NEUROCHEM RES, V25, P43, DOI 10.1023/A:1007583214722; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bussiere T, 1999, ACTA NEUROPATHOL, V97, P221, DOI 10.1007/s004010050978; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001; Fath T, 2002, J NEUROSCI, V22, P9733; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Gong CX, 2005, J NEURAL TRANSM, V112, P813, DOI 10.1007/s00702-004-0221-0; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Gruhler A, 2005, MOL CELL PROTEOMICS, V4, P310, DOI 10.1074/mcp.M400219-MCP200; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LETERRIER JF, 1982, J CELL BIOL, V95, P982, DOI 10.1083/jcb.95.3.982; Lim JN, 2005, BBA-MOL BASIS DIS, V1739, P311, DOI 10.1016/j.bbadis.2004.10.003; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Mandell JW, 1996, J NEUROSCI, V16, P5727; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MIYATA Y, 1986, J BIOL CHEM, V261, P3026; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Nemes Z, 2004, FASEB J, V18, P1135, DOI 10.1096/fj.04-1493fje; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; REBHAN M, 1995, NEUROREPORT, V6, P429, DOI 10.1097/00001756-199502000-00006; RENDON A, 1990, BIOCHEM J, V269, P555, DOI 10.1042/bj2690555; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200; Uboga NV, 2000, NEUROBIOL AGING, V21, P1, DOI 10.1016/S0197-4580(00)00091-9; Vega IE, 2005, MOL BRAIN RES, V138, P135, DOI 10.1016/j.molbrainres.2005.04.015; Vincent I, 1998, NEUROBIOL AGING, V19, P287, DOI 10.1016/S0197-4580(98)00071-2; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Wischik CM, 2001, NEUROBIOLOGY ALZHEIM, P103; Zhang JY, 2005, J NEURAL TRANSM, V112, P547, DOI 10.1007/s00702-004-0196-x	57	215	223	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10825	10838		10.1074/jbc.M512786200	http://dx.doi.org/10.1074/jbc.M512786200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16443603	hybrid			2022-12-27	WOS:000236822200022
J	Miyazaki, K; Takenouchi, M; Kondo, H; Noro, N; Suzuki, M; Tsuda, S				Miyazaki, K; Takenouchi, M; Kondo, H; Noro, N; Suzuki, M; Tsuda, S			Thermal stabilization of Bacillus subtilis family-11 xylanase by directed evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHODERMA-REESEI ENDO-1,4-BETA-XYLANASE-II; STRUCTURAL BASIS; PROTEIN; MUTAGENESIS; THERMOSTABILITY; COMBINATION; STABILITY; INCREASES; RESIDUES; PROGRAM	We used directed evolution to enhance the thermostability of glycosyl hydrolase family-11 xylanase from Bacillus subtilis. By combining random point mutagenesis, saturation mutagenesis, and DNA shuffling, a thermostable variant, Xyl(st), was identified which contained three amino acid substitutions: Q7H, N8F, and S179C. The half-inactivation temperature (the midpoint of the melting curves) for the Xyl(st) variant compared with the wild-type enzyme after incubation for 10 min was elevated from 58 to 68 C. At 60 C the wild-type enzyme was inactivated within 5 min, but Xyl(st) retained full activity for at least 2 h. The stabilization was accompanied by evidence of thermophilicity; that is, an increase in the optimal reaction temperature from 55 to 65 C and lower activity at low temperatures and higher activity at higher temperatures relative to wild type. To elucidate the mechanism of thermal stabilization, three-dimensional structures were determined for the wild-type and Xyl(st) enzymes. A cavity was identified around Gln-7/Asn-8 in wild type that was filled with bulky, hydrophobic residues in Xyl(st). This site was not identified by previous approaches, but directed evolution identified the region as a weak point. Formation of an intermolecular disulfide bridge via Cys-179 was observed between monomers in Xyl(st). However, the stability was essentially the same in the presence and absence of a reducing agent, indicating that the increased hydrophobicity around the Cys-179 accounted for the stability.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Res Inst Genome Based Biofactory, Sapporo, Hokkaido 0628517, Japan; Osaka Univ, Inst Prot Res, Res Ctr Struct & Funct Proteom, Suita, Osaka 5650871, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Osaka University; Hokkaido University	Miyazaki, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	miyazaki-kentaro@aist.go.jp	Miyazaki, Kentaro/F-7022-2010; Tsuda, Sakae/M-2756-2018; Kondo, Hidemasa/M-7465-2018; Suzuki, Mamoru/G-6576-2016	Miyazaki, Kentaro/0000-0002-4349-566X; Tsuda, Sakae/0000-0002-1399-0619; Kondo, Hidemasa/0000-0003-2799-1775; Suzuki, Mamoru/0000-0001-7071-5093				Arnold F H, 1997, Adv Biochem Eng Biotechnol, V58, P1; Arnold FH, 1998, NAT BIOTECHNOL, V16, P617, DOI 10.1038/nbt0798-617; Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bajpai P, 2004, CRIT REV BIOTECHNOL, V24, P1, DOI 10.1080/07388550490465817; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; Funahashi J, 2000, BIOCHEMISTRY-US, V39, P14448, DOI 10.1021/bi0015717; Georis J, 2000, PROTEIN SCI, V9, P466; Harris GW, 1997, PROTEINS, V29, P77, DOI 10.1002/(SICI)1097-0134(199709)29:1<77::AID-PROT6>3.3.CO;2-K; Ishikawa K, 1998, J BIOL CHEM, V273, P17726, DOI 10.1074/jbc.273.28.17726; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagano N, 1999, FEBS LETT, V458, P69, DOI 10.1016/S0014-5793(99)01122-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAICE MG, 1986, ARCH MICROBIOL, V144, P201, DOI 10.1007/BF00410947; Polizeli MLTM, 2005, APPL MICROBIOL BIOT, V67, P577, DOI 10.1007/s00253-005-1904-7; SUNG WL, 1993, PROTEIN EXPRES PURIF, V4, P200, DOI 10.1006/prep.1993.1026; Turunen O, 2002, PROTEIN ENG, V15, P141, DOI 10.1093/protein/15.2.141; Turunen O, 2001, J BIOTECHNOL, V88, P37, DOI 10.1016/S0168-1656(01)00253-X; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDENBURG B, 1994, EUR J BIOCHEM, V220, P981; WAKARCHUK WW, 1994, PROTEIN ENG, V7, P1379, DOI 10.1093/protein/7.11.1379; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WOOD PJ, 1983, J HISTOCHEM CYTOCHEM, V31, P823, DOI 10.1177/31.6.6841974; Xiong HR, 2004, EXTREMOPHILES, V8, P393, DOI 10.1007/s00792-004-0400-9; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	35	98	115	2	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10236	10242		10.1074/jbc.M511948200	http://dx.doi.org/10.1074/jbc.M511948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16467302	hybrid			2022-12-27	WOS:000236594300051
J	Fahling, M; Mrowka, R; Steege, A; Martinka, P; Persson, PB; Thiele, BJ				Fahling, M; Mrowka, R; Steege, A; Martinka, P; Persson, PB; Thiele, BJ			Heterogeneous nuclear ribonucleoprotein-A2/B1 modulate collagen prolyl 4-hydroxylase, alpha(I) mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PATTERNS; MICROARRAY ANALYSIS REVEALS; POSTTRANSCRIPTIONAL REGULATION; 3-UNTRANSLATED REGION; RESPONSE ELEMENT; BINDING PROTEIN; NITRIC-OXIDE; HNRNP A2; TRAFFICKING; CELLS	Collagen prolyl 4-hydroxylase (C-P4H) alpha-subunit is of regulatory importance in the assembling of C-P4H tetramers, which are necessary for the hydroxylation of procollagen chains. Change in collagen expression by hypoxia or iron diminishment is a significant issue in extracellular matrix remodeling. It was proposed that C-P4H-alpha (I) is regulated at the posttrancriptional level under these conditions. Here we report that the induction of C-P4H-alpha (I) in human fibrosarcoma cells HT1080 by the iron chelator 2,2-dipyridyl is predominantly caused by an enhancement of mRNA stability. This effect is mediated by an increased synthesis and binding of heterogeneous nuclear ribonucleoprotein (hnRNP)-A2/B1, which interacts with a (U) 16 element located in the 3'-untranslated region of C-P4H-alpha (I) mRNA. Luciferase reporter gene assays depending on C-P4H-alpha (I) 3'-untranslated region and co-transfection with hnRNP-A2/B1 provide evidence that the (U) 16 element is necessary and sufficient for posttranscriptional control of C-P4H-alpha (I) synthesis under the analyzed conditions. Further indication for the significance of hnRNP-A2/B1 in C-P4H-alpha (I) induction was obtained by micro array experiments. In a data set representing 686 independent physiological conditions, we found a significant positive correlation between hnRNP-A2/B1 and C-P4H-alpha (I) mRNAs.	Univ Med Berlin, Charite, Inst Vegetat Physiol, D-10117 Berlin, Germany; Free Univ Berlin, Inst Biol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Fahling, M (corresponding author), Univ Med Berlin, Charite, Inst Vegetat Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	Michael.Faehling@charite.de	Fähling, Michael/E-5018-2011; Mrowka, Ralf/AAW-1480-2021; Steege, Andreas/F-3885-2010	Mrowka, Ralf/0000-0002-0991-3418; Persson, Pontus/0000-0003-0926-2878; Fahling, Michael/0000-0003-1079-5049				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; BERG RA, 1980, BIOCHEM J, V189, P491, DOI 10.1042/bj1890491; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Brooks S A, 2000, Nucleic Acids Res, V28, pE49, DOI 10.1093/nar/28.10.e49; Carson JH, 2005, BIOL CELL, V97, P51; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cuadras MA, 2002, J VIROL, V76, P4467, DOI 10.1128/JVI.76.9.4467-4482.2002; Detweiler CS, 2001, P NATL ACAD SCI USA, V98, P5850, DOI 10.1073/pnas.091110098; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahling M, 2005, BBA-GENE STRUCT EXPR, V1731, P32, DOI 10.1016/j.bbaexp.2005.08.005; Fahling M, 2004, COMP BIOCHEM PHYS C, V139, P119, DOI 10.1016/j.cca.2004.09.013; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hamilton BJ, 1999, BIOCHEM BIOPH RES CO, V261, P646, DOI 10.1006/bbrc.1999.1040; He YW, 2005, J CELL SCI, V118, P3173, DOI 10.1242/jcs.02448; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOZU T, 1995, GENOMICS, V25, P365, DOI 10.1016/0888-7543(95)80035-K; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LASKO P, 2003, SCI STKE, pRE6; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje; Ma ASW, 2002, J BIOL CHEM, V277, P18010, DOI 10.1074/jbc.M200050200; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pesole G, 1997, GENE, V205, P95, DOI 10.1016/S0378-1119(97)00407-1; Raghavan A, 2002, NUCLEIC ACIDS RES, V30, P5529, DOI 10.1093/nar/gkf682; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; SIERRA JM, 1994, MOL BIOL REP, V19, P211, DOI 10.1007/BF00986963; Smith R, 2004, NEUROSCIENTIST, V10, P495, DOI 10.1177/1073858404266759; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Tsukamoto H, 1996, J CLIN INVEST, V97, P2823, DOI 10.1172/JCI118738; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	57	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9279	9286		10.1074/jbc.M510925200	http://dx.doi.org/10.1074/jbc.M510925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464861	hybrid			2022-12-27	WOS:000236404700035
J	Isin, EM; Guengerich, FP				Isin, EM; Guengerich, FP			Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-DRUG INTERACTIONS; ISOTHERMAL TITRATION CALORIMETRY; HUMAN LIVER-MICROSOMES; RATE-LIMITING STEPS; P450 REDUCTASE; ACTIVE-SITE; HETEROTROPIC COOPERATIVITY; ELECTRON-TRANSFER; IN-VITRO; ACTIVATION	Cytochrome P450 (P450) 3A4, the major catalyst involved in human drug oxidation, displays substrate- and reaction-dependent homotropic and heterotropic cooperative behavior. Although several models have been proposed, these mainly rely on steady-state kinetics and do not provide information on the contribution of the individual steps of P450 catalytic cycle to the observed cooperativity. In this work, we focused on the kinetics of substrate binding, and the fluorescent properties of bromocriptine and alpha-naphthoflavone allowed analysis of an initial ligand-P450 3A4 interaction that does not cause a perturbation of the heme spectrum. The binding stoichiometry for bromocriptine was determined to be unity using isothermal titration calorimetry and equilibrium dialysis methods, suggesting that the ligand bound to the peripheral site during the initial encounter dissociates subsequently. A three-step substrate binding model is proposed, based on absorbance and fluorescence stopped-flow kinetic data and equilibrium binding data obtained with bromocriptine, and evaluated using kinetic modeling. The results are consistent with the substrate molecule binding at a site peripheral to the active site and subsequently moving toward the active site to bind to the heme and resulting in a low to high spin iron shift. The last step is attributed to a conformational change in the enzyme active site. The later steps of binding were shown to have rate constants comparable with the subsequent steps of the catalytic cycle. The P450 3A4 binding process is more complex than a two-state system, and the overlap of rates of some of the events with subsequent steps is proposed to underlie the observed cooperativity.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Isin, Emre/0000-0003-3402-7685	NATIONAL CANCER INSTITUTE [R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090426] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkins WM, 2001, CHEM RES TOXICOL, V14, P338, DOI 10.1021/tx0002132; Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; BUENING MK, 1978, BIOCHEM BIOPH RES CO, V82, P348, DOI 10.1016/0006-291X(78)90616-2; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; CINTI DL, 1979, BIOCHEMISTRY-US, V18, P36, DOI 10.1021/bi00568a006; Cliff MJ, 2003, J MOL RECOGNIT, V16, P383, DOI 10.1002/jmr.648; Cliff MJ, 2004, J MOL RECOGNIT, V17, P513, DOI 10.1002/jmr.714; COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197; Dabrowski MJ, 2002, J AM CHEM SOC, V124, P11866, DOI 10.1021/ja027552x; Davydov DR, 2005, BIOCHEMISTRY-US, V44, P13902, DOI 10.1021/bi0509346; Egnell AC, 2005, J PHARMACOL EXP THER, V312, P926, DOI 10.1124/jpet.104.078519; Ekins S, 1997, PHARMACOGENETICS, V7, P165, DOI 10.1097/00008571-199706000-00001; Ekins S, 1998, INT J CLIN PHARM TH, V36, P642; Fersht A, 1999, STRUCTURE MECH PROTE, P159; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; Guengerich FP, 2005, ARCH BIOCHEM BIOPHYS, V440, P204, DOI 10.1016/j.abb.2005.06.019; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; Harlow GR, 1997, J BIOL CHEM, V272, P5396, DOI 10.1074/jbc.272.9.5396; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; He YA, 2003, ARCH BIOCHEM BIOPHYS, V409, P92, DOI 10.1016/S0003-9861(02)00484-8; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; Houston JB, 2005, ARCH BIOCHEM BIOPHYS, V433, P351, DOI 10.1016/j.abb.2004.09.010; Hutzler JM, 2001, DRUG METAB DISPOS, V29, P1029; Hutzler JM, 2002, DRUG METAB DISPOS, V30, P355, DOI 10.1124/dmd.30.4.355; Inaba T, 1997, TOXICOL LETT, V93, P215, DOI 10.1016/S0378-4274(97)00098-2; JOHNSON KA, 2003, KINETIC ANAL MACROMO, V267, P1; KAPITULNIK J, 1977, CLIN PHARMACOL THER, V22, P475; Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644; Koley AP, 1996, BIOCHIMIE, V78, P706, DOI 10.1016/S0300-9084(97)82528-X; Koley AP, 1997, BIOCHEM PHARMACOL, V53, P455, DOI 10.1016/S0006-2952(96)00836-2; Koley AP, 1997, J BIOL CHEM, V272, P3149, DOI 10.1074/jbc.272.6.3149; Krauser JA, 2005, J BIOL CHEM, V280, P19496, DOI 10.1074/jbc.M501854200; Krauser JA, 2004, EUR J BIOCHEM, V271, P3962, DOI 10.1111/j.1432-1033.2004.04339.x; KUBY SA, 1991, STUDY ENZYMES, V1, P300; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Ladbury JE, 2004, BIOTECHNIQUES, V37, P885, DOI 10.2144/04376TE01; Miller GP, 2001, BIOCHEMISTRY-US, V40, P7262, DOI 10.1021/bi010402z; Mueller Ernest J., 1995, P83; OMURA T, 1964, J BIOL CHEM, V239, P2370; Ortiz de Montellano P.R., 2005, CYTOCHROME P450 STRU, P183, DOI [10.1007/b139087, DOI 10.1007/B139087]; PALMER G, 1992, J BIOL CHEM, V267, P665; Patil PV, 2000, ANAL BIOCHEM, V286, P187, DOI 10.1006/abio.2000.4802; PATTEN CJ, 1993, CHEM RES TOXICOL, V6, P511, DOI 10.1021/tx00034a019; PEYRONNEAU MA, 1994, EUR J BIOCHEM, V223, P947, DOI 10.1111/j.1432-1033.1994.tb19072.x; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; Roberts AG, 2005, BIOCHEMISTRY-US, V44, P1353, DOI 10.1021/bi0481390; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Scott EE, 2005, TRENDS BIOCHEM SCI, V30, P5, DOI 10.1016/j.tibs.2004.11.004; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Shou MG, 2002, METHOD ENZYMOL, V357, P261; Stresser DM, 2000, DRUG METAB DISPOS, V28, P1440; Szklarz GD, 1998, DRUG METAB DISPOS, V26, P1179; Tang W, 2001, CURR DRUG METAB, V2, P185, DOI 10.2174/1389200013338658; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; Venkatakrishnan K, 1998, J CLIN PHARMACOL, V38, P112, DOI 10.1002/j.1552-4604.1998.tb04399.x; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Xue LL, 2001, CHEM RES TOXICOL, V14, P483, DOI 10.1021/tx000218z; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Zhang QY, 1999, DRUG METAB DISPOS, V27, P804	74	115	117	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9127	9136		10.1074/jbc.M511375200	http://dx.doi.org/10.1074/jbc.M511375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467307	hybrid			2022-12-27	WOS:000236404700018
J	Luo, Y; Nita-Lazar, A; Haltiwanger, RS				Luo, Y; Nita-Lazar, A; Haltiwanger, RS			Two distinct pathways for O-fucosylation of epidermal growth factor-like or thrombospondin type 1 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; FUCOSE GLYCOSYLATION PATHWAY; NOTCH-DELTA INTERACTIONS; FACTOR-LIKE MODULES; HUMAN FACTOR-IX; LINKED FUCOSE; PROTEIN O-FUCOSYL-TRANSFERASE-1; LIGAND-BINDING; PLASMINOGEN-ACTIVATOR; ENZYMATIC ADDITION	Epidermal growth factor-like (EGF) repeats and thrombospondin type 1 repeats (TSRs) are both small cysteine-knot motifs known to be O-fucosylated. The enzyme responsible for the addition of O-fucose to EGF repeats, protein O-fucosyltransferase 1 (POFUT1), has been identified and shown to be essential in Notch signaling. Fringe, an O-fucose beta 1,3-N-acetylglucosaminyltransferase, elongates O-fucose on specific EGF repeats from Notch to form a disaccharide that can be further elongated to a tetrasaccharide. TSRs are found in many extracellular matrix proteins and are involved in protein-protein interactions. The O-fucose moiety on TSRs can be further elongated with glucose to form a disaccharide. The discovery of O-fucose on TSRs raised the question of whether POFUT1, or a different enzyme, adds O-fucose to TSRs. Here we demonstrate the existence of a TSR-specific O-fucosyltransferase distinct from POFUT1. Similar to POFUT1, the novel TSR-specific O-fucosyltransferase is a soluble enzyme that requires a properly folded TSR as an acceptor substrate. In addition, we found that a previously identified fucose-specific beta 1,3-glucosyltransferase adds glucose to O-fucose on TSRs, but it does not modify O-fucose on an EGF repeat. Similarly, Lunatic fringe, Manic fringe, and Radical fringe are all capable of modifying O-fucose on an EGF repeat, but not on a TSR. Taken together, these results suggest that two distinct O-fucosylation pathways exist in cells, one specific for EGF repeat and the other for TSRs.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.	rhaltiwanger@ms.cc.sunysb.edu	Nita-Lazar, Aleksandra/N-3740-2018	Nita-Lazar, Aleksandra/0000-0002-8523-605X	NIGMS NIH HHS [R01 GM061126, GM 61126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, DEV DYNAM, V218, P280; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Rampal R, 2005, J BIOL CHEM, V280, P42454, DOI 10.1074/jbc.M509552200; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shao L, 2003, CELL MOL LIFE SCI, V60, P241, DOI 10.1007/s000180300019; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; WANG Y, 1996, GLYCOBIOLOGY, V6, P759; Xu AG, 2005, J BIOL CHEM, V280, P30158, DOI 10.1074/jbc.M505569200; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614	46	86	88	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9385	9392		10.1074/jbc.M511974200	http://dx.doi.org/10.1074/jbc.M511974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464858	hybrid			2022-12-27	WOS:000236404700047
J	Klenk, C; Humrich, J; Quitterer, U; Lohse, MJ				Klenk, C; Humrich, J; Quitterer, U; Lohse, MJ			SUMO-1 controls the protein stability and the biological function of phosducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; BETA-GAMMA; TRANSCRIPTION FACTORS; REGULATOR PHOSDUCIN; CONJUGATING ENZYME; E3 LIGASE; BINDING; PHOSPHORYLATION; KINASE; COMPLEX	Phosducin regulates G beta gamma- stimulated signaling by binding to G beta gamma subunits of heterotrimeric G- proteins. Control of phosducin activity by phosphorylation is well established. However, little is known about other mechanisms that may control phosducin activity. Here we report that phosducin is regulated at the posttranslational level by modification with the small ubiquitin- related modifier, SUMO. We demonstrate modification with SUMO for phosducin in vitro expressed in cells and for native phosducin purified from retina and the heart. A consensus motif for SUMOylation was identified in phosducin at amino acid positions 32 - 35. Mutation of the conserved lysine 33 to arginine in this motif abolished SUMOylation of phosducin, indicating that SUMO is attached to lysine 33 of phosducin. In transfected cells the steady- state levels of the K33R mutant protein were much lower compared with wildtype phosducin. The investigation of the stability of wild- type phosducin and of phosducin(K33R) showed a decreased protein stability of the SUMOylation- deficient mutant. The decreased protein stability correlated with increased ubiquitinylation of the SUMOylation- deficient mutant. These findings indicate that SUMOylation protects phosducin from proteasomal degradation. SUMOylation of phosducin decreased its ability to bind G beta gamma. PhlP, a closely related member of the phosducin family, was not a target for SUMOylation, but its SUMOylation can be achieved by a single amino acid insertion in the conserved N terminus of PhlP. Together, these findings show that phosducin is a previously unrecognized target of SUMO modification and that SUMOylation controls phosducin stability in cells as well as its functional properties.	Univ Wurzburg, Inst Pharmacol, D-97078 Wurzburg, Germany	University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Klenk, Christoph/E-5158-2014	Lohse, Martin J/0000-0002-0599-3510; Klenk, Christoph/0000-0001-5199-7144				Barhite S, 1998, BBA-MOL CELL RES, V1402, P95, DOI 10.1016/S0167-4889(97)00141-9; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Boddy MN, 1996, ONCOGENE, V13, P971; Boggio R, 2004, MOL CELL, V16, P549, DOI 10.1016/j.molcel.2004.11.007; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; HAWES BE, 1994, J BIOL CHEM, V269, P29825; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Humrich J, 2005, J BIOL CHEM, V280, P20042, DOI 10.1074/jbc.M409233200; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kasahara S, 2000, P NATL ACAD SCI USA, V97, P412, DOI 10.1073/pnas.97.1.412; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Lee BY, 2004, J BIOL CHEM, V279, P54008, DOI 10.1074/jbc.M405669200; LEE RH, 1990, J BIOL CHEM, V265, P15860; LOLLEY RN, 1992, NEUROCHEM RES, V17, P81, DOI 10.1007/BF00966868; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Lukov GL, 2005, EMBO J, V24, P1965, DOI 10.1038/sj.emboj.7600673; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Okura T, 1996, J IMMUNOL, V157, P4277; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schroder S, 2000, N-S ARCH PHARMACOL, V362, P435, DOI 10.1007/s002100000298; Sobko A, 2002, DEV CELL, V2, P745, DOI 10.1016/S1534-5807(02)00186-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Thibault C, 1999, BBA-GENE STRUCT EXPR, V1444, P346, DOI 10.1016/S0167-4781(99)00006-8; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Weger S, 2005, FEBS LETT, V579, P5007, DOI 10.1016/j.febslet.2005.07.088; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zhu X, 1998, Mol Vis, V4, P13; Zhu XM, 2000, BIOCHEM BIOPH RES CO, V270, P504, DOI 10.1006/bbrc.2000.2414	59	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8357	8364		10.1074/jbc.M513703200	http://dx.doi.org/10.1074/jbc.M513703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16421094	hybrid			2022-12-27	WOS:000236247100009
J	Lim, JH; Kim, MS; Kim, HE; Yano, T; Oshima, Y; Aggarwal, K; Goldman, WE; Silverman, N; Kurata, S; Oh, BH				Lim, JH; Kim, MS; Kim, HE; Yano, T; Oshima, Y; Aggarwal, K; Goldman, WE; Silverman, N; Kurata, S; Oh, BH			Structural basis for preferential recognition of diaminopimelic acid-type peptidoglycan by a subset of peptidoglycan recognition proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; DROSOPHILA-IMD-PATHWAY; PATTERN-RECOGNITION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; INNATE IMMUNITY; ANTIBACTERIAL DEFENSE; TOLL PATHWAY; I-ALPHA; RECEPTOR	Drosophila peptidoglycan recognition protein (PGRP)-LCx and - LCa are receptors that preferentially recognize meso-diaminopimelic acid (DAP)-type peptidoglycan (PGN) present in Gram-negative bacteria over lysine-type PGN of Gram-positive bacteria and initiate the IMD signaling pathway, whereas PGRP-LE plays a synergistic role in this process of innate immune defense. How these receptors can distinguish the two types of PGN remains unclear. Here the structure of the PGRP domain of Drosophila PGRP-LE in complex with tracheal cytotoxin (TCT), the monomeric DAP-type PGN, reveals a buried ionic interaction between the unique carboxyl group of DAP and a previously unrecognized arginine residue. This arginine is conserved in the known DAP-type PGN-interacting PGRPs and contributes significantly to the affinity of the protein for the ligand. Unexpectedly, TCT induces infinite head-to-tail dimerization of PGRP-LE, in which the disaccharide moiety, but not the peptide stem, of TCT is positioned at the dimer interface. A sequence comparison suggests that TCT induces heterodimerization of the ectodomains of PGRP-LCx and - LCa in a closely analogous manner to prime the IMD signaling pathway, except that the heterodimer formation is nonperpetuating.	Pohang Univ Sci & Technol, Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01605 USA; Washington Univ, Sch Med, Dept Microbiol, St Louis, MO 63110 USA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Tohoku University; University of Massachusetts System; University of Massachusetts Worcester; Washington University (WUSTL)	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea.	bhoh@postech.ac.kr	Oh, Byung-Ha/C-2061-2011; Yano, Tamaki/AHB-5620-2022	Yano, Tamaki/0000-0002-5576-1128; Goldman, William/0000-0002-1551-6718; Silverman, Neal/0000-0002-4259-456X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CI, 2004, PLOS BIOL, V2, P1293, DOI 10.1371/journal.pbio.0020277; Chang CI, 2005, P NATL ACAD SCI USA, V102, P10279, DOI 10.1073/pnas.0504547102; Cho JH, 2005, BLOOD, V106, P2551, DOI 10.1182/blood-2005-02-0530; Choe KM, 2005, P NATL ACAD SCI USA, V102, P1122, DOI 10.1073/pnas.0404952102; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Guan RJ, 2004, J BIOL CHEM, V279, P31873, DOI 10.1074/jbc.M404920200; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko T, 2005, CELL MICROBIOL, V7, P461, DOI 10.1111/j.1462-5822.2005.00504.x; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kumar S, 2005, J BIOL CHEM, V280, P37005, DOI 10.1074/jbc.M506385200; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2005, P NATL ACAD SCI USA, V102, P6455, DOI 10.1073/pnas.0407559102; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JT, 2001, J BACTERIOL, V183, P3842, DOI 10.1128/JB.183.13.3842-3847.2001; Pili-Floury S, 2004, J BIOL CHEM, V279, P12848, DOI 10.1074/jbc.M313324200; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Reiser JB, 2004, J MOL BIOL, V340, P909, DOI 10.1016/j.jmb.2004.04.077; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Stenbak CR, 2004, J IMMUNOL, V173, P7339, DOI 10.4049/jimmunol.173.12.7339; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	46	137	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8286	8295		10.1074/jbc.M513030200	http://dx.doi.org/10.1074/jbc.M513030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428381	hybrid			2022-12-27	WOS:000236031000068
J	Vigetti, D; Ori, M; Viola, M; Genasetti, A; Karousou, E; Rizzi, M; Pallotti, F; Nardi, I; Hascall, VC; De Luca, G; Passi, A				Vigetti, D; Ori, M; Viola, M; Genasetti, A; Karousou, E; Rizzi, M; Pallotti, F; Nardi, I; Hascall, VC; De Luca, G; Passi, A			Molecular cloning and characterization of UDP-glucose dehydrogenase from the amphibian Xenopus laevis and its involvement in hyaluronan synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GROUP-A STREPTOCOCCI; N-ACETYLGALACTOSAMINE; EXTRACELLULAR-MATRIX; EARLY EMBRYOGENESIS; GROWTH-FACTOR; GENE; EXPRESSION; CELLS; MOUSE	UDP-glucose dehydrogenase (UGDH) supplies the cell with UDP-glucuronic acid (UDP-GlcUA), a precursor of glycosaminoglycan and proteoglycan synthesis. Here we reported the cloning and the characterization of the UGDH from the amphibian Xenopus laevis that is one of the model organisms for developmental biology. We found that X. laevis UGDH (xUGDH) maintained a very high degree of similarity with other known UGDH sequences both at the genomic and the protein levels. Also its kinetic parameters are similar to those of UGDH from other species. During X. laevis development, UDGH is always expressed but clearly increases its mRNA levels at the tail bud stage (i.e. 30 h post-fertilization). This result fits well with our previous observation that hyaluronan, a glycosaminoglycan that is synthesized using UDP-GlcUA and UDP-N-acetylglucosamine, is abundantly detected at this developmental stage. The expression of UGDH was found to be related to hyaluronan synthesis. In human smooth muscle cells the overexpression of xUGDH or endogenous abrogation of UGDH modulated hyaluronan synthesis specifically. Our findings were confirmed by in vivo experiments where the silencing of xUGDH in X. laevis embryos decreased glycosaminoglycan synthesis causing severe embryonic malformations because of a defective gastrulation process.	Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, I-21100 Varese, Italy; Univ Pisa, Dipartimento Fisiol & Biochim, Lab Biol Cellulare & Sviluppo, I-56010 Pisa, Italy; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthopaed Res Ctr ND20, Cleveland, OH 44195 USA	University of Insubria; University of Pisa; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Passi, A (corresponding author), Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, Via JH Dunant 5, I-21100 Varese, Italy.	alberto.passi@uninsubria.it	Vigetti, Davide/C-9861-2010; Rizzi, Manuela/AAE-9202-2021; Viola, Manuela/B-7120-2011; Ori, Michela/G-6835-2017; Ori, Michela/M-8003-2013; passi, alberto g/A-1752-2018; Ori, Michela/N-3452-2019	Vigetti, Davide/0000-0002-6339-8453; Rizzi, Manuela/0000-0002-6174-7111; Viola, Manuela/0000-0002-0634-6390; Ori, Michela/0000-0002-6777-0208; passi, alberto g/0000-0003-3328-3089; Pallotti, Francesco/0000-0001-9946-8516				Anderson RB, 1998, DEV BIOL, V202, P235, DOI 10.1006/dbio.1998.9006; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; Bakkers J, 2004, DEVELOPMENT, V131, P525, DOI 10.1242/dev.00954; BALDUINI C, 1973, BIOCHEM J, V133, P243, DOI 10.1042/bj1330243; BDOLAH A, 1968, BIOCHIM BIOPHYS ACTA, V159, P176, DOI 10.1016/0005-2744(68)90256-8; Beck CW, 2001, GENOME BIOL, V2; Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Bontemps Y, 2000, BIOCHEM BIOPH RES CO, V275, P981, DOI 10.1006/bbrc.2000.3389; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Campbell RE, 1997, J BIOL CHEM, V272, P3416, DOI 10.1074/jbc.272.6.3416; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; DALESSANDRO G, 1977, BIOCHEM J, V162, P281, DOI 10.1042/bj1620281; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; Dutton G.F., 1980, GLUCURONIDATION DRUG; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; Galli A, 2003, DEVELOPMENT, V130, P4919, DOI 10.1242/dev.00706; Garcia-Garcia MJ, 2003, CELL, V114, P727, DOI 10.1016/S0092-8674(03)00715-3; Ge X, 2004, EUR J BIOCHEM, V271, P14, DOI 10.1046/j.1432-1033.2003.03876.x; Grangeasse C, 2003, J BIOL CHEM, V278, P39323, DOI 10.1074/jbc.M305134200; GRUNZ H, 1990, CELL DIFFER DEV, V32, P117, DOI 10.1016/0922-3371(90)90105-6; Hacker U, 1997, DEVELOPMENT, V124, P3565; HADDON CM, 1991, DEVELOPMENT, V112, P541; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; Hickery MS, 2003, J BIOL CHEM, V278, P53063, DOI 10.1074/jbc.M209632200; Hoflich J, 2004, J BIOL CHEM, V279, P30440, DOI 10.1074/jbc.M402429200; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14224, DOI 10.1073/pnas.172522499; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Johansson H, 2002, BBA-GENE STRUCT EXPR, V1576, P53, DOI 10.1016/S0167-4781(02)00292-0; Kakizaki I, 2004, J BIOL CHEM, V279, P33281, DOI 10.1074/jbc.M405918200; Karousou EG, 2004, ELECTROPHORESIS, V25, P2919, DOI 10.1002/elps.200406034; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; Latinkic BV, 2003, DEVELOPMENT, V130, P2429, DOI 10.1242/dev.00449; Lehmann R, 2000, ELECTROPHORESIS, V21, P3010, DOI 10.1002/1522-2683(20000801)21:14<3010::AID-ELPS3010>3.0.CO;2-C; Lind T, 1999, GLYCOBIOLOGY, V9, P595, DOI 10.1093/glycob/9.6.595; Magee C, 2001, BIOCHEM J, V360, P667, DOI 10.1042/0264-6021:3600667; Mijakovic I, 2003, EMBO J, V22, P4709, DOI 10.1093/emboj/cdg458; MOLZ RJ, 1971, BIOCHIM BIOPHYS ACTA, V250, P6, DOI 10.1016/0005-2744(71)90114-8; Mullegger J, 2002, MOL REPROD DEV, V61, P312, DOI 10.1002/mrd.10097; Nardini M, 2004, GENE EXPR PATTERNS, V4, P303, DOI 10.1016/j.modgep.2003.10.006; Oppenheimer N. J., 1992, ENZYMES, P453; PEROZICH J, 1995, ADV EXP MED BIOL, V372, P79; Pitsillides AA, 2003, CELL BIOCHEM FUNCT, V21, P235, DOI 10.1002/cbf.1079; Princivalle M, 2002, INT J DEV BIOL, V46, P267; RODEN L, 1980, BIOCH GLYCOPROTEINS; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sander V, 2001, MECH DEVELOP, V102, P251, DOI 10.1016/S0925-4773(01)00302-1; SCHILLER JG, 1973, BIOCHIM BIOPHYS ACTA, V293, P1, DOI 10.1016/0005-2744(73)90369-0; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Somasekhar T, 1997, DEV BRAIN RES, V99, P208, DOI 10.1016/S0165-3806(97)00011-4; Sommer BJ, 2004, J BIOL CHEM, V279, P23590, DOI 10.1074/jbc.M401928200; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Torrado Mario, 2005, J Mol Cell Cardiol, V38, P353, DOI 10.1016/j.yjmcc.2004.11.034; Vigetti D, 2000, ARCH BIOCHEM BIOPHYS, V379, P90, DOI 10.1006/abbi.2000.1863; Vigetti D, 2003, MATRIX BIOL, V22, P511, DOI 10.1016/S0945-053X(03)00082-9; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289	64	92	93	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8254	8263		10.1074/jbc.M508516200	http://dx.doi.org/10.1074/jbc.M508516200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418163	hybrid, Green Published			2022-12-27	WOS:000236031000065
J	Sabina, J; Soll, D				Sabina, J; Soll, D			The RNA-binding PUA domain of archaeal tRNA-guanine transglycosylase is not required for archaeosine formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; GLUTAMINYL-TRANSFER-RNA; COLI YADB GENE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; POSTTRANSCRIPTIONAL MODIFICATION; QUEUOSINE MODIFICATION; S-ADENOSYLMETHIONINE; QSTAR NUCLEOSIDE; ANTICODON LOOP	Bacterial tRNA-guanine transglycosylase (TGT) replaces the G in position 34 of tRNA with preQ(1), the precursor to the modified nucleoside queuosine. Archaeal TGT, in contrast, substitutes preQ(0) for the G in position 15 of tRNA as the first step in archaeosine formation. The archaeal enzyme is about 60% larger than the bacterial protein; a carboxyl-terminal extension of 230 amino acids contains the PUA domain known to contact the four 3'-terminal nucleotides of tRNA. Here we show that the C-terminal extension of the enzyme is not required for the selection of G15 as the site of base exchange; truncated forms of Pyrococcus furiosus TGT retain their specificity for guanine exchange at position 15. Deletion of the PUA domain causes a 4-fold drop in the observed k(cat) (2.8 x 10(-3) s(-1)) and results in a 75-fold increased K-m for tRNA(Asp) (1.2 x 10(-5) M) compared with full-length TGT. Mutations in tRNAAsp altering or abolishing interactions with the PUA domain can compete with wildtype tRNA(Asp) for binding to full-length and truncated TGT enzymes. Whereas the C-terminal domains do not appear to play a role in selection of the modification site, their relevance for enzyme function and their role in vivo remains to be discovered.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu			NIGMS NIH HHS [GM 022854] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022854, R01GM022854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; Arluison V, 1999, J MOL BIOL, V289, P491, DOI 10.1006/jmbi.1999.2789; Bai Y, 2000, J BIOL CHEM, V275, P28731, DOI 10.1074/jbc.M002174200; BARON C, 1991, J BIOL CHEM, V266, P20375; Blaise M, 2004, NUCLEIC ACIDS RES, V32, P2768, DOI 10.1093/nar/gkh608; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campanacci V, 2004, J MOL BIOL, V337, P273, DOI 10.1016/j.jmb.2004.01.027; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; Dirheimer G., 1995, P93; Dubois DY, 2004, P NATL ACAD SCI USA, V101, P7530, DOI 10.1073/pnas.0401634101; Garcia GA, 2005, BIOORG CHEM, V33, P229, DOI 10.1016/j.bioorg.2005.01.001; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; Grosjean H, 2004, TRENDS BIOCHEM SCI, V29, P519, DOI 10.1016/j.tibs.2004.08.005; Grosjean H, 2004, TRENDS BIOCHEM SCI, V29, P165, DOI 10.1016/j.tibs.2004.02.009; Gu XR, 1998, BIOCHEMISTRY-US, V37, P339, DOI 10.1021/bi971590p; GUPTA R, 1984, J BIOL CHEM, V259, P9461; HAUMONT E, 1987, EUR J BIOCHEM, V168, P219, DOI 10.1111/j.1432-1033.1987.tb13408.x; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; Ishitani R, 2002, J MOL BIOL, V318, P665, DOI 10.1016/S0022-2836(02)00090-6; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; Iwata-Reuyl D, 2003, BIOORG CHEM, V31, P24, DOI 10.1016/S0045-2068(02)00513-8; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; Korencic D, 2004, J BIOL CHEM, V279, P48780, DOI 10.1074/jbc.M408753200; Kung FL, 1998, FEBS LETT, V431, P427, DOI 10.1016/S0014-5793(98)00801-1; Lauhon CT, 2004, J BIOL CHEM, V279, P23022, DOI 10.1074/jbc.M401757200; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mathews I, 2005, PROTEINS, V59, P869, DOI 10.1002/prot.20419; McCloskey JA, 2001, NUCLEIC ACIDS RES, V29, P4699, DOI 10.1093/nar/29.22.4699; MEIER F, 1985, EMBO J, V4, P823, DOI 10.1002/j.1460-2075.1985.tb03704.x; Morris RC, 2001, MOL GENET METAB, V74, P147, DOI 10.1006/mgme.2001.3216; Morris RC, 1999, J BIOMOL STRUCT DYN, V16, P757, DOI 10.1080/07391102.1999.10508291; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NOGUCHI S, 1982, J BIOL CHEM, V257, P6544; Nonekowski ST, 2002, J BIOL CHEM, V277, P7178, DOI 10.1074/jbc.M111077200; Nonekowski ST, 2001, RNA, V7, P1432; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P2931, DOI 10.1093/nar/4.8.2931; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P415, DOI 10.1093/nar/4.2.415; OKADA N, 1979, J BIOL CHEM, V254, P3061; Raczniak G, 2001, J BIOL CHEM, V276, P45862, DOI 10.1074/jbc.M109494200; Reader JS, 2004, J BIOL CHEM, V279, P6280, DOI 10.1074/jbc.M310858200; Rinehart J, 2004, J BIOL CHEM, V279, P1161, DOI 10.1074/jbc.M310100200; Romier C, 1997, FEBS LETT, V416, P93, DOI 10.1016/S0014-5793(97)01175-7; Salazar JC, 2004, P NATL ACAD SCI USA, V101, P7536, DOI 10.1073/pnas.0401982101; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Van Lanen SG, 2005, P NATL ACAD SCI USA, V102, P4264, DOI 10.1073/pnas.0408056102; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Waters E, 2003, P NATL ACAD SCI USA, V100, P12984, DOI 10.1073/pnas.1735403100; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Xie W, 2003, NAT STRUCT BIOL, V10, P781, DOI 10.1038/nsb976; YARUS M, 1970, ANAL BIOCHEM, V35, P450, DOI 10.1016/0003-2697(70)90207-1	55	20	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6993	7001		10.1074/jbc.M512841200	http://dx.doi.org/10.1074/jbc.M512841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407303	hybrid			2022-12-27	WOS:000236030900012
J	Watanabe, S; Ikebe, R; Ikebe, M				Watanabe, S; Ikebe, R; Ikebe, M			Drosophila myosin VIIA is a high duty ratio motor with a unique kinetic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							USHER-SYNDROME 1B; UNCONVENTIONAL MYOSINS; FLUORESCENT-PROBE; MOLECULAR MOTOR; LARGE STEP; ACTIN; GENE; DEAFNESS; DOMAIN; SUBFRAGMENT-1	Mutations of myosin VIIA cause deafness in various species from human and mice to Zebrafish and Drosophila. We analyzed the kinetic mechanism of the ATPase cycle of Drosophila myosin VIIA by using a single-headed construct with the entire neck domain. The steady-state ATPase activity (0.06 s(-1)) was markedly activated by actin to yield V-max and K-ATPase of 1.72 s(-1) and 3.2 mu M, respectively. The most intriguing finding is that the ATP hydrolysis predominantly takes place in the actin-bound form (actin-attached hydrolysis) for the actomyosin VIIA ATPase reaction. The ATP hydrolysis rate was much faster for the actin-attached form than the dissociated form, in contrast to other myosins reported so far. Both the ATP hydrolysis step and the phosphate release step were significantly faster than the entire ATPase cycle rate, thus not rate-determining. The rate of ADP dissociation from actomyosin VIIA was 1.86 s(-1), which was comparable with the overall ATPase cycle rate, thus assigned to be a rate-determining step. The results suggest that Drosophila myosin VIIA spends the majority of the ATPase cycle in an actomyosin . ADP form, a strong actin binding state. The duty ratio calculated from our kinetic model was similar to 0.9. Therefore, myosin VIIA is classified to be a high duty ratio motor. The present results suggested that myosin VIIA can be a processive motor to serve cargo trafficking in cells once it forms a dimer structure.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR048898, R01AR048526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 41653, AR 048526, AR 048898] Funding Source: Medline; NIDCD NIH HHS [DC 006103] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Friedman TB, 1999, AM J MED GENET, V89, P147, DOI 10.1002/(SICI)1096-8628(19990924)89:3<147::AID-AJMG5>3.0.CO;2-6; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Hasson T, 1999, CURR BIOL, V9, pR838, DOI 10.1016/S0960-9822(00)80040-8; Henn A, 2005, J BIOL CHEM, V280, P39665, DOI 10.1074/jbc.M507667200; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; Knight PJ, 2005, J BIOL CHEM, V280, P34702, DOI 10.1074/jbc.M504887200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Liu XR, 1999, J NEUROSCI, V19, P6267; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Self T, 1998, DEVELOPMENT, V125, P557; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Soni LE, 2005, CELL MOTIL CYTOSKEL, V62, P13, DOI 10.1002/cm.20080; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Todi SV, 2005, CURR BIOL, V15, P862, DOI 10.1016/j.cub.2005.03.050; Todorov PT, 2001, BIOCHEM J, V354, P267, DOI 10.1042/0264-6021:3540267; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Watanabe TM, 2004, P NATL ACAD SCI USA, V101, P9630, DOI 10.1073/pnas.0402914101; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yang Y, 2005, J BIOL CHEM, V280, P32061, DOI 10.1074/jbc.M506765200	48	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7151	7160		10.1074/jbc.M511592200	http://dx.doi.org/10.1074/jbc.M511592200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415346	hybrid			2022-12-27	WOS:000236030900030
J	Ikeda, H; Omoteyama, K; Yoshida, K; Nishi, S; Sakai, M				Ikeda, H; Omoteyama, K; Yoshida, K; Nishi, S; Sakai, M			CCAAT enhancer-binding protein alpha suppresses the rat placental glutathione S-transferase gene in normal liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GENE; CHEMICAL HEPATOCARCINOGENESIS; SILENCER ELEMENT; RESPONSIVE ELEMENTS; FUNCTIONAL-ANALYSIS; GST-P; CELLS; TRANSCRIPTION; EXPRESSION; FAMILY	The rat placental glutathione S-transferase (GST-P), an isozyme of glutathione S-transferase, is not expressed in normal liver but is highly induced at an early stage of chemical hepatocarcinogenesis and in hepatomas. Recently, we reported that the NF-E2 p45-related factor 2 (Nrf2)/MafK heterodimer binds to GST-P enhancer 1 (GPE1), a strong enhancer of the GST-P gene, and activates this gene in preneoplastic lesions and hepatomas. In addition to the positive regulation during hepatocarcinogenesis, negative regulatory mechanisms might work to repress GST-P in normal liver, but this remains to be clarified. In this work, we identify the CCAAT enhancer-binding protein alpha(C/EBP alpha) as a negative regulator that binds to GPE1 and suppresses GST-P expression in normal liver. C/EBP alpha binds to part of the GPE1 sequence, and the binding of Nrf2/MafK and C/EBP alpha to GPE1 is mutually exclusive. In a transient-transfection analysis, C/EBP alpha activated GPE1 in F9 embryonal carcinoma cells but strongly inhibited GPE1 activity in hepatoma cells. The expression of C/EBP alpha was specifically suppressed in GST-P-positive preneoplastic foci in the livers of carcinogen-treated rats. A chromatin immunoprecipitation analysis showed that C/EBP alpha bound to GPE1 in the normal liver in vivo but did not bind in preneoplastic hepatocytes. Introduction of the C/EBP alpha gene fused with the estrogen receptor ligand-binding domain into hepatoma cells, and subsequent activation by beta-estradiol led to the suppression of endogenous GST-P expression. These results indicate that C/EBP alpha is a negative regulator of GST-P gene expression in normal liver.	Hokkaido Univ, Sch Med, Dept Hlth Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Grad Sch Med, Dept Biochem, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Sakai, M (corresponding author), Hokkaido Univ, Sch Med, Dept Hlth Sci, Kita Ku, N12,W5, Sapporo, Hokkaido 0600812, Japan.	m_sakai@med.hokudai.ac.jp	Sakai, Masaharu/A-4773-2012					BAMMLER TK, 1994, BIOCHEM J, V298, P385, DOI 10.1042/bj2980385; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARBER E, 1984, CAN J BIOCHEM CELL B, V62, P486, DOI 10.1139/o84-066; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HATAYAMA I, 1993, CARCINOGENESIS, V14, P537, DOI 10.1093/carcin/14.3.537; Ikeda H, 2004, BIOCHEM J, V380, P515, DOI 10.1042/BJ20031948; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KITAHARA A, 1984, CANCER RES, V44, P2698; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; MOORE MA, 1987, CARCINOGENESIS, V8, P483, DOI 10.1093/carcin/8.3.483; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osada S, 1997, J BIOCHEM, V121, P355; Osada S, 1996, J BIOL CHEM, V271, P3891; Osada S, 1995, J BIOL CHEM, V270, P31288, DOI 10.1074/jbc.270.52.31288; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; SAKAI M, 1990, PROG CLIN BIOL RES, V344, P123; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SAKAI M, 1995, CANCER RES, V55, P5370; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO K, 1989, ADV CANCER RES, V52, P205; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; Satoh K, 2002, CARCINOGENESIS, V23, P1193, DOI 10.1093/carcin/23.7.1193; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; SUGIOKA Y, 1985, CANCER RES, V45, P365; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; SUZUKI T, 1995, CANCER RES, V55, P2651; Tanabe A, 2002, BIOL PHARM BULL, V25, P970, DOI 10.1248/bpb.25.970; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; XU X, 1994, J BIOL CHEM, V269, P30268	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6734	6741		10.1074/jbc.M513014200	http://dx.doi.org/10.1074/jbc.M513014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407263	hybrid			2022-12-27	WOS:000236030800071
J	Kuwae, A; Matsuzawa, T; Ishikawa, N; Abe, H; Nonaka, T; Fukuda, H; Imajoh-Ohmi, S; Abe, A				Kuwae, A; Matsuzawa, T; Ishikawa, N; Abe, H; Nonaka, T; Fukuda, H; Imajoh-Ohmi, S; Abe, A			BopC is a novel type III effector secreted by Bordetella bronchiseptica and has a critical role in type III-dependent necrotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LEGIONELLA-PNEUMOPHILA; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; PROTEIN FAMILIES; PRODOM DATABASE; RNA-POLYMERASE; VIRULENCE; SHIGELLA	In Bordetella bronchiseptica, the functional type III secretion system (TTSS) is required for the induction of necrotic cell death in infected mammalian cells. To identify the factor(s) involved in necrotic cell death, type III-secreted proteins from B. bronchiseptica were analyzed using matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry and electrospray ionization tandem mass spectrometry. We identified a 69-kDa secreted protein designated BopC. The gene encoding BopC is located outside of the TTSS locus and is also highly conserved in both Bordetella parapertussis and Bordetella pertussis. The results of a lactate dehydrogenase release assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling assay demonstrated that BopC is required for necrotic cell death. It has been reported that tyrosine-phosphorylated proteins (PY) of host cells are dephosphorylated during B. bronchiseptica infection in a TTSS-dependent manner. We found that BopC is also involved in PY dephosphorylation in infected host cells. It appears that the necrotic cell death triggered by BopC occurs prior to the PY reduction in host cells, because Bordetella-induced cell death was not affected even in the presence of a dephosphorylation inhibitor. Furthermore, a translocation assay showed that the signal sequence for both secretion into culture supernatant and translocation into the host cell is located in 48 amino acid residues of the BopC N terminus. This report reveals for the first time that a novel type III effector, BopC, is required for the induction of necrotic cell death during Bordetella infection.	Kitasato Univ, Kitasato Inst Life Sci, Lab Bacterial Infect, Minato Ku, Tokyo 1088641, Japan; Kitasato Inst, Minato Ku, Tokyo 1088642, Japan; Osaka Univ, Grad Sch Med, Div Appl Bacteriol, Osaka 5650871, Japan; Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, Tokyo 1568585, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Lab Ctr Prote Res,Minato Ku, Tokyo 1088639, Japan	Kitasato University; Osaka University; Tokyo Institute of Psychiatry; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Kuwae, A (corresponding author), Kitasato Univ, Kitasato Inst Life Sci, Lab Bacterial Infect, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	kuwae@lisci.kitasato-u.ac.jp	Abe, Akio/AAQ-2464-2020; Nonaka, Takashi/L-8572-2017	Nonaka, Takashi/0000-0002-0830-9403				Anderson DM, 1999, P NATL ACAD SCI USA, V96, P12839, DOI 10.1073/pnas.96.22.12839; ATTWOOD TK, 1994, PROTEIN ENG, V7, P841, DOI 10.1093/protein/7.7.841; Attwood TK, 2002, NUCLEIC ACIDS RES, V30, P239, DOI 10.1093/nar/30.1.239; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOUCHER PE, 1995, J BACTERIOL, V177, P6486, DOI 10.1128/jb.177.22.6486-6491.1995; Boucher PE, 1997, J BACTERIOL, V179, P1755, DOI 10.1128/jb.179.5.1755-1763.1997; Charpentier X, 2004, J BACTERIOL, V186, P5486, DOI 10.1128/JB.186.16.5486-5495.2004; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; Corpet F, 1999, NUCLEIC ACIDS RES, V27, P263, DOI 10.1093/nar/27.1.263; Cotter PA, 1997, MOL MICROBIOL, V24, P671, DOI 10.1046/j.1365-2958.1997.3821741.x; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; Creasey EA, 2003, MICROBIOL-SGM, V149, P3639, DOI 10.1099/mic.0.26735-0; Creasey EA, 2003, MOL MICROBIOL, V47, P209, DOI 10.1046/j.1365-2958.2003.03290.x; deTejada GM, 1996, MOL MICROBIOL, V22, P895, DOI 10.1046/j.1365-2958.1996.01538.x; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Elliott SJ, 2001, INFECT IMMUN, V69, P4027, DOI 10.1128/IAI.69.6.4027-4033.2001; Feldman MF, 2003, FEMS MICROBIOL LETT, V219, P151, DOI 10.1016/S0378-1097(03)00042-9; Foley JE, 2002, PREV VET MED, V54, P141, DOI 10.1016/S0167-5877(02)00022-3; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; GOODNOW RA, 1980, MICROBIOL REV, V44, P722, DOI 10.1128/MMBR.44.4.722-738.1980; Gruenheid S, 2004, MOL MICROBIOL, V51, P1233, DOI 10.1046/j.1365-2958.2003.03911.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; HEININGER U, 1994, PEDIATR INFECT DIS J, V13, P306, DOI 10.1097/00006454-199404000-00011; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; Henikoff S, 1999, BIOINFORMATICS, V15, P471, DOI 10.1093/bioinformatics/15.6.471; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Karimova G, 1996, MOL MICROBIOL, V20, P489, DOI 10.1046/j.1365-2958.1996.5231057.x; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kuwae A, 2001, J BIOL CHEM, V276, P32230, DOI 10.1074/jbc.M103831200; Kuwae A, 2003, CELL MICROBIOL, V5, P973, DOI 10.1046/j.1462-5822.2003.00341.x; LEVINE MM, 1985, J INFECT DIS, V152, P550, DOI 10.1093/infdis/152.3.550; Lord JM, 2005, CURR BIOL, V15, pR169, DOI 10.1016/j.cub.2005.02.043; Magyar T, 2002, VACCINE, V20, P1797, DOI 10.1016/S0264-410X(02)00023-3; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; Nagai H, 2001, EMBO J, V20, P5962, DOI 10.1093/emboj/20.21.5962; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Nogawa H, 2004, J BACTERIOL, V186, P3806, DOI 10.1128/JB.186.12.3806-3813.2004; Nonaka T, 2003, MICROBIOL-SGM, V149, P2513, DOI 10.1099/mic.0.26341-0; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ogino T, 2004, J VIROL, V78, P11766, DOI 10.1128/JVI.78.21.11766-11777.2004; Olsson J, 2004, J BACTERIOL, V186, P4110, DOI 10.1128/JB.186.13.4110-4123.2004; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Rossier O, 1999, P NATL ACAD SCI USA, V96, P9368, DOI 10.1073/pnas.96.16.9368; Roy CR, 1997, INFECT IMMUN, V65, P571, DOI 10.1128/IAI.65.2.571-578.1997; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; Stockbauer KE, 2003, CELL MICROBIOL, V5, P123, DOI 10.1046/j.1462-5822.2003.00260.x; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Toyotome T, 2001, J BIOL CHEM, V276, P32071, DOI 10.1074/jbc.M101882200; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; Van Nhieu GT, 1999, CURR OPIN MICROBIOL, V2, P51; VanderZee A, 1997, J BACTERIOL, V179, P6609, DOI 10.1128/jb.179.21.6609-6617.1997; Yeh Sylvia H, 2003, Expert Rev Vaccines, V2, P113, DOI 10.1586/14760584.2.1.113; YODA H, 1982, Experimental Animals (Tokyo), V31, P113; Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319; Yuk MH, 2000, MOL MICROBIOL, V35, P991, DOI 10.1046/j.1365-2958.2000.01785.x; Yuk MH, 1998, MOL MICROBIOL, V28, P945, DOI 10.1046/j.1365-2958.1998.00850.x	65	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6589	6600		10.1074/jbc.M512711200	http://dx.doi.org/10.1074/jbc.M512711200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407269	hybrid			2022-12-27	WOS:000236030800055
J	Mattioli, I; Geng, H; Sebald, A; Hodel, M; Bucher, C; Kracht, M; Schmitz, ML				Mattioli, I; Geng, H; Sebald, A; Hodel, M; Bucher, C; Kracht, M; Schmitz, ML			Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-RELATED KINASES; LIVER DEGENERATION; REGULATORY SUBUNIT; GENE-EXPRESSION; PHORBOL ESTER; ACTIVATION; ALPHA; BETA; BINDING; TBK1	Here we identify IKK epsilon as a novel NF-kappa B p65 kinase that mediates inducible phosphorylation of Ser(468) and Ser(536) in response to T cell costimulation. In addition, the kinase activity of IKK epsilon contributes to the control of p65 nuclear uptake. Serines 468 and 536 are evolutionarily conserved, and the surrounding amino acids display sequence homology. Down-regulation of IKK epsilon levels by small interfering RNA does not affect inducible phosphorylation of Ser(536) but largely prevents Ser(468) phosphorylation induced by T cell costimulation. Ser(536)-phosphorylated p65 is found predominantly in the cytosol. In contrast, the Ser(468) phosphorylated form of this transcription factor occurs mainly in the nucleus, suggesting a function for transactivation. Reconstitution of p65(-/-) cells with either wild type p65 or point-mutated p65 variants showed that inducible phosphorylation of Ser(468) serves to enhance p65-dependent transactivation. These results also provide a mechanistic link that helps to explain the relevance of IKK epsilon for the expression of a subset of NF-kappa B target genes without affecting cytosolic I kappa B degradation.	Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	Justus Liebig University Giessen; Hannover Medical School; University of Bern	Schmitz, ML (corresponding author), Univ Giessen, Fac Med, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	lienhard.schmitz@biochemie.med.uni-giessen.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X				Bae JS, 2003, BIOCHEM BIOPH RES CO, V305, P1094, DOI 10.1016/S0006-291X(03)00869-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Ben-Neriah Y, 2004, EMBO REP, V5, P668, DOI 10.1038/sj.embor.7400187; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Frelin C, 2003, ONCOGENE, V22, P8187, DOI 10.1038/sj.onc.1206963; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Mattioli I, 2004, BLOOD, V104, P3302, DOI 10.1182/blood-2004-04-1536; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Tanahashi M, 2001, HUM IMMUNOL, V62, P771, DOI 10.1016/S0198-8859(01)00276-2; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wang NZ, 2005, GENE, V353, P118, DOI 10.1016/j.gene.2005.04.013; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	47	103	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6175	6183		10.1074/jbc.M508045200	http://dx.doi.org/10.1074/jbc.M508045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407239	hybrid			2022-12-27	WOS:000236030800009
J	Samino, Y; Lopez, D; Guil, S; Saveanu, L; van Endert, PM; Del Val, M				Samino, Y; Lopez, D; Guil, S; Saveanu, L; van Endert, PM; Del Val, M			A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural Ligands from HIV envelope protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; EPITOPE PRECURSOR PEPTIDES; ENDOPLASMIC-RETICULUM; 3-DIMENSIONAL STRUCTURE; ENDOGENOUS PEPTIDES; T-LYMPHOCYTES; CELL-LINE; MOLECULES; AMINOPEPTIDASE; BINDING	Viral antigens complexed with major histocompatibility complex (MHC) class Imolecules are recognized by cytotoxic T lymphocytes on infected cells. Assays with synthetic peptides identify optimal MHC class I ligands often used for vaccines. However, when natural peptides are analyzed, more complex mixtures including long peptides bulging in the middle of the binding site or with carboxyl extensions are found, reflecting lack of exposure to carboxypeptidases in the antigen processing pathway. In contrast, precursor peptides are exposed to extensive cytosolic aminopeptidase activity, and fewer than 1% survive, only to be further trimmed in the endoplasmic reticulum. We show here a striking example of a nested set of at least three highly antigenic and similarly abundant natural MHC class I ligands, 15, 10, and 9 amino acids in length, derived from a single human immunodeficiency virus gp160 epitope. Antigen processing, thus, gives rise to a rich pool of possible ligands from which MHC class I molecules can choose. The natural peptide set includes a 15-residue-long peptide with unprecedented 6 N-terminal residues that most likely extend out of the MHC class I binding groove. This 15-mer is the longest natural peptide known recognized by cytotoxic T lymphocytes and is surprisingly protected from aminopeptidase trimming in living cells.	Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain; Univ Paris 05, INSERM, U580, F-75015 Paris, France	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Del Val, M (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.	mdval@isciii.es	López, Daniel/I-2632-2014; van Endert, Peter/R-4606-2017; Saveanu, Loredana/K-6821-2017; SAVEANU, Loredana/Q-1241-2019; Del Val, Margarita/E-4769-2010	López, Daniel/0000-0003-0268-5878; van Endert, Peter/0000-0003-3782-0750; SAVEANU, Loredana/0000-0003-3138-7968; Del Val, Margarita/0000-0001-6769-4279				ABASTADO JP, 1987, J EXP MED, V166, P327, DOI 10.1084/jem.166.2.327; Achour A, 2002, IMMUNITY, V17, P757, DOI 10.1016/S1074-7613(02)00478-8; Balendiran GK, 1997, P NATL ACAD SCI USA, V94, P6880, DOI 10.1073/pnas.94.13.6880; BERGMANN CC, 1994, J IMMUNOL, V152, P5603; Brouwenstijn N, 2001, IMMUNITY, V15, P95, DOI 10.1016/S1074-7613(01)00174-1; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; CHEN Y, 1994, J IMMUNOL, V152, P2874; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CRUMPACKER DB, 1992, J IMMUNOL, V148, P3004; Daniel S, 1997, J IMMUNOL, V159, P2350; DEL VM, 1991, CELL, V66, P1145; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; Flyer DC, 2002, INFECT IMMUN, V70, P2926, DOI 10.1128/IAI.70.6.2926-2932.2002; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fruci D, 2001, IMMUNITY, V15, P467, DOI 10.1016/S1074-7613(01)00203-5; FRUMENTO G, 1993, CELL IMMUNOL, V152, P623, DOI 10.1006/cimm.1993.1318; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HENGEL H, 1995, J IMMUNOL, V154, P4557; Herr W, 1999, P NATL ACAD SCI USA, V96, P12033, DOI 10.1073/pnas.96.21.12033; KORBER BTM, 2005, LAUR060036 LOS AL NA; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KOZLOWSKI S, 1993, J IMMUNOL, V151, P4033; Lauvau G, 1999, J EXP MED, V190, P1227, DOI 10.1084/jem.190.9.1227; Lopez D, 2000, J IMMUNOL, V164, P5070, DOI 10.4049/jimmunol.164.10.5070; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; OZATO K, 1980, J IMMUNOL, V125, P2473; PARKER KC, 1994, J IMMUNOL, V152, P163; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Probst-Kepper M, 2001, J EXP MED, V193, P1189, DOI 10.1084/jem.193.10.1189; Probst-Kepper M, 2004, J IMMUNOL, V173, P5610, DOI 10.4049/jimmunol.173.9.5610; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Samino Y, 2004, J BIOL CHEM, V279, P1151, DOI 10.1074/jbc.M305343200; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Serwold T, 1999, J IMMUNOL, V162, P4712; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Speir JA, 2001, IMMUNITY, V14, P81, DOI 10.1016/S1074-7613(01)00091-7; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860	51	31	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6358	6365		10.1074/jbc.M512263200	http://dx.doi.org/10.1074/jbc.M512263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407287	Green Published, hybrid			2022-12-27	WOS:000236030800029
J	Xie, ZL; Dong, YZ; Zhang, M; Cui, MZ; Cohen, RA; Riek, U; Neumann, D; Schlattner, U; Zou, MH				Xie, ZL; Dong, YZ; Zhang, M; Cui, MZ; Cohen, RA; Riek, U; Neumann, D; Schlattner, U; Zou, MH			Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE; TUMOR-SUPPRESSOR; UPSTREAM KINASE; NITRIC-OXIDE; LKB1; GLUCOSE; PHOSPHORYLATION; BETA; STIMULATION	We previously reported the phosphoinositide 3-kinase-dependent activation of the 5'-AMP-activated kinase ( AMPK) by peroxynitrite (ONOO-) and hypoxia-reoxygenation in cultured endothelial cells. Here we show the molecular mechanism of activation of this pathway. Exposure of bovine aortic endothelial cells to ONOO- significantly increased the phosphorylation of both Thr(172) of AMPK and Ser(1179) of endothelial nitric-oxide synthase, a known downstream enzyme of AMPK. In addition, activation of AMPK by ONOO- was accompanied by increased phosphorylation of protein kinase C zeta (PKC zeta) ( Thr(410/403)) and translocation of cytosolic PKC zeta into the membrane. Further, inhibition of PKC zeta abrogated ONOO--induced AMPK-Thr(172) phosphorylation as that of endothelial nitric-oxide synthase. Furthermore, overexpression of a constitutively active PKC zeta mutant enhanced the phosphorylation of AMPK-Thr(172), suggesting that PKC zeta is upstream of AMPK activation. In contrast, ONOO- activated PKC zeta in LKB1-deficient HeLa-S3 but affected neither AMPK-Thr(172) nor AMPK activity. These data suggest that LKB1 is required for PKC zeta-enhanced AMPK activation. In vitro, recombinant PKC zeta phosphorylated LKB1 at Ser(428), resulting in phosphorylation of AMPK at Thr(172). Further, direct mutation of Ser(428) of LKB1 into alanine, like the kinase-inactive LKB1 mutant, abolished ONOO--induced AMPK activation. In several cell types originating from human, rat, and mouse, inhibition of PKC zeta significantly attenuated the phosphorylation of both LKB1-Ser(428) and AMPK-Thr(172) that were enhanced by ONOO-. Taken together, we conclude that PKC zeta can regulate AMPK activity by increasing the Ser(428) phosphorylation of LKB1, resulting in association of LKB1 with AMPK and consequent AMPK Thr(172) phosphorylation by LKB1.	Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Endocrinol & Diabet, Oklahoma City, OK 73104 USA; Univ Tennessee, Coll Vet Med, Dept Pathol, Knoxville, TN 37996 USA; Boston Univ, Sch Med, Vasc Biol Unit, Boston, MA 02118 USA; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Boston University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zou, MH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Endocrinol & Diabet, 941 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	ming-hui-zou@ouhsc.edu	Schlattner, Uwe/D-1267-2009	Schlattner, Uwe/0000-0003-1159-5911; Neumann, Dietbert/0000-0002-4316-684X; Cui, Mei-Zhen/0000-0003-4745-6999; /0000-0002-1070-6408	NHLBI NIH HHS [HL68758, HL080499, HL079584, HL07439] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079584, R01HL080499, T32HL007439, P01HL068758] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beauloye C, 2002, FEBS LETT, V531, P324, DOI 10.1016/S0014-5793(02)03552-4; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Carling D, 2005, BIOCHIMIE, V87, P87, DOI 10.1016/j.biochi.2004.10.017; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; DAVIS B, 2006, IN PRESS DIABETES; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Fleming I, 2003, THROMB HAEMOSTASIS, V90, P863, DOI 10.1160/TH03-04-0228; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Green Jeremy B A, 2004, Cell Cycle, V3, P12; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; HUTBER CA, 1996, AM J PHYSIOL, V272, pE262; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shizukuda Y, 2002, AM J PHYSIOL-HEART C, V282, pH320, DOI 10.1152/ajpheart.2002.282.1.H320; Tan MQ, 2003, J BIOL CHEM, V278, P2824, DOI 10.1074/jbc.M211523200; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xie ZL, 2004, J BIOL CHEM, V279, P39513, DOI 10.1074/jbc.M405844200; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	56	156	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6366	6375		10.1074/jbc.M511178200	http://dx.doi.org/10.1074/jbc.M511178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407220	hybrid			2022-12-27	WOS:000236030800030
J	Ghosh, DK; Holliday, MA; Thomas, C; Weinberg, JB; Smith, SME; Salerno, JC				Ghosh, Dipak K.; Holliday, Michael A.; Thomas, Clayton; Weinberg, J. Brice; Smith, Susan M. E.; Salerno, John C.			Nitric-oxide synthase output state - Design and properties of nitric-oxide synthase oxygenase/FMN domain constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; ELECTRON-TRANSFER; TETRAHYDROBIOPTERIN INTERACTION; CRYSTAL-STRUCTURE; NO SYNTHASE; BINDING; FLAVIN; HEME; CALMODULIN; SUBSTRATE	Mammalian nitric-oxide synthases are large modular enzymes that evolved from independently expressed ancestors. Calmodulin-controlled isoforms are signal generators; calmodulin activates electron transfer from NADPH through three reductase domains to an oxygenase domain. Structures of the reductase unit and its homologs show FMN and FAD in contact but too isolated from the protein surface to permit exit of reducing equivalents. To study states in which FMN/heme electron transfer is feasible, we designed and produced constructs including only oxygenase and FMN binding domains, eliminating strong internal reductase complex interactions. Constructs for all mammalian isoforms were expressed and purified as dimers. All synthesize NO with peroxide as the electron donor at rates comparable with corresponding oxygenase constructs. All bind cofactors nearly stoichiometrically and have native catalytic sites by spectroscopic criteria. Modest differences in electrochemistry versus independently expressed heme and FMN binding domains suggest interdomain interactions. These interactions can be convincingly demonstrated via calmodulin-induced shifts in high spin ferriheme EPR spectra and through mutual broadening of heme and FMNH center dot radical signals in inducible nitric-oxide synthase constructs. Blue neutral FMN semiquinone can be readily observed; potentials of one electron couple ( in inducible nitric-oxide synthase oxygenase FMN, FMN oxidized/semiquione couple = +70 mV, FMN semiquinone/hydroquinone couple = -180 mV, and heme = -180 mV) indicate that FMN is capable of serving as a one electron heme reductant. The construct will serve as the basis for future studies of the output state for NADPH derived reducing equivalents.	Rensselaer Polytech Inst, Dept Biol, Ithaca, NY 14853 USA; Duke Univ, Dept Med, Durham, NC 27705 USA; Vet Affairs Med Ctr, Durham, NC USA	Rensselaer Polytechnic Institute; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ghosh, DK (corresponding author), Rensselaer Polytech Inst, Dept Biol, Ithaca, NY 14853 USA.	dgx@acpub.duke.edu; salerj@rpi.edu	salerno, john c/A-2595-2014					ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 2001, BIOCHEM SOC T, V29, P147, DOI 10.1042/0300-5127:0290147; Dutton P L, 1978, Methods Enzymol, V54, P411; Fedorov R, 2004, P NATL ACAD SCI USA, V101, P5892, DOI 10.1073/pnas.0306588101; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gao YT, 2004, J BIOL CHEM, V279, P18759, DOI 10.1074/jbc.M308936200; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Garnaud PE, 2004, BIOCHEMISTRY-US, V43, P11035, DOI 10.1021/bi049312v; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Ghosh DK, 2001, P NATL ACAD SCI USA, V98, P10392, DOI 10.1073/pnas.181251298; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Govindaraj S, 1997, J BIOL CHEM, V272, P7915, DOI 10.1074/jbc.272.12.7915; Harris D, 1998, KEIO UNIV SYMP LIFE, V1, P289; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; Jones RJ, 2004, J BIOL CHEM, V279, P36876, DOI 10.1074/jbc.M402808200; KWON NS, 1989, J BIOL CHEM, V264, P20496; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sessa WC, 2005, MEM I OSWALDO CRUZ, V100, P15, DOI 10.1590/S0074-02762005000900004; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Smith S. M. E., 2000, Nitric Oxide, V4, P224; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	44	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14173	14183		10.1074/jbc.M509937200	http://dx.doi.org/10.1074/jbc.M509937200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16461329	hybrid			2022-12-27	WOS:000237512300041
J	Su, LT; Agapito, MA; Li, MJ; Sinomson, WTN; Huttenlocher, A; Habas, R; Yue, LX; Runnels, LW				Su, LT; Agapito, MA; Li, MJ; Sinomson, WTN; Huttenlocher, A; Habas, R; Yue, LX; Runnels, LW			TRPM7 regulates cell adhesion by controlling the calcium-dependent protease calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE RETRACTION; POLYVALENT CATIONS; NEURONAL DEATH; MIC CHANNELS; GROWTH CONE; ACTIVATION; KINASE; RHO; MOTILITY; TRANSFORMATION	m-Calpain is a protease implicated in the control of cell adhesion through focal adhesion disassembly. The mechanism by which the enzyme is spatially and temporally controlled is not well understood, particularly because the dependence of calpain on calcium exceeds the submicromolar concentrations normally observed in cells. Here we show that the channel kinase TRPM7 localizes to peripheral adhesion complexes with m-calpain, where it regulates cell adhesion by controlling the activity of the protease. Our research revealed that overexpression of TRPM7 in cells caused cell rounding with a concomitant loss of cell adhesion that is dependent upon the channel of the protein but not its kinase activities. Knockdown of m-calpain blocked TRPM7-induced cell rounding and cell detachment. Silencing of TRPM7 by RNA interference, however, strengthened cell adhesion and increased the number of peripheral adhesion complexes in the cells. Together, our results suggest that the ion channel TRPM7 regulates cell adhesion through m-calpain by mediating the local influx of calcium into peripheral adhesion complexes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT 06030 USA; Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Connecticut; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Rutgers State University New Brunswick; Rutgers State University Medical Center	Runnels, LW (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	runnellw@umdnj.edu		Runnels, Loren/0000-0002-2537-7360	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL078960-02, R01 HL078960] Funding Source: Medline; NIGMS NIH HHS [T32 GM008692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Elizondo MR, 2005, CURR BIOL, V15, P667, DOI 10.1016/j.cub.2005.02.050; Fleig Andrea, 2004, Novartis Found Symp, V258, P248; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hanano T, 2004, J PHARMACOL SCI, V95, P403, DOI 10.1254/jphs.FP0040273; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Inserte J, 2005, CIRC RES, V97, P465, DOI 10.1161/01.RES.0000181170.87738.f3; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jiang JM, 2005, J GEN PHYSIOL, V126, P137, DOI 10.1085/jgp.200409185; Kerschbaum HH, 2003, BIOPHYS J, V84, P2293, DOI 10.1016/S0006-3495(03)75035-8; Kozak JA, 2005, J GEN PHYSIOL, V126, P499, DOI 10.1085/jgp.200509324; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Liu XL, 2001, AM J PHYSIOL-RENAL, V281, pF728, DOI 10.1152/ajprenal.2001.281.4.F728; Mamoune A, 2003, CANCER RES, V63, P4632; Marzocco S, 2004, SHOCK, V21, P38, DOI 10.1097/01.shk.0000095056.62263.b2; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; Mehendale HM, 2005, TRENDS PHARMACOL SCI, V26, P232, DOI 10.1016/j.tips.2005.03.008; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nagy Z, 2004, ADV EXP MED BIOL, V541, P39; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nilius Bernd, 2004, Novartis Found Symp, V258, P140; Ortiz-Urda S, 2005, SCIENCE, V307, P1773, DOI 10.1126/science.1106209; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; PERRIN BJ, 2005, MOL BIOL CELL; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Schmitz C, 2005, J BIOL CHEM, V280, P37763, DOI 10.1074/jbc.M509175200; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; SONG DK, 1994, J NEUROSCI RES, V39, P474, DOI 10.1002/jnr.490390414; Spira ME, 2003, J COMP NEUROL, V457, P293, DOI 10.1002/cne.10569; Starling A, 2003, J MOL NEUROSCI, V21, P233, DOI 10.1385/JMN:21:3:233; Tamada Y, 2002, COMP BIOCHEM PHYS B, V131, P221, DOI 10.1016/S1096-4959(01)00489-4; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Wells A, 2005, INT REV CYTOL, V245, P1, DOI 10.1016/S0074-7696(05)45001-9; Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Zatz M, 2005, NEW ENGL J MED, V352, P2413, DOI 10.1056/NEJMra043361	67	185	193	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11260	11270		10.1074/jbc.M512885200	http://dx.doi.org/10.1074/jbc.M512885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16436382	Green Accepted, hybrid			2022-12-27	WOS:000236822200069
J	Wu, WF; Misra, RS; Russell, JQ; Flavell, RA; Rincon, M; Budd, RC				Wu, WF; Misra, RS; Russell, JQ; Flavell, RA; Rincon, M; Budd, RC			Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TH2 CYTOKINE PRODUCTION; CELLULAR FLIP; LONG FORM; GEL-ELECTROPHORESIS; APOPTOSIS; DEATH; PROLIFERATION; TRANSCRIPTION; DIFFERENTIATION; LYMPHOCYTES	The nuclear factor of activated T (NFAT) cell family of transcription factors is important in regulating the expression of a broad array of genes, including cytokines, T cell surface receptors, and other transcription factors. NFATc1 and NFATc2 are two principal NFAT members that are expressed in peripheral T cells. Levels of NFAT expression in T cells are partly transcriptionally regulated, but less is understood regarding their post-transcriptional control. We show here that NFATc1 and NFATc2 are rapidly degraded in apoptotic T cells. NFATc2 is highly sensitive to cleavage by caspase-3, whereas NFATc1 is only weakly sensitive to caspase-3 or caspase-8. Two potential caspase-3 cleavage sites were identified in the N-terminal transactivation domain. These sites were confirmed by in vitro caspase cleavage assays. Abolition of NFATc2 cleavage by mutation of these two cleavage sites resulted in augmented NFAT transcriptional activity. Furthermore, NFAT activity could be augmented in wild-type effector T cells by inhibition of caspase activity. Of particular interest was that non-apoptotic T cells from cellular FLIP long transgenic (c-FLIPL-Tg) mice that manifest elevated caspase activity have greatly reduced levels of NFATc2 protein and NFAT transcriptional activity. Our findings reveal a new post-transcriptional regulation of NFATc2 that operates, not only during apoptosis, but also in non-apoptotic effector T cells.	Univ Vermont, Coll Med, Immunobiol Program, Dept Med, Burlington, VT 05405 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Howard Hughes Med Inst, New Haven, CT 06510 USA	University of Vermont; Yale University; Howard Hughes Medical Institute	Budd, RC (corresponding author), Univ Vermont, Coll Med, Immunobiol Program, Dept Med, Given Med Bldg,D305,89 Beaumont Dr, Burlington, VT 05405 USA.	ralph.budd@uvm.edu			NIAID NIH HHS [AI36333, AI45666] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036333, P01AI045666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMESS B, 1995, ELECTROPHORESIS, V16, P1255, DOI 10.1002/elps.11501601207; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Caetano MS, 2002, FASEB J, V16, P1940, DOI 10.1096/fj.02-0282fje; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dohrman A, 2005, J IMMUNOL, V175, P311, DOI 10.4049/jimmunol.175.1.311; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Liu JQ, 2001, IMMUNITY, V15, P23, DOI 10.1016/S1074-7613(01)00162-5; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Misra RS, 2005, J IMMUNOL, V174, P3999, DOI 10.4049/jimmunol.174.7.3999; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; ROBAYE B, 1994, ELECTROPHORESIS, V15, P503, DOI 10.1002/elps.1150150168; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Wu WF, 2004, J IMMUNOL, V172, P4724, DOI 10.4049/jimmunol.172.8.4724; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	39	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10682	10690		10.1074/jbc.M511759200	http://dx.doi.org/10.1074/jbc.M511759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16455648	hybrid			2022-12-27	WOS:000236822200006
J	Krumins, AM; Gilman, AG				Krumins, AM; Gilman, AG			Targeted knockdown of G protein subunits selectively prevents receptor-mediated modulation of effectors and reveals complex changes in non-targeted signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; ADENYLATE-CYCLASE; BINDING; EXPRESSION; GAMMA; PURIFICATION; SPECIFICITY; ACTIVATION	Heterotrimeric G protein signaling specificity has been attributed to select combinations of G alpha, beta, and gamma subunits, their interactions with other signaling proteins, and their localization in the cell. With few exceptions, the G protein subunit combinations that exist in vivo and the significance of these specific combinations are largely unknown. We have begun to approach these problems in HeLa cells by: 1) determining the concentrations of G alpha and G beta subunits; 2) examining receptor-dependent activities of two effector systems (adenylyl cyclase and phospholipase C beta); and 3) systematically silencing each of the G alpha and G beta subunits by using small interfering RNA while quantifying resultant changes in effector function and the concentrations of other relevant proteins in the network. HeLa cells express equimolar amounts of total G alpha and G beta subunits. The most prevalent G alpha proteins were one member of each G alpha subfamily (G alpha(s), G alpha(i3), G alpha(11), and G alpha(13)). We substantially abrogated expression of most of the G alpha and G beta proteins expressed in these cells, singly and some in combinations. As expected, agonist-dependent activation of adenylyl cyclase or phospholipase C beta was specifically eliminated following the silencing of G alpha(s) or G alpha(q/11), respectively. We also confirmed that G beta subunits are necessary for stable accumulation of G alpha proteins in vivo. G beta subunits demonstrated little isoform specificity for receptor-dependent modulation of effector activity. We observed compensatory changes in G protein accumulation following silencing of individual genes, as well as an apparent reciprocal relationship between the expression of certain G alpha(q) and G alpha(i) subfamily members. These findings provide a foundation for understanding the mechanisms that regulate the adaptability and remarkable resilience of G protein signaling networks.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), 6001 Forest Pk, Dallas, TX 75390 USA.	Alfred.Gilman@UTSouthwestern.edu			NIGMS NIH HHS [GM 34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GAO B, 1987, J BIOL CHEM, V262, P17254; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1994, METHOD ENZYMOL, V237, P191; Hwang JI, 2005, P NATL ACAD SCI USA, V102, P9493, DOI 10.1073/pnas.0503503102; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1999, CRC METH SIG TRANS, P23; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; ROSS EM, 1977, J BIOL CHEM, V252, P5761; Rosskopf D, 2003, FEBS LETT, V544, P27, DOI 10.1016/S0014-5793(03)00441-1; Ruiz-Velasco V, 2002, PHYSIOL GENOMICS, V8, P41, DOI 10.1152/physiolgenomics.00085.2001; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Steinberg SE, 2004, J MOL CELL CARDIOL, V37, P407, DOI 10.1016/j.yjmcc.2004.04.018; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VANDERVOORN L, 1993, J BIOL CHEM, V268, P5131; Wettschureck N, 2004, PHARMACOL THERAPEUT, V101, P75, DOI 10.1016/j.pharmthera.2003.10.005	34	88	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10250	10262		10.1074/jbc.M511551200	http://dx.doi.org/10.1074/jbc.M511551200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16446365	hybrid			2022-12-27	WOS:000236594300053
J	Uruno, T; Remmert, K; Hammer, JA				Uruno, T; Remmert, K; Hammer, JA			CARMIL is a potent capping protein antagonist - Identification of a conserved CARMIL domain that inhibits the activity of capping protein and uncaps capped actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARBED-END; ARP2/3 COMPLEX; ACANTHAMOEBA-CASTELLANII; ENA/VASP PROTEINS; FAMILY PROTEINS; MYOSIN-I; POLYMERIZATION; MOTILITY; BINDING; DICTYOSTELIUM	Acanthamoeba CARMIL was previously shown to co-purify with capping protein (CP) and to bind pure CP. Here we show that this interaction inhibits the barbed end-capping activity of CP. Even more strikingly, this interaction drives the uncapping of actin filaments previously capped with CP. These activities are CP-specific; CARMIL does not inhibit the capping activities of either gelsolin or CapG and does not uncap gelsolin-capped filaments. Although full-length (FL) CARMIL (residues 1-1121) possesses both anti-CP activities, C-terminal fragments like glutathione S-transferase (GST)-P (940-1121) that contain the CARMIL CP binding site are at least 10 times more active. We localized the full activities of GST-P to its C-terminal 51 residues (1071-1121). This sequence contains a stretch of 25 residues that is highly conserved in CARMIL proteins from protozoa, flies, worms, and vertebrates (CARMIL Homology domain 3; CAH3). Point mutations showed that the majority of the most highly conserved residues within CAH3 are critical for the anti-CP activity of GST-AP (862-1121). Finally, we found that GST-AP binds CP similar to 20-fold more tightly than does FL-CARMIL. This observation together with the elevated activities of C-terminal fragments relative to FL-CARMIL suggests that FL-CARMIL might exist primarily in an autoinhibited state. Consistent with this idea, proteolytic cleavage of FL-CARMIL with thrombin generated an similar to 14-kDa C-terminal fragment that expresses full anti-CP activities. We propose that, after some type of physiological activation event, FL-CARMIL could function in vivo as a potent CP antagonist. Given the pivotal role that CP plays in determining the global actin phenotype of cells, our results suggest that CARMIL may play an important role in the physiological regulation of actin assembly.	NHLBI, Cell Biol Lab, Sect Mol Cell Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hammer, JA (corresponding author), NHLBI, Cell Biol Lab, Sect Mol Cell Biol, NIH, Bldg 50,Rm 2523,9000 Rockville Pike, Bethesda, MD 20892 USA.	hammerj@nhlbi.nih.gov	Uruno, Takehito/AAF-7998-2019	Uruno, Takehito/0000-0002-2812-9645	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000514, Z01HL000514] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BHATTACHARYA N, 2004, 44 ANN M AM SOC CELL; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; GORDON DJ, 1976, J BIOL CHEM, V251, P4778; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hopmann R, 1996, J CELL BIOL, V133, P1293, DOI 10.1083/jcb.133.6.1293; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; Kelleher JF, 1998, METHOD ENZYMOL, V298, P42, DOI 10.1016/S0076-6879(98)98007-7; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lee WL, 1999, J BIOL CHEM, V274, P35159, DOI 10.1074/jbc.274.49.35159; Matsuzaka Y, 2004, GENE, V343, P291, DOI 10.1016/j.gene.2004.09.004; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Mullins RD, 2000, METHOD ENZYMOL, V325, P214; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; Remmert K, 2004, J BIOL CHEM, V279, P3068, DOI 10.1074/jbc.M308829200; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Takenawa T, 2001, J CELL SCI, V114, P1801; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wear MA, 2004, TRENDS BIOCHEM SCI, V29, P418, DOI 10.1016/j.tibs.2004.06.003; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; Xu P, 1997, P NATL ACAD SCI USA, V94, P3685, DOI 10.1073/pnas.94.8.3685; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; Yang CS, 2005, DEV CELL, V9, P209, DOI 10.1016/j.devcel.2005.06.008; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	48	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10635	10650		10.1074/jbc.M513186200	http://dx.doi.org/10.1074/jbc.M513186200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16434392	hybrid			2022-12-27	WOS:000236594300096
J	Varsano, T; Wolf, SG; Pick, U				Varsano, T; Wolf, SG; Pick, U			A chlorophyll a/b-binding protein homolog that is induced by iron deficiency is associated with enlarged photosystem I units in the eucaryotic alga Dunaliella salina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; TRANSFERRIN-LIKE PROTEIN; CHLAMYDOMONAS-REINHARDTII; PLASMA-MEMBRANE; PHOTOSYNTHESIS; ISIA; SUPERCOMPLEXES; ACCUMULATION; FLUORESCENCE; PROTEOMICS	Adaptation of the halotolerant alga Dunaliella salina to iron deprivation involves extensive changes of chloroplast morphology, photosynthetic activities, and induction of a major 45-kDa chloroplast protein termed Tidi. Partial amino acid sequencing of proteolytic peptides suggested that Tidi resembles chlorophyll a/b-binding proteins which compose light-harvesting antenna complexes (LHC) ( Varsano, T., Kaftan, D., and Pick, U. ( 2003) J. Plant Nutr. 26, 2197 - 2210). Here we show that Tidi shares the highest amino acid sequence similarity with light-harvesting I chlorophyll a/b-binding proteins from higher plants but has an extended proline-rich N-terminal domain. The accumulation of Tidi is reversed by iron supplementation, and its level is inversely correlated with photosystem I(PS-I) reaction center proteins. In native gel electrophoresis, Tidi co-migrates with enlarged PS-I-LHC-I super-complexes. Single particle electron microscopy analysis revealed that PS-I units from iron-deficient cells are larger ( 31 and 37 nm in diameter) than PS-I units from control cells ( 22 nm). The 77 K chlorophyll fluorescence emission spectra of isolated complexes suggest that the Tidi-LHC-I antenna are functionally coupled to the reaction centers of PS-I. These findings indicate that Tidi acts as an accessory antenna of PS-I. The enlargement of PS-I antenna in algae and in cyanobacteria under iron deprivation suggests a common limitation that requires rebalancing of the energy distribution between the two photosystems.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Electron Microscopy Unit, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Pick, U (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	uri.pick@weizmann.ac.il	WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				Andrizhiyevskaya EG, 2002, BBA-BIOENERGETICS, V1556, P265, DOI 10.1016/S0005-2728(02)00371-7; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Bibby TS, 2001, J BIOL CHEM, V276, P43246, DOI 10.1074/jbc.M106541200; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Braun P, 1996, PLANT PHYSIOL, V110, P1405, DOI 10.1104/pp.110.4.1405; Cardol P, 2003, PLANT PHYSIOL, V133, P2010, DOI 10.1104/pp.103.028076; Desquilbet TE, 2003, PLANT CELL PHYSIOL, V44, P1141, DOI 10.1093/pcp/pcg139; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Fisher M, 1997, J BIOL CHEM, V272, P1565, DOI 10.1074/jbc.272.3.1565; FISHER M, 1994, PLANT PHYSIOL, V106, P1359, DOI 10.1104/pp.106.4.1359; Fleischmann MM, 1999, J BIOL CHEM, V274, P30987, DOI 10.1074/jbc.274.43.30987; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Germano M, 2002, FEBS LETT, V525, P121, DOI 10.1016/S0014-5793(02)03100-9; HOHENBERG H, 1994, J MICROSC-OXFORD, V175, P34, DOI 10.1111/j.1365-2818.1994.tb04785.x; Humbel BM, 2001, YEAST, V18, P433, DOI 10.1002/yea.694; Kargul J, 2003, J BIOL CHEM, V278, P16135, DOI 10.1074/jbc.M300262200; KATZ A, 1986, FEBS LETT, V202, P141, DOI 10.1016/0014-5793(86)80665-2; Kouril R, 2005, FEBS LETT, V579, P3253, DOI 10.1016/j.febslet.2005.03.051; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1991, J BIOL CHEM, V266, P13698; Liska AJ, 2004, PLANT PHYSIOL, V136, P2806, DOI 10.1104/pp.104.039438; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Morgan-Kiss R, 2002, BBA-BIOMEMBRANES, V1561, P251, DOI 10.1016/S0005-2736(02)00352-8; Moseley JL, 2002, EMBO J, V21, P6709, DOI 10.1093/emboj/cdf666; Moseley JL, 2002, PLANT CELL, V14, P673, DOI 10.1105/tpc.010420; Murakami A, 1997, PHOTOSYNTH RES, V53, P141, DOI 10.1023/A:1005818317797; Naumann B, 2005, J BIOL CHEM, V280, P20431, DOI 10.1074/jbc.M414486200; Sandstrom S, 2001, PHOTOCHEM PHOTOBIOL, V74, P431, DOI 10.1562/0031-8655(2001)074<0431:CTIGPF>2.0.CO;2; Schwarz M, 2003, BBA-PROTEINS PROTEOM, V1649, P190, DOI 10.1016/S1570-9639(03)00185-7; SEKLER I, 1994, PLANT PHYSIOL, V105, P1125, DOI 10.1104/pp.105.4.1125; SPILLER S, 1980, PLANT PHYSIOL, V65, P121, DOI 10.1104/pp.65.1.121; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Straus N. A., 1994, IRON DEPRIVATION PHY; Strzepek RF, 2004, NATURE, V431, P689, DOI 10.1038/nature02954; Varsano T, 2003, J PLANT NUTR, V26, P2197, DOI 10.1081/PLN-120024275; VASSILIEV IR, 1995, PLANT PHYSIOL, V109, P963, DOI 10.1104/pp.109.3.963; Watson AJ, 2000, NATURE, V407, P730, DOI 10.1038/35037561	40	37	40	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10305	10315		10.1074/jbc.M511057200	http://dx.doi.org/10.1074/jbc.M511057200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469742	hybrid			2022-12-27	WOS:000236594300059
J	Camacho, JA; Hensellek, S; Rougier, JS; Blechschmidt, S; Abriel, H; Benndorf, K; Zimmer, T				Camacho, JA; Hensellek, S; Rougier, JS; Blechschmidt, S; Abriel, H; Benndorf, K; Zimmer, T			Modulation of Na(v)1.5 channel function by an alternatively spliced sequence in the DII/DIII linker region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT SODIUM-CHANNEL; ISOFORM-SPECIFIC MANNER; DORSAL-ROOT GANGLIA; GATED NA+ CHANNELS; ALPHA-SUBUNIT; BRUGADA-SYNDROME; RAT-BRAIN; CALMODULIN BINDS; XENOPUS OOCYTES; HUMAN HEART	In the present study, we identified a novel splice variant of the human cardiac Na+ channel Na(v)1.5 (Na(v)1.5d), in which a 40-amino acid sequence of the DII/DIII intracellular linker is missing due to a partial deletion of exon 17. Expression of Na(v)1.5d occurred in embryonic and adult hearts of either sex, indicating that the respective alternative splicing is neither age-dependent nor gender-specific. In contrast, Na(v)1.5d was not detected in the mouse heart, indicating that alternative splicing of Na(v)1.5 is species-dependent. In HEK293 cells, splice variant Na(v)1.5d generated voltage-dependent Na+ currents that were markedly reduced compared with wild-type Na(v)1.5. Experiments with mexiletine and 8-bromo-cyclic AMP suggested that the trafficking of Na(v)1.5d channels was not impaired. However, single-channel recordings showed that the whole-cell current reduction was largely due to a significantly reduced open probability. Additionally, steady-state activation and inactivation were shifted to depolarized potentials by 15.9 and 5.1 mV, respectively. Systematic mutagenesis analysis of the spliced region provided evidence that a short amphiphilic region in the DII/DIII linker resembling an S4 voltage sensor of voltage-gated ion channels is an important determinant of Na(v)1.5 channel gating. Moreover, the present study identified novel short sequence motifs within this amphiphilic region that specifically affect the voltage dependence of steady-state activation and inactivation and current amplitude of human Na(v)1.5.	Univ Jena, Inst Physiol 2, D-07740 Jena, Germany; Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Hosp, Serv Cardiol, CH-1005 Lausanne, Switzerland	Friedrich Schiller University of Jena; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Zimmer, T (corresponding author), Univ Jena, Inst Physiol 2, Kollegiengasse 9, D-07743 Jena, Germany.	Thomas.Zimmer@mti.uni-jena.de	Abriel, Hugues/B-9800-2009; Rougier, Jean-Sébastien/AAX-5038-2021	Abriel, Hugues/0000-0003-0465-5138; Benndorf, Klaus/0000-0002-0707-4083; ROUGIER, Jean-Sebastien/0000-0002-8710-0260				AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; Balser JR, 2001, J MOL CELL CARDIOL, V33, P599, DOI 10.1006/jmcc.2000.1346; Bennett ES, 2004, J MEMBRANE BIOL, V197, P155, DOI 10.1007/s00232-004-0650-6; Bennett ES, 2001, J PHYSIOL-LONDON, V535, P371, DOI 10.1111/j.1469-7793.2001.t01-1-00371.x; Chahine M, 1996, AM J PHYSIOL-HEART C, V271, pH498, DOI 10.1152/ajpheart.1996.271.2.H498; Deschenes I, 2002, CIRC RES, V90, pE49, DOI 10.1161/01.RES.0000012502.92751.E6; Deschenes I, 2001, J MEMBRANE BIOL, V183, P103, DOI 10.1007/s00232-001-0058-5; Dib-Hajj SD, 2002, MOL NEUROBIOL, V26, P235, DOI 10.1385/MN:26:2-3:235; Dietrich PS, 1998, J NEUROCHEM, V70, P2262; Diss JKJ, 2004, EUR BIOPHYS J BIOPHY, V33, P180, DOI 10.1007/s00249-004-0389-0; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herzog RI, 2003, J NEUROSCI, V23, P8261; Hong K, 2005, J MOL CELL CARDIOL, V38, P555, DOI 10.1016/j.yjmcc.2004.10.015; Keller DI, 2005, CARDIOVASC RES, V67, P510, DOI 10.1016/j.cardiores.2005.03.024; Kerr NCH, 2004, J BIOL CHEM, V279, P24826, DOI 10.1074/jbc.M401281200; Korsgaard MPG, 2001, PFLUG ARCH EUR J PHY, V443, P18, DOI 10.1007/s004240100625; Li RA, 2002, MOL PHARMACOL, V61, P136, DOI 10.1124/mol.61.1.136; Makielski JC, 2003, CIRC RES, V93, P821, DOI 10.1161/01.RES.0000096652.14509.96; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; Mechaly I, 2005, NEUROSCIENCE, V130, P389, DOI 10.1016/j.neuroscience.2004.09.034; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Nuss HB, 1995, J GEN PHYSIOL, V106, P1171, DOI 10.1085/jgp.106.6.1171; O'Reilly JP, 1999, J PHYSIOL-LONDON, V515, P61, DOI 10.1111/j.1469-7793.1999.061ad.x; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Probst V, 2003, J AM COLL CARDIOL, V41, P643, DOI 10.1016/S0735-1097(02)02864-4; Raymond CK, 2004, J BIOL CHEM, V279, P46234, DOI 10.1074/jbc.M406387200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; Schott JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618; Shang LJL, 2005, J BIOL CHEM, V280, P933, DOI 10.1074/jbc.M409977200; Tan HL, 2002, NATURE, V415, P442, DOI 10.1038/415442a; Valdivia CR, 2004, CARDIOVASC RES, V62, P53, DOI 10.1016/j.cardiores.2004.01.022; van Bemmelen MX, 2004, CIRC RES, V95, P284, DOI 10.1161/01.RES.0000136816.05109.89; Young KA, 2005, J PHYSIOL-LONDON, V565, P349, DOI 10.1113/jphysiol.2004.081422; Zhou JS, 2000, CIRC RES, V87, P33, DOI 10.1161/01.RES.87.1.33; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zimmer T, 2002, J GEN PHYSIOL, V120, P887, DOI 10.1085/jgp.20028703; Zimmer T, 2002, J MEMBRANE BIOL, V186, P1, DOI 10.1007/s00232-001-0130-1; Zimmer T, 2002, AM J PHYSIOL-HEART C, V282, pH1007, DOI 10.1152/ajpheart.00644.2001	44	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9498	9506		10.1074/jbc.M509716200	http://dx.doi.org/10.1074/jbc.M509716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469732	hybrid			2022-12-27	WOS:000236404700060
J	Hales, TG; Dunlop, JI; Deeb, TZ; Carland, JE; Kelley, SP; Lambert, JJ; Peters, JA				Hales, TG; Dunlop, JI; Deeb, TZ; Carland, JE; Kelley, SP; Lambert, JJ; Peters, JA			Common determinants of single channel conductance within the large cytoplasmic loop of 5-hydroxytryptamine type 3 and alpha(4)beta(2) nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HT3 RECEPTORS; ANGSTROM RESOLUTION; ION SELECTIVITY; AMINO-ACIDS; EXPRESSION; SUBUNIT	Homomeric 5-hydroxytryptamine type 3A receptors (5-HT(3A)Rs) have a single channel conductance (gamma) below the resolution of single channel recording (966 +/- 75 fS, estimated by variance analysis). By contrast, heteromeric 5-HT3A/B and nicotinic acetylcholine receptors (nAChRs) have picosiemen range gamma values. In this study, single channel recordings revealed that replacement of cytoplasmic membrane-associated (MA) helix arginine 432 (-4'), 436 (0'), and 440 (4') residues by 5-HT3B (-4'Gln, 0'Asp, and 4'Ala) residues increases gamma to 36.5 +/- 1.0 pS. The 0' residue makes the most substantial contribution to gamma of the 5-HT3AR. Replacement of 0' Arg by aspartate, glutamate (alpha(7)nAChR subunit MA 0'), or glutamine (beta(2) subunit MA 0') increases gamma to the resolvable range (>6 pS). By contrast, replacement of 0' Arg by phenylalanine (alpha(4) subunit MA 0') reduced gamma to 416 +/- 107 fS. In reciprocal experiments with alpha(4)beta(2) nAChRs (gamma=31.3 +/- 0.8 pS), replacement of MA 0' residues by arginine in alpha(4)beta(2)(Q443R) and alpha(4)(F588R) beta(2) reduced gamma slightly. By contrast, the gamma of double mutant alpha 4(F588R)beta(2)(Q443R) was halved. The MA -4' and 4' residues also influenced gamma of 5-HT(3A)Rs. Replacement of nAChR alpha(4) or beta(2) MA 4' residues by arginine made current density negligible. By contrast, replacement of both -4' residues by arginine produced functional nAChRs with substantially reduced gamma (11.4 +/- 0.5 pS). Homology models of the 5-HT3A and alpha(4)beta(2) nAChRs against Torpedo nAChR revealed MA -4', 0', and 4' residues within five intracellular portals. This locus may be a common determinant of ion conduction throughout the Cys loop receptor family.	George Washington Univ, Dept Physiol & Pharmacol, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA; Univ Dundee, Inst Neurosci, Div Pathol & neurosci, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland	George Washington University; George Washington University; University of Dundee	Hales, TG (corresponding author), George Washington Univ, Dept Physiol & Pharmacol, Med Ctr, 2300 Eye St NW, Washington, DC 20037 USA.	phmtgh@gwumc.edu		Carland, Jane/0000-0002-1456-876X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander SPH, 2004, BRIT J PHARMACOL, V141, pS1; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; Buisson B, 1996, J NEUROSCI, V16, P7880; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; Davies PA, 2001, J PHYSIOL-LONDON, V537, P101, DOI 10.1111/j.1469-7793.2001.0101k.x; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; Fucile S, 2002, P NATL ACAD SCI USA, V99, P3956, DOI 10.1073/pnas.052699599; HILLE B, 1992, IONIC CHANNELS EXCIT, P274; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Kuryatov A, 1997, J NEUROSCI, V17, P9035; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Peters JA, 2005, TRENDS PHARMACOL SCI, V26, P587, DOI 10.1016/j.tips.2005.09.011; Reeves DC, 2005, J NEUROSCI, V25, P9358, DOI 10.1523/JNEUROSCI.1045-05.2005; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031	21	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8062	8071		10.1074/jbc.M513222200	http://dx.doi.org/10.1074/jbc.M513222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407231	hybrid, Green Accepted			2022-12-27	WOS:000236031000043
J	Liu, XH; Alexander, C; Serrano, J; Borg, E; Dawson, DC				Liu, XH; Alexander, C; Serrano, J; Borg, E; Dawson, DC			Variable reactivity of an engineered cysteine at position 338 in cystic fibrosis transmembrane conductance regulator reflects different chemical states of the thiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; SULFHYDRYL-SPECIFIC REAGENTS; METAL-BINDING SITES; DISULFIDE INTERCHANGE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; LINING RESIDUES; S-NITROSOTHIOLS; ANION-BINDING; COPPER	In a previous study of T338C CFTR ( cystic fibrosis transmembrane conductance regulator) we found that protons and thiol-directed reagents modified channel properties in a manner consistent with the hypothesis that this residue lies within the conduction path, but the observed reactivity was not consistent with the presence of a single thiolate species in the pore. Here we report results consistent with the notion that the thiol moiety can exist in at least three chemical states, the simple thiol, and two altered states. One of the altered states displays reactivity toward thiols like dithiothreitol and 2-mercaptoethanol as well as mixed disulfides ( methanethiosulfonate reagents: MTSET+, MTSES-) and an alkylating agent ( iodoacetamide). The other altered state is unreactive. The phenotype associated with the reactive, altered state could be replicated by exposing oocytes expressing T338C CFTR to CuCl2, but not by glutathionylation or nitrosylation of the thiol or by oxidation with hydrogen peroxide. The results are consistent with the hypothesis that substituting a cysteine at 338 can create an adventitious metal binding site. Metal liganding alters thiol reactivity and may, in some cases, catalyze oxidation of the thiol to an unreactive form such as a sulfinic or sulfonic acid.	Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA	Oregon Health & Science University	Dawson, DC (corresponding author), L334,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	dawsonda@ohsu.edu			NIDDK NIH HHS [DK45880, DK60312, DK070755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK045880, K01DK070755, F32DK060312, R01DK045880] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Baty JW, 2002, PROTEOMICS, V2, P1261, DOI 10.1002/1615-9861(200209)2:9<1261::AID-PROT1261>3.0.CO;2-Q; BELTRAMINI M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P24, DOI 10.1016/0167-4838(92)90420-I; BERNHARD WR, 1986, BIOCHEMISTRY-US, V25, P1975, DOI 10.1021/bi00356a021; Chan KM, 2000, J GEN PHYSIOL, V116, P163, DOI 10.1085/jgp.116.2.163; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Chiou SJ, 2003, P NATL ACAD SCI USA, V100, P3695, DOI 10.1073/pnas.0637221100; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; DAWSON DC, 2003, CFTR CHLORIDE CHANNE, P1; FELIX K, 1988, BIOCHEM J, V252, P577, DOI 10.1042/bj2520577; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; FORMICKA G, 1992, FEBS LETT, V309, P92, DOI 10.1016/0014-5793(92)80747-5; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Giles NM, 2003, CHEM BIOL, V10, P677, DOI 10.1016/S1074-5521(03)00174-1; Gong XD, 2003, J PHYSIOL-LONDON, V549, P375, DOI 10.1113/jphysiol.2002.038216; Gong XD, 2003, J PHYSIOL-LONDON, V549, P387, DOI 10.1113/jphysiol.2002.038232; Grapperhaus CA, 1998, INORG CHEM, V37, P4052, DOI 10.1021/ic971599f; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; Gruss M, 2004, MOL PHARMACOL, V66, P530; Hammes BS, 2001, INORG CHEM, V40, P919, DOI 10.1021/ic001178p; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Huynh PD, 1997, J GEN PHYSIOL, V110, P229, DOI 10.1085/jgp.110.3.229; JONES JG, 1975, BIOCHEMISTRY-US, V14, P2396, DOI 10.1021/bi00682a020; KAEGI JH, 1961, J BIOL CHEM, V236, P2435; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KAWABATA T, 1986, ACTA MED OKAYAMA, V40, P163; Kenyon G L, 1977, Methods Enzymol, V47, P407; Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; Krezel A, 2001, J INORG BIOCHEM, V84, P77, DOI 10.1016/S0162-0134(00)00212-9; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; Leichert LI, 2004, PLOS BIOL, V2, P1723, DOI 10.1371/journal.pbio.0020333; Li Y, 2005, BIOPHYS J, V88, P3936, DOI 10.1529/biophysj.104.055012; Liebeskind LS, 2002, PURE APPL CHEM, V74, P115, DOI 10.1351/pac200274010115; LIU X, 2002, PED PULM S, V24, pA37; Liu XH, 2004, BIOPHYS J, V86, p284A; Liu XH, 2004, BIOPHYS J, V87, P3826, DOI 10.1529/biophysj.104.050534; Liu XH, 2001, J GEN PHYSIOL, V118, P433, DOI 10.1085/jgp.118.4.433; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Luo DY, 2005, J PHARM SCI-US, V94, P304, DOI 10.1002/jps.20253; Mallis RJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P60, DOI 10.1006/abbi.2000.2048; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; McGuirl MA, 1997, J BIOL INORG CHEM, V2, P336, DOI 10.1007/s007750050140; Means G.E., 1971, CHEM MODIFICATION PR; MENSE M, 2002, PEDIATR PULM, V24, pA58; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; Morera FJ, 2003, J MEMBRANE BIOL, V192, P65, DOI 10.1007/s00232-002-1064-y; NOMIZU T, 1993, MOL REPROD DEV, V36, P419, DOI 10.1002/mrd.1080360403; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Rabenstein DL, 1996, J ORG CHEM, V61, P7391, DOI 10.1021/jo960917+; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Sharonova IN, 1998, EUR J NEUROSCI, V10, P522, DOI 10.1046/j.1460-9568.1998.00057.x; Smith SS, 2001, J GEN PHYSIOL, V118, P407, DOI 10.1085/jgp.118.4.407; Smith SS, 1999, J GEN PHYSIOL, V114, P799, DOI 10.1085/jgp.114.6.799; Sohn J, 2003, BIOCHEMISTRY-US, V42, P10060, DOI 10.1021/bi0345081; SPEAR N, 1994, ARCH BIOCHEM BIOPHYS, V312, P198, DOI 10.1006/abbi.1994.1299; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STROTHKAMP KG, 1981, BIOCHEMISTRY-US, V20, P7488, DOI 10.1021/bi00529a025; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Thomas C, 2004, PFLUG ARCH EUR J PHY, V448, P431; Van Horn JD, 2003, J BIOL INORG CHEM, V8, P601, DOI 10.1007/s00775-003-0454-7; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; WANG G, 2003, BIOPHYS J, V82, pL59; Warthen CR, 2001, J BIOL INORG CHEM, V6, P82, DOI 10.1007/s007750000171; Webster SM, 2004, NATURE, V428, P864, DOI 10.1038/nature02468; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627; Zhang H, 1997, BIOCHEMISTRY-US, V36, P15856, DOI 10.1021/bi972357u; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101; Zhang ZR, 2005, J BIOL CHEM, V280, P458, DOI 10.1074/jbc.M409626200	82	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8275	8285		10.1074/jbc.M512458200	http://dx.doi.org/10.1074/jbc.M512458200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436375	hybrid			2022-12-27	WOS:000236031000067
J	Aachmann, FL; Svanem, BIG; Guntert, P; Petersen, SB; Valla, S; Wimmer, R				Aachmann, FL; Svanem, BIG; Guntert, P; Petersen, SB; Valla, S; Wimmer, R			NMR structure of the R-module - A parallel beta-roll subunit from an Azotobacter vinelandii mannuronan C-5 epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; PSEUDOMONAS-AERUGINOSA; ALGINIC ACID; C-5-EPIMERASE GENE; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; ABC-TRANSPORTERS; CHEMICAL-SHIFT; PROTEIN; SEQUENCE	In the bacterium Azotobacter vinelandii, a family of seven secreted and calcium-dependent mannuronan C-5 epimerases ( AlgE1 - 7) has been identified. These epimerases are responsible for the epimerization of beta-D-mannuronic acid to alpha-L-guluronic acid in alginate polymers. The epimerases consist of two types of structural modules, designated A ( one or two copies) and R ( one to seven copies). The structure of the catalytically active A-module from the smallest epimerase AlgE4 ( consisting of AR) has been solved recently. This paper describes the NMR structure of the R-module from AlgE4 and its titration with a substrate analogue and paramagnetic thulium ions. The R-module folds into a right-handed parallel beta-roll. The overall shape of the R-module is an elongated molecule with a positively charged patch that interacts with the substrate. Titration of the R-module with thulium indicated possible calcium binding sites in the loops formed by the nonarepeat sequences in the N-terminal part of the molecule and the importance of calcium binding for the stability of the R-module. Structure calculations showed that calcium ions can be incorporated in these loops without structural violations and changes. Based on the structure and the electrostatic surface potential of both the A- and R-module from AlgE4, a model for the appearance of the whole protein is proposed.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; Univ Aalborg, Dept Life Sci, DK-9000 Aalborg, Denmark; RIKEN Genom Sci Ctr, Tatsuo Miyazawa Mem Program, Yokohama, Kanagawa 2300045, Japan; Univ Aalborg, Inst Phys & Nanotechnol, DK-9000 Aalborg, Denmark	Norwegian University of Science & Technology (NTNU); Aalborg University; RIKEN; Aalborg University	Valla, S (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.	svein.valla@biotech.ntnu.no; rw@bio.aau.dk	Wimmer, Reinhard/A-7901-2012; Petersen, Steffen B/F-8280-2010; Aachmann, Finn/G-4136-2015; Petersen, Steffen b/E-8727-2015; Wimmer, Reinhard/M-2346-2019; Güntert, Peter/L-5577-2013	Wimmer, Reinhard/0000-0001-6942-5056; Aachmann, Finn/0000-0003-1613-4663; Petersen, Steffen b/0000-0002-0739-2751; Güntert, Peter/0000-0002-2911-7574				Aachmann FL, 2005, J BIOMOL NMR, V31, P259, DOI 10.1007/s10858-004-7911-7; Aghajari N, 2003, PROTEINS, V50, P636, DOI 10.1002/prot.10264; Amada K, 2000, BBA-PROTEIN STRUCT M, V1478, P201, DOI 10.1016/S0167-4838(00)00046-7; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Bertini I, 2001, J AM CHEM SOC, V123, P4181, DOI 10.1021/ja0028626; Billeter M, 1995, J BIOMOL NMR, V5, P1; Bjerkan TM, 2004, J BIOL CHEM, V279, P28920, DOI 10.1074/jbc.M313293200; BJERKAN TM, 2003, THESIS NORWEGIAN U S; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; COTE GL, 1988, CARBOHYD RES, V181, P143, DOI 10.1016/0008-6215(88)84030-8; Donati I, 2005, BIOMACROMOLECULES, V6, P1031, DOI 10.1021/bm049306e; Douthit SA, 2005, J BACTERIOL, V187, P4573, DOI 10.1128/JB.187.13.4573-4583.2005; Duong F, 1996, MOL MICROBIOL, V21, P459, DOI 10.1111/j.1365-2958.1996.tb02555.x; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; Ertesvag H, 1999, J BACTERIOL, V181, P3033; Ertesvag H, 1999, METAB ENG, V1, P262, DOI 10.1006/mben.1999.0130; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FELMLEE T, 1988, P NATL ACAD SCI USA, V85, P5269, DOI 10.1073/pnas.85.14.5269; FELMLEE T, 1985, J BACTERIOL, V163, P88, DOI 10.1128/JB.163.1.88-93.1985; FETT WF, 1986, APPL ENVIRON MICROB, V52, P466, DOI 10.1128/AEM.52.3.466-473.1986; Fischer F. G., 1955, Z PHYSL CHEM, V302, P186; FREI E, 1962, NATURE, V196, P130, DOI 10.1038/196130a0; Gimmestad M, 2003, J BACTERIOL, V185, P3515, DOI 10.1128/JB.185.12.3515-3523.2003; GORIN PAJ, 1966, CAN J CHEMISTRY, V44, P993, DOI 10.1139/v66-147; GOVAN JRW, 1981, J GEN MICROBIOL, V125, P217; GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P531, DOI 10.1016/0022-2836(91)90755-U; Hamada K, 1996, J BIOCHEM, V119, P844, DOI 10.1093/oxfordjournals.jbchem.a021320; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; HAUG A, 1971, CARBOHYD RES, V17, P297, DOI 10.1016/S0008-6215(00)82537-9; HELLEBUST JA, 1972, CAN J BOTANY, V50, P177, DOI 10.1139/b72-023; HIRST EL, 1964, J CHEM SOC, P1493, DOI 10.1039/jr9640001493; Hoidal HK, 2000, ENVIRON MICROBIOL, V2, P27, DOI 10.1046/j.1462-2920.2000.00074.x; Hui D, 2000, J BIOL CHEM, V275, P2713, DOI 10.1074/jbc.275.4.2713; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 2000, COMPUT PHYS COMMUN, V124, P139, DOI 10.1016/S0010-4655(99)00436-1; Kwon HJ, 2002, J BIOSCI BIOENG, V93, P157, DOI 10.1263/jbb.93.157; LARSEN B, 1971, CARBOHYD RES, V20, P225, DOI 10.1016/S0008-6215(00)81375-0; LETOFFE S, 1992, J BACTERIOL, V174, P4920; Lilie H, 2000, FEBS LETT, V470, P173, DOI 10.1016/S0014-5793(00)01308-9; Mustafi SM, 2004, BIOCHEMISTRY-US, V43, P9320, DOI 10.1021/bi049657d; Omori K, 2003, J BIOSCI BIOENG, V95, P1; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; SADOFF HL, 1975, BACTERIOL REV, V39, P516, DOI 10.1128/MMBR.39.4.516-539.1975; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SHERBROCKCOX V, 1984, CARBOHYD RES, V135, P147, DOI 10.1016/0008-6215(84)85012-0; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; Sletmoen M, 2004, BIOMACROMOLECULES, V5, P1288, DOI 10.1021/bm0345211; Smidsrod O., 1996, CARBOHYDR EUR, V14, P6; STOKKE BT, 1991, MACROMOLECULES, V24, P6637; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; Walling AE, 1997, J PHYS CHEM A, V101, P7299, DOI 10.1021/jp971783m; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3	59	29	29	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7350	7356		10.1074/jbc.M510069200	http://dx.doi.org/10.1074/jbc.M510069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407237	hybrid			2022-12-27	WOS:000236030900054
J	Allan, RK; Mok, D; Ward, BK; Ratajczak, T				Allan, RK; Mok, D; Ward, BK; Ratajczak, T			Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90 - Evidence that coumarin antibiotics disrupt Hsp90 dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; STEROID-RECEPTOR COMPLEXES; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONE; MUTATIONAL ANALYSIS; ANDROGEN RECEPTOR; PROSTATE-CANCER; BINDING SITE; ATP-BINDING	The C-terminal domain of Hsp90 displays independent chaperone activity, mediates dimerization, and contains the MEEVD motif essential for interaction with tetratricopeptide repeat-containing immunophilin cochaperones assembled in mature steroid receptor complexes. An alpha-helical region, upstream of the MEEVD peptide, helps form the dimerization interface and includes a hydrophobic microdomain that contributes to the Hsp90 interaction with the immunophilin cochaperones and corresponds to the binding site for novobiocin, a coumarin-related Hsp90 inhibitor. Mutation of selected residues within the hydrophobic microdomain significantly impacted the chaperone function of a recombinant C-terminal Hsp90 fragment and novobiocin inhibited wild-type chaperone activity. Prior incubation of the Hsp90 fragment with novobiocin led to a direct blockade of immunophilin cochaperone binding. However, the drug had little influence on the pre-formed Hsp90-immunophilin complex, suggesting that bound cochaperones mask the novobiocin-binding site. We observed a differential effect of the drug on Hsp90-immunophilin interaction, suggesting that the immunophilins make distinct contacts within the C-terminal domain to specifically modulate Hsp90 function. Novobiocin also precluded the interaction of full-length Hsp90 with the p50(cdc37) cochaperone, which targets the N-terminal nucleotide-binding domain, and is prevalent in Hsp90 complexes with protein kinase substrates. Novobiocin therefore acts locally and allosterically to induce conformational changes within multiple regions of the Hsp90 protein. We provide evidence that coumermycin A1, a coumarin structurally related to novobiocin, interferes with dimerization of the Hsp90 C-terminal domain. Coumarin-based inhibitors then may antagonize Hsp90 function by inducing a conformation favoring separation of the C-terminal domains and release of substrate.	Western Australian Inst Med Res, Mol Endocrinol Lab, Nedlands, WA 6009, Australia; Med Res Ctr, Nedlands, WA 6009, Australia; Univ Western Australia, Nedlands, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia; Queen Elizabeth II Med Ctr, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Ratajczak, T (corresponding author), Western Australian Inst Med Res, Mol Endocrinol Lab, Nedlands, WA 6009, Australia.	tomr@cyllene.uwa.edu.au	Mok, Danny/A-5328-2011					Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BINART N, 1995, BIOCHEM J, V311, P797, DOI 10.1042/bj3110797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchanan G, 2001, CLIN CANCER RES, V7, P1273; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Daikoku T, 2005, MOL ENDOCRINOL, V19, P683, DOI 10.1210/me.2004-0332; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Denny WB, 2005, ENDOCRINOLOGY, V146, P3194, DOI 10.1210/en.2005-0027; Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200; Harris SF, 2004, STRUCTURE, V12, P1087, DOI 10.1016/j.str.2004.03.020; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Itoh H, 1999, BIOCHEM J, V343, P697, DOI 10.1042/0264-6021:3430697; Jibard N, 1999, EXP CELL RES, V247, P461, DOI 10.1006/excr.1998.4375; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Meng X, 1996, J CELL SCI, V109, P1677; Munster PN, 2002, CANCER RES, V62, P3132; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Ratajczak T, 2003, CURR TOP MED CHEM, V3, P1348, DOI 10.2174/1568026033451934; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; Riggs DL, 2004, CRIT REV BIOCHEM MOL, V39, P279, DOI 10.1080/10409230490892513; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Rosenhagen MC, 2003, MOL ENDOCRINOL, V17, P1991, DOI 10.1210/me.2003-0141; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SHUE GL, 1994, J BIOL CHEM, V269, P2707; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith DF, 2004, CELL STRESS CHAPERON, V9, P109, DOI 10.1379/CSC-31.1; Soga S, 1999, CANCER RES, V59, P2931; Solit DB, 2002, CLIN CANCER RES, V8, P986; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Tranguch S, 2005, P NATL ACAD SCI USA, V102, P14326, DOI 10.1073/pnas.0505775102; Ward BK, 2002, J BIOL CHEM, V277, P40799, DOI 10.1074/jbc.M207097200; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wei H, 2005, J BIOL CHEM, V280, P37041, DOI 10.1074/jbc.M506520200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; Yamada S, 2003, EUR J BIOCHEM, V270, P146, DOI 10.1046/j.1432-1033.2003.03375.x; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Yu XM, 2005, J AM CHEM SOC, V127, P12778, DOI 10.1021/ja0535864; Yun BG, 2004, BIOCHEMISTRY-US, V43, P8217, DOI 10.1021/bi0497998	72	122	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7161	7171		10.1074/jbc.M512406200	http://dx.doi.org/10.1074/jbc.M512406200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421106	hybrid			2022-12-27	WOS:000236030900031
J	Joo, NS; Irokawa, T; Robbins, RC; Wine, JJ				Joo, NS; Irokawa, T; Robbins, RC; Wine, JJ			Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; SINGLE SUBMUCOSAL GLANDS; EPITHELIAL NA+ CHANNELS; NEUTROPHIL ELASTASE; MUCUS SECRETION; SODIUM-CHANNEL; ION-TRANSPORT; EXPRESSION; CELLS; CFTR	Human airways and glands express the anion channel cystic fibrosis transmembrane conductance regulator, CFTR, and the epithelial Na+ channel, ENaC. Cystic fibrosis (CF) airway glands fail to secrete mucus in response to vasoactive intestinal peptide or forskolin; the failure was attributed to loss of CFTR-mediated anion and fluid secretion. Alternatively, CF glands might secrete acinar fluid via CFTR-independent pathways, but the exit of mucus from the glands could be blocked by hyperabsorption of fluid in the gland ducts. This could occur because CFTR loss can disinhibit ENaC, and ENaC activity can drive absorption. To test these two hypotheses, we measured single gland mucus secretion optically and applied ENaC inhibitors to determine whether they augmented secretion. Human CF glands were pretreated with benzamil and then stimulated with forskolin in the continued presence of benzamil. Benzamil did not rescue the lack of secretion to forskolin ( 50 glands, 6 CF subjects) nor did it increase the rate of cholinergically mediated mucus secretion from CF glands. Finally, neither benzamil nor amiloride increased forskolin-stimulated mucus secretion from porcine submucosal glands ( 75 glands, 7 pigs). One possible explanation for these results is that ENaC within the gland ducts was not active in our experiments. Consistent with that possibility, we discovered that human airway glands express Kunitz-type and non-Kunitz serine protease inhibitors, which might prevent proteolytic activation of ENaC. Our results suggest that CF glands do not display excessive, ENaC-mediated fluid absorption, leaving defective, anion-mediated fluid secretion as the most likely mechanism for defective mucus secretion from CF glands.	Stanford Univ, Cyst Fibrosis Res Lab, Stanford, CA 94305 USA; Stanford Univ, Cardiothorac Surg & Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Joo, NS (corresponding author), Stanford Univ, Cyst Fibrosis Res Lab, Rm 516,Bldg 420,Main Quad, Stanford, CA 94305 USA.	nsjoo@psych.stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballard ST, 2004, J PHYSIOL-LONDON, V556, P1, DOI 10.1113/jphysiol.2003.052779; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; Gaillard D, 2000, AM J PHYSIOL-LUNG C, V278, pL177, DOI 10.1152/ajplung.2000.278.1.L177; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Hirsh AJ, 2004, J PHARMACOL EXP THER, V311, P929, DOI 10.1124/jpet.104.071886; Irokawa T, 2004, AM J PHYSIOL-LUNG C, V287, pL784, DOI 10.1152/ajplung.00124.2004; Itoh M, 2000, EUR J BIOCHEM, V267, P3351, DOI 10.1046/j.1432-1327.2000.01368.x; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Joo NS, 2004, J BIOL CHEM, V279, P38854, DOI 10.1074/jbc.M407077200; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; Joo NS, 2002, J BIOL CHEM, V277, P28167, DOI 10.1074/jbc.M202712200; Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Phillips JE, 2002, J APPL PHYSIOL, V93, P873, DOI 10.1152/japplphysiol.00174.2002; Reddy MM, 2003, PFLUG ARCH EUR J PHY, V445, P499, DOI 10.1007/s00424-002-0959-x; Salinas D, 2004, FASEB J, V18, P431, DOI 10.1096/fj.04-2879fje; Singh M, 1997, AM J PHYSIOL-LUNG C, V272, pL690, DOI 10.1152/ajplung.1997.272.4.L690; SONG Y, 2006, IN PRESS AM J PHYSL; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Wine Jeffrey J, 2004, Proc Am Thorac Soc, V1, P47, DOI 10.1513/pats.2306015; YAMAYA M, 1991, AM J PHYSIOL, V261, pL485, DOI 10.1152/ajplung.1991.261.6.L485	29	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7392	7398		10.1074/jbc.M512766200	http://dx.doi.org/10.1074/jbc.M512766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410244	hybrid			2022-12-27	WOS:000236030900059
J	Qiao, M; Shapiro, P; Fosbrink, M; Rus, H; Kumar, R; Passaniti, A				Qiao, M; Shapiro, P; Fosbrink, M; Rus, H; Kumar, R; Passaniti, A			Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SKELETAL GENE-EXPRESSION; TGF-BETA SUPERFAMILY; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; BONE SIALOPROTEIN; MAMMALIAN-CELLS; DNA-BINDING; CBFA1; GROWTH	RUNX2 is a member of the runt family of DNA-binding transcription factors. RUNX2 mediates endothelial cell migration and invasion during tumor angiogenesis and is expressed in metastatic breast and prostate tumors. Our published studies showed that RUNX2 DNA-binding activity is low during growth arrest, but elevated in proliferating endothelial cells. To investigate its role in cell proliferation and cell cycle regulation, RUNX2 was depleted in human bone marrow endothelial cells using RNA interference. Specific RUNX2 depletion inhibited DNA-binding activity as measured by electrophoretic mobility shift assay resulting in inhibition of cell proliferation. Cells were synchronized at the G(1)/S boundary with excess thymidine or in mitosis ( M phase) with nocodazole. Endogenous or ectopic RUNX2 activity was maximal at late G(2) and during M phase. Inhibition of RUNX2 expression by RNA interference delayed entry into and exit out of the G(2)/M phases of the cell cycle. RUNX2 was coimmunoprecipitated with cyclin B1 in mitotic cells, which further supported a role for RUNX2 in cell cycle progression. Moreover, in vitro kinase assays using recombinant cdc2 kinase showed that RUNX2 was phosphorylated at Ser(451). The cdc2 inhibitor roscovitine dose dependently inhibited in vivo RUNX2 DNA-binding activity during mitosis and the RUNX2 mutant S451A exhibited lower DNA-binding activity and reduced stimulation of anchorage-independent growth relative to wild type RUNX2. These results suggest for the first time that RUNX2 phosphorylation by cdc2 may facilitate cell cycle progression possibly through regulation of G(2) and M phases, thus promoting endothelial cell proliferation required for tumor angiogenesis.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Univ Texas, MD Anderson Canc Ctr, Dept Cellular & Mol Oncol, Houston, TX 77030 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Marlene & Stewart Greenbaum Canc Ctr Progrom Onco, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Marlene & Stewart Greenbaum Canc Ctr Progrom Onco, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Passaniti, A (corresponding author), 655 W Baltimore St, Baltimore, MD 21201 USA.	apass001@umaryland.edu	Rus, Horea/AAF-2583-2020		NATIONAL CANCER INSTITUTE [R21CA095350] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA 95350-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anglin Ian, 2004, Cancer Treat Res, V119, P189; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Gonczy P, 2002, CURR BIOL, V12, pR242, DOI 10.1016/S0960-9822(02)00781-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hart SM, 2002, HAEMATOLOGICA, V87, P1307; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; John PCL, 2001, PROTOPLASMA, V216, P119, DOI 10.1007/BF02673865; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KREK W, 1995, METHOD ENZYMOL, V254, P114; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Lian JB, 2003, CONNECT TISSUE RES, V44, P141, DOI 10.1080/03008200390152232; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Miyazono K, 2004, ONCOGENE, V23, P4232, DOI 10.1038/sj.onc.1207131; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Oettgen P, 2001, CIRC RES, V89, P380, DOI 10.1161/hh1701.095958; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Pratap J, 2003, CANCER RES, V63, P5357; Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200; Riminucci M, 2003, CALCIFIED TISSUE INT, V73, P281, DOI 10.1007/s00223-002-2134-y; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; Sato Y, 2000, PHARMACOL THERAPEUT, V87, P51, DOI 10.1016/S0163-7258(00)00067-X; Shekhar MPV, 2000, CANCER RES, V60, P439; Stein GS, 2003, CONNECT TISSUE RES, V44, P149, DOI 10.1080/03008900390152241; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Sun LX, 2001, CANCER RES, V61, P4994; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Yang J, 2001, CANCER RES, V61, P5652; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200	75	93	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7118	7128		10.1074/jbc.M508162200	http://dx.doi.org/10.1074/jbc.M508162200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407259	hybrid			2022-12-27	WOS:000236030900026
J	Vadolas, J; Nefedov, M; Wardan, H; Mansooriderakshan, S; Voullaire, L; Jamsai, D; Williams, R; Ioannou, PA				Vadolas, J; Nefedov, M; Wardan, H; Mansooriderakshan, S; Voullaire, L; Jamsai, D; Williams, R; Ioannou, PA			Humanized beta-thalassemia mouse model containing the common IVSI-110 splicing mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ARTIFICIAL CHROMOSOMES; TRANSGENIC KNOCKOUT MICE; GLOBIN LOCUS; DEVELOPMENTAL REGULATION; PREMESSENGER RNA; GENE-EXPRESSION; HEMOGLOBIN; RECOMBINATION; OLIGONUCLEOTIDES; RESTORATION	Splicing mutations are common causes of beta-thalassemia. Some splicing mutations permit normal splicing as well as aberrant splicing, which can give a reduced level of normal beta-globin synthesis causing mild disease (thalassemia intermedia). For other mutations, normal splicing is reduced to low levels, and patients are transfusion dependent when homozygous for the disease. The development of therapies for beta-thalassemia will require suitable mouse models for preclinical studies. In this study, we report the generation of a humanized mouse model carrying the common IVSI-110 splicing mutation on a BAC including the human beta-globin ((hu)beta-globin) locus. We examined heterozygous murine beta-globin knock-out mice ((mu)beta(th-3/+)) carrying either the IVSI-110 or the normal (hu)beta-globin locus. Our results show a 90% decrease in (hu)beta-globin chain synthesis in the IVSI-110 mouse model compared with the mouse model carrying the normal (hu)beta-globin locus. This notable difference is attributed to aberrant splicing. The humanized IVSI-110 mouse model accurately recapitulates the splicing defect found in comparable beta-thalassemia patients. This mouse model is available as a platform for testing strategies for the restoration of normal splicing.	Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Res Grp, Melbourne, Vic 3052, Australia; Cyprus Inst Neurol & Genet, CY-1683 Nicosia, Cyprus	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Vadolas, J (corresponding author), Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Res Grp, Melbourne, Vic 3052, Australia.	jim.vadolas@mcri.edu.au		Vadolas, Jim/0000-0002-3072-3512				Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chang JC, 1998, P NATL ACAD SCI USA, V95, P14886, DOI 10.1073/pnas.95.25.14886; Danckwardt S, 2002, BLOOD, V99, P1811, DOI 10.1182/blood.V99.5.1811; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Fabry ME, 2000, BLOOD CELL MOL DIS, V26, P331, DOI 10.1006/bcmd.2000.0313; Gaensler KML, 2003, P NATL ACAD SCI USA, V100, P3374, DOI 10.1073/pnas.0634132100; Huang Y, 2000, BLOOD CELL MOL DIS, V26, P598, DOI 10.1006/bcmd.2000.0339; IOANNOU P, 1995, COLLOQ INSE, V234, P143; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jamsai D, 2005, GENOMICS, V85, P453, DOI 10.1016/j.ygeno.2004.11.016; Jamsai D, 2003, GENOMICS, V82, P68, DOI 10.1016/S0888-7543(03)00100-9; Jamsai D, 2003, MOL BIOTECHNOL, V23, P29, DOI 10.1385/MB:23:1:29; Lacerra G, 2000, P NATL ACAD SCI USA, V97, P9591, DOI 10.1073/pnas.97.17.9591; Lewis J, 1998, BLOOD, V91, P2152, DOI 10.1182/blood.V91.6.2152.2152_2152_2156; Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555; Narayanan K, 1999, GENE THER, V6, P442, DOI 10.1038/sj.gt.3300901; Navas PA, 2002, HUM MOL GENET, V11, P893, DOI 10.1093/hmg/11.8.893; Nefedov M, 2000, Nucleic Acids Res, V28, pE79, DOI 10.1093/nar/28.17.e79; Olivieri NF, 1998, HUM MOL GENET, V7, P1655, DOI 10.1093/hmg/7.10.1655; ORFORD MR, 2003, METH MOL B, V240, P243; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Porcu S, 1997, BLOOD, V90, P4602, DOI 10.1182/blood.V90.11.4602.4602_4602_4609; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; Sarsero JP, 2004, MAMM GENOME, V15, P370, DOI 10.1007/s00335-004-3019-3; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Skordis LA, 2003, P NATL ACAD SCI USA, V100, P4114, DOI 10.1073/pnas.0633863100; SPRITZ RA, 1981, P NATL ACAD SCI-BIOL, V78, P2455, DOI 10.1073/pnas.78.4.2455; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; Swaminathan S, 2001, GENESIS, V29, P14, DOI 10.1002/1526-968X(200101)29:1<14::AID-GENE1001>3.0.CO;2-X; Vadolas J, 2005, BBA-GENE STRUCT EXPR, V1728, P150, DOI 10.1016/j.bbaexp.2005.02.008; Vadolas J, 2002, BLOOD, V100, P4209, DOI 10.1182/blood-2001-12-0365; Zhang Y, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-42	35	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7399	7405		10.1074/jbc.M512931200	http://dx.doi.org/10.1074/jbc.M512931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421096	hybrid			2022-12-27	WOS:000236030900060
J	Vaughan, DJ; Millman, EE; Godines, V; Friedman, J; Tran, TM; Dai, WP; Knoll, BJ; Clark, RB; Moore, RH				Vaughan, DJ; Millman, EE; Godines, V; Friedman, J; Tran, TM; Dai, WP; Knoll, BJ; Clark, RB; Moore, RH			Role of the G protein-coupled receptor kinase site serine cluster in beta(2)-adrenergic receptor internalization, desensitization, and beta-arrestin translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; ADRENERGIC-RECEPTOR; VISUAL ARRESTIN; BETA-2-ADRENERGIC RECEPTOR; AGONIST STIMULATION; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; WILD-TYPE; PHOSPHORYLATION; BINDING	There is considerable evidence for the role of carboxyl-terminal serines 355, 356, and 364 in G protein-coupled receptor kinase (GRK)-mediated phosphorylation and desensitization of beta(2)-adrenergic receptors (beta(2)ARs). In this study we used receptors in which these serines were changed to alanines (SA3) or to aspartic acids (SD3) to determine the role of these sites in beta-arrestin-dependent beta(2)AR internalization and desensitization. Coupling efficiencies for epinephrine activation of adenylyl cyclase were similar in wild-type and mutant receptors, demonstrating that the SD3 mutant did not drive constitutive GRK desensitization. Treatment of wild-type and mutant receptors with 0.3 nM isoproterenol for 5 min induced similar to 2-fold increases in the EC50 for agonist activation of adenylyl cyclase, consistent with protein kinase A (PKA) site-mediated desensitization. When exposed to 1 mu M isoproterenol to trigger GRK site-mediated desensitization, only wild-type receptors showed significant further desensitization. Using a phospho site-specific antibody, we determined that there is no requirement for these GRK sites in PKA-mediated phosphorylation at high agonist concentration. The rates of agonist-induced internalization of the SD3 and SA3 mutants were 44 and 13%, respectively, relative to that of wild-type receptors, but the SD3 mutant recruited enhanced green fluorescent protein (EGFP)-beta-arrestin 2 to the plasma membrane, whereas the SA3 mutant did not. EGFP-beta-Arrestin2 overexpression triggered a significant increase in the extent of SD3 mutant desensitization but had no effect on the desensitization of wild-type receptors or the SA3 mutant. Expression of a phosphorylation-independent beta-arrestin 1 mutant (R169E) significantly rescued the internalization defect of the SA3 mutant but inhibited the phosphorylation of serines 355 and 356 in wild-type receptors. Our data demonstrate that (i) the lack of GRK sites does not impair PKA site phosphorylation, (ii) the SD3 mutation inhibits GRK-mediated desensitization although it supports some agonist-induced beta-arrestin binding and receptor internalization, and (iii) serines 355, 356, and 364 play a pivotal role in the GRK-mediated desensitization, beta-arrestin binding, and internalization of beta(2)ARs.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Houston System; University of Houston	Moore, RH (corresponding author), Baylor Coll Med, Dept Pediat, 6621 Fannin,CCC1040, Houston, TX 77030 USA.	rmoore@bcm.tmc.edu	Vaughan, David/AAZ-3873-2020		NHLBI NIH HHS [HL 64934] Funding Source: Medline; NIGMS NIH HHS [GM 031208] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; January B, 1998, BRIT J PHARMACOL, V123, P701, DOI 10.1038/sj.bjp.0701658; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Millman EE, 2004, BRIT J PHARMACOL, V141, P277, DOI 10.1038/sj.bjp.0705504; Moore RH, 2004, J CELL SCI, V117, P3107, DOI 10.1242/jcs.01168; MOORE RH, 1995, J CELL SCI, V108, P2983; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; Raman D, 2003, J NEUROCHEM, V84, P1040, DOI 10.1046/j.1471-4159.2003.01598.x; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Seibold A, 2000, MOL PHARMACOL, V58, P1162, DOI 10.1124/mol.58.5.1162; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Trester-Zedlitz M, 2005, BIOCHEMISTRY-US, V44, P6133, DOI 10.1021/bi0475469; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; VON ZM, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	46	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7684	7692		10.1074/jbc.M500328200	http://dx.doi.org/10.1074/jbc.M500328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407241	hybrid			2022-12-27	WOS:000236030900089
J	Martinez-Martinez, S; Rodriguez, A; Lopez-Maderuelo, MD; Ortega-Perez, I; Vazquez, J; Redondo, JM				Martinez-Martinez, S; Rodriguez, A; Lopez-Maderuelo, MD; Ortega-Perez, I; Vazquez, J; Redondo, JM			Blockade of NFAT activation by the second calcineurin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; T-CELLS; CYCLOSPORINE-A; NUCLEAR FACTOR; SELECTIVE-INHIBITION; MUSCLE-CELLS; DOMAIN; PROTEINS; CALCIUM; SIGNAL	Activation of NFAT transcription factors requires their dephosphorylation by the phosphatase calcineurin (CN). NFATs contain two CN binding motifs: PxIxIT and CnBP-B/CNBR2 ( which we call LxVP). Here we carry out a detailed comparative analysis of the CN binding activity displayed by the PxIxIT and LxVP sites from different NFATs. Dose-response CN binding experiments with GST fusion proteins of NFATc1 and NFATc2 showed that NFATc1 binds CN in vitro more efficiently than does NFATc2. This difference in binding appears to be caused by the different CN binding potencies of the corresponding LxVP sites; thus while the LxVPc2 peptide fused to GST did not bind CN, GST-LxVPc1 bound it more efficiently than did GST-PxIxITc1 or GST-PxIxITc2. Furthermore, an NFATc2 chimera protein containing the LxVP motif from NFATc1 interacted with CN much more potently than did wild-type NFATc2. Free peptides spanning the LxVP motifs from NFATc1, c3 or c4 displaced CN from GST-NFATc1 and GST-NFATc2 more efficiently than any PxIxIT peptide. PxIxITc2 and LxVPc1 peptides were each able to cross-compete GST-LxVPc1-CN and GST-PxIx-ITc2-CN binding. In contrast with PxIxITc2, the LxVP peptide not only blocked CN-NFAT binding but also inhibited CN phosphatase activity in vitro. Furthermore, exogenous LxVPc1 blocked NFATc2 phosphorylation and nuclear translocation in vivo. These results suggest a model in which the different CN binding characteristics of the PxIxIT and LxVP sites enable different NFAT members to influence each others activities in cells where they are co-expressed.	CNIC, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Fac Ciencias, E-28049 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Redondo, JM (corresponding author), CNIC, Melchor Femandez Almagro 3, Madrid 28029, Spain.	jmredondo@cbm.uam.es	Marquez, Antonio A. Rodriguez/L-2422-2013; Redondo, Juan Miguel/H-6351-2015; Vazquez, Jesus/B-7697-2015	Marquez, Antonio A. Rodriguez/0000-0003-2455-6583; Redondo, Juan Miguel/0000-0001-5779-9122; Vazquez, Jesus/0000-0003-1461-5092				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bandyopadhyay A, 2000, BIOCHEM J, V352, P61, DOI 10.1042/0264-6021:3520061; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Chow CW, 1999, MOL CELL BIOL, V19, P2300; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lambrechts D, 2004, CELL, V118, P532, DOI 10.1016/j.cell.2004.08.022; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; Liu J, 1999, J IMMUNOL, V162, P4755; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu J, 2001, J IMMUNOL, V167, P2677, DOI 10.4049/jimmunol.167.5.2677; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Molkentin JD, 2001, CIRC RES, V88, P1220, DOI 10.1161/hh1201.093159; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rodriguez A, 2005, J BIOL CHEM, V280, P9980, DOI 10.1074/jbc.C400401200; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; Serfling E, 2004, INT J BIOCHEM CELL B, V36, P1166, DOI 10.1016/j.biocel.2003.07.002; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	44	62	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6227	6235		10.1074/jbc.M513885200	http://dx.doi.org/10.1074/jbc.M513885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407284	hybrid			2022-12-27	WOS:000236030800015
J	Yoo, EJ; Chung, JJ; Choe, SS; Kim, KH; Kim, JB				Yoo, EJ; Chung, JJ; Choe, SS; Kim, KH; Kim, JB			Down-regulation of histone deacetylases stimulates adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; SUBEROYLANILIDE HYDROXAMIC ACID; SODIUM-BUTYRATE; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVITY; COACTIVATORS P300; BINDING-PROTEIN; PPAR-GAMMA; C/EBP-BETA; ACETYLATION	Specific cell type differentiation is driven by programmed regulation of gene expression, which is the result of coordinated modulation of the transcription machinery and chromatin-remodeling factors. We present evidence here that the down-regulation of histone deacetylases is an important process during adipocyte differentiation. In 3T3-L1 cells, histone hyperacetylation was selectively induced at the promoter regions of adipogenic genes during adipocyte differentiation. Interestingly, this was accompanied by a dramatic decrease in the expression level of several histone deacetylases including HDAC1, - 2, and - 5 and a reduction in overall histone deacetylase enzyme activity. Inhibition of histone deacetylase activity using sodium butyrate resulted in stimulation of adipogenic gene expression and adipocyte differentiation. Consistently, HDAC1 knock-down promoted adipogenesis whereas HDAC1 overexpression attenuated adipocyte differentiation in 3T3-L1 cells. Together, these results suggest that the regulation of not only adipogenic transcription factors, but also chromatin-modifying enzymes is crucial for the execution of bona fide adipogenesis.	Seoul Natl Univ, Dept Biol Sci, Res Ctr Funct Cellul, Seoul 151742, South Korea	Seoul National University (SNU)	Kim, JB (corresponding author), Seoul Natl Univ, Dept Biol Sci, Res Ctr Funct Cellul, San 56-1, Seoul 151742, South Korea.	jaebkim@snu.ac.kr	Song, Minsun/I-5701-2015	Chung, Jun-Jae/0000-0002-3053-5693; KIM, Jae Bum/0000-0003-2337-6935				Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Lee YS, 2003, NUCLEIC ACIDS RES, V31, P7165, DOI 10.1093/nar/gkg934; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; Mal A, 2003, P NATL ACAD SCI USA, V100, P1735, DOI 10.1073/pnas.0437843100; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Mariadason JM, 2000, CANCER RES, V60, P4561; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rahmani M, 2003, CANCER RES, V63, P8420; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Rosen ED, 2000, GENE DEV, V14, P1293; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Seo JB, 2003, MOL ENDOCRINOL, V17, P1522, DOI 10.1210/me.2003-0028; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000	56	137	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6608	6615		10.1074/jbc.M508982200	http://dx.doi.org/10.1074/jbc.M508982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407282	hybrid			2022-12-27	WOS:000236030800057
J	Mishra, S; Saleh, A; Espino, PS; Davie, JR; Murphy, LJ				Mishra, S; Saleh, A; Espino, PS; Davie, JR; Murphy, LJ			Phosphorylation of histones by tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; BINDING PROTEIN; ACTIVATION; APOPTOSIS; PATHWAY; KINASE; GTP; H3	Tissue transglutaminase 2 (TG2) has recently been shown to have intrinsic serine/threonine kinase activity. Since histones are known to be cross-linked by TG2, we investigated whether histones are also substrates for TG2 kinase activity. TG2 was able to phosphorylate H1, H2A, H2B, H3, and H4 histones in vitro. Using peptide substrates and phosphospecific antibodies we demonstrated that TG2 phosphorylated Ser(10) in H3 and that this phosphorylation was reduced by acetylation, whereas phosphorylation of Ser10 by TG2 enhanced acetylation. Furthermore we demonstrated that exogenous TG2 phosphorylated H1 and H3 in nucleosome preparations. We examined the abundance of TG2 in DNA-associated proteins from MCF-7 cells treated with phorbol ester (TPA) and 17 beta-estradiol (E2). TG2 abundance was significantly reduced in E2-treated cells and enhanced in TPA-treated cells. In summary we have demonstrated that TG2 is able to phosphorylate purified histone proteins, and H3 and H1 in chromatin preparations, and it is associated with chromatin in breast cancer cells. These studies suggest a novel role for TG2 in the regulation of chromatin structure and function.	Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba; University of Manitoba	Murphy, LJ (corresponding author), Univ Manitoba, John Buhler Res Ctr, Rm 843,715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	ljmurph@cc.umanitoba.ca	Espino, Paula/A-9459-2008; Mishra, Suresh/W-1633-2019	Davie, James/0000-0002-0420-6888; Mishra, Suresh/0000-0002-0364-1538				Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Ballestar E, 2001, BIOCHEMISTRY-US, V40, P1922, DOI 10.1021/bi001575b; BODE AM, 2005, SCI STKE, V281, pRE4; Bonelli G, 1996, EXP CELL RES, V228, P292, DOI 10.1006/excr.1996.0329; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Dunn KL, 2005, ONCOGENE, V24, P3492, DOI 10.1038/sj.onc.1208521; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Enomoto R, 2004, NEUROCHEM INT, V44, P459, DOI 10.1016/S0197-0186(03)00175-X; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Han JA, 2000, MOL CELLS, V10, P612, DOI 10.1007/s100590000020; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Ientile R, 2003, J NEUROSCI RES, V74, P52, DOI 10.1002/jnr.10702; Johnson KA, 2005, J BIOL CHEM, V280, P15004, DOI 10.1074/jbc.M500962200; Kim JH, 2002, BIOCHEM BIOPH RES CO, V293, P1453, DOI 10.1016/S0006-291X(02)00393-5; Kweon SM, 2004, J BIOCHEM MOL BIOL, V37, P185; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nicholas B, 2003, BIOCHEM J, V371, P413, DOI 10.1042/BJ20021949; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Peng XJ, 1999, FEBS LETT, V446, P35, DOI 10.1016/S0014-5793(99)00018-6; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; Robitaille K, 2004, CELL DEATH DIFFER, V11, P542, DOI 10.1038/sj.cdd.4401392; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; Sato N, 2003, J PROTEIN CHEM, V22, P303, DOI 10.1023/A:1025032906494; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Song LW, 2003, CHINESE MED J-PEKING, V116, P742; Takeuchi Y, 1998, Z NATURFORSCH C, V53, P352; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; Zhang Y, 2004, J BIOL CHEM, V279, P21866, DOI 10.1074/jbc.M400099200	38	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5532	5538		10.1074/jbc.M506864200	http://dx.doi.org/10.1074/jbc.M506864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407273	hybrid			2022-12-27	WOS:000235568900027
J	Giannakis, M; Stappenbeck, TS; Mills, JC; Leip, DG; Lovett, M; Clifton, SW; Ippolito, JE; Glasscock, JI; Arumugam, M; Brent, MR; Gordon, JI				Giannakis, M; Stappenbeck, TS; Mills, JC; Leip, DG; Lovett, M; Clifton, SW; Ippolito, JE; Glasscock, JI; Arumugam, M; Brent, MR; Gordon, JI			Molecular properties of adult mouse gastric and intestinal epithelial progenitors in their niches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL NICHE; INDUCED APOPTOSIS; PARIETAL-CELLS; SELF-RENEWAL; STOMACH; DIFFERENTIATION; DYNAMICS; COLUMNAR; ORIGIN; IMPACT	We have sequenced 36,641 expressed sequence tags from laser capture microdissected adult mouse gastric and small intestinal epithelial progenitors, obtaining 4031 and 3324 unique transcripts, respectively. Using Gene Ontology ( GO) terms, each data set was compared with cDNA libraries from intact adult stomach and small intestine. Genes in GO categories enriched in progenitors were filtered against genes in GO categories represented in hematopoietic, neural, and embryonic stem cell transcriptomes and mapped onto transcription factor networks, plus canonical signal transduction and metabolic pathways. Wnt/beta-catenin, phosphoinositide-3/Akt kinase, insulin-like growth factor-1, vascular endothelial growth factor, integrin, and gamma-aminobutyric acid receptor signaling cascades, plus glycerolipid, fatty acid, and amino acid metabolic pathways are among those prominently represented in adult gut progenitors. The results reveal shared as well as distinctive features of adult gut stem cells when compared with other stem cell populations.	Washington Univ, Ctr Genome Sci, St Louis, MO 63108 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63108 USA; Washington Univ, Dept Pathol & Immunol, St Louis, MO 63108 USA; Washington Univ, Dept Genet, St Louis, MO 63108 USA; Washington Univ, Lab Computat Genom, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Ctr Genome Sci, 4444 Forest Pk Rd,Campus Box 8510, St Louis, MO 63108 USA.	jgordon@wustl.edu	Brent, Michael/AAK-3702-2020; Arumugam, Manimozhiyan/AAJ-2394-2020; Giannakis, Marios/Z-4908-2019; Arumugam, Manimozhiyan/E-1211-2011; Mills, Jason/AAA-6688-2021	Brent, Michael/0000-0002-8689-0299; Arumugam, Manimozhiyan/0000-0002-0886-9101; Arumugam, Manimozhiyan/0000-0002-0886-9101; Mills, Jason/0000-0002-0402-4662	NIDDK NIH HHS [DK63483] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063483] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberg MAI, 2003, MOL CELL NEUROSCI, V24, P23, DOI 10.1016/S1044-7431(03)00082-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; Bjerknes M, 2002, AM J PHYSIOL-GASTR L, V283, pG767, DOI 10.1152/ajpgi.00415.2001; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Bjerknes M, 2001, P NATL ACAD SCI USA, V98, P12497, DOI 10.1073/pnas.211278098; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CROFT DN, 1973, DIGESTION, V8, P144, DOI 10.1159/000197310; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hawkins RD, 2003, HUM MOL GENET, V12, P1261, DOI 10.1093/hmg/ddg150; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Lin PT, 2000, J NEUROSCI, V20, P9152; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Mills JC, 2002, P NATL ACAD SCI USA, V99, P14819, DOI 10.1073/pnas.192574799; Mills JC, 2003, J BIOL CHEM, V278, P46138, DOI 10.1074/jbc.M308385200; Mott R, 1997, COMPUT APPL BIOSCI, V13, P477; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Syder AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI 10.1073/pnas.0307983101; Syder AJ, 2003, P NATL ACAD SCI USA, V100, P3467, DOI 10.1073/pnas.0230380100; Syder AJ, 1999, MOL CELL, V3, P263, DOI 10.1016/S1097-2765(00)80454-2; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; ZHONG Z, 2004, APPL BIOINFORMATICS, V3, P261	34	136	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11292	11300		10.1074/jbc.M512118200	http://dx.doi.org/10.1074/jbc.M512118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464855	hybrid			2022-12-27	WOS:000236822200072
J	O'Donnell, M				O'Donnell, M			Replisome architecture and dynamics in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-POLYMERASE-III; CLAMP LOADER COMPLEX; BETA-SLIDING CLAMP; CHROMOSOMAL REPLICATION MACHINE; LAGGING-STRAND REPLICATION; ONE HOLOENZYME PARTICLE; CRYSTAL-STRUCTURE; DELTA-SUBUNIT; HELICASE ACTIVITY; ENERGY-TRANSFER		Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, 1230 York Ave, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214				ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; Ason B, 2003, J BIOL CHEM, V278, P10033, DOI 10.1074/jbc.M211741200; Bowman GD, 2005, FEBS LETT, V579, P863, DOI 10.1016/j.febslet.2004.11.038; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Breier AM, 2005, P NATL ACAD SCI USA, V102, P3942, DOI 10.1073/pnas.0500812102; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; De Saro FJL, 2003, P NATL ACAD SCI USA, V100, P14689, DOI 10.1073/pnas.2435454100; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; Fujii S, 2004, EMBO J, V23, P4342, DOI 10.1038/sj.emboj.7600438; Goedken ER, 2005, NAT STRUCT MOL BIOL, V12, P183, DOI 10.1038/nsmb889; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; Indiani C, 2005, MOL CELL, V19, P805, DOI 10.1016/j.molcel.2005.08.011; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kazmirski SL, 2005, P NATL ACAD SCI USA, V102, P13801, DOI 10.1073/pnas.0506430102; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; LEHMAN IR, 1958, J BIOL CHEM, V233, P163; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; Lenne-Samuel N, 2002, EMBO REP, V3, P45, DOI 10.1093/embo-reports/kvf007; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; Leu FP, 2001, J BIOL CHEM, V276, P47185, DOI 10.1074/jbc.M106780200; MAKI H, 1988, J BIOL CHEM, V263, P6570; McHenry CS, 2003, MOL MICROBIOL, V49, P1157, DOI 10.1046/j.1365-2958.2003.03645.x; McInerney P, 2004, J BIOL CHEM, V279, P21543, DOI 10.1074/jbc.M401649200; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Miyata T, 2005, P NATL ACAD SCI USA, V102, P13795, DOI 10.1073/pnas.0506447102; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; Takahashi TS, 2005, TRENDS BIOCHEM SCI, V30, P437, DOI 10.1016/j.tibs.2005.06.007; TOUGU K, 1994, J BIOL CHEM, V269, P4675; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WU CA, 1992, J BIOL CHEM, V267, P4064; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	69	102	104	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10653	10656		10.1074/jbc.R500028200	http://dx.doi.org/10.1074/jbc.R500028200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16421093	hybrid			2022-12-27	WOS:000236822200002
J	Hanington, PC; Barreda, DR; Belosevic, M				Hanington, PC; Barreda, DR; Belosevic, M			A novel hematopoietic granulin induces proliferation of goldfish (Carassius auratus L.) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 BETA-HAIRPINS; GROWTH-FACTOR; EPITHELIN PRECURSOR; GENE-EXPRESSION; CELLULAR-LOCALIZATION; EMERGING FAMILY; IN-VITRO; PROGRANULIN; ACROGRANIN; PEPTIDE	Granulins are a group of highly conserved growth factors that have been described from a variety of organisms spanning the metazoa. In this study, goldfish granulin was one of the most commonly identified transcripts in the differential cross-screening of macrophage cDNA libraries and was preferentially expressed in proliferating macrophages. Unlike mammalian granulins, which possess 7.5 repeats of a characteristic signature of 12 cysteine residues, the goldfish granulin encoded a putative peptide possessing only 1.5 cysteine repeats. Northern blot and real-time PCR analyses indicated that goldfish granulin was expressed only in the hematopoietic tissues of the goldfish, specifically the kidney and spleen, and in activated peripheral blood mononuclear cells. We expressed granulin using a prokaryotic expression system and produced an affinity-purified rabbit anti-goldfish granulin IgG. Recombinant goldfish granulin induced a dose-dependent proliferative response of goldfish macrophages that was inversely related to the myeloid differentiation stage of the cells studied. The highest proliferative response was observed in macrophage progenitor cells and monocytes. This proliferative response of macrophages was abrogated by the addition of anti-granulin IgG. These results indicate that goldfish granulin is a growth factor that positively modulates cell proliferation at distinct junctures of macrophage differentiation.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E9, Canada; Univ Penn, Dept Hematol & Oncol, Philadelphia, PA 19104 USA	University of Alberta; University of Alberta; University of Pennsylvania	Belosevic, M (corresponding author), Univ Alberta, Dept Biol Sci, CW-405 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.	mike.belosevic@ualberta.ca	Belosevic, Miodrag/C-6729-2008; Belosevic, Miodrag/G-9396-2018; Belosevic, Mike/A-2617-2014; Barreda, Daniel/A-2613-2014	Belosevic, Miodrag/0000-0002-6412-8236; Belosevic, Miodrag/0000-0002-6412-8236; Belosevic, Mike/0000-0001-6512-3587; Barreda, Daniel/0000-0003-4630-2840; Hanington, Patrick/0000-0002-3964-5012				ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317; Avrova AO, 1999, MOL PLANT MICROBE IN, V12, P1114, DOI 10.1094/MPMI.1999.12.12.1114; BABA T, 1993, FEBS LETT, V322, P89, DOI 10.1016/0014-5793(93)81544-A; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P727, DOI 10.1016/j.dci.2003.11.005; Barreda DR, 2000, DEV COMP IMMUNOL, V24, P395, DOI 10.1016/S0145-305X(99)00059-2; Barreda DR, 2001, FISH SHELLFISH IMMUN, V11, P169, DOI 10.1006/fsim.2000.0305; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; BELCOURT DR, 1995, J LEUKOCYTE BIOL, V57, P94, DOI 10.1002/jlb.57.1.94; BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; BELOSEVIC M, 1988, J IMMUNOL, V141, P890; BERKS M, 1995, GENOME RES, V5, P99, DOI 10.1101/gr.5.2.99; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; BHANDARI V, 1993, ENDOCRINOLOGY, V133, P2682, DOI 10.1210/en.133.6.2682; Cadieux B, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-156; COUTO MA, 1992, INFECT IMMUN, V60, P3065, DOI 10.1128/IAI.60.8.3065-3071.1992; COUTO MA, 1992, INFECT IMMUN, V60, P5042, DOI 10.1128/IAI.60.12.5042-5047.1992; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Deloffre L, 1999, B SOC ZOOL FR, V124, P337; Diaz-Cueto L, 2000, DEV BIOL, V217, P406, DOI 10.1006/dbio.1999.9564; Donald CD, 2001, ANTICANCER RES, V21, P3739; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Hall VJ, 2005, MOL REPROD DEV, V72, P16, DOI 10.1002/mrd.20337; He ZH, 1999, CANCER RES, V59, P3222; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; He ZH, 2002, CANCER RES, V62, P5590; Hoque M, 2005, J BIOL CHEM, V280, P13648, DOI 10.1074/jbc.M409575200; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Jones MB, 2003, CLIN CANCER RES, V9, P44; Liau LM, 2000, CANCER RES, V60, P1353; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; Nara K, 2004, BBA-GEN SUBJECTS, V1675, P147, DOI 10.1016/j.bbagen.2004.08.016; Neumann NF, 2000, FISH SHELLFISH IMMUN, V10, P167, DOI 10.1006/fsim.1999.0236; Neumann NF, 2000, FISH SHELLFISH IMMUN, V10, P1, DOI 10.1006/fsim.1999.0221; Neumann NF, 1998, DEV COMP IMMUNOL, V22, P417, DOI 10.1016/S0145-305X(98)00023-8; Neumann NF, 1995, DEV COMP IMMUNOL, V19, P473, DOI 10.1016/0145-305X(95)00032-O; Ong CHP, 2003, HISTOL HISTOPATHOL, V18, P1275, DOI 10.14670/HH-18.1275; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Qin JW, 2005, BIOL REPROD, V73, P434, DOI 10.1095/biolreprod.105.040030; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Sparro G, 1997, PROTEIN EXPRES PURIF, V10, P169, DOI 10.1006/prep.1997.0726; Stafford JL, 2003, DEV COMP IMMUNOL, V27, P685, DOI 10.1016/S0145-305X(03)00041-7; Suzuki M, 2002, MOL GENET METAB, V75, P31, DOI 10.1006/mgme.2001.3274; Suzuki M, 2001, NEUROSCI LETT, V297, P199, DOI 10.1016/S0304-3940(00)01699-2; Suzuki M, 2000, PHYSIOL BEHAV, V68, P707, DOI 10.1016/S0031-9384(99)00241-3; Tolkatchev D, 2001, J PEPT RES, V57, P227, DOI 10.1046/j.1397-002X.2000.00828.x; Tolkatchev D, 2000, BIOCHEMISTRY-US, V39, P2878, DOI 10.1021/bi992130u; UESAKA T, 1995, GEN COMP ENDOCR, V99, P298, DOI 10.1006/gcen.1995.1113; Wang WG, 2003, CLIN CANCER RES, V9, P2221; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	60	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9963	9970		10.1074/jbc.M600631200	http://dx.doi.org/10.1074/jbc.M600631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16473876	hybrid			2022-12-27	WOS:000236594300018
J	Inoue, Y; Yoneda, M; Zhao, JS; Miyaishi, O; Ohno-Jinno, A; Kataoka, T; Isogai, Z; Kimata, K; Iwaki, M; Zako, M				Inoue, Y; Yoneda, M; Zhao, JS; Miyaishi, O; Ohno-Jinno, A; Kataoka, T; Isogai, Z; Kimata, K; Iwaki, M; Zako, M			Molecular cloning and characterization of chick SPACRCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BOVINE INTERPHOTORECEPTOR MATRIX; PINEAL-GLAND; MOUSE RETINA; PG-M; HYALURONAN; BINDING; PROTEINS; TISSUE; EXPRESSION	MY-174, a monoclonal antibody that reacts with specific sialylated O-linked glycoconjugates of chick SPACR ( sialoprotein associated with cones and rods), also recognizes another molecule of 300 kDa. Here, we verified that this 300-kDa molecule is chick SPACRCAN ( sialoproteoglycan associated with cones and rods), another member of a novel interphotoreceptor matrix molecule family. Screening for chick SPACRCAN was carried out by plaque hybridization using a probe for chick SPACR. Specific polyclonal antibodies raised against chick SPACRCAN were used for the following experiments. To determine whether the 300-kDa molecule detected by MY-174 was identical to 300-kDa chick SPACRCAN, the migrations of these bands were examined after various glycosidase digestions. Furthermore, the expression levels were measured during retinal development and compared with those of chick SPACR. The results demonstrated that the 300-kDa molecule recognized by MY-174 was chick SPACRCAN, and we further identified it as a proteoglycan with chondroitin sulfate chains. SPACRCAN had heavily sialylated N- and O-linked glycoconjugates, and its MY-174 antigenicity was abolished by O-glycanase treatment after neuraminidase treatment, as observed for chick SPACR. During retinal development, the mRNA and core protein expression levels, MY-174 antigenicity, and hyaluronan binding ability of SPACRCAN peaked around embryonic day 17 and then gradually decreased, whereas the corresponding expression levels of SPACR simply increased, but not its hyaluronan binding ability. The MY-174 reactivity of SPACRCAN in the adult retina was decreased compared with that in the newborn retina, whereas that of SPACR was increased. The decreased hyaluronan binding of SPACR was induced by an inhibitory effect of the excess of sialic acids in the adult stage. Thus, with similar core protein structures and specific sialylated glycoconjugates but distinct chondroitin sulfate chains, SPACRCAN and SPACR may have separate roles in the retina due to their differing expression profiles during development.	Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Dept Pathol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Aichi Prefectural Coll Nursing & Hlth, Aichi 4638502, Japan; Natl Ctr Geriatr & Gerontol, Dept Dermatol, Aichi 4748511, Japan	Aichi Medical University; Aichi Medical University; Aichi Medical University; National Center for Geriatrics & Gerontology	Zako, M (corresponding author), Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.	zako@aichi-med-u.ac.jp	Isogai, Zenzo/AAD-3690-2022					Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Acharya S, 1998, GLYCOBIOLOGY, V8, P997, DOI 10.1093/glycob/8.10.997; Acharya S, 2000, J BIOL CHEM, V275, P6945, DOI 10.1074/jbc.275.10.6945; ADLER AJ, 1982, EXP EYE RES, V34, P423, DOI 10.1016/0014-4835(82)90088-4; ADLER AJ, 1981, EXP EYE RES, V32, P755, DOI 10.1016/0014-4835(81)90025-7; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; Chen QY, 2004, J BIOL CHEM, V279, P23142, DOI 10.1074/jbc.M401584200; Chen QY, 2003, EXP EYE RES, V76, P1, DOI 10.1016/S0014-4835(02)00273-7; Foletta VC, 2001, J COMP NEUROL, V435, P354, DOI 10.1002/cne.1035; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hollyfield JG, 1997, EXP EYE RES, V65, P603, DOI 10.1006/exer.1997.0369; Hollyfield JG, 1999, EXP EYE RES, V69, P311, DOI 10.1006/exer.1999.0707; Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422; Hollyfield JG, 2001, EXP EYE RES, V72, P49, DOI 10.1006/exer.2000.0922; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P4338; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Lee JW, 2000, EXP EYE RES, V71, P341, DOI 10.1006/exer.2000.0888; RING C, 1995, DEV BIOL, V168, P11, DOI 10.1006/dbio.1995.1057; Wang C, 1996, GENE, V174, P299, DOI 10.1016/0378-1119(96)00080-7; Wang X, 1996, MOL BRAIN RES, V41, P269, DOI 10.1016/0169-328X(96)00107-6; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 2002, J BIOL CHEM, V277, P25592, DOI 10.1074/jbc.M201279200; Zako M, 1997, J NEUROCHEM, V69, P2155	26	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10381	10388		10.1074/jbc.M508161200	http://dx.doi.org/10.1074/jbc.M508161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469746	hybrid			2022-12-27	WOS:000236594300067
J	Shivaswamy, S; Bhargava, P				Shivaswamy, S; Bhargava, P			Positioned nucleosomes due to sequential remodeling of the yeast U6 small nuclear RNA chromatin are essential for its transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; SNRNA GENE; DNA TRANSLOCATION; IN-VIVO; PROMOTER; CEREVISIAE; TFIIIB; IDENTIFICATION; ACCESSIBILITY; MAINTENANCE	Transcription from the yeast SNR6 (U6 small nuclear RNA) chromatin, a gene transcribed by the enzyme RNA polymerase III, depends on its transcription factor IIIC ( TFIIIC) and the promoter elements ( the intragenic box A and box B located downstream to its terminator) to which TFIIIC binds. The genes transcribed by polymerase III generally lack the upstream promoter elements where TFIIIC is known to recruit the transcription initiation factor TFIIIB. The TFIIIC-dependent chromatin remodeling of the gene in vitro that involves translational positioning of a nucleosome between boxes A and B is found to be essential for its transcriptional activation. We show here that the role of TFIIIC is not limited to the recruitment of TFIIIB on chromatin templates. The pre-binding of TFIIIB to the SNR6 TATA box in the upstream gene region does not alleviate TFIIIC requirement for transcriptional activation of the chromatin. Binding of TFIIIC to an array of pre-positioned nucleosomes results in an upward shift of the single nucleosome between boxes A and B. The similar to 40-bp shift of this nucleosome in the 3' to 5' direction leads to increased nuclease sensitivity of the similar to 40-bp DNA 3' to the upstream TATA box. Further chromatin remodeling accompanies the binding of TFIIIB in the next step. This two-step remodeling mechanism using the basal factors of the gene yields high transcription levels and generates a chromatin structure similar to that reported for the gene in vivo.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Bhargava, P (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	purnima@ccmb.res.in						Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Bachman N, 2005, GENE DEV, V19, P955, DOI 10.1101/gad.1299105; Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; Bulger M., 1994, METH MOL G, V5, P241; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; CHEN J, 1994, J BIOL CHEM, V269, P12482; CONAWAY RC, 1994, TRANSCRIPTION MECH R, P107; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Gelbart ME, 2005, GENE DEV, V19, P942, DOI 10.1101/gad.1298905; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 2003, J BIOL CHEM, V278, P17912, DOI 10.1074/jbc.M300743200; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Lorch Y, 2001, MOL CELL, V7, P89, DOI 10.1016/S1097-2765(01)00157-5; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; Pusarla RH, 2005, FEBS J, V272, P5149, DOI 10.1111/j.1742-4658.2005.04930.x; Saha A, 2005, NAT STRUCT MOL BIOL, V12, P747, DOI 10.1038/nsmb973; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; Shivaswamy S, 2004, MOL CELL BIOL, V24, P3596, DOI 10.1128/MCB.24.9.3596-3606.2004; Strohner R, 2005, NAT STRUCT MOL BIOL, V12, P683, DOI 10.1038/nsmb966; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178	35	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10461	10472		10.1074/jbc.M512425200	http://dx.doi.org/10.1074/jbc.M512425200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16461347	hybrid			2022-12-27	WOS:000236594300075
J	Kamp, F; Beyer, K				Kamp, F; Beyer, K			Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PHOSPHOLIPID-VESICLES; PARKINSONS-DISEASE; PHASE-TRANSITION; MEMBRANE; MUTATION; POLARIZATION; PATHOGENESIS; CHOLESTEROL; MECHANISM	The intracellular deposition of fibrillar aggregates of alpha-synuclein is a characteristic feature of Parkinson disease. Alternatively, as a result of its unusual conformational plasticity, alpha-synuclein may fold into an amphipathic helix upon contact with a lipid-water interface. Using spin label ESR and fluorescence spectroscopy, we show here that alpha-synuclein affects the lipid packing in small unilamellar vesicles. The ESR hyperfine splittings of spin-labeled phospholipid probes revealed that alpha-synuclein induces chain ordering at carbon 14 of the acyl chains below the chain melting phase transition temperature but not in the liquid crystalline state of electroneutral vesicle membranes. Binding of alpha-synuclein leads to an increase in the temperature and cooperativity of the phase transition according to the fluorescence anisotropy of the hydrophobic polyene 1,6-diphenylhexatriene and of the fluorescence emission maxima of the amphiphilic probe 6-dodecanoyl-2-dimethylaminonaphthalene. Binding parameters were obtained from the fluorescence anisotropy measurements in combination with our previous determinations by titration calorimetry (Nuscher, B., Kamp, F., Mehnert, T., Odoy, S., Haass, C., Kahle, P. J., and Beyer, K. (2004) J. Biol. Chem. 279, 21966-21975). We also show that alpha-synuclein interacts with vesicle membranes containing sphingomyelin and cholesterol. We propose that the protein is capable of annealing defects in curved vesicle membranes, which may prevent synaptic vesicles from premature fusion.	Univ Munich, Lehrstuhl Stoffwechselbiochim, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Beyer, K (corresponding author), Univ Munich, Lehrstuhl Stoffwechselbiochim, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	kbeyer@med.uni-muenchen.de	Rose, Louise/F-4723-2011; Presneill, Jeffrey J/B-4894-2012	Presneill, Jeffrey J/0000-0001-7177-7667				Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149; [Anonymous], 1976, THEORY APPL SPIN LAB; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1976, BIOCHEMISTRY-US, V15, P2441, DOI 10.1021/bi00656a030; Barenholz Y, 1999, CHEM PHYS LIPIDS, V102, P29, DOI 10.1016/S0009-3084(99)00072-9; Barenholz Y., 1984, PHYSL MEMBRANE FLUID, V1, P131; Cabin DE, 2002, J NEUROSCI, V22, P8797; CALHOUN WI, 1979, BIOCHIM BIOPHYS ACTA, V555, P436, DOI 10.1016/0005-2736(79)90397-3; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Collado MI, 2005, BIOCHEMISTRY-US, V44, P4911, DOI 10.1021/bi0474970; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEUTSCH JW, 1981, BIOCHEMISTRY-US, V20, P378, DOI 10.1021/bi00505a024; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; ESTEP TN, 1980, BIOCHEMISTRY-US, V19, P20, DOI 10.1021/bi00542a004; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; FREDERIK PM, 1991, BIOCHIM BIOPHYS ACTA, V1062, P133, DOI 10.1016/0005-2736(91)90384-K; GABER BP, 1982, BIOCHIM BIOPHYS ACTA, V685, P87, DOI 10.1016/0005-2736(82)90038-4; GAFFNEY BJ, 1974, J MAGN RESON, V16, P1, DOI 10.1016/0022-2364(74)90193-0; Gaffney BJ, 1976, SPIN LABELING THEORY, P567; GRUENEWALD B, 1979, FEBS LETT, V102, P227, DOI 10.1016/0014-5793(79)80006-X; Harris FM, 2002, BBA-BIOMEMBRANES, V1565, P123, DOI 10.1016/S0005-2736(02)00514-X; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hooper NM, 2005, BIOCHEM SOC T, V33, P335, DOI 10.1042/BST0330335; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; KODAMA M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P90; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2005, J BIOL CHEM, V280, P31664, DOI 10.1074/jbc.M504894200; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LAWACZECK R, 1975, NATURE, V256, P584, DOI 10.1038/256584a0; LENTZ BR, 1993, CHEM PHYS LIPIDS, V64, P99, DOI 10.1016/0009-3084(93)90060-G; Marsh D, 1998, BBA-REV BIOMEMBRANES, V1376, P267, DOI 10.1016/S0304-4157(98)00009-4; MARSH D, 1976, BIOCHEMISTRY-US, V15, P3570, DOI 10.1021/bi00661a027; Mehnert T, 2006, BIOPHYS J, V90, P939, DOI 10.1529/biophysj.105.063271; MICHAELSON DM, 1983, BIOCHEM J, V211, P155, DOI 10.1042/bj2110155; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; PARASASSI T, 1990, BIOPHYS J, V57, P1179, DOI 10.1016/S0006-3495(90)82637-0; PARENTE RA, 1985, BIOCHEMISTRY-US, V24, P6178, DOI 10.1021/bi00343a022; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SUURKUUSK J, 1976, BIOCHEMISTRY-US, V15, P1393, DOI 10.1021/bi00652a007; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	59	92	93	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9251	9259		10.1074/jbc.M512292200	http://dx.doi.org/10.1074/jbc.M512292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455667	hybrid			2022-12-27	WOS:000236404700032
J	Marzia, M; Chiusaroli, R; Neff, L; Kim, NY; Chishti, AH; Baron, R; Horne, WC				Marzia, M; Chiusaroli, R; Neff, L; Kim, NY; Chishti, AH; Baron, R; Horne, WC			Calpain is required for normal osteoclast function and is down-regulated by calcitonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; 3,5-CYCLIC ADENOSINE-MONOPHOSPHATE; VIRUS-TRANSFORMED FIBROBLASTS; MU-CALPAIN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ALPHA(V)BETA(3) INTEGRIN; ACID-PHOSPHATASE	Osteoclast motility is thought to depend on rapid podosome assembly and disassembly. Both mu-calpain and m-calpain, which promote the formation and disassembly of focal adhesions, were observed in the podosome belt of osteoclasts. Calpain inhibitors disrupted the podosome belt, blocked the constitutive cleavage of the calpain substrates filamin A, talin, and Pyk2, which are enriched in the podosome belt, induced osteoclast retraction, and reduced osteoclast motility and bone resorption. The motility and resorbing activity of mu-calpain(-/-) osteoclast-like cells were also reduced, indicating that mu-calpain is required for normal osteoclast activity. Histomorphometric analysis of tibias from mu-calpain(-/-) mice revealed increased osteoclast numbers and decreased trabecular bone volume that was apparent at 10 weeks but not at 5 weeks of age. In vitro studies suggested that the increased osteoclast number in the mu-calpain(-/-) bones resulted from increased osteoclast survival, not increased osteoclast formation. Calcitonin disrupted the podosome ring, induced osteoclast retraction, and reduced osteoclast motility and bone resorption in a manner similar to the effects of calpain inhibitors and had no further effect on these parameters when added to osteoclasts pretreated with calpain inhibitors. Calcitonin inhibited the constitutive cleavage of a fluorogenic calpain substrate and transiently blocked the constitutive cleavage of filamin A, talin, and Pyk2 by a protein kinase C-dependent mechanism, demonstrating that calcitonin induces the inhibition of calpain in osteoclasts. These results indicate that calpain activity is required for normal osteoclast activity and suggest that calcitonin inhibits osteoclast bone resorbing activity in part by down-regulating calpain activity.	Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Tufts Univ, Sch Med, Dept Med, St Elizabeths Med Ctr, Boston, MA 02135 USA; Univ Illinois, Coll Med, Dept Pharmacol, Ctr Canc, Chicago, IL 60607 USA	Yale University; Yale University; St. Elizabeth's Medical Center; Tufts University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Horne, WC (corresponding author), Yale Univ, Sch Med, Dept Orthopaed & Rehabil, POB 208044, New Haven, CT 06520 USA.	william.horne@yale.edu			NHLBI NIH HHS [R56 HL051445, HL-51445, R01 HL089517, R01 HL051445] Funding Source: Medline; NIAMS NIH HHS [P30 AR046032, R01 AR057769, R56 AR049879, AR-49879, R01 AR049879, AR-46032] Funding Source: Medline; NIDCR NIH HHS [R37 DE004724, R01 DE004724, DE-04724] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL051445, R01HL051445, R01HL089517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049879, R01AR049879, P30AR046032, R01AR057769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Baron R, 2005, TOP BON BIO, V2, P34; Baron Roland, 1993, P445; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; Chiusaroli R, 2003, DEV BIOL, V261, P537, DOI 10.1016/S0012-1606(03)00299-9; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; CONG JY, 1989, J BIOL CHEM, V264, P10096; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; COTTIN P, 1981, FEBS LETT, V136, P221, DOI 10.1016/0014-5793(81)80622-9; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; David JP, 1998, J BONE MINER RES, V13, P1730, DOI 10.1359/jbmr.1998.13.11.1730; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; GOLDBERG AF, 1962, NATURE, V195, P297, DOI 10.1038/195297a0; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hayashi M, 1999, ARCH BIOCHEM BIOPHYS, V371, P133, DOI 10.1006/abbi.1999.1427; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; IMAJOH S, 1985, FEBS LETT, V187, P47, DOI 10.1016/0014-5793(85)81211-4; JANCKILA AJ, 1978, AM J CLIN PATHOL, V70, P45; Lee FYI, 2005, J BIOL CHEM, V280, P29929, DOI 10.1074/jbc.M414600200; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1988, BLOOD, V72, P830; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MELLONI E, 1984, ARCH BIOCHEM BIOPHYS, V232, P513, DOI 10.1016/0003-9861(84)90568-X; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; Murray SS, 1997, EXP CELL RES, V233, P297, DOI 10.1006/excr.1997.3550; Naro F, 1998, ENDOCRINOLOGY, V139, P3241, DOI 10.1210/en.139.7.3241; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; Nikki M, 2002, J BIOL CHEM, V277, P11432, DOI 10.1074/jbc.M111753200; OTSUKA Y, 1987, J BIOL CHEM, V262, P5839; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PAVALKO FM, 1989, J CELL SCI, V94, P109; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; Pfaff M, 2001, J CELL SCI, V114, P2775; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Raja S, 1997, J BIOL CHEM, V272, P10941; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; SALAMINO F, 1994, BIOCHEM BIOPH RES CO, V202, P1197, DOI 10.1006/bbrc.1994.2057; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Santhanagopal A, 2001, ENDOCRINOLOGY, V142, P4401, DOI 10.1210/en.142.10.4401; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303-7207(96)03870-1; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Shiraha H, 1999, J CELL BIOL, V146, P243; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Shyu JF, 1999, EUR J BIOCHEM, V262, P95, DOI 10.1046/j.1432-1327.1999.00346.x; Smith SD, 2003, FEBS LETT, V542, P115, DOI 10.1016/S0014-5793(03)00361-2; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; TRANQUI L, 1995, EXP CELL RES, V217, P149, DOI 10.1006/excr.1995.1074; Wang K K, 1997, Adv Pharmacol, V37, P117; Wong JK, 2003, J NEUROSCI, V23, P4984; Xi XD, 2003, J CELL BIOL, V162, P329, DOI 10.1083/jcb.200303120; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756-3282(02)00834-7	89	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9745	9754		10.1074/jbc.M513516200	http://dx.doi.org/10.1074/jbc.M513516200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461769	hybrid, Green Accepted			2022-12-27	WOS:000236404700087
J	Eccleston, JF; Petrovic, A; Davis, CT; Rangachari, K; Wilson, RJM				Eccleston, JF; Petrovic, A; Davis, CT; Rangachari, K; Wilson, RJM			The kinetic mechanism of the SufC ATPase - The cleavage step is accelerated by SufB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1; PROTEIN; COMPLEX; GTPASE; MYOSIN; ASSOCIATION; ANALOGS; NIFS	Protein products of the suf operon are involved in iron- sulfur metabolism. SufC is an ATPase that can interact with SufB in the absence of nucleotide. We have studied the transient kinetics of the SufC ATPase mechanism using the fluorescent ATP analogue, 2'(3')- O- N- methylanthraniloyl- ATP ( mantATP). mantATP initially binds to SufC weakly. A conformational change of the SufC . mantATP complex then occurs followed by the very slow cleavage of mantATP to mantADP and the rapid release of P-i. In the presence of SufB, the cleavage step is accelerated and the release of mantADP is inhibited. Both of these effects promote the formation of a SufC . mantADP complex. In the absence and presence of SufB, mantADP remains more tightly bound to SufC than mantATP. These studies provide a basis for how the SufB and - C proteins interact in the processes involved in regulating iron- sulfur transfer.	Natl Inst Med Res, MRC, London NW7 1AA, England	MRC National Institute for Medical Research	Eccleston, JF (corresponding author), Natl Inst Med Res, MRC, Ridgeway,Mill Hill, London NW7 1AA, England.	jeccles@nimr.mrc.ac.uk		Petrovic, Arsen/0000-0003-4448-4230	Medical Research Council [MC_U117532067, MC_U117532072] Funding Source: Medline; MRC [MC_U117532072, MC_U117532067] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAGSHAW CR, 1973, COLD SPRING HARB SYM, V37, P127, DOI 10.1101/SQB.1973.037.01.020; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Eccleston JF, 2002, EUR BIOPHYS J BIOPHY, V31, P275, DOI 10.1007/s00249-002-0226-2; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; GOODY RS, 1977, EUR J BIOCHEM, V78, P317, DOI 10.1111/j.1432-1033.1977.tb11742.x; GUTFREUND H, 1987, BIOPHYS CHEM, V26, P117, DOI 10.1016/0301-4622(87)80016-9; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hutchinson JP, 2000, METHOD ENZYMOL, V325, P71; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MOORE KJM, 1992, PHILOS T ROY SOC B, V336, P49, DOI 10.1098/rstb.1992.0043; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Rangachari K, 2002, FEBS LETT, V514, P225, DOI 10.1016/S0014-5793(02)02369-4; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Watanabe S, 2005, J MOL BIOL, V353, P1043, DOI 10.1016/j.jmb.2005.09.017; Wilson RJM, 2003, PHILOS T R SOC B, V358, P155, DOI 10.1098/rstb.2002.1187; Wittpoth C, 1996, PLANT SCI, V114, P171, DOI 10.1016/0168-9452(96)04334-8; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Xu XM, 2005, J BIOL CHEM, V280, P6648, DOI 10.1074/jbc.M413082200; Xu XM, 2004, P NATL ACAD SCI USA, V101, P9143, DOI 10.1073/pnas.0400799101; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	29	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8371	8378		10.1074/jbc.M513455200	http://dx.doi.org/10.1074/jbc.M513455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431905	hybrid			2022-12-27	WOS:000236247100011
J	Tomita, Y; Marchenko, N; Erster, S; Nemajerova, A; Dehner, A; Klein, C; Pan, HG; Kessler, H; Pancoska, P; Moll, UM				Tomita, Y; Marchenko, N; Erster, S; Nemajerova, A; Dehner, A; Klein, C; Pan, HG; Kessler, H; Pancoska, P; Moll, UM			WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; INDUCED APOPTOSIS; X-L; PROTEIN; OVEREXPRESSION; CANCER; PUMA; MICE; LOCALIZATION; ACTIVATION	The induction of apoptosis by p53 in response to cellular stress is its most conserved function and crucial for p53 tumor suppression. We recently reported that p53 directly induces oligomerization of the BH1,2,3 effector protein Bak, leading to outer mitochondrial membrane permeabilization (OMMP) with release of apoptotic activator proteins. One important mechanism by which p53 achieves OMMP is by forming an inhibitory complex with the antiapoptotic BclXL protein. In contrast, the p53 complex with the Bcl2 homolog has not been interrogated. Here we have undertaken a detailed characterization of the p53-Bcl2 interaction using structural, biophysical, and mutational analyses. We have identified the p53 DNA binding domain as the binding interface for Bcl2 using solution NMR. The affinity of the p53-Bcl2 complex was determined by surface plasmon resonance analysis (BIAcore) to have a dominant component K-D 535 +/- 24 nM. Moreover, in contrast to wild type p53, endogenous missense mutants of p53 are unable to form complexes with endogenous Bcl2 in human cancer cells. Functionally, these mutants are all completely or strongly compromised in mediating OMMP, as measured by cytochrome c release from isolated mitochondria. These data implicate p53-Bcl2 complexes in contributing to the direct mitochondrial p53 pathway of apoptosis and further support the notion that the DNA binding domain of p53 is a dual function domain, mediating both its transactivation function and its direct mitochondrial apoptotic function.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Roche Diagnost GmbH, Pharma Res, D-82372 Penzberg, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Georgetown University; Roche Holding; Technical University of Munich	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu	Klein, Christian/G-1336-2010; Kessler, Horst/C-1178-2010	Klein, Christian/0000-0001-7594-7280; Pancoska, Petr/0000-0002-6724-8559	NCI NIH HHS [CA060664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060664, R29CA060664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Athanassiadou P, 1998, DIAGN CYTOPATHOL, V19, P255, DOI 10.1002/(SICI)1097-0339(199810)19:4<255::AID-DC5>3.0.CO;2-9; Berardo MD, 1998, CANCER, V82, P1296, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.3.CO;2-I; Bonafe M, 2004, CELL DEATH DIFFER, V11, P962, DOI 10.1038/sj.cdd.4401415; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2004, CELL CYCLE, V3, P429; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Klein C, 2004, BIOL CHEM, V385, P95, DOI 10.1515/BC.2004.012; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mihara Motohiro, 2003, Methods Mol Biol, V234, P203; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; PETROS AM, 2004, FEBS LETT, P1; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Sasaki M, 2001, MECH AGEING DEV, V122, P1695, DOI 10.1016/S0047-6374(01)00281-0; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	36	193	200	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8600	8606		10.1074/jbc.M507611200	http://dx.doi.org/10.1074/jbc.M507611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16443602	hybrid			2022-12-27	WOS:000236247100036
J	Chen, CG; Li, JG; Chen, Y; Huang, P; Wang, YL; Liu-Chen, LY				Chen, CG; Li, JG; Chen, Y; Huang, P; Wang, YL; Liu-Chen, LY			GEC1 interacts with the kappa opioid receptor and enhances expression of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; MEMBRANE-TRANSPORT MODULATOR; CELL-SURFACE EXPRESSION; HAMSTER OVARY CELLS; RAT SPINAL-CORD; GABA(A) RECEPTOR; DOWN-REGULATION; U50,488H-INDUCED INTERNALIZATION; DEPENDENT MECHANISM; PROTEIN GABARAP	We identified a truncated form (38-117) of GEC1 that interacts with the C-tail of the human kappa opioid receptor (hKOR) by yeast two-hybrid screening. GEC1-(38-117) did not interact with the C-tail of the mu or delta opioid receptors. GEC1, a 117-amino acid protein (Pellerin, I., Vuillermoz, C., Jouvenot, M., Ordener, C., Royez, M., and Adessi, G. L. (1993) Mol. Cell Endocrinol. 90, R17-R21), is highly homologous to GABARAP, GATE-16, and Apg8/aut7, all members of the microtubule associated protein (MAP) family. In pull-down assays, GST-GEC1 interacted directly with the hKOR C-tail, full-length hKOR, and tubulin. When expressed in Chinese hamster ovary (CHO) cells, GEC1 co-immunoprecipitated with FLAG-hKOR. Expression of GEC1 greatly increased total and cell-surface KOR but not mu or delta opioid receptors. GEC1 expression slightly reduced U50,488H-promoted down-regulation, without affecting ligand binding affinity, receptor-G protein coupling, or U50,488H-induced desensitization and internalization. HA-GEC1 expressed in CHO cells was localized in the Golgi apparatus and endoplasmic reticulum (ER). When cells were pulsed with [S-35]Met/Cys, GEC1 expression enhanced the level of the mature form (55-kDa band) of FLAG-hKOR at 4, 8, and 22 h after pulse without affecting the precursors (39- and 45-kDa bands), indicating that GEC1 facilitates trafficking of FLAG-hKOR from the ER/Golgi to plasma membranes. GEC1 interacted with N-ethylmaleimide-sensitive factor (NSF) in pull-down assays and co-immunoprecipitated with NSF in rat brain extracts. The interaction with NSF may contribute to GEC1 effects. This is the first report on biological functions of GEC1 and the first demonstration that a GPCR interacts with a protein of the MAP family. The interaction is important for trafficking of the receptor in the biosynthesis pathway.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Substance Abuse Res, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liu-Chen, LY (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@temple.edu			NIDA NIH HHS [DA17302, DA04745] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA004745, R01DA004745] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ango F, 2002, MOL CELL NEUROSCI, V20, P323, DOI 10.1006/mcne.2002.1100; Bermak J C, 2001, Mol Interv, V1, P282; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Chang PC, 2000, BRAIN RES, V861, P168, DOI 10.1016/S0006-8993(99)02461-0; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; Elazar Z, 2003, BBA-MOL CELL RES, V1641, P145, DOI 10.1016/S0167-4889(03)00086-7; Everitt AB, 2004, J BIOL CHEM, V279, P21701, DOI 10.1074/jbc.M312806200; Green F, 2002, FEBS LETT, V518, P101, DOI 10.1016/S0014-5793(02)02655-8; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Harris JA, 2004, NEUROSCIENCE, V124, P879, DOI 10.1016/j.neuroscience.2003.12.042; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; Huang P, 2004, J BIOL CHEM, V279, P25002, DOI 10.1074/jbc.M313366200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Knight D, 2002, J BIOL CHEM, V277, P5556, DOI 10.1074/jbc.M109753200; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; Leil TA, 2004, J NEUROSCI, V24, P11429, DOI 10.1523/JNEUROSCI.3355-04.2004; Li J, 2002, MOL PHARMACOL, V61, P73, DOI 10.1124/mol.61.1.73; Li JG, 2003, J PHARMACOL EXP THER, V305, P531, DOI 10.1124/jpet.102.045559; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; LIUCHEN LY, 1993, MOL PHARMACOL, V44, P749; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malyala A, 2004, NEUROCHEM RES, V29, P1189, DOI 10.1023/B:NERE.0000023606.13670.1d; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mansuy V, 2004, BIOCHEM BIOPH RES CO, V325, P639, DOI 10.1016/j.bbrc.2004.10.072; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Nemos C, 2003, MOL BRAIN RES, V119, P216, DOI 10.1016/j.molbrainres.2003.09.011; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; PELLERIN I, 1993, MOL CELL ENDOCRINOL, V90, pR17, DOI 10.1016/0303-7207(93)90161-C; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Vernier-Magnin S, 2001, BIOCHEM BIOPH RES CO, V284, P118, DOI 10.1006/bbrc.2001.4908; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wang Y, 2005, J PHARMACOL EXP THER, V312, P220, DOI 10.1124/jpet.104.073668; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; Xin YR, 2001, GENOMICS, V74, P408, DOI 10.1006/geno.2001.6555; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28; ZHU JM, 1995, LIFE SCI, V56, pPL201, DOI 10.1016/0024-3205(94)00507-O	59	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7983	7993		10.1074/jbc.M509805200	http://dx.doi.org/10.1074/jbc.M509805200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431922	hybrid			2022-12-27	WOS:000236031000035
J	Okochi, M; Fukumori, A; Jiang, JW; Itoh, N; Kimura, R; Steiner, H; Haass, C; Tagami, S; Takeda, M				Okochi, M; Fukumori, A; Jiang, JW; Itoh, N; Kimura, R; Steiner, H; Haass, C; Tagami, S; Takeda, M			Secretion of the Notch-1 A beta-like peptide during Notch signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; REGULATED INTRAMEMBRANE PROTEOLYSIS; DISEASE GAMMA-SECRETASE; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; PRESENILIN-1 MUTATIONS; TRANSMEMBRANE DOMAIN; DROSOPHILA NOTCH; CLEAVAGE; RECEPTOR	The canonical pathway of Notch signaling is mediated by regulated intramembrane proteolysis ( RIP). In the pathway, ligand binding results in sequential proteolysis of the Notch receptor, and presenilin (PS)-dependent intramembrane proteolysis at the interface between the membrane and cytosol liberates the Notch-1 intracellular domain (NICD), a transcription modifier. Because the degradation of the Notch-1 transmembrane domain is thought to require an additional cleavage near the middle of the transmembrane domain, extracellular small peptides (Notch-1 A beta-like peptide (N beta)) should be produced. Here we showed that N beta species are indeed secreted during the process of Notch signaling. We identified mainly two distinct molecular species of novel N beta, N beta 21 and C-terminally elongated N beta 25, which were produced in an similar to 5: 1 ratio. This process is reminiscent of the production of Alzheimer disease-associated A beta. PS pathogenic mutants increased the production of the longer species of A beta(A beta 42) from beta-amyloid protein precursor. We revealed that several Alzheimer disease mutants also cause a parallel increase in the secretion of the longer form of N beta. Strikingly, chemicals that modify the A beta 42 level caused parallel changes in the N beta 25 level. These results demonstrated that the characteristics of C-terminal elongation of N beta and A beta are almost identical. In addition, because many other type 1 membrane-bound receptors release intracellular domains by PS-dependent intramembrane proteolysis, we suspect that the release of A beta- or N beta-like peptides is a common feature of the proteolysis during RIP signaling. We anticipate that this study will open the door to searches for markers of RIP signaling and surrogate markers for A beta 42 production.	Osaka Univ, Grad Sch Med, Dept Psychiat & Behav Prote, Dept Post Genom & Dis, Osaka 5650871, Japan; Shionogi & Co Ltd, Discovery Res Labs, Shiga 5203423, Japan; Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimer & Parkinsons Dis Res, D-80336 Munich, Germany	Osaka University; Shionogi & Company Limited; University of Munich	Okochi, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Psychiat & Behav Prote, Dept Post Genom & Dis, D3,2-2 Yamadaoka, Osaka 5650871, Japan.	mokochi@psy.med.osaka-u.ac.jp		Okochi, Masayasu/0000-0002-2318-7651				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NYE JS, 1994, DEVELOPMENT, V120, P2421; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Okochi M, 1997, FEBS LETT, V418, P162, DOI 10.1016/S0014-5793(97)01378-1; Okochi M, 2000, J BIOL CHEM, V275, P40925, DOI 10.1074/jbc.M005254200; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Sagi SA, 2003, J BIOL CHEM, V278, P31825, DOI 10.1074/jbc.M303588200; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yoshiike Y, 2003, J BIOL CHEM, V278, P23648, DOI 10.1074/jbc.M212785200; Zhang JM, 2002, J BIOL CHEM, V277, P15069, DOI 10.1074/jbc.M105375200	46	90	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7890	7898		10.1074/jbc.M513250200	http://dx.doi.org/10.1074/jbc.M513250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434391	hybrid			2022-12-27	WOS:000236031000024
J	Riuzzi, F; Sorci, G; Donato, R				Riuzzi, F; Sorci, G; Donato, R			The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness - Functional inactivation of rage in L6 myoblasts results in tumor formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; SKELETAL-MUSCLE DIFFERENTIATION; MYOGENIC DIFFERENTIATION; MYOTUBE FORMATION; GENE-EXPRESSION; CELL-SURVIVAL; RESERVE-CELLS; ALPHA-7-BETA-1 INTEGRIN; MUSCULAR-DYSTROPHIES	We reported that RAGE ( receptor for advanced glycation end products), amultiligand receptor of the immunoglobulin superfamily expressed in myoblasts, when activated by its ligand amphoterin (HMGB1), stimulates rat L6 myoblast differentiation via a Cdc42-Rac-MKK6-p38 mitogen-activated protein kinase pathway, and that RAGE expression in skeletal muscle tissue is developmentally regulated. We show here that inhibition of RAGE function via overexpression of a signaling deficient RAGE mutant (RAGE Delta cyto) results in increased myoblast proliferation, migration, and invasiveness, and decreased apoptosis and adhesiveness, whereas myoblasts overexpressing RAGE behave the opposite, compared with mock-transfected myoblasts. These effects are accompanied by a decreased induction of the proliferation inhibitor, p21(Waf1), and increased induction of cyclin D1 and extent of Rb, ERK1/2, and JNK phosphorylation in L6/RAGE Delta cyto myoblasts, the opposite occurring in L6/RAGE myoblasts. Neutralization of culture medium amphoterin negates effects of RAGE activation, suggesting that amphoterin is the RAGE ligand involved in RAGE-dependent effects in myoblasts. Finally, mice injected with L6/RAGE Delta cyto myoblasts develop tumors as opposed to mice injected with L6/RAGE or L6/mock myoblasts that do not. Thus, the amphoterin/RAGE pair stimulates myoblast differentiation by the combined effect of stimulation of differentiation and inhibition of proliferation, and deregulation of RAGE expression in myoblasts might contribute to their neoplastic transformation.	Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, I-06122 Perugia, Italy; Univ Perugia, Ist Interuniv Miol, I-06122 Perugia, Italy	University of Perugia; University of Perugia	Donato, R (corresponding author), Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, Via Giochetto,Casella Postale 81 Succursale 3, I-06122 Perugia, Italy.	donato@unipg.it	Donato, Rosario/I-3943-2019; li, tao/B-2402-2008	Riuzzi, Francesca/0000-0001-7908-3379; Sorci, Guglielmo/0000-0002-1973-9679				Ahmadzadeh M, 1999, J IMMUNOL, V163, P3053; Allen DL, 2003, AM J PHYSIOL-CELL PH, V284, pC805, DOI 10.1152/ajpcell.00215.2002; Allikian MJ, 2004, J CELL SCI, V117, P3821, DOI 10.1242/jcs.01234; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Bour BA, 2000, GENE DEV, V14, P1498; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Carnac G, 2000, CURR BIOL, V10, P543, DOI 10.1016/S0960-9822(00)00471-1; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj/cdd/4400930; Fazeli S, 1996, J CELL BIOL, V135, P241, DOI 10.1083/jcb.135.1.241; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Friday BB, 2001, J CELL SCI, V114, P303; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Hodges BL, 1997, J CELL SCI, V110, P2873; Huttunen HJ, 2004, J INTERN MED, V255, P351, DOI 10.1111/j.1365-2796.2003.01301.x; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ito H, 2004, BIOCHEM BIOPH RES CO, V318, P594, DOI 10.1016/j.bbrc.2004.04.070; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Lee J, 2002, BIOCHEM BIOPH RES CO, V298, P765, DOI 10.1016/S0006-291X(02)02562-7; Li YQ, 2000, CELL SIGNAL, V12, P751, DOI 10.1016/S0898-6568(00)00120-0; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ostrovsky O, 2003, J BIOL CHEM, V278, P21221, DOI 10.1074/jbc.M211357200; Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Sorci G, 2004, MOL CELL BIOL, V24, P4880, DOI 10.1128/MCB.24.11.4880-4894.2004; Sorci G, 2004, J CELL PHYSIOL, V199, P274, DOI 10.1002/jcp.10462; Sorci G, 2003, MOL CELL BIOL, V23, P4870, DOI 10.1128/MCB.23.14.4870-4881.2003; Spence HJ, 2002, BIOESSAYS, V24, P542, DOI 10.1002/bies.10098; Tietze L, 1999, EXP MOL PATHOL, V66, P131, DOI 10.1006/exmp.1999.2252; Tortorella LL, 2001, J BIOL CHEM, V276, P13709, DOI 10.1074/jbc.M100091200; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371; Yoshida N, 1998, J CELL SCI, V111, P769; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	57	98	107	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8242	8253		10.1074/jbc.M509436200	http://dx.doi.org/10.1074/jbc.M509436200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407300	hybrid			2022-12-27	WOS:000236031000064
J	Amici, C; Rossi, A; Costanzo, A; Ciafre, S; Marinari, B; Balsamo, M; Levrero, M; Santoro, MG				Amici, C; Rossi, A; Costanzo, A; Ciafre, S; Marinari, B; Balsamo, M; Levrero, M; Santoro, MG			Herpes simplex virus disrupts NF-kappa B regulation by blocking its recruitment on the I kappa B alpha promoter and directing the factor on viral genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPENTENONE PROSTAGLANDINS; TYPE-1; REPLICATION; ACTIVATION; CELLS; INHIBITION; INFECTION; KINASE; PROTEINS; HISTONES	Herpes simplex viruses (HSVs) are able to hijack the host-cell I kappa B kinase (IKK)/NF-kappa B pathway, which regulates critical cell functions from apoptosis to inflammatory responses; however, the molecular mechanisms involved and the outcome of the signaling dysregulation on the host-virus interaction are mostly unknown. Here we show that in human keratinocytes HSV-1 attains a sophisticated control of the IKK/NF-kappa B pathway, inducing two distinct temporally controlled waves of IKK activity and disrupting the NF-kappa B autoregulatory mechanism. Using chromatin immunoprecipitation we demonstrate that dysregulation of the NF-kappa B-response is mediated by a virus-induced block of NF-kappa B recruitment to the promoter of the I kappa B alpha gene, encoding the main NF-kappa B-inhibitor. We also show that HSV-1 redirects NF-kappa B recruitment to the promoter of ICP0, an immediate-early viral gene with a key role in promoting virus replication. The results reveal a new level of control of cellular functions by invading viruses and suggest that persistent NF-kappa B activation in HSV-1-infected cells, rather than being a host response to the virus, may play a positive role in promoting efficient viral replication.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; Univ Roma La Sapienza, Dept Internal Med, I-00185 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Santoro, MG (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	santoro@bio.uniroma2.it	Costanzo, Antonio/D-3896-2012; ciafrè, stefania g.l./B-5158-2015; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	ciafrè, stefania g.l./0000-0002-2629-8787; Costanzo, Antonio/0000-0001-9697-2557; Santoro, Maria Gabriella/0000-0003-1432-4949; Levrero, Massimo/0000-0002-4978-0875; ROSSI, ANTONIO/0000-0003-0383-3828				Amici C, 2004, AIDS, V18, P1271, DOI 10.1097/00002030-200406180-00005; Amici C, 2001, J BIOL CHEM, V276, P28759, DOI 10.1074/jbc.M103408200; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; Davido DJ, 1998, J GEN VIROL, V79, P2093, DOI 10.1099/0022-1317-79-9-2093; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goodkin ML, 2003, J VIROL, V77, P7261, DOI 10.1128/JVI.77.13.7261-7280.2003; Gregory D, 2004, J VIROL, V78, P13582, DOI 10.1128/JVI.78.24.13582-13590.2004; Herrera FJ, 2004, J VIROL, V78, P9689, DOI 10.1128/JVI.78.18.9689-9696.2004; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kent JR, 2004, J VIROL, V78, P10178, DOI 10.1128/JVI.78.18.10178-10186.2004; Kubat NJ, 2004, J VIROL, V78, P1139, DOI 10.1128/JVI.78.3.1139-1149.2004; Kubat NJ, 2004, J VIROL, V78, P12508, DOI 10.1128/JVI.78.22.12508-12518.2004; LEINBACH SS, 1980, J GEN VIROL, V51, P45, DOI 10.1099/0022-1317-51-1-45; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MUGGERIDGE MI, 1986, J VIROL, V59, P764, DOI 10.1128/JVI.59.3.764-767.1986; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; RONG BL, 1992, VIROLOGY, V189, P750, DOI 10.1016/0042-6822(92)90599-K; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; Taddeo B, 2004, J VIROL, V78, P11615, DOI 10.1128/JVI.78.21.11615-11621.2004; Taddeo B, 2002, P NATL ACAD SCI USA, V99, P17031, DOI 10.1073/pnas.252588599; Taddeo B, 2003, P NATL ACAD SCI USA, V100, P12408, DOI 10.1073/pnas.2034952100	35	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7110	7117		10.1074/jbc.M512366200	http://dx.doi.org/10.1074/jbc.M512366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407234	hybrid			2022-12-27	WOS:000236030900025
J	Choi, SY; Kim, MJ; Kang, CM; Bae, S; Cho, CK; Soh, JW; Kim, JH; Kang, S; Chung, HY; Lee, YS; Lee, SJ				Choi, SY; Kim, MJ; Kang, CM; Bae, S; Cho, CK; Soh, JW; Kim, JH; Kang, S; Chung, HY; Lee, YS; Lee, SJ			Activation of Bak and Bax through c-Abl-protein kinase C delta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-INDUCED APOPTOSIS; CYTOCHROME-C; PKC-DELTA; TYROSINE PHOSPHORYLATION; IN-VITRO; DEATH; TRANSLOCATION; MITOCHONDRIA; RELEASE; GROWTH	Intracellular signaling molecules and apoptotic factors seem to play an important role in determining the radiation response of tumor cells. However, the basis for the link between signaling pathway and apoptotic cell death machinery after ionizing irradiation remains still largely unclear. In this study, we showed that c-Abl-PKC delta-Rac1- p38 MAPK signaling is required for the conformational changes of Bak and Bax during ionizing radiation-induced apoptotic cell death in human non-small cell lung cancer cells. Ionizing radiation induced conformational changes and subsequent oligomerizations of Bak and Bax, dissipation of mitochondrial membrane potential, and cytochrome c release from mitochondria. Small interference ( siRNA) targeting of Bak and Bax effectively protected cells from radiation-induced mitochondrial membrane potential loss and apoptotic cell death. p38 MAPK was found to be selectively activated in response to radiation treatment. Inhibition of p38 MAPK completely suppressed radiation-induced Bak and Bax activations, dissipation of mitochondrial membrane potential, and cell death. Moreover, expression of a dominant negative form of protein kinase C delta (PKC delta) or siRNA targeting of PKC delta attenuated p38 MAPK activation and conformational changes of Bak and Bax. In addition, ectopic expression of RacN17, a dominant negative form of Rac1, markedly inhibited p38 MAPK activation but did not affect PKC delta activation. Upon stimulation of cells with radiation, PKC delta was phosphorylated dramatically on tyrosine. c-Abl-PKC delta complex formation was also increased in response to radiation. Moreover, siRNA targeting of c-Abl attenuated radiation-induced PKC delta and p38 MAPK activations, and Bak and Bax modulations. These data support a notion that activation of the c-Abl-PKC delta-Rac1- p38 MAPK pathway in response to ionizing radiation signals conformational changes of Bak and Bax, resulting in mitochondrial activation-mediated apoptotic cell death in human non-small cell lung cancer cells.	Korea Inst Radiol & Med Sci, Lab Radiat Expt Therapeut, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Radiat Cytogenet & Epidemiol, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Inha Univ, Dept Chem, Coll Nat Sci, Inchon 402751, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Inha University; Korea University; Hanyang University	Lee, SJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Expt Therapeut, Seoul 139706, South Korea.	sjlee@kcch.re.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brachat A, 2000, ONCOGENE, V19, P5073, DOI 10.1038/sj.onc.1203882; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Choi JA, 2004, ONCOGENE, V23, P9, DOI 10.1038/sj.onc.1206982; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Eom YW, 2001, BIOCHEM BIOPH RES CO, V284, P126, DOI 10.1006/bbrc.2001.4937; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; Garcia-Fernandez LF, 2002, ONCOGENE, V21, P7533, DOI 10.1038/sj.onc.1205972; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HarmsRingdahl M, 1996, MUTAT RES-REV GENET, V366, P171, DOI 10.1016/S0165-1110(96)90038-X; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lee YJ, 2005, ONCOGENE, V24, P3715, DOI 10.1038/sj.onc.1208440; Lee YJ, 2005, J BIOL CHEM, V280, P18108, DOI 10.1074/jbc.M501131200; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Maloney JA, 1998, AM J PHYSIOL-CELL PH, V274, pC974, DOI 10.1152/ajpcell.1998.274.4.C974; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Marshall CJ, 1998, CURR OPIN GENET DEV, V8, P11, DOI 10.1016/S0959-437X(98)80055-5; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Sodhi A, 2005, CELL SIGNAL, V17, P377, DOI 10.1016/j.cellsig.2004.08.004; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Ting HC, 2002, IMMUNOL LETT, V82, P205, DOI 10.1016/S0165-2478(02)00044-5; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; YANG J, 1997, SCIENCE, V275, P1132; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zheng YH, 2005, ONCOGENE, V24, P3339, DOI 10.1038/sj.onc.1208484; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	58	72	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7049	7059		10.1074/jbc.M512000200	http://dx.doi.org/10.1074/jbc.M512000200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410245	hybrid			2022-12-27	WOS:000236030900018
J	Struewing, IT; Toborek, A; Mao, CD				Struewing, IT; Toborek, A; Mao, CD			Mitochondrial and nuclear forms of Wnt13 are generated via alternative promoters, alternative RNA splicing, and alternative translation start sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; ENDOPLASMIC-RETICULUM; CELL POLARIZATION; FAMILY PROTEINS; PORCUPINE; MECHANISMS; DROSOPHILA; POLARITY; GENE	Wnt proteins play a key role in cell survival, cell proliferation, and cell fate during development. In endothelial cells, we identified the expression of Wnt13A, Wnt13B, and Wnt13C mRNAs, which are generated by alternative promoters and alternative RNA splicing. Wnt13A and Wnt13B proteins differ only in their N-terminal sequences. Wnt13A, a typical Wnt, is N-glycosylated and localized in the endoplasmic reticulum, with only a small fraction being secreted. Wnt13B proteins appear as a protein doublet, L-Wnt13B and S-Wnt13B, which are neither N-glycosylated nor secreted. Wnt13B proteins localized mainly to mitochondria, as demonstrated using detection in mitochondria enriched fractions and colocalization with Mitotracker and HSP60. A nuclear localization was also observed in 20% of Wnt13B-expressing cells. Both the N-terminal hydrophobic stretch ( residues 1 - 17) and alpha-helix ( residues 26 - 50) were the main determinants for Wnt13B mitochondrial targeting. Serial deletions of Wnt13B N-terminal sequences abolished its association with mitochondria and favored instead a nuclear localization. The production of S-Wnt13B was independent of the mitochondrial targeting but dependent on an alternative translation start corresponding to Met(74) in L-Wnt13B. The same translation start is used in Wnt13C mRNA to encode a protein undistinguishable from S-Wnt13B. S-Wnt13B when expressed alone localized to the nucleus like Wnt13C, whereas L-Wnt13B localized to mitochondria. Wnt13 nuclear forms increased the beta-catenin/T-cell factor activity in HEK293 cells and increased apoptosis in bovine aortic endothelial cells. Altogether our results demonstrate that, in addition to alternative promoters and RNA splicing, an alternative translation start in Wnt13B and Wnt13C mRNAs increases the complexity of both human wnt13 expression and functions.	Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky	Mao, CD (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, 900 Limestone St, Lexington, KY 40536 USA.	cdmao2@uky.edu			NHLBI NIH HHS [HL 68698, R01 HL068698-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068698] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Goldstein B, 2000, DEV DYNAM, V218, P23, DOI 10.1002/(SICI)1097-0177(200005)218:1<23::AID-DVDY3>3.0.CO;2-Z; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Jasoni C, 1999, DEV DYNAM, V215, P215, DOI 10.1002/(SICI)1097-0177(199907)215:3<215::AID-AJA4>3.0.CO;2-W; Julius MA, 1999, ONCOGENE, V18, P149, DOI 10.1038/sj.onc.1202268; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Katoh M, 2000, BIOCHEM BIOPH RES CO, V275, P209, DOI 10.1006/bbrc.2000.3252; Katoh M, 2001, BIOCHEM BIOPH RES CO, V289, P1093, DOI 10.1006/bbrc.2001.6076; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kubo F, 2003, DEVELOPMENT, V130, P587, DOI 10.1242/dev.00244; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Liu H, 2003, DEV DYNAM, V227, P323, DOI 10.1002/dvdy.10315; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; Lynn BD, 2001, J NEUROSCI RES, V65, P6, DOI 10.1002/jnr.1122; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Nakagawa S, 2003, DEV BIOL, V260, P414, DOI 10.1016/S0012-1606(03)00320-8; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200	47	22	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7282	7293		10.1074/jbc.M511182200	http://dx.doi.org/10.1074/jbc.M511182200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407296	hybrid			2022-12-27	WOS:000236030900046
J	Lu, XH; Gilbert, L; He, XF; Rubin, J; Nanes, MS				Lu, XH; Gilbert, L; He, XF; Rubin, J; Nanes, MS			Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELL-DIFFERENTIATION; ESTROGEN DEFICIENCY; FACTOR-ALPHA; EXTRACELLULAR-MATRIX; BONE-FORMATION; EXPRESSION; P38; APOPTOSIS; RUNX2; GENE	Osteoblast ( OB) differentiation is suppressed by tumor necrosis factor-alpha (TNF-alpha), an inflammatory stimulus that is elevated in arthritis and menopause. Because OB differentiation requires the expression of the transcription factor osterix (Osx), we investigated TNF effects on Osx. TNF inhibited Osx mRNA in pre-osteoblastic cells without affecting Osx mRNA half-life. Inhibition was independent of new protein synthesis. Analysis of the Osx promoter revealed two transcription start sites that direct the expression of an abundant mRNA(Osx1) and an alternatively spliced mRNA(Osx2). Promoter fragments driving the expression of luciferase were constructed to identify TNF regulatory sequences. Two independent promoters were identified upstream of each transcription start site. TNF potently inhibited transcription of both promoters. Deletion and mutational analysis identified a TNF-responsive region proximal to the Osx2 start site that retained responsiveness when inserted upstream of a heterologous promoter. The TNF response region was a major binding site for nuclear proteins, although TNF did not change binding at the site. The roles of MAPK and NF kappa B were investigated as signal mediators of TNF. Inhibitors of MEK1 and ERK1, but not of JNK or p38 kinase, abrogated TNF inhibition of Osx mRNA and promoter activity. TNF action was not prevented by blockade of NF kappa B nuclear entry. The forced expression of high levels of NF kappa B uncovered a proximal promoter enhancer; however, this site was not activated by TNF. The inhibitory effect of TNF on Osx expression may decrease OB differentiation in arthritis and osteoporosis.	Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipids, Decatur, GA 30033 USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Nanes, MS (corresponding author), Vet Affairs Med Ctr, Mail Code 111,1670 Clairmont Rd, Decatur, GA 30033 USA.	mnanes@emory.edu			NIAMS NIH HHS [AR046452] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046452] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Bingham CO, 2002, J RHEUMATOL, V29, P3; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Farmer PK, 2000, AM J PHYSIOL-ENDOC M, V279, pE213, DOI 10.1152/ajpendo.2000.279.1.E213; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gao YG, 2004, GENE, V341, P101, DOI 10.1016/j.gene.2004.05.026; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; GILBERT LC, 2004, AM J PHYSIOL, V288, pE1011; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785; Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002-220863; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; LIAN JB, 2001, OSTEOPOROSIS, V1, P21; Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143; Milona M, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-43; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378-1119(03)00841-2; Noth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014-4827(03)00386-0; Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005-0303; Pacifici R, 1999, CALCIFIED TISSUE INT, V65, P345, DOI 10.1007/s002239900710; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; Tai GP, 2004, TISSUE ENG, V10, P1456, DOI 10.1089/1076327042500300; Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101	34	116	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6297	6306		10.1074/jbc.M507804200	http://dx.doi.org/10.1074/jbc.M507804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16410254	hybrid			2022-12-27	WOS:000236030800023
J	Um, M; Lodish, HF				Um, M; Lodish, HF			Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BCL-X-L; TRANSCRIPTION FACTOR; IN-VITRO; TYROSINE PHOSPHORYLATION; STAT5A(-/-)5B(-/-) MICE; INDUCED APOPTOSIS; PROTECTS NEURONS; GENE-EXPRESSION; MAP KINASE	The hematopoietic cytokine erythropoietin (Epo) prevents neuronal death during ischemic events in the brain and in neurodegenerative diseases, presumably through its antiapoptotic effects. To explore the role of different signaling pathways in Epo-mediated antiapoptotic effects in differentiated human neuroblastoma SH-SY5Y cells, we employed a prolactin receptor (PrlR)/ erythropoietin receptor (EpoR) chimera system, in which binding of prolactin (Prl) to the extracellular domain activates EpoR signaling in the cytosol. On induction of apoptosis by staurosporine, Prl supports survival of the SH-SY5Y cells expressing the wild-type PrlR/ EpoR chimera. In these cells Prl treatment strongly activates the STAT5, AKT, and MAPK signaling pathways and induces weak activation of the p65 NF-kappa B factor. Selective mutation of the eight tyrosine residues of the EpoR cytoplasmic domain results in impaired or absent activation of either STAT5 ( mutation of Tyr(343)) or AKT ( mutation of Tyr(479)) or both ( mutation of all eight tyrosine residues). Most interestingly, Prl treatment does not prevent apoptosis in cells expressing mutant PrlR/ EpoR chimeras in which either the STAT5 or the AKT signaling pathways are not activated. In contrast, ERK 1/2 is fully activated by all mutant PrlR/ EpoR chimeras, comparable with the level seen with the wild-type PrlR/ EpoR chimera, implying that activation of the MAPK signaling pathway per se is not sufficient for antiapoptotic activity. Therefore, the antiapoptotic effects of Epo in neuronal cells require the combinatorial activation of multiple signaling pathways, including STAT5, AKT, and potentially MAPK as well, in a manner similar to that observed in hematopoietic cells.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr,Ste 601, Cambridge, MA 02142 USA.	lodish@wi.mit.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrassy M, 2002, CLIN NEPHROL, V58, P179; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Boudot C, 1999, J BIOL CHEM, V274, P33966, DOI 10.1074/jbc.274.48.33966; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carvalho G, 2005, ONCOGENE, V24, P737, DOI 10.1038/sj.onc.1208205; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Chun SJ, 2003, J CELL BIOL, V163, P397, DOI 10.1083/jcb.200304154; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Diaz Z, 2005, J NEUROCHEM, V93, P392, DOI 10.1111/j.1471-4159.2005.03038.x; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Fiordaliso F, 2005, P NATL ACAD SCI USA, V102, P2046, DOI 10.1073/pnas.0409329102; Gaffen SL, 1999, BLOOD, V94, P74, DOI 10.1182/blood.V94.1.74.413k36_74_86; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Haq R, 2002, J BIOL CHEM, V277, P17359, DOI 10.1074/jbc.M201842200; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KORNER M, 1994, J NEUROCHEM, V62, P1716; Lee SM, 2004, BIOCHEM BIOPH RES CO, V320, P1087, DOI 10.1016/j.bbrc.2004.06.060; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Marszalek JR, 2004, J BIOL CHEM, V279, P23882, DOI 10.1074/jbc.M313460200; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Nakamura T, 2002, J BIOL CHEM, V277, P6254, DOI 10.1074/jbc.M109878200; Nakata S, 2004, J BIOL CHEM, V279, P55578, DOI 10.1074/jbc.M408238200; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Ozes ON, 1999, NATURE, V401, P82; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Posmantur R, 1997, J NEUROCHEM, V68, P2328; REN HY, 1994, J BIOL CHEM, V269, P19633; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Suzuki N, 2002, BLOOD, V100, P2279, DOI 10.1182/blood-2002-01-0124; Tang T, 1999, BIOCHEM J, V343, P615, DOI 10.1042/0264-6021:3430615; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	77	89	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5648	5656		10.1074/jbc.M510943200	http://dx.doi.org/10.1074/jbc.M510943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407271	hybrid			2022-12-27	WOS:000235568900041
J	Itoh, R; Fujiki, Y				Itoh, R; Fujiki, Y			Functional domains and dynamic assembly of the peroxin Pex14p, the entry site of matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; OVARY CELL MUTANTS; TARGETING SIGNALS; RECEPTOR DOCKING; COMPLEMENTATION GROUP; BIOGENESIS DISORDERS; IMPORT MACHINERY; POTENTIAL ROLE; CDNA CLONING; YEAST PEX14P	The 41-kDa membrane-anchored peroxin Pex14p functions as the peroxisome targeting signal (PTS) receptor-mediated, initial import site for matrix proteins. We here identify the functional domains of Pex14p involved in the assembly of import site subcomplexes. The minimal region of Pex14p required for restoring impaired protein import in pex14 Chinese hamster ovary cell mutant lies at residues 21-260 in the primary sequence. A highly conserved N-terminal region, encompassing residues 21-70, interacts with the PTS1 receptor Pex5p, Pex13p, and Pex19p that is essential for membrane biogenesis. N-terminal residues 21-140, including a hydrophobic segment at 110-138, function as a topogenic sequence. Site-directed mutagenesis, size fractionation, and chemical cross-linking analyses demonstrate that the coiled-coil domain at residues 156-197 regulates homodimerization of Pex14p. Moreover, AXXXA and GXXXG motifs in the transmembrane segment mediate homomeric oligomerization of Pex14p, giving rise to assembly of high molecular mass complexes and thereby assuring Pex13p-dependent localization of Pex14p to peroxisomes. Pex5p, Pex13p, and Pex19p bind to Pex14p homo-oligomers with different molecular masses, whereas cargo-unloaded Pex5p apparently disassembles Pex14p homo-oligomers. Thus, Pex14p most likely forms several distinct peroxin complexes involved in peroxisomal matrix protein import.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, Fukuoka 8128581, Japan; Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp						Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; BAJAJ M, 1984, ANNU REV BIOPHYS BIO, V13, P453; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Choe J, 2003, BIOCHEMISTRY-US, V42, P10915, DOI 10.1021/bi034248n; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Madrid KP, 2005, BIOCHEM J, V391, P105, DOI 10.1042/BJ20050328; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Matsuzono Y, 2006, J BIOL CHEM, V281, P36, DOI 10.1074/jbc.M509819200; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Miyata N, 2005, MOL CELL BIOL, V25, P10822, DOI 10.1128/MCB.25.24.10822-10832.2005; Mukai S, 2002, J BIOL CHEM, V277, P9548, DOI 10.1074/jbc.M108635200; Niederhoff K, 2005, J BIOL CHEM, V280, P35571, DOI 10.1074/jbc.M502460200; Nito K, 2002, PLANT CELL PHYSIOL, V43, P355, DOI 10.1093/pcp/pcf057; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 2001, J BIOL CHEM, V276, P2858, DOI 10.1074/jbc.M007730200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; Platta HW, 2005, NAT CELL BIOL, V7, P817, DOI 10.1038/ncb1281; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 1999, HUM MOL GENET, V8, P1077, DOI 10.1093/hmg/8.6.1077; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Will GK, 1999, MOL CELL BIOL, V19, P2265; Yan MD, 2005, CURR OPIN CELL BIOL, V17, P376, DOI 10.1016/j.ceb.2005.06.003	48	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10196	10205		10.1074/jbc.M600158200	http://dx.doi.org/10.1074/jbc.M600158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459329	hybrid			2022-12-27	WOS:000236594300046
J	Xu, J; Gong, NL; Bondi, I; Aronow, BJ; Backx, PH; Molkentin, JD				Xu, J; Gong, NL; Bondi, I; Aronow, BJ; Backx, PH; Molkentin, JD			Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; MUSCLE FIBER-TYPE; PROTEIN-KINASE-C; ACTION-POTENTIAL REPOLARIZATION; II HISTONE DEACETYLASES; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; IN-VIVO; NUCLEAR EXPORT; TARGETED INHIBITION	Cardiac hypertrophy and dilation are mediated by neuroendocrine factors and/or mitogens as well as through internal stretch- and stress-sensitive signaling pathways, which in turn transduce alterations in cardiac gene expression through specific signaling pathways. The transcription factor family known as myocyte enhancer factor 2( MEF2) has been implicated as a signal-responsive mediator of the cardiac transcriptional program. For example, known hypertrophic signaling pathways that utilize calcineurin, calmodulin-dependent protein kinase, and MAPKs can each affect MEF2 activity. Here we demonstrate that MEF2 transcription factors induced dilated cardiomyopathy and lengthening of myocytes. Specifically, multiple transgenic mouse lines with cardiac-specific overexpression of MEF2A or MEF2C presented with cardiomyopathy at base line or were predisposed to more fulminant disease following pressure overload stimulation. The cardiomyopathic response associated with MEF2A and MEF2C was not further altered by activated calcineurin, suggesting that MEF2 functions independently of calcineurin in this response. In cultured cardiomyocytes, MEF2A, MEF2C, and MEF2-VP16 overexpression induced sarcomeric disorganization and focal elongation. Mechanistically, MEF2A and MEF2C each programmed similar profiles of altered gene expression in the heart that included extracellular matrix remodeling, ion handling, and metabolic genes. Indeed, adenoviral transfection of cultured cardiomyocytes with MEF2A or of myocytes from the hearts of MEF2A transgenic adult mice showed reduced transient outward K+ currents, consistent with the alterations in gene expression observed in transgenic mice and partially suggesting a proximal mechanism underlying MEF2-dependent cardiomyopathy.	Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Med Ctr, Dept Pharmacol, Cincinnati Childrens Hosp, Cincinnati, OH 45229 USA; Univ Toronto, Div Cardiol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Heart & Stroke Richard Lewar Ctr, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3E2, Canada	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Molkentin, JD (corresponding author), Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Xu, Jian/AAE-1415-2019; Aronow, Bruce J/F-8438-2012	Molkentin, Jeffery/0000-0002-3558-6529				Balke CW, 1998, CARDIOVASC RES, V37, P290, DOI 10.1016/S0008-6363(97)00272-1; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Harris DM, 2005, CIRC RES, V96, P543, DOI 10.1161/01.RES.0000158966.58380.37; Karasseva N, 2003, MOL CELL BIOL, V23, P5143, DOI 10.1128/MCB.23.15.5143-5164.2003; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kassiri Z, 2002, CIRC RES, V90, P578, DOI 10.1161/01.RES.0000012223.86441.A1; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Lebeche D, 2004, CIRCULATION, V110, P3435, DOI 10.1161/01.CIR.0000148176.33730.3F; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Nishida K, 2004, MOL CELL BIOL, V24, P10611, DOI 10.1128/MCB.24.24.10611-10620.2004; Notterman DA, 2001, CANCER RES, V61, P3124; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Pan F, 2004, J BIOL CHEM, V279, P14477, DOI 10.1074/jbc.C300487200; Parsons SA, 2004, J BIOL CHEM, V279, P26192, DOI 10.1074/jbc.M313800200; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Petrashevskaya NN, 2002, CARDIOVASC RES, V54, P117, DOI 10.1016/S0008-6363(02)00241-9; Rao S, 1998, J BIOL CHEM, V273, P26123, DOI 10.1074/jbc.273.40.26123; Sah R, 2003, J PHYSIOL-LONDON, V546, P5, DOI 10.1113/jphysiol.2002.026468; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Skerjanc IS, 2000, FEBS LETT, V472, P53, DOI 10.1016/S0014-5793(00)01438-1; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tessier S, 1999, CIRC RES, V85, P810, DOI 10.1161/01.RES.85.9.810; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wickenden AD, 1999, CIRC RES, V85, P1067; Wickenden AD, 1997, J PHYSIOL-LONDON, V504, P271, DOI 10.1111/j.1469-7793.1997.271be.x; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang SS, 2003, J CLIN INVEST, V111, P833, DOI 10.1172/JCI200316290; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zobel C, 2002, CIRCULATION, V106, P2385, DOI 10.1161/01.CIR.0000033970.22130.93	70	150	157	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9152	9162		10.1074/jbc.M510217200	http://dx.doi.org/10.1074/jbc.M510217200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469744	hybrid			2022-12-27	WOS:000236404700021
J	Ahern, GP; Wang, XB; Miyares, RL				Ahern, GP; Wang, XB; Miyares, RL			Polyamines are potent ligands for the capsaicin receptor TRPV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CHANNEL BLOCK; SPERMINE; RECTIFICATION; IDENTIFICATION; ACTIVATION; MECHANISM; TRANSPORT; CATIONS; PROTONS	Polyamines are important endogenous regulators of ion channels and are known to modulate inflammation and nociception. Here we investigated effects of polyamines on the capsaicin receptor TRPV1, a major ion channel expressed in nociceptive sensory afferents. Extracellular spermine, spermidine, and putrescine directly activated TRPV1 in a charge-dependent manner, both in heterologous expression systems and sensory neurons. The threshold for activation by spermine was similar to 500 mu M at room temperature. At lower concentrations, spermine enhanced capsaicin-evoked currents with an EC50 of similar to 5 mu M. Further, polyamines freely permeated TRPV1 (estimated relative permeabilities compared with Na+ were between 3 and 16), and spermine reduced the single channel conductance from 96 to 49 pS. Experiments with TRPV1 mutants identified extracellular acidic residues critical for polyamine regulation. Neutralization of aspartate 646 (D646N) abolished direct activation by spermine, whereas neutralization of this same aspartate (D646N) or glutamate 648 (E648A) inhibited spermine-induced sensitization. These data show that polyamines, by virtue of their cationic charge, can regulate the activity of TRPV1. Extracellular polyamines are present in considerable concentrations in the gastrointestinal tract and at synapses, and these levels increase during inflammation and cancer. Therefore, polyamine regulation of TRPV1 in these tissues may be relevant to a variety of physiological and pathophysiological states.	Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University	Ahern, GP (corresponding author), Georgetown Univ, Dept Pharmacol, MedDent SW401,3900 Reservoir Rd, Washington, DC 20007 USA.	gpa3@georgetown.edu						Ahern GP, 2005, J NEUROSCI, V25, P5109, DOI 10.1523/JNEUROSCI.0237-05.2005; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Deloyer P, 2001, EUR J GASTROEN HEPAT, V13, P1027, DOI 10.1097/00042737-200109000-00005; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; Kerschbaum HH, 2003, BIOPHYS J, V84, P2293, DOI 10.1016/S0006-3495(03)75035-8; Kitaguchi T, 2005, BIOCHEMISTRY-US, V44, P15544, DOI 10.1021/bi051494l; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Masuko T, 2003, J NEUROCHEM, V84, P610, DOI 10.1046/j.1471-4159.2003.01558.x; Milovic V, 2001, EUR J GASTROEN HEPAT, V13, P1021, DOI 10.1097/00042737-200109000-00004; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Nilius B, 2004, PFLUG ARCH EUR J PHY, V448, P70, DOI 10.1007/s00424-003-1221-x; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; ROCK DM, 1992, MOL PHARMACOL, V42, P157; ROCK DM, 1992, MOL PHARMACOL, V41, P83; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SPEIGHT JG, 2006, LANGES HDB CHEM, P299; Tan-No K, 2000, PAIN, V86, P55, DOI 10.1016/S0304-3959(99)00312-7; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tousova K, 2005, MOL CELL NEUROSCI, V30, P207, DOI 10.1016/j.mcn.2005.07.004; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Xie XZ, 1997, J BIOL CHEM, V272, P20484, DOI 10.1074/jbc.272.33.20484; Zhang C., 2000, J HUAZHONG U SCI TEC, V28, P60; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883	30	123	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8991	8995		10.1074/jbc.M513429200	http://dx.doi.org/10.1074/jbc.M513429200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431906	hybrid			2022-12-27	WOS:000236247100079
J	Bhonde, MR; Hanski, ML; Budczies, J; Cao, M; Gillissen, B; Moorthy, D; Simonetta, F; Scherubl, H; Truss, M; Hagemeier, C; Mewes, HW; Daniel, PT; Zeitz, M; Hanski, C				Bhonde, MR; Hanski, ML; Budczies, J; Cao, M; Gillissen, B; Moorthy, D; Simonetta, F; Scherubl, H; Truss, M; Hagemeier, C; Mewes, HW; Daniel, PT; Zeitz, M; Hanski, C			DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1 - The lack of this suppression in p53(MUT) cells contributes to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; HUMAN MPS1 KINASE; TRANSCRIPTIONAL REGULATION; WILD-TYPE; CATASTROPHE; ARREST; GENES; DEATH; 14-3-3-SIGMA; REGULATORS	DNA damage induced by the topoisomerase I inhibitor irinotecan (CPT-11) triggers in p53(WT) colorectal carcinoma cells a long term cell cycle arrest and in p53(MUT) cells a transient arrest followed by apoptosis (Magrini, R., Bhonde, M. R., Hanski, M. L., Notter, M., Scherubl, H., Boland, C. R., Zeitz, M., and Hanski, C. ( 2002) Int. J. Cancer 101, 23 - 31; Bhonde, M. R., Hanski, M. L., Notter, M., Gillissen, B. F., Daniel, P. T., Zeitz, M., and Hanski, C. ( 2006) Oncogene 25, 165 - 175). The mechanism of the p53-independent apoptosis still remains largely unclear. Here we used five p53(WT) and five p53(MUT) established colon carcinoma cell lines to identify gene expression alterations associated with apoptosis in p53MUT cells after treatment with SN-38, the irinotecan metabolite. After treatment, 16 mitosis-related genes were found to be expressed at least 2-fold stronger in the apoptosis-executing p53(MUT) cells than in the cell cycle-arrested p53(WT) cells by oligonucleotide microarray analysis. One of the genes whose strong post-treatment expression was associated with apoptosis was the mitotic checkpoint kinase hMps1 ( human ortholog of the yeast monopolar spindle 1 kinase). hMps1 mRNA and protein expression were suppressed by the treatment-induced and by the exogenous adenovirus-coded p53 protein. The direct suppression of hMps1 on RNA level or inhibition of its activity by a dominant-negative hMps1 partly suppressed apoptosis. Together, these data indicate that the high expression of mitotic genes in p53(MUT) cells after SN-38 treatment contributes to DNA damage-induced apoptosis, whereas their suppression in p53(WT) cells acts as a safeguard mechanism preventing mitosis initiation and the subsequent apoptosis. hMps1 kinase is one of the mitotic checkpoint proteins whose expression after DNA damage in p53(MUT) cells activates the checkpoint and contributes to apoptosis.	Charite Univ Med Berlin, Dept Gastroenterol, D-12200 Berlin, Germany; GSF Natl Res Ctr Environm & Hlth, Inst Bioinformat, D-85764 Neuherberg, Germany; Univ Med Ctr Charite, D-13353 Berlin, Germany; Univ Genoa, Dept Internal Med, Div Internal Med & Clin Immunol, I-16132 Genoa, Italy; Humboldt Univ, Charite CCM, Childrens Hosp, Mol Biol Lab, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Genoa; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hanski, C (corresponding author), Charite Univ Med Berlin, Dept Gastroenterol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christoph.hanski@charite.de	Simonetta, Federico/CAH-2436-2022; Budczies, Jan/AAG-8122-2020; Moorthy, Dhatchana/AAD-7680-2019; Mewes, Hans-Werner/A-8204-2019	Moorthy, Dhatchana/0000-0002-0071-4762; Mewes, Hans-Werner/0000-0002-9713-6398; Simonetta, Federico/0000-0002-0399-689X; Gillissen, Bernhard/0000-0002-1815-2091				Andreassen PR, 2001, CANCER RES, V61, P7660; Bhonde MR, 2006, ONCOGENE, V25, P165, DOI 10.1038/sj.onc.1209017; Bhonde MR, 2005, ONCOGENE, V24, P148, DOI 10.1038/sj.onc.1207842; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen ZH, 2003, MOL CANCER THER, V2, P543; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hattangadi DK, 2004, BIOCHEM PHARMACOL, V68, P1699, DOI 10.1016/j.bcp.2004.06.033; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Liu QH, 2000, GENE DEV, V14, P1448; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Lock RB, 1996, CANCER RES, V56, P4006; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Semizarov D, 2004, NUCLEIC ACIDS RES, V32, P3836, DOI 10.1093/nar/gkh714; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Sihn CR, 2003, CANCER LETT, V201, P203, DOI 10.1016/S0304-3835(03)00465-8; St Clair S, 2004, MOL CELL, V16, P725; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; te Poele RH, 1999, BRIT J CANCER, V81, P1285; Tu SP, 2003, CANCER RES, V63, P7724; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhou Y, 2002, CANCER RES, V62, P1688	50	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8675	8685		10.1074/jbc.M511333200	http://dx.doi.org/10.1074/jbc.M511333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446370	hybrid			2022-12-27	WOS:000236247100045
J	Christensen, EN; Mendelsohn, ME				Christensen, EN; Mendelsohn, ME			Cyclic GMP-dependent protein kinase I alpha inhibits thrombin receptor-mediated calcium mobilization in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MYOSIN PHOSPHATASE; SUBSTRATE IRAG; PHOSPHORYLATION; RELAXATION; BETA; DIMERIZATION; MECHANISM; CA(V)1.2; CHANNEL	Vascular smooth muscle contractile state is regulated by intracellular calcium levels. Nitric oxide causes vascular relaxation by stimulating production of cyclic GMP, which activates type I cGMP- dependent protein kinase ( PKGI) in vascular smooth muscle cells ( VSMC), inhibiting agonist- induced intracellular Ca2+ mobilization ([Ca2+] (i)). The relative roles of the two PKGI isozymes, PKGI alpha and PKGI beta, in cyclic GMP- mediated inhibition of [Ca2+] (i) in VSMCs are unclear. Here we have investigated the ability of PKGI isoforms to inhibit [Ca2+](i) in response to VSMC activation. Stable Chinese hamster ovary cell lines expressing PKGI alpha or PKGI beta were created, and the ability of PKGI isoforms to inhibit [Ca2+](i) in response to thrombin receptor stimulation was examined. In Chinese hamster ovary cells stably expressing PKGI alpha or PKGI beta, 8- Br- cGMP activation suppressed [ Ca2+](i) by thrombin receptor activation peptide ( TRAP) by 98 +/- 1 versus 42 +/- 5%, respectively ( p < 0.002). Immunoblotting studies of cultured human VSMC cells from multiple sites using PKGI alpha- and PKGI beta- specific antibodies showed PKGI alpha is the predominant VSMC PKGI isoform. [Ca2+](i) following thrombin receptor stimulation was examined in the absence or presence of cyclic GMP in human coronary VSMC cells ( Co403). 8- Br- cGMP significantly inhibited TRAP- induced [Ca2+](i) in Co403, causing a 4- fold increase in the EC50 for [Ca2+](i). In the absence of 8- Br- cGMP, suppression of PKGI alpha levels by RNA interference ( RNAi) led to a significantly greater TRAP- stimulated rise in [Ca-i(2+]) as compared with control RNAi- treated Co403 cells. In the presence of 8- Br- cGMP, the suppression of PKGI alpha expression by RNAi led to the complete loss of cGMP- mediated inhibition of [Ca2+](i). Adenoviral overexpression of PKGI beta in Co403 cells was unable to alter TRAP- stimulated Ca2+ mobilization either before or after suppression of PKGI alpha expression by RNAi. These results support that PKGI alpha is the principal cGMP- dependent protein kinase isoform mediating inhibition of VSMC activation by the nitric oxide/ cyclic GMP pathway.	Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 80, Boston, MA 02111 USA.	mmendelsohn@tufts-nemc.org			NHLBI NIH HHS [HL535309] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; CASTEEL DE, 2005, J BIOL CHEM; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Fritsch RM, 2004, J BIOL CHEM, V279, P12551, DOI 10.1074/jbc.M313365200; Geiselhoringer A, 2004, EMBO J, V23, P4222, DOI 10.1038/sj.emboj.7600440; Geiselhoringer A, 2004, FEBS LETT, V575, P19, DOI 10.1016/j.febslet.2004.08.030; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann F, 2005, J BIOL CHEM, V280, P1, DOI 10.1074/jbc.R400035200; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Pace MC, 1999, AM J PHYSIOL-LUNG C, V277, pL106, DOI 10.1152/ajplung.1999.277.1.L106; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Reid HM, 2003, J BIOL CHEM, V278, P51190, DOI 10.1074/jbc.M309314200; Richie-Jannetta R, 2003, J BIOL CHEM, V278, P50070, DOI 10.1074/jbc.M306796200; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 2005, J BIOL CHEM, V280, P42543, DOI 10.1074/jbc.M506863200; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Taylor MS, 2004, MOL PHARMACOL, V65, P1111, DOI 10.1124/mol.65.5.1111; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200	35	17	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8409	8416		10.1074/jbc.M512770200	http://dx.doi.org/10.1074/jbc.M512770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446362	hybrid			2022-12-27	WOS:000236247100015
J	Jeong, MH; Bae, J; Kim, WH; Yoo, SM; Kim, JW; Song, PI; Choi, KH				Jeong, MH; Bae, J; Kim, WH; Yoo, SM; Kim, JW; Song, PI; Choi, KH			p19(ras) interacts with and activates p73 by involving the MDM2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSICAL INTERACTION; TRANSCRIPTIONAL ACTIVATION; P53-RELATED PROTEIN; VIRAL ONCOPROTEINS; BINDING-PROTEIN; CELL-CYCLE; C-MYC; P53; RAS; APOPTOSIS	p73 beta is a structural and functional homologue of p53, a tumor suppressor gene. In this study, we identified a novel p73 beta-binding protein, p19(ras), by the yeast two-hybrid screening method. Alternative splicing of the proto-oncogene H-ras pre-mRNA has led to two distinct transcripts, p19(ras) and p21(ras). In both endogenous and overexpressed systems, we confirmed that p19(ras) binds to full-length p73 beta in vivo and in vitro. Coexpression of p19(ras) with p73 beta stimulated the transcriptional activity of p73 beta. Ras proteins are known to be small membrane-localized guanine nucleotide-binding proteins. However, unlike other Ras proteins, p19(ras) is localized in the nucleus and the cytosol and its interaction with p73 beta occurred exclusively in the nucleus. Oncogenic MDM2 ( mouse double minutes 2) is a known repressor of p73 transcriptional activity. In this study, when p19(ras) was bound to MDM2, it further inhibited the association of MDM2 to the p73 beta protein. In addition, p19(ras) abolished MDM2-mediated transcriptional repression of p73 beta. Therefore, this study presents a novel pathway of Ras signaling that occurs in the nucleus, involving p19(ras) and p73 beta. Furthermore, a p19(ras)-mediated novel regulatory mechanism of p73 involving the MDM2 protein is described.	Chung Ang Univ, Coll Nat Sci, Dept Biol Sci, Mol Biol Lab, Seoul 156756, South Korea; Pochon CHA Univ, Grad Sch Life Sci & Biotechnol, Lab Mol Om Therapy, Seongnam 463836, South Korea; Norean Natl Inst Hlth, Korea Ctr Dis Control & Prevent, Seoul 122701, South Korea; Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Aurora, CO 80045 USA	Chung Ang University; Pochon Cha University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); University of Colorado System; University of Colorado Anschutz Medical Campus	Choi, KH (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Biol Sci, Mol Biol Lab, Seoul 156756, South Korea.	khchoi@cau.ac.kr		Kim, Won-Ho/0000-0002-4849-472X; bae, jeehyeon/0000-0003-1995-1378				Agami R, 1999, NATURE, V399, P809; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; CHEN CY, 1995, ONCOGENE, V11, P1487; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; Guil S, 2003, CANCER RES, V63, P5178; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang KH, 2002, FEBS LETT, V522, P161, DOI 10.1016/S0014-5793(02)02921-6; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kim KC, 2001, ONCOGENE, V20, P6689, DOI 10.1038/sj.onc.1204839; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOODIE SA, 1995, ONCOGENE, V11, P447; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Vikhanskaya F, 2001, CANCER RES, V61, P935; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wurzer G, 2001, J CELL BIOCHEM, P1; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061; Zwahlen D, 2000, INT J CANCER, V88, P66	47	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8707	8715		10.1074/jbc.M513853200	http://dx.doi.org/10.1074/jbc.M513853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16436381	hybrid			2022-12-27	WOS:000236247100048
J	Shojania, S; O'Neil, JD				Shojania, S; O'Neil, JD			HIV-1 Tat is a natively unfolded protein - The solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-MAGNETIC-RESONANCE; HUMAN COACTIVATOR CBP; UREA-DENATURED STATE; MODEL-FREE APPROACH; BACKBONE DYNAMICS; STRUCTURAL-CHARACTERIZATION; CHEMICAL-SHIFT; SECONDARY STRUCTURE; FOLDED PROTEINS	Tat ( transactivator of transcription) is a small RNA- binding protein that plays a central role in the regulation of human immunodeficiency virus type 1 replication and in approaches to treating latently infected cells. Its interactions with a wide variety of both intracellular and extracellular molecules is well documented. A molecular understanding of the multitude of Tat activities requires a determination of its structure and interactions with cellular and viral partners. To increase the dispersion of NMR signals and permit dynamics analysis by multinuclear NMR spectroscopy, we have prepared uniformly N-15- and N-15/C-13- labeled Tat-( 1 - 72) protein. The cysteine- rich protein is unambiguously reduced at pH 4.1, and NMR chemical shifts and coupling constants suggest that it exists in a random coil conformation. Line broadening and multiple peaks in the Cys- rich and core regions suggest that transient folding occurs in two of the five sequence domains. NMR relaxation parameters were measured and analyzed by spectral density and Lipari- Szabo approaches, both confirming the lack of structure throughout the length of the molecule. The absence of a fixed conformation and the observation of fast dynamics are consistent with the ability of Tat protein to interact with a wide variety of proteins and nucleic acid and support the concept of a natively unfolded protein.	Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	O'Neil, JD (corresponding author), Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada.	joneil@cc.umanitoba.ca	O'Neil, Joe/R-2356-2019	O'Neil, Joe/0000-0002-5917-0392				ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; Alimonti JB, 2003, J GEN VIROL, V84, P1649, DOI 10.1099/vir.0.19110-0; Andrec M, 1999, J MAGN RESON, V139, P408, DOI 10.1006/jmre.1999.1839; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Avraham HK, 2004, J IMMUNOL, V173, P6228, DOI 10.4049/jimmunol.173.10.6228; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bannwarth S, 2005, CURR HIV RES, V3, P61, DOI 10.2174/1570162052772924; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bhavesh NS, 2003, J BIOL CHEM, V278, P19980, DOI 10.1074/jbc.M301615200; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bourgeois CF, 2002, MOL CELL BIOL, V22, P1079, DOI 10.1128/MCB.22.4.1079-1093.2002; Buevich AV, 2001, J BIOMOL NMR, V20, P233, DOI 10.1023/A:1011243116136; Campbell GR, 2004, J BIOL CHEM, V279, P48197, DOI 10.1074/jbc.M406195200; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DERSE D, 1991, J VIROL, V65, P7012, DOI 10.1128/JVI.65.12.7012-7015.1991; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; Dyson HJ, 2005, METHOD ENZYMOL, V394, P299, DOI 10.1016/S0076-6879(05)94011-1; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Farrow NA, 1997, BIOCHEMISTRY-US, V36, P2390, DOI 10.1021/bi962548h; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; FRANK MK, 1995, PROTEIN SCI, V4, P2605, DOI 10.1002/pro.5560041218; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FREUND J, 1995, J MOL BIOL, V250, P672, DOI 10.1006/jmbi.1995.0407; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; Gillespie JR, 1997, J MOL BIOL, V268, P170, DOI 10.1006/jmbi.1997.0953; Greenbaum NL, 1996, STRUCTURE, V4, P5, DOI 10.1016/S0969-2126(96)00003-2; Gregoire C, 2001, BIOPOLYMERS, V62, P324, DOI 10.1002/bip.10000; Gregoire CJ, 1996, J BIOL CHEM, V271, P22641, DOI 10.1074/jbc.271.37.22641; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Gunasekaran K, 2003, TRENDS BIOCHEM SCI, V28, P81, DOI 10.1016/S0968-0004(03)00003-3; Guo XF, 2003, VIROLOGY, V307, P154, DOI 10.1016/S0042-6822(02)00068-5; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Habazettl J, 1996, BIOCHEMISTRY-US, V35, P9335, DOI 10.1021/bi952524v; Hakansson S, 2003, BIOCHEMISTRY-US, V42, P8999, DOI 10.1021/bi020715+; HU Y, 1990, J CHEM PHYS, V93, P822, DOI 10.1063/1.459452; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lassen K, 2004, TRENDS MOL MED, V10, P525, DOI 10.1016/j.molmed.2004.09.006; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Metzger AU, 1997, BIOCHEM BIOPH RES CO, V241, P31, DOI 10.1006/bbrc.1997.7770; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Opi S, 2004, VACCINE, V22, P3105, DOI 10.1016/j.vaccine.2004.01.057; Otzen DE, 2004, BIOCHEMISTRY-US, V43, P12964, DOI 10.1021/bi048509k; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Peloponese JM, 2000, CR ACAD SCI III-VIE, V323, P883, DOI 10.1016/S0764-4469(00)01228-2; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; Peti W, 2001, J BIOMOL NMR, V19, P153, DOI 10.1023/A:1008307323283; Plattt GW, 2005, J MOL BIOL, V346, P279, DOI 10.1016/j.jmb.2004.11.035; Pocernich CB, 2005, BRAIN RES REV, V50, P14, DOI 10.1016/j.brainresrev.2005.04.002; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Pumfery A, 2003, CURR HIV RES, V1, P343, DOI 10.2174/1570162033485186; Redfield C, 2004, METHODS, V34, P121, DOI 10.1016/j.ymeth.2004.03.009; Schulte A, 2005, J BIOL CHEM, V280, P24968, DOI 10.1074/jbc.M501431200; SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127; Schwalbe H, 1997, BIOCHEMISTRY-US, V36, P8977, DOI 10.1021/bi970049q; Schwarzinger S, 2002, BIOCHEMISTRY-US, V41, P12681, DOI 10.1021/bi020381o; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Seewald MJ, 1998, J BIOMOL STRUCT DYN, V16, P683, DOI 10.1080/07391102.1998.10508280; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; Smith SM, 2003, J BIOL CHEM, V278, P44816, DOI 10.1074/jbc.M307546200; Spyracopoulos L, 1996, J BIOMOL NMR, V7, P283, DOI 10.1007/BF00200430; SZYPERSKI T, 1993, J BIOMOL NMR, V3, P151; Tafer H, 2004, BIOCHEMISTRY-US, V43, P860, DOI 10.1021/bi0356606; Teilum K, 2002, J MOL BIOL, V324, P349, DOI 10.1016/S0022-2836(02)01039-2; Thormann T, 2004, BIOCHEMISTRY-US, V43, P10364, DOI 10.1021/bi0495679; Ulrich DL, 2005, J MOL BIOL, V347, P297, DOI 10.1016/j.jmb.2005.01.039; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vendel AC, 2004, BIOCHEMISTRY-US, V43, P904, DOI 10.1021/bi035612l; Vendel AC, 2003, BIOCHEMISTRY-US, V42, P910, DOI 10.1021/bi0270034; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; Yao J, 1997, FEBS LETT, V419, P285, DOI 10.1016/S0014-5793(97)01474-9; ZHANG O, 1995, BIOCHEMISTRY-US, V34, P6784, DOI 10.1021/bi00020a025; Zhang OW, 1997, J BIOMOL NMR, V9, P181, DOI 10.1023/A:1018658305040; [No title captured]	104	103	107	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8347	8356		10.1074/jbc.M510748200	http://dx.doi.org/10.1074/jbc.M510748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16423825	hybrid, Green Submitted			2022-12-27	WOS:000236247100008
J	Luo, WB; Wang, YF; Hanck, T; Stricker, R; Reiser, G				Luo, WB; Wang, YF; Hanck, T; Stricker, R; Reiser, G			Jab1, a novel protease-activated receptor-2 (PAR-2)-interacting protein, is involved in PAR-2-induced activation of activator protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARRESTIN-DEPENDENT ENDOCYTOSIS; MODULATE AP-1 ACTIVITY; MAST-CELL TRYPTASE; COP9 SIGNALOSOME; INTRACELLULAR PRECURSOR; THROMBIN RECEPTOR; PROSTAGLANDIN E-2; DOWN-REGULATION; RAT ASTROCYTES; 26S PROTEASOME	Protease-activated receptor-2 (PAR-2), a G protein-coupled receptor for trypsin and tryptase, exerts important physiological and pathological functions in multiple systems. However, unlike PAR-1, the PAR-2-mediated intracellular signal transductions are hardly known. Here, using yeast two-hybrid screening with a human brain cDNA library, we identified an interacting partner of human PAR-2, the Jun activation domain-binding protein 1 (Jab1). The interaction was confirmed by glutathione S-transferase pull-down assays in vitro, and by co-immunoprecipitation assays in vivo. Jab1 was also shown to be colocalized with PAR-2 in both transfected HEK293 cells and in normal primary human astrocytes by double immunofluorescence staining. Further experiments demonstrated that multiple intracellular domains of PAR-2 are required for the interaction with Jab1. We then showed that agonist stimulation of PAR-2 disrupted the interaction, which could be prevented by the inhibitor of receptor endocytosis phenylarsine oxide, but not by the lysosomal protease inhibitor ZPAD. Importantly, we found that activation of PAR-2 induced the redistribution of Jab1 from the plasma membrane to the cytosol, but did not influence expression of Jab1. Furthermore, Jab1 mediated PAR-2-induced c-Jun activation, which was followed by increased activation of activator protein-1. Loss-of-function studies, using Jab1 small interfering RNA, demonstrated that Jab1 knockdown blocked PAR-2-induced activator protein-1 activation. Taken together, our data demonstrate that Jab1 is an important effector that mediates a novel signal transduction pathway for PAR-2-dependent gene expression.	Otto Von Guericke Univ, Inst Neurobiochem, Fak Med, D-39120 Magdeburg, Germany	Otto von Guericke University	Reiser, G (corresponding author), Otto Von Guericke Univ, Inst Neurobiochem, Fak Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	georg.reiser@medizin.uni-magdeburg.de		wang, yingfei/0000-0002-8723-252X; Luo, Weibo/0000-0002-1992-0320				Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; Ascoli M, 2005, ENDOCRINOLOGY, V146, P3221, DOI 10.1210/en.2005-0590; Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Burger-Kentischer A, 2005, FEBS LETT, V579, P1693, DOI 10.1016/j.febslet.2005.01.080; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Cottrell GS, 2003, BIOCHEM SOC T, V31, P1191; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; FENG DM, 1995, J MED CHEM, V38, P4125, DOI 10.1021/jm00020a029; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Hanck T, 2004, J NEUROCHEM, V88, P326, DOI 10.1046/j.1471-4159.2003.02143.x; Hirano K, 2005, J PHARMACOL SCI, V97, P31, DOI 10.1254/jphs.FMJ04005X6; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Jin G, 2005, J CEREBR BLOOD F MET, V25, P302, DOI 10.1038/sj.jcbfm.9600021; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lundberg AH, 2000, PANCREAS, V21, P41, DOI 10.1097/00006676-200007000-00050; Luo WB, 2005, BRAIN RES, V1047, P159, DOI 10.1016/j.brainres.2005.04.040; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Noorbakhsh F, 2003, NAT REV NEUROSCI, V4, P981, DOI 10.1038/nrn1255; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Schwechheimer C, 2004, BBA-MOL CELL RES, V1695, P45, DOI 10.1016/j.bbamcr.2004.09.023; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; SmithSwintosky VL, 1997, J NEUROCHEM, V69, P1890; Sokolova E, 2005, AM J PHYSIOL-LUNG C, V288, pL793, DOI 10.1152/ajplung.00343.2004; Somasundaram P, 2005, J PATHOL, V205, P102, DOI 10.1002/path.1690; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Temkin V, 2002, J IMMUNOL, V169, P2662, DOI 10.4049/jimmunol.169.5.2662; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Wang H, 2003, J NEUROCHEM, V84, P1349, DOI 10.1046/j.1471-4159.2003.01637.x; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Yun JS, 2004, J BIOL CHEM, V279, P31296, DOI 10.1074/jbc.M401411200	50	27	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7927	7936		10.1074/jbc.M510784200	http://dx.doi.org/10.1074/jbc.M510784200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16410250	hybrid			2022-12-27	WOS:000236031000028
J	Yan, WS; Chen, XB				Yan, WS; Chen, XB			GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL GLUTATHIONE-PEROXIDASE; SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; P53 FAMILY; GI-GPX; FUNCTIONAL DOMAINS; GROWTH SUPPRESSION; CANCER; P21; P73	The p53 family consists of p53, p63, and p73, each of which has multiple isoforms due to transcription at two separate promoters and alternative splicing. Although p53 is a bona fide tumor suppressor, p63 appears to have a Janus-faced function as a tumor suppressor and an oncogene. To address the two opposing functions of p63, we analyzed its target genes. Here, we found that GPX2, which encodes a glutathione peroxidase, is up-regulated by p63 but not p53. Accordingly, a unique responsive element was found in the promoter of the GPX2 gene that can be activated and bound by p63 but not p53. We also found that upon overexpression, GPX2 alleviates the apoptotic response of MCF7 cells to oxidative stresses. Interestingly, the protective function of GPX2 is p53 dependent. Likewise, we showed that a deficiency in GPX2 renders MCF7 cells susceptible to oxidative stress-induced apoptosis. Given that the Delta N isoform of p63 is frequently overexpressed in tumor cells, the observations here provide an insight into the mechanism by which some isoforms of p63 serve as a pro-survival factor by up-regulating GPX2 to reduce the p53-dependent oxidative stress-induced apoptotic response.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu			NATIONAL CANCER INSTITUTE [R29CA076069, R01CA102188, R01CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102188, CA076069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banning A, 2005, MOL CELL BIOL, V25, P4914, DOI 10.1128/MCB.25.12.4914-4923.2005; Brigelius-Flohe R, 2001, BIOFACTORS, V14, P101, DOI 10.1002/biof.5520140114; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; CHEN XB, 1995, CANCER RES, V55, P4257; Chu FF, 2004, FREE RADICAL BIO MED, V36, P1481, DOI 10.1016/j.freeradbiomed.2004.04.010; CHU FF, 1993, J BIOL CHEM, V268, P2571; Chu FF, 1999, J NUTR, V129, P1846, DOI 10.1093/jn/129.10.1846; Chu FF, 2004, CANCER RES, V64, P962, DOI 10.1158/0008-5472.CAN-03-2272; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dohn Michael, 2003, Methods Mol Biol, V223, P221; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Florian S, 2001, FREE RADICAL RES, V35, P655, DOI 10.1080/10715760100301181; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.0.CO;2-S; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Mork H, 2003, INT J CANCER, V105, P300, DOI 10.1002/ijc.11087; Mork H, 2000, NUTR CANCER, V37, P108, DOI 10.1207/S15327914NC3701_14; Nozell S, 2003, ONCOGENE, V22, P4333, DOI 10.1038/sj.onc.1206470; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Serewko MM, 2002, CANCER RES, V62, P3759; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	42	123	126	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7856	7862		10.1074/jbc.M512655200	http://dx.doi.org/10.1074/jbc.M512655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16446369	hybrid			2022-12-27	WOS:000236031000020
J	Wootton, LL; Michelangeli, F				Wootton, LL; Michelangeli, F			The effects of the phenylalanine 256 to valine mutation on the sensitivity of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) Ca2+ pump isoforms 1, 2, and 3 to thapsigargin and other inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; AMINO-ACID 256; TRANSPORT ATPASE; CYCLOPIAZONIC ACID; CALCIUM PUMPS; CA2+-ATPASE; EXPRESSION; RESISTANCE; MECHANISM; CURCUMIN	Three isoforms of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) are known to exist in mammalian cells. This study investigated the effects of thapsigargin and a variety of commonly used hydrophobic inhibitors on these SERCA isoforms (i.e. SERCA1b, SERCA2b, and SERCA3a), which were transiently expressed in COS-7 cells. In addition, the study assessed whether the introduction of the phenylalanine to valine mutation at position 256 (F256V), known to reduce the potency of thapsigargin inhibition in avian SERCA1, affects the other SERCA isoforms in a similar manner and whether this mutation also affects the inhibition by other inhibitors. This study has shown that the sensitivity to thapsigargin is different for the SERCA isoforms ( apparent K-i values being 0.21, 1.3, and 12 nM for SERCA1b, SERCA2b, and SERCA3a, respectively). The reduction in thapsigargin sensitivity caused by the F256V mutation was also different for the three isoforms, with SERCA2b only being modestly affected by this mutation. Although some of the other inhibitors investigated (i.e. cyclopiazonic acid and curcumin) showed some differences in their sensitivity toward the SERCA isoforms, most were little affected by the F256V mutation, indicating that they inhibit the Ca2+-ATPase by binding to sites on SERCA distinct from that of thapsigargin.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Michelangeli, F (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	F.Michelangeli@bham.ac.uk						BAPP B, 1992, BIOCHEM J, V288, P297; Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bilmen JG, 2002, CELL SIGNAL, V14, P955, DOI 10.1016/S0898-6568(02)00042-6; Bilmen JG, 2001, EUR J BIOCHEM, V268, P6318, DOI 10.1046/j.0014-2956.2001.02589.x; BURK SE, 1989, J BIOL CHEM, V264, P18561; Dyer JL, 2002, CELL CALCIUM, V31, P45, DOI 10.1054/ceca.2001.0259; GERSHONI JM, 1985, ANAL BIOCHEM, V144, P32, DOI 10.1016/0003-2697(85)90080-6; GOEGER DE, 1988, BIOCHEM PHARMACOL, V37, P978, DOI 10.1016/0006-2952(88)90195-5; Hughes PJ, 2000, BIOCHEM BIOPH RES CO, V277, P568, DOI 10.1006/bbrc.2000.3710; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; KASS GEN, 1989, J BIOL CHEM, V264, P15192; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Logan-Smith MJ, 2002, BIOCHEMISTRY-US, V41, P2869, DOI 10.1021/bi011938n; Longland CL, 1998, CELL CALCIUM, V24, P27, DOI 10.1016/S0143-4160(98)90086-0; Lopez JJ, 2005, BIOCHEM J, V390, P243, DOI 10.1042/BJ20050168; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3091, DOI 10.1021/bi00464a028; MICHELANGELI F, 1990, BIOCHEM J, V267, P423, DOI 10.1042/bj2670423; MURAYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Somura F, 2001, CIRCULATION, V104, P658, DOI 10.1161/hc3101.093869; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Xu C, 2004, J BIOL CHEM, V279, P17973, DOI 10.1074/jbc.M313263200; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; Zador E, 1996, BIOCHEM J, V320, P107, DOI 10.1042/bj3200107	33	60	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6970	6976		10.1074/jbc.M510978200	http://dx.doi.org/10.1074/jbc.M510978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410239	hybrid			2022-12-27	WOS:000236030900009
J	Beima, KM; Miazgowicz, MM; Lewis, MD; Yan, PS; Huang, THM; Weinmann, AS				Beima, KM; Miazgowicz, MM; Lewis, MD; Yan, PS; Huang, THM; Weinmann, AS			T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; TRANSCRIPTION FACTOR; CHROMATIN IMMUNOPRECIPITATION; LINEAGE COMMITMENT; EXPRESSION; DIFFERENTIATION; EOMESODERMIN; SITES	Recently developed target gene identification strategies based upon the chromatin immunoprecipitation assay provide a powerful method to determine the localization of transcription factor binding within mammalian genomes. However, in many cases, it is unclear if the binding capacity of a transcription factor correlates with an obligate role in gene regulation in diverse contexts. It is therefore important to carefully examine the relationship between transcription factor binding and its ability to functionally regulate gene expression. T-bet is a T-box transcription factor expressed in several hematopoietic cell types. By utilizing a chromatin immunoprecipitation assay coupled to genomic microarray technology approach, we identified numerous promoters, including CXCR3, IL2R beta, and CCL3, that are bound by T-bet in B cells. Most surprisingly, the ability of T-bet to associate with the target promoters is not dependent upon the cell type background. Several of the promoters appear to be functionally regulated by T-bet. However, we could not detect a functional consequence for T-bet association with many of the identified promoters in overexpression studies or an examination of wild type and T-bet(-/-) primary B, CD4(+), and CD8(+) T cells. Thus, there is a high variability in the functional consequences, if any, that result from the association of T-bet with individual target promoters.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Ohio State Univ, Columbus, OH 43210 USA	University of Washington; University of Washington Seattle; University System of Ohio; Ohio State University	Weinmann, AS (corresponding author), Univ Washington, Dept Immunol, Box 357650,1959 NE Pacific St, Seattle, WA 98195 USA.	weinmann@u.washington.edu	Yan, Pearlly S/E-4339-2011	Yan, Pearlly S/0000-0003-1965-4920	NCI NIH HHS [CA09537] Funding Source: Medline; NIAID NIH HHS [AI061061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI061061, R01AI061061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Cho JY, 2003, INT IMMUNOL, V15, P1149, DOI 10.1093/intimm/dxg113; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Liu NS, 2003, NAT IMMUNOL, V4, P687, DOI 10.1038/ni941; Lord GM, 2005, BLOOD, V106, P3432, DOI 10.1182/blood-2005-04-1393; Lovett-Racke AE, 2004, IMMUNITY, V21, P719, DOI 10.1016/j.immuni.2004.09.010; Lugo-Villarino G, 2003, P NATL ACAD SCI USA, V100, P7749, DOI 10.1073/pnas.1332767100; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Peng SL, 2002, P NATL ACAD SCI USA, V99, P5545, DOI 10.1073/pnas.082114899; PHILLIP PL, 2005, PLOS GENET, V1, pE16; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Shnyreva M, 2004, P NATL ACAD SCI USA, V101, P12622, DOI 10.1073/pnas.0400849101; Sullivan BM, 2003, P NATL ACAD SCI USA, V100, P15818, DOI 10.1073/pnas.2636938100; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Tada M, 2001, DEV GROWTH DIFFER, V43, P1; Townsend MJ, 2004, IMMUNITY, V20, P477, DOI 10.1016/S1074-7613(04)00076-7; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3	24	110	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11992	12000		10.1074/jbc.M513613200	http://dx.doi.org/10.1074/jbc.M513613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16473879	hybrid			2022-12-27	WOS:000236988100069
J	Meadow, ND; Savtchenko, RS; Remington, SJ; Roseman, S				Meadow, ND; Savtchenko, RS; Remington, SJ; Roseman, S			Effects of mutations and truncations on the kinetic Behavior of IIA(Glc), a phosphocarrier and regulatory protein of the phosphoenolpyruvate phosphotransferase system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCING PROTEIN; PHOSPHORYL TRANSFER COMPLEX; SUGAR-TRANSPORT; SALMONELLA-TYPHIMURIUM; GLUCOSE-TRANSPORTER; MOLECULAR-CLONING; IIIGLC; SITE; HPR; PURIFICATION	IIA(Glc), a component of the glucose-specific phosphoenolpyruvate: phosphotransferase system ( PTS) of Escherichia coli, is important in regulating carbohydrate metabolism. In Glc uptake, the phosphotransfer sequence is: phosphoenolpyruvate -> Enzyme -> I HPr -> IIA(Glc) -> IICBGlc -> Glc. ( HPr is the first phosphocarrier protein of the PTS.) We previously reported two classes of IIAGlc mutations that substantially decrease the P-transfer rate constants to/from IIA(Glc). A mutant of His(75) which adjoins the active site ( His(90)), ( H75Q), was 0.5% as active as wild-type IIAGlc in the reversible P-transfer to HPr. Two possible explanations were offered for this result: ( a) the imidazole ring of His75 is required for charge delocalization and ( b) H75Q disrupts the hydrogen bond network: Thr73, His75, phospho-His90. The present studies directly test the H-bond network hypothesis. Thr73 was replaced by Ser, Ala, or Val to eliminate the network. Because the rate constants for phosphotransfer to/from HPr were largely unaffected, we conclude that the H-bond network hypothesis is not correct. In the second class of mutants, proteolytic truncation of seven residues of the IIAGlc N terminus caused a 20-fold reduction in phosphotransfer to membrane-bound IICBGlc from Salmonella typhimurium. Here, we report the phosphotransfer rates between two genetically constructed N-terminal truncations of IIAGlc ( Delta 7 and Delta 16) and the proteins IICBGlc and IIBGlc ( the soluble cytoplasmic domain of IICBGlc). The truncations did not significantly affect reversible P-transfer to IIBGlc but substantially decreased the rate constants to IICBGlc in E. coli and S. typhimurium membranes. The results support the hypothesis ( Wang, G., Peterkofsky, A., and Clore, G. M. ( 2000) J. Biol. Chem. 275, 39811-39814) that the N-terminal 18-residue domain "docks" IIAGlc to the lipid bilayer of membranes containing IICBGlc.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Univ Oregon, Dept Phys, Eugene, OR 97403 USA	Johns Hopkins University; University of Oregon	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	roseman@jhu.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; AUSTIN PW, 1963, J CHEM SOC, P5350, DOI 10.1039/jr9630005350; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BENESKI DA, 1982, J BIOL CHEM, V257, P4492; Bollenback G.N., 1963, METHODS CARBOHYDRATE, VII, P326; BOUMA CL, 1987, P NATL ACAD SCI USA, V84, P930, DOI 10.1073/pnas.84.4.930; BUHR A, 1994, J BIOL CHEM, V269, P23437; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P33; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; Meadow N. D., 1985, ENZYMES BIOL MEMBR, P523; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; Meadow ND, 1996, J BIOL CHEM, V271, P33440, DOI 10.1074/jbc.271.52.33440; Meadow ND, 2005, J BIOL CHEM, V280, P41872, DOI 10.1074/jbc.M501440200; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; MEINS M, 1988, J BIOL CHEM, V263, P12986; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; Pelton JG, 1996, J BIOL CHEM, V271, P33446, DOI 10.1074/jbc.271.52.33446; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1976, J BIOL CHEM, V251, P6606; Seok YJ, 1997, J BIOL CHEM, V272, P26511, DOI 10.1074/jbc.272.42.26511; Toptygin D, 2001, J PHYS CHEM B, V105, P2043, DOI 10.1021/jp003405e; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Wang GS, 2003, PROTEIN SCI, V12, P1087, DOI 10.1110/ps.0301503; Wang GS, 2000, J BIOL CHEM, V275, P39811, DOI 10.1074/jbc.C000709200; WAYGOOD EB, 1982, METHOD ENZYMOL, V90, P423; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	38	7	7	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11450	11455		10.1074/jbc.M507417200	http://dx.doi.org/10.1074/jbc.M507417200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16439362	hybrid			2022-12-27	WOS:000236988100005
J	Caruso, JA; Mathieu, PA; Joiakim, A; Zhang, H; Reiners, JJ				Caruso, JA; Mathieu, PA; Joiakim, A; Zhang, H; Reiners, JJ			Aryl hydrocarbon receptor modulation of tumor necrosis factor-alpha-induced apoptosis and lysosomal disruption in a hepatoma model that is caspase-8-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM STRESS; INDUCED CELL-DEATH; CATHEPSIN-D; TNF-ALPHA; OXIDATIVE STRESS; PHOTOSENSITIZER NPE6; MEDIATED APOPTOSIS; OLIGOMERIZES BAK; LIPID RAFTS	Recent studies suggest that the aryl hydrocarbon receptor (AhR) modulates susceptibilities to some pro-apoptotic agents. AhR-containing murine hepatoma 1c1c7 cultures underwent apoptosis following exposure to tumor necrosis factor-alpha (TNF alpha) + cycloheximide (CHX). In contrast, Tao cells, an AhR-deficient variant of the 1c1c7 line, were refractory to this treatment. AhR sense/antisense transfection studies demonstrated that AhR contents influenced susceptibility to the pro-apoptotic effects of TNF alpha + CHX. 1c1c7 cells and all variants expressed comparable amounts of TNF receptor-1 and TRADD. However, no cell line expressed FADD, and consequently pro-caspase-8 was not activated. AhR content did not influence JNK and NF-kappa B activation. However, Bid and procaspase-9, -3, and -12 processing occurred only in AhR-containing cells. Analyses of cathepsin B and D activities in digitonin-permeabilized cultures and the monitoring of cathepsin B/D co-localization with Lamp-1 indicated that TNF alpha + CHX disrupted late endosomes/lysosomes in only AhR-containing cells. Stabilization of acidic organelles with 3-O-methylsphingomyelin inhibited TNF alpha + CHX-induced apoptosis. The cathepsin D inhibitor pepstatin A suppressed in vitro cleavage of Bid by 1c1c7 lysosomal extracts. It also delayed the induction of apoptosis and partially prevented Bid cleavage and the activation of pro-caspases-3/7 in cultures treated with TNF alpha + CHX. Similar suppressive effects occurred in cultures transfected with murine Bid antisense oligonucleotides. These studies showed that in cells where pro-caspase-8 is not activated, TNF alpha + CHX can initiate apoptosis through lysosomal disruption. Released proteases such as cathepsin D trigger the apoptotic program by activating Bid. Furthermore, in the absence of exogenous ligand, the AhR modulates lysosomal disruption/permeability.	Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; ISIS Pharmaceut, Gene Trove Div, Carlsbad, CA 92008 USA	Wayne State University; Isis Pharmaceuticals Inc	Reiners, JJ (corresponding author), Wayne State Univ, Inst Environm Hlth Sci, 2727 2nd Ave, Detroit, MI 48201 USA.	john.reiners.jr@wayne.edu	Caruso, Joseph A./U-8429-2019	Caruso, Joseph A./0000-0003-2900-3996	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009392, P30ES006639] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES009392, P30 ES06639] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Becattini B, 2004, CHEM BIOL, V11, P1107, DOI 10.1016/j.chembiol.2004.05.022; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boverhof DR, 2005, TOXICOL SCI, V85, P1048, DOI 10.1093/toxsci/kfi162; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Caruso JA, 2005, BIOCHEM J, V392, P325, DOI 10.1042/BJ20050313; Caruso JA, 2004, MOL PHARMACOL, V65, P1016, DOI 10.1124/mol.65.4.1016; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Colell A, 2002, FEBS LETT, V526, P135, DOI 10.1016/S0014-5793(02)03140-X; Dare E, 2001, FREE RADICAL BIO MED, V30, P1347, DOI 10.1016/S0891-5849(01)00526-3; Duncan DM, 1998, GENE DEV, V12, P1290, DOI 10.1101/gad.12.9.1290; Emert-Sedlak L, 2005, MOL CANCER THER, V4, P733, DOI 10.1158/1535-7163.MCT-04-0301; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Harzer K, 2003, FEBS LETT, V537, P177, DOI 10.1016/S0014-5793(03)00100-5; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Ishisaka R, 1998, FEBS LETT, V435, P233, DOI 10.1016/S0014-5793(98)01080-1; ISHISAKA R, 2001, J BIOCHEM-TOKYO, V129, P34; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Joiakim A, 2004, MOL PHARMACOL, V66, P936, DOI 10.1124/mol.66.4.936; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LISTER MD, 1995, BBA-LIPID LIPID MET, V1256, P25, DOI 10.1016/0005-2760(94)00249-X; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Neuzil J, 2002, BIOCHEM J, V362, P709, DOI 10.1042/0264-6021:3620709; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; Park KT, 2005, MOL PHARMACOL, V67, P612, DOI 10.1124/mol.104.005223; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Qin HT, 2004, DEV BIOL, V270, P64, DOI 10.1016/j.ydbio.2004.02.004; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sun YV, 2004, NUCLEIC ACIDS RES, V32, P4512, DOI 10.1093/nar/gkh782; Tardy C, 2004, J BIOL CHEM, V279, P52914, DOI 10.1074/jbc.M408261200; Terman A, 2002, EXP CELL RES, V274, P9, DOI 10.1006/excr.2001.5441; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wei MC, 2000, GENE DEV, V14, P2060; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Xue X, 2005, J BIOL CHEM, V280, P33917, DOI 10.1074/jbc.M505818200; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zhang H, 2003, J PHARMACOL EXP THER, V307, P24, DOI 10.1124/jpet.103.050435; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x	70	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10954	10967		10.1074/jbc.M508383200	http://dx.doi.org/10.1074/jbc.M508383200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16446372	hybrid			2022-12-27	WOS:000236822200036
J	Song, F; Zhuang, ZH; Finci, L; Dunaway-Mariano, D; Kniewel, R; Buglino, JA; Solorzano, V; Wu, J; Lima, CD				Song, F; Zhuang, ZH; Finci, L; Dunaway-Mariano, D; Kniewel, R; Buglino, JA; Solorzano, V; Wu, J; Lima, CD			Structure, function, and mechanism of the phenylacetate pathway hot dog-fold thioesterase PaaI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC BENZOATE METABOLISM; PSEUDOMONAS-PUTIDA U; CATABOLIC PATHWAY; 4-HYDROXYBENZOYL-COA THIOESTERASE; MOLECULAR CHARACTERIZATION; AROMATIC-HYDROCARBONS; ESCHERICHIA-COLI; AZOARCUS-EVANSII; BETA-OXIDATION; ACID	The structure and biochemical function of the hot dog-fold thioesterase PaaI operative in the aerobic phenylacetate degradation pathway are examined. PaaI showed modest activity with phenylacetyl-coenzyme A, suggestive of a role in coenzyme A release from this pathway intermediate in the event of limiting downstream pathway enzymes. Minimal activity was observed with aliphatic acyl-coenzyme A thioesters, which ruled out PaaI function in the lower phenylacetate pathway. PaaI was most active with ring-hydroxylated phenylacetyl-coenzyme A thioesters. The x-ray crystal structure of the Escherichia coli thioesterase is reported and analyzed to define the structural basis of substrate recognition and catalysis. The contributions of catalytic and substrate binding residues, thus, identified were examined through steady-state kinetic analysis of site-directed mutant proteins.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	University of New Mexico; Memorial Sloan Kettering Cancer Center; Cornell University	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	dd39@unm.edu		Kniewel, Ryan/0000-0003-3462-6450; Lima, Christopher/0000-0002-9163-6092	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688, P50GM062529] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28688, 1P50GM62529] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO MJ, 1988, J ANTIBIOT, V41, P1074, DOI 10.7164/antibiotics.41.1074; Alonso S, 2003, GENE, V319, P71, DOI 10.1016/S0378-1119(03)00794-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartolome-Martin D, 2004, GENE, V341, P167, DOI 10.1016/j.gene.2004.06.042; Boyd DR, 2005, CHEM COMMUN, P3989, DOI 10.1039/b506944k; Boyd DR, 2005, ORG BIOMOL CHEM, V3, P1953, DOI 10.1039/b502009c; Boyd DR, 2004, ORG BIOMOL CHEM, V2, P2530, DOI 10.1039/b409149c; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAUDHRY GR, 1991, MICROBIOL REV, V55, P59, DOI 10.1128/MMBR.55.1.59-79.1991; D'Annibale A, 2005, BIOTECHNOL BIOENG, V90, P723, DOI 10.1002/bit.20461; DeLano WL, 2002, PYMOL USERS MANUAL; Diaz E, 2004, INT MICROBIOL, V7, P173; Diaz E, 2001, MICROBIOL MOL BIOL R, V65, P523, DOI 10.1128/MMBR.65.4.523-569.2001; Dillon SC, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-109; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; ERLICH HA, 1991, PCR TECHNOLOGY PRINC; Ferrandez A, 2000, J BIOL CHEM, V275, P12214, DOI 10.1074/jbc.275.16.12214; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; FERSHT A, 1990, STRUCTURE MECH PROTE, P164; Garcia B, 2000, APPL ENVIRON MICROB, V66, P4575, DOI 10.1128/AEM.66.10.4575-4578.2000; Gescher J, 2005, MOL MICROBIOL, V56, P1586, DOI 10.1111/j.1365-2958.2005.04637.x; Gescher J, 2002, J BACTERIOL, V184, P6301, DOI 10.1128/JB.184.22.6301-6315.2002; Gibson J, 2002, ANNU REV MICROBIOL, V56, P345, DOI 10.1146/annurev.micro.56.012302.160749; HAGGBLOM MM, 1992, FEMS MICROBIOL LETT, V103, P29; Haller T, 2000, BIOCHEMISTRY-US, V39, P4622, DOI 10.1021/bi992888d; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Ismail W, 2003, EUR J BIOCHEM, V270, P3047, DOI 10.1046/j.1432-1033.2003.03683.x; Jimenez JI, 2002, ENVIRON MICROBIOL, V4, P824, DOI 10.1046/j.1462-2920.2002.00370.x; Johnson GR, 2003, APPL MICROBIOL BIOT, V62, P110, DOI 10.1007/s00253-003-1341-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komives T, 2005, Z NATURFORSCH C, V60, P179; Kunishima N, 2005, J MOL BIOL, V352, P212, DOI 10.1016/j.jmb.2005.07.008; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; Luo LS, 2001, BIOCHEMISTRY-US, V40, P15684, DOI 10.1021/bi011536f; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MERKEL SM, 1989, J BACTERIOL, V171, P1; Mohamed ME, 2000, J BACTERIOL, V182, P286, DOI 10.1128/JB.182.2.286-294.2000; Mohamed MES, 2002, ARCH MICROBIOL, V178, P180, DOI 10.1007/s00203-002-0438-y; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parales RE, 2004, CURR OPIN BIOTECH, V15, P374, DOI 10.1016/j.copbio.2004.06.003; Peres C M, 2000, Biotechnol Annu Rev, V6, P197, DOI 10.1016/S1387-2656(00)06023-3; Poppe L, 2005, ANGEW CHEM INT EDIT, V44, P3668, DOI 10.1002/anie.200461377; Ramos JL, 2005, CURR OPIN BIOTECH, V16, P275, DOI 10.1016/j.copbio.2005.03.010; Ren Y, 2004, J BIOL CHEM, V279, P11042, DOI 10.1074/jbc.M310032200; Rost R, 2002, MOL GENET GENOMICS, V267, P656, DOI 10.1007/s00438-002-0699-9; Samanta SK, 2002, TRENDS BIOTECHNOL, V20, P243, DOI 10.1016/S0167-7799(02)01943-1; SCHOLTEN JD, 1991, SCIENCE, V253, P182, DOI 10.1126/science.1853203; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THEILACKER W, 1950, LIEBIGS ANN CHEM, V570, P15; Thoden JB, 2003, J BIOL CHEM, V278, P43709, DOI 10.1074/jbc.M308198200; Thoden JB, 2002, J BIOL CHEM, V277, P27468, DOI 10.1074/jbc.M203904200; Yu WF, 2004, J BIOL CHEM, V279, P52160, DOI 10.1074/jbc.M409640200; Zaar A, 2004, MOL MICROBIOL, V54, P223, DOI 10.1111/j.1365-2958.2004.04263.x; Zaar A, 2001, J BIOL CHEM, V276, P24997, DOI 10.1074/jbc.M100291200; Zhang CL, 2005, APPL MICROBIOL BIOT, V67, P600, DOI 10.1007/s00253-004-1864-3; ZHUANG Z, 2003, THESIS U NEW MEXICO; Zhuang ZH, 2004, J BACTERIOL, V186, P393, DOI 10.1128/JB.186.2.393-399.2004; Zhuang ZH, 2003, APPL ENVIRON MICROB, V69, P2707, DOI 10.1128/AEM.69.5.2707-2711.2003; Zhuang ZH, 2002, BIOCHEMISTRY-US, V41, P11152, DOI 10.1021/bi0262303	69	54	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11028	11038		10.1074/jbc.M513896200	http://dx.doi.org/10.1074/jbc.M513896200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464851	hybrid			2022-12-27	WOS:000236822200044
J	Vidi, PA; Kanwischer, M; Baginsky, S; Austin, JR; Csucs, G; Dormann, P; Kessler, F; Brehelin, C				Vidi, PA; Kanwischer, M; Baginsky, S; Austin, JR; Csucs, G; Dormann, P; Kessler, F; Brehelin, C			Tocopherol cyclase (VTE1) localization and vitamin E accumulation in chloroplast plastoglobule lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; ALLENE OXIDE SYNTHASE; 9-CIS-EPOXYCAROTENOID DIOXYGENASE GENE; CHROMOPLAST-SPECIFIC PROTEINS; CAROTENOID-ASSOCIATED PROTEIN; MOLECULAR CHARACTERIZATION; PLASTOQUINONE SYNTHESIS; ARABIDOPSIS MUTANT; ALPHA-TOCOPHEROL; IMPORT RECEPTOR	Chloroplasts contain lipoprotein particles termed plastoglobules. Plastoglobules are generally believed to have little function beyond lipid storage. Here we report on the identification of plastoglobule proteins using mass spectrometry methods in Arabidopsis thaliana. We demonstrate specific plastoglobule association of members of the plastid lipid-associated proteins/fibrillin family as well as known metabolic enzymes, including the tocopherol cyclase (VTE1), a key enzyme of tocopherol ( vitamin E) synthesis. Moreover, comparative analysis of chloroplast membrane fractions shows that plastoglobules are a site of vitamin E accumulation in chloroplasts. Thus, in addition to their lipid storage function, we propose that plastoglobules are metabolically active, taking part in tocopherol synthesis and likely other pathways.	Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, CH-2007 Neuchatel, Switzerland; Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany; Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Univ Chicago, Chicago, IL 60637 USA; Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	University of Neuchatel; Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Chicago; Swiss Federal Institutes of Technology Domain; ETH Zurich	Kessler, F (corresponding author), Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, Emile Argand 11, CH-2007 Neuchatel, Switzerland.	felix.kessler@unine.ch	Kessler, Felix Henrique/AAO-1722-2020	Kessler, Felix/0000-0001-6409-5043; Brehelin, Claire/0000-0002-1889-9582; Baginsky, Sacha/0000-0002-5440-3898; Kanwischer, Marion/0000-0002-2317-0112; Vidi, Pierre-Alexandre/0000-0002-9117-8896				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Bailey JL, 1963, BIOCHIM BIOPHYS ACTA, V78, P163; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bondada BR, 2003, TREE PHYSIOL, V23, P553, DOI 10.1093/treephys/23.8.553; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Chen HC, 1998, PLANT J, V14, P317, DOI 10.1046/j.1365-313X.1998.00127.x; Chen XJ, 2002, PLANT CELL, V14, P641, DOI 10.1105/tpc.010336; Cheng ZG, 2003, PLANT CELL, V15, P2343, DOI 10.1105/tpc.013656; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; DERUERE J, 1994, BIOCHEM BIOPH RES CO, V199, P1144, DOI 10.1006/bbrc.1994.1350; DERUERE J, 1994, PLANT CELL, V6, P119, DOI 10.1105/tpc.6.1.119; Eymery F, 1999, PLANT PHYSIOL BIOCH, V37, P305, DOI 10.1016/S0981-9428(99)80029-1; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Froehlich JE, 2001, PLANT PHYSIOL, V125, P306, DOI 10.1104/pp.125.1.306; Ghosh S, 2001, PLANT PHYSIOL BIOCH, V39, P777, DOI 10.1016/S0981-9428(01)01296-7; Gillet B, 1998, PLANT J, V16, P257, DOI 10.1046/j.1365-313x.1998.00292.x; GREENWOOD AD, 1963, BIOCHIM BIOPHYS ACTA, V78, P148, DOI 10.1016/0006-3002(63)91620-2; Guiamet JJ, 1999, PLANT CELL PHYSIOL, V40, P986, DOI 10.1093/oxfordjournals.pcp.a029632; Havaux M, 2003, PLANT PHYSIOL, V132, P300, DOI 10.1104/pp.102.017178; Havaux M, 2005, PLANT CELL, V17, P3451, DOI 10.1105/tpc.105.037036; Hernandez-Pinzon I, 1999, PLANTA, V208, P588, DOI 10.1007/s004250050597; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Kanwischer M, 2005, PLANT PHYSIOL, V137, P713, DOI 10.1104/pp.104.054908; Kaup MT, 2002, PLANT PHYSIOL, V129, P1616, DOI 10.1104/pp.003087; Kessler F, 1999, PLANTA, V208, P107, DOI 10.1007/s004250050540; Kim HU, 2001, PLANT PHYSIOL, V126, P330, DOI 10.1104/pp.126.1.330; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Laizet Y., 2004, J GENOME SCI TECHNOL, V3, P19, DOI DOI 10.1166/GL.2004.038; Langenkamper G, 2001, J EXP BOT, V52, P1545, DOI 10.1093/jexbot/52.360.1545; Laudert D, 1998, PLANT J, V15, P675, DOI 10.1046/j.1365-313x.1998.00245.x; Laudert D, 1996, PLANT MOL BIOL, V31, P323, DOI 10.1007/BF00021793; LICHTENT.HK, 1967, PLANTA, V72, P1; LICHTENTHALER HK, 1968, ENDEAVOUR, V27, P144; LICHTENTHALER HK, 1966, Z NATURFORSCH PT B, VB 21, P690; Locy RD, 1996, PLANT PHYSIOL, V110, P321, DOI 10.1104/pp.110.1.321; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; Michelis R, 2000, PLANT MOL BIOL, V44, P487, DOI 10.1023/A:1026528319769; Monte E, 1999, PLANT J, V19, P399, DOI 10.1046/j.1365-313X.1999.00537.x; NEWMAN LA, 1989, PLANT PHYSIOL, V91, P455, DOI 10.1104/pp.91.2.455; Otegui MS, 2001, PLANT CELL, V13, P2033, DOI 10.1105/tpc.13.9.2033; Porfirova S, 2002, P NATL ACAD SCI USA, V99, P12495, DOI 10.1073/pnas.182330899; PozuetaRomero J, 1997, PLANT PHYSIOL, V115, P1185, DOI 10.1104/pp.115.3.1185; Provencher LM, 2001, PLANT CELL, V13, P1127, DOI 10.1105/tpc.13.5.1127; Pruvot G, 1996, PHYSIOL PLANTARUM, V97, P123, DOI 10.1111/j.1399-3054.1996.tb00488.x; Qin XQ, 2002, PLANT PHYSIOL, V128, P544, DOI 10.1104/pp.010663; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Rey P, 2000, PLANT J, V21, P483, DOI 10.1046/j.1365-313x.2000.00699.x; Sattler SE, 2003, PLANT PHYSIOL, V132, P2184, DOI 10.1104/pp.103.024257; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; Shabanowitz J, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P163; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shintani D, 1998, SCIENCE, V282, P2098, DOI 10.1126/science.282.5396.2098; SOLL J, 1985, ARCH BIOCHEM BIOPHYS, V238, P290, DOI 10.1016/0003-9861(85)90167-5; SOLL J, 1987, METHOD ENZYMOL, V148, P383; SOLL J, 1980, FEBS LETT, V112, P243, DOI 10.1016/0014-5793(80)80189-X; SPREY B, 1966, Z NATURFORSCH PT B, VB 21, P697; STEINMULLER D, 1985, PLANTA, V163, P201, DOI 10.1007/BF00393507; Tan BC, 2003, PLANT J, V35, P44, DOI 10.1046/j.1365-313X.2003.01786.x; TEVINI M, 1985, PLANTA, V163, P91, DOI 10.1007/BF00395902; THOMPSON JN, 1979, J LIQ CHROMATOGR, V2, P327, DOI 10.1080/01483917908060067; THOMSON WW, 1966, BOT GAZ, V127, P133, DOI 10.1086/336354; Ting JTL, 1998, PLANT J, V16, P541, DOI 10.1046/j.1365-313x.1998.00325.x; Van Eenennaam AL, 2003, PLANT CELL, V15, P3007, DOI 10.1105/tpc.015875; Vishnevetsky M, 1996, PLANT J, V10, P1111, DOI 10.1046/j.1365-313X.1996.10061111.x; Vishnevetsky M, 1999, PLANT J, V20, P423, DOI 10.1046/j.1365-313x.1999.00615.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wu SSH, 1997, P NATL ACAD SCI USA, V94, P12711, DOI 10.1073/pnas.94.23.12711	73	229	258	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11225	11234		10.1074/jbc.M511939200	http://dx.doi.org/10.1074/jbc.M511939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16414959	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000236822200066
J	Wijewickrama, GT; Kim, JH; Kim, YJ; Abraham, A; Oh, YS; Ananthanarayanan, B; Kwatia, M; Ackerman, SJ; Cho, W				Wijewickrama, GT; Kim, JH; Kim, YJ; Abraham, A; Oh, YS; Ananthanarayanan, B; Kwatia, M; Ackerman, SJ; Cho, W			Systematic evaluation of transcellular activities of secretory phospholipases A(2) - High activity of group V phospholipases A(2) to induce eicosanoid biosynthesis in neighboring inflammatory cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HUMAN GROUP-IIA; HUMAN NEUTROPHILS; LEUKOTRIENE BIOSYNTHESIS; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; GROUP-IV; BINDING; EOSINOPHIL; GENERATION	The mechanisms by which secretory phospholipase A(2) (PLA(2)) exerts cellular effects are not fully understood. To elucidate these mechanisms, we systematically and quantitatively assessed the activities of human group IIA, V, and X PLA(2)s on originating and neighboring cells using orthogonal fluorogenic substrates in various mixed cell systems. When HEK293 cells stably expressing each of these PLA(2)s were mixed with non-transfected HEK293 cells, group V and X PLA(2)s showed strong transcellular lipolytic activity, whereas group IIA PLA(2) exhibited much lower transcellular activity. The transcellular activity of group V PLA(2) was highly dependent on the presence of cell surface heparan sulfate proteoglycans of acceptor cells. Activation of RBL-2H3 and DLD-1 cells that express endogenous group V PLA(2) led to the secretion of group V PLA(2) and its transcellular action on neighboring human neutrophils and eosinophils, respectively. Similarly, activation of human bronchial epithelial cells, BEAS-2B, caused large increases in arachidonic acid and leukotriene C-4 release from neighboring human eosinophils. Collectively, these studies show that group V and X PLA(2)s can act transcellularly on mammalian cells and suggest that group V PLA(2) released from neighboring cells may function in triggering the activation of inflammatory cells under physiological conditions.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu			NCRR NIH HHS [M01-RR-13987] Funding Source: Medline; NIAID NIH HHS [AI25230] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR013987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Du J, 2000, J BIOL CHEM, V275, P33167, DOI 10.1074/jbc.M003655200; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hendrickson HS, 1999, ANAL BIOCHEM, V276, P27, DOI 10.1006/abio.1999.4280; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Jawien J, 2002, J PHYSIOL PHARMACOL, V53, P127; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koprivnjak T, 2002, J BIOL CHEM, V277, P47636, DOI 10.1074/jbc.M205104200; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2000, HYBRIDOMA, V19, P171, DOI 10.1089/02724570050031220; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Munoz NM, 2002, J IMMUNOL METHODS, V262, P41, DOI 10.1016/S0022-1759(01)00573-7; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Murakami M, 1997, FEBS LETT, V413, P249, DOI 10.1016/S0014-5793(97)00916-2; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Sato M, 1997, INT ARCH ALLERGY IMM, V113, P203, DOI 10.1159/000237547; Sexton DW, 2002, CLIN EXP ALLERGY, V32, P811, DOI 10.1046/j.1365-2745.2002.01428.x; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; VADAS P, 1986, LAB INVEST, V55, P391; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Walsh GM, 2001, CLIN EXP ALLERGY, V31, P351, DOI 10.1046/j.1365-2222.2001.01032.x; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	47	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10935	10944		10.1074/jbc.M512657200	http://dx.doi.org/10.1074/jbc.M512657200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476735	hybrid			2022-12-27	WOS:000236822200034
J	Aglipay, JA; Martin, SA; Tawara, H; Lee, SW; Ouchi, T				Aglipay, JA; Martin, SA; Tawara, H; Lee, SW; Ouchi, T			ATM activation by ionizing radiation requires BRCA1-associated BAAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; TELANGIECTASIA MUTATED ATM; DNA-DAMAGE RESPONSE; BRCA1 PHOSPHORYLATION; OVARIAN-CANCER; DEPENDENT PHOSPHORYLATION; GENE BRCA1; PROTEIN; COMPLEX; KINASE	ATM ( ataxia telangiectasia mutated) is required for the early response to DNA-damaging agents such as ionizing radiation (IR) that induce DNA double-strand breaks. Cells deficient in ATM are extremely sensitive to IR. It has been shown that IR induces immediate phosphorylation of ATM at Ser(1981), leading to catalytic activation of the protein. We recently isolated a novel BRCA1-associated protein, BAAT1 (BRCA1-associated protein required for ATM activation-1), by yeast two-hybrid screening and found that BAAT1 also binds to ATM, localizes to double-strand breaks, and is required for Ser(1981) phosphorylation of ATM. Small interfering RNA-mediated stable or transient reduction of BAAT1 resulted in decreased phosphorylation of both ATM at Ser(1981) and CHK2 at Thr(68). Treatment of BAAT1-depleted cells with okadaic acid greatly restored phosphorylation of ATM at Ser(1981), suggesting that BAAT1 is involved in the regulation of ATM phosphatase. Protein phosphatase 2A-mediated dephosphorylation of ATM was partially blocked by purified BAAT1 in vitro. Significantly, acute loss of BAAT1 resulted in increased p53, leading to apoptosis. These results demonstrate that DNA damage-induced ATM activation requires a coordinated assembly of BRCA1, BAAT1, and ATM.	NYU, Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Icahn School of Medicine at Mount Sinai; New York University; Harvard University; Massachusetts General Hospital	Ouchi, T (corresponding author), NYU, Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,POB 1130, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu		Martin, Sarah/0000-0003-3321-6601	NATIONAL CANCER INSTITUTE [R01CA090631, R01CA079892, P01CA080058, R01CA078356, R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM064148] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79892, R01 CA08568, R01 CA078356, R01CA90631, P01 CA80058, R24CA095823] Funding Source: Medline; NIGMS NIH HHS [F31 GM64148-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CHAMBERLAIN JS, 1993, AM J HUM GENET, V52, P792; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Chun HH, 2004, BIOCHEM BIOPH RES CO, V322, P74, DOI 10.1016/j.bbrc.2004.07.085; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Martin SA, 2005, CANCER RES, V65, P10657, DOI 10.1158/0008-5472.CAN-05-2087; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mochan TA, 2003, CANCER RES, V63, P8586; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Venkitaraman AR, 2004, NAT REV CANCER, V4, P266, DOI 10.1038/nrc1321; WU X, 1999, NAT GENET, V22, P37; Xu B, 2002, CANCER RES, V62, P4588	41	34	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9710	9718		10.1074/jbc.M510332200	http://dx.doi.org/10.1074/jbc.M510332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452482	hybrid			2022-12-27	WOS:000236404700083
J	da Costa, CA; Dunys, J; Brau, F; Wilk, S; Cappai, R; Checler, F				da Costa, CA; Dunys, J; Brau, F; Wilk, S; Cappai, R; Checler, F			6-hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; DOPAMINERGIC NEURONAL DEATH; INCLUSION-BODY FORMATION; PARKINSONS-DISEASE; CELL-DEATH; WILD-TYPE; MOLECULAR PATHWAYS; PROTECTS; MUTATION; MICE	We established previously that alpha-synuclein displayed a protective anti-apoptotic phenotype in neurons, mainly by down-regulating p53-dependent caspase-3 activation (Alves da Costa, C., Ancolio, K., and Checler, F. ( 2000) J. Biol. Chem. 275, 24065 - 24069; Alves da Costa, C., Paitel, E., Vincent, B., and Checler, F. ( 2002) J. Biol. Chem. 277, 50980 50984). This function was abolished by Parkinson disease-linked pathogenic mutations and by the dopaminergic toxin, 6-hydroxydopamine (6OH-DOPA)( Alves da Costa, C., Paitel, E., Vincent, B., and Checler, F. ( 2002) J. Biol. Chem. 277, 50980 - 50984). However, the mechanisms by which 6OH-DOPA interfered with alpha-synuclein function remained unclear. Here we showed that 6OH-DOPA prevents alpha-synuclein-mediated anti-apoptotic function by altering its degradation. Thus, 6OH-DOPA-treatment of TSM1 neurons and SH-SY5Y neuroblastoma cells enhances endogenous alpha-synuclein-like immunoreactivity and inhibits the catabolism of endogenous and recombinant alpha-synucleins by purified 20 S proteasome. Furthermore, we demonstrated that 6OH-DOPA directly inhibits endogenous proteasomal activity in TSM1 and SH-SY5Y cells and also blocks purified proteasome activity in vitro. This inhibitory effect can be prevented by the anti-oxidant phenyl-N-butylnitrone. We also established that 6OH-DOPA triggers the aggregation of recombinant alpha-synuclein in vitro. Therefore, we conclude that 6OH-DOPA abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation, thereby increasing its intracellular concentration and potential propensity to aggregation, the latter phenomenon being directly exacerbated by 6OH-DOPA itself. Interestingly, 1-methyl-4-phenylpyridinium (MPP+), another toxin inducer of Parkinson disease-like pathology, does not affect alpha-synuclein protective function and fails to trigger aggregation of recombinant alpha-synuclein. Furthermore, MPP+ does not alter cellular proteasomal activity, and only high concentrations of the toxin affect purified 20 S proteasome by a mechanism that remains insensitive to phenyl-N-butylnitrone. The drastically distinct effects of 6OH-DOPA and MPP+ on alpha-synuclein function are discussed with respect to Parkinson disease pathology and animal models mimicking this pathology.	CNRS, IPMC, UMR6097, Equipe Labellisee FRM, F-06560 Valbonne, France; CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Univ Melbourne, Ctr Neurosci, Dept Pathol, Parkville, Vic 3010, Australia	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Melbourne	da Costa, CA (corresponding author), CNRS, IPMC, UMR6097, Equipe Labellisee FRM, 660 Route Lucioles, F-06560 Valbonne, France.	acosta@ipmc.cnrs.fr; checler@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011; Cappai, Roberto/B-3347-2010	Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X; Cappai, Roberto/0000-0002-9505-8496				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Barzilai A, 2003, TRENDS MOL MED, V9, P126, DOI 10.1016/S1471-4914(03)00020-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Biasini E, 2004, J NEUROCHEM, V88, P545, DOI 10.1046/j.1471-4159.2003.02152.x; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Blum D, 1997, BRAIN RES, V751, P139, DOI 10.1016/S0006-8993(96)01358-3; Bradbury J, 2003, LANCET NEUROL, V2, P715, DOI 10.1016/S1474-4422(03)00601-X; Cappai R, 2005, FASEB J, V19, P1377, DOI 10.1096/fj.04-3437fje; Carr J, 2003, PARKINSONISM RELAT D, V9, P201, DOI 10.1016/S1353-8020(02)00048-2; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Checler F., 1993, TEC BEHAV N 2, P375; Choi WS, 1999, EXP NEUROL, V159, P274, DOI 10.1006/exnr.1999.7133; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fioriti L, 2005, J BIOL CHEM, V280, P11320, DOI 10.1074/jbc.M412441200; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hirata H, 1997, J NEUROCHEM, V69, P780; Hirsch EC, 1999, MOVEMENT DISORD, V14, P383, DOI 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Jensen PJ, 2003, J NEUROCHEM, V86, P196, DOI 10.1046/j.1471-4159.2003.01835.x; Kaul S, 2005, MOL BRAIN RES, V139, P137, DOI 10.1016/j.molbrainres.2005.05.022; Kitamura Y, 1998, MOL PHARMACOL, V54, P1046, DOI 10.1124/mol.54.6.1046; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Li WX, 2005, J NEUROCHEM, V93, P1542, DOI 10.1111/j.1471-4159.2005.03146.x; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lotharius J, 1999, J NEUROSCI, V19, P1284; Manning-Bog AB, 2003, J NEUROSCI, V23, P3095; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nicotra A, 2000, TOXICOLOGY, V153, P157, DOI 10.1016/S0300-483X(00)00311-5; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Pan TH, 2005, FEBS LETT, V579, P6716, DOI 10.1016/j.febslet.2005.10.067; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; Serra PA, 2002, J BIOL CHEM, V277, P34451, DOI 10.1074/jbc.M202099200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; von Bohlen und Halbach O, 2004, PROG NEUROBIOL, V73, P151, DOI 10.1016/j.pneurobio.2004.05.002; Wang XX, 2002, J NEUROCHEM, V83, P1094, DOI 10.1046/j.1471-4159.2002.01224.x; WILK S, 2001, CURRENT PROTOCOLS PR; Windisch M, 2002, J MOL NEUROSCI, V19, P63, DOI 10.1007/s12031-002-0012-8; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	67	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9824	9831		10.1074/jbc.M513903200	http://dx.doi.org/10.1074/jbc.M513903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464850	hybrid			2022-12-27	WOS:000236404700095
J	Fujioka, A; Terai, K; Itoh, RE; Aoki, K; Nakamura, T; Kuroda, S; Nishida, E; Matsuda, M				Fujioka, A; Terai, K; Itoh, RE; Aoki, K; Nakamura, T; Kuroda, S; Nishida, E; Matsuda, M			Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPATIOTEMPORAL CONTROL; SIGNAL-TRANSDUCTION; NUCLEAR EXPORT; KINASE CASCADE; PROTEIN; RAS; EGF; ERK; PHOSPHORYLATION; MECHANISMS	To comprehend the Ras/ERK MAPK cascade, which comprises Ras, Raf, MEK, and ERK, several kinetic simulation models have been developed. However, a large number of parameters that are essential for the development of these models are still missing and need to be set arbitrarily. Here, we aimed at collecting these missing parameters using fluorescent probes. First, the levels of the signaling molecules were quantitated. Second, to monitor both the activation and nuclear translocation of ERK, we developed probes based on the principle of fluorescence resonance energy transfer. Third, the dissociation constants of Ras.Raf, Raf.MEK, and MEK.ERK complexes were estimated using a fluorescent tag that can be highlighted very rapidly. Finally, the same fluorescent tag was used to measure the nucleocytoplasmic shuttling rates of ERK and MEK. Using these parameters, we developed a kinetic simulation model consisting of the minimum essential members of the Ras/ERK MAPK cascade. This simple model reproduced essential features of the observed activation and nuclear translocation of ERK. In this model, the concentration of Raf significantly affected the levels of phospho-MEK and phospho-ERK upon stimulation. This prediction was confirmed experimentally by decreasing the level of Raf using the small interfering RNA technique. This observation verified the usefulness of the parameters collected in this study.	Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Informat Sci & Technol, Undergrad Program Bioinformat & Syst Biol, Bunkyo Ku, Tokyo 1130033, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Osaka University; University of Tokyo; Kyoto University	Matsuda, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	matsudam@biken.osaka-u.ac.jp	Aoki, Kazuhiro/I-5483-2019; Aoki, Kazuhiro/B-5777-2013; 寺井, 健太/AFQ-7663-2022	Aoki, Kazuhiro/0000-0001-7263-1555; Aoki, Kazuhiro/0000-0001-7263-1555; 寺井, 健太/0000-0001-7638-3720; Matsuda, Michiyuki/0000-0002-5876-9969; Itoh, Reina/0000-0001-6385-7886				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bhalla US, 2004, BIOPHYS J, V87, P745, DOI 10.1529/biophysj.104.040501; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Brightman FA, 2000, FEBS LETT, V482, P169, DOI 10.1016/S0014-5793(00)02037-8; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Day RN, 2005, MOL ENDOCRINOL, V19, P1675, DOI 10.1210/me.2005-0028; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Hailey DW, 2002, METHOD ENZYMOL, V351, P34; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Terai K, 2005, EMBO REP, V6, P251, DOI 10.1038/sj.embor.7400349; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Yamada S, 2004, BIOCHEM BIOPH RES CO, V314, P1113, DOI 10.1016/j.bbrc.2004.01.009; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	44	242	248	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8917	8926		10.1074/jbc.M509344200	http://dx.doi.org/10.1074/jbc.M509344200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16418172	hybrid			2022-12-27	WOS:000236247100072
J	Li, ZH; Dai, J; Dai, LJ; Deng, MC; Zhu, Z; Hu, WJ; Liang, SP				Li, ZH; Dai, J; Dai, LJ; Deng, MC; Zhu, Z; Hu, WJ; Liang, SP			Function and solution structure of huwentoxin-X, a specific blocker of N-type calcium channels, from the Chinese bird spider Ornithoctonus huwena	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-CONOTOXIN GVIA; SELENOCOSMIA-HUWENA; CA2+ CHANNELS; HAINANTOXIN-IV; PEPTIDE TOXINS; VENOM; AFFINITY; RELEASE; ANTINOCICEPTION; IDENTIFICATION	Huwentoxin-X (HWTX-X) is a novel peptide toxin, purified from the venom of the spider Ornithoctonus huwena. It comprises 28 amino acid residues including six cysteine residues as disulfide bridges linked in the pattern of I - IV, II - V, and III - VI. Its cDNA, determined by rapid amplification of 3' and 5' cDNA ends, encodes a 65-residue prepropeptide. HWTX-X shares low sequence homology with omega-conotoxins GVIA and MVIIA, two well known blockers of N-type Ca2+ channels. Nevertheless, whole cell studies indicate that it can block N-type Ca2+ channels in rat dorsal root ganglion cells (IC50 40 nM) and the blockage by HWTX-X is completely reversible. The rank order of specificity for N-type Ca2+ channels is GVIA approximate to HWTX- X > MVIIA. In contrast to GVIA and MVIIA, HWTX- X had no detectable effect on the twitch response of rat vas deferens to low frequency electrical stimulation, indicating that HWTX- X has different selectivity for isoforms of N-type Ca2+ channels, compared with GVIA or MVIIA. A comparison of the structures of HWTX- X and GVIA reveals that they not only adopt a common structural motif ( inhibitor cystine knot), but also have a similar functional motif, a binding surface formed by the critical residue Tyr, and several basic residues. However, the dissimilarities of their binding surfaces provide some insights into their different selectivities for isoforms of N-type Ca2+ channels.	Peking Univ, Coll Life Sci, Beijing 100087, Peoples R China; Hunan Normal Univ, Coll Life Sci, Hunan 410081, Peoples R China	Peking University; Hunan Normal University	Liang, SP (corresponding author), Peking Univ, Coll Life Sci, Beijing 100087, Peoples R China.	liangsp@hunnu.edu.cn						Adams DJ, 2003, J BIOL CHEM, V278, P4057, DOI 10.1074/jbc.M209969200; Altier C, 2004, TRENDS PHARMACOL SCI, V25, P465, DOI 10.1016/j.tips.2004.07.004; Bernard C, 2001, BIOCHEMISTRY-US, V40, P12795, DOI 10.1021/bi015537j; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Corzo G, 2001, FEBS LETT, V499, P256, DOI 10.1016/S0014-5793(01)02558-3; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; Diao JB, 2003, TOXICON, V42, P715, DOI 10.1016/j.toxicon.2003.08.007; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Feng ZP, 2001, J BIOL CHEM, V276, P15728, DOI 10.1074/jbc.M100406200; Garber K, 2005, NAT BIOTECHNOL, V23, P399, DOI 10.1038/nbt0405-399; Gelly JC, 2004, NUCLEIC ACIDS RES, V32, pD156, DOI 10.1093/nar/gkh015; Hansson K, 2004, J BIOL CHEM, V279, P32453, DOI 10.1074/jbc.M313825200; HERTZ A, 2001, BIOCHEMISTRY-US, V40, P7973; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hu ZH, 1997, J PHYSIOL-LONDON, V501, P67, DOI 10.1111/j.1469-7793.1997.067bo.x; ISABELLE MM, 1991, P NATL ACAD SCI USA, V88, P6628; Kaneko S, 2002, J NEUROSCI, V22, P82, DOI 10.1523/JNEUROSCI.22-01-00082.2002; KIM JI, 1994, J BIOL CHEM, V269, P23876; Lew MJ, 1997, J BIOL CHEM, V272, P12014, DOI 10.1074/jbc.272.18.12014; Lewis RJ, 2000, J BIOL CHEM, V275, P35335, DOI 10.1074/jbc.M002252200; Li DL, 2004, J BIOL CHEM, V279, P37734, DOI 10.1074/jbc.M405765200; Liang SP, 2000, TOXICON, V38, P1237, DOI 10.1016/S0041-0101(99)00224-X; Liang SP, 2004, TOXICON, V43, P575, DOI 10.1016/j.toxicon.2004.02.005; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Liu Z, 2003, CELL MOL LIFE SCI, V60, P972, DOI 10.1007/s00018-003-2354-x; Lu SY, 1999, J PROTEIN CHEM, V18, P609, DOI 10.1023/A:1020663619657; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; Mould J, 2004, J BIOL CHEM, V279, P34705, DOI 10.1074/jbc.M310848200; NADASDI L, 1995, BIOCHEMISTRY-US, V34, P8076, DOI 10.1021/bi00025a013; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Peng K, 2001, TOXICON, V39, P491, DOI 10.1016/S0041-0101(00)00150-1; Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SCROGGS RS, 1992, J PHYSIOL-LONDON, V445, P639, DOI 10.1113/jphysiol.1992.sp018944; Shu Q, 1999, J PEPT RES, V53, P486, DOI 10.1034/j.1399-3011.1999.00039.x; Shu Q, 2002, PROTEIN SCI, V11, P245, DOI 10.1110/ps.30502; Sidach SS, 2000, J NEUROSCI, V20, P7174; Smith MT, 2002, PAIN, V96, P119, DOI 10.1016/S0304-3959(01)00436-5; Tedford HW, 2004, TOXICON, V43, P601, DOI 10.1016/j.toxicon.2004.02.010; Wuthrich K, 1986, NMR PROTEIN NUCL ACI	49	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8628	8635		10.1074/jbc.M513542200	http://dx.doi.org/10.1074/jbc.M513542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16439354	hybrid			2022-12-27	WOS:000236247100040
J	Maliga, Z; Xing, J; Cheung, H; Juszczak, LJ; Friedman, JM; Rosenfeld, SS				Maliga, Z; Xing, J; Cheung, H; Juszczak, LJ; Friedman, JM; Rosenfeld, SS			A pathway of structural changes produced by monastrol binding to eg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC KINESIN EG5; MOTOR PROTEIN; BIPOLAR KINESIN; CROSS-LINKS; INHIBITOR; KSP; CONFORMATIONS; MICROTUBULES; SPECTROSCOPY; MECHANISM	Monastrol is a small molecule inhibitor that is specific for Eg5, a member of the kinesin 5 family of mitotic motors. Crystallographic models of Eg5 in the presence and absence of monastrol revealed that drug binding produces a variety of structural changes in the motor, including in loop L5 and the neck linker. What is not clear from static crystallographic models, however, is the sequence of structural changes produced by drug binding. Furthermore, because crystallographic structures can be influenced by the packing forces in the crystal, it also remains unclear whether these drug-induced changes occur in solution, at physiologically active concentrations of monastrol or of other drugs that target this site. We have addressed these issues by using a series of spectroscopic probes to monitor the structural consequences of drug binding. Our results demonstrated that the crystallographic model of an Eg5-ADP-monastrol ternary complex is consistent with several solution-based spectroscopic probes. Furthermore, the kinetics of these spectroscopic signal changes allowed us to determine the temporal sequence of drug-induced structural transitions. These results suggested that L5 may be an element in the pathway that links the state of the nucleotide-binding site to the neck linker in kinesin motors.	Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; Columbia Univ, Neurol Inst, New York, NY 10032 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Harvard Univ, Program Biophys, Boston, MA 02115 USA	Columbia University; Columbia University; Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham; Harvard University	Rosenfeld, SS (corresponding author), 710 W 168th St,Rm 204, New York, NY 10032 USA.	sr2327@columbia.edu						Asbury CL, 2005, CURR OPIN CELL BIOL, V17, P89, DOI 10.1016/j.ceb.2004.12.002; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Brier S, 2004, BIOCHEMISTRY-US, V43, P13072, DOI 10.1021/bi049264e; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; COLE DG, 1994, J BIOL CHEM, V269, P22913; Cox CD, 2005, BIOORG MED CHEM LETT, V15, P2041, DOI 10.1016/j.bmcl.2005.02.055; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; HEIDECKER M, 1995, BIOCHEMISTRY-US, V34, P11017, DOI 10.1021/bi00035a007; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Juszczak LJ, 1998, J RAMAN SPECTROSC, V29, P963, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<963::AID-JRS332>3.0.CO;2-4; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; KINOSITA K, 1982, BIOPHYS J, V37, P461, DOI 10.1016/S0006-3495(82)84692-4; Luo LS, 2004, BIOCHEMISTRY-US, V43, P15258, DOI 10.1021/bi048282t; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MIURA T, 1989, J RAMAN SPECTROSC, V20, P667, DOI 10.1002/jrs.1250201007; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; Rosenfeld SS, 2005, J BIOL CHEM, V280, P35684, DOI 10.1074/jbc.M506561200; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Wordeman L, 2005, CURR OPIN CELL BIOL, V17, P82, DOI 10.1016/j.ceb.2004.12.003; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	33	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7977	7982		10.1074/jbc.M511955200	http://dx.doi.org/10.1074/jbc.M511955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434397	hybrid			2022-12-27	WOS:000236031000034
J	Qin, CL; Huang, BZ; Wygant, JN; McIntyre, BW; McDonald, CH; Cook, RG; Butler, WT				Qin, CL; Huang, BZ; Wygant, JN; McIntyre, BW; McDonald, CH; Cook, RG; Butler, WT			A chondroitin sulfate chain attached to the bone dentin matrix protein 1 NH2-terminal fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PHOSPHOPROTEIN; SIBLING PROTEINS; IN-VIVO; SIALOPROTEIN; EXPRESSION; GENE; IDENTIFICATION; SEQUENCE; BIOMINERALIZATION; PROTEOGLYCANS	Dentin matrix protein 1 (DMP1) is an acidic noncollagenous protein shown by gene ablations to be critical for the proper mineralization of bone and dentin. In the extracellular matrix of these tissues DMP1 is present as fragments representing the NH2-terminal (37 kDa) and COOH-terminal (57 kDa) portions of the cDNA-deduced amino acid sequence. During our separation of bone noncollagenous proteins, we observed a high molecular weight, DMP1-related component (designated DMP1-PG). We purified DMP1-PG with a monoclonal anti-DMP1 antibody affinity column. Amino acid analysis and Edman degradation of tryptic peptides proved that the core protein for DMP1-PG is the 37-kDa fragment of DMP1. Chondroitinase treatments demonstrated that the slower migration rate of DMP1-PG is due to the presence of glycosaminoglycan. Quantitative disaccharide analysis indicated that the glycosaminoglycan is made predominantly of chondroitin 4-sulfate. Further analysis on tryptic peptides led us to conclude that a single glycosaminoglycan chain is linked to the core protein via Ser(74), located in the Ser(74)-Gly(75) dipeptide, an amino acid sequence specific for the attachment of glycosaminoglycans. Our findings show that in addition to its existence as a phosphoprotein, the NH2-terminal fragment from DMP1 occurs as a proteoglycan. Amino acid sequence alignment analysis showed that the Ser(74)-Gly(75) dipeptide and its flanking regions are highly conserved among a wide range of species from caiman to the Homo sapiens, indicating that this glycosaminoglycan attachment domain has survived an extremely long period of evolution pressure, suggesting that the glycosaminoglycan may be critical for the basic biological functions of DMP1.	Univ Texas, Hlth Sci Ctr, Dept Endodont, Dent Branch, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Prot Chem Core Lab, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Qin, CL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Endodont, Dent Branch, MD Anderson Blvd,DBB,Ste 307, Houston, TX 77030 USA.	Chunlin.Qin@uth.tmc.edu			NIDCR NIH HHS [DE 005092] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE005092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005092] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baba O, 2004, EUR J ORAL SCI, V112, P163, DOI 10.1111/j.0909-8836.2004.00110.x; Baba O, 2004, MATRIX BIOL, V23, P371, DOI 10.1016/j.matbio.2004.07.008; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Gluhak-Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; Hirst KL, 1997, J DENT RES, V76, P754, DOI 10.1177/00220345970760030701; Jain A, 2002, J BIOL CHEM, V277, P13700, DOI 10.1074/jbc.M110757200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kulkarni GV, 2000, ARCH ORAL BIOL, V45, P475, DOI 10.1016/S0003-9969(00)00010-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Ogbureke KUE, 2005, KIDNEY INT, V68, P155, DOI 10.1111/j.1523-1755.2005.00389.x; Ogbureke KUE, 2004, J DENT RES, V83, P664, DOI 10.1177/154405910408300902; Prydz K, 2000, J CELL SCI, V113, P193; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Qin CL, 2003, J BIOL CHEM, V278, P34700, DOI 10.1074/jbc.M305315200; Qin CL, 2003, EUR J ORAL SCI, V111, P235, DOI 10.1034/j.1600-0722.2003.00043.x; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; RODEN L, 1985, FED PROC, V44, P373; ROUGHLEY PJ, 2003, PROTEOLYCANS LUNG DI, P4; Tartaix PH, 2004, J BIOL CHEM, V279, P18115, DOI 10.1074/jbc.M314114200; Toyosawa S, 1999, GENE, V234, P307, DOI 10.1016/S0378-1119(99)00195-X; Toyosawa S, 2000, J MOL EVOL, V50, P31, DOI 10.1007/s002399910004; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; Yamakoshi Y, 2005, J BIOL CHEM, V280, P1552, DOI 10.1074/jbc.M409606200; Ye L, 2005, J BIOL CHEM, V280, P6197, DOI 10.1074/jbc.M412911200; Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200	33	64	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8034	8040		10.1074/jbc.M512964200	http://dx.doi.org/10.1074/jbc.M512964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421105	hybrid			2022-12-27	WOS:000236031000040
J	Yao, CJ; Karabasil, MR; Purwanti, N; Li, XF; Akamatsu, T; Kanamori, N; Hosoi, K				Yao, CJ; Karabasil, MR; Purwanti, N; Li, XF; Akamatsu, T; Kanamori, N; Hosoi, K			Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1 beta in the submandibular gland of mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1-BETA CONVERTING-ENZYME; PAROTID ACINAR-CELLS; MURINE MACROPHAGES; GENE FAMILY; INACTIVE PRECURSOR; MOUSE; PRORENIN; CLONING; CDNA; IDENTIFICATION	By using Western blot analysis, high levels of 17.5- and 20-kDa interleukin-1 beta(IL-1 beta) proteins were detected in the submandibular gland(SMG) of mice. Despite this fact, the amount of pro-IL-1 beta protein, a precursor of IL-1 beta, with a molecular size of 35 kDa in this tissue was below the detectable level, although strong expression of pro-IL-1 beta mRNA was observed. A large amount of 17.5- kDa IL-1 beta also appeared in the saliva of mice injected with lipopolysaccharide, suggesting that this IL-1 beta is a secretory form produced by the SMG. The protein for IL-1 beta-converting enzyme, a processing enzyme for pro-IL-1 beta, was expressed only at a low level in the SMG as compared with its level in various epithelial tissues or lipopolysaccharide-stimulated macrophages. On the other hand, mK1, mK9, mK13, and mK22, members of the kallikrein family, were detected strongly in the SMG but not in other tissues. By incubation with mK13, but not with mK1, mK9, or mK22, the 35-kDa pro-IL-1 beta was cleaved into two major products with molecular masses of 17.5 and 22 kDa, and production was inhibited by phenylmethylsulfonyl fluoride, a serine protease inhibitor, but not by IL-1 beta-converting enzyme inhibitors. A peptide segment corresponding to amino acid residues 107-121 of mouse pro-IL-1 beta ((WDDDDNLLVCDVPIR)-W-107) was cleaved by incubation with mK13, generating two peptides, (WDDDDNL)-W-107 and (LVCDVPIR)-L-114. Therefore, kallikrein mK13 would appear to hydrolyze pro-IL-1 beta between its Leu(113) and Leu(114) residues. The results of immunohistochemistry and an autonomic therapy experiment showed that IL-1 beta and kallikrein mK13 were co-localized in the secretory granules of granular convoluted tubular cells. Our present results thus suggest kallikrein mK13 is a plausible candidate for the processing enzyme for pro-IL-1 beta in the SMG of mice.	Univ Tokushima, Grad Sch, Dept Mol Oral Physiol, Tokushima 7708504, Japan	Tokushima University	Hosoi, K (corresponding author), Univ Tokushima, Grad Sch, Dept Mol Oral Physiol, 3-18-15 Kuramoto Cho, Tokushima 7708504, Japan.	hosoi@dent.tokushima-u.ac.jp		Hosoi, Kazuo/0000-0001-5165-5056				ADUCCI P, 2004, HDB PROTEOLYTIC ENZY, P1847; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; Berg T, 1992, Agents Actions Suppl, V38 ( Pt 1), P19; BEUSCHER HU, 1990, J IMMUNOL, V144, P2179; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BLACK RA, 1989, J BIOL CHEM, V264, P5323; BLACK RA, 1988, J BIOL CHEM, V263, P9437; Brough D, 2003, J IMMUNOL, V170, P3029, DOI 10.4049/jimmunol.170.6.3029; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DAVID GP, 2002, J IMMUNOL, V168, P3024; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Fantuzzi G, 1997, J IMMUNOL, V158, P1818; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOSOI K, 1978, CAN J PHYSIOL PHARM, V56, P634, DOI 10.1139/y78-101; HOSOI K, 1983, ARCH ORAL BIOL, V28, P5, DOI 10.1016/0003-9969(83)90020-1; HOSOI K, 1983, BIOCHIM BIOPHYS ACTA, V756, P163, DOI 10.1016/0304-4165(83)90088-0; HOSOI K, 1994, J BIOCHEM-TOKYO, V115, P137, DOI 10.1093/oxfordjournals.jbchem.a124288; HOSOI K, 2004, HDB PROTEOLYTIC ENZY, P1599; Kikkawa Y, 1998, BBA-PROTEIN STRUCT M, V1382, P55, DOI 10.1016/S0167-4838(97)00144-1; KIM WS, 1990, J BIOL CHEM, V265, P5930; KIM WS, 1991, J BIOL CHEM, V266, P19283; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; Kurabuchi S, 1999, HISTOCHEM J, V31, P19, DOI 10.1023/A:1003506302065; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MILLER BE, 1995, J IMMUNOL, V154, P1331; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; Tanda N, 1998, AM J PHYSIOL-GASTR L, V274, pG147, DOI 10.1152/ajpgi.1998.274.1.G147; TAYLOR JM, 1970, P NATL ACAD SCI USA, V67, P164, DOI 10.1073/pnas.67.1.164; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Yamakawa M, 2000, J HISTOCHEM CYTOCHEM, V48, P1033, DOI 10.1177/002215540004800802; Yao CJ, 2005, IMMUNOLOGY, V116, P213, DOI 10.1111/j.1365-2567.2005.02212.x; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; Yousef GM, 2000, BIOCHEM BIOPH RES CO, V276, P125, DOI 10.1006/bbrc.2000.3448; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	43	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7968	7976		10.1074/jbc.M507705200	http://dx.doi.org/10.1074/jbc.M507705200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16423834	hybrid			2022-12-27	WOS:000236031000033
J	Arnold, JN; Wallis, R; Willis, AC; Harvey, DJ; Royle, L; Dwek, RA; Rudd, PM; Sim, RB				Arnold, JN; Wallis, R; Willis, AC; Harvey, DJ; Royle, L; Dwek, RA; Rudd, PM; Sim, RB			Interaction of mannan binding lectin with alpha(2) macroglobulin via exposed oligomannose glycans - A conserved feature of the thiol ester protein family?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C1S-LIKE SERINE-PROTEASE; COMPLEMENT COMPONENT C3; ALPHA-2-MACROGLOBULIN; COMPLEXES; PATHWAY; GLYCOSYLATION; ACTIVATION; MBL; ASSOCIATION; INHIBITORS	The serum collectin mannan-binding lectin (MBL) binds to oligomannose and GlcNAc-terminating glycans present on microorganisms. Using a commercial affinity chromatography resin containing immobilized MBL we screened human and mouse serum for endogenous MBL-binding targets. We isolated the serum protease inhibitor alpha(2) macroglobulin (alpha 2M), a heavily glycosylated thiol ester protein (TEP) composed of four identical 180-kDa subunits, each of which has eight N-linked glycosylation sites. alpha 2M has previously been reported to interact with MBL; however, the interaction was not characterized. We investigated the mechanism of formation of complexes between alpha 2M and MBL and concluded that they form by the direct binding of oligomannose glycans Man(5-7) occupying Asn-846 on alpha 2M to the lectin domains ( carbohydrate recognition domains) of MBL. The oligomannose glycans are accessible for lectin binding on both active alpha 2M ( thiol ester intact) and protease-cleaved alpha 2M( thiol ester cleaved). We demonstrate that MBL is able to interact with alpha 2M in the fluid phase, but the interaction does not inhibit the binding of MBL to mannan-coated surfaces. In addition to alpha 2M, two other members of the TEP family, C3 and C4, which also contain oligomannose glycans, were captured from human serum using the MBL resin. MBL binding may be a conserved feature of the TEPs, dating from their ancestral origins. We suggest that the inhibition of proteases on the surface of microorganisms by an ancestral alpha 2M-like TEP may generate "arrays" of oligomannose glycans to which MBL or other lectins can bind. Binding would lead to opsonization or activation of enzyme systems such as complement.	Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England; Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HH, Leics, England	University of Oxford; University of Oxford; University of Leicester	Sim, RB (corresponding author), Univ Oxford, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	bob.sim@bioch.ox.ac.uk	Sim, Bob/A-1354-2008; Arnold, James/ABE-3900-2021; Harvey, David/A-5579-2013	Sim, Bob/0000-0002-2855-7455; Arnold, James/0000-0002-6949-0613; Wallis, Russell/0000-0002-8705-5295; Harvey, David/0000-0003-0544-771X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; ARAKAWA H, 1989, J BIOL CHEM, V264, P2350; Arnold JN, 2005, J BIOL CHEM, V280, P29080, DOI 10.1074/jbc.M504528200; Arnold JN, 2004, J IMMUNOL, V173, P6831, DOI 10.4049/jimmunol.173.11.6831; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; Crispin MDM, 2004, FEBS LETT, V566, P270, DOI 10.1016/j.febslet.2004.04.045; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Dodds AW, 2002, IMMUNOBIOLOGY, V205, P340, DOI 10.1078/0171-2985-00137; GONIAS SL, 1983, J BIOL CHEM, V258, P4682; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Hajela K, 2002, IMMUNOBIOLOGY, V205, P467, DOI 10.1078/0171-2985-00147; HARPEL PC, 1983, ANN NY ACAD SCI, V421, P1, DOI 10.1111/j.1749-6632.1983.tb18088.x; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Holmskov U, 1996, FEBS LETT, V393, P314, DOI 10.1016/0014-5793(96)00915-5; HOWARD JB, 1983, ANN NY ACAD SCI, V421, P160, DOI 10.1111/j.1749-6632.1983.tb18106.x; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Kolodziej SJ, 2002, J BIOL CHEM, V277, P28031, DOI 10.1074/jbc.M202714200; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Lahteenmaki K, 2001, FEBS LETT, V504, P69, DOI 10.1016/S0014-5793(01)02775-2; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Nyberg P, 2004, J BIOL CHEM, V279, P52820, DOI 10.1074/jbc.C400485200; Petersen SV, 2000, MOL IMMUNOL, V37, P803, DOI 10.1016/S0161-5890(01)00004-9; Presanis JS, 2004, MOL IMMUNOL, V40, P921, DOI 10.1016/j.molimm.2003.10.013; Qazi U, 2000, J STRUCT BIOL, V131, P19, DOI 10.1006/jsbi.2000.4269; Qazi U, 1999, J BIOL CHEM, V274, P8137, DOI 10.1074/jbc.274.12.8137; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; Ritchie GE, 2002, CHEM REV, V102, P305, DOI 10.1021/cr990294a; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SIM RB, 1981, BIOCHEM J, V193, P129, DOI 10.1042/bj1930129; SIM RB, 1979, BIOCHEM J, V179, P449, DOI 10.1042/bj1790449a; SOLIS D, 1994, J BIOL CHEM, V269, P11555; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1985, P NATL ACAD SCI USA, V82, P9, DOI 10.1073/pnas.82.1.9; STORGAARD P, 1995, SCAND J IMMUNOL, V42, P373, DOI 10.1111/j.1365-3083.1995.tb03670.x; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; TERAI I, 1995, INT IMMUNOL, V7, P1579, DOI 10.1093/intimm/7.10.1579; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Wong NKH, 1999, MOL IMMUNOL, V36, P853, DOI 10.1016/S0161-5890(99)00106-6	53	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6955	6963		10.1074/jbc.M511432200	http://dx.doi.org/10.1074/jbc.M511432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407218	hybrid			2022-12-27	WOS:000236030900007
J	Kim, EA; Noh, YT; Ryu, MJ; Kim, HT; Lee, SE; Kim, CH; Lee, C; Kim, YH; Choi, CY				Kim, EA; Noh, YT; Ryu, MJ; Kim, HT; Lee, SE; Kim, CH; Lee, C; Kim, YH; Choi, CY			Phosphorylation and transactivation of Pax6 by homeodomain-interacting protein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED-DOMAIN; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; GENE-TRANSCRIPTION; P300 COACTIVATOR; CRYSTALLIN GENES; EYE DEVELOPMENT; NEURONAL FATE; MOUSE; P53	Pax6 is a transcriptional activator that contains two DNA binding domains and a potent transcription activation domain in the C terminus, which regulates organogenesis of the eye, nose, pancreas, and central nervous system. Homeodomain-interacting protein kinase 2 (HIPK2) interacts with transcription factors, including homeoproteins, and regulates activities of transcription factors. Here we show that HIPK2 phosphorylates the activation domain of Pax6, which augments Pax6 transactivation by enhancing its interaction with p300. Mass spectrometric analysis identified three Pax6 phosphorylation sites as threonines 281, 304, and 373. The substitutions of these threonines with alanines decreased Pax6 transactivation, whereas substitutions to glutamic acids increased transactivation in mimicry of phosphorylation. Furthermore, the knock-down of either endogenous or exogenous HIPK2 expression with HIPK2 shRNA markedly inhibited Pax6 phosphorylation and its transactivating function on proglucagon promoter in cultured cells. These results strongly indicate that HIPK2 is an upstream protein kinase for Pax6 and suggest that it modulates Pax6-mediated transcriptional regulation.	Digital Biotech, Ansan 425839, South Korea; Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea; Korea Inst Sci & Technol, Div Life Sci, Seoul 136791, South Korea; Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Univ Hawaii, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA	Sungkyunkwan University (SKKU); Korea Institute of Science & Technology (KIST); Chungnam National University; University of Hawaii System	Kim, YH (corresponding author), Digital Biotech, 1227 Shingildong, Ansan 425839, South Korea.	youngho@digitalbiotech.com; choicy@skku.ac.kr	Lee, Sung-Eun/E-3786-2015	Lee, Sung-Eun/0000-0001-7690-9956; Kim, Cheol-Hee/0000-0002-3019-0699				Andersen FG, 1999, FEBS LETT, V445, P315, DOI 10.1016/S0014-5793(99)00144-1; Ashery-Padan R, 2004, DEV BIOL, V269, P479, DOI 10.1016/j.ydbio.2004.01.040; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chan HM, 2001, J CELL SCI, V114, P2363; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 2005, J BIOL CHEM, V280, P21427, DOI 10.1074/jbc.M500496200; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Chow RL, 1999, DEVELOPMENT, V126, P4213; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Favor J, 2001, GENETICS, V159, P1689; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Hanson I, 1999, HUM MOL GENET, V8, P165, DOI 10.1093/hmg/8.2.165; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jun S, 1996, DEVELOPMENT, V122, P2639; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; Li YH, 2005, DIABETES, V54, P482, DOI 10.2337/diabetes.54.2.482; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Mishra R, 2002, J BIOL CHEM, V277, P49488, DOI 10.1074/jbc.M206478200; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Onuma Y, 2002, P NATL ACAD SCI USA, V99, P2020, DOI 10.1073/pnas.022626999; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; Raska CS, 2002, ANAL CHEM, V74, P3429, DOI 10.1021/ac0111199; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; Simpson TI, 2002, BIOESSAYS, V24, P1041, DOI 10.1002/bies.10174; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Singh S, 2000, J BIOL CHEM, V275, P17306, DOI 10.1074/jbc.M000359200; Sisodiya SM, 2001, NAT GENET, V28, P214, DOI 10.1038/90042; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tabb DL, 2003, ANAL CHEM, V75, P1155, DOI 10.1021/ac026122m; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Tholey A, 1999, J MASS SPECTROM, V34, P117, DOI 10.1002/(SICI)1096-9888(199902)34:2<117::AID-JMS769>3.0.CO;2-V; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; Wawersik S, 2000, HUM MOL GENET, V9, P917, DOI 10.1093/hmg/9.6.917; Yang Y, 2004, J MOL BIOL, V344, P351, DOI 10.1016/j.jmb.2004.07.102	51	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7489	7497		10.1074/jbc.M507227200	http://dx.doi.org/10.1074/jbc.M507227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407227	hybrid			2022-12-27	WOS:000236030900071
J	Kuwasako, K; Cao, YN; Chu, CP; Iwatsubo, S; Eto, T; Kitamura, K				Kuwasako, K; Cao, YN; Chu, CP; Iwatsubo, S; Eto, T; Kitamura, K			Functions of the cytoplasmic tails of the human receptor activity-modifying protein components of calcitonin gene-related peptide and adrenomedullin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST BINDING; UBIQUITINATION; ENDOCYTOSIS; MOTIF; INTERNALIZATION; IDENTIFICATION; TRAFFICKING; SUFFICIENT; TRANSPORT; TERMINUS	Receptor activity-modifying proteins (RAMPs) enable calcitonin receptor-like receptor (CRLR) to function as a calcitonin gene-related peptide receptor (CRLR/RAMP1) or an adrenomedullin ( AM) receptor (CRLR/RAMP2 or - 3). Here we investigated the functions of the cytoplasmic C-terminal tails (C-tails) of human RAMP1, - 2, and - 3 (hRAMP1, - 2, and - 3) by cotransfecting their C-terminal deletion or progressive truncation mutants into HEK-293 cells stably expressing hCRLR. Deletion of the C-tail from hRAMP1 had little effect on the surface expression, function, or intracellular trafficking of the mutant heterodimers. By contrast, deletion of the C-tail from hRAMP2 disrupted transport of hCRLR to the cell surface, resulting in significant reductions in I-125-hAM binding and evoked cAMP accumulation. The transfection efficiency for the hRAMP2 mutant was comparable with that for wildtype hRAMP2; moreover, immunocytochemical analysis showed that the mutant hRAMP2 remained within the endoplasmic reticulum. FACS analysis revealed that deleting the C-tail from hRAMP3 markedly enhances AM-evoked internalization of the mutant heterodimers, although there was no change in agonist affinity. Truncating the C-tails by removing the six C-terminal amino acids of hRAMP2 and - 3 or exchanging their C-tails with one another had no effect on surface expression, agonist affinity, or internalization of hCRLR, which suggests that the highly conserved Ser-Lys sequence within hRAMP C-tails is involved in cellular trafficking of the two AM receptors. Notably, deleting the respective C-tails from hRAMPs had no effect on lysosomal sorting of hCRLR. Thus, the respective C-tails of hRAMP2 and - 3 differentially affect hCRLR surface delivery and internalization.	Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan; Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan	University of Miyazaki; University of Miyazaki	Kuwasako, K (corresponding author), Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan.	kuwasako@fc.miyazaki-med.ac.jp	Kuwasako, Kenji/H-8065-2016					Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Bomberger JM, 2005, J BIOL CHEM, V280, P23926, DOI 10.1074/jbc.M501751200; Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200; Cao YN, 2005, BIOCHEM BIOPH RES CO, V332, P866, DOI 10.1016/j.bbrc.2005.05.034; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Eto T, 2001, PEPTIDES, V22, P1693, DOI 10.1016/S0196-9781(01)00513-7; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fitzsimmons TJ, 2003, J BIOL CHEM, V278, P14313, DOI 10.1074/jbc.M211946200; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hay DL, 2006, PHARMACOL THERAPEUT, V109, P173, DOI 10.1016/j.pharmthera.2005.06.015; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hilaire S, 2001, J BIOL CHEM, V276, P42182, DOI 10.1074/jbc.M107323200; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Kuwasako K, 2004, PEPTIDES, V25, P2003, DOI 10.1016/j.peptides.2004.06.002; Kuwasako K, 2004, MOL PHARMACOL, V65, P207, DOI 10.1124/mol.65.1.207; Kuwasako K, 2003, J BIOL CHEM, V278, P22623, DOI 10.1074/jbc.M302571200; Kuwasako K, 2002, FEBS LETT, V519, P113, DOI 10.1016/S0014-5793(02)02721-7; Kuwasako K, 2001, J BIOL CHEM, V276, P49459, DOI 10.1074/jbc.M108369200; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Muff R, 2003, HYPERTENS RES, V26, pS3, DOI 10.1291/hypres.26.S3; Nagoshi Y, 2004, BIOCHEM BIOPH RES CO, V314, P1057, DOI 10.1016/j.bbrc.2004.01.004; Nagoshi Y, 2002, EUR J PHARMACOL, V450, P237, DOI 10.1016/S0014-2999(02)02184-2; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Xu JH, 1999, J BIOL CHEM, V274, P19095, DOI 10.1074/jbc.274.27.19095	44	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7205	7213		10.1074/jbc.M511147200	http://dx.doi.org/10.1074/jbc.M511147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410241	hybrid			2022-12-27	WOS:000236030900037
J	Ishihara, Y; Shimamoto, N				Ishihara, Y; Shimamoto, N			Involvement of endonuclease G in nucleosomal DNA fragmentation under sustained endogenous oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; PEROXIDE-INDUCED APOPTOSIS; CASPASE-ACTIVATED DNASE; PROGRAMMED CELL-DEATH; HYDROGEN-PEROXIDE; HEPATOCYTE APOPTOSIS; DEOXYRIBONUCLEASE-II; REDOX REGULATION; PRIMARY CULTURES; FREE-RADICALS	We have previously shown that inhibition of catalase and glutathione peroxidase activities by 3-amino-1,2,4-triazole (ATZ) and mercaptosuccinic acid (MS), respectively, in rat primary hepatocytes caused sustained endogenous oxidative stress and apoptotic cell death without caspase-3 activation. In this study, we investigated the mechanism of this apoptotic cell death in terms of nucleosomal DNA fragmentation. Treatment with ATZ + MS time-dependently increased the number of deoxynucleotidyl transferase-mediated nickend-labeling (TUNEL)-positive nuclei from 12 h, resulting in clear DNA laddering at 24 h. The deoxyribonuclease ( DNase) inhibitor, aurintricarboxylic acid (ATA), completely inhibited nucleosomal DNA fragmentation but the pan-caspase inhibitor, z-VAD-fmk was without effects; furthermore, the cleavage of inhibitor of caspase-activated DNase was not detected, indicating the involvement of DNase(s) other than caspase-activated DNase. Considering that endonuclease G (EndoG) reportedly acts in a caspase-independent manner, we cloned rat EndoG cDNA for the first time. Recombinant EndoG alone digested plasmid DNA and induced nucleosomal DNA fragmentation in isolated hepatocyte nuclei. Recombinant EndoG activity was inhibited by ATA but not by hydrogen peroxide, even at 10 mM. ATZ + MS stimulation elicited decreases in mitochondrial membrane potential and EndoG translocation from mitochondria to nuclei. By applying RNA interference, the mRNA levels of EndoG were almost completely suppressed and the amount of EndoG protein was decreased to approximately half the level of untreated cells. Under these conditions, decreases in TUNEL-positive nuclei were significantly suppressed. These results indicate that EndoG is responsible, at least in part, for nucleosomal DNA fragmentation under endogenous oxidative stress conditions induced by ATZ + MS.	Tokushima Bunri Univ, Fac Pharmaceut Sci, Kagawa 7692193, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5328686, Japan	Tokushima Bunri University; Osaka University	Shimamoto, N (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Kagawa Campus,1314-1 Shido, Kagawa 7692193, Japan.	n-shimamoto@kph.bunri-u.ac.jp	Ishihara, Yasuhiro/U-6511-2017	Ishihara, Yasuhiro/0000-0001-9751-7660				Adachi T, 2005, HEPATOLOGY, V41, P1272, DOI 10.1002/hep.20719; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Djordjevic VB, 2004, INT REV CYTOL, V237, P57, DOI 10.1016/S0074-7696(04)37002-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Galli F, 2005, CONTRIB NEPHROL, V149, P240, DOI 10.1159/000085686; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HAROSH I, 1991, EUR J BIOCHEM, V202, P479, DOI 10.1111/j.1432-1033.1991.tb16397.x; Ishihara Y, 2005, FREE RADICAL RES, V39, P163, DOI 10.1080/10715760500043231; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; Kanno S, 2000, BIOL PHARM BULL, V23, P37; Katoh S, 1999, BIOCHEM J, V338, P465, DOI 10.1042/0264-6021:3380465; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kim HA, 2002, BIOCHEM BIOPH RES CO, V295, P937, DOI 10.1016/S0006-291X(02)00789-1; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Lee SJ, 2005, BRIT J PHARMACOL, V145, P469, DOI 10.1038/sj.bjp.0706206; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liao J, 2005, MED HYPOTHESES, V65, P23, DOI 10.1016/j.mehy.2005.01.028; LUTTER LC, 1979, NUCLEIC ACIDS RES, V6, P41, DOI 10.1093/nar/6.1.41; MASLANSKY CJ, 1982, IN VITRO CELL DEV B, V18, P683; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; MIYAZAKI M, 1985, EXP CELL RES, V159, P176, DOI 10.1016/S0014-4827(85)80047-1; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Prats E, 1997, DNA CELL BIOL, V16, P1111, DOI 10.1089/dna.1997.16.1111; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Schafer P, 2004, J MOL BIOL, V338, P217, DOI 10.1016/j.jmb.2004.02.069; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shiba D, 1999, FREE RADICAL BIO MED, V27, P1019, DOI 10.1016/S0891-5849(99)00150-1; Shih CM, 2004, J CELL BIOCHEM, V91, P384, DOI 10.1002/jcb.10761; Shiokawa D, 2001, BIOCHEMISTRY-US, V40, P143, DOI 10.1021/bi001041a; Shiokawa D, 1998, BIOCHEM J, V332, P713, DOI 10.1042/bj3320713; Sloviter RS, 2002, TRENDS PHARMACOL SCI, V23, P19, DOI 10.1016/S0165-6147(00)01867-8; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; Steinbeck MJ, 1998, J CELL PHYSIOL, V176, P574, DOI 10.1002/(SICI)1097-4652(199809)176:3<574::AID-JCP14>3.0.CO;2-#; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki YJ, 2003, ANTIOXID REDOX SIGN, V5, P741, DOI 10.1089/152308603770380043; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447; TIRANTI V, 1995, GENOMICS, V25, P559, DOI 10.1016/0888-7543(95)80058-T; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xu Y, 1997, AM J PHYSIOL-GASTR L, V273, pG795, DOI 10.1152/ajpgi.1997.273.4.G795; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; YASUDA T, 1992, BIOCHIM BIOPHYS ACTA, V1119, P185, DOI 10.1016/0167-4838(92)90390-Y; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zheng YH, 2005, ONCOGENE, V24, P3339, DOI 10.1038/sj.onc.1208484; Zhou X, 2000, J IMMUNOL, V165, P1252, DOI 10.4049/jimmunol.165.3.1252	69	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6726	6733		10.1074/jbc.M510382200	http://dx.doi.org/10.1074/jbc.M510382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407272	hybrid			2022-12-27	WOS:000236030800070
J	Alfalah, M; Krahn, MP; Wetzel, G; von Horsten, S; Wolke, C; Hooper, N; Kalinski, T; Krueger, S; Naim, HY; Lendeckel, U				Alfalah, M; Krahn, MP; Wetzel, G; von Horsten, S; Wolke, C; Hooper, N; Kalinski, T; Krueger, S; Naim, HY; Lendeckel, U			A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; VASOACTIVE PEPTIDES; CYTOMEGALOVIRUS-INFECTION; METHIONINE-ENKEPHALIN; ALANYL AMINOPEPTIDASE; CYSTIC-FIBROSIS; MOLECULAR-BASIS; EXPRESSION; METABOLISM; DEGRADATION	Human aminopeptidase N (APN) is used as a routine marker for myelomonocytic cells in hematopoietic malignant disorders. Its gene and surface expressions are increased in cases of malignant transformation, inflammation, or T cell activation, whereas normal B and resting T cells lack detectable APN protein expression. In this study we elucidated the intracellular distribution, expression pattern, and enzymatic activity of a naturally occurring mutation in the coding region of the APN gene. At physiological temperatures the mutant protein is enzymatically inactive, persists as a mannose-rich polypeptide in the endoplasmic reticulum, and is ultimately degraded by an endoplasmic reticulum-associated degradation pathway. It shows in part the distinct behavior of a temperature-sensitive mutant with a permissive temperature of 32 degrees C, leading to correct sorting of the Golgi compartment accompanied by the acquisition of proper glycosylation but without reaching the cell-surface membrane and without regaining its enzymatic activity. Because the patient bearing this mutation suffered from leukemia, possible links to the pathogenesis of leukemia are discussed.	Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany; Hannover Med Sch, Dept Funct & Appl Anat, D-30625 Hannover, Germany; Otto Von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany	University of Veterinary Medicine Hannover, Foundation; Hannover Medical School; Otto von Guericke University; University of Leeds; Otto von Guericke University	Alfalah, M (corresponding author), Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.	Marwan.Alfalah@tiho-hannover.de	Lendeckel, Uwe/Q-6922-2016; von Hörsten, Stephan/G-9005-2015; Al Falah, Dr. Marwan/C-6281-2011; Krahn, Michael/AAD-4476-2022	Lendeckel, Uwe/0000-0002-0684-9959; von Hörsten, Stephan/0000-0001-6409-0664; Krahn, Michael/0000-0001-7718-9890; Hooper, Nigel/0000-0002-5811-3484				AHMAD S, 1992, J PHARMACOL EXP THER, V260, P1257; Barnes K, 1997, J NEUROCHEM, V68, P570; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; BNAK U, 2006, IN PRESS ADV EXP MED, V575; Chansel D, 1998, AM J PHYSIOL-RENAL, V275, pF535, DOI 10.1152/ajprenal.1998.275.4.F535; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DELMAS B, 1993, ADV EXP MED BIOL, V342, P293; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dong X, 2000, J IMMUNOL, V164, P129, DOI 10.4049/jimmunol.164.1.129; DREXLER HG, 1991, LEUKEMIA, V5, P637; Esapa CT, 2005, HUM MOL GENET, V14, P295, DOI 10.1093/hmg/ddi026; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Firla B, 2002, FREE RADICAL BIO MED, V32, P584, DOI 10.1016/S0891-5849(01)00827-9; FUJII H, 1995, CLIN EXP METASTAS, V13, P337; FURUHASHI M, 1988, EXP CLIN ENDOCRINOL, V92, P235, DOI 10.1055/s-0029-1210807; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GIROS B, 1986, MOL PHARMACOL, V29, P281; HOFFMANN T, 1993, FEBS LETT, V336, P61, DOI 10.1016/0014-5793(93)81609-4; Ino K, 1995, ANTICANCER RES, V15, P2081; IWAHASHI M, 1994, ANTICANCER RES, V14, P1563; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JACOB R, 1994, J BIOL CHEM, V269, P2712; KANAYAMA N, 1995, J LEUKOCYTE BIOL, V57, P129, DOI 10.1002/jlb.57.1.129; Kasman LM, 2005, VIROLOGY, V334, P1, DOI 10.1016/j.virol.2005.01.028; Kowalski Jan, 1995, Archivum Immunologiae et Therapiae Experimentalis, V43, P265; Krueger S, 2006, J BIOL CHEM, V281, P2868, DOI 10.1074/jbc.m511053200; Larsen SL, 1996, J EXP MED, V184, P183, DOI 10.1084/jem.184.1.183; Larsson S, 1998, TRANSPLANTATION, V65, P411, DOI 10.1097/00007890-199802150-00021; Lendeckel U, 1999, INT J MOL MED, V4, P17; LENDECKEL U, 1994, CELL IMMUNOL, V153, P214, DOI 10.1006/cimm.1994.1019; Lendeckel U, 1996, BIOCHEM J, V319, P817, DOI 10.1042/bj3190817; LUCIUS R, 1995, J NEUROCHEM, V64, P1841; Mathe G, 1987, Cancer Detect Prev Suppl, V1, P445; MATSUSHITA A, 1994, INT J HEMATOL, V60, P157; MILLER BC, 1994, REGUL PEPTIDES, V50, P87, DOI 10.1016/0167-0115(94)90194-5; MILLER BC, 1994, ARCH BIOCHEM BIOPHYS, V311, P174, DOI 10.1006/abbi.1994.1223; Mina-Osorio P, 2005, J LEUKOCYTE BIOL, V77, P1008, DOI 10.1189/jlb.1204714; MIZUTANI S, 1993, RES COMMUN CHEM PATH, V82, P65; Moffatt S, 2005, HUM GENE THER, V16, P57, DOI 10.1089/hum.2005.16.57; Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004; OKAMURA T, 1992, ACTA HAEMATOL-BASEL, V87, P94; PALMIERI FE, 1985, BIOCHEM PHARMACOL, V34, P2309, DOI 10.1016/0006-2952(85)90787-7; PALMIERI FE, 1989, BIOCHEM PHARMACOL, V38, P173, DOI 10.1016/0006-2952(89)90165-2; PINTO A, 1991, ANN ONCOL, V2, P107, DOI 10.1093/annonc/2.suppl_2.107; Propsting MJ, 2003, J BIOL CHEM, V278, P16310, DOI 10.1074/jbc.C300093200; Ron I, 2005, HUM MOL GENET, V14, P2387, DOI 10.1093/hmg/ddi240; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; Sakuraya M, 2000, J INT MED RES, V28, P214, DOI 10.1177/147323000002800503; Sato Y, 2004, BIOL PHARM BULL, V27, P772, DOI 10.1248/bpb.27.772; Sawafuji K, 2003, LEUKEMIA LYMPHOMA, V44, P1987, DOI 10.1080/1042819031000122033; Shen S, 2004, VIROLOGY, V326, P288, DOI 10.1016/j.virol.2004.06.016; SHIBANOKI S, 1991, REGUL PEPTIDES, V32, P267, DOI 10.1016/0167-0115(91)90020-H; SHIMAMURA M, 1988, BRAIN RES, V445, P350, DOI 10.1016/0006-8993(88)91197-3; SHIMAMURA M, 1991, J BIOCHEM-TOKYO, V109, P492, DOI 10.1093/oxfordjournals.jbchem.a123409; SODERBERG C, 1993, J VIROL, V67, P6576; WARD PE, 1990, BIOCHEM PHARMACOL, V40, P1725, DOI 10.1016/0006-2952(90)90348-O; Woodhead VE, 2000, INT IMMUNOL, V12, P1051, DOI 10.1093/intimm/12.7.1051; YAMAGISHI H, 1991, BIOMED PHARMACOTHER, V45, P117, DOI 10.1016/0753-3322(91)90131-C; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; [No title captured]	62	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11894	11900		10.1074/jbc.M511364200	http://dx.doi.org/10.1074/jbc.M511364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16469741	hybrid			2022-12-27	WOS:000236988100057
J	Syeda, F; Grosjean, J; Houliston, RA; Keogh, RJ; Carter, TD; Paleolog, E; Wheeler-Jones, CPD				Syeda, F; Grosjean, J; Houliston, RA; Keogh, RJ; Carter, TD; Paleolog, E; Wheeler-Jones, CPD			Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappa B pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; THROMBIN; EXPRESSION; PHOSPHORYLATION; TRANSACTIVATION; TRANSCRIPTION; INHIBITION; SIGNAL; BETA	The functional significance of protease-activated receptors (PARs) in endothelial cells is largely undefined, and the intracellular consequences of their activation are poorly understood. Here, we show that the serine protease thrombin, a PAR-1-selective peptide (TFLLRN), and SLIGKV ( PAR-2-selective peptide) induce cyclooxygenase-2 (COX-2) protein and mRNA expression in human endothelial cells without modifying COX-1 expression. COX-2 induction was accompanied by sustained production of 6-keto-PGF(1 alpha), the stable hydrolysis product of prostacyclin, and this was inhibited by indomethacin and the COX-2-selective inhibitor NS398. PAR-1 and PAR-2 stimulation rapidly activated both ERK1/2 and p38(MAPK), and pharmacological blockade of MEK with either PD98059 or U0126 or of p38(MAPK) by SB203580 or SB202190 strongly inhibited thrombin- and SLIGKV-induced COX-2 expression and 6-keto-PGF(1 alpha) formation. Thrombin and peptide agonists of PAR-1 and PAR-2 increased luciferase activity in human umbilical vein endothelial cells infected with an NF-kappa B-dependent luciferase reporter adenovirus, and this, as well as PAR-induced 6-keto-PGF(1 alpha) synthesis, was inhibited by co-infection with adenovirus encoding wild-type or mutated (Y42F) I kappa B alpha. Thrombin- and SLIGKV-induced COX-2 expression and 6-keto-PGF(1 alpha) generation were markedly attenuated by the NF-kappa B inhibitor PG490 and partially inhibited by the proteasome pathway inhibitor MG-132. Activation of PAR-1 or PAR-2 promoted nuclear translocation and phosphorylation of p65-NF-kappa B, and thrombin- induced but not PAR-2-induced p65-NF-kappa B phosphorylation was reduced by inhibition of MEK or p38MAPK. Activation of PAR-4 by AYPGKF increased phosphorylation of ERK1/2 and p38MAPK without modifying NF-kappa B activation or COX-2 induction. Our data show that PAR-1 and PAR-2, but not PAR-4, are coupled with COX-2 expression and sustained endothelial production of vasculoprotective prostacyclin by mechanisms that depend on ERK1/2, p38(MAPK), and I kappa B alpha-dependent NF-kappa B activation.	Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, London W6 8LH, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Surg Oncol Reprod Biol & Anaesthet, London W6 8LH, England; Natl Inst Med Res, London NW7 1AA, England	University of London; University of London Royal Veterinary College; Imperial College London; University of Oxford; Imperial College London; MRC National Institute for Medical Research	Wheeler-Jones, CPD (corresponding author), Univ London Royal Vet Coll, Dept Vet Basic Sci, Royal Coll St, London NW1 0TU, England.	cwheeler@rvc.ac.uk	Carter, Tom/E-5035-2016	Carter, Tom/0000-0002-6248-7278	Medical Research Council [MC_U117573808] Funding Source: Medline; MRC [MC_U117573808] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Bretschneider E, 1999, BRIT J PHARMACOL, V126, P1735, DOI 10.1038/sj.bjp.0702509; Bretschneider E, 1997, BIOCHEM BIOPH RES CO, V235, P365, DOI 10.1006/bbrc.1997.6788; Brown M, 2005, AM J PHYSIOL-HEART C, V289, pH466, DOI 10.1152/ajpheart.00170.2004; Brueckmann M, 2005, THROMB HAEMOSTASIS, V93, P743, DOI 10.1160/TH04-08-0511; CARAMORI G, 2004, CURR OPIN INVESTIG D, V11, P1141; Chen J, 2005, J BIOL CHEM, V280, P16354, DOI 10.1074/jbc.M411134200; Chung A, 2005, J THORAC CARDIOV SUR, V129, P782, DOI 10.1016/j.jtcvs.2004.06.049; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Fitzpatrick FA, 2004, CURR PHARM DESIGN, V10, P577, DOI 10.2174/1381612043453144; Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Hollenberg MD, 2005, J PHARMACOL SCI, V97, P8, DOI 10.1254/jphs.FMJ04005X2; Holzhausen M, 2005, J DENT RES, V84, P154, DOI 10.1177/154405910508400209; Houliston RA, 2002, THROMB HAEMOSTASIS, V88, P321; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Kataoka H, 2003, BLOOD, V102, P3224, DOI 10.1182/blood-2003-04-1130; Kawabata A, 2004, J PHARMACOL EXP THER, V309, P1098, DOI 10.1124/jpet.103.061010; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V290, P1470, DOI 10.1006/bbrc.2002.6350; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V294, P1001, DOI 10.1016/S0006-291X(02)00568-5; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Lin CC, 2004, J BIOMED SCI, V11, P377, DOI 10.1159/000077107; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mason JC, 2001, ARTHRITIS RHEUM, V44, P138, DOI 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; May MJ, 1998, AM J PHYSIOL-CELL PH, V274, pC789, DOI 10.1152/ajpcell.1998.274.3.C789; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Misra A, 2003, CIRCULATION, V108, P3075, DOI 10.1161/01.CIR.0000108929.93074.0B; Monaco C, 2004, CARDIOVASC RES, V61, P671, DOI 10.1016/j.cardiores.2003.11.038; Nadjar A, 2005, J CEREBR BLOOD F MET, V25, P1047, DOI 10.1038/sj.jcbfm.9600106; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Pru James K, 2003, Reprod Biol Endocrinol, V1, P17, DOI 10.1186/1477-7827-1-17; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; Rudic RD, 2005, CIRC RES, V96, P1240, DOI 10.1161/01.RES.0000170888.11669.28; Sabri A, 2003, J BIOL CHEM, V278, P11714, DOI 10.1074/jbc.M213091200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Sato T, 1999, J PHARMACOL TOX MET, V41, P173, DOI 10.1016/S1056-8719(99)00039-8; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SHIROTANI M, 1991, PROSTAG OTH LIPID M, V41, P97, DOI 10.1016/0090-6980(91)90023-9; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tang H, 2005, BLOOD, V105, P1977, DOI 10.1182/blood-2004-08-3308; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wang Y, 2004, CIRC RES, V95, P84, DOI 10.1161/01.RES.0000133679.38825.a6; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9	56	87	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11792	11804		10.1074/jbc.M509292200	http://dx.doi.org/10.1074/jbc.M509292200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16467309	Green Published, hybrid			2022-12-27	WOS:000236988100045
J	Calipel, A; Mouriaux, F; Glotin, AL; Malecaze, F; Faussat, AM; Mascarelli, F				Calipel, A; Mouriaux, F; Glotin, AL; Malecaze, F; Faussat, AM; Mascarelli, F			Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE BRAF; B-RAF; MAP KINASE; MALIGNANT MELANOMAS; TUMOR PROGRESSION; MUTATIONS; CAMP; MELANOCYTES; ACTIVATION; GROWTH	Mutated B-Raf-mediated constitutive activation of ERK1/2 is involved in about 66% of cutaneous melanoma. By contrast, activating mutations in B-RAF are rare in ocular melanoma. This study aimed to determine the role of wild-type B-Raf (B-WT-Raf) in uveal melanoma cell growth. We used cell lines derived from primary tumors of uveal melanoma to assess the role of B-WT-Raf in cell proliferation and to characterize its upstream regulators and downstream effectors. Melanoma cell lines expressing B-WT-Raf and (WT)Ras grew with similar proliferation rates, showed constitutive activation of ERK1/2, and had similar levels of B-Raf expression and B-Raf kinase activity as melanoma cell lines expressing the activating V600E mutation (B-V600E-Raf). They were equally as sensitive to pharmacological inhibition of MEK1/2 for cell proliferation and transformation as (EB)-E-V600-Raf cells. siRNA-mediated depletion of Raf-1 did not affect either ERK1/2 activation, whereas siRNA-mediated depletion of B-Raf reduced cell proliferation by up to 65% through the inhibition of ERK1/2 activation, irrespective of the mutational status of B-Raf. Pharmacological inhibition of cAMP-dependent protein kinase (PKA) and siRNA-mediated depletion of PKA greatly reduced B-Raf activity, ERK1/2 activation, and cell proliferation in B-WT-Raf cells, whereas it did not affect B-V600E-Raf cells, demonstrating a key role of PKA in mediating B-WT-Raf/ERK signaling for uveal melanoma cell growth. Moreover, inactivation or depletion of PKA did not affect Rap-1 activity, and Rap-1 depletion did not affect either B-Raf activity or ERK1/2 activation. This ruled out a role for Rap1 in the PKA-mediated B-Raf/ERK activation in B-WT-Raf cells. Finally, we demonstrated the importance of cyclin D1 in mediating PKA/B-WT-Raf signaling for cell proliferation. Altogether, our results suggest that the PKA/B-Raf pathway is a potential target for therapeutic strategies against B-WT-Raf-expressing uveal melanoma.	INSERM, Inst Biomed Cordeliers, U598, F-75006 Paris, France; CHU Caen, Serv Ophtalmol, F-14000 Caen, France; Hop Purpan, CHRU, Serv Ophthalmol, F-31000 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Toulouse	Mascarelli, F (corresponding author), INSERM, Inst Biomed Cordeliers, U598, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mouriaux, Frederic/T-1440-2019; Mascarelli, Frederic/L-8916-2018					BECKER D, 1990, ONCOGENE, V5, P1133; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Crepieux P, 2001, ONCOGENE, V20, P4696, DOI 10.1038/sj.onc.1204632; Cruz F, 2003, CANCER RES, V63, P5761; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Gear J, 2004, INVEST OPHTH VIS SCI, V45, P2484, DOI 10.1167/iovs.04-0093; Hingorani SR, 2003, CANCER RES, V63, P5198; Hu DN, 2000, EXP EYE RES, V70, P113, DOI 10.1006/exer.1999.0760; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kilic E, 2004, MELANOMA RES, V14, P203, DOI 10.1097/cmr.0000130006.46885.a0; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200; Lefevre G, 2003, ONCOGENE, V22, P8813, DOI 10.1038/sj.onc.1207099; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Lou TF, 2003, OLIGONUCLEOTIDES, V13, P313, DOI 10.1089/154545703322616998; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; MOOY CM, 1991, BRIT J CANCER, V64, P411, DOI 10.1038/bjc.1991.319; Mouriaux F, 2001, EXP EYE RES, V73, P151, DOI 10.1006/exer.2001.1017; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Rimoldi D, 2003, CANCER RES, V63, P5712; Saavedra AP, 2002, ONCOGENE, V21, P778, DOI 10.1038/sj.onc.1205123; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Spendlove HE, 2004, MELANOMA RES, V14, P449, DOI 10.1097/00008390-200412000-00003; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Vandeput F, 2003, ENDOCRINOLOGY, V144, P1341, DOI 10.1210/en.2001-211316; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	49	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9238	9250		10.1074/jbc.M600228200	http://dx.doi.org/10.1074/jbc.M600228200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452469	hybrid			2022-12-27	WOS:000236404700031
J	Yang, JM; O'Neill, P; Jin, W; Foty, R; Medina, DJ; Xu, ZD; Lomas, M; Arndt, GM; Tang, Y; Nakada, M; Yan, L; Hait, WN				Yang, JM; O'Neill, P; Jin, W; Foty, R; Medina, DJ; Xu, ZD; Lomas, M; Arndt, GM; Tang, Y; Nakada, M; Yan, L; Hait, WN			Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; FOCAL ADHESION KINASE; TUMOR PROGRESSION; GROWTH-FACTOR; EXPRESSION; APOPTOSIS; EMMPRIN; PROTEIN; FIBRONECTIN; METASTASIS	Overexpression of extracellular matrix metalloproteinase inducer ( EMMPRIN or CD147), a member of the immunoglobulin family and a glycoprotein enriched on the surface of tumor cells, promotes invasion, metastasis, and growth and survival of malignant cells and confers resistance to some chemotherapeutic drugs. However, the molecular mechanisms underlying the actions of EMMPRIN are not fully understood. In this study we sought to determine whether EMMPRIN contributes to the malignant phenotype of breast cancer by inhibiting anoikis, a form of apoptosis induced by loss or alteration of cell-cell or cell-matrix anchorage, and to explore the signaling pathways involved. We found that in the absence of attachment, human breast carcinoma cells expressing high levels of EMMPRIN formed less compact aggregates with larger surface area and less fibronectin matrix assembly, had higher viability, and were resistant to anoikis. Knockdown of EMMPRIN expression by RNA interference ( small interfering RNA or short hairpin RNA) sensitized cancer cells to anoikis, as demonstrated by activation of caspase-3, increased DNA fragmentation, and decreased cellular viability. Furthermore, we observed that the accumulation of Bim, a proapoptotic BH3-only protein, was reduced in EMMPRIN-expressing cells and that silencing of EMMPRIN expression elevated Bim protein levels and enhanced cellular sensitivity to anoikis. Treatment of cells with a MEK inhibitor (U0126) or proteasome inhibitor ( epoxomicin) also up-regulated Bim accumulation and rendered cells more sensitive to anoikis. These results indicated that expression of EMMPRIN protects cancer cells from anoikis and that this effect is mediated at least in part by a MAP kinase-dependent reduction of Bim. Because anoikis deficiency is a key feature of neoplastic transformation and invasive growth of epithelial cancer cells, our study on the role of EMMPRIN in anoikis resistance and the mechanism involved underscores the potential of EMMPRIN expression as a prognostic marker and novel target for cancer therapy.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Centocor Inc, Oncol Res, Malvern, PA 19355 USA; Johnson & Johnson Res, Sydney, NSW 1430, Australia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Johnson & Johnson	Yang, JM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08901 USA.	jyang@umdnj.edu; haitwn@umdnj.edu	Medina, Daniel/B-8196-2013	Medina, Daniel/0000-0003-4830-6941	NCI NIH HHS [CA 66077, CA 72720] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066077, P30CA072720] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Curtin KD, 2005, J CELL SCI, V118, P2649, DOI 10.1242/jcs.02408; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Davidson B, 2004, CLIN CANCER RES, V10, P7335, DOI 10.1158/1078-0432.CCR-04-0183; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Marieb EA, 2004, CANCER RES, V64, P1229, DOI 10.1158/0008-5472.CAN-03-2832; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Reimers N, 2004, CLIN CANCER RES, V10, P3422, DOI 10.1158/1078-0432.CCR-03-0610; Robinson EE, 2004, MOL BIOL CELL, V15, P973, DOI 10.1091/mbc.E03-07-0528; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Tang Y, 2004, MOL CANCER RES, V2, P73; Toole BP, 2003, CURR TOP DEV BIOL, V54, P371, DOI 10.1016/S0070-2153(03)54015-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Yang JM, 2003, MOL CANCER RES, V1, P420; Yurchenko V, 2001, BIOCHEM BIOPH RES CO, V288, P786, DOI 10.1006/bbrc.2001.5847; Zhang Y, 2004, J BIOL CHEM, V279, P48342, DOI 10.1074/jbc.M407953200; Zhivotovsky B, 2003, ESSAYS BIOCHEM, V39, P25, DOI 10.1042/bse0390025; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	37	93	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9719	9727		10.1074/jbc.M508421200	http://dx.doi.org/10.1074/jbc.M508421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16443928	hybrid			2022-12-27	WOS:000236404700084
J	Kubota, N; Terauchi, Y; Kubota, T; Kumagai, H; Itoh, S; Satoh, H; Yano, W; Ogata, H; Tokuyama, K; Takamoto, I; Mineyama, T; Ishikawa, M; Moroi, M; Sugi, K; Yamauchi, T; Ueki, K; Tobe, K; Noda, T; Nagai, R; Kadowaki, T				Kubota, N; Terauchi, Y; Kubota, T; Kumagai, H; Itoh, S; Satoh, H; Yano, W; Ogata, H; Tokuyama, K; Takamoto, I; Mineyama, T; Ishikawa, M; Moroi, M; Sugi, K; Yamauchi, T; Ueki, K; Tobe, K; Noda, T; Nagai, R; Kadowaki, T			Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-RELATED PROTEIN; ACTIVATED RECEPTOR-GAMMA; NECROSIS-FACTOR-ALPHA; FATTY-ACID OXIDATION; OBESE ZUCKER RATS; PPAR-GAMMA; ADIPOSE-TISSUE; ADIPOCYTE; GLUCOSE; MICE	Thiazolidinediones have been shown to up-regulate adiponectin expression in white adipose tissue and plasma adiponectin levels, and these up-regulations have been proposed to be a major mechanism of the thiazolidinedione-induced amelioration of insulin resistance linked to obesity. To test this hypothesis, we generated adiponectin knock-out (adipo(-/-)) ob/ob mice with a C57B/6 background. After 14 days of 10 mg/kg pioglitazone, the insulin resistance and diabetes of ob/ob mice were significantly improved in association with significant up-regulation of serum adiponectin levels. Amelioration of insulin resistance in ob/ob mice was attributed to decreased glucose production and increased AMP-activated protein kinase in the liver but not to increased glucose uptake in skeletal muscle. In contrast, insulin resistance and diabetes were not improved in adipo(-/-) ob/ob mice. After 14 days of 30 mg/kg pioglitazone, insulin resistance and diabetes of ob/ob mice were again significantly ameliorated, which was attributed not only to decreased glucose production in the liver but also to increased glucose uptake in skeletal muscle. Interestingly, adipo(-/-) ob/ob mice also displayed significant amelioration of insulin resistance and diabetes, which was attributed to increased glucose uptake in skeletal muscle but not to decreased glucose production in the liver. The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo(-/-) ob/ob mice were unchanged after 10 mg/kg pioglitazone but were significantly reduced to a similar degree after 30 mg/kg pioglitazone. Moreover, the expressions of TNF alpha and resistin in adipose tissues of ob/ob and adipo(-/-) ob/ob mice were unchanged after 10 mg/kg pioglitazone but were decreased after 30 mg/kg pioglitazone. Thus, pioglitazone-induced amelioration of insulin resistance and diabetes may occur adiponectin dependently in the liver and adiponectin independently in skeletal muscle.	Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Natl Inst Hlth & Nutr, Div Appl Nutr, Tokyo 1628636, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3050006, Japan; Toho Univ, Ohashi Hosp, Div Cardiovasc Med, Tokyo 1538515, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1358550, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan	University of Tokyo; National Institute of Health & Nutrition - Japan; University of Tsukuba; Toho University; Japanese Foundation for Cancer Research; Tohoku University; University of Tokyo	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Terauchi, Yasuo/AAO-4347-2020; Kubota, Naoto/N-7892-2015	Yano, Wataru/0000-0002-6866-8520; Itoh, Shinsuke/0000-0001-9567-8188				Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; Chandran M, 2003, DIABETES CARE, V26, P2442, DOI 10.2337/diacare.26.8.2442; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hirose H, 2002, METABOLISM, V51, P314, DOI 10.1053/meta.2002.30506; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Mauvais-Jarvis F, 2000, DIABETES METAB, V26, P433; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Suzuki R, 2004, J BIOL CHEM, V279, P25039, DOI 10.1074/jbc.M311956200; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Wellen KE, 2004, ENDOCRINOLOGY, V145, P2214, DOI 10.1210/en.2003-1580; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968	41	261	278	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8748	8755		10.1074/jbc.M505649200	http://dx.doi.org/10.1074/jbc.M505649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431926	hybrid			2022-12-27	WOS:000236247100053
J	Lu, J; Lin, WH; Chen, SY; Longnecker, R; Tsai, SC; Chen, CL; Tsai, CH				Lu, J; Lin, WH; Chen, SY; Longnecker, R; Tsai, SC; Chen, CL; Tsai, CH			Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CYTOPLASMIC DOMAINS; SH2 DOMAINS; SIGNAL-TRANSDUCTION; NASOPHARYNGEAL CARCINOMA; REGULATES REACTIVATION; ANTIGEN RECEPTOR; IN-VIVO; ACTIVATION; LMP2A; PHOSPHORYLATION	Although spleen tyrosine kinase (Syk) is known to be important in hematopoietic cell development, the roles of Syk in epithelial cells have not been well studied. Limited data suggest that Syk plays alternate roles in carcinogenesis under different circumstances. In breast cancer, Syk has been suggested to be a tumor suppressor. In contrast, Syk is essential for murine mammary tumor virus-mediated transformation. However, the roles of Syk in tumor migration are still largely unknown. Nasopharyngeal carcinoma, an unusually highly metastatic tumor, expresses Epstein-Barr virus LMP2A (latent membrane protein 2A) in most clinical specimens. Previously, we demonstrated LMP2A triggers epithelial cell migration. LMP2A contains an immunoreceptor tyrosine-based activation motif, which is important for Syk kinase activation in B cells. In this study, we explored whether Syk is important for LMP2A-mediated epithelial cell migration. We demonstrate that LMP2A expression can activate endogenous Syk activity. The activation requires the tyrosine residues in LMP2A ITAM but not YEEA motif, which is important for Syk activation by Lyn in B cells. LMP2A interacts with Syk as demonstrated by coimmunoprecipitation and confocal microscopy. Furthermore, LMP2A-induced cell migration is inhibited by a Syk inhibitor and short interfering RNA. Tyrosines 74 and 85 in the LMP2A immunoreceptor tyrosine-based activation motif are essential for both Syk activation and LMP2A-mediated cell migration, indicating the involvement of Syk in LMP2A-triggered cell migration. The LMP2A-Syk pathway may provide suitable drug targets for treatment of nasopharyngeal carcinoma.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10063, Taiwan; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Natl Taiwan Univ, Coll Med, Dept Pathol, Taipei 10063, Taiwan	National Taiwan University; Northwestern University; National Taiwan University	Tsai, CH (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Rm 714,Number 1,Sect 1,Jen Ai Rd, Taipei 10063, Taiwan.	chtsai@ha.mc.ntu.edu.tw			NATIONAL CANCER INSTITUTE [R01CA093444, R01CA062234, R01CA073507] Funding Source: NIH RePORTER; NCI NIH HHS [CA93444, CA62234, CA73507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Fabbro D, 2002, CURR OPIN DRUG DISC, V5, P701; Fabbro D, 2002, CURR OPIN PHARMACOL, V2, P374, DOI 10.1016/S1471-4892(02)00179-0; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTAFSON RO, 1989, CANCER HEAD NECK, P495; Harnett M, 1996, IMMUNOL TODAY, V17, P4, DOI 10.1016/0167-5699(96)80558-5; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Hsu JL, 2000, CRIT REV ONCOL HEMAT, V34, P27, DOI 10.1016/S1040-8428(00)00046-9; Inatome R, 2001, BIOCHEM BIOPH RES CO, V286, P195, DOI 10.1006/bbrc.2001.5355; Islam TC, 2000, J GENE MED, V2, P204; Islam TC, 2000, IMMUNOL REV, V178, P49, DOI 10.1034/j.1600-065X.2000.17811.x; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LENNETTE ET, 1995, EUR J CANCER, V31A, P1875, DOI 10.1016/0959-8049(95)00354-L; Longnecker R, 1996, TRENDS MICROBIOL, V4, P38; Longnecker R, 2000, ADV CANCER RES, V79, P175, DOI 10.1016/S0065-230X(00)79006-3; Lu J, 2000, J VIROL, V74, P7391, DOI 10.1128/JVI.74.16.7391-7399.2000; Lu J, 2003, CANCER RES, V63, P256; MILLER CL, 1994, INFECT AGENT DIS, V3, P128; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Renedo MA, 2001, EUR J IMMUNOL, V31, P1361, DOI 10.1002/1521-4141(200105)31:5<1361::AID-IMMU1361>3.0.CO;2-7; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 1999, J VIROL, V73, P4767, DOI 10.1128/JVI.73.6.4767-4775.1999; Scholle F, 2001, VIROLOGY, V291, P208, DOI 10.1006/viro.2001.1197; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Swanson-Mungerson MA, 2005, J VIROL, V79, P7355, DOI 10.1128/JVI.79.12.7355-7362.2005; Tsai CH, 1997, J BIOMED SCI, V4, P69, DOI 10.1007/BF02255596; Tsubata T, 2001, Int Rev Immunol, V20, P675, DOI 10.3109/08830180109045584; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Yanagi S, 2001, BLOOD, V98, P2869, DOI 10.1182/blood.V98.9.2869; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; Zhang J, 2000, J BIOL CHEM, V275, P35442, DOI 10.1074/jbc.M004549200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	75	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8806	8814		10.1074/jbc.M507305200	http://dx.doi.org/10.1074/jbc.M507305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431925	hybrid			2022-12-27	WOS:000236247100060
J	Shen, YH; Zhang, L; Gan, YH; Wang, XW; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL				Shen, YH; Zhang, L; Gan, YH; Wang, XW; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL			Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling - A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; INFLAMMATORY CYTOKINES; METABOLIC SYNDROME; SKELETAL-MUSCLE; INDUCED PHOSPHORYLATION; DEPENDENT DILATATION; RECEPTOR SUBSTRATE-1; LEPTIN LEVELS; IN-VIVO; GLUCOSE	The key feature of metabolic syndrome, a cluster of metabolic and cardiovascular disorders, is systemic insulin resistance, which is associated with dysregulated endothelial nitric-oxide synthase ( eNOS). Stress signaling induced by inflammation can inhibit insulin signaling. However, molecular mechanisms for the cross-talk between stress signaling and insulin resistance are only partially understood. Resistin, an adipokine/ cytokine, is involved in inflammatory processes that could lead to insulin resistance status and vascular diseases. In the current study, we observed that resistin inhibited insulin signaling and eNOS activation in endothelial cells. Up-regulation of PTEN ( phosphatase and tensin homolog deleted on chromosome ten) expression by resistin may mediate the inhibitory effects. Activated stress signaling p38 MAPK, but not JNK, is involved in PTEN up-regulation. We further found that p38 target transcriptional factor activating transcription factor-2 (ATF-2) bound to ATF sites in the PTEN promoter. The phosphorylation/ activation of ATF-2 and its binding to PTEN promoter were increased by resistin treatment. In summary, up-regulation of PTEN is involved in the inhibitory effects of resistin on insulin signaling and eNOS activation in endothelial cells. Resistin induces PTEN expression by activating stress signaling p38 pathway, which may activate target transcription factor ATF-2, which in turn induces PTEN expression. Our findings suggest that resistin-mediated inhibition of insulin signaling and eNOS activation may contribute to cardiovascular diseases.	Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA	Baylor College of Medicine; Saint Lukes Episcopal Hospital; Texas Heart Institute	Shen, YH (corresponding author), Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, NAB 2010,1 Baylor Plaza, Houston, TX 77030 USA.	hyshen@bcm.tmc.edu; xlwang@bcm.tmc.edu	shen, ying/HHS-5635-2022	LeMaire, Scott/0000-0002-8736-4266	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071608, R01HL066053] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL066053, R01-HL071608] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Azuma K, 2003, OBES RES, V11, P997, DOI 10.1038/oby.2003.137; Banerjee RR, 2003, J MOL MED, V81, P218, DOI 10.1007/s00109-003-0428-9; Baron AD, 1999, AM J CARDIOL, V84, p25J; Begum N, 2003, FRONT BIOSCI-LANDMRK, V8, pS796, DOI 10.2741/1146; Bhagat K, 1997, CIRCULATION, V96, P3042, DOI 10.1161/01.CIR.96.9.3042; Bokarewa M, 2005, J IMMUNOL, V174, P5789, DOI 10.4049/jimmunol.174.9.5789; Bonora E, 1998, DIABETES, V47, P1643, DOI 10.2337/diabetes.47.10.1643; Calabro P, 2004, CIRCULATION, V110, P3335, DOI 10.1161/01.CIR.0000147825.97879.E7; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Fujinami A, 2004, CLIN CHIM ACTA, V339, P57, DOI 10.1016/j.cccn.2003.09.009; GAN Y, 2005, J BIOL CHEM; Graveleau C, 2005, J BIOL CHEM, V280, P31679, DOI 10.1074/jbc.M504008200; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Haffner S, 2003, CIRCULATION, V108, P1541, DOI 10.1161/01.CIR.0000088845.17586.EC; Hall JF, 2000, P NATL ACAD SCI USA, V97, P14022, DOI 10.1073/pnas.97.26.14022; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hingorani AD, 2000, CIRCULATION, V102, P994, DOI 10.1161/01.CIR.102.9.994; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hockings SC, 1998, P NATL ACAD SCI USA, V95, P1410, DOI 10.1073/pnas.95.4.1410; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JIANG G, 2002, FRONT BIOSCI, V7, P903; Kaser S, 2003, BIOCHEM BIOPH RES CO, V309, P286, DOI 10.1016/j.bbrc.2003.07.003; Kereiakes DJ, 2003, CIRCULATION, V108, P1552, DOI 10.1161/01.CIR.0000093203.00632.2B; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kitagawa Y, 2004, DIABETOLOGIA, V47, P1847, DOI 10.1007/s00125-004-1530-4; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Lu SC, 2002, FEBS LETT, V530, P158, DOI 10.1016/S0014-5793(02)03450-6; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Moon B, 2003, AM J PHYSIOL-ENDOC M, V285, pE106, DOI 10.1152/ajpendo.00457.2002; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ohkawa F, 1995, CARDIOVASC RES, V30, P711, DOI 10.1016/S0008-6363(95)00101-8; Ort T, 2005, ENDOCRINOLOGY, V146, P2200, DOI 10.1210/en.2004-1421; Palanivel R, 2005, FEBS LETT, V579, P5049, DOI 10.1016/j.febslet.2005.08.011; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Patel SD, 2004, SCIENCE, V304, P1154, DOI 10.1126/science.1093466; Rangwala SM, 2004, DIABETES, V53, P1937, DOI 10.2337/diabetes.53.8.1937; Reaven Gerald M., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P387; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Reilly MP, 2004, J CLIN ENDOCR METAB, V89, P3872, DOI 10.1210/jc.2003-031676; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Reusch JEB, 2002, AM J CARDIOL, V90, p19G; Sato N, 2005, ENDOCRINOLOGY, V146, P273, DOI 10.1210/en.2004-0985; Satoh H, 2004, J CLIN INVEST, V114, P224, DOI 10.1172/JCI200420785; Silha JV, 2003, EUR J ENDOCRINOL, V149, P331, DOI 10.1530/eje.0.1490331; Silswal N, 2005, BIOCHEM BIOPH RES CO, V334, P1092, DOI 10.1016/j.bbrc.2005.06.202; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Verma S, 2003, CIRCULATION, V108, P736, DOI 10.1161/01.CIR.0000084503.91330.49; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wyatt AW, 2002, FASEB J, V16, P1584, DOI 10.1096/fasebj.16.12.1584; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhang JL, 2003, DIABETIC MED, V20, P828, DOI 10.1046/j.1464-5491.2003.01057.x; Zhao M, 1999, MOL CELL BIOL, V19, P21	77	113	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7727	7736		10.1074/jbc.M511105200	http://dx.doi.org/10.1074/jbc.M511105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418168	hybrid			2022-12-27	WOS:000236031000005
J	Bietrix, F; Yan, DG; Nauze, M; Rolland, C; Bertrand-Michel, J; Camera, C; Schaak, S; Barbaras, R; Groen, AK; Perret, B; Terce, F; Collet, X				Bietrix, F; Yan, DG; Nauze, M; Rolland, C; Bertrand-Michel, J; Camera, C; Schaak, S; Barbaras, R; Groen, AK; Perret, B; Terce, F; Collet, X			Accelerated lipid absorption in mice overexpressing intestinal SR-BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; HIGH-DENSITY-LIPOPROTEIN; BRUSH-BORDER MEMBRANE; SCAVENGER RECEPTOR; CHOLESTEROL ABSORPTION; DIETARY-CHOLESTEROL; TRANSGENIC MICE; INBRED STRAINS; IDENTIFICATION; TRANSPORT	Dietary cholesterol absorption contributes to a large part of the circulating cholesterol. However, the mechanism of sterol intestinal uptake is not clearly elucidated. Scavenger receptor class B type I (SR-BI), major component in the control of cholesterol homeostasis, is expressed in the intestine, but its role in this organ remains unclear. We have generated transgenic mice overexpressing SR-BI primarily in the intestine by using the mouse SR-BI gene under the control of intestinal specific "apoC-III enhancer coupled with apoA-IV promoter." We found SR-BI overexpression with respect to the natural protein along the intestine and at the top of the villosities. After a meal containing [C-14] cholesterol and [H-3] triolein, SR-BI transgenic mice presented a rise in intestinal absorption of both lipids that was not due to a defect in chylomicron clearance nor to a change in the bile flow or the bile acid content. Nevertheless, SR-BI transgenic mice showed a decrease of total cholesterol but an increase of triglyceride content in plasma without any change in the high density lipoprotein apoA-I level. Thus, we described for the first time a functional role in vivo for SR-BI in cholesterol but also in triglyceride intestinal absorption.	Acad Med Ctr, Ctr Liver, NL-1105 BK Amsterdam, Netherlands; Ctr Physiopathol Toulouse Purpan, INSERM, U563, Dept Lipoprot & Med Lipid, F-31024 Toulouse 3, France; Univ Toulouse 3, F-31024 Toulouse 3, France	University of Amsterdam; Academic Medical Center Amsterdam; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Collet, X (corresponding author), Hop Purpan, INSERM, U563, CPTP Bat C, F-31024 Toulouse, France.	xcollet@toulouse.inserm.fr	PERRET, Bertrand/Y-2326-2019; Tercé, François/M-5863-2018; Eckhardt, Erik/G-1567-2010; Collet, Xavier/M-6938-2017	Tercé, François/0000-0003-4488-2167; Bertrand, PERRET/0000-0001-7568-445X				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cai SF, 2001, J LIPID RES, V42, P902; Compassi S, 1995, BIOCHEMISTRY-US, V34, P16473, DOI 10.1021/bi00050a031; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Drover VA, 2005, J CLIN INVEST, V115, P1290, DOI 10.1172/JCI200521514; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Hansen GH, 2003, GUT, V52, P1424, DOI 10.1136/gut.52.10.1424; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Hui DY, 2005, SEMIN CELL DEV BIOL, V16, P183, DOI 10.1016/j.semcdb.2005.01.003; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Kirby RJ, 2004, J LIPID RES, V45, P89, DOI 10.1194/jlr.M300148-JLR200; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kramer W, 2003, BBA-MOL CELL BIOL L, V1633, P13, DOI 10.1016/S1388-1981(03)00068-4; Kruit JK, 2005, GASTROENTEROLOGY, V128, P147, DOI 10.1053/j.gastro.2004.10.006; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Mardones P, 2001, J LIPID RES, V42, P170; MCGILL HC, 1979, AM J CLIN NUTR, V32, P2664, DOI 10.1093/ajcn/32.12.2664; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Out R, 2004, J BIOL CHEM, V279, P18401, DOI 10.1074/jbc.M401170200; Perez-Martinez P, 2004, J MOL ENDOCRINOL, V32, P237, DOI 10.1677/jme.0.0320237; Reboul E, 2006, J BIOL CHEM, V281, P4739, DOI 10.1074/jbc.M509042200; Ros E, 2000, ATHEROSCLEROSIS, V151, P357, DOI 10.1016/S0021-9150(00)00456-1; Schulthess G, 1996, J LIPID RES, V37, P2405; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; THURNHOFER H, 1990, BIOCHEMISTRY-US, V29, P2142, DOI 10.1021/bi00460a026; Torchia EC, 2001, ANAL BIOCHEM, V298, P293, DOI 10.1006/abio.2001.5379; TRABER MG, 1990, J LIPID RES, V31, P675; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; van Bennekum A, 2005, BIOCHEMISTRY-US, V44, P4517, DOI 10.1021/bi0484320; Vieu C, 1996, J LIPID RES, V37, P1153; Wang DQH, 2001, J LIPID RES, V42, P1820; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Werder M, 2001, BIOCHEMISTRY-US, V40, P11643, DOI 10.1021/bi0109820; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	42	101	104	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7214	7219		10.1074/jbc.M508868200	http://dx.doi.org/10.1074/jbc.M508868200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421100	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000236030900038
J	Schonfeld, P; Reiser, G				Schonfeld, P; Reiser, G			Rotenone-like action of the branched-chain phytanic acid induces oxidative stress in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDOREDUCTASE COMPLEX-I; ELECTRON-TRANSPORT CHAIN; ALPHA-KETOGLUTARATE DEHYDROGENASE; OXYGEN SPECIES GENERATION; RAT-HEART MITOCHONDRIA; SUPEROXIDE-PRODUCTION; BRAIN MITOCHONDRIA; HYDROGEN-PEROXIDE; FATTY-ACIDS; RESPIRATORY-CHAIN	Phytanic acid (Phyt) increase is associated with the hereditary neurodegenerative Refsum disease. To elucidate the still unclear toxicity of Phyt, mitochondria from brain and heart of adult rats were exposed to free Phyt. Phyt at low micromolar concentrations (maximally: 100 nmol/mg of protein) enhances superoxide (O-2(radical anion))(2) generation. Phyt induces O-2(radical anion) in state 3 ( phosphorylating), as well as in state 4 ( resting). Phyt stimulates O-2(radical anion) generation when the respiratory chain is fed with electrons derived from oxidation of glutamate/ malate, pyruvate/ malate, or succinate in the presence of rotenone. With succinate alone, Phyt suppresses O-2(radical anion) generation caused by reverse electron transport from succinate to complex I. The enhanced O-2(radical anion) generation by Phyt in state 4 is in contrast to the mild uncoupling concept. In this concept uncoupling by nonesterified fatty acids should abolish O-2(radical anion) generation. Stimulation of O-2(radical anion) generation by Phyt is paralleled by inhibition of the electron transport within the respiratory chain or electron leakage from the respiratory chain. The interference of Phyt with the electron transport was demonstrated by inhibition of state 3- and p-trifluoromethoxyphenylhydrazone (FCCP)-dependent respiration, inactivation of the NADH-ubiquinone oxidoreductase complex in permeabilized mitochondria, decrease in reduction of the synthetic electron acceptor 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in state 4, and increase of the mitochondrial NAD(P) H level in FCCP-uncoupled mitochondria. Thus, we suggest that complex I is the main site of Phyt-stimulated O-2(radical anion) generation. Furthermore, inactivation of aconitase and oxidation of the mitochondrial glutathione pool show that enhanced O-2(radical anion) generation with chronic exposure to Phyt causes oxidative damage.	Univ Magdeburg, Fak Med, Inst Biochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Fak Med, Inst Neurobiochem, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Schonfeld, P (corresponding author), Univ Magdeburg, Fak Med, Inst Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	peter.schoenfeld@medizin.uni-magdeburg.de						Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; CHANCE B, 1961, J BIOL CHEM, V236, P1534; Cocco T, 1999, FREE RADICAL BIO MED, V27, P51, DOI 10.1016/S0891-5849(99)00034-9; Dacremont G, 1995, J INHERIT METAB DIS, V18, P76, DOI 10.1007/BF00711430; Esposti MD, 2002, METHODS, V26, P335, DOI 10.1016/S1046-2023(02)00039-7; FRIEDMAN KJ, 1982, J MEMBRANE BIOL, V64, P1, DOI 10.1007/BF01870763; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gyulkhandanyan AV, 2004, J NEUROCHEM, V90, P405, DOI 10.1111/j.1471-4159.2004.02489.x; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; HINKLE PC, 1967, J BIOL CHEM, V242, P5169; Kahlert S, 2005, NEUROBIOL DIS, V18, P110, DOI 10.1016/j.nbd.2004.08.010; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Loskovich MV, 2005, BIOCHEM J, V387, P677, DOI 10.1042/BJ20041703; Mannaerts GP, 2000, CELL BIOCHEM BIOPHYS, V32, P73, DOI 10.1385/CBB:32:1-3:73; Mukherji M, 2003, PROG LIPID RES, V42, P359, DOI 10.1016/S0163-7827(03)00016-X; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Nicholls D., 2002, BIOENERGETICS, V3; PATTON S, 1966, BIOCHIM BIOPHYS ACTA, V125, P22, DOI 10.1016/0005-2760(66)90140-8; REISER G, 2006, IN PRESS INT J DEV N; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; SCHALLER H, 1978, ACTA BIOL MED GER, V37, P31; Schonfeld P, 2004, BIOCHEM J, V383, P121, DOI 10.1042/BJ20040583; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Steinberg D., 1995, METABOLIC MOL BASES, P2351; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wanders RJA, 2003, BBA-MOL CELL BIOL L, V1631, P119, DOI 10.1016/S1388-1981(03)00003-9; WANDERS RJA, 2001, METABOLIC MOL BASES, P3303; Wierzbicki AS, 2002, J NEUROCHEM, V80, P727, DOI 10.1046/j.0022-3042.2002.00766.x; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	52	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7136	7142		10.1074/jbc.M513198200	http://dx.doi.org/10.1074/jbc.M513198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410242	hybrid			2022-12-27	WOS:000236030900028
J	Cariou, B; van Harmelen, K; Duran-Sandoval, D; van Dijk, TH; Grefhorst, A; Abdelkarim, M; Caron, S; Torpier, G; Fruchart, JC; Gonzalez, FJ; Kuipers, F; Staels, B				Cariou, B; van Harmelen, K; Duran-Sandoval, D; van Dijk, TH; Grefhorst, A; Abdelkarim, M; Caron, S; Torpier, G; Fruchart, JC; Gonzalez, FJ; Kuipers, F; Staels, B			The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; HEPATIC CARBOHYDRATE-METABOLISM; BILE-ACID; DIABETES-MELLITUS; 3T3-L1 ADIPOCYTES; DEFICIENT MICE; FXR; ACTIVATION; RESISTANCE; EXPRESSION	The farnesoid X receptor (FXR) is a bile acid (BA)-activated nuclear receptor that plays a major role in the regulation of BA and lipid metabolism. Recently, several studies have suggested a potential role of FXR in the control of hepatic carbohydrate metabolism, but its contribution to the maintenance of peripheral glucose homeostasis remains to be established. FXR-deficient mice display decreased adipose tissue mass, lower serum leptin concentrations, and elevated plasma free fatty acid levels. Glucose and insulin tolerance tests revealed that FXR deficiency is associated with impaired glucose tolerance and insulin resistance. Moreover, whole-body glucose disposal during a hyperinsulinemic euglycemic clamp is decreased in FXR-deficient mice. In parallel, FXR deficiency alters distal insulin signaling, as reflected by decreased insulin-dependent Akt phosphorylation in both white adipose tissue and skeletal muscle. Whereas FXR is not expressed in skeletal muscle, it was detected at a low level in white adipose tissue in vivo and induced during adipocyte differentiation in vitro. Moreover, mouse embryonic fibroblasts derived from FXR-deficient mice displayed impaired adipocyte differentiation, identifying a direct role for FXR in adipocyte function. Treatment of differentiated 3T3-L1 adipocytes with the FXR-specific synthetic agonist GW4064 enhanced insulin signaling and insulin-stimulated glucose uptake. Finally, treatment with GW4064 improved insulin resistance in genetically obese ob/ob mice in vivo. Although the underlying molecular mechanisms remain to be unraveled, these results clearly identify a novel role of FXR in the regulation of peripheral insulin sensitivity and adipocyte function. This unexpected function of FXR opens new perspectives for the treatment of type 2 diabetes.	Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France; INSERM, U545, F-59019 Lille, France; Univ Lille 2, F-59006 Lille, France; Univ Groningen, Med Ctr, Pediat Lab, Ctr Liver Digest & Metab Dis, NL-9700 RB Groningen, Netherlands; NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Staels, Bart/N-9497-2016; CARON, Sandrine/R-6624-2018	Staels, Bart/0000-0002-3784-1503; CARON, Sandrine/0000-0002-4660-7436; Abdelkarim, Mouaadh/0000-0003-3538-2566; Kuipers, Folkert/0000-0003-2518-737X; Cariou, Bertrand/0000-0002-1580-8040				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cariou B, 2005, ENDOCRINOLOGY, V146, P981, DOI 10.1210/en.2004-1595; Cariou B, 2005, FEBS LETT, V579, P4076, DOI 10.1016/j.febslet.2005.06.033; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duran-Sandoval D, 2005, J BIOL CHEM, V280, P29971, DOI 10.1074/jbc.M501931200; Duran-Sandoval D, 2004, DIABETES, V53, P890, DOI 10.2337/diabetes.53.4.890; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Kuipers F, 2004, REV ENDOCR METAB DIS, V5, P319, DOI 10.1023/B:REMD.0000045103.00467.9a; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Li JL, 2005, J BIOL CHEM, V280, P7427, DOI 10.1074/jbc.M411473200; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; RANDLE PJ, 1963, LANCET, V1, P785; Rosen ED, 2000, GENE DEV, V14, P1293; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stayrook KR, 2005, ENDOCRINOLOGY, V146, P984, DOI 10.1210/en.2004-0965; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang XQ, 2005, J BIOL CHEM, V280, P22523, DOI 10.1074/jbc.M501949200; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; van Dijk TH, 2003, ANAL BIOCHEM, V322, P1, DOI 10.1016/j.ab.2003.07.008; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Yamagata K, 2004, J BIOL CHEM, V279, P23158, DOI 10.1074/jbc.M314322200; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	39	413	453	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11039	11049		10.1074/jbc.M510258200	http://dx.doi.org/10.1074/jbc.M510258200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16446356	hybrid			2022-12-27	WOS:000236822200045
J	He, L; Simmen, FA; Mehendale, HM; Ronis, MJJ; Badger, TM				He, L; Simmen, FA; Mehendale, HM; Ronis, MJJ; Badger, TM			Chronic ethanol intake impairs insulin signaling in rats by disrupting akt association with the cell membrane - Role of TRB3 in inhibition of Akt/protein kinase B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I ALCOHOL-DEHYDROGENASE; GLYCOGEN-SYNTHASE KINASE-3; TYROSINE PHOSPHORYLATION; BINDING-PROTEINS; POTENTIAL ROLE; LIVER; RESISTANCE; IDENTIFICATION; CONSUMPTION; PHOSPHATASE	Chronic and excessive alcohol consumption is an important and modifiable risk factor for type 2 diabetes. We previously reported elevations in hepatic Class 1 alcohol dehydrogenase (ADH) expression in ethanol-fed rats correspondent with reduced levels of mature, nuclear sterol-regulatory element-binding protein-1 (SREBP-1), an insulin-induced transcriptional repressor of the ADH gene. In this report, we have studied the effects of insulin and ethanol on ADH gene expression in a highly differentiated rat hepatoma cell line (FGC-4), as well as the in vivo effects of chronic intake of an ethanol-containing diet on hepatic insulin signaling. Insulin inhibited ADH gene expression, and this was abolished by LY294002 ( a phosphatidylinositol 3-kinase inhibitor) and small interfering RNA knockdown of SREBP-1. Chronic ethanol intake led to decreased phosphorylation of Akt ( protein kinase B) at Thr(308), increased phosphorylation of Akt at Ser(473), and decreased phosphorylation of glycogen synthase kinase-3 beta ( a downstream effector of Akt). Hepatic membrane-associated Akt content was decreased and cytosolic Akt content was increased in rats fed an ethanol-containing diet. Thus, disruptive effects of ethanol on insulin signaling occurred via impaired phosphorylation of Akt at Thr(308). TRB3, a negative regulator of Akt, was induced in liver of ethanol-fed rats. In ethanol-treated FGC-4 cells, small interfering RNA knockdown of TRB3 increased membrane-associated Akt and the phosphorylation of Akt at Thr(308). Our results suggest that ethanol induces TRB3, which, through binding to the pleckstrin homology domain of Akt, prevents its plasma membrane association, Akt-Thr(308) phosphorylation, and subsequent Akt-mediated signaling. Ethanol inhibition of insulin signaling reduces nuclear SREBP accumulation and results in disinhibition of Class 1 ADH transcription.	Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72202 USA; Univ Louisiana, Dept Toxicol, Monroe, LA 71209 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Louisiana System; University of Louisiana Monroe	Badger, TM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, 1120 Marshall St, Little Rock, AR 72202 USA.	badgerthomasm@uams.edu	Simmen, Frank A/J-9464-2012	Simmen, Frank/0000-0001-6842-7754	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008645] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA008645] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Atkinson KJ, 2001, AM J PHYSIOL-GASTR L, V280, pG1280, DOI 10.1152/ajpgi.2001.280.6.G1280; BADGER TM, 1993, J PHARMACOL EXP THER, V264, P938; BADGER TM, 1993, J PHARMACOL EXP THER, V264, P438; Badger TM, 2000, BIOCHEM BIOPH RES CO, V274, P684, DOI 10.1006/bbrc.2000.3186; Bell DSH, 1996, DIABETES CARE, V19, P509, DOI 10.2337/diacare.19.5.509; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CRABB DW, 1986, ALCOHOL CLIN EXP RES, V10, P77, DOI 10.1111/j.1530-0277.1986.tb05619.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; He L, 2004, J BIOL CHEM, V279, P28113, DOI 10.1074/jbc.M400906200; He L, 2002, J BIOL CHEM, V277, P43572, DOI 10.1074/jbc.M204535200; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Kao WHL, 2001, AM J EPIDEMIOL, V154, P748, DOI 10.1093/aje/154.8.748; Kim KH, 2004, J BIOL CHEM, V279, P51999, DOI 10.1074/jbc.M405522200; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Lazarus R, 1997, AM J EPIDEMIOL, V145, P909, DOI 10.1093/oxfordjournals.aje.a009050; Onishi Y, 2003, BIOCHEM BIOPH RES CO, V303, P788, DOI 10.1016/S0006-291X(03)00407-8; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sawant SP, 2004, J PHARMACOL EXP THER, V308, P694, DOI 10.1124/jpet.103.058834; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tanaka M, 1999, BIOCHEM BIOPH RES CO, V255, P169, DOI 10.1006/bbrc.1999.0162; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wannamethee SG, 2002, J EPIDEMIOL COMMUN H, V56, P542, DOI 10.1136/jech.56.7.542; Wei M, 2000, DIABETES CARE, V23, P18, DOI 10.2337/diacare.23.1.18; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yeon JE, 2003, HEPATOLOGY, V38, P703, DOI 10.1053/jhep.2003.50368	36	86	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11126	11134		10.1074/jbc.M510724200	http://dx.doi.org/10.1074/jbc.M510724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16452480	hybrid			2022-12-27	WOS:000236822200055
J	Taylor, EJ; Gloster, TM; Turkenburg, JP; Vincent, F; Brzozowski, AM; Dupont, C; Shareck, F; Centeno, MSJ; Prates, JAM; Puchart, V; Ferreira, LMA; Fontes, CMGA; Biely, P; Davies, GJ				Taylor, EJ; Gloster, TM; Turkenburg, JP; Vincent, F; Brzozowski, AM; Dupont, C; Shareck, F; Centeno, MSJ; Prates, JAM; Puchart, V; Ferreira, LMA; Fontes, CMGA; Biely, P; Davies, GJ			Structure and activity of two metal ion-dependent acetylxylan esterases involved in plant cell wall degradation reveals a close similarity to peptidoglycan deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERULOYL ESTERASE; CLOSTRIDIUM-THERMOCELLUM; CRYSTAL-STRUCTURE; STREPTOMYCES-LIVIDANS; CARBOHYDRATE ESTERASE; SUBSTRATE-SPECIFICITY; TRICHODERMA-REESEI; XYLAN ESTERASE; CATALYTIC CORE; INSIGHTS	The enzymatic degradation of plant cell wall xylan requires the concerted action of a diverse enzymatic syndicate. Among these enzymes are xylan esterases, which hydrolyze the O-acetyl substituents, primarily at the O-2 position of the xylan backbone. All acetylxylan esterase structures described previously display a alpha/beta hydrolase fold with a "Ser-His-Asp" catalytic triad. Here we report the structures of two distinct acetylxylan esterases, those from Streptomyces lividans and Clostridium thermocellum, in native and complex forms, with x-ray data to between 1.6 and 1.0 angstrom resolution. We show, using a novel linked assay system with PNP-2-O-acetyl-xyloside and a beta-xylosidase, that the enzymes are sugar-specific and metal ion-dependent and possess a single metal center with a chemical preference for Co2+. Asp and His side chains complete the catalytic machinery. Different metal ion preferences for the two enzymes may reflect the surprising diversity with which the metal ion coordinates residues and ligands in the active center environment of the S. lividans and C. thermocellum enzymes. These "CE4" esterases involved in plant cell wall degradation are shown to be closely related to the de-N-acetylases involved in chitin and peptidoglycan degradation (Blair, D. E., Schuettelkopf, A. W., MacRae, J.I., and Aalten, D. M. (2005) Proc. Natl. Acad. Sci. U.S.A., 102, 15429-15434), which form the NodB deacetylase "superfamily."	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Quebec, Inst Armand Frappier, INRA, Laval, PQ H7V 1B7, Canada; Univ Tecn Lisboa, Fac Vet Med, Ctr Interdisciplinar Invest Sanidade Anim, P-1300477 Lisbon, Portugal; Slovak Acad Sci, Inst Chem, Bratislava 84538, Slovakia	University of York - UK; University of Quebec; Universidade de Lisboa; Slovak Academy of Sciences	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Puchart, Vladimir/AAD-6496-2019; Prates, José A M/K-9934-2013; Vincent, Florence/F-7137-2016; Biely, Peter/ABF-3465-2020; Davies, Gideon J/A-9042-2011	Prates, José A M/0000-0003-1032-5987; Biely, Peter/0000-0002-9915-7707; Davies, Gideon J/0000-0002-7343-776X; Puchart, Vladimir/0000-0002-6434-3462; Taylor, Edward/0000-0003-4024-0976; Ferreira, Luis/0000-0002-3543-9166; Turkenburg, Johan/0000-0001-6992-6838; Fontes, Carlos/0000-0002-1219-9753; vincent, Florence/0000-0002-8564-4184; Centeno, Maria S. Jose/0000-0002-8586-5542				Altaner C, 2003, J BIOTECHNOL, V105, P95, DOI 10.1016/S0168-1656(03)00187-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biely P, 2004, ANAL BIOCHEM, V332, P109, DOI 10.1016/j.ab.2004.04.022; Biely P, 2003, BBA-GEN SUBJECTS, V1622, P82, DOI 10.1016/S0304-4165(03)00130-2; Blair DE, 2005, P NATL ACAD SCI USA, V102, P15429, DOI 10.1073/pnas.0504339102; Blair DE, 2004, FEBS LETT, V570, P13, DOI 10.1016/j.febslet.2004.06.013; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Bornscheuer UT, 2002, FEMS MICROBIOL REV, V26, P73, DOI 10.1016/S0168-6445(01)00075-4; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Caufrier F, 2003, CARBOHYD RES, V338, P687, DOI 10.1016/S0008-6215(03)00002-8; Collins T, 2005, FEMS MICROBIOL REV, V29, P3, DOI 10.1016/j.femsre.2004.06.005; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Crepin VF, 2004, APPL MICROBIOL BIOT, V63, P647, DOI 10.1007/s00253-003-1476-3; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fernandes AC, 1999, BIOCHEM J, V342, P105, DOI 10.1042/0264-6021:3420105; Ghosh D, 2001, J BIOL CHEM, V276, P11159, DOI 10.1074/jbc.M008831200; Hakulinen N, 2000, J STRUCT BIOL, V132, P180, DOI 10.1006/jsbi.2000.4318; Hekmat O, 2003, BIOCHEM J, V374, P369, DOI 10.1042/BJ20030204; Henrissat B, 2001, PLANT MOL BIOL, V47, P55, DOI 10.1023/A:1010667012056; Hermoso JA, 2004, J MOL BIOL, V338, P495, DOI 10.1016/j.jmb.2004.03.003; Hernick M, 2005, ARCH BIOCHEM BIOPHYS, V433, P71, DOI 10.1016/j.abb.2004.08.006; Kleywegt GJ, 1997, J MOL BIOL, V272, P383, DOI 10.1006/jmbi.1997.1243; Kosugi A, 2002, APPL ENVIRON MICROB, V68, P6399, DOI 10.1128/AEM.68.12.6399-6402.2002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Mathew S, 2004, CRIT REV BIOTECHNOL, V24, P59, DOI 10.1080/07388550490491467; McAuley KE, 2004, ACTA CRYSTALLOGR D, V60, P878, DOI 10.1107/S0907444904004937; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Prates JAM, 2001, STRUCTURE, V9, P1183, DOI 10.1016/S0969-2126(01)00684-0; Psylinakis E, 2005, J BIOL CHEM, V280, P30856, DOI 10.1074/jbc.M407426200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schubot FD, 2001, BIOCHEMISTRY-US, V40, P12524, DOI 10.1021/bi011391c; SHARECK F, 1995, GENE, V153, P105, DOI 10.1016/0378-1119(94)00763-I; Tarbouriech N, 2005, ACTA CRYSTALLOGR D, V61, P194, DOI 10.1107/S0907444904029695; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vincent F, 2003, J MOL BIOL, V330, P593, DOI 10.1016/S0022-2836(03)00632-6; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742	46	91	94	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10968	10975		10.1074/jbc.M513066200	http://dx.doi.org/10.1074/jbc.M513066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16431911	hybrid, Green Published			2022-12-27	WOS:000236822200037
J	English, JL; Kassiri, Z; Koskivirta, I; Atkinson, SJ; Di Grappa, M; Soloway, PD; Nagase, H; Vuorio, E; Murphy, G; Khokha, R				English, JL; Kassiri, Z; Koskivirta, I; Atkinson, SJ; Di Grappa, M; Soloway, PD; Nagase, H; Vuorio, E; Murphy, G; Khokha, R			Individual Timp deficiencies differentially impact pro-MMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; HUMAN TISSUE INHIBITOR; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; GELATINASE-A; TUMOR INVASION; CELL-SURFACE; 1-MATRIX METALLOPROTEINASE; EFFICIENT ACTIVATION; EXPRESSION SYSTEM	Membrane-type matrix metalloproteinases (MT-MMPs) have emerged as key enzymes in tumor cell biology. The importance of MT1-MMP, in particular, is highlighted by its ability to activate pro-MMP-2 at the cell surface through the formation of a trimolecular complex comprised of MT1-MMP/tissue inhibitor of metalloproteinase-2 (TIMP-2)/pro-MMP-2. TIMPs1-4 are physiological MMP inhibitors with distinct roles in the regulation of pro-MMP-2 processing. Here, we have shown that individual Timp deficiencies differentially affect MMP-2 processing using primary mouse embryonic fibroblasts (MEFs). Timp-3 deficiency accelerated pro-MMP-2 activation in response to both cytochalasin D and concanavalin A. Exogenous TIMP-2 and N-TIMP-3 inhibited this activation, whereas TIMP-3 containing matrix from wild-type MEFs did not rescue the enhanced MMP-2 activation in Timp-3(-/-) cells. Increased processing of MMP-2 did not arise from increased expression of MT1-MMP, MT2-MMP, or MT3-MMP or altered expression of TIMP-2 and MMP-2. To test whether increased MMP-2 processing in Timp-3(-/-) MEFs is dependent on TIMP-2, double deficient Timp-2(-/-)/-3(-/-) MEFs were used. In these double deficient cells, the cleavage of pro-MMP-2 to its intermediate form was substantially increased, but the subsequent cleavage of intermediate-MMP-2 to fully active form, although absent in Timp-2(-/-) MEFs, was detectable with combined Timp-2(-/-)/-3(-/-) deficiency. TIMP-4 associates with MMP-2 and MT1-MMP in a manner similar to TIMP-3, but its deletion had no effect on pro-MMP-2 processing. Thus, TIMP-3 provides an inherent regulation over the kinetics of pro-MMP-2 processing, serving at a level distinct from that of TIMP-2 and TIMP-4.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Turku, Dept Med Biochem & Mol Biol, FI-20520 Turku, Finland; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, London W6 8LH, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turku; University of Cambridge; Cornell University; Imperial College London; University of Oxford	Khokha, R (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca	Soloway, Paul/T-8243-2019	Vuorio, Eero/0000-0003-3404-2439; Soloway, Paul/0000-0003-1967-0437; Khokha, Rama/0000-0002-6028-1524	MRC [G0400637] Funding Source: UKRI; Medical Research Council [G0400637] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ailenberg M, 1996, BIOCHEM J, V313, P879, DOI 10.1042/bj3130879; Atkinson SJ, 2004, FEBS LETT, V566, P65, DOI 10.1016/j.febslet.2004.04.040; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hornebeck W, 2002, SEMIN CANCER BIOL, V12, P231, DOI 10.1016/S1044-579X(02)00026-3; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Lafleur MA, 2003, FEBS LETT, V553, P457, DOI 10.1016/S0014-5793(03)01094-9; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Llano E, 1999, CANCER RES, V59, P2570; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mohammed FF, 2003, ANN RHEUM DIS, V62, P43; Monea S, 2002, J CELL PHYSIOL, V192, P160, DOI 10.1002/jcp.10126; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nabeshima K, 2000, CANCER RES, V60, P3364; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Peterson JT, 2001, CIRCULATION, V103, P2303; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Soloway PD, 1996, ONCOGENE, V13, P2307; STASKUS PW, 1991, J BIOL CHEM, V266, P449; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Velasco G, 2000, CANCER RES, V60, P877; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200	68	97	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10337	10346		10.1074/jbc.M512009200	http://dx.doi.org/10.1074/jbc.M512009200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469749	hybrid			2022-12-27	WOS:000236594300062
J	Buwitt-Beckmann, U; Heine, H; Wiesmuller, KH; Jung, G; Brock, R; Akira, S; Ulmer, AJ				Buwitt-Beckmann, U; Heine, H; Wiesmuller, KH; Jung, G; Brock, R; Akira, S; Ulmer, AJ			TLR1- and TLR6-independent recognition of bacterial lipopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; INNATE IMMUNE-SYSTEM; CELL WALL COMPONENTS; CUTTING EDGE; DIACYLATED LIPOPEPTIDES; PATTERN-RECOGNITION; ESCHERICHIA-COLI; LIPOPROTEINS; ACTIVATION; PATHWAYS	Bacterial cell walls contain lipoproteins/peptides, which are strong modulators of the innate immune system. Triacylated lipopeptides are assumed to be recognized by TLR2/TLR1-, whereas diacylated lipopeptides use TLR2/TLR6 heteromers for signaling. Following our initial discovery of TLR6-independent diacylated lipopeptides, we could now characterize di- and triacylated lipopeptides (e.g. Pam(2)C-SK4, Pam(3)C-GNNDESNISFKEK), which have stimulatory activity in TLR1- and in TLR6-deficient mice. Furthermore, for the first time, we present triacylated lipopeptides with short length ester-bound fatty acids (like PamOct(2)C-SSNASK(4)), which induce no response in TLR1- deficient cells. No differences in the phosphorylation of MAP kinases by lipopeptide analogs having different TLR2-coreceptor usage were observed. Blocking experiments indicated that different TLR2 heteromers recognize their specific lipopeptide ligands independently from each other. In summary, a triacylation pattern is necessary but not sufficient to render a lipopeptide TLR1- dependent, and a diacylation pattern is necessary but not sufficient to render a lipopeptide TLR6-dependent. Contrary to the current model, distinct lipopeptides are recognized by TLR2 in a TLR1- and TLR6-independent manner.	Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; EMC Microcollect GmbH, D-72070 Tubingen, Germany; Univ Tubingen, Inst Cell Biol, D-72076 Tubingen, Germany; Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	Forschungszentrum Borstel; Eberhard Karls University of Tubingen; EMC Microcollections GmbH; Eberhard Karls University of Tubingen; Osaka University	Ulmer, AJ (corresponding author), Res Ctr Borstel, Dept Immunol & Cell Biol, Pk Allee 22, D-23845 Borstel, Germany.	ajulmer@fz-borstel.de	Brock, Roland/O-9411-2019; Heine, Holger/H-4552-2012; Akira, Shizuo/C-3134-2009; Brock, Roland/K-2590-2012	Heine, Holger/0000-0001-8128-5068; Brock, Roland/0000-0003-1395-6127				Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akira S, 2003, J INFECT DIS, V187, pS356, DOI 10.1086/374749; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Boncheva M, 1996, LANGMUIR, V12, P5636, DOI 10.1021/la9605753; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; Buwitt-Beckmann U, 2005, FEBS J, V272, P6354, DOI 10.1111/j.1742-4658.2005.05029.x; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Grabiec A, 2004, J BIOL CHEM, V279, P48004, DOI 10.1074/jbc.M405311200; Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Into T, 2004, CELL MICROBIOL, V6, P187, DOI 10.1046/j.1462-5822.2003.00356.x; Kurt-Jones EA, 2004, J ENDOTOXIN RES, V10, P419, DOI 10.1179/096805104225006516; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; METZGER J, 1991, INT J PEPT PROT RES, V37, P46; Metzger J W, 1995, J Pept Sci, V1, P184, DOI 10.1002/psc.310010305; METZGER JW, 1993, BIOCHIM BIOPHYS ACTA, V1149, P29, DOI 10.1016/0005-2736(93)90021-Q; Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Omueti KO, 2005, J BIOL CHEM, V280, P36616, DOI 10.1074/jbc.M504320200; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; PRASS W, 1987, BIOCHIM BIOPHYS ACTA, V900, P116, DOI 10.1016/0005-2736(87)90283-5; Reichel F, 1999, J AM CHEM SOC, V121, P7989, DOI 10.1021/ja991319q; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Reschner A, 2003, EUR J IMMUNOL, V33, P2044, DOI 10.1002/eji.200323776; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; Spohn R, 2004, VACCINE, V22, P2494, DOI 10.1016/j.vaccine.2003.11.074; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; ULMER AJ, 1992, INFECT IMMUN, V60, P3309, DOI 10.1128/IAI.60.8.3309-3314.1992; WIESMULLER KH, 1992, INT J PEPT PROT RES, V40, P255; Yoshimura A, 1999, J IMMUNOL, V163, P1	40	198	203	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9049	9057		10.1074/jbc.M512525200	http://dx.doi.org/10.1074/jbc.M512525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455646	Green Published, hybrid			2022-12-27	WOS:000236404700009
J	Chen, L; Patel, RP; Teng, XJ; Bosworth, CA; Lancaster, JR; Matalon, S				Chen, L; Patel, RP; Teng, XJ; Bosworth, CA; Lancaster, JR; Matalon, S			Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitrosoglutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALVEOLAR EPITHELIAL-CELLS; DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; CHLORIDE CHANNELS; AIRWAY EPITHELIA; SODIUM-CHANNELS; CL-CHANNEL; CFTR; TRANSPORT; NITROSOTHIOLS	We investigated the mechanisms by which S-nitrosoglutathione (GSNO) alters cystic fibrosis transmembrane conductance regulator (CFTR) mediated chloride (Cl-) secretion across Calu-3 cells, an extensively used model of human airway gland serous cells. Confluent monolayers of Calu-3 cells, grown under an air-liquid interface, were mounted in Ussing chambers for the measurements of chloride short circuit current (I-sc) and trans-epithelial resistance (R-t). Addition of GSNO into the apical compartment of these chambers resulted in significant and sustained increase of I-sc with an IC50 of 3.2 +/- 1 mu M (mean +/- 1 S.E.; n = 6). Addition of either glibenclamide or pre-treatment of Calu-3 cells with the soluble guanylate cyclase inhibitor 1H-(1,2,4)-oxadiazolo[4,3-a]quinoxalin-1-one totally prevented the GSNO-induced increase of I-sc. Conversely, BAY 41-2272, a sGC stimulator, increased I-sc in a dose-response fashion. The GSNO increase of I-sc was reversed by addition of two phosphatases (PP2A1, PP2A2) into the apical compartment of Ussing chambers containing Calu-3 monolayers. Oxy-myoglobin (oxy-Mb, 300 mu M) added into the apical compartment of Ussing chambers either prior or after GSNO either completely prevented or immediately reversed the increase of I-sc. However, smaller concentrations of oxy-Mb (1-10 mu M), sufficient to scavenge NO in the medium (as assessed by direct measurement of NO in the Ussing chamber using an ISO-NO meter) decreased I-sc partially. Oxy-Mb did not reverse the increase of I-sc following addition of GSNO and cysteine (50 mu M). These findings indicate that GSNO stimulates Cl secretion via both cGMP-dependent and cGMP-independent mechanisms.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35205 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35205 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35205 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Matalon, S (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 901 19th St S,BMR 2,Rm 224, Birmingham, AL 35205 USA.	sadis@uab.edu		Patel, Rakesh/0000-0002-1526-4303	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031197, R01HL075540, R01HL070146, R37HL031197, R01HL071189, R01HL074391] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL71189, HL31197, HL075540, HL70146, HL51173, HL074391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; BERGER HA, 1993, J BIOL CHEM, V268, P2037; Chen L, 2004, AM J PHYSIOL-RENAL, V286, pF1202, DOI 10.1152/ajprenal.00352.2003; Cornwell TL, 2003, AM J PHYSIOL-CELL PH, V284, pC1516, DOI 10.1152/ajpcell.00268.2002; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; DEJONGE HR, 1976, NATURE, V262, P590, DOI 10.1038/262590a0; DuVall MD, 1998, AM J PHYSIOL-CELL PH, V274, pC1417, DOI 10.1152/ajpcell.1998.274.5.C1417; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Grasemann H, 1999, J PEDIATR-US, V135, P770, DOI 10.1016/S0022-3476(99)70101-0; Guo Y, 1998, AM J PHYSIOL-LUNG C, V274, pL369, DOI 10.1152/ajplung.1998.274.3.L369; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL898, DOI 10.1152/ajplung.1996.270.6.L898; He H, 2003, AM J PHYSIOL-RENAL, V284, pF1235, DOI 10.1152/ajprenal.00192.2002; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Jilling T, 1999, AM J PHYSIOL-LUNG C, V277, pL89, DOI 10.1152/ajplung.1999.277.1.L89; KOTAMRAJU S, 2005, IN PRESS FREE RADIC; Lancaster JR, 1996, METHOD ENZYMOL, V268, P31; Lazrak A, 2002, AM J PHYSIOL-LUNG C, V282, pL650, DOI 10.1152/ajplung.00370.2001; Matalon S, 2003, AM J PHYSIOL-LUNG C, V285, pL1184, DOI 10.1152/ajplung.00281.2003; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; MATALON S, 2005, P AM THORACIC SOC, V2, P299; MCCRAY PB, 1993, AM J RESP CELL MOL, V9, P578, DOI 10.1165/ajrcmb/9.6.578; Muanprasat C, 2004, J GEN PHYSIOL, V124, P125, DOI 10.1085/jgp.200409059; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Thome U, 2003, FREE RADICAL BIO MED, V35, P662, DOI 10.1016/S0891-5849(03)00392-7; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Wang W, 2005, J GEN PHYSIOL, V125, P127, DOI 10.1085/jgp.200409115; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; Zaman K, 2004, BIOCHEM J, V380, P67, DOI 10.1042/BJ20031687; Zaman K, 2001, BIOCHEM BIOPH RES CO, V284, P65, DOI 10.1006/bbrc.2001.4935; Zhang YH, 2005, FREE RADICAL BIO MED, V38, P831, DOI 10.1016/j.freeradbiomed.2004.12.016; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101	39	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9190	9199		10.1074/jbc.M513231200	http://dx.doi.org/10.1074/jbc.M513231200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16421103	hybrid			2022-12-27	WOS:000236404700025
J	Hirao, K; Natsuka, Y; Tamura, T; Wada, I; Morito, D; Natsuka, S; Romero, P; Sleno, B; Tremblay, LO; Herscovics, A; Nagata, K; Hosokawa, N				Hirao, K; Natsuka, Y; Tamura, T; Wada, I; Morito, D; Natsuka, S; Romero, P; Sleno, B; Tremblay, LO; Herscovics, A; Nagata, K; Hosokawa, N			EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; CLASS-I ALPHA-1,2-MANNOSIDASE; EARLY SECRETORY PATHWAY; SHORT-LIVED VARIANT; N-LINKED GLYCANS; QUALITY-CONTROL; SACCHAROMYCES-CEREVISIAE; ALPHA-MANNOSIDASE; MISFOLDED GLYCOPROTEINS; STRUCTURAL BASIS	Quality control in the endoplasmic reticulum ensures that only properly folded proteins are retained in the cell through mechanisms that recognize and discard misfolded or unassembled proteins in a process called endoplasmic reticulum-associated degradation (ERAD). We previously cloned EDEM ( ER degradation-enhancing alpha-mannosidase- like protein) and showed that it accelerates ERAD of misfolded glycoproteins. We now cloned mouse EDEM3, a soluble homolog of EDEM. EDEM3 consists of 931 amino acids and has all the signature motifs of Class I alpha-mannosidases ( glycosyl hydrolase family 47) in its N-terminal domain and a protease-associated motif in its C-terminal region. EDEM3 accelerates glycoprotein ERAD in transfected HEK293 cells, as shown by increased degradation of misfolded alpha 1-antitrypsin variant ( null ( Hong Kong)) and of TCR alpha. Overexpression of EDEM3 also greatly stimulates mannose trimming not only from misfolded alpha 1-AT null ( Hong Kong) but also from total glycoproteins, in contrast to EDEM, which has no apparent alpha 1,2-mannosidase activity. Furthermore, overexpression of the E147Q EDEM3 mutant, which has the mutation in one of the conserved acidic residues essential for enzyme activity of alpha 1,2-mannosidases, abolishes the stimulation of mannose trimming and greatly decreases the stimulation of ERAD by EDEM3. These results show that EDEM3 has alpha 1,2-mannosidase activity in vivo, suggesting that the mechanism whereby EDEM3 accelerates glycoprotein ERAD is different from that of EDEM.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068397, Japan; JST, CREST, Saitama 3320012, Japan; Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan; Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	Kyoto University; Japan Science & Technology Agency (JST); Fukushima Medical University; Osaka University; McGill University	Hosokawa, N (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068397, Japan.	nobuko@frontier.kyoto-u.ac.jp	Natsuka, Shunji/L-9330-2018	Morito, Daisuke/0000-0003-2263-8200; Natsuka, Shunji/0000-0003-1726-8946; Tamura, Taku/0000-0001-6074-9273; Wada, Ikuo/0000-0001-5668-6994				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Carninci P, 2003, GENOME RES, V13, P1273, DOI 10.1101/gr.1119703; Chillaron J, 2000, BIOL CHEM, V381, P1155, DOI 10.1515/BC.2000.143; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ermonval M, 2001, GLYCOBIOLOGY, V11, P565, DOI 10.1093/glycob/11.7.565; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Frenkel Z, 2003, J BIOL CHEM, V278, P34119, DOI 10.1074/jbc.M305929200; HASE S, 1994, METHOD ENZYMOL, V230, P225; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Huyer G, 2004, J BIOL CHEM, V279, P38369, DOI 10.1074/jbc.M402468200; Jakob CA, 2001, EMBO REP, V2, P423; Kitzmuller C, 2003, BIOCHEM J, V376, P687, DOI 10.1042/BJ20030887; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; Luo XM, 2001, TRENDS BIOCHEM SCI, V26, P147, DOI 10.1016/S0968-0004(00)01768-0; Mast SW, 2005, GLYCOBIOLOGY, V15, P421, DOI 10.1093/glycob/cwi014; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Movsichoff F, 2005, MOL BIOL CELL, V16, P4714, DOI 10.1091/mbc.E05-03-0246; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Olivari S, 2005, J BIOL CHEM, V280, P2424, DOI 10.1074/jbc.C400534200; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Sood R, 2001, GENOMICS, V73, P211, DOI 10.1006/geno.2001.6500; Tempel W, 2004, J BIOL CHEM, V279, P29774, DOI 10.1074/jbc.M403065200; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	49	189	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9650	9658		10.1074/jbc.M512191200	http://dx.doi.org/10.1074/jbc.M512191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431915	hybrid			2022-12-27	WOS:000236404700077
J	Sommer, ME; Smith, WC; Farrens, DL				Sommer, ME; Smith, WC; Farrens, DL			Dynamics of arrestin-rhodopsin interactions - Acidic phospholipids enable binding of arrestin to purified rhodopsin in detergent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PROTEIN-CONTAINING MEMBRANES; METARHODOPSIN-II; FUNCTIONAL-CHARACTERIZATION; PHOTORECEPTOR-MEMBRANES; VISUAL TRANSDUCTION; SIGNAL-TRANSDUCTION; COUPLED RECEPTOR; META-III; OPSIN	We report that acidic phospholipids can restore the binding of visual arrestin to purified rhodopsin solubilized in n-dodecyl-beta-D-maltopyranoside. We used this finding to investigate the interplay between arrestin binding and the status of the retinal chromophore ligand in the receptor binding pocket. Our results showed that arrestin can interact with the late photoproduct Meta III and convert it to a Meta II-like species. Interestingly in these mixed micelles, the release of retinal and arrestin was no longer directly coupled as it is in the native rod disk membrane. For example, up to similar to 50% of the retinal could be released even though arrestin remains bound to the receptor in a long lived complex. We anticipate that this new ability to study these proteins in a defined, purified system will facilitate further structural and dynamic studies of arrestin-rhodopsin interactions.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	Oregon Health & Science University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Farrens, DL (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	farrensd@ohsu.edu	Smith, W. Clay/AAQ-1589-2021	Sommer, Martha E./0000-0003-0493-8584	NEI NIH HHS [EY06225, EY08571] Funding Source: Medline; NIDA NIH HHS [DA14896] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alves ID, 2005, BIOPHYS J, V88, P198, DOI 10.1529/biophj.104.046722; ANDERSON RE, 1976, INVEST OPHTH VISUAL, V15, P232; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; AVELDANO MI, 1983, J LIPID RES, V24, P620; BOWNDS D, 1965, NATURE, V205, P254, DOI 10.1038/205254a0; Bubis J, 1998, BIOL RES, V31, P59; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6; Dupuy C, 1997, LANGMUIR, V13, P3965, DOI 10.1021/la9604285; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2003, VISION RES, V43, P3003, DOI 10.1016/j.visres.2003.08.011; Hessel E, 2003, J BIOL CHEM, V278, P22853, DOI 10.1074/jbc.M302747200; Hessel E, 2001, J BIOL CHEM, V276, P2538, DOI 10.1074/jbc.M009061200; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Kiselev A, 1996, BIOCHEMISTRY-US, V35, P1848, DOI 10.1021/bi951399k; KOSOWER EM, 1986, J PHYS CHEM-US, V90, P5552, DOI 10.1021/j100280a014; Kragh-Hansen U, 1998, BIOPHYS J, V75, P2932, DOI 10.1016/S0006-3495(98)77735-5; KRAGHHANSEN U, 1993, BIOCHEMISTRY-US, V32, P1648, DOI 10.1021/bi00057a032; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lichtenberg D, 2000, BBA-BIOMEMBRANES, V1508, P1, DOI 10.1016/S0304-4157(00)00004-6; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Mansoor SE, 2004, BIOCHEMISTRY-US, V43, P9426, DOI 10.1021/bi036259m; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Marsh D, 2004, BBA-BIOMEMBRANES, V1666, P118, DOI 10.1016/j.bbamem.2004.08.006; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Niu L, 2002, P NATL ACAD SCI USA, V99, P13409, DOI 10.1073/pnas.212518899; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pepe IM, 2001, PROG RETIN EYE RES, V20, P733, DOI 10.1016/S1350-9462(01)00013-1; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Seddon AM, 2004, BBA-BIOMEMBRANES, V1666, P105, DOI 10.1016/j.bbamem.2004.04.011; Sommer ME, 2005, J BIOL CHEM, V280, P6861, DOI 10.1074/jbc.M411341200; Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2004, BIOCHEMISTRY-US, V43, P9457, DOI 10.1021/bi049337u; Wang Y, 2002, J AM CHEM SOC, V124, P7690, DOI 10.1021/ja0200488; Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200	57	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9407	9417		10.1074/jbc.M510037200	http://dx.doi.org/10.1074/jbc.M510037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16428804	hybrid			2022-12-27	WOS:000236404700050
J	Acker, MG; Shin, BS; Dever, TE; Lorsch, JR				Acker, MG; Shin, BS; Dever, TE; Lorsch, JR			Interaction between eukaryotic initiation factors 1A and 5B is required for efficient ribosomal subunit joining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START-SITE SELECTION; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; TRANSFER-RNA; FACTOR IF2; FACTOR-II; IN-VIVO; BINDING; COMPLEX	Eukaryotic initiation factor 5B ( eIF5B) is aGTPase that facilitates joining of the 60 S ribosomal subunit to the 40 S ribosomal subunit during translation initiation. Formation of the resulting 80 S initiation complex triggers eIF5B to hydrolyze its bound GTP, reducing the affinity of the factor for the complex and allowing it to dissociate. Here we present a kinetic analysis of GTP hydrolysis by eIF5B in the context of the translation initiation pathway. Our data indicate that stimulation of GTP hydrolysis by eIF5B requires the completion of early steps in translation initiation, including the eIF1- and eIF1A- dependent delivery of initiator methionyl- tRNA to the 40 S ribosomal subunit and subsequent GTP hydrolysis by eIF2. Full activation of GTP hydrolysis by eIF5B requires the extreme C terminus of eIF1A, which has previously been shown to interact with the C terminus of eIF5B. Disruption of either isoleucine residue in the eIF1A C- terminal sequence DIDDI reduces the rate constant for GTP hydrolysis by similar to 20- fold, whereas changing the aspartic acid residues has no effect. Changing the isoleucines in the C terminus of eIF1A also disrupts the ability of eIF5B to facilitate subunit joining. These data indicate that the interaction of the C terminus of eIF1A with eIF5B promotes ribosomal subunit joining and possibly provides a checkpoint for correct complex formation, allowing full activation of GTP hydrolysis only upon formation of a properly organized 80 S initiation complex.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lorsch, JR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	jlorsch@jhmi.edu	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678; Lorsch, Jon/0000-0002-4521-4999; Acker, Michael/0000-0002-3565-9601	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Algire MA, 2005, MOL CELL, V20, P251, DOI 10.1016/j.molcel.2005.09.008; Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Allen GS, 2005, CELL, V121, P703, DOI 10.1016/j.cell.2005.03.023; Antoun A, 2003, EMBO J, V22, P5593, DOI 10.1093/emboj/cdg525; Battiste JL, 2000, MOL CELL, V5, P109, DOI 10.1016/S1097-2765(00)80407-4; BOILEAU G, 1983, BIOCHEMISTRY-US, V22, P3162, DOI 10.1021/bi00282a020; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; Choi SK, 2000, MOL CELL BIOL, V20, P7183, DOI 10.1128/MCB.20.19.7183-7191.2000; FAKUNDING JL, 1973, J BIOL CHEM, V248, P4206; Fekete CA, 2005, EMBO J, V24, P3588, DOI 10.1038/sj.emboj.7600821; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; Guillon L, 2005, BIOCHEMISTRY-US, V44, P15594, DOI 10.1021/bi051514j; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kapp LD, 2004, J MOL BIOL, V335, P923, DOI 10.1016/j.jmb.2003.11.025; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; Laursen BS, 2005, MICROBIOL MOL BIOL R, V69, P101, DOI 10.1128/MMBR.69.1.101-123.2005; Lee JH, 2002, P NATL ACAD SCI USA, V99, P16689, DOI 10.1073/pnas.262569399; Lomakin IB, 2006, EMBO J, V25, P196, DOI 10.1038/sj.emboj.7600904; Lomakin IB, 2003, GENE DEV, V17, P2786, DOI 10.1101/gad.1141803; Lorsch JR, 1999, EMBO J, V18, P6705, DOI 10.1093/emboj/18.23.6705; Maag D, 2006, J MOL BIOL, V356, P724, DOI 10.1016/j.jmb.2005.11.083; Maag D, 2005, MOL CELL, V17, P265, DOI 10.1016/j.molcel.2004.11.051; Maag D, 2003, J MOL BIOL, V330, P917, DOI 10.1016/S0022-2836(03)00665-X; Marintchev A, 2004, Q REV BIOPHYS, V37, P197, DOI 10.1017/S0033583505004026; Marintchev A, 2003, P NATL ACAD SCI USA, V100, P1535, DOI 10.1073/pnas.0437845100; Moreno JMP, 1999, FEBS LETT, V455, P130, DOI 10.1016/S0014-5793(99)00858-3; Myasnikov AG, 2005, NAT STRUCT MOL BIOL, V12, P1145, DOI 10.1038/nsmb1012; Olsen DS, 2003, EMBO J, V22, P193, DOI 10.1093/emboj/cdg030; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Roll-Mecak A, 2001, TRENDS BIOCHEM SCI, V26, P705, DOI 10.1016/S0968-0004(01)02024-2; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; Shin BS, 2002, CELL, V111, P1015, DOI 10.1016/S0092-8674(02)01171-6; WAKAO H, 1989, J BIOL CHEM, V264, P20363	34	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8469	8475		10.1074/jbc.M600210200	http://dx.doi.org/10.1074/jbc.M600210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16461768	hybrid			2022-12-27	WOS:000236247100022
J	Heinemann, S; Biesinger, B; Fleckenstein, B; Albrecht, JC				Heinemann, S; Biesinger, B; Fleckenstein, B; Albrecht, JC			NF kappa B signaling is induced by the oncoprotein tio through direct interaction with TRAF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; RECEPTOR-ASSOCIATED FACTORS; LATENT MEMBRANE-PROTEIN; HUMAN T-CELLS; HERPESVIRUS SAIMIRI STP; LCK-BINDING ELEMENTS; GROWTH TRANSFORMATION; TRANSCRIPTION FACTORS; LYMPHOCYTE-TRANSFORMATION; GENE-EXPRESSION	The transcription factor NF kappa B is a major regulator of genes involved in inflammation and oncogenesis. NF kappa B is induced upon stimulation of cellular receptors coupled to different intracellular signaling molecules. Further downstream, TRAF6 links at least two receptor pathways to take control of I kappa B, the administrator of NF kappa B activity. Here we report on a strong NF kappa B activation by Tio, a unique herpesviral oncoprotein promoting transformation of human T cells in a Src-kinase-dependent manner. NF kappa B induction by Tio is independent of Src-kinase interaction and tyrosine phosphorylation of Tio. Mutation of a glutamic acid-rich motif at the N terminus of Tio, corresponding to a TRAF6 consensus binding motif, completely abrogated NF kappa B activation. Cotransfection of a dominant negative TRAF6 construct led to a decrease in NF kappa B activation. Furthermore, we provide evidence that TRAF6 directly binds to the Tio oncoprotein. Identification of TRAF6 as the direct target of Tio describes a novel mechanism for the constitutive activation of NF kappa B through an oncoprotein.	Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Heinemann, S (corresponding author), Univ Erlangen Nurnberg, Inst Klin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	stefanie.heinemann@viro.med.uni-erlangen.de						AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Albrecht JC, 2005, J VIROL, V79, P10507, DOI 10.1128/JVI.79.16.10507-10513.2005; Albrecht JC, 2004, J VIROL, V78, P9814, DOI 10.1128/JVI.78.18.9814-9819.2004; Albrecht JC, 1999, J VIROL, V73, P4631, DOI 10.1128/JVI.73.6.4631-4639.1999; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bauer F, 2004, BIOCHEMISTRY-US, V43, P14932, DOI 10.1021/bi0485068; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Choi JK, 2000, J VIROL, V74, P8102, DOI 10.1128/JVI.74.17.8102-8110.2000; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; FALK L, 1974, INT J CANCER, V14, P244, DOI 10.1002/ijc.2910140213; FALK L, 1978, INT J CANCER, V21, P652, DOI 10.1002/ijc.2910210517; FALK LA, 1974, INT J CANCER, V14, P473, DOI 10.1002/ijc.2910140407; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; Heck E, 2005, J VIROL, V79, P5713, DOI 10.1128/JVI.79.9.5713-5720.2005; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Izumi KM, 2004, PROG MOL SUBCELL BIO, V36, P269; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jung JU, 1999, SEMIN CANCER BIOL, V9, P231, DOI 10.1006/scbi.1998.0115; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kundu JK, 2004, MUTAT RES-FUND MOL M, V555, P65, DOI 10.1016/j.mrfmmm.2004.05.019; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li YQ, 2005, J BIOL CHEM, V280, P1217, DOI 10.1074/jbc.M409492200; Li ZW, 2004, MOL IMMUNOL, V41, P701, DOI 10.1016/j.molimm.2004.04.012; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Rincon M, 1996, MOL CELL BIOL, V16, P1074; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; TSAN MF, 2005, SEMIN CANC BIOL; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wehner LE, 2001, DNA CELL BIOL, V20, P81, DOI 10.1089/104454901750070283; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	72	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8565	8572		10.1074/jbc.M510891200	http://dx.doi.org/10.1074/jbc.M510891200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452479	hybrid			2022-12-27	WOS:000236247100032
J	Robertson, A; Pattishall, SR; Matson, SW				Robertson, A; Pattishall, SR; Matson, SW			The DNA binding activity of MutL is required for methyl-directed mismatch repair in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HELICASE-II; GENE-PRODUCT; D(GATC) SEQUENCES; DEPENDENT MANNER; IN-VIVO; UVRD; RECOMBINATION; MUTATIONS; PROTEINS	The DNA binding properties of the mismatch repair protein MutL and their importance in the repair process have been controversial for nearly two decades. We have addressed this issue using a point mutant of MutL ( MutL- R266E). The biochemical and genetic data suggest that DNA binding by MutL is required for dam methylation-directed mismatch repair. We demonstrate that purified MutL- R266E retains wild- type biochemical properties that do not depend on DNA binding, such as basal ATP hydrolysis in the absence of DNA and the ability to interact with other mismatch repair proteins. However, purified MutL- R266E binds DNA poorly in vitro as compared with MutL, and consistent with this observation, its DNA- dependent biochemical activities, like DNA- stimulated ATP hydrolysis and helicase II stimulation, are severely compromised. In addition, there is a modest effect on stimulation of MutH- catalyzed nicking. Finally, genetic assays show that MutLR-266E has a strong mutator phenotype, demonstrating that the mutant is unable to function in dam methylation- directed mismatch repair in vivo.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Matson, SW (corresponding author), Univ N Carolina, Dept Biol, CB 3280,Coker Hall, Chapel Hill, NC 27599 USA.	smatson@bio.unc.edu						Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BRUNI R, 1988, NUCLEIC ACIDS RES, V16, P4875, DOI 10.1093/nar/16.11.4875; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; FEINSTEIN SI, 1986, GENETICS, V113, P13; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Giron-Monzon L, 2004, J BIOL CHEM, V279, P49338, DOI 10.1074/jbc.M409307200; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 2003, NUCLEIC ACIDS RES, V31, P2025, DOI 10.1093/nar/gkg324; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; Kosinski J, 2005, J MOL BIOL, V351, P895, DOI 10.1016/j.jmb.2005.06.044; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Luria SE, 1943, GENETICS, V28, P491; MATSON SW, 1986, J BIOL CHEM, V261, P169; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICKOLOFF JA, 1998, DNA DAMAGE REPAIR, P205; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Rosche WA, 2000, METHODS, V20, P4, DOI 10.1006/meth.1999.0901; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6	48	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8399	8408		10.1074/jbc.M509184200	http://dx.doi.org/10.1074/jbc.M509184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446358	hybrid			2022-12-27	WOS:000236247100014
J	Schlenker, O; Hendricks, A; Sinning, I; Wild, K				Schlenker, O; Hendricks, A; Sinning, I; Wild, K			The structure of the mammalian signal recognition particle (SRP) receptor as prototype for the interaction of small GTPases with longin domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ADP-RIBOSYLATION FACTOR; BETA-SUBUNIT; CRYSTAL-STRUCTURE; SPONDYLOEPIPHYSEAL DYSPLASIA; DEPENDENT BINDING; RIBOSOME BINDING; ALPHA-SUBUNIT; RAB GTPASES; PROTEIN	The eukaryotic signal recognition particle (SRP) and its receptor (SR) play a central role in co-translational targeting of secretory and membrane proteins to the endoplasmic reticulum. The SR is a heterodimeric complex assembled by the two GTPases SR alpha and SR beta, which is membrane-anchored. Here we present the 2.45-angstrom structure of mammalian SR beta in its Mg2+ GTP-bound state in complex with the minimal binding domain of SR alpha termed SRX. SR beta is a member of the Ras-GTPase superfamily closely related to Arf and Sar1, while SRX belongs to the SNARE-like superfamily with a fold also known as longin domain. SRX binds to the P loop and the switch regions of SR beta-GTP. The binding mode and structural similarity with other GTPase-effector complexes suggests a co-GAP (GTPase-activating protein) function for SRX. Comparison with the homologous yeast structure and other longin domains reveals a conserved adjustable hydrophobic surface within SRX which is of central importance for the SR beta-GTP:SRX interface. A helix swap in SRX results in the formation of a dimer in the crystal structure. Based on structural conservation we present the SR beta-GTP:SRX structure as a prototype for conserved interactions in a variety of GTPase regulated targeting events occurring at endomembranes.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Wild, K (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	klemens.wild@bzh.uni-heidelberg.de	Sinning, Irmgard/A-2982-2010					Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Cheng ZL, 2005, J CELL BIOL, V168, P67, DOI 10.1083/jcb.200408188; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Doudna JA, 2004, ANNU REV BIOCHEM, V73, P539, DOI 10.1146/annurev.biochem.73.011303.074048; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; Egea PF, 2005, CURR OPIN STRUC BIOL, V15, P213, DOI 10.1016/j.sbi.2005.03.007; Filippini F, 2001, TRENDS BIOCHEM SCI, V26, P407, DOI 10.1016/S0968-0004(01)01861-8; Focia PJ, 2004, SCIENCE, V303, P373, DOI 10.1126/science.1090827; Fulga TA, 2001, EMBO J, V20, P2338, DOI 10.1093/emboj/20.9.2338; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Heldwein EE, 2004, P NATL ACAD SCI USA, V101, P14108, DOI 10.1073/pnas.0406102101; Helmers J, 2003, J BIOL CHEM, V278, P23686, DOI 10.1074/jbc.C300180200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang MD, 2001, J CELL BIOL, V155, P937, DOI 10.1083/jcb.200106039; Jang SB, 2002, J BIOL CHEM, V277, P49863, DOI 10.1074/jbc.M207436200; Jekely G, 2003, BIOESSAYS, V25, P1129, DOI 10.1002/bies.10353; Jones S, 2000, MOL BIOL CELL, V11, P4403, DOI 10.1091/mbc.11.12.4403; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Legate KR, 2000, J BIOL CHEM, V275, P27439; Legate KR, 2003, J BIOL CHEM, V278, P27712, DOI 10.1074/jbc.M302158200; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; MacKenzie JJ, 1996, J MED GENET, V33, P823, DOI 10.1136/jmg.33.10.823; Mandon EC, 2003, J CELL BIOL, V162, P575, DOI 10.1083/jcb.200303143; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Memon AR, 2004, BBA-BIOMEMBRANES, V1664, P9, DOI 10.1016/j.bbamem.2004.04.005; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rossi V, 2004, TRENDS BIOCHEM SCI, V29, P682, DOI 10.1016/j.tibs.2004.10.002; Sacher M, 2003, FEBS LETT, V550, P1, DOI 10.1016/S0014-5793(03)00854-8; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schwartz T, 2003, CELL, V112, P793, DOI 10.1016/S0092-8674(03)00161-2; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wang W, 2000, J CELL BIOL, V151, P289, DOI 10.1083/jcb.151.2.289; Wild K, 2004, MOL MICROBIOL, V53, P357, DOI 10.1111/j.1365-2958.2004.04139.x; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198	60	39	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8898	8906		10.1074/jbc.M512415200	http://dx.doi.org/10.1074/jbc.M512415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16439358	hybrid			2022-12-27	WOS:000236247100070
J	Xu, DG; Xie, DQ; Guo, H				Xu, DG; Xie, DQ; Guo, H			Catalytic mechanism of class B2 metallo-beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-FUNCTIONAL-THEORY; SCC-DFTB METHOD; BACILLUS-CEREUS; BACTEROIDES-FRAGILIS; ACTIVE-SITE; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; COORDINATION GEOMETRY; ALKALINE-HYDROLYSIS; ANGSTROM RESOLUTION	The initial nucleophilic substitution step of biapenem hydrolysis catalyzed by a subclass B2 metallo-beta-lactamase (CphA from Aeromonas hydrophila) is investigated using hybrid quantum mechanical/ molecular mechanical methods and density functional theory. We focused on a recently proposed catalytic mechanism that involves a non-metal-binding water nucleophile in the active site of the monozinc CphA. Both theoretical models identified a single transition state featuring nearly concomitant nucleophilic addition and elimination steps, and the activation free energy from the potential of mean force calculations was estimated to be similar to 14 kcal/ mol. The theoretical results also identified the general base for activating the water nucleophile to be the metal-binding Asp-120 rather than His-118, as suggested earlier. The protonation of Asp-120 leads to cleavage of the O-delta 2-Zn coordination bond, whereas the negatively charged nitrogen leaving group resulting from the ring opening replaces Asp-120 as the fourth ligand of the sole zinc ion. The electrophilic catalysis by the metal ion provides sufficient stabilization for the leaving group to avoid a tetrahedral intermediate. The theoretical studies provided detailed insights into the catalytic strategy of this unique metallo-beta-lactamase.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Nanjing Univ, Inst Theoret & Computat Chem, Dept Chem, Nanjing 210093, Peoples R China	University of New Mexico; Nanjing University	Guo, H (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	hguo@unm.edu	Guo, H./J-2685-2014	Guo, H./0000-0001-9901-053X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P7208, DOI 10.1021/bi00370a066; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1989, J MOL BIOL, V208, P159, DOI 10.1016/0022-2836(89)90093-4; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Coll M, 2000, J PHYS CHEM B, V104, P11389, DOI 10.1021/jp001989e; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crawford PA, 2005, BIOCHEMISTRY-US, V44, P5168, DOI 10.1021/bi047463s; Cui Q, 2001, J PHYS CHEM B, V105, P569, DOI 10.1021/jp0029109; Dal Peraro M, 2004, J AM CHEM SOC, V126, P12661, DOI 10.1021/ja048071b; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; Diaz N, 2000, J AM CHEM SOC, V122, P4197, DOI 10.1021/ja994462s; Diaz N, 2002, CHEM-EUR J, V8, P859, DOI 10.1002/1521-3765(20020215)8:4<859::AID-CHEM859>3.0.CO;2-I; Elstner M, 1998, PHYS REV B, V58, P7260, DOI 10.1103/PhysRevB.58.7260; Elstner M, 2003, J COMPUT CHEM, V24, P565, DOI 10.1002/jcc.10201; Elstner M, 2001, J CHEM PHYS, V114, P5149, DOI 10.1063/1.1329889; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; FISCHER S, 1992, CHEM PHYS LETT, V194, P252, DOI 10.1016/0009-2614(92)85543-J; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Gao JL, 2002, ANNU REV PHYS CHEM, V53, P467, DOI 10.1146/annurev.physchem.53.091301.150114; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Garrity JD, 2005, BIOCHEMISTRY-US, V44, P1078, DOI 10.1021/bi048385b; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812; LIM HM, 1991, BIOCHEM J, V276, P401, DOI 10.1042/bj2760401; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Olsen L, 2003, J PHYS CHEM B, V107, P2366, DOI 10.1021/jp0275950; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Park H, 2005, J AM CHEM SOC, V127, P4232, DOI 10.1021/ja042607b; Prosperi-Meys C, 2001, CELL MOL LIFE SCI, V58, P2136, DOI 10.1007/PL00000843; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; RICCARDI D, IN PRESS J PHYS CH B; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; TORRIE GM, 1977, J COMPUT PHYS, V23, P187, DOI 10.1016/0021-9991(77)90121-8; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Warshel A, 2003, ANNU REV BIOPH BIOM, V32, P425, DOI 10.1146/annurev.biophys.32.110601.141807; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; Xu DG, 2005, J MED CHEM, V48, P6679, DOI 10.1021/jm0505112; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	49	64	67	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8740	8747		10.1074/jbc.M512517200	http://dx.doi.org/10.1074/jbc.M512517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16423823	hybrid			2022-12-27	WOS:000236247100052
J	Park, JW; Je, BR; Piao, S; Inamura, S; Fujimoto, Y; Fukase, K; Kusumoto, S; Soderhall, K; Ha, NC; Lee, BL				Park, JW; Je, BR; Piao, S; Inamura, S; Fujimoto, Y; Fukase, K; Kusumoto, S; Soderhall, K; Ha, NC; Lee, BL			A synthetic peptidoglycan fragment as a competitive inhibitor of the melanization cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TENEBRIO-MOLITOR LARVAE; PROPHENOLOXIDASE-ACTIVATING SYSTEM; PATTERN-RECOGNITION PROTEIN; IMMUNE-RESPONSES; INNATE IMMUNITY; BOMBYX-MORI; BORDETELLA-PERTUSSIS; DIAMINOPIMELIC ACID; PRO-PHENOLOXIDASE; SERINE-PROTEASE	Melanin synthesis is essential for defense and development but must be tightly controlled because systemic hyperactivation of the prophenoloxidase and excessive melanin synthesis are deleterious to the hosts. The melanization cascade of the arthropods can be activated by bacterial lysine-peptidoglycan (PGN), diaminopimelic acid (DAP)-PGN, or fungal beta-1,3-glucan. The molecular mechanism of how DAP- or Lys-PGN induces melanin synthesis and which molecules are involved in distinguishing these PGNs are not known. The identification of PGN derivatives that can work as inhibitors of the melanization cascade and the characterization of PGN recognition molecules will provide important information to clarify how the melanization is regulated and controlled. Here, we report that a novel synthetic Lys-PGN fragment ((GlcNAc-Mur-NAc- L-Ala-D-isoGln-L-Lys-D-Ala)(2), T-4P(2)) functions as a competitive inhibitor of the natural PGN-induced melanization reaction. By using a T-4P(2)-coupled column, we purified the Tenebrio molitor PGN recognition protein (Tm-PGRP) without causing activation of the prophenoloxidase. The purified Tm-PGRP recognized both Lys- and DAP- PGN. In vitro reconstitution experiments showed that Tm-PGRP functions as a common recognition molecule of Lys- and DAP- PGN-dependent melanization cascades.	Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Pusan National University; Osaka University; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Fujimoto, Yukari/M-7282-2014	Fujimoto, Yukari/0000-0001-5320-3192				Ashida Masaaki, 1998, P135; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Cho JH, 2005, BLOOD, V106, P2551, DOI 10.1182/blood-2005-02-0530; COOKSON BT, 1989, INFECT IMMUN, V57, P2223, DOI 10.1128/IAI.57.7.2223-2229.1989; COOKSON BT, 1989, BIOCHEMISTRY-US, V28, P1744, DOI 10.1021/bi00430a048; DAQUINAG AC, 1995, P NATL ACAD SCI USA, V92, P2964, DOI 10.1073/pnas.92.7.2964; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Guan RJ, 2005, J MOL BIOL, V347, P683, DOI 10.1016/j.jmb.2005.01.070; GUPTA D, 1995, J IMMUNOL, V155, P2620; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Iketani M, 1999, INSECT BIOCHEM MOLEC, V29, P19, DOI 10.1016/S0965-1748(98)00099-X; Inamura S, 2006, ORG BIOMOL CHEM, V4, P232, DOI 10.1039/b511866b; Inamura S, 2001, TETRAHEDRON LETT, V42, P7613, DOI 10.1016/S0040-4039(01)01619-7; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kanost Michael R, 2004, Immunol Rev, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kumar S, 2005, J BIOL CHEM, V280, P37005, DOI 10.1074/jbc.M506385200; Lee HS, 1999, FEBS LETT, V444, P255, DOI 10.1016/S0014-5793(99)00067-8; Lee KM, 2000, EUR J BIOCHEM, V267, P3695, DOI 10.1046/j.1432-1327.2000.01402.x; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liang ZC, 1997, P NATL ACAD SCI USA, V94, P6682, DOI 10.1073/pnas.94.13.6682; Lien E, 2001, J BIOL CHEM, V276, P1873, DOI 10.1074/jbc.M009040200; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; Mellroth P, 2005, P NATL ACAD SCI USA, V102, P6455, DOI 10.1073/pnas.0407559102; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Nikulina M, 2004, J IMMUNOL, V173, P1925, DOI 10.4049/jimmunol.173.3.1925; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Parker LC, 2004, J IMMUNOL, V172, P4977, DOI 10.4049/jimmunol.172.8.4977; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Piao S, 2005, BBA-PROTEINS PROTEOM, V1752, P103, DOI 10.1016/j.bbapap.2005.05.008; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHLEIFER KH, 1983, ANNU REV MICROBIOL, V37, P143, DOI 10.1146/annurev.mi.37.100183.001043; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; YOSHIDA H, 1986, BIOCHEM BIOPH RES CO, V141, P1177, DOI 10.1016/S0006-291X(86)80168-1; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200; Zhao MY, 2005, J BIOL CHEM, V280, P24744, DOI 10.1074/jbc.M504173200; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200	52	46	52	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7747	7755		10.1074/jbc.M510058200	http://dx.doi.org/10.1074/jbc.M510058200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421099	hybrid			2022-12-27	WOS:000236031000007
J	Song, K; Krebs, TL; Danielpour, D				Song, K; Krebs, TL; Danielpour, D			Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression - Mediation by stabilization of TGF-beta receptor type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC EPITHELIAL-CELLS; BREAST-CANCER CELLS; MALIGNANT-TRANSFORMATION; INDUCED APOPTOSIS; MESSENGER-RNA; EXPRESSION; ACTIVATION; PATHWAY; PROTEIN; GROWTH-FACTOR-BETA-1	Transforming growth factor beta (TGF-beta) signals through TGF-beta receptor serine/threonine kinases (T beta RI and T beta RII) and Smads, regulating cell growth and apoptosis. Although loss of TGF-beta receptor levels is strongly selected for during the progression of most cancers, tumor cells frequently escape from complete loss of TGF-beta receptors through unknown mechanisms. Here, we provide the first evidence that epidermal growth factor (EGF) signaling, which is generally enhanced in cancer, is permissive for regulation of gene expression and growth suppression by TGF-beta in LNCaP prostate adenocarcinoma cells. Our results support that these permissive effects occur through enhanced stability of T beta RII mRNA and reversal of TGF-beta-mediated T beta RII mRNA loss. Changes in stability of T beta RII mRNA occur soon after EGF or TGF-beta 1 addition ( optimal within 3 h) and are independent of de novo protein synthesis or transcription. Remarkably, such loss of T beta RII by TGF-beta can be mediated by a kinase-dead T beta RII (K277R), as well as by other forms of this receptor harboring mutations at prominent autophosphorylation sites. Moreover, Smad3 small interfering RNA, which blocks TGF-beta-induced AP-1 promoter activity, does not block changes in the expression of T beta RII by EGF or TGF-beta. We have also shown that changes in T beta RII levels by EGF are EGF receptor-kinase-dependent and are controlled by signals downstream of MEK1/2. Our findings provide invaluable insights on the role of the EGF receptor-kinase in enhancing TGF-beta responses during prostate carcinogenesis.	Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Danielpour, D (corresponding author), Case Canc Ctr Res Labs, Wolstein Res Bldg,Rm 3532,2103 Cornell Rd, Cleveland, OH 44106 USA.	dxd49@case.edu			NCI NIH HHS [R01CA102074, R01CA092102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102074, R01CA092102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Chang J, 1997, CANCER RES, V57, P2856; Chen XY, 2004, ONCOGENE, V23, P1854, DOI 10.1038/sj.onc.1207308; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; DANIELPOUR D, 1995, J IMMUNOL METHODS, V180, P265, DOI 10.1016/0022-1759(94)00322-N; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; DANIELPOUR D, 1991, J CELL PHYSIOL, V148, P235, DOI 10.1002/jcp.1041480208; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Dore JJE, 2001, MOL BIOL CELL, V12, P675, DOI 10.1091/mbc.12.3.675; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Fombonne J, 2004, MOL BIOL CELL, V15, P4938, DOI 10.1091/mbc.E04-07-0601; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; Garamszegi N, 2001, MOL BIOL CELL, V12, P2881, DOI 10.1091/mbc.12.9.2881; Guo YP, 1999, CANCER RES, V59, P1366; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hsing AY, 1996, CANCER RES, V56, P5146; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ilio KY, 1995, J ANDROL, V16, P482; Jakowlew SB, 1997, ANTICANCER RES, V17, P1849; Jones HE, 1997, PROSTATE, V30, P219, DOI 10.1002/(SICI)1097-0045(19970301)30:4<219::AID-PROS1>3.0.CO;2-G; Juarranz MG, 2001, CELL SIGNAL, V13, P887, DOI 10.1016/S0898-6568(01)00199-1; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1998, EXP CELL RES, V241, P151, DOI 10.1006/excr.1998.4034; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kutz SM, 2001, J CELL SCI, V114, P3905; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LANDIS MD, 2005, ONCOGENE; Lee BI, 2001, CANCER RES, V61, P931; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; McCaffrey TA, 1999, J MOL CELL CARDIOL, V31, P1627, DOI 10.1006/jmcc.1999.0999; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; ROBERTS AB, 1983, FED PROC, V42, P2621; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, P414; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Song K, 2003, CANCER RES, V63, P4358; Stewart LMV, 2003, EXP CELL RES, V284, P303, DOI 10.1016/S0014(02)00037-X; Tang BW, 1999, CANCER RES, V59, P4834; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yamane K, 2003, ARTHRITIS RHEUM-US, V48, P1652, DOI 10.1002/art.11029; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521	70	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7765	7774		10.1074/jbc.M511781200	http://dx.doi.org/10.1074/jbc.M511781200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428382	hybrid			2022-12-27	WOS:000236031000009
J	Bachmann, RA; Kim, JH; Wu, AL; Park, IH; Chen, J				Bachmann, RA; Kim, JH; Wu, AL; Park, IH; Chen, J			A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; REPRESSOR PHAS-I; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; SEQUENCE REQUIREMENTS; BINDING PARTNER; EXPORT SIGNAL; PHOSPHORYLATION; DOMAIN; RAPTOR; MTOR	The mammalian target of rapamycin ( mTOR) regulates nutrient-dependent cell growth and proliferation through cytoplasmic targets, such as S6 kinase 1 (S6K1). Consistent with its main function in the cytoplasm, mTOR is predominantly cytoplasmic. However, previously we have found that mTOR shuttles between the nucleus and cytoplasm, and we have proposed that the nucleocytoplasmic shuttling of mTOR is required for the maximal activation of S6K1. The intrinsic signals directing mTOR nuclear transport and the underlying mechanisms are unknown. In this study we initially set out to identify nuclear export signals in mTOR. A systematic scan of the mTOR sequence revealed 16 peptides conforming to the canonical leucine-rich nuclear export signal, of which 3 were found by reporter assays to contain leptomycin B-sensitive and leucine-dependent nuclear export activity. Unexpectedly, mTOR proteins with those conserved leucines mutated to alanines were unable to enter the nucleus. Further investigation revealed that the L982A/ L984A and L1287A/L1289A mutations likely induced a global structural change in mTOR, whereas the L545A/L547A mutation directly impaired the nuclear import of the protein, potentially regulated by a nucleocytoplasmic shuttling signal. The loss of nuclear import was accompanied by the significantly reduced ability of the L545A/L547A mutant to activate S6K1 in cells. Most importantly, when nuclear import was restored in the L545A/L547A mutant by the addition of an exogenous nuclear import signal, signaling to S6K1 was rescued. Taken together, our observations suggest the existence of a nuclear shuttling signal in mTOR and provide definitive evidence for the requirement of mTOR nuclear import in its cytoplasmic signaling to S6K1.	Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), 601 S Goodwin Ave,B107, Urbana, IL 61801 USA.	jiechen@uiuc.edu		Chen, Jie/0000-0002-7887-3747	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058064, R55GM058064] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 48914] Funding Source: Medline; NIGMS NIH HHS [GM 58064] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; DRENAN RM, 2003, J BIOL CHEM, V24, P24; Dupont S, 1999, NATURE, V402, P681, DOI 10.1038/45272; Erbay E., 2005, Nutrients and cell signaling, P353; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Tirado OM, 2003, CANCER RES, V63, P6290; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200	47	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7357	7363		10.1074/jbc.M512218200	http://dx.doi.org/10.1074/jbc.M512218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407298	hybrid			2022-12-27	WOS:000236030900055
J	Ge, WT; Hu, HG; Ding, KF; Sun, LF; Zheng, S				Ge, WT; Hu, HG; Ding, KF; Sun, LF; Zheng, S			Protein interaction analysis of ST14 domains and their point and deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; SERINE-PROTEASE; MATRIPTASE; IDENTIFICATION; TMEFF1; HYBRIDIZATION; LOCALIZATION; INHIBITORS; ACTIVATOR	ST14 ( suppression of tumorigenicity 14) is a transmembrane serine protease that contains a serine protease catalytic (SP) domain, an SEA domain, two complement subcomponent C1r/s ( CUB) domains, and four low density lipoprotein receptor class A domains. Glutathione S-transferase fusion proteins with SP, CUB, and low density lipoprotein receptor domains and their corresponding mutants were generated to analyze protein interactions with these domains. Modified glutathione S-transferase pull-down assays demonstrated the interaction between the SP domain and hepatocyte growth factor activator inhibitor-1. With the same method, a CUB domain-interacting protein was isolated and turned out to be the transmembrane protein with epidermal growth factor-like and two follistatin-like domains 1 (TMEFF1). Quantitative real time PCR revealed that the expression of the TMEFF1 gene was dependent on the transfection of the ST14 gene in the RKO cell line. Our results also suggested that ST14 and TMEFF1 were co-expressed in the human breast cancer cell line MCF7, human placenta, kidney, and liver tissues. Interestingly, these two genes were co-upregulated in kidney tumors versus normal tissues, consistent with our results that showed the dependence of TMEFF1 expression on ST14 in RKO cells. Finally, homology modeling studies suggested that TMEFF1 might form a complex with ST14 by an interaction between epidermal growth factor and CUB domains.	Zhejiang Univ, Coll Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310009, Peoples R China; Zhejiang Univ, Coll Life Sci, Hangzhou 310029, Peoples R China	Zhejiang University; Zhejiang University	Zheng, S (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310009, Peoples R China.	zhengshu@zju.edu.cn	GE, Weiting/AAK-5197-2020	GE, Weiting/0000-0002-4769-0251				Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Bhatt AS, 2003, BIOL CHEM, V384, P257, DOI 10.1515/BC.2003.029; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Cao J, 2001, CHINESE MED J-PEKING, V114, P726; Cao Jiang, 2005, Shi Yan Sheng Wu Xue Bao, V38, P183; Cao JN, 1997, J CANCER RES CLIN, V123, P447, DOI 10.1007/s004320050085; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; Gery S, 2003, ONCOGENE, V22, P2723, DOI 10.1038/sj.onc.1206351; Grimmond SM, 2003, GENOME RES, V13, P1350, DOI 10.1101/gr.983703; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kanemoto N, 2001, MOL BRAIN RES, V86, P48, DOI 10.1016/S0169-328X(00)00257-6; Kang JY, 2003, CANCER RES, V63, P1101; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Li WZ, 2002, PROTEIN ENG, V15, P643, DOI 10.1093/protein/15.8.643; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Orlinick JR, 1996, J BIOL CHEM, V271, P8627, DOI 10.1074/jbc.271.15.8627; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Sambrook J., 2001, MOL CLONING LAB MANU, P16; Satomi S, 2001, BIOCHEM BIOPH RES CO, V287, P995, DOI 10.1006/bbrc.2001.5686; SHI Y, 2004, ZHONGHUA BING LI SHE, V20, P1329; SHI YE, 1993, CANCER RES, V53, P1409; Shi Ying, 2005, Zhejiang Da Xue Xue Bao Yi Xue Ban, V34, P38; Sun Li-feng, 2004, Zhonghua Yi Xue Za Zhi, V84, P843; Szabo R, 2005, BIOCHEM J, V390, P231, DOI 10.1042/BJ20050299; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Yamasaki Y, 2003, J NUTR SCI VITAMINOL, V49, P27, DOI 10.3177/jnsv.49.27; Ye S, 2003, RHEUMATOLOGY, V42, P1155, DOI 10.1093/rheumatology/keg315; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125; Zheng S, 1997, Zhonghua Yi Xue Za Zhi, V77, P256	45	15	22	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7406	7412		10.1074/jbc.M510687200	http://dx.doi.org/10.1074/jbc.M510687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407223	hybrid			2022-12-27	WOS:000236030900061
J	McGrath, MJ; Cottle, DL; Nguyen, MA; Dyson, JM; Coghill, ID; Robinson, PA; Holdsworth, M; Cowling, BS; Hardeman, EC; Mitchell, CA; Brown, S				McGrath, MJ; Cottle, DL; Nguyen, MA; Dyson, JM; Coghill, ID; Robinson, PA; Holdsworth, M; Cowling, BS; Hardeman, EC; Mitchell, CA; Brown, S			Four and a half LIM protein 1 binds myosin-binding protein C and regulates myosin filament formation and sarcomere assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE HYPERTROPHY; CARDIAC MYOSIN; MYBP-C; ONLY PROTEIN; ALPHA-ACTININ; DILATED CARDIOMYOPATHY; X-PROTEIN; H-PROTEIN; DOMAIN; EXPRESSION	Four and a half LIM protein 1 (FHL1/SLIM1) is highly expressed in skeletal and cardiac muscle; however, the function of FHL1 remains unknown. Yeast two-hybrid screening identified slow type skeletal myosin-binding protein C as an FHL1 binding partner. Myosin-binding protein C is the major myosin-associated protein in striated muscle that enhances the lateral association and stabilization of myosin thick filaments and regulates actomyosin interactions. The interaction between FHL1 and myosin-binding protein C was confirmed using co-immunoprecipitation of recombinant and endogenous proteins. Recombinant FHL2 and FHL3 also bound myosin-binding protein C. FHL1 impaired co-sedimentation of myosin-binding protein C with reconstituted myosin filaments, suggesting FHL1 may compete with myosin for binding to myosin-binding protein C. In intact skeletal muscle and isolated myofibrils, FHL1 localized to the I-band, M-line, and sarcolemma, co-localizing with myosin-binding protein C at the sarcolemma in intact skeletal muscle. Furthermore, in isolated myofibrils FHL1 staining at the M-line appeared to extend partially into the C-zone of the A-band, where it co-localized with myosin-binding protein C. Overexpression of FHL1 in differentiating C2C12 cells induced "sac-like" myotube formation (myosac), associated with impaired Z-line and myosin thick filament assembly. This phenotype was rescued by co-expression of myosin-binding protein C. FHL1 knockdown using RNAi resulted in impaired myosin thick filament formation associated with reduced incorporation of myosin-binding protein C into the sarcomere. This study identified FHL1 as a novel regulator of myosin-binding protein C activity and indicates a role for FHL1 in sarcomere assembly.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Childrens Med Res Inst, Muscle Dev Unit, Westmead, NSW 2145, Australia	Monash University; Children's Medical Research Institute - Australia	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	christina.mitchell@med.monash.edu.au	Cottle, Denny/G-4278-2013; Hardeman, Edna C/F-8872-2012; Cowling, Belinda S/O-2730-2016; Cottle, Denny/AAN-1574-2020	Cowling, Belinda S/0000-0001-6915-2596; Cottle, Denny/0000-0001-5047-6515; Hardeman, Edna/0000-0003-1649-7712; McGrath, Meagan/0000-0002-9414-6558; Mitchell, Christina A/0000-0001-9372-3192				Alyonycheva TN, 1997, J BIOL CHEM, V272, P20866, DOI 10.1074/jbc.272.33.20866; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENNETT P, 1986, J MUSCLE RES CELL M, V7, P550, DOI 10.1007/BF01753571; Berthier C, 1997, BIOL CELL, V89, P413, DOI 10.1016/S0248-4900(97)89313-6; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Brown S, 1999, J MOL CELL CARDIOL, V31, P837, DOI 10.1006/jmcc.1998.0922; Carbo N, 2000, BRIT J CANCER, V83, P526, DOI 10.1054/bjoc.2000.1299; Carrier L, 2004, CARDIOVASC RES, V63, P293, DOI 10.1016/j.cardiores.2004.04.009; Carrier L, 1997, CIRC RES, V80, P427, DOI 10.1161/01.res.0000435859.24609.b3; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; DENNIS JE, 1984, J CELL BIOL, V98, P1514, DOI 10.1083/jcb.98.4.1514; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Flashman E, 2004, CIRC RES, V94, P1279, DOI 10.1161/01.RES.0000127175.21818.C2; Flick MJ, 2000, J CELL SCI, V113, P1553; Gaussin V, 2003, CIRCULATION, V108, P2926, DOI 10.1161/01.CIR.0000101922.18151.7B; Gilbert R, 1996, J CELL SCI, V109, P101; Gruen M, 1999, J MOL BIOL, V286, P933, DOI 10.1006/jmbi.1998.2522; Harris SP, 2002, CIRC RES, V90, P594, DOI 10.1161/01.RES.0000012222.70819.64; Hwang DM, 2000, GENOMICS, V66, P1, DOI 10.1006/geno.2000.6171; Hwang DM, 1997, CIRCULATION, V96, P4146; KANG SJ, 1995, J CELL BIOL, V130, P1127, DOI 10.1083/jcb.130.5.1127; KNIGHT PJ, 1982, METHOD ENZYMOL, V85, P9; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; KORETZ JF, 1979, BIOPHYS J, V27, P433, DOI 10.1016/S0006-3495(79)85227-3; LANE BP, 1977, J HISTOCHEM CYTOCHEM, V25, P69, DOI 10.1177/25.1.833423; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; Lim DS, 2001, J AM COLL CARDIOL, V38, P1175, DOI 10.1016/S0735-1097(01)01509-1; LIN ZX, 1987, J CELL BIOL, V105, P1365, DOI 10.1083/jcb.105.3.1365; LIN ZX, 1989, J CELL BIOL, V108, P1079, DOI 10.1083/jcb.108.3.1079; Littlefield R, 2002, BIOPHYS J, V82, P2548, DOI 10.1016/S0006-3495(02)75598-7; Loughna P. T., 2000, Molecular Cell Biology Research Communications, V3, P136, DOI 10.1006/mcbr.2000.0206; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Marian AJ, 2001, J MOL CELL CARDIOL, V33, P655, DOI 10.1006/jmcc.2001.1340; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; McGrath MJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1513, DOI 10.1152/ajpcell.00207.2003; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Mermelstein CD, 1996, J MUSCLE RES CELL M, V17, P199, DOI 10.1007/BF00124242; Miyamoto CA, 1999, J MUSCLE RES CELL M, V20, P703, DOI 10.1023/A:1005513312939; Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2; MOOS C, 1975, J MOL BIOL, V97, P1, DOI 10.1016/S0022-2836(75)80017-9; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P245, DOI 10.1006/bbrc.1999.0179; MORGAN MJ, 1995, BIOCHEM BIOPH RES CO, V212, P840, DOI 10.1006/bbrc.1995.2045; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; Palmer S, 2001, J CELL BIOL, V153, P985, DOI 10.1083/jcb.153.5.985; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669; Quinn LS, 2002, EXP CELL RES, V280, P55, DOI 10.1006/excr.2002.5624; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; Robinson PA, 2003, AM J PHYSIOL-CELL PH, V284, pC681, DOI 10.1152/ajpcell.00370.2002; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; SAITOH O, 1988, CELL TISSUE RES, V252, P263; Samson T, 2004, J BIOL CHEM, V279, P28641, DOI 10.1074/jbc.M312894200; Sato N, 2003, MOL BIOL CELL, V14, P3180, DOI 10.1091/mbc.E02-10-0685; Sebillon P, 2001, CR ACAD SCI III-VIE, V324, P251, DOI 10.1016/S0764-4469(00)01292-0; Seiler SH, 1996, MOL BIOL CELL, V7, P113, DOI 10.1091/mbc.7.1.113; STARR R, 1985, J MUSCLE RES CELL M, V6, P227, DOI 10.1007/BF00713063; STARR R, 1978, BIOCHEM J, V171, P813, DOI 10.1042/bj1710813; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; Welikson RE, 2002, J CELL SCI, V115, P3517; Winegrad S, 1999, CIRC RES, V84, P1117, DOI 10.1161/01.RES.84.10.1117; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yan JH, 2003, FEBS LETT, V553, P183, DOI 10.1016/S0014-5793(03)00978-5; Yang QL, 1999, CIRC RES, V85, P841, DOI 10.1161/01.RES.85.9.841; Yang QL, 1998, J CLIN INVEST, V102, P1292, DOI 10.1172/JCI3880; Yang YG, 2000, CELL STRUCT FUNCT, V25, P177, DOI 10.1247/csf.25.177; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	91	96	102	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7666	7683		10.1074/jbc.M512552200	http://dx.doi.org/10.1074/jbc.M512552200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407297	hybrid			2022-12-27	WOS:000236030900088
J	Mishra, P; Akhtar, MS; Bhakuni, V				Mishra, P; Akhtar, MS; Bhakuni, V			Unusual structural features of the bacteriophage-associated hyaluronate lyase (hylp2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; GENOME SEQUENCE; PYOGENES; GENE; MECHANISM; COMPLEX; ACID; HYALURONIDASES; DEGRADATION; PROTEINS	Hyaluronate lyases are a class of endoglycosaminidase enzymes, which are of considerable complexity and heterogeneity. Their primary function is to degrade hyaluronan and certain other glycosaminoglycans and facilitate the spread of disease. Among hyaluronate lyases, the bacteriophage-associated enzymes are unique as they have the lowest molecular mass, very low amino acid sequence homology with bacterial hyaluronate lyases, and exhibit absolute specificity for one type of glycosaminoglycan, i.e. hyaluronan. Despite such unique characteristics significant details on structural features of these lyases are not available. The Streptococcus pyogenes bacteriophage 10403 contains a gene, hylP2, which encodes for hyaluronate lyase (HylP2) in this organism. HylP2 was cloned, overexpressed, and purified to homogeneity. The recombinant HylP2 exists as a homotrimer of molecular mass about 110 kDa, under physiological conditions. Limited proteolysis and guanidine hydrochloride denaturation studies demonstrated that the N-terminal region of the protein is flexible, whereas the C-terminal portion has a compact conformation. The enzyme shows sequential unfolding, with the N-terminal unfolding first followed by the simultaneous unfolding and dissociation of the stabilized trimeric C-terminal domain. We isolated a functionally active C-terminal fragment (Ser(128) - Lys(337)) of the protein that was stabilized in a trimeric configuration. Comparative functional studies with full-length protein, N:C complex, and isolated C-terminal domain demonstrated that the active site of HylP2 is present in the C-terminal portion of the enzyme, and the N-terminal portion modulates the substrate specificity and enzymatic activity of the C-terminal domain.	Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bhakuni, V (corresponding author), Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India.	bhakuniv@rediffmail.com	Akhtar, Sohail/A-2300-2010; Mishra, Parul/AAY-2911-2020	Mishra, Parul/0000-0002-2989-7371				Akhtar MS, 2003, J BIOL CHEM, V278, P25509, DOI 10.1074/jbc.M301894200; Ali V, 1999, BIOCHEMISTRY-US, V38, P13635, DOI 10.1021/bi9907835; ANDREWS P, 1965, BIOCHEM J, V96, P569; Baker JR, 2002, BIOCHEM J, V365, P317, DOI 10.1042/BJ20020149; BENCHETRIT LC, 1978, J BACTERIOL, V134, P221, DOI 10.1128/JB.134.1.221-228.1978; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; Chaturvedi S, 2003, J BIOL CHEM, V278, P40793, DOI 10.1074/jbc.M306192200; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Harrington DJ, 2002, MICROBES INFECT, V4, P501, DOI 10.1016/S1286-4579(02)01565-4; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Hynes WL, 2000, FEMS MICROBIOL LETT, V184, P109, DOI 10.1016/S0378-1097(00)00029-X; Hynes WL, 2000, FEMS MICROBIOL LETT, V183, P201, DOI 10.1111/j.1574-6968.2000.tb08958.x; HYNES WL, 1989, INFECT IMMUN, V57, P533, DOI 10.1128/IAI.57.2.533-539.1989; HYNES WL, 1995, INFECT IMMUN, V63, P3015, DOI 10.1128/IAI.63.8.3015-3020.1995; KJEMS EBBE, 1958, ACTA PATHOL ET MICROBIOL SCAND, V42, P56; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Lackowicz J.R., 2006, PRINCIPLES FLUORESCE, DOI 10.1007/978-0-387-46312-4; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; LUI GY, 2004, FRONT BIOSCI, V9, P1794; Marciel AM, 1997, MICROB PATHOGENESIS, V22, P209, DOI 10.1006/mpat.1996.9999; MAXTED WR, 1952, NATURE, V170, P1020, DOI 10.1038/1701020b0; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; NIEMANN H, 1976, ACTA PATH MICRO IM B, V84, P145; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Pritchard DG, 2000, PROTEINS, V40, P126; Rigden DJ, 2003, J BIOL CHEM, V278, P50596, DOI 10.1074/jbc.M307596200; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P557; Smith NL, 2005, P NATL ACAD SCI USA, V102, P17652, DOI 10.1073/pnas.0504782102; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; SONGLIN L, 2001, J BIOL CHEM, V276, P41407; Starr CR, 2006, INFECT IMMUN, V74, P40, DOI 10.1128/IAI.74.1.40-48.2006; STERN M, 1992, MOL BIOL EVOL, V9, P1179	34	13	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7143	7150		10.1074/jbc.M510991200	http://dx.doi.org/10.1074/jbc.M510991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415347	hybrid			2022-12-27	WOS:000236030900029
J	Rosenblat, M; Gaidukov, L; Khersonsky, O; Vaya, J; Oren, R; Tawfik, DS; Aviram, M				Rosenblat, M; Gaidukov, L; Khersonsky, O; Vaya, J; Oren, R; Tawfik, DS; Aviram, M			The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; PLATELET-ACTIVATING-FACTOR; LACTONASE ACTIVITY; LIPID PEROXIDES; TRANSGENIC MICE; HIGH-AFFINITY; ATHEROSCLEROSIS; CELLS; ANTIOXIDANTS; STRESS	High density lipoprotein (HDL)-associated paraoxonase-1 (PON1) anti-atherogenic properties in macrophages, i.e. inhibition of cell-mediated oxidation of low density lipoprotein (LDL) and stimulation of cholesterol efflux, were studied using recombinant variants of PON1 and apoA-I expressed in Escherichia coli and reconstituted HDL(rHDL) particles composed of phosphatidylcholine/free cholesterol (PC/FC) and apoA-I. PON1 lactonase activity is stimulated by apoA-I by similar to 7-fold relative to PC/FC particles. Wild-type (WT) PON1 bound to rHDL inhibited macrophage-mediated LDL oxidation and stimulated cholesterol efflux from the cells to 2.3- and 3.2-fold greater extents, respectively, compared with WT PON1 bound to PC/FC particles without apoA-I. We also tested PON1 catalytic histidine dyad mutants (H115Q and H134Q) that are properly folded and that bind HDL in a similar mode compared with WT PON1, but that exhibit almost no lactonase activity. These could not inhibit macrophage-mediated LDL oxidation or stimulate rHDL-mediated cholesterol efflux from the cells. Furthermore, whereas HDL-bound WT PON1 induced the formation of lysophosphatidylcholine (LPC) in macrophages, the His dyad mutants did not, suggesting that the above anti-atherogenic properties of HDL-associated PON1 involve LPC release. Indeed, enrichment of macrophages with increasing concentrations of LPC resulted in inhibition of the cells' capability to oxidize LDL and in stimulation of HDL-mediated cholesterol efflux from the macrophages in an LPC dose-dependent manner. Thus, we provide the first direct indication that the anti-atherogenic properties of PON1 are related to its lipolactonase activity and propose a model in which PON1 acts as a lipolactonase to break down oxidized lipids and to generate LPC.	Rambam Med Ctr, Lipid Res Lab, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Lipid Res Lab, IL-31096 Haifa, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Migal Galilee Technol Ctr, Lab Nat Med Cpds, IL-11016 Kiryat Shmona, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Weizmann Institute of Science	Aviram, M (corresponding author), Rambam Med Ctr, Lipid Res Lab, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel.	aviram@tx.technion.ac.il						Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Ahmed Z, 2001, J BIOL CHEM, V276, P24473, DOI 10.1074/jbc.M010459200; AVIRAM M, 1983, BIOCHEM MED METAB B, V30, P111, DOI 10.1016/0006-2944(83)90013-3; Aviram M, 1999, MOL MED TODAY, V5, P381, DOI 10.1016/S1357-4310(99)01546-4; Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510; Aviram M, 2004, FREE RADICAL BIO MED, V37, P1304, DOI 10.1016/j.freeradbiomed.2004.06.030; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; Bilenko MV, 2003, B EXP BIOL MED+, V135, P349, DOI 10.1023/A:1024656613633; Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Buege J A, 1978, Methods Enzymol, V52, P302; Connelly PW, 2005, FREE RADICAL BIO MED, V38, P164, DOI 10.1016/j.freeradbiomed.2004.10.010; Deakin S, 2005, ATHEROSCLEROSIS, V179, P17, DOI 10.1016/j.atherosclerosis.2004.08.039; Deakin S, 2002, J BIOL CHEM, V277, P4301, DOI 10.1074/jbc.M107440200; Draganov DI, 2005, J LIPID RES, V46, P1239, DOI 10.1194/jlr.M400511-JLR200; ELSAADANI M, 1989, J LIPID RES, V30, P627; Fuhrman B, 2005, ATHEROSCLEROSIS, V180, P55, DOI 10.1016/j.atherosclerosis.2004.12.009; Fuhrman B, 2002, ATHEROSCLEROSIS, V161, P307, DOI 10.1016/S0021-9150(01)00646-3; Gaidukov L, 2005, BIOCHEMISTRY-US, V44, P11843, DOI 10.1021/bi050862i; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P1253, DOI 10.1038/nsmb1204-1253a; James RW, 2004, FREE RADICAL BIO MED, V37, P1986, DOI 10.1016/j.freeradbiomed.2004.08.012; Khersonsky O, 2006, J BIOL CHEM, V281, P7649, DOI 10.1074/jbc.M512594200; Khersonsky O, 2006, CHEMBIOCHEM, V7, P49, DOI 10.1002/cbic.200500334; Khersonsky O, 2005, BIOCHEMISTRY-US, V44, P6371, DOI 10.1021/bi047440d; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mackness B, 2003, CIRCULATION, V107, P2775, DOI 10.1161/01.CIR.0000070954.00271.13; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; MATZ CE, 1982, J BIOL CHEM, V257, P4535; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1325, DOI 10.1161/01.ATV.0000165694.39518.95; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; Oda MN, 2002, BIOCHEM BIOPH RES CO, V290, P921, DOI 10.1006/bbrc.2001.6295; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Rosenblat M, 2005, ATHEROSCLEROSIS, V179, P69, DOI 10.1016/j.atherosclerosis.2004.10.028; ROSENBLAT M, 2006, IN PRESS ATHEROSCLER; Rozenberg O, 2005, ATHEROSCLEROSIS, V181, P9, DOI 10.1016/j.atherosclerosis.2004.12.030; Rozenberg O, 2003, ARTERIOSCL THROM VAS, V23, P461, DOI 10.1161/01.ATV.0000060462.35946.B3; Rozenberg O, 2003, FREE RADICAL BIO MED, V34, P774, DOI 10.1016/S0891-5849(02)01429-6; Segrest JP, 2000, TRENDS CARDIOVAS MED, V10, P246, DOI 10.1016/S1050-1738(00)00078-5; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; Stadler N, 2004, ARTERIOSCL THROM VAS, V24, P949, DOI 10.1161/01.ATV.0000124892.90999.cb; Teiber JF, 2004, J LIPID RES, V45, P2260, DOI 10.1194/jlr.M400213-JLR200; Teiber JF, 2003, BIOCHEM PHARMACOL, V66, P887, DOI 10.1016/S0006-2952(03)00401-5; Tward A, 2002, CIRCULATION, V106, P484, DOI 10.1161/01.CIR.0000023623.87083.4F	55	185	191	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7657	7665		10.1074/jbc.M512595200	http://dx.doi.org/10.1074/jbc.M512595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407304	hybrid			2022-12-27	WOS:000236030900087
J	Courtney, HS; Zhang, YM; Frank, MW; Rock, CO				Courtney, HS; Zhang, YM; Frank, MW; Rock, CO			Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE PROTEIN; CHOLESTEROL; PYOGENES; METABOLISM; MECHANISMS; DOMAIN; MICE	Serum opacity factor (SOF) is a virulence determinant of group A streptococci that opacifies mammalian sera. We analyzed the specificity and mechanism of the opacity reaction using a recombinant form of the amino-terminal opacification domain of SOF, rSOF. Our data indicate that rSOF is neither a protease nor a lipase, but rather it is the binding of rSOF to high density lipoprotein (HDL) that triggers the opacity reaction. rSOF did not opacify plasma from apoA-I-/- mice or purified low or very low density lipoproteins but readily opacified HDL. rSOF binding to HDL was characterized by two high affinity binding sites; it bound to apoA-I (K-d = 6 nM) and apoA-II (K-d = 30 nM), and both apoA-I and apoA-II blocked the binding of rSOF to HDL. Electron microscopic examination and biochemical analyses of HDL treated with rSOF revealed the formation of lipid droplets devoid of apolipoproteins. Thus, SOF interacts with HDL in human blood by binding to apoA-I and apoA-II and causing the release of HDL lipid cargo, which coalesces to form lipid droplets, resulting in opacification. The disruption of HDL may attenuate its anti-inflammatory functions and contribute to the pathogenesis of group A streptococcal infections.	Vet Affairs Med Ctr, Res Serv 151, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38104 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Courtney, HS (corresponding author), Vet Affairs Med Ctr, Res Serv 151, 1030 Jefferson Ave, Memphis, TN 38104 USA.	hcourtney@utmem.edu		Frank, Matthew/0000-0002-4914-1440	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Courtney HS, 2006, MOL MICROBIOL, V59, P936, DOI 10.1111/j.1365-2958.2005.04977.x; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Courtney HS, 2003, INFECT IMMUN, V71, P5097, DOI 10.1128/IAI.71.9.5097-5103.2003; Courtney HS, 2002, CURR MICROBIOL, V44, P236, DOI 10.1007/s00284-001-0037-1; Courtney HS, 2002, ANN MED, V34, P77, DOI 10.1080/07853890252953464; COURTNEY HS, 2004, BACTERIAL INVASION H, P239; Fielding P. E., 1996, BIOCH LIPIDS LIPOPRO, P495; Grunfeld C, 1999, J LIPID RES, V40, P245; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P7200, DOI 10.1021/bi00346a028; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Kreikemeyer B, 1999, FEMS MICROBIOL LETT, V178, P305, DOI 10.1016/S0378-1097(99)00373-0; KRUMWIEDE E, 1954, J EXP MED, V100, P629, DOI 10.1084/jem.100.6.629; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; O'Brien KL, 2002, CLIN INFECT DIS, V35, P268, DOI 10.1086/341409; Oehmcke S, 2004, INFECT IMMUN, V72, P4302, DOI 10.1128/IAI.72.7.4302-4308.2004; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; PARKER TS, 1995, INFECT IMMUN, V63, P253, DOI 10.1128/IAI.63.1.253-258.1995; Petrovic N, 2001, J LIPID RES, V42, P1706; RAKONJAC JV, 1995, INFECT IMMUN, V63, P622, DOI 10.1128/IAI.63.2.622-631.1995; ROWEN R, 1961, J EXP MED, V114, P807, DOI 10.1084/jem.114.5.807; ROWEN R, 1963, BIOCHIM BIOPHYS ACTA, V70, P396, DOI 10.1016/0926-6542(63)90058-1; RUSBRIDGE NM, 1990, FEBS LETT, V268, P133, DOI 10.1016/0014-5793(90)80991-Q; SARAVANI GA, 1990, FEMS MICROBIOL LETT, V68, P35; Wadham C, 2004, CIRCULATION, V109, P2116, DOI 10.1161/01.CIR.0000127419.45975.26; WARD HUGH K., 1938, AUSTRALIAN JOUR EXP BIOL AND MED SCI, V16, P181, DOI 10.1038/icb.1938.19; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; Wu AH, 2004, SHOCK, V21, P210, DOI 10.1097/01.shk.0000111661.09279.82; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200	34	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5515	5521		10.1074/jbc.M512538200	http://dx.doi.org/10.1074/jbc.M512538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407233	hybrid			2022-12-27	WOS:000235568900025
J	Blumberg, JM; Tzameli, I; Astapova, I; Lam, FS; Flier, JS; Hollenberg, AN				Blumberg, JM; Tzameli, I; Astapova, I; Lam, FS; Flier, JS; Hollenberg, AN			Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR RECEPTOR; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; PPAR-GAMMA; C/EBP-BETA; NEGATIVE REGULATION; BINDING PROTEINS; CO-REPRESSOR; N-COR	The vitamin D receptor (VDR) and its ligand 1,25-OH2-VD3 (calcitriol) play an essential role in mineral homeostasis in mammals. Interestingly, the VDR is expressed very early in adipogenesis in 3T3-L1 cells, suggesting that the VDR signaling pathway may play a role in adipocyte biology and function. Indeed, it has been known for a number of years that calcitriol is a potent inhibitor of adipogenesis in this model but with no clear mechanism identified. In this study, we have further defined the molecular mechanism by which the unliganded VDR and calcitriol-liganded VDR regulate adipogenesis. In the presence of calcitriol, the VDR blocks adipogenesis by down-regulating both C/EBP beta mRNA expression and C/EBP beta nuclear protein levels at a critical stage of differentiation. In addition, calcitriol allows for the up-regulation of the recently described C/EBP beta corerepressor, ETO, which would further inhibit the action of any remaining C/EBP beta, whose action is required for adipogenesis. In contrast, in the absence of calcitriol, the unliganded VDR appears necessary for lipid accumulation, since knock-down of the VDR using siRNA both delays and prevents this process. Taken together, these data support the notion that the intracellular concentrations of calcitriol can play an important role in either promoting or inhibiting adipogenesis via the VDR and the transcriptional pathways that it targets. Further examination of this hypothesis in vivo may shed new light on the biology of adipogenesis.	Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hollenberg, AN (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, 330 Brookline Ave, Boston, MA 02215 USA.	thollenb@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [DK056123, R37DK28081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056123, R01DK056123, R01DK028081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; Dhawan P, 2005, MOL CELL BIOL, V25, P472, DOI 10.1128/MCB.25.1.472-487.2005; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2000, GENE DEV, V14, P121; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hsieh JC, 2003, J BIOL CHEM, V278, P38665, DOI 10.1074/jbc.M304886200; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KAMEI Y, 1993, BIOCHEM BIOPH RES CO, V193, P948, DOI 10.1006/bbrc.1993.1717; KAWADA T, 1996, INT J OBESITY, V20, P52; Kelly KA, 1998, ENDOCRINOLOGY, V139, P2622, DOI 10.1210/en.139.5.2622; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KONG J, 2005, IN PRESS AM J PHYSL; KRISHNAN AV, 1992, MOL ENDOCRINOL, V6, P198, DOI 10.1210/me.6.2.198; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Lee S, 2005, MOL ENDOCRINOL, V19, P399, DOI 10.1210/me.2004-0324; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157; Potter GB, 2001, GENE DEV, V15, P2687, DOI 10.1101/gad.916701; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SATO M, 1988, J CELL PHYSIOL, V135, P545, DOI 10.1002/jcp.1041350326; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; Skorija K, 2005, MOL ENDOCRINOL, V19, P855, DOI 10.1210/me.2004-0415; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tzameli I, 2004, J BIOL CHEM, V279, P36093, DOI 10.1074/jbc.M405346200; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101	49	160	169	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11205	11213		10.1074/jbc.M510343200	http://dx.doi.org/10.1074/jbc.M510343200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16467308	hybrid			2022-12-27	WOS:000236822200064
J	Croucher, D; Saunders, DN; Ranson, M				Croucher, D; Saunders, DN; Ranson, M			The urokinase/PAI-2 complex - A new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; MEDIATES ENDOCYTOSIS; BOUND UROKINASE; BINDING-SITE; INTERNALIZATION; DEGRADATION; SURFACE; PROUROKINASE; CATABOLISM; EXPRESSION	The efficient inactivation of urokinase plasminogen activator (uPA) by plasminogen activator inhibitor type 2 (PAI-2) at the surface of carcinoma cells is followed by rapid endocytosis of the uPA-PAI-2 complex. We now show that one pathway of this receptor-mediated endocytosis is mediated via the low density lipoprotein receptor-related protein (LRP) in prostate cancer cells. Detailed biochemical analyses using ligand binding assays and surface plasmon resonance revealed a novel and distinct interaction mechanism between native, human LRP and uPA-PAI-2. As reported previously for PAI-1, inhibition of uPA by PAI-2 significantly increased the affinity of the complex for LRP (K-D of 36 nM for uPA-PAI-2 versus 200 nM for uPA). This interaction was maintained in the presence of uPAR, confirming the validity of this interaction at the cell surface. However, unlike PAI-1, no interaction was observed between LRP and PAI-2 in either the stressed or the relaxed conformation. This suggests that the uPA-PAI-2-LRP interaction is mediated by site(s) within the uPA molecule alone. Thus, as inhibition of uPA by PAI-2 resulted in accelerated clearance of uPA from the cell surface possibly via its increased affinity for LRP, this represents a mechanism through which PAI-2 can clear proteolytic activity from the cell surface. Furthermore, lack of a direct interaction between PAI-2 and LRP implies that downstream signaling events initiated by PAI-1 may not be activated by PAI-2.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	University of Wollongong; Garvan Institute of Medical Research	Ranson, M (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mranson@uow.edu.Au	Ranson, Marie/AAC-4468-2019; Ranson, Marie/GRO-5792-2022; Saunders, Darren/B-7677-2008; Ranson, Marie/A-6324-2008	Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Croucher, David/0000-0003-4965-8674; Saunders, Darren/0000-0003-0924-0513	Wellcome Trust [052458] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Ejeh F, 2004, EXP CELL RES, V297, P259, DOI 10.1016/j.yexcr.2004.03.030; Allen BJ, 2003, BRIT J CANCER, V88, P944, DOI 10.1038/sj.bjc.6600838; Allen BJ, 2001, CRIT REV ONCOL HEMAT, V39, P139, DOI 10.1016/S1040-8428(01)00113-5; Andersen OM, 2001, BIOCHEM J, V357, P289, DOI 10.1042/0264-6021:3570289; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Andronicos NM, 2001, BRIT J CANCER, V85, P909, DOI 10.1054/bjoc.2001.2022; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FOEKENS JA, 1995, CANCER RES, V55, P1423; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; Li Y, 2002, BRIT J CANCER, V86, P1197, DOI 10.1038/sj/bjc/6600179; Misra UK, 2002, J BIOL CHEM, V277, P42082, DOI 10.1074/jbc.M206174200; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; Ranson M, 2003, FRONT BIOSCI, V8, pS294, DOI 10.2741/1044; Ranson M, 2002, BREAST CANCER RES TR, V71, P149, DOI 10.1023/A:1013850107791; Ranson M, 1998, BRIT J CANCER, V77, P1586, DOI 10.1038/bjc.1998.261; Rettenberger PM, 1999, J BIOL CHEM, V274, P8973, DOI 10.1074/jbc.274.13.8973; Rodenburg KW, 1998, BIOCHEM J, V329, P55; Saunders DN, 1998, J BIOL CHEM, V273, P10965, DOI 10.1074/jbc.273.18.10965; Saunders DN, 2001, J BIOL CHEM, V276, P43383, DOI 10.1074/jbc.M103123200; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STEFANSSON S, 1995, J CELL SCI, V108, P2361; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; Wang SX, 2004, J CELL BIOCHEM, V91, P766, DOI 10.1002/jcb.10781; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wu LH, 2005, J CELL BIOCHEM, V96, P1021, DOI 10.1002/jcb.20596; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273	54	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10206	10213		10.1074/jbc.M513645200	http://dx.doi.org/10.1074/jbc.M513645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459332	hybrid			2022-12-27	WOS:000236594300047
J	Holger, S; Kurtzer, R; Eisenreich, W; Schwab, W				Holger, S; Kurtzer, R; Eisenreich, W; Schwab, W			The carotenase AtCCD1 from Arabidopsis thaliana is a dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; PSEUDOMONAS-PAUCIMOBILIS TMY1009; CLEAVAGE DIOXYGENASE; BETA-CAROTENE; OXYGENASE; FLOWERS; PLANTS; GENE; IDENTIFICATION; METABOLISM	Apocarotenoids resulting from the oxidative cleavage of carotenoids serve as important signaling and accessory molecules in a variety of biological processes. The enzymes catalyzing these reactions are referred to as carotenases or carotenoid oxygenases. Whether they act according to a monooxygenase mechanism, requiring two oxygens from different sources, or a dioxygenase mechanism is still a topic of controversy. In this study, we utilized the readily available beta-apo-8'-carotenal as a substrate for the heterologously expressed AtCCD1 protein from Arabidopsis thaliana to investigate the oxidative cleavage mechanism of the 9,10 double bond of carotenoids. beta-Ionone and a C-17-dialdehyde were detected as products by gas and liquid chromatography-mass spectrometry as well as NMR analysis. Labeling experiments using H-2 O-18 or O-18(2) showed that the oxygen in the keto-group of beta-ionone is derived solely from molecular dioxygen. When experiments were performed in an O-18(2)-enriched atmosphere, a substantial fraction of the C-17-dialdehyde contained labeled oxygen. The results unambiguously demonstrate a dioxygenase mechanism for the carotenase AtCCD1 from A. thaliana.	Tech Univ Munich, Fdn Biomol Food Technol, D-84354 Freising Weihenstephan, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich; Technical University of Munich	Holger, S (corresponding author), Tech Univ Munich, Fdn Biomol Food Technol, Lise Meitner Str 34, D-84354 Freising Weihenstephan, Germany.	holger.schmidt@mytum.de	Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Bouvier F, 2005, TRENDS PLANT SCI, V10, P187, DOI 10.1016/j.tplants.2005.02.007; Bouvier F, 2003, SCIENCE, V300, P2089, DOI 10.1126/science.1085162; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; BYRN M, 1966, J AM CHEM SOC, V88, P1916, DOI 10.1021/ja00961a013; Camara B, 2004, ARCH BIOCHEM BIOPHYS, V430, P16, DOI 10.1016/j.abb.2004.06.028; Cao YR, 2005, PLANT GROWTH REGUL, V46, P61, DOI 10.1007/s10725-005-5667-z; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; CREELMAN RA, 1984, PLANT PHYSIOL, V75, P166, DOI 10.1104/pp.75.1.166; CREELMAN RA, 1987, PLANT PHYSIOL, V85, P726, DOI 10.1104/pp.85.3.726; During A, 2004, ARCH BIOCHEM BIOPHYS, V430, P77, DOI 10.1016/j.abb.2004.03.024; Gessler NN, 2002, APPL BIOCHEM MICRO+, V38, P536, DOI 10.1023/A:1020770426304; Giuliano G, 2003, TRENDS PLANT SCI, V8, P145, DOI 10.1016/S1360-1385(03)00053-0; Gomez E, 1997, J SCI FOOD AGR, V74, P541, DOI [10.1002/(SICI)1097-0010(199708)74:4<541::AID-JSFA851>3.3.CO;2-4, 10.1002/(SICI)1097-0010(199708)74:4&lt;541::AID-JSFA851&gt;3.0.CO;2-D]; HENEHAN GTM, 1993, BIOCHEMISTRY-US, V32, P736, DOI 10.1021/bi00054a001; JUTTNER F, 1985, ARCH MICROBIOL, V141, P337, DOI 10.1007/BF00428846; KAISER R, 2002, CAROTENOID DERIVED A; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; KAMODA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1866, DOI 10.1271/bbb.59.1866; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; LI Y, 1990, PLANT PHYSIOL, V92, P551, DOI 10.1104/pp.92.3.551; Maia JGS, 2000, J ESSENT OIL RES, V12, P322, DOI 10.1080/10412905.2000.9699526; Mathieu S, 2005, J EXP BOT, V56, P2721, DOI 10.1093/jxb/eri265; Moise AR, 2005, TRENDS PLANT SCI, V10, P178, DOI 10.1016/j.tplants.2005.02.006; Poliakov E, 2005, J BIOL CHEM, V280, P29217, DOI 10.1074/jbc.M500409200; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Reeder MR, 1999, TETRAHEDRON LETT, V40, P3115, DOI 10.1016/S0040-4039(99)00454-2; ROBERTSON GW, 1995, PHYTOCHEMISTRY, V38, P1175, DOI 10.1016/0031-9422(94)00782-O; Ruch S, 2005, MOL MICROBIOL, V55, P1015, DOI 10.1111/j.1365-2958.2004.04460.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Simkin AJ, 2004, PLANT PHYSIOL, V136, P3504, DOI 10.1104/pp.104.049718; Svensson S, 1996, FEBS LETT, V394, P217, DOI 10.1016/0014-5793(96)00954-4; Vartapetian B B, 1966, Biokhimiia, V31, P881; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; WILLOWS RD, 1992, PHYTOCHEMISTRY, V31, P2649, DOI 10.1016/0031-9422(92)83604-W; Wise KJ, 2002, TRENDS BIOTECHNOL, V20, P387, DOI 10.1016/S0167-7799(02)02023-1; ZEEVAART JAD, 1989, PLANT PHYSIOL, V91, P1594, DOI 10.1104/pp.91.4.1594	40	102	110	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9845	9851		10.1074/jbc.M511668200	http://dx.doi.org/10.1074/jbc.M511668200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459333	hybrid			2022-12-27	WOS:000236594300005
J	Le Moan, N; Clement, G; Le Maout, S; Tacnet, F; Toledano, MB				Le Moan, N; Clement, G; Le Maout, S; Tacnet, F; Toledano, MB			The Saccharomyces cerevisiae proteome of oxidized protein thiols - Contrasted functions for the thioredoxin and glutathione pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; CYSTEINE-SULFINIC ACID; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; COPPER CHAPERONE; RELAY SYSTEM; YAP1; CELL; PEROXIREDOXINS; IDENTIFICATION	Protein thiol oxidation subserves important biological functions and constitutes a sequel of reactive oxygen species toxicity. We developed two distinct thiol-labeling approaches to identify oxidized cytoplasmic protein thiols in Saccharomyces cerevisiae. In one approach, we used N-(6-(biotinamido)hexyl)-3'-(2'- pyridyldithio)propionamide to purify oxidized protein thiols, and in the other, we used N-[C-14] ethylmaleimide to quantify this oxidation. Both approaches showed a large number of the same proteins with oxidized thiols ( similar to 200), 64 of which were identified by mass spectrometry. We show that, irrespective of its mechanism, protein thiol oxidation is dependent upon molecular O-2. We also show that H2O2 does not cause de novo protein thiol oxidation, but rather increases the oxidation state of a select group of proteins. Furthermore, our study reveals contrasted differences in the oxidized proteome of cells upon inactivation of the thioredoxin or GSH pathway suggestive of very distinct thiol redox control functions, assigning an exclusive role for thioredoxin in H2O2 metabolism and the presumed thiol redox buffer function for GSH. Taken together, these results suggest the high selectivity of cytoplasmic protein thiol oxidation.	CEA Saclay, DBJC DSV, SBMS, LSOC, F-91191 Gif Sur Yvette, France; CEA Saclay, INRA, CEA,Lab Immunoallergie Alimentaire, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Toledano, MB (corresponding author), CEA Saclay, DBJC DSV, SBMS, LSOC, F-91191 Gif Sur Yvette, France.	Michel.Toledano@cea.fr	TACNET, Frédérique/B-3074-2009					Allen S, 2005, J MOL BIOL, V353, P937, DOI 10.1016/j.jmb.2005.08.049; Bardwell J, 2005, NAT BIOTECHNOL, V23, P42, DOI 10.1038/nbt0105-42; Baty JW, 2005, BIOCHEM J, V389, P785, DOI 10.1042/BJ20050337; Baty JW, 2002, PROTEOMICS, V2, P1261, DOI 10.1002/1615-9861(200209)2:9<1261::AID-PROT1261>3.0.CO;2-Q; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Brennan JP, 2004, J BIOL CHEM, V279, P41352, DOI 10.1074/jbc.M403827200; Carmel-Harel O, 2001, MOL MICROBIOL, V39, P595, DOI 10.1046/j.1365-2958.2001.02255.x; Cumming RC, 2005, FASEB J, V19, P2060, DOI 10.1096/fj.05-4195fje; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Ghezzi P, 2005, FREE RADICAL RES, V39, P573, DOI 10.1080/10715760500072172; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Jacob C, 2003, ANGEW CHEM INT EDIT, V42, P4742, DOI 10.1002/anie.200300573; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Leichert LI, 2004, PLOS BIOL, V2, P1723, DOI 10.1371/journal.pbio.0020333; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Shackelford RE, 2005, ANTIOXID REDOX SIGN, V7, P940, DOI 10.1089/ars.2005.7.940; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; SIKORSKI RS, 1989, GENETICS, V122, P19; Spector D, 2001, J BIOL CHEM, V276, P7011, DOI 10.1074/jbc.M009814200; Tanaka T, 2005, J BIOL CHEM, V280, P42078, DOI 10.1074/jbc.M508622200; Thomas JA, 2001, EXP GERONTOL, V36, P1519, DOI 10.1016/S0531-5565(01)00137-1; Tokatlidis K, 2005, CELL, V121, P965, DOI 10.1016/j.cell.2005.06.019; Toledano MB, 2004, TRENDS BIOCHEM SCI, V29, P351, DOI 10.1016/j.tibs.2004.05.005; Toledano MB, 2003, TOP CURR GENET, V1, P241; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200	53	132	135	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10420	10430		10.1074/jbc.M513346200	http://dx.doi.org/10.1074/jbc.M513346200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16418165	hybrid			2022-12-27	WOS:000236594300071
J	Oka, M; Rodic, N; Graddy, J; Chang, LJ; Terada, N				Oka, M; Rodic, N; Graddy, J; Chang, LJ; Terada, N			CpG sites preferentially methylated by Dnmt3a in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; FIBROBLAST GROWTH-FACTORS; DNA CYTOSINE-5 METHYLTRANSFERASES; DE-NOVO; PWWP DOMAIN; DIFFERENTIAL EXPRESSION; MAMMALIAN DEVELOPMENT; MESSENGER-RNA; TRANSCRIPTION; MAINTENANCE	Dnmt3a and Dnmt3b are two major de novo DNA methyltransferases essential for embryonic development in mammals. It has been shown that Dnmt3a and Dnmt3b have distinct substrate preferences for certain genomic loci, including major and minor satellite repeats. However, the exact target CpG sites where Dnmt3a and Dnmt3b catalyze DNA methylation remains largely unknown. To identify a CpG site that is specifically methylated by Dnmt3a or Dnmt3b, we screened methylated genomic loci by methylation sensitive restriction fingerprinting using genomic DNA from wildtype, Dnmt3a null, Dnmt3b null, and Dnmt3a-Dnmt3b double null ES cells. Interestingly, one of the CpG sites was preferentially methylated in wild-type and Dnmt3b null ES cells but not in Dnmt3a null or Dnmt3a-Dnmt3b double null ES cells, suggesting that the site-specific methylation was Dnmt3a-dependent. Sequencing results revealed that the isolated CpG site is located within the 1st exon of the G isoform of fibroblast growth factor (Fgf-1.G) on mouse chromosome 18. Exogenous expression of Dnmt3a but not Dnmt3b in the double null ES cells restored DNA methylation of this CpG site. When we examined alternative transcription initiation sites, we determined that another CpG site in the 5'-flanking region of the Fgf-1. A isoform was also methylated specifically by Dnmt3a. Using chimeric constructs between Dnmt3a and Dnmt3b, we further determined that the NH2-terminal regulatory domain of Dnmt3a was responsible for establishing its substrate specificity. These results indicate that certain CpG sites within the Fgf-1 gene locus are preferentially methylated by Dnmt3a but not by Dnmt3b. Selective methylation by a specific member of Dnmt3 may therefore play a role in the orchestration of gene expression during embryonic development.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	terada@pathology.ufl.edu			NCRR NIH HHS [RR 17001] Funding Source: Medline; NIDDK NIH HHS [DK 59699] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR017001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004; Chiu IM, 2001, PROG NUCLEIC ACID RE, V70, P155, DOI 10.1016/S0079-6603(01)70016-5; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Handa V, 2005, J MOL BIOL, V348, P1103, DOI 10.1016/j.jmb.2005.02.044; Hattori N, 2004, GENOME RES, V14, P1733, DOI 10.1101/gr.2431504; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Huang THM, 1997, CANCER RES, V57, P1030; Iwakuma T, 1999, VIROLOGY, V261, P120, DOI 10.1006/viro.1999.9850; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lin IG, 2002, MOL CELL BIOL, V22, P704, DOI 10.1128/MCB.22.3.704-723.2002; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; MYERS RL, 1993, ONCOGENE, V8, P341; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540; Oka M, 2002, MOL BIOL CELL, V13, P1274, DOI 10.1091/mbc.02-01-0600; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; RYDEL RE, 1987, J NEUROSCI, V7, P3639; UNSICKER K, 1987, P NATL ACAD SCI USA, V84, P5459, DOI 10.1073/pnas.84.15.5459; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Zaiss AK, 2002, J VIROL, V76, P7209, DOI 10.1128/JVI.76.14.7209-7219.2002; Zhang YX, 2001, BBA-GENE STRUCT EXPR, V1521, P45, DOI 10.1016/S0167-4781(01)00282-2	37	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9901	9908		10.1074/jbc.M511100200	http://dx.doi.org/10.1074/jbc.M511100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16439359	hybrid			2022-12-27	WOS:000236594300011
J	Hasan, Z; Renirie, R; Kerkman, R; Ruijssenaars, HJ; Hartog, AF; Wever, R				Hasan, Z; Renirie, R; Kerkman, R; Ruijssenaars, HJ; Hartog, AF; Wever, R			Laboratory-evolved vanadium chloroperoxidase exhibits 100-fold higher halogenating activity at alkaline pH - Catalytic effects from first and second coordination sphere mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS CURVULARIA-INAEQUALIS; CONTAINING ENZYME CHLOROPEROXIDASE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; SITE MUTANTS; BROMOPEROXIDASE; HALOPEROXIDASE; MECHANISM; INACTIVATION; PURIFICATION	Directed evolution was performed on vanadium chloroperoxidase from the fungus Curvularia inaequalis to increase its brominating activity at a mildly alkaline pH for industrial and synthetic applications and to further understand its mechanism. After successful expression of the enzyme in Escherichia coli, two rounds of screening and selection, saturation mutagenesis of a "hot spot," and rational recombination, a triple mutant (P395D/L241V/T343A) was obtained that showed a 100-fold increase in activity at pH 8 (k(cat) = 100 s(-1)). The increased K-m values for Br- (3.1 mM) and H2O2 (16 mu M) are smaller than those found for vanadium bromoperoxidases that are reasonably active at this pH. In addition the brominating activity at pH 5 was increased by a factor of 6 (k(cat) = 575 s(-1)), and the chlorinating activity at pH 5 was increased by a factor of 2 (k(cat) = 36 s(-1)), yielding the "best" vanadium haloperoxidase known thus far. The mutations are in the first and second coordination sphere of the vanadate cofactor, and the catalytic effects suggest that fine tuning of residues Lys-353 and Phe-397, along with addition of negative charge or removal of positive charge near one of the vanadate oxygens, is very important. Lys-353 and Phe-397 were previously assigned to be essential in peroxide activation and halide binding. Analysis of the catalytic parameters of the mutant vanadium bromoperoxidase from the seaweed Ascophyllum nodosum also adds fuel to the discussion regarding factors governing the halide specificity of vanadium haloperoxidases. This study presents the first example of directed evolution of a vanadium enzyme.	Univ Amsterdam, Vant Hoff Inst Mol Sci, NL-1018 WS Amsterdam, Netherlands; Dutch States Mines Antiinfect BV, Delft, Netherlands	University of Amsterdam	Wever, R (corresponding author), Univ Amsterdam, Vant Hoff Inst Mol Sci, Nieuwe Achtergracht 129, NL-1018 WS Amsterdam, Netherlands.	rwever@science.uva.nl	Wever, Ron/AAM-4520-2020					Brochardt SA, 2001, APPL ENVIRON MICROB, V67, P3174, DOI 10.1128/AEM.67.7.3174-3179.2001; CABRI W, 1995, ACCOUNTS CHEM RES, V28, P2, DOI 10.1021/ar00049a001; Carter JN, 2002, J INORG BIOCHEM, V91, P59, DOI 10.1016/S0162-0134(02)00400-2; CHASTEEN ND, 1983, STRUCT BOND, V53, P105; CHEN KQ, 1993, P NATL ACAD SCI USA, V90, P5618, DOI 10.1073/pnas.90.12.5618; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DEBOER E, 1988, J BIOL CHEM, V263, P12326; DEBOER E, 1986, BIOCHIM BIOPHYS ACTA, V872, P104, DOI 10.1016/0167-4838(86)90153-6; DEBOER E, 1987, BIOTECHNOL BIOENG, V30, P607, DOI 10.1002/bit.260300504; DeLano W.L, PYMOL MOL GRAPHICS S; Dembitsky VM, 2003, TETRAHEDRON, V59, P4701, DOI 10.1016/S0040-4020(03)00701-4; Hansen EH, 2005, J APPL MICROBIOL, V98, P581, DOI 10.1111/j.1365-2672.2004.02491.x; Hansen EH, 2003, APPL ENVIRON MICROB, V69, P4611, DOI 10.1128/AEM.69.8.4611-4617.2003; HECK RF, 1972, J ORG CHEM, V37, P2320, DOI 10.1021/jo00979a024; Hemrika W, 1999, J BIOL CHEM, V274, P23820, DOI 10.1074/jbc.274.34.23820; JOHANSEN C, 1999, Patent No. 9908531; Leung DW, 1989, TECHNIQUE, V1, P11; Littlechild J, 1999, CURR OPIN CHEM BIOL, V3, P28, DOI 10.1016/S1367-5931(99)80006-4; Littlechild J, 2003, COORDIN CHEM REV, V237, P65, DOI 10.1016/S0010-8545(02)00226-6; Littlechild J, 2002, J MOL RECOGNIT, V15, P291, DOI 10.1002/jmr.590; Macedo-Ribeiro S, 1999, J BIOL INORG CHEM, V4, P209, DOI 10.1007/s007750050306; Messerschmidt A, 1997, BIOL CHEM, V378, P309, DOI 10.1515/bchm.1997.378.3-4.309; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; Ohshiro T, 2004, PROTEIN SCI, V13, P1566, DOI 10.1110/ps.03496004; Ortiz-Bermudez P, 2003, APPL ENVIRON MICROB, V69, P5015, DOI 10.1128/AEM.69.8.5015-5018.2003; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; Renirie R, 2003, ADV SYNTH CATAL, V345, P849, DOI 10.1002/adsc.200303008; RILEY JP, 1971, INTRO MARINE CHEM, P60; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Shimonishi M, 1998, FEBS LETT, V428, P105, DOI 10.1016/S0014-5793(98)00500-6; SOEDJAK HS, 1995, BIOCHEMISTRY-US, V34, P12689, DOI 10.1021/bi00039a027; SVENDSEN A, 2002, Patent No. 6372465; Tanaka N, 2004, J INORG BIOCHEM, V98, P625, DOI 10.1016/j.jinorgbio.2004.02.001; Tanaka N, 2003, INORG CHIM ACTA, V356, P288, DOI 10.1016/S0020-1693(03)00476-6; VANSCHIJNDEL JWPM, 1994, EUR J BIOCHEM, V225, P151; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WEVER R, 1991, ENVIRON SCI TECHNOL, V25, P446, DOI 10.1021/es00015a010; Wever R., 2001, HDB METALLOPROTEINS, P1417; WEVER R, 1995, Patent No. 9527009; Zampella G, 2005, J AM CHEM SOC, V127, P953, DOI 10.1021/ja046016x	40	63	64	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9738	9744		10.1074/jbc.M512166200	http://dx.doi.org/10.1074/jbc.M512166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455658	hybrid			2022-12-27	WOS:000236404700086
J	Tu, XM; Kumar, P; Li, ZY; Wang, CC				Tu, XM; Kumar, P; Li, ZY; Wang, CC			An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM-FORM; CELL-CYCLE; RNA INTERFERENCE; MITOTIC SPINDLE; PROCYCLIC FORM; BUDDING YEAST; ALPHA-TUBULIN; MORPHOGENESIS; MICROTUBULES; SEGREGATION	The chromosomal passenger protein aurora kinases have been implicated in regulating chromosome segregation and cell division. Three aurora kinase homologues were identified (TbAUK1, - 2 and - 3) in the Trypanosome Genomic Data Base, and their expressions in the procyclic form of Trypanosoma brucei were knocked down individually by using the RNA interference technique. Only a knockdown of TbAUK1 arrested the cells in G(2)/M phase with each cell showing an extended posterior end, two kinetoplasts, and an enlarged nucleus, apparently the result of an inhibited kinetoplast multiplication and a failed mitosis. There is no mitotic spindle structure in the TbAUK1-depleted cell. The two kinetoplasts moved apart from each other but stopped just before cytokinesis, suggesting that cytokinesis was blocked in its early phase. Overexpression of TbAUK1 in the cells resulted in little change in cell growth. By immunofluorescence, TbAUK1 was primarily localized to the nucleus in interphase and to the mitotic spindle during apparent metaphase and anaphase. Thus, differing from other eukaryotes, TbAUK1 has an apparent triple function in coupling mitosis and kinetoplast replication with cytokinesis in T. brucei. T. brucei polo-like kinase, previously identified as the initiator of cytokinesis without apparent involvement in mitosis in the trypanosome, was either depleted or overexpressed in the TbAUK1-deficient cells. A dominant TbAUK1-depleted phenotype was demonstrated in both cases, suggesting that TbAUK1 plays an essential role in cytokinesis that cannot be affected by changes in the level of T. brucei polo-like kinase. To our knowledge, this is the first time that the function of an aurora B-like kinase is a prerequisite for polo-like kinase action in initiating cytokinesis. TbAUK1 is also the first identified protein that couples both mitosis and kinetoplast replication with cytokinesis in the trypanosome.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu	Tu, Xiaoming/G-5090-2018	Li, Ziyin/0000-0002-3960-9716	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786, R56AI021786] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21786, R01 AI021786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Baldauf SL, 2003, SCIENCE, V300, P1703, DOI 10.1126/science.1085544; Bapteste E, 2003, TRENDS GENET, V19, P696, DOI 10.1016/j.tig.2003.10.004; Bastin P, 2000, J CELL SCI, V113, P3321; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chen HL, 2005, J BIOMED SCI, V12, P297, DOI 10.1007/s11373-005-0980-0; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; Desai A, 1998, J CELL BIOL, V141, P703, DOI 10.1083/jcb.141.3.703; Giet R, 1999, J CELL SCI, V112, P3591; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kumar P, 2006, EUKARYOT CELL, V5, P92, DOI 10.1128/EC.5.1.92-102.2006; Kumar P, 2005, J BIOL CHEM, V280, P31783, DOI 10.1074/jbc.M504326200; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; MATTHEWS KR, 1994, PARASITOL TODAY, V10, P473, DOI 10.1016/0169-4758(94)90159-7; McKean PG, 2003, CURR OPIN MICROBIOL, V6, P600, DOI 10.1016/j.mib.2003.10.010; Mishima M, 2003, CURR BIOL, V13, pR589, DOI 10.1016/S0960-9822(03)00521-9; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Ogbadoyi E, 2000, CHROMOSOMA, V108, P501, DOI 10.1007/s004120050402; Ploubidou A, 1999, J CELL SCI, V112, P4641; PLOUBIDOU A, 1991, NATURE, V352, P731; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tanaka TU, 2002, CURR OPIN CELL BIOL, V14, P365, DOI 10.1016/S0955-0674(02)00328-9; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tu XM, 2005, MOL BIOL CELL, V16, P97, DOI 10.1091/mbc.E04-05-0368; Tu XM, 2005, EUKARYOT CELL, V4, P755, DOI 10.1128/EC.4.4.755-764.2005; Tu XM, 2004, J BIOL CHEM, V279, P20519, DOI 10.1074/jbc.M312862200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WEHLAND J, 1983, J CELL BIOL, V97, P1467, DOI 10.1083/jcb.97.5.1467; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODS A, 1989, J CELL SCI, V93, P491; Yan XM, 2005, GENES CELLS, V10, P617, DOI 10.1111/j.1365-2443.2005.00863.x; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	43	79	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9677	9687		10.1074/jbc.M511504200	http://dx.doi.org/10.1074/jbc.M511504200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16436376	hybrid			2022-12-27	WOS:000236404700080
J	Lee, DY; Northrop, JP; Kuo, MH; Stallcup, MR				Lee, DY; Northrop, JP; Kuo, MH; Stallcup, MR			Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN METHYLTRANSFERASE; P160 COACTIVATORS; METHYLATION; ACTIVATION; CHROMATIN; DOMAINS; ACETYLTRANSFERASE; RECRUITS; COMPLEX; PRMT1	Methylation of Lys- 9 of histone H3 has been associated with repression of transcription. G9a is a histone H3 Lys- 9 methyltransferase localized in euchromatin and acts as a corepressor for specific transcription factors. Here we demonstrate that G9a also functions as a coactivator for nuclear receptors, cooperating synergistically with nuclear receptor coactivators glucocorticoid receptor interacting protein 1, coactivator- associated arginine methyltransferase 1 ( CARM1), and p300 in transient transfection assays. This synergy depends strongly on the arginine- specific protein methyltransferase activity of CARM1 but does not absolutely require the enzymatic activity of G9a and is specific to CARM1 and G9a among various protein methyltransferases. Reduction of endogenous G9a diminished hormonal activation of an endogenous target gene by the androgen receptor, and G9a associated with regulatory regions of this same gene. G9a fused to Gal4 DNA binding domain can repress transcription in a lysine methyltransferase- dependent manner; however, the histone modifications associated with transcriptional activation can inhibit the methyltransferase activity of G9a. These findings suggest a link between histone arginine and lysine methylation and a mechanism for controlling whether G9a functions as a corepressor or coactivator.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	University of Southern California; Michigan State University	Stallcup, MR (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, 1333 San Pablo St,MCA-51A, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32 DE007211, DE07211] Funding Source: Medline; NIDDK NIH HHS [R37 DK055274, R01 DK055274, DK55274] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen YH, 2005, MOL CELL BIOL, V25, P5965, DOI 10.1128/MCB.25.14.5965-5972.2005; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lee YH, 2004, MOL CELL BIOL, V24, P2103, DOI 10.1128/MCB.24.5.2103-2117.2004; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Ma H, 2003, METHOD ENZYMOL, V364, P284; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507	33	142	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8476	8485		10.1074/jbc.M511093200	http://dx.doi.org/10.1074/jbc.M511093200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16461774	hybrid, Green Accepted			2022-12-27	WOS:000236247100023
J	Adrain, C; Duriez, PJ; Brumatti, G; Delivani, P; Martin, SJ				Adrain, C; Duriez, PJ; Brumatti, G; Delivani, P; Martin, SJ			The cytotoxic lymphocyte protease, Granzyme B, targets the cytoskeleton and perturbs microtubule polymerization dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENDED SUBSTRATE-SPECIFICITY; GRANULE EXOCYTOSIS; CYTOPLASMIC DYNEIN; MASS-SPECTROMETRY; INDUCED APOPTOSIS; T-LYMPHOCYTES; C-TERMINUS; TUBULIN; FAMILY; DEATH	Granzyme B, a serine protease derived from cytotoxic T lymphocyte (CTL) and Natural Killer (NK) cell granules, plays an important role in coordinating apoptosis of CTL and NK target cells. Here, we report that granzyme B targets the cytoskeleton by cleaving and removing the acidic C-terminal tail of alpha-tubulin. Consistent with this, Granzyme B markedly enhanced rates of microtubule polymerization in vitro, most likely by removal of an autoinhibitory domain within the tubulin C terminus. Moreover, delivery of Granzyme B into HeLa target cells promoted dramatic reorganization of the microtubule network in a caspase-independent manner. These data reveal that granzyme B directly attacks a major component of the cell cytoskeleton, which may contribute to the incapacitation of target cells during CTL/NK-mediated killing.	Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland.	martinsj@tcd.ie	Adrain, Colin/I-6259-2013	Adrain, Colin/0000-0001-7597-4393; Duriez, Patrick/0000-0003-1814-2552; Martin, Seamus/0000-0002-8539-3143				Adrain C, 2005, J BIOL CHEM, V280, P4663, DOI 10.1074/jbc.M410915200; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Catalfamo M, 2003, CURR OPIN IMMUNOL, V15, P522, DOI 10.1016/S0952-7915(03)00114-6; Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tim.2005.05.010; Edwards HM, 1999, J BIOL CHEM, V274, P30468, DOI 10.1074/jbc.274.43.30468; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Graubert TA, 1996, BLOOD, V87, P1232, DOI 10.1182/blood.V87.4.1232.bloodjournal8741232; Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Mahrus S, 2004, J BIOL CHEM, V279, P54275, DOI 10.1074/jbc.M411482200; MARTIN SJ, 1990, CELL TISSUE KINET, V23, P545, DOI 10.1111/j.1365-2184.1990.tb01345.x; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Rugles SW, 2004, J BIOL CHEM, V279, P30751, DOI 10.1074/jbc.M400949200; SACKETT DL, 1985, J BIOL CHEM, V260, P43; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; Skiniotis G, 2004, EMBO J, V23, P989, DOI 10.1038/sj.emboj.7600118; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Trapani JA, 1999, IMMUNOL TODAY, V20, P351, DOI 10.1016/S0167-5699(99)01488-7; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Verdier-Pinard P, 2003, BIOCHEMISTRY-US, V42, P12019, DOI 10.1021/bi0350147; Verdier-Pinard P, 2003, BIOCHEMISTRY-US, V42, P5349, DOI 10.1021/bi027293o; Wang ZH, 2000, BIOPHYS J, V78, P1955, DOI 10.1016/S0006-3495(00)76743-9; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200	37	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8118	8125		10.1074/jbc.M509361200	http://dx.doi.org/10.1074/jbc.M509361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415351	hybrid			2022-12-27	WOS:000236031000049
J	Lee, YK; Choi, YH; Chua, S; Park, YJ; Moore, DM				Lee, YK; Choi, YH; Chua, S; Park, YJ; Moore, DM			Phosphorylation of the hinge domain of the nuclear hormone receptor LRH-1 stimulates transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BILE-ACID SYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; FEEDBACK-REGULATION; ESTROGEN-RECEPTOR; REGULATES EXPRESSION; COACTIVATOR ACTIVITY; UP-REGULATION	The nuclear receptor LRH-1 (NR5A2) functions to regulate expression of a number of genes associated with bile acid homeostasis and other liver functions, but mechanisms that modulate its activity remain unclear. We have found that mitogenic stimuli, including treatment with phorbol myristate (PMA), increase LRH-1 transactivation. This response maps to the hinge and ligand binding domains of LRH-1 and is blocked by the mitogen-activated protein kinase ERK1/2 inhibitor U0126. LRH-1 is a phosphoprotein and hinge domain serine residues at 238 and 243 are required for effective phosphorylation, both in vitro and in cells. Preventing phosphorylation of these residues by mutating both to alanine decreases PMA-dependent LRH-1 transactivation and mimicking phosphorylation by mutation to positively charged aspartate residues increases basal transactivation. Although serine phosphorylation of the hinge of SF-1 (NR5A1), the closest relative of LRH-1, confers a similar response, the specific targets differ in the two closely related orphan receptors. These results define a novel pathway for the modulation of LRH-1 transactivation and identify specific LRH-1 residues as downstream targets of mitogenic stimuli. This pathway may contribute to recently described proliferative functions of LRH-1.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Lee, YK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	ylee@bcm.tmc.edu	Park, Young Joo/J-4161-2012	Park, Young Joo/0000-0002-3671-6364	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068804] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK068804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balasenthil S, 2004, FEBS LETT, V567, P243, DOI 10.1016/j.febslet.2004.04.071; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Bohan A, 2003, J BIOL CHEM, V278, P36688, DOI 10.1074/jbc.M304011200; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Broadus J, 1999, MOL CELL, V3, P143, DOI 10.1016/S1097-2765(00)80305-6; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Chiang JYL, 2004, J HEPATOL, V40, P539, DOI 10.1016/j.jhep.2003.11.006; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Crestani M, 1996, BIOCHEM BIOPH RES CO, V225, P585, DOI 10.1006/bbrc.1996.1215; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; Feingold KR, 1996, J LIPID RES, V37, P223; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ortlund EA, 2005, NAT STRUCT MOL BIOL, V12, P357, DOI 10.1038/nsmb910; Pare JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200; Parker KL, 1998, MOL CELL ENDOCRINOL, V145, P15, DOI 10.1016/S0303-7207(98)00164-6; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; Schoonjans K, 2002, EMBO REP, V3, P1181, DOI 10.1093/embo-reports/kvf238; Stroup D, 2005, FRONT BIOSCI-LANDMRK, V10, P1678, DOI 10.2741/1652; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang W, 2005, P NATL ACAD SCI USA, V102, P7505, DOI 10.1073/pnas.0409482102; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu PL, 2004, MOL ENDOCRINOL, V18, P1887, DOI 10.1210/me.2003-0334; Yu FQ, 2005, J ENDOCRINOL, V186, P85, DOI 10.1677/joe.1.05955	52	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7850	7855		10.1074/jbc.M509115200	http://dx.doi.org/10.1074/jbc.M509115200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439367	hybrid			2022-12-27	WOS:000236031000019
J	Zuo, Y; Qiang, L; Farmer, SR				Zuo, Y; Qiang, L; Farmer, SR			Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/ebp alpha gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; TRANSCRIPTION FACTORS; DIFFERENTIATION; PERILIPIN; PHOSPHORYLATION; FIBROBLASTS; INDUCTION; PATHWAY; LIGAND	Studies have shown that CCAAT/enhancer-binding protein beta (C/EBP beta) can stimulate adipogenesis in noncommitted fibroblasts by activating expression of peroxisome proliferator-activated receptor-gamma (PPAR gamma). Other investigations have established a role for C/EBP alpha as well as PPAR gamma in orchestrating the complex program of adipogenic gene expression during terminal preadipocyte differentiation. Consequently, it is important to identify factors regulating transcription of the C/ebp alpha gene. In this study, we demonstrated that inhibition of PPAR gamma activity by exposure of 3T3-L1 preadipocytes to a potent and selective PPAR gamma antagonist inhibits adipogenesis but also blocks the activation of C/EBP alpha expression at the onset of differentiation. Ectopic expression of C/EBP beta in Swiss 3T3 mouse fibroblasts (Swiss-LAP cells) induces PPAR gamma expression without any significant enhancement of C/EBP alpha expression. Treatment of Swiss-LAP cells with a PPAR gamma agonist induces adipogenesis, which includes activation of C/EBP alpha expression. To further establish a role for PPAR gamma in regulating C/EBP alpha expression, we expressed C/EBP beta in PPAR gamma-deficient mouse embryo fibroblasts (MEFs). The data show that C/EBP beta is capable of inducing PPAR gamma in Ppar gamma+/- MEFs, which leads to activation of adipogenesis, including C/EBP alpha expression following exposure to a PPAR gamma ligand. In contrast, C/EBP beta is not able to induce C/EBP alpha expression or adipogenesis in Ppar gamma-/- MEFs. Chromatin immunoprecipitation analysis reveals that C/EBP beta is bound to the minimal promoter of the C/ebp alpha gene in association with HDAC1 in unstimulated Swiss-LAP cells. Exposure of the cells to a PPAR gamma ligand dislodges HDAC1 from the proximal promoter of the C/ebp alpha gene, which involves degradation of HDAC1 in the 26 S proteasome. These data suggest that C/EBP beta activates a single unified pathway of adipogenesis involving its stimulation of PPAR gamma expression, which then activates C/EBP alpha expression by dislodging HDAC1 from the promoter for degradation in the proteasome.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@biochem.bumc.bu.edu	Qiang, Li/C-9560-2012	Farmer, Stephen/0000-0003-2483-2795; Qiang, Li/0000-0001-8322-1797	NIDDK NIH HHS [DK51586, DK58825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058825, R01DK058825, R01DK051586, R56DK051586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Dalen KT, 2004, DIABETES, V53, P1243, DOI 10.2337/diabetes.53.5.1243; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elberg G, 2000, J BIOL CHEM, V275, P27815; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Liu JQ, 2004, J BIOL CHEM, V279, P24493, DOI [10.1074/jbc.M402920200, 10.1074/jbc.M407050200]; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Nagai S, 2004, ENDOCRINOLOGY, V145, P2346, DOI 10.1210/en.2003-1180; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yamamoto H, 2002, J CELL SCI, V115, P3601, DOI 10.1242/jcs.00044; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	30	153	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7960	7967		10.1074/jbc.M510682200	http://dx.doi.org/10.1074/jbc.M510682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431920	hybrid			2022-12-27	WOS:000236031000032
J	Kim, C; Cha, JY; Yan, HG; Vakulenko, SB; Mobashery, S				Kim, C; Cha, JY; Yan, HG; Vakulenko, SB; Mobashery, S			Hydrolysis of ATP by aminoglycoside 3 '-phosphotransferases - An unexpected cost to bacteria for harboring an antibiotic resistance enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOLOGICAL COST; GENES; PURIFICATION; MECHANISM; FITNESS; PROTEIN	Aminoglycoside 3'-phosphotransferases (APH(3') s) are common bacterial resistance enzymes to aminoglycoside antibiotics. These enzymes transfer the gamma-phosphoryl group of ATP to the 3'-hydroxyl of the antibiotics, whereby the biological activity of the drugs is lost. Pre-steady-state and steady-state kinetics with two of these enzymes from Gram-negative bacteria, APH(3')-Ia and APH(3')IIa, were performed. It is demonstrated that these enzymes in both ternary and binary complexes facilitate an ATP hydrolase activity ( ATPase), which is competitive with the transfer of phosphate to the antibiotics. Because these enzymes are expressed constitutively in resistant bacteria, the turnover of ATP is continuous during the lifetime of the organism both in the absence and the presence of aminoglycosides. Concentrations of the enzyme in vivo were determined, and it was estimated that in a single generation of bacterial growth there exists the potential that this activity would consume as much as severalfold of the total existing ATP. Studies with bacteria harboring the aph(3')-Ia gene revealed that bacteria are able to absorb the cost of this ATP turnover, as ATP is recycled. However, the cost burden of this adventitious activity manifests a selection pressure against maintenance of the plasmids that harbor the aph(3')-Ia gene, such that similar to 50% of the plasmid is lost in 1500 bacterial generations in the absence of antibiotics. The implication is that, in the absence of selection, bacteria harboring an enzyme that catalyzes the consumption of key metabolites could experience the loss of the plasmid that encodes for the given enzyme.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	University of Notre Dame; Michigan State University	Mobashery, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mobashery@nd.edu		Kim, Choon/0000-0003-0306-8935				Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; Andersson DI, 2003, CURR OPIN MICROBIOL, V6, P452, DOI 10.1016/j.mib.2003.09.001; Bagel S, 1999, ANTIMICROB AGENTS CH, V43, P868, DOI 10.1128/AAC.43.4.868; Becker EC, 1997, J BACTERIOL, V179, P5947, DOI 10.1128/jb.179.18.5947-5950.1997; DiezGonzalez F, 1997, FEMS MICROBIOL LETT, V151, P71, DOI 10.1111/j.1574-6968.1997.tb10396.x; Gillespie SH, 1997, TRENDS MICROBIOL, V5, P337, DOI 10.1016/S0966-842X(97)01101-3; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; GOSS SR, 1988, FEBS LETT, V228, P245, DOI 10.1016/0014-5793(88)80008-5; GUIHARD G, 1993, J BIOL CHEM, V268, P17775; Kim C, 2005, BIOORG CHEM, V33, P149, DOI 10.1016/j.bioorg.2004.11.001; Kim C, 2004, BIOCHEMISTRY-US, V43, P2373, DOI 10.1021/bi036095+; Lasko DR, 1996, BIOTECHNOL BIOENG, V52, P364, DOI 10.1002/(SICI)1097-0290(19961105)52:3<364::AID-BIT2>3.0.CO;2-I; LENSKI RE, 1997, ANTIBIOTIC RESISTANC, P131; Louie TM, 2003, BIOCHEMISTRY-US, V42, P7509, DOI 10.1021/bi034092r; Magnet S, 2005, CHEM REV, V105, P477, DOI 10.1021/cr0301088; NANNINGA N, 1985, MOL CYTOLOGY ESCHERI, P161; Reisbig MD, 2003, J ANTIMICROB CHEMOTH, V51, P1141, DOI 10.1093/jac/dkg204; Rohwer JM, 1996, EUR J BIOCHEM, V235, P225, DOI 10.1111/j.1432-1033.1996.00225.x; Rozkov A, 1999, BIOTECHNOL BIOENG, V62, P730, DOI 10.1002/(SICI)1097-0290(19990320)62:6<730::AID-BIT12>3.0.CO;2-Q; Salyers AA, 1997, ANTIMICROB AGENTS CH, V41, P2321, DOI 10.1128/AAC.41.11.2321; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Seyer K, 2003, APPL ENVIRON MICROB, V69, P3231, DOI 10.1128/AEM.69.6.3231-3237.2003; SIREGAR JJ, 1995, BIOCHEMISTRY-US, V34, P12681, DOI 10.1021/bi00039a026; SIREGAR JJ, 1994, ANTIMICROB AGENTS CH, V38, P641, DOI 10.1128/AAC.38.4.641; Smith MA, 1998, CAN J MICROBIOL, V44, P351, DOI 10.1139/cjm-44-4-351; Vakulenko SB, 2003, CLIN MICROBIOL REV, V16, P430, DOI 10.1128/CMR.16.3.430-450.2003; Wright GD, 1999, CURR OPIN MICROBIOL, V2, P499, DOI 10.1016/S1369-5274(99)00007-7; Wright GD, 1998, ADV EXP MED BIOL, V456, P27	30	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6964	6969		10.1074/jbc.M513257200	http://dx.doi.org/10.1074/jbc.M513257200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407230	hybrid			2022-12-27	WOS:000236030900008
J	Ogden, SK; Casso, DJ; Ascano, M; Yore, MM; Kornberg, TB; Robbins, DJ				Ogden, SK; Casso, DJ; Ascano, M; Yore, MM; Kornberg, TB; Robbins, DJ			Smoothened regulates activator and repressor functions of hedgehog signaling via two distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN-RELATED PROTEIN; TARGET GENE-EXPRESSION; CUBITUS-INTERRUPTUS; KINASE-A; TRANSCRIPTIONAL ACTIVATOR; REQUIRES PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; IMAGINAL DISCS; DROSOPHILA; TRANSDUCTION	The secreted protein Hedgehog (Hh) plays an important role in metazoan development and as a survival factor for many human tumors. In both cases, Hh signaling proceeds through the activation of the seven-transmembrane protein Smoothened (Smo), which is thought to convert the Gli family of transcription factors from transcriptional repressors to transcriptional activators. Here, we provide evidence that Smo signals to the Hh signaling complex, which consists of the kinesin-related protein Costal2 (Cos2), the protein kinase Fused (Fu), and the Drosophila Gli homolog cubitus interruptus (Ci), in two distinct manners. We show that many of the commonly observed molecular events following Hh signaling are not transmitted in a linear fashion but instead are activated through two signals that bifurcate at Smo to independently affect activator and repressor pools of Ci.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Cincinnati, Med Ctr, Dept Mol Genet Grad Program, Cincinnati, OH 45267 USA	Dartmouth College; University of California System; University of California San Francisco; University System of Ohio; University of Cincinnati	Robbins, DJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, HB 7650 Remson, Hanover, NH 03755 USA.	David.J.Robbins@dartmouth.edu	Ogden, Stacey K/N-2528-2018; Ascano, Manuel/ABA-3586-2020; Ogden, Stacey K/P-9585-2019	Ascano, Manuel/0000-0002-9370-5493; Ogden, Stacey K/0000-0001-8991-3065	NCI NIH HHS [CA 82628, R01 CA082628] Funding Source: Medline; NIEHS NIH HHS [T32 ES007250, T32 ES 07250-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Apionishev S, 2005, NAT CELL BIOL, V7, P86, DOI 10.1038/ncb1210; Ascano M, 2004, MOL CELL BIOL, V24, P10397, DOI 10.1128/MCB.24.23.10397-10405.2004; Ascano M, 2002, MOL CELL BIOL, V22, P1555, DOI 10.1128/MCB.22.5.1555-1566.2002; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Fasken MB, 2000, J BIOL CHEM, V275, P1878, DOI 10.1074/jbc.275.3.1878; Hooper JE, 2003, DEVELOPMENT, V130, P3951, DOI 10.1242/dev.00594; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jia JH, 2003, GENE DEV, V17, P2709, DOI 10.1101/gad.1136603; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Nakano Y, 2004, MECH DEVELOP, V121, P507, DOI 10.1016/j.mod.2004.04.015; Ogden SK, 2004, BIOCHEM PHARMACOL, V67, P805, DOI 10.1016/j.bcp.2004.01.002; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Price MA, 1999, DEVELOPMENT, V126, P4331; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Stegman MA, 2004, J BIOL CHEM, V279, P7064, DOI 10.1074/jbc.M311794200; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wang QT, 1999, DEVELOPMENT, V126, P5097; Zhang C, 2004, P NATL ACAD SCI USA, V101, P17900, DOI 10.1073/pnas.0408093101; Zhang WS, 2005, DEV CELL, V8, P267, DOI 10.1016/j.devcel.2005.01.001; Zhu AJ, 2003, GENE DEV, V17, P1240, DOI 10.1101/gad.1080803	38	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7237	7243		10.1074/jbc.M510169200	http://dx.doi.org/10.1074/jbc.M510169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423832	hybrid, Green Accepted			2022-12-27	WOS:000236030900041
J	Sawaya, MR; Cannon, GC; Heinhorst, S; Tanaka, S; Williams, EB; Yeates, TO; Kerfeld, CA				Sawaya, MR; Cannon, GC; Heinhorst, S; Tanaka, S; Williams, EB; Yeates, TO; Kerfeld, CA			The structure of beta-carbonic anhydrase from the carboxysomal shell reveals a distinct subclass with one active site for the price of two	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO2 CONCENTRATING MECHANISMS; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; CYANOBACTERIUM; MODELS; GENES	CsoSCA (formerly CsoS3) is a bacterial carbonic anhydrase localized in the shell of a cellular microcompartment called the carboxysome, where it converts HCO3- to CO2 for use in carbon fixation by ribulose-bisphosphate carboxylase/oxygenase (RuBisCO). CsoSCA lacks significant sequence similarity to any of the four known classes of carbonic anhydrase (alpha, beta, gamma, or delta), and so it was initially classified as belonging to a new class, epsilon. The crystal structure of CsoSCA from Halothiobacillus neapolitanus reveals that it is actually a representative member of a new subclass of beta-carbonic anhydrases, distinguished by a lack of active site pairing. Whereas a typical beta-carbonic anhydrase maintains a pair of active sites organized within a two-fold symmetric homodimer or pair of fused, homologous domains, the two domains in CsoSCA have diverged to the point that only one domain in the pair retains a viable active site. We suggest that this defunct and somewhat diminished domain has evolved a new function, specific to its carboxysomal environment. Despite the level of sequence divergence that separates CsoSCA from the other two subclasses of beta-carbonic anhydrases, there is a remarkable level of structural similarity among active site regions, which suggests a common catalytic mechanism for the interconversion of HCO3- and CO2. Crystal packing analysis suggests that CsoSCA exists within the carboxysome shell either as a homodimer or as extended filaments.	Univ Calif Los Angeles, DOE Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ So Mississippi, Dept Chem & Biochem, Hattiesburg, MS 39406 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Life Sci Core, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Southern Mississippi; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kerfeld, CA (corresponding author), Univ Calif Los Angeles, DOE Inst Genom & Proteom, Box 951570, Los Angeles, CA 90095 USA.	kerfeld@mbi.ucla.edu		Yeates, Todd/0000-0001-5709-9839; Sawaya, Michael/0000-0003-0874-9043				Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SH, 2000, ARCH MICROBIOL, V173, P278, DOI 10.1007/s002030000141; BEUDEKER RF, 1980, ARCH MICROBIOL, V124, P185, DOI 10.1007/BF00427725; Boggon TJ, 2000, STRUCTURE, V8, pR143, DOI 10.1016/S0969-2126(00)00168-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANNON GC, 1983, ARCH MICROBIOL, V134, P52, DOI 10.1007/BF00429407; Cannon GC, 2002, FUNCT PLANT BIOL, V29, P175, DOI 10.1071/PP01200; Cannon GC, 2001, APPL ENVIRON MICROB, V67, P5351, DOI 10.1128/AEM.67.12.5351-5361.2001; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Covarrubias AS, 2005, J BIOL CHEM, V280, P18782, DOI 10.1074/jbc.M414348200; Cronk JD, 2001, PROTEIN SCI, V10, P911, DOI 10.1110/ps.46301; DeLano WL, 2002, PYMOL USERS MANUAL; Fabiola F, 2002, PROTEIN SCI, V11, P1415, DOI 10.1110/ps.4890102; Gao YQ, 2005, CELL, V123, P195, DOI 10.1016/j.cell.2005.10.001; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; HATCH MD, 1990, PLANT PHYSIOL, V93, P825, DOI 10.1104/pp.93.2.825; HOLTHUIJZEN YA, 1986, ARCH MICROBIOL, V144, P258, DOI 10.1007/BF00410959; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Kerfeld CA, 2005, SCIENCE, V309, P936, DOI 10.1126/science.1113397; Kimber MS, 2000, EMBO J, V19, P1407, DOI 10.1093/emboj/19.7.1407; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Ludwig M, 2000, J PHYCOL, V36, P1109, DOI 10.1046/j.1529-8817.2000.00028.x; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ponstingl H, 2000, PROTEINS, V41, P47; PRICE GD, 1992, PLANT PHYSIOL, V100, P784, DOI 10.1104/pp.100.2.784; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; REINHOLD L, 1991, CAN J BOT, V69, P984, DOI 10.1139/b91-126; Sheldrick GM, 2001, NATO SCI SER I LIFE, V325, P72; SHIVELY JM, 1973, J BACTERIOL, V116, P1405, DOI 10.1128/JB.116.3.1405-1411.1973; So AKC, 2005, CAN J BOT, V83, P721, DOI 10.1139/B05-057; So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004; So AKC, 1998, PLANT MOL BIOL, V37, P205, DOI 10.1023/A:1005959200390; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240	40	128	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7546	7555		10.1074/jbc.M510464200	http://dx.doi.org/10.1074/jbc.M510464200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407248	hybrid, Green Submitted			2022-12-27	WOS:000236030900076
J	Stirling, PC; Cuellar, J; Alfaro, GA; El Khadali, F; Beh, CT; Valpuesta, JM; Melki, R; Leroux, MR				Stirling, PC; Cuellar, J; Alfaro, GA; El Khadali, F; Beh, CT; Valpuesta, JM; Melki, R; Leroux, MR			PhLP3 modulates CCT-mediated actin and tubulin folding via ternary complexes with substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSDUCIN-LIKE PROTEIN; CYTOSOLIC CHAPERONIN CCT; EUKARYOTIC CHAPERONIN; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; ATP HYDROLYSIS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE HYDROLYSIS; ELECTRON-MICROSCOPY; UNFOLDED PROTEINS	Many ATP-dependent molecular chaperones, including Hsp70, Hsp90, and the chaperonins GroEL/Hsp60, require cofactor proteins to regulate their ATPase activities and thus folding functions in vivo. One conspicuous exception has been the eukaryotic chaperonin CCT, for which no regulator of its ATPase activity, other than non-native substrate proteins, is known. We identify the evolutionarily conserved PhLP3 (phosducin-like protein 3) as a modulator of CCT function in vitro and in vivo. PhLP3 binds CCT, spanning the cylindrical chaperonin cavity and contacting at least two subunits. When present in a ternary complex with CCT and an actin or tubulin substrate, PhLP3 significantly diminishes the chaperonin ATPase activity, and accordingly, excess PhLP3 perturbs actin or tubulin folding in vitro. Most interestingly, however, the Saccharomyces cerevisiae PhLP3 homologue is required for proper actin and tubulin function. This cellular role of PhLP3 is most apparent in a strain that also lacks prefoldin, a chaperone that facilitates CCT-mediated actin and tubulin folding. We propose that the antagonistic actions of PhLP3 and prefoldin serve to modulate CCT activity and play a key role in establishing a functional cytoskeleton in vivo.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Simon Fraser University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Leroux, MR (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	leroux@sfu.ca	Valpuesta, José M/T-1977-2017; Cuéllar, Jorge/GOH-3100-2022; Cuéllar, Jorge/S-4269-2017; Valpuesta, Jose M/AAA-6002-2019	Valpuesta, José M/0000-0001-7468-8053; Cuéllar, Jorge/0000-0002-7789-807X; Cuéllar, Jorge/0000-0002-7789-807X; Beh, Christopher/0000-0003-0201-6316; Stirling, Peter/0000-0003-2651-4539				Abruzzi KC, 2002, MOL CELL BIOL, V22, P138, DOI 10.1128/MCB.22.1.138-147.2002; Adams Alison, 1997, P139; Alvarez P, 1998, GENETICS, V149, P857; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Blaauw M, 2003, EMBO J, V22, P5047, DOI 10.1093/emboj/cdg508; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Cowan NJ, 1998, METHOD ENZYMOL, V290, P230, DOI 10.1016/S0076-6879(98)90022-2; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Flanary PL, 2000, J BIOL CHEM, V275, P18462, DOI 10.1074/jbc.M002163200; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gebauer M, 1998, J BIOL CHEM, V273, P29475, DOI 10.1074/jbc.273.45.29475; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoyt MA, 1997, GENETICS, V146, P849; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; KUZNETSOV SA, 1981, FEBS LETT, V135, P237, DOI 10.1016/0014-5793(81)80790-9; Lacefield S, 2003, GENETICS, V165, P531; Leroux MR, 2000, METH MOL B, V140, P195; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Llorca O, 2000, EMBO J, V19, P5971, DOI 10.1093/emboj/19.22.5971; Lopez-Fanarraga M, 2001, J STRUCT BIOL, V135, P219, DOI 10.1006/jsbi.2001.4386; Lukov GL, 2005, EMBO J, V24, P1965, DOI 10.1038/sj.emboj.7600673; Lundin VF, 2004, P NATL ACAD SCI USA, V101, P4367, DOI 10.1073/pnas.0306276101; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Martin-Benito J, 2004, P NATL ACAD SCI USA, V101, P17410, DOI 10.1073/pnas.0405070101; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; MELKI R, 1990, BIOCHEMISTRY-US, V29, P8921, DOI 10.1021/bi00490a007; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Ogawa S, 2004, GENES CELLS, V9, P83, DOI 10.1111/j.1356-9597.2004.00708.x; Rommelaere H, 2001, J BIOL CHEM, V276, P41023, DOI 10.1074/jbc.M106591200; Scheres SHW, 2005, J MOL BIOL, V348, P139, DOI 10.1016/j.jmb.2005.02.031; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stirling PC, 2003, EMBO REP, V4, P565, DOI 10.1038/sj.embor.embor869; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930	49	56	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7012	7021		10.1074/jbc.M513235200	http://dx.doi.org/10.1074/jbc.M513235200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415341	hybrid			2022-12-27	WOS:000236030900014
J	Forsee, WT; Cartee, RT; Yother, J				Forsee, WT; Cartee, RT; Yother, J			Role of the carbohydrate binding site of the Streptococcus pneumoniae capsular polysaccharide type 3 synthase in the transition from oligosaccharide to polysaccharide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN SYNTHASES; BIOSYNTHESIS; MECHANISM; GLYCOSYLTRANSFERASES; EQUISIMILIS; RECOGNITION; MODULES; ACID	The type 3 synthase catalyzes the formation of the Streptococcus pneumoniae type 3 capsular polysaccharide [- 3)-beta-D-GlcUA-(1, 4)-beta-D-Glc-(1-](n). Synthesis is comprised of two distinct catalytic phases separated by a transition step whereby an oligosaccharylphosphatidylglycerol primer becomes tightly bound to the carbohydrate acceptor recognition site of the synthase. Using the recombinant synthase in Escherichia coli membranes, we determined that a critical oligosaccharide length of similar to 8 monosaccharides was required for recognition of the growing chain by the synthase. Upon binding of the oligosaccharide- lipid to the carbohydrate recognition site, the polymerization reaction entered a highly processive phase to produce polymer of high molecular weight. The initial oligosaccharide-synthetic phase also appeared to be processive, the duration of which was enhanced by the concentration of UDP-GlcUA and diminished by an increase in temperature. The overall reaction approached a steady state equilibrium between the polymer- and oligosaccharide- forming phases that was shifted toward the former by higher UDP-GlcUA levels or lower temperatures and toward the latter by lower concentrations of UDP-GlcUA or higher temperatures. The transition step between the two enzymatic phases demonstrated cooperative kinetics, which is predicted to reflect a possible reorientation of the oligosaccharide- lipid in conjunction with the formation of a tight binding complex.	Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Yother, J (corresponding author), Univ Alabama Birmingham, Dept Microbiol, 845 19th St S BBRB 661-12, Birmingham, AL 35294 USA.	jyother@uab.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CAMPBELL JH, 1966, IMMUNOCHEMISTRY, V3, P195, DOI 10.1016/0019-2791(66)90184-4; Cartee RT, 2005, J BACTERIOL, V187, P4470, DOI 10.1128/JB.187.13.4470-4479.2005; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; Cartee RT, 2001, J BIOL CHEM, V276, P48831, DOI 10.1074/jbc.M106481200; Charnock SJ, 2001, PLANT PHYSIOL, V125, P527, DOI 10.1104/pp.125.2.527; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Davies GJ, 2001, TRENDS GLYCOSCI GLYC, V13, P105, DOI 10.4052/tigg.13.105; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; Flint J, 2005, J BIOL CHEM, V280, P23718, DOI 10.1074/jbc.M501551200; Forsee WT, 2000, J BIOL CHEM, V275, P25972, DOI 10.1074/jbc.M002613200; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; Ramos A, 2001, APPL ENVIRON MICROB, V67, P33, DOI 10.1128/AEM.67.1.33-41.2001; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Tlapak-Simmons VL, 2005, J BIOL CHEM, V280, P13012, DOI 10.1074/jbc.M409788200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 2004, BIOCHEMISTRY-US, V43, P9234, DOI 10.1021/bi049468v; TORRIANI A, 1962, J BIOL CHEM, V237, P3; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269	22	27	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6283	6289		10.1074/jbc.M511124200	http://dx.doi.org/10.1074/jbc.M511124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16410247	hybrid			2022-12-27	WOS:000236030800021
J	Liu, ZP; Li, HB; Derouet, M; Berezkin, A; Sasazuki, T; Shirasawa, S; Rosen, K				Liu, Zaiping; Li, Hongbing; Derouet, Mathieu; Berezkin, Alexander; Sasazuki, Takehiko; Shirasawa, Senji; Rosen, Kirill			Oncogenic Ras inhibits anoikis of intestinal epithelial cells by preventing the release of a mitochondrial pro-apoptotic protein Omi/HtrA2 into the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; SERINE-PROTEASE; DOWN-REGULATION; BCL-X; INDUCED TRANSFORMATION; EXTRACELLULAR-MATRIX; BCL-X(L) EXPRESSION; HUMAN KERATINOCYTES; PROMOTES APOPTOSIS; CASPASE ACTIVATION	Resistance of cancer cells to anoikis, apoptosis induced by cell detachment from the extracellular matrix, is thought to represent a critical feature of the malignant phenotype. Mechanisms that control anoikis of normal and cancer cells are understood only in part. Previously we found that anoikis of non-malignant intestinal epithelial cells is driven by detachment-induced down-regulation of Bcl-X-L, a protein that blocks apoptosis through preventing the release of death-promoting factors from the mitochondria. Mitochondrial proteins the release of which causes anoikis are presently unknown. Similar to what was previously observed by others for keratinocytes and fibroblasts, we show here that anoikis of intestinal epithelial cells does not involve caspase-9, a target of a mitochondrial protein cytochrome c. Furthermore, Smac/Diablo, another mitochondrial pro-apoptotic factor, does not appear to play a role in detachment-dependent apoptosis of these cells either. Instead, anoikis of intestinal epithelial cells is triggered by the release of a mitochondrial protein Omi/HtrA2, an event driven by detachment-induced down-regulation of Bcl-XL. Moreover, we established that oncogenic ras inhibits anoikis by preventing the release of Omi/HtrA2. This effect of ras required ras-induced down-regulation of a pro-apoptotic protein Bak and could be blocked by an inhibitor of phosphoinositide 3-kinase, a target of Ras that was previously implicated by us in the down-regulation of Bak and blockade of anoikis. We conclude that Omi/HtrA2 is an inducer of anoikis and an important regulator of ras-induced transformation.	Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Int Med Ctr Japan, Dept Pathol, Res Inst, Shinjyuku Ku, Tokyo 1628655, Japan	Dalhousie University; Dalhousie University; National Center for Global Health & Medicine - Japan	Rosen, K (corresponding author), CRC, Rm C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	Kirill.Rosen@Dal.Ca		Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Bian X, 2004, J BIOL CHEM, V279, P4663, DOI 10.1074/jbc.M306905200; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; FILMUS J, 1993, ONCOGENE, V8, P1017; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140-6736(03)13915-3; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Krajewska M, 1996, CANCER RES, V56, P2422; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lebowitz PF, 1997, CANCER RES, V57, P708; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Miyazaki T, 2004, J BIOL CHEM, V279, P44667, DOI 10.1074/jbc.M408101200; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Ozoren N, 2000, CANCER RES, V60, P6259; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sevignani C, 1999, CANCER RES, V59, P5882; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang J, 2000, J CELL SCI, V113, P753; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	73	39	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14738	14747		10.1074/jbc.M508664200	http://dx.doi.org/10.1074/jbc.M508664200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16461771	hybrid			2022-12-27	WOS:000237671300027
J	Kimura, T; Sakisaka, T; Baba, T; Yamada, T; Takai, Y				Kimura, T; Sakisaka, T; Baba, T; Yamada, T; Takai, Y			Involvement of the Ras-Ras-activated rab5 guanine nucleotide exchange factor RIN2-Rab5 pathway in the hepatocyte growth factor-induced endocytosis of E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; SMALL G-PROTEINS; CANINE KIDNEY-CELLS; ADHERENS JUNCTIONS; BINDING-PROTEIN; FACTOR RECEPTOR; MDCK CELLS; RHO; TRANSLOCATION; PURIFICATION	E-cadherin is a key cell-cell adhesion molecule at adherens junctions (AJs) and undergoes endocytosis when AJs are disrupted by the action of an extracellular signal, such as hepatocyte growth factor (HGF)/scatter factor. Rab5 small G protein has been implicated in the HGF-induced endocytosis of E-cadherin, but the molecular mechanism for the regulation of Rab5 activity remains unknown. We first studied this mechanism by using the cell-free assay system for the endocytosis of E-cadherin of the AJ-enriched fraction from rat livers. HGF induced activation of Ras small G protein, which then bound to RIN2, a Rab5 GDP/GTP exchange factor with the Vps9p-like guanine nucleotide exchange factor and Ras association domains, and activated it. Activated RIN2 then activated Rab5, eventually inducing the endocytosis of E-cadherin. We then studied whether RIN2 was involved in the HGF-induced endocytosis of E-cadherin in intact Madin-Darby canine kidney cells. RIN2 localized at the cell-cell adhesion sites, and its guanine nucleotide exchange factor activity was required for the HGF-induced endocytosis of E-cadherin in Madin-Darby canine kidney cells. These results indicate that RIN2 connects Ras to Rab5 in the HGF-induced endocytosis of E-cadherin.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp						Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; Martinu L, 2002, J BIOL CHEM, V277, P50996, DOI 10.1074/jbc.M204869200; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10598	10609		10.1074/jbc.M510531200	http://dx.doi.org/10.1074/jbc.M510531200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16423831	hybrid			2022-12-27	WOS:000236594300092
J	Cougoule, C; Hoshino, S; Dart, A; Lim, J; Caron, E				Cougoule, C; Hoshino, S; Dart, A; Lim, J; Caron, E			Dissociation of recruitment and activation of the small G-protein Rac during Fc gamma receptor-mediated phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYK TYROSINE KINASE; DISTINCT MECHANISMS; PLASMA-MEMBRANE; FAMILY KINASES; RHO-GTPASES; VAV; CDC42; PHOSPHORYLATION; MACROPHAGES; INVOLVEMENT	Rho-family proteins play a central role in most actin-dependent processes, including the control and maintenance of cell shape, adhesion, motility, and phagocytosis. Activation of these GTP-binding proteins is tightly regulated spatially and temporally; however, very little is known of the mechanisms involved in their recruitment and activation in vivo. Because of its inducible, restricted signaling, phagocytosis offers an ideal physiological system to delineate the pathways linking surface receptors to actin remodeling via Rho GTPases. In this study, we investigated the involvement of early regulators of Fc gamma receptor signaling in Rac recruitment and activation. Using a combination of receptor mutagenesis, cellular, molecular, and pharmacological approaches, we show that Src family and Syk kinases control Rac and Vav function during phagocytosis. Importantly, both the immunoreceptor tyrosine-based activation motif within Fc gamma receptor cytoplasmic domain and Src kinase control the recruitment of Vav and Rac. However, Syk activity is dispensable for Vav and Rac recruitment. Moreover, we show that Rac and Cdc42 activities coordinate F-actin accumulation at nascent phagosomes. Our results provide new insights in the understanding of the spatiotemporal regulation of Rho-family GTPase function, and of Rac in particular, during phagocytosis. We believe they will contribute to a better understanding of more complex cellular processes, such as cell adhesion and migration.	Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Cell & Mol Cell Biol, London SW7 2AZ, England	Imperial College London; Imperial College London	Caron, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, CMMI2, Flowers Bldg,Armstrong Rd, London SW7 2AZ, England.	e.caron@imperial.ac.uk	COUGOULE, Céline/ABB-4180-2021	Dart, Anna/0000-0002-2412-3502; Lim, Jenson/0000-0001-7417-356X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billker O, 2002, EMBO J, V21, P560, DOI 10.1093/emboj/21.4.560; Bonilla FA, 2000, P NATL ACAD SCI USA, V97, P1725, DOI 10.1073/pnas.040543597; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Carreno S, 2000, J BIOL CHEM, V275, P36223, DOI 10.1074/jbc.M003901200; Carreno S, 2002, J BIOL CHEM, V277, P21007, DOI 10.1074/jbc.M201212200; Castellano F, 2001, SEMIN IMMUNOL, V13, P347, DOI 10.1006/smim.2001.0331; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Castellano F, 2000, J CELL SCI, V113, P2955; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Coppolino MG, 2001, J CELL SCI, V114, P4307; Cougoule C, 2004, SEMIN CELL DEV BIOL, V15, P679, DOI 10.1016/j.semcdb.2004.09.001; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; DARBY C, 1994, J IMMUNOL, V152, P5429; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dombroski D, 2005, J IMMUNOL, V174, P1385, DOI 10.4049/jimmunol.174.3.1385; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; Dransart E, 2005, J BIOL CHEM, V280, P4674, DOI 10.1074/jbc.M409741200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fitzer-Attas CJ, 2000, J EXP MED, V191, P669, DOI 10.1084/jem.191.4.669; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Groysman M, 2002, J BIOL CHEM, V277, P50121, DOI 10.1074/jbc.M204299200; Groysman M, 2000, FEBS LETT, V467, P75, DOI 10.1016/S0014-5793(00)01121-2; Guignot J, 2004, J CELL SCI, V117, P1033, DOI 10.1242/jcs.00949; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Huang ZY, 2004, J LEUKOCYTE BIOL, V76, P491, DOI 10.1189/jlb.1103562; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Ivetic A, 2004, IMMUNOLOGY, V112, P165, DOI 10.1111/j.1365-2567.2004.01882.x; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Majeed M, 2001, J LEUKOCYTE BIOL, V70, P801; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; MITCHELL MA, 1994, BLOOD, V84, P1753; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schirmer J, 2004, BBA-GEN SUBJECTS, V1673, P66, DOI 10.1016/j.bbagen.2004.03.014; Schmitter T, 2004, J EXP MED, V199, P35, DOI 10.1084/jem.20030204; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Simon M, 2005, J BIOL CHEM, V280, P4510, DOI 10.1074/jbc.M410326200; Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Wiedemann Agnes, 2005, P72, DOI 10.1007/978-0-387-28669-3_6; Yamada M, 2004, J BIOL CHEM, V279, P36228, DOI 10.1074/jbc.M403101200; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788	67	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8756	8764		10.1074/jbc.M513731200	http://dx.doi.org/10.1074/jbc.M513731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16434390	hybrid			2022-12-27	WOS:000236247100054
J	Zhao, KH; Su, P; Li, J; Tu, JM; Zhou, M; Bubenzer, C; Scheer, H				Zhao, KH; Su, P; Li, J; Tu, JM; Zhou, M; Bubenzer, C; Scheer, H			Chromophore attachment to phycobiliprotein beta-subunits - Phycocyanobilin : Cysteine-beta 84 phycobiliprotein lyase activity of CpeS-like protein from Anabaena sp PCC7120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLO-ALPHA SUBUNIT; MASTIGOCLADUS-LAMINOSUS; C-PHYCOCYANIN; PHYCOVIOLOBILIN CHROMOPHORE; PHYCOERYTHROCYANIN OPERON; REVERSIBLE PHOTOCHEMISTRY; PHYCOBILISOME STRUCTURE; INVITRO ATTACHMENT; SP PCC-7120; CYANOBACTERIUM	The gene alr0617, from the cyanobacterium Anabaena sp. PCC7120, which is homologous to cpeS from Gloeobacter violaceus PCC 7421, Fremyella diplosiphon (Calothrix PCC7601), and Synechococcus sp. WH8102, and to cpcS from Synechococcus sp. PCC7002, was overexpressed in Escherichia coli. CpeS acts as a phycocyanobilin: Cys-beta 84-phycobiliprotein lyase that can attach, in vitro and in vivo, phycocyanobilin (PCB) to cysteine-beta 84 of the apo-beta-subunits of C-phycocyanin (CpcB) and phycoerythrocyanin (PecB). We found the following: ( a) In vitro, CpeS attaches PCB to native CpcB and PecB, and to their C155 I-mutants, but not to the C84S mutants. Under optimal conditions (150 mM NaCl and 500 mM potassium phosphate, 37 degrees C, and pH 7.5), no cofactors are required, and the lyase had a K-m(PCB) = 2.7 and 2.3 mu M, and a k(cat) = 1.7 x 10(-5) and 1.1 x 10(-5) s(-1) for PCB attachment to CpcB (C155I) and PecB (C155I), respectively; (b) Reconstitution products had absorption maxima at 619 and 602 nm and fluorescence emission maxima at 643 and 629 nm, respectively; and (c) PCB-CpcB(C155I) and PCB-PecB(C155I), with the same absorption and fluorescence maxima, were also biosynthesized heterologously in vivo, when cpeS was introduced into E. coli with cpcB( C155I) or pecB( C155I), respectively, together with genes ho1 ( encoding heme oxygenase) and pcyA ( encoding PCB: ferredoxin oxidoreductase), thereby further proving the lyase function of CpeS.	Huazhong Univ Sci & Technol, Coll Environm Sci & Engn, Wuhan 430074, Peoples R China; Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430074, Peoples R China; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Munich	Scheer, H (corresponding author), Huazhong Univ Sci & Technol, Coll Environm Sci & Engn, Wuhan 430074, Peoples R China.	hugo.scheer@lmu.de						ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; Beale S. I., 1994, MOL BIOL CYANOBACTER, P519; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; BHALERAO RP, 1994, PHYSIOL PLANTARUM, V90, P187; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai YA, 2001, ANAL BIOCHEM, V290, P186, DOI 10.1006/abio.2000.4979; Cobley JG, 2002, MOL MICROBIOL, V44, P1517, DOI 10.1046/j.1365-2958.2002.02966.x; COLE WJ, 1968, BIOCHEMISTRY-US, V7, P2929, DOI 10.1021/bi00848a033; DEBRECZENY MP, 1995, J PHYS CHEM-US, V99, P8412, DOI 10.1021/j100020a080; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; Ducret A, 1996, EUR J BIOCHEM, V236, P1010, DOI 10.1111/j.1432-1033.1996.01010.x; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P8686; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; FRANKENBERG N, 2002, PORPHYRIN HDB, P211; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; Gantt E., 2003, LIGHT HARVESTING ANT, P307, DOI DOI 10.1007/978-94-017-2087-8_10; GLAUSER M, 1992, EUR J BIOCHEM, V205, P907, DOI 10.1111/j.1432-1033.1992.tb16857.x; Glazer A. N, 1994, ADV MOL CELL BIOL, V10, P119; GLAZER AN, 1973, J BIOL CHEM, V248, P659; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARIAS JC, 1988, J BIOL CHEM, V263, P12977; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Landgraf FT, 2001, FEBS LETT, V508, P459, DOI 10.1016/S0014-5793(01)02988-X; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; MacColl R, 1998, J STRUCT BIOL, V124, P311, DOI 10.1006/jsbi.1998.4062; NAGY JO, 1985, J BIOL CHEM, V260, P4864; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Parbel A, 1997, PHOTOSYNTH RES, V54, P25, DOI 10.1023/A:1005877531271; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUER K, 1988, BIOCHIM BIOPHYS ACTA, V936, P157, DOI 10.1016/0005-2728(88)90232-0; Scheer H., 1982, LIGHT REACTION PATH, P7; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; Schluchter W.M., 2002, HEME CHLOROPHYLL BIL, P311, DOI DOI 10.1385/1-59259-243-0:311; Schluchter W. M., 1999, PHOTOTROPHIC PROKARY, P83; Shen G., 2004, PS 2004 LIGHT HARV S, P14; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; Six C, 2005, J BACTERIOL, V187, P1685, DOI 10.1128/JB.187.5.1685-1694.2005; Storf M, 2001, BIOCHEMISTRY-US, V40, P12444, DOI 10.1021/bi010776s; STORF M, 2004, THESIS L MAXIMILIANS; SWANSON RV, 1992, J BACTERIOL, V174, P2640, DOI 10.1128/jb.174.8.2640-2647.1992; Terauchi K, 2004, MOL MICROBIOL, V51, P567, DOI 10.1046/j.1365-2958.2003.03853.x; Tooley AJ, 2002, J BACTERIOL, V184, P4666, DOI 10.1128/JB.184.17.4666-4671.2002; Tooley AJ, 2001, P NATL ACAD SCI USA, V98, P10560, DOI 10.1073/pnas.181340998; Willows RD, 2000, PLANT MOL BIOL, V43, P113, DOI 10.1023/A:1006489129449; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Zhao KH, 2005, BIOCHEMISTRY-US, V44, P8126, DOI 10.1021/bi0500168; Zhao KH, 2005, BBA-BIOENERGETICS, V1706, P81, DOI 10.1016/j.bbabio.2004.09.008; Zhao KH, 2004, BIOCHEMISTRY-US, V43, P11576, DOI 10.1021/bi0491548; Zhao KH, 2004, BBA-BIOENERGETICS, V1657, P131, DOI 10.1016/j.bbabio.2004.04.010; Zhao KH, 2002, EUR J BIOCHEM, V269, P4542, DOI 10.1046/j.1432-1033.2002.03148.x; ZHAO KH, 1995, BBA-BIOENERGETICS, V1228, P244, DOI 10.1016/0005-2728(94)00180-D; ZHAO KH, 1995, BBA-BIOENERGETICS, V1228, P235, DOI 10.1016/0005-2728(94)00181-4; Zhao KH, 2000, FEBS LETT, V469, P9, DOI 10.1016/S0014-5793(00)01245-X; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	60	58	76	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8573	8581		10.1074/jbc.M513796200	http://dx.doi.org/10.1074/jbc.M513796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452471	hybrid			2022-12-27	WOS:000236247100033
J	Ruchalski, K; Mao, HP; Li, ZJ; Wang, ZY; Gillers, S; Wang, YH; Mosser, DD; Gabai, V; Schwartz, JH; Borkan, SC				Ruchalski, K; Mao, HP; Li, ZJ; Wang, ZY; Gillers, S; Wang, YH; Mosser, DD; Gabai, V; Schwartz, JH; Borkan, SC			Distinct hsp70 domains mediate apoptosis-inducing factor release and nuclear accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CYTOCHROME-C RELEASE; N-TERMINAL KINASE; MOLECULAR CHAPERONES; FACTOR AIF; INHIBITS APOPTOSIS; ATPASE ACTIVITY; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; SUBSTRATE-BINDING	Although hsp70 antagonizes apoptosis-inducing factor (AIF)mediated cell death, the relative importance of preventing its release from mitochondria versus sequestering leaked AIF in the cytosol remains controversial. To dissect these two protective mechanisms, hsp70 deletion mutants lacking either the chaperone function ( hsp70-Delta EEVD) or ATPase function (hsp70-Delta ATPase) were selectively overexpressed before exposing cells to a metabolic inhibitor, an insult sufficient to cause mitochondrial AIF release, nuclear AIF accumulation, and apoptosis. Compared with empty vector, overexpression of wild type human hsp70 inhibited bax activation and reduced mitochondrial AIF release after injury. In contrast, mutants lacking either the chaperone function (hsp70-Delta EEVD) or the ATP hydrolytic domain (hsp70-Delta ATPase) failed to prevent mitochondrial AIF release. Although hsp70-Delta EEVD did not inhibit bax activation or mitochondrial membrane injury after cell stress, this hsp70 mutant co-immunoprecipitated with leaked AIF in injured cells and decreased nuclear AIF accumulation. In contrast, hsp70-Delta ATPase did not interact with AIF either in intact cells or in a cell-free system and furthermore, failed to prevent nuclear AIF accumulation. These results demonstrate that mitochondrial protection against bax-mediated injury requires both intact chaperone and ATPase functions, whereas the ATPase domain is critical for sequestering AIF in the cytosol.	Zhongshan Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Peoples R China; Boston Univ, Boston Med Ctr, Dept Med, Renal Sect, Boston, MA 02118 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Sun Yat Sen University; Boston Medical Center; Boston University; Vanderbilt University; University of Guelph; Boston University	Borkan, SC (corresponding author), Evans Biomed Res Ctr, Renal Sect, Rm 546,650 Albany St, Boston, MA 02118 USA.	sborkan@bu.edu	Mosser, Dick D/A-7391-2008; Gabai, Vladimir L/I-1650-2013; Schwartz, John/AAO-8158-2021	Gabai, Vladimir L/0000-0003-4505-4718; Schwartz, John/0000-0002-1660-8681; Wang, Zhiyon/0000-0002-6471-266X; Mao, Haiping/0000-0002-3608-3851; Mosser, Richard/0000-0002-9183-2288; Borkan, Steven/0000-0003-3062-9486	NIDDK NIH HHS [DK-53387, DK-52898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053387, R01DK052898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonsson B, 2004, MOL CELL BIOCHEM, V256, P141, DOI 10.1023/B:MCBI.0000009865.70898.36; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Beissinger M, 1998, BIOL CHEM, V379, P245; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Borkan SC, 2002, ANNU REV PHYSIOL, V64, P503, DOI 10.1146/annurev.physiol.64.081501.155819; Caldarone CA, 2004, ANN THORAC SURG, V78, P948, DOI 10.1016/j.athoracsur.2004.04.031; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Carrello A, 2004, CELL STRESS CHAPERON, V9, P167, DOI 10.1379/CSC-26R.1; Chien CT, 2005, AM J TRANSPLANT, V5, P1194, DOI 10.1111/j.1600-6143.2005.00826.x; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deaciuc IV, 2004, ALCOHOL CLIN EXP RES, V28, P160, DOI 10.1111/j.1530-0277.2004.tb02981.x; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hou Q, 2005, AM J PHYSIOL-HEART C, V289, pH477, DOI 10.1152/ajpheart.00879.2004; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; Kim GT, 2003, BIOCHEM BIOPH RES CO, V309, P619, DOI 10.1016/j.bbrc.2003.08.045; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Mallouk Y, 1999, INT J MOL MED, V4, P463; Mao HP, 2004, J BIOL CHEM, V279, P15472, DOI 10.1074/jbc.M313484200; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Miernyk JA, 1996, PLANT PHYSIOL, V110, P419, DOI 10.1104/pp.110.2.419; Mikami KI, 2004, J GASTROEN HEPATOL, V19, P884, DOI 10.1111/j.1440-1746.2004.03401.x; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Orrenius S, 2004, TOXICOL LETT, V149, P19, DOI 10.1016/j.toxlet.2003.12.017; Osipiuk J, 1999, ACTA CRYSTALLOGR D, V55, P1105, DOI 10.1107/S0907444999002103; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Peherstorfer E, 2002, AM J PHYSIOL-RENAL, V283, pF190, DOI 10.1152/ajprenal.00317.2001; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Price VR, 2002, J AM SOC NEPHROL, V13, P1152, DOI 10.1097/01.ASN.0000012609.22035.44; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ruchalski K, 2003, AM J PHYSIOL-CELL PH, V285, pC1483, DOI 10.1152/ajpcell.00049.2003; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Schwartz JH, 1999, J AM SOC NEPHROL, V10, P2297; Shoskes DA, 1998, TRANSPLANTATION, V66, P147, DOI 10.1097/00007890-199807270-00001; SINHA D, 2003, AM J PHYSIOL-RENAL, V248, P488; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tafani M, 2001, CANCER RES, V61, P2459; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Volloch V, 1999, FEBS LETT, V461, P73, DOI 10.1016/S0014-5793(99)01428-3; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wang YH, 2002, CELL STRESS CHAPERON, V7, P137, DOI 10.1379/1466-1268(2002)007<0137:HEESIA>2.0.CO;2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223; Yaglom JA, 2003, J BIOL CHEM, V278, P50483, DOI 10.1074/jbc.M306903200; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	86	91	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7873	7880		10.1074/jbc.M513728200	http://dx.doi.org/10.1074/jbc.M513728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407317	hybrid			2022-12-27	WOS:000236031000022
J	Schiller, D; Ott, V; Kramer, R; Morbach, S				Schiller, D; Ott, V; Kramer, R; Morbach, S			Influence of membrane composition on osmosensing by the betaine carrier BetP from Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC-TRANSPORT-SYSTEM; COMPATIBLE SOLUTES; PROP; SECRETION; RESPONDS; BACTERIA; STRESS; SENSOR; STATE; K+	The glycine betaine carrier BetP from Corynebacterium glutamicum was recently shown to function as both an osmosensor and osmoregulator in proteoliposomes made from Escherichia coli phospholipids by sensing changes in the internal K+ concentration as a measure of hyperosmotic stress ( Rubenhagen, R., Morbach, S., and Kramer, R. ( 2001) EMBO J. 20, 5412 - 5420). Furthermore, evidence was provided that a stretch of 25 amino acids of the C-terminal domain of BetP is critically involved in K+ sensing. This K+-sensitive region has been further characterized. Glu(572) turned out to be important for osmosensing in E. coli cells and in proteoliposomes made from E. coli phospholipids. BetP mutants E572K, E572P, and E572A/ H573A/ R574A were unable to detect an increase in the internal K+ concentration in this membrane environment. However, these BetP variants regained their ability to detect osmotic stress in membranes with increased phosphatidylglycerol content, i.e. in intact C. glutamicum cells or in proteoliposomes mimicking the composition of the C. glutamicum membrane. Mutants E572P and Y550P were still insensitive to osmotic stress also in this membrane background. These results led to the following conclusions. (i) The K+ sensor in mutants E572Q, E572D, and E572K is only partially impaired. (ii) Restoration of activity regulation is not possible if the correct conformation or orientation of the C-terminal domain is compromised by a proline residue at position 572 or 550. (iii) Phosphatidylglycerol in the membrane of C. glutamicum seems to stabilize the inactive conformation of BetP C252T and other mutants.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Cologne; University of Wisconsin System; University of Wisconsin Madison	Morbach, S (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	s.morbach@uni-koeln.de						Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; Cantor RS, 1999, CHEM PHYS LIPIDS, V101, P45, DOI 10.1016/S0009-3084(99)00054-7; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GUILLOUET S, 1995, APPL MICROBIOL BIOT, V43, P315, DOI 10.1007/s002530050409; HAARDT M, 1995, MOL GEN GENET, V246, P783, DOI 10.1007/BF00290728; HOISCHEN C, 1990, J BACTERIOL, V172, P3409, DOI 10.1128/jb.172.6.3409-3416.1990; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Jakoby M, 1999, BIOTECHNOL TECH, V13, P437, DOI 10.1023/A:1008968419217; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; KRAMER R, 1994, FEMS MICROBIOL REV, V13, P75, DOI 10.1111/j.1574-6976.1994.tb00036.x; Morbach S, 2002, CHEMBIOCHEM, V3, P385, DOI 10.1002/1439-7633(20020503)3:5<384::AID-CBIC384>3.0.CO;2-H; Peter H, 1998, J BIOL CHEM, V273, P2567, DOI 10.1074/jbc.273.5.2567; Peter H, 1998, J BACTERIOL, V180, P6005, DOI 10.1128/JB.180.22.6005-6012.1998; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; POOLMAN B, 2004, BIOCHIM BIOPHYS ACTA, V1667, P88; PRASAD R, 1996, MANUAL MEMBRANE LIPI; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; RECORD MT, 1995, TRENDS BIOCHEM SCI, V23, P143; Rubenhagen R, 2000, J BIOL CHEM, V275, P735, DOI 10.1074/jbc.275.2.735; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Schiller D, 2004, BIOCHEMISTRY-US, V43, P5583, DOI 10.1021/bi0359628; Schiller D, 2004, FEBS LETT, V563, P108, DOI 10.1016/S0014-5793(04)00279-0; Steger R, 2004, FEBS LETT, V573, P155, DOI 10.1016/j.febslet.2004.07.067; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; White GF, 2000, BBA-BIOMEMBRANES, V1468, P175, DOI 10.1016/S0005-2736(00)00255-8; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	30	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7737	7746		10.1074/jbc.M513052200	http://dx.doi.org/10.1074/jbc.M513052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421104	hybrid			2022-12-27	WOS:000236031000006
J	Ueno, S; Saito, S; Wada, T; Yamaguchi, K; Satoh, M; Arai, Y; Miyagi, T				Ueno, S; Saito, S; Wada, T; Yamaguchi, K; Satoh, M; Arai, Y; Miyagi, T			Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GANGLIOSIDE SIALIDASE; CANCER CELLS; EXPRESSION; NEU3; PROLIFERATION; GLYCOSYLATION; INVOLVEMENT; ACTIVATION; MALIGNANCY	Human plasma membrane-associated sialidase (NEU3), specifically hydrolyzing gangliosides, plays crucial roles in the regulation of cell surface functions. Here we demonstrate that NEU3 mRNA level are increased in renal cell carcinomas (RCCs) compared with adjacent non-tumor tissues, significantly correlating with elevation of interleukin-6 (IL-6), a pleiotropic cytokine that has been implicated in immune responses and pathogenesis of several cancers, including RCCs. In human RCC ACHN cells, IL-6 treatment enhanced NEU3 promoter luciferase activity 2.5-fold and the endogenous sialidase activity significantly. NEU3 transfection or IL-6 treatment resulted in both suppression of apoptosis and promotion of cell motility, and the combination had synergistic effects. NEU3 scarcely affected MAPK- or IL-6-induced STAT3 activation but promoted the phosphatidylinositol 3-kinase (PI3K)/Akt cascade in both IL-6-dependent and - independent ways. Consistent with these data, NEU3 markedly inhibited staurosporine-induced caspase-3 activity and enhanced IL-6-dependent inhibition, which was abolished by LY294002, a PI3K inhibitor. Furthermore, IL-6 promoted Rho activation, and the effect was potentiated by NEU3, leading to increased cell motility that was again affected by LY294002. NEU3 silencing by siRNA resulted in the opposite: decreased Akt phosphorylation and inhibition of Rho activation. Gycolipid analysis showed a decrease in ganglioside GM3 and increase in lactosylceramide after NEU3 transfection, with these lipids apparently affecting cell apoptosis and motility. The results indicate that NEU3 activated by IL-6 exerts IL-6-mediated signaling, largely via the PI3K/Akt cascade, in a positive feedback manner and contributes to expression of a malignant phenotype in RCCs. NEU3 thus may be a useful target for RCC diagnosis and therapy.	Miyagi Canc Ctr Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Tohoku Univ, Grad Sch Med, Dept Urol, Sendai, Miyagi 9808574, Japan	Miyagi Cancer Center; Japan Science & Technology Agency (JST); Tohoku University	Miyagi, T (corresponding author), Miyagi Canc Ctr Res Inst, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	miyagi-ta173@pref.miyagi.jp		Saito, Seiichi/0000-0001-8734-4591				Angelo LS, 2002, CANCER RES, V62, P932; ATLAS I, 1992, CANCER RES, V52, P3335; Badache A, 2001, CANCER RES, V61, P383; BLAY JY, 1992, CANCER RES, V52, P3317; Cantrell DA, 2001, J CELL SCI, V114, P1439; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Horiguchi A, 2002, KIDNEY INT, V61, P926, DOI 10.1046/j.1523-1755.2002.00206.x; Hsu JH, 2004, ONCOGENE, V23, P3368, DOI 10.1038/sj.onc.1207459; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; KISHIMOTO T, 1992, SCIENCE, V257, P88; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Nakamura T, 2001, ONCOGENE, V20, P7610, DOI 10.1038/sj.onc.1204975; Proshin S, 2002, NEUROCHEM RES, V27, P841, DOI 10.1023/A:1020269326825; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; Sasaki A, 2003, J BIOL CHEM, V278, P27896, DOI 10.1074/jbc.M212200200; TAKENAWA J, 1991, J NATL CANCER I, V83, P1668, DOI 10.1093/jnci/83.22.1668; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang XQ, 2002, J BIOL CHEM, V277, P40410, DOI 10.1074/jbc.M207117200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017	31	101	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7756	7764		10.1074/jbc.M509668200	http://dx.doi.org/10.1074/jbc.M509668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428383	hybrid			2022-12-27	WOS:000236031000008
J	Zhang, XQ; Ahlers, BA; Tucker, AL; Song, JL; Wang, JF; Moorman, JR; Mounsey, JP; Carl, LL; Rothblum, LI; Cheung, JY				Zhang, XQ; Ahlers, BA; Tucker, AL; Song, JL; Wang, JF; Moorman, JR; Mounsey, JP; Carl, LL; Rothblum, LI; Cheung, JY			Phospholemman inhibition of the cardiac Na+/Ca2(+) exchanger - Role of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADULT-RAT MYOCYTES; VENTRICULAR MYOCYTES; NA+-CA2+ EXCHANGER; POSTINFARCTION MYOCYTES; ALTERS CONTRACTILITY; <CA2+>(I) TRANSIENTS; DEPENDENT REGULATION; DOWN-REGULATION; NA/CA EXCHANGE	We have demonstrated previously that phospholemman (PLM), a 15-kDa integral sarcolemmal phosphoprotein, inhibits the cardiac Na+/Ca2+ exchanger (NCX1). In addition, protein kinase A phosphorylates serine 68, whereas protein kinase C phosphorylates both serine 63 and serine 68 of PLM. Using human embryonic kidney 293 cells that are devoid of both endogenous PLM and NCX1, we first demonstrated that the exogenous NCX1 current (I-NaCa) was increased by phorbol 12-myristate 13-acetate (PMA) but not by forskolin. When co-expressed with NCX1, PLM resulted in: (i) decreases in I-NaCa, (ii) attenuation of the increase in I-NaCa by PMA, and (iii) additional reduction in I-NaCa in cells treated with forskolin. Mutating serine 63 to alanine (S63A) preserved the sensitivity of PLM to forskolin in terms of suppression of I-NaCa, whereas mutating serine 68 to alanine (S68A) abolished the inhibitory effect of PLM on I-NaCa. Mutating serine 68 to glutamic acid (phosphomimetic) resulted in additional suppression of I-NaCa as compared with wildtype PLM. These results suggest that PLM phosphorylated at serine 68 inhibited I-NaCa. The physiological significance of inhibition of NCX1 by phosphorylated PLM was evaluated in PLM-knock-out (KO) mice. When compared with wild-type myocytes, I-NaCa was significant larger in PLM-KO myocytes. In addition, the PMA-induced increase in I-NaCa was significantly higher in PLM-KO myocytes. By contrast, forskolin had no effect on I-NaCa in wild-type myocytes. We conclude that PLM, when phosphorylated at serine 68, inhibits Na+/Ca2+ exchange in the heart.	Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA; Geisinger Med Ctr, Weis Ctr Res, Danville, PA 17822 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Geisinger Medical Center; University of Virginia	Cheung, JY (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, MC-H166, Hershey, PA 17033 USA.	jyc1@psu.edu	Moorman, J Randall/ABG-9946-2020		NHLBI NIH HHS [HL-69074, R01 HL074854, R01 HL058672, R01 HL069074, HL-74854, R01 HL070548, HL-70548, HL-58672] Funding Source: Medline; NIDDK NIH HHS [DK-46678] Funding Source: Medline; NIGMS NIH HHS [GM-64640, R01 GM064640, R01 GM069841, GM-69841] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069074, R01HL058672, R01HL070548, R01HL074854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064640, R01GM069841] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlers BA, 2005, J BIOL CHEM, V280, P19875, DOI 10.1074/jbc.M414703200; Ballard C, 1996, J MOL CELL CARDIOL, V28, P11, DOI 10.1006/jmcc.1996.0002; Bossuyt J, 2005, CIRC RES, V97, P558, DOI 10.1161/01.RES.0000181172.27931.c3; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Ginsburg KS, 2005, J MOL CELL CARDIOL, V39, P972, DOI 10.1016/j.yjmcc.2005.09.005; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; He LP, 2003, J PHYSIOL-LONDON, V548, P677, DOI 10.1113/jphysiol.2002.036426; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; LEVESQUE PC, 1995, CARDIOVASC RES, V29, P336, DOI 10.1016/0008-6363(96)88590-7; Lin X, 2006, AM J PHYSIOL-CELL PH, V290, pC601, DOI 10.1152/ajpcell.00452.2005; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Mirza MA, 2004, AM J PHYSIOL-HEART C, V286, pH1322, DOI 10.1152/ajpheart.00997.2003; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Perchenet L, 2000, PFLUG ARCH EUR J PHY, V439, P822, DOI 10.1007/s004240051010; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Rembold CM, 2005, J VASC RES, V42, P483, DOI 10.1159/000088102; Ruknudin A, 2000, J PHYSIOL-LONDON, V529, P599, DOI 10.1111/j.1469-7793.2000.00599.x; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Song JL, 2005, AM J PHYSIOL-HEART C, V288, pH2342, DOI 10.1152/ajpheart.01133.2004; Song JL, 2002, AM J PHYSIOL-HEART C, V283, pH576, DOI 10.1152/ajpheart.00197.2002; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tadros GM, 2002, AM J PHYSIOL-HEART C, V283, pH1616, DOI 10.1152/ajpheart.00186.2002; WAALAS SI, 1994, BIOCHEM J, V304, P635; Wei SK, 2003, CIRC RES, V92, P897, DOI 10.1161/01.RES.0000069701.19660.14; Zhang XQ, 1996, AM J PHYSIOL-CELL PH, V271, pC1800, DOI 10.1152/ajpcell.1996.271.6.C1800; Zhang XQ, 2006, J APPL PHYSIOL, V100, P212, DOI 10.1152/japplphysiol.00757.2005; Zhang XQ, 2003, AM J PHYSIOL-HEART C, V284, pH225, DOI 10.1152/ajpheart.00698.2002; Zhang XQ, 2001, AM J PHYSIOL-HEART C, V281, pH2079, DOI 10.1152/ajpheart.2001.281.5.H2079; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	38	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7784	7792		10.1074/jbc.M512092200	http://dx.doi.org/10.1074/jbc.M512092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434394	hybrid, Green Accepted			2022-12-27	WOS:000236031000011
J	Gadd, ME; Broekemeier, KM; Crouser, ED; Kumar, J; Graff, G; Pfeiffer, DR				Gadd, ME; Broekemeier, KM; Crouser, ED; Kumar, J; Graff, G; Pfeiffer, DR			Mitochondrial iPLA(2) activity modulates the release of cytochrome c from mitochondria and influences the permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PHOSPHOLIPASE A(2); CYCLOSPORINE-A; ENDONUCLEASE-G; PORE; INHIBITION; APOPTOSIS; ACTIVATION; INDUCTION; OXIDATION	The mitochondrial Ca2+-independent phospholipase A(2) is activated during energy-dependent Ca2+ accumulation under conditions where there is a sustained depression of the membrane potential. This activation is not dependent on induction of the mitochondrial permeability transition. Bromoenol lactone, which inhibits the phospholipase, is effective as an inhibitor of the transition, and this action can be overcome by low levels of exogenous free fatty acids. Apparently, activation of the Ca2+-independent phospholipase is a factor in the mechanisms by which depolarization and Ca2+ accumulation promote opening of the permeability transition pore. Sustained activity of the Ca2+-independent phospholipase A(2) promotes rupture of the outer mitochondrial membrane and spontaneous release of cytochrome c on a time scale similar to that of apoptosis occurring in cells. However, more swelling of the matrix space must occur to provoke release of a given cytochrome c fraction when the enzyme is active, compared with when it is inhibited. Through its effects on the permeability transition and release of intermembrane space proteins, the mitochondrial Ca2+-independent phospholipase A(2) may be an important factor governing cell death caused by necrosis or apoptosis.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Inst Mitochondrial Biol, Columbus, OH 43210 USA; Ohio No Univ, Dept Chem, Ada, OH 45018 USA; Alcon Labs Inc, Ft Worth, TX 76134 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Ohio Northern University; Novartis; Alcon	Pfeiffer, DR (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 1645 Neil Ave,310A Hamilton Hall, Columbus, OH 43210 USA.	pfeiffer.17@osu.edu	Crouser, Elliott/ABC-2602-2021; Crouser, Elliott/E-2933-2011		NHLBI NIH HHS [T32 HL 007946, K08 HL 04335] Funding Source: Medline; NIGMS NIH HHS [R21 GM 071396, R01 GM 66206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004335, T32HL007946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066206, R21GM071396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P486; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Broekemeier KM, 1998, BIOCHEMISTRY-US, V37, P13059, DOI 10.1021/bi980820c; Broekemeier KM, 2002, BIOCHEMISTRY-US, V41, P7771, DOI 10.1021/bi020157z; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; CHERNYAK BV, 1995, FEBS LETT, V365, P75, DOI 10.1016/0014-5793(95)00411-2; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crouser ED, 2003, ANAL BIOCHEM, V317, P67, DOI 10.1016/S0003-2697(03)00044-7; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; Davies AM, 2003, NUCLEIC ACIDS RES, V31, P1364, DOI 10.1093/nar/gkg205; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Gadd ME, 2002, BIOPHYS J, V82, p111A; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; Johans M, 2005, J BIOL CHEM, V280, P12130, DOI 10.1074/jbc.M413454200; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LENTING HBM, 1988, BIOCHIM BIOPHYS ACTA, V961, P129, DOI 10.1016/0005-2760(88)90138-5; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LIHUA H, 2002, FEBS LETT, V512, P1; Linder MD, 2002, J BIOL CHEM, V277, P937, DOI 10.1074/jbc.M107610200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; NG LT, 1993, BIOCHIM BIOPHYS ACTA, V1143, P29, DOI 10.1016/0005-2728(93)90212-X; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; Penzo D, 2004, J BIOL CHEM, V279, P25219, DOI 10.1074/jbc.M310381200; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; Picklo MJ, 1999, ANAL BIOCHEM, V276, P166, DOI 10.1006/abio.1999.4349; POWERS MF, 1994, J BIOL CHEM, V269, P10614; REED PW, 1972, J BIOL CHEM, V247, P6970; SCHLENK H, 1960, ANAL CHEM, V32, P1412, DOI 10.1021/ac60167a011; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WAITE M, 1971, BIOCHEMISTRY-US, V10, P2377, DOI 10.1021/bi00788a031; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023	52	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6931	6939		10.1074/jbc.M510845200	http://dx.doi.org/10.1074/jbc.M510845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407316	hybrid			2022-12-27	WOS:000236030900005
J	Liden, M; Eriksson, U				Liden, M; Eriksson, U			Understanding retinol metabolism: Structure and function of retinol dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ADENOMATOUS POLYPOSIS-COLI; DELAYED DARK-ADAPTATION; BINDING-PROTEIN; 11-CIS-RETINOL DEHYDROGENASE; INTESTINAL DEVELOPMENT; ALCOHOL-DEHYDROGENASE; MEMBRANE-RECEPTOR; CDNA CLONING; IN-VIVO; GENE		Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.	ulf.eriksson@licr.ki.se						Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; Belyaeva OV, 2003, BIOCHEMISTRY-US, V42, P14838, DOI 10.1021/bi035288u; Belyaeva OV, 2003, CHEM-BIOL INTERACT, V143, P279, DOI 10.1016/S0009-2797(02)00181-3; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; Bonilha VL, 2004, MOL CELL PROTEOMICS, V3, P1119, DOI 10.1074/mcp.M400106-MCP200; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chen P, 2001, J BIOL CHEM, V276, P21098, DOI 10.1074/jbc.M010441200; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Duester G, 1999, ADV EXP MED BIOL, V463, P311; Duester G, 2003, CHEM-BIOL INTERACT, V143, P201, DOI 10.1016/S0009-2797(02)00204-1; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Higy M, 2004, BIOCHEMISTRY-US, V43, P12716, DOI 10.1021/bi048368m; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kasus-Jacobi A, 2005, J BIOL CHEM, V280, P20413, DOI 10.1074/jbc.M413789200; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lapshina EA, 2003, BIOCHEMISTRY-US, V42, P776, DOI 10.1021/bi026836r; Liden M, 2005, EXP CELL RES, V311, P205, DOI 10.1016/j.yexcr.2005.07.032; Liden M, 2005, EXP CELL RES, V310, P401, DOI 10.1016/j.yexcr.2005.08.002; Liden M, 2001, J BIOL CHEM, V276, P49251, DOI 10.1074/jbc.M107337200; Lin BY, 2001, CANCER RES, V61, P1611; Luo WQ, 2004, J NEUROSCI, V24, P2623, DOI 10.1523/JNEUROSCI.5302-03.2004; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Matt N, 2005, DEV DYNAM, V233, P167, DOI 10.1002/dvdy.20313; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Moore T., 1957, VITAMIN; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; Nadauld LD, 2005, J BIOL CHEM, V280, P30490, DOI 10.1074/jbc.M504973200; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Nawrot M, 2004, INVEST OPHTH VIS SCI, V45, P393, DOI 10.1167/iovs.03-0989; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; Saari JC, 2005, EXP EYE RES, V81, P245, DOI 10.1016/j.exer.2005.06.015; Sato M, 1998, J BIOL CHEM, V273, P25203, DOI 10.1074/jbc.273.39.25203; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1999, J CELL SCI, V112, P549; Tryggvason K, 2001, J BIOL CHEM, V276, P19253, DOI 10.1074/jbc.M100215200; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Wang J, 2001, BIOCHEMISTRY-US, V40, P12533, DOI 10.1021/bi011396+; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Zhang M, 2004, J BIOL CHEM, V279, P51482, DOI 10.1074/jbc.M409051200	49	73	76	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13001	13004		10.1074/jbc.R500027200	http://dx.doi.org/10.1074/jbc.R500027200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16428379	hybrid			2022-12-27	WOS:000237336600001
J	Maeda, K; Das, D; Ogata-Aoki, H; Nakata, H; Miyakawa, T; Tojo, Y; Norman, R; Takaoka, Y; Ding, JP; Arnold, GF; Arnold, E; Mitsuya, H				Maeda, K; Das, D; Ogata-Aoki, H; Nakata, H; Miyakawa, T; Tojo, Y; Norman, R; Takaoka, Y; Ding, JP; Arnold, GF; Arnold, E; Mitsuya, H			Structural and molecular interactions of CCR5 inhibitors with CCR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CCR5; ACCURATE DOCKING; HIV-1 INFECTION; GP120 BINDING; IN-VITRO; CORECEPTOR; POTENT; ANTAGONIST; RANTES	We have characterized the structural and molecular interactions of CC-chemokine receptor 5 (CCR5) with three CCR5 inhibitors active against R5 human immunodeficiency virus type 1 (HIV-1) including the potent in vitro and in vivo CCR5 inhibitor aplaviroc (AVC). The data obtained with saturation binding assays and structural analyses delineated the key interactions responsible for the binding of CCR5 inhibitors with CCR5 and illustrated that their binding site is located in a predominantly lipophilic pocket in the interface of extracellular loops and within the upper transmembrane (TM) domain of CCR5. Mutations in the CCR5 binding sites of AVC decreased gp120 binding to CCR5 and the susceptibility to HIV-1 infection, although mutations in TM4 and TM5 that also decreased gp120 binding and HIV-1 infectivity had less effects on the binding of CC-chemokines, suggesting that CCR5 inhibition targeting appropriate regions might render the inhibition highly HIV-1-specific while preserving the CC chemokine-CCR5 interactions. The present data delineating residue by residue interactions of CCR5 with CCR5 inhibitors should not only help design more potent and more HIV-1-specific CCR5 inhibitors, but also give new insights into the dynamics of CC-chemokine-CCR5 interactions and the mechanisms of CCR5 involvement in the process of cellular entry of HIV-1.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Infect Dis, Kumamoto 8608556, Japan; NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; Ono Pharmaceut Co Ltd, Minase Res Inst, Osaka 6188585, Japan; Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	Kumamoto University; Kumamoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ono Pharmaceutical Co Ltd; Rutgers State University New Brunswick	Mitsuya, H (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan.	hmitsuya@helix.nih.gov	Maeda, Kenji/B-7708-2019	Maeda, Kenji/0000-0002-9424-1491; ding, jian ping/0000-0001-7029-7346; Arnold, Gail/0000-0002-3335-6965	NATIONAL CANCER INSTITUTE [ZIASC006738, Z01SC006738] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; *DHHS, 2005, GUID US ANT AG HIV 1; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; EVANS EA, 1974, TRITIUM ITS COMPOUND, P271; Exner T, 1998, J MOL MODEL, V4, P340, DOI 10.1007/s008940050091; Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; GRIBBLE GW, 1975, J CHEM SOC CHEM COMM, P535, DOI 10.1039/c39750000535; Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; LALEZARI J, 2005, 44 INT C ANT AG CHEM; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004; Maeda K, 2001, J BIOL CHEM, V276, P35194, DOI 10.1074/jbc.M105670200; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; Maeda Y, 2000, J VIROL, V74, P1787, DOI 10.1128/JVI.74.4.1787-1793.2000; Mitsuya H, 1999, TXB AIDS MED, P751; Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005; Navenot JM, 2001, J MOL BIOL, V313, P1181, DOI 10.1006/jmbi.2001.5086; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; Sarafianos SG, 2004, CURR OPIN STRUC BIOL, V14, P716, DOI 10.1016/j.sbi.2004.10.013; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; SPARKS S, 2005, 12 C RETR OPP INF BO; Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Tsamis F, 2003, J VIROL, V77, P5201, DOI 10.1128/JVI.77.9.5201-5208.2003; VISWANADHAN VN, 1989, J CHEM INF COMP SCI, V29, P163, DOI 10.1021/ci00063a006; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Xiang ZX, 2001, J MOL BIOL, V311, P421, DOI 10.1006/jmbi.2001.4865	38	143	150	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12688	12698		10.1074/jbc.M512688200	http://dx.doi.org/10.1074/jbc.M512688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16476734	hybrid			2022-12-27	WOS:000237134700060
J	Xu, WD; Stamnes, M				Xu, WD; Stamnes, M			The actin-depolymerizing factor homology and charged/helical domains of drebrin and mAbp1 direct membrane binding and localization via distinct interactions with actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; GOLGI-COMPLEX; ENDOPLASMIC-RETICULUM; CYTOSKELETON; RECRUITMENT; CDC42; ENDOCYTOSIS; VESICLES; ASSOCIATION; MACHINERY	Cytoskeletal dynamics are important for efficient function of the secretory pathway. ADP-ribosylation factor, ARF1, triggers vesicle coat assembly and, in concert with Cdc42, regulates actin polymerization and molecular motor-based motility. Drebrin and mammalian Abp1 (mAbp1) are actin-binding proteins found previously to bind to Golgi membranes in an ARF1-dependent manner in vitro. Despite sharing homology through two shared actin binding domains, drebrin and mAbp1 have different subcellular localization and bind to distinct actin structures on the Golgi apparatus. We find that the actin-depolymerizing factor homology (ADFH) and charged/ helical actin binding domains of drebrin and mAbp1 are sufficient for regulated binding to Golgi membranes and subcellular localization. We have used mutant proteins and chimeras between mAbp1 and drebrin to identify motifs that direct targeting. We find that a linker region between the ADFH and charged/ helical domains confers Golgi binding properties to mAbp1. mAbp1 binds to a specific actin pool through its ADFH/linker domain that is not bound by drebrin. Drebrin localization to the cell surface was found to involve motifs within the charged/ helical domain. Our results indicate that targeting of these proteins is directed through multiple distinct interactions with the actin cytoskeleton. The mechanisms for selective recruitment of mAbp1 and drebrin to Golgi membranes indicate how actin-based structures are able to select specific actin-binding proteins and, thus, carry out multiple different functions within cells.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Stamnes, M (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	mark-stamnes@uiowa.edu		Stamnes, Mark/0000-0002-5869-7985	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068674] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068674] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahluwalia JP, 2001, J BIOL CHEM, V276, P34148, DOI 10.1074/jbc.M105398200; Butkevich E, 2004, CURR BIOL, V14, P650, DOI 10.1016/j.cub.2004.03.063; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Chen JL, 2005, J CELL BIOL, V169, P383, DOI 10.1083/jcb.200501157; Chen JL, 2004, FEBS LETT, V566, P281, DOI 10.1016/j.febslet.2004.04.061; Donaldson Julie G, 2002, Methods Mol Biol, V189, P191; Dubois T, 2005, NAT CELL BIOL, V7, P353, DOI 10.1038/ncb1244; Duran JM, 2003, MOL BIOL CELL, V14, P445, DOI 10.1091/mbc.E02-04-0214; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Fucini RV, 2000, J BIOL CHEM, V275, P18824, DOI 10.1074/jbc.M000024200; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Hayashi K, 1999, EXP CELL RES, V253, P673, DOI 10.1006/excr.1999.4663; Hiroyama M, 2005, J CELL PHYSIOL, V202, P608, DOI 10.1002/jcp.20156; Inoue HK, 1997, J ELECTRON MICROSC, V46, P497, DOI 10.1093/oxfordjournals.jmicro.a023549; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matas OB, 2004, TRAFFIC, V5, P838, DOI 10.1111/j.1600-0854.2004.00225.x; Newpher TM, 2005, DEV CELL, V9, P87, DOI 10.1016/j.devcel.2005.04.014; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Percival JM, 2004, MOL BIOL CELL, V15, P268, DOI 10.1091/mbc.e03-03-0176; Quintero-Monzon O, 2005, MOL BIOL CELL, V16, P3128, DOI 10.1091/mbc.E05-01-0059; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; Takahashi H, 2003, J NEUROSCI, V23, P6586; Valderrama F, 2000, P NATL ACAD SCI USA, V97, P1560, DOI 10.1073/pnas.97.4.1560; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585	30	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11826	11833		10.1074/jbc.M510141200	http://dx.doi.org/10.1074/jbc.M510141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16452483	hybrid			2022-12-27	WOS:000236988100049
J	Li, ZR; Benard, O; Margolskee, RF				Li, ZR; Benard, O; Margolskee, RF			G gamma 13 interacts with PDZ domain-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMERIC G-PROTEINS; GAMMA-SUBUNIT; BETA-GAMMA; MEMBRANE LOCALIZATION; NMDA RECEPTOR; COMPLEX; CELLS; ASSOCIATION; PRENYLATION; FAMILY	The G protein gamma 13 subunit (G gamma 13) is expressed in taste and retinal and neuronal tissues and plays a key role in taste transduction. We identified PSD95, Veli-2, and other PDZ domain-containing proteins as binding partners for G gamma 13 by yeast two-hybrid and pull-down assays. In two-hybrid assays, G gamma 13 interacted specifically with the third PDZ domain of PSD95, the sole PDZ domain of Veli-2, and the third PDZ domain of SAP97, a PSD95-related protein. G gamma 13 did not interact with the other PDZ domains of PSD95. Coexpression of G gamma 13 with its G beta 1 partner did not interfere with these two-hybrid interactions. The physical interaction of G gamma 13 with PSD95 in the cellular milieu was confirmed in pull-down assays following heterologous expression in HEK293 cells. The interaction of G gamma 13 with the PDZ domain of PSD95 was via the C-terminal CAAX tail of G gamma 13 (where AA indicates the aliphatic amino acid); alanine substitution of the CTAL sequence at the C terminus of G gamma 13 abolished its interactions with PSD95 in two-hybrid and pull-down assays. Veli-2 and SAP97 were identified in taste tissue and in G gamma 13-expressing taste cells. Coimmunoprecipitation of G gamma 13 and PSD95 from brain and of G gamma 13 and SAP97 from taste tissue indicates that G gamma 13 interacts with these proteins endogenously. This is the first demonstration that PDZ domain proteins interact with heterotrimeric G proteins via the CAAX tail of G gamma subunits. The interaction of G gamma 13 with PDZ domain-containing proteins may provide a means to target particular G beta gamma subunits to specific subcellular locations and/or macromolecular complexes involved in signaling pathways.	CUNY Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Margolskee, RF (corresponding author), CUNY Mt Sinai Sch Med, Dept Neurosurg, 1425 Madison Ave,Box 1065, New York, NY 10029 USA.	robert.margolskee@mssm.edu		Margolskee, Robert/0000-0002-9572-2887	NIDCD NIH HHS [DC003055, DC003155] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003155, R01DC003055] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AGATEP R, 1998, TECHNICAL TIPS ONLIN, V1, P51; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Dietrich A, 1996, BIOCHEMISTRY-US, V35, P15174, DOI 10.1021/bi960305j; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fukaya M, 1999, NEUROSCI RES, V33, P111, DOI 10.1016/S0168-0102(98)00120-5; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Harris BZ, 2001, J CELL SCI, V114, P3219; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Huang LQ, 2003, J COMP NEUROL, V455, P1, DOI 10.1002/cne.10396; Huber A, 2001, EUR J NEUROSCI, V14, P769, DOI 10.1046/j.0953-816x.2001.01704.x; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; James P, 1996, GENETICS, V144, P1425; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kawachi H, 1999, MOL BRAIN RES, V72, P47, DOI 10.1016/S0169-328X(99)00204-1; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koulen P, 1999, EUR J NEUROSCI, V11, P2007, DOI 10.1046/j.1460-9568.1999.00622.x; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	41	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11066	11073		10.1074/jbc.M600113200	http://dx.doi.org/10.1074/jbc.M600113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16473877	hybrid			2022-12-27	WOS:000236822200048
J	Yamasaki, E; Wada, A; Kumatori, A; Nakagawa, I; Funao, J; Nakayama, M; Hisatsune, J; Kimura, M; Moss, J; Hirayama, T				Yamasaki, E; Wada, A; Kumatori, A; Nakagawa, I; Funao, J; Nakayama, M; Hisatsune, J; Kimura, M; Moss, J; Hirayama, T			Helicobacter pylori vacuolating cytotoxin induces activation of the proapoptotic proteins Bax and Bak, leading to cytochrome C release and cell death, independent of vacuolation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; LIPID-BILAYERS; CANCER-CELLS; VACA TOXIN; APOPTOSIS; INDUCTION; EXPRESSION; INFECTION; PATHWAY; DOMAIN	Helicobacter pylori vacuolating cytotoxin, VacA, which causes vacuolation of gastric epithelial cells and other types of cultured cells, is known to stimulate apoptosis via a mitochondria-dependent pathway. In the present study, we examined the mechanisms of VacA-induced mitochondrial damage. Intracellular VacA localization was monitored by immunostaining and confocal microscopy; in AZ-521 cells in which cytochrome c release was stimulated, most of VacA was localized to vacuoles rather than mitochondria. VacA reduced the membrane potential of isolated mitochondria without inducing cytochrome c release, suggesting that it did not act directly to induce cytochrome c release from mitochondria and that in intact cells, VacA-induced cytochrome c release involved apoptosis-related factor(s), such as a proapoptotic Bcl-2 family protein. In agreement, flow cytometric analyses using antibodies specific for activated Bax revealed that intracellular Bax was activated by VacA in a concentration- and time-dependent manner. Using active form-specific antibodies, we also observed that the Bcl-2 family protein, Bak, was activated. By confocal microscopy, Bax and Bak were activated in AZ-521 cells in which cytochrome c release was induced by VacA. In addition, small interfering RNA-induced silencing of the bax gene resulted in reduction of VacA-stimulated cytochrome c release, consistent with a contribution of VacA-induced Bax activation to cytochrome c release. NH4Cl enhanced both VacA-induced vacuolation and Bax activation, whereas Bax activation was not inhibited by bafilomycin A1, which inhibited vacuolation caused by VacA. These results suggest that VacA acts through different signaling pathways to induce apoptosis via Bax activation, independent of vacuolation.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Japan Sci & Technol Corp, PRESTO, Saitama 3320012, Japan; Chiba Inst Technol, Fac Risk & Crisis Management, Dept Disaster Prevent Syst, Div Med Sci, Chiba 2880025, Japan; Osaka Univ, Grad Sch Dent, Dept Oral & Mol Microbiol, Suita, Osaka 5650871, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Dept Med Technol, Okayama 7008558, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Japan Science & Technology Agency (JST); Chiba Institute of Technology; Osaka University; Okayama University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wada, A (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	a-wada@net.nagasaki-u.ac.jp			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Ashktorab H, 2004, GUT, V53, P805, DOI 10.1136/gut.2003.024372; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Boquet P, 2003, TRENDS MICROBIOL, V11, P410, DOI 10.1016/S0966-842X(03)00211-7; Cho SJ, 2003, TOXICON, V42, P601, DOI 10.1016/j.toxicon.2003.08.003; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J INFECT DIS, V166, P1073, DOI 10.1093/infdis/166.5.1073; Cover TL, 2003, CANCER RES, V63, P951; COVER TL, 1992, HUM PATHOL, V23, P1004, DOI 10.1016/0046-8177(92)90261-Z; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Eaton KA, 1997, INFECT IMMUN, V65, P3462, DOI 10.1128/IAI.65.8.3462-3464.1997; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Hofman V, 2001, LAB INVEST, V81, P375, DOI 10.1038/labinvest.3780245; Jones NL, 1999, INFECT IMMUN, V67, P4237, DOI 10.1128/IAI.67.8.4237-4242.1999; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; Li Y, 2004, MOL BIOL CELL, V15, P1946, DOI 10.1091/mbc.e03-08-0618; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Menaker RJ, 2004, INFECT IMMUN, V72, P2889, DOI 10.1128/IAI.72.5.2889-2898.2004; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Nakagawa I, 2001, CELL MICROBIOL, V3, P395, DOI 10.1046/j.1462-5822.2001.00122.x; Nakayama M, 2004, J BIOL CHEM, V279, P7024, DOI 10.1074/jbc.M308898200; NEITHERCUT WD, 1991, GUT, V32, P973, DOI 10.1136/gut.32.9.973; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; Ray S, 2003, CANCER RES, V63, P4713; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Supajatura V, 2002, J IMMUNOL, V168, P2603, DOI 10.4049/jimmunol.168.6.2603; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Torres VJ, 2004, J BIOL CHEM, V279, P2324, DOI 10.1074/jbc.M310159200; Wang J, 2001, J IMMUNOL, V167, P926, DOI 10.4049/jimmunol.167.2.926; Willhite DC, 2004, CELL MICROBIOL, V6, P143, DOI 10.1046/j.1462-5822.2003.00347.x; Willhite DC, 2003, J BIOL CHEM, V278, P48204, DOI 10.1074/jbc.M304131200; Yahiro K, 2004, J BIOL CHEM, V279, P51013, DOI 10.1074/jbc.M406473200; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277; Yilmaz O, 2004, INFECT IMMUN, V72, P3743, DOI 10.1128/IAI.72.7.3743-3751.2004; Zhang H, 2004, WORLD J GASTROENTERO, V10, P227	51	114	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11250	11259		10.1074/jbc.M509404200	http://dx.doi.org/10.1074/jbc.M509404200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16436379	hybrid			2022-12-27	WOS:000236822200068
J	Moreira, PI; Custodio, J; Moreno, A; Oliveira, CR; Santos, MS				Moreira, PI; Custodio, J; Moreno, A; Oliveira, CR; Santos, MS			Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; STIMULATED GROWTH; OXIDATIVE STRESS; ATHYMIC MICE; ESTROGEN; RAT; INHIBITION; CELL; APOPTOSIS; HYDROXYTAMOXIFEN	This study evaluated the action of tamoxifen and estradiol on the function of isolated liver mitochondria. We observed that although tamoxifen and estradiol per se did not affect mitochondrial complexes II, III, or IV, complex I is affected, this effect being more drastic (except for state 4 of respiration) when mitochondria were coincubated with both drugs. Furthermore, using two respiratory chain inhibitors, rotenone and diphenyliodonium chloride, we identified the flavin mononucleotide site of complex I as the target of tamoxifen and/or estradiol action(s). Tamoxifen (25 mu M) per se induced a significant increase in hydrogen peroxide production and state 4 of respiration. Additionally, a significant decrease in respiratory control ratio, transmembrane, and depolarization potentials were observed. Estradiol per se decreased carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP)-stimulated respiration, state 3 of respiration, and respiratory control ratio and increased lag phase of repolarization. With the exception of state 4 of respiration whose increase induced by tamoxifen was reversed by the presence of estradiol, the effects of tamoxifen were highly exacerbated when estradiol was present. We observed that 10 mu M tamoxifen in the presence of estradiol affected mitochondria significantly by decreasing FCCP-stimulated respiration, state 3 of respiration, respiratory control ratio, and ADP depolarization and increasing the lag phase of repolarization. All of the deleterious effects induced by 25 mu M tamoxifen were highly exacerbated in the presence of estradiol. Furthermore, we observed that the effects of both compounds were independent of estrogen receptors because the pure estrogen antagonist ICI 182,780 did not interfere with tamoxifen and/or estradiol detrimental effects. Altogether, our data provide a mechanistic explanation for the multiple cytotoxic effects of tamoxifen including its capacity to destroy tamoxifen-resistant breast cancer cells in the presence of estradiol. This new piece of information provides a basis for the development of new and promising anticancer therapeutic strategies.	Univ Coimbra, Fac Sci & Technol, Dept Zool, P-3004517 Coimbra, Portugal; Univ Coimbra, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal; Univ Coimbra, Fac Pharm, Biochem Lab, P-3004517 Coimbra, Portugal; Univ Coimbra, Marine Res Inst, P-3004517 Coimbra, Portugal; Univ Coimbra, Fac Med, Inst Biochem, P-3004517 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Santos, MS (corresponding author), Univ Coimbra, Fac Sci & Technol, Dept Zool, P-3004517 Coimbra, Portugal.	mssantos@cl.uc.pt	Moreira, Paula/B-3608-2009; Oliveira, Catarina R./F-3685-2010	Moreira, Paula/0000-0001-5177-6747; Custodio, Jose/0000-0001-5694-966X; Oliveira, Catarina/0000-0001-6942-4328; santos, maria sancha/0000-0002-6881-9392; Moreno, Antonio/0000-0003-3575-7604				Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Baum M, 2002, LANCET, V359, P2131; Bergan RC, 1999, CLIN CANCER RES, V5, P2366; CARACENI P, 1995, BBA-MOL CELL RES, V1268, P249, DOI 10.1016/0167-4889(95)00077-6; Cardoso CMP, 2001, TOXICOL APPL PHARM, V176, P145, DOI 10.1006/taap.2001.9265; Clarke M, 1998, LANCET, V351, P1451; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; CUSTODIO JBA, 1991, BIOCHEM BIOPH RES CO, V176, P1079, DOI 10.1016/0006-291X(91)90394-M; Custodio JBA, 1998, TOXICOL APPL PHARM, V152, P10, DOI 10.1006/taap.1998.8510; CUSTODIO JBA, 1994, BIOCHEM PHARMACOL, V47, P1989, DOI 10.1016/0006-2952(94)90073-6; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Felty Quentin, 2005, J Carcinog, V4, P1, DOI 10.1186/1477-3163-4-1; FROMSON JM, 1973, XENOBIOTICA, V3, P711, DOI 10.3109/00498257309151595; Gauduchon J, 2005, CLIN CANCER RES, V11, P2345, DOI 10.1158/1078-0432.CCR-04-1668; Gazotti P., 1979, LAB MANUAL TRANSPORT, P62; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; GOTTARDIS MM, 1989, CANCER RES, V49, P4090; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hagen T, 2004, BIOCHEM BIOPH RES CO, V322, P923, DOI 10.1016/j.bbrc.2004.07.204; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V240, P464, DOI 10.1006/bbrc.1997.7681; Hensley K, 1998, J NEUROCHEM, V71, P2549; HOWELL A, 1992, ANN ONCOL, V3, P611, DOI 10.1093/oxfordjournals.annonc.a058286; JENSEN BD, 1984, BIOPHYS J, V45, pA92; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; JORDAN VC, 1990, BREAST CANCER RES TR, V15, P125, DOI 10.1007/BF01806350; JORDAN VC, 1983, BREAST CANCER RES TR, V3, pS73, DOI 10.1007/BF01855131; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kennedy AM, 2005, ENDOCRINOLOGY, V146, P201, DOI 10.1210/en.2004-0486; KUSS E, 1967, H-S Z PHYSIOL CHEM, V348, P913, DOI 10.1515/bchm2.1967.348.1.913; LAURENCE J, 1990, BLOOD, V75, P696; LERNER LJ, 1996, ENDOCRINOLOGY, V138, P863; Lewis JS, 2004, BRIT J CANCER, V90, P944, DOI 10.1038/sj.bjc.6601627; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LIEN EA, 1991, CANCER RES, V51, P4837; Luxo C, 2001, TOXICOL IN VITRO, V15, P303, DOI 10.1016/S0887-2333(01)00024-8; McDonnell DP, 2000, J SOC GYNECOL INVEST, V7, pS10, DOI 10.1177/1071557600007001S05; Mishra DP, 2005, J BIOL CHEM, V280, P6181, DOI 10.1074/jbc.M405970200; Moats RK, 1998, BIOL REPROD, V58, P531, DOI 10.1095/biolreprod58.2.531; Moreira PI, 2005, NEUROPHARMACOLOGY, V48, P435, DOI 10.1016/j.neuropharm.2004.10.012; Moreira PI, 2004, BIOCHEM PHARMACOL, V68, P195, DOI 10.1016/j.bcp.2004.03.019; MURATSUGU M, 1977, BIOCHIM BIOPHYS ACTA, V464, P613, DOI 10.1016/0005-2736(77)90035-9; ODONNELL VB, 1994, MOL PHARMACOL, V46, P778; Osipo C, 2005, J STEROID BIOCHEM, V93, P249, DOI 10.1016/j.jsbmb.2004.12.005; PALMER G, 1968, J BIOL CHEM, V243, P844; Rowlands JC, 1998, PHARMACOL TOXICOL, V83, P214, DOI 10.1111/j.1600-0773.1998.tb01471.x; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Schafer JM, 2000, CLIN CANCER RES, V6, P4373; Trope C, 2000, EUR J CANCER, V36, pS59; Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007; Tuquet C, 2000, CELL BIOL TOXICOL, V16, P207, DOI 10.1023/A:1007695308257; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; WINGROVE DE, 1985, FED PROC, V44, P1082; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Zheng JB, 1999, EUR J PHARMACOL, V368, P95, DOI 10.1016/S0014-2999(99)00012-6	60	92	96	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10143	10152		10.1074/jbc.M510249200	http://dx.doi.org/10.1074/jbc.M510249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16410252	Green Published, hybrid			2022-12-27	WOS:000236594300040
J	Shiroishi, M; Kuroki, K; Ose, T; Rasubala, L; Shiratori, I; Arase, H; Tsumoto, K; Kumagai, I; Kohda, D; Maenaka, K				Shiroishi, M; Kuroki, K; Ose, T; Rasubala, L; Shiratori, I; Arase, H; Tsumoto, K; Kumagai, I; Kohda, D; Maenaka, K			Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; FC-ALPHA-RI; CELL-SURFACE; INHIBITORY RECEPTORS; DENDRITIC CELLS; QUALITY-CONTROL; CUTTING EDGE; G MOLECULES; G PROTEIN; T-CELL	HLA-G is a nonclassical major histocompatibility complex class I (MHCI) molecule, which is expressed in trophoblasts and confers immunological tolerance in the maternal-fetal interface by binding to leukocyte Ig-like receptors (LILRs, also called as LIR/ILT/CD85) and CD8. HLA-G is expressed in disulfide-linked dimer form both in solution and at the cell surface. Interestingly, MHCI dimer formations have been involved in pathogenesis and T cell activation. The structure and receptor binding characteristics of MHCI dimers have never been evaluated. Here we performed binding studies showing that the HLA-G dimer exhibited higher overall affinity to LILRB1/2 than the monomer by significant avidity effects. Furthermore, the cell reporter assay demonstrated that the dimer formation remarkably enhanced the LILRB1-mediated signaling at the cellular level. We further determined the crystal structure of the wild-type dimer of HLA-G with the intermolecular Cys(42)-Cys(42) disulfide bond. This dimer structure showed the oblique configuration to expose two LILR/CD8-binding sites upward from the membrane easily accessible for receptors, providing plausible 1: 2 (HLA-G dimer: receptors) complex models. These results indicated that the HLA-G dimer conferred increased avidity in a proper structural orientation to induce efficient LILR signaling, resulting in the dominant immunosuppressive effects. Moreover, structural and functional implications for other MHCI dimers observed in activated T cells and the pathogenic allele, HLA-B27, are discussed.	Kyushu Univ, Med Inst Bioregulat, Div Struct Biol, Higashi Ku, Fukuoka 8128582, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Immunochem, Osaka 5650871, Japan; Japan Sci & Technol Agcy, PRESTO, Saitama 3320012, Japan; Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan	Kyushu University; Osaka University; Japan Science & Technology Agency (JST); Tohoku University	Maenaka, K (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Struct Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kmaenaka@bioreg.kyushu-u.ac.jp	Kohda, Daisuke/I-4990-2019; Arase, Hisashi/C-8442-2009; Ose, Toyoyuki/AAW-7821-2020; Kuroki, Kimiko/F-6906-2012	Kohda, Daisuke/0000-0001-8234-3776; Arase, Hisashi/0000-0002-1153-3166; Ose, Toyoyuki/0000-0002-2001-9388; Shiroishi, Mitsunori/0000-0002-3133-157X; Shiratori, Ikuo/0000-0003-3713-4910				Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Appel H, 2000, J BIOL CHEM, V275, P312, DOI 10.1074/jbc.275.1.312; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P16180, DOI 10.1073/pnas.212643199; Brown D, 2004, TISSUE ANTIGENS, V64, P215, DOI 10.1111/j.0001-2815.2004.00290.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Clements CS, 2005, P NATL ACAD SCI USA, V102, P3360, DOI 10.1073/pnas.0409676102; Colbert RA, 2004, CURR MOL MED, V4, P21, DOI 10.2174/1566524043479293; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Damjanovich S, 2002, IMMUNOL LETT, V82, P93, DOI 10.1016/S0165-2478(02)00024-X; De Crescenzo G, 2003, J MOL BIOL, V328, P1173, DOI 10.1016/S0022-2836(03)00360-7; Diehl M, 1996, CURR BIOL, V6, P305, DOI 10.1016/S0960-9822(02)00481-5; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; FUJII T, 1994, J IMMUNOL, V153, P5516; Gao GF, 2000, J BIOL CHEM, V275, P15232, DOI 10.1074/jbc.275.20.15232; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Gonen-Gross T, 2003, HUM IMMUNOL, V64, P1011, DOI 10.1016/j.humimm.2003.08.355; Gonen-Gross T, 2005, J IMMUNOL, V175, P4866, DOI 10.4049/jimmunol.175.8.4866; Gonen-Gross T, 2003, J IMMUNOL, V171, P1343, DOI 10.4049/jimmunol.171.3.1343; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947; Ishitani A, 2003, J IMMUNOL, V171, P1376, DOI 10.4049/jimmunol.171.3.1376; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kollnberger S, 2002, ARTHRITIS RHEUM, V46, P2972, DOI 10.1002/art.10605; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Bouteiller P, 2003, PLACENTA, V24, pS10, DOI 10.1053/plac.2002.0931; LEE N, 1995, IMMUNITY, V3, P591, DOI 10.1016/1074-7613(95)90130-2; LeMaoult J, 2003, TISSUE ANTIGENS, V62, P273, DOI 10.1034/j.1399-0039.2003.00143.x; Lenfant F, 2003, J GEN VIROL, V84, P307, DOI 10.1099/vir.0.18735-0; Liang SY, 2003, HUM IMMUNOL, V64, P1025, DOI 10.1016/j.humimm.2003.08.348; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; McMichael A, 2002, ARTHRITIS RES THER, V4, pS153, DOI 10.1186/ar571; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morales PJ, 2003, J IMMUNOL, V171, P6215, DOI 10.4049/jimmunol.171.11.6215; O'Callaghan CA, 1998, MOL CELL, V1, P531, DOI 10.1016/S1097-2765(00)80053-2; Ohtsuka M, 2004, P NATL ACAD SCI USA, V101, P8126, DOI 10.1073/pnas.0401119101; Park B, 2003, J BIOL CHEM, V278, P14337, DOI 10.1074/jbc.M212882200; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Santos SG, 2004, J BIOL CHEM, V279, P53062, DOI 10.1074/jbc.M408794200; Shiratori I, 2004, J EXP MED, V199, P525, DOI 10.1084/jem.20031885; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Shiroishi M, 2006, BBA-PROTEINS PROTEOM, V1764, P985, DOI 10.1016/j.bbapap.2005.10.006; Smith KJ, 1996, IMMUNITY, V4, P203, DOI 10.1016/S1074-7613(00)80429-X; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961	51	162	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10439	10447		10.1074/jbc.M512305200	http://dx.doi.org/10.1074/jbc.M512305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455647	hybrid			2022-12-27	WOS:000236594300073
J	Vanwildemeersch, M; Olsson, AK; Gottfridsson, E; Claesson-Welsh, L; Lindahl, U; Spillmann, D				Vanwildemeersch, M; Olsson, AK; Gottfridsson, E; Claesson-Welsh, L; Lindahl, U; Spillmann, D			The anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION; TUMOR VASCULARIZATION; FIBROBLAST-GROWTH; HIGH-AFFINITY; DOMAIN; ENDOSTATIN; PROLINE; PROTEIN; PLASMA; GLYCOSAMINOGLYCANS	The plasma protein histidine-rich glycoprotein ( HRGP), which has been identified as an angiogenesis inhibitor, binds to heparan sulfate (HS) in a Zn2+-dependent manner. We wished to test whether this interaction is mechanistically important in mediation of the anti-angiogenic effect of HRGP. Inhibition of angiogenesis by HRGP is exerted through its central His/Pro-rich domain, which is proteolytically released. A35-amino-acid residue synthetic peptide, HRGP330, derived from the His/Pro-rich domain retains the inhibitory effect on blood vessel formation in vitro and in vivo, an effect dependent on the presence of Zn2+. We now show that HRGP330 binds heparin/HS with the same capacity as full-length HRGP, and the binding is Zn2+-dependent. Peptides derived from the His/Pro-rich domain of HRGP downstream of HRGP330 fail to inhibit endothelial cell migration and display a significantly reduced heparin-binding capacity. An even shorter peptide, HRGP335, covering a 26-amino-acid sequence within HRGP330 retains full heparin/HS-binding capacity. Characterization of the HS interaction shows that there is a tissue-specific HS pattern recognized by HRGP335 and that the minimal length of heparin/HS required for binding to HRGP335 is an 8-mer oligosaccharide. Saturation of the HS binding sites in HRGP330 by pre-incubation with heparin abrogates the HRGP330-induced rearrangement of endothelial cell focal adhesions, suggesting that interaction with cell surface HS is needed for HRGP330 to exert its anti-angiogenic effect.	Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University	Spillmann, D (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Dorothe.Spillmann@imbim.uu.se						AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; DIXELIUS J, 2005, CANCER RES, V6, P2089; Donate F, 2004, CANCER RES, V64, P5812, DOI 10.1158/0008-5472.CAN-04-0440; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Guimond S, 2004, MOL CELL, V16, P159, DOI 10.1016/j.molcel.2004.10.008; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Jones AL, 2005, IMMUNOL CELL BIOL, V83, P106, DOI 10.1111/j.1440-1711.2005.01320.x; Jones AL, 2004, J BIOL CHEM, V279, P38267, DOI 10.1074/jbc.M406027200; Juarez JC, 2002, CANCER RES, V62, P5344; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kluszynski BA, 1997, J BIOL CHEM, V272, P13541, DOI 10.1074/jbc.272.21.13541; Kreuger J, 2003, METHOD ENZYMOL, V363, P327; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; LANE DA, 1986, J BIOL CHEM, V261, P3980; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINKER A, 1973, CARBOHYD RES, V29, P41, DOI 10.1016/S0008-6215(00)82069-8; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; Olsson AK, 2004, CANCER RES, V64, P9012, DOI 10.1158/0008-5472.CAN-04-2172; Olsson AK, 2004, CANCER RES, V64, P599, DOI 10.1158/0008-5472.CAN-03-1941; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	43	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10298	10304		10.1074/jbc.M508483200	http://dx.doi.org/10.1074/jbc.M508483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16436387	hybrid			2022-12-27	WOS:000236594300058
J	Edinger, RS; Yospin, J; Perry, C; Kleyman, TR; Johnson, JP				Edinger, RS; Yospin, J; Perry, C; Kleyman, TR; Johnson, JP			Regulation of epithelial Na+ channels (ENaC) by methylation - A novel methyltransferase stimulates ENaC activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNELS; OPEN PROBABILITY; APICAL MEMBRANE; BETA-SUBUNIT; CELL-LINE; ALDOSTERONE; EXPRESSION; TRANSPORT; INCREASES	Aldosterone acts to increase apical membrane permeability by activation of epithelial Na+ channels (ENaC). We have previously shown that aldosterone activates ENaC early in the course of its action by stimulating the methylation of the beta subunit of this heteromeric channel in A6 cells. Aldosterone also stimulates the expression and methylation of k-ras in A6 cells. To determine whether aldosterone-stimulated methylations are seen in mammalian cells, we examined the effect of aldosterone on methylation and ras activation in a continuous line of cultured epithelial cells derived from mouse cortical collecting duct (CCD) and determined that beta mENaC is a substrate for methylation by an enzyme contained in CCD cells. Aldosterone stimulated protein base labile methylation in CCD cells. Aldosterone stimulated Na+ transport in CCD cells within 1 h of addition and without an increase in cellular amount of any ENaC subunits over the first 4 h. Inhibition of methylation, using the inhibitor 3-deaza-adenosine, blocked the stimulation of Na+ transport induced by aldosterone at early time points (1-4 h) without affecting cellular amounts of any ENaC subunits. In contrast to 3-deaza-adenosine (3-DZA), which inhibits all methylation reactions, specific inhibitors of small G-protein methylation or prenylation had no effect on the early aldosterone-induced current. Over expression of isoprenylcysteine carboxylmethyl-transferase (PCMTase), the enzyme that methylates ras, had little effect on basal transport but enhanced aldosterone-stimulated transport in A6 cells. Overexpression of PCMTase in CCD cells had no effect on either basal or aldosterone- stimulated transport. Moreover PCMTase had no effect on ENaC activity when co-expressed in Xenopus oocytes. Aldosterone had no effect on either message or protein levels of k-ras in CCD cells. Searching a mouse kidney library, we identified a methyltransferase that stimulates ENaC activity in Xenopus oocytes without affecting surface expression of ENaC. Our results demonstrate that aldosterone stimulates protein methylation in CCD cells, and this is required for expression of the early transport response. In CCD cells this effect is not mediated via methylation of ras, which is not induced by aldosterone in these cells, and the enzyme that methylates ras has no direct effect on ENaC activity. beta ENaC is a substrate for methylation in CCD cells. A novel methyltransferase that stimulates ENaC directly has been identified in CCD cells.	Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Johnson, JP (corresponding author), Univ Pittsburgh, Med Ctr, 935 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15213 USA.	Johnson@dom.pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057718, R01DK047874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57718, R01DK47874] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Baldawi NF, 2000, AM J PHYSIOL-CELL PH, V279, pC429, DOI 10.1152/ajpcell.2000.279.2.C429; ARIMA S, 2006, IN PRESS STEROIDS; Becchetti A, 2000, J BIOL CHEM, V275, P16550, DOI 10.1074/jbc.M000954200; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun TY, 2004, TRENDS ENDOCRIN MET, V15, P353, DOI 10.1016/j.tem.2004.08.002; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Flores SY, 2005, J AM SOC NEPHROL, V16, P2279, DOI 10.1681/ASN.2004100828; Frindt G, 2001, AM J PHYSIOL-RENAL, V280, pF112, DOI 10.1152/ajprenal.2001.280.1.F112; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; JOHNSON JP, 1992, PHARMACOL THERAPEUT, V53, P1, DOI 10.1016/0163-7258(92)90042-X; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; LE MC, 2004, CELL MOL BIOL NOISY, V50, P833; Lebowitz J, 2004, J BIOL CHEM, V279, P41985, DOI 10.1074/jbc.M403923200; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; McCormick JA, 2005, PHYSIOLOGY, V20, P134, DOI 10.1152/physiol.00053.2004; Mohan S, 2004, J BIOL CHEM, V279, P32071, DOI 10.1074/jbc.M405091200; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Stockand JD, 2000, NEWS PHYSIOL SCI, V15, P161; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 1999, J BIOL CHEM, V274, P26912, DOI 10.1074/jbc.274.38.26912; Stockand JD, 1999, J BIOL CHEM, V274, P3842, DOI 10.1074/jbc.274.6.3842; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZH, 2001, AM J PHYSIOL-CELL PH, V281, pC1118, DOI 10.1152/ajpcell.2001.281.4.C1118	34	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9110	9117		10.1074/jbc.M509232200	http://dx.doi.org/10.1074/jbc.M509232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469734	hybrid			2022-12-27	WOS:000236404700016
J	Korotchkina, LG; Sidhu, S; Patel, MS				Korotchkina, LG; Sidhu, S; Patel, MS			Characterization of testis-specific isoenzyme of human pyruvate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; E1-ALPHA SUBUNIT; AMINO-ACIDS; COMPLEX; GENE; DEFICIENCY; MUTATIONS; COMPONENT; PHOSPHATASE; ORGANIZATION	Pyruvate dehydrogenase (PDH), the first component of the human pyruvate dehydrogenase complex, has two isoenzymes, somatic cell-specific PDH1 and testis-specific PDH2 with 87% sequence identity in the alpha subunit of alpha(2)beta(2) PDH. The presence of functional testis-specific PDH2 is important for sperm cells generating nearly all their energy from carbohydrates via pyruvate oxidation. Kinetic and regulatory properties of recombinant human PDH2 and PDH1 were compared in this study. Site-specific phosphorylation/ dephosphorylation of the three phosphorylation sites by four PDH kinases (PDK1 - 4) and two PDH phosphatases (PDP1 - 2) were investigated by substituting serines with alanine or glutamate in PDHs. PDH2 was found to be very similar to PDH1 as follows: (i) in specific activities and kinetic parameters as determined by the pyruvate dehydrogenase complex assay; ( ii) in thermostability at 37 degrees C;( iii) in the mechanism of inactivation by phosphorylation of three sites; and (iv) in the phosphorylation of sites 1 and 2 by PDK3. In contrast, the differences for PDH2 were indicated as follows: ( i) by a 2.4-fold increase in binding affinity for the PDH-binding domain of dihydrolipoamide acetyltransferase as measured by surface plasmon resonance; ( ii) by possible involvement of Ser-264 ( site 1) of PDH2 in catalysis as evident by its kinetic behavior; and ( iii) by the lower activities of PDK1, PDK2, and PDK4 as well as PDP1 and PDP2 toward PDH2. These differences between PDH2 and PDH1 are less than expected from substitution of 47 amino acids in each PDH2 alpha subunit. The multiple substitutions may have compensated for any drastic alterations in PDH2 structure thereby preserving its kinetic and regulatory characteristics largely similar to that of PDH1.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Patel, MS (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	mspatel@buffalo.edu			NIDDK NIH HHS [DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bajotto G, 2004, LIFE SCI, V75, P2117, DOI 10.1016/j.lfs.2004.04.016; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown RM, 2004, HUM GENET, V115, P123, DOI 10.1007/s00439-004-1124-8; CATE RL, 1980, J BIOL CHEM, V255, P7556; CHUN K, 1995, AM J HUM GENET, V56, P558; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; DAHL HHM, 1994, HUM MUTAT, V3, P152, DOI 10.1002/humu.1380030210; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Han ZC, 2005, MOL GENET METAB, V84, P221; Harris RA, 2001, ADV ENZYME REGUL, V41, P269, DOI 10.1016/S0065-2571(00)00020-0; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Hiromasa Y, 2004, J BIOL CHEM, V279, P6921, DOI 10.1074/jbc.M308172200; HO L, 1988, BIOCHEM BIOPH RES CO, V150, P904, DOI 10.1016/0006-291X(88)90714-0; Huang BL, 2003, DIABETES, V52, P1371, DOI 10.2337/diabetes.52.6.1371; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Jacobia SJ, 2002, BBA-MOL BASIS DIS, V1586, P32, DOI 10.1016/S0925-4439(01)00083-7; Jacobia SJ, 2001, ARCH BIOCHEM BIOPHYS, V395, P121, DOI 10.1006/abbi.2001.2576; Jeng JJ, 1998, COMP BIOCHEM PHYS B, V120, P205, DOI 10.1016/S0305-0491(98)10010-X; Johnson MT, 2001, MOL GENET METAB, V74, P293, DOI 10.1006/mgme.2001.3249; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Karpova T, 2003, BBA-PROTEINS PROTEOM, V1652, P126, DOI 10.1016/j.bbapap.2003.08.010; Kerr D. S., 1996, ALPHA KETO ACID DEHY, P249; KERR DS, 1987, PEDIATR RES, V22, P312, DOI 10.1203/00006450-198709000-00015; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; Korotchkina LG, 2004, ARCH BIOCHEM BIOPHYS, V429, P171, DOI 10.1016/j.abb.2004.06.027; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; Lessard IAD, 1996, BIOCHEMISTRY-US, V35, P16863, DOI 10.1021/bi961683r; Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.0.CO;2-K; MARAGOS C, 1989, J BIOL CHEM, V264, P12294; NAITO E, 1994, PEDIATR RES, V36, P340, DOI 10.1203/00006450-199409000-00013; Patel MS, 2003, BIOCHEM MOL BIOL EDU, V31, P5, DOI 10.1002/bmb.2003.494031010156; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Seyda A, 2000, HUM MOL GENET, V9, P1041, DOI 10.1093/hmg/9.7.1041; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; TAKAKUBO F, 1992, EXP CELL RES, V199, P39, DOI 10.1016/0014-4827(92)90459-L; Tripatara A, 1999, ARCH BIOCHEM BIOPHYS, V367, P39, DOI 10.1006/abbi.1999.1231; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	44	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9688	9696		10.1074/jbc.M511481200	http://dx.doi.org/10.1074/jbc.M511481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16436377	hybrid			2022-12-27	WOS:000236404700081
J	Lo, KWH; Kan, HM; Pfister, KK				Lo, KWH; Kan, HM; Pfister, KK			Identification of a novel region of the cytoplasmic dynein intermediate chain important for dimerization in the absence of the light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW AXONAL-TRANSPORT; HEAVY-CHAIN; MICROTUBULE MOTOR; DIFFERENTIAL EXPRESSION; SUBUNIT HETEROGENEITY; DYNACTIN COMPLEX; GENETIC-ANALYSIS; BINDING; PHOSPHORYLATION; TCTEX-1	Cytoplasmic dynein is the multisubunit protein complex responsible for many microtubule-based intracellular movements. Its cargo binding domain consists of dimers of five subunits: the intermediate chains, the light intermediate chains, and the Tctex1, Roadblock, and LC8 light chains. The intermediate chains have a key role in the dynein complex. They bind the three light chains and the heavy chains, which contain the motor domains, but little is known about how the two intermediate chains interact. There are six intermediate chain isoforms, and it has been hypothesized that different isoforms may regulate specific dynein functions. However, there are little data on the potential combinations of the intermediate chain isoforms in the dynein complexes. We used co-immunoprecipitation analyses to demonstrate that all combinations of homo- and heterodimers of the six intermediate chains are possible. Therefore the formation of dynein complexes with different combinations of isoforms is not limited by interaction between the various intermediate chains. We further sought to identify the domain necessary for the dimerization of the intermediate chains. Analysis of a series of truncation and deletion mutants showed that a 61-amino-acid region is necessary for dimerization of the intermediate chain. This region does not include the N-terminal coiled-coil, the C-terminal WD repeat domain, or the three different binding sites for the Tctex1, LC8, and Roadblock light chains. Analytical gel filtration and covalent cross-linking of purified recombinant polypeptides further demonstrated that the intermediate chains can dimerize in vitro in the absence of the light chains.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA	University of Virginia; University of Virginia	Pfister, KK (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	kkp9w@virginia.edu						Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; Boylan K, 2000, MOL BIOL CELL, V11, P3791, DOI 10.1091/mbc.11.11.3791; Brill LB, 2000, METHODS, V22, P307, DOI 10.1006/meth.2000.1083; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; Dillman JF, 1996, P NATL ACAD SCI USA, V93, P141, DOI 10.1073/pnas.93.1.141; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Dillman JF, 1996, J NEUROSCI, V16, P6742; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; Hendrickson TW, 2004, MOL BIOL CELL, V15, P5431, DOI 10.1091/mbc.E04-08-0694; Huang CYF, 1999, J BIOL CHEM, V274, P14262, DOI 10.1074/jbc.274.20.14262; Ilangovan U, 2005, J MOL BIOL, V352, P338, DOI 10.1016/j.jmb.2005.07.002; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; King SJ, 2002, PROTEIN SCI, V11, P1239, DOI 10.1110/ps.2520102; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Liang J, 1999, NAT STRUCT BIOL, V6, P735; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Nikulina K, 2004, CELL MOTIL CYTOSKEL, V57, P233, DOI 10.1002/cm.10172; Nyarko A, 2004, BIOCHEMISTRY-US, V43, P15595, DOI 10.1021/bi048451+; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; Pfister KK, 2006, PLOS GENET, V2, P11, DOI 10.1371/journal.pgen.0020001; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; Sakato M, 2004, J STRUCT BIOL, V146, P58, DOI 10.1016/j.jsb.2003.09.026; Salata MW, 2001, J NEUROSCI RES, V65, P408, DOI 10.1002/jnr.1168; SOBER HA, 1970, HDB BIOCH, pC10; Song J, 2005, J MOL BIOL, V354, P1043, DOI 10.1016/j.jmb.2005.10.017; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; Susalka SJ, 2002, J BIOL CHEM, V277, P32939, DOI 10.1074/jbc.M205510200; Susalka SJ, 2000, J NEUROCYTOL, V29, P819, DOI 10.1023/A:1010995408343; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Tynan SH, 2000, J BIOL CHEM, V275, P32763, DOI 10.1074/jbc.M001536200; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan PS, 2001, J BIOL CHEM, V276, P26171, DOI 10.1074/jbc.M102649200; Wagner OI, 2004, MOL BIOL CELL, V15, P5092, DOI 10.1091/mbc.E04-05-0401; Wang L, 2004, BIOCHEMISTRY-US, V43, P4611, DOI 10.1021/bi036328x; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; Williams JC, 2005, J BIOL CHEM, V280, P21981, DOI 10.1074/jbc.M414643200; Wu HW, 2005, STRUCTURE, V13, P213, DOI 10.1016/j.str.2004.11.013	51	32	33	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9552	9559		10.1074/jbc.M511721200	http://dx.doi.org/10.1074/jbc.M511721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452477	hybrid			2022-12-27	WOS:000236404700066
J	Ullah, MS; Davies, AJ; Halestrap, AP				Ullah, MS; Davies, AJ; Halestrap, AP			The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1 alpha-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCARBOXYLATE TRANSPORTER; LACTIC-ACID EFFLUX; SKELETAL-MUSCLE; INDUCIBLE FACTOR-1; GENE-EXPRESSION; RAT MUSCLE; FAMILY; CD147; INDUCTION; PROTEIN	The monocarboxylate transporter MCT4 mediates lactic acid efflux from most tissues that are dependent on glycolysis for their ATP production. Here we demonstrate that expression of MCT4 mRNA and protein was increased >3-fold by a 48-h exposure to 1% O-2, whereas MCT1 expression was not increased. The effect was mimicked by CoCl2 (50 mu M), suggesting transcriptional regulation by hypoxia-inducible factor 1 alpha (HIF-1 alpha). The predicted promoters for human MCT1, MCT2, and MCT4 were cloned into the pGL3 vector and shown to be active ( luciferase luminescence) under basal conditions. Only the MCT4 promoter was activated (>2-fold) by hypoxia. No response was found in cells lacking HIF-1 alpha. Four potential hypoxia-response elements were identified, but deletion analysis implicated only two in the hypoxia response. These were just upstream from the transcription start site and also found in the mouse MCT4 promoter. Mutation of site 2 totally abolished the hypoxic response, whereas mutation of site 1 only reduced the response. Gel-shift analysis demonstrated that nuclear extracts of hypoxic but not normoxic HeLa cells contained two transcription factors that bound to DNA probes containing these hypoxia-response elements. The major shifted band was abolished by mutation of site 2, and supershift analysis confirmed that HIF-1 alpha bound to this site. Binding of the second factor was abolished by mutation of site 1. We conclude that MCT4, like other glycolytic enzymes, is up-regulated by hypoxia through a HIF-1 alpha-mediated mechanism. This adaptive response allows the increased lactic acid produced during hypoxia to be rapidly lost from the cell.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	a.halestrap@bristol.ac.uk	Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778				Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Behrooz A, 1999, NEWS PHYSIOL SCI, V14, P105; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; Chaudary N, 2002, BIOCHEM CELL BIOL, V80, P655, DOI 10.1139/O02-143; Coles L, 2004, J PHYSIOL-LONDON, V561, P253, DOI 10.1113/jphysiol.2004.073478; Cuff MA, 2002, BIOCHEM BIOPH RES CO, V292, P1048, DOI 10.1006/bbrc.2002.6763; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Grollman EF, 2000, BIOCHEMISTRY-US, V39, P9351, DOI 10.1021/bi000464+; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Moeller LC, 2005, MOL ENDOCRINOL, V19, P2955, DOI 10.1210/me.2004-0542; Muramatsu T, 2003, HISTOL HISTOPATHOL, V18, P981, DOI 10.14670/HH-18.981; Ord JJ, 2005, BRIT J CANCER, V93, P346, DOI 10.1038/sj.bjc.6602666; Price NT, 1998, BIOCHEM J, V329, P321; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Py G, 2005, METABOLISM, V54, P634, DOI 10.1016/j.metabol.2004.12.007; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; van der Meer DLM, 2005, AM J PHYSIOL-REG I, V289, pR1512, DOI 10.1152/ajpregu.00089.2005; Wang YX, 2003, AM J PHYSIOL-ENDOC M, V285, pE622, DOI 10.1152/ajpendo.00069.2003; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; Yoon H, 1998, EXP EYE RES, V67, P417, DOI 10.1006/exer.1998.0533	31	618	643	3	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9030	9037		10.1074/jbc.M511397200	http://dx.doi.org/10.1074/jbc.M511397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452478	hybrid			2022-12-27	WOS:000236404700007
J	Boskovic, J; Arnold, JN; Stilion, R; Gordon, S; Sim, RB; Rivera-Calzada, A; Wienke, D; Isacke, CM; Martinez-Pomares, L; Llorca, O				Boskovic, J; Arnold, JN; Stilion, R; Gordon, S; Sim, RB; Rivera-Calzada, A; Wienke, D; Isacke, CM; Martinez-Pomares, L; Llorca, O			Structural model for the mannose receptor family uncovered by electron microscopy of Endo180 and the mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PHOSPHOLIPASES A(2); HIGH-AFFINITY BINDING; CYSTEINE-RICH DOMAIN; MEMBRANE-RECEPTOR; LIGAND-BINDING; COLLAGEN; RECOGNITION; IDENTIFICATION; PROTEIN; LECTIN	The mannose receptor family comprises four members in mammals, Endo180 (CD280), DEC-205 (CD205), phospholipase A(2) receptor (PLA2R) and the mannose receptor (MR, CD206), whose extracellular portion contains a similar domain arrangement: an N-terminal cysteine-rich domain (CysR) followed by a single fibronectin type II domain (FNII) and 8-10 C-type lectin-like domains (CTLDs). These proteins mediate diverse functions ranging from extracellular matrix turnover through collagen uptake to homeostasis and immunity based on sugar recognition. Endo180 and the MR are multivalent transmembrane receptors capable of interacting with multiple ligands; in both receptors FNII recognizes collagens, and a single CTLD retains lectin activity (CTLD2 in Endo180 and CTLD4 in MR). It is expected that the overall conformation of these multivalent molecules would deeply influence their function as the availability of their binding sites could be altered under different conditions. However, conflicting reports have been published on the three-dimensional arrangement of these receptors. Here, we have used single particle electron microscopy to elucidate the three-dimensional organization of the MR and Endo180. Strikingly, we have found that both receptors display distinct three-dimensional structures, which are, however, conceptually very similar: a bent and compact conformation built upon interactions of the CysR domain and the lone functional CTLD. Biochemical and electron microscopy experiments indicate that, under a low pH mimicking the endosomal environment, both MR and Endo180 experience large conformational changes. We propose a structural model for the mannose receptor family where at least two conformations exist that may serve to regulate differences in ligand selectivity.	CSIC, Ctr Invest Biol, Madrid 28040, Spain; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Oxford; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oxford	Llorca, O (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9,Campus Univ Complutense, Madrid 28040, Spain.	ollorca@cib.csic.es	Llorca, Oscar/K-1144-2014; Rivera-Calzada, Angel/K-3617-2014; Sim, Bob/A-1354-2008; boskovic, jasminka/L-5117-2018; Arnold, James/ABE-3900-2021; Llorca, Oscar/P-2784-2019	Llorca, Oscar/0000-0001-5705-0699; Rivera-Calzada, Angel/0000-0003-2472-5535; Sim, Bob/0000-0002-2855-7455; boskovic, jasminka/0000-0001-6135-0686; Arnold, James/0000-0002-6949-0613; Llorca, Oscar/0000-0001-5705-0699; Martinez-Pomares, Luisa/0000-0002-2331-127X; Isacke, Clare/0000-0002-9222-3345	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Curino AC, 2005, J CELL BIOL, V169, P977, DOI 10.1083/jcb.200411153; Dube P, 2005, MOL CELL, V20, P867, DOI 10.1016/j.molcel.2005.11.008; East L, 2002, J BIOL CHEM, V277, P50469, DOI 10.1074/jbc.M208985200; East L, 2003, EMBO REP, V4, P710, DOI 10.1038/sj.embor.embor882; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kjoller L, 2004, EXP CELL RES, V293, P106, DOI 10.1016/j.yexcr.2003.10.008; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Llorca O, 2005, ACTA PHARMACOL SIN, V26, P1153, DOI 10.1111/j.1745-7254.2005.00203.x; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Martinez-Pomares L, 2003, J LEUKOCYTE BIOL, V73, P604, DOI 10.1189/jlb.0902450; Mould AP, 2004, NATURE, V432, P27, DOI 10.1038/432027a; Napper CE, 2001, J BIOL CHEM, V276, P14759, DOI 10.1074/jbc.M100425200; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rivera-Calzada A, 2003, EMBO REP, V4, P807, DOI 10.1038/sj.embor.embor898; Simpson DZ, 1999, BIOCHEM J, V343, P403, DOI 10.1042/0264-6021:3430403; Sturge J, 2003, J CELL BIOL, V162, P789, DOI 10.1083/jcb.200302124; Su YP, 2005, J BIOL CHEM, V280, P32811, DOI 10.1074/jbc.M503457200; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Taylor PR, 2005, TRENDS IMMUNOL, V26, P104, DOI 10.1016/j.it.2004.12.001; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Thomas EK, 2005, J BIOL CHEM, V280, P22596, DOI 10.1074/jbc.M501155200; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; West AP, 2004, IMMUNITY, V20, P601, DOI 10.1016/S1074-7613(04)00113-X; Wienke D, 2003, MOL BIOL CELL, V14, P3592, DOI 10.1091/mbc.E02-12-0814; Zamze S, 2002, J BIOL CHEM, V277, P41613, DOI 10.1074/jbc.M207057200	35	61	70	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8780	8787		10.1074/jbc.M513277200	http://dx.doi.org/10.1074/jbc.M513277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452473	hybrid, Green Published			2022-12-27	WOS:000236247100057
J	Branham, MAT; Mayorga, LS; Tomes, CN				Branham, MAT; Mayorga, LS; Tomes, CN			Calcium-induced acrosomal exocytosis requires cAMP acting through a protein kinase A-independent, Epac-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE ADENYLYL-CYCLASE; PANCREATIC BETA-CELLS; CA2+-INDUCED CA2+ RELEASE; HUMAN SPERM CAPACITATION; EXCHANGE FACTOR EPAC; MALE GERM-CELLS; CYCLIC-AMP; TYROSINE PHOSPHORYLATION; HUMAN SPERMATOZOA; REGULATED EXOCYTOSIS	Epac, a guanine nucleotide exchange factor for the small GTPase Rap, binds to and is activated by the second messenger cAMP. In sperm, there are a number of signaling pathways required to achieve egg-fertilizing ability that depend upon an intracellular rise of cAMP. Most of these processes were thought to be mediated by cAMP- dependent protein kinases. Here we report a new dependence for the cAMP- induced acrosome reaction involving Epac. The acrosome reaction is a specialized type of regulated exocytosis leading to a massive fusion between the outer acrosomal and the plasma membranes of sperm cells. Ca2+ is the archetypical trigger of regulated exocytosis, and we show here that its effects on acrosomal release are fully mediated by cAMP. Ca2+ failed to trigger acrosomal exocytosis when intracellular cAMP was depleted by an exogenously added phosphodiesterase or when Epac was sequestered by specific blocking antibodies. The nondiscriminating dibutyryl-cAMP and the Epac-selective 8-(p-chlorophenylthio)-2'-O-methyladenosine-3', 5'-cyclic monophosphate analogues triggered the acrosome reaction in the effective absence of extracellular Ca2+. This indicates that cAMP, via Epac activation, has the ability to drive the whole cascade of events necessary to bring exocytosis to completion, including tethering and docking of the acrosome to the plasma membrane, priming of the fusion machinery, mobilization of intravesicular Ca2+, and ultimately, bilayer mixing and fusion. cAMP- elicited exocytosis was sensitive to anti-alpha-SNAP, anti-NSF, and anti-Rab3A antibodies, to intra-acrosomal Ca2+ chelators, and to botulinum toxins but was resistant to cAMP- dependent protein kinase blockers. These experiments thus identify Epac in human sperm and evince its indispensable role downstream of Ca2+ in exocytosis.	Univ Nacl Cuyo, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, IHEM,Lab Biol Celular & Mol, RA-5500 Mendoza, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza	Tomes, CN (corresponding author), Univ Nacl Cuyo, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, IHEM,Lab Biol Celular & Mol, CC 56, RA-5500 Mendoza, Argentina.	ctomes@fcm.uncu.edu.ar		Mayorga, Luis S/0000-0002-5995-0671				Aitken RJ, 1998, J CELL SCI, V111, P645; Aronoff DM, 2005, J IMMUNOL, V174, P595, DOI 10.4049/jimmunol.174.2.595; Berruti G, 2003, CELL MOL BIOL, V49, P381; BIELFELD P, 1994, FERTIL STERIL, V61, P536; Breitbart H, 1999, REV REPROD, V4, P151; Breitbart H, 2003, CELL MOL BIOL, V49, P321; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chin EC, 2004, J ENDOCRINOL, V183, P51, DOI 10.1677/joe.1.05550; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Darszon A, 2005, INT REV CYTOL, V243, P79, DOI 10.1016/S0074-7696(05)43002-8; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; De Blas GA, 2005, PLOS BIOL, V3, P1801, DOI 10.1371/journal.pbio.0030323; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DEJONGE CJ, 1991, J EXP ZOOL, V258, P113, DOI 10.1002/jez.1402580113; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fujimoto K, 2002, J BIOL CHEM, V277, P50497, DOI 10.1074/jbc.M210146200; Harrison DA, 2000, BIOL REPROD, V62, P811, DOI 10.1095/biolreprod62.3.811; Herrick SB, 2005, J CELL PHYSIOL, V202, P663, DOI 10.1002/jcp.20172; Hochbaum D, 2003, J BIOL CHEM, V278, P33738, DOI 10.1074/jbc.M305208200; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Jaiswal BS, 2003, P NATL ACAD SCI USA, V100, P10676, DOI 10.1073/pnas.1831008100; Kaneko M, 2004, J NEUROSCI, V24, P5202, DOI 10.1523/JNEUROSCI.0999-04.2004; Kang GX, 2005, J PHYSIOL-LONDON, V566, P173, DOI 10.1113/jphysiol.2005.087510; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; KATZ BM, 1989, INT J PEPT PROT RES, V33, P439; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Kwon G, 2004, J BIOL CHEM, V279, P8938, DOI 10.1074/jbc.M310330200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Leclerc P, 1998, J ANDROL, V19, P434; Lefievre L, 2002, J ANDROL, V23, P709; Litvin TN, 2003, J BIOL CHEM, V278, P15922, DOI 10.1074/jbc.M212475200; Luconi M, 2005, BIOL REPROD, V72, P22, DOI 10.1095/biolreprod.104.032490; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; MENDOZA C, 1992, J REPROD FERTIL, V95, P755; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rehmann H, 2003, J BIOL CHEM, V278, P38548, DOI 10.1074/jbc.M306292200; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; Sakaba T, 2003, NATURE, V424, P775, DOI 10.1038/nature01859; Sakaba T, 2001, P NATL ACAD SCI USA, V98, P331, DOI 10.1073/pnas.021541098; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Sedej S, 2005, J PHYSIOL-LONDON, V567, P799, DOI 10.1113/jphysiol.2005.090381; Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005; Shibasaki T, 2004, J BIOL CHEM, V279, P7956, DOI 10.1074/jbc.M309068200; Shimomura H, 2004, ARCH BIOCHEM BIOPHYS, V431, P124, DOI 10.1016/j.abb.2004.07.021; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Steegborn C, 2005, NAT STRUCT MOL BIOL, V12, P32, DOI 10.1038/nsmb880; Sunahara Roger K, 2002, Mol Interv, V2, P168, DOI 10.1124/mi.2.3.168; Tardif S, 2004, MOL REPROD DEV, V69, P428, DOI 10.1002/mrd.20178; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Tomes CN, 1998, MOL HUM REPROD, V4, P17, DOI 10.1093/molehr/4.1.17; Tomes CN, 2005, MOL HUM REPROD, V11, P43, DOI 10.1093/molehr/gah126; Tomes CN, 2004, DEV BIOL, V265, P399, DOI 10.1016/j.ydbio.2003.09.032; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Ueno H, 2001, GENOMICS, V78, P91, DOI 10.1006/geno.2001.6641; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; Wuttke M S, 2001, JOP, V2, P154; Yanagimachi R., 1994, P189; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084; Yunes R, 2002, FEBS LETT, V525, P126, DOI 10.1016/S0014-5793(02)03102-2; Zhong N, 2005, J NEUROSCI, V25, P208, DOI 10.1523/JNEUROSCI.3703-04.2005; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	84	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8656	8666		10.1074/jbc.M508854200	http://dx.doi.org/10.1074/jbc.M508854200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407249	hybrid			2022-12-27	WOS:000236247100043
J	Chakraborty, A; Nagaraja, V				Chakraborty, A; Nagaraja, V			Dual role for transactivator protein C in activation of mom promoter of bacteriophage Mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABLE RNA PROMOTER; TRANSCRIPTION INITIATION; ESCHERICHIA-COLI; PHAGE-MU; MALT PROMOTER; DNA-BINDING; POLYMERASE; MECHANISM; GENE; SEQUENCE	Transactivator C protein of bacteriophage Mu activates the mom gene of the phage by an unusual mechanism. DNA binding by C to its site results in unwinding of the neighboring sequences, realigning the out- of- phase promoter elements to facilitate RNA polymerase ( RNAP) binding. High level stimulation of a C- independent constitutive promoter mutant ( where RNAP is already bound) by the transactivator suggested an additional mechanism of transcription activation at a step after RNAP recruitment. In this study, we have investigated the various steps of promoter- polymerase interactions during transcription initiation by using both the promoter mutant and a positive control ( pc) mutant of C protein. The transactivator does not influence formation of the open complex or its stability after facilitating the RNAP binding. However, at a subsequent step, the protein exerts an important role, enhancing the promoter clearance by increasing the productive RNAP . promoter complex. The pc mutant of the transactivator C is compromised at this step, supporting the additional downstream role for C in mom transcription activation. We suggest that this unusual multistep activation of P-mom has evolved to ensure irreversibility of the switch during the late lytic cycle of the phage.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Nagaraja, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	vraj@mcbl.iisc.ernet.in						Anthony LC, 2002, J BIOL CHEM, V277, P46433, DOI 10.1074/jbc.M208205200; BALKE V, 1992, NUCLEIC ACIDS RES, V20, P2777, DOI 10.1093/nar/20.11.2777; Basak S, 2001, J BIOL CHEM, V276, P46941, DOI 10.1074/jbc.M107476200; Basak S, 1998, J MOL BIOL, V284, P893, DOI 10.1006/jmbi.1998.2213; Basak S, 2001, J BIOL CHEM, V276, P19836, DOI 10.1074/jbc.M011790200; BOLKER M, 1989, EMBO J, V8, P2403, DOI 10.1002/j.1460-2075.1989.tb08370.x; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Callen BP, 2004, MOL CELL, V14, P647, DOI 10.1016/j.molcel.2004.05.010; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Eichenberger P, 1997, P NATL ACAD SCI USA, V94, P9022, DOI 10.1073/pnas.94.17.9022; Glinkowska M, 2003, J BIOL CHEM, V278, P22250, DOI 10.1074/jbc.M212492200; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HATTMAN S, 1985, GENE, V39, P71, DOI 10.1016/0378-1119(85)90109-X; HATTMAN S, 1991, P NATL ACAD SCI USA, V88, P10027, DOI 10.1073/pnas.88.22.10027; HATTMAN S, 1984, GENE, V29, P185, DOI 10.1016/0378-1119(84)90179-3; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; KAHMANN R, 1985, GENE, V39, P61, DOI 10.1016/0378-1119(85)90108-8; Kahmann R., 1987, PHAGE MU, P93; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KUMAR KP, 1988, J BIOCHEM BIOPH METH, V15, P235; Liu MF, 2004, J BIOL CHEM, V279, P54552, DOI 10.1074/jbc.M408609200; Liu MF, 2004, P NATL ACAD SCI USA, V101, P6911, DOI 10.1073/pnas.0401929101; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; McLeod SM, 2002, J MOL BIOL, V316, P517, DOI 10.1006/jmbi.2001.5391; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; Miller JH., 1992, SHORT COURSE BACTERI, P72; Muskhelishvili G, 1997, EMBO J, V16, P3655, DOI 10.1093/emboj/16.12.3655; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; Opel ML, 2004, MOL MICROBIOL, V53, P665, DOI 10.1111/j.1365-2958.2004.04147.x; Paul BD, 2003, PROTEINS, V52, P272, DOI 10.1002/prot.10413; RAMESH V, 1994, PROTEIN EXPRES PURIF, V5, P379, DOI 10.1006/prep.1994.1055; RAMESH V, 1994, PROTEIN ENG, V7, P1053, DOI 10.1093/protein/7.8.1053; Ramesh V, 1996, J MOL BIOL, V260, P22, DOI 10.1006/jmbi.1996.0379; SHIH MC, 1984, J MOL BIOL, V172, P489, DOI 10.1016/S0022-2836(84)80019-4; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; Sun WY, 1998, J MOL BIOL, V284, P885, DOI 10.1006/jmbi.1998.2228; WARNE SE, 1993, BIOCHEMISTRY-US, V32, P6134, DOI 10.1021/bi00075a003; WULCZYN FG, 1991, CELL, V65, P259, DOI 10.1016/0092-8674(91)90160-Z; Zhi HJ, 2003, J BIOL CHEM, V278, P47340, DOI 10.1074/jbc.M305430200	39	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8511	8517		10.1074/jbc.M512906200	http://dx.doi.org/10.1074/jbc.M512906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446361	hybrid			2022-12-27	WOS:000236247100026
J	Matoba, Y; Kumagai, T; Yamamoto, A; Yoshitsu, H; Sugiyama, M				Matoba, Y; Kumagai, T; Yamamoto, A; Yoshitsu, H; Sugiyama, M			Crystallographic evidence that the dinuclear copper center of tyrosinase is flexible during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR REFINEMENT; II HEMOCYANIN; EXPRESSION; COMPLEX; CLONING; GENE; RESOLUTION; SEQUENCE; MODEL	At high resolution, we determined the crystal structures of copper-bound and metal-free tyrosinase in a complex with ORF378 designated as a "caddie" protein because it assists with transportation of two Cu(II) ions into the tyrosinase catalytic center. These structures suggest that the caddie protein covers the hydrophobic molecular surface of tyrosinase and interferes with the binding of a substrate tyrosine to the catalytic site of tyrosinase. The caddie protein, which consists of one six-stranded beta-sheet and one alpha-helix, has no similarity with all proteins deposited into the Protein Data Bank. Although tyrosinase and catechol oxidase are classified into the type 3 copper protein family, the latter enzyme lacks monooxygenase activity. The difference in catalytic activity is based on the structural observations that a large vacant space is present just above the active center of tyrosinase and that one of the six His ligands for the two copper ions is highly flexible. These structural characteristics of tyrosinase suggest that, in the reaction that catalyzes the ortho-hydroxylation of monophenol, one of the two Cu(II) ions is coordinated by the peroxide-originated oxygen bound to the substrate. Our crystallographic study shows evidence that the tyrosinase active center formed by dinuclear coppers is flexible during catalysis.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Frontier Ctr Microbiol, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University; Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	sugi@hiroshima-u.ac.jp						Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERMAN V, 1985, GENE, V37, P101; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CHEN LY, 1993, J BIOL CHEM, V268, P18710; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; Harrenga A, 1999, J BIOL CHEM, V274, P33296, DOI 10.1074/jbc.274.47.33296; HAZES B, 1993, PROTEIN SCI, V2, P597; Hazes B, 1996, J MOL BIOL, V262, P532, DOI 10.1006/jmbi.1996.0533; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER M, 1985, BIOCHEMISTRY-US, V24, P6038, DOI 10.1021/bi00343a003; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Ikeda K, 1996, APPL MICROBIOL BIOT, V45, P80, DOI 10.1007/s002530050652; Ikeda K, 1996, J BIOCHEM-TOKYO, V120, P1141; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Kohashi PY, 2004, PROTEIN EXPRES PURIF, V34, P202, DOI 10.1016/j.pep.2003.11.015; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LERCH K, 1982, J BIOL CHEM, V257, P6414; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RODRIGUEZLOPEZ JN, 1992, J BIOL CHEM, V267, P3801; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Siegbahn PEM, 2003, J BIOL INORG CHEM, V8, P567, DOI 10.1007/s00775-003-0449-4; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; VOLBEDA A, 1989, EUR J BIOCHEM, V181, P669, DOI 10.1111/j.1432-1033.1989.tb14775.x; Wichers HJ, 2003, APPL MICROBIOL BIOT, V61, P336, DOI 10.1007/s00253-002-1194-2; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu YM, 1998, J NEUROSCI RES, V54, P691, DOI 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	47	603	621	1	140	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8981	8990		10.1074/jbc.M509785200	http://dx.doi.org/10.1074/jbc.M509785200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16436386	hybrid			2022-12-27	WOS:000236247100078
J	Zouzoulas, A; Blostein, R				Zouzoulas, A; Blostein, R			Regions of the catalytic alpha subunit of Na,K-ATPase important for functional interactions with FXYD 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; GAMMA-SUBUNIT; SODIUM-PUMP; IMMUNOCYTOCHEMICAL LOCALIZATION; RENAL NA,K-ATPASE; MAMMALIAN-CELLS; BETA-SUBUNIT; AMINO-ACIDS; CROSS-LINKS; PROTEINS	The gamma modulator (FXYD 2) is a member of the FXYD family of single transmembrane proteins that modulate the kinetic behavior of Na,K-ATPase. This study concerns the identification of regions in the alpha subunit that are important for its functional interaction with gamma. An important effect of gamma is to increase K+ antagonism of cytoplasmic Na+ activation apparent as an increase in K-Na' at high [K+]. We show that although gamma associates with alpha 1, alpha 2, and alpha 3 isoforms, it increases the K-Na' of alpha 1 and alpha 3 but not alpha 2. Accordingly, chimeras of alpha 1 and alpha 2 were used to identify regions of alpha critical for the increased K-Na'. As with alpha 1 and alpha 2, all chimeras associate with gamma. Kinetic analysis of alpha 2(front)/alpha 1(back) chimeras indicate that the C-terminal (Lys(907-)Tyr(1018)) region of alpha 1, which includes transmembrane (TM) 9 close to gamma, is important for the increase in K-Na'. However, similar experiments with alpha 1(front)/alpha 2(back) chimeras indicate a modulatory role of the loop between TMs 7 and 8. Thus, as long as the alpha 1 L7/8 loop is present, replacement of TM9 of alpha 1 with that of alpha 2 does not abrogate the gamma effect on K-Na'. In contrast, as long as TM9 is that of alpha 1, replacement of L7/8 of alpha 1 with that of alpha 2 does not abolish the effect. It is suggested that structural association of the TM regions of alpha and FXYD 2 is not the sole determinant of this effect of FXYD on K-Na' but is subject to long range modulation by the extramembranous L7/8 loop of alpha.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada	McGill University	Blostein, R (corresponding author), Montreal Gen Hosp, Res Inst, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	rhoda.blostein@mcgill.ca						Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; CRAMBERT G, 2003, SCI STKE, V66, P21; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Garty H, 2006, ANNU REV PHYSIOL, V68, P431, DOI 10.1146/annurev.physiol.68.040104.131852; Geering K, 2003, ANN NY ACAD SCI, V986, P388, DOI 10.1111/j.1749-6632.2003.tb07219.x; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; LANE LK, 1993, J BIOL CHEM, V268, P17930; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LOWRY K, 1973, BIOCHEM PHARMACOL, V22, P1369, DOI 10.1016/0006-2952(73)90310-9; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Segall L, 2003, J BIOL CHEM, V278, P9027, DOI 10.1074/jbc.M211636200; Therien AG, 1999, AM J PHYSIOL-CELL PH, V277, pC891, DOI 10.1152/ajpcell.1999.277.5.C891; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; THERIEN AG, 2000, AM J PHYSIOL, V279, pC511; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Wang SG, 1998, J BIOL CHEM, V273, P29400, DOI 10.1074/jbc.273.45.29400; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531; Zouzoulas A, 2005, J MEMBRANE BIOL, V204, P49, DOI 10.1007/s00232-005-0746-7; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	37	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8539	8544		10.1074/jbc.M512700200	http://dx.doi.org/10.1074/jbc.M512700200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446368	hybrid			2022-12-27	WOS:000236247100029
J	Zietkiewicz, S; Lewandowska, A; Stocki, P; Liberek, K				Zietkiewicz, S; Lewandowska, A; Stocki, P; Liberek, K			Hsp70 chaperone machine remodels protein aggregates at the initial step of Hsp70-Hsp100-dependent disaggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI PROTEINS; LAMBDA-DNA REPLICATION; ATP-BINDING-SITES; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL HSP78; CLPB; HSP104; SOLUBILIZATION; MECHANISM	Exposure to temperatures over a certain limit leads to massive protein aggregation in the cell. Disaggregation of such aggregates is largely dependent on the Hsp100 and Hsp70 chaperones. The exact role of the Hsp70 chaperone machine ( composed of DnaK, DnaJ, and GrpE) in the Hsp100-dependent process remains unknown. In this study we focused on the Hsp70 role at the initial step of the disaggregation process. Two different aggregated model substrates, green fluorescent protein (GFP) and firefly luciferase, were incubated with the Hsp70 machine resulting in efficient fragmentation of large aggregates into smaller ones. Our data suggest that the observed fragmentation is achieved first by extraction of polypeptides from aggregates in Hsp70 chaperone machine-dependent manner and not by direct fragmentation of large aggregates. In the absence of Hsp100 ( ClpB) these "extracted" polypeptides were not able to fold properly and promptly reassociated into new aggregates. The extracted GFP molecules were efficiently recognized and sequestered by a molecular trap, the mutant GroEL D87K, which binds stably to unfolded but not to native polypeptides. The binding of extracted GFP molecules to the GroEL trap prevented their reaggregation. We propose that the Hsp70 machine disentangles polypeptides from protein aggregates prior to Hsp100 action.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk	Liberek, K (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, Kladki 24, PL-80822 Gdansk, Poland.	liberek@biotech.univ.gda.pl	Liberek, Krzysztof/F-5812-2011; Lewandowska, Agnieszka/M-9281-2018; Ziętkiewicz, Szymon/L-5259-2014	Lewandowska, Agnieszka/0000-0001-6387-7318; Liberek, Krzysztof/0000-0002-7532-9279; Zietkiewicz, Szymon/0000-0002-3435-4603				Ben-Zvi A, 2004, J BIOL CHEM, V279, P37298, DOI 10.1074/jbc.M405627200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; Liu QL, 2003, SCIENCE, V300, P139, DOI 10.1126/science.1083379; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Schlieker C, 2004, FEBS LETT, V578, P351, DOI 10.1016/j.febslet.2004.11.051; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; Shorter J, 2005, NAT STRUCT MOL BIOL, V12, P4, DOI 10.1038/nsmb0105-4; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; WALL D, 1994, J BIOL CHEM, V269, P5446; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEIZBEZAHN J, 2003, J BIOL CHEM, V278, P32608; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zietkiewicz S, 2004, J BIOL CHEM, V279, P44376, DOI 10.1074/jbc.M402405200; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	43	76	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7022	7029		10.1074/jbc.M507893200	http://dx.doi.org/10.1074/jbc.M507893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415353	hybrid			2022-12-27	WOS:000236030900015
J	Pegg, AE				Pegg, Anthony E.			Regulation of ornithine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							INTERNAL RIBOSOME ENTRY; PROTEASOMAL DEGRADATION; ANTIZYME INHIBITOR; POLYAMINE TRANSPORT; HOMOLOGOUS PROTEIN; ACTIVE-SITE; INDUCTION; EXPRESSION; GROWTH; TARGET	Ornithine decarboxylase (ODC) initiates the polyamine biosynthetic pathway. The amount of ODC is altered in response to many growth factors, oncogenes, and tumor promoters and to changes in polyamine levels. Susceptibility to tumor development is increased in transgenic mice expressing high levels of ODC and is decreased in mice with reduced ODC due to loss of one ODC allele or elevated expression of antizyme, a protein that stimulates ODC degradation. This review describes key factors that contribute to the regulation of ODC levels, which can occur at the levels of transcription, translation, and protein turnover.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pegg, AE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	aep1@psu.edu			NATIONAL CANCER INSTITUTE [R37CA018138, R01CA018138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NCI NIH HHS [CA 18138] Funding Source: Medline; NIGMS NIH HHS [GM 26290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; Asher G, 2005, MOL CELL, V17, P645, DOI 10.1016/j.molcel.2005.01.020; Bauer PM, 2001, J BIOL CHEM, V276, P34458, DOI 10.1074/jbc.M105219200; Bercovich Z, 2004, J BIOL CHEM, V279, P54097, DOI 10.1074/jbc.M410234200; Bewley MC, 2006, P NATL ACAD SCI USA, V103, P2063, DOI 10.1073/pnas.0511008103; Chattopadhyay MK, 2005, P NATL ACAD SCI USA, V102, P16158, DOI 10.1073/pnas.0507299102; Chen H, 2002, J BIOL CHEM, V277, P45957, DOI 10.1074/jbc.M206799200; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; COHEN SS, 1998, GUIDE POLYAMINES, P231; Coleman CS, 2004, BIOCHEM J, V379, P849, DOI 10.1042/BJ20040035; COLEMAN CS, 1994, J BIOL CHEM, V269, P3155; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; Gandre S, 2003, MITOCHONDRION, V2, P245, DOI 10.1016/S1567-7249(02)00105-8; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; George K, 2005, MOL CARCINOGEN, V44, P212, DOI 10.1002/mc.20130; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GRENS A, 1990, J BIOL CHEM, V265, P11810; Gritli-Linde A, 2001, DEV DYNAM, V220, P259, DOI 10.1002/1097-0177(20010301)220:3<259::AID-DVDY1100>3.0.CO;2-#; Gruendler C, 2001, J BIOL CHEM, V276, P46533, DOI 10.1074/jbc.M105500200; Guo YJ, 2005, CANCER RES, V65, P1146, DOI 10.1158/0008-5472.CAN-04-3244; Guo YJ, 2000, CANCER RES, V60, P6314; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HAYES CS, 2006, IN PRESS ONCOGENE; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; Hoffman DW, 2005, BIOCHEMISTRY-US, V44, P11777, DOI 10.1021/bi051081k; Hoshino K, 2005, J BIOL CHEM, V280, P42801, DOI 10.1074/jbc.M505445200; Ike A, 2004, FEBS LETT, V559, P159, DOI 10.1016/S0014-5793(04)00065-1; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; Ivanov IP, 2004, J MOL BIOL, V339, P495, DOI 10.1016/j.jmb.2004.03.082; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Jackson LK, 2004, BIOCHEMISTRY-US, V43, P12990, DOI 10.1021/bi048933l; JCKSON LK, 2003, BIOCHEMISTRY-US, V42, P2933; Kahana C, 2005, CELL CYCLE, V4, P1461, DOI 10.4161/cc.4.11.2115; Mackintosh CA, 2000, BIOCHEM J, V350, P645, DOI 10.1042/0264-6021:3500645; Mangold U, 2005, IUBMB LIFE, V57, P671, DOI 10.1080/15216540500307031; Mangold U, 2005, BIOCHEM J, V385, P21, DOI 10.1042/BJ20040547; Martinez ME, 2003, P NATL ACAD SCI USA, V100, P7859, DOI 10.1073/pnas.1332465100; Matsuzawa S, 2005, P NATL ACAD SCI USA, V102, P14982, DOI 10.1073/pnas.0507512102; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; Mitchell JLA, 2004, BIOCHEM J, V384, P271, DOI 10.1042/BJ20040972; Mitchell JLA, 2002, BIOCHEM J, V366, P663, DOI 10.1042/BJ20011612; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Nilsson J, 1997, EUR J BIOCHEM, V250, P223, DOI 10.1111/j.1432-1033.1997.0223a.x; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Nilsson JA, 2004, MOL CELL BIOL, V24, P1560, DOI 10.1128/MCB.24.4.1560-1569.2004; O'Brien TG, 2004, MOL CARCINOGEN, V41, P120, DOI 10.1002/mc.20047; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; Palanimurugan R, 2004, EMBO J, V23, P4857, DOI 10.1038/sj.emboj.7600473; PEGG AE, 1988, CANCER RES, V48, P759; Pegg AE, 2003, BIOCHEM SOC T, V31, P356, DOI 10.1042/BST0310356; Persson L, 2003, BIOCHEM SOC T, V31, P411, DOI 10.1042/BST0310411; Petros LM, 2005, BIOCHEM BIOPH RES CO, V338, P1478, DOI 10.1016/j.bbrc.2005.10.115; Pyronnet S, 2005, CELL MOL LIFE SCI, V62, P1267, DOI 10.1007/s00018-005-5020-8; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Qin CH, 2004, MOL CARCINOGEN, V40, P160, DOI 10.1002/mc.20030; Schipper RG, 2004, J HISTOCHEM CYTOCHEM, V52, P1259, DOI 10.1369/jhc.4C6389.2004; Shah R, 2004, J BIOL CHEM, V279, P35760, DOI 10.1074/jbc.M405366200; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; Shantz LM, 1996, CANCER RES, V56, P3265; Soulet D, 2004, J BIOL CHEM, V279, P49355, DOI 10.1074/jbc.M401287200; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; Tang XW, 2004, J CLIN INVEST, V113, P867, DOI 10.1172/JCI200420732; Wallstrom EL, 2001, BIOCHEM J, V356, P627, DOI 10.1042/bj3560627; Zhang J, 2005, FEBS LETT, V579, P559, DOI 10.1016/j.febslet.2004.10.112; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; Zhang MS, 2004, J BIOL CHEM, V279, P20959, DOI 10.1074/jbc.M314043200; Zhao BW, 2001, MOL CARCINOGEN, V32, P92, DOI 10.1002/mc.1068	75	342	363	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14529	14532		10.1074/jbc.R500031200	http://dx.doi.org/10.1074/jbc.R500031200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16459331	hybrid			2022-12-27	WOS:000237671300002
J	Ackers, GK; Holt, JM				Ackers, GK; Holt, JM			Asymmetric cooperativity in a symmetric tetramer: Human hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ELECTRON-PARAMAGNETIC RESONANCE; QUATERNARY STRUCTURAL-CHANGE; MOLECULAR CODE; BINDING CASCADE; FREE-ENERGY; ALLOSTERY; DIMER; RESOLUTION; HYBRIDS; ALPHA(1)BETA(1)		Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Ackers, GK (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave,Box 8231, St Louis, MO 63110 USA.	ackers@wustl.edu						Ackers GK, 2000, PROTEINS, P23; ACKERS GK, 1974, P NATL ACAD SCI USA, V71, P4312, DOI 10.1073/pnas.71.11.4312; Ackers GK, 1998, ADV PROTEIN CHEM, V51, P185; Ackers GK, 2002, P NATL ACAD SCI USA, V99, P9777, DOI 10.1073/pnas.152225999; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; Balakrishnan G, 2004, J MOL BIOL, V340, P857, DOI 10.1016/j.jmb.2004.05.013; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BUNN HF, 1974, BIOCHEMISTRY-US, V13, P988, DOI 10.1021/bi00702a024; CASSOLY R, 1978, J BIOL CHEM, V253, P3602; Chang CK, 2002, BIOCHEMISTRY-US, V41, P5644, DOI 10.1021/bi011919d; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; Goldbeck RA, 2004, BIOCHEMISTRY-US, V43, P12065, DOI 10.1021/bi0493923; Goldbeck RA, 2004, BIOCHEMISTRY-US, V43, P12048, DOI 10.1021/bi049393v; Holt JM, 2005, BIOCHEMISTRY-US, V44, P11925, DOI 10.1021/bi050709o; Holt JM, 2005, BIOCHEMISTRY-US, V44, P11939, DOI 10.1021/bi050710n; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; Kavanaugh JS, 2005, BIOCHEMISTRY-US, V44, P6101, DOI 10.1021/bi047813a; KITAGISHI K, 1988, ARCH BIOCHEM BIOPHYS, V264, P176, DOI 10.1016/0003-9861(88)90583-8; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Lukin JA, 2004, CHEM REV, V104, P1219, DOI 10.1021/cr940325w; Mihailescu MR, 2001, P NATL ACAD SCI USA, V98, P3773, DOI 10.1073/pnas.071493598; MIURA S, 1980, J MOL BIOL, V143, P213, DOI 10.1016/0022-2836(80)90199-0; MIURA S, 1984, BIOCHEMISTRY-US, V23, P2492, DOI 10.1021/bi00306a027; Nichols WL, 1997, J MOL BIOL, V270, P598, DOI 10.1006/jmbi.1997.1087; Perrella M, 2004, BIOPHYS CHEM, V109, P201, DOI 10.1016/j.bpc.2003.11.003; Ramadas N, 1999, BIOPHYS J, V76, P1796, DOI 10.1016/S0006-3495(99)77340-6; SILVA MM, 1992, J BIOL CHEM, V267, P17248; Yonetani T, 2002, J BIOL CHEM, V277, P34508, DOI 10.1074/jbc.M203135200	28	38	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11441	11443		10.1074/jbc.R500019200	http://dx.doi.org/10.1074/jbc.R500019200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16423822	hybrid			2022-12-27	WOS:000236988100002
J	Dogra, C; Changotra, H; Mohan, S; Kumar, A				Dogra, C; Changotra, H; Mohan, S; Kumar, A			Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappa B and degradation of MyoD protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; CELL-CYCLE; MYOBLAST PROLIFERATION; SIGNALING PATHWAYS; MULTIPLE PATHWAYS; TNF SUPERFAMILY; KINASE-ACTIVITY; MESSENGER-RNA; TWEAK; DIFFERENTIATION	In this study we have investigated the effect and the mechanisms by which tumor necrosis factor-like weak inducer of apoptosis ( TWEAK) modulates myogenic differentiation. Treatment of C2C12 myoblasts with TWEAK inhibited their differentiation evident by a decrease in the expression of creatine kinase, myosin heavy chain-fast twitch, myogenin, and the formation of multinucleated myotubes. TWEAK also inhibited the differentiation of mouse primary myoblasts. Conversely, the proliferation of C2C12 myoblasts and the expression of a cell-cycle regulator cyclin D1 were increased in response to TWEAK treatment. Inhibition of cellular proliferation using hydroxyurea only partially reversed the inhibitory effect of TWEAK on myogenic differentiation. Treatment of C2C12 myoblasts with TWEAK resulted in the activation of nuclear factor-kappa B (NF-kappa B), the ( IkappaB) I kappa B kinase (IKK) complex, and the phosphorylation and degradation of I kappa B alpha protein. Inhibition of NF-kappa B activity by overexpression of a dominant negative mutant of I kappa B alpha (I kappa B alpha Delta N) significantly increased the myogenic differentiation in TWEAK-treated C2C12 cultures. Furthermore, overexpression of a dominant negative mutant of IKK beta (IKK beta K44A) but not IKK alpha (IKK alpha K44M) reversed the inhibitory effect of TWEAK onmyogenesis. TWEAK inhibited the expression of myogenic regulatory factors MyoD and myogenin and also induced the degradation of MyoD protein. Finally, inhibition of NF-kappa B activation through overexpression of IKK beta K44A prevented the degradation of MyoD protein. Overall, our data suggest that TWEAK inhibits myogenesis through the activation of NF-kappa B signaling pathway and degradation of MyoD protein.	Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Div Mol Genet, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Div Mol Genet, 11201 Benton St 151, Loma Linda, CA 92357 USA.	Ashok.Kumar2@med.va.gov	Changotra, Harish/H-2105-2011	Changotra, Harish/0000-0002-1465-5257; Kumar, Ashok/0000-0001-8571-2848				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal Bharat B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P327, DOI 10.2174/1568010023344571; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; CARUSO M, 1993, ONCOGENE, V8, P267; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Desplat-Jego S, 2002, J NEUROIMMUNOL, V133, P116, DOI 10.1016/S0165-5728(02)00368-5; Di Marco S, 2005, MOL CELL BIOL, V25, P6533, DOI 10.1128/MCB.25.15.6533-6545.2005; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GUO K, 1995, MOL CELL BIOL, V15, P3823; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; GUTTRIDGE DC, 2000, SCIENCE, V289, P2363, DOI [10.1126/sci-ence.289.5488.2363, DOI 10.1126/SCI-ENCE.289.5488.2363, DOI 10.1126/science.289.5488.2363, DOI 10.1126/SCIENCE.289.5488.2363]; Han SY, 2003, BIOCHEM BIOPH RES CO, V305, P789, DOI 10.1016/S0006-291X(03)00852-0; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kawakita T, 2005, INT J ONCOL, V26, P87; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kim SH, 2004, CIRC J, V68, P396, DOI 10.1253/circj.68.396; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kumar A, 2003, FASEB J, V17, P1800, DOI 10.1096/fj.02-1148com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; Kumar A, 1998, J IMMUNOL, V161, P776; Kumar A, 2005, J BIOL CHEM, V280, P37782, DOI 10.1074/jbc.M505278200; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Maecker H, 2005, CELL, V123, P931, DOI 10.1016/j.cell.2005.09.022; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Masinde Godfred L, 2002, Funct Integr Genomics, V2, P120, DOI 10.1007/s10142-002-0067-1; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Xu HR, 2004, BIOCHEM BIOPH RES CO, V318, P422, DOI 10.1016/j.bbrc.2004.04.036; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	74	128	131	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10327	10336		10.1074/jbc.M511131200	http://dx.doi.org/10.1074/jbc.M511131200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16461349	hybrid			2022-12-27	WOS:000236594300061
J	Williams, MV; Lee, SH; Pollack, M; Blair, IA				Williams, MV; Lee, SH; Pollack, M; Blair, IA			Endogenous lipid hydroperoxide-mediated DNA-adduct formation in min mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; FAMILIAL ADENOMATOUS POLYPOSIS; LIQUID-CHROMATOGRAPHY; HUMAN URINE; MALONDIALDEHYDE-2'-DEOXYGUANOSINE ADDUCT; 1,N-2-ETHENO-2'-DEOXYGUANOSINE ADDUCTS; BIFUNCTIONAL ELECTROPHILES; CYCLOOXYGENASE-2 LEVELS; CIGARETTE-SMOKING; ARACHIDONIC-ACID	Despite intensive research over the last two decades, there are still no specific markers of endogenous lipid hydroperoxide-mediated DNA damage. We recently demonstrated that heptanoneetheno-2'-deoxyguanosine adducts are formed in the DNA of rat intestinal epithelial cells that stably express cyclooxygenase-2. Heptanone-etheno adducts can only arise from the reaction of lipid hydroperoxide-derived 4-oxo-2(E)-nonenal with DNA. This raised the possibility that similar adducts would be formed in vivo in settings where cyclooxygenase-2 expression is increased. Therefore, DNA-adduct formation was studied in C57BL/6JAPC(min) mice, a colorectal cancer mouse model in which cyclooxygenase-2 is up-regulated. 15(S)-Hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid is the major lipid hydroperoxide produced endogenously by cyclooxygenase-2. It undergoes homolytic decomposition to the DNA-reactive bifunctional electrophile4-oxo-2(E)-nonenal, which forms heptanone-etheno adducts with DNA. A quantitative comparison was made of the heptanone-etheno-DNA adducts present in C57BL/6J and C57BL/6JAPC(min) mice. Using highly specific and sensitive methodology based on stable isotope dilution liquid chromatography/tandem mass spectrometry, we have detected the endogenous formation of heptanone-etheno adducts in mammalian tissue DNA for the first time. In addition, we found that there were statistically significant increased levels of the heptanone-etheno-2'- deoxyguanosine and heptanone-etheno-2'-deoxycytidine adducts in the C57BL/6JAPC(min) mice when compared with the control C57BL/6J mice.	Univ Penn, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Blair, IA (corresponding author), Univ Penn, Ctr Canc Pharmacol, 854 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	ian@spirit.gcrc.upenn.edu	Blair, Ian A/B-3320-2010	Lee, Seon Hwa/0000-0003-1095-5516	NATIONAL CANCER INSTITUTE [R01CA091016] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 91016] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka S, 1999, CHEM RES TOXICOL, V12, P501, DOI 10.1021/tx980259j; BARBIN A, 1986, CHEM-BIOL INTERACT, V59, P43, DOI 10.1016/S0009-2797(86)80054-0; Barnes CJ, 1998, GASTROENTEROLOGY, V114, P873, DOI 10.1016/S0016-5085(98)70305-1; BOLT HM, 1988, CRIT REV TOXICOL, V18, P299, DOI 10.3109/10408448809037469; Carvalho VM, 2000, CHEM RES TOXICOL, V13, P397, DOI 10.1021/tx9901682; CHANDHARY AK, 1994, BIOL MASS SPECTROM, V23, P457, DOI 10.1002/bms.1200230802; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chen HJC, 2004, CHEM RES TOXICOL, V17, P963, DOI 10.1021/tx0341963; Chen HJC, 2004, CHEM RES TOXICOL, V17, P896, DOI 10.1021/tx0342013; Chen HJC, 2003, TOXICOL SCI, V76, P321, DOI 10.1093/toxsci/kfg219; Chen HJC, 1996, CHEM RES TOXICOL, V9, P306, DOI 10.1021/tx9501389; Chen HJC, 1998, CHEM RES TOXICOL, V11, P1474, DOI 10.1021/tx980107o; Chen HJC, 1999, CHEM RES TOXICOL, V12, P1119, DOI 10.1021/tx990074s; Chulada PC, 2000, CANCER RES, V60, P4705; Doerge DR, 2000, CHEM RES TOXICOL, V13, P1259, DOI 10.1021/tx0001575; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Egner PA, 2003, MUTAT RES-FUND MOL M, V523, P209, DOI 10.1016/S0027-5107(02)00337-8; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gonzalez-Reche LM, 2002, TOXICOL LETT, V134, P71, DOI 10.1016/S0378-4274(02)00165-0; Ham AJL, 2004, DNA REPAIR, V3, P257, DOI 10.1016/j.dnarep.2003.11.003; Ham AJL, 1999, CHEM RES TOXICOL, V12, P1240, DOI 10.1021/tx990150r; HECKER M, 1989, J BIOL CHEM, V264, P141; Hillestrom PR, 2004, FREE RADICAL BIO MED, V36, P1383, DOI 10.1016/j.freeradbiomed.2004.02.068; Hoberg AM, 2004, J MASS SPECTROM, V39, P38, DOI 10.1002/jms.547; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Jian WY, 2005, FREE RADICAL BIO MED, V39, P1162, DOI 10.1016/j.freeradbiomed.2005.06.008; Jian WY, 2005, CHEM RES TOXICOL, V18, P599, DOI 10.1021/tx049693d; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P698, DOI 10.1016/j.freeradbiomed.2004.09.017; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2005, J BIOL CHEM, V280, P28337, DOI 10.1074/jbc.M504178200; Lee SH, 2005, CHEM RES TOXICOL, V18, P780, DOI 10.1021/tx0497088; Lee SH, 2002, CHEM RES TOXICOL, V15, P300, DOI 10.1021/tx010147j; Levine RL, 2000, CANCER RES, V60, P4098; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Loureiro APM, 2000, CHEM RES TOXICOL, V13, P601, DOI 10.1021/tx000004h; Loureiro APM, 2002, CHEM RES TOXICOL, V15, P1302, DOI 10.1021/tx025554p; Mahmoud NN, 1998, SURGERY, V124, P225, DOI 10.1016/S0039-6060(98)70124-2; Otteneder M, 2003, ANAL BIOCHEM, V315, P147, DOI 10.1016/S0003-2697(02)00697-8; Petrik MBH, 2000, J NUTR, V130, P1153, DOI 10.1093/jn/130.5.1153; Pollack M, 2003, CHEM RES TOXICOL, V16, P893, DOI 10.1021/tx030009p; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Rindgen D, 2000, CHEM RES TOXICOL, V13, P846, DOI 10.1021/tx0000771; Roberts DW, 2001, ANAL CHEM, V73, P303, DOI 10.1021/ac000866n; Rouzer CA, 1997, CHEM RES TOXICOL, V10, P181, DOI 10.1021/tx9601216; Sansom OJ, 2001, CANCER RES, V61, P7060; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Swenberg JA, 1999, IARC SCI PUBL, P29; Thun MJ, 1996, GASTROENTEROL CLIN N, V25, P333, DOI 10.1016/S0889-8553(05)70250-8; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams MV, 2005, RAPID COMMUN MASS SP, V19, P849, DOI 10.1002/rcm.1854; Yen TY, 1998, CHEM RES TOXICOL, V11, P810, DOI 10.1021/tx9800194; Zhou XF, 2005, J BIOL CHEM, V280, P25377, DOI 10.1074/jbc.M503079200	65	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10127	10133		10.1074/jbc.M600178200	http://dx.doi.org/10.1074/jbc.M600178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16449227	hybrid			2022-12-27	WOS:000236594300038
J	Atoda, H; Yokota, E; Morita, T				Atoda, H; Yokota, E; Morita, T			Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUSSELLS VIPER VENOM; CLOTTING FACTOR-IX; BINDING-PROTEIN; POSTTRANSLATIONAL MODIFICATIONS; TRIMERESURUS-FLAVOVIRIDIS; GLA DOMAIN; SITE	Blood coagulation factor IX (FIX) undergoes various post-translational modifications such as gamma-carboxylation and glycosylation. Non-phosphorylated recombinant FIX has been reported to rapidly disappear from plasma, indicating that phosphorylation of FIX plays an important role in the physiological activity of this coagulation factor. In this study, we characterized the human FIX activation peptide (AP) using a monoclonal antibody that recognizes phosphorylated Ser-158 in the AP region. Murine monoclonal antibody B1 against human FIX recognized FIX with an apparent K-d value of 5 nM in the presence of Ca2+ (EC50 = 0.58 mM). B1 bound to the isolated AP of FIX and retained the Ca2+ dependence of binding to the isolated AP. The deglycosylation of AP did not affect the binding of B1 to AP, while B1 failed to bind to recombinant AP expressed in Escherichia coli. MALDI-TOF mass spectrometry showed that the m/z of plasma-derived deglycosylated AP is 82.54 Da greater than that of recombinant AP. The binding ability of B1 to AP was lost by the dephosphorylation of plasma-derived AP. B1 bound to synthetic peptide AP-(5-19), including phosphoserine-13, but not to the non-phosphorylated AP-(5-19) in the presence of Ca2+. These data provide direct evidence that Ser-13 of the plasma-derived FIX AP region (Ser-158 of FIX) is phosphorylated and that B1 recognizes the epitope, which includes Ca2+-bound phosphoserine-158. B1 should be useful in the quality control of biologically active recombinant FIX containing phosphoserine-158.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	Meiji Pharmaceutical University	Morita, T (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, 2-522-1 Noshio, Tokyo 2048588, Japan.	tmorita@my-pharm.ac.jp						AGARWALA KL, 1994, BIOCHEMISTRY-US, V33, P5167, DOI 10.1021/bi00183a021; Arruda VR, 2001, BLOOD, V97, P130, DOI 10.1182/blood.V97.1.130; ATODA H, 1995, J BIOCHEM-TOKYO, V118, P965, DOI 10.1093/jb/118.5.965; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; Cheung WF, 1996, THROMB RES, V81, P65, DOI 10.1016/0049-3848(95)00214-6; HAMAGUCHI N, 1991, J BIOL CHEM, V266, P15213; Kaufman RJ, 1998, THROMB HAEMOSTASIS, V79, P1068; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; Kurachi S, 1999, SCIENCE, V285, P739, DOI 10.1126/science.285.5428.739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; Makino Y, 2000, J BIOCHEM-TOKYO, V128, P175, DOI 10.1093/oxfordjournals.jbchem.a022738; Schmidt AE, 2005, J MOL BIOL, V350, P78, DOI 10.1016/j.jmb.2005.04.052; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUEHIRO K, 1989, J BIOL CHEM, V264, P21257; White GC, 1997, THROMB HAEMOSTASIS, V78, P261; Yang LK, 2004, J BIOL CHEM, V279, P38519, DOI 10.1074/jbc.M407304200; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	21	8	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9314	9320		10.1074/jbc.M512940200	http://dx.doi.org/10.1074/jbc.M512940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467297	hybrid			2022-12-27	WOS:000236404700039
J	Lack, G; Homberger-Zizzari, E; Folkers, G; Scapozza, L; Perozzo, R				Lack, G; Homberger-Zizzari, E; Folkers, G; Scapozza, L; Perozzo, R			Recombinant expression and biochemical characterization of the unique elongating beta-ketoacyl-acyl carrier protein synthase involved in fatty acid biosynthesis of Plasmodium falciparum using natural and artificial substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; GLOBAL DISTRIBUTION; CONDENSING ENZYMES; THIOLACTOMYCIN; MALARIA; SYNTHETASE; CERULENIN; TARGETS; APICOMPLEXAN	The human malaria parasite Plasmodium falciparum synthesizes fatty acids by using a type II synthase that is structurally different from the type I system found in eukaryotes. Because of this difference and the vital role of fatty acids, the enzymes involved in fatty acid biosynthesis of P. falciparum represent interesting targets for the development of new antimalarial drugs. beta-Ketoacyl-acyl carrier protein (ACP) synthase (PfFabBF), being the only elongating beta-ketoacyl-ACP synthase in P. falciparum, is a potential candidate for inhibition. In this study we present the cloning, expression, purification, and characterization of PfFabBF. Soluble protein was obtained when PfFabBF was expressed as a NusA fusion protein in Escherichia coli BL21(DE3)-CodonPlus-RIL cells under conditions of osmotic stress. The fusion protein was purified by affinity and ion exchange chromatography. Various acyl-P. falciparum acyl carrier protein (PfACP) substrates were tested for their specific activities, and their kinetic parameters were determined. Activity of PfFabBF was highest with C-4:0- to C-10:0- acyl-PfACPs and decreased with use of longer chain acyl-PfACPs. Consistent with the fatty acid synthesis profile found in the parasite cell, no activity could be detected with C-16:0- PfACP, indicating that the enzyme is lacking the capability of elongating acyl chains that are longer than 14 carbon atoms. PfFabBF was found to be specific for acyl-PfACPs, and it displayed much lower activities with the corresponding acyl-CoAs. Furthermore, PfFabBF was shown to be sensitive to cerulenin and thiolactomycin, known inhibitors of beta-ketoacyl-ACP synthases. These results represent an important step toward the evaluation of P. falciparum beta-ketoacyl-ACP synthase as a novel antimalaria target.	Univ Geneva, Univ Lausanne, Sch Pharmaceut Sci,Pharmaceut Biochem Grp, Lab Chim Therapeut,Sect Sci Pharmaceut, CH-1211 Geneva 4, Switzerland; Swiss Fed Inst Technol, Dept Chem & Appl BioSci, CH-8057 Zurich, Switzerland; Univ Zurich, Coll Helveticum, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland	University of Geneva; University of Lausanne; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Perozzo, R (corresponding author), Univ Geneva, Univ Lausanne, Sch Pharmaceut Sci,Pharmaceut Biochem Grp, Lab Chim Therapeut,Sect Sci Pharmaceut, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	remo.perozzo@pharm.unige.ch		Folkers, Gerd/0000-0002-3620-705X; Scapozza, Leonardo/0000-0003-1079-648X				ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Chopra S, 2002, ACTA CRYSTALLOGR D, V58, P179, DOI 10.1107/S0907444901019874; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; Domergue F, 2000, BIOCHEM SOC T, V28, P610, DOI 10.1042/BST0280610; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; Gornicki P, 2003, INT J PARASITOL, V33, P885, DOI 10.1016/S0020-7519(03)00133-4; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Jones AL, 2000, BIOCHEM J, V347, P205, DOI 10.1042/0264-6021:3470205; Jones SM, 2004, BIOORGAN MED CHEM, V12, P683, DOI 10.1016/j.bmc.2003.11.023; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; McGuire KA, 2001, BIOCHEMISTRY-US, V40, P9836, DOI 10.1021/bi0105577; NISHIDA I, 1986, J BIOCHEM-TOKYO, V99, P1447, DOI 10.1093/oxfordjournals.jbchem.a135614; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Prigge ST, 2003, BIOCHEMISTRY-US, V42, P1160, DOI 10.1021/bi026847k; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 2003, ANTIMICROB AGENTS CH, V47, P297, DOI 10.1128/AAC.47.1.297-301.2003; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Waters NC, 2002, MOL BIOCHEM PARASIT, V123, P85, DOI 10.1016/S0166-6851(02)00140-8	43	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9538	9546		10.1074/jbc.M509119200	http://dx.doi.org/10.1074/jbc.M509119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467310	hybrid			2022-12-27	WOS:000236404700064
J	Nakaya, M; Tanaka, M; Okabe, Y; Hanayama, R; Nagata, S				Nakaya, M; Tanaka, M; Okabe, Y; Hanayama, R; Nagata, S			Opposite effects of Rho family GTPases on engulfment of apoptotic cells by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRKII/DOCK180/RAC PATHWAY; PHAGOCYTOSIS; DEATH; IDENTIFICATION; EXPRESSION; MIGRATION; RAC; MECHANISMS; CLEARANCE	The efficient engulfment of apoptotic cells by professional or nonprofessional phagocytes is critical to maintain mammalian homeostasis. To identify molecules involved in the engulfment of apoptotic cells, we established a retrovirus-based expression cloning system coupled with the engulfment assay. By screening a cDNA library of a mouse macrophage cell line, we identified two small GTPase family members (RhoG and Rab5) that enhanced the engulfment of apoptotic cells. By examining other small GTPase family members, we found that Rac1 enhanced the engulfment of apoptotic cells, whereas RhoA inhibited the process. Accordingly, the expression of a dominant-negative form of RhoG or Rac1 in primary macrophage cultures severely reduced the ability of the macrophages to engulf apoptotic cells, and a dominant-negative form of RhoA enhanced the process. These results indicated that the efficient engulfment of apoptotic cells requires the concerted action of small GTPase family members. We demonstrated previously that NIH3T3 cells expressing the alpha(v)beta(3) integrin efficiently engulf apoptotic cells in the presence of milk fat globule epidermal growth factor 8 via a phosphatidylserine-dependent mechanism. The dominant-negative form of RhoG or Rac1 inhibited this process, which suggested RhoG and Rac1 are also involved in the integrin-mediated engulfment.	Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Integrated Biol Labs, Genet Lab, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan; RIKEN Res Ctr Allergy & Immunol, Lab Innate Cellular Immun, Kanagawa 2300045, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); RIKEN	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, B-3,2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	nagata@genetic.med.osaka-u.ac.jp	Nagata, Shigekazu/AAG-3203-2019; Hanayama, Rikinari/D-2940-2011; Hanayama, Rikinari/AAO-4959-2021	Nagata, Shigekazu/0000-0001-9758-8426; Hanayama, Rikinari/0000-0003-2102-3386; Okabe, Yasutaka/0000-0002-1913-7280				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; DeBakker CD, 2004, CURR BIOL, V14, P2208, DOI 10.1016/j.cub.2004.12.029; Debidda M, 2005, J BIOL CHEM, V280, P17275, DOI 10.1074/jbc.M413187200; ELLIS RE, 1991, GENETICS, V129, P79; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Hanayama R, 2004, J IMMUNOL, V172, P3876, DOI 10.4049/jimmunol.172.6.3876; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Miyasaka K, 2004, EUR J IMMUNOL, V34, P1414, DOI 10.1002/eji.200424930; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagata S, 2005, ANNU REV IMMUNOL, V23, P853, DOI 10.1146/annurev.immunol.23.021704.115811; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OHKI K, 1983, J CELL PHYSIOL, V114, P291, DOI 10.1002/jcp.1041140307; Onishi M, 1996, EXP HEMATOL, V24, P324; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Tada K, 2003, J IMMUNOL, V171, P5718, DOI 10.4049/jimmunol.171.11.5718; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tosello-Trampont AC, 2003, J BIOL CHEM, V278, P49911, DOI 10.1074/jbc.M306079200; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	40	119	121	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8836	8842		10.1074/jbc.M510972200	http://dx.doi.org/10.1074/jbc.M510972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16439364	hybrid			2022-12-27	WOS:000236247100063
J	Short, KM; Cox, TC				Short, KM; Cox, TC			Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; SYNDROME GENE-PRODUCT; RING FINGER PROTEIN; OPITZ-SYNDROME; MULIBREY NANISM; MID1; IDENTIFICATION; ENCODES; FAMILY; MUTATIONS	The biological significance of RBCC (N-terminal (R) under bar ING finger/ (B) under bar -box/(c) under bar oiled (c) under bar oil) proteins is increasingly being appreciated following demonstrated roles in disease pathogenesis, tumorigenesis, and retroviral protective activity. Found in all multicellular eukaryotes, RBCC proteins are involved in a vast array of intracellular functions; but as a general rule, they appear to function as part of large protein complexes and possess ubiquitin-protein isopeptide ligase activity. Those members characterized to date have diverse C-terminal domain compositions and equally diverse subcellular localizations and functions. Using a bioinformatics approach, we have identified some new RBCC proteins that help define a subfamily that shares an identical domain arrangement (MID1, MID2, TRIM9, TNL, TRIM36, and TRIFIC). Significantly, we show that all analyzed members of this subfamily associate with the microtubule cytoskeleton, suggesting that subcellular compartmentalization is determined by the unique domain architecture, which may in turn reflect basic functional similarities. We also report a new motif called the COS box, which is found within these proteins, the MURF family, and a distantly related non-RBCC microtubule-binding protein. Notably, we demonstrate that mutations in the COS box abolish microtubule binding ability, whereas its incorporation into a non-microtubule-binding RBCC protein redirects it to microtubule structures. Further bioinformatics investigation permitted subclassification of the entire human RBCC complement into nine subfamilies based on their varied C-terminal domain compositions. This classification schema may aid the understanding of the molecular function of members of each subgroup and their potential involvement in both basic cellular processes and human disease.	Monash Univ, Dept Anat & Cell Biol, Clayton, Vic 3800, Australia; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	Monash University; University of Adelaide	Cox, TC (corresponding author), Monash Univ, Dept Anat & Cell Biol, Bldg 13C,Rm C180, Clayton, Vic 3800, Australia.	timothy.cox@med.monash.edu.au	Short, Kieran/O-4476-2019; Short, Kieran/A-2604-2012	Short, Kieran/0000-0001-9137-008X; Short, Kieran/0000-0001-9137-008X				Attwood TK, 2003, NUCLEIC ACIDS RES, V31, P400, DOI 10.1093/nar/gkg030; Balint I, 2004, GENE, V332, P45, DOI 10.1016/j.gene.2004.02.045; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BENNER SA, 1994, PROTEIN ENG, V7, P1323, DOI 10.1093/protein/7.11.1323; Berti C, 2002, MECH DEVELOP, V113, P159, DOI 10.1016/S0925-4773(02)00013-8; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Carim-Todd L, 2001, BBA-GENE STRUCT EXPR, V1518, P200, DOI 10.1016/S0167-4781(01)00178-6; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Cox TC, 2000, HUM MOL GENET, V9, P2553, DOI 10.1093/hmg/9.17.2553; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FELSENSTEIN J, 2004, PHYLIP VERSION 3 62; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kallijarvi J, 2005, EXP CELL RES, V308, P146, DOI 10.1016/j.yexcr.2005.04.001; Kallijarvi J, 2002, AM J HUM GENET, V70, P1215, DOI 10.1086/340256; Kitamura K, 2003, J BIOL CHEM, V278, P44417, DOI 10.1074/jbc.M304306200; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Manabe R, 2002, CURR BIOL, V12, P1946, DOI 10.1016/S0960-9822(02)01299-X; MORGAN K, 2005, CURRENT PROTOCOLS CE; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Perry J, 1999, GENOMICS, V62, P385, DOI 10.1006/geno.1999.6043; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rhodes DA, 2002, IMMUNOLOGY, V106, P246, DOI 10.1046/j.1365-2567.2002.01417.x; Schweiger S, 1999, P NATL ACAD SCI USA, V96, P2794, DOI 10.1073/pnas.96.6.2794; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; Stein PA, 2002, J CELL SCI, V115, P3389; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Truong K, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-1; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200	43	223	235	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8970	8980		10.1074/jbc.M512755200	http://dx.doi.org/10.1074/jbc.M512755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16434393	hybrid			2022-12-27	WOS:000236247100077
J	Jones, EM; Surewicz, K; Surewicz, WK				Jones, EM; Surewicz, K; Surewicz, WK			Role of N-terminal familial mutations in prion protein fibrillization and prion amyloid propagation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; VARIANT CJD; CONFORMATIONAL CONVERSION; THERMODYNAMIC STABILITY; POLYMORPHISM; TRANSMISSION; GENERATION; EXPRESSION; MECHANISM; INSERTION	A self-perpetuating conformational conversion of the prion protein (PrP) is believed to underlie pathology and transmission of prion diseases. Here we explore the effects of N-terminal pathogenic mutations (P102L, P105L, A117V) and the residue 129 polymorphism on amyloid fibril formation by the human PrP fragment 23 - 144, an in vitro conversion model that can reproduce certain characteristics of prion replication such as strains and species barriers. We find that these amino acid substitutions neither affect PrP23 - 144 amyloidogenicity nor introduce barriers to cross-seeding of soluble protein. However, the polymorphism strongly influences the conformation of the amyloid fibrils, as determined by infrared spectroscopy. Intriguingly, unlike conformational features governed by the critical amyloidogenic region of PrP23 - 144 ( residues 138 - 139), the structural features distinguishing Met-129 and Val-129 PrP23 - 144 amyloid fibrils are not transmissible by cross-seeding. While based only on in vitro data, these findings provide fundamental insight into the mechanism of prion-based conformational transmission, indicating that only conformational features controlling seeding specificity ( e. g. those in critical intermolecular contact sites of amyloid fibrils) are necessarily transmissible by cross-seeding; conformational traits in other parts of the PrP molecule may not be "heritable" from the amyloid template.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	witold.surewicz@case.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044158] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 44158] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Apetri AC, 2005, BIOCHEMISTRY-US, V44, P15880, DOI 10.1021/bi051455+; Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Bruce M E, 1991, Curr Top Microbiol Immunol, V172, P125; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Dzwolak W, 2004, PROTEIN SCI, V13, P1927, DOI 10.1110/ps.03607204; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; KAZMIRSKI SL, 1995, CHEM BIOL, V2, P305, DOI 10.1016/1074-5521(95)90049-7; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KITAMOTO T, 1994, PHILOS T R SOC B, V343, P391, DOI 10.1098/rstb.1994.0034; Kong Qingzhong, 2004, VVolume 41, P673; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Mishra RS, 2002, J BIOL CHEM, V277, P24554, DOI 10.1074/jbc.M200213200; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Okimoto N, 2002, BIOPHYS J, V82, P2746, DOI 10.1016/S0006-3495(02)75615-4; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; Priola SA, 2001, ADV PROTEIN CHEM, V57, P1; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Puoti G, 2000, ANN NEUROL, V48, P269, DOI 10.1002/1531-8249(200008)48:2<269::AID-ANA24>3.3.CO;2-M; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; Uelhoff A, 2005, J BIOL CHEM, V280, P5137, DOI 10.1074/jbc.C400560200; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932; Weissmann C, 2005, CELL, V122, P165, DOI 10.1016/j.cell.2005.07.001; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; Yamaguchi K, 2005, J MOL BIOL, V352, P952, DOI 10.1016/j.jmb.2005.07.061; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904	55	32	32	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8190	8196		10.1074/jbc.M513417200	http://dx.doi.org/10.1074/jbc.M513417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16443601	hybrid			2022-12-27	WOS:000236031000058
J	Hong, HD; Patel, DR; Tamm, LK; van den Berg, B				Hong, HD; Patel, DR; Tamm, LK; van den Berg, B			The outer membrane protein OmpW forms an eight-stranded beta-barrel with a hydrophobic channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEOMIC ANALYSIS; ENZYME PAGP; EXPRESSION; SEQUENCE; PORE; REPLACEMENT; DYNAMICS	Escherichia coli OmpW belongs to a family of small outer membrane proteins that are widespread in Gram-negative bacteria. Their functions are unknown, but recent data suggest that they may be involved in the protection of bacteria against various forms of environmental stress. To gain insight into the function of these proteins we have determined the crystal structure of E. coli OmpW to 2.7-angstrom resolution. The structure shows that OmpW forms an 8-stranded beta-barrel with a long and narrow hydrophobic channel that contains a bound n-dodecyl-N, N-dimethylamine-N-oxide detergent molecule. Single channel conductance experiments show that Omp W functions as an ion channel in planar lipid bilayers. The channel activity can be blocked by the addition of n-dodecyl-N, N-dimethylamine-N-oxide. Taken together, the data suggest that members of the Omp W family could be involved in the transport of small hydrophobic molecules across the bacterial outer membrane.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Virginia; University of Massachusetts System; University of Massachusetts Worcester	van den Berg, B (corresponding author), 373 Plantat St, Worcester, MA 01605 USA.	bert.vandenberg@umassmed.edu	Hong, Heedeok/E-9231-2018	Hong, Heedeok/0000-0003-0118-5193; van den Berg, Bert/0000-0003-1966-8804	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051329, R01GM074824] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 051329, GM 074824, R01 GM051329] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn VE, 2004, EMBO J, V23, P2931, DOI 10.1038/sj.emboj.7600320; Arora A, 2000, J BIOL CHEM, V275, P1594, DOI 10.1074/jbc.275.3.1594; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENZ R, 1988, EUR J BIOCHEM, V176, P699, DOI 10.1111/j.1432-1033.1988.tb14333.x; Bond PJ, 2002, BIOPHYS J, V83, P763, DOI 10.1016/S0006-3495(02)75207-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busch Wolfgang, 2003, Methods Mol Biol, V227, P21, DOI 10.1385/1-59259-387-9:21; Das M, 1998, FEMS IMMUNOL MED MIC, V22, P303, DOI 10.1111/j.1574-695X.1998.tb01219.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2002, PYMOL USERS MANUAL; EATON RW, 1994, J BACTERIOL, V176, P7757, DOI 10.1128/JB.176.24.7757-7762.1994; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hamilton JA, 2003, CURR OPIN LIPIDOL, V14, P263, DOI 10.1097/00041433-200306000-00006; Ho EM, 2004, CURR MICROBIOL, V49, P346, DOI 10.1007/s00284-004-4322-7; Hu WS, 2005, ANTIMICROB AGENTS CH, V49, P3955, DOI 10.1128/AAC.49.9.3955-3958.2005; Hwang PM, 2004, P NATL ACAD SCI USA, V101, P9618, DOI 10.1073/pnas.0402324101; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; JALAJAKUMARI MB, 1990, NUCLEIC ACIDS RES, V18, P2180, DOI 10.1093/nar/18.8.2180; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; MAIER C, 1988, J BIOL CHEM, V263, P2493; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nandi B, 2005, MICROBIOL-SGM, V151, P2975, DOI 10.1099/mic.0.27995-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pilsl H, 1999, J BACTERIOL, V181, P3578, DOI 10.1128/JB.181.11.3578-3581.1999; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; Soderblom T, 2005, CELL MICROBIOL, V7, P779, DOI 10.1111/j.1462-5822.2005.00510.x; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Tamm LK, 2003, FEBS LETT, V555, P139, DOI 10.1016/S0014-5793(03)01127-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van den Berg B, 2005, CURR OPIN STRUC BIOL, V15, P401, DOI 10.1016/j.sbi.2005.06.003; van den Berg B, 2004, SCIENCE, V304, P1506, DOI 10.1126/science.1097524; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; Vandeputte-Rutten L, 2003, J BIOL CHEM, V278, P24825, DOI 10.1074/jbc.M302803200; Xu CG, 2005, PROTEOMICS, V5, P3142, DOI 10.1002/pmic.200401128; Xu CX, 2004, RES MICROBIOL, V155, P835, DOI 10.1016/j.resmic.2004.07.001; Ye JQ, 2004, EMBO J, V23, P3187, DOI 10.1038/sj.emboj.7600330	42	160	174	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7568	7577		10.1074/jbc.M512365200	http://dx.doi.org/10.1074/jbc.M512365200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16414958	hybrid			2022-12-27	WOS:000236030900078
J	Lu, XH; Gross, AW; Lodish, HF				Lu, XH; Gross, AW; Lodish, HF			Active conformation of the erythropoietin receptor - Random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; SIGNAL-TRANSDUCTION; INDEPENDENT ACTIVATION; ENDOPLASMIC-RETICULUM; PSEUDOKINASE DOMAIN; POINT MUTATION; LIGAND; JAK2; GENERATION; RESIDUES	In the absence of erythropoietin (Epo) cell surface Epo receptors (EpoR) are dimeric; dimerization is mediated mainly by the transmembrane domain. Binding of Epo changes the orientation of the two receptor subunits. This conformational change is transmitted through the juxtamembrane and transmembrane domains, leading to activation of JAK2 kinase and induction of proliferation and survival signals. To define the active EpoR conformation(s) we screened libraries of EpoRs with random mutations in the transmembrane domain and identified several point mutations that activate the EpoR in the absence of ligand, including changes of either of the first two transmembrane domain residues (Leu(226) and Ile(227)) to cysteine. Following this discovery, we performed cysteine-scanning mutagenesis in the EpoR juxtamembrane and transmembrane domains. Many mutants formed disulfide-linked receptor dimers, but only EpoR dimers linked by cysteines at positions 223, 226, or 227 activated EpoR signal transduction pathways and supported proliferation of Ba/F3 cells in the absence of cytokines. These data suggest that activation of dimeric EpoR by Epo binding is achieved by reorienting the EpoR transmembrane and the connected cytosolic domains and that certain disulfide-bonded dimers represent the activated dimeric conformation of the EpoR, constitutively activating downstream signaling. Based on our data and the previously determined structure of Epo bound to a dimer of the EpoR extracellular domain, we present a model of the active and inactive conformations of the Epo receptor.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu			NHLBI NIH HHS [P01 HL 32262, 5F32 HL 077036] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL077036, P01HL032262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe M, 2002, LEUKEMIA, V16, P1500, DOI 10.1038/sj.leu.2402554; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	29	75	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7002	7011		10.1074/jbc.M512638200	http://dx.doi.org/10.1074/jbc.M512638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16414957	hybrid			2022-12-27	WOS:000236030900013
J	Durham, JT; Brand, OM; Arnold, M; Reynolds, JG; Muthukumar, L; Weiler, H; Richardson, JA; Naya, FJ				Durham, JT; Brand, OM; Arnold, M; Reynolds, JG; Muthukumar, L; Weiler, H; Richardson, JA; Naya, FJ			Myospryn is a direct transcriptional target for MEF2A that encodes a striated muscle, alpha-actinin-interacting, costamere-localized protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER; DOMAIN; HEART; DIFFERENTIATION; REQUIREMENT; EXPRESSION; DEFICIENT; MUTATIONS; DYSBINDIN; FORM	The full repertoire of proteins that comprise the striated muscle Z-disc and peripheral structures, such as the costamere, have yet to be discovered. Recent studies suggest that this elaborate protein network, which acts as a structural and signaling center for striated muscle, harbors factors that function as mechanosensors to ensure coordinated contractile activity. Mutations in genes whose products reside in this region often result in skeletal and cardio myopathies, demonstrating the importance of this macromolecular complex in muscle structure and function. Here, we describe the characterization of a direct, downstream target gene for the MEF2A transcription factor encoding a large, muscle-specific protein that localizes to the costamere in striated muscle. This gene, called myospryn, was identified by microarray analysis as a transcript down-regulated in MEF2A knock-out mice. MEF2A knock-out mice develop cardiac failure during the perinatal period with mutant hearts exhibiting several cardiac abnormalities including myofibrillar disarray. Myospryn is the mouse ortholog of a partial human cDNA of unknown function named cardiomyopathy-associated gene 5 (CMYA5). Myospryn is expressed as a single, large transcript of similar to 12 kilobases in adult heart and skeletal muscle with an open reading frame of 3739 amino acids. This protein, belonging to the tripartite motif superfamily of proteins, contains a B-box coiled-coil ( BBC), two fibronectin type III (FN3) repeats, and SPRY domains and interacts with the sarcomeric Z-disc protein, alpha-actinin-2. Our findings demonstrate that myospryn functions directly downstream of MEF2A at the costamere in striated muscle potentially playing a role in myofibrillogenesis.	Boston Univ, Dept Biol, Cell & Mol Biol Program, Boston, MA 02215 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Med Coll Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA	Boston University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Medical College of Wisconsin; Versiti Blood Center of Wisconsin	Naya, FJ (corresponding author), Boston Univ, Dept Biol, Cell & Mol Biol Program, 24 Cummington St, Boston, MA 02215 USA.	fnaya@bu.edu	Arnold, Michael/GPW-8074-2022	Arnold, Michael/0000-0002-6921-3720	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073304] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73304] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Benson MA, 2004, J BIOL CHEM, V279, P10450, DOI 10.1074/jbc.M312664200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; GONZALEZ P, 2005, IN PRESS J MED GENET; Hauser MA, 2000, HUM MOL GENET, V9, P2141, DOI 10.1093/hmg/9.14.2141; Kajimoto K, 2005, CIRC J, V69, P1192, DOI 10.1253/circj.69.1192; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Moreira ES, 2000, NAT GENET, V24, P163, DOI 10.1038/72822; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rybkin II, 2003, J BIOL CHEM, V278, P15927, DOI 10.1074/jbc.M213102200; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; Torok M, 2001, DIFFERENTIATION, V67, P63, DOI 10.1046/j.1432-0436.2001.067003063.x; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Weng L, 2005, J CLIN INVEST, V115, P1016, DOI 10.1172/JCI24186; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092; Zolk O, 2000, CIRCULATION, V101, P2674, DOI 10.1161/01.CIR.101.23.2674	30	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6841	6849		10.1074/jbc.M510499200	http://dx.doi.org/10.1074/jbc.M510499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407236	hybrid			2022-12-27	WOS:000236030800082
J	Mishra, VK; Anantharamaiah, GM; Segrest, JP; Palgunachari, MN; Chaddha, M; Sham, SWS; Krishna, NR				Mishra, VK; Anantharamaiah, GM; Segrest, JP; Palgunachari, MN; Chaddha, M; Sham, SWS; Krishna, NR			Association of a model class a (apolipoprotein) amphipathic alpha helical peptide with lipid - High resolution NMR studies of peptide-lipid discoidal complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SECONDARY STRUCTURE; CHEMICAL-SHIFTS; MEMBRANE INTERACTIONS; BIOLOGICAL-ACTIVITY; DISTANCE GEOMETRY; AMINO-ACIDS; ATHEROSCLEROSIS; ANALOGS; LIPOPROTEINS	Class A amphipathic helical peptides have been shown to mimic apolipoprotein A-I, the major protein component of high density lipoproteins and have been shown to inhibit atherosclerosis in several dyslipidemic mouse models. Previously we reported the NMR structure of Ac-18A-NH2, the base-line model class A amphipathic helical peptide in a 50% (v/v) trifluoroethanol-d(3)/water mixture, a membrane-mimic environment (Mishra, V. K., Palgunachari, M. N., Anantharamaiah, G. M., Jones, M. K., Segrest, J. P., and Krishna, N. R. ( 2001) Peptides 22, 567 - 573). The peptide Ac-18A-NH2 forms discoidal nascent high density lipoprotein-like particles with 1,2-dimyristoyl-sn-glycero-3-phosphocholine. Because subtle structural changes in the peptide . lipid complexes have been shown to be responsible for their antiatherogenic properties, we undertook high resolution NMR studies to deduce detailed structure of recombinant peptide . 1,2-dimyristoyl-sn-glycero-3-phosphocholine complexes. The peptide adopts a well defined amphipathic alpha helical structure in association with the lipid at a 1: 1 peptide: lipid weight ratio. Nuclear Overhauser effect spectroscopy revealed a number of intermolecular close contacts between the aromatic residues in the hydrophobic face of the helix and the lipid acyl chain protons. The pattern of observed peptide-lipid nuclear Overhauser effects is consistent with a parallel orientation of the amphipathic alpha helix, with respect to the plane of the lipid bilayer, on the edge of the disc ( the belt model). Based on the results of chemical cross-linking and molecular modeling, we propose that peptide helices are arranged in a head to tail fashion to cover the edge of the disc. This arrangement of peptides is also consistent with the pK(a) values of the Lys residues determined previously. Taken together, these results provide for the first time a high resolution structural view of the peptide . lipid discoidal complexes formed by a class A amphipathic alpha helical peptide.	Univ Alabama Birmingham, Birmingham Med Ctr, Dept Med, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Birmingham Med Ctr, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Birmingham Med Ctr, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Anantharamaiah, GM (corresponding author), Univ Alabama Birmingham, Birmingham Med Ctr, Dept Med, Atherosclerosis Res Unit, D806,1808 7th Ave S, Birmingham, AL 35294 USA.	vmishra@uab.edu; ananth@uab.edu; NRKrishna@bmg.bhs.uab.edu	Mishra, Vinod/S-1151-2019	Mishra, Vinod/0000-0002-4527-1512	NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13148] Funding Source: Medline; NHLBI NIH HHS [P01 HL34343, P01 HL034343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; CHUNG BH, 1985, J BIOL CHEM, V260, P256; Datta G, 2004, J BIOL CHEM, V279, P26509, DOI 10.1074/jbc.M314276200; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; Epand RM, 2004, J BIOL CHEM, V279, P51404, DOI 10.1074/jbc.M408581200; Epand RM, 2004, BIOCHEMISTRY-US, V43, P5073, DOI 10.1021/bi049786u; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; Gurtovenko AA, 2004, BIOPHYS J, V86, P3461, DOI 10.1529/biophysj.103.038760; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; HWANG TL, 1992, J AM CHEM SOC, V114, P3157, DOI 10.1021/ja00034a083; KUNTZ ID, 1991, J AM CHEM SOC, V113, P1406, DOI 10.1021/ja00004a050; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li L, 2004, J MOL BIOL, V343, P1293, DOI 10.1016/j.jmb.2004.09.017; LUNDKATZ S, 1995, BIOCHEMISTRY-US, V34, P9219, DOI 10.1021/bi00028a035; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Mishra VK, 2001, PEPTIDES, V22, P567, DOI 10.1016/S0196-9781(01)00365-5; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKAI TT, 1993, BIOCHEMISTRY-US, V32, P5650, DOI 10.1021/bi00072a022; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042; Zhu HL, 2004, BIOCHEMISTRY-US, V43, P13156, DOI 10.1021/bi0487894	39	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6511	6519		10.1074/jbc.M511475200	http://dx.doi.org/10.1074/jbc.M511475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407255	hybrid			2022-12-27	WOS:000236030800046
J	Panwar, SL; Moye-Rowley, WS				Panwar, SL; Moye-Rowley, WS			Long chain base tolerance in Saccharomyces cerevisiae is induced by retrograde signals from the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; MULTIDRUG-RESISTANCE; N-GLYCOSYLATION; TRANSCRIPTIONAL CONTROL; VACUOLAR DEGRADATION; YEAST SACCHAROMYCES; ALKALINE CERAMIDASE; GENE-PRODUCT; GENOME-WIDE; TRANSPORTER	Saccharomyces cerevisiae cells lacking their mitochondrial DNA (rho(0) cells) respond to this loss of genetic information by induction of a program of nuclear gene expression called the retrograde response. Expression of genes involved in multidrug resistance and sphingolipid biosynthesis is coordinately induced in rho(0) cells by the zinc cluster transcription factor Pdr3p. In this report, we identify a membrane protein involved in control of intracellular levels of a sphingolipid precursor as a transcriptional target of the Pdr3p-mediated retrograde response. These sphingolipid precursors are called long chain bases (LCBs) and increased LCB levels are growth inhibitory. This membrane protein has been designated Rsb1p and has previously been shown to act as a LCB transporter protein and to be a component of the endoplasmic reticulum. These earlier studies used an amino-terminal truncated form of Rsb1p. Here we employ a full-length form of Rsb1p and find that this protein is localized to the plasma membrane and is modified by N-linked glycosylation. Two glycosylation sites are present in the Rsb1p and both are required for normal LCB resistance. Mutational analysis of the RSB1 promoter revealed that two Pdr3p binding sites are present and both of these are required for normal retrograde induction of transcription. LCB tolerance is strongly increased in rho(0) cells but this increase is ablated in rho(0) rsb1 Delta cells. Together, these data indicate Pdr3p activation of RSB1 transcription is an important feature of the retrograde response allowing normal detoxification of an endogenous sphingolipid precursor.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 6-530 Bowen Sci Bldg, Iowa City, IA 52242 USA.	scott-moye-rowley@uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120				Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Gerami-Nejad M, 2001, YEAST, V18, P859, DOI 10.1002/yea.738; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Hallstrom TC, 2001, J BIOL CHEM, V276, P23674, DOI 10.1074/jbc.M101568200; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Kihara A, 2004, MOL BIOL CELL, V15, P4949, DOI 10.1091/mbc.E04-06-0458; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kolaczkowski M, 2004, EUKARYOT CELL, V3, P880, DOI 10.1128/EC.3.4.880-892.2004; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Mandala SM, 1998, J BIOL CHEM, V273, P14942, DOI 10.1074/jbc.273.24.14942; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Marini AM, 2000, MOL MICROBIOL, V38, P552, DOI 10.1046/j.1365-2958.2000.02151.x; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Ogawa A, 1998, ANTIMICROB AGENTS CH, V42, P755, DOI 10.1128/AAC.42.4.755; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F, 1979, METHODS YEAST GENETI; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Yan AX, 2005, J BIOL CHEM, V280, P3121, DOI 10.1074/jbc.R400036200; Zhang XT, 2001, J BIOL CHEM, V276, P47844, DOI 10.1074/jbc.M106285200; Zhang XT, 2005, J BIOL CHEM, V280, P2759, DOI 10.1074/jbc.M408333200	53	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6376	6384		10.1074/jbc.M512115200	http://dx.doi.org/10.1074/jbc.M512115200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407254	hybrid			2022-12-27	WOS:000236030800031
J	Anrather, J; Racchumi, G; Iadecola, C				Anrather, J; Racchumi, G; Iadecola, C			NF-kappa B regulates phagocytic NADPH oxidase by inducing the expression of gp91(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; MYELOID DIFFERENTIATION; PROMOTER ACTIVITY; NAD(P)H OXIDASE; GENE-EXPRESSION; MOLECULAR-BASIS; NITRIC-OXIDE	The superoxide-generating phagocytic NADPH oxidase is an important component of the innate immune response against microbial agents, and is involved in shaping the cellular response to a variety of physiological and pathological signals. One of the downstream targets of NADPH oxidase-derived radicals is the ubiquitous transcription factor NF-kappa B, which controls the expression of a large array of genes involved in immune function and cell survival. Here we show that NF-kappa B itself is a key factor in controlling NADPH oxidase expression and function. In monocytic and microglial cell lines, the expression of the NADPH oxidase subunit gp91(phox) was induced by lipopolysaccharide/interferon gamma treatment and was inhibited in cells constitutively expressing I kappa B alpha. Furthermore, inducible reactive oxygen species production was inhibited in I kappa B alpha overexpressing cells. gp91(phox) expression was very low in RelA(-/-) fibroblasts and could be induced by reconstituting these cells with p65/RelA. Thus, gp91(phox) expression is dependent on the presence of p65/RelA. We also found that gp91(phox) transcription is dependent on NF-kappa B and we identified two potential cis-acting elements in the murine gp91(phox) promoter that control NF-kappa B-dependent regulation. The findings raise the possibility of a positive feedback loop in which NF-kappa B activation by oxidative stress leads to further radical production via NADPH oxidase.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Neurobiol, New York, NY 10021 USA	Cornell University	Anrather, J (corresponding author), 411 E 69th St KB410, New York, NY 10021 USA.	joa2006@med.cornell.edu	Iadecola, c/ABB-8377-2020	Iadecola, Costantino/0000-0001-9797-073X	NHLBI NIH HHS [HL 018974, HL 077308] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077308, P01HL018974] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ago T, 2005, STROKE, V36, P1040, DOI 10.1161/01.STR.0000163111.05825.0b; Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70; Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Aviram M, 1996, METABOLISM, V45, P1069, DOI 10.1016/S0026-0495(96)90005-0; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; Basile JR, 2003, MOL CANCER RES, V1, P262; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Bengtsson SH, 2003, CLIN EXP PHARMACOL P, V30, P849, DOI 10.1046/j.1440-1681.2003.03929.x; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Brostjan C, 1997, J IMMUNOL, V158, P3836; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; Chamseddine AH, 2003, AM J PHYSIOL-HEART C, V285, pH2284, DOI 10.1152/ajpheart.00459.2003; Clark RA, 2004, MECH AGEING DEV, V125, P799, DOI 10.1016/j.mad.2004.08.009; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200; Fujii Y, 2003, MICROBIOL IMMUNOL, V47, P803, DOI 10.1111/j.1348-0421.2003.tb03438.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; GREENBERG ME, 1997, IDENTIFICATION NEWLY; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; Kazama K, 2004, CIRC RES, V95, P1019, DOI 10.1161/01.RES.0000148637.85595.c5; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Li SL, 1997, J BIOL CHEM, V272, P17802, DOI 10.1074/jbc.272.28.17802; Li SL, 2001, J BIOL CHEM, V276, P39368, DOI 10.1074/jbc.M106111200; Li SL, 2002, BLOOD, V99, P4578, DOI 10.1182/blood.V99.12.4578; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MOST J, 1992, J IMMUNOL, V148, P1635; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park L, 2005, J NEUROSCI, V25, P1769, DOI 10.1523/JNEUROSCI.5207-04.2005; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Skalnik DG, 2002, GENE, V284, P1, DOI 10.1016/S0378-1119(02)00387-6; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; Tammariello SP, 2000, J NEUROSCI, V20; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262	60	272	286	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5657	5667		10.1074/jbc.M506172200	http://dx.doi.org/10.1074/jbc.M506172200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407283	hybrid			2022-12-27	WOS:000235568900042
J	Wu, JS; Katrekar, A; Honigberg, LA; Smith, AM; Conn, MT; Tang, J; Jeffery, D; Mortara, K; Sampang, J; Williams, SR; Buggy, J; Clark, JM				Wu, JS; Katrekar, A; Honigberg, LA; Smith, AM; Conn, MT; Tang, J; Jeffery, D; Mortara, K; Sampang, J; Williams, SR; Buggy, J; Clark, JM			Identification of substrates of human protein-tyrosine phosphatase PTPN22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; GROWTH-FACTOR RECEPTOR; AAA-ATPASE CDC48/P97; T-CELLS; PHOSPHORYLATION SITE; ESCHERICHIA-COLI; TRAPPING MUTANT; KINASE ZAP-70; SH2 DOMAIN; ACTIVATION	Stimulation of mature T cells activates a downstream signaling cascade involving temporally and spatially regulated phosphorylation and dephosphorylation events mediated by protein-tyrosine kinases and phosphatases, respectively. PTPN22 (Lyp), a non-receptor protein-tyrosine phosphatase, is expressed exclusively in cells of hematopoietic origin, notably in T cells where it represses signaling through the T cell receptor. We used substrate trapping coupled with mass spectrometry-based peptide identification in an unbiased approach to identify physiological substrates of PTPN22. Several potential substrates were identified in lysates from pervanadate-stimulated Jurkat cells using PTPN22-D195A/C227S, an optimized substrate trap mutant of PTPN22. These included three novel PTPN22 substrates (Vav, CD3 epsilon, and valosin containing protein) and two known substrates of PEP, the mouse homolog of PTPN22 (Lck and Zap70). T cell antigen receptor (TCR) zeta was also identified as a potential substrate in Jurkat lysates by direct immunoblotting. In vitro experiments with purified recombinant proteins demonstrated that PTPN22-D195A/C227S interacted directly with activated Lck, Zap70, and TCR zeta, confirming the initial substrate trap results. Native PTPN22 dephosphorylated Lck and Zap70 at their activating tyrosine residues Tyr-394 and Tyr-493, respectively, but not at the regulatory tyrosines Tyr-505 (Lck) or Tyr-319 (Zap70). Native PTPN22 also dephosphorylated TCR zeta in vitro and in cells, and its substrate trap variant co-immunoprecipitated with TCR zeta when both were coexpressed in 293T cells, establishing TCR zeta as a direct substrate of PTPN22.	Celera Genom, San Francisco, CA 94080 USA		Wu, JS (corresponding author), 615 John Muir Dr D616, San Francisco, CA 94132 USA.	lakedaly@yahoo.com	Clark, Jeanne/AGG-8199-2022	Clark, Jeanne/0000-0003-1194-0092				Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chiang GG, 2001, J BIOL CHEM, V276, P23173, DOI 10.1074/jbc.M101219200; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Di Bartolo V, 1999, J BIOL CHEM, V274, P6285, DOI 10.1074/jbc.274.10.6285; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT NA, 1994, J CELL BIOCHEM, V55, P389, DOI 10.1002/jcb.240550317; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Guntermann C, 2002, J IMMUNOL, V168, P4420, DOI 10.4049/jimmunol.168.9.4420; Hasegawa K, 2004, SCIENCE, V303, P685, DOI 10.1126/science.1092138; Huang JY, 2000, P NATL ACAD SCI USA, V97, P10923, DOI 10.1073/pnas.97.20.10923; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Kyogoku C, 2004, AM J HUM GENET, V75, P504, DOI 10.1086/423790; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mustelin T, 2004, MOL IMMUNOL, V41, P687, DOI 10.1016/j.molimm.2004.04.015; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Pelosi M, 1999, J BIOL CHEM, V274, P14229, DOI 10.1074/jbc.274.20.14229; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sechi AS, 2004, TRENDS IMMUNOL, V25, P257, DOI 10.1016/j.it.2004.03.003; Sozio MS, 2004, J BIOL CHEM, V279, P7760, DOI 10.1074/jbc.M309994200; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673; VEILLETTE A, 1992, ONCOGENE, V7, P971; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	47	184	192	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11002	11010		10.1074/jbc.M600498200	http://dx.doi.org/10.1074/jbc.M600498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16461343	hybrid			2022-12-27	WOS:000236822200041
J	Voigt, P; Dorner, MB; Schaefer, M				Voigt, P; Dorner, MB; Schaefer, M			Characterization of p87(PIKAP), a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; 3-KINASE P110-GAMMA; IN-VIVO; DOMAINS; CELLS; ACTIVATION; PI3K-GAMMA; KINASE; SENSITIVITY; MIGRATION	Phosphoinositide 3- kinase (PI3K) gamma has been implicated in a vast array of physiological settings including the activation of different leukocyte species and the regulation of myocardial contractility. Activation of PI3K gamma is primarily mediated by G beta gamma subunits of heterotrimeric G proteins, which are recognized by a p101 regulatory subunit. Here, we describe the identification and characterization of a novel regulatory subunit of PI3K gamma, which we termed p87(PIKAP) (PI3K gamma adapter protein of 87 kDa). It is homologous to p101 in areas that we have recently shown that they mediate binding to the catalytic p110 gamma subunit and to G beta gamma. Like p101, p87(PIKAP) binds to both p110 gamma and G beta gamma and mediates activation of p110 gamma downstream of G protein-coupled receptors. In contrast to p101, p87(PIKAP) is highly expressed in heart and may therefore be crucial to PI3K gamma cardiac function. Moreover, p87(PIKAP) and p101 are both expressed in dendritic cells, macrophages, and neutrophils, raising the possibility of regulatory subunit-dependent differences in PI3K gamma signaling within the same cell type. We further provide evidence that p87(PIKAP) physically interacts with phosphodiesterase (PDE) 3B, suggesting that p87(PIKAP) is also involved in the recently described noncatalytic scaffolding interaction of p110 gamma with PDE3B. However, coexpression of PDE3B and PI3K gamma subunits was not sufficient to reconstitute the regulatory effect of PI3K gamma on PDE3B activity observed in heart, implying further molecules to be present in the complex regulating PDE3B in heart.	Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Robert Koch Inst, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Robert Koch Institute	Schaefer, M (corresponding author), Charite Univ Med Berlin, Inst Pharmakol, Campus Benjamin Franklin,Thielallee 67-73, D-14195 Berlin, Germany.	m.schaefer@charite.de	Dorner, Martin B/C-5703-2013	Dorner, Martin B/0000-0002-8176-797X; Voigt, Philipp/0000-0003-4366-0490				Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Del Prete A, 2004, EMBO J, V23, P3505, DOI 10.1038/sj.emboj.7600361; Dorner BG, 2002, P NATL ACAD SCI USA, V99, P6181, DOI 10.1073/pnas.092141999; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Kerchner KR, 2004, J BIOL CHEM, V279, P44554, DOI 10.1074/jbc.M406071200; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; Shepherd MC, 2004, BRIT J PHARMACOL, V142, P339, DOI 10.1038/sj.bjp.0705770; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Voigt P, 2005, N-S ARCH PHARMACOL, V371, pR44; Voigt P, 2005, J BIOL CHEM, V280, P5121, DOI 10.1074/jbc.M413104200; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011	28	97	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9977	9986		10.1074/jbc.M512502200	http://dx.doi.org/10.1074/jbc.M512502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476736	hybrid			2022-12-27	WOS:000236594300020
J	Borgia, A; Bonivento, D; Travaglini-Allocatelli, C; Di Matteo, A; Brunori, M				Borgia, A; Bonivento, D; Travaglini-Allocatelli, C; Di Matteo, A; Brunori, M			Unveiling a hidden folding intermediate in c-type cytochromes by protein engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-MOLECULES CONTRIBUTE; ON-PATHWAY INTERMEDIATE; PSEUDOMONAS-AERUGINOSA; HYDROGENOBACTER-THERMOPHILUS; TRANSITION-STATES; MECHANISM; STABILITY; C(551); KINETICS; CAVITIES	Several investigators have highlighted a correlation between the basic features of the folding process of a protein and its topology, which dictates the folding pathway. Within this conceptual framework we proposed that different members of the cytochrome c (cyt c) family share the same folding mechanism, involving a consensus partially structured state. Pseudomonas aeruginosa cyt c(551) (Pa cyt c(551)) folds via an apparent two-state mechanism through a high energy intermediate. Here we present kinetic evidence demonstrating that it is possible to switch its folding mechanism from two to three state, stabilizing the high energy intermediate by rational mutagenesis. Characterization of the folding kinetics of one single-site mutant of the Pa cyt c(551) (Phe(7) to Ala) indeed reveals an additional refolding phase and a fast unfolding process which are explained by the accumulation of a partially folded species. Further kinetic analysis highlights the presence of two parallel processes both leading to the native state, suggesting that the above mentioned species is a non obligatory on-pathway intermediate. Determination of the crystallographic structure of F7A shows the presence of an extended internal cavity, which hosts three "bound" water molecules and a H-bond in the N-terminal helix, which is shorter than in the wild type protein. These two features allow us to propose a detailed structural interpretation for the stabilization of the native and especially the intermediate states induced by a single crucial mutation. These results show how protein engineering, x-ray crystallography and state-of-the-art kinetics concur to unveil a folding intermediate and the structural determinants of its stability.	Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Dipartimento Sci Biochim, Ist Biol & Patol Mol, I-00185 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Brunori, M (corresponding author), Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Ple A Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	Borgia, Alessandro/AAF-9203-2019; Di Matteo, Adele/AAC-8338-2019	Borgia, Alessandro/0000-0002-4701-8967; Di Matteo, Adele/0000-0002-5921-7365; Brunori, Maurizio/0000-0002-7795-1635; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126				Bai YW, 1999, P NATL ACAD SCI USA, V96, P477, DOI 10.1073/pnas.96.2.477; Binkowski TA, 2003, NUCLEIC ACIDS RES, V31, P3352, DOI 10.1093/nar/gkg512; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; Diez J, 2001, J MOL BIOL, V305, P905, DOI 10.1006/jmbi.2000.4203; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERNST JA, 1995, SCIENCE, V267, P1813, DOI 10.1126/science.7892604; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; Friel CT, 2003, J MOL BIOL, V326, P293, DOI 10.1016/S0022-2836(02)01249-4; Gianni S, 2003, J MOL BIOL, V330, P1145, DOI 10.1016/S0022-2836(03)00689-2; Gianni S, 2001, J MOL BIOL, V309, P1177, DOI 10.1006/jmbi.2001.4728; Gorski SA, 2001, J MOL BIOL, V312, P849, DOI 10.1006/jmbi.2001.5001; Griffin S, 2002, ARCH BIOCHEM BIOPHYS, V404, P335, DOI 10.1016/S0003-9861(02)00333-8; Gunasekaran K, 2001, CURR OPIN STRUC BIOL, V11, P83, DOI 10.1016/S0959-440X(00)00173-1; Hagen SJ, 2000, J MOL BIOL, V301, P1019, DOI 10.1006/jmbi.2000.3969; Hasegawa J, 2000, J BIOL CHEM, V275, P37824, DOI 10.1074/jbc.M005861200; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KIEFHABER T, 1992, J MOL BIOL, V224, P217, DOI 10.1016/0022-2836(92)90585-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maity H, 2004, J MOL BIOL, V343, P223, DOI 10.1016/j.jmb.2004.08.005; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oliveberg M, 2001, CURR OPIN STRUC BIOL, V11, P94, DOI 10.1016/S0959-440X(00)00171-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Sanchez IE, 2003, J MOL BIOL, V327, P867, DOI 10.1016/S0022-2836(03)00171-2; Sauder JM, 1996, BIOCHEMISTRY-US, V35, P16852, DOI 10.1021/bi961976k; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Takano K, 2003, PROTEIN ENG, V16, P5, DOI 10.1093/proeng/gzg001; Travaglini-Allocatelli C, 1999, J MOL BIOL, V289, P1459, DOI 10.1006/jmbi.1999.2852; Travaglini-Allocatelli C, 2005, J BIOL CHEM, V280, P25729, DOI 10.1074/jbc.M502628200; Travaglini-Allocatelli C, 2004, TRENDS BIOCHEM SCI, V29, P535, DOI 10.1016/j.tibs.2004.08.004; Travaglini-Allocatelli C, 2003, J BIOL CHEM, V278, P41136, DOI 10.1074/jbc.M303990200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; Zarrine-Afsar A, 2005, CURR OPIN STRUC BIOL, V15, P42, DOI 10.1016/j.sbi.2005.01.011	47	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9331	9336		10.1074/jbc.M512127200	http://dx.doi.org/10.1074/jbc.M512127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452476	hybrid			2022-12-27	WOS:000236404700041
J	Higashi, K; Kashiwagi, K; Taniguchi, S; Terui, Y; Yamamoto, K; Ishihama, A; Igarashi, K				Higashi, K; Kashiwagi, K; Taniguchi, S; Terui, Y; Yamamoto, K; Ishihama, A; Igarashi, K			Enhancement of+1 frameshift by polyamines during translation of polypeptide release factor 2 in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							30S RIBOSOMAL-SUBUNIT; ORNITHINE DECARBOXYLASE ANTIZYME; OLIGOPEPTIDE-BINDING PROTEIN; TISSUE-CULTURE CELLS; MESSENGER-RNA; BOVINE LYMPHOCYTES; READING FRAME; FREE SYSTEM; RAT-LIVER; FACTOR-II	Polypeptide release factor 2 (RF2) in Escherichia coli is known to be synthesized by a +1 frameshift at the 26th UGA codon of RF2 mRNA. Polyamines were found to stimulate the +1 frameshift of RF2 synthesis, an effect that was reduced by excess RF2. Polyamine stimulation of +1 frameshift of RF2 synthesis was observed at the early logarithmic phase, which is the important phase in determination of the overall rate of cell growth. A Shine-Dalgarno-like sequence was necessary for an efficient +1 frameshift of RF2 synthesis, but not for polyamine stimulation. Spectinomycin, tetracycline, streptomycin, and neomycin reduced polyamine stimulation of the +1 frameshift of RF2 synthesis. The results suggest that a structural change of the A site on 30 S ribosomal subunits is important for polyamine stimulation of the +1 frameshift. The level of mRNAs of ribosomal proteins and elongation factors having UAA as termination codon was enhanced by polyamines, and OppA synthesis from OppA mRNA having UAA as termination codon was more enhanced by polyamines than that from OppA mRNA having a UGA termination codon. Furthermore, synthesis of ribosomal protein L20 and elongation factor G from the mRNA shaving a UAA termination codon was enhanced by polyamines at the level of translation and transcription. The results suggest that some protein synthesis from mRNAs having a UAA termination codon is enhanced at the level of translation through polyamine stimulation of +1 frameshift of RF2 synthesis. It is concluded that prfB encoding RF2 is a new member of the polyamine modulon.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; Kinki Univ, Grad Sch Agr, Nara 6318505, Japan; Nippon Inst Biol Sci, Div Mol Biol, Tokyo 1980024, Japan	Chiba University; Kindai University (Kinki University)	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Higashi, Kyohei/0000-0002-2622-4825; Igarashi, Kazuei/0000-0003-3751-3187				Amarantos I, 2002, NUCLEIC ACIDS RES, V30, P2832, DOI 10.1093/nar/gkf404; ATKINS JF, 1975, J BIOL CHEM, V250, P5688; AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; ECHANDI G, 1975, BIOCHEM BIOPH RES CO, V67, P1185, DOI 10.1016/0006-291X(75)90798-6; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; Hirokawa G, 2005, RNA, V11, P1317, DOI 10.1261/rna.2520405; Hirvonen CA, 2001, J BACTERIOL, V183, P6305, DOI 10.1128/JB.183.21.6305-6314.2001; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ICHIBA T, 1995, BBA-GENE STRUCT EXPR, V1262, P83, DOI 10.1016/0167-4781(95)00062-L; IGARASHI K, 1977, J BIOCHEM-TOKYO, V81, P1091, DOI 10.1093/oxfordjournals.jbchem.a131533; Igarashi K, 2006, J BIOCHEM, V139, P11, DOI 10.1093/jb/mvj020; IGARASHI K, 1981, EUR J BIOCHEM, V113, P587, DOI 10.1111/j.1432-1033.1981.tb05103.x; IGARASHI K, 1984, CANCER RES, V44, P5332; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; IGARASHI K, 1979, BIOCHEM BIOPH RES CO, V91, P440, DOI 10.1016/0006-291X(79)91541-9; IGARASHI K, 1979, EUR J BIOCHEM, V93, P345, DOI 10.1111/j.1432-1033.1979.tb12829.x; IGARASHI K, 1974, EUR J BIOCHEM, V48, P495, DOI 10.1111/j.1432-1033.1974.tb03790.x; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; ITO K, 1990, J BIOL CHEM, V265, P13036; Ito K, 1998, P NATL ACAD SCI USA, V95, P8165, DOI 10.1073/pnas.95.14.8165; ITO K, 1986, EUR J BIOCHEM, V156, P505, DOI 10.1111/j.1432-1033.1986.tb09609.x; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; KAKEGAWA T, 1986, ARCH BIOCHEM BIOPHYS, V251, P413, DOI 10.1016/0003-9861(86)90347-4; KAKEGAWA T, 1986, EUR J BIOCHEM, V158, P265, DOI 10.1111/j.1432-1033.1986.tb09746.x; KALTSCHM.E, 1970, P NATL ACAD SCI USA, V67, P1276, DOI 10.1073/pnas.67.3.1276; KASHIWAGI K, 1989, ARCH BIOCHEM BIOPHYS, V268, P379, DOI 10.1016/0003-9861(89)90598-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P341; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Marquez V, 2004, CELL, V118, P45, DOI 10.1016/j.cell.2004.06.012; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; Palanimurugan R, 2004, EMBO J, V23, P4857, DOI 10.1038/sj.emboj.7600473; Pavlov MY, 1998, J MOL BIOL, V284, P579, DOI 10.1006/jmbi.1998.2220; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Recht MI, 1999, EMBO J, V18, P3133, DOI 10.1093/emboj/18.11.3133; Sambrook J., 2001, MOL CLONING LAB MANU; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200; Yoshida M, 2002, J BIOL CHEM, V277, P37139, DOI 10.1074/jbc.M206668200; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; Yoshida M, 1999, J BIOL CHEM, V274, P22723, DOI 10.1074/jbc.274.32.22723; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	63	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9527	9537		10.1074/jbc.M513752200	http://dx.doi.org/10.1074/jbc.M513752200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16476727	hybrid			2022-12-27	WOS:000236404700063
J	Nowak, E; Panjikar, S; Konarev, P; Svergun, DI; Tucker, PA				Nowak, E; Panjikar, S; Konarev, P; Svergun, DI; Tucker, PA			The structural basis of signal transduction for the response regulator PrrA from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; 2-COMPONENT SYSTEM; CRYSTAL-STRUCTURE; RECEIVER DOMAIN; ALPHA-SUBUNIT; DNA-BINDING; PHOB; TRANSCRIPTION; MODEL; PHOSPHORYLATION	The structure of the two-domain response regulator PrrA from Mycobacterium tuberculosis shows a compact structure in the crystal with a well defined interdomain interface. The interface, which does not include the interdomain linker, makes the recognition helix and the trans-activation loop of the effector domain inaccessible for interaction with DNA. Part of the interface involves hydrogen-bonding interactions of a tyrosine residue in the receiver domain that is believed to be involved in signal transduction, which, if disrupted, would destabilize the interdomain interface, allowing a more extended conformation of the molecule, which would in turn allow access to the recognition helix. In solution, there is evidence for an equilibrium between compact and extended forms of the protein that is far toward the compact form when the protein is inactivated but moves toward a more extended form when activated by the cognate sensor kinase PrrB.	DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Tucker, PA (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	tucker@embl-hamburg.de	Panjikar, Santosh/D-2709-2012; Konarev, Petr V/W-1380-2017	Panjikar, Santosh/0000-0001-7429-3879; Svergun, Dmitri/0000-0003-0830-5696; Konarev, Petr/0000-0002-5606-1596				Appleby JL, 1998, J BACTERIOL, V180, P3563, DOI 10.1128/JB.180.14.3563-3569.1998; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett JF, 1998, ANTIMICROB AGENTS CH, V42, P1529, DOI 10.1128/AAC.42.7.1529; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; Bent CJ, 2004, J BACTERIOL, V186, P2872, DOI 10.1128/JB.186.9.2872-2879.2004; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Birck C, 2003, J BACTERIOL, V185, P254, DOI 10.1128/JB.185.1.254-261.2003; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; BOULIN CJ, 1998, NUCL INSTRUM METH A, V269, P312; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckler DR, 2002, STRUCTURE, V10, P153, DOI 10.1016/S0969-2126(01)00706-7; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; Ellison DW, 2000, J BACTERIOL, V182, P6592, DOI 10.1128/JB.182.23.6592-6597.2000; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ewann F, 2004, MICROBIOL-SGM, V150, P241, DOI 10.1099/mic.0.26516-0; Ewann F, 2002, INFECT IMMUN, V70, P2256, DOI 10.1128/IAI.70.5.2256-2263.2002; Gardino AK, 2003, J MOL BIOL, V331, P245, DOI 10.1016/S0022-2836(03)00733-2; Gouet P, 1999, STRUCTURE, V7, P1517, DOI 10.1016/S0969-2126(00)88342-2; Graham JE, 1999, P NATL ACAD SCI USA, V96, P11554, DOI 10.1073/pnas.96.20.11554; Guillet V, 2002, J BIOL CHEM, V277, P42003, DOI 10.1074/jbc.M204789200; Guinier A., 1939, ANN PHYS-NEW YORK, V11, P161, DOI DOI 10.1051/ANPHYS/193911120161; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko T, 2005, PROTEIN SCI, V14, P558, DOI 10.1110/ps.041170005; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Makino K, 1996, J MOL BIOL, V259, P15, DOI 10.1006/jmbi.1996.0298; MartinezHackert E, 1997, J MOL BIOL, V269, P301, DOI 10.1006/jmbi.1997.1065; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Morth JP, 2005, FEBS LETT, V579, P4145, DOI 10.1016/j.febslet.2005.06.043; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nowak E, 2006, STRUCTURE, V14, P275, DOI 10.1016/j.str.2005.10.006; Okamura H, 2000, J MOL BIOL, V295, P1225, DOI 10.1006/jmbi.1999.3379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Robinson VL, 2003, J BACTERIOL, V185, P4186, DOI 10.1128/JB.185.14.4186-4194.2003; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toro-Roman A, 2005, PROTEIN SCI, V14, P3077, DOI 10.1110/ps.051722805; Tyagi JS, 2004, CURR SCI INDIA, V86, P93; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	60	63	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9659	9666		10.1074/jbc.M512004200	http://dx.doi.org/10.1074/jbc.M512004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16434396	hybrid			2022-12-27	WOS:000236404700078
J	Paul, S; Gable, K; Beaudoin, F; Cahoon, E; Jaworski, J; Napier, JA; Dunn, TM				Paul, S; Gable, K; Beaudoin, F; Cahoon, E; Jaworski, J; Napier, JA; Dunn, TM			Members of the Arabidopsis FAE1-like3-ketoacyl-CoA synthase gene family substitute for the Elop proteins of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ELONGASE; KETOACYL-COA SYNTHASE; FUNCTIONAL-CHARACTERIZATION; CHAIN ELONGATION; FAE1 KCS; REDUCTASE; ENZYME; BIOSYNTHESIS; ENCODES; CLONING	Several 3-keto-synthases have been studied, including the soluble fatty acid synthases, those involved in polyketide synthesis, and the FAE1-like 3-ketoacyl-CoA synthases. All of these condensing enzymes have a common ancestor and an enzymatic mechanism that involves a catalytic triad consisting of Cys, His, and His/Asn. In contrast to the FAE1-like family of enzymes that mediate plant microsomal fatty acid elongation, the condensation step of elongation in animals and in fungi appears to be mediated by the Elop homologs. Curiously these proteins bear no resemblance to the well characterized 3-keto-synthases. There are three ELO genes in yeast that encode the homologous Elo1p, Elo2p, and Elo3p proteins. Elo2p and Elo3p are required for synthesis of the very long-chain fatty acids, and mutants lacking both Elo2p and Elo3p are inviable confirming that the very long-chain fatty acids are essential for cellular functions. In this study we show that heterologous expression of several Arabidopsis FAE1-like genes rescues the lethality of an elo2 Delta elo3 Delta yeast mutant. We further demonstrate that FAE1 acts in conjunction with the 3-keto and trans-2,3-enoyl reductases of the elongase system. These studies indicate that even though the plant-specific FAE1 family of condensing enzymes evolved independently of the Elop family of condensing enzymes, they utilize the same reductases and presumably dehydratase that the Elop proteins rely upon.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20184 USA; Rothamsted Res, Crop Performance & Improvement, Harpenden AL5 2JQ, Herts, England; Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; USDA ARS, Plant Genet Res Unit, St Louis, MO 63132 USA	Uniformed Services University of the Health Sciences - USA; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Donald Danforth Plant Science Center; United States Department of Agriculture (USDA)	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20184 USA.	tdunn@usuhs.mil	Jaworski, Jan/N-2255-2014	Jaworski, Jan/0000-0003-3309-4915; Napier, Johnathan/0000-0003-3580-3607; PAUL, SHILPI/0000-0001-5075-2081	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004156] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Agaba M, 2004, MAR BIOTECHNOL, V6, P251, DOI 10.1007/s10126-003-0029-1; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; Beaudoin F, 2002, J BIOL CHEM, V277, P11481, DOI 10.1074/jbc.M111441200; Beaudoin F, 2000, BIOCHEM SOC T, V28, P661, DOI 10.1042/BST0280661; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; Blacklock BJ, 2002, EUR J BIOCHEM, V269, P4789, DOI 10.1046/j.1432-1033.2002.03176.x; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; Dietrich CR, 2005, PLANT J, V42, P844, DOI 10.1111/j.1365-313X.2005.02418.x; Dittrich F, 1998, EUR J BIOCHEM, V252, P477, DOI 10.1046/j.1432-1327.1998.2520477.x; Gable K, 2004, J EXP BOT, V55, P543, DOI 10.1093/jxb/erh061; Ghanevati M, 2002, EUR J BIOCHEM, V269, P3531, DOI 10.1046/j.1432-1033.2002.03039.x; Ghanevati M, 2001, BBA-MOL CELL BIOL L, V1530, P77, DOI 10.1016/S1388-1981(00)00168-2; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Lassner MW, 1996, PLANT CELL, V8, P281, DOI 10.1105/tpc.8.2.281; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; LESTER RL, 1993, J BIOL CHEM, V268, P845; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Parker-Barnes JM, 2000, P NATL ACAD SCI USA, V97, P8284, DOI 10.1073/pnas.97.15.8284; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; Schneiter R, 2000, J BACTERIOL, V182, P3655, DOI 10.1128/JB.182.13.3655-3660.2000; Sherman F., 1986, METHODS YEAST GENETI; Todd J, 1999, PLANT J, V17, P119, DOI 10.1046/j.1365-313X.1999.00352.x; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Trenkamp S, 2004, P NATL ACAD SCI USA, V101, P11903, DOI 10.1073/pnas.0404600101; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Zank TK, 2002, PLANT J, V31, P255, DOI 10.1046/j.1365-313X.2002.01354.x; Zank TK, 2000, BIOCHEM SOC T, V28, P654; ZHAO C, 1994, J BIOL CHEM, V269, P21480; Zheng HQ, 2005, PLANT CELL, V17, P1467, DOI 10.1105/tpc.104.030155	38	104	116	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9018	9029		10.1074/jbc.M507723200	http://dx.doi.org/10.1074/jbc.M507723200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16449229	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000236404700006
J	Wasilenko, J; Fridovich-Keil, JL				Wasilenko, J; Fridovich-Keil, JL			Relationship between UDP-galactose 4 '-epimerase activity and galactose sensitivity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIMERASE-DEFICIENCY GALACTOSEMIA; GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE DEFICIENCY; DIPHOSPHATE GALACTOSE-4-EPIMERASE DEFICIENCY; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; EXPRESSION SYSTEM; LELOIR PATHWAY; 4-EPIMERASE; METABOLISM; PROMOTER	UDP- galactose 4'- epimerase ( GALE) catalyzes the final step of the highly conserved Leloir pathway of galactose metabolism. Loss of GALE in humans results in a variant form of the metabolic disorder, galactosemia. Loss of GALE in yeast results in galactose- dependent growth arrest. Although the role of GALE in galactose metabolism has been recognized for decades, the precise relationship between GALE activity and galactose sensitivity has remained unclear. Here we have explored this relationship by asking the following. 1) Is GALE rate- limiting for galactose metabolism in yeast? 2) What is the relationship between GALE activity and galactose-dependent growth arrest in yeast? 3) What is the relationship between GALE activity and the abnormal accumulation of galactose metabolites in yeast? To answer these questions we engineered a strain of yeast in which GALE was doxycycline- repressible and studied these cells under conditions of intermediate GALE expression. Our results demonstrated a smooth linear relationship between galactose metabolism and GALE activity over a range from 0 to similar to 5% but a steep threshold relationship between growth rate in galactose and GALE activity over the same range. The relationship between abnormal accumulation of metabolites and GALE activity was also linear over the range from 0 to similar to 5%, suggesting that if the abnormal accumulation of metabolites underlies galactose- dependent growth- arrest in GALE- impaired yeast, either the impact of individual metabolites must be synergistic and/ or the threshold of sensitivity must be very steep. Together these data reveal important points of similarity and contrast between the roles of GALE and galactose- 1- phosphate uridylyltransferase in galactose metabolism in yeast and provide a framework for future studies in mammalian systems.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.	jfridov@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046403, R01DK059904, R01DK046403] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46403, DK59904] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Alano A, 1998, J INHERIT METAB DIS, V21, P341, DOI 10.1023/A:1005342306080; [Anonymous], 1991, Methods Enzymol, V194, P1; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; DOUGLAS HC, 1964, GENETICS, V49, P837; GITZELMANN R, 1972, HELV PAEDIATR ACTA, V27, P125; GITZELMANN R, 1977, HELV PAEDIATR ACTA, V31, P441; GITZELMANN R, 1973, HELV PAEDIATR ACTA, V28, P497; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Holton J. B., 2000, METABOLIC MOL BASES, P1553; HOLTON JB, 1981, ARCH DIS CHILD, V56, P885, DOI 10.1136/adc.56.11.885; Kabir MA, 2000, MOL GEN GENET, V262, P1113, DOI 10.1007/PL00008654; Lai K, 2000, BIOCHEM BIOPH RES CO, V271, P392, DOI 10.1006/bbrc.2000.2629; Leslie N, 2005, MOL GENET METAB, V85, P21, DOI 10.1016/j.ymgme.2005.01.004; Leslie ND, 1996, BIOCHEM MOL MED, V59, P7, DOI 10.1006/bmme.1996.0057; Leslie ND, 2001, MOL GENET METAB, V72, P31, DOI 10.1006/mgme.2000.3116; Majumdar S, 2004, EUR J BIOCHEM, V271, P753, DOI 10.1111/j.1432-1033.2003.03974.x; Mehta DV, 1999, BBA-MOL BASIS DIS, V1454, P217, DOI 10.1016/S0925-4439(99)00037-X; Ning C, 2001, MOL GENET METAB, V72, P306, DOI 10.1006/mgme.2001.3152; Ning C, 2000, PEDIATR RES, V48, P211, DOI 10.1203/00006450-200008000-00015; Openo KK, 2006, AM J HUM GENET, V78, P89, DOI 10.1086/498985; Pilauri V, 2005, GENETICS, V169, P1903, DOI 10.1534/genetics.104.036723; PILLER F, 1983, J BIOL CHEM, V258, P774; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; Riehman K, 2001, J BIOL CHEM, V276, P10634, DOI 10.1074/jbc.M009583200; Ross KL, 2004, MOL GENET METAB, V83, P103, DOI 10.1016/j.ymgme.2004.07.005; SARDHARWALLA IB, 1988, J INHERIT METAB DIS, V11, P249, DOI 10.1007/BF01804249; SCHULPIS KH, 1993, J INHERIT METAB DIS, V16, P1059, DOI 10.1007/BF00711534; SCHULPIS KH, 1993, J INHERIT METAB DIS, V16, P903, DOI 10.1007/BF00714292; Schulz JM, 2005, J BIOL CHEM, V280, P13493, DOI 10.1074/jbc.M414045200; Schulz JM, 2004, J BIOL CHEM, V279, P32796, DOI 10.1074/jbc.M405005200; Shin YS, 2000, J INHERIT METAB DIS, V23, P383, DOI 10.1023/A:1005699719068; Thoden JB, 2005, J BIOL CHEM, V280, P21900, DOI 10.1074/jbc.M502411200; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; Walter JH, 1999, ARCH DIS CHILD, V80, P374, DOI 10.1136/adc.80.4.374; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784	37	14	14	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8443	8449		10.1074/jbc.M600778200	http://dx.doi.org/10.1074/jbc.M600778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452467	hybrid			2022-12-27	WOS:000236247100019
J	Gonda, K; Wudel, J; Nelson, D; Katoku-Kikyo, N; Reed, P; Tamada, H; Kikyo, N				Gonda, K; Wudel, J; Nelson, D; Katoku-Kikyo, N; Reed, P; Tamada, H; Kikyo, N			Requirement of the protein B23 for nucleolar disassembly induced by the FRGY2a family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I TRANSCRIPTION; MESSENGER-RNA; EMBRYONIC-DEVELOPMENT; NUCLEOPLASMIN FAMILY; NUCLEAR-LOCALIZATION; RIBOSOME BIOGENESIS; XENOPUS-LAEVIS; CELLS; P53; IDENTIFICATION	In Xenopus somatic cell nuclear cloning, the nucleoli of donor nuclei rapidly and almost completely disappear in egg cytoplasm. We previously showed that the germ cell-specific proteins FRGY2a and FRGY2b were responsible for this unusually drastic nucleolar disassembly. The nucleolar disassembly occurs without inhibition of pre-rRNA transcription, a well known trigger for nucleolar segregation, and the mechanism for the nucleolar disassembly by FRGY2a and FRGY2b remains largely unknown. In this study, we searched for FRGY2a-interacting proteins and investigated the functional consequences of their interactions through a series of experiments. We showed that during the nucleolar disassembly, FRGY2a localized to the nucleoli of isolated nuclei and was capable of disassembling purified nucleoli, suggesting a direct interaction between FRGY2a and nucleolar components. Using a His tag pull-down approach, we identified the abundant and multifunctional nucleolar protein B23 as a potential target of FRGY2a and its related human protein YB1. A specific interaction between FRGY2a/YB1 and B23 was confirmed by co-immunoprecipitation. Finally, B23 knockdown using short interfering RNA and a subsequent add-back experiment confirmed that B23 was necessary for nucleolar disassembly by YB1. We propose that FRGY2a and YB1 disassemble nucleoli by sequestering B23, which is associated with pre-ribosomes and other structurally important nucleolar components.	Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kikyo, N (corresponding author), Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Stem Cell Inst, MMC 716,420 Delaware St SE, Minneapolis, MN 55455 USA.	kikyo001@tc.umn.edu			NIGMS NIH HHS [R01 GM068027-03, R01 GM068027-01A1, R01 GM068027-02, R01 GM068027] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068027] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; CAIRNS C, 1995, NUCLEIC ACIDS RES, V23, P4583, DOI 10.1093/nar/23.22.4583; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; Gonda K, 2003, NAT CELL BIOL, V5, P205, DOI 10.1038/ncb939; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; GURDON JB, 1965, J MOL BIOL, V12, P27, DOI 10.1016/S0022-2836(65)80279-0; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Leung AKL, 2003, CRIT REV EUKAR GENE, V13, P39, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.40; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SCHMIDTZACHMANN MS, 1984, EXP CELL RES, V153, P327, DOI 10.1016/0014-4827(84)90604-9; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Simard R, 1970, Int Rev Cytol, V28, P169, DOI 10.1016/S0074-7696(08)62543-7; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Verheggen C, 1998, J CELL BIOL, V142, P1167, DOI 10.1083/jcb.142.5.1167; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Winokur ST, 1998, HUM MOL GENET, V7, P1947, DOI 10.1093/hmg/7.12.1947; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Yang JX, 2005, P NATL ACAD SCI USA, V102, P5755, DOI 10.1073/pnas.0408718102; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; Zirwes RF, 1997, P NATL ACAD SCI USA, V94, P11387, DOI 10.1073/pnas.94.21.11387	41	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8153	8160		10.1074/jbc.M512890200	http://dx.doi.org/10.1074/jbc.M512890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415342	Green Accepted, hybrid			2022-12-27	WOS:000236031000053
J	Hakansson, P; Hofer, A; Thelander, L				Hakansson, P; Hofer, A; Thelander, L			Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT MOUSE; RENAL-FAILURE; SMALL-SUBUNIT; CYCLE; REPLICATION; EXPRESSION; PROTEIN; LOCALIZATION; INHIBITION; CHECKPOINT	Ribonucleotide reductase (RNR) provides the cell with a balanced supply of deoxyribonucleoside triphosphates ( dNTP) for DNA synthesis. In budding yeast DNA damage leads to an up-regulation of RNR activity and an increase in dNTP pools, which are essential for survival. Mammalian cells contain three non-identical subunits of RNR; that is, one homodimeric large subunit, R1, carrying the catalytic site and two variants of the homodimeric small subunit, R2 and the p53-inducible p53R2, each containing a tyrosyl free radical essential for catalysis. S-phase-specific DNA replication is supported by an RNR consisting of the R1 and R2 subunits. In contrast, DNA damage induces expression of the R1 and the p53R2 subunits. We now show that neither logarithmically growing nor G(o)/G(1)-synchronized mammalian cells show any major increase in their dNTP pools after DNA damage. However, non-dividing fibroblasts expressing the p53R2 protein, but not the R2 protein, have reduced dNTP levels if exposed to the RNR-specific inhibitor hydroxyurea, strongly indicating that there is ribonucleotide reduction in resting cells. The slow, 4-fold increase in p53R2 protein expression after DNA damage results in a less than 2-fold increase in the dNTP pools in G(o)/G(1) cells, where the pools are about 5% that of the size of the pools in S-phase cells. Our results emphasize the importance of the low constitutive levels of p53R2 in mammalian cells, which together with low levels of R1 protein may be essential for the supply of dNTPs for basal levels of DNA repair and mitochondrial DNA synthesis in G(o)/G(1) cells.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Hakansson, P (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	pelle.hakanson@medchem.umu.se		Hakansson, Pelle/0000-0003-0421-2433; Hofer, Anders/0000-0003-2890-2957				AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hakansson P, 2006, J BIOL CHEM, V281, P1778, DOI 10.1074/jbc.M511716200; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Imaizumi T, 1996, J DERMATOL SCI, V11, P134, DOI 10.1016/0923-1811(95)00431-9; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; Lembo D, 2000, J VIROL, V74, P11557, DOI 10.1128/JVI.74.24.11557-11565.2000; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; MANN GJ, 1988, CANCER RES, V48, P5151; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; NORDLUND P, 2006, IN PRESS ANN REV BIO; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; Powell DR, 2005, PEDIATR NEPHROL, V20, P432, DOI 10.1007/s00467-004-1696-5; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Sandrini MPB, 2005, TRENDS BIOCHEM SCI, V30, P225, DOI 10.1016/j.tibs.2005.03.003; SETO S, 1986, J IMMUNOL, V136, P2839; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	45	220	224	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7834	7841		10.1074/jbc.M512894200	http://dx.doi.org/10.1074/jbc.M512894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436374	hybrid			2022-12-27	WOS:000236031000017
J	Knapp, AM; Ramsey, JE; Wang, SX; Godburn, KE; Strauch, AR; Kelm, RJ				Knapp, AM; Ramsey, JE; Wang, SX; Godburn, KE; Strauch, AR; Kelm, RJ			Nucleoprotein interactions governing cell type-dependent repression of the mouse smooth muscle alpha-actin promoter by single-stranded DNA-binding proteins Pur alpha and Pur beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; MYELIN BASIC-PROTEIN; CD43 GENE PROMOTER; MYOSIN HEAVY-CHAIN; MYOFIBROBLAST DIFFERENTIATION; TRANSCRIPTIONAL ACTIVITY; FUNCTIONAL INTERACTION; MCAT ENHANCER; NIH3T3 CELLS; IN-VITRO	Pur alpha and Pur beta are structurally related single-stranded DNA/RNA-binding proteins implicated in the control of cell growth and differentiation. The goal of this study was to determine whether Pur alpha and Pur beta function in a redundant, distinct, or collaborative manner to suppress smooth muscle alpha-actin gene expression in cell types relevant to wound repair and vascular remodeling. RNA interference-mediated loss-of-function analyses revealed that, although Pur beta was the dominant repressor, the combined action of endogenous Pur alpha and Pur beta was necessary to fully repress the full-length smooth muscle alpha-actin promoter in cultured fibroblasts but to a lesser extent in vascular smooth muscle cells. The activity of a minimal core enhancer containing a truncated 5' Pur repressor binding site was unaffected by knockdown of Pur alpha and/or Pur beta in fibroblasts. Conversely, gain-of-function studies indicated that Pur alpha or Pur beta could each independently repress core smooth muscle alpha-actin enhancer activity albeit in a cell type-dependent fashion. Biochemical analyses indicated that purified recombinant Pur alpha and Pur beta were essentially identical in terms of their binding affinity and specificity for GGN repeat-containing strands of several cis-elements comprising the core enhancer. However, Pur alpha and Pur beta exhibited more distinctive protein interaction profiles when evaluated for binding to enhancer-associated transcription factors in extracts from fibroblasts and vascular smooth muscle cells. These findings support the hypothesis that Pur alpha and Pur beta repress smooth muscle alpha-actin gene transcription by means of DNA strand-selective cis-element binding and cell type-dependent protein-protein interactions.	Univ Vermont, Coll Med, Dept Biochem, Cardiovasc Res Inst, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Med, Cardiovasc Res Inst, Burlington, VT 05405 USA; Ohio State Univ, Coll Med & Publ Hlth, Dorothy M Davis Heart & Lung Res Inst, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University of Vermont; University of Vermont; University System of Ohio; Ohio State University	Kelm, RJ (corresponding author), UVM, Colchester Res Facil, 208 S Pk Dr, Colchester, VT 05446 USA.	Robert.Kelm@uvm.edu			NHLBI NIH HHS [HL07594, HL 54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ban CG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh109; Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; Becker NA, 2000, J BIOL CHEM, V275, P15384, DOI 10.1074/jbc.M909687199; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; Bot I, 2003, CIRC RES, V93, P464, DOI 10.1161/01.RES.0000090993.01633.D4; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Chen YB, 2004, J CELL BIOCHEM, V92, P178, DOI 10.1002/jcb.20058; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; Da Silva N, 2002, BLOOD, V100, P3536, DOI 10.1182/blood.V100.10.3536; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; Darbinian N, 2001, J CELL BIOCHEM, V80, P589, DOI 10.1002/1097-4644(20010315)80:4<589::AID-JCB1013>3.0.CO;2-0; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; de Oliveira FMB, 2004, MOL BIOCHEM PARASIT, V135, P21, DOI 10.1016/j.molbiopara.2003.12.009; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Ding Y, 1997, NEUROCHEM INT, V31, P45, DOI 10.1016/S0197-0186(96)00127-1; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Engelse MA, 2002, CIRC RES, V90, P1128, DOI 10.1161/01.RES.0000021044.53156.F5; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; Gallia GL, 1998, J BIOL CHEM, V273, P32662, DOI 10.1074/jbc.273.49.32662; Gallia GL, 1999, J CELL BIOCHEM, V74, P334, DOI 10.1002/(SICI)1097-4644(19990901)74:3<334::AID-JCB3>3.0.CO;2-O; Gallia GL, 2001, J CELL BIOCHEM, V83, P355, DOI 10.1002/jcb.1247; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Gupta M, 2003, J BIOL CHEM, V278, P44935, DOI 10.1074/jbc.M307696200; Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; Itoh S, 2002, CIRCULATION, V105, P2288, DOI 10.1161/01.CIR.0000015607.33345.1F; Johnson EM, 2003, ANTICANCER RES, V23, P2093; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Juliano RL, 2005, J CELL BIOL, V169, P847, DOI 10.1083/jcb.200501053; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kelm RJ, 2003, J BIOL CHEM, V278, P38749, DOI 10.1074/jbc.M306163200; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1999, J BIOL CHEM, V274, P38268, DOI 10.1074/jbc.274.53.38268; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Khalili K, 2003, MOL CELL BIOL, V23, P6857, DOI 10.1128/MCB.23.19.6857-6875.2003; Kolodgie FD, 2001, CURR OPIN CARDIOL, V16, P285, DOI 10.1097/00001573-200109000-00006; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; Li YM, 2001, BIOL PHARM BULL, V24, P231, DOI 10.1248/bpb.24.231; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Limesand SW, 2004, MOL ENDOCRINOL, V18, P447, DOI 10.1210/me.2003-0392; Liu H, 2005, BIOCHEM BIOPH RES CO, V328, P851, DOI 10.1016/j.bbrc.2005.01.038; Liu H, 2002, NUCLEIC ACIDS RES, V30, P2417, DOI 10.1093/nar/30.11.2417; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Melnikova IN, 2000, EUR J PHARMACOL, V393, P75, DOI 10.1016/S0014-2999(99)00884-5; Muralidharan V, 1997, J CELL BIOCHEM, V66, P524, DOI 10.1002/(SICI)1097-4644(19970915)66:4<524::AID-JCB11>3.0.CO;2-B; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Penberthy WT, 2004, DEV BIOL, V275, P225, DOI 10.1016/j.ydbio.2004.08.007; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sadakata T, 2000, MOL BRAIN RES, V77, P47, DOI 10.1016/S0169-328X(00)00039-5; Safak R, 1999, MOL CELL BIOL, V19, P2712; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Schildmeyer LA, 2000, FASEB J, V14, P2213, DOI 10.1096/fj.99-0927com; Schneider DJ, 1997, CIRCULATION, V96, P2868, DOI 10.1161/01.CIR.96.9.2868; Shelley CS, 2002, J IMMUNOL, V168, P3887, DOI 10.4049/jimmunol.168.8.3887; Shelley CS, 2001, BRIT J HAEMATOL, V115, P159, DOI 10.1046/j.1365-2141.2001.03066.x; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; Subramanian SV, 2004, MOL BIOL CELL, V15, P4532, DOI 10.1091/mbc.E04-04-0348; Subramanian SV, 2002, CARDIOVASC RES, V54, P539, DOI 10.1016/S0008-6363(02)00270-5; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Wang SX, 2005, J BIOL CHEM, V280, P6204, DOI 10.1074/jbc.M409506200; Wei Q, 2005, J BIOL CHEM, V280, P16284, DOI 10.1074/jbc.M500491200; Wilcox JN, 2001, ANN NY ACAD SCI, V947, P68; Wortman MJ, 2005, BBA-MOL CELL RES, V1743, P64, DOI 10.1016/j.bbamcr.2004.08.010; Yoshida T, 2005, CIRC RES, V96, P280, DOI 10.1161/01.RES.0000155951.62152.2e; Zeng LH, 2005, NEUROSCI RES, V51, P105, DOI 10.1016/j.neures.2004.09.009; Zhang AW, 2005, MOL BIOL CELL, V16, P4931, DOI 10.1091/mbc.E05-03-0216; Zhang QB, 2005, GENE, V348, P25, DOI 10.1016/j.gene.2004.12.050	77	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7907	7918		10.1074/jbc.M509682200	http://dx.doi.org/10.1074/jbc.M509682200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436378	hybrid			2022-12-27	WOS:000236031000026
J	Hattori, K; Uchino, S; Isosaka, T; Maekawa, M; Iyo, M; Sato, T; Kohsaka, S; Yagi, T; Yuasa, S				Hattori, K; Uchino, S; Isosaka, T; Maekawa, M; Iyo, M; Sato, T; Kohsaka, S; Yagi, T; Yuasa, S			Fyn is required for haloperidol-induced catalepsy in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; PROTEIN-KINASE-C; ENHANCED TYROSINE PHOSPHORYLATION; INDUCED GENE-EXPRESSION; NMDA-RECEPTOR; ANTIPSYCHOTIC-DRUGS; DEFICIENT MICE; INCREASED FEARFULNESS; FOS PROTEIN; SRC-FAMILY	Fyn-mediated tyrosine phosphorylation of N-methyl-D-aspartate ( NMDA) receptor subunits has been implicated in various brain functions, including ethanol tolerance, learning, and seizure susceptibility. In this study, we explored the role of Fyn in haloperidol-induced catalepsy, an animal model of the extrapyramidal side effects of antipsychotics. Haloperidol induced catalepsy and muscle rigidity in the control mice, but these responses were significantly reduced in Fyn-deficient mice. Expression of the striatal dopamine D-2 receptor, the main site of haloperidol action, did not differ between the two genotypes. Fyn activation and enhanced tyrosine phosphorylation of the NMDA receptor NR2B subunit, as measured by Western blotting, were induced after haloperidol injection of the control mice, but both responses were significantly reduced in Fyn-deficient mice. Dopamine D2 receptor blockade was shown to increase both NR2B phosphorylation and the NMDA-induced calcium responses in control cultured striatal neurons but not in Fyn-deficient neurons. Based on these findings, we proposed a new molecular mechanism underlying haloperidol-induced catalepsy, in which the dopamine D2 receptor antagonist induces striatal Fyn activation and the subsequent tyrosine phosphorylation of NR2B alters striatal neuronal activity, thereby inducing the behavioral changes that are manifested as a cataleptic response.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan; Osaka Univ, KOKORO Biol Grp, FBS, Suita, Osaka 5650871, Japan; Univ Grad Sch Med, Dept Psychiat, Chiba 2608670, Japan; Univ Grad Sch Med, Dept Anat & Dev Biol, Chiba 2608670, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Osaka University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Hattori, K (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo 1878502, Japan.	hattori@ncnp.go.jp						Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; Boulay D, 2000, EUR J PHARMACOL, V391, P63, DOI 10.1016/S0014-2999(99)00916-4; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; Chartoff EH, 1999, J PHARMACOL EXP THER, V291, P531; Chase TN, 2004, PARKINSONISM RELAT D, V10, P305, DOI 10.1016/j.parkreldis.2004.02.012; Chen JF, 2001, P NATL ACAD SCI USA, V98, P1970, DOI 10.1073/pnas.98.4.1970; Cheung HH, 2001, J NEUROCHEM, V78, P524, DOI 10.1046/j.1471-4159.2001.00433.x; Crocker AD, 2001, PROG NEURO-PSYCHOPH, V25, P573, DOI 10.1016/S0278-5846(00)00176-7; De Souza IEJ, 1999, SYNAPSE, V32, P243, DOI 10.1002/(SICI)1098-2396(19990615)32:4<243::AID-SYN1>3.0.CO;2-O; DRAGUNOW M, 1990, NEUROSCIENCE, V37, P287, DOI 10.1016/0306-4522(90)90399-O; Dwivedi Y, 1999, J PHARMACOL EXP THER, V291, P688; Hironaka N, 2002, MOL BRAIN RES, V98, P102, DOI 10.1016/S0169-328X(01)00329-1; Kojima N, 1998, LEARN MEMORY, V5, P429; Kosinski CM, 1998, J COMP NEUROL, V390, P63; Kotecha SA, 2002, NEURON, V35, P1111, DOI 10.1016/S0896-6273(02)00859-0; Kulagowski JJ, 1996, J MED CHEM, V39, P1941, DOI 10.1021/jm9600712; Leveque JC, 2000, J NEUROSCI, V20, P4011; LorencKoci E, 1996, EXP BRAIN RES, V109, P268; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; Millan MJ, 2000, J PHARMACOL EXP THER, V293, P1063; MILLER AL, 1993, BIOL PSYCHIAT, V34, P178, DOI 10.1016/0006-3223(93)90389-U; Miyakawa T, 1996, MOL BRAIN RES, V37, P145; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; MOORE NA, 1993, EUR J PHARMACOL, V237, P1, DOI 10.1016/0014-2999(93)90085-V; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Oh JD, 1998, BRAIN RES, V813, P150, DOI 10.1016/S0006-8993(98)01049-X; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Saga Y, 1999, GENES CELLS, V4, P219, DOI 10.1046/j.1365-2443.1999.00253.x; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Svensson TH, 2000, BRAIN RES REV, V31, P320, DOI 10.1016/S0165-0173(99)00048-X; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tsai GC, 2002, ANNU REV PHARMACOL, V42, P165, DOI 10.1146/annurev.pharmtox.42.082701.160735; Uchino S, 2001, FEBS LETT, V506, P117, DOI 10.1016/S0014-5793(01)02899-X; Viviani B, 2003, J NEUROSCI, V23, P8692; Wadenberg MLG, 2001, NEUROPSYCHOPHARMACOL, V25, P633, DOI 10.1016/S0893-133X(01)00261-5; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Watanabe M, 1998, EUR J NEUROSCI, V10, P478, DOI 10.1046/j.1460-9568.1998.00063.x; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAGI T, 1993, ONCOGENE, V8, P3343; Yaka R, 2003, J NEUROSCI, V23, P3623; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yanahashi S, 2004, BRAIN RES, V1011, P84, DOI 10.1016/j.brainres.2003.12.059; Yasunaga M, 1996, J CELL BIOL, V132, P91, DOI 10.1083/jcb.132.1.91; Yuasa S, 1996, ANAT EMBRYOL, V194, P223; ZIOLKOWSKA B, 1993, NEUROSCI LETT, V156, P39, DOI 10.1016/0304-3940(93)90434-M	51	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7129	7135		10.1074/jbc.M511608200	http://dx.doi.org/10.1074/jbc.M511608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407246	hybrid			2022-12-27	WOS:000236030900027
J	Weigert, C; Hennige, AM; Lehmann, R; Brodbeck, K; Baumgartner, F; Schauble, M; Haring, HU; Schleicher, ED				Weigert, C; Hennige, AM; Lehmann, R; Brodbeck, K; Baumgartner, F; Schauble, M; Haring, HU; Schleicher, ED			Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CIRCULATING INTERLEUKIN-6; INDUCED APOPTOSIS; IN-VIVO; PHOSPHORYLATION; PROTEIN; KINASE; EXERCISE; IRS-1; IL-6	The exercise-induced interleukin (IL)-6 production and secretion within skeletal muscle fibers has raised the question of a putative tissue-specific function of IL-6 in the energy metabolism of the muscle during and after the exercise. In the present study, we followed the hypothesis that IL-6 signaling may directly interact with insulin receptor substrate (IRS)-1, a keystone in the insulin signaling cascade. We showed that IL-6 induces a rapid recruitment of IRS-1 to the IL-6 receptor complex in cultured skeletal muscle cells. Moreover, IL-6 induced a rapid and transient phosphorylation of Ser-318 of IRS-1 in muscle cells and in muscle tissue, but not in the liver of IL-6-treated mice, probably via the IL-6-induced co-recruitment of protein kinase C-delta. This Ser-318 phosphorylation improved insulin-stimulated Akt phosphorylation and glucose uptake in myotubes since transfection with an IRS-1/Glu-318 mutant simulating a permanent phospho-Ser-318 modification increased Akt phosphorylation and glucose uptake. Noteworthily, two inhibitory mechanisms of IL-6 on insulin action, phosphorylation of the inhibitory Ser-307 residue of IRS-1 and induction of SOCS-3 expression, were only found in liver but not in muscle of IL-6-treated mice. Thus, the data provided evidence for a possible molecular mechanism of the physiological metabolic effects of IL-6 in skeletal muscle, thereby exerting short term beneficial effects on insulin action.	Univ Tubingen, Dept Internal Med, Div Endocrinol Metab Pathobiochem & Clin Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Weigert, C (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Metab Pathobiochem & Clin Chem, Otfried Muller Str 10, D-72076 Tubingen, Germany.	caweiger@med.uni-tuebingen.de	Lehmann, Rainer/AAF-4281-2019	Lehmann, Rainer/0000-0003-1218-6810				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; Bruce CR, 2004, AM J PHYSIOL-ENDOC M, V287, pE616, DOI 10.1152/ajpendo.00150.2004; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Faldt J, 2004, ENDOCRINOLOGY, V145, P2680, DOI 10.1210/en.2003-1319; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Fernandez-Real JM, 2001, J CLIN ENDOCR METAB, V86, P1154, DOI 10.1210/jc.86.3.1154; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Hawley JA, 2004, DIABETES-METAB RES, V20, P383, DOI 10.1002/dmrr.505; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Krutzfeldt J, 2000, DIABETES, V49, P992, DOI 10.2337/diabetes.49.6.992; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Mussig K, 2005, J BIOL CHEM, V280, P32693, DOI 10.1074/jbc.M506549200; Novotny-Diermayr V, 2002, J BIOL CHEM, V277, P49134, DOI 10.1074/jbc.M206727200; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pedersen BK, 2003, J MUSCLE RES CELL M, V24, P113, DOI 10.1023/A:1026070911202; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Petersen EW, 2005, AM J PHYSIOL-ENDOC M, V288, pE155, DOI 10.1152/ajpendo.00257.2004; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Rosendal L, 2004, ACTA PHYSIOL SCAND, V182, P379, DOI 10.1111/j.1365-201X.2004.01356.x; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sakamoto K, 2004, BIOCHEM BIOPH RES CO, V319, P419, DOI 10.1016/j.bbrc.2004.05.020; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Steensberg A, 2002, AM J PHYSIOL-ENDOC M, V283, pE1272, DOI 10.1152/ajpendo.00255.2002; Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687; Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weigert C, 2005, J BIOL CHEM, V280, P37393, DOI 10.1074/jbc.M506134200; Weigert C, 2005, AM J PHYSIOL-ENDOC M, V289, pE251, DOI 10.1152/ajpendo.00448.2004; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Wojtaszewski JFP, 2003, ACTA PHYSIOL SCAND, V178, P321, DOI 10.1046/j.1365-201X.2003.01151.x; Wojtaszewski JFP, 2000, DIABETES, V49, P325, DOI 10.2337/diabetes.49.3.325	51	101	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7060	7067		10.1074/jbc.M509782200	http://dx.doi.org/10.1074/jbc.M509782200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16418171	hybrid			2022-12-27	WOS:000236030900019
J	Kurosu, H; Ogawa, Y; Miyoshi, M; Yamamoto, M; Nandi, A; Rosenblatt, KP; Baum, MG; Schiavi, S; Hu, CM; Moe, OW; Kuro-o, M				Kurosu, H; Ogawa, Y; Miyoshi, M; Yamamoto, M; Nandi, A; Rosenblatt, KP; Baum, MG; Schiavi, S; Hu, CM; Moe, OW; Kuro-o, M			Regulation of fibroblast growth factor-23 signaling by Klotho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT HYPOPHOSPHATEMIC RICKETS; BILE-ACID SYNTHESIS; HORMONE KLOTHO; PHOSPHATE; MICE; PROTEIN; FGF-23; FGF23; SUPPRESSION; HOMEOSTASIS	The aging suppressor gene Klotho encodes a single-pass transmembrane protein. Klotho-deficient mice exhibit a variety of aging-like phenotypes, many of which are similar to those observed in fibroblast growth factor-23 (FGF23)-deficient mice. To test the possibility that Klotho and FGF23 may function in a common signal transduction pathway(s), we investigated whether Klotho is involved in FGF signaling. Here we show that Klotho protein directly binds to multiple FGF receptors (FGFRs). The Klotho-FGFR complex binds to FGF23 with higher affinity than FGFR or Klotho alone. In addition, Klotho significantly enhanced the ability of FGF23 to induce phosphorylation of FGF receptor substrate and ERK in various types of cells. Thus, Klotho functions as a cofactor essential for activation of FGF signaling by FGF23.	Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Appl Genom, Dallas, TX 75390 USA	Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kuro-o, M (corresponding author), Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Pathol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	makoto.kuroo@utsouthwestern.edu	Ogawa, Yasushi/I-1140-2012; Ogawa, Yasushi/M-8900-2014	Ogawa, Yasushi/0000-0003-3553-9607	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025326, R01AG019712] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG25326, R01AG19712, R01 AG025326, R01 AG019712-05, R01 AG025326-03, R01 AG019712] Funding Source: Medline; NIDDK NIH HHS [R01DK065842, R01 DK065842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baum M, 2005, KIDNEY INT, V68, P1148, DOI 10.1111/j.1523-1755.2005.00506.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Ikushima M, 2006, BIOCHEM BIOPH RES CO, V339, P827, DOI 10.1016/j.bbrc.2005.11.094; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Ito S, 2005, J CLIN INVEST, V115, P2202, DOI 10.1172/JCI23076; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Liu SG, 2003, J BIOL CHEM, V278, P37419, DOI 10.1074/jbc.M304544200; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200; Yamashita T, 2002, J BIOL CHEM, V277, P28265, DOI 10.1074/jbc.M202527200; Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105; Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Yu XJ, 2005, ENDOCRINOLOGY, V146, P4647, DOI 10.1210/en.2005-0670	24	989	1077	0	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6120	6123		10.1074/jbc.C500457200	http://dx.doi.org/10.1074/jbc.C500457200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16436388	Green Accepted, hybrid			2022-12-27	WOS:000236030800002
J	Mattera, R; Tsai, YC; Weissman, AM; Bonifacino, JS				Mattera, R; Tsai, YC; Weissman, AM; Bonifacino, JS			The Rab5 guanine nucleotide exchange factor Rabex-5 binds ubiquitin (Ub) and functions as a Ub ligase through an atypical Ub-interacting motif and a zinc finger domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUE DOMAIN; RECEPTOR ENDOCYTOSIS; PROTEIN; COMPLEX; RABAPTIN-5; FAMILY; VPS9P; A20; IDENTIFICATION; RECOGNITION	Rabex-5, the mammalian orthologue of yeast Vps9p, is a guanine nucleotide exchange factor for Rab5. Rabex-5 forms a tight complex with Rabaptin-5, a multivalent adaptor protein that also binds to Rab4, Rab5, and to domains present in gamma-adaptins and the Golgi-localized, gamma-ear-containing, ARF-binding proteins ( GGAs). Rabaptin-5 augments the Rabex-5 exchange activity, thus generating GTP-bound, membrane-associated Rab5 that, in turn, binds Rabaptin-5 and stabilizes the Rabex-5 . Rabaptin-5 complex on endosomes. Although the Rabex-5 . Rabaptin-5 complex is critical to the regulation of endosomal fusion, the structural determinants of this interaction are unknown. Likewise, the possible binding and covalent attachment of ubiquitin to Rabex-5, two modifications that are critical to the function of yeast Vps9p in endosomal transport, have not been studied. In this study, we identify the 401 - 462 and 551 - 661 coiled-coils as the regions in Rabex-5 and Rabaptin-5, respectively, that interact with one another. We also demonstrate that Rabex-5 undergoes ubiquitination and binds ubiquitin, though not via its proposed C-terminal CUE-like domain. Instead, the N-terminal region of Rabex-5 ( residues 1 - 76), comprising an A20-like Cys(2)/ Cys(2) zinc finger and an adjacent alpha-helix, is important for ubiquitin binding and ubiquitination. Importantly, we demonstrate that the Rabex-5 zinc finger displays ubiquitin ligase (E3) activity. These observations extend our understanding of the regulation of Rabex-5 by Rabaptin-5. Moreover, the demonstration that Rabex-5 is a ubiquitin ligase that binds ubiquitin and undergoes ubiquitination indicates that its role in endosome fusion may be subject to additional regulation by ubiquitin-dependent modifications.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Prot Dynam & Signaling, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010292, Z01BC010292] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Fujiwara K, 2004, J BIOL CHEM, V279, P4760, DOI 10.1074/jbc.M309448200; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Mattera R, 2004, J BIOL CHEM, V279, P31409, DOI 10.1074/jbc.M402183200; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhu GY, 2004, EMBO J, V23, P3909, DOI 10.1038/sj.emboj.7600411	35	91	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6874	6883		10.1074/jbc.M509939200	http://dx.doi.org/10.1074/jbc.M509939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407276	hybrid			2022-12-27	WOS:000236030800085
J	Swem, LR; Gong, X; Yu, CA; Bauer, CE				Swem, LR; Gong, X; Yu, CA; Bauer, CE			Identification of a ubiquinone-binding site that affects autophosphorylation of the sensor kinase RegB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; RHODOBACTER-SPHAEROIDES 2.4.1; CYTOCHROME-C REDUCTASE; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; DOMAIN; CAPSULATUS; EXPRESSION; PROTEIN; OXIDASE	Rhodobacter capsulatus regulates many metabolic processes in response to the level of environmental oxygen and the energy state of the cell. One of the key global redox regulators of the cell's metabolic physiology is the sensor kinase RegB that controls the synthesis of numerous energy generation and utilization processes. In this study, we have succeeded in purifying full-length RegB containing six transmembrane-spanning elements. Exogenous addition of excess oxidized coenzyme Q(1) is capable of inhibiting RegB autophosphorylation similar to 6-fold. However, the addition of reduced coenzyme Q(1) exhibits no inhibitory effect on kinase activity. A ubiquinone-binding site, as defined by azidoquinone photo affinity cross-linking, was determined to lie within a periplasmic loop between transmembrane helices 3 and 4 that contains a fully conserved heptapeptide sequence of GGXXNPF. Mutation of the phenylalanine in this heptapeptide renders RegB constitutively active in vivo, indicating that this domain is responsible for sensing the redox state of the ubiquinone pool and subsequently controlling RegB autophosphorylation.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Indiana University System; Indiana University Bloomington; Oklahoma State University System; Oklahoma State University - Stillwater	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	cbauer@bio.indiana.edu			NIGMS NIH HHS [R37 GM040941, R01 GM053940, R01 GM040941, GM53940, R01 GM030721, R37 GM040941-21, R37 GM030721, GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R37GM040941, R01GM053940, R01GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bird TH, 1999, J BIOL CHEM, V274, P16343, DOI 10.1074/jbc.274.23.16343; Bock A, 2002, EUR J BIOCHEM, V269, P3479, DOI 10.1046/j.1432-1033.2002.03029.x; BOLTON JR, 1978, PHOTOSYNTHETIC BACTE, P419; BUGGY JJ, 1994, J BACTERIOL, V176, P6936, DOI 10.1128/JB.176.22.6936-6943.1994; DOYLE MP, 1989, J BIOL CHEM, V264, P1387; Dubbs JM, 2000, J BIOL CHEM, V275, P19224, DOI 10.1074/jbc.M002125200; Elsen S, 2000, J BACTERIOL, V182, P2831, DOI 10.1128/JB.182.10.2831-2837.2000; Elsen S, 2004, MICROBIOL MOL BIOL R, V68, P263, DOI 10.1128/MMBR.68.2.263-279.2004; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; HE DY, 1994, J BIOL CHEM, V269, P2292; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; MADIGAN MT, 1978, ARCH MICROBIOL, V117, P119, DOI 10.1007/BF00402298; Malpica R, 2004, P NATL ACAD SCI USA, V101, P13318, DOI 10.1073/pnas.0403064101; Oh JI, 2004, BIOCHEMISTRY-US, V43, P7915, DOI 10.1021/bi0496440; Oh JI, 2001, J BACTERIOL, V183, P6807, DOI 10.1128/JB.183.23.6807-6814.2001; Ouchane S, 1999, J BIOL CHEM, V274, P17290, DOI 10.1074/jbc.274.24.17290; Parson W. W., 1978, PHOTOSYNTHETIC BACTE, P455; Potter CA, 2002, J MOL BIOL, V320, P201, DOI 10.1016/S0022-2836(02)00424-2; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; Swem LR, 2003, EMBO J, V22, P4699, DOI 10.1093/emboj/cdg461; WELTER R, 1994, J BIOL CHEM, V269, P28834; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; YANG FD, 1986, J BIOL CHEM, V261, P4987; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1986, BIOCHIM BIOPHYS ACTA, V848, P305, DOI 10.1016/0005-2728(86)90204-5; YU L, 1987, J BIOL CHEM, V262, P1137	30	77	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6768	6775		10.1074/jbc.M509687200	http://dx.doi.org/10.1074/jbc.M509687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407278	hybrid, Green Accepted			2022-12-27	WOS:000236030800075
J	Richter, K; Moser, S; Hagn, F; Friedrich, R; Hainzl, O; Heller, M; Schlee, S; Kessler, H; Reinstein, J; Buchner, J				Richter, K; Moser, S; Hagn, F; Friedrich, R; Hainzl, O; Heller, M; Schlee, S; Kessler, H; Reinstein, J; Buchner, J			Intrinsic inhibition of the Hsp90 ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; HEAT-SHOCK PROTEINS; GYRASE-B-PROTEIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; CLIENT PROTEIN; IN-VIVO; CONFORMATIONAL-CHANGE; STEROID-RECEPTOR; STRUCTURAL BASIS	The molecular chaperone Hsp90 is required for the folding and activation of a large number of substrate proteins. These are involved in essential cellular processes ranging from signal transduction to viral replication. For the activation of its substrates, Hsp90 binds and hydrolyzes ATP, which is the key driving force for conformational conversions within the dimeric chaperone. Dimerization of Hsp90 is mediated by a C-terminal dimerization site. In addition, there is a transient ATP-induced dimerization of the two N-terminal ATP-binding domains. The resulting ring-like structure is thought to be the ATPase-active conformation. Hsp90 is a slow ATPase with a turnover number of 1 ATP/min for the yeast protein. A key question for understanding the molecular mechanism of Hsp90 is how ATP hydrolysis is regulated and linked to conformational changes. In this study, we analyzed the activation process structurally and biochemically with a view to identify the conformational limitations of the ATPase reaction cycle. We showed that the firs t24 amino acids stabilize the N-terminal domain in a rigid state. Their removal confers flexibility specifically to the region between amino acids 98 and 120. Most surprisingly, the deletion of this structure results in the complete loss of ATPase activity and in increased N-terminal dimerization. Complementation assays using heterodimeric Hsp90 show that this rigid lid acts as an intrinsic kinetic inhibitor of the Hsp90 ATPase cycle preventing N-terminal dimerization in the ground state. On the other hand, this structure acts, in concert with the 24 N-terminal amino acids of the other N-terminal domain, to form an activated ATPase and thus regulates the turnover number of Hsp90.	Tech Univ Munich, Inst Organ Chem & Biochem, Dept Chem, D-85747 Garching, Germany; Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Hagn, Franz X/N-9553-2016; Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010; Kessler, Horst/C-1178-2010	Hagn, Franz X/0000-0002-1315-459X; Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Cole R, 2003, J BIOMOL NMR, V26, P203, DOI 10.1023/A:1023808801134; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; Dehner A, 2003, CHEMBIOCHEM, V4, P870, DOI 10.1002/cbic.200300658; Dollins DE, 2005, J BIOL CHEM, V280, P30438, DOI 10.1074/jbc.M503761200; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GODDARD TD, 2000, SPARKY VERSION 3 110; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Huai Q, 2005, STRUCTURE, V13, P579, DOI 10.1016/j.str.2004.12.018; Immormino RM, 2004, J BIOL CHEM, V279, P46162, DOI 10.1074/jbc.M405253200; JAHNKE W, 1995, J MAGN RESON SER B, V106, P86, DOI 10.1006/jmrb.1995.1015; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Leutner M, 1998, J BIOMOL NMR, V11, P31, DOI 10.1023/A:1008298226961; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Meyer P, 2004, EMBO J, V23, P511, DOI 10.1038/sj.emboj.7600060; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Richter K, 2004, J MOL BIOL, V342, P1403, DOI 10.1016/j.jmb.2004.07.064; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; RICHTER K, 2005, PROTEIN FOLDING HDB, P768; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Salek RM, 2002, J BIOMOL NMR, V23, P327, DOI 10.1023/A:1020268712347; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; Tsai FTF, 1997, PROTEINS, V28, P41; Wegele H, 2003, J BIOL CHEM, V278, P39303, DOI 10.1074/jbc.M305751200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	57	63	65	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11301	11311		10.1074/jbc.M510142200	http://dx.doi.org/10.1074/jbc.M510142200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16461354	hybrid			2022-12-27	WOS:000236822200073
J	Atteia, A; van Lis, R; Gelius-Dietrich, G; Adrait, A; Garin, J; Joyard, J; Rolland, N; Martin, W				Atteia, A; van Lis, R; Gelius-Dietrich, G; Adrait, A; Garin, J; Joyard, J; Rolland, N; Martin, W			Pyruvate formate-lyase and a novel route of eukaryotic ATP synthesis in Chlamydomonas mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVATING ENZYME; RUMINAL BACTERIUM; PROTEIN; REINHARDTII; OXIDOREDUCTASE; DEHYDROGENASE; SEQUENCE; IDENTIFICATION; PURIFICATION	Pyruvate formate-lyase (PFL) catalyzes the non-oxidative conversion of pyruvate to formate and acetyl-CoA.PFL and its activating enzyme (PFL-AE) are common among strict anaerobic and microaerophilic prokaryotes but are very rare among eukaryotes. In a proteome survey of isolated Chlamydomonas reinhardtii mitochondria, we found several PFL-specific peptides leading to the identification of cDNAs for PFL and PFL-AE, establishing the existence of a PFL system in this photosynthetic algae. Anaerobiosis and darkness led to increased PFL transcripts but had little effect on protein levels, as determined with antiserum raised against C. reinhardtii PFL. Protein blots revealed the occurrence of PFL in both chloroplast and mitochondria purified from aerobically grown cells. Mass spectrometry sequencing of C. reinhardtii mitochondrial proteins, furthermore, identified peptides for phosphotransacetylase and acetate kinase. The phosphotransacetylase-acetate kinase pathway is a common route of ATP synthesis or acetate assimilation among prokaryotes but is novel among eukaryotes. In addition to PFL and pyruvate dehydrogenase, the algae also expresses pyruvate: ferredoxin oxidoreductase and bifunctional aldehyde/alcohol dehydrogenase. Among eukaryotes, the oxygen producer C. reinhardtii has the broadest repertoire of pyruvate-, ethanol-, and acetate-metabolizing enzymes described to date, many of which were previously viewed as specific to anaerobic eukaryotic lineages.	Univ Dusseldorf, Inst Bot, D-40225 Dusseldorf, Germany; CEA, INRA, UJF, Lab Physiol Cellulaire Vegetale,CNRS,UMR5168, F-38054 Grenoble, France; CEA, Lab Chim Prot, INSERM, ERM 0201, F-38054 Grenoble, France	Heinrich Heine University Dusseldorf; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Atteia, A (corresponding author), CEA Grenoble, INRA, UJF, Lab Physiol Vegetale,CNRS,UMR5168, 17 Rue Martyrs, F-38054 Grenoble, France.	aatteia@cea.fr	Martin, William F./O-5446-2015; ROLLAND, Norbert/B-4405-2012; Martin, William/C-5680-2008	Martin, William F./0000-0003-1478-6449; ROLLAND, Norbert/0000-0003-1959-6636; Adrait, Annie/0000-0002-1565-2859				Akhmanova A, 1999, MOL MICROBIOL, V32, P1103, DOI 10.1046/j.1365-2958.1999.01434.x; Andersson SGE, 1999, CURR OPIN MICROBIOL, V2, P535, DOI 10.1016/S1369-5274(99)00013-2; Asanuma N, 1999, MICROBIOL-UK, V145, P151, DOI 10.1099/13500872-145-1-151; Asanuma N, 2004, ARCH MICROBIOL, V181, P122, DOI 10.1007/s00203-003-0638-0; Atteia A, 2003, PLANT MOL BIOL, V53, P175, DOI 10.1023/B:PLAN.0000009274.19340.36; Bollivar DW, 1996, PLANT PHYSIOL, V112, P105, DOI 10.1104/pp.112.1.105; Boxma B, 2005, NATURE, V434, P74, DOI 10.1038/nature03343; Broderick JB, 2000, BIOCHEM BIOPH RES CO, V269, P451, DOI 10.1006/bbrc.2000.2313; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; DESFRANCSSMALL CC, 1993, PLANT PHYSIOL, V102, P1171, DOI 10.1104/pp.102.4.1171; Dyall SD, 2004, NATURE, V431, P1103, DOI 10.1038/nature02990; ERIKSSON M, 1995, PLANT PHYSIOL, V107, P479, DOI 10.1104/pp.107.2.479; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; FRANZEN LG, 1992, PLANT MOL BIOL, V19, P771, DOI 10.1007/BF00027073; Happe T, 2002, EUR J BIOCHEM, V269, P1022, DOI 10.1046/j.0014-2956.2001.02743.x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Heifetz PB, 2000, PLANT PHYSIOL, V122, P1439, DOI 10.1104/pp.122.4.1439; Himo F, 2005, BBA-BIOENERGETICS, V1707, P24, DOI 10.1016/j.bbabio.2004.04.006; Horner DS, 1999, MOL BIOL EVOL, V16, P1280, DOI 10.1093/oxfordjournals.molbev.a026218; Hrdy I, 2004, NATURE, V432, P618, DOI 10.1038/nature03149; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394; KESSLER D, 1992, J BIOL CHEM, V267, P18073; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KREUZBERG K, 1984, PHYSIOL PLANTARUM, V61, P87, DOI 10.1111/j.1399-3054.1984.tb06105.x; KREUZBERG K, 1987, PHYSIOL PLANTARUM, V69, P481, DOI 10.1111/j.1399-3054.1987.tb09229.x; Lehtio L, 2004, PROTEIN ENG DES SEL, V17, P545, DOI 10.1093/protein/gzh059; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Melchiorsen CR, 2000, J BACTERIOL, V182, P4783, DOI 10.1128/JB.182.17.4783-4788.2000; Muller M., 2003, MOL MED PARASITOLOGY, P125, DOI DOI 10.1016/B978-012473346-6/50008-9; PECHER A, 1982, ARCH MICROBIOL, V132, P365, DOI 10.1007/BF00413390; Raynaud C, 2003, P NATL ACAD SCI USA, V100, P5010, DOI 10.1073/pnas.0734105100; RODEL W, 1988, EUR J BIOCHEM, V177, P153, DOI 10.1111/j.1432-1033.1988.tb14356.x; Rotte C, 2001, MOL BIOL EVOL, V18, P710, DOI 10.1093/oxfordjournals.molbev.a003853; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAWERS G, 1988, J BACTERIOL, V170, P5330, DOI 10.1128/jb.170.11.5330-5336.1988; Silflow Carolyn D., 1998, Advances in Photosynthesis, V7, P25; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Stechmann A, 2002, SCIENCE, V297, P89, DOI 10.1126/science.1071196; Thollesson M, 2004, BIOINFORMATICS, V20, P416, DOI 10.1093/bioinformatics/btg422; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Wolfe AJ, 2005, MICROBIOL MOL BIOL R, V69, P12, DOI 10.1128/MMBR.69.1.12-50.2005; Zhang WH, 2001, BIOCHEMISTRY-US, V40, P4123, DOI 10.1021/bi002589k	48	96	131	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9909	9918		10.1074/jbc.M507862200	http://dx.doi.org/10.1074/jbc.M507862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16452484	Green Published, hybrid			2022-12-27	WOS:000236594300012
J	Kupzig, S; Deaconescu, D; Bouyoucef, D; Walker, SA; Liu, Q; Polte, CL; Daumke, O; Ishizaki, T; Lockyer, PJ; Wittinghofer, A; Cullen, PJ				Kupzig, S; Deaconescu, D; Bouyoucef, D; Walker, SA; Liu, Q; Polte, CL; Daumke, O; Ishizaki, T; Lockyer, PJ; Wittinghofer, A; Cullen, PJ			GAP1 family members constitute bifunctional Ras and Rap GTPase-activating proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,3,4,5-TETRAKISPHOSPHATE RECEPTORS GAP1(IP4BP); PLECKSTRIN HOMOLOGY DOMAIN; BINDING PROTEIN; ARGININE-FINGER; GENETIC SCREEN; KINASE-II; IDENTIFICATION; CALCIUM; SYNGAP; SPECTROSCOPY	GAP1(IP4BP) is a member of the GAP1 family of Ras GTPase-activating proteins ( Ras GAPs) that includes GAP1(m), CAPRI, and RASAL. Composed of a central Ras GAP domain, surrounded by amino-terminal C-2 domains and a carboxyl-terminal pleckstrin homology/Bruton's tyrosine kinase domain, GAP1(IP4BP) has previously been shown to possess an unexpected GAP activity on the Ras-related protein Rap, besides the predicted Ras GAP activity (Cullen, P. J., Hsuan, J. J., Truong, O., Letcher, A. J., Jackson, T. R., Dawson, A. P., and Irvine, R. F. ( 1995) Nature 376, 527 - 530). Here we have shown that GAP1IP4BP is indeed an efficient Ras/Rap GAP, having K(m)s of 213 and 42 mu M and estimated k(cat)s of 48 and 16 s(-1) for Ras and Rap, respectively. For this dual activity, regions outside the Ras GAP domain are required, as the isolated domain ( residues 291 - 569) retains a pronounced Ras GAP activity yet has very low activity toward Rap. Interestingly, mutagenesis of the RasGAP arginine finger, and surrounding residues important in Ras binding, inhibit both Ras and Rap GAP activity of GAP1(IP4BP). Although the precise details by which GAP1(IP4BP) can function as a Rap GAP remain to be determined, these data are consistent with Rap associating with GAP1(IP4BP) through the Ras-binding site within the Ras GAP domain. Finally, we have established that such dual Ras/Rap GAP activity is not restricted to GAP1(IP4BP). Although GAP1(m) appears to constitute a specific Ras GAP, CAPRI and RASAL display dual activity. For CAPRI, its Rap GAP activity is modulated upon its Ca2+-induced association with the plasma membrane.	Univ Bristol, Sch Med Sci, Dept Biochem, Henry Wellcome Integrated Signaling Labs, Bristol BS8 1TD, Avon, England; Max Planck Inst Mol Physiol, D-44202 Dortmund, Germany; Babraham Inst, Signaling Programme, Cambridge CB2 4AT, England	University of Bristol; Max Planck Society; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Henry Wellcome Integrated Signaling Labs, Bristol BS8 1TD, Avon, England.	Pete.Cullen@bris.ac.uk	Polte, Christian Lars/AAA-9490-2021	Polte, Christian Lars/0000-0001-7125-9747; Cullen, Peter/0000-0002-9070-8349; Walker, Simon/0000-0001-9185-4922	Wellcome Trust [072166] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Allen M, 1998, GENE, V218, P17, DOI 10.1016/S0378-1119(98)00394-1; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Bottomley JR, 1998, BIOCHEM BIOPH RES CO, V250, P143, DOI 10.1006/bbrc.1998.9179; Brinkmann T, 2002, J BIOL CHEM, V277, P12525, DOI 10.1074/jbc.M109176200; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Chakrabarti PP, 2004, J BIOL CHEM, V279, P46226, DOI 10.1074/jbc.M405603200; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Cozier GE, 2000, J BIOL CHEM, V275, P28261; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Fauchereau F, 2003, MOL CELL NEUROSCI, V23, P574, DOI 10.1016/S1044-7431(03)00078-2; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Kupzig S, 2005, P NATL ACAD SCI USA, V102, P7577, DOI 10.1073/pnas.0409611102; Liu Q, 2005, J CELL BIOL, V170, P183, DOI 10.1083/jcb.200504167; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Moskwa P, 2005, J BIOL CHEM, V280, P6716, DOI 10.1074/jbc.M412563200; Oh JS, 2004, J BIOL CHEM, V279, P17980, DOI 10.1074/jbc.M314109200; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Zhang J, 2005, NAT IMMUNOL, V6, P911, DOI 10.1038/ni1232; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	46	57	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9891	9900		10.1074/jbc.M512802200	http://dx.doi.org/10.1074/jbc.M512802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16431904	Green Accepted, hybrid			2022-12-27	WOS:000236594300010
J	Han, GS; Wu, WI; Carman, GM				Han, GS; Wu, WI; Carman, GM			The Saccharomyces cerevisiae lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; PROTEIN-KINASE-C; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLCHOLINE BREAKDOWN; SIGNAL-TRANSDUCTION; GENETIC-REGULATION; ESCHERICHIA-COLI; SHUTTLE VECTORS; 104-KDA FORMS; YEAST	Mg2+-dependent phosphatidate (PA) phosphatase (3-sn-phosphatidate phosphohydrolase, EC3.1.3.4) catalyzes the dephosphorylation of PA to yield diacylglycerol and Pi. In this work, we identified the Saccharomyces cerevisiae PAH1 (previously known as SMP2) gene that encodes Mg2+-dependent PA phosphatase using amino acid sequence information derived from a purified preparation of the enzyme (Lin, Y.-P., and Carman, G. M. (1989) J. Biol. Chem. 264, 8641-8645). Overexpression of PAH1 in S. cerevisiae directed elevated levels of Mg2+-dependent PA phosphatase activity, whereas the pah1 Delta mutation caused reduced levels of enzyme activity. Heterologous expression of PAH1 in Escherichia coli confirmed that Pah1p is a Mg2+-dependent PA phosphatase enzyme and showed that its enzymological properties were very similar to those of the enzyme purified from S. cerevisiae. The PAH1-encoded enzyme activity was associated with both the membrane and cytosolic fractions of the cell, and the membrane-bound form of the enzyme was salt-extractable. Lipid analysis showed that mutants lacking PAH1 accumulated PA and had reduced amounts of diacyl-glycerol and its derivative triacylglycerol. The PAH1-encoded Mg2+-dependent PA phosphatase shows homology to mammalian lipin, a fat-regulating protein whose molecular function is unknown. Heterologous expression of human LPIN1 in E. coli showed that lipin 1 is also a Mg2+-dependent PA phosphatase enzyme.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28140, R37 GM028140, R01 GM028140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BEGGS JD, 1981, GENETIC ENG, P175; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CULBERTSON MR, 1975, GENETICS, V80, P23; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DONAHUE TF, 1981, GENETICS, V98, P491; ESKO JD, 1980, J BIOL CHEM, V255, P4474; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Furneisen JM, 2000, BBA-MOL CELL BIOL L, V1484, P71, DOI 10.1016/S1388-1981(99)00202-4; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2004, J BIOL CHEM, V279, P5338, DOI 10.1074/jbc.M311779200; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; Henderson RJ, 1992, LIPID ANAL PRACTICAL, P65; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P102; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; IRIE K, 1993, MOL GEN GENET, V236, P283, DOI 10.1007/BF00277124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Madera M, 2004, NUCLEIC ACIDS RES, V32, pD235, DOI 10.1093/nar/gkh117; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Oshiro J, 2003, BBA-MOL CELL BIOL L, V1635, P1, DOI 10.1016/j.bbalip.2003.10.002; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Phan J, 2005, DRUG NEWS PERSPECT, V18, P5, DOI 10.1358/dnp.2005.18.1.877165; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; PHAN J, 2005, OBSTET GYNECOL SURV, V60, P652; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santos-Rosa H, 2005, EMBO J, V24, P1931, DOI 10.1038/sj.emboj.7600672; Sciorra VA, 2002, BBA-MOL CELL BIOL L, V1582, P45, DOI 10.1016/S1388-1981(02)00136-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SMITH SW, 1957, J BIOL CHEM, V228, P915; Sorger D, 2003, APPL MICROBIOL BIOT, V61, P289, DOI 10.1007/s00253-002-1212-4; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; Stukey J, 1997, PROTEIN SCI, V6, P469; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f	80	396	424	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9210	9218		10.1074/jbc.M600425200	http://dx.doi.org/10.1074/jbc.M600425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467296	Green Accepted, hybrid			2022-12-27	WOS:000236404700028
J	Kong, KY; Kedes, L				Kong, KY; Kedes, L			Leucine 135 of tropomodulin-1 regulates its association with tropomyosin, its cellular localization, and the integrity of sarcomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; CARDIAC MYOCYTES; SKELETAL-MUSCLE; POINTED ENDS; COILED-COIL; ACTIN; ISOFORM; CLONING; IDENTIFICATION; EXPRESSION	Tropomodulin-1 (Tmod-1) is a well defined actin-capping protein that interacts with tropomyosin (TM) at the pointed end of actin filaments. Previous studies by others have mapped its TM-binding domain to the amino terminus from amino acid 39 to 138. In this study, we have identified several amino acid residues on Tmod-1 that are important for its interaction with TM5 ( a nonmuscle TM isoform). Glutathione S-transferase affinity chromatography and immunoprecipitation assays reveal that Tmod sense mutations of either amino acid 134, 135, or 136 causes various degrees of loss of function of Tmod TM-binding ability. The reduction of TM-binding ability was relatively mild ( reduced similar to 20 - 40%) from the G136A Tmod mutant but more substantially ( reduced similar to 50 - 100%) from the I134D, L135E, and L135V Tmod mutants. In addition, mutation at any of these three sites dramatically alters the subcellular location of Tmod-1 when introduced into mammalian cells. Further analysis of these three mutants uncovered a previously unknown nuclear trafficking function of Tmod-1, and residues 134, 135, and 136 are located within a nuclear export signal motif. As a result, mutation on either residue 134 or residue 135 not only will cause a significant reduction of the Tmod-1 ability to bind to TM5 but also lead to predominant nuclear localization of Tmod-1 by crippling its nuclear export mechanism. The failure of the Tmod mutations to fully associate with TM5 when introduced into neonatal rat cardiomyocytes was also associated with an accelerated and severe fragmentation of sarcomeric structures compared with overexpression of wild type Tmod-1. The multiple losses of function of Tmod engendered by these missense mutations are most severe with the single substitution of residue 135.	Univ So Calif, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Kedes, L (corresponding author), Univ So Calif, Inst Med Genet, 2250 Alcazar St, Los Angeles, CA 90033 USA.	kedes@usc.edu			NATIONAL CANCER INSTITUTE [C06CA062528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR010600, C06RR014514] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012941] Funding Source: NIH RePORTER; NCI NIH HHS [C06 CA62528-01] Funding Source: Medline; NCRR NIH HHS [C06 RR014514-01, C06 RR10600-01] Funding Source: Medline; NHLBI NIH HHS [HL52771] Funding Source: Medline; NIDCR NIH HHS [DE12941] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLUCCIO LM, 1994, J CELL BIOL, V127, P1497, DOI 10.1083/jcb.127.6.1497; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Fischer RS, 2003, TRENDS CELL BIOL, V13, P593, DOI 10.1016/j.tcb.2003.09.007; Fowler VM, 2003, J BIOL CHEM, V278, P40000, DOI 10.1074/jbc.M306895200; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Greenfield NJ, 2005, BIOPHYS J, V88, P372, DOI 10.1529/biophysj.104.051128; Greenfield NJ, 2002, BIOPHYS J, V82, P2580, DOI 10.1016/S0006-3495(02)75600-2; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; Kong KY, 2004, J BIOL CHEM, V279, P30856, DOI 10.1074/jbc.M302845200; Kostyukova AS, 2005, BIOCHEMISTRY-US, V44, P4905, DOI 10.1021/bi047468p; Kostyukova AS, 2004, J BIOL CHEM, V279, P5066, DOI 10.1074/jbc.M311186200; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; Sakoda T, 1999, J MOL CELL CARDIOL, V31, P2037, DOI 10.1006/jmcc.1999.1035; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SUNG LA, 1992, J BIOL CHEM, V267, P2616; Sussman MA, 1998, CIRC RES, V82, P94; SUSSMAN MA, 1994, CIRC RES, V75, P221, DOI 10.1161/01.RES.75.2.221; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; URSITTI JA, 1994, J CELL SCI, V107, P1633; Vera C, 2005, ARCH BIOCHEM BIOPHYS, V444, P130, DOI 10.1016/j.abb.2005.10.002; Watakabe A, 1996, J CELL SCI, V109, P2299; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627	29	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9589	9599		10.1074/jbc.M512064200	http://dx.doi.org/10.1074/jbc.M512064200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16434395	hybrid			2022-12-27	WOS:000236404700070
J	Morris, KE; Schang, LM; Brindley, DN				Morris, KE; Schang, LM; Brindley, DN			Lipid phosphate phosphatase-2 activity regulates S-phase entry of the cell cycle in Rat2 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; GROWTH ARREST; CANCER-CELLS; IN-VIVO; ACID; CERAMIDE; PROTEIN; ACTIVATION; INHIBITION; SENESCENCE	Lipid phosphates are potent mediators of cell signaling and control processes including development, cell migration and division, blood vessel formation, wound repair, and tumor progression. Lipid phosphate phosphatases (LPPs) regulate the dephosphorylation of lipid phosphates, thus modulating their signals and producing new bioactive compounds both at the cell surface and in intracellular compartments. Knock-down of endogenous LPP2 in fibroblasts delayed cyclin A accumulation and entry into S-phase of the cell cycle. Conversely, overexpression of LPP2, but not a catalytically inactive mutant, caused premature S-phase entry, accompanied by premature cyclin A accumulation. At high passage, many LPP2 overexpressing cells arrested in G(2)/M and the rate of proliferation declined severely. This was accompanied by changes in proteins and lipids characteristic of senescence. Additionally, arrested LPP2 cells contained decreased lysophosphatidate concentrations and increased ceramide. These effects of LPP2 activity were not reproduced by overexpression or knock-down of LPP1 or LPP3. This work identifies a novel and specific role for LPP2 activity and bioactive lipids in regulating cell cycle progression.	Univ Alberta, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Brindley, DN (corresponding author), 357 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca	Schang, Luis/F-9576-2012	Schang, Luis Maria/0000-0002-5789-8590				Abe A, 1998, J BIOL CHEM, V273, P8467, DOI 10.1074/jbc.273.14.8467; Alderton F, 2001, J BIOL CHEM, V276, P13452, DOI 10.1074/jbc.M006582200; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Burnett Camilla, 2004, BMC Biochemistry, V5, P2, DOI 10.1186/1471-2091-5-2; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Duncan RE, 2004, J BIOL CHEM, V279, P33079, DOI 10.1074/jbc.M400732200; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Gomez-Munoz A, 2004, J LIPID RES, V45, P99, DOI 10.1194/jlr.M300158-JLR200; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Han EKH, 1999, APOPTOSIS, V4, P213, DOI 10.1023/A:1009618824145; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Jaiswal AS, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-3; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097; Long J, 2005, BIOCHEM J, V391, P25, DOI 10.1042/BJ20050342; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Renault AD, 2004, SCIENCE, V305, P1963, DOI 10.1126/science.1102421; Roberts RZ, 2000, BBA-MOL CELL BIOL L, V1487, P33, DOI 10.1016/S1388-1981(00)00081-0; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Song MS, 2003, NEUROPHARMACOLOGY, V45, P1130, DOI 10.1016/S0028-3908(03)00284-3; SULLARDS MC, 2001, SCI STKE, V67, P1; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Tanyi JL, 2003, CANCER RES, V63, P1073; Theocharis S, 2004, CANCER TREAT REV, V30, P545, DOI 10.1016/j.ctrv.2004.04.004; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WANG J, 1992, ONCOGENE, V7, P1653; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yue JM, 2004, CELL SIGNAL, V16, P385, DOI 10.1016/j.cellsig.2003.08.012; Zhang N, 2002, GENESIS, V33, P21, DOI 10.1002/gene.10081; Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181; ZHAO Y, 1999, MOL BIOL CELL, V12, P3601; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160	55	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9297	9306		10.1074/jbc.M511710200	http://dx.doi.org/10.1074/jbc.M511710200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467304	hybrid			2022-12-27	WOS:000236404700037
J	Wang, XY; McGrath, SC; Cotter, RJ; Raetz, CRH				Wang, XY; McGrath, SC; Cotter, RJ; Raetz, CRH			Expression cloning and periplasmic orientation of the Francisella novicida lipid A4 '-phosphatase LpxF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MSBB GENE; ESCHERICHIA-COLI; RHIZOBIUM-LEGUMINOSARUM; SALMONELLA-TYPHIMURIUM; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; TULARENSIS LIPOPOLYSACCHARIDE; MULTICOPY SUPPRESSOR; RESISTANT MUTANTS; NMR-SPECTROSCOPY; A BIOSYNTHESIS	Francisella tularensis and related intracellular pathogens synthesize lipid A molecules that differ from their Escherichia coli counterparts. Although a functional orthologue of lpxK, the gene encoding the lipid A 4'-kinase, is present in Francisella, no 4'-phosphate moiety is attached to Francisella lipid A. We now demonstrate that a membrane-bound phosphatase present in Francisella novicida U112 selectively removes the 4'-phosphate residue from tetra- and pentaacylated lipid A molecules. A clone that expresses the F. novicida 4'-phosphatase was identified by assaying lysates of E. coli colonies, harboring members of an F. novicida genomic DNA library, for 4'-phosphatase activity. Sequencing of a 2.5-kb F. novicida DNA insert from an active clone located the structural gene for the 4'-phosphatase, designated lpxF. It encodes a protein of 222 amino acid residues with six predicted membrane-spanning segments. Rhizobium leguminosarum and Rhizobium etli contain functional lpxF orthologues, consistent with their lipid A structures. When F. novicida LpxF is expressed in an E. coli LpxM mutant, a strain that synthesizes pentaacylated lipid A, over 90% of the lipid A molecules are dephosphorylated at the 4'-position. Expression of LpxF in wildtype E. coli has no effect, because wild-type hexaacylated lipid A is not a substrate. However, newly synthesized lipid A is not dephosphorylated in LpxM mutants by LpxF when the MsbA flippase is inactivated, indicating that LpxF faces the outer surface of the inner membrane. The availability of the lpxF gene will facilitate re-engineering lipid A structures in diverse bacteria.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM051796-10, R37 GM051796, GM-54882, R37-GM-51796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ancuta P, 1996, INFECT IMMUN, V64, P2041, DOI 10.1128/IAI.64.6.2041-2046.1996; Ausubel FM, 1988, MOL REPROD DEV; Baldridge JR, 2004, EXPERT OPIN BIOL TH, V4, P1129, DOI 10.1517/14712598.4.7.1129; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Clementz T, 1997, J BIOL CHEM, V272, P10353; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Ellis J, 2002, CLIN MICROBIOL REV, V15, P631, DOI 10.1128/CMR.15.4.631-646.2002; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ishikawa K, 2000, EMBO J, V19, P2412, DOI 10.1093/emboj/19.11.2412; Ismaili J, 2002, J IMMUNOL, V168, P926, DOI 10.4049/jimmunol.168.2.926; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; Kieffer TL, 2003, MICROBES INFECT, V5, P397, DOI 10.1016/S1286-4579(03)00052-2; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Larsson P, 2005, NAT GENET, V37, P153, DOI 10.1038/ng1499; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; McDonald MK, 1997, J BACTERIOL, V179, P7638, DOI 10.1128/jb.179.24.7638-7643.1997; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Nano FE, 2004, J BACTERIOL, V186, P6430, DOI 10.1128/JB.186.19.6430-6436.2004; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5; Phillips NJ, 2004, INFECT IMMUN, V72, P5340, DOI 10.1128/IAI.72.9.5340-5348.2004; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2004, J BIOL CHEM, V279, P25420, DOI 10.1074/jbc.M400598200; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J., 2001, MOL CLONING LAB MANU; SANDSTROM G, 1992, FEMS MICROBIOL IMMUN, V105, P201, DOI 10.1111/j.1574-6968.1992.tb05902.x; Sasaki S, 1997, INFECT IMMUN, V65, P3520, DOI 10.1128/IAI.65.9.3520-3528.1997; Sjostedt A, 2003, CURR OPIN MICROBIOL, V6, P66, DOI 10.1016/S1369-5274(03)00002-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stukey J, 1997, PROTEIN SCI, V6, P469; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tran AX, 2004, J BIOL CHEM, V279, P55780, DOI 10.1074/jbc.M406480200; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	70	74	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9321	9330		10.1074/jbc.M600435200	http://dx.doi.org/10.1074/jbc.M600435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467300	Green Accepted, hybrid			2022-12-27	WOS:000236404700040
J	Nelson, SW; Yang, JS; Benkovic, SJ				Nelson, SW; Yang, JS; Benkovic, SJ			Site-directed mutations of T4 helicase loading protein (gp59) reveal multiple modes of DNA polymerase inhibition and the mechanism of unlocking by gp41 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPLICATION FORK; BINDING-PROTEIN; LEADING-STRAND; BACTERIOPHAGE-T4 PRIMOSOME; MEDIATOR PROTEINS; PRIMER SYNTHESIS; GENE-59 PROTEIN; SLIDING CLAMP; COMPLEX	The T4 helicase loading protein (gp59) interacts with amultitude of DNA replication proteins. In an effort to determine the functional consequences of these protein-protein interactions, point mutations were introduced into the gp59 protein. Mutations were chosen based on the available crystal structure and focused on hydrophobic residues with a high degree of solvent accessibility. Characterization of the mutant proteins revealed a single mutation, Y122A, which is defective in polymerase binding and has weakened affinity for the helicase. The interaction between single-stranded DNA-binding protein and Y122A is unaffected, as is the affinity of Y122A for DNA substrates. When standard concentrations of helicase are employed, Y122A is unable to productively load the helicase onto forked DNA substrates. As a result of the loss of polymerase binding, Y122A cannot inhibit the polymerase during nucleotide idling or prevent it from removing the primer strand of a D-loop. However, Y122A is capable of inhibiting strand displacement synthesis by polymerase. The retention of strand displacement inhibition by Y122A, even in the absence of a gp59-polymerase interaction, indicates that there are two modes of polymerase inhibition by gp59. Inhibition of the polymerase activity only requires gp59 to bind to the replication fork, whereas inhibition of the exonuclease activity requires an interaction between the polymerase and gp59. The inability of Y122A to interact with both the polymerase and the helicase suggests a mechanism for polymerase unlocking by the helicase based on a direct competition between the helicase and polymerase for an overlapping binding site on gp59.	Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA.	sjb1@psu.edu			NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; Alley SC, 1999, J BIOL CHEM, V274, P24485, DOI 10.1074/jbc.274.35.24485; Alley SC, 2001, J BIOL CHEM, V276, P39340, DOI 10.1074/jbc.M104956200; Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; BARRY J, 1994, J BIOL CHEM, V269, P33049; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1989, J BIOL CHEM, V264, P12220; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; Dudas KC, 2005, J BIOL CHEM, V280, P21561, DOI 10.1074/jbc.m502351200; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jones CE, 2004, J BIOL CHEM, V279, P25721, DOI 10.1074/jbc.M402128200; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; Jones CE, 2000, J BIOL CHEM, V275, P27145; JONGENEEL CV, 1984, ADV EXP MED BIOL, V179, P17; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; Kadyrov FA, 2003, J BIOL CHEM, V278, P25247, DOI 10.1074/jbc.M302564200; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MANNIATIS T, 1994, MOL CLONING LAB MANU; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; MUNN MM, 1991, J BIOL CHEM, V266, P20024; Neuvirth H, 2004, J MOL BIOL, V338, P181, DOI 10.1016/j.jmb.2004.02.040; Norcum MT, 2005, P NATL ACAD SCI USA, V102, P3623, DOI 10.1073/pnas.0500713102; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; SELICK HE, 1988, J BIOL CHEM, V263, P11336; Sexton DJ, 1997, CURR OPIN CHEM BIOL, V1, P316, DOI 10.1016/S1367-5931(97)80068-3; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Sun SY, 2003, J BIOL CHEM, V278, P3876, DOI 10.1074/jbc.M210497200; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; Xi J, 2005, BIOCHEMISTRY-US, V44, P7747, DOI 10.1021/bi047296w; Xi J, 2005, BIOCHEMISTRY-US, V44, P2305, DOI 10.1021/bi0479508; Yang JS, 2005, J BIOL CHEM, V280, P25416, DOI 10.1074/jbc.M501847200; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; Zhang ZQ, 2005, P NATL ACAD SCI USA, V102, P3254, DOI 10.1073/pnas.0500327102	50	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8697	8706		10.1074/jbc.M512185200	http://dx.doi.org/10.1074/jbc.M512185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407253	hybrid			2022-12-27	WOS:000236247100047
J	Takekawa, H; Ina, C; Sato, R; Toma, K; Ogawa, H				Takekawa, H; Ina, C; Sato, R; Toma, K; Ogawa, H			Novel carbohydrate-binding activity of pancreatic trypsins to N-linked glycans of glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; PORCINE THYROGLOBULIN; SUGAR CHAINS; PROTEOLYTIC CLEAVAGE; AMINOPEPTIDASE-N; UNIT-A; GLYCOSYLATION; BOVINE; MOIETY; RAT	How glycosylation affects the reactivity of proteins to trypsin is not well understood. Bovine and porcine pancreatic trypsins were discovered to bind to alpha-Man, Neu5Ac alpha 2,6Gal beta 1,4Glc, and alpha-galactose sequences by binding studies with biotinylated sugar-polymers. Quantitative kinetic studies supported that phenylmethylsulfonyl fluoride (PMSF)-treated trypsin binds to glycolipid analogues possessing alpha- Man or alpha-NeuAc but not to those possessing beta-galactose or beta-GlcNAc residue. Enzyme-linked immunosorbent assay ( ELISA) showed that trypsin binds to six kinds of biotinylated glycoproteins possessing high mannose-type and complex-type N-glycans but not to bovine submaxillary mucin, which possesses only O-glycans. Further, the binding of trypsin to glycoproteins was differentially changed by treatments with sequential exoglycosidases, endoglycosidase H, or N-glycosidase F. Quantitative kinetic studies indicated that PMSF-treated trypsin binds with bovine thyroglobulin with the affinity constant of 10(10) M-1, which was the highest among the glycoproteins examined, and that alpha-galactosidase treatment decreased it to 10(5) M-1. PMSF-treated trypsin bound to other glycoproteins, including ovomucoid, a trypsin inhibitor, with the affinity constants of 10(8)- 10(5) mol(-1) and were markedly changed by glycosidase treatments in manners consistent with the sugar-binding specificities suggested by ELISA. Thus, the binding site for glycans was shown to be distinct from the catalytic site, allowing trypsin to function as an uncompetitive activator in the hydrolysis of a synthetic peptide substrate. Correspondingly the carbohydrate-binding activities of trypsin were unaffected by treatment with PMSF or soybean trypsin inhibitor. The results indicate the presence of an allosteric regulatory site on trypsin that sugar-specifically interacts with glycoproteins in addition to the proteolytic catalytic site.	Ochanomizu Univ, Grad Sch Humanities & Sci, Bunkyo Ku, Tokyo 1128610, Japan; Ochanomizu Univ, Glycosci Inst, Bunkyo Ku, Tokyo 1128610, Japan; Noguchi Inst, Itabashi Ku, Tokyo 1730003, Japan	Ochanomizu University; Ochanomizu University	Ogawa, H (corresponding author), Ochanomizu Univ, Grad Sch Humanities & Sci, Bunkyo Ku, Tokyo 1128610, Japan.	hogawa@cc.ocha.ac.jp						ABBOTT F, 1975, BIOCHEMISTRY-US, V14, P4935, DOI 10.1021/bi00693a024; Arnold U, 1998, J PROTEIN CHEM, V17, P397, DOI 10.1023/A:1022562316513; Ashida H, 2000, BIOSCI BIOTECH BIOCH, V64, P2266, DOI 10.1271/bbb.64.2266; Azefu Y, 2002, BIOORGAN MED CHEM, V10, P4013, DOI 10.1016/S0968-0896(02)00266-3; BERMAN E, 1987, MAGN RESON CHEM, V25, P784, DOI 10.1002/mrc.1260250910; Chen JM, 2000, PANCREAS, V21, P57, DOI 10.1097/00006676-200007000-00052; ERICKSON RH, 1983, BIOCHIM BIOPHYS ACTA, V743, P37, DOI 10.1016/0167-4838(83)90415-6; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FU DT, 1992, ANAL BIOCHEM, V206, P53, DOI 10.1016/S0003-2697(05)80010-7; GENTILE F, 1993, EUR J BIOCHEM, V218, P603, DOI 10.1111/j.1432-1033.1993.tb18414.x; GU JX, 1989, J BIOCHEM-TOKYO, V106, P66, DOI 10.1093/oxfordjournals.jbchem.a122821; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mann DA, 1998, J AM CHEM SOC, V120, P10575, DOI 10.1021/ja9818506; MARTH JD, 1999, ESSENTIALS GLYCOBIOL, P85; Matsushita H, 2002, J BIOL CHEM, V277, P4680, DOI 10.1074/jbc.M105877200; ORIOL R, 1994, TRANSPLANT INT, V7, P405, DOI 10.1111/j.1432-2277.1994.tb01259.x; PHILLIPS MA, 1992, CURR OPIN STRUC BIOL, V2, P713; PUSZTAI A, 1995, GLYCOCONJUGATE J, V12, P22, DOI 10.1007/BF00731865; Pusztai A, 1996, TRENDS GLYCOSCI GLYC, V8, P149, DOI 10.4052/tigg.8.149; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1993, HISTOCHEM J, V25, P687; Sato R, 2004, J CARBOHYD CHEM, V23, P375, DOI 10.1081/CAR-200039362; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P570, DOI 10.1016/0006-3002(55)90280-8; SHARON N, 1975, COMPLEX CARBOHYDRATE, P109; Shen H, 2001, PEDIATR RES, V49, P789, DOI 10.1203/00006450-200106000-00013; TAKASAKI S, 1986, BIOCHEMISTRY-US, V25, P5709, DOI 10.1021/bi00367a054; TAKASAKI S, 1991, BIOCHEMISTRY-US, V30, P9102, DOI 10.1021/bi00101a028; THALL A, 1990, BIOCHEMISTRY-US, V29, P3959, DOI 10.1021/bi00468a024; Toba SY, 2000, BIOCHEM BIOPH RES CO, V271, P281, DOI 10.1006/bbrc.2000.2618; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; TSUJI T, 1981, BIOCHEM J, V195, P691, DOI 10.1042/bj1950691; Uchibori-Iwaki H, 2000, GLYCOBIOLOGY, V10, P865, DOI 10.1093/glycob/10.9.865; Ueda H, 1999, FEBS LETT, V448, P75, DOI 10.1016/S0014-5793(99)00334-8; VANDIJK W, 1995, GLYCOCONJUGATE J, V12, P227, DOI 10.1007/BF00731324; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809	41	11	12	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8528	8538		10.1074/jbc.M513773200	http://dx.doi.org/10.1074/jbc.M513773200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16418164	Green Published, hybrid			2022-12-27	WOS:000236247100028
J	Abbasi, S; Lee, JD; Su, B; Chen, X; Alcon, JL; Yang, JH; Kellems, RE; Xia, Y				Abbasi, S; Lee, JD; Su, B; Chen, X; Alcon, JL; Yang, JH; Kellems, RE; Xia, Y			Protein kinase-mediated regulation of calcineurin through the phosphorylation of modulatory calcineurin-interacting protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CRITICAL REGION; CARDIAC-HYPERTROPHY; ELECTRICAL-STIMULATION; TARGETED INHIBITION; RECEPTOR ACTIVATION; GENE-EXPRESSION; GROWTH-FACTOR; C-JUN; FAMILY; PATHWAY	Calcineurin is a serine/threonine protein phosphatase that plays a critical role in many physiologic processes such as T-cell activation, skeletal myocyte differentiation, and cardiac hypertrophy. We previously showed that active MEKK3 is capable of stimulating calcineurin/ nuclear factor of activated T-cells ( NFAT) signaling in cardiac myocytes through phosphorylation of modulatory calcineurin-interacting protein 1 (MCIP1). However, the protein kinases that function downstream of MEKK3 to mediate MCIP1 phosphorylation and the mechanism of MCIP1-mediated calcineurin regulation have not been defined. Here, we show that MEK5 and big MAP kinase 1 (BMK1) function downstream of MEKK3 in a signaling cascade that induces calcineurin activity through phosphorylation of MCIP1. Genetic studies showed that BMK1-deficient mouse lung fibroblasts failed to mediate MCIP1 phosphorylation and activate calcineurin/ NFAT in response to angiotensin II, a potent NFAT activator. Conversely, restoring BMK1 to the deficient cells restored angiotensin II-mediated calcineurin/ NFAT activation. Thus, using BMK1-deficient mouse lung fibroblast cells, we provided the genetic evidence that BMK1 is required for angiotensin II-mediated calcineurin/ NFAT activation through MICP1 phosphorylation. Finally, we discovered that phosphorylated MCIP1 dissociates from calcineurin and binds with 14-3-3, thereby relieving its inhibitory effect on calcineurin activity. In summary, our findings reveal a previously unrecognized essential regulatory role of mitogen-activated protein kinase signaling in calcineurin activation through the reversible phosphorylation of a calcineurin-interacting protein, MCIP1.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston Med Sch, Houston, TX 77030 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Texas Childrens Hosp, Ctr Canc, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Pediat, Houston, TX 77030 USA; Cent S Univ, XiangYa Hosp, Dept Urol, Changsha 410078, Hunan, Peoples R China	University of Texas System; University of Texas Health Science Center Houston; Scripps Research Institute; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; Central South University	Xia, Y (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston Med Sch, 6431 Fannin St, Houston, TX 77030 USA.	Yang.Xia@uth.tmc.edu						Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Bueno OF, 2002, CARDIOVASC RES, V53, P806, DOI 10.1016/S0008-6363(01)00493-X; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hilioti Z, 2003, BIOCHEM BIOPH RES CO, V311, P1089, DOI 10.1016/S0006-291X(03)01515-8; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kato Y, 2000, IMMUNOL RES, V21, P233, DOI 10.1385/IR:21:2-3:233; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MFREY N, 2000, NAT MED, V6, P1221; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; SHAHRZAD A, 2005, J BIOL CHEM, V280, P36737; Thway TM, 2004, CIRCULATION, V110, P1612, DOI 10.1161/01.CIR.0000142855.68398.3A; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Xia Y, 2002, J BIOL CHEM, V277, P24601, DOI 10.1074/jbc.M201369200; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769	52	60	62	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7717	7726		10.1074/jbc.M510775200	http://dx.doi.org/10.1074/jbc.M510775200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415348	hybrid			2022-12-27	WOS:000236031000004
J	Bode, L; Murch, S; Freeze, HH				Bode, L; Murch, S; Freeze, HH			Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; BARRIER FUNCTION; TNF-ALPHA; FONTAN CIRCULATION; EPITHELIAL BARRIER; IFN-GAMMA; EXPRESSION; OPERATION; REVERSAL	Protein-losing enteropathy (PLE), the loss of plasma proteins through the intestine, is a symptom in ostensibly unrelated diseases. Emerging commonalities indicate that genetic insufficiencies predispose for PLE and environmental insults, e. g. viral infections and inflammation, trigger PLE onset. The specific loss of heparan sulfate (HS) from the basolateral surface of intestinal epithelial cells only during episodes of PLE suggests a possible mechanistic link. In the first tissue culture model of PLE using a monolayer of intestinal epithelial HT29 cells, we proved that HS loss directly causes protein leakage and amplifies the effects of the proinflammatory cytokine tumor necrosis factor alpha(TNF alpha). Here, we extend our in vitro model to assess the individual and combined effects of HS loss, interferon gamma (IFN gamma), TNF alpha, and increased pressure, and find that HS plays a central role in the patho-mechanisms underlying PLE. Increased pressure, mimicking venous hypertension seen in post-Fontan PLE patients, substantially increased protein leakage, but HS loss, IFN gamma, or TNF alpha alone had only minor effects. However, IFN gamma up-regulated TNFR1 expression and amplified TNF alpha-induced protein leakage. IFN gamma and TNF alpha compromised the integrity of the HT29 monolayer and made it more susceptible to increased pressure. HS loss itself compromises the integrity of the monolayer, amplifying the effects of pressure, but also amplifies the effects of both cytokines. In the absence of HS a combination of increased pressure, IFN gamma, and TNF alpha caused maximum protein leakage. Soluble heparin fully compensated for HS loss, providing a reasonable explanation for patient favorable response to heparin therapy.	Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, La Jolla, CA 92037 USA; Warwick Med Sch, Clin Sci Res Inst, Coventry CV2 2DX, W Midlands, England	Sanford Burnham Prebys Medical Discovery Institute; University of Warwick	Freeze, HH (corresponding author), Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hudson@burnham.org		Freeze, Hudson/0000-0001-6316-0501	NHLBI NIH HHS [R21 HL 078997] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL078997] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEEKEN WL, 1972, GASTROENTEROLOGY, V62, P207; Bode L, 2005, AM J PHYSIOL-GASTR L, V288, pG1015, DOI 10.1152/ajpgi.00461.2004; BODE L, 2005, IN PRESS BIOCH BIOPH; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Chakravortty D, 1999, MICROBIOL IMMUNOL, V43, P527, DOI 10.1111/j.1348-0421.1999.tb02438.x; Cheong JLY, 2004, ARCH DIS CHILD-FETAL, V89, pF367, DOI 10.1136/adc.2003.032821; Day RM, 2003, CYTOKINE, V21, P224, DOI 10.1016/S1043-4666(03)00091-7; Donnelly JP, 1997, J PEDIATR-US, V130, P474, DOI 10.1016/S0022-3476(97)70214-2; Fink Mitchell P, 2003, Curr Opin Crit Care, V9, P143, DOI 10.1097/00075198-200304000-00011; Fish SM, 1999, GUT, V45, P191, DOI 10.1136/gut.45.2.191; Fritchley SJ, 2000, CLIN EXP IMMUNOL, V120, P247, DOI 10.1046/j.1365-2249.2000.01178.x; Fujii T, 2003, J PEDIATR GASTR NUTR, V37, P577, DOI 10.1097/00005176-200311000-00014; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Harvima IT, 2004, J CELL BIOCHEM, V92, P372, DOI 10.1002/jcb.20068; Holmgren D, 2001, PEDIATR TRANSPLANT, V5, P135, DOI 10.1034/j.1399-3046.2001.005002135.x; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Kelly AM, 1998, MAYO CLIN PROC, V73, P777, DOI 10.4065/73.8.777; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; Lenz D, 2003, CRIT CARE, V7, P185, DOI 10.1186/cc2166; LORTAT-JACOB H, 1991, FEBS LETT, V280, P152, DOI 10.1016/0014-5793(91)80225-R; LORTAT-JACOB H, 1991, CELL MOL BIOL, V37, P253; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Marino BS, 2002, CURR OPIN PEDIATR, V14, P620, DOI 10.1097/00008480-200210000-00010; Mertens L, 1998, J THORAC CARDIOV SUR, V115, P1063, DOI 10.1016/S0022-5223(98)70406-4; Michell NP, 2001, EUR J GASTROEN HEPAT, V13, P449, DOI 10.1097/00042737-200104000-00026; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Murch SH, 1996, LANCET, V347, P1299, DOI 10.1016/S0140-6736(96)90941-1; MURCH SH, 1993, LANCET, V341, P711, DOI 10.1016/0140-6736(93)90485-Y; OSTROW A, 2004, IN PRESS J AM COLL C; Rychik Jack, 2002, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V5, P3, DOI 10.1053/pcsu.2002.31498; SALVESTRINI C, 2004, J PEDIAT GASTROENTER, V39, P278; Schmitz H, 1999, J CELL SCI, V112, P137; Shimizu T, 2003, J PEDIATR GASTR NUTR, V37, P504, DOI 10.1097/00005176-200310000-00019; Suenaert P, 2002, AM J GASTROENTEROL, V97, P2000; Thorne SA, 1998, EUR HEART J, V19, P514, DOI 10.1053/euhj.1997.0777; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; Tveit H, 2005, J BIOL CHEM, V280, P29596, DOI 10.1074/jbc.M503691200; Westphal V, 2000, AM J PATHOL, V157, P1917, DOI 10.1016/S0002-9440(10)64830-4; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279, DOI 10.1152/ajpgi.1999.276.5.G1279	39	52	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7809	7815		10.1074/jbc.M510722200	http://dx.doi.org/10.1074/jbc.M510722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434407	hybrid			2022-12-27	WOS:000236031000014
J	Lelj-Garolla, B; Mauk, AG				Lelj-Garolla, B; Mauk, AG			Self-association and chaperone activity of Hsp27 are thermally activated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SEDIMENTATION COEFFICIENT DISTRIBUTIONS; CRYSTAL-STRUCTURE; ANALYTICAL ULTRACENTRIFUGATION; ALPHA-CRYSTALLIN; CYTOCHROME-C; INDUCED OLIGOMERIZATION; REGULATED CHAPERONE; PROTECTIVE ACTIVITY; UNFOLDING PROTEINS	The small heat shock protein 27 (Hsp27) is an oligomeric, molecular chaperone in vitro. This chaperone activity and other physiological roles attributed to Hsp27 have been reported to depend on the state of self-association. In the present work, we have used sedimentation velocity experiments to demonstrate that the self-association of Hsp27 is independent of pH and ionic strength but increases significantly as the temperature is increased from 10 to 40 degrees C. The largest oligomers formed at 10 degrees C are similar to 8 - 12 mer, whereas at 40 degrees C oligomers as large as 22 - 30 mer are observed. Similarly, the chaperone activity of Hsp27 as indicated by its ability to inhibit dithiothreitol-induced insulin aggregation also increases with increased temperature, with a particularly sharp increase in activity as temperature is increased from 34 to 43 degrees C. Similar studies of an Hsp27 triple variant that mimics the behavior of the phosphorylated protein establish that this protein has greatly diminished chaperone activity that responds minimally to increased temperature. We conclude that Hsp27 can exploit a large number of oligomerization states and that the range of oligomer size and the magnitude of chaperone activity increase significantly as temperature is increased over the range that is relevant to the physiological heat shock response.	Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Mauk, AG (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mauk@interchange.ubc.ca		Lelj-Garolla, Barbara/0000-0002-6436-3850				Akhtar MW, 2004, J BIOL CHEM, V279, P55760, DOI 10.1074/jbc.M406333200; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; CANTOR CR, 1980, BIOPHYSICAL CHEM M 2; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chadli A, 1999, J BIOL CHEM, V274, P4133, DOI 10.1074/jbc.274.7.4133; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Dam J, 2005, BIOPHYS J, V89, P619, DOI 10.1529/biophysj.105.059568; Dam J, 2005, BIOPHYS J, V89, P651, DOI 10.1529/biophysj.105.059584; Dam J, 2004, METHOD ENZYMOL, V384, P185; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4559, DOI 10.1021/bi00692a001; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P19; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lelj-Garolla B, 2005, J MOL BIOL, V345, P631, DOI 10.1016/j.jmb.2004.10.056; Lentze N, 2004, EUR J BIOCHEM, V271, P2494, DOI 10.1111/j.1432-1033.2004.04180.x; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN CS, 1995, BIOCHEMISTRY-US, V34, P5831, DOI 10.1021/bi00017a015; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Thorne ME, 2004, BIOCHEM BIOPH RES CO, V323, P1163, DOI 10.1016/j.bbrc.2004.08.215; Usui K, 2004, BIOCHEM BIOPH RES CO, V315, P113, DOI 10.1016/j.bbrc.2004.01.031; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Wang XM, 1999, BIOCHEMISTRY-US, V38, P16876, DOI 10.1021/bi992005i	43	77	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8169	8174		10.1074/jbc.M512553200	http://dx.doi.org/10.1074/jbc.M512553200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436384	hybrid			2022-12-27	WOS:000236031000055
J	Choi, SH; Hwang, SB				Choi, SH; Hwang, SB			Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TGF-BETA; NS5A PROTEIN; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR SUPPRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; LIVER FIBROSIS	Transforming growth factor-beta (TGF-beta) is implicated in the pathogenesis of liver disease. TGF-beta is involved both in liver regeneration and in the fibrotic and cirrhotic transformation with hepatitis viral infection. Hepatitis C virus (HCV) infection often leads to cirrhosis and hepatocellular carcinoma. HCV nonstructural 5A (NS5A) protein is a multifunctional protein that modulates cytokine-mediated signal transduction pathways. To elucidate the molecular mechanism of HCV pathogenesis, we examined the effect of NS5A protein on TGF-beta-stimulated signaling cascades. We show that NS5A protein inhibited the TGF-beta-mediated signaling pathway in hepatoma cell lines as determined by reporter gene assay. To further investigate the role of NS5A, we examined the protein/protein interaction between NS5A and TGF-beta signal transducers. Both in vitro and in vivo binding data showed that NS5A protein directly interacted with TGF-beta receptor I (T beta R-I) in hepatoma cell lines. This interaction was mapped to amino acids 148 - 238 of NS5A. We also found that NS5A protein co-localized with T beta R-I in the cytoplasm of Huh7 cells and inhibited TGF-beta-mediated nuclear translocation of Smad2. Furthermore, we demonstrate that NS5A protein abrogated the phosphorylation of Smad2 and the heterodimerization of Smad3 and Smad4. To further explore the relevance to viral infection, we examined the effect of the HCV subgenomic replicon on the TGF-beta signaling pathway. We show that the HCV subgenomic replicon also inhibited TGF-beta-induced signaling cascades. These results indicate that HCV NS5A modulates TGF-beta signaling through interaction with T beta R-I and that NS5A may be an important risk factor in HCV-associated liver pathogenesis.	Hallym Univ, Ilsong Inst Life Sci, Chunchon 200702, South Korea	Hallym University	Hwang, SB (corresponding author), Hallym Univ, Ilsong Inst Life Sci, 1 Ockcheon Dong, Chunchon 200702, South Korea.	sbhwang@hallym.ac.kr						AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHO YG, 1993, MOL CELLS, V3, P195; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DI B, 1994, J CLIN GASTROENTEROL, V19, P222; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Ghosh AK, 2000, VIRUS RES, V67, P173, DOI 10.1016/S0168-1702(00)00141-6; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee MN, 2002, J GEN VIROL, V83, P2145, DOI 10.1099/0022-1317-83-9-2145; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Majumder M, 2002, VIROLOGY, V294, P94, DOI 10.1006/viro.2001.1309; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki K, 2000, HEPATOLOGY, V32, P218, DOI 10.1053/jhep.2000.9145; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NEWMAN MJ, 1993, CANCER METAST REV, V12, P239, DOI 10.1007/BF00665956; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Park KJ, 2003, J BIOL CHEM, V278, P30711, DOI 10.1074/jbc.M209623200; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Ray S, 2003, J GASTROEN HEPATOL, V18, P393, DOI 10.1046/j.1440-1746.2003.02985.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; Schuppan D, 2003, CELL DEATH DIFFER, V10, pS59, DOI 10.1038/sj.cdd.4401163; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Shimizu Ichiro, 2001, Current Drug Targets - Infectious Disorders, V1, P227, DOI 10.2174/1568005014606053; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Ueno T, 2001, INT J ONCOL, V18, P49; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	60	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7468	7478		10.1074/jbc.M512438200	http://dx.doi.org/10.1074/jbc.M512438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407286	hybrid			2022-12-27	WOS:000236030900069
J	Otyepka, M; Bartova, I; Kriz, Z; Koca, J				Otyepka, M; Bartova, I; Kriz, Z; Koca, J			Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; PROTEIN-KINASE; MOLECULAR-DYNAMICS; STRUCTURAL BASIS; RECRUITMENT PEPTIDES; SUBSTRATE; SPECIFICITY; PHOSPHORYLATION; INHIBITION; SITE	A detailed analysis is presented of the dynamics of human CDK5 in complexes with the protein activator p25 and the purine-like inhibitor roscovitine. These and other findings related to the activation of CDK5 are critically reviewed from a molecular perspective. In addition, the results obtained on the behavior of CDK5 are compared with data on CDK2 to assess the differences and similarities between the two kinases in terms of (i) roscovitine binding, (ii) regulatory subunit association, (iii) conformational changes in the T-loop following CDK/regulatory subunit complex formation, and (iv) specificity in CDK/regulatory subunit recognition. An energy decomposition analysis, used for these purposes, revealed why the binding of p25 alone is sufficient to stabilize the extended active T-loop conformation of CDK5, whereas the equivalent conformational change in CDK2 requires both the binding of cyclin A and phosphorylation of the Thr(160) residue. The interaction energy of the CDK5 T-loop with p25 is about 26 kcal . mol(-1) greater than that of the CDK2T-loop with cyclin A. The binding pattern between CDK5 and p25 was compared with that of CDK2/cyclin A to find specific regions involved in CDK/regulatory subunit recognition. The analyses performed revealed that the alpha NT-helix of cyclin A interacts with the alpha 6-alpha 7 loop and the alpha 7 helix of CDK2, but these regions do not interact in the CDK5/p25 complex. Further differences between the CDK5/p25 and CDK2/cyclin A systems studied are discussed with respect to their specific functionality.	Palacky Univ, Dept Phys Chem, Olomouc 77146, Czech Republic; Palacky Univ, Ctr Biomol & Complex Mol Syst, Olomouc 77146, Czech Republic; Masaryk Univ, Fac Sci, Natl Ctr Biomol Res, Brno 62500, Czech Republic	Palacky University Olomouc; Palacky University Olomouc; Masaryk University Brno	Otyepka, M (corresponding author), Palacky Univ, Dept Phys Chem, Tr Svobody 26, Olomouc 77146, Czech Republic.	otyepka@aix.upol.cz; jkoca@chemi.muni.cz	Otyepka, Michal/D-1220-2017; Kriz, Zdenek/D-9929-2012; Koca, Jaroslav/E-4460-2012; Otyepka, Michal/A-5922-2008	Otyepka, Michal/0000-0002-1066-5677; Koca, Jaroslav/0000-0002-2780-4901; Otyepka, Michal/0000-0002-1066-5677				Ahn JS, 2005, CHEM BIOL, V12, P811, DOI 10.1016/j.chembiol.2005.05.011; Aimes RT, 2000, BIOCHEMISTRY-US, V39, P8325, DOI 10.1021/bi992800w; Barrett CP, 2005, J BIOL CHEM, V280, P13993, DOI 10.1074/jbc.M407371200; Bartova I, 2005, PROTEIN SCI, V14, P445, DOI 10.1110/ps.04959705; Bartova I, 2004, PROTEIN SCI, V13, P1449, DOI 10.1110/ps.03578504; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Cheng YH, 2005, J AM CHEM SOC, V127, P1553, DOI 10.1021/ja0464084; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; de Azevedo WF, 2002, BIOCHEM BIOPH RES CO, V297, P1154, DOI 10.1016/S0006-291X(02)02352-5; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; DUKE RE, 2003, PMEMD VERSION 3 01; Golsteyn RM, 2005, CANCER LETT, V217, P129, DOI 10.1016/j.canlet.2004.08.005; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Honda R, 2005, EMBO J, V24, P452, DOI 10.1038/sj.emboj.7600554; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jurecka P, 2004, J PHYS CHEM B, V108, P5466, DOI 10.1021/jp049956c; Kesavapany S, 2004, BBA-PROTEINS PROTEOM, V1697, P143, DOI 10.1016/j.bbapap.2003.11.020; Kriz Z, 2004, PROTEINS, V55, P258, DOI 10.1002/prot.20026; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mapelli M, 2005, J MED CHEM, V48, P671, DOI 10.1021/jm049323m; Mapelli M, 2003, NEUROSIGNALS, V12, P164, DOI 10.1159/000074617; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muller-Dethlefs K, 2000, CHEM REV, V100, P143, DOI 10.1021/cr9900331; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Otyepka M, 2002, J BIOMOL STRUCT DYN, V20, P141, DOI 10.1080/07391102.2002.10506830; PEARLMAN DA, 1999, COMP PHYS COMMUN, V91, P1; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sakaue F, 2005, J BIOL CHEM, V280, P31522, DOI 10.1074/jbc.M504792200; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Sharma P, 1999, J BIOL CHEM, V274, P9600, DOI 10.1074/jbc.274.14.9600; Smith DS, 2002, TRENDS CELL BIOL, V12, P28, DOI 10.1016/S0962-8924(01)02181-X; Smith DS, 2001, CELL GROWTH DIFFER, V12, P277; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Weishaupt JH, 2003, CELL TISSUE RES, V312, P1, DOI 10.1007/s00441-003-0703-7; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	51	41	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7271	7281		10.1074/jbc.M509699200	http://dx.doi.org/10.1074/jbc.M509699200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407256	hybrid			2022-12-27	WOS:000236030900045
J	Wood, TC; Salavagionne, OE; Mukherjee, B; Wang, LW; Klumpp, AF; Thomae, BA; Eckloff, BW; Schaid, DJ; Wieben, ED; Weinshilboum, RM				Wood, TC; Salavagionne, OE; Mukherjee, B; Wang, LW; Klumpp, AF; Thomae, BA; Eckloff, BW; Schaid, DJ; Wieben, ED; Weinshilboum, RM			Human arsenic methyltransferase (AS3MT) pharmacogenetics - Gene resequencing and functional genomics studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOMETHYLARSONOUS ACID MMA(III); PROTEASOMAL DEGRADATION; ENZYMATIC METHYLATION; ASSOCIATION; TOXICITY; SEQUENCE; LIVER; RAT; INHIBITION; HAPLOTYPES	Arsenic contaminates ground water worldwide. Methylation is an important reaction in the biotransformation of arsenic. We set out to study the pharmacogenetics of human arsenic methyltransferase (AS3MT, previously CYT19). After cloning the human AS3MT cDNA, we annotated the human gene and resequenced its 5'-flanking region, exons, and splice junctions using 60 DNA samples from African-American ( AA) and 60 samples from Caucasian-American(CA) subjects. We observed 26 single nucleotide polymorphisms ( SNPs), including 3 non-synonymous cSNPs, as well as a variable number of tandem repeats in exon 1 within an area encoding the cDNA 5'-untranslated region. The nonsynonymous cSNPs included T860C (M287T) with frequencies of 10.8 and 10% in AA and CA subjects, respectively, as well as C517T (A173W) in one AA and C917T (T306I) in one CA sample. Haplotype analysis showed that Ile(306) was linked to Thr(287), so this double variant allozyme was also studied functionally. After expression in COS-1 cells and correction for transfection efficiency, the Trp(173) allozyme displayed 31%, Thr(287) 350%, Ile(306) 4.8%, and Thr(287)/ Ile(306) 6.2% of the activity of the wild type (WT) allozyme, with 20, 190, 4.4, and 7.9% of the level of WT immunoreactive protein, respectively. Apparent Km values for S-adenosyl-L-methionine were 4.6, 3.1, and 11 mu M for WT, Trp(173), and Thr(287) allozymes, with K-m values for sodium arsenite with the same allozymes of 11.8, 8.9, and 4.5 mu M. The Ile(306) and Thr(287)/Ile(306) allozymes expressed too little activity for inclusion in the substrate kinetic studies. Expression of reporter gene constructs for the 5'-flanking region and the variable number of tandem repeats in the 5'-untranslated region demonstrated cell line-dependent variation in reporter gene expression, with shorter repeats associated with increased transcription in HepG2 cells. These results raise the possibility that inherited variation in AS3MT may contribute to variation in arsenic metabolism and, perhaps, arsenic-dependent carcinogenesis in humans.	Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Weinshilboum, RM (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	weinshilboum.richard@mayo.edu			NIGMS NIH HHS [R01 GM 35720, R01 GM 28157, U01 GM 61388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061388, R01GM028157, R01GM035720] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abernathy C.O., 1997, ARSENIC EXPOSURE HLT; Brodde OE, 2005, PHARMACOGENET GENOM, V15, P267, DOI 10.1097/01213011-200505000-00001; Chadwick RB, 1996, BIOTECHNIQUES, V20, P676; Chen CJ, 2005, TOXICOL APPL PHARM, V206, P198, DOI 10.1016/j.taap.2004.10.023; Chouchane S, 2001, CHEM RES TOXICOL, V14, P517, DOI 10.1021/tx000123x; CLELAND WW, 1963, NATURE, V198, P463, DOI 10.1038/198463a0; CRECELIUS EA, 1977, ENVIRON HEALTH PERSP, V19, P147, DOI 10.2307/3428467; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Fullerton SM, 2000, AM J HUM GENET, V67, P881, DOI 10.1086/303070; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hart TR, 2000, MOD LANG REV, V95, P107, DOI 10.2307/3736374; HENDRICK PW, 2000, GENETICS POPULATIONS, P396; Ji Y, 2005, J NEUROCHEM, V95, P1766, DOI 10.1111/j.1471-4159.2005.03453.x; Jones KD, 2003, J HAZARD MATER, V103, P93, DOI 10.1016/S0304-3894(03)00227-9; Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007; Li JX, 2005, TOXICOL APPL PHARM, V204, P164, DOI 10.1016/j.taap.2004.12.002; Lin S, 1999, CHEM RES TOXICOL, V12, P924, DOI 10.1021/tx9900775; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; Lin S, 2001, CHEM RES TOXICOL, V14, P305, DOI 10.1021/tx0001878; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Petrick JS, 2000, TOXICOL APPL PHARM, V163, P203, DOI 10.1006/taap.1999.8872; Petrick JS, 2001, CHEM RES TOXICOL, V14, P651, DOI 10.1021/tx000264z; Preuss CV, 1998, MOL PHARMACOL, V53, P708, DOI 10.1124/mol.53.4.708; Raftogianis RB, 1997, BIOCHEM BIOPH RES CO, V239, P298, DOI 10.1006/bbrc.1997.7466; Salavaggione OE, 2005, PHARMACOGENET GENOM, V15, P801, DOI 10.1097/01.fpc.0000174788.69991.6b; Sanz MA, 2005, HAEMATOLOGICA, V90, P1231; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Shield AJ, 2004, MOL PSYCHIATR, V9, P151, DOI 10.1038/sj.mp.4001386; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Simeonova PP, 2004, TOXICOL APPL PHARM, V198, P444, DOI 10.1016/j.taap.2003.10.018; Sirulnik L Andres, 2005, Clin Adv Hematol Oncol, V3, P391; SIRULNIK LA, 2005, CLIN ADV HEMATOL ONC, V3, P429; SMITH TJ, 1977, ENVIRON HEALTH PERSP, V19, P89, DOI 10.2307/3428456; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Styblo M, 1997, CHEM RES TOXICOL, V10, P27, DOI 10.1021/tx960139g; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; Tai HL, 1999, PHARMACOGENETICS, V9, P641, DOI 10.1097/01213011-199910000-00011; TAJIMA F, 1989, GENETICS, V123, P585; Tchounwou PB, 2004, MOL CELL BIOCHEM, V255, P47, DOI 10.1023/B:MCBI.0000007260.32981.b9; Thomae BA, 2003, J NEUROCHEM, V87, P809, DOI 10.1046/j.1471-4159.2003.02027.x; Wang LW, 2003, PHARMACOGENETICS, V13, P555, DOI 10.1097/00008571-200309000-00004; Weinshilboum R, 2004, CLIN PHARMACOL THER, V75, P253, DOI 10.1016/j.clpt.2003.12.002; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; Wulff M, 1996, ACTA ONCOL, V35, P179, DOI 10.3109/02841869609098499; Yoshida T, 2004, TOXICOL APPL PHARM, V198, P243, DOI 10.1016/j.taap.2003.10.022; ZAKHARYAN R, 1995, CHEM RES TOXICOL, V8, P1029, DOI 10.1021/tx00050a006; Zakharyan RA, 1999, TOXICOL APPL PHARM, V158, P9, DOI 10.1006/taap.1999.8687	49	111	118	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7364	7373		10.1074/jbc.M512227200	http://dx.doi.org/10.1074/jbc.M512227200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407288	hybrid			2022-12-27	WOS:000236030900056
J	Kalabis, J; Rosenberg, I; Podolsky, DK				Kalabis, J; Rosenberg, I; Podolsky, DK			Vangl1 protein acts as a downstream effector of intestinal trefoil factor (ITF)/TFF3 signaling and regulates wound healing of intestinal epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; DISCS-LARGE; GENE; STRABISMUS; PEPTIDES; POLARITY; IDENTIFICATION; MIGRATION; FAMILY; PHOSPHORYLATION	The intestinal trefoil factor (ITF/TFF3) protects intestinal epithelia from a range of insults and contributes to mucosal repair. However, the signaling events that mediate healing responses are only partially understood. To identify ITF signaling pathways, proteins that were Ser/Thr phosphorylated in response to ITF stimulation were immunoprecipitated from human colon carcinoma cell lines and identified by mass spectrometry. We demonstrated that Van Gogh-like protein 1 ( also designated Vang-like 1 or Vangl1), a protein with four transmembrane domains, was Ser/Thr phosphorylated in response to ITF stimulation. Vangl1 was present in normal human colon and all intestinal epithelial cell lines (IEC) tested. In transfected IEC, FLAG-Vangl1 was mostly present in the Nonidet P-40 soluble fraction as detected by Western blotting, corresponding to the localization of endogenous protein in cytoplasmic vesicular structures by confocal microscopy with rabbit polyclonal antihuman Vangl1 antibody (alpha-Vangl1). Vangl1 cell membrane association increased with differentiation, as demonstrated by co-localization with E-cadherin in differentiated IEC. Increased Vangl1 phosphorylation after stimulation with ITF corresponded to decreased cell membrane association with E-cadherin. Functionally, Vangl1 overexpression enhanced ITF unstimulated and stimulated wound closure of IEC, whereas siRNA directed against Vangl1 inhibited the migratory response to ITF. Vangl1 protein may serve as an effector mediating the ITF healing response of the intestinal mucosa.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA.	dpodolsky@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK046906] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30DK043351, R01DK046906] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chan VYW, 2005, REGUL PEPTIDES, V127, P87, DOI 10.1016/j.regpep.2004.10.016; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Iizuka-Kogo A, 2005, HISTOCHEM CELL BIOL, V123, P67, DOI 10.1007/s00418-004-0729-2; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275; Lee OK, 2003, NAT CELL BIOL, V5, P987, DOI 10.1038/ncb1055; Liu D, 1997, LAB INVEST, V77, P557; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Muskett FW, 2003, BIOCHEMISTRY-US, V42, P15139, DOI 10.1021/bi030182k; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Schmoranzer J, 2003, J CELL SCI, V116, P4513, DOI 10.1242/jcs.00748; SEFTON B, 1997, CURRENT PROTOCOLS MO; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Wolff T, 1998, DEVELOPMENT, V125, P1149; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	34	36	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6434	6441		10.1074/jbc.M512905200	http://dx.doi.org/10.1074/jbc.M512905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16410243	hybrid			2022-12-27	WOS:000236030800037
J	Lovmar, M; Nilsson, K; Vimberg, V; Tenson, T; Nervall, M; Ehrenberg, M				Lovmar, M; Nilsson, K; Vimberg, V; Tenson, T; Nervall, M; Ehrenberg, M			The molecular mechanism of peptide-mediated erythromycin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE RIBOSOMAL-SUBUNIT; RECYCLING FACTOR RRF; RELEASE FACTOR RF3; ESCHERICHIA-COLI; MACROLIDE ANTIBIOTICS; RNA; TRANSLATION; EXPRESSION; INDUCTION; REVEALS	The macrolide antibiotic erythromycin binds at the entrance of the nascent peptide exit tunnel of the large ribosomal subunit and blocks synthesis of peptides longer than between six and eight amino acids. Expression of a short open reading frame in 23 S rRNA encoding five amino acids confers resistance to erythromycin by a mechanism that depends strongly on both the sequence and the length of the peptide. In this work we have used a cell-free system for protein synthesis with components of high purity to clarify the molecular basis of the mechanism. We have found that the nascent resistance peptide interacts with erythromycin and destabilizes its interaction with 23 S rRNA. It is, however, in the termination step when the pentapeptide is removed from the peptidyl-tRNA by a class 1 release factor that erythromycin is ejected from the ribosome with high probability. Synthesis of a hexa- or heptapeptide with the same five N-terminal amino acids neither leads to ejection of erythromycin nor to drug resistance. We propose a structural model for the resistance mechanism, which is supported by docking studies. The rate constants obtained from our biochemical experiments are also used to predict the degree of erythromycin resistance conferred by varying levels of resistance peptide expression in living Escherichia coli cells subjected to varying concentrations of erythromycin. These model predictions are compared with experimental observations from growing bacterial cultures, and excellent agreement is found between theoretical prediction and experimental observation.	Uppsala Univ, BMC, Dept Cell & Mol Biol, Program Mol Biol, S-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Biometry & Engn, S-75007 Uppsala, Sweden; Univ Tartu, Inst Technol, EE-51010 Tartu, Estonia; Uppsala Univ, Dept Cell & Mol Biol, Struct Biol Program, S-75124 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences; University of Tartu; Uppsala University	Lovmar, M (corresponding author), Uppsala Univ, BMC, Dept Cell & Mol Biol, Program Mol Biol, Box 596, S-75124 Uppsala, Sweden.		Tenson, Tanel/I-6431-2015; Vimberg, Vladimir/AAE-2265-2020; Vimberg, Vladimir/W-9132-2019	Tenson, Tanel/0000-0002-0260-3601; Vimberg, Vladimir/0000-0003-3396-2380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSSON S, 1987, BIOCHIMIE, V69, P901, DOI 10.1016/0300-9084(87)90218-5; Cruz-Vera LR, 2005, MOL CELL, V19, P333, DOI 10.1016/j.molcel.2005.06.013; EHRENBERG M, 1990, DESIGN USE FAST ACCU, P101; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; HEATH MT, 1997, SCI COMPUTING INTRO, P274; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Lovmar M, 2004, J BIOL CHEM, V279, P53506, DOI 10.1074/jbc.M401625200; MacDougall J, 1997, BIOCHIMIE, V79, P243, DOI 10.1016/S0300-9084(97)83511-0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MAYFORD M, 1990, J BACTERIOL, V172, P3772, DOI 10.1128/jb.172.7.3772-3779.1990; Pavlov MY, 1996, ARCH BIOCHEM BIOPHYS, V328, P9, DOI 10.1006/abbi.1996.0136; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Schmeing TM, 2003, RNA, V9, P1345, DOI 10.1261/rna.5120503; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Tenson T, 2003, J MOL BIOL, V330, P1005, DOI 10.1016/S0022-2836(03)00662-4; Tenson T, 1997, J BIOL CHEM, V272, P17425, DOI 10.1074/jbc.272.28.17425; Tenson T, 1996, P NATL ACAD SCI USA, V93, P5641, DOI 10.1073/pnas.93.11.5641; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Tenson T, 2001, PEPTIDES, V22, P1661, DOI 10.1016/S0196-9781(01)00501-0; Tripathi S, 1998, J BIOL CHEM, V273, P20073, DOI 10.1074/jbc.273.32.20073; Tu D, 2005, CELL, V121, P257, DOI 10.1016/j.cell.2005.02.005; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Vimberg V, 2004, MOL MICROBIOL, V54, P376, DOI 10.1111/j.1365-2958.2004.04290.x; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	26	33	35	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6742	6750		10.1074/jbc.M511918200	http://dx.doi.org/10.1074/jbc.M511918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16410246	hybrid			2022-12-27	WOS:000236030800072
J	Solda, T; Garbi, N; Hammerling, GJ; Molinari, M				Solda, T; Garbi, N; Hammerling, GJ; Molinari, M			Consequences of ERp57 deletion on oxidative folding of obligate and facultative clients of the calnexin cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; PROTEIN DISULFIDE-ISOMERASE; DEPENDENT REDUCTASE ERP57; PEPTIDE-LOADING COMPLEX; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; INFLUENZA HEMAGGLUTININ; GLYCOPROTEIN-SYNTHESIS; REDUCED RIBONUCLEASE; OXIDOREDUCTASE ERP57	Members of the protein-disulfide isomerase superfamily catalyze the formation of intra- and intermolecular disulfide bonds, a rate-limiting step of protein folding in the endoplasmic reticulum ( ER). Here we compared maturation of one obligate and two facultative calnexin substrates in cells with and without ERp57, the calnexin-associated, glycoprotein-specific oxidoreductase. ERp57 deletion did not prevent the formation of disulfide bonds during co-translational translocation of nascent glycopolypeptides in the ER. It affected, however, the post-translational phases of oxidative influenza virus hemagglutinin ( HA) folding, resulting in significant loss of folding efficiency for this obligate calnexin substrate. Without ERp57, HA also showed reduced capacity to recover from an artificially induced aberrant conformation, thus revealing a crucial role of ERp57 during post-translational reshuffling to the native set of HA disulfides. ERp57 deletion did not affect maturation of the model facultative calnexin substrates E1 and p62 ( and of most cellular proteins, as shown by lack of induction of ER stress). ERp72 was identified as one of the ER-resident oxidoreductases associating with the orphan ERp57 substrates to maintain their folding competence.	Inst Biomed Res, CH-6500 Bellinzona, Switzerland; DKFZ, German Canc Res Ctr, D-69120 Heidelberg, Germany	Universita della Svizzera Italiana; Helmholtz Association; German Cancer Research Center (DKFZ)	Molinari, M (corresponding author), Inst Biomed Res, CH-6500 Bellinzona, Switzerland.	maurizio.molinari@irb.unisi.ch	Molinari, Maurizio/N-2587-2019; Garbi, Natalio/B-9147-2009; Garbi, Natalio/H-7666-2014	Molinari, Maurizio/0000-0002-7636-5829; 				ANFINSEN C, 1961, J BIOL CHEM, V236, P1361; Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; Cresswell P, 2000, TRAFFIC, V1, P301, DOI 10.1034/j.1600-0854.2000.010402.x; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Denzel A, 2002, MOL CELL BIOL, V22, P7398, DOI 10.1128/MCB.22.21.7398-7404.2002; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Elliott T, 2005, IMMUNOL REV, V207, P89, DOI 10.1111/j.0105-2896.2005.00311.x; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; Garbi N, 2005, IMMUNOL REV, V207, P77, DOI 10.1111/j.0105-2896.2005.00303.x; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2005, MOL CELL, V20, P503, DOI 10.1016/j.molcel.2005.09.027; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 2002, METHOD ENZYMOL, V348, P35, DOI 10.1016/S0076-6879(02)48623-5; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Pieren M, 2005, J BIOL CHEM, V280, P28265, DOI 10.1074/jbc.M501020200; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; Solda T, 2005, BIOL PROCED ONLINE, V7, P136, DOI 10.1251/bpo111; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; VENETIANER P, 1963, BIOCHIM BIOPHYS ACTA, V67, P166; WAECHTER CJ, 1976, ANNU REV BIOCHEM, V45, P95, DOI 10.1146/annurev.bi.45.070176.000523; WHITE FH, 1961, J BIOL CHEM, V236, P1353; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	49	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6219	6226		10.1074/jbc.M513595200	http://dx.doi.org/10.1074/jbc.M513595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407314	hybrid			2022-12-27	WOS:000236030800014
J	Peter, GJ; During, L; Ahmed, A				Peter, GJ; During, L; Ahmed, A			Carbon catabolite repression regulates amino acid permeases in Saccharomyces cerevisiae via the TOR signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPTAKE SYSTEMS; BUDDING YEAST; GENE; NITROGEN; EXPRESSION; PRODUCT	We have identified carbon catabolite repression (CCR) as a regulator of amino acid permeases in Saccharomyces cerevisiae, elucidated the permeases regulated by CCR, and identified the mechanisms involved in amino acid permease regulation by CCR. Transport of L-arginine and L-leucine was increased by similar to 10-25-fold in yeast grown in carbon sources alternate to glucose, indicating regulation by CCR. In wild type yeast the uptake (pmol/10(6) cells/ h), in glucose versus galactose medium, of L-[C-14] arginine was (0.24 +/- 0.04 versus 6.11 +/- 0.42) and L-[C-14] leucine was (0.30 +/- 0.02 versus 3.60 +/- 0.50). The increase in amino acid uptake was maintained when galactose was replaced with glycerol. Deletion of gap1 Delta and agp1 Delta from the wild type strain did not alter CCR induced increase in L- leucine uptake; however, deletion of further amino acid permeases reduced the increase in L- leucine uptake in the following manner: 36% (gnp1 Delta), 62% (bap2 Delta), 83% (Delta(bap2tat1)). Direct immunofluorescence showed large increases in the expression of Gnp1 and Bap2 proteins when grown in galactose compared with glucose medium. By extending the functional genomic approach to include major nutritional transducers of CCR in yeast, we concluded that SNF/MIG, GCN, or PSK pathways were not involved in the regulation of amino acid permeases by CCR. Strikingly, the deletion of TOR1, which regulates cellular response to changes in nitrogen availability, from the wild type strain abolished the CCR-induced amino acid uptake. Our results provide novel insights into the regulation of yeast amino acid permeases and signaling mechanisms involved in this regulation.	UCL, Inst Urol & Nephrol, London W1W 7EY, England; Carlsberg Res Lab, DK-2500 Copenhagen, Denmark	University of London; University College London	Ahmed, A (corresponding author), UCL, Inst Urol & Nephrol, 67 Riding House St, London W1W 7EY, England.	aamir.ahmed@ucl.ac.uk		Ahmed, Aamir/0000-0001-7405-5336	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed A, 1999, CELL, V99, P283, DOI 10.1016/S0092-8674(00)81659-1; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Caspary F, 1997, MOL GEN GENET, V255, P619, DOI 10.1007/s004380050536; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P4455, DOI 10.1128/MCB.11.9.4455; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Cutler NS, 2001, MOL BIOL CELL, V12, P4103, DOI 10.1091/mbc.12.12.4103; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; During-Olsen L, 1999, CURR GENET, V35, P609, DOI 10.1007/s002940050459; Forsberg H, 2001, MOL MICROBIOL, V42, P215, DOI 10.1046/j.1365-2958.2001.02627.x; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1982, EUR J BIOCHEM, V121, P643, DOI 10.1111/j.1432-1033.1982.tb05834.x; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Horak J, 1997, BBA-REV BIOMEMBRANES, V1331, P41, DOI 10.1016/S0304-4157(96)00015-9; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; KRATZER S, 1995, GENE, V161, P75, DOI 10.1016/0378-1119(95)00289-I; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Rutter J, 2002, CELL, V111, P17, DOI 10.1016/S0092-8674(02)00974-1; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; Wilson WA, 2002, CELL, V111, P155, DOI 10.1016/S0092-8674(02)01043-7; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	31	27	27	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5546	5552		10.1074/jbc.M513842200	http://dx.doi.org/10.1074/jbc.M513842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407266	hybrid			2022-12-27	WOS:000235568900029
J	Yao, ZQ; Li, P; Zhang, Q; Schwarz, EM; Keng, P; Arbini, A; Boyce, BF; Xing, LP				Yao, ZQ; Li, P; Zhang, Q; Schwarz, EM; Keng, P; Arbini, A; Boyce, BF; Xing, LP			Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; IN-VIVO; RHEUMATOID-ARTHRITIS; RECEPTOR-ACTIVATOR; JOINT DESTRUCTION; TRANSGENIC MICE; PROGENITOR; CELLS; LIGAND; TRANSCRIPTION	Osteoclasts are essential cells for bone erosion in inflammatory arthritis and are derived from cells in the myeloid lineage. Recently, we reported that tumor necrosis factor-alpha (TNF alpha) increases the blood osteoclast precursor (OCP) numbers in arthritic patients and animals, which are reduced by anti-TNF therapy, implying that circulating OCPs may have an important role in the pathogenesis of erosive arthritis. The aim of this study is to investigate the mechanism by which TNF alpha induces this increase in OCP frequency. We found that TNF alpha stimulated cell division and conversion of CD11b(+)/Gr-1(-/lo)/c-Fms(-) to CD11b(+)/Gr-1(-/lo)/c-Fms(-) cells, which was not blocked by neutralizing macrophage colony-stimulating factor (M-CSF) antibody. Ex vivo analysis of monocytes demonstrated the following: (i) blood CD11b(+)/Gr-1(-/lo) but not CD11b(-)/Gr-1(-) cells give rise to osteoclasts when they were cultured with receptor activator NF-kappa B ligand and M-CSF; and (ii) TNF-transgenic mice have a significant increase in blood CD11b(+)/Gr-1(-/lo) cells and bone marrow proliferating CD11b(+)/Gr-1(-/lo) cells. Administration of TNF alpha to wild type mice induced bone marrow CD11b(+)/Gr-1(-/lo) cell proliferation, which was associated with an increase in CD11b(+)/Gr-1(-/lo) OCPs in the circulation. Thus, TNF alpha directly stimulates bone marrow OCP genesis by enhancing c-Fms expression. This results in progenitor cell proliferation and differentiation in response to M-CSF, leading to an enlargement of the marrow OCP pool. Increased marrow OCPs subsequently egress to the circulation, forming a basis for elevated OCP frequency. Therefore, the first step of TNF-induced osteoclastogenesis is at the level of OCP genesis in the bone marrow, which represents another layer of regulation to control erosive disease.	Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Orthoped, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Canc Res Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Xing, LP (corresponding author), Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	Lianping_xing@urmc.rochester.edu		Arbini, Arnaldo/0000-0003-0345-4174	NIAMS NIH HHS [AR43510, AR48697] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048697, R01AR043510] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Alford PB, 1997, BIOCHEM BIOPH RES CO, V240, P442, DOI 10.1006/bbrc.1997.7670; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cashman JD, 1999, BLOOD, V94, P3722, DOI 10.1182/blood.V94.11.3722.423k20_3722_3729; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Fan X, 1997, J BONE MINER RES, V12, P1387, DOI 10.1359/jbmr.1997.12.9.1387; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223-002-1049-y; Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Huang W, 2003, ARTHRITIS RES THER, V5, pR49, DOI 10.1186/ar612; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kaplan DL, 1996, J CELL PHYSIOL, V168, P199; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978; Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lam J, 2002, ANN RHEUM DIS, V61, P82; Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Quinones MP, 2004, J CLIN INVEST, V113, P856, DOI 10.1172/JCI200420126; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Xing LP, 2005, CURR RHEUMATOL REV, V1, P21, DOI 10.2174/1573397052954127; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Zhang Q, 2005, ARTHRITIS RHEUM-US, V52, P2708, DOI 10.1002/art.21236	33	155	177	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11846	11855		10.1074/jbc.M512624200	http://dx.doi.org/10.1074/jbc.M512624200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16461346	hybrid			2022-12-27	WOS:000236988100051
J	Kubo, M; Inagaki, S; Yoshioka, S; Uchida, T; Mizutani, Y; Aono, S; Kitagawa, T				Kubo, M; Inagaki, S; Yoshioka, S; Uchida, T; Mizutani, Y; Aono, S; Kitagawa, T			Evidence for displacements of the C-helix by CO Ligation and DNA binding to CooA revealed by UV resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR COOA; PROTEIN SECONDARY STRUCTURE; HEME-BASED SENSORS; RHODOSPIRILLUM-RUBRUM; RECEPTOR PROTEIN; CRYSTAL-STRUCTURE; HISTIDINE 77; SIDE-CHAINS; TRYPTOPHAN; RESOLUTION	The UV and visible resonance Raman spectra are reported for CooA from Rhodospirillum rubrum, which is a transcriptional regulator activated by growth in a CO atmosphere. CO binding to heme in its sensor domain causes rearrangement of its DNA-binding domain, allowing binding of DNA with a specific sequence. The sensor and DNA-binding domains are linked by a hinge region that follows a long C-helix. UV resonance Raman bands arising from Trp-110 in the C-helix revealed local movement around Trp-110 upon CO binding. The indole side chain of Trp-110, which is exposed to solvent in the CO-free ferrous state, becomes buried in the CO-bound state with a slight change in its orientation but maintains a hydrogen bond with a water molecule at the indole nitrogen. This is the first experimental data supporting a previously proposed model involving displacement of the C-helix and heme sliding. The UV resonance Raman spectra for the CooA-DNA complex indicated that binding of DNA to CooA induces a further displacement of the C-helix in the same direction during transition to the complete active conformation. The Fe-CO and C-O stretching bands showed frequency shifts upon DNA binding, but the Fe-His stretching band did not. Moreover, CO-geminate recombination was more efficient in the DNA-bound state. These results suggest that the C-helix displacement in the DNA-bound form causes the CO binding pocket to narrow and become more negative.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 4448585, Japan; Kobe Univ, Mol Photosci Res Ctr, Kobe, Hyogo 6578501, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Kobe University	Kitagawa, T (corresponding author), 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp	Aono, Shigetoshi/ABD-7618-2020; Mizutani, Yasuhisa/B-3809-2009; Asano, Yasuhisa/K-5898-2016; Uchida, Takeshi/A-6455-2017	Aono, Shigetoshi/0000-0002-2870-3694; Asano, Yasuhisa/0000-0003-3645-3952; Uchida, Takeshi/0000-0001-9270-8329				Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Akiyama S, 2004, J MOL BIOL, V341, P651, DOI 10.1016/j.jmb.2004.06.040; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Asher S.A., 1993, ANAL CHEM, V65, P201; Asher SA, 2001, J AM CHEM SOC, V123, P11775, DOI 10.1021/ja0039738; AUSTIN JC, 1993, BIOMOLECULAR SPECT A, V20, P55; Chi ZH, 1998, BIOCHEMISTRY-US, V37, P2854, DOI 10.1021/bi971160z; Chi ZH, 1998, J PHYS CHEM B, V102, P9595, DOI 10.1021/jp9828336; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; FODOR SPA, 1989, J AM CHEM SOC, V111, P5509, DOI 10.1021/ja00197a001; Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; Holtz JSW, 1996, APPL SPECTROSC, V50, P1459, DOI 10.1366/0003702963904683; Inagaki S, 2005, J BIOL CHEM, V280, P3269, DOI 10.1074/jbc.M409884200; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; Kim JE, 2003, BIOCHEMISTRY-US, V42, P5169, DOI 10.1021/bi030026d; Kitagawa T., 2002, RAMAN SPECTROSCOPY P, V5; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Kumazaki S, 2000, J BIOL CHEM, V275, P38378, DOI 10.1074/jbc.M005533200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MIURA T, 1989, J RAMAN SPECTROSC, V20, P667, DOI 10.1002/jrs.1250201007; MIURA T, 1988, BIOCHEMISTRY-US, V27, P88, DOI 10.1021/bi00401a015; Mizutani Y, 2001, CHEM REC, V1, P258, DOI 10.1002/tcr.1012; Mizutani Y, 2001, J PHYS CHEM B, V105, P10992, DOI 10.1021/jp010923w; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Roberts GP, 2005, J INORG BIOCHEM, V99, P280, DOI 10.1016/j.jinorgbio.2004.10.032; Roberts GP, 2004, MICROBIOL MOL BIOL R, V68, P453, DOI 10.1128/MMBR.68.3.453-473.2004; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rubtsov IV, 2001, J AM CHEM SOC, V123, P10056, DOI 10.1021/ja011023w; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Spiro TG, 2005, J INORG BIOCHEM, V99, P34, DOI 10.1016/j.jinorgbio.2004.09.026; Takeuchi H, 2003, BIOPOLYMERS, V72, P305, DOI 10.1002/bip.10440; Takeuchi H., 1986, ADV SPECTROSCOPY SPE, V13, P113; Tsuboi M, 2005, BIOCHEMISTRY-US, V44, P4861, DOI 10.1021/bi0479306; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uchida T, 2005, ACCOUNTS CHEM RES, V38, P662, DOI 10.1021/ar030267d; Uesugi Y, 1997, REV SCI INSTRUM, V68, P4001, DOI 10.1063/1.1148373; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Wen ZQ, 1998, BIOPOLYMERS, V45, P247, DOI 10.1002/(SICI)1097-0282(199803)45:3<247::AID-BIP7>3.0.CO;2-R; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Yamashita T, 2004, J BIOL CHEM, V279, P47320, DOI 10.1074/jbc.M407766200; Youn H, 2005, J BACTERIOL, V187, P2573, DOI 10.1128/JB.187.8.2573-2581.2005; Youn H, 2004, J BACTERIOL, V186, P1320, DOI 10.1128/JB.186.5.1320-1329.2004	56	21	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11271	11278		10.1074/jbc.M513261200	http://dx.doi.org/10.1074/jbc.M513261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16439368	hybrid			2022-12-27	WOS:000236822200070
J	Fuda, C; Hesek, D; Lee, M; Heilmayer, W; Novak, R; Vakulenko, SB; Mobashery, S				Fuda, C; Hesek, D; Lee, M; Heilmayer, W; Novak, R; Vakulenko, SB; Mobashery, S			Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; BINDING PROTEIN 2A; STREPTOCOCCUS-PNEUMONIAE; KINETICS; CELL; IDENTIFICATION; TRANSPEPTIDASE; INVOLVEMENT; EXPRESSION	Emergence of methicillin-resistant Staphylococcus aureus (MRSA) has created challenges in treatment of nosocomial infections. The recent clinical emergence of vancomycin-resistant MRSA is a new disconcerting chapter in the evolution of these strains. S. aureus normally produces four PBPs, which are susceptible to modification by beta-lactam antibiotics, an event that leads to bacterial death. The gene product of mecA from MRSA is a penicillin-binding protein (PBP) designated PBP 2a. PBP 2a is refractory to the action of all commercially available beta-lactam antibiotics. Furthermore, PBP2a is capable of taking over the functions of the other PBPs of S. aureus in the face of the challenge by beta-lactam antibiotics. Three cephalosporins ( compounds 1 - 3) have been studied herein, which show antibacterial activities against MRSA, including the clinically important vancomycin-resistant strains. These cephalosporins exhibit substantially smaller dissociation constants for the preacylation complex compared with the case of typical cephalosporins, but their pseudo-second-order rate constants for encounter with PBP2a (k(2)/K-s) are not very large (<= 200 M-1 s(-1)). It is documented herein that these cephalosporins facilitate a conformational change in PBP 2a, a process that is enhanced in the presence of a synthetic surrogate for cell wall, resulting in increases in the k(2)/K-s parameter and in more facile enzyme inhibition. These findings argue that the novel cephalosporins are able to co-opt interactions between PBP 2a and the cell wall in gaining access to the active site in the inhibition process, a set of events that leads to effective inhibition of PBP 2a and the attendant killing of the MRSA strains.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Sandoz GmbH, Antibiot Res Inst, A-1235 Vienna, Austria	University of Notre Dame; Novartis; Sandoz	Mobashery, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mobashery@nd.edu	Lee, Mijoon/AFK-1543-2022	Lee, Mijoon/0000-0001-7432-0427	NIAID NIH HHS [N01 AI 95359] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095359] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACAR JF, 1996, ANTIBIOTICS LAB MED, P15; Bartley Judene, 2002, Infect Control Hosp Epidemiol, V23, P480; Bogdanovich T, 2005, ANTIMICROB AGENTS CH, V49, P4210, DOI 10.1128/AAC.49.10.4210-4219.2005; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P931; Chambers HF, 2003, TRENDS MICROBIOL, V11, P145, DOI 10.1016/S0966-842X(03)00046-5; Di Guilmi AM, 1998, J BACTERIOL, V180, P5652, DOI 10.1128/JB.180.21.5652-5659.1998; Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184; Fuda C, 2004, J BIOL CHEM, V279, P40802, DOI 10.1074/jbc.M403589200; Garcia-Castellanos R, 2004, J BIOL CHEM, V279, P17888, DOI 10.1074/jbc.M313123200; Gardete S, 2004, J BACTERIOL, V186, P1705, DOI 10.1128/JB.186.6.1705-1713.2004; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Graves-Woodward K, 1998, BIOCHEM J, V332, P755, DOI 10.1042/bj3320755; Gruebele M, 1999, ANNU REV PHYS CHEM, V50, P485, DOI 10.1146/annurev.physchem.50.1.485; Hujer AM, 2005, ANTIMICROB AGENTS CH, V49, P612, DOI 10.1128/AAC.49.2.612-618.2005; Iizawa Yuji, 2004, Journal of Infection and Chemotherapy, V10, P146; JAMIN M, 1993, FEBS LETT, V331, P101, DOI 10.1016/0014-5793(93)80305-E; Katayama Y, 2004, ANTIMICROB AGENTS CH, V48, P453, DOI 10.1128/AAC.48.2.453-459.2004; Katayama Y, 2003, J BACTERIOL, V185, P5465, DOI 10.1128/JB.185.18.5465-5472.2003; Lee M, 2003, J AM CHEM SOC, V125, P16322, DOI 10.1021/ja038445l; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; Lu WP, 1999, BIOCHEMISTRY-US, V38, P6537, DOI 10.1021/bi990025e; MAZZELLA LJ, 1989, BIOCHEM J, V259, P255, DOI 10.1042/bj2590255; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; *NAT COMM CLIN LAB, 2003, M7A6 NAT COMM CLIN L; Osvath S, 2003, J MOL BIOL, V333, P187, DOI 10.1016/j.jmb.2003.08.011; Pagliero E, 2004, ANTIMICROB AGENTS CH, V48, P1848, DOI 10.1128/AAC.48.5.1848-1855.2004; PRATT RF, 1986, J AM CHEM SOC, V108, P5328, DOI 10.1021/ja00277a044; Pucci MJ, 2002, J BACTERIOL, V184, P588, DOI 10.1128/JB.184.2.588-591.2002; Severin A, 2004, J BIOL CHEM, V279, P3398, DOI 10.1074/jbc.M309593200; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Sobral RG, 2003, MICROB DRUG RESIST, V9, P231, DOI 10.1089/107662903322286436; Swinney DC, 2004, NAT REV DRUG DISCOV, V3, P801, DOI 10.1038/nrd1500; Vouillamoz J, 2004, ANTIMICROB AGENTS CH, V48, P4322, DOI 10.1128/AAC.48.11.4322-4327.2004; Yang WY, 2003, J AM CHEM SOC, V125, P16220, DOI 10.1021/ja0360081	37	30	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10035	10041		10.1074/jbc.M508846200	http://dx.doi.org/10.1074/jbc.M508846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459335	hybrid			2022-12-27	WOS:000236594300027
J	Tan, J; Zhuang, L; Jiang, X; Yang, KK; Karuturi, KM; Yu, Q				Tan, J; Zhuang, L; Jiang, X; Yang, KK; Karuturi, KM; Yu, Q			Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; CELL-CYCLE; GENE-EXPRESSION; P53; INDUCTION; PATHWAYS; P73; RB; IDENTIFICATION; REPLICATION	The oncogenic retinoblastoma protein (Rb)/E2F pathway links cellular proliferation control to apoptosis as a fail-safe mechanism to protect aberrant oncogenic transformation. We have previously shown that histone deacetylase inhibitors (HDACIs) activate the E2F1-Bim apoptotic pathway, leading to efficient cell killing in cancer cells with deregulated E2F1 activity. To identify additional gene cassettes that might contribute HDACI-induced apoptosis upon E2F1 activation, we investigated the apoptotic transcriptional network affected by HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) in cancer cells with inducible E2F1. Data analysis focusing on 220 apoptosis-related genes identified apoptosis signal-regulating kinase 1 (ASK1) as one of a few genes in addition to Bim that are substantially up-regulated by SAHA upon E2F1 activation. We show that ASK1 is directly regulated by E2F1 and that prevention of ASK1 induction by RNA interference decreases SAHA-induced apoptosis. We further show that the role of ASK1 in the SAHA apoptotic response is not associated with its downstream effectors p38 or JNK. Instead, ASK1 knockdown results in reduced E2F1 transcriptional activity, leading to decreased Bim induction by SAHA. Moreover, ASK1 expression reverses the negative effect of Rb on E2F1 activity. These results indicate that ASK1 induction by E2F1 provides positive feedback regulation of E2F1 activity via Rb inhibition, which allows an efficient E2F1-Bim activation. Thus, the concomitant induction of E2F1 targets ASK1 and Bim by HDACIs warrants an effective activation of E2F1-dependent apoptosis in response to SAHA.	Genome Inst Singapore, Mol Pharmacol Lab, Singapore 138672, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Yu, Q (corresponding author), Genome Inst Singapore, Mol Pharmacol Lab, Genome Bldg,02-01,60 Biopolis St, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg		Yu, Qiang/0000-0003-2132-8278				Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Dasgupta P, 2004, J BIOL CHEM, V279, P38762, DOI 10.1074/jbc.M312273200; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Marks PA, 2004, CELL CYCLE, V3, P534; MIZUMURA K, 2005, J CELL PHYSL; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	39	61	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10508	10515		10.1074/jbc.M512719200	http://dx.doi.org/10.1074/jbc.M512719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476732	hybrid			2022-12-27	WOS:000236594300080
J	Kino, T; Souvatzoglou, E; Charmandari, E; Ichijo, T; Driggers, P; Mayers, C; Alatsatianos, A; Manoli, I; Westphal, H; Chrousos, GP; Segars, JH; James, HS				Kino, T; Souvatzoglou, E; Charmandari, E; Ichijo, T; Driggers, P; Mayers, C; Alatsatianos, A; Manoli, I; Westphal, H; Chrousos, GP; Segars, JH; James, HS			Rho family guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL ACTIVITY; NUCLEAR-LOCALIZATION; POLYBASIC REGION; SMALL GTPASES; RECEPTOR; PROTEIN; FKBP51; ACTIVATION; SENSITIVITY	Glucocorticoids regulate many crucial biologic functions through their cytoplasmic/nuclear glucocorticoid receptors (GR). Excess, deficiency, or alteration in tissue sensitivity to glucocorticoids has been associated with major causes of human morbidity and mortality. Brx, a cytoplasmic Rho family guanine nucleotide exchange factor, binds to and influences the activity of several nuclear hormone receptors. We examined the functional and molecular interactions between GR and Brx. The glucocorticoid sensitivity of lymphocytes obtained from mice haplo-insufficient for Brx was significantly decreased. Conversely, GR-mediated transcriptional activity of a glucocorticoid response element (GRE)-mediated glucocorticoid-responsive promoter was enhanced by Brx in a guanine nucleotide exchange factor domain-dependent fashion. Brx interacted with GR, forming a ternary complex with RhoA. In a chromatin immunoprecipitation assay, Brx and RhoA were co-precipitated with GREs only in the presence of ligand-activated GR. Extracellularly administered lysophosphatidic acid, which activates its signaling cascade through a specific membrane GTP-binding protein (G-protein)-coupled receptor in a G-protein alpha(13)-, Brx-, and RhoA-dependent fashion, enhanced GR transcriptional activity, whereas depletion of endogenous Brx attenuated this effect. These findings suggest that glucocorticoid signaling and, hence, the tissue sensitivity to glucocorticoids, may be coupled to extracellular signals via Brx and small G-proteins. Nuclear Brx might act as a local GRE-GR-transcriptosome activator by mediating the effect of small G-proteins on glucocorticoid-regulated genes.	NICHD, Pediat Endocrinol Sect, Reprod Biol & Med Branch, Clin Res Ctr,NIH, Bethesda, MD 20892 USA; NICHD, Natl Ctr Complementary & Alternat Med, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA; Univ Athens, Sch Med, Dept Pediat 1, GR-11527 Athens, Greece	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Uniformed Services University of the Health Sciences - USA; Athens Medical School; National & Kapodistrian University of Athens	Kino, T (corresponding author), NICHD, Pediat Endocrinol Sect, Reprod Biol & Med Branch, Clin Res Ctr,NIH, Bldg 10,Rm 1-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA.	kinot@mail.nih.gov	Charmandari, Evangelia/AAF-2038-2019; Charmandari, Evangelia/B-6701-2011	Charmandari, Evangelia/0000-0002-0851-6998; Manoli, Irini/0000-0003-1543-2941	Intramural NIH HHS [Z99 HD999999, Z01 HD008732-06] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618, Z01HD008737, Z01HD008732, Z01HD000071] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; Baughman G, 1997, BIOCHEM BIOPH RES CO, V232, P437, DOI 10.1006/bbrc.1997.6307; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chrousos G.P., 2001, ENDOCRINOLOGY METABO, V4th ed., P609; Chrousos GP, 2004, AM J MED, V117, P204, DOI 10.1016/j.amjmed.2004.05.006; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Colwell JA, 2003, DIABETES CARE, V26, P2181, DOI 10.2337/diacare.26.7.2181; De Martino MU, 2004, MOL ENDOCRINOL, V18, P820, DOI 10.1210/me.2003-0341; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Diviani D, 2004, EMBO J, V23, P2811, DOI 10.1038/sj.emboj.7600287; Driggers PH, 2001, J BIOL CHEM, V276, P46792, DOI 10.1074/jbc.M106927200; Enmark E, 2001, TRENDS PHARMACOL SCI, V22, P611, DOI 10.1016/S0165-6147(00)01859-9; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Ichijo T, 2005, J BIOL CHEM, V280, P42067, DOI 10.1074/jbc.M509338200; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Karl M, 1996, P ASSOC AM PHYSICIAN, V108, P296; Kino T, 2005, J CELL BIOL, V169, P885, DOI 10.1083/jcb.200409150; Kino T, 2003, J STEROID BIOCHEM, V85, P457, DOI 10.1016/S0960-0760(03)00218-8; Kino T, 2003, J BIOL CHEM, V278, P25651, DOI 10.1074/jbc.M302818200; Kino T, 2002, J ALLERGY CLIN IMMUN, V109, P609, DOI 10.1067/mai.2002. 123708; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDaniel K, 2004, J SOC GYNECOL INVEST, V11, p199A; Miller WL., 2001, ENDOCRINOLOGY METABO, P387; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Siess W, 2002, BBA-MOL CELL BIOL L, V1582, P204, DOI 10.1016/S1388-1981(02)00173-7; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vermeer H, 2004, MOL CELL ENDOCRINOL, V218, P49, DOI 10.1016/j.mce.2003.12.011; Vermeer H, 2003, J CLIN ENDOCR METAB, V88, P277, DOI 10.1210/jc.2002-020354; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6	50	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9118	9126		10.1074/jbc.M509339200	http://dx.doi.org/10.1074/jbc.M509339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469733	Green Accepted, hybrid			2022-12-27	WOS:000236404700017
J	Takatsume, Y; Izawa, S; Inoue, Y				Takatsume, Y; Izawa, S; Inoue, Y			Methylglyoxal as a signal initiator for activation of the stress-activated protein kinase cascade in the fission yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PAP1; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; GLYOXALASE-I; OXIDATIVE STRESS; RESPONSE REGULATOR; DIABETES-MELLITUS; PATHWAY; GENES; IDENTIFICATION	Methylglyoxal (MG) is a typical 2-oxoaldehyde derived from glycolysis. We have recently found that MG activates transcription factors such as Yap1 and Msn2, and triggers a Hog1 mitogen-activated protein kinase cascade in Saccharomyces cerevisiae. Regarding the activation of Hog1 by MG, we found that Sln1, an osmosensor possessing histidine kinase activity, functions as a sensor of MG (Maeta, K., Izawa, S., and Inoue, Y. (2005) J. Biol. Chem. 280, 253-260). To gain further insight into the role of MG as a signal initiator, here we analyze the response of Schizosaccharomyces pombe to extracellular MG. Spc1, a stress-activated protein kinase (SAPK), was phosphorylated following the treatment with MG. No phosphorylation was observed in a wis1 Delta mutant. The His-to-Asp phosphorelay system consisting of three histidine kinases (Phk1, Phk2, and Phk3), a phosphorelay protein (Spy1), and a response regulator (Mcs4) exists upstream of the Spc1-SAPK pathway. The phosphorylation of Spc1 following MG treatment was observed in phk1 Delta phk2 Delta phk3 Delta and spy1 Delta cells, but not in mcs4 Delta cells. These results suggest that S. pombe has an alternative module(s) that directs the MG signal to the SAPK pathway via Mcs4. Additionally, we found that the transcription factor Pap1 is concentrated in the nucleus in response to MG, independent of the Spc1-SAPK pathway.	Kyoto Univ, Mol Microbiol Lab, Div Appl Life Sci, Grad Sch Agr, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Mol Microbiol Lab, Div Appl Life Sci, Grad Sch Agr, Kyoto 6110011, Japan.	y_inoue@kais.kyoto-u.ac.jp		Izawa, Shingo/0000-0002-4920-2450; Takatsume, Yoshifumi/0000-0002-9467-2021				Aguilera J, 2005, MOL MICROBIOL, V56, P228, DOI 10.1111/j.1365-2958.2005.04533.x; Aguilera J, 2001, CURR GENET, V39, P273, DOI 10.1007/s002940100213; Ahmed N, 2005, J NEUROCHEM, V92, P255, DOI 10.1111/j.1471-4159.2004.02864.x; Akhand AA, 2001, FREE RADICAL BIO MED, V31, P20, DOI 10.1016/S0891-5849(01)00550-0; Aoyama K, 2001, BIOSCI BIOTECH BIOCH, V65, P2347, DOI 10.1271/bbb.65.2347; Beisswenger PJ, 1999, DIABETES, V48, P198, DOI 10.2337/diabetes.48.1.198; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Castillo EA, 2003, J BIOL CHEM, V278, P40565, DOI 10.1074/jbc.M305859200; Castillo EA, 2002, MOL MICROBIOL, V45, P243, DOI 10.1046/j.1365-2958.2002.03020.x; Chen CN, 2003, YEAST, V20, P545, DOI 10.1002/yea.979; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Inoue Y, 1999, P JPN ACAD B-PHYS, V75, P127, DOI 10.2183/pjab.75.127; Junaid MA, 2004, AM J MED GENET A, V131A, P11, DOI 10.1002/ajmg.a.30349; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Maeta K, 2004, MOL CELL BIOL, V24, P8753, DOI 10.1128/MCB.24.19.8753-8764.2004; Maeta K, 2005, FEMS MICROBIOL LETT, V243, P87, DOI 10.1016/j.femsle.2004.11.046; Maeta K, 2005, J BIOL CHEM, V280, P253, DOI 10.1074/jbc.M408061200; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168; Nakamichi N, 2003, BIOSCI BIOTECH BIOCH, V67, P547, DOI 10.1271/bbb.67.547; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; O'Rourke SM, 2002, MOL CELL BIOL, V22, P4739, DOI 10.1128/MCB.22.13.4739-4749.2002; Ohmiya R, 1999, J BIOCHEM, V125, P1061, DOI 10.1093/oxfordjournals.jbchem.a022387; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; Shieh JC, 1998, MOL BIOL CELL, V9, P311, DOI 10.1091/mbc.9.2.311; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; Takatsume Y, 2005, ARCH MICROBIOL, V183, P224, DOI 10.1007/s00203-005-0762-0; Takatsume Y, 2004, ARCH MICROBIOL, V181, P371, DOI 10.1007/s00203-004-0666-4; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Veal EA, 2003, J BIOL CHEM, V278, P30896, DOI 10.1074/jbc.M303542200; Vivancos AP, 2004, MOL MICROBIOL, V52, P1427, DOI 10.1111/j.1365-2958.2004.04065.x; Zuin A, 2005, J BIOL CHEM, V280, P36708, DOI 10.1074/jbc.M508400200	49	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9086	9092		10.1074/jbc.M511037200	http://dx.doi.org/10.1074/jbc.M511037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464860	hybrid			2022-12-27	WOS:000236404700013
J	Xu, Y; Sengupta, PK; Seto, E; Smith, BD				Xu, Y; Sengupta, PK; Seto, E; Smith, BD			Regulatory factor for X-box family proteins differentially interact with histone deacetylases to repress collagen alpha 2(I) gene (COL1A2) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOXO TRANSCRIPTION FACTORS; TRICHOSTATIN-A; DNA-BINDING; NUCLEOSOME STRUCTURE; MODIFYING ENZYMES; MOUSE ALPHA-2(I); RFX FAMILY; START SITE; 1ST EXON; ACETYLATION	Our studies indicate that the regulatory factor for X-box (RFX) family proteins repress collagen alpha 2(I) gene (COL1A2) expression (Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. (2003) J. Biol. Chem. 278, 49134-49144; Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. (2004) J. Biol. Chem. 279, 41319-41332). In this study, we examined the mechanism(s) underlying the repression of collagen gene by RFX proteins. Two members of the RFX family, RFX1 and RFX5, associate with distinct sets of co-repressors on the collagen transcription start site in vitro. RFX5 specifically interacts with histone deacetylase 2 (HDAC2) and the mammalian transcriptional repressor (mSin3B), whereas RFX1 preferably interacts with HDAC1 and mSin3A. HDAC2 cooperates with RFX5 to down-regulate collagen promoter activity, whereas HDAC1 enhances inhibition of collagen promoter activity by RFX1. Interferon-gamma promotes the recruitment of RFX5/HDAC2/mSin3B to the collagen transcription start site but decreases the occupancy by RFX1/mSin3A as manifested by chromatin immunoprecipitation assay. RFX1 binds to the methylated collagen sequence with much higher affinity than unmethylated sequence, recruiting more HDAC1 and mSin3A. The DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine, which inhibits DNA methylation, reduces RFX1/HDAC1 binding to the collagen transcription start site in chromatin immunoprecipitation assays. Finally, both RFX1 and RFX5 are acetylated in vivo. Trichostatin A stimulates the acetylation of RFX proteins and activates the collagen promoter activity. Collectively, our data strongly indicate two separate pathways for RFX proteins to repress collagen gene expression as follows: one for RFX5/HDAC2 in interferon-gamma-mediated repression, and the other for RFX1/HDAC1 in methylation-mediated collagen silencing.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02118 USA; H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA	Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, R01HL068094] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL068094, P01-HL013262-31, P01 HL013262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504; Biade S, 2001, INT J RADIAT BIOL, V77, P1033, DOI 10.1080/09553000110066068; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Chiba T, 2005, EUR J CANCER, V41, P1185, DOI 10.1016/j.ejca.2005.02.014; Chiba T, 2004, ONCOLOGY-BASEL, V66, P481, DOI 10.1159/000079503; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Dangond F, 2001, INT J ONCOL, V19, P773; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kang JE, 2005, CELL PHYSIOL BIOCHEM, V16, P23, DOI 10.1159/000087728; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; KRIEGER DE, 1974, J BIOL CHEM, V249, P332; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Loury R, 2003, METHODS, V31, P40, DOI 10.1016/S1046-2023(03)00086-0; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Matsumura T, 2005, J BIOL CHEM, V280, P12123, DOI 10.1074/jbc.M410578200; Medugno L, 2005, GENE, V359, P35, DOI 10.1016/j.gene.2005.06.021; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Mudhasani R, 2005, MOL IMMUNOL, V42, P673, DOI 10.1016/j.molimm.2004.09.021; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Rombouts K, 2002, EXP CELL RES, V278, P184, DOI 10.1006/excr.2002.5577; Rombouts K, 2001, ACTA GASTRO-ENT BELG, V64, P239; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200; Sengupta PK, 2003, CANCER RES, V63, P1789; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; TISHCHEN.LI, 1971, BIOCHEMISTRY-USSR+, V36, P595; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Xu Y, 2004, J BIOL CHEM, V279, P41319, DOI 10.1074/jbc.M404174200; Xu Y, 2003, J BIOL CHEM, V278, P49134, DOI 10.1074/jbc.M309003200; You H, 2005, CELL CYCLE, V4, P37, DOI 10.4161/cc.4.1.1401; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhao SJ, 2003, CANCER RES, V63, P2624; Zika E, 2005, CURR OPIN IMMUNOL, V17, P58, DOI 10.1016/j.coi.2004.11.008; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	78	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9260	9270		10.1074/jbc.M511724200	http://dx.doi.org/10.1074/jbc.M511724200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464847	Green Accepted, hybrid			2022-12-27	WOS:000236404700033
J	Delfino, FJ; Stevenson, H; Smithgall, TE				Delfino, FJ; Stevenson, H; Smithgall, TE			A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; STEM-CELL; COILED-COIL; TUMOR-SUPPRESSOR; LEUKEMIA-CELLS; SRC; DIFFERENTIATION; ACTIVATION; EXPRESSION; DOMAINS	The human c-fes locus encodes a non-receptor protein-tyrosine kinase implicated in myeloid, vascular endothelial, and neuronal cell differentiation. A recent analysis of the tyrosine kinome in colorectal cancer identified c-fes as one of only seven genes with consistent kinase domain mutations. Although four mutations were identified (M704V, R706Q, V743M, S759F), the consequences of these mutations on Fes kinase activity were not explored. To address this issue, Fes mutants with these substitutions were co-expressed with STAT3 in human 293T cells. Surprisingly, the M704V, R706Q, and V743M mutations substantially reduced Fes autophosphorylation and STAT3 Tyr-705 phosphorylation compared with wild-type Fes, whereas S759F had little effect. These mutations had a similar impact on Fes kinase activity in a yeast expression system, suggesting that they inhibit Fes by affecting kinase domain structure. We have also demonstrated for the first time that endogenous Fes is strongly expressed at the base of colonic crypts where it co-localizes with epithelial cells positive for the progenitor cell marker Musashi-1. In contrast to normal colonic epithelium, Fes expression was reduced or absent in colon tumor sections from most individuals. Fes protein levels were also low or absent in a panel of human colorectal cancer cell lines, including HT-29 and HCT 116 cells. Introduction of Fes into these lines with a recombinant retrovirus suppressed their growth in soft agar. Together, our findings strongly implicate the c-Fes protein-tyrosine kinase as a tumor suppressor rather than a dominant oncogene in colorectal cancer.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			NCI NIH HHS [CA58667, CA101828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101828, R01CA058667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Brittan M, 2004, GUT, V53, P899, DOI 10.1136/gut.2003.025478; Brittan M, 2004, CELL PROLIFERAT, V37, P35, DOI 10.1111/j.1365-2184.2004.00299.x; CARE A, 1994, ONCOGENE, V9, P739; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; Cheng HY, 2001, MOL CELL BIOL, V21, P6170, DOI 10.1128/MCB.21.18.6170-6180.2001; Cole LA, 1999, PROTEIN ENG, V12, P155, DOI 10.1093/protein/12.2.155; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Irby RB, 2002, CANCER RES, V62, P2669; Kanda S, 2000, J BIOL CHEM, V275, P10105, DOI 10.1074/jbc.275.14.10105; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; Kim J, 2002, MOL CELL BIOL, V22, P1903, DOI 10.1128/MCB.22.6.1903-1918.2002; Laird AD, 2003, MOL CANCER THER, V2, P461; Laurent CE, 2004, MOL CELL BIOL, V24, P9351, DOI 10.1128/MCB.24.21.9351-9358.2004; Laurent CE, 2004, EXP CELL RES, V299, P188, DOI 10.1016/j.yexcr.2004.05.010; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nishimura S, 2003, DIGEST DIS SCI, V48, P1523, DOI 10.1023/A:1024763723240; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Park WY, 1998, CANCER LETT, V129, P29, DOI 10.1016/S0304-3835(98)00077-9; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Sangrar W, 2005, CANCER RES, V65, P3518, DOI 10.1158/0008-5472.CAN-04-3468; Shibata A, 2003, CELL SIGNAL, V15, P279, DOI 10.1016/S0898-6568(02)00089-X; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Takashima Y, 2003, BIOCHEMISTRY-US, V42, P3567, DOI 10.1021/bi0272499; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Vlahovic G, 2003, ONCOLOGIST, V8, P531, DOI 10.1634/theoncologist.8-6-531; Walkenhorst J, 1996, ONCOGENE, V12, P1513; Xu G, 2004, J CELL SCI, V117, P3207, DOI 10.1242/jcs.01174; YU G, 1989, J BIOL CHEM, V264, P10276	45	25	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8829	8835		10.1074/jbc.M507331200	http://dx.doi.org/10.1074/jbc.M507331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455651	hybrid			2022-12-27	WOS:000236247100062
J	Seymour, KJ; Roberts, LE; Fini, MA; Parmley, LA; Oustitch, TL; Wright, RM				Seymour, KJ; Roberts, LE; Fini, MA; Parmley, LA; Oustitch, TL; Wright, RM			Stress activation of mammary epithelial cell xanthine oxidoreductase is mediated by p38 MAPK and CCAAT/Enhancer-binding protein-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-BETA; CASEIN GENE; DNA-BINDING; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; EXPRESSION; INDUCTION; RECEPTOR; KINASE; SIGNAL	Xanthine oxidoreductase (XOR) catalyzes the formation of uric acid from xanthine and hypoxanthine and is recognized as a source of reactive oxygen and nitrogen species. Unexpectedly, XOR was found to play an essential role in milk secretion in the differentiating mammary gland, where it is an integral component of the milk fat globule. XOR gene expression in both mammary glands and differentiating mammary epithelial cells in culture is regulated by the lactogenic hormones prolactin and cortisol. Expression in mammary epithelial cells is also regulated by inflammatory cytokines and induced by cycloheximide. Cycloheximide was found to stimulate XOR gene expression in differentiating HC11 mouse mammary epithelial cells. Activation of XOR gene expression by both cycloheximide and inflammatory cytokines suggested that XOR may be regulated by stress-activated protein kinases, the MAPKs. We demonstrate here that XOR was induced in HC11 cells by low dose cycloheximide and that expression was blocked by inhibitors of p38 MAPK. Accumulation of phospho-p38 was stimulated by low dose cycloheximide. Low dose cycloheximide stress promoted phosphorylation and nuclear accumulation of the CCAAT/enhancer-binding protein-beta(C/EBP beta) transcription factor, which was blocked by inhibition of p38. Furthermore, C/EBP beta was found to activate the mouse XOR promoter, and XOR promoter-C/EBP beta protein complexes were induced by low dose cycloheximide stress. These data demonstrate, for the first time, that mouse mammary epithelial cell XOR is regulated by p38 MAPK. They identify an essential function of the C/EBP beta transcription factor in mouse XOR expression and suggest a potential role for p38 MAPK activation of C/EBP beta in mammary epithelial cells.	Univ Colorado, Hlth Sci Ctr, Webb Waring Inst Canc Aging & Antioxidant Res, Denver, CO 80262 USA; Univ Bath, Dept Biochem, Bath BA2 7AY, Avon, England; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pulm Sci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Bath; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wright, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Webb Waring Inst Canc Aging & Antioxidant Res, Campus Box C-322,4200 E 9th Ave, Denver, CO 80262 USA.	richard.m.wright@uchsc.edu			NHLBI NIH HHS [HL45582, HL52509] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045582, R29HL052509] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; Cortes-Canteli M, 2004, J BIOL CHEM, V279, P14409, DOI 10.1074/jbc.M313253200; Cui TX, 2005, MOL ENDOCRINOL, V19, P2175, DOI 10.1210/me.2004-0502; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Garattini E, 2003, BIOCHEM J, V372, P15, DOI 10.1042/BJ20030121; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Itani OA, 2003, AM J PHYSIOL-RENAL, V284, pF778, DOI 10.1152/ajprenal.00088.2002; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lin WW, 2000, CELL SIGNAL, V12, P457, DOI 10.1016/S0898-6568(00)00090-5; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; Ma Q, 2002, ARCH BIOCHEM BIOPHYS, V404, P309, DOI 10.1016/S0003-9861(02)00339-9; Marczin N, 1998, BRIT J PHARMACOL, V123, P1000, DOI 10.1038/sj.bjp.0701687; McManaman JL, 2000, ARCH BIOCHEM BIOPHYS, V373, P318, DOI 10.1006/abbi.1999.1573; McManaman JL, 2002, J PHYSIOL-LONDON, V545, P567, DOI 10.1113/jphysiol.2002.027185; McManaman JL, 1999, ARCH BIOCHEM BIOPHYS, V371, P308, DOI 10.1006/abbi.1999.1432; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Ohtsubo T, 2004, CIRC RES, V95, P1118, DOI 10.1161/01.RES.0000149571.96304.36; Page S, 1998, BBA-GEN SUBJECTS, V1381, P191, DOI 10.1016/S0304-4165(98)00028-2; Penner G, 2002, AM J PHYSIOL-REG I, V282, pR439, DOI 10.1152/ajpregu.00512.2001; Piwien-Pilipuk G, 2002, J BIOL CHEM, V277, P44557, DOI 10.1074/jbc.M206886200; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Rosen JM, 1999, ANNU REV NUTR, V19, P407, DOI 10.1146/annurev.nutr.19.1.407; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; Vorbach C, 2003, TRENDS IMMUNOL, V24, P512, DOI 10.1016/S1471-4906(03)00237-0; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wright RM, 2004, AM J RESP CELL MOL, V30, P479, DOI 10.1165/rcmb.2003-0309OC; Wright RM, 1997, REDOX REP, V3, P135, DOI 10.1080/13510002.1997.11747101; Wright RM, 2000, DNA CELL BIOL, V19, P459, DOI 10.1089/10445490050128395; Wyszomierski SL, 2001, MOL ENDOCRINOL, V15, P228, DOI 10.1210/me.15.2.228; Xu P, 2000, J BIOL CHEM, V275, P5918, DOI 10.1074/jbc.275.8.5918; Xu P, 2004, J BIOL CHEM, V279, P16057, DOI 10.1074/jbc.M305856200; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523	47	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8545	8558		10.1074/jbc.M507349200	http://dx.doi.org/10.1074/jbc.M507349200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452486	hybrid			2022-12-27	WOS:000236247100030
J	Deka, RK; Brautigam, CA; Yang, XFF; Blevins, JS; Machius, M; Tomchick, DR; Norgard, MV				Deka, RK; Brautigam, CA; Yang, XFF; Blevins, JS; Machius, M; Tomchick, DR; Norgard, MV			The PnrA (Tp0319; TmpC) lipoprotein represents a new family of bacterial purine nucleoside receptor encoded within an ATP-binding cassette (ABC)-like operon in Treponema pallidum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; OUTER-MEMBRANE PROTEIN; X-RAY STRUCTURE; ESCHERICHIA-COLI; SYPHILIS SPIROCHETE; SUBSP PALLIDUM; PERIPLASMIC LYSINE; PORIN ACTIVITY; LIGAND; CRYSTALLOGRAPHY	Treponema pallidum, the bacterial agent of syphilis, cannot be cultivated in vitro. This constraint has severely impeded the study of the membrane biology of this complex human pathogen. A structure-to-function approach thus was adopted as a means of discerning the likely function of Tp0319, a 35-kDa cytoplasmic membrane-associated lipoprotein of T. pallidum formerly designated as TmpC. A 1.7-angstrom crystal structure showed that recombinant Tp0319 (rTp0319) consists of two alpha/beta domains, linked by three crossovers, with a deep cleft between them akin to ATP-binding cassette (ABC) receptors. In the cleft, a molecule of inosine was bound. Isothermal titration calorimetry demonstrated that rTp0319 specifically binds purine nucleosides (dissociation constant (K-d) similar to 10(-7) M). This predilection for purine nucleosides by rTp0319 is consistent with its likely role as a receptor component of a cytoplasmic membrane-associated transporter system. Reverse transcription-PCR analysis of RNA isolated from rabbit tissue-extracted T. pallidum additionally showed that tp0319 is transcriptionally linked to four other downstream open reading frames, thereby supporting the existence of an ABC-like operon (tp0319-0323). We herein thus re-name tp0319 as purine nucleoside receptor A (pnrA), with its operonic partners tp0320-0323 designated as pnrB-E, respectively. Our study not only infers that PnrA transports purine nucleosides essential for the survival of T. pallidum within its obligate human host, but to our knowledge, this is the first description of an ABC-type nucleoside transport system in any bacterium. PnrA has been grouped with a functionally uncharacterized protein family (HBG016869), thereby implying that other members of the family may have similar nucleoside-binding function(s).	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis	Norgard, MV (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.norgard@utsouthwestern.edu	Yang, X. Frank/F-3266-2010; Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Brautigam, Chad/0000-0001-6563-1338	NIAID NIH HHS [AI-56305] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER PS, 1994, INFECT IMMUN, V62, P1381, DOI 10.1128/IAI.62.4.1381-1391.1994; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; Blanco DR, 1996, J BACTERIOL, V178, P6685, DOI 10.1128/jb.178.23.6685-6692.1996; BLANCO DR, 1995, J BACTERIOL, V177, P3556, DOI 10.1128/jb.177.12.3556-3562.1995; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Deka RK, 2004, J BIOL CHEM, V279, P55644, DOI 10.1074/jbc.M409263200; Deka RK, 2004, J BACTERIOL, V186, P2303, DOI 10.1128/JB.186.8.2303-2308.2004; FALKOW S, 1988, REV INFECT DIS, V10, pS274; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Haake DA, 2000, MICROBIOL-SGM, V146, P1491, DOI 10.1099/00221287-146-7-1491; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Hazlett KRO, 2005, J BACTERIOL, V187, P6499, DOI 10.1128/JB.187.18.6499-6508.2005; HERSHFIELD MS, 1976, J BIOL CHEM, V251, P7348; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MAO B, 1982, J BIOL CHEM, V257, P1131; MCFALL E, 1960, J BIOL CHEM, V235, P2103; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Munch-Petersen A, 1983, METABOLISM NUCLEOTID, P259; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; NORRIS SJ, 1993, MICROBIOL REV, V57, P750, DOI 10.1128/MMBR.57.3.750-779.1993; Ochsner UA, 1999, J BACTERIOL, V181, P1099, DOI 10.1128/JB.181.4.1099-1109.1999; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P26323; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; Porcella SF, 1996, GENE, V177, P115, DOI 10.1016/0378-1119(96)00286-7; RADOLF JD, 1989, P NATL ACAD SCI USA, V86, P2051, DOI 10.1073/pnas.86.6.2051; RADOLF JD, 1995, INFECT IMMUN, V63, P4244, DOI 10.1128/IAI.63.11.4244-4252.1995; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; Radolf Justin D., 1994, Trends in Microbiology, V2, P307, DOI 10.1016/0966-842X(94)90446-4; Ren QH, 2004, NUCLEIC ACIDS RES, V32, pD284, DOI 10.1093/nar/gkh016; ROBERTSON SM, 1982, INFECT IMMUN, V36, P1076, DOI 10.1128/IAI.36.3.1076-1085.1982; SCHOULS LM, 1991, INFECT IMMUN, V59, P3536, DOI 10.1128/IAI.59.10.3536-3546.1991; SCHOULS LM, 1989, MICROB PATHOGENESIS, V7, P175, DOI 10.1016/0882-4010(89)90053-3; SELL S, 1983, INT REV EXP PATHOL, V24, P203; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TURNER TB, 1957, BIOLOGY TREPONEMATOS, P31; WALKER EM, 1989, J BACTERIOL, V171, P5005, DOI 10.1128/jb.171.9.5005-5011.1989; WEIGEL LM, 1992, INFECT IMMUN, V60, P1568, DOI 10.1128/IAI.60.4.1568-1576.1992; Ye JQ, 2004, EMBO J, V23, P3187, DOI 10.1038/sj.emboj.7600330; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	59	50	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8072	8081		10.1074/jbc.M511405200	http://dx.doi.org/10.1074/jbc.M511405200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418175	hybrid			2022-12-27	WOS:000236031000044
J	Liu, Q; Chen, BJ; Gaier, E; Joshi, J; Wang, ZW				Liu, Q; Chen, BJ; Gaier, E; Joshi, J; Wang, ZW			Low conductance gap junctions mediate specific electrical coupling in body-wall muscle cells of Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCARIS-LUMBRICOIDES; C-ELEGANS; SOMATIC MUSCULATURE; ACTION-POTENTIALS; NEMATODE ASCARIS; GENETIC-ANALYSIS; MAMMALIAN BRAIN; SPINAL-CORD; NERVE CORD; SYNAPSES	Invertebrate innexins and their mammalian homologues, the pannexins, are gap junction proteins. Although a large number of such proteins have been identified, few of the gap junctions that they form have been characterized to provide combined information of biophysical properties, coupling pattern, and molecular compositions. We adapted the dual whole cell voltage clamp technique to in situ analysis of electrical coupling in Caenorhabditis elegans body-wall muscle. We found that body-wall muscle cells were electrically coupled in a highly organized and specific pattern. The coupling was characterized by small ( 350 pS or less) junctional conductance (G(j)), which showed a bell-shaped relationship with junctional potential (V-j) but was independent of membrane potential (V-m). Injection of currents comparable to the junctional current (I-j) into body-wall muscle cells caused significant depolarization, suggesting important functional relevance. The innexin UNC-9 appeared to be a key component of the gap junctions. Both Myc- and green fluorescent protein-tagged UNC-9 was localized to muscle intercellular junctions. G(j) was greatly inhibited in unc-9(fc16), a putative null mutant. Specific inhibition of UNC-9 function in muscle cells reduced locomotion velocity. Despite UNC-9 expression in both motor neurons and body-wall muscle cells, analyses of miniature and evoked postsynaptic currents in the unc-9 mutant showed normal neuromuscular transmission. These analyses provide a relatively detailed description of innexin-based gap junctions in a native tissue and suggest that innexin-based small conductance gap junctions can play an important role in processes such as locomotion.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	University of Connecticut	Wang, ZW (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	zwwang@uchc.edu		Liu, Qiang/0000-0002-9232-1420	NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH070739] Funding Source: NIH RePORTER; NIMH NIH HHS [MH070739] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AVERY L, 1993, GENETICS, V133, P897; Bao L, 2004, FEBS LETT, V572, P65, DOI 10.1016/j.febslet.2004.07.009; Baranova A, 2004, GENOMICS, V83, P706, DOI 10.1016/j.ygeno.2003.09.025; Barnes TM, 1997, J NEUROCHEM, V69, P2251; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BODMER R, 1988, J NEUROSCI, V8, P1656; BOSWELL MV, 1990, FASEB J, V4, P2506, DOI 10.1096/fasebj.4.8.2335273; BRENNER S, 1974, GENETICS, V77, P71; BRINK PR, 1988, BIOPHYS J, V53, P795, DOI 10.1016/S0006-3495(88)83159-X; Bruzzone R, 2003, P NATL ACAD SCI USA, V100, P13644, DOI 10.1073/pnas.2233464100; Bukauskas FF, 2004, BBA-BIOMEMBRANES, V1662, P42, DOI 10.1016/j.bbamem.2004.01.008; BUKAUSKAS FF, 1994, BIOPHYS J, V67, P613, DOI 10.1016/S0006-3495(94)80521-1; Bukauskas FF, 1997, J PHYSIOL-LONDON, V499, P701, DOI 10.1113/jphysiol.1997.sp021962; CHALFIE M, 2000, NEMATODE CAENORHABID, V20, pRC113; Chang Q, 1999, J NEUROSCI, V19, P10813, DOI 10.1523/JNEUROSCI.19-24-10813.1999; Connors BW, 2004, ANNU REV NEUROSCI, V27, P393, DOI 10.1146/annurev.neuro.26.041002.131128; De-Miguel FF, 2001, J EXP BIOL, V204, P3241; DEBELL JT, 1963, J CELL COMPAR PHYSL, V62, P159, DOI 10.1002/jcp.1030620206; DELCASTILLO J, 1989, Q J EXP PHYSIOL CMS, V74, P1071, DOI 10.1113/expphysiol.1989.sp003334; DELCASTILLO J, 1967, J EXP BIOL, V46, P263; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; Dixon SJ, 2005, DEVELOPMENT, V132, P3079, DOI 10.1242/dev.01883; Dykes IM, 2004, J NEUROSCI, V24, P886, DOI 10.1523/JNEUROSCI.3676-03.2004; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Hecht RM, 1996, GENOME, V39, P459, DOI 10.1139/g96-058; Hidaka S, 2004, J NEUROSCI, V24, P10553, DOI 10.1523/JNEUROSCI.3319-04.2004; Jospin M, 2002, J CELL BIOL, V159, P337, DOI 10.1083/jcb.200203055; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Landesman Y, 1999, J CELL SCI, V112, P2391; LeBeau FEN, 2005, TRENDS NEUROSCI, V28, P552, DOI 10.1016/j.tins.2005.08.005; Li SL, 2003, MOL BIOL CELL, V14, P2630, DOI 10.1091/mbc.E02-11-0716; Li W, 2004, NAT NEUROSCI, V7, P751, DOI 10.1038/nn1275; Liu Q, 2005, J NEUROSCI, V25, P6745, DOI 10.1523/JNEUROSCI.1730-05.2005; Mello C, 1995, METHOD CELL BIOL, V48, P451; Nolan MF, 1999, J PHYSIOL-LONDON, V519, P753, DOI 10.1111/j.1469-7793.1999.0753n.x; Nonet ML, 1997, J NEUROSCI, V17, P8061; OKKEMA PG, 1993, GENETICS, V135, P385; Pakhotin P, 2005, MOL CELL NEUROSCI, V28, P79, DOI 10.1016/j.mcn.2004.08.014; Panchin Y, 2000, CURR BIOL, V10, pR473, DOI 10.1016/S0960-9822(00)00576-5; Panchin YV, 2005, J EXP BIOL, V208, P1415, DOI 10.1242/jeb.01547; Phelan P, 1998, NATURE, V391, P181, DOI 10.1038/34426; Phelan P, 2001, BIOESSAYS, V23, P388, DOI 10.1002/bies.1057; Phelan P, 1996, J NEUROSCI, V16, P1101; Rekling JC, 2000, J NEUROSCI, V20, part. no.; SEDENSKY MM, 1987, SCIENCE, V236, P952, DOI 10.1126/science.3576211; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Starich T, 2001, CELL COMMUN ADHES, V8, P311, DOI 10.3109/15419060109080744; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; Starich TA, 2003, DEV BIOL, V256, P403, DOI 10.1016/S0012-1606(02)00116-1; STARICH TA, 1993, GENETICS, V133, P527; STRETTON AOW, 1976, J EXP BIOL, V64, P773; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Tresch MC, 2000, NAT NEUROSCI, V3, P593, DOI 10.1038/75768; Vandecasteele M, 2005, J NEUROSCI, V25, P291, DOI 10.1523/JNEUROSCI.4167-04.2005; Venance L, 2004, J PHYSIOL-LONDON, V559, P215, DOI 10.1113/jphysiol.2004.065672; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; Waterston R., 1988, NEMATODE C ELEGANS, P281; WEISBLAT DA, 1976, J COMP PHYSIOL, V107, P293, DOI 10.1007/BF00656739; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; White TW, 1999, ANNU REV PHYSIOL, V61, P283, DOI 10.1146/annurev.physiol.61.1.283; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670	69	54	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7881	7889		10.1074/jbc.M512382200	http://dx.doi.org/10.1074/jbc.M512382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434400	hybrid			2022-12-27	WOS:000236031000023
J	Mok, H; Mlodnicka, AE; Hentze, MW; Muckenthaler, M; Schumacher, A				Mok, H; Mlodnicka, AE; Hentze, MW; Muckenthaler, M; Schumacher, A			The molecular circuitry regulating the switch between iron deficiency and overload in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; POLYCYTHEMIA MICE; FERROPORTIN; METABOLISM; HEMOCHROMATOSIS; HEPCIDIN; HOMEOSTASIS; MUTATIONS; LIVER; INFLAMMATION	Recent positional cloning of the radiation-induced polycythaemia (Pcm) mutation revealed a 58-bp microdeletion in the promoter region of ferroportin 1 (Fpn1), the sole cellular iron exporter identified to date. Here we report a molecular definition of the regulatory mechanisms governing the dynamic changes in iron balance in Pcm heterozygous mice between 3 and 12 weeks of age. Hepatic and/or duodenal response patterns of iron metabolism genes, such as Trfr, cybrd1, and Slc11a2, explained the transition from early postnatal iron deficiency to iron overload by 12 weeks of age. A significant delay in developmental up-regulation of hepcidin (Hamp), the pivotal hormonal regulator of iron homeostasis, correlated with high levels of Fpn1 expression in hepatic Kupffer cells and duodenal epithelial cells at 7 weeks of age. Conversely, upon up-regulation of Hamp expression at 12 weeks of age, Fpn1 expression decreased, indicative of a Hamp-mediated homeostatic loop. Hamp regulation due to iron did not appear dependent on transcription-level changes of the murine homolog of Hemojuvelin (Rgmc). Aged cohorts of Pcm mice exhibited low levels of Fpn1 expression in the context of an iron-deficient erythropoiesis and profound iron sequestration in reticuloendothelial macrophages, duodenum, and other tissues. Thus, similar to the anemia of chronic disease, these findings demonstrate decreased iron bioavailability due to sustained down-regulation of Fpn1 levels by Hamp. We conclude that regulatory alleles, such as Pcm, with highly dynamic changes in iron balance are ideally suited to interrogate the genetic circuitry regulating iron metabolism.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Med Sci Training Program, Houston, TX 77030 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany	Baylor College of Medicine; Baylor College of Medicine; European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg	Schumacher, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,S-803, Houston, TX 77030 USA.	armins@bcm.tmc.edu	Hentze, Matthias W/V-3980-2017	Hentze, Matthias W/0000-0002-4023-7876; Muckenthaler, Martina/0000-0002-3778-510X				Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Adams PC, 2003, BLOOD CELL MOL DIS, V31, P256, DOI 10.1016/S1079-9796(03)00136-0; Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5; Celec P, 2005, J MOL MED-JMM, V83, P521, DOI 10.1007/s00109-005-0668-y; De Domenico I, 2005, P NATL ACAD SCI USA, V102, P8955, DOI 10.1073/pnas.0503804102; Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003; Drakesmith H, 2005, BLOOD, V106, P1092, DOI 10.1182/blood-2005-02-0561; Dupic F, 2002, GUT, V51, P648, DOI 10.1136/gut.51.5.648; Frazer DM, 2003, BLOOD CELL MOL DIS, V30, P288, DOI 10.1016/S1079-9796(03)00039-1; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210; Knutson MD, 2003, BLOOD, V102, P4191, DOI 10.1182/blood-2003-04-1250; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; Latunde-Dada GO, 2004, BBA-MOL BASIS DIS, V1690, P169, DOI 10.1016/j.bbadis.2004.06.011; Liu XB, 2005, BLOOD CELL MOL DIS, V35, P33, DOI 10.1016/j.bcmd.2005.04.005; Liu XB, 2002, BLOOD CELL MOL DIS, V29, P315, DOI 10.1006/bcmd.2002.0572; Martini LA, 2002, J NUTR, V132, P693, DOI 10.1093/jn/132.4.693; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Mok H, 2004, DEVELOPMENT, V131, P4871, DOI 10.1242/dev.01342; Mok H, 2004, DEVELOPMENT, V131, P1859, DOI 10.1242/dev.01081; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Pietrangelo A, 2004, BLOOD CELL MOL DIS, V32, P131, DOI 10.1016/j.bcmd.2003.08.003; Ponka P, 2004, ANN NY ACAD SCI, V1012, P267, DOI 10.1196/annals.1306.022; Richter A, 2002, BIOTECHNIQUES, V33, P620, DOI 10.2144/02333rr05_11834a; Schimanski LM, 2005, BLOOD, V105, P4096, DOI 10.1182/blood-2004-11-4502; Viatte L, 2005, BLOOD, V105, P4861, DOI 10.1182/blood-2004-12-4608; Zoller H, 2002, BLOOD CELL MOL DIS, V29, P488, DOI 10.1006/bcmd.2002.0587	31	13	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7946	7951		10.1074/jbc.M509857200	http://dx.doi.org/10.1074/jbc.M509857200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418170	hybrid			2022-12-27	WOS:000236031000030
J	Reinboth, B; Thomas, J; Hanssen, E; Gibson, MA				Reinboth, B; Thomas, J; Hanssen, E; Gibson, MA			beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; 5Q31-LINKED CORNEAL DYSTROPHIES; MATRIX PROTEIN BETA-IG-H3; RGD-CAP BETA-IG-H3; CELL-ADHESION; IN-VITRO; EXTRACELLULAR-MATRIX; TERMINAL REGION; MICROFIBRILS; IDENTIFICATION	Recombinant human beta ig-h3 was found to bind I-125-labeled small leucine-rich proteoglycans (SLRPs), biglycan, and decorin, in co-immunoprecipitation experiments. In each instance the binding could be blocked by an excess of the unlabeled proteoglycan, confirming the specificity of the interaction. Scatchard analysis showed that biglycan bound beta ig-h3 more avidly than decorin with K-d values estimated as 5.88 x 10(-8) and 1.02 x 10(-7) M, respectively. In reciprocal blocking experiments both proteoglycans inhibited the others binding to beta ig-h3 indicating that they may share the same binding site or that the two binding sites are in close proximity on the beta ig-h3 molecule. Since beta ig-h3 and the SLRPs are known to be associated with the amino-terminal region of collagen VI in tissue microfibrils, the effects of including collagen VI in the incubations were investigated. Co-immunoprecipitation of I-125-labeled biglycan incubated with equimolar mixtures of beta ig-h3 and pepsin-collagen VI was increased 6-fold over beta ig-h3 alone and 3-fold over collagen VI alone. Similar increases were also observed for decorin. The findings indicate that beta ig-h3 participates in a ternary complex with collagen VI and SLRPs. Static light scattering techniques were used to show that beta ig-h3 rapidly forms very high molecular weight complexes with both native and pepsin-collagen VI, either alone or with the SLRPs. Indeed beta ig-h3 was shown to form a complex with collagen VI and biglycan, which appeared to be much more extensive than that formed by beta ig-h3 with collagen VI and decorin or those formed between the collagen and beta ig-h3, biglycan, or decorin alone. Biglycan core protein was shown to inhibit the extent of complexing of beta ig-h3 with native and pepsin-collagen VI suggesting that the glycosaminoglycan side chains of the proteoglycan were important for the formation of the large ternary complexes. Further studies showed that the direct interaction between beta ig-h3 and biglycan and between biglycan and collagen VI were also important for the formation of these complexes. The globular domains of collagen VI also appeared to have an influence on the interaction of the three components. Overall the results indicate that beta ig-h3 can differentially modulate the aggregation of collagen VI with biglycan and decorin. Thus this interplay is likely to be important in tissues such as cornea where such complexes are considered to occur.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Phys, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	mark.gibson@adelaide.edu.au	Thomas, John C/D-1259-2011; Hanssen, Eric/A-7217-2013	Thomas, John C/0000-0001-8966-5014; Hanssen, Eric/0000-0002-4064-1844				Aitkenhead M, 2002, MICROVASC RES, V63, P159, DOI 10.1006/mvre.2001.2380; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; Clout N, 2003, MOL VIS, V9, P440; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; Ferguson JW, 2003, MECH DEVELOP, V120, P851, DOI 10.1016/S0925-4773(03)00165-5; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; Hanssen E, 2003, J BIOL CHEM, V278, P24334, DOI 10.1074/jbc.M303455200; Hashimoto K, 1997, BBA-MOL CELL RES, V1355, P303, DOI 10.1016/S0167-4889(96)00147-4; Hirano K, 1996, CURR EYE RES, V15, P965, DOI 10.3109/02713689609017642; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kitahama S, 2000, BONE, V27, P61, DOI 10.1016/S8756-3282(00)00292-1; Lampe AK, 2005, J MED GENET, V42, P673, DOI 10.1136/jmg.2002.002311; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Oh JE, 2005, J BIOL CHEM, V280, P21629, DOI 10.1074/jbc.m412293200; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Ohno S, 2002, BBA-GEN SUBJECTS, V1572, P114, DOI 10.1016/S0304-4165(02)00286-6; Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Streeten BW, 1999, ARCH OPHTHALMOL-CHIC, V117, P67; Thapa N, 2005, BONE, V36, P232, DOI 10.1016/j.bone.2004.08.007; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200	39	71	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7816	7824		10.1074/jbc.M511316200	http://dx.doi.org/10.1074/jbc.M511316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434404	hybrid			2022-12-27	WOS:000236031000015
J	Stathopulos, PB; Rumfeldt, JAO; Karbassi, F; Siddall, CA; Lepock, JR; Meiering, EM				Stathopulos, PB; Rumfeldt, JAO; Karbassi, F; Siddall, CA; Lepock, JR; Meiering, EM			Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosisassociated Gly-93 mutants of superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; HANDED HELICAL CONFORMATION; HEAT-CAPACITY; CU,ZN-SUPEROXIDE DISMUTASE; GUANIDINIUM CHLORIDE; RECOMBINANT HUMAN; GENE-MUTATIONS; FREE CYSTEINES; SURFACE-AREAS; SCLEROSIS	Differential scanning calorimetry was used to measure changes in thermodynamic stability and aggregation for glycine 93 mutants of human copper, zinc-superoxide dismutase ( SOD). Glycine 93 is a conserved residue at position i + 3 of a tight turn and has been found to be a mutational hot spot in familial amyotrophic lateral sclerosis (fALS). The fALS-associated mutations, G93A, G93S, G93R, G93D, and G93V, were made in a pseudo wild-type background containing no free cysteines, which prevented the formation of aberrant disulfide bonds upon thermal unfolding, and enabled quantitative thermodynamic analysis of the effects of the mutations. Thermal unfolding was highly reversible for all the SODs in both the fully metallated ( holo) and metal-free (apo) forms. The data for all the holo-SODs and for the apo-pseudo-wild-type SOD were well fit by a 2-state unfolding model for native dimer (N-2) to two unfolded monomers (2U), N-2 <-> 2U. The holo- and apo-forms of the mutants are significantly destabilized ( by 1.5 - 3.5 kcal mol(-1) monomer) relative to the corresponding forms of pseudo wild-type, with the relative stabilities being correlated with statistical preferences for amino acids in this structural context. Although van't Hoff (Delta H-vH) to calorimetric (Delta H-cal) enthalpy ratios are close to unity for all the holo-SODs and for apo-pseudo-wild-type, consistent with a 2-state transition, Delta H-vH is considerably larger than Delta H-cal for all the apo-mutants. This suggests that the mutations cause apo-SOD to have an increased propensity to misfold or aggregate, which may be linked to increased toxic mutant SOD aggregation in fALS.	Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Waterloo; University of Waterloo; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Meiering, EM (corresponding author), Univ Waterloo, Dept Chem, 200 Univ Ave, Waterloo, ON N2L 3G1, Canada.	meiering@uwaterloo.ca		Stathopulos, Peter B./0000-0002-0536-6656				Andersen PM, 2003, AMYOTROPH LATERAL SC, V4, P62, DOI 10.1080/14660820310011700; Assfalg M, 2003, J MOL BIOL, V330, P145, DOI 10.1016/S0022-2836(03)00533-3; BANNISTER WH, 1991, FREE RADICAL RES COM, V12-3, P349, DOI 10.3109/10715769109145804; Barrera FN, 2002, BIOCHEMISTRY-US, V41, P5743, DOI 10.1021/bi0159478; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cooper A, 2000, PROTEIN LIGAND INTER; Creamer TP, 1995, BIOCHEMISTRY-US, V34, P16245, DOI 10.1021/bi00050a003; Crow JP, 1997, J NEUROCHEM, V69, P1936; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; di Patti MCB, 2002, METHOD ENZYMOL, V349, P49; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Durr E, 2000, BIOCHEMISTRY-US, V39, P4472, DOI 10.1021/bi992948f; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Freire E, 1995, Methods Mol Biol, V40, P191; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; Gregersen N, 2005, MOL BIOTECHNOL, V31, P141, DOI 10.1385/MB:31:2:141; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; Hosler BA, 1996, NEUROMUSCULAR DISORD, V6, P361, DOI 10.1016/0960-8966(96)00353-7; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Iwai K, 2002, J NEUROL NEUROSUR PS, V72, P819, DOI 10.1136/jnnp.72.6.819; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Juneja T, 1997, NEUROLOGY, V48, P55, DOI 10.1212/WNL.48.1.55; Khare SD, 2004, P NATL ACAD SCI USA, V101, P15094, DOI 10.1073/pnas.0406650101; KIMURA S, 1992, J BIOL CHEM, V267, P22014; KLIBANOV AM, 1987, PROTEIN ENG, P213; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; LEPOCK JR, 1985, ARCH BIOCHEM BIOPHYS, V241, P243, DOI 10.1016/0003-9861(85)90380-7; LEPOCK JR, 1992, BIOCHEMISTRY-US, V31, P12706, DOI 10.1021/bi00165a023; Lindberg MJ, 2005, P NATL ACAD SCI USA, V102, P9754, DOI 10.1073/pnas.0501957102; Lindberg MJ, 2004, P NATL ACAD SCI USA, V101, P15893, DOI 10.1073/pnas.0403979101; Liu CS, 2001, BIOCHEMISTRY-US, V40, P3817, DOI 10.1021/bi002609i; Liu YF, 1996, BIOCHEMISTRY-US, V35, P3059, DOI 10.1021/bi952198j; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; Masumoto K, 2000, PROTEIN ENG, V13, P691, DOI 10.1093/protein/13.10.691; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; McCrary BS, 1996, J MOL BIOL, V264, P784, DOI 10.1006/jmbi.1996.0677; MCREE DE, 1990, J BIOL CHEM, V265, P14234; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; ORRELL R, 1995, NATURE, V374, P504, DOI 10.1038/374504a0; Orrell RW, 1999, J NEUROL SCI, V169, P56, DOI 10.1016/S0022-510X(99)00216-6; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Radunovic A, 1999, AMYOTROPH LATERAL SC, V1, P45; Ramos CHI, 2005, PROTEIN PEPTIDE LETT, V12, P213, DOI 10.2174/0929866053587156; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rumfeldt JAO, 2006, J MOL BIOL, V355, P106, DOI 10.1016/j.jmb.2005.10.042; Shipp EL, 2003, BIOCHEMISTRY-US, V42, P1890, DOI 10.1021/bi026704y; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; SVENSSON AKE, 2004, FASEB M PROT MISF AM, P12; Takano K, 2001, PROTEINS, V44, P233, DOI 10.1002/prot.1088; Takano K, 2001, PROTEINS, V45, P274, DOI 10.1002/prot.1147; TAMURA A, 1994, BIOCHEMISTRY-US, V33, P14512, DOI 10.1021/bi00252a018; Taylor JR., 1982, INTRO ERROR ANAL, V2nd edition; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; WENISCH E, 1994, ELECTROPHORESIS, V15, P647, DOI 10.1002/elps.1150150191; Wittung-Stafshede P, 2002, ACCOUNTS CHEM RES, V35, P201, DOI 10.1021/ar010106e	74	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6184	6193		10.1074/jbc.M509496200	http://dx.doi.org/10.1074/jbc.M509496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407238	hybrid			2022-12-27	WOS:000236030800010
J	Spengler, ML; Brattain, MG				Spengler, ML; Brattain, MG			Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; SUMO-1 MODIFICATION; GROWTH-FACTOR; UBIQUITIN; PROTEINS; GLYCOSYLATION; TRICHOSTATIN; EXPRESSION; REPRESSION; MECHANISM	Sp1 is a ubiquitously expressed transcription factor that binds GC-rich cis elements. Many posttranslational modifications have been implicated in the regulation of Sp1 activity. We now provide evidence for a novel mechanism of Sp1 regulation involving the small ubiquitin-like modifier (SUMO-1). Western blot analysis revealed a high molecular mass Sp1 of 125 kDa that is stabilized by a selective SUMO hydrolase inhibitor and destabilized by a specific SUMO-1 hydrolase. The covalent modification of Sp1 by endogenous SUMO-1 and SUMO-1 that has been fused to green fluorescent protein was demonstrated using transient transfection assays. A high probability sumoylation consensus motif, (VKIE18)-I-16, is located within the N-terminal negative regulatory domain of Sp1. Either arginine substitution for lysine 16 ( Sp1(K16R)) or alanine substitution for glutamic acid 18 ( Sp1(E18A)), abrogated Sp1 sumoylation. In vitro SUMO-1 covalently bound affinity-purified GST-Sp1, but not GST-Sp1(K16R). In vivo Sp1 was determined to be N- terminally cleaved, while Sp1( K16R) could not be cleaved indicating that sumoylation and cleavage are coupled through the key regulatory lysine 16. This coupling was evident by the demonstration of an inverse relationship between cellular SUMO-modified Sp1 and N- terminally cleaved Sp1. Compared with Sp1, sumoylation-deficient Sp1( E18A) exhibited enhanced cleavage and was a better transcriptional activator, while constitutively SUMO-1-modified Sp1 was deficient in proteolytic processing and repressed Sp1 transcriptional activity. The repressive effect of sumoylation on Sp1 activity is emphasized through the use of a GAL4 based transactivation assay. A model is proposed defining a mechanism by which sumoylation preserves the integrity of a negative regulatory domain thereby allowing for the inhibition of Sp-dependent transcription.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton Sts, Buffalo, NY 14263 USA.	Michael.Brattain@roswellpark.org			NCI NIH HHS [CA 72001, CA 38173, F32 CA 86500-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA038173, R01CA072001, F32CA086500, R01CA038173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lee JA, 2005, J BIOL CHEM, V280, P28061, DOI 10.1074/jbc.M414134200; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Spengler ML, 2005, CELL SIGNAL, V17, P153, DOI 10.1016/j.cellsig.2004.06.007; Spengler ML, 2002, J VIROL, V76, P2990, DOI 10.1128/JVI.76.6.2990-2996.2002; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	37	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5567	5574		10.1074/jbc.M600035200	http://dx.doi.org/10.1074/jbc.M600035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407261	hybrid			2022-12-27	WOS:000235568900032
J	Liu, WS; Konduri, SD; Bansal, S; Nayak, BK; Rajasekaran, SA; Karuppayil, SM; Rajasekaran, AK; Das, GM				Liu, WS; Konduri, SD; Bansal, S; Nayak, BK; Rajasekaran, SA; Karuppayil, SM; Rajasekaran, AK; Das, GM			Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; NUCLEAR ANTIGEN GENE; C-TERMINUS; CELLS; EXPRESSION; TRANSCRIPTION; ACTIVATION; TRANSACTIVATION; RESISTANCE; STABILITY	Estrogen receptor-alpha (ER alpha) promotes proliferation of breast cancer cells, whereas tumor suppressor protein p53 impedes proliferation of cells with genomic damage. Whether there is a direct link between these two antagonistic pathways has remained unclear. Here we report that ER alpha binds directly to p53 and represses its function. The activation function-2 (AF-2) domain of ER alpha and the C-terminal regulatory domain of p53 are necessary for the interaction. Knocking down p53 and ER alpha by small interfering RNA elicits opposite effects on p53-target gene expression and cell cycle progression. Remarkably, ionizing radiation that causes genomic damage disrupts the interaction between ER alpha and p53. Ionizing radiation together with ER alpha knock down results in an additive effect on transcription of endogenous p53-target gene p21 (CDKN1) in human breast cancer cells. Our findings reveal a novel mechanism for regulating p53 and suggest that suppressing p53 function is an important component in the proproliferative role of ER alpha.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA	Roswell Park Cancer Institute; University of California System; University of California Los Angeles	Das, GM (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	gokul.das@roswellpark.org	Das, Gokul M/A-5772-2013; Bansal, Sanjay/F-5944-2012	Das, Gokul M/0000-0003-2937-8093; Langhans, Sigrid/0000-0003-4695-7468	NCI NIH HHS [CA 79911, R01 CA079911] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Clarke RB, 2004, TRENDS ENDOCRIN MET, V15, P316, DOI 10.1016/j.tem.2004.07.004; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Lane DP, 2004, NATURE, V427, P789, DOI 10.1038/427789a; Liu GZ, 2000, CANCER RES, V60, P1810; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McDonnell DP, 2004, MATURITAS, V48, pS7, DOI 10.1016/j.maturitas.2004.03.006; Medina D, 2004, CLIN CANCER RES, V10, p380S, DOI 10.1158/1078-0432.CCR-031211; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Qin CH, 2002, MOL ENDOCRINOL, V16, P1793, DOI 10.1210/me.2002-0006; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Shan B, 2003, J BIOL CHEM, V278, P44009, DOI 10.1074/jbc.M302671200; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	31	121	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9837	9840		10.1074/jbc.C600001200	http://dx.doi.org/10.1074/jbc.C600001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469747	hybrid			2022-12-27	WOS:000236594300003
J	Bartolommei, G; Tadini-Buoninsegni, F; Hua, SM; Moncelli, MR; Inesi, G; Guidelli, R				Bartolommei, G; Tadini-Buoninsegni, F; Hua, SM; Moncelli, MR; Inesi, G; Guidelli, R			Clotrimazole inhibits the Ca2+-ATPase (SERCA) by interfering with Ca2+ binding and favoring the E2 conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID SUPPORTED MEMBRANES; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CHARGE TRANSLOCATION; TRANSPORT MECHANISM; ESCHERICHIA-COLI; MUSCLE DISEASE; ATPASE; PUMP; NA+,K+-ATPASE; THAPSIGARGIN	Clotrimazole (CLT) is an antimycotic imidazole derivative that is known to inhibit cytochrome P-450, ergosterol biosynthesis and proliferation of cells in culture, and to interfere with cellular Ca2+ homeostasis. We found that CLT inhibits the Ca2+-ATPase of rabbit fast-twitch skeletal muscle (SERCA1), and we characterized in detail the effect of CLT on this calcium transport ATPase. We used biochemical methods for characterization of the ATPase and its partial reactions, and we also performed measurements of charge movements following adsorption of sarcoplasmic reticulum vesicles containing the ATPase onto a gold-supported biomimetic membrane. CLT inhibits Ca2+-ATPase and Ca2+ transport with a K-I of 35 mu M. Ca2+ binding in the absence of ATP and phosphoenzyme formation by the utilization of ATP in the presence of Ca2+ are also inhibited within the same CLT concentration range. On the other hand, phosphoenzyme formation by utilization of Pi in the absence of Ca2+ is only minimally inhibited. It is concluded that CLT inhibits primarily Ca2+ binding and, consequently, the Ca2+-dependent reactions of the SERCA cycle. It is suggested that CLT resides within the membrane-bound region of the transport ATPase, thereby interfering with binding and the conformational effects of the activating cation.	Univ Florence, Dept Chem, I-50019 Florence, Italy; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University of Florence; University System of Maryland; University of Maryland Baltimore	Guidelli, R (corresponding author), Univ Florence, Dept Chem, Via Lastruccia 3, I-50019 Florence, Italy.	guidelli@unifi.it	Tadini-Buoninsegni, Francesco/CAJ-5745-2022	TADINI-BUONINSEGNI, Francesco/0000-0001-5594-2554	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069830] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL69830] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; BAMBERG E, 1979, BIOPHYS STRUCT MECH, V5, P277, DOI 10.1007/BF02426663; Bartolommei G, 2004, BIOELECTROCHEMISTRY, V63, P157, DOI 10.1016/j.bioelechem.2003.07.010; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; Berman MC, 2003, BIOCHEMISTRY-US, V42, P3556, DOI 10.1021/bi026071n; Buoninsegni FT, 2004, BIOPHYS J, V86, P3671, DOI 10.1529/biophysj.103.036608; Butscher C, 1999, J MEMBRANE BIOL, V168, P169, DOI 10.1007/s002329900507; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Georgopapadakou NH, 1998, CURR OPIN MICROBIOL, V1, P547, DOI 10.1016/S1369-5274(98)80087-8; Gommans IMP, 2002, J MUSCLE RES CELL M, V23, P59, DOI 10.1023/A:1019984714528; Groll AH, 1998, TRENDS MICROBIOL, V6, P117, DOI 10.1016/S0966-842X(97)01206-7; Hartung K, 1997, BIOPHYS J, V72, P2503, DOI 10.1016/S0006-3495(97)78895-7; Hua SM, 2005, J BIOL CHEM, V280, P17579, DOI 10.1074/jbc.M500472200; INESI G, 1980, J BIOL CHEM, V255, P3025; Jan CR, 2000, LIFE SCI, V66, P2289, DOI 10.1016/S0024-3205(00)00558-0; Kaplan J.H., 2004, HDB ATPASES BIOCH CE, P63; KHAN YM, 1995, BIOCHEMISTRY-US, V34, P14385, DOI 10.1021/bi00044a015; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAUGER P, 1991, ELECTROGENIC ION PUM, P104; Lax A, 2002, AM J PHYSIOL-CELL PH, V283, pC85, DOI 10.1152/ajpcell.00580.2001; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Pintschovius J, 1999, BIOPHYS J, V76, P814, DOI 10.1016/S0006-3495(99)77245-0; Pintschovius J, 1999, BIOPHYS J, V76, P827, DOI 10.1016/S0006-3495(99)77246-2; RAO R, 2004, MEMBRANE TRANSPORTER, P365; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SEIFERT K, 1993, BIOPHYS J, V64, P384, DOI 10.1016/S0006-3495(93)81379-1; Snajdrova L, 1998, J BIOL CHEM, V273, P28032, DOI 10.1074/jbc.273.43.28032; Sohoel H, 2005, J MED CHEM, V48, P7005, DOI 10.1021/jm058036v; Sumbilla C, 2002, J BIOL CHEM, V277, P13900, DOI 10.1074/jbc.M111155200; Tadini-Buoninsegni F, 2003, BBA-BIOMEMBRANES, V1611, P70, DOI 10.1016/S0005-2736(02)00722-8; Uhlemann AC, 2005, NAT STRUCT MOL BIOL, V12, P628, DOI 10.1038/nsmb947; Zhou A, 2004, J MOL BIOL, V343, P931, DOI 10.1016/j.jmb.2004.09.002	40	38	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9547	9551		10.1074/jbc.M510550200	http://dx.doi.org/10.1074/jbc.M510550200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452481	hybrid			2022-12-27	WOS:000236404700065
J	Greenall, A; Williams, ES; Martin, KA; Palmer, JM; Gray, J; Liu, C; Whitehall, SK				Greenall, A; Williams, ES; Martin, KA; Palmer, JM; Gray, J; Liu, C; Whitehall, SK			Hip3 interacts with the HIRA proteins Hip1 and Slm9 and is required for transcriptional silencing and accurate chromosome segregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY FACTOR-I; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; AFFINITY PURIFICATION; LYSINE-9 METHYLATION; RNA INTERFERENCE; REGULATORY GENES; HISTONE GENES; HUMAN HOMOLOG; EXPRESSION	The fission yeast HIRA proteins Hip1 and Slm9 are members of an evolutionarily conserved family of histone chaperones that are implicated in nucleosome assembly. Here we have used single-step affinity purification and mass spectrometry to identify factors that interact with both Hip1 and Slm9. This analysis identified Hip3, a previously uncharacterized 187-kDa protein, with similarity to S. cerevisiae Hir3. Consistent with this, cells disrupted for hip3(+) exhibit a range of growth defects that are similar to those associated with loss of Hip1 and Slm9. These include temperature sensitivity, a cell cycle delay, and synthetic lethality with cdc25-22. Furthermore, genetic analysis also indicates that disruption of hip3(+) is epistatic with mutation of hip1(+) and slm9(+). Mutation of hip3(+) alleviates transcriptional silencing at several heterochromatic loci, including in the outer (otr) centromeric repeats, indicating that Hip3 is required for the integrity of pericentric heterochromatin. As a result, loss of Hip3 function leads to high levels of minichromosome loss and an increased frequency of lagging chromosomes during mitosis. Importantly, the function of Hip1, Slm9, and Hip3 is not restricted to constitutive heterochromatic loci, since these proteins also repress the expression of a number of genes, including the Tf2 retrotransposons.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	Newcastle University - UK; University of Sussex	Whitehall, SK (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	S.K.Whitehall@ncl.ac.uk	Liu, Cong/GOE-5572-2022	Liu, Cong/0000-0001-5192-6784; Gray, Joseph/0000-0003-2338-0301				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Blackwell C, 2004, MOL CELL BIOL, V24, P4309, DOI 10.1128/MCB.24.10.4309-4320.2004; Bowen NJ, 2003, GENOME RES, V13, P1984, DOI 10.1101/gr.1191603; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Ekwall K, 1999, GENETICS, V153, P1153; Formosa T, 2002, GENETICS, V162, P1557; Gunjan A, 2005, BIOCHIMIE, V87, P625, DOI 10.1016/j.biochi.2005.02.008; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; Hansen KR, 2005, MOL CELL BIOL, V25, P590, DOI 10.1128/MCB.25.2.590-601.2005; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Huang Y, 2002, NUCLEIC ACIDS RES, V30, P1465, DOI 10.1093/nar/30.7.1465; Kanoh J, 2000, GENETICS, V155, P623; Kaufman PD, 1998, MOL CELL BIOL, V18, P4793, DOI 10.1128/MCB.18.8.4793; Kirov N, 1998, GENE, V212, P323, DOI 10.1016/S0378-1119(98)00143-7; Kniola B, 2001, MOL BIOL CELL, V12, P2767, DOI 10.1091/mbc.12.9.2767; LAMOUR V, 1995, HUM MOL GENET, V4, P791, DOI 10.1093/hmg/4.5.791; Lippman Z, 2003, PLOS BIOL, V1, P420, DOI 10.1371/journal.pbio.0000067; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; Partridge JF, 2000, GENE DEV, V14, P783; Pidoux AL, 2004, CHROMOSOME RES, V12, P521, DOI 10.1023/B:CHRO.0000036586.81775.8b; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Prochasson P, 2005, GENE DEV, V19, P2534, DOI 10.1101/gad.1341105; Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199; Qian ZJ, 1998, MOL CELL BIOL, V18, P4783, DOI 10.1128/MCB.18.8.4783; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Roberts C, 1997, HUM MOL GENET, V6, P237, DOI 10.1093/hmg/6.2.237; Scamps C, 1996, BBA-GENE STRUCT EXPR, V1306, P5, DOI 10.1016/0167-4781(96)00010-3; Sharp JA, 2002, GENE DEV, V16, P85, DOI 10.1101/gad.925302; Spector MS, 1997, MOL CELL BIOL, V17, P545, DOI 10.1128/MCB.17.2.545; SPECTOR MS, 1993, GENETICS, V135, P25; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Thon G, 2000, GENETICS, V155, P551; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; XU HX, 1992, MOL CELL BIOL, V12, P5249, DOI 10.1128/MCB.12.11.5249; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	50	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8732	8739		10.1074/jbc.M512170200	http://dx.doi.org/10.1074/jbc.M512170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16428807	hybrid			2022-12-27	WOS:000236247100051
J	Lamb, HK; Mee, C; Xu, WM; Liu, LZ; Blond, S; Cooper, A; Charles, IG; Hawkins, AR				Lamb, HK; Mee, C; Xu, WM; Liu, LZ; Blond, S; Cooper, A; Charles, IG; Hawkins, AR			The affinity of a major Ca2+ binding site on GRP78 is differentially enhanced by ADP and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; CHAPERONE PROTEIN; CELL-DEATH; ER STRESS; BIP; HEAT; DISSOCIATION; BIP/GRP78; APOPTOSIS; CALCIUM	GRP78 is a major protein regulated by the mammalian endoplasmic reticulum stress response, and up-regulation has been shown to be important in protecting cells from challenge with cytotoxic agents. GRP78 has ATPase activity, acts as a chaperone, and interacts specifically with other proteins, such as caspases, as part of a mechanism regulating apoptosis. GRP78 is also reported to have a possible role as a Ca2+ storage protein. In order to understand the potential biological effects of Ca2+ and ATP/ADP binding on the biology of GRP78, we have determined its ligand binding properties. We show here for the first time that GRP78 can bind Ca2+, ATP, and ADP, each with a 1:1 stoichiometry, and that the binding of cation and nucleotide is cooperative. These observations do not support the hypothesis that GRP78 is a dynamic Ca2+ storage protein. Furthermore, we demonstrate that whereas Mg2+ enhances GRP78 binding to ADP and ATP to the same extent, Ca2+ shows a differential enhancement. In the presence of Ca2+, the K-D for ATP is lowered similar to 11-fold, and the K-D for ADP is lowered around 930-fold. The K-D for Ca2+ is lowered similar to 40-fold in the presence of ATP and around 880-fold with ADP. These findings may explain the biological requirement for a nucleotide exchange factor to remove ADP from GRP78. Taken together, our data suggest that the Ca2+-binding property of GRP78 may be part of a signal transduction pathway that modulates complex interactions between GRP78, ATP/ADP, secretory proteins, and caspases, and this ultimately has important consequences for cell viability.	Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; UCL, Wolfson Inst Biomed Res, London WC1E 6AU, England; Univ Illinois, Ctr Pharmaceut Biotechnol, Dept Med Chem & Pharmacognosy, Chicago, IL USA; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	Newcastle University - UK; University of London; University College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Glasgow	Hawkins, AR (corresponding author), Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	a.r.hawkins@ncl.ac.uk	Cooper, Alan/F-7813-2011; Xu, Weiming/A-6274-2008	Cooper, Alan/0000-0001-6709-7343; Xu, Weiming/0000-0002-7085-7814; Hornby, David/0000-0002-8188-7023	Biotechnology and Biological Sciences Research Council [B20089] Funding Source: Medline; Medical Research Council [G0500364] Funding Source: Medline; MRC [G0500364] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Chevalier M, 2000, J BIOL CHEM, V275, P19620, DOI 10.1074/jbc.M001333200; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; Cooper A, 2001, BIOPHYS CHEM, V93, P215, DOI 10.1016/S0301-4622(01)00222-8; Cooper A., 1999, PROTEIN C T, P217; Cooper A, 2000, PROTEIN LIGAND INTER; Demaurex N., 2003, CALRETICULIN, P134; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; Hendershot LM, 2004, MT SINAI J MED, V71, P289; Horvitz HR, 1999, CANCER RES, V59, p1701S; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; King L, 2001, PROTEIN EXPRES PURIF, V22, P148, DOI 10.1006/prep.2001.1424; KOZUTSUMI Y, 1989, J CELL SCI, P115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reid SL, 2001, BIOCHEMISTRY-US, V40, P2484, DOI 10.1021/bi001956p; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHMID SL, 1985, J BIOL CHEM, V260, P44; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Sriram M, 1997, STRUCTURE, V5, P403, DOI 10.1016/S0969-2126(97)00197-4; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Woody RW, 1996, CIRCULAR DICHROISM C, P109; Wu XJ, 2004, BIOCHEM J, V378, P793, DOI 10.1042/BJ20031680; Xu WM, 2004, NAT CELL BIOL, V6, P1129, DOI 10.1038/ncb1188; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	45	44	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8796	8805		10.1074/jbc.M503964200	http://dx.doi.org/10.1074/jbc.M503964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16418174	hybrid			2022-12-27	WOS:000236247100059
J	Schoenhofen, IC; Lunin, VV; Julien, JP; Li, YG; Ajamian, E; Matte, A; Cygler, M; Brisson, JR; Aubry, A; Logan, SM; Bhatia, S; Wakarchuk, WW; Young, NM				Schoenhofen, IC; Lunin, VV; Julien, JP; Li, YG; Ajamian, E; Matte, A; Cygler, M; Brisson, JR; Aubry, A; Logan, SM; Bhatia, S; Wakarchuk, WW; Young, NM			Structural and functional characterization of PseC, an aminotransferase involved in the biosynthesis of pseudaminic acid, an essential flagellar modification in Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME SEQUENCE; CAMPYLOBACTER; GLYCOSYLATION; IDENTIFICATION; MUTANTS; 4-AMINO-4-DEOXY-L-ARABINOSE; TRANSFORMATION; INHIBITORS; STRAINS; GENES	Helicobacter pylori flagellin is heavily glycosylated with the novel sialic acid-like nonulosonate, pseudaminic acid (Pse). The glycosylation process is essential for assembly of functional flagellar filaments and consequent bacterial motility. Because motility is a key virulence factor for this and other important pathogens, the Pse biosynthetic pathway offers potential for novel therapeutic targets. From recent NMR analyses, we determined that the conversion of UDP-alpha-D-GlcNAc to the central intermediate in the pathway, UDP-4-amino-4,6-dideoxy-beta-L-AltNAc, proceeds by formation of UDP-2-acetamido-2,6-dideoxy-beta-L-arabino-4-hexulose by the dehydratase/epimerase PseB (HP0840) followed with amino transfer by the aminotransferase, PseC (HP0366). The central role of PseC in the H. pylori Pse biosynthetic pathway prompted us to determine crystal structures of the native protein, its complexes with pyridoxal phosphate alone and in combination with the UDP-4-amino-4,6-dideoxy-beta-L-AltNAc product, the latter being converted to the external aldimine form in the active site of the enzyme. In the binding site, the AltNAc sugar ring adopts a C-4(1) chair conformation, which is different from the predominant C-1(4) form found in solution. The enzyme forms a homodimer where each monomer contributes to the active site, and these structures have permitted the identification of key residues involved in stabilization, and possibly catalysis, of the beta-L-arabino intermediate during the amino transfer reaction. The essential role of Lys(183) in the catalytic event was confirmed by site-directed mutagenesis. This work presents for the first time a nucleotide-sugar aminotransferaseco-crystallized with its natural ligand, and, in conjunction with the recent functional characterization of this enzyme, these results will assist in elucidating the aminotransferase reaction mechanism within the Pse biosynthetic pathway.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	National Research Council Canada; National Research Council Canada; McGill University	Young, NM (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	Martin.Young@nrc-cnrc.gc.ca	Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Julien, Jean-Philippe/0000-0001-7602-3995				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Arora SK, 2005, INFECT IMMUN, V73, P4395, DOI 10.1128/IAI.73.7.4395-4398.2005; Arora SK, 2001, P NATL ACAD SCI USA, V98, P9342, DOI 10.1073/pnas.161249198; Berces A, 2001, TETRAHEDRON, V57, P477, DOI 10.1016/S0040-4020(00)01019-X; Berman HM, 2000, NAT STRUCT BIOL, V7, P957, DOI 10.1038/80734; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Chou WK, 2005, J BIOL CHEM, V280, P35922, DOI 10.1074/jbc.M507483200; Eaton KA, 1996, INFECT IMMUN, V64, P2445, DOI 10.1128/IAI.64.7.2445-2448.1996; Field RA, 2003, BIOCHEMISTRY-US, V42, P7637, DOI 10.1021/bi0345079; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; HAAS R, 1993, MOL MICROBIOL, V8, P753, DOI 10.1111/j.1365-2958.1993.tb01618.x; Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677; Hwang BY, 2004, CHEM BIOL, V11, P915, DOI 10.1016/j.chembiol.2004.04.015; JANSONIUS JN, 1996, CURR OPIN STRUC BIOL, V8, P759; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; Kauppi AM, 2003, CHEM BIOL, V10, P241, DOI 10.1016/S1074-5521(03)00046-2; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; Logan SM, 2000, MOL MICROBIOL, V35, P1156, DOI 10.1046/j.1365-2958.2000.01784.x; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; Nordfelth R, 2005, INFECT IMMUN, V73, P3104, DOI 10.1128/IAI.73.5.3104-3114.2005; Obhi RK, 2005, J BIOL CHEM, V280, P20902, DOI 10.1074/jbc.M413832200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Schirm M, 2004, J BACTERIOL, V186, P6721, DOI 10.1128/JB.186.20.6721-6727.2004; Schirm M, 2004, J BACTERIOL, V186, P2523, DOI 10.1128/JB.186.9.2523-2531.2004; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; Szymanski CM, 2003, TRENDS MICROBIOL, V11, P233, DOI 10.1016/S0966-842X(03)00079-9; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trefzer A, 1999, NAT PROD REP, V16, P283, DOI 10.1039/a804431g; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409	41	79	82	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8907	8916		10.1074/jbc.M512987200	http://dx.doi.org/10.1074/jbc.M512987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16421095	hybrid			2022-12-27	WOS:000236247100071
J	Oh, CS; Martin, CE				Oh, CS; Martin, CE			Candida albicans Spt23p controls the expression of the Ole1p Delta 9 fatty acid desaturase and regulates unsaturated fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HETEROLOGOUS EXPRESSION; ENDOPLASMIC-RETICULUM; MORTIERELLA FUNGUS; MEMBRANE-PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPTION; YEAST; ACTIVATION	In Saccharomyces cerevisiae the endoplasmic reticulum membrane proteins scSpt23p and scMga2p control the formation of unsaturated fatty acids by a mechanism that involves their release from the membrane by ubiquitin-mediated proteolysis. The resulting soluble polypeptides act as transcription activators that specifically control the expression of scOLE1, a gene that encodes scOle1p, a Delta 9 fatty acid desaturase that forms cis-monounsaturated fatty acids (9Z-16: 1 and 9Z-18: 1) from saturated fatty acyl-CoA precursors. ScOle1p is the only long chain fatty acid desaturase in Saccharomyces and its membrane and storage lipids contain only saturated fatty acids and the monounsaturated products of that enzyme. Most other fungi, however, express multiple endoplasmic reticulum desaturases, including enzymes that form both mono- and polyunsaturated fatty acids. These typically include Delta 12 and Delta 15 enzymes that form the polyunsaturated species, 9Z, 12Z-18: 2, and 9Z, 12Z, 15Z-18: 3, which are the most abundant fatty acids in membrane and storage lipids. An analysis of genomic DNA sequences shows that Candida albicans has a single homologue of the Saccharomyces scSPT23 and scMGA2 genes that we designate here as caSPT23. This study describes the characterization of the caSPT23 gene product and shows that it can repair the unsaturated fatty acid auxotrophy when it is expressed in a Saccharomyces scspt23 Delta; sc-mga2 Delta strain. In addition we show caSPT23 is essential for the expression of one of the two Delta 9 desaturase homologues in Candida and potentially other functions associated with fatty acid metabolism.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Martin, CE (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.	martin@biology.rutgers.edu			NIGMS NIH HHS [GM 45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Backen AC, 2000, YEAST, V16, P1121, DOI 10.1002/1097-0061(20000915)16:12&lt;1121::AID-YEA614&gt;3.0.CO;2-U; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; Brown A J, 2000, Contrib Microbiol, V5, P112; Chellappa R, 2001, J BIOL CHEM, V276, P43548, DOI 10.1074/jbc.M107845200; Choi JY, 1996, J BIOL CHEM, V271, P3581; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEBER A, 1992, J BACTERIOL, V174, P6992, DOI 10.1128/JB.174.21.6992-6996.1992; Gola S, 2003, YEAST, V20, P1339, DOI 10.1002/yea.1044; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Kandasamy P, 2004, J BIOL CHEM, V279, P36586, DOI 10.1074/jbc.M401557200; Krishnamurthy S, 2004, MICROBIOL-SGM, V150, P1991, DOI 10.1099/mic.0.27029-0; LAEMMLI UK, 1970, J MOL BIOL, V49, P99, DOI 10.1016/0022-2836(70)90379-7; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Michaelson LV, 1998, J BIOL CHEM, V273, P19055, DOI 10.1074/jbc.273.30.19055; PUGH EL, 1977, J BIOL CHEM, V252, P68; PUGH EL, 1975, BIOCHIM BIOPHYS ACTA, V380, P442, DOI 10.1016/0005-2760(75)90112-5; Sakuradani E, 1999, GENE, V238, P445, DOI 10.1016/S0378-1119(99)00359-5; Sakuradani E, 1999, EUR J BIOCHEM, V261, P812, DOI 10.1046/j.1432-1327.1999.00333.x; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Sudbery P, 2004, TRENDS MICROBIOL, V12, P317, DOI 10.1016/j.tim.2004.05.008; Tocher DR, 1998, PROG LIPID RES, V37, P73, DOI 10.1016/S0163-7827(98)00005-8; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Vemula M, 2003, J BIOL CHEM, V278, P45269, DOI 10.1074/jbc.M308812200; Wilson RB, 2000, YEAST, V16, P65, DOI 10.1002/(SICI)1097-0061(20000115)16:1&lt;65::AID-YEA508&gt;3.0.CO;2-M; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; Zhang SR, 1999, GENETICS, V151, P473	31	17	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7030	7039		10.1074/jbc.M510746200	http://dx.doi.org/10.1074/jbc.M510746200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415349	hybrid			2022-12-27	WOS:000236030900016
J	Zihni, C; Mitsopoulos, C; Tavares, IA; Ridley, AJ; Morris, JDH				Zihni, C; Mitsopoulos, C; Tavares, IA; Ridley, AJ; Morris, JDH			Prostate-derived sterile 20-like kinase 2 (PSK2) regulates apoptotic morphology via C-jun N-terminal kinase and Rho kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED ACTIVATION; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; ROCK-I; MEMBRANE; PATHWAY; CLEAVAGE; JNK; INDUCTION; SUBFAMILY	We have reported previously that human prostate-derived sterile 20-like kinase (PSK) 1 alters actin cytoskeletal organization and binds to microtubules, regulating their organization and stability. We have shown a structurally related protein kinase PSK2, which lacks amicrotubule-binding site, activated c-Jun N-terminal kinase (JNK), and induced apoptotic morphological changes that include cell contraction, membrane blebbing, and apoptotic body formation. Apoptotic stimuli increased the catalytic activity of endogenous PSK2 and JNK, and dominant negative JNK or a physiological inhibitor of JNK blocked these apoptotic morphological responses to PSK2, demonstrating a requirement for JNK. PSK2 also stimulated the cleavage of Rho kinase-1 (ROCK-I), and the activity of ROCK-I was required for PSK2 to induce cell contraction and membrane blebbing. The activation of caspases was also needed for the induction of membrane blebbing by PSK2, which was itself a substrate for caspase 3. PSK2 therefore regulates apoptotic morphology associated with the execution phase of apoptosis, which involves dynamic reorganization of the actin cytoskeleton, via downstream targets that include JNK and ROCK-I. Our findings suggest that PSKs form a subgroup of sterile 20 (STE20)-like kinases that regulate different cytoskeletal processes.	Kings Coll London, KCL Sch Med & Dent, Rayne Inst, London SE5 9NU, England; Ludwig Inst Canc Res, Univ Coll London Branch, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), Kings Coll London, KCL Sch Med & Dent, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Mitsopoulos, Costas/0000-0002-9116-5921; Ridley, Anne/0000-0001-8186-5708; Morris, Jonathan/0000-0002-3211-1798				Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Mitsopoulos C, 2003, J BIOL CHEM, V278, P18085, DOI 10.1074/jbc.M213064200; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Schwab BL, 1998, EXP CELL RES, V238, P415, DOI 10.1006/excr.1997.3850; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yustein JT, 2003, ONCOGENE, V22, P6129, DOI 10.1038/sj.onc.1206605; Zhou TJ, 2004, STRUCTURE, V12, P1891, DOI 10.1016/j.str.2004.07.021	41	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7317	7323		10.1074/jbc.M513769200	http://dx.doi.org/10.1074/jbc.M513769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407310	hybrid			2022-12-27	WOS:000236030900050
J	Deregowski, V; Gazzerro, E; Priest, L; Rydziel, S; Canalis, E				Deregowski, V; Gazzerro, E; Priest, L; Rydziel, S; Canalis, E			Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-DIFFERENTIATION; PROTEOLYTIC RELEASE; TUMOR-SUPPRESSOR; PROGENITOR CELLS; WNT FAMILY; EXPRESSION; ACTIVATION; SCLEROSTIN; APOPTOSIS	Notch proteins are transmembrane receptors that control cell-fate decisions. Upon ligand binding, Notch receptors undergo proteolytic cleavage leading to the release of their intracellular domain ( NICD). Overexpression of NICD impairs osteoblastogenesis, but the mechanisms are not understood. We examined consequences of the constitutive activation of Notch 1 in ST-2 cells. Notch opposed the effects of bone morphogenetic protein (BMP)-2 and Wnt 3a on alkaline phosphatase activity (APA). BMP-2 induced the phosphorylation of Smad 1/5/8 and the transactivation of a BMP/Smad-responsive construct ( 12 x SBE-Oc-pGL3), but the effect was not modified by Notch. BMP-2 had minimal effects on the phosphorylation of the mitogen-activated protein kinases ERK, p38, and JNK, in the absence or presence of NICD. Notch overexpression decreased the transactivating effect of Wnt 3a, cytoplasmic beta-catenin levels, and Wnt-dependent gene expression. Transfection of a mutant beta-catenin expression construct, or the use of a glycogen synthase kinase 3 beta inhibitor to stabilize beta-catenin, partially blocked the inhibitory effect of NICD on Wnt signaling and on APA. HES-1 or Groucho1/TLE1 RNA interference enhanced basal and induced Wnt/beta-catenin signaling opposing NICD effects, but only HES-1 silencing enhanced Wnt 3a effects on APA. In conclusion, NICD overexpression prevents BMP-2 and Wnt biological effects by suppressing Wnt but not BMP signaling. HES-1 appears to mediate effects of Notch on osteoblastogenesis.	St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	Saint Francis Hospital & Medical Center; University of Connecticut	Canalis, E (corresponding author), St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.	ecanalis@stfranciscare.org			NIAMS NIH HHS [AR21707] Funding Source: Medline; NIDDK NIH HHS [DK45227] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045227] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413; Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Dale TC, 1998, BIOCHEM J, V329, P209; DANIELS DL, 2005, NAT STRUCT MOL BIOL; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; Egan SE, 1998, CURR TOP MICROBIOL, V228, P273; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004-0766; Ghosh-Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; MILLER JR, 2001, GENOME BIOL; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Nohe A, 2003, J CELL SCI, V116, P3277, DOI 10.1242/jcs.00519; Noll E, 2000, DEV BIOL, V227, P450, DOI 10.1006/dbio.2000.9925; NYE JS, 1994, DEVELOPMENT, V120, P2421; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; OWEN M, 1988, CIBA F SYMP, V136, P42; Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756-3282(02)00687-7; Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125; Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756-3282(01)00422-7; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Reddi H, 1995, Adv Dent Res, V9, P13; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Ross DA, 2004, MOL CELL BIOL, V24, P3505, DOI 10.1128/MCB.24.8.3505-3513.2004; Schnabel M, 2002, INT J MOL MED, V9, P229; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Shindo K, 2003, EXP CELL RES, V290, P370, DOI 10.1016/S0014-4827(03)00349-5; Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004-1050; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	73	169	185	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6203	6210		10.1074/jbc.M508370200	http://dx.doi.org/10.1074/jbc.M508370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407293	hybrid			2022-12-27	WOS:000236030800012
J	Teer, JK; Machida, YJ; Labit, H; Novac, O; Hyrien, O; Marheineke, K; Zannis-Hadjopoulos, M; Dutta, A				Teer, JK; Machida, YJ; Labit, H; Novac, O; Hyrien, O; Marheineke, K; Zannis-Hadjopoulos, M; Dutta, A			Proliferating human cells hypomorphic for origin recognition complex 2 and pre-replicative complex formation have a defect in p53 activation and Cdk2 kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; EUKARYOTIC DNA-REPLICATION; CYCLIN-E; CHECKPOINT PATHWAY; SACCHAROMYCES-CEREVISIAE; ECTOPIC EXPRESSION; G(1)/S TRANSITION; DAMAGE CHECKPOINT; CDC6 PROTEIN; PHOSPHORYLATION	The Origin Recognition Complex (ORC) is a critical component of replication initiation. We have previously reported generation of an Orc2 hypomorph cell line (Delta/-) that expresses very low levels of Orc2 but is viable. We have shown here that Chk2 is phosphorylated, suggesting that DNA damage checkpoint pathways are activated. p53 was inactivated during the derivation of the Orc2 hypomorphic cell lines, accounting for their survival despite active Chk2. These cells also show a defect in the G(1) to S-phase transition. Cdk2 kinase activation in G(1) is decreased due to decreased Cyclin E levels, preventing progression into S-phase. Molecular combing of bromodeoxyuridine-labeled DNA revealed that once the Orc2 hypomorphic cells enter S-phase, fork density and fork progression are approximately comparable with wild type cells. Therefore, the low level of Orc2 hinders normal cell cycle progression by delaying the activation of G(1) cyclin-dependent kinases. The results suggest that hypomorphic mutations in initiation factor genes may be particularly deleterious in cancers with mutant p53 or increased activity of Cyclin E/Cdk2.	Univ Virginia, Dept Biochem, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA; Ecole Normale Super, F-75230 Paris, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	University of Virginia; Harvard University; Harvard Medical School; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); McGill University; McGill University	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016; Marheineke, Kathrin/C-1797-2008; Machida, Yuichi/AAO-3533-2021; Hyrien, Olivier/R-5108-2017	Machida, Yuichi/0000-0003-1414-0568; Hyrien, Olivier/0000-0001-8879-675X; Marheineke, Kathrin/0000-0002-1514-0167; Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA060499-13, R01 CA60499, R01 CA089406, R01 CA060499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089406, R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bunz F, 2002, CANCER RES, V62, P1129; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KATO J, 1993, GENE DEV, V7, P331; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Marheineke K, 2004, J BIOL CHEM, V279, P28071, DOI 10.1074/jbc.M401574200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	60	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6253	6260		10.1074/jbc.M507150200	http://dx.doi.org/10.1074/jbc.M507150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407251	hybrid			2022-12-27	WOS:000236030800018
J	Zhou, WX; Lepesheva, GI; Waterman, MR; Nes, WD				Zhou, WX; Lepesheva, GI; Waterman, MR; Nes, WD			Mechanistic analysis of a multiple product sterol methyltransferase implicated in ergosterol biosynthesis in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; METHYL TRANSFERASE; ACTIVE-SITE; ENZYME; (S)-ADENOSYL-L-METHIONINE; PURIFICATION; AZASTEROLS; INHIBITORS; ANALOGS; C-25	Sterol methyltransferase (SMT) plays a key role in sterol biosynthesis in different pathogenic organisms by setting the pattern of the side chain structure of the final product. This catalyst, absent in humans, provides critical pathway-specific enzymatic steps in the production of ergosterol in fungi or phytosterols in plants. The new SMT gene was isolated from Trypanosoma brucei genomic DNA and cloned into an Escherichia coli expression system. The recombinant SMT was purified to homogeneity to give a band at 40.0 kDa upon SDS-PAGE and showed a tetrameric subunit organization by gel chromatography. It has a pH optimum of 7.5, an apparent k(cat) value of 0.01 s(-1), and a K-m of 47 +/- 4 mu M for zymosterol. The products of the reaction were a mixture of C24-monoalkylated sterols, ergosta-8,24 ( 25)-dienol, ergosta-8,25 ( 27)-dienol, and ergosta-8,24 ( 28)-dienol ( fecosterol), and an unusual double C24-alkylated sterol, 24,24-dimethyl ergosta-8,25 ( 27)- dienol, typically found in plants. Inhibitory profile studies with 25-azalanosterol (K-i value of 39 nM) or 24( R, S), 25- epiminolanosterol (K-i value of 49 nM), ergosterol (K-i value of 27 mu M) and 26,27-dehydrozymosterol (K-i and k(inact) values of 29 mu M and 0.26 min(-1), respectively) and data showing zymosterol as the preferred acceptor strongly suggest that the protozoan SMT has an active site topography combining properties of the SMT1 from plants and yeast ( 37 - 47% identity). The enzymatic activation of this and other SMTs reveals that the catalytic requirements for the C-methyl reaction are remarkably versatile, whereas the inhibition studies provide a powerful approach to rational design of new anti-sleeping sickness chemotherapeutic drugs.	Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Texas Tech University System; Texas Tech University; Vanderbilt University	Nes, WD (corresponding author), Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.	wdavid.nes@ttu.edu	Zhou, Wenxu/T-6917-2019					AKIHISA T, 1990, J CHEM SOC PERK T 1, P2213, DOI 10.1039/p19900002213; Arigoni D., 1978, CIBA FDN S, P243; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON H, 1972, COMP BIOCHEM PHYSIOL, V41, P1, DOI 10.1016/0305-0491(72)90002-8; FONTENEAU P, 1977, PLANT SCI LETT, V10, P147, DOI 10.1016/0304-4211(77)90122-5; Fujimoto Y, 1997, CHEM COMMUN, P681, DOI 10.1039/a700492c; GOAD LJ, 1974, LIPIDS, V9, P582, DOI 10.1007/BF02532508; Guo DA, 1996, TETRAHEDRON LETT, V37, P6823, DOI 10.1016/0040-4039(96)01534-1; Hannaert V, 2003, P NATL ACAD SCI USA, V100, P1067, DOI 10.1073/pnas.0335769100; Joubert BM, 2001, ORG LETT, V3, P1957, DOI 10.1021/ol0160506; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KALINOWSKA M, 1990, PHYTOCHEMISTRY, V29, P3427, DOI 10.1016/0031-9422(90)85251-A; Kanagasabai R, 2004, LIPIDS, V39, P737, DOI 10.1007/s11745-004-1290-7; Lepesheva GI, 2004, BIOCHEMISTRY-US, V43, P10789, DOI 10.1021/bi048967t; Lorente SO, 2004, ANTIMICROB AGENTS CH, V48, P2937, DOI 10.1128/AAC.48.8.2937-2950.2004; LOW P, 1991, J BIOL CHEM, V266, P19250; Magaraci F, 2003, J MED CHEM, V46, P4714, DOI 10.1021/jm021114j; Mangla AT, 2000, BIOORGAN MED CHEM, V8, P925, DOI 10.1016/S0968-0896(00)00040-7; Nes WD, 2005, BIOCHEM SOC T, V33, P1189, DOI 10.1042/BST0331189; Nes WD, 2004, BIOCHEMISTRY-US, V43, P569, DOI 10.1021/bi035257z; Nes WD, 2003, PHYTOCHEMISTRY, V64, P75, DOI 10.1016/S0031-9422(03)00349-2; Nes WD, 2003, J BIOL CHEM, V278, P34505, DOI 10.1074/jbc.M303359200; Nes WD, 2002, J BIOL CHEM, V277, P42549, DOI 10.1074/jbc.M204223200; NES WD, 1990, P NATL ACAD SCI USA, V87, P7565, DOI 10.1073/pnas.87.19.7565; Nes WD, 2000, BBA-MOL CELL BIOL L, V1529, P63, DOI 10.1016/S1388-1981(00)00138-4; NES WD, 1991, J BIOL CHEM, V266, P15202; Nes WD, 1998, ARCH BIOCHEM BIOPHYS, V353, P297, DOI 10.1006/abbi.1998.0665; Nes WD, 1999, J ORG CHEM, V64, P1535, DOI 10.1021/jo9819943; NES WR, 1980, LIPIDS EVOLUTION, P157; Pourshafie M, 2004, ANTIMICROB AGENTS CH, V48, P2409, DOI 10.1128/AAC.48.7.2409-2414.2004; RAHIER A, 1984, J BIOL CHEM, V259, P5215; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Zhou WX, 2004, MOLECULES, V9, P185, DOI 10.3390/90400185; Zhou WX, 2003, ARCH BIOCHEM BIOPHYS, V420, P18, DOI 10.1016/j.abb.2003.08.029	35	44	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6290	6296		10.1074/jbc.M511749200	http://dx.doi.org/10.1074/jbc.M511749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16414960	hybrid			2022-12-27	WOS:000236030800022
J	van Holde, K; Zlatanova, J				van Holde, K; Zlatanova, J			Scanning chromatin: A new paradigm?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION FACTOR-BINDING; RESONANCE ENERGY-TRANSFER; DNA TARGET SITES; NUCLEOSOMAL DNA; EQUILIBRIUM ACCESSIBILITY; PROTEIN DYNAMICS; HISTONE OCTAMER; LIVING CELLS; MECHANISM; EXCHANGE		Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA	Oregon State University; University of Wyoming	van Holde, K (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	vanholdk@onid.orst.edu	Zlatanova, Jordanka/B-3273-2009					Agresti A, 2005, MOL CELL, V18, P109, DOI 10.1016/j.molcel.2005.03.005; Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Bjorklund S, 2004, ADV PROTEIN CHEM, V67, P43; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; Catez F, 2004, MOL CELL BIOL, V24, P4321, DOI 10.1128/MCB.24.10.4321-4328.2004; Chen DY, 2005, J CELL BIOL, V168, P41, DOI 10.1083/jcb.200407182; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Goulian M, 2000, BIOPHYS J, V79, P2188, DOI 10.1016/S0006-3495(00)76467-8; Green MR, 2005, MOL CELL, V18, P399, DOI 10.1016/j.molcel.2005.04.017; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; ILYIN YV, 1971, EUR J BIOCHEM, V22, P235, DOI 10.1111/j.1432-1033.1971.tb01537.x; Imbalzano AN, 2004, ADV PROTEIN CHEM, V67, P157; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; Langst G, 2004, BBA-GENE STRUCT EXPR, V1677, P58, DOI 10.1016/j.bbaexp.2003.10.011; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Li G, 2004, NAT STRUCT MOL BIOL, V11, P763, DOI 10.1038/nsmb801; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MARKY NL, 1991, BIOPOLYMERS, V31, P1543, DOI 10.1002/bip.360311310; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Morse RH, 2003, BIOCHEM CELL BIOL, V81, P101, DOI 10.1139/o03-039; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Poirier M. G., 2005, European Biophysics Journal, V34, P637; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Protacio RU, 1997, J MOL BIOL, V274, P708, DOI 10.1006/jmbi.1997.1440; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SZABO A, 1982, J CHEM PHYS, V77, P4484, DOI 10.1063/1.444397; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; Tomschik M, 2005, P NATL ACAD SCI USA, V102, P3278, DOI 10.1073/pnas.0500189102; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; van Holde K.E., 1988, CHROMATIN; Verschure PJ, 2003, EMBO REP, V4, P861, DOI 10.1038/sj.embor.embor922; White CL, 2004, J MOL BIOL, V342, P1391, DOI 10.1016/j.jmb.2004.07.080; Zhou HX, 1998, J CHEM PHYS, V108, P8146, DOI 10.1063/1.476255; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev; Zlatanova J, 2005, BIOCHEM CELL BIOL, V83, P251, DOI 10.1139/o05-048; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421; Zlatanova J, 1998, BIOESSAYS, V20, P584, DOI 10.1002/(SICI)1521-1878(199807)20:7<584::AID-BIES10>3.0.CO;2-W	49	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12197	12200		10.1074/jbc.R500025200	http://dx.doi.org/10.1074/jbc.R500025200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16428380	hybrid			2022-12-27	WOS:000237134700001
J	Gray, P; Dunne, A; Brikos, C; Jefferies, CA; Doyle, SL; O'Neill, LAJ				Gray, P; Dunne, A; Brikos, C; Jefferies, CA; Doyle, SL; O'Neill, LAJ			MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOMAIN-CONTAINING ADAPTER; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; CYTOKINE PRODUCTION; INTERFERON-BETA; ACTIVATION; PATHWAY; MOLECULE; PROTEIN	Members of the Toll-like receptor (TLR) family are essential players in activating the host innate immune response against infectious microorganisms. All TLRs signal through Toll/interleukin 1 receptor domain-containing adapter proteins. MyD88 adapter-like (Mal) is one such adapter that specifically is involved in TLR2 and TLR4 signaling. When overexpressed we have found that Mal undergoes tyrosine phosphorylation. Three possible phospho-accepting tyrosines were identified at positions 86, 106, and 187, and two mutant forms of Mal in which tyrosines 86 and 187 were mutated to phenylalanine acted as dominant negative inhibitors of NF-kappa B activation by lipopolysaccharide (LPS). Activation of THP-1 monocytic cells with the TLR4 agonist LPS and the TLR2 agonist macrophage-activating lipopeptide-2 induced phosphorylation of Mal on tyrosine residues. We found that the Bruton's tyrosine kinase (Btk) inhibitor LFM-A13 could block the endogenous phosphorylation of Mal on tyrosine in cells treated with macrophage-activating lipopeptide-2 or LPS. Furthermore, Btk immunoprecipitated from THP-1 cells activated by LPS could phosphorylate Mal. Our study therefore provides the first demonstration of the key role of Mal phosphorylation on tyrosine during signaling by TLR2 and TLR4 and identifies a novel function for Btk as the kinase involved.	Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland	Trinity College Dublin	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland.	laoneill@tcd.ie	Doyle, Sarah/C-1453-2014; Jefferies, Caroline/AAI-1543-2021	Jefferies, Caroline/0000-0002-8879-6722; dunne, aisling/0000-0002-2342-9518; O'Neill, Luke/0000-0002-4333-2748; Doyle, Sarah/0000-0002-6294-9380				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606; Ben-Yehoyada M, 2003, J BIOL CHEM, V278, P34475, DOI 10.1074/jbc.M301051200; Bin LH, 2003, J BIOL CHEM, V278, P24526, DOI 10.1074/jbc.M303451200; Chen LY, 2003, AM J PHYSIOL-LUNG C, V284, pL607, DOI 10.1152/ajplung.00116.2002; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; Dunne A, 2005, FEBS LETT, V579, P3330, DOI 10.1016/j.febslet.2005.04.024; Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Hazeki K, 2003, EUR J IMMUNOL, V33, P740, DOI 10.1002/eji.200323375; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; Napolitani G, 2003, EUR J IMMUNOL, V33, P2832, DOI 10.1002/eji.200324073; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668	36	165	171	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10489	10495		10.1074/jbc.M508892200	http://dx.doi.org/10.1074/jbc.M508892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16439361	Green Published, hybrid			2022-12-27	WOS:000236594300078
J	McGill, GG; Haq, R; Nishimura, EK; Fisher, DE				McGill, GG; Haq, R; Nishimura, EK; Fisher, DE			c-Met expression is regulated by Mitf in the melanocyte lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; MICROPHTHALMIA TRANSCRIPTION FACTOR; MALIGNANT-MELANOMA; NEURAL CREST; STIMULATING HORMONE; SIGNAL-TRANSDUCTION; MUSCLE DEVELOPMENT; HGF RECEPTOR; CELLS	Hepatocyte growth factor (HGF)/c-Met signaling is thought to be a key pathway in both melanocyte development and melanoma metastasis. Here, HGF stimulation of melanocytes was seen to upregulate c-Met expression. In an effort to decipher the mechanism by which HGF up-regulates its receptor, we found that c-Met is a direct transcriptional target of Mitf. This was confirmed with chromatin immunoprecipitation experiments of the human c-Met promoter, as well as by the ability of adenovirally expressed Mitf to modulate endogenous c-Met protein levels in melanocytes. Disruption of Mitf blocked HGF-dependent increases in endogenous c-Met message and protein levels, indicating that HGF regulates its own receptor levels via Mitf. Finally, dominant-negative inhibition of Mitf resulted in profound resistance of melanocytes and melanoma cells to HGF-dependent matrix invasion, suggesting a physiologic role for this pathway in melanocytic development and melanoma.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Johns Hopkins Univ Hosp, Dept Internal Med, Baltimore, MD 21205 USA; Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Creat Res Inst Sousei, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine; Hokkaido University; Hokkaido University	Fisher, DE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu						Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; Chen QY, 1997, HEPATOLOGY, V26, P59; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Goding CR, 2000, GENE DEV, V14, P1712; HALABAN R, 1992, ONCOGENE, V7, P2195; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hendrix MJC, 1998, AM J PATHOL, V152, P855; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; King R, 2001, AM J SURG PATHOL, V25, P51, DOI 10.1097/00000478-200101000-00005; Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; Kunisada T, 2000, MECH DEVELOP, V94, P67, DOI 10.1016/S0925-4773(00)00308-7; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; LIVANT DL, 1995, CANCER RES, V55, P5085; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Otsuka T, 1998, CANCER RES, V58, P5157; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; RUSCIANO D, 1995, ONCOGENE, V11, P1979; Rusciano D, 1999, J CELL SCI, V112, P623; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Vetrini F, 2004, MOL CELL BIOL, V24, P6550, DOI 10.1128/mcb.24.15.6550-6559.2004; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Yu YL, 2002, CANCER RES, V62, P2951	55	134	139	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10365	10373		10.1074/jbc.M513094200	http://dx.doi.org/10.1074/jbc.M513094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455654	hybrid			2022-12-27	WOS:000236594300065
J	Benson, LJ; Gu, YL; Yakovleva, T; Tong, K; Barrows, C; Strack, CL; Cook, RG; Mizzen, CA; Annunziato, AT				Benson, LJ; Gu, YL; Yakovleva, T; Tong, K; Barrows, C; Strack, CL; Cook, RG; Mizzen, CA; Annunziato, AT			Modifications of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NEWLY SYNTHESIZED HISTONES; DEPOSITION-RELATED ACETYLATION; INACTIVE X-CHROMOSOME; RNA-POLYMERASE-II; DNA-SYNTHESIS; ACTIVE CHROMATIN; HELA-CELLS; IN-VIVO; FUNCTIONALLY DISTINCT; LYSINE-9 METHYLATION	Histone posttranslational modifications that accompany DNA replication, nucleosome assembly, and H2A/H2B exchange were examined in human tissue culture cells. Through microsequencing analysis and chromatin immunoprecipitation, it was found that a subset of newly synthesized H3.2/H3.3 is modified by acetylation and methylation at sites that correlate with transcriptional competence. Immunoprecipitation experiments suggest that cytosolic predeposition complexes purified from cells expressing FLAG-H4 contain H3/H4 dimers, not tetramers. Studies of the deposition of newly synthesized H2A/H2B onto replicating and nonreplicating chromatin demonstrated that H2A/H2B exchange takes place in chromatin regions that contain acetylated H4; however, there is no single pattern of H4 acetylation that accompanies exchange. H2A/H2B exchange is also largely independent of the deposition of replacement histone variant, H3.3. Finally, immunoprecipitation of nucleosomes replicated in the absence of de novo nucleosome assembly showed that histone modifications do not prevent the transfer of parental histones to newly replicated DNA and thus have the potential to serve as means of epigenetic inheritance. Our experiments provide an in-depth analysis of the "histone code" associated with chromatin replication and dynamic histone exchange in human cells.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Boston College; University of Illinois System; University of Illinois Urbana-Champaign; Baylor College of Medicine	Annunziato, AT (corresponding author), Boston Coll, Dept Biol, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.	anthony.annunziato@bc.edu			NIGMS NIH HHS [GM35837, GM53122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035837] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; ALBIG W, 1995, GENOMICS, V30, P264, DOI 10.1006/geno.1995.9878; Albig W, 1997, GENOMICS, V40, P314, DOI 10.1006/geno.1996.4592; ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; ANNUNZIATO AT, 1982, BIOCHEMISTRY-US, V21, P5431, DOI 10.1021/bi00265a008; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Annunziato AT, 2005, J BIOL CHEM, V280, P12065, DOI 10.1074/jbc.R400039200; ANNUNZIATO AT, 1981, J BIOL CHEM, V256, P1880; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; ANNUNZIATO AT, 1982, J BIOL CHEM, V257, P8507; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BONNER WM, 1988, BIOCHEMISTRY-US, V27, P6542, DOI 10.1021/bi00417a052; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Chang L, 1999, METHOD ENZYMOL, V304, P76; Cheung P, 2005, MOL ENDOCRINOL, V19, P563, DOI 10.1210/me.2004-0496; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; Choi ES, 2005, NUCLEIC ACIDS RES, V33, P7102, DOI 10.1093/nar/gki1011; Chow CM, 2005, EMBO REP, V6, P354, DOI 10.1038/sj.embor.7400366; COUSENS LS, 1982, J BIOL CHEM, V257, P3945; Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533; CUSICK ME, 1981, BIOCHEMISTRY-US, V20, P6648, DOI 10.1021/bi00526a020; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; FRANKLIN SG, 1977, NATURE, V266, P273, DOI 10.1038/266273a0; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; Glowczewski L, 2004, MOL CELL BIOL, V24, P10180, DOI 10.1128/MCB.24.23.10180-10192.2004; Hake SB, 2006, J BIOL CHEM, V281, P559, DOI 10.1074/jbc.M509266200; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; JACKSON V, 1985, BIOCHEMISTRY-US, V24, P6921, DOI 10.1021/bi00345a026; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Koessler H, 2003, DNA CELL BIOL, V22, P233, DOI 10.1089/104454903321908629; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; KUMAR S, 1986, BIOCHEMISTRY-US, V25, P2055, DOI 10.1021/bi00356a033; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; LEFFAK IM, 1984, NATURE, V307, P82, DOI 10.1038/307082a0; LEFFAK M, 1988, BIOCHEMISTRY-US, V27, P686, DOI 10.1021/bi00402a029; Levchenko V, 2005, BIOCHEMISTRY-US, V44, P5357, DOI 10.1021/bi047786o; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; LU MJ, 1994, CHROMOSOMA, V103, P111; Lucchini R, 2001, EMBO J, V20, P7294, DOI 10.1093/emboj/20.24.7294; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; NADEAU P, 1978, BIOCHEMISTRY-US, V17, P4885, DOI 10.1021/bi00616a005; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; OLIVER D, 1974, BIOCHEMISTRY-US, V13, P746, DOI 10.1021/bi00701a017; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13615, DOI 10.1021/bi00212a029; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; RUSSEV G, 1981, NUCLEIC ACIDS RES, V9, P4129, DOI 10.1093/nar/9.16.4129; RYAN CA, 1999, CURR PROT MOL BIOL, V21, P1; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schermer UJ, 2005, MOL CELL, V19, P279, DOI 10.1016/j.molcel.2005.05.028; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; SEALE RL, 1978, P NATL ACAD SCI USA, V75, P2717, DOI 10.1073/pnas.75.6.2717; SEALE RL, 1976, CELL, V9, P423, DOI 10.1016/0092-8674(76)90087-8; SEALE RL, 1981, BIOCHEMISTRY-US, V20, P6432, DOI 10.1021/bi00525a023; SEALE RL, 1975, J MOL BIOL, V94, P479, DOI 10.1016/0022-2836(75)90216-8; SEALE RL, 1977, BIOCHEMISTRY-US, V16, P2847, DOI 10.1021/bi00632a007; SEALY L, 1979, ARCH BIOCHEM BIOPHYS, V197, P78, DOI 10.1016/0003-9861(79)90221-2; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Thiriet C, 2005, GENE DEV, V19, P677, DOI 10.1101/gad.1265205; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Valls E, 2005, J BIOL CHEM, V280, P42592, DOI 10.1074/jbc.M507407200; van Holde K.E., 1988, CHROMATIN; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WEINTRAUB H, 1973, COLD SPRING HARB SYM, V38, P247, DOI 10.1101/SQB.1974.038.01.028; WEINTRAUB H, 1976, CELL, V9, P419, DOI 10.1016/0092-8674(76)90086-6; Wirbelauer C, 2005, GENE DEV, V19, P1761, DOI 10.1101/gad.347705; Witt O, 1996, EXP CELL RES, V229, P301, DOI 10.1006/excr.1996.0375; Wolffe A. P., 1999, CHROMATIN STRUCTURE; WU RS, 1983, BIOCHEMISTRY-US, V22, P3868, DOI 10.1021/bi00285a023; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	110	115	120	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9287	9296		10.1074/jbc.M512956200	http://dx.doi.org/10.1074/jbc.M512956200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464854	hybrid			2022-12-27	WOS:000236404700036
J	Clausen, JD; McIntosh, DB; Woolley, DG; Anthonisen, AN; Vilsen, B; Andersen, JP				Clausen, JD; McIntosh, DB; Woolley, DG; Anthonisen, AN; Vilsen, B; Andersen, JP			Asparagine 706 and glutamate 183 at the catalytic site of sarcoplasmic reticulum Ca2+-ATPase play critical but distinct roles in E2 states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED PHOSPHORYLATION LOOP; P-TYPE ATPASE; CALCIUM-PUMP; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; PHOSPHOENZYME INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; DEHALOGENASE FOLD; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE	Mutants with alteration to Asn(706) of the highly conserved (701)TGDGVND(707) motif in domain P of sarcoplasmic reticulum Ca2+-ATPase were analyzed for changes in transport cycle kinetics and binding of the inhibitors vanadate, BeF, AlF, and MgF. The fluorides likely mimic the phosphoryl group/P-i in the respective ground, transition, and product states of phosphoenzyme hydrolysis (Danko, S., Yamasaki, K., Daiho, T., and Suzuki, H. ( 2004) J. Biol. Chem. 279, 14991 - 14998). Binding of BeF, AlF, and MgF was also studied for mutant Glu(183) --> Ala, where the glutamate of the (181)TGES(184) motif in domain A is replaced. Mutations of Asn(706) and Glu(183) have in common that they dramatically impede the function of the enzyme in E2 states, but have little effect in E1. Contrary to the Glu(183) mutant, in which E2P slowly accumulates (Clausen, J. D., Vilsen, B., McIntosh, D. B., Einholm, A. P., and Andersen, J. P. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 2776 - 2781), E2P formation was not detectable with the Asn(706) mutants. Differential sensitivities of the mutants to inhibition by AlF, MgF, and BeF made it possible to distinguish different roles of Asn(706) and Glu(183). Hence, Asn(706) is less important than Glu(183) for gaining the transition state during E2P hydrolysis but plays critical roles in stabilization of E2P ground and E2 . P-i product states and in the major conformational changes associated with the Ca(2)E1P --> E2P and E2 --> Ca(2)E1 transitions, which seem to be facilitated by interaction of Asn(706) with domain A.	Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark; Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	Aarhus University; University of Cape Town	Andersen, JP (corresponding author), Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LEBERER E, 1986, BIOCHEM J, V235, P67, DOI 10.1042/bj2350067; Ma HL, 2005, BIOCHEMISTRY-US, V44, P8090, DOI 10.1021/bi050332m; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; McIntosh DB, 2004, J BIOL CHEM, V279, P32515, DOI 10.1074/jbc.M403242200; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1982, J BIOL CHEM, V257, P6111; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1458; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wang GL, 2005, J BIOL CHEM, V280, P26508, DOI 10.1074/jbc.M503789200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; WEBER K, 1969, J BIOL CHEM, V244, P4406	45	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9471	9481		10.1074/jbc.M512371200	http://dx.doi.org/10.1074/jbc.M512371200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16449230	hybrid, Green Published			2022-12-27	WOS:000236404700057
J	Gustafson, B; Smith, U				Gustafson, B; Smith, U			Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; GLYCOGEN-SYNTHASE KINASE-3-BETA; MITOTIC CLONAL EXPANSION; NECROSIS-FACTOR-ALPHA; BINDING PROTEIN-BETA; ADIPOCYTE DIFFERENTIATION; INSULIN-RESISTANCE; C/EBP-ALPHA; ADIPOSE-TISSUE; PPAR-GAMMA	Obesity with enlarged fat cells is associated with high local concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha) in the adipose tissue. We examined the effects of this inflammatory state on 3T3-L1 preadipocyte development and differentiation to mature adipose cells. Both IL-6 and TNF alpha impaired the normal differentiation pattern and lipid accumulation. However, IL-6 allowed a normal early induction of differentiation with inhibition of Wnt10b and Pref-1, whereas expression of CCAAT/ enhancer-binding protein alpha, in contrast to peroxisome proliferator-activated receptor gamma, was markedly reduced. TNF alpha also allowed a normal early induction of differentiation, whereas the terminal differentiation to adipose cells was completely prevented. However, both cytokines induced an inflammatory phenotype of the cells but with different profiles. Remarkably, both IL-6 and TNF alpha maintained and augmented the canonical Wnt signaling associated with low axin and high low density lipoprotein receptor-related protein (LRD), Dishevelled, and beta-catenin levels. TNF alpha, but not IL-6, activated Wnt10b expression, whereas IL-6 increased the apparent phosphorylation of Dishevelled. Thus, both IL-6 and TNF alpha prevent the normal development of preadipocytes to fully differentiated adipose cells and, instead, promote an inflammatory phenotype of the adipocytes. These results provide an explanation as to why obesity and diabetes are associated with both local and systemic inflammation, insulin resistance, and ectopic lipid accumulation.	Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Salgrenska Univ Hosp,Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden	University of Gothenburg	Smith, U (corresponding author), Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Salgrenska Univ Hosp,Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden.	ulf.smith@medic.gu.se						Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Camp HS, 2002, TRENDS MOL MED, V8, P442, DOI 10.1016/S1471-4914(02)02396-1; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Jansson PA, 2003, FASEB J, V17, P1434, DOI 10.1096/fj.02-1132com; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Liu JJ, 2004, J BIOL CHEM, V279, P45020, DOI 10.1074/jbc.M407050200; Liu KN, 2002, MOL CELL ENDOCRINOL, V194, P51, DOI 10.1016/S0303-7207(02)00188-0; Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mei BS, 2002, BIOCHEM J, V364, P137, DOI 10.1042/bj3640137; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pu YS, 2004, PROSTATE, V60, P120, DOI 10.1002/pros.20057; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sharma C, 2004, J BIOL CHEM, V279, P35583, DOI 10.1074/jbc.M403143200; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	51	196	212	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9507	9516		10.1074/jbc.M512077200	http://dx.doi.org/10.1074/jbc.M512077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464856	hybrid			2022-12-27	WOS:000236404700061
J	Ralph, J; Akiyama, T; Kim, H; Lu, FC; Schatz, PF; Marita, JM; Ralph, SA; Reddy, MSS; Chen, F; Dixon, RA				Ralph, J; Akiyama, T; Kim, H; Lu, FC; Schatz, PF; Marita, JM; Ralph, SA; Reddy, MSS; Chen, F; Dixon, RA			Effects of coumarate 3-hydroxylase down-regulation on lignin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CINNAMYL-ALCOHOL-DEHYDROGENASE; CYTOCHROME P450-DEPENDENT MONOOXYGENASE; O-METHYLTRANSFERASE ACTIVITY; P-HYDROXYCINNAMYL ALCOHOLS; CELL-WALL DEGRADABILITY; TRANSITION-METAL SALTS; NMR CHARACTERIZATION; FERULATE 5-HYDROXYLASE; TRANSGENIC POPLARS; MOLECULAR-BASIS	Down-regulation of the gene encoding 4-coumarate 3-hydroxylase (C3H) in alfalfa massively but predictably increased the proportion of p-hydroxyphenyl (P) units relative to the normally dominant guaiacyl (G) and syringyl (S) units. Stem levels of up to similar to 65% P (from wild-type levels of similar to 1%) resulting from down-regulation of C3H were measured by traditional degradative analyses as well as two-dimensional C-13-H-1 correlative NMR methods. Such levels put these transgenics well beyond the P:G:S compositional bounds of normal plants; p-hydroxyphenyl levels are reported to reach a maximum of 30% in gymnosperm severe compression wood zones but are limited to a few percent in dicots. NMR also revealed structural differences in the interunit linkage distribution that characterizes a lignin polymer. Lower levels of key beta-aryl ether units were relatively augmented by higher levels of phenylcoumarans and resinols. The C3H-deficient alfalfa lignins were devoid of beta-1 coupling products, highlighting the significant differences in the reaction course for p-coumaryl alcohol versus the two normally dominant monolignols, coniferyl and sinapyl alcohols. A larger range of dibenzodioxocin structures was evident in conjunction with an approximate doubling of their proportion. The nature of each of the structural units was revealed by long range C-13-H-1 correlation experiments. For example, although beta-ethers resulted from the coupling of all three monolignols with the growing polymer, phenylcoumarans were formed almost solely from coupling reactions involving p-coumaryl alcohol; they resulted from both coniferyl and sinapyl alcohol in the wild-type plants. Such structural differences form a basis for explaining differences in digestibility and pulping performance of C3H-deficient plants.	ARS, US Dairy Forage Res Ctr, USDA, Madison, WI 53706 USA; Univ Wisconsin, Dept Forestry, Madison, WI 53706 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; US Forest Serv, US Forest Prod Lab, USDA, Madison, WI 53705 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73401 USA	United States Department of Agriculture (USDA); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; United States Department of Agriculture (USDA); United States Forest Service; Noble Research Institute	Ralph, J (corresponding author), ARS, US Dairy Forage Res Ctr, USDA, 1925 Linden Dr W, Madison, WI 53706 USA.	jralph@wisc.edu	Ralph, John/C-3161-2009; Kim, Hoon/E-8245-2013; Lu, Fachuang/K-6487-2019	Ralph, John/0000-0002-6093-4521; Kim, Hoon/0000-0001-7425-7464; Akiyama, Takuya/0000-0003-0484-2291				[Anonymous], 1986, COMPRESSION WOOD GYM; Barriere Y, 2004, CR BIOL, V327, P847, DOI 10.1016/j.crvi.2004.05.010; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; Baucher M, 2003, CRIT REV BIOCHEM MOL, V38, P305, DOI 10.1080/10409230390242443; Baucher M, 1998, POLYM DEGRAD STABIL, V59, P47, DOI 10.1016/S0141-3910(97)00201-2; BERNARDVAILHE MA, 1998, J SCI FOOD AGR, V76, P505; Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938; Boerjan W, 2001, PROGR BIOTECHNOL, V18, P187, DOI 10.1016/S0921-0423(01)80072-1; Boudet AM, 1996, MOL BREEDING, V2, P25; Chen CY, 2001, EUPHYTICA, V118, P185, DOI 10.1023/A:1004176714883; Chen L, 2003, PLANT BIOTECHNOL J, V1, P437, DOI 10.1046/j.1467-7652.2003.00040.x; Franke R, 2002, PLANT J, V30, P33, DOI 10.1046/j.1365-313X.2002.01266.x; Franke R, 2002, PLANT J, V30, P47, DOI 10.1046/j.1365-313X.2002.01267.x; Fukushima RS, 2001, J AGR FOOD CHEM, V49, P3133, DOI 10.1021/jf010449r; Gang DR, 1999, CHEM BIOL, V6, P143, DOI 10.1016/S1074-5521(99)89006-1; Grabber JH, 2003, J AGR FOOD CHEM, V51, P4984, DOI 10.1021/jf030027c; Guo DG, 2001, TRANSGENIC RES, V10, P457, DOI 10.1023/A:1012278106147; HATFIELD RD, 1995, J SCI FOOD AGR, V69, P185, DOI 10.1002/jsfa.2740690208; He X, 2003, CROP SCI, V43, P2240, DOI 10.2135/cropsci2003.2240; Hu WJ, 1999, NAT BIOTECHNOL, V17, P808, DOI 10.1038/11758; Humphreys JM, 1999, P NATL ACAD SCI USA, V96, P10045, DOI 10.1073/pnas.96.18.10045; Huntley SK, 2003, J AGR FOOD CHEM, V51, P6178, DOI 10.1021/jf034320o; Jung HJG, 1999, J SCI FOOD AGR, V79, P922, DOI 10.1002/(SICI)1097-0010(19990501)79:6&lt;922::AID-JSFA307&gt;3.0.CO;2-9; KARHUNEN P, 1995, TETRAHEDRON LETT, V36, P169, DOI 10.1016/0040-4039(94)02203-N; Kim BH, 2003, SOLID STATE IONICS, V158, P281, DOI 10.1016/S0167-2738(02)00909-8; Kim H, 2005, J AGR FOOD CHEM, V53, P3693, DOI 10.1021/jf047787n; Kim H, 2000, ORG LETT, V2, P2197, DOI 10.1021/ol005906o; Krause DO, 2003, FEMS MICROBIOL REV, V27, P663, DOI 10.1016/S0168-6445(03)00072-X; LANDUCCI LL, 1995, J WOOD CHEM TECHNOL, V15, P493, DOI 10.1080/02773819508009522; Landucci LL, 2000, J WOOD CHEM TECHNOL, V20, P243, DOI 10.1080/02773810009349635; Lapierre C, 1999, PLANT PHYSIOL, V119, P153, DOI 10.1104/pp.119.1.153; LAPIERRE C, 1993, FORAGE CELL WALL STRUCTURE AND DIGESTIBILITY, P133; Lapierre C, 2000, ACS SYM SER, V742, P145; Li L, 2003, P NATL ACAD SCI USA, V100, P4939, DOI 10.1073/pnas.0831166100; Li LG, 2000, J BIOL CHEM, V275, P6537, DOI 10.1074/jbc.275.9.6537; Lu FC, 1997, J AGR FOOD CHEM, V45, P4655, DOI 10.1021/jf970539p; Lu FC, 2003, PLANT J, V35, P535, DOI 10.1046/j.1365-313X.2003.01817.x; Lu FC, 1999, J AGR FOOD CHEM, V47, P1988, DOI 10.1021/jf981140j; Marita JM, 2003, PHYTOCHEMISTRY, V62, P53, DOI 10.1016/S0031-9422(02)00434-X; Marita JM, 2001, J CHEM SOC PERK T 1, P2939, DOI 10.1039/b107219f; Marita JM, 1999, P NATL ACAD SCI USA, V96, P12328, DOI 10.1073/pnas.96.22.12328; Meyer K, 1998, P NATL ACAD SCI USA, V95, P6619, DOI 10.1073/pnas.95.12.6619; Morreel K, 2004, PLANT PHYSIOL, V136, P3537, DOI 10.1104/pp.104.049304; Morrison WH, 1999, IND CROP PROD, V10, P21, DOI 10.1016/S0926-6690(99)00002-3; Nakano J., 1992, METHODS LIGNIN CHEM, DOI 10.1007/978-3-642-74065-7_2; O'Connell A, 2002, TRANSGENIC RES, V11, P495, DOI 10.1023/A:1020362705497; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; QUIDEAU S, 1994, HOLZFORSCHUNG, V48, P12, DOI 10.1515/hfsg.1994.48.1.12; Ralph J, 2004, CR BIOL, V327, P467, DOI 10.1016/j.crvi.2004.03.004; Ralph J, 2004, ORG BIOMOL CHEM, V2, P2714, DOI 10.1039/b412633e; Ralph J, 2001, PHYTOCHEMISTRY, V57, P993, DOI 10.1016/S0031-9422(01)00109-1; Ralph J, 1996, J NAT PROD, V59, P341, DOI 10.1021/np960143s; Ralph J, 1998, P NATL ACAD SCI USA, V95, P12803, DOI 10.1073/pnas.95.22.12803; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; Ralph J, 2001, J AGR FOOD CHEM, V49, P86, DOI 10.1021/jf001042+; Ralph J., 1999, PROGR LIGNOCELLULOSI, P55; Ralph John, 2004, Phytochemistry Reviews, V3, P29, DOI 10.1023/B:PHYT.0000047809.65444.a4; Reddy MSS, 2005, P NATL ACAD SCI USA, V102, P16573, DOI 10.1073/pnas.0505749102; REINHOUDT DN, 1981, TETRAHEDRON, V37, P1753, DOI 10.1016/S0040-4020(01)98941-0; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; Sarkanen K. V., 1971, LIGNINS OCCURRENCE F, P43; Schoch G, 2001, J BIOL CHEM, V276, P36566, DOI 10.1074/jbc.M104047200; Sederoff RR, 1999, CURR OPIN PLANT BIOL, V2, P145, DOI 10.1016/S1369-5266(99)80029-6; Syrjanen K, 2000, J CHEM SOC PERK T 1, P183, DOI 10.1039/a907919j; WHETTEN R, 1991, FOREST ECOL MANAG, V43, P301, DOI 10.1016/0378-1127(91)90133-G; Wu S, 2003, J PULP PAP SCI, V29, P235; ZHANG L, 2006, IN PRESS J WOOD CHEM; Zhang LM, 2001, CHEM COMMUN, P2744, DOI 10.1039/b108285j	69	189	208	1	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8843	8853		10.1074/jbc.M511598200	http://dx.doi.org/10.1074/jbc.M511598200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16421107	hybrid, Green Submitted			2022-12-27	WOS:000236247100064
J	Michos, A; Gryllos, I; Hakansson, A; Srivastava, A; Kokkotou, E; Wessels, MR				Michos, A; Gryllos, I; Hakansson, A; Srivastava, A; Kokkotou, E; Wessels, MR			Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the group A streptococcal toxin, NAD-glycohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYSIN-MEDIATED TRANSLOCATION; HYALURONIC-ACID CAPSULE; CYCLIC ADP-RIBOSE; HEMOLYTIC STREPTOCOCCI; III SECRETION; IDENTIFICATION; PYOGENES; KERATINOCYTES; PURIFICATION; PATHOGENESIS	Streptolysin O (SLO) is a cholesterol-dependent cytolysin produced by the important human pathogen, group A Streptococcus ( Streptococcus pyogenes or GAS). In addition to its cytolytic activity, SLO mediates the translocation of GAS NAD-glycohydrolase ( NADase) into human epithelial cells in vitro. Production of both NADase and SLO is associated with augmented host cell injury beyond that produced by SLO alone, but the mechanism of enhanced cytotoxicity is not known. We have now shown that expression of NADase together with SLO dramatically enhanced the lytic activity of GAS culture supernatants for erythrocytes but had no effect on SLO-mediated poration of synthetic cholesterol-rich liposomes. This result revealed a previously unknown contribution of NADase to the cytolytic activity associated with GAS production of SLO. Purified recombinant SLO bound NADase in vitro, supporting a specific, physical interaction of the two proteins. Exposure of human keratinocytes to wild-type GAS, but not to a NADase-deficient mutant strain, resulted in profound depletion of cellular NAD(+) and ATP. Furthermore, expression of recombinant GASNADase in yeast, in the absence of SLO, induced growth arrest, depletion of NAD(+) and ATP, and cell death. These findings have provided evidence that the augmentation of SLO-mediated cytotoxicity by NADase is a consequence of depletion of host cell energy stores through the enzymatic action of NADase. Together, the results have provided mechanistic insight into the cytotoxic effects of a unique bipartite bacterial toxin.	Childrens Hosp, Div Infect Dis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Wessels, MR (corresponding author), Childrens Hosp, Div Infect Dis, 300 Longwood Ave, Boston, MA 02215 USA.	michael.wessels@childrens.harvard.edu	Hakansson, Anders/H-8190-2014; Hakansson, Anders P/AAX-1225-2020; Michos, Athanasios/H-2389-2012	Hakansson, Anders/0000-0002-2834-6009; Hakansson, Anders P/0000-0002-2834-6009; Michos, Athanasios/0000-0003-1745-1118	NIAID NIH HHS [AI30040, AI29952] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029952] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALOUF JE, 1973, BIOCHIMIE, V55, P1187, DOI 10.1016/S0300-9084(74)80322-6; ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; Alouf JE, 2000, METH MOL B, V145, P1; AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Bricker AL, 2005, INFECT IMMUN, V73, P6562, DOI 10.1128/IAI.73.10.6562-6566.2005; Bricker AL, 2002, MOL MICROBIOL, V44, P257, DOI 10.1046/j.1365-2958.2002.02876.x; Chaussee MS, 2001, INFECT IMMUN, V69, P822, DOI 10.1128/IAI.69.2.822-831.2001; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Everse K E, 1980, Methods Enzymol, V66, P137; Fischetti VA, 2000, GRAM-POSITIVE PATHOGENS, P11; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Gryllos I, 2003, P NATL ACAD SCI USA, V100, P4227, DOI 10.1073/pnas.0636231100; Guse AH, 2004, CURR MOL MED, V4, P239, DOI 10.2174/1566524043360771; Hakansson A, 2005, P NATL ACAD SCI USA, V102, P5192, DOI 10.1073/pnas.0408721102; HALPERN BN, 1968, BRIT J PHARMACOL, V32, P441, DOI 10.1111/j.1476-5381.1968.tb00445.x; KARASAWA T, 1995, FEMS MICROBIOL LETT, V130, P201; KARASAWA T, 1995, FEMS MICROBIOL LETT, V128, P289, DOI 10.1016/0378-1097(95)00120-T; KIM UH, 1993, ARCH BIOCHEM BIOPHYS, V305, P147, DOI 10.1006/abbi.1993.1404; Kimoto H, 2005, BBA-GENE STRUCT EXPR, V1681, P134, DOI 10.1016/j.bbaexp.2004.10.011; Kristian T, 2004, BRAIN RES PROTOC, V13, P176, DOI 10.1016/j.brainresprot.2004.05.001; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lee VT, 1999, IMMUNOL REV, V168, P241, DOI 10.1111/j.1600-065X.1999.tb01296.x; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; Meehl MA, 2004, MOL MICROBIOL, V52, P1665, DOI 10.1111/j.1365-2958.2004.04082.x; Meehl MA, 2005, PLOS PATHOG, V1, P362, DOI 10.1371/journal.ppat.0010035; Millard PJ, 1997, APPL ENVIRON MICROB, V63, P2897, DOI 10.1128/AEM.63.7.2897-2905.1997; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Palmer M, 2001, TOXICON, V39, P1681, DOI 10.1016/S0041-0101(01)00155-6; Ruiz N, 1998, MOL MICROBIOL, V27, P337, DOI 10.1046/j.1365-2958.1998.00681.x; Sambrook J., 2001, MOL CLONING LAB MANU; Savic DJ, 2002, INFECT IMMUN, V70, P2730, DOI 10.1128/IAI.70.5.2730-2733.2002; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; Stevens DL, 2000, J INFECT DIS, V182, P1117, DOI 10.1086/315850; Sumby P, 2005, J INFECT DIS, V192, P771, DOI 10.1086/432514; Ziegler M, 1997, Rev Physiol Biochem Pharmacol, V131, P89; Zitzer A, 2001, J BIOL CHEM, V276, P14628, DOI 10.1074/jbc.M100241200	40	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8216	8223		10.1074/jbc.M511674200	http://dx.doi.org/10.1074/jbc.M511674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431917	hybrid			2022-12-27	WOS:000236031000061
J	Wu, PL; Lee, SC; Chuang, CC; Mori, S; Akakura, N; Wu, WG; Takada, Y				Wu, PL; Lee, SC; Chuang, CC; Mori, S; Akakura, N; Wu, WG; Takada, Y			Non-cytotoxic cobra cardiotoxin A5 binds to alpha v beta 3 integrin and inhibits bone resorption - Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT ACTIVATION; PHOSPHOLIPASE A(2); STRUCTURAL REQUIREMENTS; DOMAIN; VENOM; MECHANISM; LIGAND; CELLS; ALPHA(V)BETA(3); ECHISTATIN	Severe tissue necrosis with a retarded wound healing process is a major symptom of a cobra snakebite. Cardiotoxins (CTXs) are major components of cobra venoms that belong to the Ly-6 protein family and are implicated in tissue damage. The interaction of the major CTX from Taiwan cobra, i.e. CTX A3, with sulfatides in the cell membrane has recently been shown to induce pore formation and cell internalization and to be responsible for cytotoxicity in cardiomyocytes (Wang, C.-H., Liu, J.-H., Lee, S.-C., Hsiao, C.-D., and Wu, W.-g. (2006) J. Biol. Chem. 281, 656-667). We show here that one of the non-cytotoxic CTXs, i.e. CTX A5 or cardiotoxin-like basic polypeptide, from Taiwan cobra specifically bound to alpha v beta 3 integrin and inhibited bone resorption activity. We found that both membrane-bound and recombinant soluble alpha v beta 3 integrins bound specifically to CTX A5 in a dose-dependent manner. Surface plasmon resonance analysis showed that human soluble alpha v beta 3 bound to CTX A5 with an apparent affinity of similar to 0.3 mu M. Calf pulmonary artery endothelial cells, which constitutively express alpha v beta 3, showed a CTX A5 binding profile similar to that of membrane-bound and soluble alpha v beta 3 integrins, suggesting that endothelial cells are a potential target for CTX action. We tested whether CTXA5 inhibits osteoclast differentiation and bone resorption, a process known to be involved in alpha v beta 3 binding and inhibited by RGD-containing peptides. We demonstrate that CTXA5 inhibited both activities at a micromolar range by binding to murine alpha v beta 3 integrin in osteoclasts and that CTX A5 co-localized with beta 3 integrin. Finally, after comparing the integrin binding affinity among CTX homologs, we propose that the amino acid residues near the two loops of CTXA5 are involved in integrin binding. These results identify CTXA5 as a non-RGD integrin-binding protein with therapeutic potential as an integrin antagonist.	Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 30043, Taiwan; Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA	National Tsing Hua University; University of California System; University of California Davis	Wu, WG (corresponding author), Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 30043, Taiwan.	wgwu@life.nthu.edu.tw; ytakada@ucdavis.edu		takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adermann K, 1999, PROTEIN SCI, V8, P810, DOI 10.1110/ps.8.4.810; Ariyoshi W, 2005, J BIOL CHEM, V280, P18967, DOI 10.1074/jbc.M412740200; Bazan-Socha S, 2004, BIOCHEMISTRY-US, V43, P1639, DOI 10.1021/bi035853t; Boilard E, 2003, BLOOD, V102, P2901, DOI 10.1182/blood-2002-12-3702; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Calvete JJ, 2000, BIOCHEM J, V345, P573, DOI 10.1042/0264-6021:3450573; Chattopadhyay Anindya, 2004, Indian Journal of Pediatrics, V71, P397, DOI 10.1007/BF02725623; Chen TS, 2005, BIOCHEMISTRY-US, V44, P7414, DOI 10.1021/bi050172e; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Eble JA, 2003, J BIOL CHEM, V278, P26488, DOI 10.1074/jbc.M301860200; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; EVANS RA, 1979, MINER ELECTROL METAB, V2, P179; Forouhar F, 2003, J BIOL CHEM, V278, P21980, DOI 10.1074/jbc.M208650200; Gentzsch C, 2003, CALCIFIED TISSUE INT, V72, P698, DOI 10.1007/s00223-002-2020-7; GRZESIAK JJ, 1995, J CLIN INVEST, V95, P227, DOI 10.1172/JCI117644; Guan JL, 2004, SCIENCE, V303, P773, DOI 10.1126/science.1094376; Hirata A, 2003, AM J PATHOL, V163, P203, DOI 10.1016/S0002-9440(10)63644-9; Horton MA, 2001, P NUTR SOC, V60, P275; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Hung DZ, 2003, TOXICON, V41, P409, DOI 10.1016/S0041-0101(02)00336-7; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lee SC, 2005, J BIOL CHEM, V280, P9567, DOI 10.1074/jbc.M412398200; Liau MY, 1997, J TOXICOL-TOXIN REV, V16, P163; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; Medved L, 1997, BIOCHEMISTRY-US, V36, P4685, DOI 10.1021/bi962795l; Miller WH, 2000, DRUG DISCOV TODAY, V5, P397, DOI 10.1016/S1359-6446(00)01545-2; Murakami M, 2004, BIOL PHARM BULL, V27, P1158, DOI 10.1248/bpb.27.1158; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SMITH JW, 1994, J BIOL CHEM, V269, P960; Sue SC, 2001, BIOCHEMISTRY-US, V40, P10436, DOI 10.1021/bi010847n; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tarui T, 2003, J BIOL CHEM, V278, P29863, DOI 10.1074/jbc.M304694200; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Vaananen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Vyas KA, 1998, BIOCHEMISTRY-US, V37, P4527, DOI 10.1021/bi972637+; Wang CH, 2006, J BIOL CHEM, V281, P656, DOI 10.1074/jbc.M507880200; Wang CH, 2005, TOXICON, V46, P430, DOI 10.1016/j.toxicon.2005.06.012; Wang CH, 2005, FEBS LETT, V579, P3169, DOI 10.1016/j.febslet.2005.05.006; Wierzbicka-Patynowski I, 1999, J BIOL CHEM, V274, P37809, DOI 10.1074/jbc.274.53.37809; Wu WG, 1998, TRENDS CARDIOVAS MED, V8, P270, DOI 10.1016/S1050-1738(98)00019-X; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yamamoto M, 1998, ENDOCRINOLOGY, V139, P1411, DOI 10.1210/en.139.3.1411; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	55	49	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7937	7945		10.1074/jbc.M513035200	http://dx.doi.org/10.1074/jbc.M513035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407244	hybrid			2022-12-27	WOS:000236031000029
J	Zufferey, R; Ben Mamoun, C				Zufferey, R; Ben Mamoun, C			Leishmania major expresses a single dihydroxyacetone phosphate acyltransferase localized in the glycosome, important for rapid growth and survival at high cell density and essential for virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LIVER; YEAST SACCHAROMYCES-CEREVISIAE; PROTOZOAN PARASITE LEISHMANIA; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; INITIAL STEP; GLYCEROLIPID BIOSYNTHESIS; DONOVANI PROMASTIGOTES; VISCERAL LEISHMANIASIS; TERMINAL EXTENSION; TRYPANOSOMA-BRUCEI	Despite major advances in the understanding of pathogenesis of the human protozoan parasite Leishmania major, little is known about the enzymes and the primary precursors involved in the initial steps of synthesis of its major glycerolipids including those involved in virulence. We have previously demonstrated that the initial step of acylation of the precursor glycerol 3-phosphate is not essential for the synthesis of ester and ether phospholipids in this parasite. Here we show that Leishmania expresses a single acyltransferase with high specificity for the precursor dihydroxyacetone phosphate and shows the best activity in the presence of palmitoyl-CoA. We have identified and characterized the LmDAT gene encoding this activity. LmDAT complements the lethality resulting from the loss of both dihydroxyacetone phosphate and glycerol-3-phosphate acyltransferase activities in yeast. Recombinant LmDAT exhibits biochemical properties similar to those of the native enzyme of the promastigote stage parasites. We show that LmDAT is a glycosomal enzyme and its loss in a Delta lmdat/Delta lmdat null mutant results in complete abrogation of the parasite dihydroxyacetone phosphate acyltransferase activity. Furthermore, lack of LmDAT causes a major alteration in parasite division during the logarithmic phase of growth, an accelerated cell death during stationary phase, and loss of virulence. Together, our results demonstrate that LmDAT is the only dihydroxyacetone phosphate acyltransferase of the L. major localized in the peroxisome, important for growth and survival and essential for virulence.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	Choukri@up.uchc.edu						Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; Barth PG, 1996, AM J MED GENET, V62, P164, DOI 10.1002/(SICI)1096-8628(19960315)62:2<164::AID-AJMG9>3.0.CO;2-W; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BEACH DH, 1979, J PARASITOL, V65, P203, DOI 10.2307/3280147; Biermann J, 1999, EUR J BIOCHEM, V261, P492, DOI 10.1046/j.1432-1327.1999.00295.x; CHAUDHURI G, 1987, INDIAN J MED RES, V85, P140; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Croft SL, 2003, MOL BIOCHEM PARASIT, V126, P165, DOI 10.1016/S0166-6851(02)00283-9; Dasgupta A, 2002, MED SCI MONITOR, V8, pCR341; de Vet ECJM, 2000, J BIOL CHEM, V275, P6276, DOI 10.1074/jbc.275.9.6276; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; Descoteaux A, 2002, MICROBES INFECT, V4, P975, DOI 10.1016/S1286-4579(02)01624-6; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; HAJRA AK, 1968, J BIOL CHEM, V243, P3458; Hajra AK, 1995, PROG LIPID RES, V34, P343, DOI 10.1016/0163-7827(95)00013-5; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; Helfert S, 2001, BIOCHEM J, V357, P117, DOI 10.1042/0264-6021:3570117; Ilg T, 2001, MED MICROBIOL IMMUN, V190, P13, DOI 10.1007/s004300100071; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; JONES CL, 1983, ARCH BIOCHEM BIOPHYS, V226, P155, DOI 10.1016/0003-9861(83)90280-1; LABELLE EF, 1972, J BIOL CHEM, V247, P5825; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Liu DL, 2005, J LIPID RES, V46, P727, DOI 10.1194/jlr.M400364-JLR200; Matlashewski G, 2001, MED MICROBIOL IMMUN, V190, P37, DOI 10.1007/s004300100076; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; MOSER HW, 1993, ADV HUM GENET, V21, P1; Murata N, 1997, BBA-LIPID LIPID MET, V1348, P10, DOI 10.1016/S0005-2760(97)00115-X; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Ofman R, 1998, HUM MOL GENET, V7, P847, DOI 10.1093/hmg/7.5.847; OFMAN R, 1994, BBA-PROTEIN STRUCT M, V1206, P27, DOI 10.1016/0167-4838(94)90068-X; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; Santiago TC, 2004, J BIOL CHEM, V279, P9222, DOI 10.1074/jbc.M310502200; Schimanski B, 2003, MOL BIOCHEM PARASIT, V126, P193, DOI 10.1016/S0166-6851(02)00273-6; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0; Thai TP, 1997, FEBS LETT, V420, P205, DOI 10.1016/S0014-5793(97)01495-6; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; WEBBER KO, 1993, ARCH BIOCHEM BIOPHYS, V300, P88, DOI 10.1006/abbi.1993.1013; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zhang K, 2003, EMBO J, V22, P6016, DOI 10.1093/emboj/cdg584; Zheng ZF, 2003, PLANT CELL, V15, P1872, DOI 10.1105/tpc.012427; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200; Zufferey R, 2005, MOL MICROBIOL, V56, P800, DOI 10.1111/j.1365-2958.2005.04579.x; Zufferey R, 2003, J BIOL CHEM, V278, P44708, DOI 10.1074/jbc.M308063200	55	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7952	7959		10.1074/jbc.M512911200	http://dx.doi.org/10.1074/jbc.M512911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16423830	hybrid			2022-12-27	WOS:000236031000031
J	Makareeva, E; Cabral, WA; Marini, JC; Leikin, S				Makareeva, E; Cabral, WA; Marini, JC; Leikin, S			Molecular mechanism of alpha 1(I)-osteogenesis Imperfecta/Ehlers-Danlos syndrome - Unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-VII; OSTEOGENESIS-IMPERFECTA; THERMAL-STABILITY; PROCOLLAGEN; PROTEINASE; MUTATIONS; DEFECT; CHAIN; TEMPERATURE; PROPEPTIDE	We demonstrate that 85 N-terminal amino acids of the alpha 1(I) chain participate in a highly stable folding domain, acting as the stabilizing anchor for the amino end of the type I collagen triple helix. This anchor region is bordered by amicrounfolding region, 15 amino acids in each chain, which include no proline or hydroxyproline residues and contain a chymotrypsin cleavage site. Glycine substitutions and amino acid deletions within the N-anchor domain induce its reversible unfolding above 34 degrees C. The overall triple helix denaturation temperature is reduced by 5 - 6 degrees C, similar to complete N-anchor removal. N-propeptide partially restores the stability of mutant procollagen but not sufficiently to prevent N-anchor unfolding and a conformational change at the N-propeptide cleavage site. The ensuing failure of N-proteinase to cleave at the misfolded site leads to incorporation of pN-collagen into fibrils. Similar, but weaker, effects are caused by G88E substitution in the adjacent triplet, which appears to alter N-anchor structure as well. As in Ehlers-Danlos syndrome (EDS) VIIA/B, fibrils containing pN-collagen are thinner and weaker causing EDS-like laxity of large and small joints and paraspinal ligaments. However, distinct structural consequences of N-anchor destabilization result in a distinct alpha 1( I)osteogenesis imperfecta (OI)/EDS phenotype.	NICHD, Sect Phys Biochem, NIH, Bethesda, MD 20892 USA; NICHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Leikin, S (corresponding author), NICHD, Sect Phys Biochem, NIH, Bldg 9,Rm 1E-127, Bethesda, MD 20892 USA.	leikins@mail.nih.gov	Leikin, Sergey/A-5518-2008; Makareeva, Elena/F-5183-2011	Leikin, Sergey/0000-0001-7095-0739; Makareeva, Elena/0000-0002-5815-0760	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000256, ZIAHD000408] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000408, Z01HD000256] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arnold WV, 1998, J BIOL CHEM, V273, P31822, DOI 10.1074/jbc.273.48.31822; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; Cabral WA, 2005, J BIOL CHEM, V280, P19259, DOI 10.1074/jbc.M414698200; Cabral WA, 2003, J BIOL CHEM, V278, P10006, DOI 10.1074/jbc.M212523200; DAVIS JM, 1993, J BIOL CHEM, V268, P25965; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; EYRE DR, 1985, J BIOL CHEM, V260, P1322; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; Kuznetsova NV, 2003, J MOL BIOL, V331, P191, DOI 10.1016/S0022-2836(03)00715-0; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Marini JC, 2004, NELSON TXB PEDIAT, P2336; NESTLER FHM, 1983, BIOPOLYMERS, V22, P1747, DOI 10.1002/bip.360220710; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2005, BIOCHEMISTRY-US, V44, P1414, DOI 10.1021/bi048216r; PRIVALOV PL, 1979, J MOL BIOL, V127, P203, DOI 10.1016/0022-2836(79)90240-7; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raff ML, 2000, HUM GENET, V106, P19, DOI 10.1007/s004390051004; SIPPOLA M, 1984, J BIOL CHEM, V259, P4094; Steinmann B., 2002, CONNECTIVE TISSUE IT, P431, DOI DOI 10.1002/0471221929.CH9; VEIS A, 1982, CONNECT TISSUE RES, V10, P11, DOI 10.3109/03008208209034402	26	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6463	6470		10.1074/jbc.M511830200	http://dx.doi.org/10.1074/jbc.M511830200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407265	hybrid			2022-12-27	WOS:000236030800041
J	Saladino, R; Crestini, C; Ciciriello, F; Di Mauro, E; Costanzo, G				Saladino, R; Crestini, C; Ciciriello, F; Di Mauro, E; Costanzo, G			Origin of informational polymers - Differential stability of phosphoester bonds in ribomonomers and ribooligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDE; PHOSPHORYLATION; DEGRADATION; ENZYMES; XENDOU; LIFE	We have measured the stabilities of the bonds that are critical for determining the half- life of ribonucleotides and the beta-glycosidic and 3'- and 5'- phosphoester bonds. Stabilities were measured under a wide range of temperatures and water/ formamide ratios. The stability of phosphodiester bonds in oligoribonucleotides was determined in the same environments. The comparison of bond stabilities in the monomer versus the polymer forms of the ribo compounds revealed that physico- chemical conditions exist in which polymerization is thermodynamically favored. These conditions were compared with those determining a similar behavior for 2 '- deoxyribonucleosides, deoxyribonucleotides, and deoxyribooligonucleotides and were shown to profoundly differ. The implications of these facts on the origin of informational polymers are discussed.	Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Tuscia, Dipartimento Agrobiol & Agrochim, I-01100 Viterbo, Italy; CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy	Sapienza University Rome; Tuscia University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Di Mauro, E (corresponding author), Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	ernesto.dimauro@uniroma1.it	Ciciriello, Fabiana/AAA-8065-2020; Crestini, Claudia/O-6781-2015	Ciciriello, Fabiana/0000-0003-1493-9767; Crestini, Claudia/0000-0001-9903-2675				Achenbach JC, 2004, CURR PHARM BIOTECHNO, V5, P321, DOI 10.2174/1389201043376751; Atkins J.F, 1999, RNA WORLD; BALES TC, 1990, J MOL BIOL, V213, P931; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; Breaker RR, 1997, NAT BIOTECHNOL, V15, P427, DOI 10.1038/nbt0597-427; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; Breaker RR, 2000, SCIENCE, V290, P2095, DOI 10.1126/science.290.5499.2095; DARWIN F, 1988, LIFE LETT C DARWIN, V3, P18; DIEKMANN S, 1989, EMBO J, V8, P1; Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a; Emilsson GM, 2002, CELL MOL LIFE SCI, V59, P596, DOI 10.1007/s00018-002-8452-4; GARRETT ER, 1966, J ORG CHEM, V31, P189; Gioia U, 2005, J BIOL CHEM, V280, P18996, DOI 10.1074/jbc.M501160200; Halvorson H. O., 1980, ORIGINS LIFE EVOL B, P31; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; JARVINEN P, 1991, J ORG CHEM, V56, P5396, DOI 10.1021/jo00018a037; Joyce GF, 2004, ANNU REV BIOCHEM, V73, P791, DOI 10.1146/annurev.biochem.73.011303.073717; Kochetkov N.K., 1972, ORGANIC CHEM NUCLE B, P425; Laneve P, 2003, J BIOL CHEM, V278, P13026, DOI 10.1074/jbc.M211937200; Millar TJ, 2004, ASTROPHYS SPACE SC L, V305, P17; MORROW JR, 1995, J CHEM SOC CHEM COMM, P2431, DOI 10.1039/c39950002431; Peracchi A, 2005, CHEMBIOCHEM, V6, P1316, DOI 10.1002/cbic.200500098; Saladino R, 2005, J BIOL CHEM, V280, P35658, DOI 10.1074/jbc.M504537200; Saladino R, 2005, CHEMBIOCHEM, V6, P1368, DOI 10.1002/cbic.200500035; Saladino R, 2004, CHEMBIOCHEM, V5, P1558, DOI 10.1002/cbic.200400119; Saladino R, 2003, CHEMBIOCHEM, V4, P514, DOI 10.1002/cbic.200300567; Saladino R, 2001, BIOORGAN MED CHEM, V9, P1249, DOI 10.1016/S0968-0896(00)00340-0; SCHOFFSTALL AM, 1988, ORIGINS LIFE EVOL B, V18, P389, DOI 10.1007/BF01808217; SCHOFFSTALL AM, 1976, ORIGINS LIFE EVOL B, V7, P399, DOI 10.1007/BF00927935; SCHOFFSTALL AM, 1982, ORIGINS LIFE EVOL B, V12, P143, DOI 10.1007/BF00927141; Travers A., 1993, DNA PROTEIN INTERACT	31	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5790	5796		10.1074/jbc.M512545200	http://dx.doi.org/10.1074/jbc.M512545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407319	hybrid			2022-12-27	WOS:000235568900057
J	Lewthwaite, JC; Bastow, ER; Lamb, KJ; Blenis, J; Wheeler-Jones, CPD; Pitsillides, AA				Lewthwaite, JC; Bastow, ER; Lamb, KJ; Blenis, J; Wheeler-Jones, CPD; Pitsillides, AA			A specific mechanomodulatory role for p38 MAPK in embryonic joint articular surface cell MEK-ERK pathway regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE A(2) CPLA(2); OSTEOBLAST-LIKE CELLS; MECHANICAL STRAIN; INFLAMMATORY CYTOKINES; SIGNALING PATHWAYS; GENE-EXPRESSION; GROWTH-FACTOR; CROSS-TALK; IN-VITRO	Mechanisms regulating cell behavior and extracellular matrix composition in response to mechanical stimuli remain unresolved. Our previous studies have established that the MEK-ERK cascade plays a specific role in the mechano-dependent joint formation process by promoting the assembly of pericellular matrices reliant upon hyaluronan (HA) for their integrity. Here we demonstrate: (i) novel cross-talk between p38 MAPK and MEK-ERK signaling pathways that is specific for mechanical stimuli and (ii) a role for p38 MAPK in facilitating HA production by cells derived from the articular surface of embryonic chick tibiotarsal joints. We find that p38 MAPK blockade restricts pericellular assembly of HA-rich matrices and reduces basal as well as mechanical strain-induced release of HA. p38 MAPK blockers potentiated early strain-induced increases but restricted sustained increases in MEK/ERK phosphorylation at later times; c-Fos hyperphosphorylation at threonine 325 was found to parallel this p38 MAPK-mediated modulation of ERK activation. In contrast, p38 MAPK inhibitors had no detectable effect on the ERK activation induced by fibroblast growth factor 2 or pervanadate, a phosphatase inhibitor, and MEK inhibitors did not influence p38 MAPK phosphorylation, confirming both the specificity and unidirectionality of p38 MAPK-ERK cross-talk. Immunochemical and immunoblotting studies revealed constitutive p38 MAPK activation in cells at, or derived from, developing articular joint surfaces. Unlike the MEK-ERK pathway, however, p38 MAPK was not further stimulated by mechanical stimulation in vitro. Thus, p38 MAPK specifically facilitates ERK activation and downstream signaling in response to mechanical stimuli. These results suggest that constitutively active p38 MAPK serves an essential, permissive role in mechanically induced changes in ERK activation and in the accumulation of HA-rich extracellular matrices that serve a key role in joint development.	Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of London; University of London Royal Veterinary College; Harvard University; Harvard Medical School	Pitsillides, AA (corresponding author), Univ London Royal Vet Coll, Dept Vet Basic Sci, Royal Coll St, London NW1 0TU, England.	apitsill@rvc.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S; Bastow ER, 2005, J BIOL CHEM, V280, P11749, DOI 10.1074/jbc.M414495200; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Birkenkamp KU, 2000, BRIT J PHARMACOL, V131, P99, DOI 10.1038/sj.bjp.0703534; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Burlando B, 2003, CELL PHYSIOL BIOCHEM, V13, P147, DOI 10.1159/000071865; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Dong Zigang, 2003, Mol Interv, V3, P306, DOI 10.1124/mi.3.6.306; Dowthwaite GP, 2003, MATRIX BIOL, V22, P311, DOI 10.1016/S0945-053X(03)00037-4; Dowthwaite GP, 1999, MATRIX BIOL, V18, P523, DOI 10.1016/S0945-053X(99)00044-X; DRACHMAN DB, 1962, LANCET, V2, P523; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fell HB, 1934, PROC R SOC SER B-BIO, V116, P316, DOI 10.1098/rspb.1934.0076; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; Helliwell PA, 2000, BIOCHEM J, V350, P163, DOI 10.1042/0264-6021:3500163; Houliston RA, 2002, THROMB HAEMOSTASIS, V88, P321; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Jessop HL, 2004, J BONE MINER RES, V19, P938, DOI 10.1359/jbmr.2004.19.6.938; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Kaur J, 2003, AM J PHYSIOL-HEART C, V284, pH1095, DOI 10.1152/ajpheart.00016.2002; Keeton AB, 2002, J BIOL CHEM, V277, P48565, DOI 10.1074/jbc.M207837200; Kolch W, 2005, FEBS LETT, V579, P1891, DOI 10.1016/j.febslet.2005.02.002; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Kurosawa M, 2000, AM J PHYSIOL-CELL PH, V278, pC500, DOI 10.1152/ajpcell.2000.278.3.C500; Lamb KJ, 2003, INT J EXP PATHOL, V84, P55, DOI 10.1046/j.1365-2613.2003.00338.x; Lee J, 2002, BIOCHEM BIOPH RES CO, V298, P765, DOI 10.1016/S0006-291X(02)02562-7; Loveridge N, 2002, BONE, V30, P866, DOI 10.1016/S8756-3282(02)00732-9; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mikic B, 2000, J REHABIL RES DEV, V37, P127; MITROVIC DR, 1977, AM J ANAT, V150, P333, DOI 10.1002/aja.1001500207; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Ohashi R, 2004, AM J PATHOL, V164, P477, DOI 10.1016/S0002-9440(10)63138-0; Osborne A. C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P448; Papakrivopoulou J, 2004, CARDIOVASC RES, V61, P736, DOI 10.1016/j.cardiores.2003.12.018; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; PITSILLIDES AA, 1995, J HISTOCHEM CYTOCHEM, V43, P263, DOI 10.1177/43.3.7868856; Pitsillides AA, 2003, METH MOLEC MED, V80, P399; Pitsillides AA, 2003, CELL BIOCHEM FUNCT, V21, P235, DOI 10.1002/cbf.1079; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; PITSILLIDES AA, 1994, BRIT J RHEUMATOL, V33, P5; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Sanz-Moreno V, 2003, MOL CELL BIOL, V23, P3079, DOI 10.1128/MCB.23.9.3079-3090.2003; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Torocsik B, 2000, EUR J NEUROSCI, V12, P527, DOI 10.1046/j.1460-9568.2000.00933.x; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Wheeler-Jones CPD, 2005, HEART, V91, P1366, DOI 10.1136/hrt.2005.072280; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	63	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11011	11018		10.1074/jbc.M510680200	http://dx.doi.org/10.1074/jbc.M510680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464862	hybrid			2022-12-27	WOS:000236822200042
J	Dong, XH; Xu, F; Gong, YH; Gao, J; Lin, P; Chen, T; Peng, Y; Qiang, BQ; Yuan, JG; Peng, XZ; Rao, ZH				Dong, XH; Xu, F; Gong, YH; Gao, J; Lin, P; Chen, T; Peng, Y; Qiang, BQ; Yuan, JG; Peng, XZ; Rao, ZH			Crystal structure of the v domain of human nectin-like molecule-1/Syncam3/Tsll1/Igsf4b, a neural tissue-specific immunoglobulin-like cell-cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPHILIC ADHESION; PROTEIN STRUCTURES; TRANS-INTERACTS; CONTACT SITES; ENTRY; MIGRATION; AFADIN; MEMBER; DIMERIZATION; SUPERFAMILY	Nectins are Ca2+-independent immunoglobulin (Ig) superfamily proteins that participate in the organization of epithelial and endothelial junctions. Nectins have three Ig-like domains in the extracellular region, and the first one is essential in cell-cell adhesion and plays a central role in the interaction with the envelope glycoprotein D of several viruses. Five Nectin-like molecules (Necl-1 through -5) with similar domain structures to those of Nectins have been identified. Necl-1 is specifically expressed in neural tissue, has Ca2+-independent homophilic and heterophilic cell-cell adhesion activity, and plays an important role in the formation of synapses, axon bundles, and myelinated axons. Here we report the first crystal structure of its N-terminal Ig-like V domain at 2.4 angstrom, providing insight into trans-cellular recognition mediated by Necl-1. The protein crystallized as a dimer, and the dimeric form was confirmed by size-exclusion chromatography and chemical cross-linking experiments, indicating this V domain is sufficient for homophilic interaction. Mutagenesis work demonstrated that Phe(82) is a key residue for the adhesion activity of Necl-1. A model for homophilic adhesion of Necl-1 at synapses is proposed based on its structure and previous studies.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Tsinghua Univ, Tsinghua IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China; Peking Union Med Coll, Natl Human Genome Ctr, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Peng, XZ (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.	pengxiaozhong@pumc.edu.cn; raozh@xtal.tsinghua.edu.cn	Lin, P/G-7702-2014; Rao, Zihe/HCH-6944-2022	Gong, Yanhua/0000-0002-2693-0498				Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2001, J VIROL, V75, P7987, DOI 10.1128/JVI.75.17.7987-7994.2001; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Fabre-Lafay S, 2005, J BIOL CHEM, V280, P19543, DOI 10.1074/jbc.M410943200; Fukami T, 2003, GENE, V323, P11, DOI 10.1016/j.gene.2003.09.018; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakunaga S, 2005, J CELL SCI, V118, P1267, DOI 10.1242/jcs.01656; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Momose Y, 2002, BIOCHEM BIOPH RES CO, V293, P45, DOI 10.1016/S0006-291X(02)00183-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; Urase K, 2001, NEUROREPORT, V12, P3217, DOI 10.1097/00001756-200110290-00015; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Yageta M, 2002, CANCER RES, V62, P5129; Zhou Y, 2005, BBA-BIOMEMBRANES, V1669, P142, DOI 10.1016/j.bbamem.2005.01.013	41	37	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10610	10617		10.1074/jbc.M513459200	http://dx.doi.org/10.1074/jbc.M513459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16467305	hybrid			2022-12-27	WOS:000236594300093
J	Siegmund, SV; Seki, E; Osawa, Y; Uchinami, H; Cravatt, BF; Schwabe, RF				Siegmund, SV; Seki, E; Osawa, Y; Uchinami, H; Cravatt, BF; Schwabe, RF			Fatty acid amide hydrolase determines anandamide-induced cell death in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID ANANDAMIDE; HEPATIC STELLATE CELLS; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; MOLECULAR CHARACTERIZATION; ENDOCANNABINOID SYSTEM; GLUTATHIONE DEPLETION; KAPPA-B; RECEPTORS; APOPTOSIS	The endocannabinoid anandamide ( AEA) induces cell death in many cell types, but determinants of AEA-induced cell death remain unknown. In this study, we investigated the role of the AEA-degrading enzyme fatty acid amide hydrolase ( FAAH) in AEA-induced cell death in the liver. Primary hepatocytes expressed high levels of FAAH and were completely resistant to AEA-induced cell death, whereas primary hepatic stellate cells (HSCs) expressed low levels of FAAH and were highly sensitive to AEA-induced cell death. Hepatocytes that were pretreated with the FAAH inhibitor URB597 or isolated from FAAH(-/-) mice displayed increased AEA-induced reactive oxygen species (ROS) formation and were susceptible to AEA-mediated death. Conversely, overexpression of FAAH in HSCs prevented AEA-induced death. Since FAAH inhibition conferred only partial AEA sensitivity in hepatocytes, we analyzed additional factors that might regulate AEA-induced death. Hepatocytes contained significantly higher levels of glutathione (GSH) than HSCs. Glutathione depletion by DL-buthionine-(S, R)-sulfoximine rendered hepatocytes susceptible to AEA-mediated ROS production and cell death, whereas GSH ethyl ester prevented ROS production and cell death in HSCs. FAAH inhibition and GSH depletion had additive effects on AEA-mediated hepatocyte cell death resulting in almost 70% death after 24 h at 50 mu M AEA and lowering the threshold for cell death to 500 nM. Following bile duct ligation, FAAH(-/-) mice displayed increased hepatocellular injury, suggesting that FAAH protects hepatocytes from AEA-induced cell death in vivo. In conclusion, FAAH and GSH are determinants of AEA-mediated cell death in the liver.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA	Columbia University; Scripps Research Institute; Scripps Research Institute	Schwabe, RF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, P&S 9-460,630 W 168th St, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021; Seki, Ekihiro/K-2481-2016	Seki, Ekihiro/0000-0002-9472-6085				Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Begg M, 2005, PHARMACOL THERAPEUT, V106, P133, DOI 10.1016/j.pharmthera.2004.11.005; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; Derkinderen P, 2003, J NEUROSCI, V23, P2371; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Fegley D, 2004, P NATL ACAD SCI USA, V101, P8756, DOI 10.1073/pnas.0400997101; Femandez-Checa JC, 2005, TOXICOL APPL PHARM, V204, P263, DOI 10.1016/j.taap.2004.10.001; Fernandez-Rodriguez CM, 2004, LIVER INT, V24, P477, DOI 10.1111/j.1478-3231.2004.0945.x; Fischer R, 2002, GASTROENTEROLOGY, V123, P845, DOI 10.1053/gast.2002.35384; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; KRAHENBUHL S, 1995, HEPATOLOGY, V22, P607, DOI 10.1016/0270-9139(95)90586-3; Ligresti A, 2004, BIOCHEM J, V380, P265, DOI 10.1042/BJ20031812; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Maccarrone M, 2003, ENDOCRINOLOGY, V144, P20, DOI 10.1210/en.2002-220544; McKallip RJ, 2002, BLOOD, V100, P627, DOI 10.1182/blood-2002-01-0098; Movsesyan VA, 2004, CELL DEATH DIFFER, V11, P1121, DOI 10.1038/sj.cdd.4401442; Nagai H, 2002, HEPATOLOGY, V36, P55, DOI 10.1053/jhep.2002.33995; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pacher P, 2005, AM J PHYSIOL-HEART C, V289, pH533, DOI 10.1152/ajpheart.00107.2005; Patricelli MP, 2001, BIOCHEMISTRY-US, V40, P6107, DOI 10.1021/bi002578r; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Schwabe RF, 2001, HEPATOLOGY, V33, P81, DOI 10.1053/jhep.2001.20799; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198	42	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10431	10438		10.1074/jbc.M509706200	http://dx.doi.org/10.1074/jbc.M509706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16418162	hybrid			2022-12-27	WOS:000236594300072
J	Yang, CL; Yan, N; Paris, J; Wang, XC; Shi, YG; Xue, D				Yang, CL; Yan, N; Paris, J; Wang, XC; Shi, YG; Xue, D			RNA aptamers targeting the cell death inhibitor CED-9 induce cell killing in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 GENE; PROTEIN; RECOGNITION; APOPTOSIS; MITOCHONDRIA; ANTAGONISTS; REGULATORS; SURVIVAL; FAMILY; BINDS	Bcl-2 family proteins include anti- and proapoptotic factors that play important roles in regulating apoptosis in diverse species. Identification of compounds that can modulate the activities of Bcl-2 family proteins will facilitate development of drugs for treatment of apoptosis-related human diseases. We used an in vitro selection method named systematic evolution of ligands by exponential enrichment (SELEX) to isolate RNA aptamers that bind the Caenorhabditis elegans Bcl-2 homolog CED-9 with high affinity and specificity and tested whether these aptamers modulate programmed cell death in C. elegans. Five CED-9 aptamers were isolated and classified into three groups based on their predicted secondary structures. Biochemical analyses indicated that two of these aptamers, R9-2 and R9-7, and EGL-1, an endogenous CED-9-binding proapoptotic protein, bound to distinct regions of CED-9. However, these two aptamers shared overlapping CED-9 binding sites with CED-4, another CED-9-binding proapoptotic factor. Importantly ectopic expression of these two aptamers in touch receptor neurons induced efficient killing of these neurons largely in a CED-3 caspase-dependent manner. These findings suggest that RNA aptamers can be used to modulate programmed cell death in vivo and can potentially be used to develop drugs to treat human diseases caused by abnormal apoptosis.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Colorado System; University of Colorado Boulder; Princeton University	Xue, D (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	ding.xue@colorado.edu		Shi, Yigong/0000-0003-2030-168X; XUE, DING/0000-0002-8429-8136	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066262] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM66262] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; Cassiday LA, 2001, BIOCHEMISTRY-US, V40, P2433, DOI 10.1021/bi002376v; Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Fan XC, 2004, P NATL ACAD SCI USA, V101, P6934, DOI 10.1073/pnas.0401523101; Finnegan EJ, 2003, J CELL SCI, V116, P4689, DOI 10.1242/jcs.00838; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X; Ghosh G, 2004, CURR OPIN STRUC BIOL, V14, P21, DOI 10.1016/j.sbi.2004.01.004; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Horvitz HR, 2003, BIOSCIENCE REP, V23, P239, DOI 10.1023/B:BIRE.0000019187.19019.e6; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; Jones AK, 2005, NAT REV DRUG DISCOV, V4, P321, DOI 10.1038/nrd1692; Lebruska LL, 1999, BIOCHEMISTRY-US, V38, P3168, DOI 10.1021/bi982515x; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; Mayer G, 2001, P NATL ACAD SCI USA, V98, P4961, DOI 10.1073/pnas.091100698; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Parrish J, 2000, P NATL ACAD SCI USA, V97, P11916, DOI 10.1073/pnas.210391597; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023; Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; Shangary S, 2003, LEUKEMIA, V17, P1470, DOI 10.1038/sj.leu.2403029; Shi H, 1999, P NATL ACAD SCI USA, V96, P10033, DOI 10.1073/pnas.96.18.10033; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Theis MG, 2004, P NATL ACAD SCI USA, V101, P11221, DOI 10.1073/pnas.0402901101; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang XD, 2001, GENE DEV, V15, P2922; White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	44	8	14	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9137	9144		10.1074/jbc.M511742200	http://dx.doi.org/10.1074/jbc.M511742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467303	hybrid			2022-12-27	WOS:000236404700019
J	Miyakoshi, M; Urata, M; Habe, H; Omori, T; Yamane, H; Nojiri, H				Miyakoshi, M; Urata, M; Habe, H; Omori, T; Yamane, H; Nojiri, H			Differentiation of carbazole catabolic operons by replacement of the regulated promoter via transposition of an insertion sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESINOVORANS STRAIN CA10; COMPLETE NUCLEOTIDE-SEQUENCE; GRAM-NEGATIVE BACTERIA; TRANSCRIPTIONAL REGULATORS; PLASMID PCAR1; PSEUDOMONAS; DEGRADATION; HYDROLASE; FADR; 1,9A-DIOXYGENASE	The carbazole catabolic car operons from Pseudomonas resinovorans CA10 and Janthinobacterium sp. J3 have nearly identical nucleotide sequences in their structural and intergenic regions but not in their flanking regions. Transposition of ISPre1 from the anthranilate catabolic ant operon located an inducible promoter P-ant upstream of the car(CA10) operon, which is regulated by the AraC/ XylS family activator AntR in response to anthranilate. The transposed P-ant drives transcription of the car(CA10) operon, which is composed of the carAaAaBaBbCAcAdDFE(CA10) structural genes. Transcriptional fusion truncating P-ant upstream of carAa(CA10) resulted in constitutive luciferase expression. Primer extension analysis identified a transcription start point of the constitutive mRNA of the car(CA10) operon at 385 nucleotides upstream of the carAa(CA10) translation start point, and the P-carAa promoter was found. On the other hand, a GntR family regulatory gene carR(J3) is divergently located upstream of the car(J3) operon. The P-u13 promoter, required for inducible transcription of the car(J3) operon in the presence of carbazole, was identified in the region upstream of carAa(J3), which had been replaced with the P-ant promoter in the car(CA10) operon. Deletion of carR(J3) from a transcriptional fusion resulted in high level constitutive expression from P-u13. Purified CarR(J3) protein bound at two operator sequences O-I and O-II, showing that CarR(J3) directly represses P-u13 in the absence of its inducer, which was identified as 2- hydroxy- 6- oxo- 6-( 2'- aminophenyl) hexa- 2,4- dienoate, an intermediate of the carbazole degradation pathway.	Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Nojiri, H (corresponding author), Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	anojiri@mail.ecc.u-tokyo.ac.jp	Miyakoshi, Masatoshi/H-5256-2018	Miyakoshi, Masatoshi/0000-0002-4901-2809; Nojiri, Hideaki/0000-0003-3091-8691				Cases I, 2001, EMBO J, V20, P1, DOI 10.1093/emboj/20.1.1; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; Dennis JJ, 2004, J MOL BIOL, V341, P753, DOI 10.1016/j.jmb.2004.06.034; Diaz E, 2000, CURR OPIN BIOTECH, V11, P467, DOI 10.1016/S0958-1669(00)00126-9; Dominguez-Cuevas P, 2004, PSEUDOMONAS, VOL 2: VIRULENCE AND GENE REGULATION, P319; Endoh T, 2005, MOL MICROBIOL, V55, P897, DOI 10.1111/j.1365-2958.2004.04431.x; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; Habe H, 2003, BIOCHEM BIOPH RES CO, V303, P631, DOI 10.1016/S0006-291X(03)00375-9; HAYAISHI O, 1951, J BACTERIOL, V62, P691, DOI 10.1128/JB.62.6.691-709.1951; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; Inoue K, 2004, BIOSCI BIOTECH BIOCH, V68, P1467, DOI 10.1271/bbb.68.1467; Iwata K, 2003, BIOSCI BIOTECH BIOCH, V67, P300, DOI 10.1271/bbb.67.300; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Li W, 2004, GENE, V336, P231, DOI 10.1016/j.gene.2004.03.027; Maeda K, 2003, J MOL BIOL, V326, P21, DOI 10.1016/S0022-2836(02)01400-6; McAdams HH, 2004, NAT REV GENET, V5, P169, DOI 10.1038/nrg1292; Nojiri H, 2005, J MOL BIOL, V351, P355, DOI 10.1016/j.jmb.2005.05.059; Nojiri H, 2003, BIOSCI BIOTECH BIOCH, V67, P36, DOI 10.1271/bbb.67.36; Nojiri H, 2002, BIOSCI BIOTECH BIOCH, V66, P2001, DOI 10.1271/bbb.66.2001; Nojiri H, 2001, J BACTERIOL, V183, P3663, DOI 10.1128/JB.183.12.3663-3679.2001; OUCHIYAMA N, 1993, BIOSCI BIOTECH BIOCH, V57, P455, DOI 10.1271/bbb.57.455; Rigali S, 2002, J BIOL CHEM, V277, P12507, DOI 10.1074/jbc.M110968200; Rist M, 1998, FEMS MICROBIOL LETT, V169, P179, DOI 10.1111/j.1574-6968.1998.tb13315.x; Sambrook J., 2001, MOL CLONING LAB MANU; Sato S, 1997, J BACTERIOL, V179, P4841, DOI 10.1128/jb.179.15.4841-4849.1997; Sato SI, 1997, J BACTERIOL, V179, P4850, DOI 10.1128/jb.179.15.4850-4858.1997; SERDAR CM, 1989, BIOCHEM BIOPH RES CO, V164, P772, DOI 10.1016/0006-291X(89)91526-X; Top EM, 2003, CURR OPIN BIOTECH, V14, P262, DOI 10.1016/S0958-1669(03)00066-1; Tropel D, 2004, MICROBIOL MOL BIOL R, V68, P474, DOI 10.1128/MMBR.68.3.474-500.2004; Urata M, 2004, J BACTERIOL, V186, P6815, DOI 10.1128/JB.186.20.6815-6823.2004; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200	33	14	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8450	8457		10.1074/jbc.M600234200	http://dx.doi.org/10.1074/jbc.M600234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455652	hybrid			2022-12-27	WOS:000236247100020
J	Sawhney, RS; Cookson, MM; Omar, Y; Hauser, J; Brattain, MG				Sawhney, RS; Cookson, MM; Omar, Y; Hauser, J; Brattain, MG			Integrin alpha 2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling - Identification of a novel signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR ACTIVATION; COLON-CANCER CELLS; GROWTH-FACTOR; MAMMALIAN-CELLS; MAP KINASE; TYROSINE PHOSPHORYLATION; DEPENDENT REGULATION; REGULATED KINASE; EPITHELIAL-CELLS; TUMOR INVASION	Higher levels of focal adhesion kinase ( FAK) are expressed in colon metastatic carcinomas. However, the signaling pathways and their mechanisms that control cell adhesion and motility, important components of cancer metastasis, are not well understood. We sought to identify the integrin- mediated mechanism of FAK cleavage and downstream signaling as well as its role in motility in human colon cancer GEO cells. Our results demonstrate that phosphorylated FAK( tyrosine 397) is cleaved at distinct sites by integrin signaling when cells attach to collagen IV. Specific blocking antibodies ( clone P1E6) to integrin alpha 2 inhibited FAK activation and cell motility ( micromotion). Ectopic expression of the FAK C- terminal domain FRNK attenuated FAK and ERK phosphorylation and micromotion. Calpain inhibitor N- acetyl-leucyl-leucyl- norleucinal blocked FAK cleavage, cell adhesion, and micromotion. Antisense approaches established an important role for mu- calpain in cell motility. Expression of wild type mu- calpain increased cell micromotion, whereas its point mutant reversed the effect. Further, cytochalasin D inhibited FAK phosphorylation and cleavage, cell adhesion, locomotion, and ERK phosphorylation, thus showing FAK activation downstream of actin assembly. We also found a pivotal role for FAK Tyr(861) phosphorylation in cell motility and ERK activation. Our results reveal a novel functional connection between integrin alpha 2 engagement, FAK, ERK, and mu- calpain activation in cell motility and a direct link between FAK cleavage and enhanced cell motility. The data suggest that blocking the integrin alpha 2/ FAK/ ERK/ mu- calpain pathway may be an important strategy to reduce cancer progression.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sawhney, RS (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	rajinder.sawhney@roswellpark.org; michael.brattain@roswellpark.org			NCI NIH HHS [CA 34432, CA 50457, CA 54807, CA 16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034432, R01CA054807, P30CA016056, R01CA050457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Cance WG, 2000, CLIN CANCER RES, V6, P2417; CARMICHAEL J, 1987, CANCER RES, V47, P936; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Cary LA, 1996, J CELL SCI, V109, P1787; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Cheshenko N, 2005, J BIOL CHEM, V280, P31116, DOI 10.1074/jbc.M503518200; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; GIAEVER I, 1989, PHYSICA D, V38, P128, DOI 10.1016/0167-2789(89)90182-6; GIAEVER I, 1984, P NATL ACAD SCI-BIOL, V81, P3761, DOI 10.1073/pnas.81.12.3761; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ILLC D, 1995, NATURE, V377, P539; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Lark AL, 2003, CLIN CANCER RES, V9, P215; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Mamoune A, 2003, CANCER RES, V63, P4632; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Petit V, 1999, CELL ADHES COMMUN, V7, P151, DOI 10.3109/15419069909010799; Reddy L, 1998, EXP CELL RES, V245, P360, DOI 10.1006/excr.1998.4273; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; Sawhney RS, 2003, J BIOL CHEM, V278, P19861, DOI 10.1074/jbc.M213162200; Sawhney RS, 2002, J BIOL CHEM, V277, P75, DOI 10.1074/jbc.M103268200; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wells A, 2000, ADV CANCER RES, V78, P31; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Zutter MM, 1998, CURR TOP MICROBIOL, V231, P167	65	87	92	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8497	8510		10.1074/jbc.M600787200	http://dx.doi.org/10.1074/jbc.M600787200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16461767	hybrid			2022-12-27	WOS:000236247100025
J	Freie, AB; Ferrato, F; Carriere, F; Lowe, ME				Freie, AB; Ferrato, F; Carriere, F; Lowe, ME			Val-407 and Ile-408 in the beta 5 '-loop of pancreatic lipase mediate lipase-colipase interactions in the presence of bile salt micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; BINDING; COMPLEX; PURIFICATION; PROCOLIPASE; ACTIVATION; TAURODEOXYCHOLATE; SUBSTRATE; RESIDUES; ABSENCE	In a previous study, we demonstrated that the beta 5'-loop in the C-terminal domain of human pancreatic triglyceride lipase (hPTL) makes a major contribution in the function of hPTL (Chahinian et al. ( 2002) Biochemistry 41, 13725 - 13735). In the present study, we characterized the contribution of three residues in the beta 5'-loop, Val-407, Ile-408, and Leu-412, to the function of hPTL. By substituting charged residues, aspartate or lysine, in these positions, we altered the hydrophilic to lipophilic ratio of the beta 5'-loop. Each of the mutants was expressed, purified, and characterized for activity and binding with both monolayers and emulsions and for binding to colipase. Experiments with monolayers and with emulsions suggested that the interaction of hPTL with a phospholipid monolayer differs from the interaction of the hPTL-colipase complex with a dicaprin monolayer or a triglyceride emulsion (i.e. neutral lipids). Val-407, Ile-408, and Leu-412 make major contributions to interactions with monolayers, whereas only Val-407 and Ile-408 appear essential for activity on triglyceride emulsions in the presence of bile salt micelles. In solutions of taurodeoxycholate at micellar concentrations, a major effect of the beta 5'-loop mutations is to change the interaction between hPTL and colipase. These observations support a major contribution of residues in the beta 5'-loop in the function of hPTL and suggest that a third partner, bile salt micelles or the lipid interface or both, influence the binding of colipase and hPTL through interactions with the beta 5'-loop.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; CNRS, Lab Enzymol Interfaciale & Physiol Lipolyse, F-13402 Marseille 20, France; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Gastroenterol, Pittsburgh, PA 15213 USA	Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lowe, ME (corresponding author), Childrens Hosp Pittsburgh, Dept Gastroenterol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	mark.lowe@chp.edu	Carrière, Frédéric/E-8408-2010	Carrière, Frédéric/0000-0003-4848-9418	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033060] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33060, R01 HD033060] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ayvazian L, 2001, J BIOL CHEM, V276, P14014, DOI 10.1074/jbc.M010328200; Bezzine S, 1998, BIOCHEMISTRY-US, V37, P11846, DOI 10.1021/bi973136r; Bezzine S, 1999, BIOCHEMISTRY-US, V38, P5499, DOI 10.1021/bi982601x; BORGSTROM B, 1975, J LIPID RES, V16, P287; BORGSTROM B, 1975, J LIPID RES, V16, P411; Chahinian H, 2002, BIOCHEMISTRY-US, V41, P13725, DOI 10.1021/bi0257944; Cordle RA, 1998, PROTEIN EXPRES PURIF, V13, P30, DOI 10.1006/prep.1998.0873; Cordle RA, 1998, J LIPID RES, V39, P1759; Crandall WV, 2001, J BIOL CHEM, V276, P12505, DOI 10.1074/jbc.M009986200; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LAIRON D, 1978, BIOCHEMISTRY-US, V17, P5263, DOI 10.1021/bi00617a028; LAIRON D, 1980, BIOCHIM BIOPHYS ACTA, V618, P119, DOI 10.1016/0005-2760(80)90059-4; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; MOMSEN WE, 1976, J BIOL CHEM, V251, P384; PATTON JS, 1978, J BIOL CHEM, V253, P4195; PATTON JS, 1978, BIOCHIM BIOPHYS ACTA, V529, P67, DOI 10.1016/0005-2760(78)90104-2; PATTON JS, 1978, FEBS LETT, V86, P179, DOI 10.1016/0014-5793(78)80558-4; Pignol D, 2000, J BIOL CHEM, V275, P4220, DOI 10.1074/jbc.275.6.4220; Ransac S, 1997, METHOD ENZYMOL, V286, P263; Reissner KJ, 2003, CELL MOL LIFE SCI, V60, P1281, DOI 10.1007/s00018-003-2287-5; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Sambrook J., 2001, MOL CLONING LAB MANU; SARI H, 1975, BIOCHIMIE, V57, P1045, DOI 10.1016/S0300-9084(75)80360-9; SARI H, 1975, EUR J BIOCHEM, V58, P561, DOI 10.1111/j.1432-1033.1975.tb02406.x; Strandberg E, 2003, FEBS LETT, V544, P69, DOI 10.1016/S0014-5793(03)00475-7; van Tilbeurgh H, 1999, BBA-MOL CELL BIOL L, V1441, P173, DOI 10.1016/S1388-1981(99)00149-3; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1993, J MOL BIOL, V229, P552, DOI 10.1006/jmbi.1993.1054; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yang YQ, 1998, PROTEIN EXPRES PURIF, V13, P36, DOI 10.1006/prep.1998.0874	32	22	24	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7793	7800		10.1074/jbc.M512984200	http://dx.doi.org/10.1074/jbc.M512984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431912	hybrid, Green Accepted			2022-12-27	WOS:000236031000012
J	Muralidhara, BK; Negi, S; Chin, CC; Braun, W; Halpert, JR				Muralidhara, BK; Negi, S; Chin, CC; Braun, W; Halpert, JR			Conformational flexibility of mammalian cytochrome P4502B4 in binding imidazole inhibitors with different ring chemistry and side chains - Solution thermodynamics and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS FLAVODOXIN; RESOLUTION CRYSTAL-STRUCTURE; ACTIVE-SITE; THERMOPHILIC CYTOCHROME-P450; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; FUNCTIONAL-ROLE; MUTAGENESIS; RESIDUES; 3A4	Recent x-ray structures of cytochrome P450 2B4 (CYP2B4) reveal an open form that undergoes a large-scale structural transition to a closed form upon binding to 4-(4-chlorophenyl) imidazole (4-CPI). Here, we report for the first time a complete solution thermodynamic study using isothermal titration calorimetry supported by spectroscopic studies to elucidate the conformational flexibility of CYP2B4 in binding imidazole inhibitors with different ring chemistry and side chains: 4-CPI, 1-benzylimidazole (1-BI), 1-CPI, 4-phenylimidazole (4-PI), 1-(2-(benzyloxy)ethyl) imidazole (BEI), and 1-PI. Each of the inhibitors induced type II spectral changes, and IC50 values for enzyme inhibition ranged from 0.1 to 2.4 mu M, following the order 1-BI<4-CPI<1-CPI<4-PI<BEI<1-PI. Calorimetric titrations using monomeric enzyme yielded a 1:1 binding stoichiometry, with the associated K-D values ranging from 0.3 to 4.8 mu M and following the same rank order as the IC50 values. Changes in enthalpy at 25 degrees C ranged from -6.5 to -8.8 kcal mol(-1). The largest difference in binding entropy (+5.9 versus -4.1 cal mol(-1) K-1) was observed between 4-CPI and BEI, respectively, with a 2- fold difference in heat capacity changes (-604 versus -331 cal mol(-1) K-1), which is inferred to result from the reduction of apolar surface area of the enzyme ensuing from a conformational change upon 4-CPI binding. Accessibility to acrylamide of the only tryptophan (Trp(121)), which is located in helix C, was greatly decreased only in protein bound to 4-CPI. Steric restrictions hindered the perfect docking of only BEI to the closed conformation of the enzyme. The thermodynamic signature obtained for structurally similar inhibitors suggests remarkable plasticity of CYP2B4.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Muralidhara, BK (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	bkmurali@utmb.edu	Braun, Werner/A-6642-2012		NIEHS NIH HHS [ES06676, ES03619] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES003619] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aoki M, 1998, BBA-PROTEIN STRUCT M, V1384, P180, DOI 10.1016/S0167-4838(98)00017-X; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Coon MJ, 2005, ANNU REV PHARMACOL, V45, P1, DOI 10.1146/annurev.pharmtox.45.120403.100030; Cupp-Vickery JR, 2001, J MOL BIOL, V311, P101, DOI 10.1006/jmbi.2001.4803; DeLano WL, 2004, PYMOL USERS MANUAL; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Edsall JT, 1935, J AM CHEM SOC, V57, P1506, DOI 10.1021/ja01311a501; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HELMS V, 1995, BIOPHYS J, V69, P810, DOI 10.1016/S0006-3495(95)79955-6; Honma W, 2005, ARCH BIOCHEM BIOPHYS, V435, P157, DOI 10.1016/j.abb.2004.12.014; Kemp CA, 2005, ARCH BIOCHEM BIOPHYS, V433, P361, DOI 10.1016/j.abb.2004.08.026; Kennedy MW, 2001, J BIOL CHEM, V276, P35008, DOI 10.1074/jbc.C100301200; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lin HL, 2003, J PHARMACOL EXP THER, V306, P744, DOI 10.1124/jpet.103.050260; Lopez Maria M, 2002, Methods Mol Biol, V173, P121; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Muralidhara BK, 2005, J MOL BIOL, V349, P87, DOI 10.1016/j.jmb.2005.03.054; Muralidhara BK, 2003, BIOCHEMISTRY-US, V42, P13074, DOI 10.1021/bi035073k; Muralidhara BK, 2004, BIOCHEMISTRY-US, V43, P12855, DOI 10.1021/bi048944e; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MURRAY M, 1984, CHEM-BIOL INTERACT, V50, P267, DOI 10.1016/0009-2797(84)90036-X; Ohtaka H, 2002, PROTEIN SCI, V11, P1908, DOI 10.1110/ps.0206402; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; Podust LM, 2003, J BIOL CHEM, V278, P12214, DOI 10.1074/jbc.M212210200; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; Renaud JP, 1996, BIOCHEM J, V319, P675, DOI 10.1042/bj3190675; Schleinkofer K, 2005, EMBO REP, V6, P584, DOI 10.1038/sj.embor.7400420; Scott EE, 2002, CHEM RES TOXICOL, V15, P1407, DOI 10.1021/tx020057u; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Spatzenegger M, 2001, MOL PHARMACOL, V59, P475, DOI 10.1124/mol.59.3.475; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; Tsai FTF, 1997, PROTEINS, V28, P41; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; Verras A, 2004, J MED CHEM, V47, P3572, DOI 10.1021/jm030608t; Weber PC, 2003, CURR OPIN STRUC BIOL, V13, P115, DOI 10.1016/S0959-440X(03)00003-4; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; WILKINSON CF, 1974, BIOCHEM PHARMACOL, V23, P2377, DOI 10.1016/0006-2952(74)90227-5; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Winn PJ, 2002, P NATL ACAD SCI USA, V99, P5361, DOI 10.1073/pnas.082522999; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; Zhao YH, 2006, J BIOL CHEM, V281, P5973, DOI 10.1074/jbc.M511464200	55	68	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8051	8061		10.1074/jbc.M509696200	http://dx.doi.org/10.1074/jbc.M509696200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439365	hybrid			2022-12-27	WOS:000236031000042
J	Yang, ML; Hsu, CT; Ting, CY; Liu, LF; Hwang, JL				Yang, ML; Hsu, CT; Ting, CY; Liu, LF; Hwang, JL			Assembly of a polymeric chain of SUMO1 on human topoisomerase I in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; DNA-REPAIR; PROTEIN SUMO-1; NUCLEAR; ACTIVATION; COMPLEX; SIGNAL; YEAST; MONOUBIQUITIN; CAMPTOTHECIN	Human ( h) DNA topoisomerase I has been identified as a major SUMO1 target in camptothecin-treated cells. In response to TOP1-mediated DNA damage induced by camptothecin, multiple SUMO1 molecules are conjugated to the N-terminal domain of a single TOP1 molecule. To investigate the molecular mechanism of SUMO1 conjugation to TOP1, an in vitro system using purified SAE1/2, Ubc9, SUMO1, and TOP1 peptides was developed. Consistent with results from in vivo studies, multiple SUMO1 molecules were found to be conjugated to the N-terminal domain of a single TOP1 molecule. Systematic analysis has identified a single major SUMO1 conjugation site located between amino acid residues 110 and 125 that contains a single lysine residue at 117 (Lys-117). Using a short peptide spanning this region, we showed that a poly-SUMO1 chain was assembled in this peptide at Lys-117. Interestingly, a Ubc9-poly-SUMO1 intermediate had accumulated to a high level when the sumoylation assay was performed in the absence of hTOP1 substrate, suggesting a possibility that the poly-SUMO1 chain is formed on Ubc9 first and then transferred en bloc onto hTOP1. This is the first definitive demonstration of the assembly of a poly-SUMO1 chain on protein substrate. These results offer new insight into hTOP1 polysumoylation in response to TOP1-mediated DNA damage and may have general implications in protein polysumoylation.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Hwang, JL (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	jaulangh@imb.sinica.edu.tw	Ting, chun-yuan/F-6448-2013	Ting, chun-yuan/0000-0002-2302-4203; Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA39662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen TY, 2000, APPL MICROBIOL BIOT, V53, P558, DOI 10.1007/s002530051657; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haluska P, 1998, ADV ENZYME REGUL, V38, P253, DOI 10.1016/S0065-2571(97)00008-3; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mayer RJ, 1998, FOLD DES, V3, pR97, DOI 10.1016/S1359-0278(98)00047-9; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	47	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8264	8274		10.1074/jbc.M510364200	http://dx.doi.org/10.1074/jbc.M510364200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428803	hybrid			2022-12-27	WOS:000236031000066
J	Bois, PRJ; O'Hara, BP; Nietlispach, D; Kirkpatrick, J; Izard, T				Bois, PRJ; O'Hara, BP; Nietlispach, D; Kirkpatrick, J; Izard, T			The vinculin binding sites of talin and alpha-actinin are sufficient to activate vinculin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ASSOCIATION; CRYSTAL-STRUCTURE; CYTOSKELETAL PROTEINS; STRUCTURAL BASIS; FOCAL ADHESIONS; CELL-ADHESION; TAIL DOMAINS; HEAD; DYNAMICS; FORCE	Vinculin regulates both cell-cell and cell-matrix junctions and anchors adhesion complexes to the actin cytoskeleton through its interactions with the vinculin binding sites of alpha-actinin or talin. Activation of vinculin requires a severing of the intramolecular interactions between its N- and C-terminal domains, which is necessary for vinculin to bind to F-actin; yet how this occurs in cells is not resolved. We tested the hypothesis that talin and alpha-actinin activate vinculin through their vinculin binding sites. Indeed, we show that these vinculin binding sites have a high affinity for full-length vinculin, are sufficient to sever the head-tail interactions of vinculin, and they induce conformational changes that allow vinculin to bind to F-actin. Finally, microinjection of these vinculin binding sites specifically targets vinculin in cells, disrupting its interactions with talin and alpha-actinin and disassembling focal adhesions. In their native ( inactive) states the vinculin binding sites of talin and alpha-actinin are buried within helical bundles present in their central rod domains. Collectively, these results support a model where the engagement of adhesion receptors first activates talin or alpha-actinin, by provoking structural changes that allow their vinculin binding sites to swing out, which are then sufficient to bind to and activate vinculin.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Cell Adhes Lab, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Cambridge	Izard, T (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, Cell Adhes Lab, 332 N Lauderdale St, Memphis, TN 38105 USA.	tina.izard@stjude.org		Nietlispach, Daniel/0000-0003-4364-9291	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 071596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann SM, 2002, STRUCTURE, V10, P1085, DOI 10.1016/S0969-2126(02)00808-0; Bailly M, 2003, TRENDS CELL BIOL, V13, P163, DOI 10.1016/S0962-8924(03)00030-8; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; Bois PRJ, 2005, MOL CELL BIOL, V25, P6112, DOI 10.1128/MCB.25.14.6112-6122.2005; Borgon RA, 2004, STRUCTURE, V12, P1189, DOI 10.1016/j.str.2004.05.009; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Chandrasekar I, 2005, J CELL SCI, V118, P1461, DOI 10.1242/jcs.01734; Chen H, 2005, J CELL BIOL, V169, P459, DOI 10.1083/jcb.200410100; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; MANGEAT P, 1984, J CELL BIOL, V99, pS95, DOI 10.1083/jcb.99.1.95s; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Pokutta S, 2002, CURR OPIN STRUC BIOL, V12, P255, DOI 10.1016/S0959-440X(02)00318-4; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Propato A, 2001, NAT MED, V7, P807, DOI 10.1038/89930; Rudiger M, 1998, BIOESSAYS, V20, P733; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; STEENBERGEN C, 1987, CIRC RES, V60, P478, DOI 10.1161/01.RES.60.4.478; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Weis WI, 2004, NATURE, V430, P513, DOI 10.1038/430513a; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xu WM, 1998, DEVELOPMENT, V125, P327; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zamir E, 2001, J CELL SCI, V114, P3583	55	103	104	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7228	7236		10.1074/jbc.M510397200	http://dx.doi.org/10.1074/jbc.M510397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407299	hybrid			2022-12-27	WOS:000236030900040
J	Chen, ZQ; Dong, JS; Ishimura, A; Daar, I; Hinnebusch, AG; Dean, M				Chen, ZQ; Dong, JS; Ishimura, A; Daar, I; Hinnebusch, AG; Dean, M			The essential vertebrate ABCE1 protein interacts with eukaryotic initiation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-L INHIBITOR; 2-5A-DEPENDENT RNASE; SEQUENCE ALIGNMENT; XENOPUS-OOCYTES; TRANSLATION; INTERFERON; PATHWAY; CELLS; BIOGENESIS; EVOLUTION	The ABCE1 gene is a member of the ATP-binding cassette (ABC) multigene family and is composed of two nucleotide binding domains and an N-terminal Fe-S binding domain. The ABCE1 gene encodes a protein originally identified for its inhibition of ribonuclease L, a nuclease induced by interferon in mammalian cells. The protein is also required for the assembly of the HIV and SIV gag polypeptides. However, ABCE1 is one of the most highly conserved proteins and is found in one or two copies in all characterized eukaryotes and archaea. Yeast ABCE1/RLI1 is essential to cell division and interacts with translation initiation factors in the assembly of the pre-initiation complex. We show here that the human ABCE1 protein is essential for in vitro and in vivo translation of mRNA and that it binds to eIF2 alpha and eIF5. Inhibition of the Xenopus ABCE1 arrests growth at the gastrula stage of development, consistent with a block in translation. The human ABCE1 gene contains 16 introns, and the extremely high degree of amino acid identity allows the evolution of its introns to be examined throughout eukaryotes. The demonstration that ABCE1 plays a role in vertebrate translation initiation extends the known functions of this highly conserved protein. Translation is a highly regulated process important to development and pathologies such as cancer, making ABCE1 a potential target for therapeutics. The evolutionary analysis supports a model in which an ancestral eukaryote had large number of introns and that many of these introns were lost in non-vertebrate lineages.	NCI, Lab Genom Divers, Ctr Canc Res, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, SAIC Frederick Inc, NIH, Frederick, MD 21702 USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; NCI, Lab Prot Dynam & Signaling, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dean, M (corresponding author), NCI, Lab Genom Divers, Ctr Canc Res, NIH, Frederick, MD 21702 USA.	dean@ncifcrf.gov	Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Daar, Ira/0000-0003-2657-526X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC005725] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01 CO 12400] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Clemens M, 1984, TRANSCRIPTION TRANSL, P231; Coelho CMA, 2005, GENETICS, V171, P597, DOI 10.1534/genetics.105.045021; Dean M, 2005, ANNU REV GENOM HUM G, V6, P123, DOI 10.1146/annurev.genom.6.080604.162122; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Dooher JE, 2004, J VIROL, V78, P1645, DOI 10.1128/JVI.78.4.1645-1656.2004; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Gorchakov R, 2005, J VIROL, V79, P9397, DOI 10.1128/JVI.79.15.9397-9409.2005; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Monnier A, 2001, NUCLEIC ACIDS RES, V29, P1453, DOI 10.1093/nar/29.7.1453; Mood K, 2004, CELL SIGNAL, V16, P631, DOI 10.1016/j.cellsig.2003.10.005; Roy SW, 2005, P NATL ACAD SCI USA, V102, P5773, DOI 10.1073/pnas.0500383102; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	24	119	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7452	7457		10.1074/jbc.M510603200	http://dx.doi.org/10.1074/jbc.M510603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421098	hybrid			2022-12-27	WOS:000236030900067
J	Meller, R; Cameron, JA; Torrey, DJ; Clayton, CE; Ordonez, AN; Henshall, DC; Minami, M; Schindler, CK; Saugstad, JA; Simon, RP				Meller, R; Cameron, JA; Torrey, DJ; Clayton, CE; Ordonez, AN; Henshall, DC; Minami, M; Schindler, CK; Saugstad, JA; Simon, RP			Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; GLOBAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE-C; HIPPOCAMPAL SLICES; CELL-DEATH; APOPTOSIS; ACTIVATION; EXPRESSION; INDUCTION; ADENOSINE	A previous exposure to a non-harmful ischemic insult ( preconditioning) protects the brain against subsequent harmful ischemia ( ischemic tolerance). In contrast to delayed gene-mediated ischemic tolerance, little is known about the molecular mechanisms that regulate rapid ischemic tolerance, which occurs within 1 h following preconditioning. Here we have investigated the degradation of the pro-apoptotic Bcl-2 family member Bim as a mechanism of rapid ischemic tolerance. Bim protein levels were reduced 1 h following preconditioning and occurred concurrent with an increase in Bim ubiquitination. Ubiquitinated proteins are degraded by the proteasome, and inhibition of the proteasome with MG132 ( a proteasome inhibitor) prevented Bim degradation and blocked rapid ischemic tolerance. Inhibition of p42/p44 mitogen-activated protein kinase activation by U0126 reduced Bim ubiquitination and Bim degradation and blocked rapid ischemic tolerance. Finally, inhibition of Bim expression using antisense oligonucleotides also reduced cell death following ischemic challenge. Our results suggest that following preconditioning ischemia, Bim is rapidly degraded by the ubiquitin-proteasome system, resulting in rapid ischemic tolerance. This suggests that the rapid degradation of cell death-promoting proteins by the ubiquitin-proteasome pathway may represent a novel therapeutic strategy to reduce cell damage following neuropathological insults, e. g. stroke.	Legacy Res, Legacy Clin Res & Technol Ctr, Robert S Dow Neurobiol Labs, Portland, OR 97232 USA; Royal Coll Surgeons Ireland, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Meller, R (corresponding author), Legacy Res, Legacy Clin Res & Technol Ctr, Robert S Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	rmeller@downeurobiology.org	Minami, Manabu/H-8540-2016; Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024728, R21NS050669] Funding Source: NIH RePORTER; NINDS NIH HHS [R42 NS065515, NS 050669, R01 NS024728, NS 24728, R21 NS050669] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Baker JE, 1997, J MOL CELL CARDIOL, V29, P845, DOI 10.1006/jmcc.1996.0361; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BISWAS SC, 2002, J BIOL CHEM, V17, P17; Bossenmeyer-Pourie C, 1998, MOL BRAIN RES, V58, P237, DOI 10.1016/S0169-328X(98)00123-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; Dave KR, 2001, J CEREBR BLOOD F MET, V21, P1401, DOI 10.1097/00004647-200112000-00004; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Harris CA, 2001, J BIOL CHEM, V276, P37754; Ishida T, 1997, SHOCK, V8, P86, DOI 10.1097/00024382-199708000-00003; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; LEY R, 2003, J BIOL CHEM; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Meller R, 2002, NEUROSCI LETT, V324, P33, DOI 10.1016/S0304-3940(02)00166-0; Miura T, 1996, EXS, V76, P365; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Nakamura M, 2002, J CEREBR BLOOD F MET, V22, P161, DOI 10.1097/00004647-200202000-00004; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ogawa T, 1996, J AM COLL CARDIOL, V27, P225, DOI 10.1016/0735-1097(95)00412-2; Perez-Pinzon MA, 1999, NEUROSCIENCE, V89, P453, DOI 10.1016/S0306-4522(98)00560-0; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Qi SH, 2001, NEUROSCI LETT, V315, P133, DOI 10.1016/S0304-3940(01)02368-0; Reshef A, 2000, ADV EXP MED BIOL, V486, P217; Reshef A, 1997, NEUROSCI LETT, V238, P37, DOI 10.1016/S0304-3940(97)00841-0; Reshef A, 1998, NEUROSCI LETT, V250, P111, DOI 10.1016/S0304-3940(98)00458-3; Reshef A, 1996, BRAIN RES, V741, P252, DOI 10.1016/S0006-8993(96)00939-0; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Shimizu S, 2001, J CEREBR BLOOD F MET, V21, P233, DOI 10.1097/00004647-200103000-00007; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Tauskela JS, 1999, BRAIN RES, V827, P143, DOI 10.1016/S0006-8993(99)01322-0; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235	51	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7429	7436		10.1074/jbc.M512138200	http://dx.doi.org/10.1074/jbc.M512138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16431916	Green Accepted, hybrid			2022-12-27	WOS:000236030900064
J	Patel, B; Gingras, AR; Bobkov, AA; Fujimoto, LM; Zhang, M; Liddington, RC; Mazzeo, D; Emsley, J; Roberts, GCK; Barsukov, IL; Critchley, DR				Patel, B; Gingras, AR; Bobkov, AA; Fujimoto, LM; Zhang, M; Liddington, RC; Mazzeo, D; Emsley, J; Roberts, GCK; Barsukov, IL; Critchley, DR			The activity of the vinculin binding sites in talin is influenced by the stability of the helical bundles that make up the talin rod	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEINS TALIN; EMBRYONIC STEM-CELLS; F-ACTIN-BINDING; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; FERM DOMAIN; INTEGRIN ACTIVATION; PLASMA-MEMBRANE; FOCAL ADHESIONS; KINASE	The talin rod contains similar to 11 vinculin binding sites (VBSs), each defined by hydrophobic residues in a series of amphipathic helices that are normally buried within the helical bundles that make up the rod. Consistent with this, talin failed to compete for binding of the vinculin Vd1 domain to an immobilized talin polypeptide containing a constitutively active VBS. However, talin did bind to GST- Vd1 in pull-down assays, and isothermal titration calorimetry measurements indicate a K-d of similar to 9 mu M. Interestingly, Vd1 binding exposed a trypsin cleavage site in the talin rod between residues 898 and 899, indicating that there are one or more active VBSs in the N-terminal part of the talin rod. This region comprises a five helix bundle ( residues 482 - 655) followed by a seven-helix bundle ( 656 - 889) and contains five VBSs ( helices 4, 6, 9, 11, and 12). The single VBS within 482 - 655 is cryptic at room temperature. In contrast, talin 482 - 889 binds Vd1 with high affinity (K-d similar to 0.14 mu M), indicating that one or more of the four VBSs within 656 - 889 are active, and this likely represents the vinculin binding region in intact talin. In support of this, hemagglutinin-tagged talin 482 - 889 localized efficiently to focal adhesions, whereas 482 - 655 did not. Differential scanning calorimetry showed a strong negative correlation between Vd1 binding and helical bundle stability, and a 755 - 889 mutant with a more stable fold bound Vd1 much less well than wild type. We conclude that the stability of the helical bundles that make up the talin rod is an important factor determining the activity of the individual VBSs.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Burnham Inst, La Jolla, CA 92037 USA; Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England	University of Leicester; Sanford Burnham Prebys Medical Discovery Institute; University of Nottingham	Critchley, DR (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	drc@le.ac.uk	emsley, jonas/A-8509-2016; Gingras, Alexandre R/E-1867-2011	emsley, jonas/0000-0002-8949-8030; Gingras, Alexandre R/0000-0002-5373-0176; Roberts, Gordon/0000-0001-6200-1373	NIGMS NIH HHS [5U54 GM 64346] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; BELKIN AM, 1986, FEBS LETT, V200, P32, DOI 10.1016/0014-5793(86)80505-1; Bellissent-Waydelich A, 1999, J HISTOCHEM CYTOCHEM, V47, P1357, DOI 10.1177/002215549904701102; Bolton SJ, 1997, CELL MOTIL CYTOSKEL, V36, P363; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; Critchley DR, 2004, BIOCHEM SOC T, V32, P831, DOI 10.1042/BST0320831; de Pereda JM, 2005, J BIOL CHEM, V280, P8381, DOI 10.1074/jbc.M413180200; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; Hemmings L, 1996, J CELL SCI, V109, P2715; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lee HS, 2004, J MOL BIOL, V343, P771, DOI 10.1016/j.jmb.2004.08.069; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCLACHLAN AD, 1994, J MOL BIOL, V235, P1278, DOI 10.1006/jmbi.1994.1081; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Morgan JR, 2004, J CELL BIOL, V167, P43, DOI 10.1083/jcb.200406020; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; OTEY CA, 1993, J BIOL CHEM, V268, P21193; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Schmidt JM, 1999, ARCH BIOCHEM BIOPHYS, V366, P139, DOI 10.1006/abbi.1999.1204; SEALOCK R, 1986, EXP CELL RES, V163, P143, DOI 10.1016/0014-4827(86)90566-5; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TIDBALL JG, 1986, J CELL BIOL, V103, P1465, DOI 10.1083/jcb.103.4.1465; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Tremuth L, 2004, J BIOL CHEM, V279, P22258, DOI 10.1074/jbc.M400947200; VOLBERG T, 1986, J MUSCLE RES CELL M, V7, P375; VOLBERG T, 1995, J CELL SCI, V108, P2253; Winkler J, 1997, EUR J BIOCHEM, V243, P430, DOI 10.1111/j.1432-1033.1997.0430a.x; Xu WM, 1998, DEVELOPMENT, V125, P327; Xu WM, 1998, J CELL SCI, V111, P1535; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	68	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7458	7467		10.1074/jbc.M508058200	http://dx.doi.org/10.1074/jbc.M508058200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407302	Green Submitted, hybrid			2022-12-27	WOS:000236030900068
J	Kim, E; Yamashita, M; Nakanishi, T; Park, KE; Kimura, M; Kashiwabara, S; Baba, T				Kim, E; Yamashita, M; Nakanishi, T; Park, KE; Kimura, M; Kashiwabara, S; Baba, T			Mouse sperm lacking ADAM1b/ADAM2 fertilin can fuse with the egg plasma membrane and effect fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRINS; MAMMALIAN FERTILIZATION; POLY(A) POLYMERASE; ANCHORED PROTEIN; EPIDIDYMAL SPERM; GENE FAMILY; MALE-MICE; SURFACE; FUSION; CALMEGIN	Fertilin, a heterodimeric protein complex composed of alpha (ADAM1) and beta (ADAM2) subunits on the sperm surface, is believed to mediate adhesion and fusion between the sperm and egg plasma membranes. Here we have shown that mutant male mice lacking ADAM1b are fertile and that the loss of ADAM1b results in no significant defect in sperm functions such as migration from the uterus into oviduct, binding to egg zona pellucida, and fusion with zona pellucida-free eggs. ADAM1b-deficient epididymal sperm showed a severe reduction of ADAM2 on the cell surface, despite the normal presence of ADAM2 in testicular germ cells. The appearance of ADAM1b and ADAM2 on the sperm surface depended on formation and abundance of ADAM1b/ADAM2 fertilin in testicular germ cells. These results suggest that mouse ADAM1b/ADAM2 fertilin may play a crucial role not in the sperm/ egg fusion but in the appearance of these two ADAMs on the sperm surface.	Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Baba, T (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba Sci City, Tsukuba, Ibaraki 3058572, Japan.	acroman@sakura.cc.tsukuba.ac.jp						Baba D, 2002, J BIOL CHEM, V277, P30310, DOI 10.1074/jbc.M204596200; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Evans JP, 2002, HUM REPROD UPDATE, V8, P297, DOI 10.1093/humupd/8.4.297; He ZY, 2003, DEV BIOL, V254, P226, DOI 10.1016/S0012-1606(02)00043-X; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Kashiwabara S, 2002, SCIENCE, V298, P1999, DOI 10.1126/science.1074632; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; Kim E, 2004, J REPROD DEVELOP, V50, P571, DOI 10.1262/jrd.50.571; Kim E, 2003, BIOCHEM BIOPH RES CO, V304, P313, DOI 10.1016/S0006-291X(03)00588-6; KIM T, 2006, BIOL REPROD; Kondoh G, 2005, NAT MED, V11, P160, DOI 10.1038/nm1179; Nakanishi T, 2004, BIOL REPROD, V71, P959, DOI 10.1095/biolreprod.104.028647; Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200; Nishimura H, 2002, GENE, V291, P67, DOI 10.1016/S0378-1119(02)00540-1; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; Stein KK, 2005, BIOL REPROD, V73, P1032, DOI 10.1095/biolreprod.105.040972; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yamagata K, 2002, DEV BIOL, V250, P348, DOI 10.1006/dbio.2002.0803; YAMAGIMACHI R, 1994, PHYSL REPROD, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]	32	61	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5634	5639		10.1074/jbc.M510558200	http://dx.doi.org/10.1074/jbc.M510558200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407235	hybrid			2022-12-27	WOS:000235568900039
J	He, LS; Wu, XL; Siegel, R; Lipsky, PE				He, LS; Wu, XL; Siegel, R; Lipsky, PE			TRAF6 regulates cell fate decisions by inducing caspase 8-dependent apoptosis and the activation of NF-kappa B.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; RECEPTOR-ASSOCIATED KINASE; LIVING CELLS; INTERLEUKIN-1 RECEPTOR; PROTEASOME INHIBITORS; CASPASE ACTIVITY; FLOW-CYTOMETRY; PROTEIN; DEATH; MEDIATE	Tumor necrosis factor receptor-associated factor 6 (TRAF6) functions as an adaptor, positively regulating the NF-kappa B pathway. Here we report a new function of human TRAF6, the direct stimulation of apoptosis. The mechanism of apoptosis induction results from the capacity of human TRAF6 to interact and activate caspase 8. Both the C-terminal TRAF domain of human TRAF6, which directly interacts with the death effector domain of pro-caspase 8, and the N-terminal RING domain, which is required for activation of caspase 8, are necessary for the induction of apoptosis. The role of endogenous TRAF6 in regulating apoptosis was confirmed by extinguishing TRAF6 expression with specific small-hairpin RNA that resulted in diminished spontaneous apoptosis and resistance to induced apoptosis. In contrast to the human molecule, murine TRAF6 displayed less ability to induce apoptosis and a greater capacity to stimulate NF-kappa B activity. Human and murine TRAF6 are similar except in the region between zinc finger 5 and the TRAF domains. Reciprocal transfer of this connecting region completely exchanged the ability of human and murine TRAF6 to induce apoptosis and activate NF-kappa B. Unique regions of TRAF6 therefore play an important role in determining cell fate.	NIAMS, Flow Cytometry Sect, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; NIAMS, Autoimmun Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	He, LS (corresponding author), NIAMS, Flow Cytometry Sect, Off Sci & Technol, NIH, Bethesda, MD 20892 USA.	Liusheng.He@Stjude.org	Siegel, Richard/C-7592-2009	Siegel, Richard/0000-0001-5953-9893	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041133, Z01AR041128, ZIAAR041133] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; He LS, 1999, RADIAT RES, V151, P283, DOI 10.2307/3579940; He LS, 2004, J BIOL CHEM, V279, P55855, DOI 10.1074/jbc.M407284200; He LS, 2004, AM J PATHOL, V164, P1901, DOI 10.1016/S0002-9440(10)63751-0; He LS, 2003, CYTOM PART A, V55A, P71, DOI 10.1002/cyto.a.10073; He LS, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni057; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hug H, 1999, BIOCHEMISTRY-US, V38, P13906, DOI 10.1021/bi9913395; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Matsumura T, 2003, IMMUNOLOGY, V109, P127, DOI 10.1046/j.1365-2567.2003.01627.x; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schleicher U, 2000, J IMMUNOL METHODS, V246, P165, DOI 10.1016/S0022-1759(00)00298-2; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; van Rheenen J, 2004, BIOPHYS J, V86, P2517, DOI 10.1016/S0006-3495(04)74307-6; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Werneburg BG, 2001, J BIOL CHEM, V276, P43334, DOI 10.1074/jbc.M104994200; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; You SA, 1999, INT J ONCOL, V15, P625; Zapata Juan M, 2002, Sci STKE, V2002, ppe27	40	30	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11235	11249		10.1074/jbc.M508779200	http://dx.doi.org/10.1074/jbc.M508779200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16436380	hybrid			2022-12-27	WOS:000236822200067
J	Ugleholdt, R; Poulsen, MLH; Holst, PJ; Irminger, JC; Orskov, C; Pedersen, J; Rosenkilde, MM; Zhu, XR; Steiner, DF; Holst, JJ				Ugleholdt, R; Poulsen, MLH; Holst, PJ; Irminger, JC; Orskov, C; Pedersen, J; Rosenkilde, MM; Zhu, XR; Steiner, DF; Holst, JJ			Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; PROHORMONE CONVERTASE PC2; MICE LACKING; PROPROTEIN CONVERTASES; RECOMBINANT ADENOVIRUS; FUNCTIONAL EXPRESSION; ENDOPROTEASES PC2; PROGLUCAGON; CELLS; GLUCAGON	The physiology of the incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and their role in type 2 diabetes currently attract great interest. Recently we reported an essential role for prohormone convertase (PC)1/3 in the cleavage of intestinal proglucagon, resulting in formation of GLP-1, as demonstrated in PC1/3-deficient mice. However, little is known about the endoproteolytic processing of the GIP precursor. This study investigates the processing of proGIP in PC1/3 and PC2 null mice and in cell lines using adenovirus-mediated overexpression. Supporting a role for PC1/3 in proGIP processing, we found co-localization of GIP and PC1/3 but not PC2 in intestinal sections by immunohistochemistry, and analysis of intestinal extracts from PC1/3-deficient animals demonstrated severely impaired processing to GIP, whereas processing to GIP was unaltered in PC2-deficient mice. Accordingly, overexpression of preproGIP in the neuroendocrine AtT-20 cell line that expresses high levels of endogenous PC1/3 and negligible levels of PC2 resulted in production of GIP. Similar results were obtained after co-expression of preproGIP and PC1/3 in GH(4) cells that express no PC2 and only low levels of PC1/3. In addition, studies in GH(4) cells and the alpha-TC1.9 cell line, expressing PC2 but not PC1/3, indicate that PC2 can mediate processing to GIP but also to other fragments not found in intestinal extracts. Taken together, our data indicate that PC1/3 is essential and sufficient for the production of the intestinal incretin hormone GIP, whereas PC2, although capable of cleaving proGIP, does not participate in intestinal proGIP processing and is not found in intestinal GIP-expressing cells.	Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Immunol & Med Microbiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Pharmacol, DK-2200 Copenhagen N, Denmark; Ctr Med Univ Geneva, Louis Jeantet Res Labs, CH-1211 Geneva 4, Switzerland; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Geneva; University of Chicago	Holst, JJ (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	holst@mfi.ku.dk	Holst, Jens/AAA-8022-2022	Ugleholdt, Randi/0000-0002-6656-0137; Holst, Peter Johannes/0000-0002-1279-304X; Holst, Jens Juul/0000-0001-6853-3805; Rosenkilde, Mette Marie/0000-0001-9600-3254				BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Christensen JP, 2003, J IMMUNOL, V171, P4733, DOI 10.4049/jimmunol.171.9.4733; Damholt AB, 1999, ENDOCRINOLOGY, V140, P4800, DOI 10.1210/en.140.10.4800; Deacon CF, 2000, J CLIN ENDOCR METAB, V85, P3575, DOI 10.1210/jc.85.10.3575; Dey A, 2005, ENDOCRINOLOGY, V146, P713, DOI 10.1210/en.2004-1118; Dey A, 2003, J BIOL CHEM, V278, P15007, DOI 10.1074/jbc.M212128200; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Furuta M, 2001, J BIOL CHEM, V276, P27197, DOI 10.1074/jbc.M103362200; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HOLST JJ, 1991, METHODS NEUROSCIENCE, V5, P3, DOI DOI 10.1016/B978-0-12-185259-7.50006-5; Hoy M, 2003, N-S ARCH PHARMACOL, V368, P284, DOI 10.1007/s00210-003-0797-1; Irminger JC, 1996, BIOCHEM J, V320, P11, DOI 10.1042/bj3200011; Kaufmann JE, 1997, DIABETES, V46, P978, DOI 10.2337/diabetes.46.6.978; KRARUP T, 1984, REGUL PEPTIDES, V9, P35, DOI 10.1016/0167-0115(84)90005-3; KRARUP T, 1988, ENDOCR REV, V9, P122, DOI 10.1210/edrv-9-1-122; KRARUP T, 1983, J CLIN ENDOCR METAB, V56, P1306, DOI 10.1210/jcem-56-6-1306; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Marzban L, 2004, DIABETES, V53, P141, DOI 10.2337/diabetes.53.1.141; MORGAN LM, 1978, ANN CLIN BIOCHEM, V15, P172, DOI 10.1177/000456327801500138; Mortensen K, 2003, REGUL PEPTIDES, V114, P189, DOI 10.1016/S0167-0115(03)00125-3; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; OTTE SC, 1984, DIG DIS SCI S, V29, P63; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Schieldrop PJ, 1996, BBA-GENE STRUCT EXPR, V1308, P111, DOI 10.1016/0167-4781(96)00103-0; SCOPSI L, 1995, J CLIN ENDOCR METAB, V80, P294, DOI 10.1210/jc.80.1.294; SIEGEL EG, 1985, DIABETOLOGIA, V28, P857, DOI 10.1007/BF00291078; TAKEDA J, 1987, P NATL ACAD SCI USA, V84, P7005, DOI 10.1073/pnas.84.20.7005; Tanaka S, 2003, ZOOL SCI, V20, P1183, DOI 10.2108/zsj.20.1183; TSENG CC, 1993, P NATL ACAD SCI USA, V90, P1992, DOI 10.1073/pnas.90.5.1992; Ugleholdt R, 2004, ENDOCRINOLOGY, V145, P1349, DOI 10.1210/en.2003-0801; Wang J, 2001, DIABETES, V50, P534, DOI 10.2337/diabetes.50.3.534; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1993, J BIOL CHEM, V268, P1763; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	45	75	77	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11050	11057		10.1074/jbc.M601203200	http://dx.doi.org/10.1074/jbc.M601203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476726	hybrid			2022-12-27	WOS:000236822200046
J	An, XL; Guo, XH; Zhang, XH; Baines, AJ; Debnath, G; Moyo, D; Salomao, M; Bhasin, N; Johnson, C; Discher, D; Gratzer, WB; Mohandas, N				An, XL; Guo, XH; Zhang, XH; Baines, AJ; Debnath, G; Moyo, D; Salomao, M; Bhasin, N; Johnson, C; Discher, D; Gratzer, WB; Mohandas, N			Conformational stabilities of the structural repeats of erythroid spectrin and their functional implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPETITIVE SEGMENTS; HELICAL REPEATS; TANDEM REPEATS; ALPHA-SPECTRIN; PROTEIN; MEMBRANE; FLEXIBILITY; FRAGMENTS; PEPTIDES; INSIGHTS	The two polypeptide chains of the erythroid spectrin heterodimer contain between them 36 structural repeating modules, which can function as independently folding units. We have expressed all 36 and determined their thermal stabilities. These vary widely, with unfolding transition mid-points (T-m) ranging from 21 to 72 C. Eight of the isolated repeats are largely unfolded at physiological temperature. Constructs comprising two or more adjacent repeats show inter-repeat coupling with coupling free energies of several kcal mol(-1). Constructs comprising five successive repeats from the beta-chain displayed cooperativity and strong temperature dependence in forced unfolding by atomic force microscopy. Analysis of aligned sequences and molecular modeling suggests that high stability is conferred by large hydrophobic side chains at position e of the heptad hydrophobic repeats in the first helix of the three-helix bundle that makes up each repeat. This inference was borne out by the properties of mutants in which the critical residues have been replaced. The marginal stability of the tertiary structure at several points in the spectrin chains is moderated by energetic coupling with adjoining structural elements but may be expected to permit adaptation of the membrane to the large distortions that the red cell experiences in the circulation.	New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10021 USA; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Kings Coll London, Randall Ctr Mol Mech Cell Funct, London SE1 1UL, England; Univ Penn, Biophys Engn Lab, Philadelphia, PA 19104 USA	New York Blood Center; University of Kent; University of London; King's College London; University of Pennsylvania	An, XL (corresponding author), New York Blood Ctr, Red Cell Physiol Lab, 310 E 67th St, New York, NY 10021 USA.	xan@nybloodcenter.org		discher, dennis/0000-0001-6163-2229; Salomao, Marcela/0000-0002-3631-2407; Baines, Anthony/0000-0003-3068-7811	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579, R01HL062352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, P01DK032094, R01DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31579, HL 062352] Funding Source: Medline; NIDDK NIH HHS [DK 26263, DK 32094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An XL, 2004, BIOCHEMISTRY-US, V43, P310, DOI 10.1021/bi035653h; Baines AJ, 2003, CELL MOL BIOL LETT, V8, P195; Batey S, 2005, J MOL BIOL, V349, P1045, DOI 10.1016/j.jmb.2005.04.028; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDTS JF, 1977, BIOCHEMISTRY-US, V16, P3450, DOI 10.1021/bi00634a024; DAVIS J, 1983, J BIOL CHEM, V258, P7757; Discher DE, 2001, CELL MOL BIOL LETT, V6, P593; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Kusunoki H, 2004, J MOL BIOL, V344, P495, DOI 10.1016/j.jmb.2004.09.019; Kusunoki H, 2004, STRUCTURE, V12, P645, DOI 10.1016/j.str.2004.02.022; Law R, 2003, BIOPHYS J, V85, P3286, DOI 10.1016/S0006-3495(03)74747-X; Law R, 2003, BIOPHYS J, V84, P533, DOI 10.1016/S0006-3495(03)74872-3; Lecomte MC, 1999, EUR BIOPHYS J BIOPHY, V28, P208, DOI 10.1007/s002490050201; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MacDonald RI, 2004, P NATL ACAD SCI USA, V101, P1502, DOI 10.1073/pnas.0308059100; MacDonald RI, 2001, BIOCHEMISTRY-US, V40, P3974, DOI 10.1021/bi0025159; Menhart N, 1996, J BIOL CHEM, V271, P30410, DOI 10.1074/jbc.271.48.30410; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Muse SV, 1997, J MOL EVOL, V44, P492, DOI 10.1007/PL00006173; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ortiz V, 2005, J MOL BIOL, V349, P638, DOI 10.1016/j.jmb.2005.03.086; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; SHOTTON D, 1979, J MOL BIOL, V131, P302; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Ursitti JA, 1996, J BIOL CHEM, V271, P6636, DOI 10.1074/jbc.271.12.6636; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZARKOWSKY HS, 1975, BRIT J HAEMATOL, V29, P537, DOI 10.1111/j.1365-2141.1975.tb02740.x	34	58	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10527	10532		10.1074/jbc.M513725200	http://dx.doi.org/10.1074/jbc.M513725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476728	hybrid			2022-12-27	WOS:000236594300082
J	Chartier, FJM; Blais, SP; Couture, M				Chartier, FJM; Blais, SP; Couture, M			A weak Fe-O bond in the oxygenated complex of the nitric-oxide synthase of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN RADICAL FORMATION; HEME-DIOXY REDUCTION; RESONANCE RAMAN; LOW-TEMPERATURE; L-ARGININE; OXYCYTOCHROME P450CAM; CYTOCHROME P450CAM; SINGLE-TURNOVER; PROTEIN; SUBSTRATE	Little is known about the intermediates formed during catalysis by nitric-oxide synthase ( NOS). We report here the characterization by resonance Raman spectroscopy of the oxygenated complex of the NOS from Staphylococcus aureus (saNOS) as well as the kinetics of formation and decay of the complex. An oxygenated complex transiently formed after mixing reduced saNOS with oxygen and decayed to the ferric enzyme with kinetics that were dependent on the substrate L-arginine and the cofactor H4B. The oxygenated complex displayed a Soret absorption band centered at 430 nm. Resonance Raman spectroscopy revealed that it can be described as a ferric superoxide form ((FeO2-)-O-III) with a single nu(O-O) mode at 1135 cm(-1). In the presence of L-arginine, an additional nu(O-O) mode at 1123 cm(-1) was observed, indicating an increased pi back-bonding electron donation to the bound oxygen induced by the substrate. With saNOS, this is the first time that the nu(Fe-O) mode of a NOS has been observed. The low frequency of this mode, at 517 cm(-1), points to an oxygenated complex that differs from that of P450(cam). The electronic structure of the oxygenated complex and the effect of L-arginine are discussed in relation to the kinetic properties of saNOS and other NOS.	Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada; Univ Laval, CREFSIP, Res Ctr, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Couture, M (corresponding author), Univ Laval, Dept Biochem & Microbiol, Pavillon Marchand,Room 4165, Quebec City, PQ G1K 7P4, Canada.	manon.couture@bcm.ulaval.ca	Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055				AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 2004, J BIOL CHEM, V279, P32243, DOI 10.1074/jbc.M404044200; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; Bruckdorfer Richard, 2005, Molecular Aspects of Medicine, V26, P3, DOI 10.1016/j.mam.2004.09.002; Buddha MR, 2004, J BIOL CHEM, V279, P49567, DOI 10.1074/jbc.C400418200; Chartier FJM, 2004, BIOPHYS J, V87, P1939, DOI 10.1529/biophysj.104.042119; CHEN YJ, 1995, J BACTERIOL, V177, P5122, DOI 10.1128/jb.177.17.5122-5128.1995; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Couture M, 2001, J BIOL CHEM, V276, P38280; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; HERZBERG G, 1950, MOL SPECTRA MOL STRU, V1, P560; HU SZ, 1991, J AM CHEM SOC, V113, P4815, DOI 10.1021/ja00013a016; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li D, 2004, J BIOL CHEM, V279, P26489, DOI 10.1074/jbc.M400968200; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; Macdonald IDG, 1999, J AM CHEM SOC, V121, P376, DOI 10.1021/ja9810383; Marchal S, 2004, J BIOL CHEM, V279, P19824, DOI 10.1074/jbc.M313587200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; Ohta T, 2004, J AM CHEM SOC, V126, P15000, DOI 10.1021/ja046896f; Ost TWB, 2005, J BIOL CHEM, V280, P965, DOI 10.1074/jbc.M411191200; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Spiro TG, 2001, COORDIN CHEM REV, V219, P923, DOI 10.1016/S0010-8545(01)00384-8; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; TAKAHASHI S, 1995, J BIOL CHEM, V270, P8405, DOI 10.1074/jbc.270.15.8405; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wei CC, 2005, J BIOL CHEM, V280, P8929, DOI 10.1074/jbc.M409737200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679	48	29	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9953	9962		10.1074/jbc.M513893200	http://dx.doi.org/10.1074/jbc.M513893200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16473878	hybrid			2022-12-27	WOS:000236594300017
J	Beuning, PJ; Simon, SM; Zemla, A; Barsky, D; Walker, GC				Beuning, PJ; Simon, SM; Zemla, A; Barsky, D; Walker, GC			A non-cleavable UmuD variant that acts as a UmuD ' mimic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; BETA-PROCESSIVITY CLAMP; RECA-MEDIATED CLEAVAGE; SOS MUTAGENESIS; SLIDING-CLAMP; MOLECULAR-DYNAMICS; COLD SENSITIVITY; INTACT UMUD; PROTEIN; SUBUNIT	UmuD(2) cleaves and removes its N-terminal 24 amino acids to form UmuD'(2), which activates UmuC for its role in UV-induced mutagenesis in Escherichia coli. Cells with a non-cleavable UmuD exhibit essentially no UV-induced mutagenesis and are hypersensitive to killing by UV light. UmuD binds to the beta processivity clamp ("beta") of the replicative DNA polymerase, pol III. A possible beta-binding motif has been predicted in the same region of UmuD shown to be important for its interaction with beta. We performed alanine-scanning mutagenesis of this motif ((TFPLF18)-T-14) in UmuD and found that it has a moderate influence on UV-induced mutagenesis but is required for the cold-sensitive phenotype caused by elevated levels of wild-type UmuD and UmuC. Surprisingly, the wild-type and the beta-binding motif variant bind to beta with similar K-d values as determined by changes in tryptophan fluorescence. However, these data also imply that the single tryptophan in beta is in strikingly different environments in the presence of the wild-type versus the variant UmuD proteins, suggesting a distinct change in some aspect of the interaction with little change in its strength. Despite the fact that this novel UmuD variant is non-cleavable, we find that cells harboring it display phenotypes more consistent with the cleaved form UmuD', such as resistance to killing by UV light and failure to exhibit the cold-sensitive phenotype. Cross-linking and chemical modification experiments indicate that the N-terminal arms of the UmuD variant are less likely to be bound to the globular domain than those of the wild-type, which may be the mechanism by which this UmuD variant acts as a UmuD' mimic.	MIT, Dept Biol, Cambridge, MA 02139 USA; Lawrence Livermore Natl Lab, Computat Directorate, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Biosci Directorate, Livermore, CA 94550 USA	Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Walker, GC (corresponding author), 68-633,77 Massachusetts Ave, Cambridge, MA 02139 USA.	gwalker@mit.edu		/0000-0001-7243-8261	NATIONAL CANCER INSTITUTE [R01CA021615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NCI NIH HHS [CA21615] Funding Source: Medline; NIEHS NIH HHS [P30ES02109] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; Becherel OJ, 2002, DNA REPAIR, V1, P703, DOI 10.1016/S1568-7864(02)00106-4; Beuning PJ, 2006, METHOD ENZYMOL, V408, P318, DOI 10.1016/S0076-6879(06)08020-7; Beuning PJ, 2006, MOL MICROBIOL, V59, P460, DOI 10.1111/j.1365-2958.2005.04959.x; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; Duzen JIM, 2004, DNA REPAIR, V3, P301, DOI 10.1016/j.dnarep.2003.11.008; Ferentz AE, 1997, NAT STRUCT BIOL, V4, P979, DOI 10.1038/nsb1297-979; Ferentz AE, 2001, EMBO J, V20, P4287, DOI 10.1093/emboj/20.15.4287; Friedberg EC, 2005, DNA REPAIR MUTAGENES; Fujii S, 2004, EMBO J, V23, P4342, DOI 10.1038/sj.emboj.7600438; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Guzzo A, 1996, J BACTERIOL, V178, P7295, DOI 10.1128/jb.178.24.7295-7303.1996; HARRIS DA, 1996, LIGHT SPECTROSCOPY; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Indiani C, 2005, MOL CELL, V19, P805, DOI 10.1016/j.molcel.2005.08.011; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kazmirski SL, 2005, P NATL ACAD SCI USA, V102, P13801, DOI 10.1073/pnas.0506430102; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KULAEVA OI, 1995, J BACTERIOL, V177, P2737, DOI 10.1128/jb.177.10.2737-2743.1995; Lee MH, 1996, J BACTERIOL, V178, P7304, DOI 10.1128/jb.178.24.7304-7307.1996; LEE MH, 1994, J BACTERIOL, V176, P4825, DOI 10.1128/jb.176.16.4825-4837.1994; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; McDonald JP, 1998, P NATL ACAD SCI USA, V95, P1478, DOI 10.1073/pnas.95.4.1478; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Opperman T, 1999, P NATL ACAD SCI USA, V96, P9218, DOI 10.1073/pnas.96.16.9218; Opperman T, 1996, J BACTERIOL, V178, P4400, DOI 10.1128/jb.178.15.4400-4411.1996; Peat TS, 1996, STRUCTURE, V4, P1401, DOI 10.1016/S0969-2126(96)00148-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Shen X, 2003, J BIOL CHEM, V278, P52546, DOI 10.1074/jbc.M310127200; Sommer S, 1998, MOL MICROBIOL, V28, P281, DOI 10.1046/j.1365-2958.1998.00803.x; Sutton MD, 1999, P NATL ACAD SCI USA, V96, P12373, DOI 10.1073/pnas.96.22.12373; Sutton MD, 2002, DNA REPAIR, V1, P77, DOI 10.1016/S1568-7864(01)00006-4; Sutton MD, 2002, P NATL ACAD SCI USA, V99, P5307, DOI 10.1073/pnas.082322099; Sutton MD, 2001, J BACTERIOL, V183, P2897, DOI 10.1128/JB.183.9.2897-2909.2001; Sutton MD, 2001, J BACTERIOL, V183, P1215, DOI 10.1128/JB.183.4.1215-1224.2001; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Wagner J, 2000, EMBO REP, V1, P484; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wijffels G, 2004, BIOCHEMISTRY-US, V43, P5661, DOI 10.1021/bi036229j; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Yang JS, 2004, P NATL ACAD SCI USA, V101, P8289, DOI 10.1073/pnas.0402625101; Zemla A, 2005, NUCLEIC ACIDS RES, V33, pW111, DOI 10.1093/nar/gki457; Zemla A, 2003, NUCLEIC ACIDS RES, V31, P3370, DOI 10.1093/nar/gkg571	50	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9633	9640		10.1074/jbc.M511101200	http://dx.doi.org/10.1074/jbc.M511101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464848	Green Submitted, hybrid			2022-12-27	WOS:000236404700075
J	Lopez-Alonso, JP; Bruix, M; Font, J; Ribo, M; Vilanova, M; Rico, M; Gotte, G; Libonati, M; Gonzalez, C; Laurents, DV				Lopez-Alonso, JP; Bruix, M; Font, J; Ribo, M; Vilanova, M; Rico, M; Gotte, G; Libonati, M; Gonzalez, C; Laurents, DV			Formation, structure, and dissociation of the ribonuclease S three-dimensional domain-swapped dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	7th International Meeting on Ribonucleases	JUN, 2005	Stara Lesna, SLOVAKIA				RNASE-A; CRYSTAL-STRUCTURE; HYDROGEN-EXCHANGE; PROTEIN; OLIGOMERIZATION; MECHANISM; RESOLUTION; PRESSURE; FIBRILS; STATE	Post-translational events, such as proteolysis, are believed to play essential roles in amyloid formation in vivo. Ribonuclease A forms oligomers by the three-dimensional domain-swapping mechanism. Here, we demonstrate the ability of ribonuclease S, a proteolytically cleaved form of ribonuclease A, to oligomerize efficiently. This unexpected capacity has been investigated to study the effect of proteolysis on oligomerization and amyloid formation. The yield of the RNase S dimer was found to be significantly higher than that of RNase A dimers, which suggests that proteolysis can activate oligomerization via the three-dimensional domain-swapping mechanism. Characterization by chromatography, enzymatic assays, and NMR spectroscopy indicate that the structure of the RNase S dimer is similar to that of the RNase A C-dimer. The RNase S dimer dissociates much more readily than the RNase A C-dimer does. By measuring the dissociation rate as a function of temperature, the activation enthalpy and entropy for RNase S dimer dissociation were found to resemble those for the release of the small fragment (S-peptide) from monomeric RNase S. Excess S-peptide strongly slows RNase S dimer dissociation. These results strongly suggest that S-peptide release is the rate-limiting step of RNase S dimer dissociation.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Girona, Fac Ciencies, Dept Biol, Lab Engn Prot, E-17071 Girona, Catalunya, Spain; Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Universitat de Girona; University of Verona	Laurents, DV (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	dlaurents@iqfr.csic.es	Ribó, Marc/M-4514-2013; López-Alonso, Jorge Pedro/U-5551-2018; Vilanova, Maria/D-9525-2011; Vilanova, Maria/ABG-5767-2020; Ribó, Marc/R-5704-2019; Bruix, Marta/H-4161-2011; Laurents, Douglas V/E-7527-2015; Sadurni, Josep Font/A-2499-2010; Gonzalez, Carlos/A-4734-2013	Ribó, Marc/0000-0001-6944-6383; López-Alonso, Jorge Pedro/0000-0003-2081-2607; Vilanova, Maria/0000-0003-0523-815X; Vilanova, Maria/0000-0003-0523-815X; Ribó, Marc/0000-0001-6944-6383; Bruix, Marta/0000-0002-0096-3558; Laurents, Douglas V/0000-0002-4187-165X; Sadurni, Josep Font/0000-0001-5284-1344; Gonzalez, Carlos/0000-0001-8796-1282; Gotte, Giovanni/0000-0003-3179-7158				BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Catanzano F, 1996, BIOCHEMISTRY-US, V35, P13378, DOI 10.1021/bi960855h; Chakshusmathi G, 1999, P NATL ACAD SCI USA, V96, P7899, DOI 10.1073/pnas.96.14.7899; COHEN JS, 1973, J BIOL CHEM, V248, P4305; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Goldberg JM, 1998, BIOCHEMISTRY-US, V37, P2556, DOI 10.1021/bi972403q; Gomez-Pinto I, 2004, J BIOL CHEM, V279, P24552, DOI 10.1074/jbc.M311751200; Gotte G, 2004, J BIOL CHEM, V279, P36670, DOI 10.1074/jbc.M404780200; Gotte G, 2003, J BIOL CHEM, V278, P10763, DOI 10.1074/jbc.M213146200; Gotte G, 2003, J BIOL CHEM, V278, P46241, DOI 10.1074/jbc.M308470200; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; Graziano G, 1996, BIOCHEMISTRY-US, V35, P13386, DOI 10.1021/bi960856+; Guo M, 2005, FEBS LETT, V579, P3574, DOI 10.1016/j.febslet.2005.05.036; Houry WA, 1996, BIOCHEMISTRY-US, V35, P11734, DOI 10.1021/bi961085c; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KUNITZ M, 1946, J BIOL CHEM, V164, P563; Libonati M, 2004, BIOCHEM J, V380, P311, DOI 10.1042/BJ20031922; Libonati M, 2001, METHOD ENZYMOL, V341, P234, DOI 10.1016/S0076-6879(01)41155-4; LIN MC, 1972, J BIOL CHEM, V247, P4768; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Nadig G, 1996, PROTEIN SCI, V5, P2104, DOI 10.1002/pro.5560051017; Nakano S, 2003, J AM CHEM SOC, V125, P8728, DOI 10.1021/ja034659r; Neira JL, 1999, J MOL BIOL, V285, P627, DOI 10.1006/jmbi.1998.2365; Nenci A, 2001, PROTEIN SCI, V10, P2017, DOI 10.1110/ps.14101; PACE CN, 1980, J BIOL CHEM, V255, P3862; Park C, 2000, PROTEIN SCI, V9, P2026, DOI 10.1110/ps.9.10.2026; Ribo M, 2001, METHOD ENZYMOL, V341, P221, DOI 10.1016/S0076-6879(01)41154-2; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Sambashivan S, 2005, NATURE, V437, P266, DOI 10.1038/nature03916; SANTORO J, 1993, J MOL BIOL, V229, P722, DOI 10.1006/jmbi.1993.1075; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; Sorrentino S, 2000, FEBS LETT, V466, P35, DOI 10.1016/S0014-5793(99)01742-1; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; Torrent J, 1999, BIOCHEMISTRY-US, V38, P15952, DOI 10.1021/bi991460b; Torrent J, 2001, PROTEIN SCI, V10, P725, DOI 10.1110/ps.43001; UNGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WYCKOFF HW, 1970, J BIOL CHEM, V245, P305	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9400	9406		10.1074/jbc.M510491200	http://dx.doi.org/10.1074/jbc.M510491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	027HB	16415350	hybrid, Green Published			2022-12-27	WOS:000236404700049
J	Maeda, Y; Hunter, TC; Loudy, DE; Dave, V; Schreiber, V; Whitsett, JA				Maeda, Y; Hunter, TC; Loudy, DE; Dave, V; Schreiber, V; Whitsett, JA			PARP-2 interacts with TTF-1 and regulates expression of surfactant protein-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; RESPIRATORY EPITHELIAL-CELLS; POLY(ADP-RIBOSE) POLYMERASE-2 PARP-2; FACTOR-KAPPA-B; GENE-EXPRESSION; NUCLEAR-FACTOR; DNA-DAMAGE; FUNCTIONAL INTERACTION; A GENE; LUNG	Thyroid transcription factor 1 (TTF-1/Nkx-2.1) plays a critical role in lung morphogenesis and regulates the expression of lung-specific genes, including the surfactant proteins required for pulmonary function after birth. The activity of TTF-1 is influenced by its interactions with other transcription factors and coactivators, including CBP/p300 and SRC-1. In this study, we have identified poly( ADP-ribose) polymerases (PARP-2 and PARP-1) as TTF-1 interacting proteins that influence its transcriptional activity. Endogenous PARP-2 was coimmunoprecipitated from transformed mouse lung epithelial cell (MLE15) extracts with TTF-1 and was identified by mass spectrometry. PARP-1 and Ku70/Ku80 were also coimmunoprecipitated from the cell extracts with TTF-1. The E domain of PARP-2 interacted via the C-terminal domain of TTF-1. Both PARP-1 and PARP-2 enhanced the activity of the promoter of surfactant protein-B (Sftpb gene) but not other surfactant proteins in vitro. PARP-2 was selectively expressed in epithelial cells of the conducting and peripheral lung tubules of the fetal mouse lung from embryonic day 12.5 and was detected in bronchial epithelial cells in the adult lung at cellular sites consistent with that of surfactant protein B. PARP-2 and PARP-1 interact with TTF-1 and regulate the expression of surfactant protein B, a protein required for lung function.	Cincinnati Childrens Hosp Med Ctr, Sect Neonatol Perinatal & Pulm Biol, Div Pulm Biol, Cincinnati, OH 45229 USA; Diversa Corp, San Diego, CA 92121 USA; Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR 7175,Lab Convent Avec,CEA, F-67412 Illkirch Graffenstaden, France	Cincinnati Children's Hospital Medical Center; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp Med Ctr, Sect Neonatol Perinatal & Pulm Biol, Div Pulm Biol, 3333 Burnet Ave,MLC 7029, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org	Dave, Vrushank/K-5262-2012; Schreiber, Valérie/M-5007-2016	Dave, Vrushank/0000-0003-4044-2658; Schreiber, Valérie/0000-0003-0507-639X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63329] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Besnard V, 2005, AM J PHYSIOL-LUNG C, V289, pL750, DOI 10.1152/ajplung.00151.2005; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; Dave V, 2004, J BIOL CHEM, V279, P34578, DOI 10.1074/jbc.M404296200; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ertsey R, 2004, AM J RESP CELL MOL, V30, P853, DOI 10.1165/rcmb.2003-0248OC; Fukazawa T, 2004, CANCER RES, V64, P363, DOI 10.1158/0008-5472.CAN-03-2507; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Glass CK, 2000, GENE DEV, V14, P121; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Haynes PA, 1998, ELECTROPHORESIS, V19, P939, DOI 10.1002/elps.1150190609; Idogawa M, 2005, GASTROENTEROLOGY, V128, P1919, DOI 10.1053/j.gastro.2005.03.007; Islam KN, 2002, MOL ENDOCRINOL, V16, P1428, DOI 10.1210/me.16.6.1428; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lebrun P, 2005, J BIOL CHEM, V280, P38203, DOI 10.1074/jbc.M504842200; Li CG, 2002, J BIOL CHEM, V277, P38399, DOI 10.1074/jbc.M203188200; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Maeda Y, 2002, MOL ENDOCRINOL, V16, P402, DOI 10.1210/me.16.2.402; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Mayeur GL, 2005, J BIOL CHEM, V280, P10827, DOI 10.1074/jbc.M413336200; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Naltner A, 2000, AM J PHYSIOL-LUNG C, V279, pL1066, DOI 10.1152/ajplung.2000.279.6.L1066; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418, DOI 10.1152/ajplung.2001.281.2.L418; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Tell G, 2002, J BIOL CHEM, V277, P14564, DOI 10.1074/jbc.M200582200; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; Whitsett JA, 1998, BBA-MOL BASIS DIS, V1408, P303, DOI 10.1016/S0925-4439(98)00076-3; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Yan C, 2002, J BIOL CHEM, V277, P10967, DOI 10.1074/jbc.M109986200; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; Yang L, 2004, BIOCHEMISTRY-US, V43, P12489, DOI 10.1021/bi049283o; Yang L, 2003, J BIOL CHEM, V278, P36841, DOI 10.1074/jbc.M304156200; Yang MCW, 2003, EUR RESPIR J, V22, P28, DOI 10.1183/09031936.03.00117702; Yang YS, 2001, AM J RESP CELL MOL, V24, P30, DOI 10.1165/ajrcmb.24.1.4050; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200	63	46	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9600	9606		10.1074/jbc.M510435200	http://dx.doi.org/10.1074/jbc.M510435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461352	hybrid			2022-12-27	WOS:000236404700071
J	Myers, JS; Cortez, D				Myers, JS; Cortez, D			Rapid activation of ATR by ionizing radiation requires ATM and Mre11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DAMAGE-INDUCED PHOSPHORYLATION; DOUBLE-STRAND BREAKS; DNA-DAMAGE; BINDING; COMPLEX; KINASE; CHK1; RECOGNITION; HELICASE	The ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases are crucial regulatory proteins in genotoxic stress response pathways that pause the cell cycle to permit DNA repair. Here we show that Chk1 phosphorylation in response to hydroxyurea and ultraviolet radiation is ATR-dependent and ATM- and Mre11-independent. In contrast, Chk1 phosphorylation in response to ionizing radiation (IR) is dependent on ATR, ATM, and Mre11. The ATR and ATM/Mre11 pathways are generally thought to be separate with ATM activation occurring early and ATR activation occurring as a late response to double strand breaks. However, we demonstrate that ATR is activated rapidly by IR, and ATM and Mre11 enhance ATR signaling. ATR-ATR-interacting protein recruitment to double strand breaks is less efficient in the absence of ATM and Mre11. Furthermore, IR-induced replication protein A foci formation is defective in ATM- and Mre11-deficient cells. Thus, ATM and Mre11 may stimulate the ATR signaling pathway by converting DNA damage generated by IR into structures that recruit and activate ATR.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Cortez, D (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.	david.cortez@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA102729, K01CA093701, T32CA009582, T32CA093240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA093240, R01CA102729, T32CA093240, K01 CA093701, R01 CA102729, T32CA009582, T32 CA009582] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Block WD, 2004, NUCLEIC ACIDS RES, V32, P997, DOI 10.1093/nar/gkh265; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; CANMAN CE, 1994, CANCER RES, V54, P5054; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 2005, GENE DEV, V19, P1007, DOI 10.1101/gad.1316905; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kim SM, 2005, J BIOL CHEM, V280, P38355, DOI 10.1074/jbc.M508673200; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wang HY, 2001, CANCER RES, V61, P8554; Wang Y, 2000, GENE DEV, V14, P927; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhong H, 2005, HUM MOL GENET, V14, P2685, DOI 10.1093/hmg/ddi302; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	38	236	243	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9346	9350		10.1074/jbc.M513265200	http://dx.doi.org/10.1074/jbc.M513265200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431910	hybrid, Green Accepted			2022-12-27	WOS:000236404700043
J	Tong, Q; Zhang, WY; Conrad, K; Mostoller, K; Cheung, JY; Peterson, BZ; Miller, BA				Tong, Q; Zhang, WY; Conrad, K; Mostoller, K; Cheung, JY; Peterson, BZ; Miller, BA			Regulation of the transient receptor potential channel TRPM2 by the Ca2(+) sensor calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ADP-RIBOSE; HYDROGEN-PEROXIDE; CA2+ CHANNELS; CALCIUM INFLUX; CELL-DEATH; CA2+-DEPENDENT INACTIVATION; TARGET RECOGNITION; OXIDATIVE STRESS; CATION CHANNELS	TRPM2, a member of the transient receptor potential (TRP) superfamily, is a Ca2+-permeable channel activated by oxidative stress or tumor necrosis factor alpha involved in susceptibility to cell death. TRPM2 activation is dependent on the level of intracellular Ca2+. We explored whether calmodulin (CaM) is the Ca2+ sensor for TRPM2. HEK 293T cells were transfected with TRPM2 and wild type CaM or mutant CaM (CaMMUT) with substitutions of all four EF hands. Treatment of cells expressing TRPM2 with H2O2 or tumor necrosis factor alpha resulted in a significant increase in intracellular calcium ([ Ca2+](i)). This was not affected by coexpression of CaM, suggesting that endogenous CaM levels are sufficient for maximal response. Cotransfection of CaMMUT with TRPM2 dramatically inhibited the increase in [Ca2+](i), demonstrating the requirement for CaM in TRPM2 activation. Immunoprecipitation confirmed direct interaction of CaM and CaMMUT with TRPM2, and the Ca2+ dependence of this association. CaM bound strongly to the TRPM2 N terminus (amino acids 1-730), but weakly to the C terminus (amino acids 1060-1503). CaM binding to an IQ-like motif (amino acids 406-416) in the TRPM2 N terminus was demonstrated utilizing gel shift, immunoprecipitation, biotinylated CaM overlay, and pull-down assays. A substitution mutant of the IQ-like motif of TRPM2 (TRPM2-IQ(MUT1)) reduced but did not eliminate CaM binding to TRPM2, suggesting the presence of at least one other CaM binding site. The functional importance of the TRPM2 IQ-like motif was demonstrated by treatment of TRPM2-IQ(MUT1)-expressing cells with H2O2. The increase in [Ca2+](i) observed with wild type TRPM2 was absent and cell viability was preserved. These data demonstrate the requirement for CaM in TRPM2 activation. They suggest that Ca2+ entering through TRPM2 enhances interaction of CaM with TRPM2 at the IQ-like motif in the N terminus, providing crucial positive feedback for channel activation.	Penn State Univ, Coll Med, Dept Pediat, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Miller, BA (corresponding author), Penn State Univ, Coll Med, Dept Pediat, Hershey, PA 17033 USA.	bmiller3@psu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074854, R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL74854, R01 HL58672] Funding Source: Medline; NIDDK NIH HHS [R01 DK46778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; Chu X, 2004, J BIOL CHEM, V279, P10514, DOI 10.1074/jbc.M308478200; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Duncan LM, 1998, CANCER RES, V58, P1515; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; Lambers TT, 2004, J BIOL CHEM, V279, P28855, DOI 10.1074/jbc.M313637200; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Mouton J, 2001, J BIOL CHEM, V276, P22359, DOI 10.1074/jbc.M100755200; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Prawitt D, 2000, HUM MOL GENET, V9, P203, DOI 10.1093/hmg/9.2.203; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tsavaler L, 2001, CANCER RES, V61, P3760; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Wu YM, 1997, AM J PHYSIOL-HEART C, V273, pH2161, DOI 10.1152/ajpheart.1997.273.5.H2161; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200; ZHANG W, 2006, IN PRESS AM J PHYSL; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200	51	95	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9076	9085		10.1074/jbc.M510422200	http://dx.doi.org/10.1074/jbc.M510422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461353	hybrid			2022-12-27	WOS:000236404700012
J	Westerheide, SD; Kawahara, TLA; Orton, K; Morimoto, RI				Westerheide, SD; Kawahara, TLA; Orton, K; Morimoto, RI			Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; PROTEIN INDUCTION; INDUCED APOPTOSIS; CARCINOMA CELLS; FACTOR-I; ACTIVATION; THERMOTOLERANCE	Molecular chaperones, inducible by heat shock and a variety of other stresses, have critical roles in protein homeostasis, balancing cell stress with adaptation, survival, and cell death mechanisms. In transformed cells and tumors, chaperones are frequently overexpressed, with constitutive activation of the heat shock transcription factor HSF1 implicated in tumor formation. Here, we describe the activity of triptolide, a diterpene triepoxide from the plant Triptergium wilfordii, as an inhibitor of the human heat shock response. Triptolide treatment of human tissue culture cells prevented the inducible expression of heat shock genes, shown by suppression of an HSP70 promoter-reporter construct and by suppression of endogenous HSP70 gene expression. Upon examining the steps in the HSF1 activation pathway, we found that triptolide abrogates the transactivation function of HSF1 without interfering in the early events of trimer formation, hyperphosphorylation, and DNA binding. The ability of triptolide to inhibit the heat shock response renders these cells sensitive to stress-induced cell death, which may be of great relevance to cancer treatments.	Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Morimoto, RI (corresponding author), Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	r-morimoto@northwestern.edu	Longo, Kenneth A/A-5631-2010		NCI NIH HHS [T32 CA70085] Funding Source: Medline; NIGMS NIH HHS [R37 GM038109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Elia G, 1996, J BIOL CHEM, V271, P16111, DOI 10.1074/jbc.271.27.16111; Elia G, 1996, CANCER RES, V56, P210; Hansen RK, 1997, BIOCHEM BIOPH RES CO, V239, P851, DOI 10.1006/bbrc.1997.7572; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; HOSOKAWA N, 1992, MOL CELL BIOL, V12, P3490, DOI 10.1128/MCB.12.8.3490; HOSOKAWA N, 1990, CELL STRUCT FUNCT, V15, P393, DOI 10.1247/csf.15.393; Jiang XH, 2001, ONCOGENE, V20, P8009, DOI 10.1038/sj.onc.1204981; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Mason PB, 1997, J BIOL CHEM, V272, P33227, DOI 10.1074/jbc.272.52.33227; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SOLOMON JM, 1991, NEW BIOL, V3, P1106; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Wissing D, 1996, INT J HYPERTHER, V12, P125, DOI 10.3109/02656739609023695; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; Yokota S, 2000, CANCER RES, V60, P2942	41	188	205	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9616	9622		10.1074/jbc.M512044200	http://dx.doi.org/10.1074/jbc.M512044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469748	hybrid			2022-12-27	WOS:000236404700073
J	Forment, JV; Flipphi, M; Ramon, D; Ventura, L; MacCabe, AP				Forment, JV; Flipphi, M; Ramon, D; Ventura, L; MacCabe, AP			Identification of the mstE gene encoding a glucose-inducible, low affinity glucose transporter in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; EXOFACIAL LIGAND-BINDING; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; SUGAR-TRANSPORT; HEXOSE TRANSPORTER; MOLECULAR-GENETICS; PROTEIN; EXPRESSION; GLUT1	The mstE gene encoding a low affinity glucose transporter active during the germination of Aspergillus nidulans conidia on glucose medium has been identified. mstE expression also occurs in hyphae, is induced in the presence of other repressing carbon sources besides glucose, and is dependent on the function of the transcriptional repressor CreA. The expression of MstE and its subcellular distribution have been studied using a MstE- sGFP fusion protein. Concordant with data on mstE expression, MstE- sGFP is synthesized in the presence of repressing carbon sources, and fluorescence at the periphery of conidia and hyphae is consistent with MstE location in the plasma membrane. Deletion of mstE has no morphological phenotype but results in the absence of low affinity glucose uptake kinetics, the latter being substituted by a high affinity system.	Consejo Super Invest Cient, Inst Agroquim & Tecnol Alimentos, Valencia 46100, Spain; Univ Valencia, Fac Farm, Dept Med Prevent & Salud Publ Bromatol Toxicol &, Valencia 46100, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); University of Valencia	MacCabe, AP (corresponding author), Consejo Super Invest Cient, Inst Agroquim & Tecnol Alimentos, Apartado Correos 73, Valencia 46100, Spain.	andrew@iata.csic.es	Forment, Josep/J-3678-2015; MacCabe, Andrew P/H-4522-2012	Forment, Josep/0000-0002-7797-2583; MacCabe, Andrew P/0000-0003-4918-7761				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARST HN, 1973, MOL GEN GENET, V126, P111, DOI 10.1007/BF00330988; ARST HN, 1990, MOL MICROBIOL, V4, P851, DOI 10.1111/j.1365-2958.1990.tb00656.x; Attwood TK, 2003, NUCLEIC ACIDS RES, V31, P400, DOI 10.1093/nar/gkg030; BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; Black M., 1990, PHYSL BIOCH PLANT CE, P4; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Boles E, 2002, TRANSMEMBRANE TRANSP, P19; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; de Vries RP, 2001, MICROBIOL MOL BIOL R, V65, P497, DOI 10.1128/MMBR.65.4.497-522.2001; Delgado-Jarana J, 2003, EUKARYOT CELL, V2, P708, DOI 10.1128/EC.2.4.708-717.2003; dEnfert C, 1997, FUNGAL GENET BIOL, V21, P163, DOI 10.1006/fgbi.1997.0975; Fischer-Parton S, 2000, J MICROSC-OXFORD, V198, P246, DOI 10.1046/j.1365-2818.2000.00708.x; Flipphi M, 2004, MYCOTA, V3, P403; Flipphi M, 2003, J BIOL CHEM, V278, P11849, DOI 10.1074/jbc.M209443200; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOFFRINI P, 1990, NUCLEIC ACIDS RES, V18, P5294, DOI 10.1093/nar/18.17.5294; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; Heiland S, 2000, J BACTERIOL, V182, P2153, DOI 10.1128/JB.182.8.2153-2162.2000; Karos M, 1999, MOL GEN GENET, V260, P510, DOI 10.1007/s004380050924; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kelly JM, 2004, MYCOTA, V3, P385; KO CH, 1993, MOL CELL BIOL, V13, P638, DOI 10.1128/MCB.13.1.638; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kurtov D, 1999, MOL GEN GENET, V262, P115, DOI 10.1007/s004380051065; LAGUNAS R, 1993, FEMS MICROBIOL LETT, V104, P229, DOI 10.1016/0378-1097(93)90598-V; Lee WJ, 2002, APPL MICROBIOL BIOT, V60, P186, DOI 10.1007/s00253-002-1085-6; MacCabe AP, 2003, MICROBIOL-SGM, V149, P2129, DOI 10.1099/mic.0.26349-0; Madi L, 1997, GENETICS, V146, P499; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARK CG, 1971, BIOCHIM BIOPHYS ACTA, V249, P216, DOI 10.1016/0005-2736(71)90098-8; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Nehls U, 1998, MOL PLANT MICROBE IN, V11, P167, DOI 10.1094/MPMI.1998.11.3.167; NEIGEBORN L, 1984, GENETICS, V108, P845; NELISSEN B, 1997, FEMS MICROBIOL REV, V21, P114; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PUNT PJ, 1988, GENE, V69, P49, DOI 10.1016/0378-1119(88)90377-0; Sambrook J., 2001, MOL CLONING LAB MANU; SCARBOROUGH GA, 1970, J BIOL CHEM, V245, P3985; SCARBOROUGH GA, 1970, J BIOL CHEM, V245, P1694; SCHNEIDER RP, 1971, J BACTERIOL, V106, P487, DOI 10.1128/JB.106.2.487-492.1971; SPECHT CA, 1982, ANAL BIOCHEM, V119, P158, DOI 10.1016/0003-2697(82)90680-7; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; Toews MW, 2004, CURR GENET, V45, P383, DOI 10.1007/s00294-004-0495-7; Valdez-Taubas J, 2004, FUNGAL GENET BIOL, V41, P42, DOI 10.1016/j.fgb.2003.09.003; vanKuyk PA, 2004, BIOCHEM J, V379, P375, DOI 10.1042/BJ20030624; Voegele RT, 2001, P NATL ACAD SCI USA, V98, P8133, DOI 10.1073/pnas.131186798; Wei HJ, 2004, FUNGAL GENET BIOL, V41, P148, DOI 10.1016/j.fgb.2003.10.006; WEUSTHUIS RA, 1994, MICROBIOL REV, V58, P616, DOI 10.1128/MMBR.58.4.616-630.1994; Wieczorke R, 1999, FEBS LETT, V464, P123, DOI 10.1016/S0014-5793(99)01698-1	55	35	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8339	8346		10.1074/jbc.M508198200	http://dx.doi.org/10.1074/jbc.M508198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16418173	hybrid			2022-12-27	WOS:000236247100007
J	Kasri, NN; Torok, K; Galione, A; Garnham, C; Callewaert, G; Missiaen, L; Parys, JB; De Smedt, H				Kasri, NN; Torok, K; Galione, A; Garnham, C; Callewaert, G; Missiaen, L; Parys, JB; De Smedt, H			Endogenously bound calmodulin is essential for the function of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS CA2+ SPARKS; FROG SKELETAL-MUSCLE; BINDING DOMAIN; TRISPHOSPHATE RECEPTORS; CALCIUM-RELEASE; CA2+-INDEPENDENT INHIBITION; ENDOPLASMIC-RETICULUM; LIGAND-BINDING; CHANNELS; CELLS	Calmodulin ( CaM) is a ubiquitous Ca2+ sensor protein that plays an important role in regulating a large number of Ca2+ channels, including the inositol 1,4,5- trisphosphate receptor ( IP3R). Despite many efforts, the exact mechanism by which CaM regulates the IP3R still remains elusive. Here we show, using unidirectional Ca-45(2+) flux experiments on permeabilized L15 fibroblasts and COS- 1 cells, that endogenously bound CaM is essential for the proper activation of the IP3R. Removing endogenously bound CaM by titration with a high affinity ( pM) CaM- binding peptide derived from smooth muscle myosin light- chain kinase ( MLCK peptide) strongly inhibited IP3- induced Ca2+ release. This inhibition was concentration- and time- dependent. Removing endogenously bound CaM affected the maximum release capacity but not its sensitivity to IP3. A mutant peptide with a strongly reduced affinity for CaM did not affect inhibited IP3- induced Ca2+ release. Furthermore, the inhibition by the MLCK peptide was fully reversible. Re- adding exogenous CaM, but not CaM1234, reactivated the IP3R. These data suggest that, by using a specific CaM- binding peptide, we removed endogenously bound CaM from a high affinity CaM- binding site on the IP3R, and this resulted in a complete loss of the IP3R activity. Our data support a new model whereby CaM is constitutively associated with the IP3R and functions as an essential subunit for proper functioning of the IP3R.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; St Georges Univ London, Dept Basic Med Sci, London SW17 0RE, England	KU Leuven; University of Oxford; St Georges University London	De Smedt, H (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,O-N Herestr 49-802, B-3000 Louvain, Belgium.	humbert.desmedt@med.kuleuven.be	Nadif Kasri, Nael/E-2270-2012; Galione, Antony/E-5884-2011	Nadif Kasri, Nael/0000-0002-7448-9289; Galione, Antony/0000-0002-4132-7646; Torok, Katalin/0000-0002-3107-4534; Parys, Jan/0000-0002-3591-4967				Adkins CE, 2000, BIOCHEM J, V345, P357, DOI 10.1042/0264-6021:3450357; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bezprozvanny I, 2005, CELL CALCIUM, V38, P261, DOI 10.1016/j.ceca.2005.06.030; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Haynes LP, 2004, J BIOL CHEM, V279, P547, DOI 10.1074/jbc.M309617200; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jan CR, 2000, J PHARMACOL EXP THER, V292, P358; Kasri NN, 2004, BIOL RES, V37, P577; Kasri NN, 2004, MOL PHARMACOL, V66, P276, DOI 10.1124/mol.66.2.276; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Kasri NN, 2002, BBA-PROTEINS PROTEOM, V1600, P19; Khan SZ, 2001, CELL SIGNAL, V13, P57, DOI 10.1016/S0898-6568(00)00140-6; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; Mak DOD, 2003, J GEN PHYSIOL, V122, P583, DOI 10.1085/jgp.200308809; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 2000, MOL PHARMACOL, V57, P564, DOI 10.1124/mol.57.3.564; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Rodney GG, 2005, J BIOL CHEM, V280, P11713, DOI 10.1074/jbc.M408189200; Rodney GG, 2003, BIOPHYS J, V85, P921, DOI 10.1016/S0006-3495(03)74531-7; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Schlatterer C, 1996, BIOCHEM J, V313, P661, DOI 10.1042/bj3130661; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Smyth JT, 2002, J BIOL CHEM, V277, P35061, DOI 10.1074/jbc.M202928200; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Taylor CW, 2004, TRENDS BIOCHEM SCI, V29, P210, DOI 10.1016/j.tibs.2004.02.010; Torok K, 1998, BIOCHEMISTRY-US, V37, P6188, DOI 10.1021/bi972773e; Varnai P, 2005, P NATL ACAD SCI USA, V102, P7859, DOI 10.1073/pnas.0407535102; WOLF BA, 1986, BIOCHEM BIOPH RES CO, V141, P418, DOI 10.1016/S0006-291X(86)80189-9; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299	42	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8332	8338		10.1074/jbc.M510971200	http://dx.doi.org/10.1074/jbc.M510971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16410249	hybrid			2022-12-27	WOS:000236247100006
J	Stamatovic, SM; Dimitrijevic, OB; Keep, RF; Andjelkovic, AV				Stamatovic, SM; Dimitrijevic, OB; Keep, RF; Andjelkovic, AV			Protein kinase C alpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION PROTEINS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; VASCULAR-PERMEABILITY; BARRIER FUNCTION; INFLAMMATORY MEDIATORS; CELL JUNCTIONS; PHOSPHORYLATION; ACTIVATION; OCCLUDIN; MODULATION	Monocyte chemoattractant protein- 1 ( MCP- 1 or CCL2) regulates blood- brain barrier permeability by inducing morphological and biochemical alterations in the tight junction ( TJ) complex between brain endothelial cells. The present study used cultured brain endothelial cells to examine the signaling networks involved in the redistribution of TJ proteins ( occludin, ZO- 1, ZO- 2, claudin-5) by CCL2. The CCL2- induced alterations in the brain endothelial barrier were associated with de novo Ser/ Thr phosphorylation of occludin, ZO- 1, ZO- 2, and claudin- 5. The phosphorylated TJ proteins were redistributed/ localized in Triton X- 100- soluble as well as Triton X- 100- insoluble cell fractions. Two protein kinase C ( PKC) isoforms, PKC alpha and PKC zeta, had a significant impact on this event. Inhibition of their activity using dominant negative mutants PKC alpha- DN and PKC zeta- DN diminished CCL2 effects on brain endothelial permeability. Previous data indicate that Rho/ Rho kinase signaling is involved in CCL2 regulation of brain endothelial permeability. The interactions between the PKC and Rho/ Rho kinase pathways were therefore examined. Rho, PKC alpha, and PKC zeta activities were knocked down using dominant negative mutants ( T17Rho, PKC alpha- DN, and PKC zeta- DN, respectively). PKC alpha and Rho, but not PKC zeta and Rho, interacted at the level of Rho, with PKC alpha being a downstream target for Rho. Double transfection experiments using dominant negative mutants confirmed that this interaction is critical for CCL2- induced redistribution of TJ proteins. Collectively these data suggest for the first time that CCL2 induces brain endothelial hyperpermeability via Rho/ PKC alpha signal pathway interactions.	Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Andjelkovic, AV (corresponding author), Univ Michigan, Sch Med, Dept Neurosurg, R5550 Kresge I, Ann Arbor, MI 48109 USA.	anuskaa@umich.edu		Keep, Richard/0000-0001-6441-5334	NINDS NIH HHS [NS044907] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044907] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Adamson RH, 2002, J PHYSIOL-LONDON, V539, P295, DOI 10.1113/jphysiol.2001.013117; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Avila-Flores A, 2001, BIOCHEM J, V360, P295, DOI 10.1042/0264-6021:3600295; Banisor I, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-7; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Chen ML, 2002, J BIOL CHEM, V277, P4247, DOI 10.1074/jbc.M109254200; Cipolla MJ, 2004, FRONT BIOSCI-LANDMRK, V9, P777, DOI 10.2741/1282; Clarke H, 2000, J CELL SCI, V113, P3187; Clarke H, 2000, ADV DRUG DELIVER REV, V41, P283, DOI 10.1016/S0169-409X(00)00047-8; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; De Groot C J, 2001, Prog Brain Res, V132, P533; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Desai TR, 2002, J SURG RES, V104, P118, DOI 10.1006/jsre.2002.6415; Farshori P, 1999, J MEMBRANE BIOL, V170, P147, DOI 10.1007/s002329900544; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; Flex A, 2004, STROKE, V35, P2270, DOI 10.1161/01.STR.0000140740.19421.fe; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gloor SM, 2001, BRAIN RES REV, V36, P258, DOI 10.1016/S0165-0173(01)00102-3; Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499; Gura T, 1996, SCIENCE, V272, P954, DOI 10.1126/science.272.5264.954; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Hirakawa M, 2004, J PHYSIOL-LONDON, V558, P479, DOI 10.1113/jphysiol.2004.065334; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; Hu LM, 2005, CLIN CANCER RES, V11, P8208, DOI 10.1158/1078-0432.CCR-05-0206; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; Kazakoff PW, 1995, IN VITRO CELL DEV-AN, V31, P846; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mucha DR, 2003, AM J PHYSIOL-HEART C, V284, pH994, DOI 10.1152/ajpheart.00862.2002; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Pellegrino M, 2004, J BIOL CHEM, V279, P6526, DOI 10.1074/jbc.M309705200; Ransohoff RM, 2002, J INFECT DIS, V186, pS152, DOI 10.1086/344266; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ross D, 1997, ENDOTHELIUM-NEW YORK, V5, P321, DOI 10.3109/10623329709052596; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Schmitz HP, 2002, MOL MICROBIOL, V44, P829, DOI 10.1046/j.1365-2958.2002.02925.x; Slater SJ, 2001, BIOCHEMISTRY-US, V40, P4437, DOI 10.1021/bi001654n; Stamatovic SM, 2003, J CELL SCI, V116, P4615, DOI 10.1242/jcs.00755; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193; van Hinsbergh VWM, 2002, J ANAT, V200, P549, DOI 10.1046/j.1469-7580.2002.00060.x; Wang YH, 2004, J CELL PHYSIOL, V198, P53, DOI 10.1002/jcp.10386; Ward PD, 2002, J BIOL CHEM, V277, P35760, DOI 10.1074/jbc.M203134200; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7; Zeng LX, 2005, FASEB J, V19, P1845, DOI 10.1096/fj.05-4240fje	60	147	155	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8379	8388		10.1074/jbc.M513122200	http://dx.doi.org/10.1074/jbc.M513122200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16439355	hybrid			2022-12-27	WOS:000236247100012
J	Thilo, C; Berglund, P; Applequist, SE; Yewdell, JW; Ljunggren, HG; Achour, A				Thilo, C; Berglund, P; Applequist, SE; Yewdell, JW; Ljunggren, HG; Achour, A			Dissection of the interaction of the human cytomegalovirus-derived US2 protein with major histocompatibility complex class I molecules - Prominent role of a single arginine residue in human leukocyte antigen-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCTS US2; T-CELL-RECEPTOR; HLA CLASS-I; CRYSTAL-STRUCTURE; HOT-SPOTS; 3-DIMENSIONAL STRUCTURE; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; PEPTIDE COMPLEX; HEAVY-CHAINS	Human cytomegalovirus encodes several proteins that interfere with expression of major histocompatibility complex (MHC) class I molecules on the surface of infected cells. The unique short protein 2 (US2) binds to many MHC class I allomorphs in the endoplasmic reticulum, preventing cell surface expression of the class I molecule in question. The molecular interactions underlying US2 binding to MHC class I molecules and its allele specificity have not been fully clarified. In the present study, we first compared the sequences and the structures of US2 retained versus non-retained human leukocyte antigen (HLA) class I allomorphs to identify MHC residues of potential importance for US2 binding. On the basis of this analysis, 18 individual HLA-A2 mutants were generated and the ability of full-length US2 to bind wild-type and mutated HLA-A2 complexes was assessed. We demonstrate that Arg(181) plays a critical role in US2-mediated inhibition of HLA-A2 cell surface expression. The structural comparison of all known crystal structures of HLA-A2 either alone, or in complex with T cell receptor or the CD8 coreceptor, indicates that binding of US2 to HLA-A2 results in a unique, large conformational change of the side chain of Arg(181). However, although the presence of Arg(181) seems to be a prerequisite for US2 binding to HLA-A2, it is not sufficient for binding to all MHC class I alleles.	Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Stockholm, Sweden; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	Karolinska Institutet; Karolinska University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Achour, A (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Stockholm, Sweden.	adnane.achour@medhs.ki.se	yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Wagner, Claudia/0000-0002-7311-2236; Achour, Adnane/0000-0003-0432-710X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000814, ZIAAI000814] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Arieh SVB, 2003, BLOOD, V101, P2858, DOI 10.1182/blood-2002-07-2158; Barel MT, 2006, MOL IMMUNOL, V43, P1258, DOI 10.1016/j.molimm.2005.07.005; Barel MT, 2003, J IMMUNOL, V171, P6757, DOI 10.4049/jimmunol.171.12.6757; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Basta S, 2002, J IMMUNOL, V168, P5403, DOI 10.4049/jimmunol.168.11.5403; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Chevalier MS, 2002, J VIROL, V76, P8265, DOI 10.1128/JVI.76.16.8265-8275.2002; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; Fan QR, 1999, J EXP MED, V190, P113, DOI 10.1084/jem.190.1.113; Fan QR, 2001, NAT IMMUNOL, V2, P452, DOI 10.1038/87766; Furman MH, 2003, J BIOL CHEM, V278, P34804, DOI 10.1074/jbc.M300913200; Furman MH, 2002, J VIROL, V76, P11753, DOI 10.1128/JVI.76.22.11753-11756.2002; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; Gewurz BE, 2001, CURR OPIN IMMUNOL, V13, P442, DOI 10.1016/S0952-7915(00)00239-9; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Gewurz BE, 2001, J VIROL, V75, P5197, DOI 10.1128/JVI.75.11.5197-5204.2001; Guerra S, 2003, J VIROL, V77, P6493, DOI 10.1128/JVI.77.11.6493-6506.2003; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; Hebert AM, 2001, BIOCHEMISTRY-US, V40, P5233, DOI 10.1021/bi002392s; Hegde NR, 2003, J VIROL, V77, P9287, DOI 10.1128/JVI.77.17.9287-9294.2003; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; Hulsmeyer M, 2004, J EXP MED, V199, P271, DOI 10.1084/jem.20031690; Hulsmeyer M, 2002, J BIOL CHEM, V277, P47844, DOI 10.1074/jbc.M206392200; Jones TR, 1997, J VIROL, V71, P2970, DOI 10.1128/JVI.71.4.2970-2979.1997; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; KAVATHAS P, 1983, P NATL ACAD SCI-BIOL, V80, P524, DOI 10.1073/pnas.80.2.524; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kirksey TJ, 1999, J BIOL CHEM, V274, P37259, DOI 10.1074/jbc.274.52.37259; Kjer-Nielsen L, 2002, J IMMUNOL, V169, P5153, DOI 10.4049/jimmunol.169.9.5153; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; Landolfo S, 2003, PHARMACOL THERAPEUT, V98, P269, DOI 10.1016/S0163-7258(03)00034-2; Li X, 2004, J MOL BIOL, V344, P781, DOI 10.1016/j.jmb.2004.09.051; Llano M, 2003, EUR J IMMUNOL, V33, P2744, DOI 10.1002/eji.200324182; Lopez-Botet M, 2004, TISSUE ANTIGENS, V63, P195, DOI 10.1111/j.1399-0039.2004.00210.x; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Mocarski ES, 2004, CELL MICROBIOL, V6, P707, DOI 10.1111/j.1462-5822.2004.00425.x; POLAKOVA K, 1993, MOL IMMUNOL, V30, P1223, DOI 10.1016/0161-5890(93)90037-C; Rehm A, 2002, J VIROL, V76, P5043, DOI 10.1128/JVI.76.10.5043-5050.2002; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Schust DJ, 1998, J EXP MED, V188, P497, DOI 10.1084/jem.188.3.497; Sharma AK, 2001, J BIOL CHEM, V276, P21443, DOI 10.1074/jbc.M010791200; Sliz P, 2001, J IMMUNOL, V167, P3276, DOI 10.4049/jimmunol.167.6.3276; Tomazin R, 1999, NAT MED, V5, P1039, DOI 10.1038/12478; Webb AI, 2004, J BIOL CHEM, V279, P23438, DOI 10.1074/jbc.M314066200; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961; Zhao R, 1999, J EXP MED, V189, P359, DOI 10.1084/jem.189.2.359	64	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8950	8957		10.1074/jbc.M507121200	http://dx.doi.org/10.1074/jbc.M507121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452487	hybrid			2022-12-27	WOS:000236247100075
J	Chang, KJ; Lin, G; Men, LC; Wang, CC				Chang, KJ; Lin, G; Men, LC; Wang, CC			Redundancy of non-AUG initiators - A clever mechanism to enhance the efficiency of translation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; MITOCHONDRIAL; CODON; PROTEIN; SELECTION; THALIANA; FEATURES; REGION	It was recently shown that ALA1, the only alanyl-tRNA synthetase gene in Saccharomyces cerevisiae, uses two successive ACG triplets as the translation initiators for its mitochondrial form. Evidence presented here argues that the second ACG triplet not only acts as a remedial initiation site for scanning ribosomes that skip the first ACG, but also enhances the activity of the preceding initiator by providing a preferable "A" at its relative position +4. Therefore, ALA1 constructs with redundant ACG initiators exhibit stronger complementing activity and express a higher level of protein than do those with a single ACG initiator. A similar scenario is seen when a single or redundant ACG triplets are placed in the positions of the first and second AUG initiators of VAS1, which serve as the start sites of the mitochondrial and cytoplasmic forms of valyl-tRNA synthetase, respectively. Cumulatively, the results suggest that this feature of redundancy of non-AUG initiators in a single mRNA per se may represent a novel paradigm for improving the efficiency of a poor or otherwise nonproductive initiation event.	Natl Cent Univ, Dept Life Sci, Jungli 32001, Taiwan; ROCAEC, Inst Nucl Energy Res, Taoyuan 32546, Taiwan	National Central University; Institute of Nuclear Energy Research - Taiwan	Wang, CC (corresponding author), Natl Cent Univ, Dept Life Sci, Jungli 32001, Taiwan.	dukewang@cc.ncu.edu.tw	Chang, Kuang-Jung/J-2193-2012					Abramczyk D, 2003, YEAST, V20, P1045, DOI 10.1002/yea.1020; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; CHATTON B, 1988, J BIOL CHEM, V263, P52; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; CLEMENTS JM, 1988, MOL CELL BIOL, V8, P4533, DOI 10.1128/MCB.8.10.4533; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MARECHALDROUARD L, 1993, ANN REV CELL BIOL, V8, P115; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Nett JH, 2001, EUR J BIOCHEM, V268, P5209, DOI 10.1046/j.0014-2956.2001.02454.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pelchat M, 1999, BIOCHEM CELL BIOL, V77, P343, DOI 10.1139/bcb-77-4-343; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SHERMAN F, 1980, CELL, V20, P215, DOI 10.1016/0092-8674(80)90249-4; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; Tang HL, 2004, J BIOL CHEM, V279, P49656, DOI 10.1074/jbc.M408081200; Turner RJ, 2000, J BIOL CHEM, V275, P27681; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Wang CC, 2003, BIOCHEMISTRY-US, V42, P1646, DOI 10.1021/bi025964c; WOLFE CL, 1994, J BIOL CHEM, V269, P13361; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x	35	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7775	7783		10.1074/jbc.M511265200	http://dx.doi.org/10.1074/jbc.M511265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431919	hybrid			2022-12-27	WOS:000236031000010
J	Fernandez-Saiz, V; Moro, F; Arizmendi, JM; Acebron, SP; Muga, A				Fernandez-Saiz, V; Moro, F; Arizmendi, JM; Acebron, SP; Muga, A			Ionic contacts at DnaK substrate binding domain involved in the allosteric regulation of lid dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE DNAK; PEPTIDE-BINDING; INTERDOMAIN COMMUNICATION; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; PROTEIN; ATPASE; HSP70; GRPE; COMPLEX	To gain further insight into the interactions involved in the allosteric transition of DnaK we have characterized wild-type (wt) protein and three mutants in which ionic interactions at the interface between the two subdomains of the substrate binding domain, and within the lid subdomain have been disrupted. Our data show that ionic contacts, most likely forming an electrically charged network, between the N-terminal region of helix B and an inner loop of the beta-sandwich are involved in maintaining the position of the lid relative to the beta-subdomain in the ADP state but not in the ATP state of the protein. Disruption of the ionic interactions between the C-terminal region of helix B and the outer loops of the beta-sandwich, known as the latch, does not have the same conformational consequences but results equally in an inactive protein. This indicates that a variety of mechanisms can inactivate this complex allosteric machine. Our results identify the ionic contacts at the subdomain and interdomain interfaces that are part of the hinge region involved in the ATP-induced allosteric displacement of the lid away from the peptide binding site. These interactions also stabilize peptide-Hsp70 complexes at physiological (37 degrees C) and stress (42 degrees C) temperatures, a requirement for productive substrate (re) folding.	Univ Basque Country, Euskal Herriko Unibertsitatea, Consejo Super Invest Cient, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Fac Ciencias, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Muga, A (corresponding author), Univ Basque Country, Euskal Herriko Unibertsitatea, Consejo Super Invest Cient, Unidad Biofis, Aptdo 644, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Fernandez, Vanesa/ABD-6688-2021; Muga, Arturo/N-1174-2014; Moro Pérez, Fernando/P-3891-2015	Muga, Arturo/0000-0003-0345-6882; Moro Pérez, Fernando/0000-0002-3568-3388; Arizmendi, Jesus M/0000-0002-1412-4042; Fernandez-Saiz, Vanesa/0000-0002-7139-8680				Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Buczynski G, 2001, J BIOL CHEM, V276, P27231, DOI 10.1074/jbc.M100237200; Chang TC, 2001, ARCH BIOCHEM BIOPHYS, V386, P30, DOI 10.1006/abbi.2000.2176; Cupp-Vickery JR, 2004, J MOL BIOL, V342, P1265, DOI 10.1016/j.jmb.2004.07.025; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Ha JH, 1997, J BIOL CHEM, V272, P27796, DOI 10.1074/jbc.272.44.27796; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hu SM, 2002, ARCH BIOCHEM BIOPHYS, V407, P135, DOI 10.1016/S0003-9861(02)00515-5; Jiang JW, 2005, MOL CELL, V20, P513, DOI 10.1016/j.molcel.2005.09.028; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; Larsen MR, 2002, PROTEOMICS, V2, P1277, DOI 10.1002/1615-9861(200209)2:9<1277::AID-PROT1277>3.0.CO;2-P; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Mehl AF, 2001, BIOCHEM BIOPH RES CO, V282, P562, DOI 10.1006/bbrc.2001.4567; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Moro F, 2005, FEBS J, V272, P3184, DOI 10.1111/j.1742-4658.2005.04737.x; Moro F, 2004, J BIOL CHEM, V279, P19600, DOI 10.1074/jbc.M400921200; Moro F, 2003, FEBS LETT, V533, P119, DOI 10.1016/S0014-5793(02)03752-3; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Revington M, 2005, J MOL BIOL, V349, P163, DOI 10.1016/j.jmb.2005.03.033; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Slepenkov SV, 2002, BIOCHEMISTRY-US, V41, P12224, DOI 10.1021/bi0263208; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Zhang YB, 2004, P NATL ACAD SCI USA, V101, P10272, DOI 10.1073/pnas.0401313101; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	36	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7479	7488		10.1074/jbc.M512744200	http://dx.doi.org/10.1074/jbc.M512744200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415343	hybrid			2022-12-27	WOS:000236030900070
J	Hamburgh, ME; Curr, KA; Monaghan, M; Rao, VR; Tripathi, S; Preston, BD; Sarafianos, S; Arnold, E; Darden, T; Prasad, VR				Hamburgh, ME; Curr, KA; Monaghan, M; Rao, VR; Tripathi, S; Preston, BD; Sarafianos, S; Arnold, E; Darden, T; Prasad, VR			Structural determinants of slippage-mediated mutations by human immunodeficiency virus type 1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE ANALOG SENSITIVITY; POLYMERASE FIDELITY; ERROR SPECIFICITY; CRYSTAL-STRUCTURE; GLU-89 RESIDUE; MINOR-GROOVE; HIV-1 RT; DNA; MUTANT; RESISTANCE	Single-base deletions at nucleotide runs or - 1 frameshifting by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) result from template slippage during polymerization. In crystal structures of HIV-1 RT complexed with DNA-DNA template-primer, the palm subdomain in the template cleft contacts the template backbone near the proposed site of slippage via the Glu(89) side chain. We investigated the role of Glu(89) in frameshifting by perturbing this interaction. Substitutions with Asp, Gly, Ala, Val, Ser, Thr, Asn, or Lys were created in recombinant HIV RT, and frameshift frequencies of the resulting mutant RTs were measured. All substitutions led to reduced -1 frameshifting by HIV-1 RT (2-40-fold). Interestingly, the suppression of -1 frameshifting frequently coincided with an enhancement of -1 frameshifting (3-47-fold) suggesting that Glu(89) can influence the slippage of both strands. Glu(89) substitutions also led to reduced rates of dNTP mis-incorporation that paralleled reductions in -1 frameshifting, suggesting a common structural mechanism for both classes of RT error. Our results reveal a major influence of Glu(89) on slippage-mediated errors and dNTP incorporation fidelity. The crystal structure of HIV-1 RT reveals a salt bridge between Glu(89) and Lys(154), which may facilitate -1 frameshifting; this concept is supported by the observed reduction in -1 frameshifting for K154A and K154R mutants.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27707 USA	Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Washington; University of Washington Seattle; Rutgers State University New Brunswick; Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Prasad, VR (corresponding author), 1300 Morris Pk Ave,Rm GB 401, Bronx, NY 10461 USA.	prasad@aecom.yu.edu	Prasad, Vinayaka R./A-1029-2011	Sarafianos, Stefan G/0000-0002-5840-154X; Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030861, R01AI030861, R21AI030861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES043010, Z01ES090601] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI030861, AI 30861] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07461] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Curr K, 2006, J GEN VIROL, V87, P419, DOI 10.1099/vir.0.81458-0; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; Fisher TS, 2002, J BIOL CHEM, V277, P22345, DOI 10.1074/jbc.M200282200; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KEW Y, 1994, J BIOL CHEM, V269, P15331; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Lavigne M, 1999, J MOL BIOL, V285, P977, DOI 10.1006/jmbi.1998.2367; Mansky LM, 2003, J VIROL, V77, P2071, DOI 10.1128/JVI.77.3.2071-2080.2003; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Natrajan G, 2003, NUCLEIC ACIDS RES, V31, P4814, DOI 10.1093/nar/gkg677; Newstein MC, 2001, J INFECT DIS, V184, P1262, DOI 10.1086/324079; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PRASAD VR, 1989, J BIOL CHEM, V264, P16689; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Quan YD, 1998, J BIOL CHEM, V273, P21918, DOI 10.1074/jbc.273.34.21918; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Shahs FS, 2000, J BIOL CHEM, V275, P27037; Sharma B, 2003, NUCLEIC ACIDS RES, V31, P5167, DOI 10.1093/nar/gkg708; SONG QG, 1992, J VIROL, V66, P7568, DOI 10.1128/JVI.66.12.7568-7571.1992; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282	40	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7421	7428		10.1074/jbc.M511380200	http://dx.doi.org/10.1074/jbc.M511380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423828	hybrid			2022-12-27	WOS:000236030900063
J	Crawley, SW; de la Roche, MA; Lee, SF; Li, ZH; Chitayat, S; Smith, SP; Cote, GP				Crawley, SW; de la Roche, MA; Lee, SF; Li, ZH; Chitayat, S; Smith, SP; Cote, GP			Identification and characterization of an 8-kDa light chain associated with Dictyostelium discoideum MyoB, a class I myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; FLUORESCENT PROTEIN; CORTICAL TENSION; DOMAINS; CALMODULIN; SEQUENCE; AFFINITY; MOTILITY; MUTANTS; ISOFORM	Dictyostelium discoideum MyoB is a single-headed class I myosin. Analysis of purified MyoB by SDS-PAGE indicated the presence of an similar to 9-kDa light chain. A tryptic digest of MyoB yielded a partial sequence for the light chain that exactly matched a sequence in a 73-amino acid, 8,296-Da protein (dictyBase number DDB0188713). This protein, termed MlcB, contains two EF-hand motifs and shares similar to 30% sequence identity with the N- and C-terminal lobes of calmodulin. FLAG-MlcB expressed in Dictyostelium co-immunoprecipitated with MyoB but not with the related class I myosins MyoC and MyoD. Recombinant MlcB bound Ca2+ with a K-d value of 0.2 mu M and underwent a Ca2+-induced change in conformation that increased alpha-helical content and surface hydrophobicity. Mutational analysis showed that the first EF-hand was responsible for Ca2+ binding. In the presence and absence of Ca2+ MlcB was a monomer in solution and bound to a MyoB IQ motif peptide with a K-d value of similar to 0.5 mu M. A MyoB head-neck construct with a Ser to Glu mutation at the TEDS site bound MlcB and displayed an actin-activated Mg2+ ATPase activity that was insensitive to Ca2+. We conclude that MlcB represents a novel type of small myosin light chain that binds to IQ motifs in a manner comparable with a single lobe of a typical four-EF-hand protein.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cote, GP (corresponding author), Queens Univ, Dept Biochem, Rm 617,Botterell Hall, Kingston, ON K7L 3N6, Canada.	coteg@post.queensu.ca		Smith, Steven/0000-0003-2710-4400				Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Dai JW, 1999, BIOPHYS J, V77, P1168, DOI 10.1016/S0006-3495(99)76968-7; De La Roche MA, 2003, BIOCHEM J, V374, P697, DOI 10.1042/BJ20030656; de la Roche MA, 2001, BBA-GEN SUBJECTS, V1525, P245, DOI 10.1016/S0304-4165(01)00110-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Falk DL, 2003, J CELL SCI, V116, P3985, DOI 10.1242/jcs.00696; Fischer M, 2004, FEBS LETT, V577, P227, DOI 10.1016/j.febslet.2004.09.084; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; Gillespie PG, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-31; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1993, J BIOL CHEM, V268, P14981; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Korn ED, 2000, P NATL ACAD SCI USA, V97, P12559, DOI 10.1073/pnas.230441597; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1993, J BIOL CHEM, V268, P20923; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; LYNCH TJ, 1991, METHOD ENZYMOL, V196, P12; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; Martin SR, 2002, PROTEIN SCI, V11, P2909, DOI 10.1110/ps.0210402; MARUTA H, 1979, J BIOL CHEM, V254, P3624; McCormack E, 2003, NEW PHYTOL, V159, P585, DOI 10.1046/j.1469-8137.2003.00845.x; Morita YS, 1996, EUR J CELL BIOL, V71, P371; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; Neuhaus EM, 2000, J CELL BIOL, V150, P1013, DOI 10.1083/jcb.150.5.1013; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; Osherov N, 2000, CELL MOTIL CYTOSKEL, V47, P163, DOI 10.1002/1097-0169(200011)47:3<163::AID-CM1>3.0.CO;2-U; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Schwarz EC, 2000, J CELL SCI, V113, P621; SLUPSKY CM, 1995, PROTEIN SCI, V4, P1279, DOI 10.1002/pro.5560040704; Smith SP, 1998, BIOCHEM CELL BIOL, V76, P324, DOI 10.1139/bcb-76-2-3-324; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Terrak M, 2003, EMBO J, V22, P362, DOI 10.1093/emboj/cdg058; Vargas M, 1997, MOL BIOCHEM PARASIT, V86, P61, DOI 10.1016/S0166-6851(97)90006-2; Wang ZY, 1997, J MUSCLE RES CELL M, V18, P395, DOI 10.1023/A:1018686428955; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; Yamaguchi K, 1999, J BIOL CHEM, V274, P3610, DOI 10.1074/jbc.274.6.3610	47	14	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6307	6315		10.1074/jbc.M508670200	http://dx.doi.org/10.1074/jbc.M508670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16415352	hybrid			2022-12-27	WOS:000236030800024
J	Mezhybovska, M; Wikstrom, K; Ohd, JF; Sjolander, A				Mezhybovska, M; Wikstrom, K; Ohd, JF; Sjolander, A			The inflammatory mediator leukotriene D-4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; ADENOCARCINOMA CELLS; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CYSLT(1) RECEPTOR; C-MYC; PATHWAY; ACTIVATION; SURVIVAL; PROTEIN	Increased levels of the inflammatory mediator leukotriene D-4 (LTD4) are present at sites of inflammatory bowel disease, and such areas also exhibit an increased risk for subsequent cancer development. It is known that LTD4 affects the expression of many proteins that influence survival and proliferation of intestinal epithelial cells. We demonstrate here that after LTD4 exposure, beta-catenin translocates to the nucleus where it signals activation of the TCF/LEF family of transcription factors. These events are mediated via a phosphatidylinositol 3-kinase-dependent phosphorylation of the inhibitory Ser-9 residue of glycogen synthase kinase 3 beta. We also show that in the presence of LTD4, free beta-catenin translocates to the mitochondria where it associates with the cell survival protein Bcl-2. We hypothesize that LTD4 may enhance cell survival via activation of beta-catenin signaling, in particular, by promoting the association of beta-catenin with Bcl-2 in the mitochondria. Similar to Wnt-1 signaling, LTD4 signals an increased level of free beta-catenin and elevated TCF/LEF promotor activity. This work in intestinal epithelial cells further lends credence to the idea that inflammatory signaling pathways are intrinsically linked with potential oncogenic signals involved in cell survival and apoptosis.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden.	anita.sjolander@med.lu.se						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cellerino A, 2000, CELL TISSUE RES, V301, P53, DOI 10.1007/s004410000178; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cullen DA, 2004, NEUROSCI LETT, V354, P54, DOI 10.1016/j.neulet.2003.09.074; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Diks SH, 2003, J BIOL CHEM, V278, P52491, DOI 10.1074/jbc.M310712200; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Hawkey CJ, 1997, GASTROENTEROLOGY, V112, P718, DOI 10.1053/gast.1997.v112.pm9041232; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HENLE G, 1957, J IMMUNOL, V79, P54; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lynch KR, 1999, NATURE, V399, P789; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nialbon C. C., 2005, SCI STKE, V2005, ppe35; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; Nielsen CK, 2005, CANCER RES, V65, P732; Nielsen CK, 2005, EXP CELL RES, V302, P31, DOI 10.1016/j.yexcr.2004.08.042; NIELSEN OH, 1991, PROSTAG LEUKOTR ESS, V42, P181, DOI 10.1016/0952-3278(91)90155-X; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park JR, 1996, J CELL BIOCHEM, V60, P12, DOI 10.1002/(SICI)1097-4644(19960101)60:1<12::AID-JCB3>3.0.CO;2-6; Paruchuri S, 2005, J BIOL CHEM, V280, P13538, DOI 10.1074/jbc.M409811200; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Samuelsson B, 1979, Harvey Lect, V75, P1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Takahashi M, 1998, CANCER RES, V58, P42; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wikstrom K, 2003, BIOCHEM BIOPH RES CO, V302, P330, DOI 10.1016/S0006-291X(03)00187-6; Wkstrom K, 2003, BIOCHEM J, V371, P115; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	57	48	49	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6776	6784		10.1074/jbc.M509999200	http://dx.doi.org/10.1074/jbc.M509999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407243	hybrid			2022-12-27	WOS:000236030800076
J	Park, YH; Lee, BR; Seok, YJ; Peterkofsky, A				Park, YH; Lee, BR; Seok, YJ; Peterkofsky, A			In vitro reconstitution of catabolite repression in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; PHOSPHORYL TRANSFER COMPLEX; ADENYLATE-CYCLASE ACTIVITY; CYTOPLASMIC DOMAIN; ENZYME IIA(GLC); PROTEIN; EXPRESSION; MONOPHOSPHATE; PURIFICATION; IIA(GLUCOSE)	A widely accepted model for catabolite repression posits that phospho-IIA(Glc) of the bacterial phosphotransferase system activates adenylyl cyclase (AC) activity. For many years, attempts to observe such regulatory properties of AC in vitro have been unsuccessful. To further study the regulation, AC was produced fused to the transmembrane segments of the serine chemoreceptor Tsr. Cells harboring Tsr-AC and normal AC, expressed from the cya promoter on a low copy number vector, exhibit similar behavior with respect to elevation of cAMP levels resulting from deletion of crp, expressing the catabolite regulatory protein. Membrane-bound Tsr-AC exhibits activity comparable with the native form of AC. Tsr-AC binds IIA(Glc) specifically, regardless of its phosphorylation state, but not the two general phosphotransferase system proteins, enzyme I and HPr; IIA(Glc) binding is localized to the C-terminal region of AC. Binding to membranes of either dephospho- or phospho-IIA(Glc) has no effect on AC activity. However, in the presence of an Escherichia coli extract, P-IIA(Glc), but not IIA(Glc), stimulates AC activity. Based on these findings of a direct interaction of IIAGlc with AC, but activity regulation only in the presence of E. coli extract, a revised model for AC activity regulation is proposed.	Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; Seowon Univ, Dept Biol, Chongju City 361742, South Korea; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); Seowon University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Seok, YJ (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 50,Rm 2316,MSC-8017, Bethesda, MD 20814 USA.	yjseok@plaza.snu.ac.kr; peterkofsky@nih.gov		Seok, Yeong-Jae/0000-0003-0379-3619	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ACKERMAN RS, 1974, J BACTERIOL, V119, P357, DOI 10.1128/JB.119.2.357-362.1974; [Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CRASNIER M, 1990, J GEN MICROBIOL, V136, P1825, DOI 10.1099/00221287-136-9-1825; DANIEL J, 1984, J BACTERIOL, V157, P940, DOI 10.1128/JB.157.3.940-941.1984; DEROBERTIS EM, 1973, BIOCHEM BIOPH RES CO, V55, P758, DOI 10.1016/0006-291X(73)91209-6; HARWOOD JP, 1975, J BIOL CHEM, V250, P4656; Higuchi R., 1989, PCR TECHNOLOGY, P61; Koo BM, 2004, J BIOL CHEM, V279, P31613, DOI 10.1074/jbc.M405048200; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LIBERMAN E, 1986, BIOCHEM BIOPH RES CO, V141, P1138, DOI 10.1016/S0006-291X(86)80162-0; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; Miller J. H., 1972, EXPT MOL GENETICS, P433; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; NIELSEN LD, 1973, J BACTERIOL, V116, P857, DOI 10.1128/JB.116.2.857-866.1973; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; Pettigrew DW, 1998, BIOCHEMISTRY-US, V37, P4875, DOI 10.1021/bi971634u; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POTTER K, 1974, BIOCHEM BIOPH RES CO, V57, P379, DOI 10.1016/0006-291X(74)90941-3; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; REDDY P, 1995, ANAL BIOCHEM, V231, P282, DOI 10.1006/abio.1995.9998; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; REDDY P, 1985, P NATL ACAD SCI USA, V82, P8300, DOI 10.1073/pnas.82.24.8300; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; ROY A, 1983, J MOL BIOL, V165, P197, DOI 10.1016/S0022-2836(83)80251-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sondej M, 2002, BIOCHEMISTRY-US, V41, P5556, DOI 10.1021/bi011990j; Takahashi H, 1998, MOL GEN GENET, V259, P317, DOI 10.1007/s004380050818; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; YANG JK, 1983, J BIOL CHEM, V258, P3750	33	90	95	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6448	6454		10.1074/jbc.M512672200	http://dx.doi.org/10.1074/jbc.M512672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407219	hybrid			2022-12-27	WOS:000236030800039
J	Korber, P; Barbaric, S; Luckenbach, T; Schmid, A; Schermer, UJ; Blaschke, D; Horz, W				Korber, P; Barbaric, S; Luckenbach, T; Schmid, A; Schermer, UJ; Blaschke, D; Horz, W			The histone chaperone Asf1 increases the rate of histone eviction at the yeast PHO5 and PHO8 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-SYNTHESIS; IN-VIVO; TRANSCRIPTIONAL REGULATION; NUCLEOSOME DISRUPTION; CHROMATIN TRANSITION; ASSEMBLY PATHWAYS; ACTIVATION; INDUCTION; BINDING	Eukaryotic gene expression starts off from a largely obstructive chromatin substrate that has to be rendered accessible by regulated mechanisms of chromatin remodeling. The yeast PHO5 promoter is a well known example for the contribution of positioned nucleosomes to gene repression and for extensive chromatin remodeling in the course of gene induction. Recently, the mechanism of this remodeling process was shown to lead to the disassembly of promoter nucleosomes and the eviction of the constituent histones in trans. This finding called for a histone acceptor in trans and thus made histone chaperones likely to be involved in this process. In this study we have shown that the histone chaperone Asf1 increases the rate of histone eviction at the PHO5 promoter. In the absence of Asf1 histone eviction is delayed, but the final outcome of the chromatin transition is not affected. The same is true for the coregulated PHO8 promoter where induction also leads to histone eviction and where the rate of histone loss is reduced in asf1 strains as well, although less severely. Importantly, the final extent of chromatin remodeling is not affected. We have also presented evidence that Asf1 and the SWI/SNF chromatin remodeling complex work in distinct parallel but functionally overlapping pathways, i.e. they both contribute toward the same outcome without being mutually strictly dependent.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Univ Zagreb, Fac Food Technol & Biotechnol, Biochem Lab, Zagreb 10000, Croatia	University of Munich; University of Zagreb	Korber, P (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	pkorber@lmu.de	Korber, Philipp/AAN-7633-2021	Korber, Philipp/0000-0001-7526-6549				Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Dhasarathy A, 2005, MOL CELL BIOL, V25, P2698, DOI 10.1128/MCB.25.7.2698-2707.2005; ERTINGER G, 1998, THESIS U MUNCHEN GER; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Gregory PD, 1999, METH MOL B, V119, P417; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Huang SD, 2005, GENETICS, V169, P1859, DOI 10.1534/genetics.104.038695; Ito T, 1996, MOL CELL BIOL, V16, P3112; KANEKO Y, 1989, MOL GEN GENET, V220, P133, DOI 10.1007/BF00260867; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Loyola A, 2001, GENE DEV, V15, P2837; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Munsterkotter M, 2000, J BIOL CHEM, V275, P22678, DOI 10.1074/jbc.M001409200; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; OSLEY MA, 1987, MOL CELL BIOL, V7, P4204, DOI 10.1128/MCB.7.12.4204; Ray-Gallet D, 2004, METHOD ENZYMOL, V375, P117; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; Sharp JA, 2005, GENETICS, V171, P885, DOI 10.1534/genetics.105.044719; Shen XT, 2003, MOL CELL, V12, P147, DOI 10.1016/S1097-2765(03)00264-8; Springer M, 2003, PLOS BIOL, V1, P261, DOI 10.1371/journal.pbio.0000028; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Sutton A, 2001, GENETICS, V158, P587; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Verreault A, 2000, GENE DEV, V14, P1430	49	89	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5539	5545		10.1074/jbc.M513340200	http://dx.doi.org/10.1074/jbc.M513340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407267	hybrid			2022-12-27	WOS:000235568900028
J	Maeda, S; Sugita, C; Sugita, M; Omata, T				Maeda, S; Sugita, C; Sugita, M; Omata, T			Latent nitrate transport activity of a novel sulfate permease-like protein of the cyanobacterium Synechococcus elongatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRITE REDUCTASE; GENE; IDENTIFICATION; CLONING; SYSTEM; EXPRESSION; ASSIMILATION; MUTAGENESIS; PCC-7942	The Synechococcus elongatus mutant lacking the nrtABCD gene cluster (NA3) is defective in active nitrate transport and requires high nitrate concentrations (> 30 mM) for sustained growth. Prolonged incubation of NA3 in medium containing 2 mM nitrate led to isolation of a pseudorevertant (NA3R) capable of transport of millimolar concentrations of nitrate, from which three mutants with improved affinity for nitrate were obtained. We identified three genes responsible for the latent transport activity for nitrate: ltnA, which encodes a response regulator with no effector domain; ltnB, which encodes a hybrid histidine kinase with two receiver domains; and ltnT, which encodes a sulfate permease-like protein with a putative cyclic nucleoside monophosphate (cNMP)-binding domain. Missense mutations of the high affinity derivatives of NA3R were found in ltnT, verifying that LtnT acts as the transporter. Overexpression of truncated LtnT lacking the cNMP-binding domain (but not full-length LtnT) conferred nitrate transport activity on NA3, suggesting that the cNMP-binding domain inhibits transport under normal conditions. A nonsense mutation in ltnB that resulted in elimination of the receiver domains of the encoded protein was responsible for expression of nitrate transport activity in NA3R. Expression of LtnB derivatives lacking the receiver domains also conferred low affinity nitrate transport activity on NA3. The phosphoryl group of the histidine kinase domain of LtnB was transferred to Asp(52) of LtnA in vitro. Overexpression of LtnA (but not LtnA(D52E)) led to manifestation of the latent nitrate transport activity in NA3, indicating involvement of phosphorylated LtnA in activation of the novel transporter.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Mol Plant Physiol, Chikusa Ku, Aichi 4648601, Japan; Nagoya Univ, Ctr Gene Res, Aichi 4648601, Japan	Nagoya University; Nagoya University	Maeda, S (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Mol Plant Physiol, Chikusa Ku, Aichi 4648601, Japan.	maeda@agr.nagoya-u.ac.jp						AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDRIESSE X, 1990, INORGANIC NITROGEN P, P303; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; DZELZKALNS VA, 1984, NUCLEIC ACIDS RES, V12, P8917, DOI 10.1093/nar/12.23.8917; Forde BG, 2000, BBA-BIOMEMBRANES, V1465, P219, DOI 10.1016/S0005-2736(00)00140-1; GREEN LS, 1989, P NATL ACAD SCI USA, V86, P1949, DOI 10.1073/pnas.86.6.1949; Guerrero M. G., 1987, The Cyanobacteria., P163; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUHLEMEIER CJ, 1983, PLASMID, V10, P156, DOI 10.1016/0147-619X(83)90068-9; KUHLEMEIER CJ, 1984, J BACTERIOL, V159, P36, DOI 10.1128/JB.159.1.36-41.1984; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; MacKinney G, 1941, J BIOL CHEM, V140, P315; Maeda S, 1998, J BACTERIOL, V180, P4080, DOI 10.1128/JB.180.16.4080-4088.1998; Maeda SI, 1997, J BIOL CHEM, V272, P3036, DOI 10.1074/jbc.272.5.3036; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; OMATA T, 1995, PLANT CELL PHYSIOL, V36, P207, DOI 10.1093/oxfordjournals.pcp.a078751; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; Price GD, 2004, P NATL ACAD SCI USA, V101, P18228, DOI 10.1073/pnas.0405211101; SILVERMAN M, 1977, J BACTERIOL, V130, P1317, DOI 10.1128/JB.130.3.1317-1325.1977; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; SUZUKI I, 1993, PLANT CELL PHYSIOL, V34, P1311; Suzuki I, 1996, J BACTERIOL, V178, P2688, DOI 10.1128/jb.178.9.2688-2694.1996; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WILLIAMS JGK, 1983, GENE, V24, P37, DOI 10.1016/0378-1119(83)90129-4; Yoshihara S, 2000, PLANT CELL PHYSIOL, V41, P1299, DOI 10.1093/pcp/pce010; Yoshimura H, 2000, J BIOL CHEM, V275, P6241, DOI 10.1074/jbc.275.9.6241	33	9	10	2	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5869	5876		10.1074/jbc.M513196200	http://dx.doi.org/10.1074/jbc.M513196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407232	hybrid			2022-12-27	WOS:000235568900067
J	Frank, M; Dzikowski, R; Costantini, D; Amulic, B; Berdougo, E; Deitsch, K				Frank, M; Dzikowski, R; Costantini, D; Amulic, B; Berdougo, E; Deitsch, K			Strict pairing of var promoters and introns is required for var gene silencing in the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE-A; ANTIGENIC VARIATION; INFECTED ERYTHROCYTES; DNA-REPLICATION; EXPRESSION; FAMILY; RECOMBINATION; TRANSFORMATION; TRANSCRIPTION; TRANSFECTION	The human malaria parasite, Plasmodium falciparum, maintains a persistent infection altering the proteins expressed on the surface of the infected red blood cells, thus avoiding the host immune response. The primary surface antigen, a protein called PfEMP1, is encoded by amulticopy gene family called var. Each individual parasite only expresses a single var gene at a time, maintaining all other members of the family in a transcriptionally silent state. Previous work using reporter genes in transiently transfected plasmid constructs implicated a conserved intron found in all var genes in the silencing process. Here we have utilized episomal recombination within stably transformed parasites to generate different var promoter and intron arrangements and show that loss of the intron results in var promoter activation. Further, in multicopy plasmid concatamers, each intron could only silence a single promoter, suggesting a one-to-one pairing requirement for silencing. Transcriptionally active, "unpaired" promoters remained active after integration into a chromosome; however, they were not recognized by the pathway that maintains mutually exclusive var gene expression. The data indicate that intron/ promoter pairing is responsible for silencing each individual var gene and that disruption of silencing of one gene does not affect the transcriptional activity of neighboring var promoters. This suggests that silencing is regulated at the level of individual genes rather than by assembly of silent chromatin throughout a chromosomal region, thus providing a possible explanation of how a var gene can be maintained in a silent state while the immediately adjacent var gene is transcriptionally active.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Int Hlth & Infect Dis, New York, NY 10021 USA	Cornell University; Cornell University	Deitsch, K (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave,Box 62, New York, NY 10021 USA.	kwd2001@med.cornell.edu	Dzikowski, Ron/HHZ-2430-2022	Amulic, Borko/0000-0002-8518-8393; si yun, feng/0000-0002-3546-824X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052390] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI052390, AI 52390] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Boscheron C, 1996, EMBO J, V15, P2184, DOI 10.1002/j.1460-2075.1996.tb00572.x; Calderwood MS, 2003, J BIOL CHEM, V278, P34125, DOI 10.1074/jbc.M213065200; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Deitsch KW, 1999, MOL BIOCHEM PARASIT, V101, P107, DOI 10.1016/S0166-6851(99)00062-6; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Deitsch KW, 2001, NUCLEIC ACIDS RES, V29, P850, DOI 10.1093/nar/29.3.850; Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Gannoun-Zaki L, 2005, EUKARYOT CELL, V4, P490, DOI 10.1128/EC.4.2.490-492.2005; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Horrocks P, 2004, P NATL ACAD SCI USA, V101, P11129, DOI 10.1073/pnas.0402347101; Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; Kraemer SM, 2003, MOL MICROBIOL, V50, P1527, DOI 10.1046/j.1365-2958.2003.03814.x; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; Kyes SA, 2003, MOL MICROBIOL, V48, P1339, DOI 10.1046/j.1365-2958.2003.03505.x; Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; O'Donnell RA, 2002, EMBO J, V21, P1231, DOI 10.1093/emboj/21.5.1231; Ralph SA, 2005, P NATL ACAD SCI USA, V102, P5414, DOI 10.1073/pnas.0408883102; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; SAMBROOK J, 1989, MOL CLONING, V2, P9; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Short Robert A, 2005, Am J Nephrol, V25, P36, DOI 10.1159/000084073; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; Williamson DH, 2002, NUCLEIC ACIDS RES, V30, P726, DOI 10.1093/nar/30.3.726; Winter G, 2003, MOL BIOCHEM PARASIT, V127, P179, DOI 10.1016/S0166-6851(03)00004-5; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	40	84	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9942	9952		10.1074/jbc.M513067200	http://dx.doi.org/10.1074/jbc.M513067200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455655	hybrid, Green Accepted			2022-12-27	WOS:000236594300016
J	Griffin, BD; Moynagh, PN				Griffin, BD; Moynagh, PN			Persistent interleukin-1 beta signaling causes long term activation of NF kappa B in a promoter-specific manner in human glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN ENDOTHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; INFLAMMATORY CYTOKINES; MAMMALIAN-CELLS; NUCLEAR EXPORT; REL PROTEINS	Nuclear factor-kappa B (NF kappa B) is an inducible transcription factor that plays a key role in regulating the expression of a wide range of immune and inflammatory response genes. The activity of NF kappa B is controlled at multiple levels, including cytoplasmic retention with inhibitor of kappa B (I kappa B) proteins in the basal state. Persistent activation of the transcription factor is seen in numerous chronic inflammatory disease states, and we have previously demonstrated sustained activation of NF kappa B in human glial cells upon stimulation with interleukin (IL)-1 beta. In these cells, NF kappa B retains DNA binding activity for up to 72 h despite the presence of resynthesized I kappa B alpha and in the absence of I kappa B beta. Here we characterized the apparent inability of newly synthesized I kappa B alpha to terminate activation of NF kappa B in glial cells. We showed unexpectedly that newly synthesized I kappa B alpha can enter the nucleus, interact with the NF kappa B subunit p65, and export it to the cytoplasm. However, in vitro analysis of enzyme activity demonstrates that IL-1 beta causes the long term activation of the I kappa B kinase complex leading to chronic phosphorylation of the newly synthesized I kappa B alpha signal response domain and persistent activation of NF kappa B. Such sustained activation of NF kappa B is dependent on the continuous presence and activity of IL-1 beta. Interestingly, the sustained nature of NF kappa B activity is promoter type-specific. Chromatin immunoprecipitation studies revealed that p65 is detected at the promoters of both intercellular adhesion molecule-1 and IL-8 1 h following IL-1 beta stimulation but is only found at the latter at 24 h. The functional significance of this finding is indicated by the transient induction of intercellular adhesion molecule-1 mRNA, but more sustained induction of IL-8 expression, by IL-1 beta. These studies thus demonstrated that persistent IL-1 signaling causes sustained activation of NF kappa B in a promoter-specific manner in human glial cells, leading to prolonged induction of selective pro-inflammatory genes. This is likely to make a key contribution to chronic inflammatory conditions of the brain.	Natl Univ Ireland Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland	University College Dublin	Moynagh, PN (corresponding author), Natl Univ Ireland Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	P.Moynagh@ucd.ie		Moynagh, Paul/0000-0002-4139-3061				ALOISI F, 1992, J IMMUNOL, V149, P2358; ARCHELOS JJ, 1993, ANN NEUROL, V34, P145, DOI 10.1002/ana.410340209; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOPP JM, 1994, J NEUROIMMUNOL, V54, P129, DOI 10.1016/0165-5728(94)90239-9; ENNIS HL, 1964, SCIENCE, V146, P1474, DOI 10.1126/science.146.3650.1474; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Kostulas N, 1998, STROKE, V29, P462, DOI 10.1161/01.STR.29.2.462; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lahrtz F, 1998, J NEUROIMMUNOL, V85, P33, DOI 10.1016/S0165-5728(97)00267-1; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee SJ, 1998, J NEUROIMMUNOL, V92, P196, DOI 10.1016/S0165-5728(98)00209-4; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Paxton LLL, 1997, J BIOL CHEM, V272, P15928, DOI 10.1074/jbc.272.25.15928; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Sprenger H, 1996, CLIN IMMUNOL IMMUNOP, V80, P155, DOI 10.1006/clin.1996.0109; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	48	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10316	10326		10.1074/jbc.M509973200	http://dx.doi.org/10.1074/jbc.M509973200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455661	Green Accepted, hybrid			2022-12-27	WOS:000236594300060
J	Cheong, N; Madesh, M; Gonzales, LW; Zhao, M; Yu, K; Ballard, PL; Shuman, H				Cheong, N; Madesh, M; Gonzales, LW; Zhao, M; Yu, K; Ballard, PL; Shuman, H			Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMELLAR BODY MEMBRANE; LYSOSOME-RELATED ORGANELLES; II CELLS; TANGIER-DISEASE; PULMONARY SURFACTANT; MISSENSE MUTATIONS; QUALITY-CONTROL; IN-VITRO; PROTEIN; BODIES	Members of the ATP binding cassette (ABC) protein superfamily actively transport a wide range of substrates across cell and intracellular membranes. Mutations in ABCA3, a member of the ABCA subfamily with unknown function, lead to fatal respiratory distress syndrome (RDS) in the newborn. Using cultured human lung cells, we found that recombinant wild-type hABCA3 localized to membranes of both lysosomes and lamellar bodies, which are the intracellular storage organelles for surfactant. In contrast, hABCA3 with mutations linked to RDS failed to target to lysosomes and remained in the endoplasmic reticulum as unprocessed forms. Treatment of those cells with the chemical chaperone sodium 4-phenylbutyrate could partially restore trafficking of mutant ABCA3 to lamellar body-like structures. Expression of recombinant ABCA3 in non-lung human embryonic kidney 293 cells induced formation of lamellar body-like vesicles that contained lipids. Small interfering RNA knockdown of endogenous hABCA3 in differentiating human fetal lung alveolar type II cells resulted in abnormal, lamellar bodies comparable with those observed in vivo with mutant ABCA3. Silencing of ABCA3 expression also reduced vesicular uptake of surfactant lipids phosphatidylcholine, sphingomyelin, and cholesterol but not phosphatidylethanolamine. We conclude that ABCA3 is required for lysosomal loading of phosphatidylcholine and conversion of lysosomes to lamellar body-like structures.	Univ Penn, Dept Physiol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Canc Biol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Div Neonatol, Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Shuman, H (corresponding author), Univ Penn, Dept Physiol, Sch Med, B400 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	shuman@mail.med.upenn.edu						Akasaki K, 2004, ARCH BIOCHEM BIOPHYS, V425, P147, DOI 10.1016/j.abb.2004.02.042; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; CHINOY MR, 1994, AM J PHYSIOL, V266, pL713, DOI 10.1152/ajplung.1994.266.6.L713; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; DOBBS LG, 1989, ANNU REV MED, V40, P431; Foster CD, 2003, AM J RESP CELL MOL, V29, P259, DOI 10.1165/rcmb.2002-0149OC; GIBSON KF, 1991, AM J RESP CELL MOL, V4, P504, DOI 10.1165/ajrcmb/4.6.504; Gonzales LW, 2002, AM J PHYSIOL-LUNG C, V283, pL940, DOI 10.1152/ajplung.00127.2002; Guo ZG, 2002, J HUM GENET, V47, P325, DOI 10.1007/s100380200044; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HOOK GER, 1982, J BIOL CHEM, V257, P9211; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Lim M, 2004, AM J RESP CELL MOL, V31, P351, DOI 10.1165/rcmb.2002-0086OC; Liu XL, 2004, J AM SOC NEPHROL, V15, P1731, DOI 10.1097/01.ASN.0000129826.28932.FD; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079; MULLER WJ, 1995, AM J PHYSIOL-LUNG C, V269, pL11, DOI 10.1152/ajplung.1995.269.1.L11; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Nagata K, 2004, BIOCHEM BIOPH RES CO, V324, P262, DOI 10.1016/j.bbrc.2004.09.043; Nishibori Y, 2004, KIDNEY INT, V66, P1755, DOI 10.1111/j.1523-1755.2004.00898.x; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Peelman F, 2003, J MOL BIOL, V325, P259, DOI 10.1016/S0022-2836(02)01105-1; Powell K, 2002, ADV DRUG DELIVER REV, V54, P1395, DOI 10.1016/S0169-409X(02)00148-5; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; Schaller-Bals S, 2000, AM J PHYSIOL-LUNG C, V279, pL631, DOI 10.1152/ajplung.2000.279.4.L631; SCHMITZ G, 1991, J LIPID RES, V32, P1539; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; SHULENIN S, 2004, NEW ENGL J MED, V350, P10; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; WASANO K, 1994, HISTOCHEMISTRY, V102, P329, DOI 10.1007/BF00268903; Weaver TE, 2002, SEMIN CELL DEV BIOL, V13, P263, DOI 10.1016/S1084952102000551; Welch WJ, 2004, SEMIN CELL DEV BIOL, V15, P31, DOI 10.1016/j.semcdb.2003.12.011; Wiszniewski W, 2005, HUM MOL GENET, V14, P2769, DOI 10.1093/hmg/ddi310; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	43	145	152	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9791	9800		10.1074/jbc.M507515200	http://dx.doi.org/10.1074/jbc.M507515200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16415354	hybrid			2022-12-27	WOS:000236404700092
J	Cho, HDD; Chen, Y; Varani, G; Weiner, AM				Cho, HDD; Chen, Y; Varani, G; Weiner, AM			A model for C74 addition by CCA-adding enzymes - C74 addition, like C75 and A76 addition, does not involve trna translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SHIBATAE; DNA-POLYMERASE; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; POLY(A) POLYMERASES; PROLINE RESIDUES; STRUCTURAL BASIS; ACTIVE-SITE; POLYMERIZATION; MECHANISM; COMPLEXES	The CCA-adding enzyme adds CCA to the 3'-end of tRNA one nucleotide at a time, using CTP and ATP as substrates. We found previously that tRNA does not rotate or translocate on the enzyme during the addition of C75 and A76. We therefore predicted that the growing 3'-end of tRNA must, upon addition of each nucleotide, refold to reposition the new 3'-hydroxyl equivalently relative to the solitary nucleotidyltransferase motif. Cocrystal structures of the class I archaeal Archaeoglobus fulgidus enzyme, poised for addition of C75 and A76, confirmed this prediction. We have also demonstrated that an evolutionarily flexible beta-turn facilitates progressive refolding of the 3'-terminal C74 and C75 residues during C75 and A76 addition. Although useful cocrystals corresponding to C74 addition have not yet been obtained, we now show experimentally that tRNA does not rotate or translocate during C74 addition. We therefore propose, based on the existing A. fulgidus cocrystal structures, that the same flexible beta-turn functions as a wedge between the discriminator base (N73) and the terminal base pair of the acceptor stem, unstacking and repositioning N73 to attack the incoming CTP. Thus a single flexible beta-turn would orchestrate consecutive addition of all three nucleotides without significant movement of the tRNA on the enzyme surface.	Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Weiner, AM (corresponding author), Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.	amweiner@u.washington.edu			NIGMS NIH HHS [GM064440, GM59804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064440, R01GM059804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4; Bhattacharyya R, 2003, J MOL BIOL, V331, P925, DOI 10.1016/S0022-2836(03)00759-9; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Cho HD, 2005, J BIOL CHEM, V280, P9555, DOI 10.1074/jbc.M412594200; Cho HD, 2003, RNA, V9, P970, DOI 10.1261/rna.2110903; Cho HDD, 2004, J BIOL CHEM, V279, P40130, DOI 10.1074/jbc.M405518200; Cho HDD, 2002, J BIOL CHEM, V277, P3447, DOI 10.1074/jbc.M109559200; DeLano W.L, PYMOL MOL GRAPHICS S; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Isaksson J, 2005, BIOCHEMISTRY-US, V44, P5390, DOI 10.1021/bi047414f; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; Kraut DA, 2003, ANNU REV BIOCHEM, V72, P517, DOI 10.1146/annurev.biochem.72.121801.161617; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; LI Y, 1999, NUCL ACIDS S SER, V42, P237; Martin G, 2004, RNA, V10, P899, DOI 10.1261/rna.5242304; Okabe M, 2003, EMBO J, V22, P5918, DOI 10.1093/emboj/cdg563; ROMBY P, 1985, J MOL BIOL, V184, P455, DOI 10.1016/0022-2836(85)90294-3; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; Stowasser R, 2002, BIOORG CHEM, V30, P420, DOI 10.1016/S0045-2068(02)00526-6; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Tomita K, 2004, NATURE, V430, P700, DOI 10.1038/nature02712; Xiong Y, 2004, NATURE, V430, P640, DOI 10.1038/nature02711; Xiong Y, 2003, MOL CELL, V12, P1165, DOI 10.1016/S1097-2765(03)00440-4; Yue DX, 1996, RNA, V2, P895; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	36	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9801	9811		10.1074/jbc.M512603200	http://dx.doi.org/10.1074/jbc.M512603200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455665	hybrid			2022-12-27	WOS:000236404700093
J	Lavillette, D; Barbouche, R; Yao, YX; Boson, B; Cosset, FL; Jones, IM; Fenouillet, E				Lavillette, D; Barbouche, R; Yao, YX; Boson, B; Cosset, FL; Jones, IM; Fenouillet, E			Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein - Comparison with HIV envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; MEMBRANE-FUSION; NEUTRALIZING ANTIBODY; MEDIATED REDUCTION; VIRUS-INFECTION; CORONAVIRUS; RECEPTOR; BINDING; BONDS; IDENTIFICATION	The capacity of the surface glycoproteins of enveloped viruses to mediate virus/cell binding and membrane fusion requires a proper thiol/disulfide balance. Chemical manipulation of their redox state using reducing agents or free sulfhydryl reagents affects virus/cell interaction. Conversely, natural thiol/disulfide rearrangements often occur during the cell interaction to trigger fusogenicity, hence the virus entry. We examined the relationship between the redox state of the 20 cysteine residues of the SARS-CoV (severe acute respiratory syndrome coronavirus) Spike glycoprotein S1 subdomain and its functional properties. Mature S1 exhibited similar to 4 unpaired cysteines, and chemically reduced S1 displaying up to similar to 6 additional unpaired cysteines still bound ACE2 and enabled fusion. In addition, virus/cell membrane fusion occurred in the presence of sulfhydryl-blocking reagents and oxidoreductase inhibitors. Thus, in contrast to various viruses including HIV (human immunodeficiency virus) examined in parallel, the functions of the SARS-CoV Spike glycoprotein exhibit a significant and surprising independence of redox state, which may contribute to the wide host range of the virus. These data suggest clues for molecularly engineering vaccine immunogens.	Fac Med Nord, IFR Jean Roche, F-13015 Marseille, France; Inst Federat Rech, Ecole Normale Super, INSERM, U758, F-69007 Lyon, France; Inst Super Biotechnol Monastir, Monastir 5000, Tunisia; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	UDICE-French Research Universities; Aix-Marseille Universite; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Monastir; University of Reading	Fenouillet, E (corresponding author), Fac Med Nord, IFR Jean Roche, Blvd P Dramard, F-13015 Marseille, France.	fenouillet.e@jean-roche.univ-mrs.fr	Cosset, François-Loïc/M-5862-2019	Cosset, François-Loïc/0000-0001-8842-3726; Lavillette, Dimitri/0000-0002-4706-1519; Boson, Bertrand/0000-0003-1920-5172	MRC [G0200000] Funding Source: UKRI; Medical Research Council [G0200000] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABELL BA, 1993, J VIROL, V67, P5496, DOI 10.1128/JVI.67.9.5496-5501.1993; ANTHONY RP, 1992, VIROLOGY, V190, P330, DOI 10.1016/0042-6822(92)91219-K; Barbouche R, 2005, MOL PHARMACOL, V67, P1111, DOI 10.1124/mol.104.008276; Barbouche R, 2003, J BIOL CHEM, V278, P3131, DOI 10.1074/jbc.M205467200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bisht H, 2005, VIROLOGY, V334, P160, DOI 10.1016/j.virol.2005.01.042; Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73; Faber M, 2005, J GEN VIROL, V86, P1435, DOI 10.1099/vir.0.80844-0; Fenouillet E, 2001, J INFECT DIS, V183, P744, DOI 10.1086/318823; Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0; Gallagher TM, 1996, J VIROL, V70, P4683, DOI 10.1128/JVI.70.7.4683-4690.1996; Gallina A, 2002, J BIOL CHEM, V277, P50579, DOI 10.1074/jbc.M204547200; Gramberg T, 2005, VIROLOGY, V340, P224, DOI 10.1016/j.virol.2005.06.026; Gros C, 1997, VIROLOGY, V230, P179, DOI 10.1006/viro.1997.8462; Hai P, 2004, J GEN VIROL, V85, P3109, DOI 10.1099/vir.0.80111-0; He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034; Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101; Krey T, 2005, J VIROL, V79, P4191, DOI 10.1128/JVI.79.7.4191-4200.2005; Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640; Markovic I, 2004, BLOOD, V103, P1586, DOI 10.1182/blood-2003-05-1390; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0; Petit CM, 2005, VIROLOGY, V341, P215, DOI 10.1016/j.virol.2005.06.046; Pinter A, 1997, J VIROL, V71, P8073, DOI 10.1128/JVI.71.10.8073-8077.1997; Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; Sanders D A, 2000, Subcell Biochem, V34, P483; STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990; Temperton NJ, 2005, EMERG INFECT DIS, V11, P411, DOI 10.3201/eid1103.040906; Wallin M, 2005, J VIROL, V79, P1678, DOI 10.1128/JVI.79.3.1678-1685.2005; Wallin M, 2004, EMBO J, V23, P54, DOI 10.1038/sj.emboj.7600012; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Xiao X, 2004, CELL MOL LIFE SCI, V61, P2428, DOI 10.1007/s00018-004-4257-y; Yao YX, 2004, J INFECT DIS, V190, P91, DOI 10.1086/421280	36	33	34	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9200	9204		10.1074/jbc.M512529200	http://dx.doi.org/10.1074/jbc.M512529200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16418166	Green Published, hybrid			2022-12-27	WOS:000236404700026
J	Luo, Y; Koles, K; Vorndam, W; Haltiwanger, RS; Panin, VM				Luo, Y; Koles, K; Vorndam, W; Haltiwanger, RS; Panin, VM			Protein O-fucosyltransferase 2 adds O-fucose to thrombospondin type 1 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; DROSOPHILA CELL-LINES; N-LINKED GLYCANS; GDP-FUCOSE; CORE FUCOSYLATION; C-MANNOSYLATION; GLYCOSYLATION; FRINGE; TRANSFERASE; GOLGI	O-Fucose is an unusual form of glycosylation found on epidermal growth factor-like (EGF) repeats and thrombospondin type 1 repeats (TSRs) in many secreted and transmembrane proteins. Recently O-fucose on EGF repeats was shown to play important roles in Notch signaling. In contrast, physiological roles for O-fucose on TSRs are unknown. In the accompanying paper (Luo, Y., Nita-Lazar, A., and Haltiwanger, R. S. (2006) J. Biol. Chem. 281, 9385-9392), we demonstrated that an enzyme distinct from protein O-fucosyltransferase 1 adds O-fucose to TSRs. A known homologue of O-fucosyltransferase 1 is putative protein O-fucosyltransferase 2. The cDNA sequence encoding O-fucosyltransferase 2 was originally identified during a data base search for fucosyltransferases in Drosophila. Like O-fucosyltransferase 1, O-fucosyltransferase 2 is conserved from Caenorhabditis elegans to humans. Although O-fucosyltransferase 2 was assumed to be another protein O-fucosyltransferase, no biochemical characterization existed supporting this contention. Here we show that RNAi-mediated reduction of the O-fucosyltransferase 2 message significantly decreased TSR-specific O-fucosyltransferase activity in Drosophila S2 cells. We also found that O-fucosyltransferase 2 is predominantly localized in the endoplasmic reticulum compartment of these cells. Furthermore, we expressed recombinant Drosophila O-fucosyltransferase 2 and showed that it O-fucosylates TSRs but not EGF repeats in vitro. These results demonstrate that O-fucosyltransferase 2 is in fact a TSR-specific O-fucosyltransferase.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Texas A&M University System; Texas A&M University College Station	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.	rhaltiwanger@ms.cc.sunysb.edu; panin@tamu.edu	Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481	NIGMS NIH HHS [GM069952, GM 61126, R01 GM061126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069952, R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, DEV DYNAM, V218, P280; Arziman Z, 2005, NUCLEIC ACIDS RES, V33, pW582, DOI 10.1093/nar/gki468; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Correia T, 2003, P NATL ACAD SCI USA, V100, P6404, DOI 10.1073/pnas.1131007100; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Dlugosz KA, 2005, GLYCOBIOLOGY, V15, P1219; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Etzioni A, 2002, AM J MED GENET, V110, P131, DOI 10.1002/ajmg.10423; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Ishikawa HO, 2005, P NATL ACAD SCI USA, V102, P18532, DOI 10.1073/pnas.0504115102; KIRKPATRICK RB, 1995, J BIOL CHEM, V270, P19800, DOI 10.1074/jbc.270.34.19800; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Martinez-Duncker I, 2003, GLYCOBIOLOGY, V13, p1C, DOI 10.1093/glycob/cwg113; Menzel O, 2004, GENOMICS, V84, P320, DOI 10.1016/j.ygeno.2004.04.002; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Opalka N, 2000, P NATL ACAD SCI USA, V97, P617, DOI 10.1073/pnas.97.2.617; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Roos C, 2002, J BIOL CHEM, V277, P3168, DOI 10.1074/jbc.m107927200; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Sisson JC, 2000, J CELL BIOL, V151, P905, DOI 10.1083/jcb.151.4.905; Sturla L, 2003, J BIOL CHEM, V278, P26727, DOI 10.1074/jbc.M304068200; Sturla L, 2005, GLYCOBIOLOGY, V15, P924, DOI 10.1093/glycob/cwi081; Sturla L, 2001, PEDIATR RES, V49, P537, DOI 10.1203/00006450-200104000-00016; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Wang XC, 2006, J BIOL CHEM, V281, P2572, DOI 10.1074/jbc.M510893200; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200	43	97	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9393	9399		10.1074/jbc.M511975200	http://dx.doi.org/10.1074/jbc.M511975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464857	hybrid			2022-12-27	WOS:000236404700048
J	Rothberg, KG; Burdette, DL; Pfannstiel, J; Jetton, N; Singh, R; Ruben, L				Rothberg, KG; Burdette, DL; Pfannstiel, J; Jetton, N; Singh, R; Ruben, L			The RACK1 homologue from Trypanosoma brucei is required for the onset and progression of cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VARIANT SURFACE GLYCOPROTEIN; CELL-CYCLE PROGRESSION; PROCYCLIC FORM; 80S RIBOSOME; ACTIVATED C-KINASE-1; AFRICAN TRYPANOSOMES; MUTATIONAL ANALYSIS; ANCHORING PROTEIN; RNA INTERFERENCE	The receptor for activated C kinase 1 (RACK1) is a conserved scaffold protein that helps regulate a range of cell activities including cell growth, shape, and protein translation. We report that a homologue of RACK1 is required for cytokinesis in pathogenic Trypanosoma brucei. The protein, referred to as TRACK, is comprised of WD repeat elements and can complement cpc2 null mutants of Schizosaccharomyces pombe. TRACK is expressed throughout the trypanosome life cycle and is distributed predominantly in a perinuclear region and the cytoplasm but not along the endoplasmic reticulum, mitochondrion, or cleavage furrow of dividing cells. When tetracycline-inducible RNA interference (RNAi) is used to deplete the cellular content of TRACK, the cells remain metabolically active, but growth is inhibited. In bloodstream forms, growth arrest is due to a delay in the onset of cytokinesis. By contrast, procyclic forms are able to initiate cytokinesis in the absence of TRACK but arrest midway through cell cleavage. The RNAi cells undergo multiple rounds of partial cytokinesis and accumulate nuclei and cytoplasmic extensions with attached flagella. The TRACK RNAi construct is also inducible within infected mice. Under these conditions parasites are eliminated from peripheral blood within 3 days post-infection. Taken as a whole, these data indicate that trypanosomes utilize a RACK1 homologue to regulate the final stages of mitosis. Moreover, disrupting the interaction between TRACK and its partners might be targeted in the design of novel therapies.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Ruben, L (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	lruben@mail.smu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051531, R01AI024627] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24627, AI051531, R01 AI051531, R01 AI051531-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angenstein F, 2002, J NEUROSCI, V22, P8827; Baum S, 2004, BIOCHEM J, V380, P823, DOI 10.1042/BJ20031962; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; DAS A, 1994, J CELL SCI, V107, P3477; Gao HX, 2005, P NATL ACAD SCI USA, V102, P10206, DOI 10.1073/pnas.0500926102; Garcia-Salcedo JA, 2004, EMBO J, V23, P780, DOI 10.1038/sj.emboj.7600094; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gerbasi VR, 2004, MOL CELL BIOL, V24, P8276, DOI 10.1128/MCB.24.18.8276-8287.2004; Giavalisco P, 2005, PLANT MOL BIOL, V57, P577, DOI 10.1007/s11103-005-0699-3; Grellier P, 1999, CELL MOTIL CYTOSKEL, V42, P36, DOI 10.1002/(SICI)1097-0169(1999)42:1&lt;36::AID-CM4&gt;3.0.CO;2-G; Hammarton TC, 2005, MOL MICROBIOL, V56, P104, DOI 10.1111/j.1365-2958.2005.04542.x; Hammarton TC, 2004, J BIOL CHEM, V279, P24757, DOI 10.1074/jbc.M401276200; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Inoue M, 2005, J BIOL CHEM, V280, P14085, DOI 10.1074/jbc.M412336200; Kelly BL, 2003, J EXP MED, V198, P1689, DOI 10.1084/jem.20031162; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Kilunga KB, 2005, J BIOL CHEM, V280, P26371, DOI 10.1074/jbc.M413884200; Kohl L, 2003, EMBO J, V22, P5336, DOI 10.1093/emboj/cdg518; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; Loreni F, 2005, FEBS LETT, V579, P5517, DOI 10.1016/j.febslet.2005.09.016; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Manuell AL, 2005, J MOL BIOL, V351, P266, DOI 10.1016/j.jmb.2005.06.022; Matthews KR, 1998, MOL BIOCHEM PARASIT, V95, P81, DOI 10.1016/S0166-6851(98)00100-5; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Moreno SNJ, 2003, CURR OPIN MICROBIOL, V6, P359, DOI 10.1016/S1369-5274(03)00091-2; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Parsons M, 2000, PARASITOL TODAY, V16, P56, DOI 10.1016/S0169-4758(99)01590-2; Ploubidou A, 1999, J CELL SCI, V112, P4641; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RUBEN L, 1991, MOL BIOCHEM PARASIT, V46, P123, DOI 10.1016/0166-6851(91)90206-L; Ruben L, 2003, MOL MED PARASITOLOGY, P241; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Sheader K, 2005, P NATL ACAD SCI USA, V102, P8716, DOI 10.1073/pnas.0501886102; Shor B, 2003, J BIOL CHEM, V278, P49119, DOI 10.1074/jbc.M303968200; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Taladriz S, 1999, FEBS LETT, V443, P375, DOI 10.1016/S0014-5793(99)00006-X; TORRI AF, 1993, MOL BIOCHEM PARASIT, V57, P305, DOI 10.1016/0166-6851(93)90206-D; Traub-Cseko YM, 1998, PARASITOL TODAY, V14, P41, DOI 10.1016/S0169-4758(97)01156-3; Tu XM, 2005, MOL BIOL CELL, V16, P97, DOI 10.1091/mbc.E04-05-0368; Tu XM, 2004, J BIOL CHEM, V279, P20519, DOI 10.1074/jbc.M312862200; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Vedrenne C, 2002, MOL BIOL CELL, V13, P1058, DOI 10.1091/mbc.01-06-0298; WANG Z, 2000, J BIOL CHEM, V211, P4998; Welburn SC, 1998, CELL DEATH DIFFER, V5, P615, DOI 10.1038/sj.cdd.4400393; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Won M, 2001, BIOCHEM BIOPH RES CO, V282, P10, DOI 10.1006/bbrc.2001.4535; WOODWARD R, 1990, J CELL SCI, V95, P49	66	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9781	9790		10.1074/jbc.M600133200	http://dx.doi.org/10.1074/jbc.M600133200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469736	Green Accepted, hybrid			2022-12-27	WOS:000236404700091
J	Wang, XL; Ye, YH; Lencer, W; Hansen, TH				Wang, XL; Ye, YH; Lencer, W; Hansen, TH			The viral E3 ubiquitin ligase mK3 uses the derlin/p97 endoplasmic reticulum-associated degradation pathway to mediate down-regulation of major histocompatibility complex class I proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; PEPTIDE-LOADING COMPLEX; ER-ASSOCIATED DEGRADATION; MEMBRANE-PROTEIN; IMMUNE EVASION; MISFOLDED PROTEINS; AAA-ATPASE; ANTIGEN PRESENTATION; FINGER PROTEIN; HEAVY-CHAINS	Ubiquitin E3 ligases are important cellular components for endoplasmic reticulum (ER)- associated degradation due to their role in substrate-specific ubiquitination, which is required for retrotranslocation ( dislocation) of most unwanted proteins from the ER to the cytosol for proteasome degradation. However, our understanding of the molecular mechanisms of how E3 ligases confer substrate-specific recognition, and their role in substrate retrotranslocation is limited especially in mammalian cells. mK3 is a type III ER membrane protein encoded by murine gamma herpesvirus 68. As conferred by its N-terminal RING-CH domain, mK3 has E3 ubiquitin ligase activity. In its role as an immune evasion protein, mK3 specifically targets nascent major histocompatibility complex class I heavy chains (HC) for rapid degradation. The mechanism by which mK3 extracts HC from the ER membrane into the cytosol for proteasome-mediated degradation is unknown. Evidence is presented here that HC down-regulation by mK3 is dependent on the p97 AAA-ATPase. By contrast, the kK5 protein of Kaposi's sarcoma-associated herpesvirus is p97-independent despite the fact that it is highly homologous to mK3. mK3 protein was also found in physical association with Derlin1, an ER protein recently implicated in the retrotranslocation of HC by immune evasion protein US11, but not US2, of human cytomegalovirus. The mechanistic implications of these findings are discussed.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Childrens Hosp Boston, Boston, MA 02115 USA; Harvard Univ, Ctr Digest Dis, Boston, MA 02115 USA	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Boston Children's Hospital; Harvard University	Hansen, TH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	hansen@immunology.wustl.edu		Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019687] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19687] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Boname JM, 2004, IMMUNITY, V20, P305, DOI 10.1016/S1074-7613(04)00047-0; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Cadwell K, 2005, SCIENCE, V309, P127, DOI 10.1126/science.1110340; Coscoy L, 2000, P NATL ACAD SCI USA, V97, P8051, DOI 10.1073/pnas.140129797; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fruh K, 2002, VIRUS RES, V88, P55, DOI 10.1016/S0168-1702(02)00120-X; Furman MH, 2003, J BIOL CHEM, V278, P34804, DOI 10.1074/jbc.M300913200; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Goto E, 2003, J BIOL CHEM, V278, P14657, DOI 10.1074/jbc.M211285200; Hassink G, 2005, BIOCHEM J, V388, P647, DOI 10.1042/BJ20041241; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kothe M, 2005, J BIOL CHEM, V280, P28127, DOI 10.1074/jbc.M503138200; Lehner PJ, 2005, IMMUNOL REV, V207, P112, DOI 10.1111/j.0105-2896.2005.00314.x; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lilley BN, 2005, IMMUNOL REV, V207, P126, DOI 10.1111/j.0105-2896.2005.00318.x; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lybarger L, 2005, CURR OPIN IMMUNOL, V17, P71, DOI 10.1016/j.coi.2004.11.009; Lybarger L, 2003, IMMUNITY, V18, P121, DOI 10.1016/S1074-7613(02)00509-5; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Miley MJ, 2003, J IMMUNOL, V170, P6090, DOI 10.4049/jimmunol.170.12.6090; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pines J, 2005, NAT CELL BIOL, V7, P731, DOI 10.1038/ncb0805-731; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sanchez DJ, 2002, J BIOL CHEM, V277, P6124, DOI 10.1074/jbc.M110265200; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Stevenson PG, 2002, NAT IMMUNOL, V3, P733, DOI 10.1038/ni818; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Wang XL, 2005, J VIROL, V79, P4099, DOI 10.1128/JVI.79.7.4099-4108.2005; Wang XL, 2004, J VIROL, V78, P8673, DOI 10.1128/JVI.78.16.8673-8686.2004; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Yu YYL, 2002, J VIROL, V76, P2796, DOI 10.1128/JVI.76.6.2796-2803.2002	51	41	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8636	8644		10.1074/jbc.M513920200	http://dx.doi.org/10.1074/jbc.M513920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446359	Green Submitted, hybrid			2022-12-27	WOS:000236247100041
J	Matsuo, Y; Morimoto, T; Kuwano, M; Loh, PC; Oshima, T; Ogasawara, N				Matsuo, Y; Morimoto, T; Kuwano, M; Loh, PC; Oshima, T; Ogasawara, N			The GTP-binding protein YlqF participates in the late step of 50 S ribosomal subunit assembly in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CROSS-LINKING; RNA HELICASE; 50S; ERA; RECONSTITUTION; IDENTIFICATION; OBG; OVEREXPRESSION; SUPPRESSION	Bacillus subtilis YlqF belongs to the Era/Obg subfamily of small GTP-binding proteins and is essential for bacterial growth. Here we report that YlqF participates in the late step of 50 S ribosomal subunit assembly. YlqF was co-fractionated with the 50 S subunit, depending on the presence of noncleavable GTP analog. Moreover, the GTPase activity of YlqF was stimulated specifically by the 50 S subunit in vitro. Dimethyl sulfate footprinting analysis disclosed that YlqF binds to a unique position in 23 S rRNA. Yeast two-hybrid data revealed interactions between YlqF and the B. subtilis L25 protein (Ctc). The interaction was confirmed by the pull-down assay of the purified proteins. Specifically, YlqF is positioned around the A-site and P-site on the 50 S subunit. Proteome analysis of the abnormal 50 S subunits that accumulated in YlqF-depleted cells showed that L16 and L27 proteins, located near the YlqF-binding domain, are missing. Our results collectively indicate that YlqF will organize the late step of 50 S ribosomal subunit assembly.	Nara Inst Sci & Technol, Grad Sch Informat Sci, Dept Bioinformat & Genom, Nara 6300101, Japan	Nara Institute of Science & Technology	Ogasawara, N (corresponding author), Nara Inst Sci & Technol, Grad Sch Informat Sci, Dept Bioinformat & Genom, 8916-5 Takayama, Nara 6300101, Japan.	nogasawa@bs.naist.jp	Ogasawara, Naotake/B-7971-2011; Loh, Pek Chin/S-9048-2017	Loh, Pek Chin/0000-0003-4865-0523				Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; Bongiorni C, 2005, J BACTERIOL, V187, P4353, DOI 10.1128/JB.187.13.4353-4361.2005; Caldon CE, 2001, MOL MICROBIOL, V41, P289, DOI 10.1046/j.1365-2958.2001.02536.x; Charollais J, 2004, NUCLEIC ACIDS RES, V32, P2751, DOI 10.1093/nar/gkh603; Charollais J, 2003, MOL MICROBIOL, V48, P1253, DOI 10.1046/j.1365-2958.2003.03513.x; Czyz A, 2005, ACTA BIOCHIM POL, V52, P35; Daigle DM, 2004, J BACTERIOL, V186, P1381, DOI 10.1128/JB.186.5.1381-1387.2004; DAMMEL CS, 1995, GENE DEV, V9, P626, DOI 10.1101/gad.9.5.626; DOHME F, 1976, J MOL BIOL, V107, P585, DOI 10.1016/S0022-2836(76)80085-X; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; HAMPL H, 1981, J BIOL CHEM, V256, P2284; Hang JQ, 2003, EUR J BIOCHEM, V270, P4164, DOI 10.1046/j.1432-1033.2003.03813.x; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HEROLD M, 1987, J BIOL CHEM, V262, P8826; Himeno H, 2004, NUCLEIC ACIDS RES, V32, P5303, DOI 10.1093/nar/gkh861; Inoue K, 2003, MOL MICROBIOL, V48, P1005, DOI 10.1046/j.1365-2958.2003.03475.x; James P, 1996, GENETICS, V144, P1425; KAZEMIE M, 1976, EUR J BIOCHEM, V67, P373, DOI 10.1111/j.1432-1033.1976.tb10701.x; KAZEMIE M, 1975, EUR J BIOCHEM, V58, P501, DOI 10.1111/j.1432-1033.1975.tb02398.x; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; LERNER CG, 1991, MOL MICROBIOL, V5, P951, DOI 10.1111/j.1365-2958.1991.tb00770.x; Lin B, 2004, J BACTERIOL, V186, P481, DOI 10.1128/JB.186.2.481-489.2004; LOTTI M, 1987, MOL GEN GENET, V210, P498, DOI 10.1007/BF00327203; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; Meier TI, 1999, J BACTERIOL, V181, P5242, DOI 10.1128/JB.181.17.5242-5249.1999; MICHELINE FR, 2003, GENE, V313, P17; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P21; MOORE VG, 1975, P NATL ACAD SCI USA, V72, P844, DOI 10.1073/pnas.72.3.844; Morimoto T, 2002, MICROBIOL-SGM, V148, P3539, DOI 10.1099/00221287-148-11-3539; Nanamiya H, 2004, MOL MICROBIOL, V52, P273, DOI 10.1111/j.1365-2958.2003.03972.x; Nishimura M, 2004, J MOL BIOL, V344, P1369, DOI 10.1016/j.jmb.2004.10.011; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; Sayed A, 1999, BIOCHEM BIOPH RES CO, V264, P51, DOI 10.1006/bbrc.1999.1471; Schmalisch M, 2002, J MOL MICROB BIOTECH, V4, P495; Scott JM, 2000, J BACTERIOL, V182, P2771, DOI 10.1128/JB.182.10.2771-2777.2000; Sharma H, 2005, INT ORTHOP, V29, P319, DOI 10.1007/s00264-005-0673-3; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; Takahashi N, 2003, MASS SPECTROM REV, V22, P287, DOI 10.1002/mas.10057; TATE WP, 1983, J BIOL CHEM, V258, P2810; TERAOKA H, 1978, FEBS LETT, V88, P223, DOI 10.1016/0014-5793(78)80179-3; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; Uchiumi T, 1999, J BIOL CHEM, V274, P681, DOI 10.1074/jbc.274.2.681; Uicker WC, 2006, MOL MICROBIOL, V59, P528, DOI 10.1111/j.1365-2958.2005.04948.x; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; WALLECZEK J, 1989, BIOCHEMISTRY-US, V28, P4099, DOI 10.1021/bi00435a071; Wilson DN, 2005, EMBO J, V24, P251, DOI 10.1038/sj.emboj.7600525; Wout P, 2004, J BACTERIOL, V186, P5249, DOI 10.1128/JB.186.16.5249-5257.2004; Wower IK, 1998, J BIOL CHEM, V273, P19847, DOI 10.1074/jbc.273.31.19847; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4; Zalacain M, 2003, J MOL MICROB BIOTECH, V6, P109, DOI 10.1159/000076741	51	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8110	8117		10.1074/jbc.M512556200	http://dx.doi.org/10.1074/jbc.M512556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431913	hybrid			2022-12-27	WOS:000236031000048
J	Li, XF; Kiedrowski, L; Tremblay, F; Fernandez, FR; Perizzolo, M; Winkfein, RJ; Turner, RW; Bains, JS; Rancourt, DE; Lytton, J				Li, XF; Kiedrowski, L; Tremblay, F; Fernandez, FR; Perizzolo, M; Winkfein, RJ; Turner, RW; Bains, JS; Rancourt, DE; Lytton, J			Importance of K+-dependent Na+/Ca2+-exchanger 2, NCKX2, in motor learning and memory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; LONG-TERM POTENTIATION; NA+/CA2+ EXCHANGERS; EXTRACELLULAR POTASSIUM; MICE LACKING; CA2+ CLEARANCE; RETINAL CONE; ROD; HOMEOSTASIS; RECEPTORS	Plasma membrane Na+/Ca2+-exchangers play a predominant role in Ca2+ extrusion in brain. Neurons express several different Na+/Ca2+-exchangers belonging to both the K+-independent NCX family and the K+-dependent NCKX family. The unique contributions of each of these proteins to neuronal Ca2+ homeostasis and/or physiology remain largely unexplored. To address this question, we generated mice in which the gene encoding the abundant neuronal K+-dependent Na+/Ca2+-exchanger protein, NCKX2, was knocked out. Analysis of these animals revealed a significant reduction in Ca2+ flux in cortical neurons, a profound loss of long term potentiation and an increase in long term depression at hippocampal Schaffer/CA1 synapses, and clear deficits in specific tests of motor learning and spatial working memory. Surprisingly, there was no obvious loss of photoreceptor function in cones, where expression of the NCKX2 protein had been reported previously. These data emphasize the critical and non-redundant role of NCKX2 in the local control of neuronal [Ca2+] that is essential for the development of synaptic plasticity associated with learning and memory.	Univ Calgary, Hlth Sci Ctr, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB T2N 4N1, Canada; Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Illinois, Inst Psychiat, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Inst Psychiat, Dept Pharmacol, Chicago, IL 60612 USA; Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3J 3G9, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Dalhousie University	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Hotchkiss Brain Inst, Rm 2518,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Bains, Jaideep/0000-0002-3634-6463; Lytton, Jonathan/0000-0003-4770-2512; Tremblay, Francois/0000-0001-7780-8719	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037390] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37390] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; Ausubel F.M., 1998, CURRENT PROTOCOLS MO; BALLYK BA, 1992, J NEUROSCI RES, V33, P598, DOI 10.1002/jnr.490330412; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; BLANKS JC, 1983, J COMP NEUROL, V221, P31, DOI 10.1002/cne.902210103; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai X, 2004, NEURON, V44, P351, DOI 10.1016/j.neuron.2004.09.026; Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177; Cai XJ, 2002, J BIOL CHEM, V277, P48923, DOI 10.1074/jbc.M208818200; Chandrasekera CP, 2003, J BIOL CHEM, V278, P12482, DOI 10.1074/jbc.M212745200; Choi DW, 2005, NATURE, V433, P696, DOI 10.1038/433696a; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; Czyz A, 2002, J NEUROCHEM, V83, P1321, DOI 10.1046/j.1471-4159.2002.01227.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; HUANG YY, 1987, NEUROSCIENCE, V22, P9, DOI 10.1016/0306-4522(87)90193-X; Imahashi K, 2005, CIRC RES, V97, P916, DOI 10.1161/01.RES.0000187456.06162.cb; Jeon D, 2003, NEURON, V38, P965, DOI 10.1016/S0896-6273(03)00334-9; Kiedrowski L, 2002, ANN NY ACAD SCI, V976, P413; Kiedrowski L, 2004, NEUROREPORT, V15, P2113, DOI 10.1097/00001756-200409150-00023; Kiedrowski L, 2004, J NEUROCHEM, V90, P117, DOI 10.1111/j.1471-4159.2004.02462.x; Kim MH, 2005, J NEUROSCI, V25, P6057, DOI 10.1523/JNEUROSCI.0454-05.2005; Kim MH, 2003, J NEUROSCI, V23, P11673; Korenbrot JI, 2002, ADV EXP MED BIOL, V514, P179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SH, 2002, J NEUROSCI, V22, P6891; Lees-Miller JP, 2003, MOL CELL BIOL, V23, P1856, DOI 10.1128/MCB.23.6.1856-1862.2003; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; LI ZP, 1994, J BIOL CHEM, V269, P17434; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Lytton J, 2002, ANN NY ACAD SCI, V976, P382; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; Medina JF, 2002, NAT REV NEUROSCI, V3, P122, DOI 10.1038/nrn728; Nakanishi S, 2005, TRENDS NEUROSCI, V28, P93, DOI 10.1016/j.tins.2004.12.004; Ngo-Anh TJ, 2005, NAT NEUROSCI, V8, P642, DOI 10.1038/nn1449; Papa M, 2003, J COMP NEUROL, V461, P31, DOI 10.1002/cne.10665; Pignataro G, 2004, NEUROPHARMACOLOGY, V46, P439, DOI 10.1016/j.neuropharm.2003.09.015; POOLOS NP, 1990, BRAIN RES, V508, P7, DOI 10.1016/0006-8993(90)91110-3; Poolos NP, 1999, J NEUROSCI, V19, P5205; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Prinsen CFM, 2002, ADV EXP MED BIOL, V514, P237; Quednau BD, 2004, PFLUG ARCH EUR J PHY, V447, P543, DOI 10.1007/s00424-003-1065-4; Reisel D, 2002, NAT NEUROSCI, V5, P868, DOI 10.1038/nn910; REUTER H, 1995, NEURON, V15, P1077, DOI 10.1016/0896-6273(95)90096-9; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SALVATERRA PM, 1980, NEUROCHEM RES, V5, P181, DOI 10.1007/BF00964331; Schnetkamp PPM, 2004, PFLUG ARCH EUR J PHY, V447, P683, DOI 10.1007/s00424-003-1069-0; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; Sharon D, 2002, INVEST OPHTH VIS SCI, V43, P1971; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; STRINGER JL, 1988, EXP NEUROL, V101, P147, DOI 10.1016/0014-4886(88)90071-4; Szel A, 1996, MICROSC RES TECHNIQ, V35, P445; Tremblay F, 2002, VISION RES, V42, P1715, DOI 10.1016/S0042-6989(02)00113-X; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Tsuzuki T, 1998, NUCLEIC ACIDS RES, V26, P988, DOI 10.1093/nar/26.4.988; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; Whishaw IQ, 1999, MODERN TECHNIQUES NE, P1243, DOI 10.1007/978-3-642-58552-4_44; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333	64	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6273	6282		10.1074/jbc.M512137200	http://dx.doi.org/10.1074/jbc.M512137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407245	Green Published, hybrid			2022-12-27	WOS:000236030800020
J	Salvatorelli, E; Guarnieri, S; Menna, P; Liberi, G; Calafiore, AM; Mariggio, MA; Mordente, A; Gianni, L; Minotti, G				Salvatorelli, E; Guarnieri, S; Menna, P; Liberi, G; Calafiore, AM; Mariggio, MA; Mordente, A; Gianni, L; Minotti, G			Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart - Relative importance of vesicular sequestration and impaired efficiency of electron addition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR OXIDATIVE STRESS; DOXORUBICIN-MEDIATED APOPTOSIS; SECONDARY ALCOHOL METABOLITE; IRON REGULATORY PROTEIN-1; HUMAN MYOCARDIUM; BREAST-CANCER; INDUCED CARDIOTOXICITY; CYTOSOLIC FRACTIONS; CARBONYL REDUCTASE; RADICAL FORMATION	One-electron quinone reduction and two-electron carbonyl reduction convert the anticancer anthracycline doxorubicin to reactive oxygen species(ROS) or a secondary alcohol metabolite that contributes to inducing a severe form of cardiotoxicity. The closely related analogue epirubicin induces less cardiotoxicity, but the determinants of its different behavior have not been elucidated. We developed a translational model of the human heart and characterized whether epirubicin exhibited a defective conversion to ROS and secondary alcohol metabolites. Small myocardial samples from cardiac surgery patients were reconstituted in plasma that contained clinically relevant concentrations of doxorubicin or epirubicin. In this model only doxorubicin formed ROS, as detected by fluorescent probes or aconitase inactivation. Experiments with cell-free systems and confocal laser scanning microscopy studies of H9c2 cardiomyocytes suggested that epirubicin could not form ROS because of its protonation-dependent sequestration in cytoplasmic acidic organelles and the consequent limited localization to mitochondrial one-electron quinone reductases. Accordingly, blocking the protonation-sequestration mechanism with the vacuolar H+-ATPase inhibitor bafilomycin A1 relocalized epirubicin to mitochondria and increased its conversion to ROS in human myocardial samples. Epirubicin also formed similar to 60% less alcohol metabolites than doxorubicin, but this was caused primarily by its higher K-m and lower V-max values for two-electron carbonyl reduction by aldo/keto-reductases of human cardiac cytosol. Thus, vesicular sequestration and impaired efficiency of electron addition have separate roles in determining a defective bioactivation of epirubicin to ROS or secondary alcohol metabolites in the human heart. These results uncover the molecular determinants of the reduced cardiotoxicity of epirubicin and serve mechanism-based guidelines to improving antitumor therapies.	Univ G DAnnunzio, Sch Med, Ctr Excellence Aging, I-66013 Chieti, Italy; Univ G DAnnunzio, Sch Med, Dept Cardiac Surg, I-66013 Chieti, Italy; European Hosp, Unit Cardiac Surg, I-00148 Rome, Italy; Univ Sacred Heart, Sch Med, Inst Biochem & Clin Biochem, I-00168 Rome, Italy; Ist Nazl Tumori, Med Oncol Unit, I-20133 Milan, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Fondazione IRCCS Istituto Nazionale Tumori Milan	Minotti, G (corresponding author), Univ G DAnnunzio, Sch Med, CeSI, Rm 412,Via Vestini, I-66013 Chieti, Italy.	gminotti@unich.it	Mordente, Alvaro/AAB-7290-2019; Mariggiò, Maria Addolorata/T-9047-2017; Guarnieri, Simone/AAA-5921-2020	Mariggiò, Maria Addolorata/0000-0001-5306-7143; GIANNI, LUCA/0000-0002-2372-9625; Mariggio, Maria Addolorata/0000-0002-3508-8706; Minotti, Giorgio/0000-0002-5678-6175; MORDENTE, Alvaro/0000-0003-3260-9796; MENNA, Pierantonio/0000-0002-7755-818X; Guarnieri, Simone/0000-0002-2916-2965; Salvatorelli, Emanuela/0000-0001-9805-4100				Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; BONADONNA G, 1993, ANN ONCOL, V4, P359, DOI 10.1093/oxfordjournals.annonc.a058514; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Charlier HA, 2005, MOL PHARMACOL, V67, P1505, DOI 10.1124/mol.104.005728; Corna G, 2004, J BIOL CHEM, V279, P13738, DOI 10.1074/jbc.M310106200; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; DOROSHOW JH, 1995, ACS SYM SER, V574, P259; EWER MS, 2000, CANC MED, P2324; Finlay GJ, 2000, CANCER CHEMOTH PHARM, V45, P417, DOI 10.1007/s002800051011; Forrest GL, 2000, CHEM-BIOL INTERACT, V129, P21, DOI 10.1016/S0009-2797(00)00196-4; Gambliel HA, 2002, BIOCHEM BIOPH RES CO, V291, P433, DOI 10.1006/bbrc.2002.6380; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gianni L, 1997, J CLIN ONCOL, V15, P1906, DOI 10.1200/JCO.1997.15.5.1906; Gille L, 1997, FREE RADICAL BIO MED, V23, P775, DOI 10.1016/S0891-5849(97)00025-7; Giraud MN, 2005, J APPL PHYSIOL, V99, P313, DOI 10.1152/japplphysiol.00609.2004; Gong YP, 2003, J BIOL CHEM, V278, P50234, DOI 10.1074/jbc.M306606200; Grasselli G, 2001, J CLIN ONCOL, V19, P2222, DOI 10.1200/JCO.2001.19.8.2222; GREGORY J, 2002, 07510 MP, P1; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Innocenti F, 2001, DRUG METAB DISPOS, V29, P686; Kalivendi SV, 2005, BIOCHEM J, V389, P527, DOI 10.1042/BJ20050285; Kang YJ, 2002, CHEM RES TOXICOL, V15, P1, DOI 10.1021/tx015532n; Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936; Kotamraju S, 2004, METHOD ENZYMOL, V378, P362; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; L'Ecuyer T, 2004, AM J PHYSIOL-HEART C, V286, pH2057, DOI 10.1152/ajpheart.00778.2003; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; MAESSEN PA, 1987, CANCER CHEMOTH PHARM, V20, P85, DOI 10.1007/BF00252968; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Menna P, 2002, CHEM RES TOXICOL, V15, P1179, DOI 10.1021/tx020055+; Minotti G, 1998, FASEB J, V12, P541, DOI 10.1096/fasebj.12.7.541; Minotti G, 2004, METHOD ENZYMOL, V378, P340; Minotti G, 2001, CLIN CANCER RES, V7, P1511; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; Minotti G, 2000, CHEM RES TOXICOL, V13, P1336, DOI 10.1021/tx000143z; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; MUSHLIN PS, 1993, BRIT J PHARMACOL, V110, P975, DOI 10.1111/j.1476-5381.1993.tb13909.x; Olson LE, 2003, CANCER RES, V63, P6602; OLSON RD, 1988, P NATL ACAD SCI USA, V85, P3585, DOI 10.1073/pnas.85.10.3585; OLSSON JM, 1991, CANCER RES, V51, P3774; OPPERMANN UCT, 1991, BIOCHEM PHARMACOL, V42, P189; Ouar Z, 2003, BIOCHEM J, V370, P185, DOI 10.1042/BJ20021411; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Raghunand N, 2000, DRUG RESIST UPDATE, V3, P39, DOI 10.1054/drup.2000.0119; Ramachandran A, 2002, P NATL ACAD SCI USA, V99, P6643, DOI 10.1073/pnas.102019899; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; Siebert GA, 2004, J PHARMACOL EXP THER, V308, P228, DOI 10.1124/jpet.103.056770; Singal P, 2000, MOL CELL BIOCHEM, V207, P77, DOI 10.1023/A:1007094214460; Wagner BA, 2005, ARCH BIOCHEM BIOPHYS, V440, P181, DOI 10.1016/j.abb.2005.06.015; Wielinga PR, 2000, EUR J BIOCHEM, V267, P649, DOI 10.1046/j.1432-1327.2000.01030.x; Yokogawa K, 2002, METHOD FIND EXP CLIN, V24, P81, DOI 10.1358/mf.2002.24.2.677131	58	85	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10990	11001		10.1074/jbc.M508343200	http://dx.doi.org/10.1074/jbc.M508343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16423826	hybrid			2022-12-27	WOS:000236822200040
J	Li, CH; Allen, A; Kwagh, J; Doliba, NM; Qin, W; Najafi, H; Collins, HW; Matschinsky, FM; Stanley, CA; Smith, TJ				Li, CH; Allen, A; Kwagh, J; Doliba, NM; Qin, W; Najafi, H; Collins, HW; Matschinsky, FM; Stanley, CA; Smith, TJ			Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERINSULINISM/HYPERAMMONEMIA SYNDROME; REGULATORY MUTATIONS; MECHANISM; METABOLISM; MESSENGER; CHILDREN; LEUCINE; RELEASE	Insulin secretion by pancreatic beta-cells is stimulated by glucose, amino acids, and other metabolic fuels. Glutamate dehydrogenase (GDH) has been shown to play a regulatory role in this process. The importance of GDH was underscored by features of hyperinsulinemia/hyperammonemia syndrome, where a dominant mutation causes the loss of inhibition by GTP and ATP. Here we report the effects of green tea polyphenols on GDH and insulin secretion. Of the four compounds tested, epigallocatechin gallate (EGCG) and epicatechin gallate were found to inhibit GDH with nanomolar ED50 values and were therefore found to be as potent as the physiologically important inhibitor GTP. Furthermore, we have demonstrated that EGCG inhibits BCH-stimulated insulin secretion, a process that is mediated by GDH, under conditions where GDH is no longer inhibited by high energy metabolites. EGCG does not affect glucose-stimulated insulin secretion under high energy conditions where GDH is probably fully inhibited. We have further shown that these compounds act in an allosteric manner independent of their antioxidant activity and that the beta-cell stimulatory effects are directly correlated with glutamine oxidation. These results demonstrate that EGCG, much like the activator of GDH (BCH), can facilitate dissecting the complex regulation of insulin secretion by pharmacologically modulating the effects of GDH.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Childrens Hosp Philadelphia, Abramson Res Ctr, Div Endocrinol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Diabet Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Donald Danforth Plant Science Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Smith, TJ (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	tsmith@danforthcenter.org	Smith, Thomas J/K-9086-2013	Smith, Thomas J/0000-0003-3528-6793; STANLEY, CHARLES/0000-0003-4881-9392	NIDDK NIH HHS [DK 072171, DK 53012, DK 19525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053012, R01DK072171, P30DK019525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen A, 2004, BIOCHEMISTRY-US, V43, P14431, DOI 10.1021/bi048817i; Anderson RA, 2002, J AGR FOOD CHEM, V50, P7182, DOI 10.1021/jf020514c; Anderson RF, 2001, CARCINOGENESIS, V22, P1189, DOI 10.1093/carcin/22.8.1189; BRUNHUBER NMW, 1994, CRIT REV BIOCHEM MOL, V29, P415, DOI 10.3109/10409239409083486; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; Fang J, 2002, BIOCHEM J, V363, P81, DOI 10.1042/0264-6021:3630081; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; HAMILTONMILLER JMT, 1995, ANTIMICROB AGENTS CH, V39, P2375, DOI 10.1128/AAC.39.11.2375; Hsu BYL, 2001, J PEDIATR-US, V138, P383, DOI 10.1067/mpd.2001.111818; Katiyar SK, 1996, INT J ONCOL, V8, P221; Konayagi S, 1933, STUDY PHYSL, V10, P449; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Lo LW, 1997, ADV EXP MED BIOL, V428, P651; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; MacMullen C, 2001, J CLIN ENDOCR METAB, V86, P1782, DOI 10.1210/jc.86.4.1782; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maron DJ, 2003, ARCH INTERN MED, V163, P1448, DOI 10.1001/archinte.163.12.1448; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; PROUGH RA, 1973, J BIOL CHEM, V248, P8528; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; Smith TJ, 2002, J MOL BIOL, V318, P765, DOI 10.1016/S0022-2836(02)00161-4; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Stanley CA, 2000, GENETIC INSIGHTS PAE, P23; Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038	29	122	128	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10214	10221		10.1074/jbc.M512792200	http://dx.doi.org/10.1074/jbc.M512792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476731	hybrid			2022-12-27	WOS:000236594300048
J	Mehta, S; Gould, KL				Mehta, S; Gould, KL			Identification of functional domains within the septation initiation network kinase, Cdc7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; SEPTUM FORMATION; PLO1 KINASE; CYTOKINESIS; RESOURCE; ONSET; CELL	The septation initiation network ( SIN) serves to coordinate cytokinesis with mitotic exit in the fission yeast Schizosaccharomyces pombe. SIN components Spg1 and Cdc7 together play a central role in regulating the onset of septation and cytokinesis. Spg1, a Ras-like GTPase, localizes to the spindle pole bodies (SPBs) throughout the cell cycle. It is converted to its GTP-bound ( active) state during mitosis, only to become inactivated at one SPB during anaphase and at both SPBs as cells exit mitosis. Cdc7 functions as an effector kinase for Spg1, binding to Spg1 in its GTP-bound state, and therefore is present at both SPBs during mitosis and asymmetrically at only one during anaphase. Interestingly, the kinase activity of Cdc7 does not vary across the cell cycle, suggesting the possibility that Cdc7 kinase activity is independent of Spg1 binding. Consistent with this, we found that Cdc7 associates with Spg1 only during mitosis. To learn more about the essential role of Cdc7 kinase in the SIN and its regulation, we undertook a structure/function analysis and identified independent functional domains within Cdc7. We found that a region adjacent to the kinase domain is responsible for Spg1 association and identified an overlapping but distinct SPB localization domain. In addition Cdc7 associates with itself and exists as a dimer in vivo.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Gould, KL (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	kathy.gould@vanderbilt.edu		Gould, Kathleen/0000-0002-3810-4070				Balasubramanian MK, 1998, GENETICS, V149, P1265; Bardin AJ, 2003, MOL CELL BIOL, V23, P5018, DOI 10.1128/MCB.23.14.5018-5030.2003; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Cerutti L, 1999, J CELL SCI, V112, P2313; Chang L, 2000, P NATL ACAD SCI USA, V97, P5249, DOI 10.1073/pnas.97.10.5249; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guertin DA, 2000, EMBO J, V19, P1803, DOI 10.1093/emboj/19.8.1803; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; James P, 1996, GENETICS, V144, P1425; Krapp A, 2004, CURR BIOL, V14, pR722, DOI 10.1016/j.cub.2004.08.049; Lu YB, 2002, GENES CELLS, V7, P1009, DOI 10.1046/j.1365-2443.2002.00582.x; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morrell JL, 2004, CURR BIOL, V14, P579, DOI 10.1016/j.cub.2004.03.036; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Petretti C, 2005, BIOL CELL, V97, P113, DOI 10.1042/BC20040077; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Salimova E, 2000, J CELL SCI, V113, P1695; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; Simanis V, 2003, J CELL SCI, V116, P4263, DOI 10.1242/jcs.00807; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P525, DOI 10.1016/S0079-6107(98)00046-7; Smith CM, 1997, TRENDS BIOCHEM SCI, V22, P444, DOI 10.1016/S0968-0004(97)01131-6; Sohrmann M, 1998, GENE DEV, V12, P84, DOI 10.1101/gad.12.1.84; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tomlin GC, 2002, MOL BIOL CELL, V13, P1203, DOI 10.1091/mbc.01-09-0455; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	37	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9935	9941		10.1074/jbc.M600160200	http://dx.doi.org/10.1074/jbc.M600160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469735	hybrid			2022-12-27	WOS:000236594300015
J	Padilla-Lopez, S; Pearce, DA				Padilla-Lopez, S; Pearce, DA			Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity to regulate pH imbalance in the vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEINS; NEURONAL CEROID-LIPOFUSCINOSES; BATTEN-DISEASE; H+-ATPASE; YEAST MODEL; TRANSPORT-SYSTEMS; MEMBRANE-VESICLES; NA+/H+ EXCHANGER; SUBUNIT-C; HOMEOSTASIS	The vacuolar H+-ATPase (V-ATPase) along with ion channels and transporters maintains vacuolar pH. V-ATPase ATP hydrolysis is coupled with proton transport and establishes an electrochemical gradient between the cytosol and vacuolar lumen for coupled transport of metabolites. Btn1p, the yeast homolog to human CLN3 that is defective in Batten disease, localizes to the vacuole. We previously reported that Btn1p is required for vacuolar pH maintenance and ATP-dependent vacuolar arginine transport. We report that extracellular pH alters both V-ATPase activity and proton transport into the vacuole of wild-type Saccharomyces cerevisiae. V-ATPase activity is modulated through the assembly and disassembly of the V-0 and V-1 V-ATPase subunits located in the vacuolar membrane and on the cytosolic side of the vacuolar membrane, respectively. V-ATPase assembly is increased in yeast cells grown in high extracellular pH. In addition, at elevated extracellular pH, S. cerevisiae lacking BTN1 (btn1-Delta), have decreased V-ATPase activity while proton transport into the vacuole remains similar to that for wild type. Thus, coupling of V-ATPase activity and proton transport in btn1-Delta is altered. We show that down-regulation of V-ATPase activity compensates the vacuolar pH imbalance for btn1-Delta at early growth phases. We therefore propose that Btn1p is required for tight regulation of vacuolar pH to maintain the vacuolar luminal content and optimal activity of this organelle and that disruption in Btn1p function leads to a modulation of V-ATPase activity to maintain cellular pH homeostasis and vacuolar luminal content.	Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Pearce, DA (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Aab Inst Biomed Sci, Box 645, Rochester, NY 14642 USA.	David_Pearce@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036610] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 036610] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali R, 2004, J BIOL CHEM, V279, P4498, DOI 10.1074/jbc.M307446200; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BANERJEE P, 1992, AM J MED GENET, V42, P549, DOI 10.1002/ajmg.1320420426; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Brett CL, 2005, MOL BIOL CELL, V16, P1396, DOI 10.1091/mbc.E04-11-0999; Camarasa C, 1996, YEAST, V12, P1301, DOI 10.1002/(SICI)1097-0061(199610)12:13<1301::AID-YEA18>3.0.CO;2-A; Chattopadhyay S, 2000, J BACTERIOL, V182, P6418, DOI 10.1128/JB.182.22.6418-6423.2000; Chattopadhyay S, 2003, BIOCHEM BIOPH RES CO, V302, P534, DOI 10.1016/S0006-291X(03)00209-2; Chattopadhyay S, 2002, EUKARYOT CELL, V1, P606, DOI 10.1128/EC.1.4.606-612.2002; Croopnick JB, 1998, BIOCHEM BIOPH RES CO, V250, P335, DOI 10.1006/bbrc.1998.9272; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forster C, 2000, J BIOL CHEM, V275, P38245, DOI 10.1074/jbc.M006650200; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; GOEBEL HH, 1995, J CHILD NEUROL, V10, P424, DOI 10.1177/088307389501000602; Graham LA, 2000, J EXP BIOL, V203, P61; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HALL NA, 1991, BIOCHEM J, V275, P269, DOI 10.1042/bj2750269; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; Hirata T, 2002, J BIOCHEM, V131, P261, DOI 10.1093/oxfordjournals.jbchem.a003097; Jezek P, 2004, PHYSIOL RES, V53, pS199; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Kim Y, 2005, EUKARYOT CELL, V4, P281, DOI 10.1128/EC.4.2.281-288.2005; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BIOCHEM SOC T, V29, P806; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Klingenberg M, 1999, J BIOENERG BIOMEMBR, V31, P419, DOI 10.1023/A:1005440221914; KOENIG H, 1964, J NEUROCHEM, V11, P729, DOI 10.1111/j.1471-4159.1964.tb06118.x; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Mole SE, 1998, NEUROBIOL DIS, V5, P287, DOI 10.1006/nbdi.1998.0209; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OKOROKOV LA, 1985, FEBS LETT, V192, P303, DOI 10.1016/0014-5793(85)80130-7; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; Pearce DA, 1998, P NATL ACAD SCI USA, V95, P6915, DOI 10.1073/pnas.95.12.6915; Pearce DA, 1997, YEAST, V13, P691, DOI 10.1002/(SICI)1097-0061(19970630)13:8<691::AID-YEA123>3.0.CO;2-D; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Pearce DA, 1999, P NATL ACAD SCI USA, V96, P11341, DOI 10.1073/pnas.96.20.11341; Plant PJ, 1999, J BIOL CHEM, V274, P37270, DOI 10.1074/jbc.274.52.37270; Russnak R, 2001, J BIOL CHEM, V276, P23849, DOI 10.1074/jbc.M008028200; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; Shimazu M, 2005, J BIOL CHEM, V280, P4851, DOI 10.1074/jbc.M412617200; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; Uemura T, 2004, BIOCHEM BIOPH RES CO, V315, P1082, DOI 10.1016/j.bbrc.2004.01.162; Weimer JM, 2002, NEUROMOL MED, V1, P111, DOI 10.1385/NMM:1:2:111	55	65	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10273	10280		10.1074/jbc.M510625200	http://dx.doi.org/10.1074/jbc.M510625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16423829	hybrid			2022-12-27	WOS:000236594300055
J	Esparza, EM; Lindsten, T; Stockhausen, JM; Arch, RH				Esparza, EM; Lindsten, T; Stockhausen, JM; Arch, RH			Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATION; FAMILY; TRAF5; GENE; IDENTIFICATION; SUPERFAMILY; INHIBITOR; INDUCTION; PROTEINS	Tumor necrosis factor receptor ( TNFR) family members such as glucocorticoid-induced TNFR ( GITR) control T cell activation, differentiation, and effector functions. Importantly, GITR functions as a pivotal regulator of physiologic and pathologic immune responses by abrogating the suppressive effects of T regulatory cells and costimulating T effector cells. However, the molecular mechanisms underlying GITR-triggered signal transduction pathways remain unclear. Interestingly, GITR-induced stimulation of TNFR-associated factor ( TRAF) 5-deficient T cells resulted in decreased activation of nuclear factor kappa B as well as the mitogen-activated protein kinases p38 and extracellular signal-regulated protein kinase, whereas activation of c-Jun N-terminal kinase was less affected. Consistent with impaired signaling, costimulatory effects of GITR were diminished in TRAF5(-/-) T cells. In sum, our studies indicate that TRAF5 plays a crucial role in GITR-induced signaling pathways that augment T cell activation.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Immunol, St Louis, MO 63110 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine	Arch, RH (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	arch@wustl.edu.2			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067312] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007317, 5 RO1 HL67312-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Esparza EM, 2006, FRONT BIOSCI-LANDMRK, V11, P1448, DOI 10.2741/1895; Esparza EM, 2005, J IMMUNOL, V174, P7875, DOI 10.4049/jimmunol.174.12.7875; Esparza EM, 2005, J IMMUNOL, V174, P7869, DOI 10.4049/jimmunol.174.12.7869; Esparza EM, 2004, CELL MOL LIFE SCI, V61, P3087, DOI 10.1007/s00018-004-4417-0; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443; Kim YS, 2005, MOL CELL BIOL, V25, P2130, DOI 10.1128/MCB.25.6.2130-2137.2005; Kohm AP, 2004, J IMMUNOL, V172, P4686, DOI 10.4049/jimmunol.172.8.4686; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Shiels H, 2000, AM J PATHOL, V157, P679, DOI 10.1016/S0002-9440(10)64578-6; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; So T, 2004, J IMMUNOL, V172, P4292, DOI 10.4049/jimmunol.172.7.4292; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Suri A, 2004, EUR J IMMUNOL, V34, P447, DOI 10.1002/eji.200324599; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	29	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8559	8564		10.1074/jbc.M512915200	http://dx.doi.org/10.1074/jbc.M512915200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452475	hybrid			2022-12-27	WOS:000236247100031
J	Mendez-Ortiz, MM; Hyodo, M; Hayakawa, Y; Membrillo-Hernandez, J				Mendez-Ortiz, MM; Hyodo, M; Hayakawa, Y; Membrillo-Hernandez, J			Genome-wide transcriptional profile of Escherichia coli in response to high levels of the second messenger 3 ',5 '-cyclic diguanylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC DI-GMP; DIRECT OXYGEN SENSOR; BIOFILM FORMATION; ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; ALLOSTERIC CONTROL; REGULATORY SYSTEM; RCS PHOSPHORELAY; PROTEIN DOMAIN; EAL DOMAINS	Cyclic diguanylic acid(c-di-GMP; cGpGp) is a global second messenger controlling motility and adhesion in bacterial cells. Intracellular concentrations of c-di-GMP depend on two opposite activities: diguanylate cyclase, recently assigned to the widespread GGDEF domain, and c-di-GMP-specific phosphodiesterase, associated with proteins harboring the EAL domain. To date, little is known about the targets of c-di-GMP in the cell or if it affects transcriptional regulation of certain genes. In order to expand our knowledge of the effect of this molecule on the bacterial metabolism, here we report on the Escherichia coli transcriptional profile under high levels of c-di-GMP. We show that an important number of genes encoding cell surface and membrane-bound proteins are altered in their transcriptional activity. On the other hand, genes encoding several transcriptional factors, such as Fur, RcsA, SoxS, and ZraR, are up-regulated, and others, such as GadE, GadX, GcvA, and MetR, are down-regulated. Transcription of motility and cell division genes were altered, and consistent with this was the physiological analysis of cells overexpressing yddV, a diguanylate cyclase; these cells displayed an abnormal cell division process when high levels of c-di-GMP were present. We also show evidence that the diguanylate cyclase gene yddV is co-transcribed with dos, a heme base oxygen sensor with c-di-GMP-specific phosphodiesterase activity. A Delta dos::kan mutation rendered the cells unable to divide properly, suggesting that dos and yddV may be part of a fine-tuning mechanism for regulating the intracellular levels of c-di-GMP.	Univ Nacl Autonoma Mexico, Dept Biol Mol & Biotecnol, Inst Invest Biomed, Lab Microbiol Genet Mol, Mexico City 04510, DF, Mexico; Nagoya Univ, Grad Sch Informat Sci Human Informat, Nagoya, Aichi 4648601, Japan; Nagoya Univ, CREST JST, Nagoya, Aichi 4648601, Japan	Universidad Nacional Autonoma de Mexico; Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Membrillo-Hernandez, J (corresponding author), Univ Nacl Autonoma Mexico, Dept Biol Mol & Biotecnol, Inst Invest Biomed, Lab Microbiol Genet Mol, POB 70-228, Mexico City 04510, DF, Mexico.	jmh@biomedicas.unam.mx	Hyodo, Mamoru/D-5496-2012; Membrillo-Hernández, Jorge/AAN-4996-2021	Hyodo, Mamoru/0000-0002-1766-3949; Membrillo-Hernández, Jorge/0000-0001-7650-8116				AMIKAM D, 1989, J BACTERIOL, V171, P6649, DOI 10.1128/jb.171.12.6649-6655.1989; AMIKAM D, 1995, BIOCHEM J, V311, P921, DOI 10.1042/bj3110921; Ausmees N, 2001, FEMS MICROBIOL LETT, V204, P163, DOI 10.1111/j.1574-6968.2001.tb10880.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Chaveroche MK, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e97; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Corona-Izquierdo FP, 2002, FEMS MICROBIOL LETT, V211, P105, DOI 10.1016/S0378-1097(02)00672-9; D'Argenio DA, 2004, MICROBIOL-SGM, V150, P2497, DOI 10.1099/mic.0.27099-0; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Francez-Charlot A, 2003, MOL MICROBIOL, V49, P823, DOI 10.1046/j.1365-2958.2003.03601.x; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Galperin MY, 2004, ENVIRON MICROBIOL, V6, P552, DOI 10.1111/j.1462-2920.2004.00633.x; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; Hayakawa Y, 2003, TETRAHEDRON, V59, P6465, DOI 10.1016/S0040-4020(03)01045-7; Hommais F, 2004, MICROBIOL-SGM, V150, P61, DOI 10.1099/mic.0.26659-0; Jenal U, 2004, CURR OPIN MICROBIOL, V7, P185, DOI 10.1016/j.mib.2004.02.007; Karaolis DKR, 2005, ANTIMICROB AGENTS CH, V49, P1029, DOI 10.1128/AAC.49.3.1029-1038.2005; Kirillina O, 2004, MOL MICROBIOL, V54, P75, DOI 10.1111/j.1365-2958.2004.04253.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Leonhartsberger S, 2001, J MOL BIOL, V307, P93, DOI 10.1006/jmbi.2000.4451; Majdalani N, 2005, ANNU REV MICROBIOL, V59, P379, DOI 10.1146/annurev.micro.59.050405.101230; Majdalani N, 2005, J BACTERIOL, V187, P6770, DOI 10.1128/JB.187.19.6770-6778.2005; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; McHugh JP, 2003, J BIOL CHEM, V278, P29478, DOI 10.1074/jbc.M303381200; O'Toole GA, 1999, METHOD ENZYMOL, V310, P91; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; Rosenow C, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.22.e112; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; ROSS P, 1990, J BIOL CHEM, V265, P18933; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Solano C, 2002, MOL MICROBIOL, V43, P793, DOI 10.1046/j.1365-2958.2002.02802.x; Takeda S, 2001, MOL MICROBIOL, V40, P440, DOI 10.1046/j.1365-2958.2001.02393.x; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; Wehland M, 2000, J BIOL CHEM, V275, P7013, DOI 10.1074/jbc.275.10.7013; Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x	45	89	92	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8090	8099		10.1074/jbc.M510701200	http://dx.doi.org/10.1074/jbc.M510701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418169	hybrid			2022-12-27	WOS:000236031000046
J	Wang, DM; Masutani, H; Oka, S; Tanaka, T; Yamaguchi-Iwai, Y; Nakamura, H; Yodoi, J				Wang, DM; Masutani, H; Oka, S; Tanaka, T; Yamaguchi-Iwai, Y; Nakamura, H; Yodoi, J			Control of mitochondrial outer membrane permeabilization and Bcl-xL levels by thioredoxin 2 in DT40 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; DEPENDENT APOPTOSIS; CASPASE ACTIVATION; DEATH; TRANSITION; PROTEINS; INVOLVEMENT; EXPRESSION; RELEASE; GLUTAREDOXIN-2	Mitochondria play a central role in the initiation of apoptosis, which is regulated by various factors such as ATP synthesis, reactive oxygen species, redox status, and outer membrane permeabilization. Disruption of chicken thioredoxin 2 (Trx2), a mitochondrial redox-regulating protein, results in apoptosis in DT40 cells. To investigate the mechanism of this apoptosis, we prepared transfectants expressing control (DT40-TRX2-/-), human thioredoxin 2 (TRX2) (DT40-hTRX2), or redox-inactive TRX2 (DT40-hTRX2CS) in conditional Trx2-deficient DT40 cells containing a tetracycline-repressible Trx2 gene. Production of ATP was not significantly changed by down-regulation of Trx2 expression. The generation of reactive oxygen species was enhanced by the down-regulation of Trx2 expression in DT40-TRX2-/-. Unexpectedly, the change was blocked in both DT40-hTRX2 and DT40-hTRX2CS cells. The down-regulation of Trx2 expression caused the release of cytochrome c and apoptosis-inducing factor on day 3, and apoptosis on day 5. These changes were also suppressed in both DT40-hTRX2 and DT40-hTRX2CS cells, suggesting that TRX2 regulates mitochondrial outer membrane permeabilization and apoptosis by redox-active site cysteine-independent mechanisms. The downregulation of Trx2 expression caused a decrease in the protein level of Bcl-xL on day 3, whereas the protein level of Bcl-2 did not change until day 4, and the mRNA level of Bcl-xL was unchanged. The decrease in Bcl-xL was not blocked by a caspase 3 inhibitor but blocked in both DT40-hTRX2 and DT40-hTRX2CS. These findings indicate a link between the redox active site cysteine-independent action of TRX2 and the level of Bcl-xL in the regulation of apoptosis.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Kyoto Univ Hosp, Translat Res Ctr, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eguchi Y, 1997, CANCER RES, V57, P1835; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hasegawa J, 1996, CANCER RES, V56, P1713; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Masutani H, 2005, CELL DEATH DIFFER, V12, P991, DOI 10.1038/sj.cdd.4401625; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nonn L, 2003, MOL CANCER RES, V1, P682; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	41	40	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7384	7391		10.1074/jbc.M509876200	http://dx.doi.org/10.1074/jbc.M509876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407224	hybrid, Green Submitted			2022-12-27	WOS:000236030900058
J	Wills, NM; Moore, B; Hammer, A; Gesteland, RF; Atkins, JF				Wills, NM; Moore, B; Hammer, A; Gesteland, RF; Atkins, JF			A functional-1 ribosomal frameshift signal in the human paraneoplastic Ma3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MAMMARY-TUMOR VIRUS; RNA PSEUDOKNOT; MESSENGER-RNA; MUTATIONAL ANALYSIS; STIMULATORY SIGNAL; SARS CORONAVIRUS; RECODING SIGNALS; HIV-1; SITE	A bioinformatics approach to finding new cases of -1 frameshifting in the expression of human genes revealed a classical retrovirus-like heptanucleotide shift site followed by a potential structural stimulator in the paraneoplastic antigen Ma3 and Ma5 genes. Analysis of the sequence 3' of the shift site demonstrated that an RNA pseudoknot in Ma3 is important for promoting efficient -1 frameshifting. Ma3 is a member of a family of six genes in humans whose protein products contain homology to retroviral Gag proteins. The -1 frameshift site and pseudoknot structure are conserved in other mammals, but there are some sequence differences. Although the functions of the Ma genes are unknown, the serious neurological effects of ectopic expression in tumor cells indicate their importance in the brain.	Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Coll Cork, Biosci Inst, Cork, Ireland	Utah System of Higher Education; University of Utah; University College Cork	Atkins, JF (corresponding author), Univ Utah, Dept Human Genet, 15 N 2030 E,Bldg 533,Rm 7410, Salt Lake City, UT 84112 USA.	john.atkins@genetics.utah.edu		Atkins, John/0000-0001-7933-0165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152, R01GM071853] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48152, GM 71853] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Atkins JF, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P369; Baranov PV, 2005, VIROLOGY, V332, P498, DOI 10.1016/j.virol.2004.11.038; Baranov PV, 2004, RNA, V10, P221, DOI 10.1261/rna.5122604; Bertrand C, 2002, RNA, V8, P16, DOI 10.1017/S1355838202012086; Bidou L, 1997, RNA, V3, P1153; Brandt J, 2005, CYTOGENET GENOME RES, V110, P307, DOI 10.1159/000084963; BRIERLEY I, 1991, J MOL BIOL, V220, P889, DOI 10.1016/0022-2836(91)90361-9; Brierley I, 2001, COLD SPRING HARB SYM, V66, P233, DOI 10.1101/sqb.2001.66.233; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CHEN XY, 1995, EMBO J, V14, P842, DOI 10.1002/j.1460-2075.1995.tb07062.x; Dulude D, 2002, NUCLEIC ACIDS RES, V30, P5094, DOI 10.1093/nar/gkf657; Gao X, 2005, TRENDS GENET, V21, P133, DOI 10.1016/j.tig.2005.01.006; Gao X, 2003, RNA, V9, P1422, DOI 10.1261/rna.5105503; Gaudin C, 2005, J MOL BIOL, V349, P1024, DOI 10.1016/j.jmb.2005.04.045; Grentzmann G, 1998, RNA, V4, P479; Griffiths A, 2003, J VIROL, V77, P4703, DOI 10.1128/JVI.77.8.4703-4709.2003; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HEROLD J, 1993, NUCLEIC ACIDS RES, V21, P5838; Hung M, 1998, J VIROL, V72, P4819, DOI 10.1128/JVI.72.6.4819-4824.1998; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; Kang HS, 1997, NUCLEIC ACIDS RES, V25, P1943, DOI 10.1093/nar/25.10.1943; Kim YG, 2001, NUCLEIC ACIDS RES, V29, P1125, DOI 10.1093/nar/29.5.1125; Kinzy TG, 2002, VIROLOGY, V300, P60, DOI 10.1006/viro.2002.1567; Larsen B, 1997, J MOL BIOL, V271, P47, DOI 10.1006/jmbi.1997.1162; Licznar P, 2003, EMBO J, V22, P4770, DOI 10.1093/emboj/cdg465; Manktelow E, 2005, NUCLEIC ACIDS RES, V33, P1553, DOI 10.1093/nar/gki299; MARCZINKE B, 1994, J VIROL, V68, P5588, DOI 10.1128/JVI.68.9.5588-5595.1994; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Napthine S, 1999, J MOL BIOL, V288, P305, DOI 10.1006/jmbi.1999.2688; Ono R, 2006, NAT GENET, V38, P101, DOI 10.1038/ng1699; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pallan PS, 2005, BIOCHEMISTRY-US, V44, P11315, DOI 10.1021/bi051061i; Pardue ML, 2003, ANNU REV GENET, V37, P485, DOI 10.1146/annurev.genet.38.072902.093115; Plant EP, 2005, PLOS BIOL, V3, P1012, DOI 10.1371/journal.pbio.0030172; Rettberg CC, 1999, J MOL BIOL, V286, P1365, DOI 10.1006/jmbi.1999.2546; Rosenfeld MR, 2001, ANN NEUROL, V50, P339, DOI 10.1002/ana.1288; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; Shigemoto K, 2001, NUCLEIC ACIDS RES, V29, P4079, DOI 10.1093/nar/29.19.4079; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Stahl G, 2001, COLD SPRING HARB SYM, V66, P249, DOI 10.1101/sqb.2001.66.249; Staple DW, 2005, J MOL BIOL, V349, P1011, DOI 10.1016/j.jmb.2005.03.038; Su MC, 2005, NUCLEIC ACIDS RES, V33, P4265, DOI 10.1093/nar/gki731; Takyar S, 2005, CELL, V120, P49, DOI 10.1016/j.cell.2004.11.042; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toulouse A, 2005, HUM MOL GENET, V14, P2649, DOI 10.1093/hmg/ddi299; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; Yu ET, 2005, J MOL BIOL, V345, P69, DOI 10.1016/j.jmb.2004.10.014; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	53	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7082	7088		10.1074/jbc.M511629200	http://dx.doi.org/10.1074/jbc.M511629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407312	hybrid			2022-12-27	WOS:000236030900022
J	Fritz, A; Brayer, KJ; McCormick, N; Adams, DG; Wadzinski, BE; Vaillancourt, RR				Fritz, A; Brayer, KJ; McCormick, N; Adams, DG; Wadzinski, BE; Vaillancourt, RR			Phosphorylation of serine 526 is required for MEKK3 activity, and association with 14-3-3 blocks dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; STRUCTURAL BASIS; CELLS; P38; TRANSFORMATION; PATHWAYS; BINDING; CLONING; DOMAIN	MAPK/ERK kinase kinase 3 (MEKK3) is a mitogen-activated protein kinase kinase kinase (MAP3K) that functions upstream of the MAP kinases and I kappa B kinase. Phosphorylation is believed to be a critical component for MEKK3-dependent signal transduction, but little is known about the phosphorylation sites of this MAP3K. To address this question, point mutations were introduced in the activation loop (T-loop), substituting alanine for serine or threonine, and the mutants were transfected into HEK293 Epstein-Barr virus nuclear antigen cells. MEKK3-dependent activation of an NF-kappa B reporter gene as well as ERK, JNK, and p38 MAP kinases correlated with a requirement for serine at position 526. Constitutively active mutants of MEKK3, consisting of S526D and S526E, were capable of activating a NF-kappa B luciferase reporter gene as well as ERK and MEK, suggesting that a negative charge at Ser(526) was necessary for MEKK3 activity and implicating Ser(526) as a phosphorylation site. An antibody was developed that specifically recognized phospho-Ser(526) of MEKK3 but did not recognize the S526A point mutant. The catalytically inactive (K391M) mutant of MEKK3 was not phosphorylated at Ser(526), indicating that phosphorylation of Ser(526) occurs via autophosphorylation. Endogenous MEKK3 was phosphorylated on Ser(526) in response to osmotic stress. In addition, phosphorylation of Ser(526) was required for MKK6 phosphorylation in vitro, whereas dephosphorylation of Ser(526) was mediated by protein phosphatase 2A and sensitive to okadaic acid and sodium fluoride. Finally, the association between MEKK3 and 14-3-3 was dependent on Ser(526) and prevented dephosphorylation of Ser(526). In summary, Ser(526) of MEKK3 is an autophosphorylation site within the T-loop that is regulated by PP2A and 14-3-3 proteins.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	University of Arizona; Vanderbilt University	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, 1703 E Mabel St, Tucson, AZ 85721 USA.	vaillancourt@pharmacy.arizona.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004940, R01ES012007, P30ES006694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062265, R01GM051366, R56GM051366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019710] Funding Source: NIH RePORTER; NIA NIH HHS [AG19710] Funding Source: Medline; NIEHS NIH HHS [P30 ES06694, ES12007, P42 ES04940] Funding Source: Medline; NIGMS NIH HHS [GM62265, GM51366] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams DG, 2002, ARCH BIOCHEM BIOPHYS, V407, P103, DOI 10.1016/S0003-9861(02)00464-2; Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Blonska M, 2004, MOL CELL BIOL, V24, P10757, DOI 10.1128/MCB.24.24.10757-10765.2004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Derbyshire ZE, 2005, MOL CELL BIOCHEM, V271, P77, DOI 10.1007/s11010-005-5386-9; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HARLOW E, 1988, ANTIBODIES LAB MANUA, P551; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nho CW, 2004, J BIOL CHEM, V279, P26019, DOI 10.1074/jbc.M309022200; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Samanta AK, 2004, J BIOL CHEM, V279, P7576, DOI 10.1074/jbc.M311659200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe Michael B, 2004, Biochem J, V379, pe1, DOI 10.1042/BJ20040284; Yang J, 2004, J MOL BIOL, V336, P473, DOI 10.1016/j.jmb.2003.11.044; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	35	42	44	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6236	6245		10.1074/jbc.M509249200	http://dx.doi.org/10.1074/jbc.M509249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407301	hybrid			2022-12-27	WOS:000236030800016
J	Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Kurumizaka, H; Yokoyama, S				Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Kurumizaka, H; Yokoyama, S			Stimulation of DNA strand exchange by the human TBPIP/Hop2-Mnd1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST RAD51 PROTEIN; RECA PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; BRANCH MIGRATION; FISSION YEAST; HOMOLOGOUS RECOMBINATION; CHROMOSOME SYNAPSIS; MOLECULAR-CLONING	In Saccharomyces cerevisiae, the Hop2 protein forms a complex with the Mnd1 protein and is required for the alignment of homologous chromosomes during meiosis, probably through extensive homology matching between them. The Rad51 and Dmc1 proteins, the eukaryotic RecA orthologs, promote strand exchange and may function in the extensive matching of homology within paired DNA molecules. In the present study, we purified the human TBPIP/ Hop2-Mnd1 complex and found that it significantly stimulates the Dmc1- and Rad51-mediated strand exchange. The human Hop2-Mnd1 complex preferentially binds to a three-stranded DNA branch, which mimics the strand-exchange intermediate. These findings are consistent with genetic data, which showed that the Hop2 and Mnd1 proteins are required for homology matching between homologous chromosomes. Therefore, the human TBPIP/ Hop2-Mnd1 complex may ensure proper pairing between homologous chromosomes through its stimulation of strand exchange during meiosis.	RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Fukui, Fac Med Sci, Dept Morphol & Physiol Sci, Div Cell Biol & Neurosci, Matsuoka, Fukui 9101193, Japan; Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan; Waseda Univ, Grad Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; RIKEN, Harima Inst SPring8, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan	RIKEN; University of Fukui; Japan Science & Technology Agency (JST); Waseda University; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo	Kurumizaka, H (corresponding author), RIKEN, Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	kurumizaka@waseda.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yagi, Hideshi/0000-0002-8506-8965; Kurumizaka, Hitoshi/0000-0001-7412-3722				Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Chen YK, 2004, P NATL ACAD SCI USA, V101, P10572, DOI 10.1073/pnas.0404195101; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; Enomoto R, 2004, J BIOL CHEM, V279, P35263, DOI 10.1074/jbc.M402481200; Gerton JL, 2002, P NATL ACAD SCI USA, V99, P6895, DOI 10.1073/pnas.102167899; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; Ijichi H, 2000, GENE, V248, P99, DOI 10.1016/S0378-1119(00)00141-4; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Kato A, 2004, P NATL ACAD SCI USA, V101, P13554, DOI 10.1073/pnas.0403659101; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Maeshima K, 1996, GENES CELLS, V1, P1057, DOI 10.1046/j.1365-2443.1996.d01-224.x; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Nabeshima K, 2001, EMBO J, V20, P3871, DOI 10.1093/emboj/20.14.3871; Petukhova GV, 2005, NAT STRUCT MOL BIOL, V12, P449, DOI 10.1038/nsmb923; Petukhova GV, 2003, DEV CELL, V5, P927, DOI 10.1016/S1534-5807(03)00369-1; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Saito TT, 2004, NUCLEIC ACIDS RES, V32, P3325, DOI 10.1093/nar/gkh654; Schommer C, 2003, PLANT J, V36, P1, DOI 10.1046/j.1365-313X.2003.01850.x; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V239, P176, DOI 10.1006/bbrc.1997.7447; Tanaka Y, 2004, METHODS, V33, P3, DOI 10.1016/j.ymeth.2003.10.024; Tracy RB, 1997, GENE DEV, V11, P3423, DOI 10.1101/gad.11.24.3423; Tsubouchi H, 2002, MOL CELL BIOL, V22, P3078, DOI 10.1128/MCB.22.9.3078-3088.2002	40	39	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5575	5581		10.1074/jbc.M506506200	http://dx.doi.org/10.1074/jbc.M506506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407260	hybrid			2022-12-27	WOS:000235568900033
J	He, Y; Zhang, W; Zhang, R; Zhang, HF; Min, W				He, Y; Zhang, W; Zhang, R; Zhang, HF; Min, W			SOCS1 inhibits tumor necrosis factor-induced activation of ASK1-JNK inflammatory signaling by mediating ASK1 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; NF-KAPPA-B; ASK1-MEDIATED APOPTOSIS; FACTOR-ALPHA; INDEPENDENT MANNER; OXIDATIVE STRESS; CYTOKINE; RECEPTOR; PROTEINS; KINASE	We have previously shown that ASK1 undergoes ubiquitination and degradation in resting endothelial cells (EC) and that proinflammatory cytokine tumor necrosis factor (TNF) induces deubiquitination and stabilization, leading to ASK1 activation. However, the mechanism for the regulation of ASK1 stability is not known. In the present study, we have shown that SOCS1, a member of suppressor of cytokine signaling, induces ASK1 degradation. SOCS1 was constitutively expressed in EC and formed a labile complex with ASK1 that can be stabilized by proteasomal inhibitors. The phosphotyrosine-binding SH2 domain of SOCS1 was critical for its association with ASK1. Thus a SOCS1 mutant defective in phosphotyrosine binding failed to bind to and induce ASK1 degradation. Phosphotyrosine of ASK1 was induced in response to growth factors, and TNF induced dephosphorylation and dissociation of ASK1 from SOCS1. ASK1 with a mutation at Tyr-718 diminished the binding to SOCS1, suggesting that the phosphotyrosine-718 of ASK1 is critical for SOCS1 binding. Moreover, ASK1 expression and activity were up-regulated in SOCS1-deficient mice and derived EC, resulting in enhanced TNF-induced activation of JNK, expression of proinflammatory molecules, and apoptotic responses. We concluded that SOCS1 functions as a negative regulator in TNF-induced inflammation in EC, in part, by inducing ASK1 degradation.	Yale Univ, Sch Med, Boyer Ctr Mol Med,Dept Pathol, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou S1008, Peoples R China	Yale University; Sun Yat Sen University	Min, W (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med,Dept Pathol, Interdepartmental Program Vasc Biol & Transplanta, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NHLBI NIH HHS [1R01 HL 65978-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Chong MMW, 2002, J BIOL CHEM, V277, P27945, DOI 10.1074/jbc.M110214200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Sepulveda P, 1999, EMBO J, V18, P904; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Galvan V, 2003, J BIOL CHEM, V278, P13325, DOI 10.1074/jbc.M211398200; Ilangumaran S, 2003, IMMUNOL REV, V192, P196, DOI 10.1034/j.1600-065X.2003.00020.x; Karmann K, 1996, J EXP MED, V184, P173, DOI 10.1084/jem.184.1.173; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Min W, 1997, J IMMUNOL, V159, P3508; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; RUI L, 2002, J BIOL CHEM, V12, P12; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	36	83	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5559	5566		10.1074/jbc.M512338200	http://dx.doi.org/10.1074/jbc.M512338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407264	hybrid			2022-12-27	WOS:000235568900031
J	Newton, DA; Rao, KMK; Dluhy, RA; Baatz, JE				Newton, DA; Rao, KMK; Dluhy, RA; Baatz, JE			Hemoglobin is expressed by alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GLOBIN GENE; SURFACTANT PROTEINS; PRIMARY CULTURE; LUNG; HEMORPHINS; PHENOTYPE; LINES; DIFFERENTIATION; COMPONENTS	Hemoglobin gene expression in non-erythroid cells has been previously reported in activated macrophages from adult mice and lens cells, and recent studies indicate that alveolar epithelial cells can be derived from hematopoietic stem cells. Our laboratory has now produced strong evidence that hemoglobin is expressed by alveolar type II (ATII) cells and Clara cells, the primary producers of pulmonary surfactant. ATII cells are also closely involved in innate immunity within the lung and are stem cells that differentiate into alveolar type I cells. Reverse transcriptase-PCR was used to measure the expression of transcripts from the alpha- and beta-globin gene clusters in several human and rodent pulmonary epithelial cells. Surprisingly, the two major globin mRNAs characteristic of adult erythroid precursor cells were clearly expressed in human A549 and H441 cell lines, mouse MLE-15 cells, and primary ATII cells isolated from normal rat and mouse lungs. DNA sequencing verified that these PCR products were indeed the result of specific amplification of globin gene cDNAs. These alveolar epithelial cells also expressed the corresponding hemoglobin protein subunits as determined by Western blotting, and tandem mass spectrometry sequencing was used to verify the presence of both alpha- and beta-globin polypeptides in rat primary ATII cells. The function of hemoglobin expression by cells of the pulmonary epithelium will be determined by future studies, but this novel finding could potentially have important implications for the physiology and pathology of the lung.	Med Univ S Carolina, Dept Pediat, Div Neonatol, Charleston, SC 29425 USA; NIOSH, Morgantown, WV 26505 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Medical University of South Carolina; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University System of Georgia; University of Georgia	Baatz, JE (corresponding author), 171 Ashley Ave, Charleston, SC 29425 USA.	baatzje@musc.edu			NHLBI NIH HHS [HL 66066] Funding Source: Medline; NIBIB NIH HHS [EB 001956] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001956] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Acierno Paula M, 2003, J Transl Med, V1, P3, DOI 10.1186/1479-5876-1-3; Baatz JE, 2001, PROTEIN EXPRES PURIF, V23, P180, DOI 10.1006/prep.2001.1492; Ballard PL, 2000, CONT ENDOCRINOL, P1; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Bhandari V, 2002, LUNG, V180, P301, DOI 10.1007/s00408-002-0102-y; Bishop AE, 2004, CELL PROLIFERAT, V37, P89, DOI 10.1111/j.1365-2184.2004.00302.x; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOROK Z, 1994, IN VITRO CELL DEV-AN, V30A, P99; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; BROWER M, 1986, CANCER RES, V46, P798; Cao A, 2002, PEDIATR RES, V51, P415, DOI 10.1203/00006450-200204000-00003; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Cheung P, 1997, J VIROL, V71, P1784, DOI 10.1128/JVI.71.3.1784-1793.1997; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Duethman D, 2000, PEPTIDES, V21, P137, DOI 10.1016/S0196-9781(99)00186-2; Fruitier I, 1999, FEBS LETT, V447, P81, DOI 10.1016/S0014-5793(99)00271-9; Fruitier-Arnaudin I, 2002, PEPTIDES, V23, P1465, DOI 10.1016/S0196-9781(02)00083-9; Fuchs S, 2003, CELL TISSUE RES, V311, P31, DOI 10.1007/s00441-002-0653-5; Glovanella B C, 1976, J Natl Cancer Inst, V56, P1131; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; GROUDINE M, 1975, P NATL ACAD SCI USA, V72, P4464, DOI 10.1073/pnas.72.11.4464; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; Hardison R. C., 2001, DISORDERS HEMOGLOBIN, P95; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hardison RC, 2001, HEMOGLOBIN, V25, P183, DOI 10.1081/HEM-100104027; HSU SL, 1988, NATURE, V331, P94, DOI 10.1038/331094a0; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Isakson BE, 2001, AM J PHYSIOL-CELL PH, V281, pC1291, DOI 10.1152/ajpcell.2001.281.4.C1291; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Kao YJ, 2001, AM J RESP CRIT CARE, V163, P532, DOI 10.1164/ajrccm.163.2.9912068; KIM JH, 1989, NUCLEIC ACIDS RES, V17, P5687, DOI 10.1093/nar/17.14.5687; Kotton DN, 2001, DEVELOPMENT, V128, P5181; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lammerich HP, 2003, BRIT J PHARMACOL, V138, P1431, DOI 10.1038/sj.bjp.0705177; Liang TS, 2001, J IMMUNOL, V167, P6609, DOI 10.4049/jimmunol.167.11.6609; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Liu LM, 1999, P NATL ACAD SCI USA, V96, P6643, DOI 10.1073/pnas.96.12.6643; Mallory G B Jr, 2001, Paediatr Respir Rev, V2, P151; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nyberg F, 1997, BIOPOLYMERS, V43, P147; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poynter SE, 2003, CRIT CARE CLIN, V19, P459, DOI 10.1016/S0749-0704(03)00011-3; Rao KMK, 2004, ENVIRON HEALTH PERSP, V112, P1679, DOI 10.1289/ehp.7295; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Rioli V, 2003, J BIOL CHEM, V278, P8547, DOI 10.1074/jbc.M212030200; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; Salinas D, 2003, AM J PHYSIOL-LUNG C, V285, pL1153, DOI 10.1152/ajplung.00084.2003; SANNES PL, 1991, EXP LUNG RES, V17, P639, DOI 10.3109/01902149109062871; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stamatoyannopoulos G, 2005, EXP HEMATOL, V33, P259, DOI 10.1016/j.exphem.2004.11.007; Sun P, 2003, EXP LUNG RES, V29, P303, DOI 10.1080/01902140303787; Vinogradov SN, 2005, P NATL ACAD SCI USA, V102, P11385, DOI 10.1073/pnas.0502103102; VOLLOCH V, 1987, EXP CELL RES, V173, P38, DOI 10.1016/0014-4827(87)90329-6; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Williams MC, 2003, ANNU REV PHYSIOL, V65, P669, DOI 10.1146/annurev.physiol.65.092101.142446; Wride MA, 2003, MOL VIS, V9, P360; Wright JR, 2003, J CLIN INVEST, V111, P1453, DOI 10.1172/JCI200318650	62	119	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5668	5676		10.1074/jbc.M509314200	http://dx.doi.org/10.1074/jbc.M509314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407281	hybrid			2022-12-27	WOS:000235568900043
J	Suram, S; Brown, GD; Ghosh, M; Gordon, S; Loper, R; Taylor, PR; Akira, S; Uematsu, S; Williams, DL; Leslie, CC				Suram, S; Brown, GD; Ghosh, M; Gordon, S; Loper, R; Taylor, PR; Akira, S; Uematsu, S; Williams, DL; Leslie, CC			Regulation of cytosolic phospholipase A(2) activation and cyclooxygenase 2 expression in macrophages by the beta-glucan receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID RELEASE; TOLL-LIKE RECEPTOR-2; ALTERNATIVE COMPLEMENT PATHWAY; PATTERN-RECOGNITION RECEPTORS; CELL-WALL COMPONENTS; BINDING LECTIN SITE; MANNOSE RECEPTOR; HUMAN-MONOCYTES; SACCHAROMYCES-CEREVISIAE	Phagocytosis of non-opsonized microorganisms bymacrophages initiates innate immune responses for host defense against infection. Cytosolic phospholipase A(2) is activated during phagocytosis, releasing arachidonic acid for production of eicosanoids, which initiate acute inflammation. Our objective was to identify pattern recognition receptors that stimulate arachidonic acid release and cyclooxygenase 2 (COX2) expression in macrophages by pathogenic yeast and yeast cell walls. Zymosan- and Candida albicans-stimulated arachidonic acid release from resident mouse peritoneal macrophages was blocked by soluble glucan phosphate. In RAW264.7 cells arachidonic acid release, COX2 expression, and prostaglandin production were enhanced by overexpressing the beta-glucan receptor, dectin-1, but not dectin-1 lacking the cytoplasmic tail. Pure particulate (1, 3)-beta-D-glucan stimulated arachidonic acid release and COX2 expression, which were augmented in a Toll-like receptor 2 (TLR2)-dependent manner by macrophage-activating lipopeptide-2. However, arachidonic acid release and leukotriene C-4 production stimulated by zymosan and C. albicans were TLR2-independent, whereas COX2 expression and prostaglandin production were partially blunted in TLR2(-/-) macrophages. Inhibition of Syk tyrosine kinase blocked arachidonic acid release and COX2 expression in response to zymosan, C. albicans, and particulate (1, 3)-beta-D-glucan. The results suggest that cytosolic phospholipase A(2) activation triggered by the beta-glucan component of yeast is dependent on the immunoreceptor tyrosine-based activation motif-like domain of dectin-1 and activation of Syk kinase, whereas both TLR2 and Syk kinase regulate COX2 expression.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 565, Japan; E Tennessee State Univ, James H Quillen Coll Med, Dept Surg, Johnson City, TN 37614 USA; Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	National Jewish Health; University of Cape Town; University of Oxford; Osaka University; East Tennessee State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org	Akira, Shizuo/C-3134-2009; brown, gordon/B-4249-2012	brown, gordon/0000-0002-0287-5383; Taylor, Philip/0000-0003-0163-1421	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053522] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61378, P01 HL034303, R01 HL061378, HL 34303] Funding Source: Medline; NIAID NIH HHS [AI 45829] Funding Source: Medline; NIGMS NIH HHS [GM 53522] Funding Source: Medline; Wellcome Trust [70579] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Aderem A, 2003, J INFECT DIS, V187, pS340, DOI 10.1086/374747; ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ADEREM AA, 1985, J EXP MED, V161, P617, DOI 10.1084/jem.161.3.617; BONNEY RJ, 1985, FED PROC, V44, P2933; BONNEY RJ, 1978, BIOCHEM J, V176, P433, DOI 10.1042/bj1760433; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Byrum RS, 1999, J IMMUNOL, V163, P6810; CASTRO M, 1993, AM J RESP CELL MOL, V9, P73, DOI 10.1165/ajrcmb/9.1.73; CASTRO M, 1994, INFECT IMMUN, V62, P3138, DOI 10.1128/IAI.62.8.3138-3145.1994; CHAKRAVARTI B, 1986, J IMMUNOL, V137, P880; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; CZOP JK, 1985, J IMMUNOL, V134, P2588; DAUM T, 1992, FEBS LETT, V309, P119, DOI 10.1016/0014-5793(92)81077-Y; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; ENSLEY HE, 1994, CARBOHYD RES, V258, P307, DOI 10.1016/0008-6215(94)84098-9; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FELS AOS, 1986, J EXP MED, V163, P752, DOI 10.1084/jem.163.3.752; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Ghomashchi F, 1999, BBA-BIOMEMBRANES, V1420, P45, DOI 10.1016/S0005-2736(99)00056-5; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Herre J, 2004, MOL IMMUNOL, V40, P869, DOI 10.1016/j.molimm.2003.10.007; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; HUMES JL, 1980, J IMMUNOL, V124, P2110; Jansen MJJM, 1997, SHOCK, V8, P261, DOI 10.1097/00024382-199710000-00005; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; Kolaczkowska E, 2002, INFLAMMATION, V26, P61, DOI 10.1023/A:1014837110735; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Lee SJ, 2003, INFECT IMMUN, V71, P437, DOI 10.1128/IAI.71.1.437-445.2003; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIM LK, 1985, MOL IMMUNOL, V22, P1365, DOI 10.1016/0161-5890(85)90058-6; LUNDY SR, 1990, J IMMUNOL, V144, P2671; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Mukhopadhyay S, 2004, IMMUNOLOGY, V112, P521, DOI 10.1111/j.1365-2567.2004.01941.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511; Panini SR, 2001, J LIPID RES, V42, P1678; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAO TS, 1994, J PHARMACOL EXP THER, V269, P917; Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031; Rice PJ, 2002, J LEUKOCYTE BIOL, V72, P140; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; STEIN M, 1991, EUR J IMMUNOL, V21, P431, DOI 10.1002/eji.1830210227; Swain SD, 2003, INFECT IMMUN, V71, P6213, DOI 10.1128/IAI.71.11.6213-6221.2003; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taylor PR, 2004, J IMMUNOL, V172, P1157, DOI 10.4049/jimmunol.172.2.1157; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Thornton BP, 1996, J IMMUNOL, V156, P1235; TRIPP CS, 1986, P NATL ACAD SCI USA, V83, P9655, DOI 10.1073/pnas.83.24.9655; TSUNAWAKI S, 1986, J BIOL CHEM, V261, P1563; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Underhill DM, 2004, MICROBES INFECT, V6, P1368, DOI 10.1016/j.micinf.2004.08.016; Underhill DM, 2003, J ENDOTOXIN RES, V9, P176, DOI 10.1179/096805103125001586; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020; Viriyakosol S., 2005, INFECT IMMUN, V73, P1553; WILLIAMS DL, 1991, CARBOHYD RES, V219, P203, DOI 10.1016/0008-6215(91)89052-H; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; Willment JA, 2003, J IMMUNOL, V171, P4569, DOI 10.4049/jimmunol.171.9.4569; Xia Y, 1999, J IMMUNOL, V162, P2281; Young SH, 2001, J BIOL CHEM, V276, P20781, DOI 10.1074/jbc.M101111200; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	89	95	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5506	5514		10.1074/jbc.M509824200	http://dx.doi.org/10.1074/jbc.M509824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407295	hybrid, Green Published			2022-12-27	WOS:000235568900024
J	Dansen, TB; Whitfield, J; Rostker, F; Brown-Swigart, L; Evan, GI				Dansen, TB; Whitfield, J; Rostker, F; Brown-Swigart, L; Evan, GI			Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; C-MYC; ENDOPLASMIC-RETICULUM; PROAPOPTOTIC BAX; DEATH; LYMPHOMAGENESIS; PROLIFERATION; PROTEINS; LEUKEMIA; TARGET	Bax and Bak comprise the mitochondrial gateway for apoptosis induced by diverse stimuli. Loss of both bax and bak is necessary to block cell death induced by such stimuli, indicating a great degree of functional overlap between Bax and Bak. Apoptosis is the major intrinsic pathway that limits the oncogenic potential of Myc. Using a switchable mouse model of Myc-induced apoptosis in pancreatic beta cells, we have shown that Myc induces apoptosis in vivo exclusively through Bax but not Bak. Furthermore, blockade of Myc-induced apoptosis by the inactivation of Bax, but not Bak, eliminates all restraints to the oncogenic potential of Myc, allowing the rapid and synchronous progression of invasive, angiogenic tumors.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Evan, GI (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0128, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Whitfield, Jonathan/N-6690-2014	Whitfield, Jonathan/0000-0002-4925-7283; Dansen, Tobias/0000-0001-5259-8815	NATIONAL CANCER INSTITUTE [R01CA098018] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA98018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chi MMY, 2000, J BIOL CHEM, V275, P40252, DOI 10.1074/jbc.M005508200; Dang CV, 1999, MOL CELL BIOL, V19, P1; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Hutcheson J, 2005, J EXP MED, V201, P1949, DOI 10.1084/jem.20041484; Jamerson MH, 2004, BRIT J CANCER, V91, P1372, DOI 10.1038/sj.bjc.6602137; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mitchell KO, 2000, CANCER RES, V60, P6318; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105	26	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10890	10895		10.1074/jbc.M513655200	http://dx.doi.org/10.1074/jbc.M513655200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464852	hybrid			2022-12-27	WOS:000236822200029
J	Krug, M; Lee, SJ; Diederichs, K; Boos, W; Welte, W				Krug, M; Lee, SJ; Diederichs, K; Boos, W; Welte, W			Crystal structure of the sugar binding domain of the archaeal transcriptional regulator TrmB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; ABC TRANSPORTER; MACROMOLECULAR STRUCTURES; BIOCHEMICAL-ANALYSIS; DIFFRACTION DATA; SYSTEM; SPECIFICITY; REFINEMENT; EXPRESSION	TrmB is an alpha-glucoside-sensing transcriptional regulator controlling two operons encoding maltose/trehalose and maltodextrin ABC transporters of Pyrococcus furiosus. The crystal structure of an N-terminal truncated derivative of TrmB (amino acids 2-109 deleted; TrmB(Delta 2-109)) was solved at 1.5 angstrom resolution. This protein has lost its DNA binding domain but has retained its sugar recognition site. The structure represents a novel sugar-binding fold. TrmB(Delta 2-109) bound maltose, glucose, sucrose, and maltotriose, exhibiting K-d values of 6.8, 25, 34, and 160 mu M, respectively. TrmB(Delta 2-109) behaved as a monomer in dilute buffer solution in contrast to the full-length protein, which is a dimer. Co-crystallization with bound maltose identified a binding site involving seven amino acid residues: Ser(229), Asn(305), Gly(320), Met(321), Val(324), Ile(325), and Glu(326). Six of these residues interact with the nonreducing glucosyl residue of maltose. The nonreducing glucosyl residue is shared by all substrates bound to TrmB, suggesting it as a common recognition motif.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Welte, W (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de	Lee, Sungjae/AAI-8586-2020	Lee, Sungjae/0000-0002-3997-9020				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell SD, 2000, J BIOL CHEM, V275, P31624, DOI 10.1074/jbc.M005422200; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 2005, TRENDS MICROBIOL, V13, P262, DOI 10.1016/j.tim.2005.03.015; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; Brinkman AB, 2002, J BIOL CHEM, V277, P29537, DOI 10.1074/jbc.M203528200; Brinkman AB, 2000, J BIOL CHEM, V275, P38160, DOI 10.1074/jbc.M005916200; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dippel R, 2005, J BACTERIOL, V187, P8322, DOI 10.1128/JB.187.24.8322-8331.2005; DiRuggiero J, 2000, MOL MICROBIOL, V38, P684, DOI 10.1046/j.1365-2958.2000.02161.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evdokimov AG, 2001, J MOL BIOL, V305, P891, DOI 10.1006/jmbi.2000.4202; Geiduschek EP, 2005, MOL MICROBIOL, V56, P1397, DOI 10.1111/j.1365-2958.2005.04627.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greller G, 1999, J BIOL CHEM, V274, P20259, DOI 10.1074/jbc.274.29.20259; Hars U, 1998, PROTEIN SCI, V7, P2511, DOI 10.1002/pro.5560071204; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Koning Sonja M., 2002, Archaea, V1, P19, DOI 10.1155/2002/529610; Kyrpides NC, 1999, P NATL ACAD SCI USA, V96, P8545, DOI 10.1073/pnas.96.15.8545; Lee SJ, 2005, MOL MICROBIOL, V57, P1797, DOI 10.1111/j.1365-2958.2005.04804.x; Lee SJ, 2003, J BIOL CHEM, V278, P983, DOI 10.1074/jbc.M210236200; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Lie TJ, 2005, J BIOL CHEM, V280, P5236, DOI 10.1074/jbc.M411778200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ouhammouch M, 2004, CURR OPIN GENET DEV, V14, P133, DOI 10.1016/j.gde.2004.01.002; Ouhammouch M, 2003, P NATL ACAD SCI USA, V100, P5097, DOI 10.1073/pnas.0837150100; Qu QH, 2004, J BIOL CHEM, V279, P47890, DOI 10.1074/jbc.M404955200; Qu QH, 2004, EXTREMOPHILES, V8, P301, DOI 10.1007/s00792-004-0392-5; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Reeve JN, 2003, MOL MICROBIOL, V48, P587, DOI 10.1046/j.1365-2958.2003.03439.x; RICHARME G, 1983, BIOCHIM BIOPHYS ACTA, V742, P16, DOI 10.1016/0167-4838(83)90353-9; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; Vierke G, 2003, J BIOL CHEM, V278, P18, DOI 10.1074/jbc.M209250200; Xie YW, 2005, J BACTERIOL, V187, P6419, DOI 10.1128/JB.187.18.6419-6429.2005	42	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10976	10982		10.1074/jbc.M512809200	http://dx.doi.org/10.1074/jbc.M512809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16473881	hybrid, Green Published			2022-12-27	WOS:000236822200038
J	Fukunaga, K; Arita, M; Takahashi, M; Morris, AJ; Pfeffer, M; Levy, BD				Fukunaga, K; Arita, M; Takahashi, M; Morris, AJ; Pfeffer, M; Levy, BD			Identification and functional characterization of a presqualene diphosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE EPOXIDE HYDROLASE; POLYISOPRENYL PHOSPHATES; SPHINGOSINE 1-PHOSPHATE; SQUALENE SYNTHASE; PHOSPHOLIPASE-D; INFLAMMATION; NEUTROPHILS; CONVERSION; PHOSPHOHYDROLASES; PYROPHOSPHATE	Presqualene diphosphate (PSDP) is a bioactive lipid that rapidly remodels to presqualene monophosphate ( PSMP) upon cell activation ( Levy, B. D., Petasis, N. A., and Serhan, C. N. ( 1997) Nature 389, 985 - 990). Here, we have identified and characterized a phosphatase that converts PSDP to PSMP. Unlike the related polyisoprenyl phosphate farnesyl diphosphate (FDP), PSDP was not a substrate for type 2 lipid phosphate phosphohydrolases. PSDP phosphatase activity was identified in activated human neutrophil (PMN) extracts and partially purified in the presence of Nonidet P-40 with gel filtration and anion exchange chromatography. Peptide sequencing of a candidate phosphatase was consistent with phosphatidic acid phosphatase domain containing 2 (PPAPDC2), an uncharacterized protein that contains a lipid phosphate phosphohydrolase consensus motif. Recombinant PPAPDC2 displayed diphosphate phosphatase activity with a substrate preference for PSDP> FDP> phosphatidic acid. PPAPDC2 activity was independent of Mg2+ and optimal at pH 7.0 to 8.0. Incubation of [C-14] FDP with recombinant human squalene synthase led to [C-14] PSDP and [C-14] squalene formation, and in the presence of PPAPDC2, [C-14] PSMP was generated from [C-14] PSDP. PPAPDC2 mRNA was detected in human PMN, and is widely expressed in human tissues. Together, these findings indicate that PPAPDC2 in human PMN is the first lipid phosphate phosphohydrolase identified for PSDP. Regulation of this activity of the enzyme may have important roles for PMN activation in innate immunity.	Brigham & Womens Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Levy, BD (corresponding author), Brigham & Womens Hosp, Dept Internal Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.	blevy@partners.org	Morris, Andrew/B-7869-2010; Takahashi, Minoru/G-4748-2011	Arita, Makoto/0000-0001-9902-0463	NHLBI NIH HHS [R01 HL068669, HL68669] Funding Source: Medline; NIDCR NIH HHS [P50-DE016191] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Drenth JPH, 2001, NEW ENGL J MED, V345, P1748, DOI 10.1056/NEJMra010200; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gu PD, 1998, J BIOL CHEM, V273, P12515, DOI 10.1074/jbc.273.20.12515; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Levy BD, 2000, BIOCHEM BIOPH RES CO, V275, P739, DOI 10.1006/bbrc.2000.3371; Levy BD, 2005, BRIT J PHARMACOL, V146, P344, DOI 10.1038/sj.bjp.0706338; Levy BD, 1999, FASEB J, V13, P903, DOI 10.1096/fasebj.13.8.903; Levy BD, 1997, NATURE, V389, P985, DOI 10.1038/40180; LEVY BD, 2003, CELL MOL LIFE SCI, V59, P1; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Newman JW, 2003, P NATL ACAD SCI USA, V100, P1558, DOI 10.1073/pnas.0437724100; RILLING HC, 1971, J AM CHEM SOC, V93, P1783; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rush JS, 2002, J BIOL CHEM, V277, P45226, DOI 10.1074/jbc.M207076200; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; SHECHTER I, 1980, J LIPID RES, V21, P277; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Stukey J, 1997, PROTEIN SCI, V6, P469; Takada K, 2003, ARTHRITIS RHEUM, V48, P2645, DOI 10.1002/art.11218; TCHEN TT, 1957, J BIOL CHEM, V226, P921; Thompson JF, 1998, ARCH BIOCHEM BIOPHYS, V350, P283, DOI 10.1006/abbi.1997.0502; Tran KL, 2005, BIOCHEMISTRY-US, V44, P12179, DOI 10.1021/bi050842g; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27	31	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9490	9497		10.1074/jbc.M512970200	http://dx.doi.org/10.1074/jbc.M512970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464866	hybrid			2022-12-27	WOS:000236404700059
J	Mason, RP; Walter, MF; Day, CA; Jacob, RF				Mason, RP; Walter, MF; Day, CA; Jacob, RF			Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE CORONARY SYNDROMES; RANDOMIZED CONTROLLED-TRIAL; CELL PLASMA-MEMBRANES; C-REACTIVE PROTEIN; OXIDATIVE STRESS; ATHEROSCLEROTIC LESIONS; PLAQUE INSTABILITY; MODEL MEMBRANES; ARTERY-DISEASE; STATIN THERAPY	The advanced atherosclerotic lesion is characterized by the formation of microscopic cholesterol crystals that contribute to mechanisms of inflammation and apoptotic cell death. These crystals develop from membrane cholesterol domains, a process that is accelerated under conditions of hyperlipidemia and oxidative stress. In this study, the comparative effects of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on oxidative stress-induced cholesterol domain formation were tested in model membranes containing physiologic levels of cholesterol using small angle x-ray diffraction approaches. In the absence of HMG-CoA reductase, only the atorvastatin active o-hydroxy metabolite (ATM) blocked membrane cholesterol domain formation as a function of oxidative stress. This effect of ATM is attributed to electron donation and proton stabilization mechanisms associated with its phenoxy group located in the membrane hydrocarbon core. ATM inhibited lipid peroxidation in human low density lipoprotein and phospholipid vesicles in a dose-dependent manner, unlike its parent and other statins (pravastatin, rosuvastatin, simvastatin). These findings indicate an atheroprotective effect of ATM on membrane lipid organization through a potent antioxidant mechanism.	Elucida Res, Beverly, MA 01915 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mason, RP (corresponding author), Elucida Res, 100 Cummings Ctr,Ste 135L,POB 7100, Beverly, MA 01915 USA.	rpmason@elucidaresearch.com		Day, Charles A/0000-0001-6277-2004				Aviram M, 1998, ATHEROSCLEROSIS, V138, P271, DOI 10.1016/S0021-9150(98)00032-X; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; CHANG HM, 1995, J MEMBRANE BIOL, V143, P51; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; CHESTER DW, 1987, BIOPHYS J, V52, P1021, DOI 10.1016/S0006-3495(87)83295-2; CRAVEN BM, 1976, NATURE, V260, P727, DOI 10.1038/260727a0; de Planque MRR, 2003, BIOCHEMISTRY-US, V42, P5341, DOI 10.1021/bi027000r; Ehara S, 2001, CIRCULATION, V103, P1955, DOI 10.1161/01.cir.103.15.1955; ELSAADANI M, 1989, J LIPID RES, V30, P627; EMMELOT P, 1977, MAMMALIAN CELL MEMBR, V2, P1; Geng YJ, 2003, BIOCHEM PHARMACOL, V66, P1485, DOI 10.1016/S0006-2952(03)00502-1; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; HOUSLAY MD, 1982, DYNAMICS BIOL MEMBRA, P1; Jacob RF, 2005, J BIOL CHEM, V280, P39380, DOI 10.1074/jbc.M507587200; Jacob RF, 1999, J BIOL CHEM, V274, P31613, DOI 10.1074/jbc.274.44.31613; Jialal I, 2003, CIRCULATION, V107, P926, DOI 10.1161/01.CIR.0000048966.26216.4C; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; Kellner-Weibel G, 1999, ARTERIOSCL THROM VAS, V19, P1891, DOI 10.1161/01.ATV.19.8.1891; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P950, DOI 10.1161/01.ATV.0000161050.77646.68; MAK IT, 1994, METHOD ENZYMOL, V234, P620; Mason RP, 2004, CIRCULATION, V109, P34, DOI 10.1161/01.CIR.0000129503.62747.03; MASON RP, 1989, BIOPHYS J, V55, P769, DOI 10.1016/S0006-3495(89)82875-9; Micheletta F, 2004, ARTERIOSCL THROM VAS, V24, P136, DOI 10.1161/01.ATV.0000104028.07929.72; Nishi K, 2002, ARTERIOSCL THROM VAS, V22, P1649, DOI 10.1161/01.ATV.0000033829.14012.18; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Phillips JE, 2001, ATHEROSCLEROSIS, V159, P125, DOI 10.1016/S0021-9150(01)00504-4; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; RUOCCO MJ, 1984, BIOPHYS J, V46, P695, DOI 10.1016/S0006-3495(84)84068-0; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; *THOMS PDR, 2005, PHYS DESK REF, P2585; Tsimikas S, 2004, CIRCULATION, V110, P1406, DOI 10.1161/01.CIR.0000141728.23033.B5; Tulenko TN, 1998, J LIPID RES, V39, P947; Walter MF, 2004, J AM COLL CARDIOL, V44, P1996, DOI 10.1016/j.jacc.2004.08.029; Walter MF, 2000, ANAL BIOCHEM, V280, P73, DOI 10.1006/abio.1999.4476	42	72	116	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9337	9345		10.1074/jbc.M513000200	http://dx.doi.org/10.1074/jbc.M513000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464853	hybrid			2022-12-27	WOS:000236404700042
J	Piening, N; Nonno, R; Di Bari, M; Walter, S; Windl, O; Agrimi, U; Kretzschmar, HA; Bertsch, U				Piening, N; Nonno, R; Di Bari, M; Walter, S; Windl, O; Agrimi, U; Kretzschmar, HA; Bertsch, U			Conversion efficiency of bank vole prion protein in vitro is determined by residues 155 and 170, but does not correlate with the high susceptibility of bank voles to sheep scrapie in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; QUANTITATIVE TRAIT LOCI; MICE EXPRESSING HUMAN; TRANSGENIC MICE; SPONGIFORM ENCEPHALOPATHIES; MASS-SPECTROMETRY; SPECIES BARRIER; RESISTANT PRP; NMR STRUCTURE	The misfolded infectious isoform of the prion protein (PrPSc) is thought to replicate in an autocatalytic manner by converting the cellular form (PrPC) into its pathogenic folding variant. The similarity in the amino acid sequence of PrPC and PrPSc influences the conversion efficiency and is considered as the major determinant for the species barrier. We performed in vitro conversion reactions on wild-type and mutated PrPC to determine the role of the primary sequence for the high susceptibility of bank voles to scrapie. Different conversion efficiencies obtained with bank vole and mouse PrPC in reactions with several prion strains were due to differences at amino acid residues 155 and 170. However, the conversion efficiencies obtained with mouse and vole PrPC in reactions with sheep scrapie did not correlate with the susceptibility of the respective species to this prion strain. This discrepancy between in vitro and in vivo data may indicate that at least in the case of scrapie transmission to bank voles additional host factors can strongly modulate the species barrier. Furthermore, in vitro conversion reactions with different prion strains revealed that the degree of alteration of the conversion efficiency induced by amino acid exchanges was varying according to the prion strain. These results support the assumption that the repertoire of conformations adopted by a certain PrPC primary sequence is decisive for its convertibility to the strain-specific PrPSc conformation.	Univ Munich, Zent Neuropathol & Prionforsch, D-81377 Munich, Germany; Ist Super Sanita, I-00161 Rome, Italy; Vet Labs Agcy, TSE Mol Biol Dept, Weybridge KT15 3NB, Surrey, England	University of Munich; Istituto Superiore di Sanita (ISS); Veterinary Laboratories Agency	Bertsch, U (corresponding author), Univ Munich, Zent Neuropathol & Prionforsch, Feodor Lynen Str 23, D-81377 Munich, Germany.	Uwe.Bertsch@med.uni-muenchen.de	Agrimi, Umberto/C-9956-2015; Windl, Otto/C-6760-2011; NONNO, ROMOLO/C-8323-2015; Di Bari, Michele Angelo/C-8327-2015; Di Bari, Michele Angelo/Q-5028-2019	Agrimi, Umberto/0000-0001-7828-0186; NONNO, ROMOLO/0000-0001-7556-1564; Di Bari, Michele Angelo/0000-0003-0943-6823; Di Bari, Michele Angelo/0000-0003-0943-6823				BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bieschke J, 2004, P NATL ACAD SCI USA, V101, P12207, DOI 10.1073/pnas.0404650101; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Bruce ME, 2002, J GEN VIROL, V83, P695, DOI 10.1099/0022-1317-83-3-695; Cartoni C, 2005, J CHROMATOGR A, V1081, P122, DOI 10.1016/j.chroma.2005.04.035; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Caughey B, 1999, MOL BIOTECHNOL, V13, P45, DOI 10.1385/MB:13:1:45; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1999, METHOD ENZYMOL, V309, P122; CHANDLER RL, 1971, LANCET, V1, P232; CHANDLER RL, 1972, RES VET SCI, V31, P219, DOI 10.1016/S0034-5288(18)34031-1; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Hill AF, 2003, BRIT MED BULL, V66, P161, DOI 10.1093/bmb/66.1.161; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Hornemann S, 2004, EMBO REP, V5, P1159, DOI 10.1038/sj.embor.7400297; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lloyd SE, 2001, P NATL ACAD SCI USA, V98, P6279, DOI 10.1073/pnas.101130398; Masel J, 2000, BIOPHYS CHEM, V88, P47, DOI 10.1016/S0301-4622(00)00197-6; MCCARTHY K, 1963, LANCET, V2, P593; Moreno CR, 2003, GENETICS, V165, P2085; Mulcahy ER, 2004, J BIOL CHEM, V279, P1643, DOI 10.1074/jbc.M307844200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1966, RES VET SCI, V7, P207; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Priola SA, 1999, BIOMED PHARMACOTHER, V53, P27, DOI 10.1016/S0753-3322(99)80057-2; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; Priola SA, 2001, J VIROL, V75, P4673, DOI 10.1128/JVI.75.10.4673-4680.2001; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Race R, 1998, NATURE, V392, P770, DOI 10.1038/33834; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; Sabuncu E, 2003, J VIROL, V77, P2696, DOI 10.1128/JVI.77.4.2696-2700.2003; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Scott MR, 2005, J VIROL, V79, P5259, DOI 10.1128/JVI.79.9.5259-5271.2005; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Steen H, 2005, OECOLOGIA, V143, P357, DOI 10.1007/s00442-004-1792-z; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; Windl O, 1999, J GEN VIROL, V80, P15, DOI 10.1099/0022-1317-80-1-15; Xiang W, 2004, J VIROL, V78, P11051, DOI 10.1128/JVI.78.20.11051-11060.2004	61	43	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9373	9384		10.1074/jbc.M512239200	http://dx.doi.org/10.1074/jbc.M512239200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455657	hybrid			2022-12-27	WOS:000236404700046
J	Miller, S; Sparacio, S; Bartenschlager, R				Miller, S; Sparacio, S; Bartenschlager, R			Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; WEST-NILE-VIRUS; TRANSMEMBRANE TOPOLOGY; DIFFERENTIAL PHOSPHORYLATION; NS2B-3 PROTEINASE; RNA REPLICATION; NS4B PROTEIN; IN-VITRO; INHIBITION	Dengue virus (DV) is a member of the family Flaviviridae. These positive strand RNA viruses encode a polyprotein that is processed in case of DV into 10 proteins. Although for most of these proteins distinct functions have been defined, this is less clear for the highly hydrophobic non-structural protein (NS) 4B. Despite its possible role as an antagonist of the interferon-induced antiviral response, this protein may play an additional more direct role for viral replication. In this study we determined the subcellular localization, membrane association, and membrane topology of DV NS4B. We found that NS4B resides primarily in cytoplasmic foci originating from the endoplasmic reticulum. NS4B colocalizes with NS3 and double-stranded RNA, an intermediate of viral replication, arguing that NS4B is part of the membrane-bound viral replication complex. Biochemical analysis revealed that NS4B is an integral membrane protein, and that its preceding 2K signal sequence is not required for this integration. We identified three membrane-spanning segments in the COOH-terminal part of NS4B that are sufficient to target a cytosolic marker protein to intracellular membranes. Furthermore, we established a membrane topology model of NS4B in which the NH2-terminal part of the protein is localized in the endoplasmic reticulum lumen, whereas the COOH-terminal part is composed of three trans-membrane domains with the COOH-terminal tail localized in the cytoplasm. This topology model provides a good starting point for a detailed investigation of the function of NS4B in the DV life cycle.	Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Sparacio, S (corresponding author), Neuenheimer Feld 345, D-69120 Heidelberg, Germany.	sandra_sparacio@med.uni-heidelberg.de; ralf_bartenschlager@med.uni-heidelberg.de	Bartenschlager, Ralf/L-2582-2015	Bartenschlager, Ralf/0000-0001-5601-9307				AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005; Benarroch D, 2004, J BIOL CHEM, V279, P35638, DOI 10.1074/jbc.M400460200; Blaney JE, 2003, VACCINE, V21, P4317, DOI 10.1016/S0264-410X(03)00487-0; BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x; BUCKLEY A, 1992, J GEN VIROL, V73, P1125, DOI 10.1099/0022-1317-73-5-1125; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1989, VIROLOGY, V169, P100, DOI 10.1016/0042-6822(89)90045-7; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHU PWG, 1992, ARCH VIROL, V125, P177, DOI 10.1007/BF01309636; CHU PWG, 1992, J VIROL METHODS, V37, P219, DOI 10.1016/0166-0934(92)90049-J; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Einav S, 2004, J VIROL, V78, P11288, DOI 10.1128/JVI.78.20.11288-11295.2004; Elazar M, 2004, J VIROL, V78, P11393, DOI 10.1128/JVI.78.20.11393-11400.2004; Escors D, 2001, J VIROL, V75, P12228, DOI 10.1128/JVI.75.24.12228-12240.2001; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; Florese RH, 2002, VIRUS RES, V90, P119, DOI 10.1016/S0168-1702(02)00146-6; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; Grassmann CW, 2001, J VIROL, V75, P7791, DOI 10.1128/JVI.75.17.7791-7802.2001; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Guo JT, 2005, J VIROL, V79, P1343, DOI 10.1128/JVI.79.3.1343-1350.2005; Hanley KA, 2003, VIROLOGY, V312, P222, DOI 10.1016/S0042-6822(03)00197-1; Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129; Khromykh AA, 2000, J VIROL, V74, P3253, DOI 10.1128/JVI.74.7.3253-3263.2000; Kim M, 2004, J VIROL METHODS, V120, P179, DOI 10.1016/j.jviromet.2004.05.005; Kretzschmar E, 1996, VIROLOGY, V220, P37, DOI 10.1006/viro.1996.0283; Lambert C, 2001, J BIOL CHEM, V276, P22265, DOI 10.1074/jbc.M100956200; LEARY K, 1980, J ULTRA MOL STRUCT R, V72, P123, DOI 10.1016/S0022-5320(80)90050-7; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997; Liu WJ, 2005, J VIROL, V79, P1934, DOI 10.1128/JVI.79.3.1934-1942.2005; Lundin M, 2003, J VIROL, V77, P5428, DOI 10.1128/JVI.77.9.5428-5438.2003; Mackenzie JM, 1998, VIROLOGY, V245, P203, DOI 10.1006/viro.1998.9156; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Munoz-Jordan JL, 2005, J VIROL, V79, P8004, DOI 10.1128/JVI.79.13.8004-8013.2005; Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100; MURRAY JM, 1993, J GEN VIROL, V74, P175, DOI 10.1099/0022-1317-74-2-175; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NG ML, 1983, ARCH VIROL, V78, P177; NG ML, 1989, ARCH VIROL, V106, P103, DOI 10.1007/BF01311042; OSTAPCHUK P, 1994, EMBO J, V13, P1048, DOI 10.1002/j.1460-2075.1994.tb06353.x; Park JS, 2000, BIOCHEM BIOPH RES CO, V267, P581, DOI 10.1006/bbrc.1999.1999; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; PRANGE R, 1995, EMBO J, V14, P247, DOI 10.1002/j.1460-2075.1995.tb06998.x; PREUGSCHAT F, 1991, VIROLOGY, V185, P689, DOI 10.1016/0042-6822(91)90540-R; Qu L, 2001, J VIROL, V75, P10651, DOI 10.1128/JVI.75.22.10651-10662.2001; RISCO C, 1995, J VIROL, V69, P5269, DOI 10.1128/JVI.69.9.5269-5277.1995; Sambrook J., 2001, MOL CLONING LAB MANU; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Westaway EG, 1997, VIROLOGY, V234, P31, DOI 10.1006/viro.1997.8629	62	209	218	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8854	8863		10.1074/jbc.M512697200	http://dx.doi.org/10.1074/jbc.M512697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16436383	hybrid			2022-12-27	WOS:000236247100065
J	Nissim, I; Daikhin, Y; Nissim, I; Luhovyy, B; Horyn, O; Wehrli, SL; Yudkoff, M				Nissim, I; Daikhin, Y; Nissim, I; Luhovyy, B; Horyn, O; Wehrli, SL; Yudkoff, M			Agmatine stimulates hepatic fatty acid oxidation - A possible mechanism for up-regulation of ureagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; PERFORMANCE LIQUID-CHROMATOGRAPHY; UREA SYNTHESIS; ISOLATED-MITOCHONDRIA; BETA-OXIDATION; METABOLISM; GLUTAMATE; ARGININE; ACETYLGLUTAMATE; HEPATOCYTES	We demonstrated previously in a liver perfusion system that agmatine increases oxygen consumption as well as the synthesis of N- acetylglutamate and urea by an undefined mechanism. In this study our aim was to identify the mechanism( s) by which agmatine up- regulates ureagenesis. We hypothesized that increased oxygen consumption and N- acetylglutamate and urea synthesis are coupled to agmatine- induced stimulation of mitochondrial fatty acid oxidation. We used C-13-labeled fatty acid as a tracer in either a liver perfusion system or isolated mitochondria to monitor fatty acid oxidation and the incorporation of C-13- labeled acetyl- CoA into ketone bodies, tricarboxylic acid cycle intermediates, amino acids, and N- acetylglutamate. With [U-C-13(16)] palmitate in the perfusate, agmatine significantly increased the output of C-13-labeled beta-hydroxybutyrate, acetoacetate, and CO2, indicating stimulated fatty acid oxidation. The stimulation of [U-C-13(16)] palmitate oxidation was accompanied by greater production of urea and a higher C-13 enrichment in glutamate, N- acetylglutamate, and aspartate. These observations suggest that agmatine leads to increased incorporation and flux of C-13- labeled acetyl- CoA in the tricarboxylic acid cycle and to increased utilization of C-13- labeled acetyl- CoA for synthesis of N- acetylglutamate. Experiments with isolated mitochondria and C-13 -labeled octanoic acid also demonstrated that agmatine increased synthesis of C-13- labeled beta- hydroxybutyrate, acetoacetate, and N- acetyl-glutamate. The current data document that agmatine stimulates mitochondrial beta- oxidation and suggest a coupling between the stimulation of hepatic beta- oxidation and up- regulation of ureagenesis. This action of agmatine may be mediated via a second messenger such as cAMP, and the effects on ureagenesis and fatty acid oxidation may occur simultaneously and/ or independently.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat,Div Child Dev Rehabil Med & Metab Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Nissim, I (corresponding author), Abramson Pediat Res Ctr, Div Child Dev, Rm 510C,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Luhovyy, Bohdan/0000-0002-5699-218X	NATIONAL CANCER INSTITUTE [R01CA079495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053761, R01DK053761] Funding Source: NIH RePORTER; NCI NIH HHS [CA-79495] Funding Source: Medline; NIDDK NIH HHS [DK-53761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; Blantz RC, 2000, ACTA PHYSIOL SCAND, V168, P21; Brosnan JT, 2001, J BIOL CHEM, V276, P31876, DOI 10.1074/jbc.M103890200; CAREY GB, 1993, BIOCHEM J, V292, P241, DOI 10.1042/bj2920241; Czok R, 1974, METHOD ENZYMAT AN, V3, P1446; DENNIS SC, 1978, J BIOL CHEM, V253, P2229; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; Dyck JRB, 2002, J MOL CELL CARDIOL, V34, P1099, DOI 10.1006/jmcc.2002.2060; Exton J H, 1968, Adv Enzyme Regul, V6, P391, DOI 10.1016/0065-2571(68)90024-1; FAHIEN LA, 1964, J BIOL CHEM, V239, P1935; Feng YZ, 1997, J CHROMATOGR B, V691, P277, DOI 10.1016/S0378-4347(96)00458-6; Garland P B, 1968, Adv Enzyme Regul, V6, P3, DOI 10.1016/0065-2571(68)90005-8; GEN L, 1994, SCIENCE, V263, P12231; Ghisla S, 2004, EUR J BIOCHEM, V271, P459, DOI 10.1046/j.1432-1033.2003.03952.x; Gibon Y, 1997, ANAL BIOCHEM, V251, P153, DOI 10.1006/abio.1997.2283; Grillo MA, 2004, AMINO ACIDS, V26, P3, DOI 10.1007/s00726-003-0030-z; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; Heilbronn L, 2004, INT J OBESITY, V28, pS12, DOI 10.1038/sj.ijo.0802853; Horyn O, 2005, BIOCHEM J, V388, P419, DOI 10.1042/BJ20041260; JAWOREK D, 1974, METHOD ENZYMAT AN, V2, P2127; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; Kasumov T, 2005, BIOCHEM J, V389, P397, DOI 10.1042/BJ20050144; Katunuma N, 1966, Adv Enzyme Regul, V4, P317, DOI 10.1016/0065-2571(66)90025-2; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; KIENTSCHENGEL RI, 1985, METHOD ENZYMAT AN, V6, P60; KREBS H. A., 1966, ADVANC ENZYME REGULAT, V4, P339, DOI 10.1016/0065-2571(66)90027-6; Krebs H A, 1969, Adv Enzyme Regul, V7, P397, DOI 10.1016/0065-2571(69)90030-2; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; Lortie MJ, 1996, J CLIN INVEST, V97, P413, DOI 10.1172/JCI118430; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MCGARRY JD, 1971, J BIOL CHEM, V246, P1149; McGarry JD, 1998, AM J CLIN NUTR, V67, p500S, DOI 10.1093/ajcn/67.3.500S; Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001; Nishiyama P, 1997, CELL BIOCHEM FUNCT, V15, P223; Nissim I, 2005, J BIOL CHEM, V280, P17715, DOI 10.1074/jbc.M500607200; Nissim I, 2003, BIOCHEM J, V376, P179, DOI 10.1042/BJ20030997; Nissim I, 1999, J BIOL CHEM, V274, P28958, DOI 10.1074/jbc.274.41.28958; Nissim I, 2002, AM J PHYSIOL-ENDOC M, V283, pE1123, DOI 10.1152/ajpendo.00246.2002; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; RAASCH W, 1995, LIFE SCI, V56, P2319, DOI 10.1016/0024-3205(95)00226-V; Regunathan S, 2000, J NEUROCHEM, V74, P2201, DOI 10.1046/j.1471-4159.2000.0742201.x; Reis DJ, 2000, TRENDS PHARMACOL SCI, V21, P187, DOI 10.1016/S0165-6147(00)01460-7; Robert R.W., 1992, RADIOACTIVE STABLE I, P49; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; SAHEKI T, 1977, J BIOCHEM-TOKYO, V82, P551; Satriano J, 1999, KIDNEY INT, V56, P1252, DOI 10.1046/j.1523-1755.1999.00697.x; SHIGESADA K, 1978, EUR J BIOCHEM, V85, P385, DOI 10.1111/j.1432-1033.1978.tb12250.x; SONODA T, 1983, J BIOL CHEM, V258, P9839; STRUCK E., 1966, ADVANC ENZYME REGULAT, V4, P219, DOI 10.1016/0065-2571(66)90016-1; Trautschold I., 1985, METHODS ENZYMATIC AN, V3rd, P346; Vatamaniuk MZ, 2003, LIFE SCI, V72, P1871, DOI 10.1016/S0024-3205(02)02506-7; Wehrli SL, 2001, NMR BIOMED, V14, P192, DOI 10.1002/nbm.694; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P5055; Yang DW, 2000, J NUTR, V130, p991S, DOI 10.1093/jn/130.4.991S; ZOLLNER H, 1982, ADV EXP MED BIOL, V153, P197	58	17	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8486	8496		10.1074/jbc.M506984200	http://dx.doi.org/10.1074/jbc.M506984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452488	hybrid			2022-12-27	WOS:000236247100024
J	Toso, R; Camire, RM				Toso, R; Camire, RM			Role of hirudin-like factor Va heavy chain sequences in prothrombinase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; REGULATORY EXOSITE-I; ACTIVATED PROTEIN-C; CLOTTING FACTOR-V; FACTOR-XA; MACROMOLECULAR SUBSTRATE; PROEXOSITE-I; COFACTOR FUNCTION; SITE; THROMBIN	Proexosite I on prothrombin has been implicated in providing a recognition site for factor Va within prothrombinase. To examine whether hirudin-like sequences (659-698) on the cofactor contribute to this interaction, we expressed and purified two-chain FVa derivatives that were intracellularly truncated at the C terminus of the heavy chain: FVa(709) (des710-1545), FVa(699) (des700-1545), FVa(692) (des693-1545), FVa(678) (des679-1545), and FVa(658) (des659-1545). We found that FVa(709), FVa(699), FVa(692), and FVa(678) exhibited specific clotting activities that were comparable with plasma-derived and recombinant FVa. Additionally, kinetic studies using prothrombin revealed that the K-m and k(cat) values for these derivatives were unaltered. Fluorescent measurements and chromatography studies indicated that FVa(709), FVa(699), FVa(692), and FVa(678) bound to FXa membranes and thrombin-agarose in a manner that was comparable with the wild-type cofactors. In contrast, FVa(658) had an similar to 1% clotting activity and reduced affinity for FXa membranes (similar to 20-fold) and did not bind to thrombin-agarose. Surprisingly, however, FVa(658) exhibited essentially normal kinetic parameters for prothrombin when the variant was fully saturated with FXa membranes. Overall our results are consistent with the interpretation that any possible binding interactions between prothrombin and the C-terminal region of the FVa heavy chain do not contribute in a detectable way to the enhanced function of prothrombinase.	Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, 302E Abramson Res Ctr,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rcamire@mail.med.upenn.edu	Toso, Raffaella/I-5202-2012		NHLBI NIH HHS [T32 HL-07349-26, P01 HL-74124-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhavan S, 2002, BLOOD, V100, P1347, DOI 10.1182/blood-2002-01-0243; Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2003, J BIOL CHEM, V278, P44482, DOI 10.1074/jbc.M306917200; Anderson PJ, 2003, J BIOL CHEM, V278, P44489, DOI 10.1074/jbc.M306916200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Boskovic DS, 2004, J BIOL CHEM, V279, P20786, DOI 10.1074/jbc.M400469200; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; CHURCH WR, 1988, BLOOD, V72, P1911; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; MANN KG, 1990, BLOOD, V76, P1; Monteiro RQ, 2002, THROMB HAEMOSTASIS, V87, P288; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Safa O, 1999, BIOCHEMISTRY-US, V38, P1829, DOI 10.1021/bi981730a; SEGAL IH, 1975, ENZYME KINETICS BEHA; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	59	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8773	8779		10.1074/jbc.M511419200	http://dx.doi.org/10.1074/jbc.M511419200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431918	hybrid			2022-12-27	WOS:000236247100056
J	Li, D; Hayden, EY; Panda, K; Stuehr, DJ; Deng, HT; Rousseau, DL; Yeh, SR				Li, D; Hayden, EY; Panda, K; Stuehr, DJ; Deng, HT; Rousseau, DL; Yeh, SR			Regulation of the monomer-dimer equilibrium in inducible nitric-oxide synthase by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; SOLUBLE GUANYLATE-CYCLASE; NO SYNTHASE; DIMERIZATION INHIBITORS; REACTION-MECHANISM; ELECTRON-TRANSFER; ESCHERICHIA-COLI; CARBON-MONOXIDE; S-NITROSOTHIOL; ZN2+ RELEASE	The oxygenase domain of inducible nitric-oxide synthase exists as a functional tight homodimer in the presence of the substrate L-arginine and the cofactor tetrahydrobiopterin (H4B). In the absence of H4B, the enzyme is a mixture of monomer and loose dimer. We show that exposure of H4B-free enzyme to NO induces dissociation of the loose dimer into monomers in a reaction that follows single exponential decay kinetics with a lifetime of similar to 300 min. It is followed by a faster autoreduction reaction of the heme iron with a lifetime of similar to 30 min and the concurrent breakage of the proximal iron - thiolate bond, forming a five-coordinate NO-bound ferrous species. Mass spectrometry revealed that the NO-induced monomerization is associated with intramolecular disulfide bond formation between Cys(104) and Cys(109), located in the zinc-binding motif. The regulatory effect of NO as a dimer inhibitor is discussed in the context of the structure/function relationships of this enzyme.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Rockefeller Univ, Proteom Resource Ctr, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation; Rockefeller University	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ullman 325,1300 Morris Pk Ave, Bronx, NY 10461 USA.	rousseau@aecom.yu.edu; syeh@aecom.yu.edu	; Panda, Koustubh/E-5273-2017	Yeh, Syun-Ru/0000-0002-9858-386X; Hayden, Eric/0000-0001-6977-5056; Panda, Koustubh/0000-0002-4783-2221	NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM054806] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL65465] Funding Source: Medline; NIGMS NIH HHS [GM54806, GM07288, GM08572, GM51491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andrew CR, 2001, BIOCHEMISTRY-US, V40, P4115, DOI 10.1021/bi0023652; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Binet MRB, 2002, FEMS MICROBIOL LETT, V213, P121, DOI 10.1016/S0378-1097(02)00803-0; Blasko E, 2002, J BIOL CHEM, V277, P295, DOI 10.1074/jbc.M105691200; Boffi A, 2002, BIOPHYS CHEM, V98, P209, DOI 10.1016/S0301-4622(02)00094-7; Chen YS, 2002, BIOCHEMISTRY-US, V41, P4618, DOI 10.1021/bi011877t; CHIEN JCW, 1969, J AM CHEM SOC, V91, P2166, DOI 10.1021/ja01036a085; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; EHRENBERG A, 1960, ACTA CHEM SCAND, V14, P1684, DOI 10.3891/acta.chem.scand.14-1684; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gautier C, 2004, J BIOL CHEM, V279, P4358, DOI 10.1074/jbc.M305048200; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; Hoshino M, 1996, J AM CHEM SOC, V118, P5702, DOI 10.1021/ja953311w; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Karow DS, 2004, BIOCHEMISTRY-US, V43, P10203, DOI 10.1021/bi049374l; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Kolodziejski PJ, 2004, P NATL ACAD SCI USA, V101, P18141, DOI 10.1073/pnas.0406711102; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; Li D, 2004, J BIOL CHEM, V279, P26489, DOI 10.1074/jbc.M400968200; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1993, ADV EXP MED BIOL, V338, P281; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Miller RT, 1999, J BIOL CHEM, V274, P14537, DOI 10.1074/jbc.274.21.14537; Mitchell DA, 2005, BIOCHEMISTRY-US, V44, P4636, DOI 10.1021/bi0474463; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Spahl DU, 2003, P NATL ACAD SCI USA, V100, P13952, DOI 10.1073/pnas.2335190100; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Voegtle HL, 2003, BIOCHEMISTRY-US, V42, P2475, DOI 10.1021/bi0271502; Vogel KM, 1999, J BIOL INORG CHEM, V4, P804, DOI 10.1007/s007750050354; Walker FA, 2005, J INORG BIOCHEM, V99, P216, DOI 10.1016/j.jinorgbio.2004.10.009; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Weichsel A, 2005, P NATL ACAD SCI USA, V102, P594, DOI 10.1073/pnas.0406549102	58	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8197	8204		10.1074/jbc.M507328200	http://dx.doi.org/10.1074/jbc.M507328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421101	hybrid			2022-12-27	WOS:000236031000059
J	Moshnikova, A; Frye, J; Shay, JW; Minna, JD; Khokhlatchev, AV				Moshnikova, A; Frye, J; Shay, JW; Minna, JD; Khokhlatchev, AV			The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLAND PROMOTER HYPERMETHYLATION; K-RAS; EPIGENETIC INACTIVATION; BINDING-PROTEIN; CELL-LINES; RASSF1A; GENE; ASSOCIATION; EFFECTOR; IDENTIFICATION	NORE1A is a growth and tumor suppressor that is inactivated in a variety of cancers. NORE1A has been shown to bind to the active Ras oncogene product. However, the mechanism of NORE1A-induced growth arrest and tumor suppression remains unknown. Using anchorage-independent growth assays, we mapped the NORE1A effector domain ( the minimal region of the protein responsible for its growth-suppressive effects) to the fragment containing the central and Ras association domains of NORE1A ( amino acids 191 - 363). Expression of the NORE1A effector domain in A549 lung adenocarcinoma cells resulted in the selective inhibition of signal transduction through the ERK pathway. The full-length NORE1A ( 416 amino acids) and its fragments capable of growth suppression were localized to centrosomes and microtubules in normal and transformed human cells in a Ras-independent manner. A mutant that was deficient in binding to centrosomes and microtubules was also deficient in inducing cell cycle arrest. This suggests that cytoskeletal localization is required for growth-suppressive effects of NORE1A. Ras binding function was required for growth-suppressive effects of the full-length NORE1A but not for the growth-suppressive effects of the effector domain. Our studies suggest that association of NORE1A with cytoskeletal elements is essential for NORE1A-induced growth suppression and that the ERK pathway is a target for NORE1A growth-suppressive activities.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Virginia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Khokhlatchev, AV (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, 415 Lane Rd, Charlottesville, VA 22908 USA.	ak9k@virginia.edu	Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA70907, CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Aoyama Y, 2004, ONCOGENE, V23, P3426, DOI 10.1038/sj.onc.1207486; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chow LSN, 2004, ONCOL REP, V12, P781; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Comincini S, 2001, MAMM GENOME, V12, P150, DOI 10.1007/s003350010239; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hull J, 2004, HUM GENET, V114, P272, DOI 10.1007/s00439-003-1038-x; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Levy P, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-20; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; PERGOLIZZI RG, 1993, CANCER INVEST, V11, P25, DOI 10.3109/07357909309020257; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Sambrook J., 2001, MOL CLONING LAB MANU; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339	40	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8143	8152		10.1074/jbc.M511837200	http://dx.doi.org/10.1074/jbc.M511837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421102	hybrid			2022-12-27	WOS:000236031000052
J	Gaultier, A; Salicioni, AM; Arandjelovic, S; Gonias, SL				Gaultier, A; Salicioni, AM; Arandjelovic, S; Gonias, SL			Regulation of the composition of the extracellular matrix by low density lipoprotein receptor-related protein-1 - Activities based on regulation of mRNA expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIUM-DERIVED FACTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; UROKINASE RECEPTOR; ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; GENE FAMILY; HUMAN-SKIN; IN-VITRO; COLLAGEN	Low density lipoprotein receptor-related protein-1 (LRP-1) is a catabolic receptor for extracellular matrix (ECM) structural proteins and for proteins that bind to ECM. LRP-1 also is implicated in integrin maturation. In this study, we applied a proteomics strategy to identify novel proteins involved in ECM modeling that are regulated by LRP-1. We show that LRP-1 deficiency in murine embryonic fibroblasts (MEFs) is associated with increased levels of type III collagen and pigment epithelium-derived factor, which accumulate in the substratum surrounding cells. The collagen receptor, uPAR-AP/ Endo-180, is also increased in LRP-1-deficient MEFs. Human LRP-1 reversed the changes in protein expression associated with LRP-1 deficiency; however, the endocytic activity of LRP-1 was not involved. Instead, regulation occurred at the mRNA level. Inhibition of c-Jun amino-terminal kinase (JNK) blocked type III collagen expression in LRP-1-deficient MEFs, suggesting regulation of JNK activity as a mechanism by which LRP-1 controls mRNA expression. The ability of LRP-1 to regulate expression of the factors identified here suggests a role for LRP-1 in determining blood vessel structure and in angiogenesis.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of California System; University of California San Diego; University of Massachusetts System; University of Massachusetts Amherst	Gonias, SL (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu	Salicioni, Ana Maria/ABD-8384-2021	Salicioni, Ana Maria/0000-0002-8951-3587	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 60551] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arandjelovic S, 2005, ARCH BIOCHEM BIOPHYS, V438, P29, DOI 10.1016/j.abb.2005.03.019; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; COTTAPEREIRA G, 1980, J CELL PHYSIOL, V102, P183, DOI 10.1002/jcp.1041020209; Curino AC, 2005, J CELL BIOL, V169, P977, DOI 10.1083/jcb.200411153; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; EPSTEIN EH, 1974, J BIOL CHEM, V249, P3225; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FOUSER L, 1991, J BIOL CHEM, V266, P18345; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; GERSTENFELD L, 1984, J BIOL CHEM, V259, P9158; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Green KA, 2005, BIOESSAYS, V27, P894, DOI 10.1002/bies.20281; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hosomichi J, 2005, BIOCHEM BIOPH RES CO, V335, P756, DOI 10.1016/j.bbrc.2005.07.140; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kanda S, 2005, J CELL SCI, V118, P961, DOI 10.1242/jcs.01686; KONTUSAARI S, 1990, AM J HUM GENET, V47, P112; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YH, 2003, FEBS LETT, V555, P346, DOI 10.1016/S0014-5793(03)01272-9; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; Ranganathan S, 2004, J BIOL CHEM, V279, P40536, DOI 10.1074/jbc.M407592200; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Sheikh H, 2000, J CELL SCI, V113, P1021; Spijkers PPEM, 2005, BLOOD, V105, P170, DOI 10.1182/blood-2004-02-0498; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wu LH, 2004, J CELL BIOCHEM, V93, P1169, DOI 10.1002/jcb.20288; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje	59	28	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7332	7340		10.1074/jbc.M511857200	http://dx.doi.org/10.1074/jbc.M511857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407289	hybrid			2022-12-27	WOS:000236030900052
J	Ridge, KD; Abdulaev, NG; Zhang, C; Ngo, T; Brabazon, DM; Marino, JP				Ridge, KD; Abdulaev, NG; Zhang, C; Ngo, T; Brabazon, DM; Marino, JP			Conformational changes associated with receptor-stimulated guanine nucleotide exchange in a heterotrimeric G-protein alpha-subunit - NMR analysis of GTP gamma S-bound states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; STRUCTURAL-CHANGES; BINDING-SITE; TRANSDUCIN BINDING; SYNTHETIC PEPTIDES; CARBOXYL-TERMINUS; BOVINE RHODOPSIN; ADP-RIBOSYLATION; ACTIVATION; LIGHT	Solution NMR studies of a N-15-labeled G-protein alpha-subunit (G(alpha)) chimera (N-15-ChiT)-reconstituted heterotrimer have shown previously that G-protein beta gamma-subunit (G(beta gamma)) association induces a "preactivated" conformation that likely facilitates interaction with the agonist-activated form of a G-protein-coupled receptor (R*) and guanine nucleotide exchange (Abdulaev, N. G., Ngo, T., Zhang, C., Dinh, A., Brabazon, D. M., Ridge, K. D., and Marino, J.P. (2005) J. Biol. Chem. 280, 38071-38080). Here we demonstrated that the N-15-ChiT-reconstituted heterotrimer can form functional complexes under NMR experimental conditions with light-activated, detergent-solubilized rhodopsin (R*), as well as a soluble mimic of R*. NMR methods were used to track R*-triggered guanine nucleotide exchange and release of guanosine 5'-O-3-thiotriphosphate (GTP gamma S)/Mg2+-bound ChiT. A heteronuclear single quantum correlation (HSQC) spectrum of R*-generated GTP gamma S/Mg2+-bound ChiT revealed (HN)-H-1, N-15 chemical shift changes relative to GDP/Mg2+-bound ChiT that were similar, but not identical, to those observed for the GDP center dot AlF4-/Mg2+-bound state. Line widths observed for R*-generated GTP gamma S/Mg2+-bound N-15-ChiT, however, indicated that it is more conformationally dynamic relative to the GDP/Mg2+- and GDP center dot AlF4-/Mg-2(+)-bound states. The increased dynamics appeared to be correlated with G(beta gamma) and R* interactions because they are not observed for GTP gamma S/Mg2+-bound ChiT generated independently of R*. In contrast to R*, a soluble mimic that does not catalytically interact with G-protein (Abdulaev, N. G., Ngo, T., Chen, R., Lu, Z., and Ridge, K. D. (2000) J. Biol. Chem. 275, 39354-39363) is found to form a stable complex with the GTP gamma S/Mg2+-exchanged heterotrimer. The HSQC spectrum of N-15-ChiT in this complex displays a unique chemical shift pattern that nonetheless shares similarities with the heterotrimer and GTP gamma S/Mg2+-bound ChiT. Overall, these results demonstrated that R*-induced changes in G(alpha) can be followed by NMR and that guanine nucleotide exchange can be uncoupled from heterotrimer dissociation.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Rockville, MD 20850 USA; Loyola Coll, Dept Chem, Baltimore, MD 21210 USA	University of Texas System; University of Texas Health Science Center Houston; National Institute of Standards & Technology (NIST) - USA; Loyola University Maryland	Ridge, KD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA.	Kevin.D.Ridge@uth.tmc.edu; john.marino@nist.gov			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015744] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013286] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P77, DOI 10.1002/352760510X.ch4; Abdulaev NG, 2005, J BIOL CHEM, V280, P38071, DOI 10.1074/jbc.M505259200; Abdulaev NG, 2005, J BIOMOL NMR, V32, P31, DOI 10.1007/s10858-005-3340-5; Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Abdulaev NG, 2000, J BIOL CHEM, V275, P39354, DOI 10.1074/jbc.M005642200; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Alves ID, 2005, BIOPHYS J, V88, P198, DOI 10.1529/biophj.104.046722; Anderson LL, 2005, J BIOL CHEM, V280, P31019, DOI 10.1074/jbc.M503690200; Arimoto R, 2001, BIOPHYS J, V81, P3285, DOI 10.1016/S0006-3495(01)75962-0; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BLAZYNSKI C, 1984, VISION RES, V24, P459, DOI 10.1016/0042-6989(84)90043-9; BLAZYNSKI C, 1981, VISION RES, V21, P833, DOI 10.1016/0042-6989(81)90183-8; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Brabazon DM, 2003, BIOCHEMISTRY-US, V42, P302, DOI 10.1021/bi0268899; CAI K, 2001, P NATL ACAD SCI USA, V98, P4819; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; KATADA T, 1984, J BIOL CHEM, V259, P3578; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Koenig BW, 2000, J BIOMOL NMR, V16, P121, DOI 10.1023/A:1008378523816; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lundstrom K, 2005, TRENDS BIOTECHNOL, V23, P103, DOI 10.1016/j.tibtech.2004.12.006; Marin EP, 2002, BIOCHEMISTRY-US, V41, P6988, DOI 10.1021/bi025514k; Marin EP, 2001, J BIOL CHEM, V276, P27400, DOI 10.1074/jbc.C100198200; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Medkova M, 2002, BIOCHEMISTRY-US, V41, P9962, DOI 10.1021/bi0255726; MITTAL R, 1994, BIOCHEMISTRY-US, V33, P10178, DOI 10.1021/bi00199a046; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PELLICONE C, 1985, BIOCHEM BIOPH RES CO, V127, P816, DOI 10.1016/S0006-291X(85)80016-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Ruan B, 2004, BIOCHEMISTRY-US, V43, P14539, DOI 10.1021/bi048177j; Salamon Z, 1996, BIOPHYS J, V71, P283, DOI 10.1016/S0006-3495(96)79224-X; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; VANDOP C, 1984, J BIOL CHEM, V259, P23; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEST RE, 1985, J BIOL CHEM, V260, P4428; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379	77	33	33	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7635	7648		10.1074/jbc.M509851200	http://dx.doi.org/10.1074/jbc.M509851200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407225	hybrid			2022-12-27	WOS:000236030900085
J	Irvin, JD; Pugh, BF				Irvin, JD; Pugh, BF			Genome-wide transcriptional dependence on TAF1 functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; EXPRESSION PATTERNS; GENE DISRUPTION; SAGA COMPLEXES; BOX-BINDING; YEAST; TAF(II)S; IDENTIFICATION; ACTIVATORS	Transcription factor IID ( TFIID) plays a central role in regulating the expression of most eukaryotic genes. Of the 14 TBP-associated factor (TAF) subunits that compose TFIID, TAF1 is one of the largest and most functionally diverse. Yeast TAF1 can be divided into four regions including a putative histone acetyltransferase domain and TBP, TAF, and promoter binding domains. Establishing the importance of each region in gene expression through deletion analysis has been hampered by the cellular requirement of TAF1 for viability. To circumvent this limitation we introduced galactose-inducible deletion derivatives of previously defined functional regions of TAF1 into a temperature-sensitive taf1(ts2) yeast strain. After galactose induction of the TAF1 mutants and temperature-induced elimination of the resident Taf1(ts2) protein, we examined the properties and phenotypes of the mutants, including their impact on genome-wide transcription. Virtually all TAF1-dependent genes, which comprise similar to 90% of the yeast genome, displayed a strong dependence upon all regions of TAF1 that were tested. This finding might reflect the need for each region of TAF1 to stabilize TAF1 against degradation or may indicate that all TAF1-dependent genes require the many activities of TAF1. Paradoxically, deletion of the region of TAF1 that is important for promoter binding interfered with the expression of many genes that are normally TFIID-independent/ SAGA (Spt-Ada-Gcn5-acetyltransferase)- dominated, suggesting that this region normally prevents TAF1 ( TFIID) from interfering with the expression of SAGA-regulated genes.	Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, 452 N Frear Lab, University Pk, PA 16802 USA.	bfp2@psu.edu		Irvin, Jordan/0000-0001-8504-5985	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059055, GM059055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Brachmann CB, 1998, YEAST, V14, P115; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURANT M, 2003, IN PRESS MOL CELL BI; Durso RJ, 2001, MOL CELL BIOL, V21, P7331, DOI 10.1128/MCB.21.21.7331-7344.2001; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kirchner J, 2001, MOL CELL BIOL, V21, P6668, DOI 10.1128/MCB.21.19.6668-6680.2001; Kirschner DB, 2002, MOL CELL BIOL, V22, P3178, DOI 10.1128/MCB.22.9.3178-3193.2002; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; Mencia M, 2001, MOL CELL BIOL, V21, P1145, DOI 10.1128/MCB.21.4.1145-1154.2001; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Ruzzi M, 1997, YEAST, V13, P365, DOI 10.1002/(SICI)1097-0061(19970330)13:4<365::AID-YEA78>3.0.CO;2-F; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Singh MV, 2004, MOL CELL BIOL, V24, P4929, DOI 10.1128/MCB.24.11.4929-4942.2004; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Zanton SJ, 2004, P NATL ACAD SCI USA, V101, P16843, DOI 10.1073/pnas.0404988101	39	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6404	6412		10.1074/jbc.M513776200	http://dx.doi.org/10.1074/jbc.M513776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407318	hybrid			2022-12-27	WOS:000236030800034
J	Arnold, M; Nath, A; Wohlwend, D; Kehlenbach, RH				Arnold, M; Nath, A; Wohlwend, D; Kehlenbach, RH			Transportin is a major nuclear import receptor for c-Fos - A novel mode of cargo interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; LOCALIZATION SIGNAL; FACTOR P97; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; PORE COMPLEX; BETA; BINDING; ALPHA; EXPORT	c-Fos, a component of the transcription factor AP-1, is rapidly imported into the nucleus after translation. We established an in vitro system using digitonin-permeabilized cells to analyze nuclear import of c-Fos in detail. Two import receptors of the importin beta superfamily, importin beta itself and transportin, promote import of c-Fos in vitro. Under conditions where importin beta-dependent transport was blocked, c-Fos still accumulated in the nucleus in the presence of cytosol. Inhibition of the transportin-dependent pathway, in contrast, abolished import of c-Fos. Furthermore, c-Fos mutants that interact with transportin but not with importin beta were efficiently imported in the presence of cytosol. Hence, transportin appears to be the predominant import receptor for c-Fos. A detailed biochemical characterization revealed that the interaction of transportin with c-Fos is distinct from the interaction with its established import cargoes, the M9 sequence of heterogeneous nuclear ribonucleoprotein A1 or the nuclear localization sequence of some basic proteins. Likewise, the binding sites on importin beta for its classic import cargo and for c-Fos can be separated. In summary, c-Fos employs a novel mode of receptor-cargo interaction. Hence, transportin may be as versatile as importin beta in recognizing different nuclear import cargoes.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Gottingen; University of Gottingen	Kehlenbach, RH (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	rkehlen@gwdg.de		Kehlenbach, Ralph/0000-0003-4920-9916				ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Bednenko J, 2003, J CELL BIOL, V162, P391, DOI 10.1083/jcb.200303085; Campos MAS, 1999, CELL BIOL INT, V23, P81, DOI 10.1006/cbir.1998.0323; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Cingolani G, 2000, FEBS LETT, V484, P291, DOI 10.1016/S0014-5793(00)02154-2; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; Dean KA, 2001, J CELL SCI, V114, P3479; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Fridell RA, 1997, J CELL SCI, V110, P1325; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Higashi N, 2004, GENES CELLS, V9, P233, DOI 10.1111/j.1356-9597.2004.00715.x; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Ng KW, 1997, EMBO J, V16, P2072, DOI 10.1093/emboj/16.8.2072; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; TRATNER I, 1991, ONCOGENE, V6, P2049; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	52	27	28	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5492	5499		10.1074/jbc.M513281200	http://dx.doi.org/10.1074/jbc.M513281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407315	hybrid			2022-12-27	WOS:000235568900022
J	Hu, J; Xiong, Y				Hu, J; Xiong, Y			An evolutionarily conserved function of proliferating cell nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE REPLICATION; GENOME STABILITY; GEMININ BINDING; FISSION YEAST; INHIBITION; CHECKPOINT; KINASE; PHASE; PCNA; PROTEOLYSIS	The DNA replication licensing factor Cdt1 is degraded by the ubiquitin-proteasome pathway during S phase of the cell cycle, to ensure one round of DNA replication during each cell division and in response to DNA damage to halt DNA replication. Constitutive expression of Cdt1 causes DNA re-replication and is associated with the development of a subset of human non-small cell-lung carcinomas. In mammalian cells, DNA damage-induced Cdt1 degradation is catalyzed by the Cul4-Ddb1-Roc1 E3 ubiquitin ligase. We report here that overexpression of the proliferating cell nuclear antigen (PCNA) inhibitory domain from the CDK inhibitors p21 and p57, but not the CDK-cyclin inhibitory domain, blocked Cdt1 degradation in cultured mammalian cells after UV irradiation. In vivo soluble Cdt1 and PCNA co-elute by gel filtration and associate with each other physically. Silencing PCNA in cultured mammalian cells or repression of pcn1 expression in fission yeast blocked Cdt1 degradation in response to DNA damage. Unexpectedly, deletion of Ddb1 in fission yeast cells also accumulated Cdt1 in the absence of DNA damage. We suggest that the Cul4-Ddb1 ligase evolved to ubiquitinate Cdt1 during normal cell growth as well as in response to DNA damage and a separate E3 ligase, possibly SCFSkp2, evolved to either share or take over the function of Cdt1 ubiquitination during normal cell growth and that PCNA is involved in mediating Cdt1 degradation by the Cul4-Ddb1 ligase in response to DNA damage.	Univ N Carolina, Lineberger Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27516 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27516 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Canc Ctr, Dept Biochem & Biophys, 22-012, Chapel Hill, NC 27516 USA.	yxiong@email.unc.edu	, Proteomics Core UNC/AFQ-7201-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067113] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067113] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Arroyo MP, 1999, METHODS, V18, P335, DOI 10.1006/meth.1999.0795; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bondar T, 2004, J BIOL CHEM, V279, P9937, DOI 10.1074/jbc.M312570200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Holmberg C, 2005, GENE DEV, V19, P853, DOI 10.1101/gad.329905; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	27	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3753	3756		10.1074/jbc.C500464200	http://dx.doi.org/10.1074/jbc.C500464200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16407242	hybrid, Green Published			2022-12-27	WOS:000235275300002
J	Viriyakosol, S; Tobias, PS; Kirkland, TN				Viriyakosol, S; Tobias, PS; Kirkland, TN			Mutational analysis of membrane and soluble forms of human MD-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; N-LINKED GLYCOSYLATIONS; CELL-SURFACE; SIGNAL-TRANSDUCTION; RECEPTOR 4-MD-2; BINDING-PROTEIN; TOLL; LPS; TLR4; CD14	Toll-like receptor 4 and MD-2 form a receptor for lipopolysaccharide (LPS), a major constituent of Gram-negative bacteria. MD-2 is a 20 - 25-kDa extracellular glycoprotein that binds to Toll-like receptor 4 (TLR4) and LPS and is a critical part of the LPS receptor. Here we have shown that the level of MD-2 expression regulates TLR4 activation by LPS. Using site-directed mutagenesis, we have found that glycosylation has no effect on MD-2 function as a membrane receptor for LPS. We used alanine-scanning mutagenesis to identify regions of human MD-2 that are important for TLR4 and LPS binding. We found that mutation in the N-terminal 46 amino acids of MD-2 did not substantially diminish LPS activation of Chinese hamster ovary (CHO) cells co-transfected with TLR4 and mutant MD-2. The residues 46 - 50 were important for LPS activation but not LPS binding. The residues 79 - 83, 121 - 124, and 125 129 are identified as important in LPS activation but not surface expression of membrane MD-2. The function of soluble MD-2 is somewhat more sensitive to mutation than membrane MD-2. Our results suggest that the 46 - 50 and 127 - 131 regions of soluble MD-2 bind to TLR4. The region 79 - 120 is not involved in LPS binding but affects monomerization of soluble MD-2 as well as TLR4 binding. We define the LPS binding region of monomeric soluble MD-2 as a cluster of basic residues 125 - 131. Studies on both membrane and soluble MD-2 suggest that domains of MD-2 for TLR4 and LPS binding are separate as well as overlapping. By mapping these regions on a three-dimensional model, we show the likely binding regions of MD-2 to TLR4 and LPS.	Vet Affairs San Diego Healthcare Syst 9151, La Jolla, CA 92161 USA; Univ Calif San Diego, Vet Affairs Med Res Fdn, La Jolla, CA 92161 USA; Univ Calif San Diego, Dept Pathol & Med, La Jolla, CA 92161 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Viriyakosol, S (corresponding author), Vet Affairs San Diego Healthcare Syst 9151, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	sviriyak@ucsd.edu; tkirkland@ucsd.edu	Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM066119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Delude RL, 1998, J IMMUNOL, V161, P3001; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Mancek M, 2002, BIOCHEM BIOPH RES CO, V292, P880, DOI 10.1006/bbrc.2002.6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Miyake K, 2000, J ENDOTOXIN RES, V6, P389, DOI 10.1179/096805100101532324; Miyake K, 1998, J IMMUNOL, V161, P1348; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Ohnishi T, 2001, J IMMUNOL, V167, P3354, DOI 10.4049/jimmunol.167.6.3354; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	29	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11955	11964		10.1074/jbc.M511627200	http://dx.doi.org/10.1074/jbc.M511627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16467306	hybrid			2022-12-27	WOS:000236988100065
J	Gurtan, AM; Stuckert, P; D'Andrea, AD				Gurtan, AM; Stuckert, P; D'Andrea, AD			The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; DNA-DAMAGE RESPONSE; NUCLEAR ACCUMULATION; PROTEINS FANCA; BRCA PATHWAY; RING DOMAIN; GENE; REVEALS; CHROMATIN; INTERACT	Fanconi anemia (FA) is an autosomal recessive disorder characterized by aplastic anemia, cancer susceptibility, and cellular sensitivity to mitomycin C. Eight of the 11 cloned Fanconi anemia gene products (FANCA, -B, -C, -E, -F, -G, -L, and -M) form a multisubunit nuclear complex ( FA core complex) required for monoubiquitination of a downstream FA protein, FANCD2. FANCL, which possesses three WD40 repeats and a plant homeodomain (PHD), is the putative E3 ubiquitin ligase subunit of the FA complex. Here, we demonstrate that the WD40 repeats of FANCL are required for interaction with other subunits of the FA complex. The PHD is dispensable for this interaction, although it is required for FANCD2 mono-ubiquitination. The PHD of FANCL also shares sequence similarity to the canonical RING finger of c-CBL, including a conserved tryptophan required for E2 binding by c-CBL. Mutation of this tryptophan in the FANCL PHD significantly impairs in vivo mono-ubiquitination of FANCD2 and in vitro auto-ubiquitination activity, and partially impairs restoration of mitomycin C resistance. We propose a model in which FANCL, via its WD40 region, binds the FA complex and, via its PHD, recruits an as-yet-unidentified E2 for mono-ubiquitination of FANCD2.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Biol & Biomed Sci Program, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	D'Andrea, AD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,M640, Boston, MA 02115 USA.	Alan_Dandrea@dfci.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052725] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL52725] Funding Source: Medline; PHS HHS [R01KD43889] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTER BP, 1995, BLOOD, V85, P1148, DOI 10.1182/blood.V85.4.1148.bloodjournal8541148; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; Dodd RB, 2004, J BIOL CHEM, V279, P53840, DOI 10.1074/jbc.M409662200; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gordon SM, 2005, J BIOL CHEM, V280, P36118, DOI 10.1074/jbc.M507758200; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Matsushita N, 2005, MOL CELL, V19, P841, DOI 10.1016/j.molcel.2005.08.018; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Naf D, 1998, MOL CELL BIOL, V18, P5952; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Rooimans MA, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Shimamura A, 2003, BLOOD, V102, P3459, DOI 10.1182/blood-2003-04-1297; Shimamura A, 2002, BLOOD, V100, P4649, DOI 10.1182/blood-2002-05-1399; Siddique MA, 2001, EXP HEMATOL, V29, P1448, DOI 10.1016/S0301-472X(01)00754-8; STRATHDEE CA, 1992, NATURE, V358, P434, DOI 10.1038/358434a0; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tischkowitz MD, 2003, J MED GENET, V40, P1, DOI 10.1136/jmg.40.1.1; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Wilson DK, 2005, J BIOL CHEM, V280, P13944, DOI 10.1074/jbc.M412919200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	49	41	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10896	10905		10.1074/jbc.M511411200	http://dx.doi.org/10.1074/jbc.M511411200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16474167	hybrid			2022-12-27	WOS:000236822200030
J	Spaziani, A; Alisi, A; Sanna, D; Balsano, C				Spaziani, A; Alisi, A; Sanna, D; Balsano, C			Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; LIVER-REGENERATION; SIGNALING PATHWAY; ACTIVATION; PROLIFERATION; EXPRESSION; PROGRESSION; CHECKPOINT	Some hepatitis C virus (HCV) proteins, including core protein, deregulate the cell cycle of infected cells, thereby playing an important role in the viral pathogenesis of HCC. Thus far, there are only few studies that have deeply investigated in depth the effects of the HCV core protein expression on the progression through the G(1)/S and G(2)/M phases of the cell cycle. To shed light on the molecular mechanisms by which the HCV core protein modulates cell proliferation, we have examined its effects on cell cycle in hepatocarcinoma cells. We show here that HCV core protein perturbs progression through both the G(1)/S and the G(2)/M phases, by modulating the expression and the activity of several cell cycle regulatory proteins. In particular, our data provided evidence that core-dependent deregulation of the G(1)/S phase and its related cyclin-CDK complexes depends upon the ERK1/2 pathway. On the other hand, the viral protein also increases the activity of the cyclin B1-CDK1 complex via the p38 MAPK and JNK pathways. Moreover, we show that HCV core protein promotes nuclear import of cyclin B1, which is affected by the inhibition of both the p38 and the RNA-dependent protein kinase (PKR) activities. The important role of p38 MAPK in regulating G(2)/M phase transition has been previously documented. It is becoming clear that PKR has an important role in regulating both the G(1)/S and the G(2)/M phase, in which it induces M phase arrest. Based on our model, we now show, for the first time, that HCV core expression leads to deregulation of the mitotic checkpoint via a p38/PKR-dependent pathway.	Univ Aquila, Dept Internal Med, Lab Clin Hepatol, I-67100 Laquila, Italy; Ist Ricovery & Cura Carattere Sci SR Pisana, Lab Dev Pathol, I-00163 Rome, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Lab Mol Virol & Oncol, I-00161 Rome, Italy	University of L'Aquila; Sapienza University Rome	Balsano, C (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Lab Mol Virol & Oncol, Clin Med 1,Policlin Umberto I, Viale Policlin N155, I-00161 Rome, Italy.	clara.balsano@uniroma1.it	Alisi, Anna/A-6469-2010; Balsano, Clara/AAK-9870-2020	Alisi, Anna/0000-0001-7241-6329; Balsano, Clara/0000-0002-9615-7031				Alisi A, 2003, LIVER INT, V23, P179, DOI 10.1034/j.1600-0676.2003.00829.x; Alisi A, 2005, J CELL PHYSIOL, V205, P25, DOI 10.1002/jcp.20363; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Cho JW, 2001, LIVER, V21, P137, DOI 10.1034/j.1600-0676.2001.021002137.x; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dagon Y, 2001, ONCOGENE, V20, P8045, DOI 10.1038/sj.onc.1204945; Donato MF, 2001, HEPATOLOGY, V34, P523, DOI 10.1053/jhep.2001.26820; Duensing S, 2002, CANCER RES, V62, P7075; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; EZAKI T, 1988, CANCER, V61, P1880, DOI 10.1002/1097-0142(19880501)61:9<1880::AID-CNCR2820610926>3.0.CO;2-S; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Huynh H, 2004, INT J ONCOL, V25, P1839; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jeong SJ, 2004, CANCER RES, V64, P8666, DOI 10.1158/0008-5472.CAN-03-3455; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Werling K, 2001, EUR J GASTROEN HEPAT, V13, P489, DOI 10.1097/00042737-200105000-00005; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127	39	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10983	10989		10.1074/jbc.M512536200	http://dx.doi.org/10.1074/jbc.M512536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16446363	hybrid			2022-12-27	WOS:000236822200039
J	Wormald, S; Zhang, JG; Krebes, DL; Mielke, LA; Silver, J; Alexander, WS; Speed, TP; Nicola, NA; Hilton, DJ				Wormald, S; Zhang, JG; Krebes, DL; Mielke, LA; Silver, J; Alexander, WS; Speed, TP; Nicola, NA; Hilton, DJ			The comparative roles of suppressor of cytokine signaling-1 and-3 in the inhibition and desensitization of cytokine signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSIOLOGICAL NEGATIVE REGULATOR; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; STAT FAMILY; IFN-GAMMA; ACTIVATION; RECEPTOR; INTERLEUKIN-6; SOCS3; TRANSCRIPTION	Negative feedback is a mechanism commonly employed in biological processes as a means of maintaining homeostasis. We have investigated the roles of suppressor of cytokine signaling ( SOCS) proteins in regulating the kinetics of negative feedback in response to cytokine signaling. In mouse livers and bone marrow-derived macrophages, both interferon-gamma (IFN gamma) and interleukin-6 (IL-6) rapidly induced the tyrosine phosphorylation of signal transducer and activator of transcription-1 (STAT1) and STAT3. STAT3 tyrosine phosphorylation was bi-phasic in response to continuous IL-6 signaling. In macrophages lacking Socs3, however, continuous IL-6 signaling induced uniformly high levels of STAT3 tyrosine phosphorylation, and early IL-6-inducible genes were inappropriately expressed at intermediate time points. SOCS3 therefore imposes bi-phasic kinetics upon IL-6 signaling. Compared with Socs3 mRNA, Socs1 mRNA was induced relatively slowly, and SOCS1 simply attenuated the duration of IFN gamma signaling. Surprisingly, heightened Socs1 mRNA expression but minimal STAT1 tyrosine phosphorylation was observed after prolonged stimulation with IFN gamma, indicating that STAT1 may not play a large role in inducing Socs1 mRNA during steady-state IFN gamma signaling. We also demonstrate that both SOCS1 and SOCS3 can desensitize primary bone marrow-derived macrophages to IFN gamma and IL-6 signaling, respectively. Consistent with the kinetics with which Socs1 and Socs3 mRNAs were induced, SOCS3 desensitized cells to IL-6 rapidly, whereas SOCS1-mediated desensitization to IFN gamma occurred at later time points. The kinetics with which SOCS proteins are induced by cytokine may therefore be a parameter that is "hard-wired" into specific cytokine signaling pathways as a means of tailoring the kinetics with which cells become desensitized.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Genet & Bioinformat, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Wormald, S (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, 1G Royal Parade, Parkville, Vic 3050, Australia.	wormald@wehi.edu.au	Silver, Jeremy/Y-4174-2019; Speed, Terence P/B-8085-2009; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Silver, Jeremy/0000-0003-1502-6249; Speed, Terence P/0000-0002-5403-7998; Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Krebs, Danielle/0000-0002-6522-7308; Mielke, Lisa/0000-0002-9522-9320	NCI NIH HHS [CA22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; COWAN DB, 2000, AM J PHYSIOL, V279, pH6719; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; HARROCH S, 1994, J BIOL CHEM, V269, P26191; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NICOLA NA, 1994, UIDEBOOK GYTOKINES T; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Reich M, 2004, BIOINFORMATICS, V20, P1797, DOI 10.1093/bioinformatics/bth138; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sakamoto S, 2004, J BIOL CHEM, V279, P3245, DOI 10.1074/jbc.M309631200; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Steinman RA, 1999, LEUKEMIA, V13, P54, DOI 10.1038/sj.leu.2401253; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	102	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11135	11143		10.1074/jbc.M509595200	http://dx.doi.org/10.1074/jbc.M509595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16473883	hybrid			2022-12-27	WOS:000236822200056
J	Burgess, A; Wigan, M; Giles, N; DePinto, W; Gillespie, P; Stevens, F; Gabrielli, B				Burgess, A; Wigan, M; Giles, N; DePinto, W; Gillespie, P; Stevens, F; Gabrielli, B			Inhibition of S/G(2) phase CDK4 reduces mitotic fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; RETINOBLASTOMA PROTEIN; HELA-CELLS; HUMAN SKIN; CENP-E; CHECKPOINT; KINASE; ACTIVATION; KINETOCHORES; EXPRESSION	Cyclin-dependent kinase 4 (CDK4)/cyclin D has a key role in regulating progression through late G(1) into S phase of the cell cycle. CDK4-cyclin D complexes then persist through the latter phases of the cell cycle, although little is known about their potential roles. We have developed small molecule inhibitors that are highly selective for CDK4 and have used these to define a role for CDK4-cyclin D in G(2) phase. The addition of the CDK4 inhibitor or small interfering RNA knockdown of cyclin D3, the cyclin D partner, delayed progression through G(2) phase and mitosis. The G(2) phase delay was independent of ATM/ATR and p38 MAPK but associated with elevated Wee1. The mitotic delay was because of failure of chromosomes to migrate to the metaphase plate. However, cells eventually exited mitosis, with a resultant increase in cells with multiple or micronuclei. Inhibiting CDK4 delayed the expression of the chromosomal passenger proteins survivin and borealin, although this was unlikely to account for the mitotic phenotype. These data provide evidence for a novel function for CDK4-cyclin D3 activity in S and G(2) phase that is critical for G(2)/M progression and the fidelity of mitosis.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia; Hoffmann La Roche Inc, Discovery Oncol, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Discovery Chem, Nutley, NJ 07110 USA	University of Queensland; Roche Holding; Roche Holding	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Burgess, Andrew/C-7952-2009; Burgess, Andrew/H-3339-2019; Gabrielli, Brian G/B-3655-2011	Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651				BATES S, 1994, ONCOGENE, V9, P1633; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castellano M, 1997, CANCER RES, V57, P4868; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Keenan SM, 2004, J BIOL CHEM, V279, P5387, DOI 10.1074/jbc.M310383200; Kozar K, 2005, CELL CYCLE, V4, P388, DOI 10.4161/cc.4.3.1551; Krauer KG, 2004, ONCOGENE, V23, P1342, DOI 10.1038/sj.onc.1207253; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Papi M, 2005, NAT CELL BIOL, V7, P1029, DOI 10.1038/ncb1303; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	35	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9987	9995		10.1074/jbc.M512714200	http://dx.doi.org/10.1074/jbc.M512714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476733	hybrid			2022-12-27	WOS:000236594300021
J	Dorval, V; Fraser, PE				Dorval, V; Fraser, PE			Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; IN-VITRO; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; SUMOYLATION; PHOSPHORYLATION; CONJUGATION; IDENTIFICATION; DEGRADATION; ACTIVATION	Sumoylation is an important post-translational modification that provides a rapid and reversible means for controlling the activity, subcellular localization, and stability of target proteins. We have examined the covalent attachment of the small ubiquitin-like modifier ( SUMO) proteins to tau and alpha-synuclein, two natively unfolded proteins that define several neurodegenerative diseases. Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences, and mutational analyses identified Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Tau is a microtubule-associated protein, whose ability to bind and stabilize microtubules is negatively regulated by phosphorylation. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation. This suggests that SUMO modification may preferentially target a free soluble pool of the substrate. These findings revealed a new, possibly regulatory, modification of tau and alpha-synuclein that may also have implications for their pathogenic roles in neurodegenerative diseases.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto	Fraser, PE (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	paul.fraser@utoronto.ca						Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Barghorn S, 2004, BIOCHEMISTRY-US, V43, P1694, DOI 10.1021/bi0357006; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Chung TL, 2004, J BIOL CHEM, V279, P39653, DOI 10.1074/jbc.M405637200; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; Denison C, 2005, MOL CELL PROTEOMICS, V4, P246, DOI 10.1074/mcp.M400154-MCP200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Gamblin TC, 2005, BBA-MOL BASIS DIS, V1739, P140, DOI 10.1016/j.bbadis.2004.08.013; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hyman BT, 2005, BBA-MOL BASIS DIS, V1739, P150, DOI 10.1016/j.bbadis.2004.06.015; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Nonaka T, 2005, BIOCHEMISTRY-US, V44, P361, DOI 10.1021/bi0485528; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pountney DL, 2005, NEUROSCI LETT, V381, P74, DOI 10.1016/j.neulet.2005.02.013; Pountney DL, 2003, EXP NEUROL, V184, P436, DOI 10.1016/j.expneurol.2003.07.004; Riley BE, 2005, J BIOL CHEM, V280, P21942, DOI 10.1074/jbc.M501677200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shinbo Y, 2006, CELL DEATH DIFFER, V13, P96, DOI 10.1038/sj.cdd.4401704; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Su HL, 2002, GENE, V296, P65, DOI 10.1016/S0378-1119(02)00843-0; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Terashima T, 2002, NEUROREPORT, V13, P2359, DOI 10.1097/00001756-200212030-00038; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Ueda H, 2002, BIOCHEM BIOPH RES CO, V293, P307, DOI 10.1016/S0006-291X(02)00211-5; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	64	214	236	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9919	9924		10.1074/jbc.M510127200	http://dx.doi.org/10.1074/jbc.M510127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16464864	hybrid			2022-12-27	WOS:000236594300013
J	Ruan, X; Bhattacharjee, H; Rosen, BP				Ruan, X; Bhattacharjee, H; Rosen, BP			Cys-113 and Cys-422 form a high affinity metalloid binding site in the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; ESCHERICHIA-COLI; RESISTANCE; DOMAINS; PUMP	The arsRDABC operon of Escherichia coli plasmid R773 encodes the ArsAB extrusion pump for the trivalent metalloids As(III) and Sb(III). ArsA, the catalytic subunit has two homologous halves, A1 and A2. Each half has a consensus signal transduction domain that physically connects the nucleotide-binding domain to the metalloid-binding domain. The relation between metalloid binding by ArsA and transport through ArsB is unclear. In this study, direct metalloid binding to ArsA was examined. The results show that ArsA binds a single Sb( III) with high affinity only in the presence of Mg2+-nucleotide. Mutation of the codons for Cys-113 and Cys-422 eliminated Sb( III) binding to purified ArsA. C113A/ C422A ArsA has basal ATPase activity similar to that of the wild type but lacks metalloid-stimulated activity. Accumulation of metalloid was assayed in intact cells, where reduced uptake results from active extrusion by the ArsAB pump. Cells expressing the arsA(C113A/C422A)B genes had an intermediate level of metalloid resistance and accumulation between those expressing only arsB alone and those expressing wild type arsAB genes. The results indicate that, whereas metalloid stimulation of ArsA activity enhances the ability of the pump to reduce the intracellular concentration of metalloid, high affinity binding of metalloid by ArsA is not obligatory for transport or resistance. Yet, in mixed populations of cells bearing either arsAB or arsA(C113A/C422A)B growing in subtoxic concentrations of arsenite, cells bearing wild type arsAB replaced cells with mutant arsA(C113A/C422A)B in less than 1 week, showing that the metalloid binding site confers an evolutionary advantage.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM 55425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; HSU CM, 1989, J BIOL CHEM, V264, P17349; Jia HW, 2003, J BIOL CHEM, V278, P6603, DOI 10.1074/jbc.M211845200; Jiang Y, 2005, J BIOL CHEM, V280, P9921, DOI 10.1074/jbc.M413391200; Kuroda M, 1998, METHOD ENZYMOL, V292, P82; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; Li JX, 2000, MOL MICROBIOL, V35, P361, DOI 10.1046/j.1365-2958.2000.01696.x; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Walmsley AR, 2001, BIOCHEM J, V360, P589, DOI 10.1042/0264-6021:3600589; WONG MD, 2004, HDB ATPASES, P159; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731; Zhou TQ, 2002, J BIOL CHEM, V277, P23815, DOI 10.1074/jbc.M203432200	22	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9925	9934		10.1074/jbc.M600125200	http://dx.doi.org/10.1074/jbc.M600125200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16467301	hybrid			2022-12-27	WOS:000236594300014
J	Ahmad, ST; Joyce, MV; Boggess, B; O'Tousa, JE				Ahmad, ST; Joyce, MV; Boggess, B; O'Tousa, JE			The role of Drosophila ninaG oxidoreductase in visual pigment chromophore biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECTOPIC EXPRESSION; BETA-CAROTENE; MELANOGASTER; RETINOIDS; PATHWAY; ISOMERIZATION; TRANSDUCTION; RHODOPSINS; OXIDATION; ISOMERS	We previously reported (Sarfare, S., Ahmad, S. T., Joyce, M. V., Boggess, B., and O'Tousa, J. E. (2005) J. Biol. Chem. 280, 11895-11901) that the Drosophila ninaG gene encodes an oxidoreductase involved in the biosynthesis of the (3S)-3-hydroxyretinal serving as chromophore for Rh1 rhodopsin and that ninaG mutant flies expressing Rh4 as the major opsin accumulate large amounts of a different retinoid. Here, we show that this unknown retinoid is 11-cis-3-hydroxyretinol. Reversed phase high performance liquid chromatography coupled with a photodiode array UV-visible absorbance detector and mass spectrometer revealed a major product eluting at a retention time, t(r), of 3.5 min with a lambda(max) of similar to 324 nm and with a base peak in the mass spectrum at m/z 285. These observations are identical with those of the 3-hydroxyretinol standard. The base peak in the electrospray ionization mass spectrum arises from the loss of a water molecule from the protonated molecule at m/z 303 because of fragmentation in the ion source. These results suggest that 11-cis-3-hydroxyretinol is an intermediate required for chromophore biogenesis in Drosophila. We further show that ninaG mutants fed on retinal as the sole source of vitamin A are able to synthesize 3-hydroxyretinoids. Thus, the NinaG oxidoreductase is not responsible for the initial hydroxylation of the retinal ring but rather acts in a subsequent step in chromophore production. These data are used to review chromophore biosynthesis and propose that NinaG acts in the conversion of (3R)-3-hydroxyretinol to the 3S enantiomer.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	jotousa@nd.edu		O'Tousa, Joseph/0000-0001-9754-6816	NEI NIH HHS [EY06808] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; Cia D, 1999, J CHROMATOGR A, V864, P257, DOI 10.1016/S0021-9673(99)01024-9; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; FEILER R, 1992, J NEUROSCI, V12, P3862; Gu G, 2004, J BIOL CHEM, V279, P18608, DOI 10.1074/jbc.M400323200; Gundersen TE, 2001, J CHROMATOGR A, V935, P13, DOI 10.1016/S0021-9673(01)01043-3; Hsu CD, 2002, VISION RES, V42, P507, DOI 10.1016/S0042-6989(01)00231-0; Kumar JP, 1995, DEVELOPMENT, V121, P4359; NICHOLS R, 1985, DROSOPH INF SERV, V61, P195; Noll GN, 1996, J CHROMATOGR A, V721, P247, DOI 10.1016/0021-9673(95)00789-X; Pak WL, 2003, RECEPTOR CHANNEL, V9, P149, DOI 10.1080/10606820308242; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Salcedo E, 1999, J NEUROSCI, V19, P10716, DOI 10.1523/JNEUROSCI.19-24-10716.1999; Sarfare S, 2005, J BIOL CHEM, V280, P11895, DOI 10.1074/jbc.M412236200; Seki T, 1998, EUR J BIOCHEM, V257, P522, DOI 10.1046/j.1432-1327.1998.2570522.x; SEKI T, 1994, EUR J BIOCHEM, V226, P691, DOI 10.1111/j.1432-1033.1994.tb20097.x; Seki T, 1998, COMP BIOCHEM PHYS B, V119, P53, DOI 10.1016/S0305-0491(97)00322-2; STARK WS, 1990, J COMP PHYSIOL A, V166, P429, DOI 10.1007/BF00192014; vanBreemen RB, 1996, FASEB J, V10, P1098, DOI 10.1096/fasebj.10.9.8801173; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wang T, 2005, J NEUROSCI, V25, P5187, DOI 10.1523/JNEUROSCI.0995-05.2005; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; Yamashita M, 1998, PROTEIN ENG, V11, P1075, DOI 10.1093/protein/11.11.1075	23	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9205	9209		10.1074/jbc.M510293200	http://dx.doi.org/10.1074/jbc.M510293200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464863	hybrid			2022-12-27	WOS:000236404700027
J	Berrone, E; Beltramo, E; Solimine, C; Ape, AU; Porta, M				Berrone, E; Beltramo, E; Solimine, C; Ape, AU; Porta, M			Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; DIABETIC COMPLICATIONS; ALDOSE REDUCTASE; ENDOTHELIAL-CELLS; HYPERGLYCEMIC DAMAGE; IN-VITRO; PERICYTES; GLYCOSYLATION; RETINOPATHY; PREVENTION	Hyperglycemia is a causal factor in the development of the vascular complications of diabetes. One of the biochemical mechanisms activated by excess glucose is the polyol pathway, the key enzyme of which, aldose reductase, transforms D-glucose into D-sorbitol, leading to imbalances of intracellular homeostasis. We aimed at verifying the effects of thiamine and benfotiamine on the polyol pathway, transketolase activity, and intracellular glucose in endothelial cells and pericytes under high ambient glucose. Human umbilical vein endothelial cells and bovine retinal pericytes were cultured in normal (5.6 mmol/liter) or high (28 mmol/liter) glucose, with or without thiamine or benfotiamine 50 or 100 mu mol/liter. Transketolase and aldose reductase mRNA expression was determined by reverse transcription-PCR, and their activity was measured spectrophotometrically; sorbitol concentrations were quantified by gas chromatography-mass spectrometry and intracellular glucose concentrations by fluorescent enzyme-linked immunosorbent assay method. Thiamine and benfotiamine reduce aldose reductase mRNA expression, activity, sorbitol concentrations, and intracellular glucose while increasing the expression and activity of transketolase, for which it is a coenzyme, in human endothelial cells and bovine retinal pericytes cultured in high glucose. Thiamine and benfotiamine correct polyol pathway activation induced by high glucose in vascular cells. Activation of transketolase may shift excess glycolytic metabolites into the pentose phosphate cycle, accelerate the glycolytic flux, and reduce intracellular free glucose, thereby preventing its conversion to sorbitol. This effect on the polyol pathway, together with other beneficial effects reported for thiamine in high glucose, could justify testing thiamine as a potential approach to the prevention and/or treatment of diabetic complications.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy	University of Turin	Berrone, E (corresponding author), Univ Turin, Dept Internal Med, Corso AM Dogliotti 14, I-10126 Turin, Italy.	elena.berrone@unito.it	Beltramo, Elena/AAE-4243-2021; Porta, Massimo/G-6146-2011; Berrone, Elena/N-4826-2019	Beltramo, Elena/0000-0002-7868-0988; Berrone, Elena/0000-0002-1731-4810; Porta, Massimo/0000-0002-3407-6017				AIDA K, 1990, DIABETES CARE, V13, P461, DOI 10.2337/diacare.13.5.461; Babaei-Jadidi R, 2003, DIABETES, V52, P2110, DOI 10.2337/diabetes.52.8.2110; Beltramo E, 2004, DIABETES-METAB RES, V20, P330, DOI 10.1002/dmrr.470; Beltramo E, 2003, DIABETOLOGIA, V46, P409, DOI 10.1007/s00125-003-1043-6; Beltramo E, 2002, DIABETOLOGIA, V45, P416, DOI 10.1007/s00125-001-0761-x; BEYER TA, 1986, METABOLISM, V35, P1, DOI 10.1016/0026-0495(86)90178-2; Booth AA, 1996, BIOCHEM BIOPH RES CO, V220, P113, DOI 10.1006/bbrc.1996.0366; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; Brignardello E, 1998, J ENDOCRINOL, V158, P21, DOI 10.1677/joe.0.1580021; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Chung SSM, 2003, CURR MED CHEM, V10, P1375, DOI 10.2174/0929867033457322; Crabbe MJC, 1998, PROG RETIN EYE RES, V17, P313, DOI 10.1016/S1350-9462(97)00013-X; Dagher Z, 2004, DIABETES, V53, P2404, DOI 10.2337/diabetes.53.9.2404; Del Corso A, 2000, EXP EYE RES, V71, P515, DOI 10.1006/exer.2000.0906; Dvornik D., 1987, ALDOSE REDUCTASE INH, P221; GORDON OG, 1984, ANAL CHEM, V56, P663; Hamada Y, 1998, DIABETES CARE, V21, P1014, DOI 10.2337/diacare.21.6.1014; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KINOSHITA JH, 1986, AM J OPHTHALMOL, V102, P685, DOI 10.1016/0002-9394(86)90394-6; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; LaSelva M, 1996, DIABETOLOGIA, V39, P1263; MCINTOSH LC, 1988, TISSUE CELL, V20, P193, DOI 10.1016/0040-8166(88)90041-9; NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NISHIMURA C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P171, DOI 10.1016/0167-4838(91)99006-E; Pomero F, 2001, ACTA DIABETOL, V38, P135, DOI 10.1007/s005920170010; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WONG HC, 1987, INVEST OPHTH VIS SCI, V28, P1767; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21	36	115	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9307	9313		10.1074/jbc.M600418200	http://dx.doi.org/10.1074/jbc.M600418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452468	hybrid			2022-12-27	WOS:000236404700038
J	Humphries, MJ; Limesand, KH; Schneider, JC; Nakayama, KI; Anderson, SM; Reyland, ME				Humphries, MJ; Limesand, KH; Schneider, JC; Nakayama, KI; Anderson, SM; Reyland, ME			Suppression of apoptosis in the protein kinase C delta null mouse in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; PKC-DELTA; SALIVARY-GLAND; ACINAR-CELLS; DNA-DAMAGE; PROTEOLYTIC ACTIVATION; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; PRIMARY CULTURE; PROLIFERATION	Protein kinase C (PKC) delta is an essential regulator of mitochondrial dependent apoptosis in epithelial cells. We have used the PKC delta(-/-) mouse to ask if loss of PKC delta protects salivary glands against gamma-irradiation-induced apoptosis in vivo and to explore the mechanism underlying protection from apoptosis. We show that gamma-irradiation in vivo results in a robust induction of apoptosis in the parotid glands of wild type mice, whereas apoptosis is suppressed by greater than 60% in the parotid glands of PKC delta(-/-) mice. Primary parotid cells from PKC delta(-/-) mice are defective in mitochondrial dependent apoptosis as indicated by suppression of etoposide-induced cytochrome c release, poly(ADP-ribose) polymerase cleavage, and caspase-3 activation. Notably, apoptotic responsiveness can be restored by re-introduction of PKC delta by adenoviral transduction. Etoposide and gamma-irradiation-induced activation of p53 is similar in primary parotid cells and parotid glands from PKC delta(+/+) and PKC delta(-/-) mice, indicating that PKC delta functions downstream of the DNA damage response. In contrast, activation of the c-Jun amino-terminal kinase is reduced in primary parotid cells from PKC delta(-/-) cells and in parotid C5 cells, which express a dominant inhibitory mutant of PKC delta. Similarly, c-Jun amino-terminal kinase activation is suppressed in vivo in gamma-irradiated parotid glands from PKC delta(-/-) mice. These studies indicate an essential role for PKC delta downstream of the p53 response and upstream of the c-Jun amino-terminal kinase activation in DNA damage-induced apoptosis in vivo and in vitro.	Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Dent, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Program Cell & Dev Biol, Denver, CO 80262 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kyushu University	Reyland, ME (corresponding author), Mailstop 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@uchsc.edu			NIDCR NIH HHS [R01 DE015648-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Anderson SM, 1999, CELL DEATH DIFFER, V6, P454, DOI 10.1038/sj.cdd.4400507; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chambers MS, 2004, HEAD NECK-J SCI SPEC, V26, P796, DOI 10.1002/hed.20045; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Eguchi K, 2001, INTERNAL MED, V40, P275, DOI 10.2169/internalmedicine.40.275; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FOX PC, 1987, J AM DENT ASSOC, V115, P581, DOI 10.1016/S0002-8177(87)54012-0; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Guchelaar HJ, 1997, SUPPORT CARE CANCER, V5, P281, DOI 10.1007/s005200050075; Ham YM, 2003, J BIOL CHEM, V278, P50330, DOI 10.1074/jbc.M302997200; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li CH, 2003, FASEB J, V17, P2106, DOI 10.1096/fj.03-0150fje; Li DW, 2004, MOL CELL BIOL, V24, P3885, DOI 10.1128/MCB.24.9.3885-3893.2004; Li LW, 1999, MOL CELL BIOL, V19, P8547; Limesand KH, 2003, IN VITRO CELL DEV-AN, V39, P170; Limesand KH, 2003, CELL DEATH DIFFER, V10, P345, DOI 10.1038/sj.cdd.4401153; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Michalak E, 2005, BIOCHEM BIOPH RES CO, V331, P786, DOI 10.1016/j.bbrc.2005.03.183; Mitsutake N, 2001, ONCOGENE, V20, P989, DOI 10.1038/sj.onc.1204179; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Muhvic-Urek M, 2006, PHYSIOL RES, V55, P89, DOI 10.33549/physiolres.930739; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; REDMAN RS, 1988, IN VITRO CELL DEV B, V24, P734; REDMAN RS, 1994, IN VITRO CELL DEV, V30, P833; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; STEPHENS LC, 1991, CANCER, V67, P1539, DOI 10.1002/1097-0142(19910315)67:6<1539::AID-CNCR2820670613>3.0.CO;2-Q; Yin YX, 2004, P NATL ACAD SCI USA, V101, P8864, DOI 10.1073/pnas.0403130101; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	51	111	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9728	9737		10.1074/jbc.M507851200	http://dx.doi.org/10.1074/jbc.M507851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452485	hybrid			2022-12-27	WOS:000236404700085
J	Jiang, JH; Chen, XN; Shen, JL; Wei, YY; Wu, T; Yang, YZ; Wang, HZ; Zong, HL; Yang, JW; Zhang, S; Xie, JH; Kong, XF; Liu, WC; Gu, JX				Jiang, JH; Chen, XN; Shen, JL; Wei, YY; Wu, T; Yang, YZ; Wang, HZ; Zong, HL; Yang, JW; Zhang, S; Xie, JH; Kong, XF; Liu, WC; Gu, JX			beta 1,4-galactosyltransferase V functions as a positive growth regulator in glioma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; OVER-EXPRESSION; BRAIN-TUMORS; CANCER-CELLS; SF-9 CELLS; CYCLIN D3; AKT; ASTROCYTOMA; GENE; TRANSCRIPTION	beta 1,4-galactosyltransferase V ( GalT V; EC 2.4.1.38) can effectively galactosylate the GlcNAc beta 1-->6Man arm of the highly branched N-glycans that are characteristic of glioma. Previously, we have reported that the expression of GalT V is increased in the process of glioma. However, currently little is known about the role of GalT V in this process. In this study, the ectopic expression of GalT V could promote the invasion and survival of glioma cells and transformed astrocytes. Furthermore, decreasing the expression of GalT V in glioma cells promoted apoptosis, inhibited the invasion and migration and the ability of tumor formation in vivo, and reduced the activation of AKT. In addition, the activity of GalT V promoter could be induced by epidermal growth factor, dominant active Ras, ERK1, JNK1, and constitutively active AKT. Taken together, our results suggest that GalT V functioned as a novel glioma growth activator and might represent a novel target in glioma therapy.	Fudan Univ, Shanghai Med Coll, Ctr Gene Res, Minist Educ & Hlth,Key Lab Med Mol Virol, Shanghai 200032, Peoples R China; Shanghai Med Univ, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Shanghai Med Coll, Ctr Gene Res, Minist Educ & Hlth,Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn	liu, weicheng/D-4173-2013; zhang, si/AAG-9094-2021; Wang, Hanzhou/G-9814-2012; Zong, Hongliang/F-9366-2013	Wang, Hanzhou/0000-0002-0493-827X; Zong, Hongliang/0000-0002-5855-5733; zhang, Si/0000-0002-5682-4995				ALBINI A, 1987, CANCER RES, V47, P3239; Alemany R, 1999, EXP CELL RES, V252, P1, DOI 10.1006/excr.1999.4623; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO;2-O; Bacon CL, 2002, J NEUROCHEM, V83, P12, DOI 10.1046/j.1471-4159.2002.01081.x; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; CAVENEE WK, 1992, CANCER, V70, P1788, DOI 10.1002/1097-0142(19920915)70:4+<1788::AID-CNCR2820701621>3.0.CO;2-L; Chen ZP, 1999, CLIN CANCER RES, V5, P4186; Claes P, 2001, BRIT J PHARMACOL, V134, P402, DOI 10.1038/sj.bjp.0704271; Couldrey C, 2000, BREAST CANCER RES, V2, P321, DOI 10.1186/bcr75; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; Hakomori S, 1996, CANCER RES, V56, P5309; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Jetzt A, 2003, CANCER RES, V63, P6697; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Maier D, 1999, CANCER RES, V59, P5479; Nagane M, 1999, JPN J CLIN ONCOL, V29, P527, DOI 10.1093/jjco/29.11.527; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Perkins E, 2003, MOL BRAIN RES, V111, P42, DOI 10.1016/S0169-328X(02)00668-X; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Reuveni H, 2000, J CELL BIOL, V151, P1179, DOI 10.1083/jcb.151.6.1179; Sato T, 2000, BIOCHEM BIOPH RES CO, V276, P1019, DOI 10.1006/bbrc.2000.3594; Sato T, 2004, J BIOL CHEM, V279, P39574, DOI 10.1074/jbc.M405805200; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Sato T, 2001, BIOCHIMIE, V83, P719, DOI 10.1016/S0300-9084(01)01304-9; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Shirane K, 1999, BIOCHEM BIOPH RES CO, V265, P434, DOI 10.1006/bbrc.1999.1684; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xu S, 2002, J EXP CLIN CANC RES, V21, P409; Xu SL, 2001, J CANCER RES CLIN, V127, P502, DOI 10.1007/s004320100246; Yamamoto H, 2000, CANCER RES, V60, P134; Zhu XY, 2003, BIOCHEM BIOPH RES CO, V309, P279, DOI 10.1016/j.bbrc.2003.04.001; Zhu XY, 2005, J BIOL CHEM, V280, P12503, DOI 10.1074/jbc.M413631200	39	30	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9482	9489		10.1074/jbc.M504489200	http://dx.doi.org/10.1074/jbc.M504489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461357	hybrid			2022-12-27	WOS:000236404700058
J	Pogni, R; Baratto, MC; Teutloff, C; Giansanti, S; Ruiz-Duenas, FJ; Choinowski, T; Piontek, K; Martinez, AT; Lendzian, F; Basosi, R				Pogni, R; Baratto, MC; Teutloff, C; Giansanti, S; Ruiz-Duenas, FJ; Choinowski, T; Piontek, K; Martinez, AT; Lendzian, F; Basosi, R			A tryptophan neutral radical in the oxidized state of versatile peroxidase from Pleurotus eryngii - A combined multifrequency EPR and density functional theory study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FIELD EPR; ELECTRON-PARAMAGNETIC-RESONANCE; I RIBONUCLEOTIDE REDUCTASE; BINDING-SITE MUTANTS; LIGNIN PEROXIDASE; CYTOCHROME-C; MANGANESE PEROXIDASE; CRYSTAL-STRUCTURE; G-TENSOR; PHANEROCHAETE-CHRYSOSPORIUM	Versatile peroxidases are heme enzymes that combine catalytic properties of lignin peroxidases and manganese peroxidases, being able to oxidize Mn2+ as well as phenolic and non-phenolic aromatic compounds in the absence of mediators. The catalytic process ( initiated by hydrogen peroxide) is the same as in classical peroxidases, with the involvement of 2 oxidizing equivalents and the formation of the so-called Compound I. This latter state contains an oxoferryl center and an organic cation radical that can be located on either the porphyrin ring or a protein residue. In this study, a radical intermediate in the reaction of versatile peroxidase from the ligninolytic fungus Pleurotus eryngii with H2O2 has been characterized by multifrequency (9.4 and 94 GHz) EPR and assigned to a tryptophan residue. Comparison of experimental data and density functional theory theoretical results strongly suggests the assignment to a tryptophan neutral radical, excluding the assignment to a tryptophan cation radical or a histidine radical. Based on the experimentally determined side chain orientation and comparison with a high resolution crystal structure, the tryptophan neutral radical can be assigned to Trp(164) as the site involved in long-range electron transfer for aromatic substrate oxidation.	Univ Siena, Dept Chem, I-53100 Siena, Italy; Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain; Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	University of Siena; Technical University of Berlin; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Swiss Federal Institutes of Technology Domain; ETH Zurich	Pogni, R (corresponding author), Univ Siena, Dept Chem, I-53100 Siena, Italy.	pogni@unisi.it; f.lendzian@tu-berlin.de	Martínez, Angel T/G-7284-2017; Ruiz-Dueñas, Francisco J/L-9837-2015; Basosi, Riccardo/E-7497-2011	Martínez, Angel T/0000-0002-1584-2863; Ruiz-Dueñas, Francisco J/0000-0002-9837-5665; Basosi, Riccardo/0000-0003-1026-7668				Banci L, 2003, J BIOL INORG CHEM, V8, P751, DOI 10.1007/s00775-003-0476-1; Barrows TP, 2004, BIOCHEMISTRY-US, V43, P8826, DOI 10.1021/bi049531g; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; Bleifuss G, 2001, BIOCHEMISTRY-US, V40, P15362, DOI 10.1021/bi010707d; Blodig W, 2001, J MOL BIOL, V305, P851, DOI 10.1006/jmbi.2000.4346; Blodig W, 1999, ARCH BIOCHEM BIOPHYS, V370, P86, DOI 10.1006/abbi.1999.1365; Blodig W, 1998, BIOCHEMISTRY-US, V37, P8832, DOI 10.1021/bi9727186; BRUDVIG GW, 1995, METHOD ENZYMOL, V246, P536; Camarero S, 1996, APPL ENVIRON MICROB, V62, P1070, DOI 10.1128/AEM.62.3.1070-1072.1996; Camarero S, 2000, FEMS MICROBIOL LETT, V191, P37, DOI 10.1111/j.1574-6968.2000.tb09316.x; Camarero S, 1999, J BIOL CHEM, V274, P10324, DOI 10.1074/jbc.274.15.10324; Choinowski T, 1999, J MOL BIOL, V286, P809, DOI 10.1006/jmbi.1998.2507; Dunford H. B., 1999, HEME PEROXIDASES; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; Ehrenberg A., 1967, MAGNETIC RESONANCE B, P221; Engstrom M, 2000, J PHYS CHEM A, V104, P5149, DOI 10.1021/jp0006633; Frisch M. J., 2019, GAUSSIAN 16 REVISION; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; Heinfling A, 1998, FEMS MICROBIOL LETT, V165, P43, DOI 10.1016/S0378-1097(98)00255-9; Heinfling A, 1998, FEBS LETT, V428, P141, DOI 10.1016/S0014-5793(98)00512-2; Heinfling A, 1998, APPL ENVIRON MICROB, V64, P2788; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Johjima T, 1999, P NATL ACAD SCI USA, V96, P1989, DOI 10.1073/pnas.96.5.1989; Kaupp M, 2003, J PHYS CHEM B, V107, P331, DOI 10.1021/jp026596p; Kishi K, 1996, BIOCHEMISTRY-US, V35, P8986, DOI 10.1021/bi960679c; KUSTERSVANSOMEREN M, 1995, BIOCHEMISTRY-US, V34, P10620, DOI 10.1021/bi00033a037; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; Lendzian F, 2005, BBA-BIOENERGETICS, V1707, P67, DOI 10.1016/j.bbabio.2004.02.011; LUBITZ W, 1996, ADV PHOTOSYNTH, V3, P255; MARQUEZ L, 1988, J BIOL CHEM, V263, P10549; Martinez AT, 2002, ENZYME MICROB TECH, V30, P425, DOI 10.1016/S0141-0229(01)00521-X; Martinez MJ, 1996, EUR J BIOCHEM, V237, P424, DOI 10.1111/j.1432-1033.1996.0424k.x; Mester T, 1998, J BIOL CHEM, V273, P15412, DOI 10.1074/jbc.273.25.15412; Mester T, 2001, J BIOL CHEM, V276, P22985, DOI 10.1074/jbc.M010739200; Miller JE, 2003, J AM CHEM SOC, V125, P14220, DOI 10.1021/ja037203i; MOMBOURQUETTE MJ, 1992, J MAGN RESON, V99, P37, DOI 10.1016/0022-2364(92)90153-X; OMalley PJ, 1996, CHEM PHYS LETT, V260, P492, DOI 10.1016/0009-2614(96)00856-1; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Perez-Boada M, 2005, J MOL BIOL, V354, P385, DOI 10.1016/j.jmb.2005.09.047; Perez-Boada M, 2002, ENZYME MICROB TECH, V30, P518, DOI 10.1016/S0141-0229(02)00008-X; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; Pogni R, 2005, BIOCHEMISTRY-US, V44, P4267, DOI 10.1021/bi047474l; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Reece SY, 2005, BBA-BIOENERGETICS, V1706, P232, DOI 10.1016/j.bbabio.2004.11.011; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; Ruiz-Duenas FJ, 1999, MOL MICROBIOL, V31, P223, DOI 10.1046/j.1365-2958.1999.01164.x; Ruiz-Duenas FJ, 2001, BIOCHEM SOC T, V29, P116, DOI 10.1042/BST0290116; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sarkar S, 1997, BBA-PROTEIN STRUCT M, V1339, P23, DOI 10.1016/S0167-4838(96)00201-4; Schaftenaar G, 2000, J COMPUT AID MOL DES, V14, P123, DOI 10.1023/A:1008193805436; Schoemaker H E, 1994, Bioorg Med Chem, V2, P509, DOI 10.1016/0968-0896(94)80021-9; Schunemann V, 2004, J BIOL CHEM, V279, P10919, DOI 10.1074/jbc.M307884200; SCHWEIGER A, 1991, ANGEW CHEM INT EDIT, V30, P265, DOI 10.1002/anie.199102651; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; SPANGLER BD, 1986, BIOCHIM BIOPHYS ACTA, V872, P155; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Sundaramoorthy M, 1997, J BIOL CHEM, V272, P17574, DOI 10.1074/jbc.272.28.17574; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; Timofeevski SL, 2000, ARCH BIOCHEM BIOPHYS, V373, P147, DOI 10.1006/abbi.1999.1562; Tommos C, 1999, BIOCHEMISTRY-US, V38, P9495, DOI 10.1021/bi990609g; Un S, 2001, J AM CHEM SOC, V123, P3048, DOI 10.1021/ja003650b; Villegas JA, 2000, CHEM BIOL, V7, P237, DOI 10.1016/S1074-5521(00)00098-3; Wertz J.E., 1986, ELECT SPIN RESONANCE	75	85	86	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9517	9526		10.1074/jbc.M510424200	http://dx.doi.org/10.1074/jbc.M510424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16443605	hybrid, Green Published			2022-12-27	WOS:000236404700062
J	Wexler-Cohen, Y; Johnson, BT; Puri, A; Blumenthal, R; Shai, Y				Wexler-Cohen, Y; Johnson, BT; Puri, A; Blumenthal, R; Shai, Y			Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SURFACE-PLASMON RESONANCE; MEMBRANE-FUSION; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDE; CELL-FUSION; GP41; AMINO; CONFORMATION; PARDAXIN	Human immunodeficiency virus 1 gp41 folds into a six-helix bundle whereby three C-terminal heptad repeat regions pack in an anti-parallel manner against the coiled-coil formed by three N-terminal heptad repeats (NHR). Peptides that inhibit bundle formation contributed significantly to the understanding of the entry mechanism of the virus. DP178, which partially overlaps C-terminal heptad repeats, prevents bundle formation through an undefined mechanism; additionally it has been suggested to bind other ENV regions and arrest fusion in an unknown manner. We used two structurally altered DP178 peptides; in each, two sequential amino acids were substituted into their D configuration, D-SQ in the hydrophilic N-terminal region and D-LW in the hydrophobic C-terminal. Importantly, we generated an elongated NHR peptide, N54, obtaining the full N-helix docking site for DP178. Interestingly, D-LW retained wild type fusion inhibitory activity, whereas D-SQ exhibited significantly reduced activity. In correlation with the inhibitory data, CD spectroscopy and fluorescence studies revealed that all the DP178 peptides interact with N54, albeit with different stabilities of the bundles. We conclude that strong binding of DP178 N-terminal region to the endogenous NHR, without significant contribution of the C-terminal sequence of DP178 to core formation, is vital for DP178 inhibition. The finding that D-amino acid incorporation in the C terminus did not affect activity or membrane binding as revealed by surface plasmon resonance correlates with an additional membrane binding site, or membrane anchoring role, for the C terminus, which works synergistically with the N terminus to inhibit fusion.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NCI, Sect Membrane Struct & Funct, Ctr Canc Res, Nanobiol Program,NIH, Frederick, MD 21702 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008303, ZIABC008303] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CIMINALE V, 1990, AIDS RES HUM RETROV, V6, P1281, DOI 10.1089/aid.1990.6.1281; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; Gerber D, 2004, J BIOL CHEM, V279, P48224, DOI 10.1074/jbc.M403436200; Gerber D, 2004, J MOL BIOL, V339, P243, DOI 10.1016/j.jmb.2004.03.004; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; LaBranche CC, 2001, ANTIVIR RES, V50, P95, DOI 10.1016/S0166-3542(01)00130-9; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LIU S, 2005, J BIOL CHEM; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P9482, DOI 10.1021/bi00154a022; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Ryu JR, 1999, BIOCHEM BIOPH RES CO, V265, P625, DOI 10.1006/bbrc.1999.1739; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	33	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9005	9010		10.1074/jbc.M512475200	http://dx.doi.org/10.1074/jbc.M512475200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455666	hybrid			2022-12-27	WOS:000236404700004
J	Machide, M; Hashigasako, A; Matsumoto, K; Nakamura, T				Machide, M; Hashigasako, A; Matsumoto, K; Nakamura, T			Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON-ANTIGEN; MATURE RAT HEPATOCYTES; PRIMARY CULTURE; MOLECULAR-CLONING; RECIPROCAL MODULATION; SUSTAINED ACTIVATION; LIVER-REGENERATION; SIGNALING PATHWAY; CELL-MIGRATION; G(1) PHASE	Contact inhibition, the inhibition of cell proliferation by tight cell-cell contact is a fundamental characteristic of normal cells. Using primary cultured hepatocytes, we investigated the mechanisms of contact inhibition that decrease the mitogenic activity of hepatocyte growth factor (HGF), focusing on the regulation of c-Met/HGF-receptor activation. In hepatocytes cultured at a sparse cell density, HGF stimulation induced prolonged c-Met tyrosine phosphorylation for over 5 h and a marked mitogenic response. In contrast, HGF stimulation induced transient c-Met tyrosine phosphorylation in <3 h and failed to induce mitogenic response in hepatocytes cultured at a confluent cell density. Treatment of the confluent cells with HGF plus orthovanadate, a broad spectrum protein-tyrosine phosphatase inhibitor, however, prolonged c-Met tyrosine phosphorylation for over 5 h and permitted the subsequent mitogenic response. The mitogenic response to HGF was associated with the duration of c-Met tyrosine phosphorylation even in the sparse cells. We found that the activity and expression of the protein-tyrosine phosphatase LAR increased following HGF stimulation specifically in confluent hepatocytes and not in sparse hepatocytes. LAR and c-Met were associated, and purified LAR dephosphorylated tyrosine-phosphorylated c-Met in in vitro phosphatase reactions. Furthermore, antisense oligonucleotides specific for LAR mRNA suppressed the expression of LAR, allowed prolonged c-Met tyrosine phosphorylation, and led to acquisition of a mitogenic response in hepatocytes even under the confluent condition. Thus functional association of LAR and c-Met underlies the inhibition of c-Met-mediated mitogenic signaling through the dephosphorylation of c-Met, which specifically occurs under the confluent condition.	Osaka Univ, Dept Biochem & Mol Biol, Grad Sch Med, Div Mol Regenerat Med, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Dept Biochem & Mol Biol, Grad Sch Med, Div Mol Regenerat Med, 2-2-B7 Yamadaoka, Suita, Osaka 5650871, Japan.	Nakamura@onbich.med.osaka-u.ac.jp	Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Honkaniemi J, 1998, MOL BRAIN RES, V60, P1, DOI 10.1016/S0169-328X(98)00151-X; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1993, J BIOCHEM-TOKYO, V114, P96, DOI 10.1093/oxfordjournals.jbchem.a124147; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1983, P NATL ACAD SCI-BIOL, V80, P7229, DOI 10.1073/pnas.80.23.7229; NAKAMURA T, 1984, J BIOL CHEM, V259, P8056; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OGRADY P, 1994, J BIOL CHEM, V269, P25193; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Stoker M, 1967, Curr Top Dev Biol, V2, P107; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; Symons JR, 2002, BIOCHEM J, V365, P513, DOI 10.1042/BJ20020381; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	42	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8765	8772		10.1074/jbc.M512298200	http://dx.doi.org/10.1074/jbc.M512298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16415345	hybrid			2022-12-27	WOS:000236247100055
J	Ye, H; Abdel-Ghany, SE; Anderson, TD; Pilon-Smits, EAH; Pilon, M				Ye, H; Abdel-Ghany, SE; Anderson, TD; Pilon-Smits, EAH; Pilon, M			CpSufE activates the cysteine desulfurase CpNifS for chloroplastic Fe-S cluster formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; SCAFFOLD PROTEIN; SELENOCYSTEINE LYASE; FERREDOXIN; NIFS; BIOGENESIS; SUFE; GLUTAREDOXIN	CpNifS, a cysteine desulfurase required to supply sulfur for iron-sulfur cluster biogenesis in Arabidopsis thaliana chloroplasts, belongs to a class of NifS-like enzymes with low endogenous cysteine desulfurase activity. Its bacterial homologue SufS is stimulated by SufE. Here we characterize the Arabidopsis chloroplast protein CpSufE, which has an N-terminal SufE-like domain and a C-terminal BolA-like domain unique to higher plants. CpSufE is targeted to the chloroplast stroma, indicated by green fluorescent protein localization and immunoblot experiments. Like CpNifS, CpSufE is expressed in all major tissues, with higher expression in green parts. Its expression is light-dependent and regulated at the mRNA level. The addition of purified recombinant CpSufE increased the V-max for the cysteine desulfurase activity of CpNifS over 40-fold and decreased the K-M toward cysteine from 0.1 to 0.043 mM. In contrast, CpSufE addition decreased the affinity of CpNifS for selenocysteine, as indicated by an increase in the K-M from 2.9 to 4.17 mM, and decreased the V-max for selenocysteine lyase activity by 30%. CpSufE forms dynamic complexes with CpNifS, indicated by gel filtration, native PAGE, and affinity chromatography experiments. A mutant of CpSufE in which the single cysteine was changed to serine was not active in stimulating CpNifS, although it did compete with WT CpSufE. The iron-sulfur cluster reconstitution activity of the CpNifS-CpSufE complex toward apoferredoxin was 20-fold higher than that of CpNifS alone. We conclude that CpNifS and CpSufE together form a cysteine desulfurase required for iron-sulfur cluster formation in chloroplasts.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA	Colorado State University	Pilon, M (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	pilon@lamar.colostate.edu	Pilon-Smits, Elizabeth/AAN-4117-2020	Pilon-Smits, Elizabeth/0000-0003-1205-8798				Abdel-Ghany SE, 2005, PLANT PHYSIOL, V138, P161, DOI 10.1104/pp.104.058602; Alves R, 2004, PROTEINS, V57, P481, DOI 10.1002/prot.20228; Balk J, 2005, TRENDS PLANT SCI, V10, P324, DOI 10.1016/j.tplants.2005.05.002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Goldsmith-Fischman S, 2004, J MOL BIOL, V344, P549, DOI 10.1016/j.jmb.2004.08.074; Huynen MA, 2005, FEBS LETT, V579, P591, DOI 10.1016/j.febslet.2004.11.111; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Leon S, 2002, BIOCHEM J, V366, P557, DOI 10.1042/BJ20020322; Lezhneva L, 2004, PLANT J, V37, P174, DOI 10.1046/j.1365-313X.2003.01952.x; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Miras S, 2002, J BIOL CHEM, V277, P47770, DOI 10.1074/jbc.M207477200; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; Murashige T., 1962, PHYSIOL PLANTARUM, V15, P437, DOI DOI 10.1111/J.1399-3054.1962.TB08052; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; PILON M, 1995, ADV MOL CELL BIOL, V1, P229; Pilon-Smits EAH, 2002, PLANT PHYSIOL, V130, P1309, DOI 10.1104/pp.010280; Raven JA, 1999, PHOTOSYNTH RES, V60, P111, DOI 10.1023/A:1006282714942; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Santos JM, 2002, MOL MICROBIOL, V45, P1729, DOI 10.1046/j.1365-2958.2002.03131.x; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; TAKAHASHI Y, 1991, PLANT PHYSIOL, V95, P97, DOI 10.1104/pp.95.1.97; TAKAHASHI Y, 1986, P NATL ACAD SCI USA, V83, P2434, DOI 10.1073/pnas.83.8.2434; TERRY N, 1986, J PLANT NUTR, V9, P609, DOI 10.1080/01904168609363470; Touraine B, 2004, PLANT J, V40, P101, DOI 10.1111/j.1365-313X.2004.02189.x; Van Hoewyk D, 2005, PLANT PHYSIOL, V139, P1518, DOI 10.1104/pp.105.068684; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Xu XM, 2005, J BIOL CHEM, V280, P6648, DOI 10.1074/jbc.M413082200; Xu XM, 2004, P NATL ACAD SCI USA, V101, P9143, DOI 10.1073/pnas.0400799101; Yabe T, 2004, PLANT CELL, V16, P993, DOI 10.1105/tpc.020511; Ye H, 2005, PLANTA, V220, P602, DOI 10.1007/s00425-004-1388-1; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	43	58	62	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8958	8969		10.1074/jbc.M512737200	http://dx.doi.org/10.1074/jbc.M512737200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455656	hybrid			2022-12-27	WOS:000236247100076
J	Ji, HL; Su, XF; Kedar, S; Li, J; Barbry, P; Smith, PR; Matalon, S; Benos, DJ				Ji, HL; Su, XF; Kedar, S; Li, J; Barbry, P; Smith, PR; Matalon, S; Benos, DJ			delta-subunit confers novel biophysical features to alpha beta gamma-human epithelial sodium channel (ENaC) via a physical interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; MOLECULAR CHARACTERIZATION; SELF-INHIBITION; ION-TRANSPORT; A549 CELLS; EXPRESSION; LUNG; CONDUCTANCE; CLONING; STOICHIOMETRY	Native amiloride-sensitive Na+ channels exhibit a variety of biophysical properties, including variable sensitivities to amiloride, different ion selectivities, and diverse unitary conductances. The molecular basis of these differences has not been elucidated. We tested the hypothesis that co-expression of delta-epithelial sodium channel ( ENaC) underlies, at least in part, the multiplicity of amiloride-sensitive Na+ conductances in epithelial cells. For example, the delta-subunit may form multimeric channels with alpha beta gamma-ENaC. Reverse transcription-PCR revealed that delta-ENaC is co-expressed with alpha beta gamma-subunits in cultured human lung (H441 and A549), pancreatic (CFPAC), and colonic epithelial cells (Caco-2). Indirect immunofluorescence microscopy revealed that delta-ENaC is co-expressed with alpha-, beta-, and gamma-ENaC in H441 cells at the protein level. Measurement of current-voltage relationships revealed that the cation selectivity ratios for Na+/Li+/ K+/Cs+/Ca2+/Mg2+, the apparent dissociation constant (K-i) for amiloride, and unitary conductances for delta alpha beta gamma-ENaC differed from those of both alpha beta gamma- and alpha beta gamma-ENaC ( n = 6). The contribution of the delta subunit to P-Li/P-Na ratio and unitary Na+ conductance under bi-ionic conditions depended on the injected cRNA concentration. In addition, the EC50 for proton activation, mean open and closed times, and the self-inhibition time of delta alpha beta gamma-ENaC differed from those of alpha beta gamma- and delta beta gamma-ENaC. Co-immunoprecipitation of delta-ENaC with alpha- and gamma-subunits in H441 and transfected COS-7 cells suggests an interaction among these proteins. We, therefore, concluded that the interactions of delta-ENaC with other subunits could account for heterogeneity of native epithelial channels.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35205 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35205 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR411, F-06560 Sophia Antipolis, France	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Benos, DJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,704 MCLM, Birmingham, AL 35294 USA.	benos@physiology.uab.edu	JI, HONGLONG/N-7822-2014; Barbry, Pascal/O-5021-2016	JI, HONGLONG/0000-0002-3228-7144; Barbry, Pascal/0000-0001-9632-6483	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075540, R01HL051173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R01DK056596, R56DK037206] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51173, HL075540] Funding Source: Medline; NIDDK NIH HHS [DK56596, DK37206] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Becchetti A, 2002, AM J PHYSIOL-RENAL, V283, pF1030, DOI 10.1152/ajprenal.00011.2002; Benos DJ, 1996, KIDNEY INT, V49, P1632, DOI 10.1038/ki.1996.237; Berdiev BK, 2004, AM J PHYSIOL-RENAL, V286, pF1100, DOI 10.1152/ajprenal.00344.2003; Biasio W, 2004, J BIOL CHEM, V279, P5429, DOI 10.1074/jbc.M311155200; Bremner HR, 2002, AM J PHYSIOL-LUNG C, V282, pL124, DOI 10.1152/ajplung.2002.282.1.L124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Clunes MT, 2004, J PHYSIOL-LONDON, V557, P809, DOI 10.1113/jphysiol.2004.061143; Cotton CU, 1998, PANCREAS, V17, P247, DOI 10.1097/00006676-199810000-00004; Fu J, 2001, J PHYSIOL-LONDON, V536, P459, DOI 10.1111/j.1469-7793.2001.0459c.xd; Fukuda M, 2000, JPN J PHYSIOL, V50, P215, DOI 10.2170/jjphysiol.50.215; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Hardiman KA, 2004, AM J RESP CELL MOL, V30, P720, DOI 10.1165/rcmb.2003-0325OC; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Ji HL, 2004, J BIOL CHEM, V279, P26939, DOI 10.1074/jbc.M401143200; Ji HL, 2004, J BIOL CHEM, V279, P8428, DOI 10.1074/jbc.M312012200; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lazrak A, 2000, AM J PHYSIOL-CELL PH, V279, pC762, DOI 10.1152/ajpcell.2000.279.3.C762; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Lazrak A, 2000, AM J PHYSIOL-LUNG C, V278, pL848, DOI 10.1152/ajplung.2000.278.4.L848; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Novak I, 2002, BBA-BIOMEMBRANES, V1566, P162, DOI 10.1016/S0005-2736(02)00598-9; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Ramminger SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL411, DOI 10.1152/ajplung.00407.2003; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Tucker JK, 1998, AM J PHYSIOL-CELL PH, V274, pC1081, DOI 10.1152/ajpcell.1998.274.4.C1081; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wodopia R, 2000, AM J PHYSIOL-LUNG C, V279, pL1110, DOI 10.1152/ajplung.2000.279.6.L1110; YUE G, 1993, AM J PHYSIOL, V265, pC630, DOI 10.1152/ajpcell.1993.265.3.C630; Zhao WC, 2003, WORLD J GASTROENTERO, V9, P2505	44	80	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8233	8241		10.1074/jbc.M512293200	http://dx.doi.org/10.1074/jbc.M512293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16423824	hybrid			2022-12-27	WOS:000236031000063
J	Costet, P; Cariou, B; Lambert, G; Lalanne, F; Lardeux, B; Jarnoux, AL; Grefhorst, A; Stels, B; Krempf, M				Costet, P; Cariou, B; Lambert, G; Lalanne, F; Lardeux, B; Jarnoux, AL; Grefhorst, A; Stels, B; Krempf, M			Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTOR; LIPOGENIC GENE-EXPRESSION; LEUCINE ZIPPER PROTEIN; FATTY-ACID SYNTHESIS; TRANSGENIC MICE; CULTURED-CELLS; DOMINANT HYPERCHOLESTEROLEMIA; TRANSCRIPTION FACTOR; APOLIPOPROTEIN-B; LDL CHOLESTEROL	Familial autosomal dominant hypercholesterolemia is associated with high risk for cardiovascular accidents and is related to mutations in the low density lipoprotein receptor or its ligand apolipoprotein B ( apoB). Mutations in a third gene, proprotein convertase subtilisin kexin 9 (PCSK9), were recently associated to this disease. PCSK9 acts as a natural inhibitor of the low density lipoprotein receptor pathway, and both genes are regulated by depletion of cholesterol cell content and statins, via sterol regulatory element-binding protein ( SREBP). Here we investigated the regulation of PCSK9 gene expression during nutritional changes. We showed that PCSK9 mRNA quantity is decreased by 73% in mice after 24 h of fasting, leading to a 2-fold decrease in protein level. In contrast PCSK9 expression was restored upon high carbohydrate refeeding. PCSK9 mRNA increased by 4-5-fold in presence of insulin in rodent primary hepatocytes, whereas glucose had no effect. Moreover, insulin up-regulated hepatic PCSK9 expression in vivo during a hyperinsulinemic-euglycemic clamp in mice. Adenoviral mediated overexpression of a dominant or negative form of SREBP-1c confirmed the implication of this transcription factor in insulin-mediated stimulation of PCSK9 expression. Liver X receptor agonist T0901317 also regulated PCSK9 expression via this same pathway ( a 2-fold increase in PCSK9 mRNA of primary hepatocytes cultured for 24 h in presence of 1 mu M T0901317). As our last investigation, we isolated PCSK9 proximal promoter and verified the functionality of a SREBP-1c responsive element located from 335 bp to 355 bp upstream of the ATG. Together, these results show that PCSK9 expression is regulated by nutritional status and insulinemia.	CHU Hotel Dieu, INSERM, U539, F-44093 Nantes, France; Univ Lille 2, Fac Pharm, Pasteur Inst Lille, F-59019 Lille, France; Univ Lille 2, INSERM, U545, F-59019 Lille, France; Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, NL-9700 RB Groningen, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; University of Groningen	Costet, P (corresponding author), CHU Hotel Dieu, INSERM, U539, 3eme Etage Nord,1 Pl Alexis Ricordeau, F-44093 Nantes, France.	philippe.costet@univ-nantes.fr	costet, philippe/A-5314-2010; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Krempf, Michel/0000-0002-4353-9511; Lambert, Gilles/0000-0001-5632-0685; Cariou, Bertrand/0000-0002-1580-8040				Attie AD, 2005, CELL METAB, V1, P290, DOI 10.1016/j.cmet.2005.04.006; Avramoglu RK, 2004, REV ENDOCR METAB DIS, V5, P293, DOI 10.1023/B:REMD.0000045100.66675.92; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; BALAVOINE S, 1993, J CELL PHYSIOL, V156, P56, DOI 10.1002/jcp.1041560109; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Brunham LR, 2005, CLIN GENET, V67, P476, DOI 10.1111/j.1399-0004.2005.0453a.x; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Commerford SR, 2004, AM J PHYSIOL-REG I, V287, pR218, DOI 10.1152/ajpregu.00377.2003; Costet P, 2003, MOL CELL BIOL, V23, P7756, DOI 10.1128/MCB.23.21.7756-7766.2003; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Dubuc G, 2004, ARTERIOSCL THROM VAS, V24, P1454, DOI 10.1161/01.ATV.0000134621.14315.43; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fromes Y, 1999, GENE THER, V6, P683, DOI 10.1038/sj.gt.3300853; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; KRAEMER FB, 1994, AM J PHYSIOL, V266, pE26, DOI 10.1152/ajpendo.1994.266.1.E26; Lalanne F, 2005, J LIPID RES, V46, P1312, DOI 10.1194/jlr.M400396-JLR200; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Maxwell KN, 2003, J LIPID RES, V44, P2109, DOI 10.1194/jlr.M300203-JLR200; Ness GC, 1996, ARCH BIOCHEM BIOPHYS, V325, P242, DOI 10.1006/abbi.1996.0030; Ouguerram K, 2004, ARTERIOSCL THROM VAS, V24, P1448, DOI 10.1161/01.ATV.0000133684.77013.88; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Rader DJ, 2003, J CLIN INVEST, V111, P1795, DOI 10.1172/JCI200318925; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Sun XM, 2005, HUM MOL GENET, V14, P1161, DOI 10.1093/hmg/ddi128; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	54	238	286	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6211	6218		10.1074/jbc.M508582200	http://dx.doi.org/10.1074/jbc.M508582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407292	hybrid			2022-12-27	WOS:000236030800013
